


2015 – 2019

Cancer in
North America



■ PARTICIPATING REGISTRIES
■ NOT PARTICIPATING

Cancer in North America: 2015–2019

Executive Summary

Members of the North American Association of Central Cancer Registries, Inc. (NAACCR) participate voluntarily in an annual call for data to develop a multi-registry, aggregated data resource for cancer surveillance and research. NAACCR issues the call, and the member registries' data submissions are combined and used to create the Cancer in North America (CiNA) monograph and other CiNA products for data analyses and cancer incidence information (e.g., NAACCR CiNA Explorer, NAACCR CiNA Maps online query system, CiNA Public Use Dataset, CiNA Research Datasets). These preeminent cancer data resources are unparalleled in geographic scope, timeliness of statistics, and assurance of standardization of information and data quality.

In May 2022, NAACCR released a five-volume monograph, *Cancer in North America: 2015–2019*. This release is the 32nd publication of the series and the 30th release that includes statistics for both Canada and the United States.

This year's publication includes cancer incidence data for all 50 U.S. states, the District of Columbia, Puerto Rico, and 11 Canadian provinces and territories. We also report data by five regions: California (excluding the Greater Bay area and Los Angeles) and four Surveillance, Epidemiology, and End Results (SEER) urban registries (Detroit, Los Angeles, San Francisco/Oakland, and Seattle). CiNA includes registry-specific data on stage at diagnosis, survival, and delay-adjusted estimates of counts and age-adjusted rates for selected cancers. These delay adjustment figures provide a projection of the likely volume of tardy reports of cancer for the time period and are recommended for use in assessing current cancer incidence trends.

New this year, all rates are age-adjusted based on 20 age groups, which now include an additional older age group, 85–90 years. As cancer is a significant burden among our older populations, this update provides more accurate descriptions of the burden of cancer in North America. To accommodate issues with underlying denominator data, racial/ethnic groups are presented differently. This change results in more accurate assessments of the burden of cancer among Asian and Pacific Islander populations and American Indian and Alaska Native (AI/AN) populations. This change in racial/ethnic calculations results in higher presented rates for these populations compared to previous monographs, particularly for AI/AN rates. It is critical to understand that these rates more accurately reflect the true burden of cancer in these populations but *do not* reflect a difference in the actual risk of cancer among these populations. These rates are a correction to previous calculations.

The CiNA monograph encompasses five separate volumes:

Volume One: Combined Cancer Incidence for the United States and Canada

Includes aggregated cancer incidence data by site, sex, race, ethnicity, and stage, including pediatric cancer and cancer by stage at diagnosis from the high-quality registries in the U.S. and Canada.

Volume Two: Registry-Specific Cancer Incidence for the United States and Canada

Includes registry-specific cancer incidence rates by cancer site, sex, race, ethnicity, and stage for all NAACCR member registries submitting data for inclusion in the monograph. To help interpret the statistics, data tables for each registry include demographic and data quality information; registry descriptions are also presented.

Volume Three: Registry-Specific Cancer Mortality for the United States and Canada

Includes registry-specific cancer death rates by cancer site, sex, race, and ethnicity.

Volume Four: Cancer Survival for the United States and Canada

Includes cancer survival data for the U.S. and Canada from 59 registries on more than 13 million cases diagnosed among North Americans between 2012 and 2018.

Volume Five: Cancer Prevalence for the United States and Canada

Includes cancer prevalence estimates for the U.S. and Canada from 59 registries on more than 18 million cases diagnosed among North Americans between 2009 and 2018.

All CiNA volumes are available to download free of charge from the NAACCR website, along with accompanying technical data, including population data and supporting appendices. Additional visualizations of CiNA data are available as online query systems available here: <https://www.naaccr.org/interactive-data-on-line/>.

This publication is made possible by the continuing efforts of the NAACCR member registries. High-quality, standardized cancer incidence data aggregated across the states, provinces, territories, and regions in North America are made possible by the dedication of our members to cancer surveillance. The Editors would like to acknowledge the fine work and support of the National Cancer Institute, the National Center for Health Statistics, and Statistics Canada for their assistance in developing this publication.

We hope that *Cancer in North America: 2015–2019*, with the companion CiNA products and resources, facilitates studies of cancer burden, so that we are better able to identify—and understand—appropriate and important measures to control the myriad diseases known collectively as cancer.

The Editors, May 2022

CANCER IN NORTH AMERICA: 2015–2019

VOLUME TWO: REGISTRY-SPECIFIC CANCER INCIDENCE IN THE UNITED STATES AND CANADA

**A Publication of the North American Association of Central Cancer Registries, Inc.
(NAACCR)**

Editors:

Recinda Sherman, NAACCR Inc.
Rick Firth, Information Management Services, Inc.
Amanda Kahl, State Health Registry of Iowa
Prithwish De, Ontario Cancer Registry
Don Green, Information Management Services, Inc.
Brenda Hofer, CalCARES Program/UC Davis Comprehensive Cancer Center
Lihua Liu, Los Angeles Cancer Surveillance Program
Mei-Chin Hsieh, Louisiana Tumor Registry
Chris Johnson, Cancer Data Registry of Idaho
Betsy Kohler, NAACCR, Inc.
Bozena Morawski, Cancer Data Registry of Idaho
Sarah Nash, SEER Alaska Native Tumor Registry
Baozhen Qiao, New York State Cancer Registry
Hannah Weir, U.S. Centers for Disease Control and Prevention



May 2022

The CiNA Editorial Workgroup of the NAACCR Steering Committee, Research and Data Use, publishes this monograph. We are grateful to the National Cancer Institute, National Institutes of Health (NCI/NIH) for providing support for the production under Contract No. HHSN261200444001C/ADB Contract No. PC-44401 and by cooperative agreement NU58DP006458 from the Centers for Disease Control and Prevention (CDC). Its contents are solely the responsibility of the editors and do not necessarily represent the official view of CDC or NCI.

CINA PARTICIPANTS 2015–2019



SUGGESTED CITATION:

Sherman R, Firth R, Kahl A, De P, Green D, Hofer B, Liu L, Hsieh M, Johnson C, Kohler B, Morawski B, Nash S, Qiao B, Weir H (eds). *Cancer in North America: 2015-2019. Volume Two: Registry-specific Cancer Incidence in the United States and Canada*. Springfield, IL: North American Association of Central Cancer Registries, Inc. May 2022.

TABLE OF CONTENTS

SECTION I: Introduction and Technical Notes	I-1

SECTION II: Average Annual Registry-Specific Cancer Incidence by Race, Ethnicity and Sex, Age-Adjusted to the 2000 U.S. and 2011 Canadian Population Standards

UNITED STATES REGISTRIES

Alabama	II-1
Alaska.....	II-11
Arizona	II-21
Arkansas.....	II-31
California	II-41
CA: Greater California.....	II-51
CA: Greater Bay Area.....	II-61
CA: Los Angeles.....	II-71
Colorado.....	II-81
Connecticut	II-91
Delaware.....	II-101
District of Columbia	II-111
Florida	II-121
Georgia.....	II-131
Hawaii	II-141
Idaho.....	II-151
Illinois	II-161
Indiana.....	II-171
Iowa.....	II-181
Kansas	II-191
Kentucky	II-201
Louisiana.....	II-211
Maine	II-221
Maryland.....	II-231
Massachusetts.....	II-241
Michigan	II-251
MI: Metropolitan Detroit.....	II-261
Minnesota.....	II-271
Mississippi	II-281
Missouri	II-291
Montana	II-301
Nebraska.....	II-311
Nevada	II-321
New Hampshire.....	II-331
New Jersey	II-341
New Mexico.....	II-351
New York.....	II-361
North Carolina.....	II-371
North Dakota.....	II-381

Ohio	II-391
Oklahoma.....	II-401
Oregon	II-411
Pennsylvania.....	II-421
Rhode Island.....	II-431
South Carolina	II-441
South Dakota	II-451
Tennessee	II-461
Texas.....	II-471
Utah	II-481
Vermont.....	II-491
Virginia.....	II-501
Washington.....	II-511
WA: Seattle/Puget Sound	II-521
West Virginia.....	II-531
Wisconsin	II-541
Wyoming	II-551
UNITED STATES TERRITORY	
Puerto Rico	II-561
 CANADIAN REGISTRIES	
Alberta	II-563
British Columbia.....	II-565
Manitoba.....	II-567
New Brunswick	II-569
Newfoundland and Labrador	II-571
Northwest Territories.....	II-573
Nunavut	II-575
Ontario	II-577
Prince Edward Island.....	II-579
Saskatchewan.....	II-581
Yukon	II-583

SECTION III: Stage at Diagnosis by Age for Select Cancer Sites

Alabama.....	III-1
Alaska	III-3
Arizona.....	III-5
Arkansas	III-7
California.....	III-9
CA: Greater California	III-11
CA: Greater Bay Area	III-13
CA: Los Angeles	III-15
Colorado	III-17

Contents

Connecticut.....	III-19
Delaware.....	III-21
District of Columbia	III-23
Florida	III-25
Georgia.....	III-27
Hawaii	III-29
Idaho.....	III-31
Illinois	III-33
Indiana.....	III-35
Iowa.....	III-37
Kansas	III-39
Kentucky	III-41
Louisiana.....	III-43
Maine	III-45
Maryland	III-47
Massachusetts.....	III-49
Michigan	III-51
MI: Metropolitan Detroit.....	III-53
Minnesota.....	III-55
Mississippi	III-57
Missouri	III-59
Montana	III-61
Nebraska.....	III-63
Nevada	III-65
New Hampshire.....	III-67
New Jersey	III-69
New Mexico	III-71
New York.....	III-73
North Carolina.....	III-75
North Dakota.....	III-77
Ohio.....	III-79
Oklahoma	III-81
Oregon.....	III-83
Pennsylvania	III-85
Rhode Island.....	III-87
South Carolina.....	III-89
South Dakota.....	III-91
Tennessee	III-93
Texas	III-95
Utah.....	III-97
Vermont	III-99
Virginia	III-101
Washington	III-103
WA: Seattle/Puget Sound.....	III-105
West Virginia	III-107
Wisconsin.....	III-109
Wyoming.....	III-111

UNITED STATES TERRITORY

Puerto Rico	III-113

CANADIAN REGISTRIES

Alberta	III-114
British Columbia.....	III-115
Manitoba.....	III-116
New Brunswick	III-117
Newfoundland and Labrador	III-118
Northwest Territories.....	III-119
Nunavut	III-120
Ontario	III-121
Prince Edward Island.....	III-122
Saskatchewan.....	III-123
Yukon	III-124

All Appendices are available on the NAACCR website:

<https://www.naaccr.org/cancer-in-north-america-cina-volumes/#Appendices>



Section I

Introduction and Technical Notes



Cancer in North America: 2015-2019, Volume Two: Registry-Specific Cancer Incidence for the United States and Canada

Introduction and Technical Notes

INTRODUCTION

The North American Association of Central Cancer Registries, Inc. (NAACCR) is a professional organization that develops and promotes uniform data standards for cancer registration; provides education and training; certifies population-based registries; aggregates and publishes data from central cancer registries; and promotes the use of cancer surveillance data and systems for cancer control and epidemiologic research, public health programs, and patient care to reduce the burden of cancer in North America. NAACCR annually produces this statistical monograph on Cancer in North America (CiNA) to provide cancer incidence, mortality, and other cancer burden statistics for the United States, Canada, and North America.

Annual cancer statistics for the U.S., Canada, and North America are presented in each of the five CiNA volumes. This year marks the 32nd annual release of the series of CiNA monographs; and the 30th year CiNA has included data from both the U.S. and Canada. The *2022 CiNA Combined Monograph* includes data from 67 central population-based cancer registries: 56 from the U.S. (49 states, the District of Columbia, and Puerto Rico, plus 5 regions [California, excluding the Greater Bay area and Los Angeles, plus 4 metropolitan areas]) and 11 from Canada (9 provinces and 2 territories).

NAACCR issues an annual call for data to member registries, which submit data to support the creation of the CiNA monograph and other CiNA products (e.g., NAACCR CiNA Explorer, NAACCR CiNA Maps online query system, CiNA Public Use Dataset, CiNA Research Datasets). For more information on these products and the process for gaining access to them, please visit <https://www.naacr.org/cina-data-products-overview/>.

This monograph is a testament to the continuing commitment by population-based cancer registries throughout the U.S. and Canada to collect timely, complete, and accurate data that make this publication possible. An Editorial Board of member volunteers, with support from NAACCR staff and staff from Information Management Services, takes on the responsibility to oversee the call for data, evaluate all submissions, and make all editorial decisions in production of the monograph. The objective of this work is to provide timely and useful information on cancer burden for all geographic areas and racial/ethnic groups in the U.S. and Canada.

CONTENTS OF THE CiNA MONOGRAPH:

Volume One: Combined Cancer Incidence for the United States and Canada

Includes aggregated cancer incidence data by site, sex, race, ethnicity, and stage, including pediatric cancer and cancer by stage at diagnosis from the high-quality registries in the U.S. and Canada.

Volume Two: Registry-Specific Cancer Incidence for the United States and Canada

Includes registry-specific cancer incidence rates by cancer site, sex, race, ethnicity, and stage for all NAACCR member registries submitting data for inclusion in the monograph. To help interpret the statistics, data tables for each registry include demographic and data quality information; registry descriptions are also presented.

Volume Three: Registry-Specific Cancer Mortality for the United States and Canada

Includes registry-specific cancer death rates by cancer site, sex, race, and ethnicity.

Volume Four: Cancer Survival for the United States and Canada

Includes cancer survival data for the U.S. and Canada from 59 registries on more than 13 million cases diagnosed among North Americans between 2012 and 2018.

Volume Five: Cancer Prevalence for the United States and Canada

Includes cancer prevalence estimates for the U.S. and Canada from 59 registries on more than 18 million cases diagnosed among North Americans between 2009 and 2018.

In the U.S., cancer statistics are calculated for by race/ethnicity. The actual racial/ethnic groups vary by volume, based on data availability and statistical stability. Race and ethnicity information is not collected in Canada; therefore, Canadian data are not presented by race/ethnicity.

Rates are presented as average annual, age-adjusted rates using three different standard million populations: the 2000 U.S. (Census P25-1130), the 2011 Canadian, and the World (World Health Organization [WHO] 2000–2025) standard populations. We believe that presenting cancer rates adjusted to all three standards enhances the meaning and utility of the rates for users in the U.S., Canada, and international settings. Recent volumes of the CiNA publication, including sections containing rates standardized to the World Standard and the population counts used in the calculation of cancer rates, are available for download on the NAACCR website: <https://www.naaccr.org/cancer-in-north-america-cina-volumes>.

CiNA Volume Two: Registry-Specific Cancer Incidence for the United States and Canada

The incidence data presented in *CiNA Registry-Specific* represent 99% population coverage of the U.S. and 74% of Canada. The CiNA Registry-Specific volume is composed of three sections:

Section 1: Introduction and Technical Notes

Section 2: Average Annual Registry-Specific Cancer Incidence by Race, Ethnicity, and Sex, Age-Adjusted to the 2000 U.S. and 2011 Canadian Population Standards

Includes average annual cancer incidence counts and rates for each population-based cancer registry. The rates for the U.S. are presented by sex for all racial/ethnic groups—non-Hispanic (NH) white, NH Black, NH Asian and Pacific Islander (API), NH American Indian and Alaska Native (AI/AN) (with AI/AN data limited to purchased/referred care delivery areas [PRCDA] counties), Hispanics all races, Hispanic white, and Hispanic Black populations—for all ages combined. The rates for Canada and North America are presented for all races combined and for all ages combined. Data tables for each registry include demographic and data quality information and registry descriptions to help interpret the statistics reported.

Section 3: Stage at Diagnosis by Age for Select Cancer Sites

Includes the frequency counts, percent distribution, and age-adjusted rates of cancer by summary stage at diagnosis for female breast, prostate, lung, uterine cervix, and colorectal cancers. Data for U.S. registries are provided for all races: NH white, NH Black, NH API, NH AI/AN (with AI/AN data limited to PRCDA counties), and for all Hispanics combined.

TECHNICAL SECTION

SOURCES OF DATA

Cancer Incidence. A cancer registry must be population-based and a NAACCR member in good standing to be included in NAACCR data publications. All cancer registries in the U.S. and Canada are NAACCR members, including three territories in Canada and three U.S. territories. An annual request is sent to all members to voluntarily submit a data file for use in CiNA, CiNA research and data information products, the U.S. *Annual Report to the Nation*, and other annual publications. All NAACCR member registries receive support from their state, province, or territory to conduct surveillance activities. In the U.S., they also participate in the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program, the Centers for Disease Control and Prevention (CDC) National Program of Cancer Registries (NPCR), or both. In Canada, all registries submit data to the Canadian Cancer Registry maintained by Statistics Canada.

It should be noted that cancer incidence data for the second largest province in Canada, Quebec, are not included in CiNA products, because Quebec did not complete a data submission for the years included in current data products. Since nearly one-quarter of Canadians live in Quebec, Canadian statistics should be interpreted accordingly.

Delay Adjustment. Starting in 2015, a joint effort by NCI, CDC, and NAACCR was mounted to develop a unified approach for estimating and reporting delay-adjusted rates across all of the U.S. and Canada. The delay-adjusted rates for NAACCR registries, including SEER registries reported in the Cancer Statistics Review, are based on historic data submitted to NAACCR. Statistical models to estimate delay are estimated for each registry by age (<50, 50–69, 70+), gender (male and female) and race/ethnicity (all races combined, white, Black, API, AI/AN PRCDA region, Hispanic, NH white, and NH Black), and delay time (e.g., for the December 1, 2021, submission a delay of 2 years for diagnosis year 2019; 3 years for diagnosis year 2018). The statistical models estimate reporting delay factors by age, race, and gender for each registry, and calculating delay-adjusted rates for any grouping is done in SEER*Stat by weighting each group appropriately.¹

For the sixth year, an improved statistical model has been used for this report with the goal of producing more stable estimates.² The details of the new modeling are described elsewhere.³

For some registries, there were insufficient historical data available to calculate registry-specific delay factors. To calculate delay-adjusted national statistics, delay factors were applied to registries with missing data using an average of the U.S. or Canadian delay factors.

Population Estimates. To assist the reader, population estimates by age, sex, and race/ethnicity (where relevant) used in the calculation of rates in the monograph are available for each central registry, the U.S., and Canada. These data are available online on the NAACCR website at <https://www.naaccr.org/cancer-in-north-america-cina-volumes/#Population>.

Population estimates for 2015 through 2019 for the U.S., individual states, and SEER metropolitan areas were obtained from the SEER program. These estimates were based on U.S. Census Bureau population estimates for these years and represent a modification of the annual time series population estimates produced by the Population Estimates Program of the Census Bureau with support from NCI. The population estimates incorporate bridged, single-race estimates that are derived from the original multiple race categories in the 2010 Census. These bridged estimates are consistent with the four race groups enumerated in the 1990 Census and were produced under a collaborative arrangement between the National Center for Health Statistics and the Census Bureau. The methodology implemented by the Census Bureau to develop these county estimates is comparable to that used to produce national and state 1990–2000 intercensal estimates and is described on the Census Bureau’s website.⁴

In 2007, the U.S. Census revised its methodology for population estimation. This revision impacts all population denominators for 2015 to 2019. The main effect of this approach was on specific age groups older than 65. In many states, the new method results in a larger population increase in the younger age category and fewer in the older age category than was estimated in previous years.

NCI modifies the Census data for the population estimates for the state of Hawaii. The Epidemiology Program of the Hawai'i Cancer Research Center has developed its own set of population estimates, based on sample survey data collected by the Hawai'i Department of Health. This effort grew out of a concern that the native Hawaiian population had been vastly undercounted in previous censuses. The "Hawai'i adjustment" to the Census Bureau estimates has the net result of reducing the estimated white population and increasing the API population for the state. The Census Bureau estimates for the total population, Black population, and AI/AN populations in Hawai'i are unaffected. The details of the methodology are described elsewhere.⁵

For Canada, Statistics Canada provided the estimates of the Canadian population for all Canadian provinces and territories, adjusted for census net under coverage.

CODING, 2015-2019

Incidence Data. All cancer registries use the International Classification of Diseases for Oncology, third edition (ICD-O-3) to code the anatomic site and morphology. Cancer incidence statistics include invasive cancers only, with the exception of *in situ* cancer of the bladder. Although tables include incidence statistics for breast cancer *in situ* and benign tumors of the brain and central nervous system, these cases are not included in any counts or rates of total cancer incidence.

The SEER program Site Recode groups were used for classifying types of cancer using anatomic site and morphology. Using this standard ontology, only squamous and basal cell carcinomas of the lip and genital organs are included in the data reported. All categories used to present pediatric cancer rates in Volume One are based on the International Classification of Childhood Cancer, third edition (ICCC-3).⁶

Summary tables of all codes and site groups for incidence can be found in the electronic copy of the CiNA Monograph Appendices on the NAACCR website, <https://www.naacr.org/cancer-in-north-america-cina-volumes/#Appendices>.

Behavior Recode Selection Used in the CiNA Publication. The CiNA publication uses the SEER Behavior Recode variable for selecting tumors for inclusion. In the CiNA publication, all *in situ* cancers of the bladder are considered malignant. Invasive cancers are selected based on the Behavior Recode variable values "Malignant", "Only malignant in ICD-O-3", and "Only malignant 2010+". For some statistics, noninvasive breast (Behavior Recode variable equals "*in situ*") and non-malignant brain and other central nervous system (Behavior Recode variable "Benign or borderline malignancy") statistics are available. For more details on the categories, how they are defined, and how the Behavior Recode variable is derived, see <https://seer.cancer.gov/behavrecode>.

Summary Stage Used in the CiNA Publication.

In this year's call for data, Derived Summary Stage 2000 (data item 3020) was reported for diagnosis years 2004–2014. The SEER Summary Stage 2000 field (data item 759) was reported for diagnosis years 2015–2017, and the Summary Stage 2018 (data item 764) was reported for diagnosis year 2018. Some registries continue to record and report this information for years outside of these ranges. In addition, for cases from 2018 forward, Canadian registries reported stage by the American Joint Committee on Cancer TNM Staging System only. For Canadian registries, we used logic based on 2016–2017 data used in the SEER Registrar Staging Assistant (SEER*RSA) to determine combined T, N, and M. Additional logic was applied to generate a Summary Stage from combined TNM. In some cases, the TNM data are not descriptive enough to determine a single Summary Stage, so these cases are reported in a combined stage group.

The CiNA publication presents data from 2014 to 2018, a time frame that spans both reporting diagnosis years for Derived Summary Stage 2000 and SEER Summary Stage 2000. For diagnosis years 2013–2014, the Derived Summary Stage 2000 field was used. If the field was blank or unknown, then the SEER Summary Stage 2000 value was used as long as it was not blank or unknown. For diagnosis years 2015–2017, SEER Summary Stage 2000 was used. If that field was blank or unknown, then the Derived Summary Stage 2000 value was used, as long as it was not blank or unknown. For diagnosis year 2018–2019, Summary Stage 2018 was used for U.S. registries.

Hispanic/Latino Ethnicity Identification. The ethnicity available in medical records and reported to cancer registries is enhanced using the NAACCR Hispanic Identification Algorithm, version 2 (NHIAv2). The NHIAv2

method is described in detail elsewhere.⁷ NHIAv2 uses a combination of NAACCR variables, including direct identification of ethnicity from the Spanish/Hispanic Origin variable (NAACCR data element 190 values 1–6, 8) and information indirectly derived based on an evaluation of the strength of birthplace, race, and surname (including maiden name when available) associations with Hispanic ethnicity status. After applying NHIAv2, cases not ultimately classified as Hispanic are classified as non-Hispanic, leaving no cases with “unknown” Hispanic status. The NHIAv2 algorithm allows the user to run the program using one of three possible options:

- 1) All Records: Surname portion is run on 0 (non-Hispanic), 7 (surname only), and 9 (unknown) for all counties. After the algorithm, item 190 codes (0, 7, 9) are either NHIA – Hispanic or non-Hispanic.
- 2) Option 1: (the default) For counties with 5% or more Hispanics, the surname portion is run the same as for the “all records” option. For counties with fewer than 5% Hispanics, surname portion is run on 7 (surname only) and 9 (unknown). After the algorithm, item 190 codes (7, 9) are either NHIA – Hispanic or non-Hispanic.
- 3) Option 2: For counties with 5% or more Hispanics, the surname portion is run the same as for the “all records” option. For counties with fewer than 5% Hispanics, surname portion is run on 7 (surname only). These become either NHIA - Hispanic or non-Hispanic. All cases coded to 9 on item 190 are converted to NHIA – non-Hispanic.

A comparison of the direct and indirect categorization of Hispanic ethnicity is provided in Appendix F, which is available on the NAACCR website: <https://www.naacr.org/cancer-in-north-america-cina-volumes/#Appendices>.

API Identification. The information on API populations is also enhanced by submitting registries using a NAACCR-developed algorithm.⁸ The NAACCR API Identification Algorithm version 1 (NAPIIA v1.2.1) uses a combination of NAACCR variables to classify cases directly or indirectly as API for analytic purposes. It is focused on coding cases with a race code of Asian NOS (race code 96) or Pacific Islander NOS (race code 97) to a more specific API race category, using birthplace and name fields (first, last, and maiden names). Birthplace can be used to indirectly assign a specific race to one of eight Asian groups (Chinese, Japanese, Vietnamese, Korean, Asian Indian, Filipino, Thai, and Cambodian) and three Pacific Islander groups (Samoan, Micronesian, and Polynesian). Names can be used to indirectly assign a specific race to one of seven Asian groups (Chinese, Japanese, Vietnamese, Korean, Asian Indian, Filipino, and Hmong) and three Pacific Islander groups (Hawaiian, Guamanian, and Samoan). The algorithm uses the following NAACCR standard variables: Race 1 through Race 5 (NAACCR Items 160 through 164), Name – Last (NAACCR Item 2230), Name – First (NAACCR Item 2240), Name – Maiden (NAACCR Item 2390), Birthplace (NAACCR Item 250), and Sex (NAACCR Item 220).

In addition, U.S. Census Bureau estimates of API population have historically been overestimated, inflating Hispanic API population denominators and artificially reducing rates for API populations. For the first time in CiNA publications, to attempt to address this issue, we present non-Hispanic API rates only. This results in slightly higher, but more accurate, API rates between previous editions of the *CiNA Monograph* and other CiNA data products, and the present versions.

AI/AN Misclassification and Underlying Population Data. The collection of accurate information on the cancer incidence in AI/AN populations is hampered by misclassification of this population within cancer case reports.⁹ To address this problem, cancer registries in the U.S. coordinate with CDC and the Bureau of Indian Affairs to link their case files to the enrollment files of the Indian Health Service.⁹ This process identifies significant numbers of AI/AN who were otherwise classified within the cancer case report. The improved information on this population enables calculation of much more accurate cancer incidence rates. As presented in the incidence volumes, the data on AI/AN are restricted to those counties where Indian Health Service Clinics are located, namely PRCDA counties (previously known as the Contract Health Service Delivery Area [CHSDA] counties)—with the exception of data from Kansas and Minnesota due to limitations in county-level reporting from those states). This restriction ensures that the incidence data presented are the best available data for this population.

In addition, U.S. Census Bureau estimates of Hispanic AI/AN population have historically been overestimated, inflating Hispanic AI/AN population denominators and artificially reducing rates for AI/AN populations. For

the first time in CiNA publications, to attempt to address this issue, we present non-Hispanic AI/AN rates only. For this reason, there is a notable increase in AI/AN rates between previous editions of the *CiNA Monograph* and other CiNA data products, and the present versions. This does not reflect additional risk of cancer for AI/AN populations, merely a more accurate depiction of the burden of cancer among AI/AN people.

DATA QUALITY INDICATORS AND REGISTRY INCLUSION

NAACCR assesses the quality of cancer incidence data from individual registries using several data quality indicators, which are described in detail below. Results for these indicators can be found in the *Cancer in North America, 2015–2019* Appendices on the NAACCR website (<https://www.naaccr.org/cancer-in-north-america-cina-volumes/#Appendices>). A dash in the tables indicates that data were not submitted for the year or were not able to be calculated.

In order to be included in the NAACCR combined rates presented in *CiNA Combined*, the data had to meet the criteria for high-quality incidence data based on the 5 years combined.

- Data for 2015 through 2019 had to be submitted to NAACCR by December 1, 2021.
- The estimate of duplicate case reports had to be fewer than 2 duplicate reports per 1,000 cases.
- All cases had to pass the edits on variables needed to compute cancer incidence rates by site, sex, race, and tumor descriptions on the NAACCR Call for Data EDITS metafile.
- Less than 3% of cases had missing information for sex, county of residence at diagnosis, and age at diagnosis, and less than 5% of the cases had an unknown race.
- Death clearance must be completed for 2015 through 2019 mortality with the percent of all cases derived from death certificates only (DCOs) of less than 5%.
- The NAACCR method to estimate completeness of case ascertainment yielded an estimate of 90% or higher. The 5-year completeness estimate was based on the average of completeness for each of the five years.
- All cases had to pass the inter-record edits on cases reporting multiple primary cancers, as determined by the standard inter-record EDITS program developed for the NAACCR Call for Data submissions.

If a registry does not meet the criteria above for the 5-year aggregated data, only years that meet the criteria are included (as long as there are 3 years that meet the criteria). When this is the case, the average annual counts and rates are based on the 3 or 4 years of data meeting the high-quality criteria. This ensures the most accurate national-level average case counts and rates.

To be included in the combined stage data, the registry must meet the requirements for being included in the combined rates (above), submit stage data for all years 2013 through 2017, and provide the derived summary stage field in their submission.

To be included in the delay-adjusted data, the registry must meet the requirements for being included in the combined rates, have submitted data for all years 2013 through 2017, and have provided the data needed to calculate the delay factors.

Duplicate Case Records. Central cancer registries rely on multiple reporting sources for cancer case reports. At the central cancer registry, multiple reports for the same patient must then be matched and the information from all records consolidated. In addition to determining whether multiple reports refer to the same individual, central cancer registry staff must also determine whether the tumor represents a new primary tumor or a duplicate report for a tumor already recorded. Failure to eliminate duplicate cases and duplicate tumors results in over-counting cancer cases. As a part of routine cancer registry operations, a variety of tools are used to ensure accurate case linkage and case consolidation. As part of the preparation of the data submission to NAACCR, each registry uses the NAACCR protocol to determine the adequacy of case linkage and consolidation operations in identifying duplicate records.

The NAACCR protocol for assessing duplicate cases can be found on the NAACCR website.¹⁰

Completeness of Case Ascertainment. To evaluate case completeness for all geographic areas included in this monograph, the NAACCR Method to Estimate Completeness is used. The method is described in detail elsewhere,¹¹ and a data analysis tool is available on the NAACCR website.¹² The tool documents and calculates

sex-, race-, and site- specific estimates based on observed incidence counts and rates, observed local cancer death rates, and a standard rate ratio of incidence to mortality. In addition, adjustments are made to the calculations to account for some variation in sex-, race- and site-specific variation in case fatality. The method assumes that the relationship between incidence rates and mortality rates are stable. However, with the recent annual decreases in cancer death rates and the awareness that the decreases are not the same in all parts of the U.S. and Canada, it appears that this assumption is being challenged with a noticeable bias in an upward migration of completeness estimates for many locales.

The completeness estimates provided in this publication used mortality data for the years 2013–2017 to determine completeness in U.S. registries and Canadian registries. The percent completeness presented for each registry and used to determine inclusion of individual registry data in the combined rates presented in Volume One were based on the average of the annual rate ratios for 2013–2017 of SEER 11 incidence rates divided by U.S. mortality rates.

Missing Case Information. NAACCR has developed standards for completeness of data on key data items that are needed to produce meaningful cancer incidence statistics. These key data items include race, sex, county of residence at diagnosis, and age at diagnosis. Cases with unknown sex or age were omitted from all calculations. Cases with unknown race and county of residence were included in the cancer counts and rates for all races and/or all counties combined.

DCO Cases. The proportion of cases identified by DCO is an indicator of data quality and completeness. Central cancer registries use death certificates to identify potentially missed cases and to conduct follow-back on cases that have cancer on the death certificate but are not incident cases in the registry. Cases without follow-back information are considered DCO cases and may have incomplete or missing information, including date of diagnosis and stage at diagnosis. For DCO cases, the date of death is used as the date of diagnosis. Registries that did not use death certificates as a source of case ascertainment have “na” listed in the DCO row on the registry description page.

Data Reliability and Accuracy. All data submitted to NAACCR are evaluated for reliability and accuracy using the EDITS program and a specific set of edits incorporated into a Call for Data Edits metafile. An edit reviews the internal consistency between and among data elements, such as anatomic site and morphology. Cases that are identified as having errors are reviewed by registry staff and resolved prior to their NAACCR submission.

The NAACCR Call for Data EDITS metafile is available on the NAACCR website here: <https://www.naaccr.org/call-for-data/#datatools>. An inter-record edits program developed by CDC is used to identify errors among the records reported for persons who have had multiple tumors diagnosed. For example, an inter-record edit will identify whether the birthplace is the same on all reports of multiple tumors that are reported for one individual.

Timeliness of Data. The NAACCR standard defines timely data as data that are available for use in incidence statistics within 23 months of the close of a diagnostic year (e.g., December 3, 2019, for all cases diagnosed in 2017).

Site-Specific Microscopic Confirmation. This criterion is not used by NAACCR to determine high quality for the purposes of this publication. However, it is a useful indicator of quality of data collection. A proportion of microscopically confirmed cases that is too high or low may suggest problems in case ascertainment or abstracting. However, this proportion varies by cancer site. For sites that are more likely to rely on a clinical or radiological diagnosis (e.g., cancers of the pancreas and brain) confirmation rates that are too high may suggest that some clinically diagnosed cases are missing. Also, registries that do not use death certificates for case-finding have an artificially high proportion of microscopically confirmed cases, because DCO cases by definition do not have information on whether the tumor was microscopically confirmed. Although no NAACCR standard has been determined for microscopic confirmation, the guideline used is that the proportion should fall between 92% and 96% of all cancer cases, based on the experience of the SEER program.

CALCULATION OF STATISTICS

Counts. Counts are the average annual count rounded to nearest whole number. Cell suppression rules were applied based on the 5-year aggregate count. Due to operational and population displacement issues related to Hurricane Maria, average annual 5-year counts include an estimate for 2017 based on data from the first half of the calendar year.

Rates. Rates are per 100,000 population and are age-adjusted by 20 five-year age groups to the 2000 U.S. standard population based on single years of age,^{13,14} the 2011 Canadian population standard,¹⁵ and to the World (WHO 2000–2025) population standard.¹⁶ Rates for children and adolescents are expressed per million population. The incidence and death rates in this monograph are annual averages for the period 2015 through 2019.

The age distributions of the three population standards are as follows:

AGE GROUP	2000 U.S.	2011 CAN	WORLD
00 years	3,794,901	376,321	17,917
01–04 years	15,191,619	1,522,743	70,652
05–09 years	19,919,840	1,810,433	86,870
10–14 years	20,056,779	1,918,164	85,970
15–19 years	19,819,518	2,238,952	84,670
20–24 years	18,257,225	2,354,354	82,171
25–29 years	17,722,067	2,369,841	79,272
30–34 years	19,511,370	2,327,955	76,073
35–39 years	22,179,956	2,273,087	71,475
40–44 years	22,479,229	2,385,918	65,877
45–49 years	19,805,793	2,719,909	60,379
50–54 years	17,224,359	2,691,260	53,681
55–59 years	13,307,234	2,353,090	45,484
60–64 years	10,654,272	2,050,443	37,187
65–69 years	9,409,940	1,532,940	29,590
70–74 years	8,725,574	1,153,822	22,092
75–79 years	7,414,559	919,338	15,195
80–84 years	4,900,234	701,140	9,097
85–89 years	2,678,567	426,739	4,398
90+ years	1,580,606	216,331	1,950
Total	274,633,642	34,342,780	1,000,000

Due to operational and population displacement issues related to Hurricane Maria, rates for Puerto Rico are calculated based on data only from the first half of the calendar for 2017.

Standard Errors. Standard errors (S.E.) of the rates were calculated using the following formula:

$$S.E. = \sqrt{\sum \frac{w_j^2 n_j}{p_j^2}}$$

where w_j = the fraction of the standard population in age group j , n_j = number of cases or deaths in that age group, and p_j = person-years denominator.¹⁷ For many registries, S.E. of the rates are small, because the population covered is large. However, for registries that cover a small population, the S.E. may be substantial.

Confidence Intervals. Although not reproduced in the printed monograph, bar charts of the registry-specific, age-adjusted rates with 95% confidence intervals¹⁸ are available on the NAACCR website

(<https://www.naaccr.org/cancer-in-north-america-cina-volumes/#Appendices>). The confidence intervals allow the user to assess the precision of the estimate and is an approximate and conservative indicator of whether a registry's rate is statistically higher or lower than the rate for the combined U.S., based on whether the upper or lower limit of the confidence interval overlaps the 95% confidence interval for the U.S.

Comparison of Rates. In addition to true regional variation in cancer risk, differences in cancer incidence or mortality rates between areas may be due to either differences in the demographic makeup of the population or differences in data quality. In making valid comparisons of cancer incidence rates among registries, it is important to review the data quality indicators for each registry and consider differences in the racial composition of the populations being compared before conclusions are drawn about variations in regional rates. Interpretation without consideration of these factors may contribute to misleading or inaccurate conclusions.

The S.E. of adjusted rates can be used to evaluate the statistical significance of rate differences among comparable populations. For example, if the adjusted rates in two populations are R_1 and R_2 and their standard errors are $S.E._1$ and $S.E._2$, an approximate confidence interval for the rate ratio can be calculated using the following formula:

$$(R_1/R_2)^{1 \pm z/x}$$

where $x = (R_1 \pm R_2) / \sqrt{(S.E._1^2 + S.E._2^2)}$ and $z = 1.96$ for 95% limits.¹⁹ If this interval does not include one, the two rates are statistically significantly different at a p value of 0.05. This test can be inaccurate for rates based on fewer than 16 cases or deaths, and it should not be used for rates based on fewer than 6 cases or deaths. It should be emphasized that this kind of comparison of adjusted rates must be undertaken with caution, because misleading conclusions may be drawn if the ratios of the age-specific rates in the two populations are not constant in all age groups. In these circumstances, the ratios of the adjusted rates will vary according to the standard populations used.²⁰

Cell Suppression. Counts and rates were suppressed (indicated by “*”) in the tables if the race, gender, and site-specific number of cases for incidence was less than six or when the number of deaths was less than 10. Complementary cell suppression was employed, when necessary, to prevent the contents of a single suppressed cell from being calculated. These counts are included in the calculation of all sites combined. “N/A” is used to indicate not applicable, as in the gender-specific cancers. If the rate was less than 0.05 per 100,000, the rate is listed as 0.0.

SEER*Stat Variables. The following SEER*Stat variables were used to create the statistics for the registry incidence pages: Year of Diagnosis, NAACCR Registry, Sex, Race Recode (W, B, AI, API) IHS Modified, PRCDA 2016, NHIAv2 Recode, Site Recode ICD-O-3/WHO 2008, and Behavior Recode for analysis.

REFERENCES

1. Midthune DN, Fay MP, Clegg LX, Feuer EJ. Modeling reporting delays and reporting corrections in cancer registry data. *J Am Stat Assoc* 2005;100(469):61-70.
Abstract available here: <https://www.tandfonline.com/doi/abs/10.1198/016214504000001899>.
2. Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF. Impact of reporting delay and reporting error on cancer incidence rates and trends. *J Natl Cancer Inst* 2002;94:1537-45.
Available here: <https://pubmed.ncbi.nlm.nih.gov/12381706/>.
3. SEER Delay Model. Available here: <http://www-surveillance.cancer.gov/delay>.
4. National Center for Health Statistics. U.S. Census Populations with Bridged Race Categories. September 2003. Available here: https://www.cdc.gov/nchs/nvss/bridged_race.htm.
5. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK (eds). SEER Cancer Statistics Review, 1975–2006, National Cancer Institute. Bethesda, MD, based on November 2008 SEER data submission, posted to the SEER web site, 2009.
Available here: https://seer.cancer.gov/archive/csr/1975_2006.

6. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, Third Edition. *Cancer* 2005;103:1457-67. Available here: <https://pubmed.ncbi.nlm.nih.gov/15712273/>.
7. NAACCR Latino Research Work Group. *NAACCR Guideline for Enhancing Hispanic/Latino Identification: Revised NAACCR Hispanic/Latino Identification Algorithm [NHIA v2]*. Springfield, IL: North American Association of Central Cancer Registries. September 2005. Available here: https://www.naaccr.org/wp-content/uploads/2016/11/NHIA_v2_2_1_09122011.pdf.
8. NAACCR Race and Ethnicity Work Group. *NAACCR Asian Pacific Islander Identification Algorithm [NAPIIA v1.2.1]*. Springfield, IL: North American Association of Central Cancer Registries, September 2010.
9. Espey DK, Wiggins CL, Jim MA, Miller BA, Johnson CJ, Becker TM. Methods for improving cancer surveillance data in American Indian and Alaska Native populations. *Cancer* 2008;113(5 Suppl):1120-30. Available here: <https://pubmed.ncbi.nlm.nih.gov/18720372/>.
10. NAACCR Duplicate Protocol. Available here: <https://www.naaccr.org/call-for-data>.
11. Wu XC, Hotes J, Fulton JP, Cormier M, Correa C, McLaughlin CC, Kosary C, Howe HL, Chen VW (eds). *Cancer in North America, 1996–2000, Volume One: Introduction and Technical Notes, Incidence*. April 2002.
12. NAACCR Method to Estimate Completeness. A Data Analysis Tool for Calculations. Available here: <https://www.naaccr.org/analysis-and-data-improvement-tools/#COMPLETENESS>.
13. SEER. 2000 U.S. Standard Population vs. Standard Million. 13 December 2004. Available here: https://seer.cancer.gov/stdpopulations/single_age.html.
14. Day JC. *Population Projections of the United States by Age, Sex, Race, and Hispanic Origin: 1995 to 2050*, U.S. Bureau of the Census, Current Population Reports, P25-1130, U.S. Government Printing Office, Washington, DC, 1996. Available here: <https://www.census.gov/content/dam/Census/library/publications/1996/demo/p25-1130.pdf>.
15. 2011 Canadian Standard Population. Statistics Canada, Table 051-0001 – Estimates of population, by age group and sex for July 1, Canada, provinces and territories, annual (persons unless otherwise noted). CANSIM (database). Available here: <http://www5.statcan.gc.ca/cansim/a26?id=510001>.
16. Ahmad O, Boschi-Pinto C, Lopez A, Murray C, Lozano R, Inoue M. Age Standardization of Rates: A New WHO Standard. GPE Discussion Paper Series: No. 31. World Health Organization 2001. Available here: https://qmul.ac.uk/pluginfile.php/154532/mod_book/chapter/3129/Age%20standardization%20of%20rates.pdf.
17. Breslow NE and Day NE. Statistical Methods in Cancer Research. Vol. II. 1987. International Agency for Research on Cancer: Lyon, France. Anderson RN, Minino AM, Hoyert DL, Rosenberg HM. Comparability of cause of death between ICD-9 and ICD-10: Preliminary estimates. *National Vital Statistics Reports* 2001;49:1-32. Available here: <http://www.medicine.mcgill.ca/epidemiology/hanley/bios602/b-d-II-ch-1-2-3/Breslow-Day-vol-II-ch-0.pdf>.
18. Tiwari RC, Clegg LX, Zou Z. Efficient interval estimation for age-adjusted cancer rates. *Stat Methods Med Res* 2006;15:547-69. Abstract available here: <https://pubmed.ncbi.nlm.nih.gov/17260923/>.
19. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. *Cancer Incidence in Five Continents*. Vol. VIII. 2002. International Agency for Research on Cancer: Lyon, France.
20. Esteve J, Benhamou E, Raymond L. Statistical Methods in Cancer Research. Vol. V. 1994. International Agency for Research on Cancer: Lyon, France.



Section II

Average Annual Registry-Specific Cancer Incidence by Race, Ethnicity and Sex


Age-Adjusted to the 2000 U.S. and
2011 Canadian Population Standards



Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	4,854,803	4,866,824	4,877,989	4,891,628	4,907,965
Non-Hispanic White	3,246,198	3,244,716	3,243,497	3,244,122	3,248,685
Non-Hispanic Black	1,307,931	1,313,183	1,318,226	1,323,186	1,327,611
Non-Hispanic Asian/Pacific Islander (NH API)	73,308	75,951	78,100	79,456	81,026
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	7,297	7,395	7,474	7,453	7,493


All Races Population 2015–2019: 24,399,209
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	198,121	203,666	208,724	215,281	220,789
Hispanic White	170,069	174,930	179,434	185,145	190,026
Hispanic Black	16,262	16,610	16,897	17,288	17,656

Hispanic/Latino Population, Census 2010: 185,602
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

ALABAMA CANCER REGISTRY

Initial Operation: 1996
Population-based Data Available: 1996
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	102.3	104.5	102.5	102.1	102.3	102.7
Missing Race	0.9	1.4	1.9	1.6	1.8	1.5
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.7	0.7	0.7	0.4	0.3	0.6
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.4	2.1	2.1	2.3	1.7	2.1
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	90.8	Ovary	88.3
Oral Cavity & Pharynx	94.7	Prostate	94.7
Esophagus	91.3	Testis	96.8
Stomach	93.7	Bladder (incl. <i>in situ</i>)	97.0
Colon & Rectum	94.3	Kidney & Renal Pelvis	90.7
Liver	50.3	Brain & Other CNS	77.1
Pancreas	80.8	Brain & Other CNS (non-malig)	45.3
Lung & Bronchus	86.0	Thyroid	98.1
Melanomas of the Skin	96.4	Hodgkin Lymphoma	97.8
Female Breast (excl. <i>in situ</i>)	96.3	Non-Hodgkin Lymphoma	94.8
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	87.4
Cervix Uteri	87.9	Leukemias	86.1
Uterus Corpus & Uterus NOS	97.7		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Alabama, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	14,432	514.2	1.97	615.2	2.32	12,975	406.5	1.65	474.3	1.89
Oral Cavity & Pharynx	560	19.7	0.38	23.9	0.46	227	7.0	0.22	8.3	0.25
Lip	32	1.2	0.10	1.4	0.11	20	0.6	0.06	0.7	0.07
Tongue	168	5.8	0.20	7.1	0.25	61	1.9	0.11	2.3	0.13
Major salivary gland	55	2.1	0.13	2.4	0.15	34	1.1	0.09	1.3	0.10
Floor of mouth	25	0.9	0.08	1.0	0.10	10	0.3	0.04	0.4	0.05
Gum & other mouth	60	2.2	0.13	2.6	0.15	47	1.4	0.10	1.7	0.11
Nasopharynx	18	0.7	0.08	0.8	0.08	8	0.2	0.04	0.3	0.05
Oropharynx	39	1.3	0.10	1.6	0.12	11	0.3	0.05	0.4	0.06
Hypopharynx	30	1.0	0.08	1.3	0.10	6	0.2	0.04	0.2	0.04
Digestive System	2,810	101.1	0.88	121.4	1.04	2,241	68.2	0.66	80.5	0.77
Esophagus	233	8.1	0.24	9.8	0.29	53	1.6	0.10	1.9	0.12
Stomach	237	8.6	0.26	10.3	0.30	169	5.2	0.18	6.1	0.21
Small intestine	79	2.9	0.15	3.4	0.17	75	2.4	0.13	2.8	0.14
Colon (excl. rectum)	943	34.7	0.52	41.1	0.61	919	28.2	0.43	33.1	0.50
Rectum & rectosigmoid	384	14.0	0.33	16.8	0.39	287	9.1	0.25	10.7	0.29
Anus, anal canal, & anorectum	38	1.4	0.11	1.7	0.12	76	2.3	0.12	2.8	0.15
Liver	338	11.2	0.28	14.2	0.35	124	3.7	0.15	4.3	0.18
Gallbladder	15	0.6	0.07	0.7	0.08	38	1.1	0.08	1.3	0.10
Pancreas	429	15.4	0.34	18.5	0.41	388	11.4	0.27	13.6	0.31
Respiratory System	2,499	87.6	0.81	105.6	0.96	1,791	51.5	0.55	62.2	0.66
Larynx	209	7.0	0.22	8.8	0.28	49	1.4	0.10	1.8	0.12
Lung & bronchus	2,259	79.4	0.77	95.5	0.91	1,720	49.4	0.54	59.6	0.65
Bones & Joints	32	1.3	0.11	1.4	0.11	24	0.9	0.08	0.9	0.08
Soft Tissue (incl. heart)	108	4.3	0.19	4.8	0.21	93	3.2	0.15	3.5	0.16
Skin (excl. basal & sq.)	812	30.6	0.50	35.7	0.57	575	19.4	0.38	21.9	0.41
Melanoma of the skin	766	28.8	0.48	33.5	0.55	544	18.4	0.37	20.7	0.40
Breast (excl. <i>in situ</i>)	42	1.5	0.11	1.8	0.13	3,872	122.9	0.92	144.1	1.05
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,389	45.1	0.56	52.2	0.64
Cervix uteri	N/A	N/A	N/A	N/A	N/A	241	9.5	0.28	10.0	0.29
Uterus corpus	N/A	N/A	N/A	N/A	N/A	642	19.5	0.36	23.6	0.42
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	32	1.0	0.08	1.2	0.09
Ovary	N/A	N/A	N/A	N/A	N/A	337	10.6	0.27	12.4	0.31
Male Genital System	3,856	129.3	0.96	159.3	1.16	N/A	N/A	N/A	N/A	N/A
Prostate	3,731	123.9	0.93	153.8	1.14	N/A	N/A	N/A	N/A	N/A
Testis	94	4.2	0.20	4.2	0.19	N/A	N/A	N/A	N/A	N/A
Penis	25	0.9	0.09	1.1	0.10	N/A	N/A	N/A	N/A	N/A
Urinary System	1,558	57.3	0.67	67.7	0.78	697	21.2	0.37	24.9	0.43
Bladder (incl. <i>in situ</i>)	835	31.1	0.49	36.6	0.58	257	7.5	0.21	8.9	0.25
Kidney & renal pelvis	695	25.2	0.44	29.9	0.51	422	13.2	0.30	15.5	0.34
Ureter	19	0.7	0.08	0.8	0.09	12	0.3	0.04	0.4	0.05
Eye & Orbit	28	1.1	0.09	1.2	0.11	20	0.6	0.07	0.7	0.07
Brain & Other CNS	199	7.5	0.25	8.4	0.27	162	5.5	0.20	5.9	0.21
Brain	190	7.2	0.24	8.0	0.26	150	5.0	0.19	5.5	0.20
Endocrine System	151	5.8	0.22	6.5	0.24	414	15.3	0.35	16.7	0.37
Thyroid gland	126	4.8	0.20	5.5	0.22	390	14.5	0.34	15.8	0.36
Lymphomas	583	22.2	0.42	25.5	0.48	479	15.1	0.32	17.3	0.36
Hodgkin lymphoma	62	2.6	0.15	2.7	0.16	57	2.3	0.14	2.3	0.14
Non-Hodgkin lymphoma	521	19.6	0.40	22.8	0.45	422	12.9	0.29	15.0	0.33
Multiple Myeloma	244	8.8	0.26	10.5	0.31	212	6.2	0.20	7.4	0.23
Leukemias	416	16.0	0.36	18.0	0.40	318	10.1	0.26	11.4	0.29
Acute lymphocytic	41	1.8	0.13	1.6	0.11	25	1.1	0.10	1.0	0.09
Chronic lymphocytic	150	5.5	0.21	6.5	0.24	99	2.9	0.13	3.4	0.16
Acute myeloid	111	4.3	0.19	4.9	0.21	97	3.1	0.15	3.5	0.16
Chronic myeloid	56	2.1	0.13	2.4	0.15	52	1.7	0.11	1.9	0.12
Other leukemias	58	2.3	0.14	2.6	0.16	45	1.4	0.10	1.6	0.11
Mesothelioma	29	1.1	0.09	1.3	0.11	8	0.2	0.04	0.3	0.04
Kaposi Sarcoma	9	0.4	0.06	0.4	0.06	*	*	*	*	*
Ill-Defined & Unknown	496	18.6	0.38	21.7	0.44	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	176	6.8	0.24	7.7	0.26	355	11.6	0.29	13.3	0.32
Breast (<i>in situ</i>)	4	0.2	0.04	0.2	0.04	747	23.7	0.40	28.0	0.47

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Alabama, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	10,718	504.2	2.25	600.6	2.64	9,642	416.7	2.00	485.2	2.27
Oral Cavity & Pharynx	459	21.4	0.46	26.1	0.55	179	7.6	0.27	8.9	0.31
Lip	29	1.4	0.12	1.6	0.14	18	0.7	0.08	0.8	0.09
Tongue	143	6.6	0.25	8.1	0.31	52	2.3	0.15	2.7	0.17
Major salivary gland	46	2.2	0.15	2.6	0.17	24	1.1	0.11	1.2	0.11
Floor of mouth	20	0.9	0.10	1.1	0.11	8	0.3	0.05	0.4	0.06
Gum & other mouth	47	2.2	0.15	2.7	0.18	36	1.4	0.11	1.7	0.13
Nasopharynx	13	0.7	0.09	0.7	0.09	4	0.2	0.04	0.2	0.05
Oropharynx	30	1.4	0.11	1.7	0.14	9	0.4	0.06	0.5	0.07
Hypopharynx	22	1.0	0.09	1.2	0.12	4	0.2	0.04	0.2	0.05
Digestive System	2,069	98.1	1.00	117.7	1.18	1,569	64.8	0.77	76.3	0.88
Esophagus	184	8.5	0.29	10.3	0.34	36	1.4	0.11	1.7	0.13
Stomach	155	7.3	0.27	8.6	0.31	100	4.2	0.20	4.9	0.22
Small intestine	56	2.8	0.17	3.3	0.20	47	2.0	0.14	2.3	0.16
Colon (excl. rectum)	684	33.1	0.59	39.3	0.68	652	27.2	0.50	31.8	0.57
Rectum & rectosigmoid	294	14.3	0.39	17.2	0.46	204	8.9	0.29	10.5	0.34
Anus, anal canal, & anorectum	26	1.3	0.12	1.5	0.14	63	2.7	0.16	3.3	0.19
Liver	244	10.8	0.32	13.6	0.39	90	3.6	0.18	4.2	0.20
Gallbladder	11	0.5	0.07	0.6	0.09	24	1.0	0.09	1.1	0.11
Pancreas	328	15.3	0.39	18.4	0.46	269	10.5	0.30	12.5	0.35
Respiratory System	1,936	88.4	0.92	106.2	1.10	1,461	56.5	0.68	68.4	0.82
Larynx	148	6.6	0.25	8.2	0.31	39	1.6	0.12	2.0	0.15
Lung & bronchus	1,767	80.6	0.88	96.7	1.04	1,406	54.2	0.66	65.6	0.80
Bones & Joints	24	1.3	0.12	1.4	0.13	17	0.9	0.11	0.9	0.10
Soft Tissue (incl. heart)	81	4.3	0.22	4.8	0.24	61	2.9	0.18	3.2	0.19
Skin (excl. basal & sq.)	793	39.2	0.65	45.7	0.74	555	26.9	0.55	30.2	0.59
Melanoma of the skin	752	37.2	0.63	43.3	0.72	530	25.9	0.54	29.0	0.58
Breast (excl. <i>in situ</i>)	31	1.5	0.12	1.8	0.14	2,798	122.1	1.09	143.2	1.25
Female Genital System	N/A	N/A	N/A	N/A	N/A	987	45.2	0.68	52.1	0.76
Cervix uteri	N/A	N/A	N/A	N/A	N/A	154	9.2	0.35	9.6	0.35
Uterus corpus	N/A	N/A	N/A	N/A	N/A	453	19.5	0.43	23.3	0.50
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	17	0.7	0.09	0.9	0.10
Ovary	N/A	N/A	N/A	N/A	N/A	256	11.0	0.33	12.9	0.37
Male Genital System	2,402	106.3	1.00	129.8	1.20	N/A	N/A	N/A	N/A	N/A
Prostate	2,301	99.9	0.95	123.2	1.16	N/A	N/A	N/A	N/A	N/A
Testis	78	5.3	0.28	5.3	0.27	N/A	N/A	N/A	N/A	N/A
Penis	20	0.9	0.10	1.1	0.11	N/A	N/A	N/A	N/A	N/A
Urinary System	1,279	61.3	0.79	72.4	0.92	521	21.8	0.45	25.5	0.51
Bladder (incl. <i>in situ</i>)	726	34.5	0.59	40.7	0.69	205	8.0	0.26	9.4	0.30
Kidney & renal pelvis	528	25.6	0.52	30.3	0.60	303	13.3	0.36	15.5	0.41
Ureter	18	0.8	0.09	1.0	0.11	11	0.4	0.06	0.5	0.07
Eye & Orbit	26	1.4	0.12	1.5	0.14	17	0.7	0.08	0.9	0.10
Brain & Other CNS	161	8.4	0.31	9.3	0.33	129	6.2	0.26	6.7	0.27
Brain	154	8.0	0.30	8.9	0.33	121	5.8	0.25	6.3	0.26
Endocrine System	118	6.3	0.27	7.1	0.30	312	17.4	0.47	18.7	0.48
Thyroid gland	103	5.5	0.25	6.2	0.28	299	16.7	0.46	17.9	0.47
Lymphomas	462	23.0	0.49	26.6	0.56	363	15.6	0.38	17.8	0.43
Hodgkin lymphoma	40	2.4	0.17	2.5	0.18	35	2.1	0.17	2.2	0.17
Non-Hodgkin lymphoma	421	20.6	0.46	24.1	0.53	328	13.4	0.35	15.7	0.40
Multiple Myeloma	150	7.1	0.27	8.4	0.31	108	4.2	0.18	5.0	0.22
Leukemias	308	15.8	0.42	17.8	0.46	229	10.1	0.32	11.3	0.34
Acute lymphocytic	32	2.2	0.17	1.9	0.15	20	1.4	0.14	1.2	0.12
Chronic lymphocytic	106	5.0	0.22	6.0	0.26	72	2.8	0.15	3.3	0.18
Acute myeloid	91	4.6	0.23	5.3	0.25	76	3.4	0.19	3.8	0.20
Chronic myeloid	35	1.8	0.14	2.0	0.15	30	1.4	0.12	1.5	0.13
Other leukemias	44	2.3	0.16	2.6	0.18	31	1.2	0.10	1.4	0.12
Mesothelioma	26	1.3	0.11	1.5	0.13	6	0.2	0.05	0.3	0.05
Kaposi Sarcoma	4	0.2	0.05	0.2	0.06	*	*	*	*	*
Ill-Defined & Unknown	388	18.9	0.44	22.2	0.51	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	132	6.9	0.28	7.8	0.31	257	11.8	0.35	13.5	0.39
Breast (<i>in situ</i>)	3	0.2	0.04	0.2	0.05	524	23.4	0.48	27.5	0.55

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

ALABAMA

II-4 Incidence – NH White

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Alabama, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3,134	534.4	4.55	647.0	5.36	2,928	386.7	3.29	453.6	3.78
Oral Cavity & Pharynx	77	12.7	0.68	15.3	0.80	40	5.2	0.38	6.2	0.44
Lip	1	0.2	0.07	0.3	0.10	*	*	*	*	*
Tongue	18	2.7	0.30	3.4	0.37	7	0.9	0.16	1.1	0.18
Major salivary gland	6	1.1	0.21	1.3	0.24	8	1.1	0.18	1.3	0.20
Floor of mouth	4	0.7	0.16	0.8	0.18	2	0.3	0.09	0.3	0.10
Gum & other mouth	9	1.7	0.27	2.0	0.30	10	1.3	0.19	1.6	0.22
Nasopharynx	4	0.7	0.17	0.9	0.20	3	0.4	0.11	0.5	0.13
Oropharynx	7	1.1	0.20	1.4	0.24	2	0.2	0.07	0.3	0.09
Hypopharynx	8	1.3	0.22	1.6	0.26	2	0.2	0.08	0.3	0.10
Digestive System	657	115.6	2.15	138.9	2.52	600	79.3	1.49	94.1	1.73
Esophagus	44	7.2	0.52	9.0	0.63	16	2.0	0.23	2.5	0.28
Stomach	75	13.6	0.75	16.4	0.89	60	8.1	0.48	9.5	0.55
Small intestine	20	3.4	0.36	4.0	0.41	26	3.5	0.31	4.1	0.36
Colon (excl. rectum)	229	41.8	1.32	49.4	1.52	239	31.7	0.94	37.5	1.10
Rectum & rectosigmoid	78	13.7	0.73	16.3	0.85	70	9.2	0.51	10.9	0.59
Anus, anal canal, & anorectum	11	1.9	0.27	2.2	0.30	11	1.4	0.19	1.7	0.23
Liver	82	11.9	0.62	15.4	0.78	28	3.5	0.30	4.2	0.36
Gallbladder	4	0.9	0.21	0.9	0.22	12	1.6	0.22	1.9	0.25
Pancreas	93	16.9	0.84	20.2	0.98	111	14.7	0.64	17.4	0.75
Respiratory System	527	91.5	1.90	111.0	2.24	299	38.7	1.03	46.5	1.21
Larynx	55	9.1	0.59	11.3	0.70	8	1.0	0.16	1.2	0.19
Lung & bronchus	466	81.1	1.80	98.2	2.11	287	37.2	1.01	44.6	1.19
Bones & Joints	7	1.2	0.22	1.2	0.23	7	0.9	0.16	0.9	0.17
Soft Tissue (incl. heart)	23	4.0	0.39	4.4	0.43	26	3.6	0.32	4.0	0.36
Skin (excl. basal & sq.)	9	1.6	0.26	1.8	0.29	13	1.7	0.22	2.0	0.25
Melanoma of the skin	6	1.1	0.22	1.3	0.25	8	1.1	0.17	1.3	0.20
Breast (excl. <i>in situ</i>)	10	1.9	0.29	2.3	0.34	971	128.1	1.89	150.4	2.17
Female Genital System	N/A	N/A	N/A	N/A	N/A	347	45.4	1.12	53.1	1.28
Cervix uteri	N/A	N/A	N/A	N/A	N/A	72	10.4	0.56	11.2	0.59
Uterus corpus	N/A	N/A	N/A	N/A	N/A	164	20.2	0.73	24.7	0.87
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	14	1.7	0.21	2.1	0.25
Ovary	N/A	N/A	N/A	N/A	N/A	72	9.5	0.52	11.0	0.59
Male Genital System	1,178	189.9	2.63	237.2	3.19	N/A	N/A	N/A	N/A	N/A
Prostate	1,165	187.5	2.61	234.7	3.17	N/A	N/A	N/A	N/A	N/A
Testis	8	1.4	0.22	1.4	0.22	N/A	N/A	N/A	N/A	N/A
Penis	4	0.7	0.18	0.9	0.20	N/A	N/A	N/A	N/A	N/A
Urinary System	244	43.9	1.34	51.7	1.54	161	21.3	0.77	25.1	0.89
Bladder (incl. <i>in situ</i>)	87	17.4	0.89	20.3	1.02	48	6.5	0.43	7.7	0.50
Kidney & renal pelvis	154	26.0	0.99	30.9	1.14	110	14.3	0.63	16.9	0.73
Ureter	1	0.2	0.10	0.3	0.12	1	0.1	0.06	0.2	0.07
Eye & Orbit	1	0.2	0.09	0.3	0.10	1	0.2	0.07	0.2	0.07
Brain & Other CNS	31	5.0	0.42	5.6	0.47	27	3.6	0.32	3.9	0.34
Brain	30	4.7	0.40	5.3	0.45	24	3.2	0.30	3.5	0.32
Endocrine System	25	4.2	0.39	4.7	0.43	83	11.3	0.57	12.5	0.62
Thyroid gland	17	2.9	0.32	3.3	0.37	73	9.9	0.54	11.1	0.58
Lymphomas	98	17.8	0.85	19.9	0.94	93	12.5	0.59	14.2	0.66
Hodgkin lymphoma	18	3.3	0.35	3.3	0.35	18	2.6	0.28	2.6	0.28
Non-Hodgkin lymphoma	80	14.6	0.77	16.6	0.87	76	9.9	0.52	11.6	0.60
Multiple Myeloma	86	15.5	0.80	18.7	0.94	98	12.9	0.60	15.3	0.70
Leukemias	66	12.0	0.70	13.7	0.80	55	7.4	0.46	8.4	0.51
Acute lymphocytic	6	1.0	0.19	0.9	0.18	4	0.5	0.12	0.5	0.12
Chronic lymphocytic	26	5.0	0.47	5.9	0.54	13	1.7	0.22	2.0	0.26
Acute myeloid	16	2.8	0.33	3.2	0.38	19	2.5	0.26	2.8	0.29
Chronic myeloid	9	1.6	0.24	1.8	0.27	12	1.6	0.22	1.8	0.24
Other leukemias	8	1.6	0.27	1.8	0.30	8	1.1	0.18	1.2	0.19
Mesothelioma	2	0.4	0.13	0.5	0.15	2	0.2	0.09	0.3	0.10
Kaposi Sarcoma	5	0.9	0.18	0.9	0.18	*	*	*	*	*
Ill-Defined & Unknown	88	16.2	0.83	18.9	0.94	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	39	6.9	0.52	8.0	0.60	88	12.0	0.59	13.7	0.66
Breast (<i>in situ</i>)	*	*	*	*	*	199	25.9	0.85	30.5	0.97

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Alabama, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	71	277.2	16.10	330.0	18.93	107	286.2	13.05	330.2	14.98
Oral Cavity & Pharynx	3	11.4	3.01	13.7	3.57	2	5.5	1.94	6.3	2.19
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	21	78.7	8.39	95.3	9.93	23	64.5	6.31	75.9	7.34
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	3	12.2	3.69	13.5	4.02	4	9.6	2.19	11.9	2.70
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	5	20.7	4.26	24.3	4.85	8	22.8	3.83	26.6	4.40
Rectum & rectosigmoid	4	11.8	2.98	14.6	3.64	3	8.1	2.10	10.0	2.57
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	4	14.0	3.18	18.2	4.11	3	8.6	2.35	9.9	2.66
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	2	9.4	3.16	11.3	3.78	4	11.7	2.90	13.6	3.34
Respiratory System	11	45.5	6.57	55.2	7.85	10	32.0	4.74	37.4	5.44
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	10	43.2	6.47	52.3	7.70	10	32.0	4.74	37.4	5.44
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	2	7.4	3.06	8.1	3.34	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	*	*	*	*	*	2	4.6	1.70	5.0	1.87
Breast (excl. <i>in situ</i>)	*	*	*	*	*	32	80.1	6.59	91.1	7.54
Female Genital System	N/A	N/A	N/A	N/A	N/A	13	31.5	4.06	37.1	4.77
Cervix uteri	N/A	N/A	N/A	N/A	N/A	3	8.3	2.08	9.0	2.28
Uterus corpus	N/A	N/A	N/A	N/A	N/A	5	11.7	2.40	14.9	3.03
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	3	9.0	2.27	9.9	2.48
Male Genital System	16	62.3	7.57	74.6	8.90	N/A	N/A	N/A	N/A	N/A
Prostate	14	59.4	7.47	71.5	8.80	N/A	N/A	N/A	N/A	N/A
Testis	1	2.9	1.19	3.1	1.28	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	5	18.6	4.20	22.2	4.95	4	11.7	2.60	14.3	3.15
Bladder (incl. <i>in situ</i>)	3	13.6	3.77	16.3	4.44	2	4.8	1.78	5.9	2.15
Kidney & renal pelvis	2	5.0	1.86	6.0	2.21	3	6.3	1.80	7.7	2.21
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	5.1	1.88	5.4	2.01	2	4.1	1.38	4.5	1.53
Brain	1	4.5	1.81	4.6	1.88	2	3.6	1.30	4.0	1.44
Endocrine System	1	4.0	1.57	3.9	1.53	7	15.8	2.69	17.4	2.99
Thyroid gland	1	3.4	1.46	3.4	1.47	7	15.4	2.66	16.8	2.93
Lymphomas	3	14.2	3.98	16.7	4.69	4	10.9	2.62	12.0	2.87
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	2	6.6	2.53	8.2	3.10	2	5.9	2.24	6.7	2.50
Leukemias	2	7.0	2.72	7.5	3.09	2	7.6	2.39	8.4	2.61
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	1	3.7	1.47	4.1	1.60
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	3	12.5	3.79	15.3	4.54	3	8.2	2.39	9.8	2.81
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	1	4.7	2.14	5.2	2.38	3	6.5	1.89	7.3	2.08
Breast (<i>in situ</i>)	*	*	*	*	*	11	26.7	3.82	30.5	4.35

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Alabama, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	10	215.8	32.15	259.6	37.67	9	198.6	31.67	231.7	35.95
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	4	86.5	20.14	105.7	24.01	1	29.9	11.73	37.1	14.39
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	1	35.3	13.99	39.6	15.36	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	1	27.1	11.53	33.3	13.68	2	29.7	10.68	37.2	13.23
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	1	27.1	11.53	33.3	13.68	2	29.7	10.68	37.2	13.23
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	2	54.7	17.45	62.8	19.52
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	2	40.9	14.03	48.6	16.39	N/A	N/A	N/A	N/A	N/A
Prostate	2	37.2	13.54	43.4	15.54	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	1	21.3	8.71	28.0	11.45	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Alabama, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	130	244.4	11.14	286.3	12.83	127	224.8	9.71	259.9	11.36
Oral Cavity & Pharynx	5	8.0	1.88	9.8	2.26	2	2.4	0.93	2.8	1.13
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	4.4	1.49	5.1	1.70	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	30	54.7	5.11	65.4	5.97	23	44.8	4.51	52.2	5.24
Esophagus	2	4.4	1.47	5.2	1.68	*	*	*	*	*
Stomach	4	5.1	1.33	6.3	1.62	2	4.7	1.51	5.5	1.73
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	11	19.2	3.01	22.6	3.49	9	17.6	2.90	20.4	3.36
Rectum & rectosigmoid	4	7.3	1.91	9.1	2.31	4	5.8	1.46	6.8	1.73
Anus, anal canal, & anorectum	*	*	*	*	*	1	2.9	1.27	3.3	1.36
Liver	5	8.6	1.93	10.5	2.30	1	2.5	1.13	3.0	1.33
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	2	5.6	1.80	6.7	2.07	3	5.9	1.55	7.3	1.93
Respiratory System	10	23.3	3.66	27.2	4.15	9	20.0	3.20	23.3	3.71
Larynx	1	1.6	0.65	2.1	0.86	*	*	*	*	*
Lung & bronchus	8	20.7	3.57	24.2	4.03	8	19.0	3.11	22.4	3.64
Bones & Joints	1	1.0	0.40	0.8	0.34	*	*	*	*	*
Soft Tissue (incl. heart)	1	1.5	0.58	1.7	0.71	2	2.5	0.83	2.9	1.06
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	5	12.5	2.82	14.1	3.16	3	4.2	1.21	5.2	1.55
Breast (excl. <i>in situ</i>)	*	*	*	*	*	34	56.6	4.59	65.7	5.49
Female Genital System	N/A	N/A	N/A	N/A	N/A	23	37.9	3.84	43.8	4.49
Cervix uteri	N/A	N/A	N/A	N/A	N/A	7	9.2	1.55	9.6	1.71
Uterus corpus	N/A	N/A	N/A	N/A	N/A	10	18.1	2.79	21.8	3.33
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	3	5.3	1.45	6.4	1.78
Male Genital System	33	64.5	5.66	79.3	6.73	N/A	N/A	N/A	N/A	N/A
Prostate	29	61.2	5.61	76.0	6.68	N/A	N/A	N/A	N/A	N/A
Testis	3	2.5	0.63	2.5	0.64	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	14	27.6	3.79	31.3	4.27	5	9.6	2.04	11.3	2.41
Bladder (incl. <i>in situ</i>)	6	14.7	3.07	16.2	3.38	*	*	*	*	*
Kidney & renal pelvis	8	12.9	2.23	15.0	2.61	4	8.0	1.86	9.3	2.16
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	3	3.4	0.92	4.1	1.19	3	3.5	1.01	3.8	1.19
Brain	3	3.2	0.89	4.0	1.17	2	2.6	0.92	3.0	1.13
Endocrine System	3	2.8	0.82	3.2	1.04	5	7.2	1.51	7.7	1.69
Thyroid gland	2	2.6	0.81	3.1	1.03	5	7.2	1.51	7.7	1.69
Lymphomas	8	13.2	2.56	14.6	2.79	8	17.2	2.92	19.8	3.34
Hodgkin lymphoma	1	1.2	0.47	1.2	0.47	1	2.5	1.11	2.8	1.24
Non-Hodgkin lymphoma	7	12.0	2.51	13.4	2.75	7	14.7	2.71	17.0	3.10
Multiple Myeloma	3	7.2	2.08	8.2	2.34	1	3.0	1.18	3.5	1.36
Leukemias	9	12.3	2.41	12.7	2.62	3	5.7	1.58	6.4	1.84
Acute lymphocytic	3	2.6	0.67	2.4	0.65	1	0.9	0.39	0.9	0.36
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	3	3.3	1.11	3.3	1.19	*	*	*	*	*
Chronic myeloid	2	3.3	1.39	3.7	1.60	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	4	9.5	2.50	10.6	2.81	4	8.3	2.10	9.0	2.27
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	4	4.2	1.22	4.5	1.39	5	8.5	1.86	9.3	2.06
Breast (<i>in situ</i>)	*	*	*	*	*	5	9.2	1.82	12.0	2.42

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

ALABAMA

II-8 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Alabama, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	94	204.2	10.88	239.7	12.57	96	198.1	9.86	229.4	11.55
Oral Cavity & Pharynx	4	7.4	1.86	9.2	2.26	1	2.1	0.85	2.5	1.11
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	3.6	1.35	4.3	1.56	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	22	46.4	5.06	55.9	5.94	19	42.6	4.76	49.5	5.52
Esophagus	2	3.4	1.31	4.3	1.57	*	*	*	*	*
Stomach	3	4.1	1.12	5.5	1.54	2	4.4	1.53	5.1	1.77
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	6	13.7	2.79	16.0	3.19	7	17.1	3.14	19.8	3.62
Rectum & rectosigmoid	2	5.1	1.74	6.6	2.18	3	4.9	1.46	5.4	1.64
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	4	8.9	2.14	10.8	2.52	1	2.9	1.31	3.5	1.55
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	2	6.4	2.03	7.6	2.35	3	5.2	1.51	6.5	1.92
Respiratory System	8	18.6	3.38	22.5	3.97	7	19.3	3.42	22.3	3.93
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	6	16.5	3.29	20.0	3.84	7	18.1	3.31	21.2	3.84
Bones & Joints	1	1.1	0.47	0.9	0.39	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	2	1.8	0.68	1.9	0.80
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	4	13.1	3.08	14.7	3.44	2	4.3	1.35	5.5	1.75
Breast (excl. <i>in situ</i>)	*	*	*	*	*	24	47.6	4.60	55.6	5.50
Female Genital System	N/A	N/A	N/A	N/A	N/A	17	31.3	3.72	36.0	4.35
Cervix uteri	N/A	N/A	N/A	N/A	N/A	5	6.9	1.44	7.2	1.59
Uterus corpus	N/A	N/A	N/A	N/A	N/A	7	15.2	2.70	18.3	3.24
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	3	5.0	1.44	6.0	1.77
Male Genital System	20	44.0	4.90	54.8	5.92	N/A	N/A	N/A	N/A	N/A
Prostate	17	41.1	4.84	51.9	5.87	N/A	N/A	N/A	N/A	N/A
Testis	2	2.1	0.62	2.1	0.62	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	11	25.6	3.99	28.8	4.46	4	8.4	2.06	9.8	2.42
Bladder (incl. <i>in situ</i>)	4	14.2	3.27	15.7	3.60	*	*	*	*	*
Kidney & renal pelvis	6	11.3	2.28	13.1	2.64	3	7.0	1.87	8.1	2.16
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	2.8	0.87	3.5	1.15	2	3.3	1.11	3.7	1.35
Brain	2	2.6	0.83	3.2	1.13	2	2.8	1.05	3.3	1.31
Endocrine System	2	2.3	0.83	2.6	1.03	4	6.5	1.60	7.1	1.81
Thyroid gland	2	2.2	0.82	2.5	1.02	4	6.5	1.60	7.1	1.81
Lymphomas	5	10.6	2.48	11.8	2.73	6	14.2	2.82	16.4	3.24
Hodgkin lymphoma	*	*	*	*	*	1	2.6	1.24	2.9	1.39
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	5	11.6	2.53	13.6	2.92
Multiple Myeloma	2	6.5	2.04	7.5	2.29	*	*	*	*	*
Leukemias	7	11.7	2.55	12.0	2.73	3	4.9	1.57	5.5	1.79
Acute lymphocytic	3	2.4	0.69	2.2	0.67	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	2	3.4	1.24	3.5	1.34	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	3	9.6	2.76	10.8	3.08	3	7.9	2.23	8.7	2.44
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	3	4.0	1.28	4.3	1.44	4	7.1	1.73	7.9	2.00
Breast (<i>in situ</i>)	*	*	*	*	*	4	7.9	1.88	10.3	2.47

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Alabama, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	5	137.6	28.50	156.9	31.99	6	118.8	23.78	139.5	27.71
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	1	32.2	13.11	37.6	14.79	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	2	39.6	12.38	46.4	14.76
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	2	64.2	19.80	76.3	23.08	N/A	N/A	N/A	N/A	N/A
Prostate	2	64.2	19.80	76.3	23.08	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


ALABAMA

II-10 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	738,430	742,575	740,983	736,624	733,603
Non-Hispanic White	478,779	478,047	472,643	467,724	463,968
Non-Hispanic Black	31,272	31,992	32,360	32,348	32,150
Non-Hispanic Asian/Pacific Islander (NH API)	58,447	60,621	62,661	62,711	63,363
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	119,552	120,080	120,314	120,472	120,500


All Races Population 2015–2019: 3,692,215
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	50,380	51,835	53,005	53,369	53,622
Hispanic White	37,289	38,328	39,208	39,252	39,459
Hispanic Black	3,931	4,016	4,084	4,168	4,180

Hispanic/Latino Population, Census 2010: 39,249
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

ALASKA CANCER REGISTRY

Initial Operation: 1996
 Population-based Data Available: 1996
 Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	104.5	102.4	111.1	104.9	106.2	105.8
Missing Race	0.5	0.3	0.4	0.4	0.6	0.5
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.7	1.1	1.0	1.0	1.5	1.3
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	91.7	Ovary	91.7
Oral Cavity & Pharynx	96.4	Prostate	91.3
Esophagus	96.5	Testis	99.1
Stomach	96.1	Bladder (incl. <i>in situ</i>)	96.2
Colon & Rectum	95.0	Kidney & Renal Pelvis	85.9
Liver	54.7	Brain & Other CNS	83.3
Pancreas	80.8	Brain & Other CNS (non-malig)	35.8
Lung & Bronchus	87.7	Thyroid	98.9
Melanomas of the Skin	98.2	Hodgkin Lymphoma	96.3
Female Breast (excl. <i>in situ</i>)	98.9	Non-Hodgkin Lymphoma	95.3
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	85.7
Cervix Uteri	99.3	Leukemias	86.0
Uterus Corpus & Uterus NOS	99.0		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Alaska, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,573	434.9	5.37	513.4	6.20	1,449	406.2	4.99	473.4	5.69
Oral Cavity & Pharynx	68	17.0	0.98	20.7	1.17	21	5.8	0.59	6.9	0.68
Lip	2	0.5	0.20	0.6	0.23	*	*	*	*	*
Tongue	19	4.4	0.49	5.4	0.58	7	1.9	0.34	2.2	0.39
Major salivary gland	4	1.1	0.30	1.3	0.35	2	0.7	0.21	0.8	0.23
Floor of mouth	*	*	*	*	*	2	0.5	0.17	0.6	0.20
Gum & other mouth	6	1.8	0.34	2.1	0.41	2	0.6	0.20	0.8	0.23
Nasopharynx	6	1.5	0.29	1.7	0.34	2	0.5	0.17	0.6	0.19
Oropharynx	6	1.3	0.25	1.7	0.31	1	0.4	0.15	0.5	0.18
Hypopharynx	5	1.2	0.26	1.4	0.30	*	*	*	*	*
Digestive System	354	97.1	2.53	115.4	2.93	248	71.2	2.12	83.6	2.43
Esophagus	30	8.1	0.74	9.8	0.86	10	2.8	0.42	3.4	0.50
Stomach	33	9.8	0.84	11.3	0.94	19	5.4	0.59	6.3	0.67
Small intestine	9	2.3	0.39	2.7	0.44	6	1.6	0.31	1.9	0.35
Colon (excl. rectum)	104	28.8	1.39	33.9	1.59	91	27.3	1.34	31.5	1.51
Rectum & rectosigmoid	58	15.5	0.99	18.6	1.15	41	11.2	0.82	13.3	0.95
Anus, anal canal, & anorectum	6	1.5	0.32	1.9	0.38	9	2.3	0.36	2.8	0.43
Liver	47	11.2	0.79	13.9	0.95	15	3.9	0.48	4.7	0.56
Gallbladder	2	0.6	0.22	0.7	0.25	4	0.9	0.22	1.1	0.27
Pancreas	49	14.3	1.00	16.9	1.15	39	11.2	0.84	13.2	0.97
Respiratory System	218	63.9	2.13	75.6	2.46	179	51.1	1.80	60.9	2.09
Larynx	15	3.8	0.47	4.7	0.56	4	1.1	0.25	1.3	0.30
Lung & bronchus	201	59.3	2.07	70.0	2.38	173	49.2	1.76	58.6	2.05
Bones & Joints	4	1.1	0.25	1.1	0.26	4	1.0	0.25	1.1	0.26
Soft Tissue (incl. heart)	12	3.0	0.41	3.5	0.46	7	1.9	0.33	2.2	0.37
Skin (excl. basal & sq.)	61	17.8	1.10	20.4	1.24	46	13.2	0.90	14.8	0.99
Melanoma of the skin	56	16.1	1.04	18.4	1.17	43	12.4	0.87	13.9	0.96
Breast (excl. <i>in situ</i>)	3	0.9	0.24	1.0	0.27	444	122.0	2.70	142.7	3.08
Female Genital System	N/A	N/A	N/A	N/A	N/A	184	48.9	1.68	58.1	1.95
Cervix uteri	N/A	N/A	N/A	N/A	N/A	27	7.7	0.68	8.5	0.74
Uterus corpus	N/A	N/A	N/A	N/A	N/A	99	25.6	1.20	31.0	1.42
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	3	0.8	0.22	1.0	0.26
Ovary	N/A	N/A	N/A	N/A	N/A	31	8.6	0.72	10.1	0.82
Male Genital System	384	98.7	2.46	119.4	2.90	N/A	N/A	N/A	N/A	N/A
Prostate	358	91.8	2.38	112.4	2.82	N/A	N/A	N/A	N/A	N/A
Testis	23	5.7	0.55	5.7	0.54	N/A	N/A	N/A	N/A	N/A
Penis	2	0.8	0.28	1.0	0.34	N/A	N/A	N/A	N/A	N/A
Urinary System	192	57.1	2.03	67.0	2.34	79	22.3	1.18	26.2	1.35
Bladder (incl. <i>in situ</i>)	104	33.2	1.62	39.1	1.87	28	7.8	0.70	9.3	0.81
Kidney & renal pelvis	84	22.5	1.18	26.3	1.35	50	14.1	0.93	16.3	1.06
Ureter	2	0.8	0.25	0.8	0.28	*	*	*	*	*
Eye & Orbit	2	0.3	0.12	0.4	0.15	3	1.0	0.25	1.1	0.27
Brain & Other CNS	28	7.1	0.63	7.9	0.70	20	5.7	0.60	6.3	0.65
Brain	27	6.9	0.62	7.7	0.70	19	5.5	0.58	6.0	0.63
Endocrine System	28	6.9	0.61	7.7	0.66	69	19.8	1.09	21.1	1.15
Thyroid gland	24	6.1	0.57	6.8	0.62	66	18.9	1.07	20.1	1.12
Lymphomas	85	23.5	1.24	27.2	1.41	58	16.4	1.01	19.0	1.15
Hodgkin lymphoma	9	2.4	0.36	2.5	0.37	7	1.8	0.33	2.0	0.37
Non-Hodgkin lymphoma	76	21.1	1.19	24.7	1.36	51	14.6	0.96	17.0	1.09
Multiple Myeloma	22	5.9	0.62	7.0	0.73	15	4.4	0.54	5.1	0.61
Leukemias	50	14.5	0.99	16.1	1.09	31	8.7	0.72	9.7	0.80
Acute lymphocytic	6	1.5	0.29	1.4	0.25	5	1.4	0.28	1.2	0.25
Chronic lymphocytic	15	4.4	0.56	5.1	0.63	6	1.7	0.31	2.0	0.38
Acute myeloid	16	4.6	0.56	5.2	0.62	10	2.7	0.40	3.0	0.44
Chronic myeloid	7	2.1	0.37	2.3	0.41	6	1.7	0.32	1.9	0.35
Other leukemias	6	1.8	0.36	2.1	0.40	5	1.3	0.29	1.6	0.34
Mesothelioma	6	2.0	0.40	2.3	0.45	2	0.6	0.20	0.7	0.21
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	31	8.9	0.78	10.1	0.87	58	16.7	1.02	18.8	1.13
Breast (<i>in situ</i>)	*	*	*	*	*	90	24.0	1.18	28.6	1.37

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Alaska, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,187	430.9	6.11	509.6	7.04	1,008	399.3	5.91	465.5	6.71
Oral Cavity & Pharynx	51	16.7	1.12	20.4	1.33	15	5.9	0.72	6.9	0.81
Lip	2	0.7	0.25	0.8	0.28	*	*	*	*	*
Tongue	16	4.8	0.57	5.9	0.68	5	2.2	0.44	2.5	0.49
Major salivary gland	3	1.2	0.35	1.5	0.42	2	0.8	0.26	0.8	0.28
Floor of mouth	*	*	*	*	*	1	0.5	0.20	0.6	0.24
Gum & other mouth	4	1.4	0.33	1.7	0.40	2	0.9	0.28	1.0	0.33
Nasopharynx	1	0.5	0.21	0.6	0.25	*	*	*	*	*
Oropharynx	5	1.3	0.29	1.7	0.36	*	*	*	*	*
Hypopharynx	3	1.0	0.28	1.2	0.32	*	*	*	*	*
Digestive System	236	84.5	2.70	100.9	3.12	151	60.9	2.33	71.3	2.66
Esophagus	22	7.8	0.83	9.5	0.98	6	2.5	0.47	2.9	0.53
Stomach	16	5.9	0.73	6.9	0.83	9	3.7	0.57	4.4	0.66
Small intestine	8	2.8	0.49	3.2	0.56	5	1.9	0.38	2.2	0.45
Colon (excl. rectum)	72	26.6	1.54	31.1	1.75	54	23.2	1.48	26.4	1.65
Rectum & rectosigmoid	37	13.0	1.05	15.7	1.22	23	8.7	0.85	10.5	0.99
Anus, anal canal, & anorectum	4	1.5	0.36	1.9	0.43	8	2.8	0.48	3.4	0.56
Liver	30	9.0	0.79	11.5	0.97	6	2.5	0.47	2.9	0.53
Gallbladder	1	0.6	0.26	0.7	0.29	2	0.7	0.25	0.8	0.28
Pancreas	33	12.7	1.07	15.0	1.24	28	11.2	0.99	13.3	1.14
Respiratory System	157	59.6	2.34	70.5	2.70	121	47.1	2.02	56.4	2.36
Larynx	10	3.1	0.47	4.0	0.57	3	1.2	0.30	1.5	0.36
Lung & bronchus	145	55.7	2.28	65.7	2.62	116	45.1	1.98	54.0	2.31
Bones & Joints	3	1.2	0.32	1.3	0.33	2	1.0	0.30	1.1	0.31
Soft Tissue (incl. heart)	8	2.8	0.47	3.2	0.52	5	2.0	0.39	2.3	0.46
Skin (excl. basal & sq.)	56	21.8	1.40	24.8	1.57	40	16.8	1.24	18.7	1.34
Melanoma of the skin	52	19.6	1.31	22.5	1.48	38	15.9	1.21	17.8	1.31
Breast (excl. <i>in situ</i>)	3	1.1	0.31	1.3	0.35	313	122.4	3.25	142.8	3.68
Female Genital System	N/A	N/A	N/A	N/A	N/A	135	49.9	2.02	60.0	2.36
Cervix uteri	N/A	N/A	N/A	N/A	N/A	17	7.0	0.79	7.7	0.85
Uterus corpus	N/A	N/A	N/A	N/A	N/A	74	26.1	1.42	32.4	1.71
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	0.7	0.24	0.9	0.29
Ovary	N/A	N/A	N/A	N/A	N/A	23	9.0	0.89	10.6	1.00
Male Genital System	311	104.1	2.87	125.8	3.37	N/A	N/A	N/A	N/A	N/A
Prostate	292	96.6	2.76	118.2	3.27	N/A	N/A	N/A	N/A	N/A
Testis	17	6.7	0.73	6.7	0.72	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	149	58.6	2.35	69.0	2.72	57	22.5	1.40	26.4	1.61
Bladder (incl. <i>in situ</i>)	88	36.4	1.91	42.9	2.21	22	8.5	0.86	10.2	1.00
Kidney & renal pelvis	58	20.9	1.32	24.6	1.51	33	13.4	1.09	15.6	1.24
Ureter	2	0.8	0.30	0.9	0.34	*	*	*	*	*
Eye & Orbit	2	0.5	0.17	0.6	0.21	3	1.1	0.31	1.2	0.34
Brain & Other CNS	24	8.3	0.81	9.3	0.88	16	6.9	0.80	7.7	0.87
Brain	23	8.0	0.80	9.0	0.87	16	6.6	0.79	7.3	0.85
Endocrine System	21	7.4	0.75	8.3	0.82	46	19.6	1.34	21.1	1.41
Thyroid gland	19	6.6	0.70	7.4	0.77	44	18.7	1.30	20.1	1.38
Lymphomas	66	24.5	1.46	28.4	1.65	43	17.6	1.26	20.4	1.42
Hodgkin lymphoma	8	2.9	0.47	3.1	0.50	5	2.2	0.44	2.4	0.49
Non-Hodgkin lymphoma	58	21.7	1.39	25.3	1.58	38	15.4	1.18	17.9	1.34
Multiple Myeloma	16	5.9	0.71	7.0	0.83	10	4.1	0.61	4.7	0.67
Leukemias	36	14.1	1.12	15.8	1.24	23	9.6	0.93	10.7	1.02
Acute lymphocytic	3	1.4	0.36	1.2	0.31	3	1.3	0.36	1.1	0.31
Chronic lymphocytic	13	4.7	0.64	5.5	0.74	5	1.8	0.40	2.3	0.48
Acute myeloid	11	4.4	0.63	5.0	0.70	9	3.7	0.57	4.1	0.62
Chronic myeloid	5	2.2	0.45	2.4	0.50	4	1.8	0.40	2.0	0.44
Other leukemias	4	1.4	0.35	1.6	0.40	2	0.9	0.29	1.2	0.35
Mesothelioma	5	2.1	0.43	2.3	0.48	1	0.5	0.20	0.5	0.22
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	20	7.3	0.79	8.2	0.86	39	16.3	1.22	18.3	1.34
Breast (<i>in situ</i>)	*	*	*	*	*	68	25.6	1.47	30.4	1.68

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Alaska, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	42	402.2	33.10	475.5	37.15	33	348.9	29.47	419.9	34.49
Oral Cavity & Pharynx	1	15.3	6.95	16.8	7.35	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	10	104.0	17.74	118.4	19.35	6	63.3	12.69	80.4	15.73
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	2	20.6	7.93	22.5	8.27	2	26.2	8.27	31.9	9.84
Rectum & rectosigmoid	1	16.8	7.90	19.8	8.84	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	2	13.1	4.70	17.2	5.91	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	2	26.8	9.01	28.9	9.44	*	*	*	*	*
Respiratory System	5	49.4	11.92	60.9	13.96	5	57.9	13.08	67.5	14.80
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	5	46.7	11.76	57.2	13.72	4	53.9	12.46	63.5	14.27
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	10	98.2	14.41	118.5	16.98
Female Genital System	N/A	N/A	N/A	N/A	N/A	3	36.0	9.54	42.9	10.82
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2	23.7	7.77	28.5	8.87
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	15	117.7	15.99	148.4	18.91	N/A	N/A	N/A	N/A	N/A
Prostate	14	116.4	15.94	147.4	18.88	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	3	32.5	10.29	37.1	11.30	2	31.3	10.10	35.4	11.20
Bladder (incl. <i>in situ</i>)	2	25.0	9.80	28.1	10.61	*	*	*	*	*
Kidney & renal pelvis	1	7.5	3.13	9.0	3.87	2	25.5	9.47	28.2	10.38
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	1	12.2	6.17	14.0	7.10	*	*	*	*	*
Brain	1	12.2	6.17	14.0	7.10	*	*	*	*	*
Endocrine System	*	*	*	*	*	2	13.0	4.38	16.0	5.55
Thyroid gland	*	*	*	*	*	2	12.0	4.26	15.3	5.51
Lymphomas	3	27.3	8.76	29.4	9.15	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	2	16.4	6.73	18.8	7.30	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	*	*	*	*	*	2	20.1	7.86	23.0	9.06
Breast (<i>in situ</i>)	*	*	*	*	*	3	31.3	8.82	38.1	10.23

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Alaska, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	60	293.3	19.01	337.9	21.52	85	285.1	14.34	325.2	16.16
Oral Cavity & Pharynx	2	11.1	3.43	12.1	3.77	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	1	4.8	2.02	5.3	2.20	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	16	84.6	10.68	96.3	11.89	13	46.8	5.98	53.9	6.80
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	3	18.4	5.24	20.7	5.82	2	9.0	2.71	10.5	3.11
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	3	12.5	4.01	15.1	4.59	3	11.5	2.90	13.5	3.37
Rectum & rectosigmoid	3	15.2	4.23	18.1	4.94	3	7.9	2.26	9.6	2.69
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	3	19.1	5.12	21.1	5.55	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	2	11.7	4.21	12.8	4.51	2	9.4	2.82	10.3	3.03
Respiratory System	9	48.1	7.95	55.3	8.91	9	31.9	5.07	36.6	5.70
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	9	46.6	7.88	53.4	8.81	9	31.9	5.07	36.6	5.70
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	2	6.2	2.40	7.2	2.68	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	26	80.1	7.27	95.8	8.53
Female Genital System	N/A	N/A	N/A	N/A	N/A	16	53.9	6.16	58.8	6.69
Cervix uteri	N/A	N/A	N/A	N/A	N/A	3	10.2	2.83	10.7	2.97
Uterus corpus	N/A	N/A	N/A	N/A	N/A	10	31.9	4.64	34.1	4.95
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	3	9.2	2.56	10.6	2.91
Male Genital System	11	50.1	7.45	61.0	8.82	N/A	N/A	N/A	N/A	N/A
Prostate	11	48.9	7.39	59.9	8.78	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	5	28.7	6.09	32.3	6.87	3	10.5	2.96	12.2	3.35
Bladder (incl. <i>in situ</i>)	2	13.8	4.57	16.1	5.31	1	5.0	2.10	5.8	2.41
Kidney & renal pelvis	3	14.9	4.03	16.2	4.36	2	5.6	2.09	6.4	2.32
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	7	21.9	3.75	22.8	3.90
Thyroid gland	*	*	*	*	*	7	21.3	3.70	22.0	3.83
Lymphomas	5	21.7	5.08	26.0	5.98	2	8.8	2.62	9.5	2.80
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	1	5.3	2.07	6.0	2.33
Leukemias	3	15.8	4.30	16.9	4.66	1	3.9	1.47	4.7	1.79
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	2	9.7	3.68	11.0	4.13	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	3	17.0	4.73	19.1	5.31	4	12.6	3.08	15.0	3.60
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	3	12.2	3.79	13.2	4.07	4	13.3	3.06	15.0	3.39
Breast (<i>in situ</i>)	*	*	*	*	*	4	13.8	3.12	16.4	3.63

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Alaska, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	235	539.7	17.43	636.9	20.31	272	539.9	15.21	631.7	17.49
Oral Cavity & Pharynx	12	22.6	3.09	27.9	3.72	4	7.9	1.84	9.3	2.14
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	4.0	1.45	5.0	1.73	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	2.5	1.09	3.0	1.26	*	*	*	*	*
Nasopharynx	3	6.1	1.52	7.5	1.84	1	2.4	0.97	2.9	1.13
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	1	2.9	1.16	3.5	1.34	*	*	*	*	*
Digestive System	81	183.5	10.02	218.6	11.71	72	147.1	8.07	175.1	9.43
Esophagus	6	12.8	2.50	15.4	2.91	3	6.1	1.62	8.0	2.07
Stomach	12	28.0	4.05	31.5	4.49	6	11.3	2.14	12.9	2.44
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	24	56.2	5.58	66.8	6.49	29	60.9	5.25	71.6	6.07
Rectum & rectosigmoid	15	33.1	4.07	40.0	4.87	13	27.6	3.52	32.5	4.08
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	9	18.9	3.02	23.1	3.63	6	11.1	2.11	13.8	2.57
Gallbladder	*	*	*	*	*	1	2.0	0.77	2.9	1.10
Pancreas	10	22.1	3.55	27.0	4.22	7	14.8	2.62	17.8	3.09
Respiratory System	42	107.5	8.17	127.0	9.47	41	84.2	6.09	100.5	7.11
Larynx	4	10.1	2.58	11.6	2.95	*	*	*	*	*
Lung & bronchus	38	96.2	7.70	114.2	8.96	41	82.4	6.02	98.7	7.05
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	3	4.7	1.32	5.5	1.55	*	*	*	*	*
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	3	5.3	1.57	5.9	1.76	3	6.2	1.53	7.0	1.72
Breast (excl. <i>in situ</i>)	*	*	*	*	*	75	146.1	7.83	171.7	8.98
Female Genital System	N/A	N/A	N/A	N/A	N/A	23	42.3	4.08	49.7	4.71
Cervix uteri	N/A	N/A	N/A	N/A	N/A	7	13.0	2.34	14.0	2.53
Uterus corpus	N/A	N/A	N/A	N/A	N/A	10	17.1	2.54	20.7	3.01
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	4	6.5	1.57	8.1	1.91
Male Genital System	34	80.1	6.93	96.5	8.26	N/A	N/A	N/A	N/A	N/A
Prostate	29	69.0	6.45	84.4	7.76	N/A	N/A	N/A	N/A	N/A
Testis	4	6.6	1.59	6.7	1.59	N/A	N/A	N/A	N/A	N/A
Penis	1	4.1	1.96	4.9	2.31	N/A	N/A	N/A	N/A	N/A
Urinary System	28	62.5	5.78	74.1	6.78	15	28.5	3.45	33.6	3.98
Bladder (incl. <i>in situ</i>)	8	21.4	3.77	26.3	4.58	3	6.2	1.65	7.2	1.89
Kidney & renal pelvis	18	38.3	4.22	44.7	4.82	12	22.4	3.03	26.4	3.51
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	3	4.7	1.54	4.8	1.81	2	3.4	1.12	3.5	1.19
Brain	3	4.5	1.52	4.6	1.80	2	3.2	1.09	3.3	1.17
Endocrine System	4	7.6	1.78	7.6	1.78	12	23.9	3.16	25.0	3.28
Thyroid gland	3	6.2	1.63	6.3	1.67	12	23.6	3.15	24.6	3.26
Lymphomas	9	18.9	3.10	22.2	3.55	8	16.3	2.66	18.9	3.04
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	3	6.5	1.98	7.3	2.28	3	6.3	1.68	7.4	1.95
Leukemias	7	14.8	2.95	16.1	3.22	5	8.3	1.79	8.6	1.89
Acute lymphocytic	2	2.3	0.77	2.0	0.68	*	*	*	*	*
Chronic lymphocytic	1	4.3	1.85	4.8	2.01	*	*	*	*	*
Acute myeloid	1	2.5	1.02	2.8	1.13	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	N/A	N/A	N/A	N/A	N/A	2	3.8	1.29	4.2	1.42
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	6	15.7	3.06	17.7	3.42	6	13.9	2.62	15.5	2.96
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	7	17.4	3.56	20.2	4.13	12	23.7	3.14	27.1	3.53
Breast (<i>in situ</i>)	*	*	*	*	*	13	24.1	3.16	28.7	3.65

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Alaska, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	39	372.9	33.03	438.9	38.03	45	339.0	25.94	385.2	29.00
Oral Cavity & Pharynx	2	18.0	7.32	21.8	8.82	1	6.6	2.71	9.0	3.72
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	11	104.0	16.95	123.0	19.19	5	43.4	9.92	48.1	10.88
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	2	17.2	6.84	20.1	7.66	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	3	22.1	7.12	27.9	8.78	2	20.4	6.78	22.3	7.19
Rectum & rectosigmoid	1	9.4	3.77	11.2	4.46	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	2	18.0	6.08	21.8	6.97	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	2	24.2	10.12	28.0	11.19	*	*	*	*	*
Respiratory System	4	45.5	11.47	53.1	13.26	4	37.1	9.73	43.8	11.10
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	4	42.9	11.37	50.4	13.15	3	34.0	9.23	40.7	10.67
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	18	133.4	15.92	150.9	17.64
Female Genital System	N/A	N/A	N/A	N/A	N/A	7	45.5	8.99	54.5	10.78
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	3	23.7	7.04	27.3	8.12
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	1	8.9	4.00	11.0	5.08
Male Genital System	10	85.1	14.53	102.6	17.04	N/A	N/A	N/A	N/A	N/A
Prostate	8	80.8	14.42	98.2	16.94	N/A	N/A	N/A	N/A	N/A
Testis	1	4.4	1.82	4.4	1.81	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	5	56.0	14.36	65.1	16.63	2	19.2	7.09	20.5	7.51
Bladder (incl. <i>in situ</i>)	2	31.6	12.18	37.9	14.38	*	*	*	*	*
Kidney & renal pelvis	3	24.4	7.60	27.2	8.34	1	14.7	6.23	15.7	6.62
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	2	11.2	3.67	10.2	3.46
Thyroid gland	*	*	*	*	*	2	9.0	2.94	7.9	2.55
Lymphomas	2	17.7	6.51	20.0	7.05	2	14.4	4.57	17.3	5.40
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	2	12.8	5.79	13.1	6.20	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	1	14.8	6.68	18.2	8.20	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	3	16.7	5.03	21.3	6.12

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

ALASKA

II-18 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Alaska, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	34	391.3	36.44	460.1	41.90	40	379.7	30.49	432.6	34.24
Oral Cavity & Pharynx	1	19.0	8.35	22.9	9.96	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	10	107.8	18.30	128.3	20.80	4	49.0	11.77	54.8	13.00
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	1	16.3	6.88	19.2	7.61	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	2	23.9	8.13	29.3	9.84	2	23.3	8.08	25.5	8.57
Rectum & rectosigmoid	1	11.6	4.65	13.9	5.49	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	2	22.2	7.49	26.8	8.57	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	2	25.2	10.85	29.6	12.06	*	*	*	*	*
Respiratory System	3	46.0	12.97	52.9	14.78	3	39.7	11.44	46.8	13.03
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	3	42.8	12.83	49.4	14.62	3	36.0	10.81	43.0	12.49
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	17	152.9	18.63	173.2	20.73
Female Genital System	N/A	N/A	N/A	N/A	N/A	6	51.4	10.96	61.4	13.15
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	3	26.7	8.56	30.6	9.90
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	1	11.4	5.18	14.0	6.55
Male Genital System	8	82.4	15.19	100.5	18.06	N/A	N/A	N/A	N/A	N/A
Prostate	7	78.2	15.08	96.1	17.95	N/A	N/A	N/A	N/A	N/A
Testis	1	4.2	1.86	4.4	1.98	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	5	63.0	16.12	72.2	18.53	2	22.1	8.56	23.5	9.04
Bladder (incl. <i>in situ</i>)	2	34.1	13.16	40.4	15.51	*	*	*	*	*
Kidney & renal pelvis	3	29.0	9.30	31.8	10.13	1	16.7	7.50	17.5	7.93
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	2	10.3	3.96	9.5	3.77
Thyroid gland	*	*	*	*	*	1	7.7	3.00	6.8	2.60
Lymphomas	2	22.0	8.07	24.8	8.71	2	17.5	5.51	21.0	6.52
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	1	14.6	7.04	14.8	7.50	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	1	15.6	7.53	19.1	9.17	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	2	15.5	4.72	20.4	6.20

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Alaska, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2	402.7	132.22	508.4	165.48	*	*	*	*	*
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	1	246.9	105.13	315.2	131.51	N/A	N/A	N/A	N/A	N/A
Prostate	1	246.9	105.13	315.2	131.51	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


ALASKA

II-20 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	6,832,810	6,944,767	7,048,088	7,164,228	7,291,843
Non-Hispanic White	3,870,839	3,905,369	3,936,087	3,977,941	4,024,941
Non-Hispanic Black	317,997	331,179	342,709	355,793	369,582
Non-Hispanic Asian/Pacific Islander (NH API)	250,149	262,073	270,557	277,405	287,395
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	285,987	288,846	291,254	294,018	296,600


All Races Population 2015–2019: 35,281,736
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	2,107,701	2,157,151	2,207,320	2,258,904	2,313,157
Hispanic White	1,918,885	1,961,568	2,004,260	2,048,680	2,095,797
Hispanic Black	55,744	57,883	60,268	62,639	64,989

Hispanic/Latino Population, Census 2010: 1,895,149
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

ARIZONA CANCER REGISTRY

Initial Operation: 1981
 Population-based Data Available: 1995
 Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	99.5	100.5	102.0	100.4	94.9	99.5
Missing Race	0.5	0.5	0.7	1.9	1.7	1.0
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.1	0.1	0.0	0.0	0.1
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.9	3.2	2.1	1.4	3.1	2.5
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.3	Ovary	92.8
Oral Cavity & Pharynx	95.7	Prostate	94.1
Esophagus	91.0	Testis	98.7
Stomach	94.2	Bladder (incl. <i>in situ</i>)	97.3
Colon & Rectum	94.6	Kidney & Renal Pelvis	89.4
Liver	54.6	Brain & Other CNS	84.5
Pancreas	83.1	Brain & Other CNS (non-malig)	48.6
Lung & Bronchus	89.5	Thyroid	99.3
Melanomas of the Skin	99.0	Hodgkin Lymphoma	97.5
Female Breast (excl. <i>in situ</i>)	97.7	Non-Hodgkin Lymphoma	94.5
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	85.3
Cervix Uteri	95.6	Leukemias	86.4
Uterus Corpus & Uterus NOS	98.0		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Arizona, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	16,864	404.3	1.42	479.7	1.67	16,316	367.4	1.33	427.9	1.53
Oral Cavity & Pharynx	588	14.0	0.26	17.2	0.32	210	4.7	0.15	5.5	0.17
Lip	16	0.4	0.04	0.5	0.05	5	0.1	0.02	0.1	0.03
Tongue	214	5.0	0.16	6.2	0.19	77	1.7	0.09	2.1	0.11
Major salivary gland	62	1.5	0.09	1.8	0.10	34	0.8	0.06	0.9	0.07
Floor of mouth	22	0.5	0.05	0.6	0.06	10	0.2	0.03	0.3	0.04
Gum & other mouth	54	1.3	0.08	1.6	0.10	38	0.8	0.06	1.0	0.07
Nasopharynx	18	0.4	0.05	0.5	0.06	8	0.2	0.03	0.2	0.04
Oropharynx	33	0.8	0.06	1.0	0.08	8	0.2	0.03	0.2	0.03
Hypopharynx	21	0.5	0.05	0.6	0.06	6	0.1	0.02	0.2	0.03
Digestive System	3,423	82.4	0.64	99.0	0.77	2,544	55.1	0.50	64.9	0.59
Esophagus	296	7.0	0.18	8.4	0.22	70	1.5	0.08	1.7	0.10
Stomach	278	6.8	0.19	8.0	0.22	176	4.0	0.14	4.6	0.16
Small intestine	88	2.2	0.11	2.6	0.12	74	1.6	0.09	1.9	0.10
Colon (excl. rectum)	983	24.1	0.35	28.6	0.41	933	20.5	0.31	23.8	0.36
Rectum & rectosigmoid	469	11.7	0.25	14.1	0.29	312	7.2	0.19	8.5	0.22
Anus, anal canal, & anorectum	39	0.9	0.07	1.1	0.08	83	1.7	0.09	2.2	0.11
Liver	468	10.8	0.23	13.6	0.29	158	3.3	0.12	4.0	0.14
Gallbladder	29	0.7	0.06	0.8	0.07	56	1.2	0.07	1.4	0.09
Pancreas	582	13.8	0.26	16.4	0.31	493	10.3	0.21	12.2	0.25
Respiratory System	2,209	51.7	0.50	61.3	0.59	2,043	41.9	0.42	49.6	0.50
Larynx	142	3.3	0.13	4.1	0.15	33	0.7	0.06	0.9	0.07
Lung & bronchus	2,023	47.3	0.48	56.0	0.56	1,986	40.7	0.41	48.2	0.49
Bones & Joints	48	1.3	0.09	1.3	0.09	35	0.9	0.07	0.9	0.07
Soft Tissue (incl. heart)	140	3.6	0.14	4.0	0.15	99	2.4	0.11	2.6	0.12
Skin (excl. basal & sq.)	1,592	38.9	0.44	45.6	0.52	887	20.6	0.32	23.8	0.36
Melanoma of the skin	1,521	37.1	0.43	43.6	0.51	855	19.9	0.32	23.0	0.36
Breast (excl. <i>in situ</i>)	55	1.3	0.08	1.6	0.10	5,017	114.6	0.75	134.9	0.87
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,901	44.0	0.47	51.6	0.54
Cervix uteri	N/A	N/A	N/A	N/A	N/A	230	6.5	0.20	7.0	0.21
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,026	22.9	0.33	27.6	0.39
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	41	0.9	0.07	1.1	0.08
Ovary	N/A	N/A	N/A	N/A	N/A	431	9.9	0.22	11.6	0.26
Male Genital System	3,664	84.1	0.63	102.6	0.77	N/A	N/A	N/A	N/A	N/A
Prostate	3,436	77.6	0.60	95.9	0.74	N/A	N/A	N/A	N/A	N/A
Testis	194	5.7	0.18	5.7	0.18	N/A	N/A	N/A	N/A	N/A
Penis	25	0.6	0.06	0.7	0.07	N/A	N/A	N/A	N/A	N/A
Urinary System	2,216	53.5	0.52	62.9	0.61	877	19.1	0.30	22.3	0.34
Bladder (incl. <i>in situ</i>)	1,279	30.4	0.39	35.7	0.45	365	7.5	0.18	8.8	0.21
Kidney & renal pelvis	892	21.9	0.34	26.0	0.39	489	11.1	0.23	12.9	0.27
Ureter	28	0.7	0.06	0.8	0.07	18	0.4	0.04	0.5	0.05
Eye & Orbit	30	0.8	0.06	0.8	0.07	31	0.7	0.06	0.8	0.07
Brain & Other CNS	266	6.9	0.19	7.7	0.21	203	4.9	0.16	5.3	0.17
Brain	252	6.5	0.19	7.3	0.21	185	4.4	0.15	4.9	0.16
Endocrine System	267	7.1	0.20	8.0	0.22	711	19.6	0.34	21.0	0.36
Thyroid gland	238	6.3	0.19	7.2	0.21	690	19.0	0.34	20.4	0.35
Lymphomas	821	20.5	0.33	23.6	0.37	617	13.8	0.26	15.8	0.29
Hodgkin lymphoma	82	2.2	0.11	2.3	0.12	65	1.8	0.10	1.8	0.10
Non-Hodgkin lymphoma	739	18.3	0.31	21.2	0.35	552	12.0	0.24	14.0	0.27
Multiple Myeloma	280	6.7	0.18	8.0	0.22	189	4.0	0.13	4.8	0.16
Leukemias	521	13.3	0.26	14.8	0.29	366	8.7	0.21	9.5	0.23
Acute lymphocytic	74	2.2	0.11	2.0	0.10	61	1.8	0.10	1.7	0.10
Chronic lymphocytic	138	3.3	0.13	3.9	0.15	85	1.8	0.09	2.1	0.10
Acute myeloid	178	4.5	0.15	5.1	0.17	129	3.0	0.12	3.3	0.13
Chronic myeloid	69	1.7	0.10	2.0	0.11	50	1.2	0.08	1.3	0.09
Other leukemias	63	1.6	0.09	1.8	0.11	42	1.0	0.07	1.1	0.08
Mesothelioma	50	1.2	0.08	1.4	0.09	16	0.3	0.04	0.4	0.05
Kaposi Sarcoma	11	0.3	0.04	0.3	0.04	1	0.0	0.01	0.0	0.01
Ill-Defined & Unknown	686	16.7	0.29	19.6	0.34	568	12.1	0.23	14.0	0.27
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	290	7.4	0.20	8.4	0.22	595	14.0	0.27	16.0	0.30
Breast (<i>in situ</i>)	7	0.2	0.03	0.2	0.04	1,044	24.2	0.35	28.8	0.41

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Arizona, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	13,319	425.4	1.73	504.2	2.03	12,321	387.8	1.72	450.9	1.93
Oral Cavity & Pharynx	500	16.5	0.35	20.2	0.42	165	5.1	0.19	6.1	0.23
Lip	14	0.5	0.06	0.5	0.07	4	0.1	0.03	0.2	0.03
Tongue	190	6.2	0.21	7.6	0.26	63	2.0	0.12	2.4	0.14
Major salivary gland	51	1.7	0.11	2.0	0.13	24	0.8	0.08	0.9	0.08
Floor of mouth	19	0.6	0.07	0.8	0.08	8	0.3	0.04	0.3	0.05
Gum & other mouth	44	1.4	0.10	1.7	0.12	31	0.9	0.07	1.0	0.09
Nasopharynx	10	0.3	0.05	0.4	0.06	4	0.2	0.04	0.2	0.04
Oropharynx	26	0.9	0.08	1.1	0.10	7	0.2	0.04	0.2	0.04
Hypopharynx	17	0.5	0.06	0.6	0.07	5	0.1	0.03	0.2	0.04
Digestive System	2,504	80.2	0.75	96.2	0.89	1,814	53.0	0.60	62.3	0.69
Esophagus	246	7.5	0.22	9.1	0.27	58	1.6	0.10	1.9	0.12
Stomach	174	5.5	0.19	6.5	0.23	93	2.7	0.14	3.2	0.16
Small intestine	69	2.3	0.13	2.7	0.15	56	1.6	0.10	1.9	0.12
Colon (excl. rectum)	748	24.6	0.42	29.1	0.49	698	20.6	0.38	23.8	0.43
Rectum & rectosigmoid	336	11.6	0.30	14.0	0.36	228	7.5	0.24	8.8	0.28
Anus, anal canal, & anorectum	32	1.0	0.09	1.3	0.10	72	2.1	0.12	2.6	0.15
Liver	278	8.5	0.24	10.8	0.30	86	2.5	0.13	3.0	0.15
Gallbladder	18	0.6	0.06	0.7	0.07	28	0.8	0.07	0.9	0.08
Pancreas	466	14.3	0.31	17.0	0.36	364	9.9	0.24	11.8	0.29
Respiratory System	1,869	55.7	0.59	66.4	0.70	1,745	46.7	0.52	55.6	0.62
Larynx	114	3.5	0.15	4.3	0.18	28	0.8	0.07	1.0	0.09
Lung & bronchus	1,721	51.0	0.56	60.7	0.67	1,701	45.4	0.51	54.0	0.61
Bones & Joints	31	1.3	0.12	1.4	0.12	22	1.0	0.11	1.0	0.10
Soft Tissue (incl. heart)	102	3.7	0.18	4.1	0.19	71	2.6	0.16	2.8	0.16
Skin (excl. basal & sq.)	1,432	47.4	0.59	55.3	0.68	770	27.0	0.49	30.6	0.53
Melanoma of the skin	1,369	45.3	0.58	52.9	0.67	742	26.2	0.48	29.6	0.52
Breast (excl. <i>in situ</i>)	44	1.5	0.11	1.7	0.12	3,829	124.0	0.99	145.7	1.12
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,346	43.5	0.58	51.5	0.67
Cervix uteri	N/A	N/A	N/A	N/A	N/A	127	5.9	0.26	6.2	0.26
Uterus corpus	N/A	N/A	N/A	N/A	N/A	740	22.4	0.40	27.5	0.48
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	27	0.8	0.07	0.9	0.09
Ovary	N/A	N/A	N/A	N/A	N/A	313	10.2	0.28	11.9	0.32
Male Genital System	2,798	85.6	0.75	104.3	0.91	N/A	N/A	N/A	N/A	N/A
Prostate	2,665	78.5	0.70	97.1	0.87	N/A	N/A	N/A	N/A	N/A
Testis	111	6.4	0.28	6.4	0.27	N/A	N/A	N/A	N/A	N/A
Penis	15	0.5	0.06	0.6	0.07	N/A	N/A	N/A	N/A	N/A
Urinary System	1,797	56.3	0.62	66.2	0.72	646	18.8	0.36	22.0	0.41
Bladder (incl. <i>in situ</i>)	1,134	34.1	0.46	40.1	0.55	317	8.5	0.22	10.0	0.26
Kidney & renal pelvis	622	21.0	0.40	24.7	0.46	311	9.8	0.27	11.3	0.31
Ureter	25	0.8	0.07	0.9	0.08	15	0.4	0.05	0.5	0.06
Eye & Orbit	25	0.9	0.09	1.0	0.10	25	0.9	0.09	1.0	0.09
Brain & Other CNS	203	7.8	0.27	8.7	0.29	152	5.6	0.23	6.1	0.24
Brain	194	7.4	0.26	8.3	0.28	138	4.9	0.21	5.4	0.22
Endocrine System	196	8.1	0.28	9.1	0.30	440	20.4	0.48	21.6	0.48
Thyroid gland	176	7.2	0.26	8.1	0.28	424	19.8	0.47	21.0	0.48
Lymphomas	620	21.5	0.41	24.6	0.46	456	14.1	0.32	16.1	0.36
Hodgkin lymphoma	54	2.5	0.16	2.6	0.17	40	1.9	0.15	2.0	0.15
Non-Hodgkin lymphoma	567	18.9	0.38	21.9	0.43	416	12.2	0.29	14.2	0.33
Multiple Myeloma	202	6.2	0.20	7.4	0.24	130	3.5	0.15	4.3	0.17
Leukemias	392	13.7	0.33	15.4	0.36	261	8.7	0.27	9.6	0.29
Acute lymphocytic	32	1.9	0.16	1.7	0.14	27	1.6	0.15	1.4	0.13
Chronic lymphocytic	122	3.7	0.16	4.4	0.18	75	2.0	0.11	2.4	0.13
Acute myeloid	137	4.6	0.19	5.3	0.21	92	2.9	0.15	3.3	0.16
Chronic myeloid	50	1.8	0.12	2.0	0.13	36	1.2	0.10	1.4	0.11
Other leukemias	51	1.7	0.11	2.0	0.13	31	1.0	0.09	1.1	0.10
Mesothelioma	38	1.1	0.08	1.3	0.10	13	0.4	0.05	0.4	0.05
Kaposi Sarcoma	3	0.2	0.04	0.2	0.05	*	*	*	*	*
Ill-Defined & Unknown	561	17.7	0.35	20.7	0.40	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	211	7.8	0.26	8.8	0.28	431	14.9	0.36	16.9	0.39
Breast (<i>in situ</i>)	5	0.2	0.04	0.2	0.05	780	26.5	0.47	31.3	0.53

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Arizona, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	523	393.9	8.38	474.9	9.87	455	320.6	6.93	375.6	8.04
Oral Cavity & Pharynx	12	8.9	1.20	10.5	1.40	4	2.9	0.63	3.4	0.75
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	3	2.2	0.61	2.7	0.70	1	0.9	0.35	1.1	0.42
Major salivary gland	1	0.8	0.36	0.9	0.43	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	1	1.1	0.44	1.3	0.52	*	*	*	*	*
Hypopharynx	1	0.9	0.40	1.0	0.44	*	*	*	*	*
Digestive System	113	85.5	3.92	103.4	4.63	90	64.4	3.14	76.5	3.68
Esophagus	4	3.8	0.93	4.5	1.05	3	1.9	0.51	2.4	0.63
Stomach	13	10.3	1.40	12.2	1.60	7	5.6	0.95	6.2	1.04
Small intestine	6	4.7	0.89	5.6	1.03	3	2.1	0.58	2.4	0.66
Colon (excl. rectum)	31	23.2	2.01	28.1	2.37	33	24.2	1.93	28.8	2.28
Rectum & rectosigmoid	13	9.6	1.26	11.5	1.51	9	6.3	0.99	7.4	1.14
Anus, anal canal, & anorectum	1	1.1	0.49	1.4	0.61	2	1.1	0.38	1.4	0.48
Liver	16	11.3	1.36	14.2	1.66	6	4.0	0.76	5.0	0.92
Gallbladder	*	*	*	*	*	3	2.0	0.56	2.4	0.64
Pancreas	22	17.9	1.85	21.7	2.20	20	14.2	1.46	17.1	1.73
Respiratory System	73	61.9	3.50	73.4	4.06	58	42.3	2.59	51.4	3.07
Larynx	5	3.4	0.75	4.2	0.89	1	0.7	0.30	0.9	0.37
Lung & bronchus	67	57.7	3.41	68.2	3.94	57	41.5	2.57	50.4	3.05
Bones & Joints	3	1.7	0.49	1.6	0.48	*	*	*	*	*
Soft Tissue (incl. heart)	5	3.3	0.74	3.8	0.86	3	2.1	0.53	2.4	0.61
Skin (excl. basal & sq.)	2	1.1	0.42	1.3	0.47	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	*	*	*	*	*	3	1.8	0.52	2.2	0.60
Breast (excl. <i>in situ</i>)	2	1.5	0.47	1.8	0.56	149	103.9	3.92	120.5	4.50
Female Genital System	N/A	N/A	N/A	N/A	N/A	48	33.1	2.19	38.6	2.53
Cervix uteri	N/A	N/A	N/A	N/A	N/A	7	4.7	0.81	5.0	0.87
Uterus corpus	N/A	N/A	N/A	N/A	N/A	26	17.8	1.61	21.2	1.89
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	3	1.8	0.52	2.1	0.59
Ovary	N/A	N/A	N/A	N/A	N/A	9	6.4	0.96	7.5	1.11
Male Genital System	169	118.0	4.34	148.0	5.29	N/A	N/A	N/A	N/A	N/A
Prostate	166	115.8	4.31	145.8	5.25	N/A	N/A	N/A	N/A	N/A
Testis	2	1.3	0.38	1.3	0.37	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	52	41.5	2.82	49.3	3.28	21	15.1	1.52	18.3	1.81
Bladder (incl. <i>in situ</i>)	19	17.6	2.01	20.4	2.29	7	5.7	0.97	6.9	1.16
Kidney & renal pelvis	33	23.2	1.94	28.0	2.30	13	9.0	1.14	10.7	1.35
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	6	4.1	0.79	4.7	0.93	4	2.5	0.60	2.8	0.69
Brain	6	4.0	0.79	4.7	0.92	3	2.3	0.58	2.6	0.67
Endocrine System	5	3.4	0.76	3.9	0.88	19	12.9	1.35	14.5	1.50
Thyroid gland	4	2.9	0.68	3.3	0.76	18	12.4	1.32	13.7	1.46
Lymphomas	25	17.4	1.66	20.1	1.90	15	10.3	1.22	11.1	1.33
Hodgkin lymphoma	5	2.6	0.56	2.7	0.60	4	2.6	0.59	2.3	0.54
Non-Hodgkin lymphoma	21	14.8	1.56	17.4	1.80	11	7.7	1.07	8.8	1.22
Multiple Myeloma	17	12.5	1.49	15.2	1.78	13	9.4	1.21	11.3	1.43
Leukemias	15	12.2	1.56	13.4	1.74	11	7.3	1.04	8.1	1.15
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	1	0.7	0.31	0.7	0.31
Chronic lymphocytic	2	2.3	0.74	2.5	0.81	1	0.9	0.38	1.1	0.43
Acute myeloid	7	5.7	1.05	6.4	1.18	5	3.0	0.65	3.4	0.73
Chronic myeloid	3	2.3	0.67	2.5	0.75	2	1.5	0.47	1.5	0.51
Other leukemias	*	*	*	*	*	2	1.2	0.43	1.4	0.50
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	2	0.9	0.32	0.9	0.32	*	*	*	*	*
Ill-Defined & Unknown	21	18.7	2.02	21.8	2.30	17	12.3	1.39	14.3	1.60
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	11	8.7	1.34	9.7	1.50	22	15.6	1.51	18.2	1.75
Breast (<i>in situ</i>)	*	*	*	*	*	41	28.1	2.02	33.0	2.33

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Arizona, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	217	220.3	7.03	258.4	8.17	343	240.7	5.94	278.5	6.86
Oral Cavity & Pharynx	8	8.0	1.33	9.4	1.54	5	3.3	0.68	3.9	0.78
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	1	1.3	0.49	1.4	0.55	2	1.2	0.42	1.5	0.49
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	2	2.5	0.83	3.0	0.97	1	0.9	0.35	1.0	0.42
Nasopharynx	1	1.3	0.54	1.5	0.62	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	62	64.2	3.83	75.6	4.46	56	41.0	2.52	48.1	2.94
Esophagus	4	3.9	0.92	4.5	1.05	*	*	*	*	*
Stomach	9	9.4	1.50	11.0	1.73	8	5.5	0.92	6.5	1.08
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	12	12.9	1.72	15.2	2.01	20	15.1	1.53	17.5	1.78
Rectum & rectosigmoid	9	8.2	1.24	9.9	1.49	7	4.7	0.81	5.4	0.93
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	16	16.4	1.93	19.7	2.29	6	4.3	0.82	5.1	0.96
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	8	8.6	1.51	9.9	1.71	8	6.6	1.04	7.8	1.22
Respiratory System	30	32.3	2.73	38.7	3.22	37	28.2	2.13	33.1	2.47
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	29	30.8	2.68	37.0	3.16	37	27.4	2.09	32.3	2.43
Bones & Joints	2	1.4	0.49	1.6	0.55	*	*	*	*	*
Soft Tissue (incl. heart)	3	2.3	0.65	2.7	0.77	3	1.8	0.49	2.1	0.56
Skin (excl. basal & sq.)	2	1.6	0.59	1.8	0.68	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	*	*	*	*	*	2	1.5	0.44	1.9	0.55
Breast (excl. <i>in situ</i>)	*	*	*	*	*	125	84.8	3.45	98.4	4.00
Female Genital System	N/A	N/A	N/A	N/A	N/A	39	25.9	1.88	30.9	2.24
Cervix uteri	N/A	N/A	N/A	N/A	N/A	5	3.4	0.67	3.9	0.77
Uterus corpus	N/A	N/A	N/A	N/A	N/A	21	13.7	1.36	16.3	1.62
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	1	0.8	0.32	1.0	0.42
Ovary	N/A	N/A	N/A	N/A	N/A	10	6.4	0.93	7.9	1.14
Male Genital System	42	42.3	3.06	50.7	3.60	N/A	N/A	N/A	N/A	N/A
Prostate	39	39.6	2.99	47.8	3.53	N/A	N/A	N/A	N/A	N/A
Testis	3	1.7	0.48	1.8	0.52	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	22	22.8	2.27	26.7	2.63	11	8.4	1.18	9.6	1.32
Bladder (incl. <i>in situ</i>)	12	13.6	1.82	15.5	2.05	5	3.8	0.81	4.3	0.91
Kidney & renal pelvis	10	9.0	1.34	11.0	1.63	5	3.9	0.78	4.4	0.87
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	3	3.0	0.75	3.2	0.81	3	2.1	0.53	2.4	0.62
Brain	3	2.9	0.73	3.1	0.80	3	1.8	0.48	2.1	0.56
Endocrine System	7	5.9	1.02	6.6	1.17	23	15.1	1.43	16.2	1.54
Thyroid gland	6	5.1	0.95	5.6	1.08	23	14.8	1.41	15.9	1.53
Lymphomas	15	14.9	1.82	17.2	2.10	14	9.6	1.18	11.1	1.36
Hodgkin lymphoma	1	1.0	0.39	1.1	0.43	2	1.1	0.38	1.2	0.39
Non-Hodgkin lymphoma	13	13.9	1.78	16.1	2.05	12	8.4	1.12	10.0	1.30
Multiple Myeloma	3	3.1	0.77	3.8	0.94	4	3.3	0.73	3.7	0.79
Leukemias	10	10.3	1.51	11.2	1.68	8	5.7	0.94	5.6	0.93
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	3	2.2	0.58	1.9	0.51
Chronic lymphocytic	1	1.6	0.66	1.9	0.78	*	*	*	*	*
Acute myeloid	4	4.5	1.03	5.0	1.15	3	2.3	0.57	2.4	0.62
Chronic myeloid	1	1.1	0.46	1.5	0.62	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	5	6.4	1.32	7.3	1.49	12	9.3	1.26	10.9	1.46
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	5	4.1	0.82	4.7	0.96	17	11.7	1.32	13.5	1.52
Breast (<i>in situ</i>)	*	*	*	*	*	32	21.3	1.70	25.5	2.03

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Arizona, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	319	298.6	7.90	350.7	9.18	392	286.8	6.64	331.5	7.59
Oral Cavity & Pharynx	8	7.2	1.16	8.6	1.36	4	2.8	0.64	3.4	0.77
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	1	1.1	0.45	1.4	0.54	1	0.8	0.31	1.0	0.40
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	2	1.3	0.49	1.5	0.55	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	106	97.4	4.45	117.1	5.27	88	66.4	3.25	77.9	3.76
Esophagus	7	6.8	1.19	7.9	1.34	1	1.0	0.43	1.2	0.50
Stomach	15	14.5	1.80	17.0	2.07	11	8.4	1.16	9.8	1.33
Small intestine	2	1.5	0.50	1.8	0.60	1	1.2	0.45	1.3	0.48
Colon (excl. rectum)	24	22.3	2.15	26.8	2.55	24	18.1	1.69	20.9	1.94
Rectum & rectosigmoid	16	13.6	1.55	16.8	1.90	9	6.4	0.97	7.7	1.17
Anus, anal canal, & anorectum	*	*	*	*	*	2	1.0	0.35	1.3	0.46
Liver	23	20.1	1.95	25.1	2.38	13	9.8	1.26	11.5	1.45
Gallbladder	2	2.0	0.72	2.2	0.82	7	5.3	0.94	6.1	1.07
Pancreas	10	9.9	1.45	11.5	1.67	12	9.2	1.23	10.7	1.43
Respiratory System	20	20.7	2.20	24.2	2.53	20	15.0	1.56	17.8	1.82
Larynx	2	1.8	0.57	2.3	0.70	*	*	*	*	*
Lung & bronchus	17	18.6	2.11	21.5	2.42	18	13.8	1.49	16.3	1.74
Bones & Joints	1	1.0	0.37	1.1	0.45	2	1.1	0.38	1.2	0.40
Soft Tissue (incl. heart)	4	3.4	0.77	3.6	0.85	3	2.1	0.54	2.4	0.62
Skin (excl. basal & sq.)	8	8.1	1.34	9.7	1.59	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	7	6.8	1.24	8.2	1.46	5	4.0	0.81	4.4	0.89
Breast (excl. <i>in situ</i>)	*	*	*	*	*	78	56.0	2.90	66.1	3.37
Female Genital System	N/A	N/A	N/A	N/A	N/A	71	51.2	2.77	58.7	3.14
Cervix uteri	N/A	N/A	N/A	N/A	N/A	9	6.7	1.00	7.3	1.09
Uterus corpus	N/A	N/A	N/A	N/A	N/A	41	29.5	2.10	33.7	2.36
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	1.9	0.55	2.2	0.63
Ovary	N/A	N/A	N/A	N/A	N/A	13	9.5	1.19	11.2	1.38
Male Genital System	57	55.1	3.48	64.4	4.02	N/A	N/A	N/A	N/A	N/A
Prostate	46	47.6	3.31	56.7	3.87	N/A	N/A	N/A	N/A	N/A
Testis	9	5.7	0.89	5.5	0.84	N/A	N/A	N/A	N/A	N/A
Penis	2	1.6	0.55	2.0	0.68	N/A	N/A	N/A	N/A	N/A
Urinary System	53	49.4	3.18	57.5	3.66	33	23.6	1.88	27.5	2.16
Bladder (incl. <i>in situ</i>)	6	6.5	1.24	7.4	1.39	2	1.4	0.50	1.5	0.52
Kidney & renal pelvis	46	42.2	2.90	49.4	3.36	31	22.0	1.80	25.9	2.09
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	5	4.2	0.88	4.3	0.93	4	2.9	0.67	3.1	0.72
Brain	5	3.8	0.84	3.9	0.88	4	2.7	0.66	3.0	0.71
Endocrine System	5	4.4	0.88	5.2	1.04	25	17.9	1.63	19.4	1.76
Thyroid gland	4	3.4	0.76	4.0	0.90	24	17.2	1.59	18.7	1.72
Lymphomas	15	14.1	1.72	16.4	1.97	19	14.2	1.49	16.3	1.69
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	10	9.7	1.43	11.6	1.67	10	7.2	1.05	8.6	1.24
Leukemias	10	8.1	1.20	8.3	1.28	10	7.2	1.05	7.6	1.11
Acute lymphocytic	4	2.5	0.60	2.2	0.52	3	2.2	0.56	2.2	0.55
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	2	1.9	0.57	2.1	0.63	3	2.5	0.63	2.6	0.67
Chronic myeloid	2	1.5	0.53	1.7	0.58	1	1.1	0.41	1.1	0.41
Other leukemias	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	14	14.0	1.81	16.6	2.13	18	13.8	1.50	15.9	1.72
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	12	10.6	1.46	11.8	1.62	18	13.0	1.40	15.3	1.64
Breast (<i>in situ</i>)	*	*	*	*	*	16	11.4	1.30	13.5	1.51

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Arizona, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,218	331.5	3.41	392.3	3.99	2,641	324.6	2.93	378.0	3.40
Oral Cavity & Pharynx	53	7.7	0.51	9.3	0.60	29	3.7	0.32	4.2	0.36
Lip	1	0.2	0.09	0.3	0.11	*	*	*	*	*
Tongue	16	2.2	0.26	2.7	0.32	9	1.2	0.19	1.4	0.22
Major salivary gland	7	1.1	0.19	1.3	0.22	7	0.9	0.15	1.0	0.18
Floor of mouth	2	0.3	0.09	0.4	0.12	*	*	*	*	*
Gum & other mouth	5	0.8	0.18	1.0	0.21	4	0.5	0.12	0.6	0.13
Nasopharynx	4	0.5	0.13	0.6	0.15	2	0.2	0.07	0.2	0.07
Oropharynx	4	0.6	0.14	0.7	0.16	*	*	*	*	*
Hypopharynx	2	0.3	0.11	0.4	0.12	*	*	*	*	*
Digestive System	619	94.2	1.82	113.1	2.15	482	63.8	1.35	75.3	1.57
Esophagus	33	5.0	0.42	6.0	0.49	7	0.9	0.16	1.1	0.19
Stomach	66	11.0	0.65	12.7	0.75	57	7.3	0.45	8.5	0.52
Small intestine	10	1.5	0.23	1.8	0.26	12	1.5	0.20	1.8	0.23
Colon (excl. rectum)	161	24.8	0.94	29.3	1.10	152	20.1	0.75	23.7	0.88
Rectum & rectosigmoid	91	12.8	0.64	15.4	0.76	57	7.0	0.43	8.3	0.50
Anus, anal canal, & anorectum	4	0.5	0.14	0.6	0.16	7	0.9	0.16	1.2	0.19
Liver	133	18.8	0.78	23.7	0.95	47	6.3	0.43	7.5	0.50
Gallbladder	7	1.3	0.23	1.5	0.26	17	2.3	0.26	2.7	0.30
Pancreas	74	12.1	0.67	14.5	0.79	87	12.3	0.61	14.5	0.71
Respiratory System	208	36.6	1.21	42.9	1.39	175	25.0	0.87	29.1	1.00
Larynx	18	2.9	0.33	3.5	0.38	3	0.4	0.10	0.5	0.12
Lung & bronchus	183	32.9	1.15	38.4	1.33	167	24.1	0.86	27.9	0.98
Bones & Joints	10	1.0	0.15	1.0	0.15	10	0.9	0.14	0.9	0.15
Soft Tissue (incl. heart)	25	3.2	0.31	3.5	0.36	18	2.1	0.23	2.4	0.27
Skin (excl. basal & sq.)	40	6.2	0.47	7.3	0.55	48	5.6	0.37	6.6	0.44
Melanoma of the skin	36	5.6	0.45	6.6	0.53	46	5.3	0.36	6.3	0.43
Breast (excl. <i>in situ</i>)	7	1.1	0.21	1.3	0.24	789	95.1	1.55	112.4	1.83
Female Genital System	N/A	N/A	N/A	N/A	N/A	385	45.0	1.05	52.1	1.23
Cervix uteri	N/A	N/A	N/A	N/A	N/A	81	8.9	0.45	9.6	0.49
Uterus corpus	N/A	N/A	N/A	N/A	N/A	192	22.4	0.74	26.6	0.88
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	7	0.8	0.14	0.9	0.16
Ovary	N/A	N/A	N/A	N/A	N/A	83	10.0	0.51	11.6	0.59
Male Genital System	513	73.9	1.57	89.7	1.87	N/A	N/A	N/A	N/A	N/A
Prostate	438	67.1	1.52	82.6	1.82	N/A	N/A	N/A	N/A	N/A
Testis	66	5.4	0.31	5.4	0.31	N/A	N/A	N/A	N/A	N/A
Penis	6	1.1	0.21	1.3	0.24	N/A	N/A	N/A	N/A	N/A
Urinary System	274	42.3	1.23	49.9	1.43	160	20.1	0.74	23.8	0.87
Bladder (incl. <i>in situ</i>)	93	17.2	0.84	19.9	0.96	31	4.2	0.35	5.0	0.41
Kidney & renal pelvis	177	24.6	0.88	29.4	1.04	126	15.5	0.64	18.3	0.75
Ureter	2	0.3	0.12	0.4	0.14	2	0.4	0.11	0.4	0.12
Eye & Orbit	4	0.4	0.11	0.4	0.11	5	0.5	0.10	0.5	0.12
Brain & Other CNS	47	5.3	0.39	5.7	0.43	39	4.2	0.32	4.6	0.36
Brain	43	5.0	0.38	5.4	0.42	35	3.9	0.31	4.2	0.35
Endocrine System	52	6.1	0.41	6.8	0.46	199	20.6	0.67	22.6	0.75
Thyroid gland	46	5.5	0.39	6.2	0.44	196	20.4	0.67	22.3	0.74
Lymphomas	138	19.5	0.82	22.5	0.94	110	13.6	0.61	15.8	0.70
Hodgkin lymphoma	20	2.1	0.23	2.2	0.25	18	1.9	0.21	2.1	0.23
Non-Hodgkin lymphoma	117	17.4	0.78	20.4	0.91	92	11.7	0.57	13.7	0.66
Multiple Myeloma	47	7.2	0.51	8.5	0.59	32	4.1	0.34	4.9	0.40
Leukemias	90	10.6	0.57	11.6	0.64	74	8.2	0.45	9.0	0.50
Acute lymphocytic	33	2.8	0.23	2.6	0.24	25	2.1	0.20	2.0	0.20
Chronic lymphocytic	10	1.7	0.26	2.0	0.31	7	1.0	0.17	1.2	0.20
Acute myeloid	26	3.4	0.33	3.7	0.37	25	3.0	0.28	3.4	0.32
Chronic myeloid	12	1.5	0.21	1.7	0.24	10	1.2	0.17	1.3	0.20
Other leukemias	9	1.4	0.23	1.5	0.26	8	1.0	0.16	1.1	0.18
Mesothelioma	9	1.7	0.27	1.9	0.31	3	0.4	0.10	0.4	0.12
Kaposi Sarcoma	4	0.5	0.12	0.5	0.13	*	*	*	*	*
Ill-Defined & Unknown	79	13.8	0.75	16.2	0.87	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	49	6.6	0.47	7.5	0.54	105	12.9	0.58	14.6	0.66
Breast (<i>in situ</i>)	*	*	*	*	*	164	19.3	0.69	23.1	0.82

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

ARIZONA

II-28 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Arizona, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,113	336.0	3.52	397.7	4.12	2,527	332.1	3.05	386.4	3.54
Oral Cavity & Pharynx	50	7.7	0.52	9.3	0.62	26	3.6	0.33	4.2	0.37
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	15	2.3	0.27	2.8	0.33	8	1.2	0.20	1.4	0.23
Major salivary gland	7	1.1	0.20	1.3	0.23	6	0.8	0.15	1.0	0.18
Floor of mouth	2	0.3	0.10	0.4	0.12	*	*	*	*	*
Gum & other mouth	4	0.7	0.16	0.8	0.19	4	0.5	0.12	0.5	0.13
Nasopharynx	4	0.6	0.14	0.7	0.16	2	0.2	0.07	0.2	0.07
Oropharynx	4	0.6	0.15	0.7	0.17	*	*	*	*	*
Hypopharynx	2	0.3	0.11	0.4	0.13	*	*	*	*	*
Digestive System	594	96.1	1.89	115.4	2.23	462	64.9	1.39	76.6	1.63
Esophagus	31	5.1	0.43	6.1	0.51	7	1.0	0.17	1.1	0.19
Stomach	65	11.4	0.68	13.2	0.78	55	7.5	0.47	8.8	0.54
Small intestine	9	1.5	0.23	1.7	0.26	11	1.5	0.21	1.7	0.24
Colon (excl. rectum)	155	25.5	0.98	30.1	1.14	146	20.4	0.78	24.0	0.91
Rectum & rectosigmoid	89	13.2	0.67	15.9	0.80	55	7.2	0.45	8.6	0.53
Anus, anal canal, & anorectum	3	0.5	0.13	0.5	0.15	7	1.0	0.17	1.2	0.20
Liver	124	18.8	0.80	23.6	0.98	45	6.4	0.44	7.6	0.52
Gallbladder	7	1.3	0.23	1.5	0.27	17	2.4	0.27	2.8	0.31
Pancreas	72	12.4	0.70	14.8	0.82	83	12.4	0.63	14.6	0.73
Respiratory System	198	36.9	1.24	43.1	1.43	169	25.6	0.91	29.7	1.04
Larynx	17	2.9	0.34	3.5	0.39	3	0.4	0.10	0.5	0.13
Lung & bronchus	174	33.1	1.18	38.7	1.36	161	24.6	0.89	28.5	1.02
Bones & Joints	10	1.0	0.16	1.0	0.16	9	0.9	0.14	0.9	0.15
Soft Tissue (incl. heart)	24	3.3	0.33	3.7	0.37	17	2.2	0.24	2.5	0.29
Skin (excl. basal & sq.)	34	5.6	0.46	6.6	0.54	43	5.5	0.38	6.3	0.44
Melanoma of the skin	30	4.9	0.43	5.9	0.51	41	5.2	0.37	6.0	0.43
Breast (excl. <i>in situ</i>)	7	1.2	0.22	1.3	0.25	758	97.8	1.63	115.6	1.92
Female Genital System	N/A	N/A	N/A	N/A	N/A	366	46.0	1.10	53.3	1.28
Cervix uteri	N/A	N/A	N/A	N/A	N/A	77	9.2	0.48	9.9	0.52
Uterus corpus	N/A	N/A	N/A	N/A	N/A	183	22.9	0.77	27.1	0.92
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	6	0.8	0.14	0.9	0.17
Ovary	N/A	N/A	N/A	N/A	N/A	79	10.2	0.53	11.8	0.61
Male Genital System	479	73.5	1.61	89.4	1.92	N/A	N/A	N/A	N/A	N/A
Prostate	410	66.6	1.56	82.2	1.87	N/A	N/A	N/A	N/A	N/A
Testis	61	5.6	0.33	5.5	0.33	N/A	N/A	N/A	N/A	N/A
Penis	6	1.1	0.22	1.3	0.25	N/A	N/A	N/A	N/A	N/A
Urinary System	263	43.3	1.27	51.1	1.48	153	20.5	0.77	24.2	0.90
Bladder (incl. <i>in situ</i>)	89	17.3	0.86	20.0	0.99	29	4.2	0.36	5.0	0.43
Kidney & renal pelvis	171	25.4	0.92	30.4	1.09	121	15.9	0.67	18.8	0.78
Ureter	2	0.3	0.12	0.4	0.14	2	0.3	0.11	0.4	0.12
Eye & Orbit	4	0.5	0.12	0.5	0.12	5	0.5	0.11	0.6	0.13
Brain & Other CNS	45	5.6	0.41	6.1	0.45	37	4.4	0.33	4.8	0.38
Brain	42	5.3	0.40	5.7	0.45	34	4.0	0.32	4.4	0.36
Endocrine System	48	6.2	0.42	6.8	0.48	193	21.7	0.71	23.7	0.79
Thyroid gland	43	5.6	0.40	6.2	0.46	190	21.4	0.71	23.4	0.79
Lymphomas	135	20.3	0.85	23.4	0.98	104	13.8	0.63	16.0	0.73
Hodgkin lymphoma	20	2.2	0.24	2.3	0.26	17	2.0	0.22	2.2	0.24
Non-Hodgkin lymphoma	115	18.1	0.82	21.2	0.95	87	11.9	0.59	13.9	0.68
Multiple Myeloma	45	7.3	0.52	8.6	0.60	31	4.3	0.35	5.0	0.41
Leukemias	87	11.1	0.59	12.0	0.67	70	8.3	0.47	9.0	0.52
Acute lymphocytic	32	3.0	0.25	2.8	0.26	23	2.2	0.21	2.1	0.21
Chronic lymphocytic	9	1.7	0.27	2.0	0.32	6	0.9	0.16	1.1	0.20
Acute myeloid	25	3.5	0.35	3.9	0.39	24	3.1	0.29	3.4	0.33
Chronic myeloid	12	1.5	0.21	1.7	0.24	9	1.2	0.18	1.4	0.21
Other leukemias	9	1.4	0.24	1.6	0.27	7	0.9	0.16	1.0	0.18
Mesothelioma	9	1.7	0.28	2.0	0.32	3	0.4	0.11	0.5	0.13
Kaposi Sarcoma	4	0.5	0.12	0.6	0.14	*	*	*	*	*
Ill-Defined & Unknown	76	14.1	0.78	16.6	0.90	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	47	6.9	0.49	7.8	0.57	101	13.3	0.61	15.0	0.69
Breast (<i>in situ</i>)	*	*	*	*	*	158	20.0	0.72	23.9	0.86

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Arizona, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	9	92.4	16.31	104.7	18.03	15	112.4	15.18	131.3	17.59
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	2	28.0	9.42	33.0	10.73	2	21.4	7.10	25.4	8.13
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	2	13.8	5.24	17.1	6.32
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	2	13.8	5.24	17.1	6.32
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	5	30.0	6.81	35.5	8.00
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	16.1	6.01	18.6	6.86
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1	8.8	4.39	10.8	5.16
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	2	23.3	7.64	28.9	9.08	N/A	N/A	N/A	N/A	N/A
Prostate	2	23.3	7.64	28.9	9.08	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	2	11.7	4.72	13.5	5.26

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


ARIZONA

II-30 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	2,979,732	2,991,815	3,003,855	3,012,161	3,020,985
Non-Hispanic White	2,211,532	2,211,617	2,212,059	2,211,304	2,210,357
Non-Hispanic Black	474,782	477,859	480,025	481,992	483,947
Non-Hispanic Asian/Pacific Islander (NH API)	56,326	59,246	61,561	62,715	64,387
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	0	0	0	0	0


All Races Population 2015–2019: 15,008,548
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	212,796	218,384	225,078	230,632	236,539
Hispanic White	194,501	199,174	204,806	209,528	214,733
Hispanic Black	7,773	8,173	8,586	8,924	9,258

Hispanic/Latino Population, Census 2010: 186,050
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

ARKANSAS CANCER REGISTRY

Initial Operation: 1996
 Population-based Data Available: 1996
 Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	105.1	107.4	108.7	113.8	116.7	110.3
Missing Race	1.0	1.3	1.4	1.7	1.0	1.3
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.6	0.5	0.5	1.2	0.6	0.7
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.7	2.6	2.2	2.3	2.2	2.4
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.2	Ovary	91.7
Oral Cavity & Pharynx	97.3	Prostate	96.6
Esophagus	94.9	Testis	98.9
Stomach	95.9	Bladder (incl. <i>in situ</i>)	97.7
Colon & Rectum	95.6	Kidney & Renal Pelvis	90.6
Liver	59.8	Brain & Other CNS	81.4
Pancreas	82.9	Brain & Other CNS (non-malig)	37.5
Lung & Bronchus	89.8	Thyroid	99.2
Melanomas of the Skin	98.2	Hodgkin Lymphoma	98.0
Female Breast (excl. <i>in situ</i>)	97.8	Non-Hodgkin Lymphoma	95.4
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	92.4
Cervix Uteri	94.6	Leukemias	89.1
Uterus Corpus & Uterus NOS	97.9		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Arkansas, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	9,519	547.1	2.57	653.4	3.03	8,388	436.8	2.21	511.8	2.54
Oral Cavity & Pharynx	384	22.1	0.52	26.9	0.62	142	7.3	0.28	8.7	0.33
Lip	17	1.0	0.11	1.2	0.13	5	0.3	0.05	0.3	0.06
Tongue	115	6.5	0.28	8.0	0.34	45	2.3	0.16	2.8	0.19
Major salivary gland	35	2.2	0.17	2.5	0.19	16	0.9	0.10	1.0	0.11
Floor of mouth	16	0.9	0.10	1.1	0.12	7	0.4	0.06	0.5	0.08
Gum & other mouth	44	2.6	0.18	3.1	0.21	30	1.4	0.12	1.7	0.14
Nasopharynx	10	0.6	0.09	0.8	0.11	5	0.3	0.06	0.3	0.07
Oropharynx	23	1.3	0.13	1.6	0.15	6	0.3	0.05	0.4	0.07
Hypopharynx	20	1.1	0.11	1.3	0.13	4	0.2	0.05	0.3	0.06
Digestive System	1,826	105.7	1.13	127.2	1.35	1,374	69.2	0.86	82.0	1.01
Esophagus	141	7.8	0.30	9.7	0.37	31	1.5	0.12	1.9	0.15
Stomach	156	9.1	0.33	10.9	0.39	87	4.5	0.22	5.3	0.26
Small intestine	61	3.5	0.20	4.2	0.25	50	2.6	0.17	3.1	0.20
Colon (excl. rectum)	597	35.5	0.67	42.0	0.78	570	28.7	0.55	33.7	0.64
Rectum & rectosigmoid	271	15.9	0.44	19.1	0.53	182	9.5	0.32	11.3	0.38
Anus, anal canal, & anorectum	27	1.6	0.14	1.9	0.17	54	2.8	0.18	3.4	0.21
Liver	218	11.8	0.37	14.9	0.45	67	3.2	0.18	3.9	0.22
Gallbladder	12	0.7	0.09	0.8	0.11	27	1.3	0.12	1.6	0.14
Pancreas	261	15.0	0.43	18.0	0.50	226	11.0	0.33	13.1	0.39
Respiratory System	1,760	99.2	1.08	119.4	1.29	1,348	64.8	0.80	78.1	0.96
Larynx	116	6.4	0.27	8.0	0.33	32	1.6	0.13	2.0	0.16
Lung & bronchus	1,626	91.7	1.04	110.1	1.24	1,302	62.5	0.79	75.3	0.95
Bones & Joints	18	1.2	0.13	1.2	0.13	16	1.0	0.12	1.0	0.12
Soft Tissue (incl. heart)	58	3.6	0.22	4.0	0.24	45	2.6	0.18	2.8	0.19
Skin (excl. basal & sq.)	549	33.1	0.65	38.6	0.75	349	19.8	0.49	22.2	0.54
Melanoma of the skin	513	30.8	0.62	36.0	0.72	330	18.8	0.48	21.1	0.53
Breast (excl. <i>in situ</i>)	22	1.3	0.13	1.6	0.15	2,314	122.4	1.18	143.9	1.36
Female Genital System	N/A	N/A	N/A	N/A	N/A	946	51.0	0.77	60.0	0.89
Cervix uteri	N/A	N/A	N/A	N/A	N/A	149	9.5	0.36	10.3	0.38
Uterus corpus	N/A	N/A	N/A	N/A	N/A	481	24.8	0.52	30.1	0.62
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	18	0.9	0.10	1.1	0.12
Ovary	N/A	N/A	N/A	N/A	N/A	196	10.5	0.35	12.2	0.40
Male Genital System	2,297	124.8	1.19	153.0	1.44	N/A	N/A	N/A	N/A	N/A
Prostate	2,205	118.4	1.15	146.4	1.41	N/A	N/A	N/A	N/A	N/A
Testis	71	5.1	0.28	5.1	0.27	N/A	N/A	N/A	N/A	N/A
Penis	19	1.1	0.12	1.3	0.14	N/A	N/A	N/A	N/A	N/A
Urinary System	1,099	64.9	0.90	76.7	1.05	475	24.3	0.52	28.6	0.60
Bladder (incl. <i>in situ</i>)	585	34.6	0.65	40.8	0.76	166	8.0	0.28	9.4	0.33
Kidney & renal pelvis	493	29.0	0.60	34.4	0.70	300	15.9	0.43	18.6	0.49
Ureter	14	0.8	0.10	0.9	0.11	5	0.2	0.05	0.3	0.06
Eye & Orbit	16	1.0	0.11	1.1	0.13	13	0.7	0.09	0.8	0.10
Brain & Other CNS	128	7.8	0.32	8.7	0.35	95	5.3	0.25	5.8	0.27
Brain	120	7.3	0.31	8.2	0.34	89	4.9	0.24	5.4	0.26
Endocrine System	120	7.6	0.32	8.5	0.35	305	19.1	0.51	20.8	0.54
Thyroid gland	108	6.8	0.30	7.6	0.33	293	18.3	0.50	20.0	0.53
Lymphomas	428	25.9	0.57	29.7	0.65	332	17.2	0.44	19.8	0.49
Hodgkin lymphoma	45	3.0	0.20	3.1	0.21	35	2.3	0.18	2.3	0.18
Non-Hodgkin lymphoma	383	22.9	0.53	26.6	0.62	297	15.0	0.40	17.5	0.46
Multiple Myeloma	145	8.4	0.32	10.0	0.38	119	6.0	0.25	7.0	0.29
Leukemias	314	19.0	0.49	21.8	0.56	221	11.6	0.36	13.2	0.40
Acute lymphocytic	27	1.8	0.16	1.7	0.15	20	1.4	0.14	1.2	0.12
Chronic lymphocytic	131	7.5	0.30	9.1	0.36	76	3.6	0.19	4.3	0.23
Acute myeloid	83	5.1	0.26	5.8	0.29	70	3.7	0.21	4.2	0.23
Chronic myeloid	39	2.4	0.18	2.7	0.20	35	1.9	0.15	2.2	0.17
Other leukemias	34	2.1	0.17	2.5	0.19	20	1.0	0.11	1.2	0.12
Mesothelioma	17	1.1	0.12	1.2	0.14	6	0.3	0.06	0.4	0.07
Kaposi Sarcoma	5	0.3	0.07	0.4	0.07	1	0.0	0.02	0.1	0.02
Ill-Defined & Unknown	335	20.1	0.50	23.5	0.58	288	14.3	0.39	16.7	0.45
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	135	8.5	0.33	9.5	0.37	275	14.9	0.42	17.1	0.47
Breast (<i>in situ</i>)	1	0.1	0.03	0.1	0.03	506	27.2	0.56	32.2	0.65

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Arkansas, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	7,876	540.7	2.80	644.2	3.30	6,869	437.7	2.49	512.0	2.85
Oral Cavity & Pharynx	335	23.3	0.59	28.5	0.71	121	7.5	0.32	9.0	0.38
Lip	16	1.1	0.13	1.3	0.15	5	0.3	0.06	0.4	0.07
Tongue	104	7.2	0.33	8.9	0.40	41	2.5	0.19	3.0	0.22
Major salivary gland	31	2.3	0.19	2.6	0.21	13	0.9	0.11	1.0	0.13
Floor of mouth	13	0.9	0.11	1.0	0.13	7	0.4	0.08	0.5	0.09
Gum & other mouth	37	2.5	0.19	3.1	0.23	24	1.4	0.13	1.6	0.15
Nasopharynx	8	0.6	0.10	0.7	0.12	3	0.2	0.05	0.2	0.06
Oropharynx	20	1.4	0.14	1.7	0.17	5	0.3	0.06	0.4	0.08
Hypopharynx	15	1.0	0.11	1.2	0.14	3	0.2	0.06	0.2	0.06
Digestive System	1,478	102.4	1.23	123.0	1.45	1,084	65.8	0.93	78.0	1.09
Esophagus	124	8.2	0.34	10.2	0.41	25	1.4	0.13	1.8	0.16
Stomach	118	8.2	0.35	9.8	0.41	62	3.8	0.22	4.5	0.26
Small intestine	50	3.4	0.22	4.2	0.27	39	2.4	0.18	2.8	0.21
Colon (excl. rectum)	479	34.1	0.72	40.2	0.84	454	27.5	0.60	32.3	0.70
Rectum & rectosigmoid	220	15.7	0.49	18.8	0.58	145	9.3	0.36	11.2	0.43
Anus, anal canal, & anorectum	23	1.6	0.16	1.9	0.19	49	3.2	0.21	3.8	0.25
Liver	173	11.2	0.39	14.1	0.49	51	3.0	0.19	3.6	0.23
Gallbladder	10	0.6	0.09	0.8	0.11	20	1.2	0.12	1.4	0.14
Pancreas	214	14.6	0.46	17.4	0.54	174	10.1	0.35	12.0	0.42
Respiratory System	1,485	98.6	1.16	118.4	1.39	1,163	66.9	0.90	80.6	1.08
Larynx	93	6.1	0.29	7.6	0.36	26	1.6	0.15	2.0	0.18
Lung & bronchus	1,377	91.3	1.12	109.4	1.34	1,125	64.5	0.88	77.7	1.06
Bones & Joints	15	1.3	0.15	1.3	0.15	12	1.0	0.14	1.0	0.13
Soft Tissue (incl. heart)	46	3.5	0.24	3.9	0.26	36	2.5	0.20	2.7	0.21
Skin (excl. basal & sq.)	514	36.8	0.75	43.0	0.86	318	22.8	0.61	25.6	0.66
Melanoma of the skin	483	34.5	0.72	40.4	0.84	303	21.9	0.60	24.5	0.65
Breast (excl. <i>in situ</i>)	17	1.2	0.14	1.5	0.16	1,871	121.1	1.32	142.4	1.52
Female Genital System	N/A	N/A	N/A	N/A	N/A	755	50.9	0.88	59.8	1.00
Cervix uteri	N/A	N/A	N/A	N/A	N/A	109	9.1	0.41	9.9	0.43
Uterus corpus	N/A	N/A	N/A	N/A	N/A	382	24.6	0.59	29.8	0.70
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	11	0.7	0.09	0.8	0.11
Ovary	N/A	N/A	N/A	N/A	N/A	167	11.0	0.40	12.8	0.46
Male Genital System	1,757	114.0	1.24	138.9	1.50	N/A	N/A	N/A	N/A	N/A
Prostate	1,681	106.8	1.18	131.6	1.45	N/A	N/A	N/A	N/A	N/A
Testis	59	6.0	0.35	5.9	0.35	N/A	N/A	N/A	N/A	N/A
Penis	16	1.1	0.13	1.3	0.15	N/A	N/A	N/A	N/A	N/A
Urinary System	967	67.8	1.00	79.9	1.17	392	24.6	0.59	28.8	0.67
Bladder (incl. <i>in situ</i>)	538	37.1	0.73	43.7	0.86	145	8.4	0.32	9.8	0.37
Kidney & renal pelvis	409	29.3	0.67	34.6	0.78	239	15.8	0.48	18.4	0.55
Ureter	13	0.9	0.12	1.0	0.13	5	0.3	0.06	0.3	0.07
Eye & Orbit	15	1.1	0.13	1.3	0.15	12	0.8	0.11	0.9	0.12
Brain & Other CNS	111	8.6	0.38	9.5	0.41	81	5.7	0.30	6.3	0.32
Brain	106	8.1	0.37	9.0	0.40	77	5.3	0.29	5.9	0.31
Endocrine System	102	8.1	0.37	9.0	0.41	246	20.1	0.61	21.8	0.64
Thyroid gland	92	7.2	0.35	8.1	0.39	238	19.5	0.60	21.2	0.63
Lymphomas	360	26.2	0.64	30.2	0.72	272	17.2	0.49	19.7	0.55
Hodgkin lymphoma	35	3.1	0.24	3.2	0.25	27	2.3	0.21	2.4	0.21
Non-Hodgkin lymphoma	326	23.1	0.59	27.0	0.68	245	14.9	0.44	17.3	0.51
Multiple Myeloma	108	7.4	0.33	8.8	0.38	82	4.9	0.25	5.7	0.29
Leukemias	260	18.8	0.54	21.7	0.61	177	11.5	0.41	12.9	0.45
Acute lymphocytic	18	1.7	0.18	1.6	0.17	14	1.3	0.17	1.2	0.14
Chronic lymphocytic	112	7.5	0.33	9.1	0.39	64	3.7	0.21	4.4	0.25
Acute myeloid	71	5.1	0.28	5.9	0.32	56	3.7	0.23	4.2	0.26
Chronic myeloid	30	2.2	0.19	2.5	0.21	28	1.9	0.17	2.2	0.19
Other leukemias	29	2.2	0.18	2.5	0.21	15	0.9	0.11	1.1	0.13
Mesothelioma	16	1.2	0.13	1.3	0.15	5	0.3	0.06	0.4	0.08
Kaposi Sarcoma	3	0.3	0.07	0.3	0.07	*	*	*	*	*
Ill-Defined & Unknown	286	20.2	0.55	23.7	0.64	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	111	8.6	0.38	9.6	0.41	217	14.7	0.47	16.7	0.52
Breast (<i>in situ</i>)	*	*	*	*	*	398	26.6	0.63	31.4	0.73

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

ARKANSAS

II-34 Incidence – NH White

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Arkansas, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,215	607.1	8.36	734.7	9.83	1,060	422.4	6.00	499.5	6.94
Oral Cavity & Pharynx	34	15.9	1.30	19.5	1.54	14	5.6	0.68	6.6	0.79
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	8	3.5	0.60	4.4	0.73	2	0.8	0.25	0.9	0.30
Major salivary gland	2	1.1	0.33	1.4	0.43	3	1.2	0.32	1.4	0.35
Floor of mouth	2	0.8	0.25	1.0	0.33	*	*	*	*	*
Gum & other mouth	4	2.1	0.47	2.5	0.55	4	1.5	0.37	1.8	0.43
Nasopharynx	2	0.8	0.29	0.9	0.32	1	0.5	0.20	0.6	0.23
Oropharynx	2	0.9	0.32	1.0	0.35	*	*	*	*	*
Hypopharynx	4	2.1	0.48	2.5	0.57	1	0.4	0.16	0.5	0.20
Digestive System	258	131.9	3.94	159.0	4.61	221	90.1	2.80	106.7	3.25
Esophagus	13	5.6	0.75	7.2	0.93	6	2.1	0.41	2.6	0.50
Stomach	30	16.2	1.41	19.2	1.63	18	7.2	0.79	8.7	0.93
Small intestine	7	3.5	0.62	4.4	0.74	9	3.8	0.57	4.4	0.65
Colon (excl. rectum)	90	47.2	2.39	56.4	2.78	93	38.0	1.82	44.9	2.11
Rectum & rectosigmoid	36	17.6	1.39	21.4	1.65	27	11.1	0.98	13.1	1.14
Anus, anal canal, & anorectum	4	1.8	0.45	2.1	0.53	3	1.3	0.34	1.6	0.40
Liver	30	13.7	1.20	17.3	1.47	9	3.4	0.53	4.1	0.62
Gallbladder	3	1.4	0.43	1.7	0.49	4	1.7	0.38	2.1	0.45
Pancreas	38	20.3	1.59	24.2	1.84	42	17.4	1.24	20.5	1.42
Respiratory System	224	115.5	3.72	140.2	4.37	141	55.3	2.16	67.3	2.57
Larynx	20	9.6	1.03	11.8	1.22	4	1.6	0.36	2.0	0.43
Lung & bronchus	203	104.9	3.56	127.2	4.18	135	53.0	2.12	64.7	2.52
Bones & Joints	3	1.1	0.31	1.0	0.30	3	1.1	0.29	1.1	0.29
Soft Tissue (incl. heart)	8	4.0	0.66	4.6	0.73	7	2.7	0.47	3.0	0.53
Skin (excl. basal & sq.)	6	3.8	0.72	4.1	0.79	6	2.4	0.46	2.6	0.50
Melanoma of the skin	3	2.1	0.56	2.4	0.63	3	1.3	0.34	1.4	0.38
Breast (excl. <i>in situ</i>)	3	2.0	0.53	2.3	0.62	311	124.0	3.25	145.7	3.73
Female Genital System	N/A	N/A	N/A	N/A	N/A	127	49.4	2.03	59.3	2.38
Cervix uteri	N/A	N/A	N/A	N/A	N/A	23	9.7	0.93	10.9	1.03
Uterus corpus	N/A	N/A	N/A	N/A	N/A	67	24.7	1.40	30.6	1.69
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	5	2.0	0.42	2.5	0.50
Ovary	N/A	N/A	N/A	N/A	N/A	20	8.0	0.83	9.4	0.96
Male Genital System	426	201.7	4.68	251.1	5.63	N/A	N/A	N/A	N/A	N/A
Prostate	420	199.4	4.65	248.5	5.60	N/A	N/A	N/A	N/A	N/A
Testis	3	1.3	0.33	1.3	0.34	N/A	N/A	N/A	N/A	N/A
Penis	2	1.0	0.33	1.2	0.42	N/A	N/A	N/A	N/A	N/A
Urinary System	92	48.3	2.41	58.0	2.82	60	24.1	1.44	28.5	1.67
Bladder (incl. <i>in situ</i>)	32	18.2	1.56	21.6	1.81	14	5.8	0.73	6.9	0.84
Kidney & renal pelvis	60	29.8	1.84	36.1	2.16	46	18.1	1.24	21.4	1.44
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	10	4.8	0.71	5.2	0.77	8	3.2	0.51	3.5	0.56
Brain	9	4.4	0.68	4.8	0.74	8	3.0	0.49	3.3	0.55
Endocrine System	10	5.1	0.75	5.8	0.84	32	13.0	1.06	14.5	1.16
Thyroid gland	9	4.5	0.69	5.1	0.77	29	11.8	1.01	13.2	1.11
Lymphomas	43	20.9	1.50	23.6	1.68	37	14.7	1.12	16.9	1.27
Hodgkin lymphoma	6	2.4	0.46	2.5	0.47	5	1.9	0.39	1.9	0.39
Non-Hodgkin lymphoma	37	18.5	1.43	21.1	1.61	32	12.8	1.05	15.0	1.20
Multiple Myeloma	29	16.0	1.41	18.9	1.63	31	11.8	0.99	14.3	1.16
Leukemias	29	14.9	1.33	17.0	1.50	25	9.8	0.90	11.5	1.04
Acute lymphocytic	4	1.6	0.37	1.4	0.34	2	0.9	0.27	0.9	0.27
Chronic lymphocytic	11	5.9	0.85	7.1	0.99	7	2.6	0.46	3.2	0.56
Acute myeloid	7	4.2	0.74	4.7	0.81	9	3.3	0.52	3.9	0.60
Chronic myeloid	4	1.7	0.43	2.1	0.51	5	1.8	0.38	2.1	0.44
Other leukemias	3	1.4	0.43	1.7	0.48	3	1.3	0.33	1.4	0.37
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	2	0.6	0.22	0.7	0.27	*	*	*	*	*
Ill-Defined & Unknown	35	20.1	1.63	23.2	1.85	36	14.9	1.15	17.5	1.33
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	19	9.6	1.04	11.1	1.19	46	18.2	1.24	21.1	1.41
Breast (<i>in situ</i>)	*	*	*	*	*	74	28.9	1.55	34.9	1.82

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Arkansas, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	54	308.4	21.50	361.3	24.55	83	339.5	17.83	389.8	20.33
Oral Cavity & Pharynx	3	14.5	3.69	16.2	4.15	1	4.7	1.80	5.6	2.18
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	6.4	2.49	7.0	2.76	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	17	91.5	11.41	109.2	13.28	15	70.0	8.73	81.2	9.91
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	2	9.9	3.42	12.6	4.41	3	11.6	3.43	13.8	4.01
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	5	23.4	5.13	27.5	6.03	5	25.5	5.30	29.7	6.02
Rectum & rectosigmoid	2	10.2	3.37	12.1	3.91	2	6.6	2.52	7.3	2.80
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	5	25.1	5.43	30.8	6.51	2	11.7	3.90	13.1	4.28
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	2	9.8	3.85	12.1	4.49	2	8.1	3.00	9.4	3.42
Respiratory System	9	48.5	7.98	58.3	9.20	8	38.1	6.38	44.9	7.38
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	8	47.0	7.90	56.6	9.10	8	37.4	6.34	44.0	7.32
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	27	106.6	9.70	124.2	11.24
Female Genital System	N/A	N/A	N/A	N/A	N/A	11	39.5	5.64	44.6	6.40
Cervix uteri	N/A	N/A	N/A	N/A	N/A	3	8.5	2.39	8.6	2.51
Uterus corpus	N/A	N/A	N/A	N/A	N/A	6	20.9	4.06	24.7	4.81
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	7.6	2.65	8.9	3.01
Male Genital System	10	64.5	9.97	76.2	11.40	N/A	N/A	N/A	N/A	N/A
Prostate	9	62.8	9.91	74.6	11.36	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	3	19.5	5.22	22.6	5.97	5	19.8	4.23	23.0	4.87
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	2	9.0	3.13	10.1	3.51
Kidney & renal pelvis	2	11.6	3.64	13.9	4.31	3	10.9	2.85	12.9	3.37
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	5	16.3	3.28	17.8	3.69
Thyroid gland	*	*	*	*	*	5	16.3	3.28	17.8	3.69
Lymphomas	4	18.7	4.60	22.5	5.58	5	19.0	4.11	21.3	4.68
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	2	19.4	7.90	21.4	8.71	2	10.5	3.28	10.8	3.44
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	1	4.3	1.79	4.7	1.99
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	3	16.9	5.26	18.5	5.66	2	7.6	2.89	8.4	3.11
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	1	5.6	2.41	7.0	2.97	3	12.8	3.18	14.9	3.77
Breast (<i>in situ</i>)	*	*	*	*	*	8	32.6	5.34	38.0	6.17

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Arkansas, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	170	321.1	13.37	379.4	15.45	191	350.3	13.11	406.8	15.09
Oral Cavity & Pharynx	5	10.0	2.32	12.2	2.74	2	4.0	1.46	4.4	1.57
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	2.4	1.22	3.0	1.47	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	38	67.0	5.86	81.0	6.92	33	69.6	6.17	81.6	7.08
Esophagus	2	5.4	1.81	6.4	2.06	*	*	*	*	*
Stomach	4	10.3	2.66	12.3	3.15	3	4.5	1.29	5.3	1.55
Small intestine	2	2.0	0.69	2.6	0.91	*	*	*	*	*
Colon (excl. rectum)	9	13.6	2.52	16.3	2.96	9	18.8	3.21	21.4	3.60
Rectum & rectosigmoid	7	8.6	1.70	10.2	1.99	5	9.1	2.07	11.3	2.49
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	7	12.3	2.37	15.3	2.80	3	8.2	2.23	9.5	2.51
Gallbladder	*	*	*	*	*	2	3.2	1.29	3.5	1.45
Pancreas	5	11.9	2.83	14.3	3.33	6	14.5	3.03	17.2	3.47
Respiratory System	21	47.3	5.36	57.4	6.28	17	44.5	5.25	51.5	5.93
Larynx	1	4.0	1.65	4.4	1.75	*	*	*	*	*
Lung & bronchus	18	42.4	5.09	52.0	6.01	17	43.0	5.19	49.7	5.86
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	2	3.8	1.60	4.1	1.77	2	2.6	1.16	2.7	1.21
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	5	12.3	2.90	13.7	3.17	2	4.4	1.53	5.0	1.67
Breast (excl. <i>in situ</i>)	*	*	*	*	*	55	94.3	6.40	112.2	7.61
Female Genital System	N/A	N/A	N/A	N/A	N/A	31	50.3	4.66	57.9	5.34
Cervix uteri	N/A	N/A	N/A	N/A	N/A	8	10.9	2.05	11.3	2.19
Uterus corpus	N/A	N/A	N/A	N/A	N/A	16	28.4	3.59	33.8	4.19
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	5	7.0	1.67	8.2	1.97
Male Genital System	43	85.3	6.90	101.6	7.98	N/A	N/A	N/A	N/A	N/A
Prostate	36	80.0	6.83	96.3	7.92	N/A	N/A	N/A	N/A	N/A
Testis	6	4.4	0.81	4.1	0.76	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	18	37.9	4.75	45.0	5.50	9	17.6	3.07	21.1	3.54
Bladder (incl. <i>in situ</i>)	6	14.5	3.17	17.3	3.65	3	6.5	1.96	7.9	2.27
Kidney & renal pelvis	12	22.4	3.47	26.6	4.04	6	11.1	2.36	13.2	2.71
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	4	4.3	1.21	4.9	1.38	3	4.1	1.27	5.0	1.54
Brain	3	3.4	1.01	4.0	1.21	3	3.7	1.22	4.4	1.45
Endocrine System	4	5.9	1.54	6.4	1.67	15	17.9	2.28	19.3	2.53
Thyroid gland	4	5.8	1.54	6.4	1.67	15	17.7	2.28	19.1	2.52
Lymphomas	11	17.3	2.92	19.8	3.29	6	9.7	2.17	10.9	2.51
Hodgkin lymphoma	3	2.6	0.69	2.8	0.79	1	1.2	0.44	1.1	0.42
Non-Hodgkin lymphoma	8	14.7	2.84	17.1	3.20	5	8.5	2.12	9.8	2.48
Multiple Myeloma	3	5.3	1.82	6.1	2.02	3	6.9	2.02	8.3	2.41
Leukemias	10	12.6	2.51	13.4	2.82	8	10.3	2.08	11.4	2.43
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	3	2.9	0.83	2.7	0.86
Chronic lymphocytic	2	4.8	1.93	5.8	2.31	*	*	*	*	*
Acute myeloid	3	3.0	1.07	2.9	1.06	2	4.6	1.70	5.2	1.96
Chronic myeloid	1	2.1	1.02	2.4	1.11	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	5	7.5	1.93	8.7	2.25	5	13.3	2.86	14.6	3.10
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	2	2.9	1.24	3.2	1.39	5	8.0	1.72	9.7	2.13
Breast (<i>in situ</i>)	*	*	*	*	*	12	19.1	2.69	22.8	3.20

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

ARKANSAS

II-38 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Arkansas, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	134	278.3	12.97	329.8	15.02	160	320.5	13.03	370.3	14.91
Oral Cavity & Pharynx	4	9.0	2.35	11.1	2.78	2	3.9	1.51	4.1	1.60
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	33	63.9	6.01	77.5	7.09	26	63.2	6.24	73.4	7.09
Esophagus	2	4.4	1.68	5.3	1.96	*	*	*	*	*
Stomach	3	9.3	2.64	11.1	3.08	3	3.9	1.26	4.5	1.49
Small intestine	2	2.2	0.75	2.8	1.00	*	*	*	*	*
Colon (excl. rectum)	7	12.5	2.62	15.0	3.07	7	18.4	3.37	21.0	3.77
Rectum & rectosigmoid	6	8.8	1.81	10.5	2.14	3	7.7	2.08	9.3	2.43
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	6	11.2	2.37	14.0	2.81	2	6.6	2.08	7.6	2.30
Gallbladder	*	*	*	*	*	1	2.9	1.33	3.1	1.46
Pancreas	4	12.4	3.04	14.9	3.58	4	12.5	2.99	14.8	3.41
Respiratory System	16	38.9	5.07	47.8	6.01	16	41.3	5.13	48.5	5.86
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	14	35.8	4.89	44.2	5.83	15	39.8	5.06	46.5	5.77
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	1	3.3	1.65	3.5	1.82	1	2.5	1.24	2.6	1.30
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	4	12.9	3.11	14.4	3.41	2	4.2	1.60	4.5	1.70
Breast (excl. <i>in situ</i>)	*	*	*	*	*	46	86.7	6.37	103.1	7.54
Female Genital System	N/A	N/A	N/A	N/A	N/A	28	50.3	4.91	57.4	5.58
Cervix uteri	N/A	N/A	N/A	N/A	N/A	7	10.8	2.17	11.1	2.30
Uterus corpus	N/A	N/A	N/A	N/A	N/A	15	29.4	3.84	34.5	4.43
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	4	6.1	1.62	7.2	1.93
Male Genital System	31	67.2	6.31	80.1	7.30	N/A	N/A	N/A	N/A	N/A
Prostate	26	63.2	6.25	76.0	7.25	N/A	N/A	N/A	N/A	N/A
Testis	4	3.3	0.73	3.2	0.69	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	15	33.5	4.65	39.7	5.38	6	14.6	2.97	17.0	3.38
Bladder (incl. <i>in situ</i>)	5	12.7	3.11	15.1	3.57	2	4.3	1.67	5.2	1.97
Kidney & renal pelvis	10	19.8	3.37	23.4	3.93	5	10.3	2.45	11.8	2.74
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	3	3.4	1.08	3.9	1.28	3	3.9	1.31	4.6	1.55
Brain	2	3.2	1.06	3.8	1.27	2	3.4	1.25	3.9	1.45
Endocrine System	3	5.2	1.58	5.7	1.69	13	16.6	2.30	17.5	2.50
Thyroid gland	3	5.1	1.57	5.6	1.68	13	16.3	2.30	17.3	2.49
Lymphomas	8	13.9	2.72	16.1	3.11	5	8.5	1.94	9.5	2.27
Hodgkin lymphoma	2	2.2	0.65	2.2	0.72	1	1.1	0.45	1.0	0.42
Non-Hodgkin lymphoma	6	11.7	2.64	13.9	3.03	4	7.4	1.89	8.5	2.23
Multiple Myeloma	2	5.4	1.95	6.2	2.17	2	4.7	1.62	5.5	1.88
Leukemias	8	11.5	2.44	12.3	2.74	6	9.0	2.04	10.2	2.37
Acute lymphocytic	3	2.4	0.59	2.0	0.50	3	2.8	0.89	2.7	0.93
Chronic lymphocytic	1	4.1	1.77	5.1	2.15	*	*	*	*	*
Acute myeloid	2	2.7	1.11	2.6	1.10	2	3.9	1.63	4.3	1.84
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	4	6.8	2.00	7.8	2.31	4	10.6	2.66	11.6	2.85
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	2	2.4	1.22	2.5	1.32	4	6.9	1.61	8.3	1.97
Breast (<i>in situ</i>)	*	*	*	*	*	11	18.1	2.69	21.6	3.21

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Arkansas, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	6	281.5	61.99	332.9	71.95	5	343.5	98.68	427.6	124.11
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	1	58.8	22.93	71.2	28.90
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	1	78.7	33.85	91.0	37.33	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	2	152.1	71.64	187.9	89.07
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	2	77.8	27.19	96.0	33.54	N/A	N/A	N/A	N/A	N/A
Prostate	2	74.4	26.99	92.4	33.35	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


ARKANSAS

II-40 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	38,904,296	39,149,186	39,337,785	39,437,463	39,437,610
Non-Hispanic White	15,384,175	15,315,950	15,220,527	15,099,268	14,933,129
Non-Hispanic Black	2,422,249	2,429,756	2,438,933	2,445,447	2,448,173
Non-Hispanic Asian/Pacific Islander (NH API)	5,900,228	6,041,960	6,176,947	6,281,380	6,361,257
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	130,697	130,555	130,848	130,532	129,590

All Races Population 2015–2019: 196,266,340
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹


Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	14,987,776	15,151,999	15,291,922	15,402,735	15,488,144
Hispanic White	13,671,404	13,816,643	13,938,119	14,032,328	14,099,249
Hispanic Black	389,708	396,452	403,274	409,589	415,587

Hispanic/Latino Population, Census 2010:
14,013,719

Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

CALIFORNIA CANCER REGISTRY

Initial Operation: 1988
Population-based Data Available: 1988
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	101.2	100.1	99.9	99.5	100.0	100.1
Missing Race	1.9	2.2	2.4	2.5	2.5	2.3
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.6	1.6	0.9	1.8	1.6	1.5
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.2	Ovary	93.5
Oral Cavity & Pharynx	97.7	Prostate	95.6
Esophagus	95.0	Testis	98.9
Stomach	96.5	Bladder (incl. <i>in situ</i>)	97.3
Colon & Rectum	96.3	Kidney & Renal Pelvis	89.7
Liver	45.6	Brain & Other CNS	86.1
Pancreas	84.7	Brain & Other CNS (non-malig)	42.8
Lung & Bronchus	88.5	Thyroid	99.4
Melanomas of the Skin	98.3	Hodgkin Lymphoma	98.8
Female Breast (excl. <i>in situ</i>)	98.9	Non-Hodgkin Lymphoma	97.2
Female Breast (<i>in situ</i>)	99.9	Multiple Myeloma	89.8
Cervix Uteri	97.7	Leukemias	92.5
Uterus Corpus & Uterus NOS	98.5		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
California, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	86,009	427.9	0.67	506.0	0.78	88,356	388.0	0.60	452.4	0.69
Oral Cavity & Pharynx	3,207	15.4	0.12	18.7	0.15	1,311	5.7	0.07	6.7	0.08
Lip	187	0.9	0.03	1.1	0.04	77	0.3	0.02	0.4	0.02
Tongue	1,054	5.0	0.07	6.1	0.08	417	1.8	0.04	2.1	0.05
Major salivary gland	302	1.6	0.04	1.8	0.05	211	0.9	0.03	1.1	0.03
Floor of mouth	87	0.4	0.02	0.5	0.02	50	0.2	0.01	0.3	0.02
Gum & other mouth	297	1.5	0.04	1.8	0.05	242	1.0	0.03	1.2	0.03
Nasopharynx	208	1.0	0.03	1.2	0.04	83	0.4	0.02	0.4	0.02
Oropharynx	168	0.8	0.03	1.0	0.03	42	0.2	0.01	0.2	0.01
Hypopharynx	148	0.7	0.03	0.9	0.03	34	0.1	0.01	0.2	0.01
Digestive System	18,345	91.0	0.31	108.7	0.36	14,696	62.9	0.24	74.2	0.28
Esophagus	1,188	5.9	0.08	7.0	0.09	350	1.5	0.04	1.7	0.04
Stomach	1,849	9.4	0.10	11.0	0.12	1,285	5.6	0.07	6.5	0.08
Small intestine	456	2.3	0.05	2.7	0.06	387	1.7	0.04	2.0	0.05
Colon (excl. rectum)	5,141	26.0	0.17	30.7	0.19	5,120	22.1	0.14	25.8	0.16
Rectum & rectosigmoid	2,680	13.1	0.12	15.7	0.14	1,918	8.4	0.09	10.0	0.10
Anus, anal canal, & anorectum	300	1.5	0.04	1.8	0.05	506	2.1	0.04	2.6	0.05
Liver	2,810	13.1	0.11	16.3	0.14	1,046	4.3	0.06	5.2	0.07
Gallbladder	163	0.8	0.03	1.0	0.03	364	1.5	0.04	1.8	0.04
Pancreas	2,721	13.7	0.12	16.3	0.14	2,580	10.9	0.10	12.8	0.11
Respiratory System	9,375	48.2	0.23	56.6	0.26	8,801	37.3	0.18	43.8	0.21
Larynx	670	3.3	0.06	4.0	0.07	139	0.6	0.02	0.7	0.03
Lung & bronchus	8,489	43.8	0.22	51.4	0.25	8,536	36.1	0.18	42.4	0.21
Bones & Joints	214	1.1	0.03	1.1	0.03	161	0.8	0.03	0.8	0.03
Soft Tissue (incl. heart)	841	4.3	0.07	4.8	0.08	673	3.1	0.05	3.4	0.06
Skin (excl. basal & sq.)	6,509	33.2	0.19	38.8	0.22	4,264	18.9	0.13	21.8	0.15
Melanoma of the skin	5,993	30.4	0.18	35.7	0.21	3,952	17.5	0.13	20.3	0.15
Breast (excl. <i>in situ</i>)	204	1.0	0.03	1.2	0.04	27,738	123.2	0.34	144.7	0.39
Female Genital System	N/A	N/A	N/A	N/A	N/A	11,280	49.6	0.21	58.6	0.25
Cervix uteri	N/A	N/A	N/A	N/A	N/A	1,499	7.4	0.09	7.9	0.09
Uterus corpus	N/A	N/A	N/A	N/A	N/A	6,086	26.0	0.15	31.6	0.18
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	251	1.1	0.03	1.3	0.04
Ovary	N/A	N/A	N/A	N/A	N/A	2,455	10.9	0.10	12.7	0.12
Male Genital System	21,624	102.5	0.32	124.2	0.38	N/A	N/A	N/A	N/A	N/A
Prostate	20,182	95.2	0.31	116.9	0.37	N/A	N/A	N/A	N/A	N/A
Testis	1,241	6.2	0.08	6.1	0.08	N/A	N/A	N/A	N/A	N/A
Penis	155	0.8	0.03	0.9	0.03	N/A	N/A	N/A	N/A	N/A
Urinary System	9,727	49.7	0.23	58.4	0.27	4,085	17.5	0.13	20.6	0.14
Bladder (incl. <i>in situ</i>)	5,334	28.0	0.17	32.7	0.20	1,586	6.6	0.08	7.8	0.09
Kidney & renal pelvis	4,183	20.6	0.15	24.4	0.17	2,376	10.4	0.10	12.2	0.11
Ureter	114	0.6	0.03	0.7	0.03	76	0.3	0.02	0.4	0.02
Eye & Orbit	196	1.0	0.03	1.1	0.04	147	0.7	0.02	0.7	0.03
Brain & Other CNS	1,389	7.0	0.09	7.8	0.09	1,056	4.9	0.07	5.3	0.07
Brain	1,315	6.6	0.08	7.4	0.09	984	4.5	0.07	5.0	0.07
Endocrine System	1,544	7.7	0.09	8.6	0.10	4,131	20.0	0.14	21.8	0.15
Thyroid gland	1,376	6.8	0.08	7.7	0.09	3,985	19.3	0.14	21.1	0.15
Lymphomas	4,777	24.2	0.16	27.9	0.18	3,822	16.8	0.12	19.3	0.14
Hodgkin lymphoma	491	2.5	0.05	2.6	0.05	387	1.9	0.04	2.0	0.04
Non-Hodgkin lymphoma	4,286	21.7	0.15	25.3	0.17	3,435	14.9	0.12	17.4	0.13
Multiple Myeloma	1,491	7.5	0.09	8.9	0.10	1,149	4.9	0.07	5.8	0.08
Leukemias	3,001	15.5	0.13	17.3	0.14	2,105	9.5	0.09	10.5	0.10
Acute lymphocytic	441	2.3	0.05	2.1	0.05	335	1.8	0.04	1.6	0.04
Chronic lymphocytic	921	4.6	0.07	5.5	0.08	569	2.4	0.04	2.8	0.05
Acute myeloid	917	4.8	0.07	5.4	0.08	729	3.2	0.05	3.7	0.06
Chronic myeloid	408	2.1	0.05	2.4	0.05	267	1.2	0.03	1.4	0.04
Other leukemias	314	1.6	0.04	1.9	0.05	204	0.9	0.03	1.0	0.03
Mesothelioma	225	1.2	0.04	1.4	0.04	91	0.4	0.02	0.5	0.02
Kaposi Sarcoma	178	0.9	0.03	1.0	0.03	15	0.1	0.01	0.1	0.01
Ill-Defined & Unknown	3,163	16.6	0.13	19.3	0.16	2,829	11.9	0.10	13.8	0.12
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	1,680	8.5	0.09	9.7	0.11	3,440	15.3	0.12	17.6	0.14
Breast (<i>in situ</i>)	21	0.1	0.01	0.1	0.01	6,133	27.4	0.16	32.6	0.19

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
California, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	51,695	475.6	0.97	561.6	1.12	49,193	429.1	0.93	499.3	1.05
Oral Cavity & Pharynx	2,200	19.9	0.20	24.3	0.23	799	6.7	0.11	7.9	0.13
Lip	148	1.4	0.05	1.6	0.06	58	0.5	0.03	0.5	0.03
Tongue	800	7.2	0.12	8.8	0.14	274	2.3	0.07	2.8	0.08
Major salivary gland	196	1.9	0.06	2.2	0.07	104	0.9	0.04	1.1	0.05
Floor of mouth	58	0.5	0.03	0.6	0.04	37	0.3	0.02	0.4	0.03
Gum & other mouth	177	1.6	0.06	1.9	0.07	152	1.2	0.05	1.4	0.05
Nasopharynx	50	0.5	0.03	0.6	0.04	21	0.2	0.02	0.2	0.02
Oropharynx	119	1.0	0.04	1.3	0.05	27	0.2	0.02	0.3	0.02
Hypopharynx	94	0.8	0.04	1.0	0.05	21	0.2	0.02	0.2	0.02
Digestive System	9,474	87.1	0.41	103.9	0.48	7,432	60.6	0.33	71.3	0.38
Esophagus	817	7.2	0.12	8.7	0.14	234	1.8	0.05	2.1	0.06
Stomach	776	7.1	0.12	8.4	0.14	410	3.3	0.08	3.9	0.09
Small intestine	265	2.5	0.07	2.9	0.08	219	1.9	0.06	2.2	0.07
Colon (excl. rectum)	2,803	26.7	0.23	31.3	0.27	2,780	22.9	0.21	26.6	0.24
Rectum & rectosigmoid	1,321	12.7	0.16	15.1	0.19	954	8.5	0.13	10.1	0.15
Anus, anal canal, & anorectum	210	2.0	0.06	2.4	0.07	367	3.0	0.07	3.7	0.09
Liver	1,085	9.1	0.13	11.4	0.16	368	2.9	0.07	3.5	0.08
Gallbladder	64	0.6	0.03	0.7	0.04	136	1.0	0.04	1.2	0.05
Pancreas	1,625	14.7	0.17	17.4	0.20	1,401	10.8	0.14	12.8	0.16
Respiratory System	5,862	52.7	0.31	62.1	0.37	5,789	44.8	0.27	52.6	0.32
Larynx	407	3.6	0.08	4.3	0.10	92	0.8	0.04	0.9	0.04
Lung & bronchus	5,341	48.0	0.30	56.5	0.35	5,632	43.4	0.27	51.1	0.31
Bones & Joints	94	1.1	0.06	1.2	0.06	78	0.9	0.05	0.9	0.05
Soft Tissue (incl. heart)	460	4.7	0.10	5.3	0.11	316	3.1	0.09	3.4	0.09
Skin (excl. basal & sq.)	5,576	52.7	0.33	61.6	0.37	3,340	31.4	0.26	35.9	0.29
Melanoma of the skin	5,194	49.1	0.32	57.4	0.36	3,152	29.9	0.26	34.2	0.28
Breast (excl. <i>in situ</i>)	134	1.2	0.05	1.5	0.06	15,452	139.1	0.54	163.1	0.61
Female Genital System	N/A	N/A	N/A	N/A	N/A	5,710	50.0	0.32	59.5	0.36
Cervix uteri	N/A	N/A	N/A	N/A	N/A	547	6.5	0.13	6.9	0.14
Uterus corpus	N/A	N/A	N/A	N/A	N/A	3,159	26.1	0.22	32.1	0.26
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	111	0.9	0.04	1.1	0.05
Ovary	N/A	N/A	N/A	N/A	N/A	1,290	11.5	0.15	13.5	0.17
Male Genital System	12,209	106.0	0.44	128.4	0.53	N/A	N/A	N/A	N/A	N/A
Prostate	11,558	97.5	0.41	119.8	0.50	N/A	N/A	N/A	N/A	N/A
Testis	559	7.6	0.15	7.6	0.14	N/A	N/A	N/A	N/A	N/A
Penis	68	0.6	0.04	0.7	0.04	N/A	N/A	N/A	N/A	N/A
Urinary System	6,280	57.8	0.34	67.9	0.39	2,307	18.6	0.18	21.8	0.21
Bladder (incl. <i>in situ</i>)	3,910	35.7	0.26	41.8	0.30	1,102	8.4	0.12	9.8	0.14
Kidney & renal pelvis	2,232	20.9	0.21	24.6	0.24	1,133	9.7	0.14	11.3	0.16
Ureter	75	0.7	0.04	0.8	0.04	45	0.3	0.02	0.4	0.03
Eye & Orbit	142	1.4	0.06	1.6	0.06	106	1.0	0.05	1.1	0.05
Brain & Other CNS	848	9.0	0.15	9.9	0.16	602	6.1	0.12	6.6	0.13
Brain	813	8.5	0.14	9.5	0.15	571	5.7	0.12	6.3	0.12
Endocrine System	821	8.8	0.14	9.8	0.16	1,720	20.2	0.23	21.7	0.24
Thyroid gland	744	7.9	0.14	8.9	0.15	1,656	19.5	0.23	21.0	0.24
Lymphomas	2,750	27.0	0.24	31.0	0.27	2,050	18.0	0.19	20.6	0.21
Hodgkin lymphoma	252	3.1	0.09	3.3	0.09	191	2.5	0.09	2.5	0.08
Non-Hodgkin lymphoma	2,498	23.9	0.22	27.8	0.25	1,858	15.5	0.17	18.1	0.19
Multiple Myeloma	814	7.4	0.12	8.8	0.14	565	4.5	0.09	5.3	0.10
Leukemias	1,800	17.7	0.20	20.1	0.22	1,167	10.4	0.15	11.6	0.16
Acute lymphocytic	129	1.9	0.08	1.7	0.07	97	1.5	0.07	1.3	0.06
Chronic lymphocytic	698	6.3	0.11	7.5	0.13	430	3.3	0.07	3.9	0.09
Acute myeloid	542	5.3	0.10	6.0	0.12	383	3.3	0.08	3.8	0.09
Chronic myeloid	237	2.3	0.07	2.7	0.08	141	1.3	0.05	1.5	0.06
Other leukemias	195	1.9	0.06	2.2	0.07	116	1.0	0.05	1.1	0.05
Mesothelioma	150	1.4	0.05	1.6	0.06	58	0.5	0.03	0.6	0.03
Kaposi Sarcoma	65	0.7	0.04	0.8	0.05	6	0.0	0.01	0.1	0.01
Ill-Defined & Unknown	2,016	18.8	0.19	21.9	0.22	1,696	13.1	0.15	15.2	0.17
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	953	9.8	0.15	11.0	0.16	1,791	16.3	0.19	18.8	0.21
Breast (<i>in situ</i>)	13	0.1	0.01	0.1	0.02	3,068	28.8	0.25	34.1	0.28

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
California, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	5,404	463.8	2.95	559.8	3.49	5,333	388.4	2.44	458.2	2.82
Oral Cavity & Pharynx	151	12.5	0.47	15.2	0.56	64	4.6	0.27	5.5	0.31
Lip	1	0.1	0.05	0.1	0.06	*	*	*	*	*
Tongue	39	3.2	0.24	3.9	0.28	15	1.0	0.12	1.3	0.15
Major salivary gland	11	1.0	0.14	1.2	0.16	13	1.0	0.12	1.1	0.14
Floor of mouth	7	0.6	0.10	0.7	0.13	3	0.2	0.05	0.2	0.06
Gum & other mouth	14	1.2	0.15	1.4	0.17	14	1.0	0.12	1.2	0.15
Nasopharynx	14	1.2	0.15	1.3	0.16	5	0.4	0.08	0.4	0.08
Oropharynx	14	1.1	0.14	1.4	0.17	4	0.3	0.06	0.3	0.07
Hypopharynx	10	0.9	0.13	1.0	0.15	3	0.2	0.06	0.3	0.07
Digestive System	1,202	104.9	1.42	126.1	1.67	1,031	74.4	1.06	88.7	1.24
Esophagus	45	3.9	0.27	4.7	0.32	22	1.6	0.15	1.9	0.18
Stomach	122	11.5	0.49	13.6	0.57	93	6.9	0.33	8.0	0.37
Small intestine	46	4.1	0.28	4.9	0.33	43	3.1	0.22	3.8	0.26
Colon (excl. rectum)	362	32.3	0.79	38.2	0.92	372	27.2	0.64	32.1	0.75
Rectum & rectosigmoid	136	11.6	0.47	14.0	0.55	111	8.1	0.35	9.6	0.41
Anus, anal canal, & anorectum	25	2.0	0.19	2.5	0.23	26	1.9	0.17	2.3	0.20
Liver	201	15.9	0.52	20.0	0.64	73	4.9	0.26	6.2	0.32
Gallbladder	13	1.1	0.15	1.4	0.17	23	1.6	0.16	2.0	0.18
Pancreas	192	17.1	0.58	20.5	0.68	204	14.5	0.46	17.5	0.55
Respiratory System	713	65.3	1.15	77.7	1.33	648	46.0	0.82	55.4	0.98
Larynx	58	5.0	0.31	6.1	0.36	13	0.9	0.12	1.1	0.14
Lung & bronchus	645	59.5	1.10	70.7	1.28	626	44.5	0.81	53.6	0.96
Bones & Joints	11	1.0	0.13	1.0	0.13	9	0.7	0.11	0.7	0.11
Soft Tissue (incl. heart)	51	4.4	0.29	5.0	0.32	47	3.5	0.24	4.0	0.26
Skin (excl. basal & sq.)	24	2.3	0.22	2.5	0.24	24	1.9	0.17	2.1	0.19
Melanoma of the skin	13	1.3	0.16	1.4	0.19	11	0.8	0.11	0.9	0.13
Breast (excl. <i>in situ</i>)	18	1.6	0.17	1.9	0.21	1,711	126.2	1.40	148.0	1.61
Female Genital System	N/A	N/A	N/A	N/A	N/A	698	49.5	0.86	59.4	1.01
Cervix uteri	N/A	N/A	N/A	N/A	N/A	91	7.3	0.35	7.9	0.37
Uterus corpus	N/A	N/A	N/A	N/A	N/A	394	26.9	0.62	33.3	0.75
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	31	2.2	0.18	2.7	0.21
Ovary	N/A	N/A	N/A	N/A	N/A	126	9.1	0.37	10.8	0.43
Male Genital System	1,850	148.0	1.61	185.6	1.96	N/A	N/A	N/A	N/A	N/A
Prostate	1,822	145.6	1.59	183.1	1.95	N/A	N/A	N/A	N/A	N/A
Testis	20	1.7	0.17	1.6	0.17	N/A	N/A	N/A	N/A	N/A
Penis	6	0.5	0.11	0.6	0.13	N/A	N/A	N/A	N/A	N/A
Urinary System	505	45.1	0.94	53.6	1.09	265	19.2	0.54	22.7	0.63
Bladder (incl. <i>in situ</i>)	204	19.4	0.64	23.1	0.74	82	6.1	0.30	7.1	0.35
Kidney & renal pelvis	293	24.9	0.68	29.6	0.79	175	12.7	0.44	15.0	0.51
Ureter	3	0.3	0.08	0.4	0.10	4	0.3	0.07	0.3	0.07
Eye & Orbit	2	0.2	0.06	0.2	0.07	4	0.3	0.07	0.3	0.08
Brain & Other CNS	57	4.9	0.30	5.3	0.32	41	3.1	0.22	3.5	0.24
Brain	52	4.4	0.29	4.8	0.31	38	2.9	0.21	3.2	0.23
Endocrine System	57	4.8	0.29	5.6	0.34	148	11.4	0.43	12.7	0.47
Thyroid gland	45	3.7	0.26	4.3	0.29	134	10.4	0.41	11.6	0.45
Lymphomas	226	19.6	0.61	22.3	0.68	191	14.3	0.47	16.4	0.53
Hodgkin lymphoma	32	2.6	0.21	2.7	0.21	28	2.2	0.19	2.3	0.20
Non-Hodgkin lymphoma	194	16.9	0.57	19.6	0.65	163	12.1	0.43	14.1	0.49
Multiple Myeloma	175	16.1	0.57	19.1	0.66	153	11.0	0.40	13.1	0.48
Leukemias	146	13.2	0.51	15.1	0.58	108	8.1	0.36	9.2	0.40
Acute lymphocytic	14	1.2	0.14	1.1	0.14	11	0.9	0.13	0.9	0.12
Chronic lymphocytic	49	4.5	0.30	5.4	0.36	24	1.7	0.16	2.1	0.19
Acute myeloid	47	4.3	0.29	4.9	0.33	41	3.0	0.22	3.4	0.24
Chronic myeloid	22	2.0	0.20	2.2	0.22	18	1.4	0.15	1.5	0.17
Other leukemias	14	1.3	0.16	1.5	0.18	14	1.1	0.13	1.2	0.15
Mesothelioma	9	0.9	0.14	1.1	0.17	3	0.2	0.06	0.2	0.06
Kaposi Sarcoma	21	1.6	0.17	1.7	0.17	1	0.1	0.04	0.1	0.04
Ill-Defined & Unknown	186	17.5	0.60	20.6	0.70	189	13.8	0.46	16.2	0.53
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	91	8.1	0.40	9.2	0.45	207	15.4	0.49	17.8	0.56
Breast (<i>in situ</i>)	3	0.2	0.07	0.3	0.08	413	29.8	0.67	35.6	0.79

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
California, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	8,943	290.6	1.40	341.8	1.63	11,899	309.8	1.29	360.4	1.49
Oral Cavity & Pharynx	336	10.7	0.27	12.6	0.31	199	5.2	0.17	6.0	0.19
Lip	3	0.1	0.03	0.1	0.03	3	0.1	0.02	0.1	0.02
Tongue	73	2.3	0.12	2.7	0.14	55	1.4	0.09	1.7	0.10
Major salivary gland	33	1.1	0.09	1.2	0.10	41	1.1	0.08	1.2	0.09
Floor of mouth	6	0.2	0.03	0.2	0.04	3	0.1	0.02	0.1	0.02
Gum & other mouth	48	1.6	0.10	1.8	0.12	33	0.8	0.07	1.0	0.08
Nasopharynx	117	3.7	0.16	4.3	0.18	44	1.2	0.08	1.4	0.09
Oropharynx	7	0.2	0.04	0.3	0.04	3	0.1	0.02	0.1	0.02
Hypopharynx	15	0.5	0.06	0.6	0.07	5	0.1	0.02	0.2	0.03
Digestive System	2,718	87.9	0.77	104.7	0.90	2,213	56.5	0.55	66.3	0.63
Esophagus	101	3.2	0.15	3.9	0.17	36	0.9	0.07	1.1	0.08
Stomach	353	11.7	0.28	13.7	0.33	282	7.2	0.19	8.4	0.23
Small intestine	48	1.6	0.10	1.8	0.12	33	0.9	0.07	1.0	0.08
Colon (excl. rectum)	692	22.5	0.39	26.7	0.46	718	18.3	0.31	21.6	0.36
Rectum & rectosigmoid	434	13.7	0.30	16.6	0.36	304	7.8	0.20	9.3	0.24
Anus, anal canal, & anorectum	12	0.4	0.05	0.4	0.06	18	0.5	0.05	0.5	0.06
Liver	547	17.2	0.33	20.9	0.40	210	5.3	0.17	6.2	0.19
Gallbladder	29	1.0	0.08	1.1	0.10	51	1.3	0.08	1.5	0.10
Pancreas	327	10.9	0.27	12.7	0.32	370	9.4	0.22	11.0	0.26
Respiratory System	1,374	45.4	0.56	53.5	0.65	1,132	28.6	0.39	33.7	0.45
Larynx	54	1.8	0.11	2.1	0.13	6	0.2	0.03	0.2	0.03
Lung & bronchus	1,288	42.6	0.54	50.3	0.63	1,107	28.0	0.38	33.0	0.45
Bones & Joints	25	0.9	0.08	0.9	0.08	19	0.6	0.06	0.6	0.06
Soft Tissue (incl. heart)	96	3.2	0.15	3.5	0.16	87	2.4	0.12	2.7	0.13
Skin (excl. basal & sq.)	66	2.3	0.13	2.5	0.14	72	1.9	0.10	2.2	0.12
Melanoma of the skin	37	1.2	0.09	1.4	0.10	46	1.2	0.08	1.4	0.09
Breast (excl. <i>in situ</i>)	19	0.6	0.06	0.7	0.08	4,149	108.4	0.77	127.0	0.89
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,592	41.2	0.47	48.7	0.55
Cervix uteri	N/A	N/A	N/A	N/A	N/A	237	6.4	0.19	7.1	0.21
Uterus corpus	N/A	N/A	N/A	N/A	N/A	873	22.2	0.34	26.8	0.41
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	32	0.8	0.07	1.0	0.08
Ovary	N/A	N/A	N/A	N/A	N/A	352	9.2	0.22	10.8	0.26
Male Genital System	1,765	55.1	0.60	66.4	0.71	N/A	N/A	N/A	N/A	N/A
Prostate	1,672	52.0	0.58	63.3	0.70	N/A	N/A	N/A	N/A	N/A
Testis	72	2.4	0.13	2.3	0.12	N/A	N/A	N/A	N/A	N/A
Penis	12	0.4	0.05	0.5	0.06	N/A	N/A	N/A	N/A	N/A
Urinary System	840	27.8	0.44	32.6	0.51	384	9.7	0.22	11.4	0.26
Bladder (incl. <i>in situ</i>)	433	14.8	0.32	17.2	0.37	138	3.4	0.13	4.0	0.15
Kidney & renal pelvis	378	12.0	0.28	14.3	0.33	223	5.7	0.17	6.7	0.20
Ureter	18	0.6	0.06	0.7	0.08	16	0.4	0.05	0.5	0.05
Eye & Orbit	11	0.4	0.05	0.4	0.05	7	0.2	0.04	0.2	0.04
Brain & Other CNS	129	4.3	0.17	4.7	0.19	105	3.0	0.13	3.2	0.14
Brain	120	4.0	0.17	4.3	0.18	93	2.6	0.13	2.8	0.13
Endocrine System	243	7.9	0.23	8.9	0.26	777	21.5	0.35	23.5	0.38
Thyroid gland	208	6.7	0.21	7.6	0.24	748	20.7	0.34	22.6	0.37
Lymphomas	552	18.2	0.35	20.8	0.40	485	12.8	0.26	14.6	0.30
Hodgkin lymphoma	46	1.5	0.10	1.6	0.10	36	1.1	0.08	1.1	0.08
Non-Hodgkin lymphoma	506	16.7	0.34	19.2	0.39	448	11.7	0.25	13.5	0.29
Multiple Myeloma	139	4.5	0.17	5.4	0.21	117	3.0	0.12	3.5	0.15
Leukemias	279	9.4	0.26	10.3	0.28	221	6.2	0.19	6.7	0.20
Acute lymphocytic	41	1.5	0.10	1.4	0.10	38	1.3	0.10	1.2	0.09
Chronic lymphocytic	38	1.2	0.09	1.5	0.11	22	0.6	0.05	0.7	0.06
Acute myeloid	128	4.3	0.17	4.8	0.19	109	2.9	0.13	3.3	0.14
Chronic myeloid	44	1.5	0.10	1.6	0.11	30	0.8	0.07	0.9	0.07
Other leukemias	27	0.9	0.08	1.0	0.09	23	0.6	0.06	0.7	0.07
Mesothelioma	16	0.5	0.06	0.6	0.07	6	0.2	0.03	0.2	0.03
Kaposi Sarcoma	11	0.4	0.05	0.4	0.06	*	*	*	*	*
Ill-Defined & Unknown	322	11.0	0.28	12.7	0.32	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	227	7.5	0.23	8.5	0.25	527	13.8	0.27	15.9	0.31
Breast (<i>in situ</i>)	2	0.1	0.02	0.1	0.02	1,218	31.6	0.41	37.5	0.48

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
California, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	289	432.2	11.89	514.9	13.89	317	417.3	10.92	484.7	12.35
Oral Cavity & Pharynx	13	18.5	2.42	22.5	2.87	5	5.8	1.21	7.2	1.46
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	2.6	0.93	3.2	1.11	2	1.8	0.65	2.3	0.81
Major salivary gland	1	2.1	0.85	2.6	1.01	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	1.8	0.76	2.1	0.87	1	1.4	0.61	1.7	0.69
Nasopharynx	1	1.4	0.61	2.0	0.82	*	*	*	*	*
Oropharynx	1	1.8	0.70	2.3	0.86	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	85	126.3	6.41	151.9	7.56	56	71.9	4.44	86.4	5.23
Esophagus	8	11.3	1.87	13.1	2.12	2	2.3	0.74	2.8	0.91
Stomach	5	7.3	1.52	8.8	1.79	3	4.1	1.07	5.2	1.32
Small intestine	2	2.4	0.90	2.9	1.06	1	2.1	0.79	2.3	0.90
Colon (excl. rectum)	18	27.9	3.10	33.4	3.65	22	29.0	2.87	33.7	3.28
Rectum & rectosigmoid	11	16.8	2.36	20.2	2.78	7	8.4	1.50	10.3	1.79
Anus, anal canal, & anorectum	2	3.6	1.06	4.5	1.31	1	1.3	0.57	1.7	0.69
Liver	23	32.1	3.08	40.0	3.77	9	10.1	1.57	12.8	1.95
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	11	17.6	2.46	20.8	2.84	7	9.4	1.67	11.1	1.94
Respiratory System	38	57.0	4.33	68.2	5.09	41	51.1	3.71	61.1	4.34
Larynx	3	3.9	1.13	4.7	1.35	*	*	*	*	*
Lung & bronchus	35	52.7	4.17	63.1	4.90	39	49.0	3.63	58.7	4.24
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	2	3.3	1.14	3.5	1.23	1	2.0	0.80	2.1	0.81
Skin (excl. basal & sq.)	10	16.8	2.47	19.4	2.82	9	11.7	1.85	13.2	2.04
Melanoma of the skin	9	14.4	2.28	16.4	2.57	7	10.0	1.69	11.3	1.88
Breast (excl. <i>in situ</i>)	*	*	*	*	*	86	112.2	5.66	130.8	6.40
Female Genital System	N/A	N/A	N/A	N/A	N/A	45	60.8	4.26	68.7	4.66
Cervix uteri	N/A	N/A	N/A	N/A	N/A	8	12.0	2.03	12.1	1.98
Uterus corpus	N/A	N/A	N/A	N/A	N/A	25	32.6	3.05	38.2	3.46
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	1	1.6	0.69	2.0	0.83
Ovary	N/A	N/A	N/A	N/A	N/A	8	10.4	1.76	11.6	1.91
Male Genital System	55	76.3	4.79	93.3	5.74	N/A	N/A	N/A	N/A	N/A
Prostate	49	66.0	4.41	82.9	5.43	N/A	N/A	N/A	N/A	N/A
Testis	5	8.6	1.71	8.3	1.64	N/A	N/A	N/A	N/A	N/A
Penis	1	1.8	0.75	2.1	0.90	N/A	N/A	N/A	N/A	N/A
Urinary System	35	52.7	4.20	62.7	4.90	21	28.3	2.88	32.9	3.26
Bladder (incl. <i>in situ</i>)	17	27.5	3.15	31.4	3.54	6	7.8	1.50	9.4	1.77
Kidney & renal pelvis	17	24.2	2.72	30.3	3.32	15	19.5	2.40	22.4	2.67
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	4	6.5	1.46	7.1	1.60	4	5.9	1.35	6.4	1.42
Brain	4	6.5	1.46	7.1	1.60	4	5.9	1.35	6.4	1.42
Endocrine System	3	5.0	1.26	5.7	1.40	13	19.2	2.44	20.7	2.57
Thyroid gland	3	5.0	1.26	5.7	1.40	13	19.2	2.44	20.7	2.57
Lymphomas	12	18.9	2.55	22.1	2.95	11	14.3	2.01	16.3	2.24
Hodgkin lymphoma	*	*	*	*	*	2	2.3	0.82	2.3	0.82
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	9	12.1	1.83	14.0	2.09
Multiple Myeloma	5	8.0	1.60	9.7	1.89	4	5.2	1.15	6.0	1.32
Leukemias	12	17.7	2.40	19.3	2.59	7	10.4	1.80	11.3	1.94
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	1	1.8	0.75	1.7	0.69
Chronic lymphocytic	3	4.9	1.23	5.7	1.41	1	1.8	0.75	2.1	0.88
Acute myeloid	3	4.7	1.20	5.3	1.32	3	4.0	1.13	4.4	1.19
Chronic myeloid	1	2.4	0.96	2.7	1.05	*	*	*	*	*
Other leukemias	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	13	21.3	2.76	24.8	3.17	13	17.4	2.20	20.4	2.55
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	7	11.7	2.05	13.0	2.24	13	16.7	2.19	19.2	2.44
Breast (<i>in situ</i>)	*	*	*	*	*	15	19.9	2.38	23.6	2.73

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
California, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	16,912	348.4	1.30	410.6	1.51	20,024	333.6	1.09	389.0	1.26
Oral Cavity & Pharynx	451	8.9	0.20	10.7	0.24	220	3.8	0.12	4.5	0.14
Lip	22	0.4	0.04	0.5	0.05	10	0.2	0.03	0.2	0.03
Tongue	126	2.5	0.11	3.0	0.13	65	1.1	0.06	1.4	0.08
Major salivary gland	53	1.1	0.07	1.2	0.08	51	0.8	0.05	0.9	0.06
Floor of mouth	15	0.3	0.04	0.4	0.05	6	0.1	0.02	0.1	0.02
Gum & other mouth	52	1.1	0.07	1.3	0.08	37	0.7	0.05	0.8	0.06
Nasopharynx	22	0.4	0.04	0.5	0.05	12	0.2	0.03	0.2	0.03
Oropharynx	24	0.5	0.05	0.6	0.06	7	0.1	0.02	0.2	0.03
Hypopharynx	27	0.6	0.06	0.7	0.07	4	0.1	0.02	0.1	0.02
Digestive System	4,653	96.2	0.68	115.1	0.80	3,785	66.7	0.50	78.8	0.58
Esophagus	209	4.6	0.15	5.5	0.18	52	1.0	0.06	1.2	0.07
Stomach	579	12.4	0.25	14.4	0.29	478	8.3	0.17	9.6	0.20
Small intestine	90	1.8	0.09	2.1	0.11	83	1.4	0.07	1.7	0.08
Colon (excl. rectum)	1,191	24.6	0.34	29.1	0.40	1,161	20.2	0.27	23.7	0.32
Rectum & rectosigmoid	722	13.7	0.24	16.5	0.29	495	8.1	0.17	9.7	0.20
Anus, anal canal, & anorectum	47	0.9	0.06	1.0	0.07	83	1.4	0.07	1.7	0.09
Liver	928	18.4	0.29	22.8	0.35	378	6.9	0.16	8.3	0.19
Gallbladder	55	1.3	0.08	1.5	0.10	152	2.7	0.10	3.3	0.12
Pancreas	549	12.3	0.25	14.6	0.29	586	10.9	0.21	12.8	0.24
Respiratory System	1,312	32.6	0.43	37.9	0.49	1,130	21.5	0.29	25.1	0.34
Larynx	134	3.0	0.13	3.6	0.14	24	0.4	0.04	0.5	0.05
Lung & bronchus	1,120	28.6	0.40	33.2	0.46	1,075	20.5	0.29	24.0	0.33
Bones & Joints	80	1.1	0.06	1.1	0.06	54	0.7	0.05	0.8	0.05
Soft Tissue (incl. heart)	215	3.7	0.12	4.1	0.14	211	3.3	0.11	3.6	0.12
Skin (excl. basal & sq.)	288	6.0	0.17	7.0	0.20	386	6.3	0.15	7.3	0.17
Melanoma of the skin	232	4.8	0.15	5.7	0.18	324	5.3	0.14	6.1	0.16
Breast (excl. <i>in situ</i>)	29	0.6	0.05	0.7	0.06	5,924	96.5	0.57	113.7	0.67
Female Genital System	N/A	N/A	N/A	N/A	N/A	3,098	49.4	0.41	58.1	0.48
Cervix uteri	N/A	N/A	N/A	N/A	N/A	596	9.1	0.17	9.9	0.19
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,556	24.7	0.29	29.9	0.35
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	73	1.2	0.06	1.4	0.08
Ovary	N/A	N/A	N/A	N/A	N/A	660	10.7	0.19	12.4	0.22
Male Genital System	4,373	88.7	0.65	106.6	0.76	N/A	N/A	N/A	N/A	N/A
Prostate	3,753	80.9	0.63	98.5	0.74	N/A	N/A	N/A	N/A	N/A
Testis	546	6.3	0.12	6.2	0.12	N/A	N/A	N/A	N/A	N/A
Penis	66	1.3	0.08	1.6	0.09	N/A	N/A	N/A	N/A	N/A
Urinary System	1,888	40.7	0.45	48.0	0.52	1,056	18.2	0.26	21.3	0.30
Bladder (incl. <i>in situ</i>)	646	16.3	0.30	19.0	0.35	228	4.3	0.13	5.1	0.15
Kidney & renal pelvis	1,211	23.6	0.33	28.0	0.38	808	13.5	0.22	15.9	0.26
Ureter	17	0.5	0.05	0.5	0.06	11	0.2	0.03	0.2	0.03
Eye & Orbit	34	0.7	0.06	0.7	0.06	28	0.4	0.04	0.5	0.04
Brain & Other CNS	340	5.6	0.15	6.2	0.17	292	4.5	0.12	4.9	0.14
Brain	316	5.3	0.14	5.8	0.16	268	4.1	0.12	4.6	0.13
Endocrine System	395	6.5	0.16	7.2	0.18	1,401	20.4	0.25	22.5	0.28
Thyroid gland	355	5.8	0.15	6.6	0.17	1,363	19.9	0.25	21.9	0.27
Lymphomas	1,139	22.2	0.32	25.7	0.37	1,002	17.0	0.25	19.6	0.29
Hodgkin lymphoma	153	2.3	0.09	2.5	0.10	124	1.7	0.07	1.8	0.08
Non-Hodgkin lymphoma	986	20.0	0.31	23.2	0.36	879	15.3	0.24	17.8	0.28
Multiple Myeloma	336	7.2	0.19	8.6	0.22	298	5.4	0.14	6.4	0.17
Leukemias	697	12.0	0.23	13.0	0.25	560	8.7	0.17	9.5	0.19
Acute lymphocytic	250	3.0	0.09	2.8	0.09	186	2.4	0.08	2.3	0.08
Chronic lymphocytic	92	2.1	0.11	2.5	0.12	68	1.3	0.07	1.5	0.08
Acute myeloid	192	3.8	0.14	4.2	0.15	191	3.1	0.11	3.5	0.12
Chronic myeloid	94	1.7	0.09	1.9	0.10	69	1.1	0.06	1.2	0.07
Other leukemias	69	1.4	0.08	1.5	0.09	47	0.8	0.05	0.9	0.06
Mesothelioma	48	1.1	0.08	1.3	0.09	23	0.4	0.04	0.5	0.05
Kaposi Sarcoma	68	1.1	0.06	1.2	0.07	5	0.1	0.02	0.1	0.02
Ill-Defined & Unknown	568	13.4	0.27	15.5	0.31	552	10.3	0.20	11.9	0.23
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	376	6.8	0.17	7.7	0.20	850	14.2	0.22	16.3	0.26
Breast (<i>in situ</i>)	3	0.0	0.01	0.1	0.02	1,302	20.9	0.26	25.1	0.32

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

CALIFORNIA

II-48 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
California, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	16,071	355.9	1.36	419.5	1.57	19,238	346.2	1.15	403.6	1.33
Oral Cavity & Pharynx	437	9.3	0.21	11.1	0.25	209	3.9	0.12	4.6	0.15
Lip	21	0.5	0.05	0.5	0.06	10	0.2	0.03	0.2	0.03
Tongue	121	2.6	0.11	3.1	0.13	63	1.2	0.07	1.4	0.08
Major salivary gland	52	1.1	0.08	1.3	0.09	47	0.8	0.06	1.0	0.06
Floor of mouth	15	0.3	0.04	0.4	0.05	6	0.1	0.02	0.1	0.02
Gum & other mouth	51	1.1	0.08	1.3	0.09	35	0.7	0.05	0.8	0.06
Nasopharynx	21	0.4	0.04	0.5	0.05	10	0.2	0.03	0.2	0.03
Oropharynx	23	0.5	0.05	0.6	0.06	7	0.1	0.02	0.2	0.03
Hypopharynx	26	0.6	0.06	0.7	0.07	4	0.1	0.02	0.1	0.02
Digestive System	4,496	100.0	0.72	119.7	0.84	3,649	69.3	0.53	81.8	0.62
Esophagus	203	4.8	0.16	5.7	0.19	50	1.0	0.07	1.2	0.08
Stomach	562	12.9	0.26	15.1	0.30	461	8.6	0.18	10.0	0.21
Small intestine	85	1.9	0.10	2.2	0.11	79	1.5	0.08	1.7	0.09
Colon (excl. rectum)	1,144	25.4	0.36	30.1	0.42	1,114	20.9	0.29	24.5	0.34
Rectum & rectosigmoid	690	14.1	0.26	17.0	0.31	469	8.3	0.17	9.9	0.21
Anus, anal canal, & anorectum	45	0.9	0.07	1.1	0.08	80	1.5	0.08	1.8	0.09
Liver	902	19.2	0.31	23.8	0.37	368	7.3	0.17	8.7	0.21
Gallbladder	54	1.4	0.09	1.6	0.10	148	2.8	0.11	3.4	0.13
Pancreas	535	12.9	0.27	15.3	0.31	570	11.4	0.22	13.3	0.25
Respiratory System	1,272	33.8	0.45	39.3	0.51	1,093	22.3	0.31	26.0	0.36
Larynx	129	3.1	0.13	3.7	0.15	24	0.4	0.04	0.5	0.05
Lung & bronchus	1,087	29.7	0.43	34.5	0.49	1,038	21.3	0.30	24.9	0.35
Bones & Joints	78	1.2	0.06	1.2	0.07	52	0.8	0.05	0.8	0.05
Soft Tissue (incl. heart)	210	3.9	0.13	4.3	0.15	203	3.4	0.11	3.8	0.12
Skin (excl. basal & sq.)	271	6.1	0.18	7.2	0.21	351	6.2	0.15	7.2	0.18
Melanoma of the skin	218	4.9	0.16	5.7	0.19	294	5.2	0.14	6.0	0.16
Breast (excl. <i>in situ</i>)	28	0.6	0.06	0.7	0.07	5,679	100.0	0.61	117.9	0.71
Female Genital System	N/A	N/A	N/A	N/A	N/A	2,989	51.7	0.43	60.6	0.51
Cervix uteri	N/A	N/A	N/A	N/A	N/A	574	9.6	0.18	10.4	0.20
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,500	25.8	0.30	31.2	0.37
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	70	1.2	0.07	1.5	0.08
Ovary	N/A	N/A	N/A	N/A	N/A	640	11.2	0.20	13.0	0.24
Male Genital System	3,974	86.3	0.66	103.7	0.77	N/A	N/A	N/A	N/A	N/A
Prostate	3,384	78.1	0.64	95.3	0.76	N/A	N/A	N/A	N/A	N/A
Testis	520	6.6	0.13	6.5	0.13	N/A	N/A	N/A	N/A	N/A
Penis	63	1.4	0.09	1.7	0.10	N/A	N/A	N/A	N/A	N/A
Urinary System	1,819	42.2	0.48	49.7	0.55	1,015	18.8	0.27	22.1	0.32
Bladder (incl. <i>in situ</i>)	621	16.8	0.32	19.6	0.37	220	4.5	0.14	5.2	0.16
Kidney & renal pelvis	1,169	24.6	0.35	29.1	0.40	776	14.0	0.23	16.4	0.27
Ureter	17	0.5	0.06	0.6	0.06	11	0.2	0.03	0.3	0.04
Eye & Orbit	33	0.7	0.06	0.8	0.07	27	0.4	0.04	0.5	0.04
Brain & Other CNS	331	5.9	0.16	6.6	0.18	284	4.7	0.13	5.2	0.15
Brain	308	5.5	0.15	6.2	0.17	261	4.3	0.12	4.8	0.14
Endocrine System	381	6.8	0.17	7.6	0.19	1,344	21.3	0.27	23.5	0.30
Thyroid gland	342	6.1	0.16	6.9	0.18	1,307	20.8	0.26	22.8	0.29
Lymphomas	1,096	23.1	0.34	26.7	0.39	961	17.6	0.26	20.3	0.30
Hodgkin lymphoma	146	2.4	0.10	2.6	0.11	119	1.8	0.08	1.9	0.08
Non-Hodgkin lymphoma	950	20.8	0.33	24.2	0.38	842	15.8	0.25	18.4	0.29
Multiple Myeloma	322	7.5	0.20	8.9	0.23	286	5.5	0.15	6.6	0.18
Leukemias	671	12.5	0.24	13.5	0.27	540	9.1	0.18	9.9	0.20
Acute lymphocytic	243	3.3	0.10	3.0	0.10	180	2.5	0.09	2.5	0.09
Chronic lymphocytic	85	2.1	0.11	2.5	0.13	63	1.2	0.07	1.5	0.08
Acute myeloid	188	4.0	0.14	4.4	0.16	185	3.3	0.11	3.7	0.13
Chronic myeloid	91	1.8	0.09	2.0	0.10	66	1.2	0.07	1.3	0.07
Other leukemias	66	1.4	0.08	1.6	0.10	46	0.8	0.06	0.9	0.06
Mesothelioma	47	1.2	0.08	1.4	0.10	22	0.4	0.04	0.5	0.05
Kaposi Sarcoma	62	1.1	0.07	1.2	0.07	4	0.1	0.02	0.1	0.02
Ill-Defined & Unknown	545	13.8	0.28	16.0	0.32	531	10.6	0.21	12.3	0.24
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	360	7.0	0.18	8.0	0.21	804	14.5	0.24	16.7	0.27
Breast (<i>in situ</i>)	3	0.0	0.01	0.1	0.02	1,239	21.5	0.28	25.8	0.33

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
California, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	86	95.2	5.32	113.1	6.18	132	116.8	4.99	138.1	5.82
Oral Cavity & Pharynx	2	2.6	0.98	3.0	1.13	2	1.1	0.35	1.2	0.41
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	20	24.5	2.77	28.9	3.17	21	18.9	2.01	22.7	2.37
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	2	2.2	0.76	2.5	0.87	3	3.1	0.82	3.6	0.94
Small intestine	1	1.9	0.83	2.1	0.91	*	*	*	*	*
Colon (excl. rectum)	7	8.3	1.60	9.6	1.82	8	7.3	1.26	8.7	1.48
Rectum & rectosigmoid	2	1.8	0.68	2.0	0.78	3	1.9	0.54	2.3	0.66
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	3	2.8	0.77	3.6	0.97	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	2	3.3	1.16	3.8	1.30	3	2.6	0.75	3.3	0.93
Respiratory System	11	14.5	2.17	17.0	2.46	11	12.6	1.79	14.6	2.01
Larynx	1	2.1	0.90	2.2	0.94	*	*	*	*	*
Lung & bronchus	9	12.2	1.97	14.6	2.27	11	12.3	1.78	14.4	2.00
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	3	2.6	0.79	3.0	0.91
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	45	39.7	2.86	47.1	3.36
Female Genital System	N/A	N/A	N/A	N/A	N/A	19	15.9	1.77	19.2	2.13
Cervix uteri	N/A	N/A	N/A	N/A	N/A	4	2.6	0.65	2.9	0.75
Uterus corpus	N/A	N/A	N/A	N/A	N/A	9	7.7	1.24	9.5	1.51
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	4	3.4	0.85	4.0	0.99
Male Genital System	25	27.8	2.81	34.5	3.33	N/A	N/A	N/A	N/A	N/A
Prostate	23	26.6	2.75	33.2	3.27	N/A	N/A	N/A	N/A	N/A
Testis	1	0.6	0.24	0.6	0.24	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	7	6.8	1.35	8.4	1.63	5	5.1	1.08	6.1	1.28
Bladder (incl. <i>in situ</i>)	3	3.5	1.11	4.3	1.31	2	1.7	0.66	2.0	0.75
Kidney & renal pelvis	4	3.3	0.76	4.2	0.97	4	3.4	0.86	4.2	1.04
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	2.2	0.81	2.3	0.87	1	0.8	0.31	0.8	0.35
Brain	2	2.2	0.81	2.3	0.87	1	0.8	0.31	0.8	0.35
Endocrine System	*	*	*	*	*	7	4.2	0.78	4.6	0.88
Thyroid gland	*	*	*	*	*	7	4.1	0.77	4.5	0.88
Lymphomas	5	3.8	0.93	4.1	1.02	6	5.1	1.04	6.0	1.19
Hodgkin lymphoma	1	0.6	0.24	0.6	0.24	*	*	*	*	*
Non-Hodgkin lymphoma	4	3.2	0.89	3.5	0.99	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	2	2.6	0.82	3.2	0.99	3	3.9	1.00	4.6	1.16
Leukemias	4	3.5	1.00	3.9	1.18	4	3.4	0.90	3.8	1.00
Acute lymphocytic	2	0.6	0.23	0.5	0.19	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	2	1.7	0.67	1.9	0.73
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	3	3.2	1.03	3.9	1.23	3	2.9	0.77	3.4	0.94
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	1	1.2	0.57	1.3	0.62	5	5.3	1.13	5.7	1.22
Breast (<i>in situ</i>)	*	*	*	*	*	9	7.8	1.27	9.5	1.51

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


CALIFORNIA

II-50 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	21,501,184	21,670,978	21,832,760	21,949,845	22,010,528
Non-Hispanic White	9,628,877	9,585,237	9,533,323	9,463,845	9,365,030
Non-Hispanic Black	1,111,316	1,124,836	1,139,574	1,152,295	1,162,026
Non-Hispanic Asian/Pacific Islander (NH API)	2,343,761	2,406,708	2,471,573	2,527,251	2,572,918
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	130,697	130,555	130,848	130,532	129,590

All Races Population 2015–2019: 108,965,295
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹


Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	8,259,865	8,397,003	8,530,874	8,649,335	8,754,505
Hispanic White	7,514,492	7,636,923	7,755,663	7,858,997	7,948,846
Hispanic Black	214,993	219,879	225,091	230,209	234,818

Hispanic/Latino Population, Census 2010:
14,013,719

Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

GREATER CALIFORNIA CANCER REGISTRY

Initial Operation: 1988
 Population-based Data Available: 1988
 Coverage Area: California (excl. GB and Los)

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	100.9	99.2	99.6	99.4	100.6	99.9
Missing Race	2.2	2.2	2.4	2.8	2.9	2.5
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.0	1.8	1.1	2.0	1.6	1.7
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.6	Ovary	92.5
Oral Cavity & Pharynx	97.4	Prostate	95.3
Esophagus	94.8	Testis	98.6
Stomach	95.9	Bladder (incl. <i>in situ</i>)	96.9
Colon & Rectum	96.0	Kidney & Renal Pelvis	89.5
Liver	44.4	Brain & Other CNS	85.5
Pancreas	83.8	Brain & Other CNS (non-malig)	40.6
Lung & Bronchus	87.6	Thyroid	99.2
Melanomas of the Skin	97.9	Hodgkin Lymphoma	98.5
Female Breast (excl. <i>in situ</i>)	98.8	Non-Hodgkin Lymphoma	96.6
Female Breast (<i>in situ</i>)	99.9	Multiple Myeloma	88.5
Cervix Uteri	97.4	Leukemias	91.9
Uterus Corpus & Uterus NOS	98.4		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Greater California, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	49,987	444.3	0.91	525.8	1.06	49,885	397.8	0.82	463.8	0.94
Oral Cavity & Pharynx	1,955	16.8	0.17	20.5	0.21	755	5.9	0.10	7.0	0.11
Lip	132	1.2	0.05	1.4	0.05	50	0.4	0.02	0.4	0.03
Tongue	657	5.6	0.10	6.8	0.12	243	1.9	0.06	2.3	0.07
Major salivary gland	183	1.7	0.06	2.0	0.07	120	1.0	0.04	1.1	0.05
Floor of mouth	55	0.5	0.03	0.6	0.04	30	0.2	0.02	0.3	0.02
Gum & other mouth	162	1.5	0.05	1.7	0.06	135	1.0	0.04	1.2	0.05
Nasopharynx	97	0.8	0.04	1.0	0.05	36	0.3	0.02	0.3	0.03
Oropharynx	103	0.9	0.04	1.1	0.05	24	0.2	0.02	0.2	0.02
Hypopharynx	88	0.8	0.04	0.9	0.04	18	0.1	0.02	0.2	0.02
Digestive System	10,304	91.4	0.41	109.4	0.49	8,097	63.0	0.32	74.2	0.37
Esophagus	736	6.5	0.11	7.8	0.13	213	1.6	0.05	1.9	0.06
Stomach	941	8.6	0.13	10.0	0.15	639	5.1	0.09	5.9	0.11
Small intestine	260	2.3	0.07	2.7	0.08	218	1.7	0.05	2.0	0.06
Colon (excl. rectum)	2,852	25.9	0.22	30.6	0.26	2,853	22.4	0.19	26.1	0.22
Rectum & rectosigmoid	1,503	13.3	0.16	15.9	0.18	1,068	8.6	0.12	10.2	0.14
Anus, anal canal, & anorectum	159	1.4	0.05	1.7	0.06	317	2.4	0.06	2.9	0.07
Liver	1,632	13.5	0.15	16.9	0.19	589	4.4	0.08	5.3	0.10
Gallbladder	91	0.8	0.04	1.0	0.05	179	1.4	0.05	1.6	0.06
Pancreas	1,571	14.1	0.16	16.8	0.19	1,424	10.9	0.13	12.8	0.15
Respiratory System	5,524	50.4	0.31	59.3	0.36	5,296	40.5	0.25	47.6	0.29
Larynx	409	3.6	0.08	4.3	0.10	87	0.7	0.03	0.8	0.04
Lung & bronchus	4,989	45.7	0.30	53.7	0.34	5,135	39.2	0.25	46.1	0.29
Bones & Joints	122	1.1	0.05	1.2	0.05	93	0.8	0.04	0.8	0.04
Soft Tissue (incl. heart)	478	4.4	0.09	5.0	0.10	375	3.1	0.07	3.5	0.08
Skin (excl. basal & sq.)	4,062	37.0	0.27	43.4	0.31	2,658	21.4	0.19	24.8	0.22
Melanoma of the skin	3,761	34.1	0.25	40.1	0.29	2,481	20.0	0.18	23.2	0.21
Breast (excl. <i>in situ</i>)	115	1.1	0.04	1.2	0.05	15,280	123.1	0.46	144.7	0.53
Female Genital System	N/A	N/A	N/A	N/A	N/A	6,218	49.7	0.29	58.7	0.34
Cervix uteri	N/A	N/A	N/A	N/A	N/A	849	7.8	0.12	8.3	0.13
Uterus corpus	N/A	N/A	N/A	N/A	N/A	3,332	25.7	0.20	31.4	0.24
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	138	1.1	0.04	1.3	0.05
Ovary	N/A	N/A	N/A	N/A	N/A	1,340	10.8	0.14	12.6	0.16
Male Genital System	12,498	105.6	0.43	128.0	0.52	N/A	N/A	N/A	N/A	N/A
Prostate	11,692	98.3	0.42	120.5	0.50	N/A	N/A	N/A	N/A	N/A
Testis	689	6.3	0.11	6.2	0.11	N/A	N/A	N/A	N/A	N/A
Penis	91	0.8	0.04	1.0	0.05	N/A	N/A	N/A	N/A	N/A
Urinary System	5,740	52.3	0.32	61.6	0.37	2,402	18.7	0.17	21.9	0.20
Bladder (incl. <i>in situ</i>)	3,147	29.4	0.24	34.4	0.28	922	7.0	0.10	8.2	0.12
Kidney & renal pelvis	2,469	21.7	0.20	25.8	0.23	1,407	11.2	0.14	13.1	0.16
Ureter	68	0.7	0.04	0.8	0.04	47	0.4	0.02	0.4	0.03
Eye & Orbit	120	1.1	0.05	1.2	0.05	83	0.7	0.03	0.8	0.04
Brain & Other CNS	808	7.3	0.12	8.1	0.13	616	5.1	0.09	5.7	0.10
Brain	763	6.8	0.11	7.7	0.13	574	4.8	0.09	5.3	0.10
Endocrine System	857	7.7	0.12	8.7	0.13	2,290	20.4	0.20	22.2	0.21
Thyroid gland	761	6.9	0.11	7.8	0.13	2,212	19.8	0.19	21.5	0.21
Lymphomas	2,644	24.1	0.21	27.7	0.24	2,091	16.7	0.17	19.2	0.19
Hodgkin lymphoma	276	2.5	0.07	2.6	0.07	218	2.0	0.06	2.0	0.06
Non-Hodgkin lymphoma	2,367	21.6	0.20	25.0	0.23	1,873	14.8	0.16	17.2	0.18
Multiple Myeloma	848	7.6	0.12	9.0	0.14	640	5.0	0.09	5.9	0.10
Leukemias	1,744	16.1	0.18	18.0	0.20	1,229	10.0	0.13	11.1	0.14
Acute lymphocytic	248	2.3	0.07	2.1	0.06	197	1.9	0.06	1.7	0.05
Chronic lymphocytic	560	5.1	0.10	6.0	0.11	343	2.6	0.06	3.1	0.07
Acute myeloid	508	4.7	0.10	5.4	0.11	410	3.3	0.08	3.7	0.08
Chronic myeloid	240	2.2	0.07	2.5	0.07	155	1.3	0.05	1.4	0.05
Other leukemias	187	1.7	0.06	2.0	0.07	125	1.0	0.04	1.1	0.05
Mesothelioma	134	1.3	0.05	1.5	0.06	54	0.4	0.03	0.5	0.03
Kaposi Sarcoma	81	0.8	0.04	0.8	0.04	8	0.1	0.01	0.1	0.01
Ill-Defined & Unknown	1,953	18.3	0.19	21.3	0.22	1,699	13.1	0.14	15.1	0.17
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	988	9.1	0.13	10.2	0.15	2,015	16.3	0.17	18.8	0.19
Breast (<i>in situ</i>)	12	0.1	0.01	0.1	0.02	3,215	26.1	0.21	31.0	0.25

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Greater California, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	32,962	478.7	1.22	565.9	1.42	31,171	427.1	1.17	497.1	1.31
Oral Cavity & Pharynx	1,468	21.0	0.26	25.7	0.31	520	6.8	0.14	8.1	0.17
Lip	106	1.6	0.07	1.9	0.08	38	0.5	0.04	0.6	0.04
Tongue	533	7.6	0.15	9.3	0.18	179	2.4	0.08	2.8	0.10
Major salivary gland	130	1.9	0.08	2.2	0.09	69	1.0	0.06	1.1	0.06
Floor of mouth	40	0.6	0.04	0.7	0.05	23	0.3	0.03	0.3	0.03
Gum & other mouth	109	1.6	0.07	1.9	0.08	96	1.2	0.06	1.4	0.07
Nasopharynx	33	0.5	0.04	0.6	0.05	14	0.2	0.03	0.2	0.03
Oropharynx	77	1.1	0.06	1.3	0.07	17	0.2	0.02	0.3	0.03
Hypopharynx	65	0.9	0.05	1.1	0.06	14	0.2	0.02	0.2	0.03
Digestive System	6,035	87.7	0.52	104.7	0.61	4,730	60.7	0.42	71.4	0.48
Esophagus	553	7.7	0.15	9.3	0.18	153	1.8	0.07	2.2	0.08
Stomach	469	6.8	0.15	8.0	0.17	245	3.2	0.10	3.7	0.11
Small intestine	165	2.4	0.09	2.9	0.10	141	1.9	0.08	2.2	0.09
Colon (excl. rectum)	1,753	26.4	0.29	31.1	0.34	1,777	23.0	0.26	26.8	0.30
Rectum & rectosigmoid	836	12.8	0.21	15.2	0.24	605	8.5	0.17	10.1	0.19
Anus, anal canal, & anorectum	122	1.8	0.08	2.2	0.09	244	3.1	0.09	3.8	0.11
Liver	736	9.7	0.17	12.3	0.20	248	3.0	0.09	3.7	0.11
Gallbladder	41	0.6	0.04	0.7	0.05	81	1.0	0.05	1.2	0.06
Pancreas	1,037	14.7	0.21	17.5	0.25	888	10.8	0.17	12.7	0.20
Respiratory System	3,927	55.5	0.40	65.4	0.47	3,922	47.4	0.35	55.9	0.41
Larynx	277	3.9	0.11	4.7	0.13	65	0.9	0.05	1.0	0.06
Lung & bronchus	3,578	50.5	0.39	59.4	0.45	3,813	46.0	0.34	54.1	0.40
Bones & Joints	60	1.1	0.07	1.2	0.07	48	0.9	0.06	0.9	0.06
Soft Tissue (incl. heart)	286	4.6	0.13	5.2	0.14	202	3.2	0.11	3.5	0.11
Skin (excl. basal & sq.)	3,493	52.3	0.41	61.2	0.47	2,102	31.4	0.33	35.9	0.37
Melanoma of the skin	3,264	48.9	0.40	57.2	0.46	1,989	29.9	0.33	34.2	0.36
Breast (excl. <i>in situ</i>)	84	1.2	0.06	1.4	0.07	9,520	134.1	0.66	157.3	0.75
Female Genital System	N/A	N/A	N/A	N/A	N/A	3,585	49.8	0.40	59.0	0.46
Cervix uteri	N/A	N/A	N/A	N/A	N/A	370	7.2	0.18	7.6	0.18
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,970	25.6	0.27	31.5	0.33
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	68	0.9	0.05	1.1	0.06
Ovary	N/A	N/A	N/A	N/A	N/A	800	11.3	0.19	13.2	0.22
Male Genital System	7,706	105.3	0.55	127.6	0.66	N/A	N/A	N/A	N/A	N/A
Prostate	7,324	97.2	0.52	119.3	0.63	N/A	N/A	N/A	N/A	N/A
Testis	321	7.3	0.19	7.2	0.18	N/A	N/A	N/A	N/A	N/A
Penis	45	0.7	0.05	0.8	0.05	N/A	N/A	N/A	N/A	N/A
Urinary System	4,010	58.3	0.42	68.6	0.49	1,515	19.3	0.24	22.6	0.27
Bladder (incl. <i>in situ</i>)	2,465	35.4	0.33	41.5	0.38	700	8.4	0.15	9.8	0.17
Kidney & renal pelvis	1,451	21.5	0.26	25.5	0.31	766	10.3	0.18	12.1	0.20
Ureter	51	0.7	0.05	0.9	0.05	32	0.4	0.03	0.4	0.04
Eye & Orbit	89	1.5	0.07	1.6	0.08	63	1.0	0.06	1.1	0.06
Brain & Other CNS	529	8.9	0.19	9.9	0.20	384	6.1	0.15	6.7	0.16
Brain	506	8.5	0.18	9.4	0.19	365	5.8	0.15	6.3	0.15
Endocrine System	495	8.5	0.18	9.5	0.20	1,070	20.0	0.30	21.5	0.30
Thyroid gland	445	7.6	0.17	8.6	0.19	1,031	19.3	0.29	20.7	0.30
Lymphomas	1,660	25.9	0.30	29.7	0.33	1,242	17.2	0.24	19.7	0.26
Hodgkin lymphoma	152	3.1	0.12	3.2	0.12	116	2.4	0.11	2.5	0.11
Non-Hodgkin lymphoma	1,507	22.9	0.27	26.6	0.31	1,126	14.8	0.21	17.2	0.24
Multiple Myeloma	506	7.2	0.15	8.6	0.17	358	4.5	0.11	5.3	0.13
Leukemias	1,132	17.6	0.25	20.0	0.27	742	10.5	0.19	11.7	0.20
Acute lymphocytic	80	1.9	0.10	1.7	0.09	62	1.5	0.09	1.4	0.08
Chronic lymphocytic	438	6.2	0.14	7.4	0.16	269	3.2	0.09	3.8	0.11
Acute myeloid	335	5.1	0.13	5.9	0.15	244	3.4	0.10	3.8	0.11
Chronic myeloid	155	2.4	0.09	2.8	0.10	89	1.3	0.07	1.4	0.07
Other leukemias	124	1.9	0.08	2.2	0.09	78	1.1	0.06	1.2	0.07
Mesothelioma	98	1.4	0.07	1.7	0.08	38	0.5	0.04	0.6	0.04
Kaposi Sarcoma	32	0.6	0.05	0.7	0.05	3	0.0	0.01	0.0	0.01
Ill-Defined & Unknown	1,352	19.9	0.25	23.3	0.29	1,127	13.8	0.20	16.0	0.22
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	605	10.0	0.19	11.2	0.21	1,157	16.8	0.24	19.2	0.26
Breast (<i>in situ</i>)	8	0.1	0.02	0.1	0.02	1,858	27.2	0.31	32.1	0.35

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Greater California, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,334	462.8	4.57	559.6	5.39	2,121	385.0	3.85	455.0	4.46
Oral Cavity & Pharynx	64	12.5	0.74	15.0	0.87	25	4.6	0.42	5.4	0.48
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	18	3.4	0.38	4.1	0.45	5	0.9	0.19	1.2	0.23
Major salivary gland	5	1.1	0.24	1.3	0.28	6	1.1	0.21	1.2	0.22
Floor of mouth	3	0.5	0.16	0.7	0.19	*	*	*	*	*
Gum & other mouth	4	0.8	0.19	1.0	0.22	6	1.1	0.21	1.3	0.24
Nasopharynx	7	1.5	0.26	1.6	0.28	1	0.3	0.11	0.3	0.11
Oropharynx	6	1.1	0.22	1.4	0.26	1	0.3	0.12	0.3	0.12
Hypopharynx	4	0.8	0.19	1.0	0.22	*	*	*	*	*
Digestive System	515	103.3	2.17	124.8	2.56	395	72.2	1.67	86.5	1.97
Esophagus	19	3.8	0.41	4.7	0.50	10	1.8	0.26	2.2	0.31
Stomach	51	11.1	0.74	13.1	0.86	37	6.9	0.52	8.1	0.60
Small intestine	22	4.5	0.45	5.4	0.53	15	2.7	0.32	3.3	0.38
Colon (excl. rectum)	148	30.4	1.19	36.0	1.38	140	25.8	1.00	30.7	1.17
Rectum & rectosigmoid	60	11.7	0.72	14.1	0.85	45	8.2	0.56	9.7	0.65
Anus, anal canal, & anorectum	8	1.4	0.24	1.8	0.28	11	1.9	0.27	2.4	0.32
Liver	88	15.6	0.79	20.0	0.98	29	5.0	0.43	6.3	0.53
Gallbladder	5	1.0	0.21	1.3	0.26	9	1.7	0.25	2.1	0.31
Pancreas	87	17.9	0.92	21.7	1.08	75	13.8	0.73	16.6	0.87
Respiratory System	287	62.5	1.76	74.3	2.04	253	46.1	1.33	55.5	1.58
Larynx	24	4.7	0.46	5.7	0.54	5	0.8	0.17	1.1	0.21
Lung & bronchus	259	56.8	1.69	67.6	1.96	244	44.5	1.31	53.6	1.55
Bones & Joints	5	0.9	0.20	1.0	0.21	5	0.8	0.16	0.8	0.16
Soft Tissue (incl. heart)	23	4.5	0.45	5.1	0.51	19	3.4	0.36	3.9	0.40
Skin (excl. basal & sq.)	8	1.7	0.29	2.0	0.32	10	1.7	0.26	2.0	0.29
Melanoma of the skin	4	0.8	0.20	0.9	0.23	5	0.9	0.19	1.0	0.21
Breast (excl. <i>in situ</i>)	8	1.7	0.29	2.0	0.35	691	125.7	2.20	147.5	2.53
Female Genital System	N/A	N/A	N/A	N/A	N/A	276	48.1	1.33	57.8	1.57
Cervix uteri	N/A	N/A	N/A	N/A	N/A	40	7.5	0.55	8.2	0.59
Uterus corpus	N/A	N/A	N/A	N/A	N/A	152	25.7	0.96	31.8	1.16
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	13	2.3	0.30	2.8	0.34
Ovary	N/A	N/A	N/A	N/A	N/A	50	8.7	0.56	10.4	0.67
Male Genital System	822	152.0	2.52	190.6	3.06	N/A	N/A	N/A	N/A	N/A
Prostate	809	149.8	2.50	188.2	3.04	N/A	N/A	N/A	N/A	N/A
Testis	9	1.5	0.23	1.5	0.23	N/A	N/A	N/A	N/A	N/A
Penis	3	0.6	0.18	0.7	0.20	N/A	N/A	N/A	N/A	N/A
Urinary System	216	44.1	1.44	52.8	1.68	110	20.2	0.89	24.0	1.03
Bladder (incl. <i>in situ</i>)	84	18.7	0.98	22.4	1.14	32	6.1	0.50	7.1	0.57
Kidney & renal pelvis	129	24.8	1.03	29.7	1.21	76	13.7	0.72	16.3	0.84
Ureter	*	*	*	*	*	2	0.3	0.11	0.4	0.13
Eye & Orbit	1	0.2	0.11	0.3	0.13	1	0.3	0.11	0.3	0.11
Brain & Other CNS	26	5.0	0.46	5.4	0.50	17	3.0	0.33	3.3	0.37
Brain	23	4.5	0.44	4.9	0.48	15	2.7	0.32	3.0	0.35
Endocrine System	27	5.1	0.46	5.9	0.52	64	11.7	0.67	13.2	0.75
Thyroid gland	22	4.1	0.42	4.8	0.48	58	10.6	0.64	12.0	0.71
Lymphomas	93	17.9	0.88	20.4	1.00	77	14.0	0.73	15.9	0.82
Hodgkin lymphoma	14	2.5	0.30	2.4	0.29	14	2.4	0.30	2.5	0.31
Non-Hodgkin lymphoma	78	15.4	0.83	18.0	0.96	63	11.5	0.67	13.4	0.76
Multiple Myeloma	78	16.6	0.90	19.8	1.05	64	11.5	0.66	13.8	0.78
Leukemias	63	13.1	0.79	15.0	0.89	40	7.4	0.54	8.3	0.60
Acute lymphocytic	5	1.0	0.20	1.0	0.20	6	1.0	0.19	1.0	0.19
Chronic lymphocytic	22	4.9	0.50	5.7	0.57	7	1.4	0.24	1.7	0.28
Acute myeloid	20	4.0	0.43	4.5	0.48	15	2.7	0.32	3.0	0.35
Chronic myeloid	10	1.9	0.30	2.1	0.32	7	1.4	0.24	1.6	0.27
Other leukemias	7	1.4	0.26	1.7	0.31	4	0.9	0.19	0.9	0.20
Mesothelioma	4	1.0	0.22	1.1	0.26	*	*	*	*	*
Kaposi Sarcoma	7	1.1	0.20	1.2	0.21	*	*	*	*	*
Ill-Defined & Unknown	86	19.4	1.00	23.0	1.17	74	14.1	0.75	16.5	0.87
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	43	8.7	0.63	9.8	0.71	89	16.5	0.80	19.0	0.91
Breast (<i>in situ</i>)	2	0.3	0.11	0.4	0.13	155	27.3	1.01	32.8	1.18

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Greater California, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3,389	290.8	2.28	341.0	2.65	4,496	306.4	2.08	355.5	2.38
Oral Cavity & Pharynx	125	10.3	0.42	12.2	0.49	68	4.6	0.26	5.4	0.29
Lip	1	0.1	0.04	0.1	0.05	*	*	*	*	*
Tongue	26	2.2	0.19	2.6	0.23	17	1.2	0.13	1.3	0.15
Major salivary gland	13	1.2	0.15	1.3	0.16	16	1.1	0.13	1.3	0.14
Floor of mouth	3	0.2	0.06	0.3	0.07	2	0.1	0.04	0.1	0.05
Gum & other mouth	20	1.6	0.17	2.0	0.20	11	0.7	0.10	0.8	0.12
Nasopharynx	41	3.4	0.24	3.9	0.27	14	1.0	0.12	1.1	0.13
Oropharynx	2	0.2	0.05	0.2	0.07	1	0.1	0.04	0.1	0.04
Hypopharynx	4	0.4	0.09	0.5	0.10	1	0.1	0.03	0.1	0.04
Digestive System	1,020	87.2	1.25	103.5	1.46	836	56.9	0.89	66.4	1.03
Esophagus	36	3.0	0.23	3.6	0.27	15	1.0	0.12	1.2	0.14
Stomach	120	10.6	0.44	12.4	0.51	106	7.2	0.32	8.4	0.37
Small intestine	18	1.6	0.17	1.8	0.19	13	0.9	0.11	1.0	0.13
Colon (excl. rectum)	252	21.6	0.62	25.6	0.73	263	18.0	0.50	21.0	0.58
Rectum & rectosigmoid	169	14.2	0.50	17.0	0.59	114	7.7	0.33	9.1	0.38
Anus, anal canal, & anorectum	4	0.3	0.08	0.4	0.09	8	0.5	0.09	0.6	0.10
Liver	224	18.5	0.56	22.5	0.68	88	5.9	0.29	7.0	0.33
Gallbladder	13	1.2	0.15	1.3	0.17	20	1.3	0.14	1.6	0.16
Pancreas	123	10.9	0.45	12.7	0.52	141	9.8	0.37	11.2	0.42
Respiratory System	511	44.9	0.91	52.9	1.06	419	28.4	0.63	33.3	0.73
Larynx	25	2.2	0.20	2.6	0.23	3	0.2	0.05	0.2	0.06
Lung & bronchus	474	41.7	0.88	49.2	1.02	409	27.7	0.62	32.5	0.72
Bones & Joints	9	0.8	0.12	0.8	0.12	8	0.6	0.10	0.6	0.10
Soft Tissue (incl. heart)	41	3.5	0.25	3.9	0.28	34	2.4	0.19	2.7	0.21
Skin (excl. basal & sq.)	26	2.4	0.21	2.7	0.24	28	1.9	0.17	2.2	0.19
Melanoma of the skin	16	1.5	0.17	1.7	0.19	19	1.3	0.14	1.5	0.15
Breast (excl. <i>in situ</i>)	6	0.5	0.10	0.6	0.11	1,536	103.9	1.20	121.5	1.39
Female Genital System	N/A	N/A	N/A	N/A	N/A	620	41.5	0.76	49.1	0.88
Cervix uteri	N/A	N/A	N/A	N/A	N/A	96	6.8	0.31	7.4	0.34
Uterus corpus	N/A	N/A	N/A	N/A	N/A	342	22.5	0.55	27.2	0.66
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	13	0.8	0.11	1.0	0.13
Ovary	N/A	N/A	N/A	N/A	N/A	131	8.8	0.35	10.4	0.41
Male Genital System	670	55.2	0.98	66.3	1.15	N/A	N/A	N/A	N/A	N/A
Prostate	631	51.9	0.95	62.9	1.13	N/A	N/A	N/A	N/A	N/A
Testis	29	2.4	0.20	2.4	0.20	N/A	N/A	N/A	N/A	N/A
Penis	5	0.5	0.10	0.5	0.11	N/A	N/A	N/A	N/A	N/A
Urinary System	312	27.3	0.71	32.0	0.82	142	9.5	0.36	11.2	0.42
Bladder (incl. <i>in situ</i>)	159	14.5	0.53	16.8	0.60	47	3.1	0.21	3.7	0.24
Kidney & renal pelvis	144	11.9	0.45	14.2	0.53	88	5.9	0.28	6.9	0.33
Ureter	7	0.6	0.11	0.7	0.12	5	0.3	0.07	0.4	0.08
Eye & Orbit	4	0.3	0.07	0.4	0.08	2	0.2	0.06	0.2	0.05
Brain & Other CNS	53	4.5	0.28	4.9	0.31	41	2.9	0.21	3.2	0.22
Brain	49	4.2	0.27	4.6	0.30	35	2.6	0.20	2.8	0.21
Endocrine System	94	7.9	0.37	8.9	0.41	309	21.9	0.56	24.0	0.61
Thyroid gland	79	6.7	0.34	7.5	0.38	299	21.1	0.55	23.2	0.60
Lymphomas	211	18.5	0.58	20.8	0.65	185	12.7	0.42	14.5	0.48
Hodgkin lymphoma	20	1.7	0.17	1.7	0.17	14	1.1	0.13	1.1	0.13
Non-Hodgkin lymphoma	191	16.8	0.56	19.1	0.63	171	11.6	0.40	13.4	0.46
Multiple Myeloma	53	4.7	0.29	5.5	0.34	43	2.9	0.20	3.4	0.23
Leukemias	109	9.5	0.41	10.3	0.45	92	6.7	0.32	7.2	0.34
Acute lymphocytic	20	1.7	0.18	1.6	0.16	18	1.5	0.16	1.4	0.15
Chronic lymphocytic	14	1.2	0.14	1.4	0.17	8	0.6	0.09	0.7	0.10
Acute myeloid	48	4.2	0.28	4.7	0.31	45	3.1	0.21	3.5	0.23
Chronic myeloid	16	1.4	0.16	1.5	0.17	12	0.8	0.11	1.0	0.12
Other leukemias	11	1.0	0.13	1.1	0.15	9	0.6	0.09	0.7	0.10
Mesothelioma	6	0.6	0.11	0.7	0.12	2	0.1	0.04	0.2	0.05
Kaposi Sarcoma	4	0.4	0.08	0.4	0.09	*	*	*	*	*
Ill-Defined & Unknown	135	12.4	0.49	14.3	0.56	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	93	8.1	0.38	9.1	0.43	217	14.8	0.46	17.1	0.52
Breast (<i>in situ</i>)	*	*	*	*	*	438	29.3	0.64	34.9	0.75

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Greater California, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	301	447.5	12.08	533.6	14.12	324	427.1	11.05	495.4	12.49
Oral Cavity & Pharynx	14	19.5	2.47	23.7	2.93	5	6.0	1.23	7.5	1.48
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	3.2	1.00	3.8	1.19	2	2.0	0.68	2.6	0.86
Major salivary gland	1	2.1	0.85	2.6	1.01	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	1.8	0.76	2.1	0.87	1	1.4	0.61	1.7	0.69
Nasopharynx	1	1.4	0.61	2.0	0.82	*	*	*	*	*
Oropharynx	1	1.8	0.70	2.3	0.86	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	87	129.3	6.47	155.5	7.63	57	72.8	4.48	87.3	5.26
Esophagus	8	11.5	1.88	13.4	2.14	2	2.0	0.70	2.6	0.87
Stomach	5	7.6	1.55	9.1	1.82	3	4.5	1.15	5.5	1.37
Small intestine	2	2.4	0.90	2.9	1.06	1	2.1	0.79	2.3	0.90
Colon (excl. rectum)	19	29.0	3.15	34.6	3.70	22	29.3	2.88	34.1	3.30
Rectum & rectosigmoid	11	17.0	2.37	20.5	2.80	7	8.4	1.50	10.3	1.79
Anus, anal canal, & anorectum	3	3.9	1.10	4.8	1.35	1	1.3	0.57	1.7	0.69
Liver	24	32.6	3.11	40.7	3.80	9	10.3	1.59	13.0	1.97
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	12	17.9	2.47	21.1	2.86	7	9.4	1.67	11.1	1.94
Respiratory System	39	58.6	4.39	70.3	5.17	41	51.4	3.72	61.3	4.34
Larynx	3	3.9	1.13	4.7	1.35	*	*	*	*	*
Lung & bronchus	36	54.4	4.23	65.3	4.98	40	49.3	3.64	59.0	4.25
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	2	3.7	1.22	3.9	1.28	1	2.0	0.80	2.1	0.81
Skin (excl. basal & sq.)	11	18.0	2.56	20.9	2.94	9	11.8	1.86	13.4	2.06
Melanoma of the skin	9	15.7	2.38	18.0	2.70	8	10.1	1.70	11.5	1.90
Breast (excl. <i>in situ</i>)	*	*	*	*	*	88	114.7	5.73	133.5	6.47
Female Genital System	N/A	N/A	N/A	N/A	N/A	46	63.3	4.35	71.3	4.75
Cervix uteri	N/A	N/A	N/A	N/A	N/A	8	12.4	2.07	12.4	2.01
Uterus corpus	N/A	N/A	N/A	N/A	N/A	26	33.7	3.11	39.2	3.51
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	1	1.6	0.69	2.0	0.83
Ovary	N/A	N/A	N/A	N/A	N/A	8	10.9	1.81	12.3	1.97
Male Genital System	57	78.8	4.85	96.5	5.81	N/A	N/A	N/A	N/A	N/A
Prostate	51	68.0	4.45	85.7	5.49	N/A	N/A	N/A	N/A	N/A
Testis	5	8.7	1.75	8.4	1.66	N/A	N/A	N/A	N/A	N/A
Penis	1	1.8	0.75	2.1	0.90	N/A	N/A	N/A	N/A	N/A
Urinary System	36	55.8	4.34	66.3	5.05	21	28.6	2.90	33.1	3.27
Bladder (incl. <i>in situ</i>)	17	29.1	3.26	33.1	3.65	6	8.1	1.53	9.6	1.80
Kidney & renal pelvis	18	25.7	2.81	32.1	3.42	15	19.6	2.40	22.3	2.66
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	4	6.5	1.46	7.1	1.60	4	5.9	1.35	6.4	1.42
Brain	4	6.5	1.46	7.1	1.60	4	5.9	1.35	6.4	1.42
Endocrine System	4	5.3	1.28	6.0	1.44	14	19.8	2.49	21.3	2.61
Thyroid gland	4	5.3	1.28	6.0	1.44	14	19.8	2.49	21.3	2.61
Lymphomas	13	19.6	2.59	23.1	3.00	11	15.0	2.07	17.1	2.31
Hodgkin lymphoma	*	*	*	*	*	2	2.6	0.89	2.7	0.91
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	9	12.4	1.87	14.4	2.13
Multiple Myeloma	6	8.4	1.64	10.0	1.91	4	5.2	1.15	6.1	1.35
Leukemias	13	19.0	2.48	21.0	2.71	7	10.7	1.82	11.7	1.97
Acute lymphocytic	3	4.2	1.17	3.7	1.04	1	1.8	0.75	1.7	0.69
Chronic lymphocytic	4	6.0	1.36	7.1	1.58	1	1.8	0.75	2.1	0.88
Acute myeloid	3	4.7	1.20	5.3	1.32	3	4.0	1.13	4.4	1.19
Chronic myeloid	1	2.4	0.96	2.7	1.05	*	*	*	*	*
Other leukemias	1	1.7	0.76	2.3	0.96	N/A	N/A	N/A	N/A	N/A
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	13	20.9	2.71	24.4	3.12	14	18.2	2.25	21.2	2.59
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	8	12.4	2.11	13.6	2.29	13	16.7	2.19	19.2	2.44
Breast (<i>in situ</i>)	*	*	*	*	*	16	20.5	2.41	24.5	2.78

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Greater California, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	9,311	360.0	1.82	424.9	2.11	10,825	343.9	1.53	401.3	1.78
Oral Cavity & Pharynx	248	9.3	0.29	11.1	0.34	122	4.0	0.17	4.7	0.20
Lip	13	0.5	0.06	0.6	0.08	5	0.2	0.04	0.2	0.04
Tongue	68	2.5	0.15	3.0	0.17	37	1.3	0.10	1.5	0.11
Major salivary gland	29	1.1	0.10	1.3	0.12	28	0.8	0.08	1.0	0.09
Floor of mouth	8	0.3	0.05	0.4	0.07	4	0.1	0.03	0.2	0.04
Gum & other mouth	25	1.1	0.10	1.3	0.12	21	0.7	0.07	0.8	0.08
Nasopharynx	12	0.4	0.06	0.5	0.07	5	0.1	0.03	0.2	0.04
Oropharynx	14	0.6	0.07	0.7	0.08	3	0.1	0.03	0.1	0.03
Hypopharynx	14	0.6	0.08	0.7	0.09	2	0.1	0.02	0.1	0.03
Digestive System	2,531	98.2	0.94	117.8	1.11	1,979	67.0	0.70	79.0	0.82
Esophagus	115	4.8	0.21	5.7	0.25	31	1.1	0.09	1.3	0.11
Stomach	287	11.7	0.33	13.7	0.39	237	7.9	0.24	9.2	0.27
Small intestine	49	1.8	0.13	2.1	0.15	43	1.4	0.10	1.7	0.12
Colon (excl. rectum)	638	24.8	0.48	29.4	0.56	614	20.4	0.38	24.0	0.45
Rectum & rectosigmoid	394	14.0	0.34	17.0	0.41	268	8.3	0.23	9.9	0.28
Anus, anal canal, & anorectum	20	0.7	0.08	0.8	0.09	46	1.5	0.10	1.9	0.12
Liver	549	20.0	0.41	25.0	0.50	211	7.4	0.24	8.9	0.28
Gallbladder	30	1.3	0.12	1.5	0.13	68	2.4	0.13	2.8	0.16
Pancreas	305	12.9	0.35	15.3	0.41	309	11.2	0.29	13.0	0.34
Respiratory System	719	33.6	0.60	39.1	0.68	626	23.2	0.43	27.2	0.49
Larynx	73	3.1	0.17	3.7	0.20	12	0.4	0.05	0.5	0.07
Lung & bronchus	611	29.4	0.56	34.2	0.64	597	22.2	0.42	26.1	0.49
Bones & Joints	45	1.1	0.08	1.2	0.09	31	0.8	0.06	0.8	0.07
Soft Tissue (incl. heart)	119	3.8	0.17	4.3	0.20	113	3.3	0.15	3.7	0.17
Skin (excl. basal & sq.)	160	6.3	0.24	7.4	0.28	224	6.9	0.21	8.0	0.25
Melanoma of the skin	127	5.0	0.22	5.9	0.25	192	5.9	0.20	6.8	0.23
Breast (excl. <i>in situ</i>)	16	0.7	0.08	0.8	0.09	3,200	99.2	0.81	117.1	0.95
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,623	49.2	0.56	57.8	0.66
Cervix uteri	N/A	N/A	N/A	N/A	N/A	325	9.3	0.24	10.2	0.26
Uterus corpus	N/A	N/A	N/A	N/A	N/A	801	24.2	0.39	29.3	0.47
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	42	1.3	0.09	1.6	0.11
Ovary	N/A	N/A	N/A	N/A	N/A	343	10.6	0.26	12.3	0.31
Male Genital System	2,410	92.4	0.91	110.8	1.07	N/A	N/A	N/A	N/A	N/A
Prostate	2,067	84.5	0.89	102.6	1.04	N/A	N/A	N/A	N/A	N/A
Testis	303	6.4	0.17	6.3	0.17	N/A	N/A	N/A	N/A	N/A
Penis	36	1.4	0.11	1.6	0.13	N/A	N/A	N/A	N/A	N/A
Urinary System	1,061	42.7	0.63	50.3	0.73	582	19.3	0.37	22.7	0.43
Bladder (incl. <i>in situ</i>)	349	16.6	0.42	19.3	0.49	119	4.4	0.19	5.2	0.22
Kidney & renal pelvis	698	25.4	0.46	30.1	0.54	450	14.4	0.31	16.9	0.37
Ureter	9	0.4	0.07	0.5	0.08	8	0.3	0.05	0.4	0.06
Eye & Orbit	20	0.7	0.08	0.8	0.09	14	0.4	0.05	0.4	0.06
Brain & Other CNS	192	5.7	0.20	6.4	0.23	165	4.8	0.18	5.3	0.20
Brain	178	5.3	0.20	5.9	0.22	151	4.4	0.17	4.9	0.19
Endocrine System	223	6.9	0.22	7.7	0.25	793	21.5	0.35	23.6	0.39
Thyroid gland	198	6.2	0.21	7.0	0.24	771	20.9	0.35	23.0	0.39
Lymphomas	613	22.6	0.45	26.1	0.52	531	17.1	0.35	19.8	0.40
Hodgkin lymphoma	85	2.3	0.12	2.5	0.13	68	1.7	0.10	1.8	0.11
Non-Hodgkin lymphoma	528	20.3	0.43	23.6	0.50	462	15.4	0.33	18.0	0.39
Multiple Myeloma	191	7.6	0.26	9.1	0.31	163	5.7	0.21	6.7	0.24
Leukemias	379	12.0	0.31	13.0	0.35	321	9.3	0.24	10.1	0.27
Acute lymphocytic	139	3.0	0.12	2.7	0.12	109	2.5	0.11	2.4	0.11
Chronic lymphocytic	51	2.2	0.15	2.6	0.17	41	1.5	0.11	1.7	0.12
Acute myeloid	100	3.7	0.18	4.1	0.21	102	3.1	0.14	3.5	0.16
Chronic myeloid	50	1.7	0.12	1.9	0.13	39	1.2	0.09	1.4	0.11
Other leukemias	39	1.4	0.11	1.6	0.13	30	1.0	0.08	1.1	0.09
Mesothelioma	25	1.0	0.10	1.2	0.12	13	0.4	0.06	0.5	0.07
Kaposi Sarcoma	32	1.0	0.09	1.1	0.10	3	0.1	0.03	0.1	0.04
Ill-Defined & Unknown	328	14.5	0.39	16.8	0.45	322	11.7	0.30	13.5	0.35
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	224	7.6	0.25	8.6	0.29	507	16.1	0.33	18.5	0.38
Breast (<i>in situ</i>)	1	0.0	0.02	0.1	0.02	675	20.7	0.36	24.8	0.43

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Greater California, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	8,790	365.8	1.89	431.7	2.20	10,326	355.2	1.62	414.3	1.88
Oral Cavity & Pharynx	239	9.6	0.30	11.6	0.35	116	4.2	0.18	4.9	0.21
Lip	13	0.5	0.07	0.6	0.08	5	0.2	0.04	0.2	0.04
Tongue	66	2.6	0.16	3.2	0.18	36	1.3	0.10	1.6	0.12
Major salivary gland	28	1.2	0.11	1.4	0.13	26	0.9	0.08	1.0	0.09
Floor of mouth	8	0.3	0.06	0.4	0.07	4	0.1	0.03	0.2	0.04
Gum & other mouth	25	1.1	0.11	1.3	0.13	20	0.7	0.08	0.9	0.09
Nasopharynx	11	0.4	0.06	0.5	0.07	4	0.1	0.03	0.1	0.03
Oropharynx	14	0.6	0.08	0.7	0.09	3	0.1	0.03	0.1	0.04
Hypopharynx	13	0.6	0.08	0.7	0.09	2	0.1	0.03	0.1	0.03
Digestive System	2,429	101.5	0.99	121.9	1.17	1,892	69.2	0.73	81.6	0.86
Esophagus	111	5.0	0.23	6.0	0.26	30	1.2	0.10	1.4	0.11
Stomach	277	12.2	0.35	14.2	0.41	227	8.2	0.25	9.5	0.29
Small intestine	46	1.9	0.13	2.2	0.15	41	1.5	0.11	1.7	0.12
Colon (excl. rectum)	606	25.5	0.50	30.1	0.58	583	21.0	0.40	24.6	0.47
Rectum & rectosigmoid	373	14.3	0.36	17.4	0.43	252	8.4	0.24	10.1	0.29
Anus, anal canal, & anorectum	19	0.7	0.08	0.9	0.10	44	1.6	0.11	1.9	0.13
Liver	531	20.8	0.43	26.0	0.53	204	7.7	0.25	9.3	0.30
Gallbladder	29	1.4	0.12	1.6	0.14	66	2.5	0.14	3.0	0.17
Pancreas	296	13.4	0.37	16.0	0.44	298	11.6	0.31	13.5	0.36
Respiratory System	693	34.7	0.63	40.4	0.72	602	23.9	0.45	28.1	0.52
Larynx	70	3.2	0.18	3.8	0.21	12	0.4	0.06	0.5	0.07
Lung & bronchus	590	30.4	0.59	35.3	0.68	574	23.0	0.44	27.0	0.51
Bones & Joints	44	1.2	0.09	1.2	0.10	31	0.8	0.07	0.8	0.07
Soft Tissue (incl. heart)	116	4.0	0.18	4.6	0.21	108	3.4	0.15	3.8	0.17
Skin (excl. basal & sq.)	150	6.4	0.25	7.6	0.30	202	6.8	0.22	7.9	0.26
Melanoma of the skin	119	5.0	0.22	6.0	0.26	173	5.8	0.20	6.7	0.24
Breast (excl. <i>in situ</i>)	15	0.7	0.09	0.8	0.10	3,042	102.1	0.85	120.6	1.00
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,559	51.3	0.60	60.2	0.70
Cervix uteri	N/A	N/A	N/A	N/A	N/A	312	9.8	0.25	10.6	0.28
Uterus corpus	N/A	N/A	N/A	N/A	N/A	767	25.1	0.42	30.5	0.50
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	41	1.4	0.10	1.6	0.12
Ovary	N/A	N/A	N/A	N/A	N/A	332	11.1	0.28	12.9	0.33
Male Genital System	2,179	89.5	0.92	107.3	1.08	N/A	N/A	N/A	N/A	N/A
Prostate	1,855	81.2	0.90	98.9	1.06	N/A	N/A	N/A	N/A	N/A
Testis	286	6.6	0.18	6.5	0.18	N/A	N/A	N/A	N/A	N/A
Penis	35	1.4	0.12	1.7	0.14	N/A	N/A	N/A	N/A	N/A
Urinary System	1,015	44.0	0.67	51.9	0.77	554	19.8	0.39	23.3	0.45
Bladder (incl. <i>in situ</i>)	332	16.9	0.44	19.8	0.51	115	4.6	0.20	5.4	0.23
Kidney & renal pelvis	668	26.3	0.49	31.2	0.57	427	14.7	0.33	17.3	0.39
Ureter	9	0.5	0.07	0.6	0.09	8	0.3	0.05	0.4	0.06
Eye & Orbit	19	0.7	0.08	0.8	0.09	14	0.4	0.05	0.5	0.06
Brain & Other CNS	185	6.0	0.22	6.7	0.25	159	5.0	0.19	5.6	0.21
Brain	172	5.6	0.21	6.2	0.24	146	4.6	0.18	5.2	0.20
Endocrine System	212	7.1	0.23	8.0	0.27	756	22.5	0.37	24.6	0.42
Thyroid gland	189	6.3	0.22	7.2	0.25	735	21.8	0.37	23.9	0.41
Lymphomas	583	23.3	0.47	26.9	0.54	507	17.7	0.37	20.5	0.42
Hodgkin lymphoma	80	2.3	0.13	2.6	0.14	66	1.8	0.11	1.9	0.11
Non-Hodgkin lymphoma	503	20.9	0.45	24.3	0.52	441	15.9	0.35	18.6	0.41
Multiple Myeloma	182	7.8	0.28	9.3	0.32	155	5.8	0.22	6.9	0.25
Leukemias	363	12.4	0.33	13.4	0.36	309	9.7	0.26	10.6	0.29
Acute lymphocytic	134	3.2	0.13	2.9	0.13	106	2.7	0.12	2.6	0.12
Chronic lymphocytic	47	2.2	0.15	2.6	0.18	37	1.4	0.11	1.7	0.13
Acute myeloid	97	3.9	0.19	4.3	0.22	99	3.3	0.15	3.7	0.17
Chronic myeloid	48	1.8	0.13	2.0	0.14	38	1.3	0.10	1.5	0.11
Other leukemias	37	1.4	0.11	1.6	0.13	29	1.0	0.09	1.1	0.10
Mesothelioma	24	1.1	0.11	1.3	0.12	12	0.5	0.06	0.5	0.07
Kaposi Sarcoma	28	0.9	0.08	1.0	0.10	2	0.1	0.03	0.1	0.03
Ill-Defined & Unknown	313	14.8	0.41	17.2	0.46	306	12.0	0.32	13.8	0.36
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	213	7.8	0.26	8.7	0.30	472	16.2	0.35	18.7	0.40
Breast (<i>in situ</i>)	1	0.0	0.02	0.1	0.02	635	21.1	0.38	25.3	0.46

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Greater California, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	37	82.6	7.17	98.1	8.31	57	96.7	6.44	114.2	7.50
Oral Cavity & Pharynx	1	3.9	1.79	4.6	2.08	1	1.2	0.50	1.3	0.59
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	8	18.4	3.41	21.7	3.91	9	13.8	2.27	17.3	2.78
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	1	1.5	0.62	1.8	0.79
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	3	6.2	1.99	7.1	2.23	3	5.5	1.55	6.8	1.83
Rectum & rectosigmoid	*	*	*	*	*	1	1.5	0.61	1.8	0.74
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	2	3.3	1.20	4.2	1.53	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	1	2.4	1.04	3.2	1.33
Respiratory System	5	13.0	3.02	15.6	3.47	5	11.9	2.57	14.1	2.92
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	4	11.2	2.81	13.5	3.26	5	11.9	2.57	14.1	2.92
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	2	3.4	1.34	3.7	1.47
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	19	34.0	3.87	39.8	4.50
Female Genital System	N/A	N/A	N/A	N/A	N/A	8	13.0	2.25	15.2	2.60
Cervix uteri	N/A	N/A	N/A	N/A	N/A	1	1.9	0.73	2.1	0.83
Uterus corpus	N/A	N/A	N/A	N/A	N/A	5	8.2	1.85	9.7	2.14
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	11	25.9	3.97	31.6	4.62	N/A	N/A	N/A	N/A	N/A
Prostate	10	24.0	3.81	29.6	4.48	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	3	5.6	1.67	7.3	2.14	2	3.1	1.11	3.8	1.38
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	2	3.6	1.23	4.7	1.60	1	2.2	0.91	2.8	1.18
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	2.8	1.29	2.8	1.31	*	*	*	*	*
Brain	2	2.8	1.29	2.8	1.31	*	*	*	*	*
Endocrine System	*	*	*	*	*	3	3.7	1.01	4.0	1.14
Thyroid gland	*	*	*	*	*	3	3.6	1.00	3.9	1.13
Lymphomas	3	4.3	1.48	4.7	1.61	2	3.6	1.16	4.5	1.42
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	1	2.5	1.11	2.8	1.21
Leukemias	2	2.7	1.25	3.1	1.57	1	1.9	0.93	2.0	0.99
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	2	3.8	1.28	4.5	1.54
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	3	4.8	1.48	5.3	1.65
Breast (<i>in situ</i>)	*	*	*	*	*	3	5.6	1.50	6.5	1.73

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

GREATER CALIFORNIA


II-60 Incidence – Hispanic Black

GREATER BAY AREA CANCER REGISTRY

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	7,325,849	7,383,343	7,412,660	7,426,085	7,415,480
Non-Hispanic White	2,951,942	2,939,934	2,914,509	2,884,890	2,845,205
Non-Hispanic Black	448,361	446,946	445,624	444,689	443,227
Non-Hispanic Asian/Pacific Islander (NH API)	2,023,569	2,083,125	2,135,481	2,178,122	2,211,241
Non-Hispanic American Indian/Alaskan Native PRCA (NH AI/AN)	0	0	0	0	0


All Races Population 2015–2019: 36,963,417
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	1,877,619	1,889,068	1,892,869	1,894,467	1,892,186
Hispanic White	1,658,979	1,668,559	1,671,144	1,671,932	1,668,360
Hispanic Black	58,585	59,147	59,647	60,157	60,759

Hispanic/Latino Population, Census 2010: 1,763,285
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

GREATER BAY AREA CANCER REGISTRY

Initial Operation: 1973
 Population-based Data Available: 1988
 Coverage Area: County

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	111.2	110.6	111.8	110.7	109.0	110.6
Missing Race	1.2	1.8	2.2	2.4	1.9	1.9
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.0	1.0	0.7	1.3	1.5	1.1
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.9	Ovary	95.2
Oral Cavity & Pharynx	98.5	Prostate	96.1
Esophagus	96.4	Testis	99.4
Stomach	97.4	Bladder (incl. <i>in situ</i>)	98.0
Colon & Rectum	96.6	Kidney & Renal Pelvis	88.9
Liver	41.4	Brain & Other CNS	86.7
Pancreas	87.3	Brain & Other CNS (non-malig)	42.2
Lung & Bronchus	89.4	Thyroid	99.5
Melanomas of the Skin	99.0	Hodgkin Lymphoma	99.7
Female Breast (excl. <i>in situ</i>)	99.2	Non-Hodgkin Lymphoma	97.8
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	93.0
Cervix Uteri	97.7	Leukemias	92.4
Uterus Corpus & Uterus NOS	98.6		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Greater Bay Area, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	16,548	420.7	1.49	497.0	1.74	17,158	387.3	1.35	451.3	1.55
Oral Cavity & Pharynx	601	14.8	0.28	17.8	0.33	267	6.0	0.17	7.0	0.19
Lip	26	0.7	0.06	0.8	0.07	14	0.3	0.04	0.4	0.04
Tongue	195	4.7	0.15	5.8	0.19	82	1.8	0.09	2.1	0.11
Major salivary gland	57	1.5	0.09	1.7	0.10	42	1.0	0.07	1.1	0.08
Floor of mouth	15	0.4	0.04	0.5	0.05	9	0.2	0.03	0.2	0.04
Gum & other mouth	63	1.6	0.09	1.9	0.11	53	1.1	0.07	1.3	0.08
Nasopharynx	62	1.6	0.09	1.8	0.10	25	0.6	0.06	0.7	0.06
Oropharynx	27	0.6	0.06	0.8	0.07	9	0.2	0.03	0.2	0.03
Hypopharynx	24	0.6	0.05	0.7	0.06	8	0.2	0.03	0.2	0.03
Digestive System	3,479	87.8	0.68	104.9	0.80	2,796	61.4	0.53	72.3	0.62
Esophagus	222	5.6	0.17	6.7	0.20	75	1.6	0.08	1.9	0.10
Stomach	368	9.6	0.23	11.2	0.26	252	5.6	0.16	6.5	0.19
Small intestine	87	2.2	0.11	2.6	0.13	74	1.7	0.09	2.0	0.10
Colon (excl. rectum)	947	24.2	0.36	28.7	0.42	962	21.3	0.31	24.9	0.36
Rectum & rectosigmoid	498	12.3	0.25	14.8	0.30	353	7.9	0.19	9.4	0.23
Anus, anal canal, & anorectum	59	1.4	0.09	1.8	0.10	85	1.8	0.09	2.2	0.11
Liver	552	13.1	0.26	16.3	0.31	190	4.0	0.13	4.9	0.16
Gallbladder	32	0.8	0.07	1.0	0.08	71	1.5	0.08	1.8	0.10
Pancreas	517	13.4	0.27	15.8	0.31	510	11.0	0.22	13.0	0.26
Respiratory System	1,713	45.0	0.50	52.8	0.58	1,655	35.9	0.40	42.1	0.47
Larynx	110	2.8	0.12	3.3	0.14	23	0.5	0.05	0.6	0.06
Lung & bronchus	1,562	41.1	0.48	48.3	0.55	1,610	34.9	0.40	41.0	0.46
Bones & Joints	38	1.1	0.08	1.1	0.08	30	0.8	0.06	0.8	0.07
Soft Tissue (incl. heart)	161	4.3	0.15	4.8	0.17	124	2.9	0.12	3.3	0.13
Skin (excl. basal & sq.)	1,478	38.4	0.46	44.8	0.53	972	22.1	0.32	25.5	0.37
Melanoma of the skin	1,356	35.0	0.43	41.0	0.50	903	20.6	0.31	23.8	0.36
Breast (excl. <i>in situ</i>)	40	1.0	0.07	1.2	0.09	5,590	128.2	0.78	150.2	0.91
Female Genital System	N/A	N/A	N/A	N/A	N/A	2,115	47.5	0.47	56.3	0.55
Cervix uteri	N/A	N/A	N/A	N/A	N/A	231	5.8	0.17	6.2	0.18
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,201	26.2	0.34	32.0	0.42
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	29	0.6	0.05	0.7	0.06
Ovary	N/A	N/A	N/A	N/A	N/A	456	10.5	0.22	12.2	0.26
Male Genital System	4,139	100.1	0.71	121.7	0.85	N/A	N/A	N/A	N/A	N/A
Prostate	3,867	93.0	0.68	114.5	0.83	N/A	N/A	N/A	N/A	N/A
Testis	238	6.2	0.18	6.1	0.18	N/A	N/A	N/A	N/A	N/A
Penis	27	0.7	0.06	0.8	0.07	N/A	N/A	N/A	N/A	N/A
Urinary System	1,796	47.1	0.51	55.1	0.59	721	15.8	0.27	18.5	0.31
Bladder (incl. <i>in situ</i>)	1,021	27.4	0.39	32.0	0.45	308	6.6	0.17	7.7	0.20
Kidney & renal pelvis	735	18.6	0.31	21.9	0.36	390	8.7	0.20	10.3	0.23
Ureter	25	0.7	0.06	0.8	0.07	13	0.3	0.04	0.3	0.04
Eye & Orbit	40	1.0	0.07	1.2	0.08	33	0.8	0.06	0.9	0.07
Brain & Other CNS	266	6.9	0.19	7.7	0.21	189	4.5	0.15	5.0	0.16
Brain	252	6.6	0.19	7.3	0.21	178	4.2	0.15	4.7	0.16
Endocrine System	303	7.7	0.20	8.6	0.22	756	18.9	0.31	20.6	0.34
Thyroid gland	270	6.8	0.19	7.6	0.21	724	18.2	0.31	19.7	0.33
Lymphomas	1,015	26.2	0.38	30.3	0.43	790	17.9	0.29	20.6	0.33
Hodgkin lymphoma	96	2.5	0.12	2.6	0.12	77	2.0	0.11	2.1	0.11
Non-Hodgkin lymphoma	919	23.7	0.36	27.6	0.41	713	15.9	0.27	18.5	0.31
Multiple Myeloma	303	7.8	0.21	9.3	0.24	226	4.9	0.15	5.9	0.18
Leukemias	557	14.8	0.29	16.6	0.32	366	8.6	0.21	9.4	0.22
Acute lymphocytic	70	2.0	0.11	1.9	0.10	53	1.6	0.10	1.4	0.09
Chronic lymphocytic	175	4.5	0.15	5.3	0.18	107	2.3	0.10	2.7	0.12
Acute myeloid	182	4.9	0.17	5.5	0.18	130	3.0	0.12	3.4	0.13
Chronic myeloid	75	2.0	0.10	2.2	0.12	46	1.1	0.07	1.2	0.08
Other leukemias	55	1.4	0.09	1.7	0.10	30	0.7	0.06	0.7	0.06
Mesothelioma	43	1.2	0.08	1.3	0.09	20	0.4	0.05	0.5	0.05
Kaposi Sarcoma	42	1.1	0.07	1.2	0.08	3	0.1	0.02	0.1	0.02
Ill-Defined & Unknown	533	14.4	0.28	16.6	0.32	505	10.8	0.22	12.4	0.25
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	340	8.8	0.22	10.1	0.25	687	15.7	0.27	18.0	0.31
Breast (<i>in situ</i>)	5	0.1	0.02	0.1	0.03	1,328	30.8	0.39	36.5	0.45

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Greater Bay Area, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	9,729	476.0	2.23	560.8	2.57	9,284	434.1	2.14	504.7	2.42
Oral Cavity & Pharynx	380	18.0	0.42	21.9	0.51	144	6.5	0.25	7.6	0.29
Lip	21	1.0	0.10	1.2	0.12	11	0.5	0.07	0.5	0.08
Tongue	146	6.7	0.26	8.3	0.31	47	2.1	0.14	2.5	0.17
Major salivary gland	33	1.7	0.14	1.9	0.15	19	0.9	0.10	1.1	0.11
Floor of mouth	10	0.5	0.07	0.6	0.08	7	0.3	0.05	0.3	0.06
Gum & other mouth	37	1.8	0.14	2.1	0.16	30	1.3	0.11	1.5	0.13
Nasopharynx	7	0.4	0.06	0.4	0.07	2	0.2	0.05	0.2	0.05
Oropharynx	18	0.8	0.09	1.0	0.11	5	0.2	0.05	0.3	0.06
Hypopharynx	14	0.6	0.08	0.7	0.09	4	0.2	0.04	0.2	0.05
Digestive System	1,725	84.1	0.93	100.0	1.09	1,357	59.5	0.76	69.8	0.88
Esophagus	145	6.8	0.26	8.2	0.31	48	2.0	0.13	2.3	0.15
Stomach	154	7.5	0.28	8.8	0.32	81	3.4	0.18	4.0	0.21
Small intestine	50	2.4	0.16	2.9	0.19	41	1.9	0.14	2.2	0.16
Colon (excl. rectum)	499	25.0	0.52	29.5	0.60	498	22.3	0.47	25.9	0.54
Rectum & rectosigmoid	245	12.4	0.37	14.7	0.42	166	7.9	0.29	9.3	0.33
Anus, anal canal, & anorectum	44	2.1	0.15	2.6	0.18	62	2.7	0.16	3.3	0.19
Liver	188	8.4	0.28	10.5	0.34	58	2.4	0.15	3.0	0.18
Gallbladder	13	0.6	0.08	0.7	0.09	30	1.2	0.10	1.4	0.12
Pancreas	297	14.4	0.38	17.0	0.45	265	11.2	0.32	13.0	0.37
Respiratory System	915	44.3	0.67	51.9	0.77	954	40.0	0.59	46.7	0.69
Larynx	64	3.0	0.17	3.6	0.20	14	0.6	0.08	0.7	0.09
Lung & bronchus	831	40.2	0.64	47.2	0.74	930	38.9	0.58	45.4	0.68
Bones & Joints	16	1.1	0.13	1.1	0.12	15	1.0	0.12	1.0	0.12
Soft Tissue (incl. heart)	89	4.8	0.24	5.4	0.26	55	2.7	0.18	3.1	0.19
Skin (excl. basal & sq.)	1,284	64.4	0.83	75.0	0.95	791	39.6	0.67	45.3	0.74
Melanoma of the skin	1,191	59.6	0.80	69.5	0.91	747	37.7	0.66	43.1	0.73
Breast (excl. <i>in situ</i>)	26	1.2	0.11	1.5	0.13	3,018	145.9	1.26	170.9	1.43
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,073	49.4	0.71	58.8	0.82
Cervix uteri	N/A	N/A	N/A	N/A	N/A	83	5.1	0.27	5.3	0.27
Uterus corpus	N/A	N/A	N/A	N/A	N/A	618	27.1	0.51	33.3	0.61
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	12	0.5	0.07	0.6	0.08
Ovary	N/A	N/A	N/A	N/A	N/A	239	11.4	0.35	13.4	0.40
Male Genital System	2,354	108.6	1.03	131.6	1.23	N/A	N/A	N/A	N/A	N/A
Prostate	2,208	98.9	0.96	121.9	1.17	N/A	N/A	N/A	N/A	N/A
Testis	130	8.9	0.36	8.8	0.35	N/A	N/A	N/A	N/A	N/A
Penis	12	0.6	0.08	0.7	0.09	N/A	N/A	N/A	N/A	N/A
Urinary System	1,134	55.9	0.76	65.4	0.88	404	17.5	0.41	20.5	0.47
Bladder (incl. <i>in situ</i>)	714	35.2	0.60	41.1	0.69	207	8.5	0.27	10.0	0.32
Kidney & renal pelvis	396	19.5	0.45	22.9	0.52	185	8.4	0.29	9.9	0.34
Ureter	15	0.7	0.09	0.9	0.10	7	0.3	0.05	0.4	0.06
Eye & Orbit	31	1.6	0.13	1.8	0.15	23	1.1	0.12	1.3	0.13
Brain & Other CNS	163	9.0	0.34	9.9	0.35	109	5.8	0.27	6.4	0.28
Brain	158	8.7	0.33	9.6	0.35	105	5.5	0.26	6.1	0.28
Endocrine System	157	8.6	0.32	9.6	0.35	299	18.4	0.51	19.9	0.53
Thyroid gland	144	7.8	0.31	8.8	0.33	287	17.7	0.50	19.2	0.52
Lymphomas	582	30.0	0.58	34.5	0.65	421	19.7	0.46	22.5	0.51
Hodgkin lymphoma	50	3.1	0.21	3.3	0.21	40	2.7	0.21	2.8	0.20
Non-Hodgkin lymphoma	532	26.9	0.54	31.2	0.61	381	17.0	0.41	19.8	0.47
Multiple Myeloma	169	8.3	0.29	9.7	0.34	112	4.7	0.21	5.6	0.24
Leukemias	334	17.5	0.45	19.8	0.49	208	9.9	0.34	11.0	0.36
Acute lymphocytic	23	1.8	0.18	1.7	0.16	18	1.5	0.17	1.3	0.14
Chronic lymphocytic	137	6.5	0.26	7.8	0.30	83	3.4	0.17	4.1	0.20
Acute myeloid	98	5.1	0.24	5.8	0.26	66	3.0	0.18	3.4	0.19
Chronic myeloid	40	2.1	0.15	2.4	0.17	25	1.2	0.12	1.4	0.13
Other leukemias	36	1.9	0.15	2.2	0.16	17	0.8	0.09	0.9	0.10
Mesothelioma	26	1.3	0.12	1.5	0.13	13	0.6	0.07	0.6	0.08
Kaposi Sarcoma	19	1.0	0.11	1.2	0.12	2	0.1	0.03	0.1	0.03
Ill-Defined & Unknown	325	16.3	0.41	18.8	0.47	286	11.8	0.33	13.6	0.37
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	187	9.8	0.33	11.2	0.37	337	16.3	0.43	18.7	0.47
Breast (<i>in situ</i>)	3	0.1	0.04	0.2	0.05	619	31.2	0.60	36.8	0.68

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Greater Bay Area, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,129	485.1	6.75	586.6	7.97	1,079	404.8	5.66	478.0	6.56
Oral Cavity & Pharynx	31	13.4	1.12	15.9	1.29	12	4.5	0.60	5.4	0.70
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	5	2.3	0.46	2.7	0.53	2	1.0	0.29	1.1	0.33
Major salivary gland	3	1.3	0.38	1.5	0.43	2	0.9	0.28	1.1	0.30
Floor of mouth	2	0.8	0.28	1.0	0.32	*	*	*	*	*
Gum & other mouth	3	1.1	0.31	1.3	0.35	2	0.8	0.24	1.0	0.29
Nasopharynx	3	1.3	0.35	1.5	0.40	*	*	*	*	*
Oropharynx	3	1.2	0.32	1.6	0.39	1	0.4	0.17	0.6	0.22
Hypopharynx	2	1.0	0.30	1.2	0.36	*	*	*	*	*
Digestive System	256	110.6	3.23	134.2	3.84	219	81.2	2.52	96.5	2.94
Esophagus	11	4.8	0.68	5.8	0.81	4	1.6	0.37	1.8	0.40
Stomach	27	12.7	1.15	15.2	1.35	19	7.2	0.76	8.5	0.88
Small intestine	10	4.2	0.64	5.2	0.77	9	3.4	0.52	4.1	0.61
Colon (excl. rectum)	71	31.3	1.73	37.2	2.01	76	28.3	1.49	33.5	1.74
Rectum & rectosigmoid	27	11.6	1.04	14.4	1.26	24	9.1	0.86	10.7	0.99
Anus, anal canal, & anorectum	5	1.9	0.39	2.4	0.50	7	2.7	0.47	3.1	0.54
Liver	54	21.4	1.36	26.8	1.66	16	5.5	0.62	6.9	0.77
Gallbladder	3	1.3	0.36	1.6	0.41	6	2.1	0.41	2.5	0.47
Pancreas	38	16.6	1.26	20.2	1.50	45	16.5	1.12	19.8	1.33
Respiratory System	151	69.4	2.65	82.4	3.07	139	50.0	1.94	60.4	2.31
Larynx	13	6.0	0.79	7.1	0.91	4	1.5	0.34	1.7	0.39
Lung & bronchus	136	62.8	2.51	74.5	2.92	133	47.9	1.90	58.0	2.26
Bones & Joints	2	0.8	0.28	0.7	0.26	2	0.6	0.22	0.7	0.26
Soft Tissue (incl. heart)	10	4.5	0.66	5.1	0.74	10	4.2	0.60	4.4	0.63
Skin (excl. basal & sq.)	8	4.1	0.67	4.6	0.75	6	2.3	0.44	2.5	0.48
Melanoma of the skin	5	2.6	0.54	2.9	0.61	2	0.9	0.28	1.0	0.31
Breast (excl. <i>in situ</i>)	4	1.6	0.40	2.0	0.47	326	125.4	3.19	146.9	3.66
Female Genital System	N/A	N/A	N/A	N/A	N/A	142	52.1	2.01	62.4	2.35
Cervix uteri	N/A	N/A	N/A	N/A	N/A	15	6.7	0.80	6.8	0.80
Uterus corpus	N/A	N/A	N/A	N/A	N/A	86	29.9	1.48	37.2	1.80
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	5	1.6	0.33	2.0	0.41
Ovary	N/A	N/A	N/A	N/A	N/A	27	10.3	0.91	12.2	1.05
Male Genital System	383	151.4	3.60	191.2	4.43	N/A	N/A	N/A	N/A	N/A
Prostate	377	148.4	3.56	188.0	4.39	N/A	N/A	N/A	N/A	N/A
Testis	5	2.2	0.46	2.1	0.44	N/A	N/A	N/A	N/A	N/A
Penis	2	0.7	0.28	0.9	0.34	N/A	N/A	N/A	N/A	N/A
Urinary System	109	48.9	2.18	58.3	2.55	56	20.7	1.27	24.7	1.48
Bladder (incl. <i>in situ</i>)	45	20.9	1.46	24.9	1.71	16	6.0	0.68	7.1	0.79
Kidney & renal pelvis	63	27.2	1.60	32.5	1.86	38	14.2	1.06	17.0	1.23
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	1	0.5	0.22	0.6	0.23
Brain & Other CNS	10	4.4	0.65	5.0	0.72	8	3.1	0.50	3.6	0.57
Brain	9	4.1	0.63	4.6	0.69	8	2.9	0.49	3.4	0.55
Endocrine System	10	4.2	0.63	4.9	0.72	24	9.5	0.90	10.6	0.98
Thyroid gland	7	3.1	0.53	3.7	0.61	21	8.6	0.86	9.6	0.93
Lymphomas	49	21.8	1.44	24.6	1.60	40	15.8	1.14	18.2	1.29
Hodgkin lymphoma	6	2.7	0.50	2.9	0.51	5	2.1	0.44	2.1	0.44
Non-Hodgkin lymphoma	43	19.1	1.35	21.8	1.52	36	13.7	1.05	16.1	1.21
Multiple Myeloma	36	16.4	1.27	19.6	1.49	31	11.3	0.94	13.5	1.10
Leukemias	28	13.0	1.14	14.7	1.27	22	8.3	0.82	9.5	0.92
Acute lymphocytic	3	1.4	0.37	1.2	0.32	2	1.1	0.33	1.1	0.32
Chronic lymphocytic	9	3.6	0.58	4.4	0.69	7	2.6	0.45	3.1	0.54
Acute myeloid	10	4.7	0.71	5.4	0.80	8	2.7	0.45	3.2	0.52
Chronic myeloid	4	1.9	0.43	2.2	0.48	2	1.0	0.30	1.1	0.32
Other leukemias	3	1.4	0.38	1.5	0.41	2	0.8	0.26	0.9	0.28
Mesothelioma	3	1.6	0.42	1.8	0.48	*	*	*	*	*
Kaposi Sarcoma	5	2.6	0.51	2.6	0.51	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	41	14.9	1.07	17.6	1.25
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	19	8.5	0.92	9.8	1.04	45	16.7	1.15	19.6	1.32
Breast (<i>in situ</i>)	*	*	*	*	*	87	33.1	1.63	39.3	1.89

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Greater Bay Area, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3,069	296.6	2.44	349.1	2.84	4,018	313.1	2.24	365.0	2.59
Oral Cavity & Pharynx	124	11.6	0.47	13.7	0.55	83	6.5	0.33	7.6	0.38
Lip	1	0.1	0.04	0.1	0.05	*	*	*	*	*
Tongue	27	2.5	0.22	3.0	0.26	25	2.0	0.18	2.3	0.20
Major salivary gland	12	1.2	0.15	1.4	0.17	14	1.1	0.13	1.3	0.15
Floor of mouth	1	0.1	0.05	0.1	0.05	*	*	*	*	*
Gum & other mouth	17	1.6	0.18	1.9	0.21	14	1.1	0.13	1.3	0.15
Nasopharynx	48	4.5	0.30	5.2	0.34	21	1.7	0.17	1.9	0.19
Oropharynx	2	0.2	0.07	0.3	0.08	*	*	*	*	*
Hypopharynx	4	0.4	0.09	0.5	0.11	2	0.2	0.05	0.2	0.06
Digestive System	876	83.9	1.29	100.3	1.52	714	54.9	0.93	64.7	1.09
Esophagus	37	3.6	0.27	4.3	0.32	13	1.0	0.12	1.1	0.14
Stomach	113	11.1	0.48	13.1	0.55	90	7.0	0.34	8.1	0.39
Small intestine	15	1.5	0.18	1.7	0.20	12	0.9	0.12	1.1	0.14
Colon (excl. rectum)	220	21.1	0.65	25.1	0.76	230	17.6	0.53	20.9	0.62
Rectum & rectosigmoid	128	11.8	0.47	14.4	0.57	98	7.6	0.35	9.0	0.41
Anus, anal canal, & anorectum	3	0.3	0.08	0.3	0.08	4	0.3	0.07	0.4	0.08
Liver	183	17.0	0.57	20.9	0.69	66	5.1	0.29	5.9	0.33
Gallbladder	10	1.0	0.14	1.1	0.16	16	1.3	0.14	1.5	0.17
Pancreas	110	10.8	0.47	12.7	0.55	122	9.4	0.39	11.0	0.45
Respiratory System	464	46.2	0.98	54.3	1.13	399	30.4	0.69	36.0	0.81
Larynx	14	1.4	0.17	1.6	0.19	1	0.1	0.04	0.1	0.05
Lung & bronchus	438	43.7	0.95	51.4	1.10	392	29.8	0.68	35.4	0.80
Bones & Joints	9	0.9	0.14	1.0	0.14	6	0.5	0.10	0.6	0.10
Soft Tissue (incl. heart)	30	2.9	0.24	3.3	0.27	29	2.3	0.20	2.7	0.22
Skin (excl. basal & sq.)	25	2.5	0.23	2.8	0.25	26	2.1	0.19	2.3	0.21
Melanoma of the skin	13	1.2	0.16	1.4	0.18	16	1.3	0.15	1.4	0.16
Breast (excl. <i>in situ</i>)	7	0.7	0.11	0.8	0.13	1,418	110.8	1.33	129.8	1.55
Female Genital System	N/A	N/A	N/A	N/A	N/A	519	40.1	0.80	47.6	0.94
Cervix uteri	N/A	N/A	N/A	N/A	N/A	68	5.4	0.29	5.9	0.32
Uterus corpus	N/A	N/A	N/A	N/A	N/A	293	22.3	0.59	27.2	0.71
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	7	0.5	0.09	0.6	0.10
Ovary	N/A	N/A	N/A	N/A	N/A	114	9.0	0.38	10.4	0.44
Male Genital System	640	60.1	1.09	72.5	1.29	N/A	N/A	N/A	N/A	N/A
Prostate	606	57.0	1.06	69.3	1.26	N/A	N/A	N/A	N/A	N/A
Testis	27	2.5	0.22	2.4	0.21	N/A	N/A	N/A	N/A	N/A
Penis	4	0.4	0.09	0.5	0.11	N/A	N/A	N/A	N/A	N/A
Urinary System	289	28.5	0.76	33.3	0.88	124	9.4	0.38	11.2	0.45
Bladder (incl. <i>in situ</i>)	150	15.4	0.57	17.8	0.65	46	3.4	0.23	4.1	0.27
Kidney & renal pelvis	129	12.2	0.49	14.4	0.57	72	5.5	0.30	6.5	0.35
Ureter	6	0.6	0.11	0.7	0.13	5	0.4	0.08	0.5	0.09
Eye & Orbit	4	0.4	0.08	0.4	0.09	3	0.3	0.08	0.3	0.08
Brain & Other CNS	47	4.6	0.31	5.0	0.33	36	3.0	0.23	3.3	0.25
Brain	44	4.2	0.29	4.6	0.32	33	2.7	0.22	3.0	0.24
Endocrine System	85	8.1	0.40	8.9	0.44	261	21.2	0.60	23.0	0.64
Thyroid gland	72	6.8	0.36	7.5	0.40	248	20.0	0.58	21.8	0.63
Lymphomas	205	19.7	0.63	22.7	0.72	175	13.8	0.48	15.8	0.54
Hodgkin lymphoma	16	1.5	0.17	1.6	0.18	14	1.2	0.16	1.2	0.15
Non-Hodgkin lymphoma	188	18.1	0.60	21.1	0.69	162	12.5	0.45	14.6	0.52
Multiple Myeloma	51	4.9	0.31	5.9	0.37	45	3.5	0.23	4.1	0.28
Leukemias	100	10.0	0.46	11.0	0.50	66	5.6	0.32	6.0	0.33
Acute lymphocytic	12	1.2	0.16	1.1	0.15	11	1.2	0.16	1.1	0.14
Chronic lymphocytic	16	1.5	0.17	1.8	0.20	8	0.6	0.10	0.7	0.12
Acute myeloid	47	4.8	0.32	5.3	0.35	32	2.6	0.21	2.9	0.23
Chronic myeloid	17	1.7	0.18	1.8	0.20	8	0.6	0.10	0.7	0.11
Other leukemias	8	0.8	0.13	0.9	0.14	7	0.6	0.10	0.6	0.11
Mesothelioma	7	0.6	0.11	0.7	0.13	3	0.2	0.06	0.3	0.07
Kaposi Sarcoma	5	0.5	0.10	0.5	0.10	*	*	*	*	*
Ill-Defined & Unknown	103	10.6	0.47	12.2	0.54	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	82	7.9	0.40	9.1	0.45	193	15.1	0.49	17.4	0.56
Breast (<i>in situ</i>)	*	*	*	*	*	438	34.1	0.74	40.5	0.87

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Greater Bay Area, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,149	356.4	3.75	420.2	4.34	2,499	339.2	3.13	395.3	3.64
Oral Cavity & Pharynx	58	8.9	0.56	10.7	0.67	26	3.8	0.34	4.4	0.40
Lip	2	0.3	0.09	0.4	0.12	1	0.2	0.09	0.3	0.10
Tongue	15	2.3	0.29	2.9	0.35	6	0.8	0.15	1.0	0.19
Major salivary gland	8	1.4	0.24	1.6	0.27	6	0.8	0.16	0.9	0.18
Floor of mouth	2	0.4	0.14	0.5	0.16	*	*	*	*	*
Gum & other mouth	6	0.8	0.17	1.0	0.19	6	0.9	0.17	1.1	0.20
Nasopharynx	2	0.3	0.10	0.3	0.11	1	0.2	0.08	0.2	0.08
Oropharynx	3	0.5	0.13	0.6	0.16	1	0.2	0.07	0.2	0.09
Hypopharynx	3	0.5	0.14	0.6	0.16	*	*	*	*	*
Digestive System	583	96.3	1.94	115.2	2.26	478	68.9	1.45	81.3	1.70
Esophagus	27	4.7	0.44	5.6	0.51	10	1.5	0.22	1.8	0.26
Stomach	72	12.3	0.71	14.4	0.81	59	8.2	0.49	9.6	0.57
Small intestine	11	1.9	0.27	2.1	0.31	11	1.6	0.23	1.8	0.25
Colon (excl. rectum)	144	23.3	0.95	27.5	1.10	146	21.1	0.80	24.5	0.93
Rectum & rectosigmoid	88	12.9	0.66	15.6	0.79	59	7.8	0.47	9.3	0.56
Anus, anal canal, & anorectum	6	0.9	0.17	1.1	0.20	11	1.5	0.21	1.9	0.26
Liver	120	19.2	0.84	23.9	1.02	49	7.3	0.48	8.9	0.57
Gallbladder	7	1.3	0.25	1.5	0.28	19	2.7	0.29	3.3	0.34
Pancreas	70	13.1	0.75	15.5	0.87	74	11.1	0.59	13.1	0.69
Respiratory System	169	34.2	1.25	40.0	1.44	154	23.7	0.88	27.8	1.01
Larynx	16	2.9	0.35	3.5	0.41	3	0.5	0.12	0.5	0.14
Lung & bronchus	146	30.3	1.19	35.4	1.36	148	22.8	0.86	26.7	0.99
Bones & Joints	11	1.1	0.15	1.1	0.17	7	0.8	0.14	0.9	0.16
Soft Tissue (incl. heart)	28	3.7	0.35	4.1	0.39	26	3.3	0.30	3.7	0.34
Skin (excl. basal & sq.)	52	8.3	0.57	9.8	0.66	60	8.1	0.48	9.2	0.55
Melanoma of the skin	43	6.9	0.51	8.0	0.59	52	6.9	0.44	8.0	0.51
Breast (excl. <i>in situ</i>)	3	0.6	0.14	0.7	0.17	762	100.9	1.67	118.2	1.96
Female Genital System	N/A	N/A	N/A	N/A	N/A	356	46.2	1.12	54.8	1.33
Cervix uteri	N/A	N/A	N/A	N/A	N/A	62	7.5	0.44	8.2	0.48
Uterus corpus	N/A	N/A	N/A	N/A	N/A	190	24.7	0.82	30.3	1.00
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	4	0.5	0.12	0.6	0.15
Ovary	N/A	N/A	N/A	N/A	N/A	72	9.7	0.53	11.1	0.60
Male Genital System	544	89.1	1.85	107.2	2.17	N/A	N/A	N/A	N/A	N/A
Prostate	468	81.3	1.80	99.3	2.13	N/A	N/A	N/A	N/A	N/A
Testis	67	6.2	0.34	6.1	0.34	N/A	N/A	N/A	N/A	N/A
Penis	9	1.4	0.24	1.6	0.27	N/A	N/A	N/A	N/A	N/A
Urinary System	235	41.8	1.32	48.9	1.52	127	17.8	0.73	20.9	0.85
Bladder (incl. <i>in situ</i>)	90	18.3	0.92	21.5	1.05	34	5.2	0.41	6.0	0.47
Kidney & renal pelvis	140	22.4	0.92	26.2	1.06	91	12.4	0.59	14.6	0.70
Ureter	3	0.6	0.18	0.7	0.20	*	*	*	*	*
Eye & Orbit	5	0.8	0.18	0.9	0.20	4	0.5	0.11	0.6	0.13
Brain & Other CNS	42	5.9	0.45	6.5	0.50	33	4.0	0.32	4.4	0.36
Brain	39	5.4	0.43	6.1	0.49	31	3.7	0.31	4.1	0.35
Endocrine System	48	5.9	0.41	6.5	0.47	158	18.5	0.67	20.3	0.75
Thyroid gland	43	5.4	0.40	6.0	0.45	154	18.0	0.66	19.7	0.74
Lymphomas	161	25.1	0.97	29.2	1.12	138	19.0	0.75	21.9	0.86
Hodgkin lymphoma	22	2.7	0.28	2.8	0.30	18	2.0	0.22	2.2	0.24
Non-Hodgkin lymphoma	139	22.5	0.93	26.4	1.08	120	17.0	0.72	19.8	0.83
Multiple Myeloma	45	7.8	0.57	9.3	0.66	37	5.5	0.42	6.5	0.48
Leukemias	86	12.1	0.66	13.2	0.74	66	8.3	0.47	9.0	0.53
Acute lymphocytic	30	2.9	0.25	2.7	0.24	20	2.0	0.20	1.9	0.20
Chronic lymphocytic	11	2.0	0.30	2.5	0.35	8	1.3	0.20	1.5	0.23
Acute myeloid	25	4.0	0.40	4.5	0.45	24	3.3	0.31	3.7	0.35
Chronic myeloid	12	1.7	0.24	2.0	0.28	10	1.3	0.19	1.5	0.21
Other leukemias	7	1.4	0.25	1.6	0.28	3	0.4	0.10	0.4	0.12
Mesothelioma	6	1.3	0.25	1.6	0.29	4	0.6	0.15	0.7	0.16
Kaposi Sarcoma	9	1.1	0.18	1.2	0.20	*	*	*	*	*
Ill-Defined & Unknown	64	12.3	0.74	14.2	0.85	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	48	7.1	0.50	8.1	0.57	106	14.4	0.65	16.4	0.74
Breast (<i>in situ</i>)	*	*	*	*	*	166	21.6	0.76	25.8	0.91

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Greater Bay Area

II-68 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Greater Bay Area, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,062	378.5	4.04	446.4	4.69	2,413	364.1	3.40	424.4	3.96
Oral Cavity & Pharynx	56	9.6	0.62	11.6	0.73	24	3.9	0.36	4.6	0.42
Lip	2	0.3	0.10	0.4	0.13	1	0.2	0.10	0.3	0.11
Tongue	15	2.5	0.32	3.1	0.38	6	0.9	0.16	1.1	0.20
Major salivary gland	8	1.5	0.27	1.7	0.30	5	0.8	0.16	0.9	0.18
Floor of mouth	2	0.5	0.16	0.6	0.17	*	*	*	*	*
Gum & other mouth	6	0.9	0.19	1.1	0.21	6	1.0	0.19	1.1	0.21
Nasopharynx	2	0.3	0.11	0.4	0.12	*	*	*	*	*
Oropharynx	3	0.5	0.14	0.7	0.18	1	0.2	0.08	0.2	0.10
Hypopharynx	3	0.5	0.15	0.7	0.18	*	*	*	*	*
Digestive System	569	104.3	2.11	124.7	2.47	464	74.1	1.58	87.4	1.85
Esophagus	27	5.1	0.47	6.1	0.55	9	1.6	0.23	1.9	0.27
Stomach	70	13.3	0.77	15.5	0.88	58	8.9	0.54	10.4	0.63
Small intestine	11	2.0	0.30	2.4	0.34	10	1.7	0.24	1.9	0.27
Colon (excl. rectum)	139	25.1	1.03	29.7	1.20	142	22.6	0.87	26.3	1.01
Rectum & rectosigmoid	85	13.9	0.73	16.9	0.87	56	8.3	0.51	9.9	0.60
Anus, anal canal, & anorectum	6	0.9	0.18	1.1	0.22	11	1.7	0.24	2.1	0.28
Liver	117	20.8	0.92	26.0	1.11	47	7.9	0.53	9.5	0.63
Gallbladder	7	1.4	0.27	1.7	0.31	18	2.9	0.32	3.5	0.37
Pancreas	69	14.3	0.82	16.9	0.95	72	11.9	0.64	14.2	0.75
Respiratory System	165	36.8	1.36	42.9	1.56	151	25.5	0.95	29.9	1.10
Larynx	16	3.2	0.38	3.7	0.44	3	0.5	0.13	0.6	0.15
Lung & bronchus	142	32.6	1.29	38.0	1.48	144	24.5	0.93	28.7	1.08
Bones & Joints	10	1.2	0.17	1.3	0.19	7	0.9	0.15	1.0	0.17
Soft Tissue (incl. heart)	27	4.1	0.39	4.5	0.43	25	3.6	0.33	4.0	0.37
Skin (excl. basal & sq.)	48	8.5	0.60	9.9	0.69	54	8.1	0.50	9.3	0.58
Melanoma of the skin	40	7.0	0.53	8.1	0.62	46	6.9	0.47	8.0	0.54
Breast (excl. <i>in situ</i>)	3	0.6	0.16	0.7	0.19	736	108.4	1.82	127.0	2.14
Female Genital System	N/A	N/A	N/A	N/A	N/A	344	49.9	1.23	59.1	1.46
Cervix uteri	N/A	N/A	N/A	N/A	N/A	59	8.0	0.48	8.8	0.53
Uterus corpus	N/A	N/A	N/A	N/A	N/A	185	26.8	0.90	32.8	1.10
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	4	0.5	0.12	0.6	0.15
Ovary	N/A	N/A	N/A	N/A	N/A	70	10.5	0.57	12.0	0.66
Male Genital System	502	90.8	1.96	109.3	2.30	N/A	N/A	N/A	N/A	N/A
Prostate	430	82.5	1.90	100.9	2.25	N/A	N/A	N/A	N/A	N/A
Testis	63	6.6	0.38	6.6	0.38	N/A	N/A	N/A	N/A	N/A
Penis	8	1.5	0.25	1.7	0.29	N/A	N/A	N/A	N/A	N/A
Urinary System	230	45.3	1.44	53.0	1.66	123	19.2	0.79	22.5	0.92
Bladder (incl. <i>in situ</i>)	88	19.7	1.00	23.0	1.14	33	5.5	0.44	6.4	0.51
Kidney & renal pelvis	138	24.4	1.01	28.6	1.16	89	13.4	0.65	15.8	0.76
Ureter	3	0.7	0.20	0.8	0.22	*	*	*	*	*
Eye & Orbit	5	0.8	0.19	0.9	0.21	4	0.6	0.12	0.7	0.15
Brain & Other CNS	42	6.4	0.49	7.1	0.55	33	4.4	0.36	4.9	0.40
Brain	38	5.9	0.47	6.6	0.53	30	4.1	0.34	4.5	0.39
Endocrine System	46	6.4	0.46	7.1	0.51	152	19.9	0.74	21.8	0.82
Thyroid gland	42	5.9	0.44	6.5	0.49	148	19.4	0.73	21.2	0.81
Lymphomas	156	27.0	1.05	31.4	1.22	133	20.4	0.82	23.5	0.94
Hodgkin lymphoma	21	2.8	0.30	3.0	0.32	17	2.2	0.24	2.3	0.26
Non-Hodgkin lymphoma	135	24.2	1.01	28.4	1.17	116	18.2	0.78	21.2	0.90
Multiple Myeloma	42	8.1	0.60	9.7	0.70	35	5.8	0.45	6.8	0.52
Leukemias	82	13.0	0.71	14.1	0.80	63	8.8	0.51	9.5	0.57
Acute lymphocytic	29	3.3	0.28	3.0	0.27	19	2.2	0.22	2.1	0.22
Chronic lymphocytic	11	2.2	0.32	2.7	0.38	8	1.3	0.22	1.6	0.25
Acute myeloid	24	4.2	0.43	4.7	0.48	23	3.4	0.33	3.8	0.37
Chronic myeloid	12	1.9	0.27	2.2	0.31	10	1.4	0.21	1.6	0.24
Other leukemias	6	1.4	0.26	1.6	0.30	3	0.4	0.11	0.5	0.13
Mesothelioma	6	1.5	0.28	1.7	0.32	4	0.7	0.16	0.7	0.17
Kaposi Sarcoma	9	1.2	0.20	1.3	0.22	*	*	*	*	*
Ill-Defined & Unknown	62	13.0	0.80	15.1	0.91	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	48	7.8	0.55	8.9	0.63	103	15.5	0.70	17.7	0.81
Breast (<i>in situ</i>)	*	*	*	*	*	160	23.2	0.83	27.7	0.99

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Greater Bay Area, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	14	91.8	12.63	110.6	14.75	21	117.5	12.50	140.6	14.73
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	3	17.6	4.99	22.6	6.23	4	26.0	5.99	30.8	7.11
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	2	10.5	3.79	12.7	4.66
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	1	7.3	3.01	9.3	3.79	2	12.2	4.14	14.2	4.68
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	1	6.5	2.89	8.6	3.73	2	11.4	4.06	13.5	4.63
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	8	40.9	7.05	48.7	8.31
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	10.0	3.41	13.2	4.46
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	4	31.5	7.56	38.4	8.77	N/A	N/A	N/A	N/A	N/A
Prostate	4	30.1	7.48	37.0	8.71	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	1	5.5	2.35	6.6	2.95	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	1	5.5	3.04	5.8	3.40	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	1	5.6	2.31	7.9	3.24

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.


N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	10,077,263	10,094,865	10,092,365	10,061,533	10,011,602
Non-Hispanic White	2,803,356	2,790,779	2,772,695	2,750,533	2,722,894
Non-Hispanic Black	862,572	857,974	853,735	848,463	842,920
Non-Hispanic Asian/Pacific Islander (NH API)	1,532,898	1,552,127	1,569,893	1,576,007	1,577,098
Non-Hispanic American Indian/Alaskan Native PRCA (NH AI/AN)	0	0	0	0	0


All Races Population 2015–2019: 50,337,628
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	4,850,292	4,865,928	4,868,179	4,858,933	4,841,453
Hispanic White	4,497,933	4,511,161	4,511,312	4,501,399	4,482,043
Hispanic Black	116,130	117,426	118,536	119,223	120,010

Hispanic/Latino Population, Census 2010: 4,687,889
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

LOS ANGELES CANCER REGISTRY

Initial Operation: 1970
Population-based Data Available: 1972
Coverage Area: County

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	95.8	95.6	93.5	92.9	101.9	95.9
Missing Race	1.9	2.4	2.6	1.8	1.9	2.1
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.1	1.5	0.7	1.6	1.4	1.3
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.1	Ovary	94.4
Oral Cavity & Pharynx	97.6	Prostate	96.0
Esophagus	94.8	Testis	99.0
Stomach	96.8	Bladder (incl. <i>in situ</i>)	97.9
Colon & Rectum	96.9	Kidney & Renal Pelvis	91.1
Liver	52.2	Brain & Other CNS	87.1
Pancreas	84.9	Brain & Other CNS (non-malig)	49.3
Lung & Bronchus	90.1	Thyroid	99.7
Melanomas of the Skin	99.2	Hodgkin Lymphoma	99.0
Female Breast (excl. <i>in situ</i>)	99.1	Non-Hodgkin Lymphoma	97.9
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	90.2
Cervix Uteri	98.2	Leukemias	93.8
Uterus Corpus & Uterus NOS	98.7		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Los Angeles, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	19,465	395.8	1.30	467.6	1.51	21,307	367.5	1.15	428.5	1.32
Oral Cavity & Pharynx	651	12.8	0.23	15.4	0.27	289	4.9	0.13	5.8	0.15
Lip	29	0.6	0.05	0.7	0.06	13	0.2	0.03	0.3	0.03
Tongue	203	3.9	0.13	4.8	0.15	92	1.5	0.07	1.8	0.09
Major salivary gland	62	1.3	0.07	1.5	0.09	49	0.9	0.06	1.0	0.06
Floor of mouth	16	0.3	0.04	0.4	0.04	10	0.2	0.02	0.2	0.03
Gum & other mouth	71	1.5	0.08	1.7	0.09	54	0.9	0.06	1.1	0.06
Nasopharynx	49	1.0	0.06	1.1	0.07	23	0.4	0.04	0.5	0.04
Oropharynx	38	0.7	0.05	0.9	0.06	10	0.2	0.02	0.2	0.03
Hypopharynx	36	0.7	0.06	0.9	0.07	8	0.1	0.02	0.2	0.02
Digestive System	4,560	92.8	0.63	110.4	0.74	3,802	64.0	0.47	75.5	0.55
Esophagus	230	4.7	0.14	5.6	0.17	62	1.0	0.06	1.2	0.07
Stomach	540	11.2	0.22	13.2	0.26	393	6.7	0.15	7.8	0.18
Small intestine	110	2.2	0.10	2.7	0.11	94	1.6	0.07	1.9	0.09
Colon (excl. rectum)	1,343	27.7	0.35	32.7	0.40	1,304	22.0	0.28	25.8	0.32
Rectum & rectosigmoid	679	13.4	0.23	16.1	0.28	497	8.5	0.17	10.1	0.20
Anus, anal canal, & anorectum	82	1.6	0.08	1.9	0.10	104	1.7	0.08	2.1	0.09
Liver	626	12.1	0.22	14.9	0.27	266	4.4	0.12	5.3	0.14
Gallbladder	41	0.9	0.06	1.0	0.07	114	1.9	0.08	2.3	0.10
Pancreas	632	13.1	0.24	15.6	0.28	645	10.7	0.19	12.7	0.23
Respiratory System	2,135	45.4	0.45	53.3	0.52	1,849	31.1	0.33	36.6	0.38
Larynx	151	3.0	0.11	3.7	0.13	29	0.5	0.04	0.6	0.05
Lung & bronchus	1,935	41.4	0.43	48.5	0.50	1,790	30.1	0.32	35.4	0.38
Bones & Joints	54	1.1	0.07	1.1	0.07	38	0.7	0.05	0.8	0.05
Soft Tissue (incl. heart)	201	4.1	0.13	4.6	0.15	174	3.1	0.11	3.5	0.12
Skin (excl. basal & sq.)	968	20.2	0.30	23.6	0.34	634	11.0	0.20	12.6	0.23
Melanoma of the skin	876	18.2	0.28	21.3	0.33	567	9.8	0.19	11.3	0.21
Breast (excl. <i>in situ</i>)	48	1.0	0.07	1.2	0.08	6,867	119.3	0.66	140.5	0.76
Female Genital System	N/A	N/A	N/A	N/A	N/A	2,946	50.9	0.43	59.9	0.50
Cervix uteri	N/A	N/A	N/A	N/A	N/A	419	7.8	0.17	8.5	0.19
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,553	26.2	0.30	31.7	0.36
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	83	1.4	0.07	1.7	0.08
Ovary	N/A	N/A	N/A	N/A	N/A	659	11.4	0.20	13.4	0.23
Male Genital System	4,985	96.8	0.63	117.5	0.75	N/A	N/A	N/A	N/A	N/A
Prostate	4,621	89.8	0.61	110.4	0.73	N/A	N/A	N/A	N/A	N/A
Testis	314	6.0	0.15	5.9	0.15	N/A	N/A	N/A	N/A	N/A
Penis	38	0.8	0.06	0.9	0.07	N/A	N/A	N/A	N/A	N/A
Urinary System	2,191	45.8	0.45	53.9	0.52	962	16.3	0.24	19.1	0.28
Bladder (incl. <i>in situ</i>)	1,166	25.2	0.34	29.5	0.39	356	5.9	0.14	6.9	0.16
Kidney & renal pelvis	979	19.6	0.29	23.1	0.33	579	10.0	0.19	11.7	0.22
Ureter	22	0.5	0.05	0.6	0.05	16	0.3	0.03	0.3	0.03
Eye & Orbit	36	0.7	0.06	0.8	0.06	31	0.5	0.04	0.6	0.05
Brain & Other CNS	315	6.4	0.16	7.1	0.18	250	4.5	0.13	4.9	0.14
Brain	300	6.1	0.16	6.8	0.18	231	4.2	0.13	4.6	0.13
Endocrine System	383	7.5	0.17	8.5	0.20	1,085	20.1	0.28	22.0	0.30
Thyroid gland	346	6.7	0.16	7.7	0.19	1,049	19.4	0.27	21.3	0.29
Lymphomas	1,118	22.9	0.31	26.4	0.36	941	16.3	0.24	18.7	0.27
Hodgkin lymphoma	119	2.4	0.10	2.5	0.10	93	1.7	0.08	1.8	0.08
Non-Hodgkin lymphoma	999	20.5	0.30	23.9	0.34	849	14.5	0.23	16.9	0.26
Multiple Myeloma	339	7.0	0.18	8.3	0.20	283	4.8	0.13	5.7	0.15
Leukemias	701	14.6	0.25	16.2	0.28	509	9.0	0.18	10.0	0.20
Acute lymphocytic	123	2.6	0.10	2.4	0.10	85	1.7	0.09	1.6	0.08
Chronic lymphocytic	185	3.8	0.13	4.6	0.15	119	1.9	0.08	2.3	0.10
Acute myeloid	228	4.8	0.15	5.4	0.16	189	3.3	0.11	3.7	0.12
Chronic myeloid	93	2.0	0.09	2.2	0.10	66	1.2	0.07	1.3	0.07
Other leukemias	71	1.5	0.08	1.7	0.09	50	0.9	0.06	1.0	0.06
Mesothelioma	48	1.1	0.07	1.2	0.08	17	0.3	0.03	0.3	0.04
Kaposi Sarcoma	56	1.1	0.07	1.2	0.07	4	0.1	0.01	0.1	0.02
Ill-Defined & Unknown	676	14.5	0.26	16.9	0.29	624	10.4	0.19	12.0	0.22
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	352	7.1	0.17	8.1	0.20	738	12.8	0.21	14.8	0.25
Breast (<i>in situ</i>)	5	0.1	0.02	0.1	0.02	1,590	27.7	0.32	33.0	0.37

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Los Angeles, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	8,993	464.3	2.25	547.5	2.60	8,776	433.5	2.20	504.6	2.49
Oral Cavity & Pharynx	351	17.9	0.44	21.7	0.52	137	6.5	0.26	7.7	0.31
Lip	21	1.1	0.11	1.3	0.13	8	0.4	0.06	0.4	0.07
Tongue	121	6.1	0.26	7.4	0.30	48	2.3	0.16	2.7	0.18
Major salivary gland	34	1.7	0.14	2.1	0.16	17	0.8	0.09	1.0	0.11
Floor of mouth	8	0.4	0.06	0.5	0.08	7	0.3	0.06	0.4	0.07
Gum & other mouth	31	1.6	0.13	1.9	0.16	27	1.3	0.12	1.5	0.13
Nasopharynx	9	0.5	0.08	0.6	0.09	4	0.3	0.06	0.3	0.06
Oropharynx	24	1.2	0.11	1.5	0.13	5	0.2	0.05	0.3	0.06
Hypopharynx	15	0.8	0.09	0.9	0.10	3	0.1	0.03	0.2	0.04
Digestive System	1,713	88.3	0.98	104.9	1.14	1,351	62.1	0.80	72.9	0.92
Esophagus	118	5.9	0.25	7.0	0.29	33	1.4	0.11	1.6	0.13
Stomach	153	7.9	0.29	9.3	0.34	85	3.8	0.19	4.5	0.23
Small intestine	50	2.6	0.17	3.1	0.20	37	1.7	0.13	2.1	0.16
Colon (excl. rectum)	551	29.3	0.57	34.2	0.66	506	23.3	0.49	27.1	0.56
Rectum & rectosigmoid	240	12.6	0.38	15.1	0.44	183	9.3	0.33	11.0	0.37
Anus, anal canal, & anorectum	43	2.2	0.15	2.7	0.18	61	2.8	0.17	3.5	0.20
Liver	161	7.7	0.28	9.5	0.34	61	2.8	0.17	3.3	0.19
Gallbladder	10	0.5	0.08	0.6	0.09	25	1.1	0.10	1.3	0.12
Pancreas	291	14.7	0.39	17.4	0.46	249	10.9	0.32	12.8	0.37
Respiratory System	1,017	51.7	0.74	60.8	0.86	915	40.2	0.61	47.3	0.71
Larynx	66	3.3	0.18	3.9	0.22	13	0.6	0.08	0.7	0.09
Lung & bronchus	930	47.3	0.71	55.5	0.82	891	39.1	0.60	45.9	0.70
Bones & Joints	18	1.3	0.15	1.3	0.14	15	1.0	0.13	1.0	0.13
Soft Tissue (incl. heart)	86	4.9	0.25	5.5	0.27	59	3.3	0.21	3.6	0.22
Skin (excl. basal & sq.)	799	41.8	0.68	48.9	0.78	450	23.1	0.52	26.4	0.58
Melanoma of the skin	739	38.6	0.65	45.2	0.75	419	21.7	0.51	24.8	0.56
Breast (excl. <i>in situ</i>)	25	1.3	0.12	1.5	0.14	2,929	150.1	1.31	176.3	1.50
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,055	52.3	0.76	62.3	0.88
Cervix uteri	N/A	N/A	N/A	N/A	N/A	95	5.9	0.29	6.3	0.30
Uterus corpus	N/A	N/A	N/A	N/A	N/A	571	27.3	0.53	33.5	0.64
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	31	1.4	0.12	1.7	0.14
Ovary	N/A	N/A	N/A	N/A	N/A	251	12.7	0.38	14.8	0.43
Male Genital System	2,146	105.6	1.04	127.8	1.24	N/A	N/A	N/A	N/A	N/A
Prostate	2,023	97.2	0.98	119.4	1.19	N/A	N/A	N/A	N/A	N/A
Testis	107	7.6	0.34	7.5	0.33	N/A	N/A	N/A	N/A	N/A
Penis	12	0.6	0.08	0.7	0.09	N/A	N/A	N/A	N/A	N/A
Urinary System	1,136	58.5	0.79	68.7	0.92	390	17.5	0.42	20.6	0.48
Bladder (incl. <i>in situ</i>)	731	37.2	0.63	43.7	0.73	195	8.3	0.28	9.8	0.32
Kidney & renal pelvis	384	20.3	0.48	23.7	0.55	183	8.7	0.31	10.3	0.35
Ureter	9	0.5	0.07	0.6	0.08	6	0.2	0.04	0.3	0.05
Eye & Orbit	21	1.1	0.12	1.3	0.13	19	1.0	0.11	1.1	0.12
Brain & Other CNS	156	9.0	0.34	10.0	0.36	109	6.2	0.29	6.7	0.30
Brain	150	8.6	0.33	9.6	0.36	101	5.8	0.28	6.3	0.29
Endocrine System	169	9.6	0.35	10.9	0.38	351	22.8	0.58	24.4	0.60
Thyroid gland	155	8.8	0.33	10.0	0.36	338	22.0	0.57	23.6	0.59
Lymphomas	507	27.9	0.57	31.9	0.64	389	19.1	0.46	22.0	0.52
Hodgkin lymphoma	50	3.4	0.23	3.5	0.23	36	2.6	0.21	2.6	0.20
Non-Hodgkin lymphoma	458	24.5	0.53	28.4	0.60	353	16.6	0.41	19.4	0.48
Multiple Myeloma	139	7.1	0.28	8.4	0.32	96	4.3	0.21	5.2	0.24
Leukemias	333	18.3	0.47	20.8	0.52	218	10.9	0.36	12.1	0.38
Acute lymphocytic	26	2.2	0.21	2.0	0.18	17	1.5	0.17	1.3	0.15
Chronic lymphocytic	122	6.1	0.25	7.4	0.30	79	3.5	0.18	4.1	0.21
Acute myeloid	110	5.9	0.26	6.8	0.29	73	3.6	0.20	4.0	0.22
Chronic myeloid	41	2.3	0.16	2.6	0.18	27	1.4	0.13	1.6	0.14
Other leukemias	34	1.9	0.15	2.1	0.17	21	1.0	0.11	1.1	0.12
Mesothelioma	26	1.3	0.12	1.5	0.14	8	0.4	0.06	0.4	0.07
Kaposi Sarcoma	14	0.8	0.10	0.9	0.11	2	0.1	0.02	0.1	0.03
Ill-Defined & Unknown	339	17.7	0.44	20.6	0.50	286	12.4	0.35	14.4	0.40
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	161	9.0	0.33	10.3	0.37	298	15.0	0.42	17.5	0.47
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.04	592	32.0	0.62	37.8	0.71

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Los Angeles, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,940	453.6	4.76	545.1	5.60	2,134	383.7	3.81	451.5	4.39
Oral Cavity & Pharynx	56	12.1	0.75	15.2	0.91	27	4.7	0.42	5.8	0.50
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	16	3.4	0.39	4.3	0.48	7	1.2	0.21	1.5	0.26
Major salivary gland	4	0.8	0.18	0.9	0.23	5	0.9	0.19	1.0	0.21
Floor of mouth	2	0.5	0.14	0.6	0.19	*	*	*	*	*
Gum & other mouth	7	1.6	0.29	2.0	0.33	6	1.0	0.19	1.2	0.23
Nasopharynx	4	0.8	0.19	0.9	0.22	3	0.5	0.15	0.6	0.16
Oropharynx	5	1.0	0.21	1.2	0.26	*	*	*	*	*
Hypopharynx	4	0.8	0.19	1.0	0.24	2	0.3	0.09	0.3	0.12
Digestive System	431	103.1	2.29	122.6	2.67	418	73.2	1.63	87.2	1.92
Esophagus	15	3.5	0.42	4.2	0.49	8	1.4	0.22	1.6	0.26
Stomach	44	11.2	0.77	13.1	0.89	37	6.6	0.50	7.7	0.57
Small intestine	15	3.5	0.43	4.2	0.49	19	3.4	0.35	4.0	0.42
Colon (excl. rectum)	143	34.7	1.34	41.0	1.56	156	27.9	1.02	32.7	1.18
Rectum & rectosigmoid	49	11.6	0.77	13.7	0.88	43	7.6	0.53	9.2	0.63
Anus, anal canal, & anorectum	12	2.8	0.37	3.3	0.43	9	1.5	0.23	1.9	0.28
Liver	60	13.1	0.78	16.3	0.95	27	4.5	0.39	5.6	0.48
Gallbladder	5	1.1	0.24	1.3	0.27	8	1.4	0.22	1.6	0.26
Pancreas	67	16.1	0.91	19.2	1.07	84	14.3	0.71	17.3	0.85
Respiratory System	275	66.5	1.85	79.3	2.16	256	44.1	1.25	52.9	1.48
Larynx	22	4.9	0.48	6.1	0.58	4	0.7	0.16	0.9	0.19
Lung & bronchus	250	60.8	1.77	72.3	2.07	249	42.9	1.23	51.5	1.46
Bones & Joints	5	1.2	0.25	1.2	0.24	3	0.7	0.19	0.7	0.17
Soft Tissue (incl. heart)	18	4.4	0.48	4.9	0.52	18	3.4	0.37	3.8	0.40
Skin (excl. basal & sq.)	8	1.9	0.32	2.1	0.36	9	1.8	0.28	2.0	0.30
Melanoma of the skin	4	1.1	0.25	1.3	0.28	4	0.7	0.17	0.8	0.19
Breast (excl. <i>in situ</i>)	7	1.5	0.28	1.9	0.33	694	127.1	2.22	148.9	2.54
Female Genital System	N/A	N/A	N/A	N/A	N/A	279	49.3	1.36	59.0	1.59
Cervix uteri	N/A	N/A	N/A	N/A	N/A	37	7.3	0.56	8.1	0.60
Uterus corpus	N/A	N/A	N/A	N/A	N/A	156	26.6	0.97	32.6	1.17
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	13	2.3	0.29	2.8	0.34
Ovary	N/A	N/A	N/A	N/A	N/A	49	9.0	0.59	10.4	0.67
Male Genital System	645	141.6	2.57	176.7	3.14	N/A	N/A	N/A	N/A	N/A
Prostate	636	139.3	2.55	174.3	3.12	N/A	N/A	N/A	N/A	N/A
Testis	6	1.6	0.30	1.6	0.29	N/A	N/A	N/A	N/A	N/A
Penis	1	0.4	0.14	0.4	0.17	N/A	N/A	N/A	N/A	N/A
Urinary System	180	43.9	1.51	51.7	1.75	98	17.5	0.81	20.4	0.93
Bladder (incl. <i>in situ</i>)	76	19.2	1.02	22.8	1.19	34	6.0	0.46	7.0	0.54
Kidney & renal pelvis	100	23.7	1.09	27.8	1.25	61	10.9	0.64	12.7	0.74
Ureter	1	0.4	0.14	0.4	0.16	2	0.3	0.11	0.3	0.12
Eye & Orbit	*	*	*	*	*	1	0.3	0.11	0.3	0.11
Brain & Other CNS	21	5.0	0.51	5.4	0.54	16	3.2	0.37	3.5	0.39
Brain	19	4.7	0.49	5.1	0.52	15	2.9	0.35	3.2	0.38
Endocrine System	20	4.7	0.48	5.5	0.55	61	12.2	0.73	13.4	0.77
Thyroid gland	16	3.6	0.41	4.2	0.48	55	11.2	0.70	12.3	0.74
Lymphomas	84	20.3	1.02	23.3	1.15	74	14.0	0.74	16.0	0.84
Hodgkin lymphoma	11	2.7	0.38	2.8	0.39	9	2.1	0.31	2.2	0.32
Non-Hodgkin lymphoma	73	17.6	0.95	20.5	1.09	65	11.9	0.68	13.9	0.78
Multiple Myeloma	61	15.1	0.90	17.9	1.04	58	10.2	0.61	12.1	0.71
Leukemias	55	13.5	0.84	15.5	0.95	47	8.7	0.59	9.9	0.65
Acute lymphocytic	6	1.5	0.28	1.4	0.26	3	0.7	0.19	0.7	0.17
Chronic lymphocytic	18	4.5	0.49	5.5	0.59	10	1.6	0.23	2.0	0.29
Acute myeloid	18	4.4	0.48	5.0	0.54	18	3.4	0.37	3.9	0.41
Chronic myeloid	8	2.0	0.32	2.3	0.37	8	1.5	0.26	1.7	0.28
Other leukemias	5	1.1	0.23	1.3	0.27	8	1.4	0.23	1.6	0.26
Mesothelioma	2	0.6	0.19	0.7	0.21	*	*	*	*	*
Kaposi Sarcoma	8	1.8	0.29	2.0	0.31	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	74	13.1	0.69	15.4	0.81
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	29	7.1	0.61	8.2	0.69	73	13.6	0.74	15.6	0.82
Breast (<i>in situ</i>)	*	*	*	*	*	170	30.6	1.08	36.4	1.25

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Los Angeles, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,487	283.9	2.60	335.1	3.02	3,388	311.2	2.46	362.5	2.82
Oral Cavity & Pharynx	87	10.1	0.49	11.7	0.57	48	4.4	0.30	5.1	0.33
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	20	2.2	0.23	2.6	0.26	13	1.2	0.15	1.4	0.17
Major salivary gland	8	1.0	0.16	1.1	0.17	10	1.0	0.15	1.1	0.16
Floor of mouth	2	0.2	0.06	0.2	0.08	*	*	*	*	*
Gum & other mouth	12	1.4	0.18	1.6	0.21	8	0.7	0.11	0.8	0.13
Nasopharynx	27	3.2	0.28	3.6	0.32	10	1.0	0.14	1.1	0.15
Oropharynx	2	0.2	0.07	0.3	0.08	*	*	*	*	*
Hypopharynx	6	0.7	0.13	0.8	0.14	2	0.1	0.05	0.2	0.06
Digestive System	823	94.0	1.49	111.9	1.75	664	57.8	1.03	68.1	1.19
Esophagus	28	3.2	0.27	3.8	0.32	8	0.7	0.11	0.8	0.13
Stomach	120	13.7	0.57	16.2	0.67	86	7.4	0.37	8.7	0.43
Small intestine	14	1.6	0.20	2.0	0.23	8	0.8	0.12	0.9	0.13
Colon (excl. rectum)	221	25.2	0.77	30.0	0.91	225	19.5	0.60	23.1	0.70
Rectum & rectosigmoid	136	15.6	0.61	18.7	0.72	92	8.3	0.40	9.9	0.47
Anus, anal canal, & anorectum	4	0.5	0.11	0.6	0.13	6	0.5	0.10	0.6	0.11
Liver	140	15.7	0.60	19.0	0.72	56	4.8	0.29	5.6	0.34
Gallbladder	7	0.8	0.14	0.9	0.16	15	1.3	0.15	1.5	0.18
Pancreas	95	10.9	0.51	12.8	0.59	107	9.2	0.41	10.8	0.47
Respiratory System	400	45.6	1.04	54.0	1.21	314	26.9	0.69	31.8	0.81
Larynx	15	1.7	0.20	2.0	0.23	2	0.2	0.06	0.2	0.07
Lung & bronchus	377	42.9	1.01	50.8	1.18	307	26.3	0.68	31.0	0.80
Bones & Joints	7	1.0	0.17	1.0	0.17	5	0.6	0.14	0.6	0.12
Soft Tissue (incl. heart)	25	3.1	0.28	3.4	0.30	24	2.4	0.23	2.6	0.24
Skin (excl. basal & sq.)	16	1.9	0.21	2.1	0.24	19	1.8	0.19	2.1	0.21
Melanoma of the skin	8	0.9	0.15	1.0	0.17	12	1.1	0.14	1.3	0.17
Breast (excl. <i>in situ</i>)	6	0.7	0.13	0.9	0.16	1,197	111.9	1.49	131.2	1.71
Female Genital System	N/A	N/A	N/A	N/A	N/A	452	42.4	0.92	49.9	1.06
Cervix uteri	N/A	N/A	N/A	N/A	N/A	73	7.4	0.40	8.2	0.43
Uterus corpus	N/A	N/A	N/A	N/A	N/A	238	21.9	0.65	26.2	0.77
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	12	1.1	0.15	1.3	0.17
Ovary	N/A	N/A	N/A	N/A	N/A	107	10.0	0.45	11.8	0.51
Male Genital System	457	49.3	1.05	59.8	1.26	N/A	N/A	N/A	N/A	N/A
Prostate	436	46.5	1.01	57.0	1.23	N/A	N/A	N/A	N/A	N/A
Testis	16	2.1	0.25	2.1	0.24	N/A	N/A	N/A	N/A	N/A
Penis	3	0.4	0.09	0.4	0.11	N/A	N/A	N/A	N/A	N/A
Urinary System	239	27.4	0.81	32.3	0.94	117	10.2	0.43	12.0	0.50
Bladder (incl. <i>in situ</i>)	124	14.3	0.58	16.8	0.68	45	3.8	0.26	4.4	0.30
Kidney & renal pelvis	105	11.9	0.53	14.2	0.62	64	5.8	0.33	6.8	0.38
Ureter	6	0.6	0.12	0.7	0.14	6	0.5	0.09	0.6	0.11
Eye & Orbit	3	0.4	0.11	0.4	0.10	2	0.2	0.06	0.2	0.06
Brain & Other CNS	29	3.7	0.31	4.0	0.33	28	3.0	0.26	3.2	0.27
Brain	27	3.4	0.30	3.7	0.32	25	2.6	0.25	2.8	0.26
Endocrine System	64	7.5	0.43	8.7	0.49	207	21.3	0.68	23.5	0.73
Thyroid gland	57	6.7	0.41	7.8	0.47	201	20.7	0.67	22.7	0.72
Lymphomas	136	16.0	0.63	18.4	0.71	125	11.7	0.48	13.2	0.54
Hodgkin lymphoma	10	1.2	0.19	1.3	0.19	8	1.0	0.16	1.0	0.16
Non-Hodgkin lymphoma	127	14.7	0.60	17.1	0.68	116	10.7	0.46	12.3	0.51
Multiple Myeloma	35	3.9	0.30	4.7	0.35	29	2.6	0.22	3.1	0.26
Leukemias	70	8.8	0.48	9.6	0.51	63	6.2	0.37	6.9	0.39
Acute lymphocytic	10	1.4	0.21	1.3	0.19	8	1.1	0.18	1.0	0.16
Chronic lymphocytic	8	0.9	0.15	1.1	0.17	6	0.5	0.09	0.6	0.11
Acute myeloid	33	4.0	0.32	4.5	0.35	32	3.0	0.25	3.4	0.27
Chronic myeloid	11	1.4	0.19	1.5	0.21	10	1.0	0.15	1.1	0.16
Other leukemias	8	1.0	0.16	1.1	0.17	8	0.7	0.12	0.8	0.13
Mesothelioma	4	0.4	0.09	0.5	0.11	2	0.1	0.05	0.2	0.06
Kaposi Sarcoma	3	0.4	0.10	0.4	0.10	*	*	*	*	*
Ill-Defined & Unknown	85	10.0	0.49	11.5	0.56	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	52	6.1	0.39	7.0	0.44	118	10.9	0.46	12.6	0.53
Breast (<i>in situ</i>)	*	*	*	*	*	343	31.9	0.79	37.8	0.92

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Los Angeles, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	5,439	326.6	2.14	384.1	2.47	6,645	314.0	1.76	366.0	2.04
Oral Cavity & Pharynx	146	8.4	0.33	10.0	0.39	72	3.5	0.19	4.1	0.22
Lip	6	0.4	0.08	0.5	0.09	3	0.2	0.04	0.2	0.05
Tongue	42	2.4	0.18	3.0	0.21	22	1.1	0.10	1.3	0.12
Major salivary gland	16	0.9	0.11	1.0	0.12	17	0.8	0.09	0.9	0.10
Floor of mouth	4	0.3	0.06	0.3	0.07	1	0.0	0.02	0.1	0.03
Gum & other mouth	21	1.2	0.13	1.4	0.15	11	0.6	0.08	0.7	0.09
Nasopharynx	8	0.4	0.07	0.5	0.08	6	0.3	0.05	0.3	0.06
Oropharynx	6	0.3	0.07	0.4	0.08	3	0.1	0.04	0.2	0.05
Hypopharynx	10	0.6	0.09	0.7	0.11	2	0.1	0.03	0.1	0.03
Digestive System	1,535	92.9	1.14	110.5	1.33	1,319	65.1	0.82	76.9	0.96
Esophagus	67	4.3	0.25	5.1	0.29	12	0.6	0.08	0.7	0.10
Stomach	220	13.4	0.44	15.7	0.50	180	8.8	0.30	10.2	0.34
Small intestine	30	1.9	0.16	2.1	0.19	28	1.4	0.12	1.6	0.14
Colon (excl. rectum)	408	24.6	0.58	29.1	0.68	399	19.5	0.45	22.9	0.52
Rectum & rectosigmoid	240	13.3	0.41	16.0	0.49	167	7.8	0.27	9.3	0.32
Anus, anal canal, & anorectum	21	1.2	0.12	1.4	0.14	25	1.2	0.11	1.4	0.13
Liver	258	15.5	0.46	18.9	0.55	119	6.2	0.26	7.3	0.30
Gallbladder	19	1.3	0.14	1.5	0.16	65	3.2	0.18	3.8	0.22
Pancreas	173	11.1	0.41	13.1	0.47	201	10.3	0.33	12.2	0.39
Respiratory System	422	30.3	0.70	35.0	0.80	346	18.2	0.45	21.1	0.51
Larynx	45	2.9	0.21	3.4	0.24	9	0.4	0.07	0.5	0.08
Lung & bronchus	361	26.6	0.66	30.7	0.75	326	17.2	0.44	20.0	0.50
Bones & Joints	24	1.1	0.10	1.1	0.11	15	0.6	0.07	0.6	0.08
Soft Tissue (incl. heart)	68	3.4	0.20	3.8	0.22	72	3.3	0.18	3.6	0.19
Skin (excl. basal & sq.)	76	4.7	0.26	5.4	0.30	98	4.6	0.21	5.3	0.25
Melanoma of the skin	61	3.8	0.23	4.4	0.27	78	3.7	0.19	4.2	0.22
Breast (excl. <i>in situ</i>)	9	0.5	0.08	0.6	0.10	1,942	89.9	0.93	106.0	1.09
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,114	50.8	0.69	59.4	0.81
Cervix uteri	N/A	N/A	N/A	N/A	N/A	208	9.4	0.30	10.2	0.32
Uterus corpus	N/A	N/A	N/A	N/A	N/A	563	25.4	0.49	30.5	0.58
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	27	1.2	0.11	1.4	0.13
Ovary	N/A	N/A	N/A	N/A	N/A	243	11.2	0.33	13.0	0.38
Male Genital System	1,417	82.8	1.06	99.5	1.24	N/A	N/A	N/A	N/A	N/A
Prostate	1,216	74.9	1.02	91.6	1.21	N/A	N/A	N/A	N/A	N/A
Testis	176	6.4	0.22	6.3	0.22	N/A	N/A	N/A	N/A	N/A
Penis	21	1.2	0.13	1.5	0.15	N/A	N/A	N/A	N/A	N/A
Urinary System	591	37.1	0.73	43.9	0.85	344	16.6	0.41	19.5	0.48
Bladder (incl. <i>in situ</i>)	207	15.1	0.50	17.6	0.57	74	3.9	0.21	4.5	0.24
Kidney & renal pelvis	373	21.2	0.53	25.2	0.62	265	12.4	0.35	14.7	0.41
Ureter	5	0.4	0.09	0.5	0.10	2	0.1	0.04	0.2	0.04
Eye & Orbit	9	0.5	0.09	0.6	0.09	9	0.4	0.06	0.4	0.07
Brain & Other CNS	105	5.3	0.25	5.9	0.28	94	4.2	0.20	4.6	0.22
Brain	99	5.0	0.24	5.6	0.27	86	3.9	0.19	4.3	0.21
Endocrine System	124	6.1	0.26	6.8	0.29	449	19.3	0.41	21.4	0.46
Thyroid gland	113	5.5	0.25	6.2	0.28	437	18.8	0.41	20.8	0.46
Lymphomas	365	20.7	0.53	23.9	0.60	331	15.9	0.40	18.4	0.46
Hodgkin lymphoma	46	2.2	0.15	2.3	0.17	36	1.5	0.11	1.6	0.12
Non-Hodgkin lymphoma	319	18.5	0.50	21.6	0.58	295	14.4	0.38	16.8	0.45
Multiple Myeloma	100	6.4	0.31	7.6	0.36	97	4.8	0.22	5.8	0.26
Leukemias	232	12.0	0.38	12.9	0.42	171	7.8	0.28	8.5	0.30
Acute lymphocytic	81	3.2	0.17	3.0	0.16	57	2.3	0.14	2.3	0.14
Chronic lymphocytic	30	2.0	0.17	2.4	0.20	18	0.9	0.10	1.1	0.12
Acute myeloid	67	3.9	0.23	4.2	0.26	64	3.1	0.18	3.5	0.20
Chronic myeloid	31	1.6	0.14	1.8	0.16	19	0.8	0.09	0.9	0.10
Other leukemias	23	1.3	0.13	1.5	0.15	13	0.7	0.08	0.7	0.09
Mesothelioma	17	1.2	0.14	1.4	0.16	6	0.3	0.06	0.4	0.07
Kaposi Sarcoma	26	1.2	0.11	1.3	0.13	1	0.1	0.03	0.1	0.03
Ill-Defined & Unknown	174	12.0	0.44	13.9	0.50	165	8.6	0.30	9.8	0.35
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	104	5.5	0.26	6.3	0.30	236	11.2	0.33	12.9	0.38
Breast (<i>in situ</i>)	1	0.0	0.02	0.1	0.02	457	20.9	0.44	25.0	0.53

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Los Angeles

II-78 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Los Angeles, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	5,207	332.0	2.21	390.4	2.56	6,443	324.4	1.85	378.0	2.14
Oral Cavity & Pharynx	142	8.6	0.35	10.3	0.41	68	3.5	0.19	4.1	0.23
Lip	6	0.4	0.08	0.5	0.09	3	0.2	0.05	0.2	0.05
Tongue	41	2.5	0.19	3.0	0.22	21	1.1	0.11	1.3	0.13
Major salivary gland	15	0.9	0.12	1.1	0.13	16	0.8	0.09	0.9	0.10
Floor of mouth	4	0.3	0.06	0.3	0.08	*	*	*	*	*
Gum & other mouth	20	1.2	0.13	1.4	0.15	10	0.6	0.08	0.7	0.09
Nasopharynx	7	0.4	0.08	0.5	0.09	5	0.3	0.05	0.3	0.06
Oropharynx	6	0.4	0.07	0.5	0.09	3	0.1	0.04	0.2	0.05
Hypopharynx	10	0.7	0.10	0.8	0.11	2	0.1	0.03	0.1	0.04
Digestive System	1,495	96.1	1.19	114.4	1.39	1,284	67.3	0.86	79.5	1.00
Esophagus	65	4.4	0.26	5.2	0.30	11	0.6	0.09	0.7	0.10
Stomach	215	13.9	0.46	16.3	0.53	175	9.1	0.31	10.5	0.36
Small intestine	28	1.8	0.16	2.1	0.19	28	1.5	0.13	1.7	0.15
Colon (excl. rectum)	397	25.4	0.61	30.1	0.71	387	20.2	0.47	23.7	0.55
Rectum & rectosigmoid	232	13.7	0.43	16.5	0.51	160	7.9	0.29	9.4	0.34
Anus, anal canal, & anorectum	21	1.2	0.13	1.4	0.15	24	1.2	0.11	1.5	0.14
Liver	252	16.1	0.49	19.7	0.57	116	6.4	0.27	7.5	0.32
Gallbladder	19	1.3	0.15	1.5	0.17	64	3.3	0.19	4.0	0.23
Pancreas	169	11.5	0.42	13.6	0.49	196	10.7	0.35	12.6	0.41
Respiratory System	412	31.3	0.73	36.2	0.83	336	18.7	0.47	21.7	0.54
Larynx	44	3.0	0.22	3.5	0.25	9	0.4	0.07	0.5	0.08
Lung & bronchus	352	27.5	0.69	31.7	0.78	316	17.7	0.46	20.5	0.52
Bones & Joints	24	1.1	0.11	1.1	0.11	15	0.7	0.08	0.7	0.08
Soft Tissue (incl. heart)	67	3.6	0.21	4.0	0.24	69	3.4	0.19	3.7	0.20
Skin (excl. basal & sq.)	72	4.8	0.27	5.6	0.31	91	4.6	0.22	5.3	0.25
Melanoma of the skin	59	3.9	0.24	4.5	0.28	72	3.7	0.20	4.2	0.23
Breast (excl. <i>in situ</i>)	9	0.5	0.09	0.6	0.10	1,884	93.1	0.98	109.7	1.14
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,080	52.6	0.73	61.5	0.85
Cervix uteri	N/A	N/A	N/A	N/A	N/A	201	9.8	0.31	10.5	0.34
Uterus corpus	N/A	N/A	N/A	N/A	N/A	547	26.3	0.51	31.6	0.61
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	26	1.3	0.11	1.5	0.13
Ovary	N/A	N/A	N/A	N/A	N/A	236	11.6	0.34	13.5	0.40
Male Genital System	1,291	79.8	1.06	96.0	1.25	N/A	N/A	N/A	N/A	N/A
Prostate	1,097	71.6	1.03	87.6	1.22	N/A	N/A	N/A	N/A	N/A
Testis	170	6.7	0.23	6.6	0.23	N/A	N/A	N/A	N/A	N/A
Penis	21	1.3	0.14	1.6	0.16	N/A	N/A	N/A	N/A	N/A
Urinary System	572	38.2	0.76	45.2	0.89	334	17.1	0.43	20.1	0.50
Bladder (incl. <i>in situ</i>)	200	15.4	0.51	18.0	0.59	72	3.9	0.21	4.6	0.25
Kidney & renal pelvis	361	21.9	0.55	26.1	0.64	257	12.9	0.37	15.2	0.43
Ureter	5	0.4	0.09	0.5	0.11	2	0.1	0.04	0.1	0.04
Eye & Orbit	9	0.6	0.09	0.6	0.10	9	0.4	0.07	0.5	0.07
Brain & Other CNS	104	5.6	0.26	6.2	0.30	91	4.4	0.21	4.8	0.23
Brain	98	5.3	0.26	5.9	0.29	84	4.0	0.20	4.4	0.22
Endocrine System	122	6.4	0.28	7.1	0.31	435	20.0	0.44	22.2	0.49
Thyroid gland	112	5.8	0.26	6.5	0.29	423	19.5	0.43	21.6	0.48
Lymphomas	356	21.6	0.55	25.0	0.63	319	16.3	0.42	18.9	0.48
Hodgkin lymphoma	45	2.3	0.16	2.4	0.18	35	1.5	0.12	1.7	0.13
Non-Hodgkin lymphoma	311	19.3	0.53	22.5	0.61	284	14.8	0.40	17.2	0.46
Multiple Myeloma	97	6.7	0.32	7.8	0.37	95	5.0	0.24	6.0	0.28
Leukemias	225	12.5	0.40	13.4	0.44	166	8.1	0.29	8.8	0.32
Acute lymphocytic	79	3.4	0.18	3.2	0.17	56	2.5	0.15	2.4	0.15
Chronic lymphocytic	27	2.0	0.18	2.3	0.21	18	0.9	0.10	1.1	0.12
Acute myeloid	66	4.1	0.24	4.5	0.27	62	3.2	0.19	3.6	0.21
Chronic myeloid	30	1.7	0.15	1.9	0.16	18	0.9	0.09	0.9	0.10
Other leukemias	23	1.4	0.14	1.5	0.16	13	0.7	0.09	0.8	0.10
Mesothelioma	17	1.2	0.14	1.4	0.16	6	0.4	0.06	0.4	0.07
Kaposi Sarcoma	25	1.2	0.12	1.3	0.13	*	*	*	*	*
Ill-Defined & Unknown	169	12.3	0.45	14.3	0.52	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	99	5.6	0.27	6.4	0.31	227	11.5	0.35	13.2	0.40
Breast (<i>in situ</i>)	1	0.0	0.02	0.1	0.03	441	21.5	0.47	25.8	0.55

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Los Angeles, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	34	112.3	9.66	132.9	11.22	53	139.3	9.17	164.1	10.69
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	10	34.9	5.57	40.2	6.32	7	20.9	3.67	24.6	4.25
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	1	3.9	1.79	4.2	1.94	1	4.0	1.70	4.5	1.87
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	3	11.5	3.12	13.0	3.53	3	8.5	2.30	9.6	2.60
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	5	19.4	4.28	22.0	4.75	4	13.2	3.05	14.8	3.36
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	4	16.1	3.82	18.7	4.34	4	13.0	3.04	14.5	3.35
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	1	2.9	1.33	3.6	1.65
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	18	45.5	5.11	54.5	6.04
Female Genital System	N/A	N/A	N/A	N/A	N/A	9	22.8	3.56	27.6	4.30
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	4.6	1.51	5.1	1.74
Uterus corpus	N/A	N/A	N/A	N/A	N/A	3	8.2	2.09	10.7	2.68
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	5.6	1.83	6.8	2.17
Male Genital System	9	28.6	4.63	36.5	5.65	N/A	N/A	N/A	N/A	N/A
Prostate	9	28.4	4.63	36.2	5.65	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	3	9.0	2.70	10.7	3.15	2	6.7	2.09	8.0	2.46
Bladder (incl. <i>in situ</i>)	1	5.5	2.42	6.4	2.77	*	*	*	*	*
Kidney & renal pelvis	2	3.5	1.20	4.2	1.50	1	3.9	1.57	4.6	1.84
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	3	5.1	1.52	5.2	1.61
Thyroid gland	*	*	*	*	*	3	5.1	1.52	5.2	1.61
Lymphomas	1	2.4	0.95	2.6	1.06	3	7.3	2.08	8.2	2.34
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	1	4.8	1.87	5.7	2.21
Leukemias	2	5.0	1.86	5.5	2.15	2	4.1	1.57	4.7	1.79
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	1	4.0	1.67	5.1	2.16	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	2	6.6	2.12	7.3	2.30
Breast (<i>in situ</i>)	*	*	*	*	*	4	11.8	2.67	14.6	3.19

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


Los Angeles

II-80 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	5,454,328	5,543,844	5,617,421	5,697,155	5,758,486
Non-Hispanic White	3,812,858	3,862,789	3,899,597	3,937,424	3,968,124
Non-Hispanic Black	247,483	253,866	258,827	265,362	269,968
Non-Hispanic Asian/Pacific Islander (NH API)	194,660	202,474	209,378	217,002	221,669
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	6,587	6,789	6,826	6,960	6,967


All Races Population 2015–2019: 28,071,234
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	1,158,286	1,182,889	1,207,176	1,234,141	1,255,050
Hispanic White	1,043,903	1,065,211	1,086,241	1,109,503	1,127,025
Hispanic Black	36,003	37,093	38,162	39,573	40,757

Hispanic/Latino Population, Census 2010: 1,038,687
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

COLORADO CANCER REGISTRY

Initial Operation: 1968
 Population-based Data Available: 1988
 Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	101.2	100.2	100.7	99.1	100.7	100.4
Missing Race	0.7	0.9	1.8	1.1	0.9	1.1
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.2	0.3	0.4	0.3	0.2
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.8	2.0	1.4	2.0	2.7	1.9
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.6	Ovary	94.1
Oral Cavity & Pharynx	97.8	Prostate	95.7
Esophagus	94.9	Testis	99.3
Stomach	95.0	Bladder (incl. <i>in situ</i>)	97.4
Colon & Rectum	95.5	Kidney & Renal Pelvis	88.2
Liver	40.7	Brain & Other CNS	84.0
Pancreas	84.6	Brain & Other CNS (non-malig)	33.3
Lung & Bronchus	85.1	Thyroid	99.3
Melanomas of the Skin	99.3	Hodgkin Lymphoma	98.9
Female Breast (excl. <i>in situ</i>)	98.4	Non-Hodgkin Lymphoma	97.1
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	89.8
Cervix Uteri	97.2	Leukemias	88.1
Uterus Corpus & Uterus NOS	98.4		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Colorado, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	12,080	414.0	1.75	489.6	2.03	12,357	388.2	1.60	451.6	1.83
Oral Cavity & Pharynx	508	16.6	0.34	20.1	0.40	187	5.7	0.19	6.8	0.23
Lip	31	1.1	0.09	1.3	0.11	14	0.4	0.05	0.5	0.06
Tongue	177	5.7	0.20	6.9	0.24	65	2.0	0.11	2.4	0.13
Major salivary gland	42	1.6	0.11	1.8	0.12	28	0.9	0.07	1.0	0.09
Floor of mouth	17	0.5	0.06	0.7	0.07	10	0.3	0.04	0.4	0.05
Gum & other mouth	43	1.5	0.11	1.8	0.12	32	1.0	0.08	1.2	0.09
Nasopharynx	17	0.6	0.06	0.7	0.07	6	0.2	0.03	0.2	0.04
Oropharynx	27	0.9	0.08	1.1	0.09	6	0.2	0.03	0.2	0.04
Hypopharynx	18	0.6	0.06	0.7	0.08	6	0.2	0.03	0.2	0.04
Digestive System	2,405	82.6	0.78	98.3	0.92	1,827	56.8	0.61	66.8	0.71
Esophagus	210	7.2	0.23	8.5	0.27	45	1.4	0.09	1.6	0.11
Stomach	209	7.3	0.24	8.6	0.27	108	3.4	0.15	4.0	0.17
Small intestine	82	2.8	0.15	3.4	0.17	70	2.2	0.12	2.6	0.14
Colon (excl. rectum)	683	24.2	0.43	28.5	0.50	675	21.3	0.38	24.8	0.43
Rectum & rectosigmoid	351	11.8	0.29	14.2	0.34	237	7.6	0.23	8.9	0.26
Anus, anal canal, & anorectum	33	1.1	0.09	1.4	0.11	74	2.2	0.12	2.7	0.14
Liver	312	9.8	0.26	12.2	0.31	101	3.0	0.14	3.6	0.16
Gallbladder	18	0.7	0.07	0.8	0.09	40	1.2	0.09	1.4	0.10
Pancreas	377	13.1	0.31	15.6	0.37	327	10.0	0.25	11.7	0.29
Respiratory System	1,300	46.1	0.59	54.4	0.69	1,298	39.7	0.50	46.8	0.59
Larynx	107	3.5	0.16	4.3	0.19	28	0.8	0.07	1.0	0.09
Lung & bronchus	1,160	41.5	0.57	48.8	0.66	1,247	38.2	0.49	44.9	0.57
Bones & Joints	36	1.2	0.09	1.3	0.10	29	1.0	0.08	1.0	0.09
Soft Tissue (incl. heart)	111	3.9	0.17	4.4	0.19	81	2.7	0.14	2.9	0.15
Skin (excl. basal & sq.)	836	29.5	0.47	34.5	0.54	596	19.2	0.36	21.8	0.40
Melanoma of the skin	782	27.4	0.45	32.1	0.52	561	18.1	0.35	20.6	0.39
Breast (excl. <i>in situ</i>)	27	0.9	0.08	1.1	0.10	4,150	130.5	0.93	153.0	1.07
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,432	43.9	0.53	52.1	0.62
Cervix uteri	N/A	N/A	N/A	N/A	N/A	176	6.2	0.21	6.6	0.22
Uterus corpus	N/A	N/A	N/A	N/A	N/A	763	22.5	0.37	27.5	0.45
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	13	0.4	0.05	0.5	0.06
Ovary	N/A	N/A	N/A	N/A	N/A	312	9.8	0.26	11.5	0.29
Male Genital System	3,116	99.6	0.83	121.2	0.99	N/A	N/A	N/A	N/A	N/A
Prostate	2,928	93.2	0.80	114.6	0.96	N/A	N/A	N/A	N/A	N/A
Testis	165	5.6	0.20	5.6	0.20	N/A	N/A	N/A	N/A	N/A
Penis	17	0.6	0.07	0.7	0.08	N/A	N/A	N/A	N/A	N/A
Urinary System	1,436	51.2	0.63	60.3	0.73	594	18.4	0.35	21.5	0.40
Bladder (incl. <i>in situ</i>)	835	30.8	0.50	36.1	0.57	250	7.6	0.22	9.0	0.26
Kidney & renal pelvis	567	19.1	0.37	22.6	0.43	327	10.3	0.26	11.9	0.30
Ureter	22	0.8	0.08	1.0	0.10	12	0.4	0.05	0.4	0.06
Eye & Orbit	31	1.1	0.09	1.2	0.10	31	1.0	0.08	1.1	0.09
Brain & Other CNS	213	7.3	0.23	8.1	0.25	165	5.5	0.20	5.9	0.21
Brain	201	6.9	0.22	7.7	0.25	155	5.1	0.19	5.6	0.20
Endocrine System	254	8.6	0.25	9.7	0.28	616	21.2	0.39	22.8	0.41
Thyroid gland	231	7.8	0.24	8.9	0.26	598	20.6	0.39	22.1	0.41
Lymphomas	667	23.6	0.42	27.0	0.48	504	16.0	0.33	18.3	0.37
Hodgkin lymphoma	84	2.8	0.14	3.0	0.15	58	2.0	0.12	2.1	0.12
Non-Hodgkin lymphoma	583	20.8	0.40	24.0	0.45	447	14.0	0.30	16.2	0.35
Multiple Myeloma	230	8.0	0.24	9.4	0.28	167	5.1	0.18	6.1	0.21
Leukemias	444	16.0	0.35	18.1	0.39	309	9.9	0.26	11.1	0.28
Acute lymphocytic	45	1.7	0.11	1.6	0.10	37	1.4	0.10	1.3	0.09
Chronic lymphocytic	158	5.5	0.20	6.6	0.24	95	2.8	0.13	3.4	0.16
Acute myeloid	131	4.8	0.19	5.4	0.22	108	3.4	0.15	3.9	0.17
Chronic myeloid	51	1.8	0.12	2.1	0.13	32	1.1	0.09	1.2	0.10
Other leukemias	58	2.2	0.13	2.5	0.15	38	1.2	0.09	1.4	0.10
Mesothelioma	34	1.3	0.11	1.5	0.12	11	0.3	0.05	0.4	0.05
Kaposi Sarcoma	11	0.4	0.05	0.4	0.06	*	*	*	*	*
Ill-Defined & Unknown	420	16.0	0.36	18.5	0.41	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	333	12.0	0.30	13.5	0.34	681	21.8	0.38	25.0	0.43
Breast (<i>in situ</i>)	3	0.1	0.02	0.1	0.03	872	27.5	0.43	32.5	0.50

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Colorado, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	9,838	418.0	1.96	493.2	2.27	9,962	395.8	1.85	459.5	2.09
Oral Cavity & Pharynx	435	17.7	0.39	21.4	0.47	158	6.1	0.22	7.2	0.26
Lip	29	1.2	0.11	1.5	0.12	13	0.5	0.07	0.6	0.08
Tongue	156	6.2	0.23	7.6	0.28	56	2.2	0.13	2.6	0.16
Major salivary gland	36	1.7	0.13	1.9	0.14	22	0.9	0.09	1.0	0.10
Floor of mouth	14	0.5	0.07	0.7	0.08	9	0.3	0.05	0.4	0.06
Gum & other mouth	36	1.6	0.12	1.9	0.14	26	1.0	0.09	1.2	0.10
Nasopharynx	9	0.4	0.06	0.5	0.07	4	0.2	0.04	0.2	0.04
Oropharynx	24	1.0	0.09	1.2	0.11	5	0.2	0.04	0.2	0.05
Hypopharynx	13	0.5	0.06	0.6	0.08	5	0.2	0.03	0.2	0.05
Digestive System	1,831	78.0	0.85	92.6	0.99	1,403	54.2	0.67	63.5	0.77
Esophagus	181	7.6	0.26	9.0	0.30	36	1.4	0.10	1.6	0.12
Stomach	147	6.3	0.24	7.4	0.28	65	2.5	0.15	2.9	0.17
Small intestine	67	2.9	0.16	3.4	0.19	55	2.1	0.13	2.5	0.15
Colon (excl. rectum)	527	23.4	0.47	27.4	0.54	538	21.1	0.42	24.5	0.48
Rectum & rectosigmoid	265	11.3	0.32	13.5	0.38	179	7.3	0.25	8.5	0.29
Anus, anal canal, & anorectum	29	1.2	0.10	1.5	0.13	66	2.4	0.14	3.0	0.17
Liver	195	7.5	0.25	9.4	0.30	58	2.1	0.13	2.6	0.15
Gallbladder	13	0.6	0.08	0.7	0.09	28	1.0	0.09	1.2	0.10
Pancreas	312	13.1	0.35	15.6	0.40	263	9.8	0.28	11.5	0.32
Respiratory System	1,084	46.4	0.65	54.8	0.76	1,096	40.9	0.57	48.3	0.66
Larynx	87	3.5	0.17	4.3	0.21	25	0.9	0.09	1.1	0.10
Lung & bronchus	971	41.8	0.62	49.2	0.72	1,052	39.2	0.55	46.2	0.64
Bones & Joints	28	1.3	0.11	1.4	0.12	23	1.1	0.10	1.1	0.11
Soft Tissue (incl. heart)	89	4.1	0.20	4.6	0.22	59	2.7	0.16	2.9	0.17
Skin (excl. basal & sq.)	809	35.5	0.58	41.4	0.66	551	23.3	0.46	26.3	0.51
Melanoma of the skin	762	33.3	0.56	38.9	0.64	522	22.1	0.45	24.9	0.50
Breast (excl. <i>in situ</i>)	24	1.0	0.10	1.2	0.11	3,387	135.4	1.09	158.4	1.24
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,134	43.8	0.61	52.0	0.70
Cervix uteri	N/A	N/A	N/A	N/A	N/A	119	5.7	0.24	6.0	0.25
Uterus corpus	N/A	N/A	N/A	N/A	N/A	614	22.5	0.42	27.6	0.51
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	10	0.4	0.05	0.4	0.06
Ovary	N/A	N/A	N/A	N/A	N/A	254	10.2	0.30	11.9	0.34
Male Genital System	2,484	97.6	0.91	118.4	1.08	N/A	N/A	N/A	N/A	N/A
Prostate	2,349	90.9	0.87	111.7	1.05	N/A	N/A	N/A	N/A	N/A
Testis	119	6.0	0.25	6.0	0.25	N/A	N/A	N/A	N/A	N/A
Penis	11	0.5	0.07	0.6	0.08	N/A	N/A	N/A	N/A	N/A
Urinary System	1,174	51.6	0.70	60.5	0.81	456	17.4	0.38	20.4	0.43
Bladder (incl. <i>in situ</i>)	718	32.1	0.55	37.6	0.64	212	7.8	0.25	9.2	0.29
Kidney & renal pelvis	425	18.0	0.41	21.2	0.47	232	9.1	0.28	10.6	0.32
Ureter	20	0.9	0.09	1.1	0.11	10	0.4	0.05	0.4	0.06
Eye & Orbit	27	1.2	0.11	1.3	0.12	26	1.1	0.10	1.3	0.11
Brain & Other CNS	173	7.8	0.28	8.7	0.30	135	6.0	0.24	6.5	0.25
Brain	164	7.3	0.27	8.2	0.29	128	5.6	0.23	6.1	0.24
Endocrine System	206	9.3	0.30	10.4	0.33	446	21.0	0.46	22.5	0.48
Thyroid gland	189	8.5	0.29	9.6	0.32	433	20.5	0.46	21.9	0.48
Lymphomas	545	24.5	0.49	27.9	0.54	403	16.3	0.38	18.6	0.42
Hodgkin lymphoma	61	2.9	0.17	3.1	0.18	42	2.1	0.15	2.2	0.15
Non-Hodgkin lymphoma	484	21.5	0.45	24.8	0.51	361	14.2	0.35	16.4	0.39
Multiple Myeloma	183	7.8	0.27	9.2	0.31	127	4.8	0.20	5.7	0.23
Leukemias	369	16.7	0.40	19.0	0.45	251	10.1	0.30	11.4	0.33
Acute lymphocytic	27	1.5	0.13	1.4	0.12	21	1.2	0.13	1.1	0.11
Chronic lymphocytic	142	6.0	0.23	7.2	0.27	82	3.0	0.15	3.6	0.18
Acute myeloid	108	4.9	0.22	5.6	0.25	90	3.6	0.18	4.1	0.20
Chronic myeloid	43	2.0	0.14	2.2	0.15	25	1.1	0.10	1.2	0.11
Other leukemias	49	2.3	0.15	2.7	0.17	32	1.2	0.10	1.4	0.11
Mesothelioma	27	1.3	0.11	1.5	0.13	10	0.4	0.06	0.4	0.06
Kaposi Sarcoma	5	0.3	0.05	0.3	0.05	*	*	*	*	*
Ill-Defined & Unknown	346	16.0	0.40	18.5	0.45	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	268	12.4	0.35	13.9	0.39	541	21.9	0.44	25.1	0.49
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.03	704	28.7	0.51	33.7	0.58

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Colorado, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	446	436.9	10.25	525.1	11.98	372	352.4	8.40	415.3	9.77
Oral Cavity & Pharynx	17	15.8	1.92	19.0	2.28	4	3.5	0.77	4.3	0.95
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	5	5.3	1.13	6.3	1.32	1	1.2	0.46	1.5	0.58
Major salivary gland	*	*	*	*	*	1	0.9	0.37	1.0	0.42
Floor of mouth	1	1.0	0.40	1.4	0.54	*	*	*	*	*
Gum & other mouth	2	2.3	0.76	2.8	0.93	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	1	1.1	0.47	1.3	0.58	*	*	*	*	*
Digestive System	92	93.6	4.80	111.8	5.61	71	68.6	3.75	81.9	4.40
Esophagus	4	3.5	0.90	4.1	1.03	2	2.4	0.73	2.7	0.84
Stomach	10	11.4	1.79	13.4	2.06	5	4.2	0.89	5.1	1.08
Small intestine	4	3.6	0.82	4.3	0.98	3	2.5	0.69	3.2	0.86
Colon (excl. rectum)	28	30.6	2.86	35.6	3.29	25	25.2	2.29	29.5	2.65
Rectum & rectosigmoid	12	10.6	1.51	12.8	1.79	10	9.5	1.34	11.3	1.58
Anus, anal canal, & anorectum	1	1.0	0.38	1.3	0.50	2	1.5	0.53	2.0	0.68
Liver	16	14.2	1.74	18.2	2.16	5	5.4	1.08	6.3	1.22
Gallbladder	*	*	*	*	*	2	1.9	0.66	2.1	0.75
Pancreas	13	13.6	1.82	16.3	2.11	11	10.5	1.45	13.0	1.76
Respiratory System	48	52.8	3.78	63.1	4.36	37	36.8	2.78	43.6	3.22
Larynx	3	3.1	0.82	3.9	0.98	*	*	*	*	*
Lung & bronchus	43	48.5	3.65	57.6	4.21	36	35.9	2.75	42.6	3.19
Bones & Joints	1	1.2	0.50	1.3	0.54	*	*	*	*	*
Soft Tissue (incl. heart)	4	3.8	0.90	4.1	1.01	4	3.2	0.75	3.5	0.82
Skin (excl. basal & sq.)	2	1.6	0.52	1.7	0.57	1	1.5	0.57	1.6	0.63
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	126	119.5	4.88	140.6	5.67
Female Genital System	N/A	N/A	N/A	N/A	N/A	45	40.8	2.81	49.6	3.36
Cervix uteri	N/A	N/A	N/A	N/A	N/A	7	6.4	1.11	7.1	1.23
Uterus corpus	N/A	N/A	N/A	N/A	N/A	23	20.5	1.95	25.8	2.41
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	1.8	0.58	2.3	0.73
Ovary	N/A	N/A	N/A	N/A	N/A	6	6.2	1.12	7.2	1.30
Male Genital System	153	140.1	5.57	174.9	6.68	N/A	N/A	N/A	N/A	N/A
Prostate	151	139.0	5.56	173.7	6.67	N/A	N/A	N/A	N/A	N/A
Testis	1	0.9	0.36	0.9	0.34	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	47	49.5	3.59	59.2	4.17	19	18.9	1.99	21.5	2.24
Bladder (incl. <i>in situ</i>)	19	22.5	2.60	26.4	2.98	5	5.8	1.14	6.6	1.28
Kidney & renal pelvis	28	25.6	2.38	31.2	2.83	13	12.7	1.60	14.5	1.81
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	7	6.2	1.15	6.7	1.28	4	3.3	0.77	3.2	0.77
Brain	6	5.9	1.14	6.4	1.26	4	3.3	0.77	3.2	0.77
Endocrine System	6	5.7	1.10	6.6	1.27	14	12.4	1.52	13.5	1.66
Thyroid gland	5	4.5	1.00	5.2	1.16	13	11.5	1.47	12.5	1.58
Lymphomas	21	17.2	1.82	20.0	2.09	14	13.3	1.62	15.6	1.88
Hodgkin lymphoma	3	2.3	0.60	2.2	0.59	2	1.8	0.55	1.9	0.60
Non-Hodgkin lymphoma	17	14.9	1.72	17.7	2.01	12	11.5	1.53	13.6	1.78
Multiple Myeloma	14	14.8	1.91	17.4	2.22	13	11.6	1.50	14.3	1.82
Leukemias	13	12.4	1.75	13.8	1.94	9	8.3	1.27	9.1	1.40
Acute lymphocytic	1	0.9	0.36	0.8	0.36	2	1.6	0.51	1.5	0.48
Chronic lymphocytic	4	4.5	1.20	5.2	1.35	1	1.2	0.50	1.4	0.59
Acute myeloid	5	4.6	1.03	4.9	1.11	3	3.2	0.79	3.7	0.92
Chronic myeloid	1	1.1	0.43	1.3	0.50	*	*	*	*	*
Other leukemias	2	1.3	0.51	1.6	0.58	N/A	N/A	N/A	N/A	N/A
Mesothelioma	1	1.2	0.56	1.5	0.64	*	*	*	*	*
Kaposi Sarcoma	1	1.3	0.50	1.3	0.51	*	*	*	*	*
Ill-Defined & Unknown	17	19.0	2.35	22.0	2.68	10	9.6	1.40	11.7	1.68
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	10	9.5	1.49	10.6	1.68	25	25.2	2.30	29.0	2.61
Breast (<i>in situ</i>)	*	*	*	*	*	27	24.9	2.18	30.5	2.62

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Colorado, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	184	259.4	9.02	306.3	10.56	279	271.2	7.44	314.4	8.62
Oral Cavity & Pharynx	8	9.7	1.59	11.2	1.84	6	5.8	1.08	6.8	1.27
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	1	1.9	0.74	2.1	0.83	1	1.4	0.53	1.6	0.61
Major salivary gland	*	*	*	*	*	1	1.2	0.51	1.4	0.58
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	1	1.4	0.54	1.6	0.60
Nasopharynx	3	3.8	1.00	4.1	1.09	1	1.2	0.45	1.6	0.60
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	60	81.9	4.99	98.8	5.95	50	50.6	3.31	60.6	3.92
Esophagus	2	3.5	1.05	4.3	1.27	1	1.6	0.62	1.9	0.72
Stomach	8	12.2	1.97	14.5	2.29	8	8.2	1.33	10.0	1.59
Small intestine	*	*	*	*	*	1	1.1	0.47	1.3	0.55
Colon (excl. rectum)	16	21.2	2.53	25.7	3.04	13	12.7	1.63	15.0	1.92
Rectum & rectosigmoid	10	13.0	1.88	15.9	2.30	7	7.2	1.21	8.8	1.47
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	12	16.0	2.17	19.3	2.58	6	6.5	1.20	8.1	1.46
Gallbladder	*	*	*	*	*	2	1.7	0.63	1.9	0.69
Pancreas	5	7.3	1.55	9.0	1.87	6	6.5	1.21	7.8	1.43
Respiratory System	24	37.9	3.61	44.8	4.21	28	31.8	2.75	36.6	3.12
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	24	36.5	3.55	43.3	4.15	28	31.6	2.74	36.3	3.11
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	2	2.6	0.87	3.1	1.07	3	2.8	0.80	3.1	0.90
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	1	1.7	0.73	2.1	0.85	2	2.0	0.58	2.4	0.71
Breast (excl. <i>in situ</i>)	*	*	*	*	*	97	89.3	4.12	104.1	4.82
Female Genital System	N/A	N/A	N/A	N/A	N/A	32	30.0	2.42	35.6	2.87
Cervix uteri	N/A	N/A	N/A	N/A	N/A	7	6.3	1.08	6.9	1.20
Uterus corpus	N/A	N/A	N/A	N/A	N/A	16	14.7	1.68	18.3	2.08
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	7	7.2	1.22	8.3	1.40
Male Genital System	35	51.3	4.05	61.9	4.80	N/A	N/A	N/A	N/A	N/A
Prostate	33	48.2	3.94	58.5	4.69	N/A	N/A	N/A	N/A	N/A
Testis	2	2.2	0.79	2.4	0.86	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	13	18.7	2.49	22.2	2.93	8	8.7	1.40	10.2	1.62
Bladder (incl. <i>in situ</i>)	6	9.8	1.90	11.6	2.23	3	3.4	0.92	3.9	1.04
Kidney & renal pelvis	7	8.6	1.58	10.2	1.86	5	4.8	1.01	5.6	1.17
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	1	1.5	0.65	1.6	0.68	*	*	*	*	*
Brain & Other CNS	4	4.8	1.15	4.7	1.14	4	3.5	0.84	3.5	0.86
Brain	4	4.6	1.13	4.5	1.13	3	3.0	0.77	3.1	0.82
Endocrine System	6	5.9	1.15	6.7	1.31	25	22.1	1.99	24.0	2.20
Thyroid gland	4	4.6	1.01	5.2	1.16	24	21.2	1.95	23.1	2.15
Lymphomas	15	19.8	2.48	22.5	2.83	9	9.0	1.37	10.3	1.56
Hodgkin lymphoma	2	2.5	0.77	2.6	0.82	1	1.0	0.42	0.9	0.37
Non-Hodgkin lymphoma	12	17.3	2.35	19.9	2.71	8	8.0	1.31	9.4	1.52
Multiple Myeloma	2	2.7	0.91	3.1	1.04	3	3.1	0.79	3.7	0.93
Leukemias	6	9.4	1.75	10.0	1.89	4	3.6	0.80	4.0	0.91
Acute lymphocytic	2	1.6	0.58	1.4	0.52	*	*	*	*	*
Chronic lymphocytic	1	1.9	0.79	2.0	0.86	*	*	*	*	*
Acute myeloid	2	3.7	1.13	4.2	1.26	2	2.1	0.61	2.5	0.73
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	5	8.0	1.70	9.6	2.01	7	7.4	1.31	8.2	1.45
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	9	11.7	1.86	13.5	2.13	19	18.8	1.97	21.8	2.28
Breast (<i>in situ</i>)	*	*	*	*	*	28	25.5	2.20	30.8	2.65

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Colorado, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	4	179.2	41.38	217.7	49.30	4	141.7	33.53	167.8	39.13
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	2	58.9	23.21	76.6	29.55	N/A	N/A	N/A	N/A	N/A
Prostate	1	49.7	22.26	67.4	28.82	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Colorado, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,305	358.2	4.83	425.0	5.66	1,557	360.6	4.24	423.1	4.97
Oral Cavity & Pharynx	39	10.3	0.79	12.2	0.92	16	3.9	0.45	4.6	0.53
Lip	2	0.6	0.21	0.6	0.23	*	*	*	*	*
Tongue	12	3.2	0.43	3.7	0.49	4	1.0	0.22	1.2	0.27
Major salivary gland	3	0.8	0.22	0.8	0.24	3	0.7	0.18	0.8	0.21
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	3	0.9	0.25	1.1	0.30	4	1.1	0.26	1.2	0.29
Nasopharynx	3	0.7	0.20	0.7	0.22	*	*	*	*	*
Oropharynx	2	0.4	0.15	0.5	0.18	*	*	*	*	*
Hypopharynx	4	1.1	0.27	1.3	0.32	*	*	*	*	*
Digestive System	385	106.2	2.62	128.0	3.10	277	69.3	1.93	82.2	2.27
Esophagus	21	5.5	0.59	6.9	0.71	5	1.2	0.26	1.5	0.31
Stomach	40	12.1	0.92	14.2	1.07	30	7.4	0.63	8.5	0.73
Small intestine	9	2.6	0.41	3.0	0.47	10	2.4	0.36	2.9	0.42
Colon (excl. rectum)	101	28.8	1.39	34.3	1.64	89	22.3	1.10	26.6	1.30
Rectum & rectosigmoid	58	13.8	0.86	17.0	1.04	35	8.1	0.64	9.6	0.75
Anus, anal canal, & anorectum	3	0.7	0.21	0.8	0.24	5	1.2	0.25	1.5	0.31
Liver	83	21.7	1.15	27.2	1.40	28	7.2	0.62	8.7	0.74
Gallbladder	4	1.3	0.32	1.6	0.39	9	2.1	0.33	2.6	0.39
Pancreas	43	12.9	0.94	15.0	1.08	43	11.2	0.79	13.2	0.91
Respiratory System	130	42.2	1.77	49.2	2.03	122	33.3	1.39	38.9	1.60
Larynx	14	3.9	0.50	4.7	0.59	3	0.6	0.17	0.8	0.21
Lung & bronchus	111	37.1	1.68	43.2	1.92	117	32.1	1.37	37.5	1.57
Bones & Joints	5	1.1	0.23	1.2	0.25	5	0.8	0.17	0.9	0.20
Soft Tissue (incl. heart)	14	3.1	0.42	3.6	0.50	15	3.1	0.37	3.5	0.43
Skin (excl. basal & sq.)	18	4.9	0.57	5.7	0.65	35	7.7	0.60	8.9	0.70
Melanoma of the skin	15	4.0	0.51	4.7	0.59	32	6.9	0.56	7.9	0.65
Breast (excl. <i>in situ</i>)	2	0.5	0.17	0.5	0.19	481	108.5	2.28	128.9	2.70
Female Genital System	N/A	N/A	N/A	N/A	N/A	196	42.4	1.39	50.4	1.66
Cervix uteri	N/A	N/A	N/A	N/A	N/A	38	7.7	0.57	8.4	0.64
Uterus corpus	N/A	N/A	N/A	N/A	N/A	97	20.8	0.97	25.5	1.18
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	1	0.3	0.12	0.3	0.13
Ovary	N/A	N/A	N/A	N/A	N/A	40	8.8	0.64	10.5	0.77
Male Genital System	287	77.3	2.22	93.8	2.63	N/A	N/A	N/A	N/A	N/A
Prostate	247	70.8	2.16	86.9	2.57	N/A	N/A	N/A	N/A	N/A
Testis	34	4.8	0.38	4.8	0.38	N/A	N/A	N/A	N/A	N/A
Penis	5	1.6	0.34	2.0	0.42	N/A	N/A	N/A	N/A	N/A
Urinary System	155	43.2	1.68	51.4	1.97	94	22.2	1.07	26.4	1.26
Bladder (incl. <i>in situ</i>)	53	17.5	1.15	20.5	1.32	19	5.3	0.56	6.3	0.65
Kidney & renal pelvis	100	25.3	1.21	30.3	1.44	72	16.3	0.89	19.4	1.06
Ureter	*	*	*	*	*	2	0.4	0.16	0.5	0.18
Eye & Orbit	2	0.6	0.18	0.6	0.22	3	0.5	0.13	0.4	0.14
Brain & Other CNS	27	5.8	0.56	6.4	0.63	21	4.5	0.47	5.0	0.53
Brain	25	5.3	0.54	5.8	0.61	19	4.1	0.45	4.6	0.52
Endocrine System	32	6.6	0.56	7.4	0.64	119	23.2	0.97	25.5	1.09
Thyroid gland	29	5.9	0.52	6.7	0.60	117	22.7	0.96	25.0	1.08
Lymphomas	77	19.9	1.13	23.0	1.30	67	15.6	0.89	18.1	1.04
Hodgkin lymphoma	15	2.9	0.38	3.2	0.43	11	1.9	0.28	2.1	0.30
Non-Hodgkin lymphoma	62	17.0	1.06	19.8	1.23	57	13.6	0.84	16.1	0.99
Multiple Myeloma	28	8.1	0.73	9.5	0.85	21	5.3	0.53	6.3	0.62
Leukemias	49	11.2	0.80	12.6	0.93	40	8.5	0.64	9.3	0.72
Acute lymphocytic	15	2.1	0.25	2.0	0.25	12	2.0	0.27	1.9	0.27
Chronic lymphocytic	9	2.4	0.40	3.0	0.49	9	2.3	0.35	2.7	0.41
Acute myeloid	14	3.6	0.48	4.0	0.54	11	2.4	0.34	2.7	0.39
Chronic myeloid	6	1.3	0.27	1.6	0.32	5	1.0	0.23	1.1	0.25
Other leukemias	6	1.7	0.34	2.0	0.41	3	0.8	0.21	1.0	0.25
Mesothelioma	4	1.6	0.38	1.9	0.43	1	0.3	0.13	0.4	0.16
Kaposi Sarcoma	3	0.7	0.18	0.7	0.19	*	*	*	*	*
Ill-Defined & Unknown	47	15.0	1.07	17.4	1.23	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	42	10.4	0.80	11.5	0.90	85	19.8	1.00	22.7	1.15
Breast (<i>in situ</i>)	*	*	*	*	*	98	21.9	1.01	26.4	1.22

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

COLORADO

II-88 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Colorado, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,238	366.1	5.03	434.5	5.89	1,468	367.8	4.43	431.4	5.20
Oral Cavity & Pharynx	37	10.5	0.82	12.3	0.96	15	4.0	0.48	4.8	0.56
Lip	1	0.5	0.20	0.5	0.22	*	*	*	*	*
Tongue	12	3.4	0.46	4.0	0.53	4	1.0	0.23	1.2	0.28
Major salivary gland	3	0.8	0.23	0.8	0.25	3	0.7	0.19	0.8	0.22
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	3	1.0	0.26	1.2	0.32	4	1.1	0.27	1.2	0.30
Nasopharynx	2	0.6	0.20	0.7	0.23	*	*	*	*	*
Oropharynx	1	0.4	0.16	0.5	0.18	*	*	*	*	*
Hypopharynx	3	1.0	0.27	1.2	0.32	*	*	*	*	*
Digestive System	365	108.6	2.73	130.8	3.23	259	69.5	1.99	82.5	2.35
Esophagus	20	5.8	0.62	7.2	0.75	5	1.3	0.27	1.6	0.33
Stomach	39	12.6	0.97	14.8	1.12	28	7.3	0.64	8.5	0.75
Small intestine	9	2.7	0.43	3.1	0.50	10	2.6	0.38	3.1	0.45
Colon (excl. rectum)	95	29.0	1.44	34.6	1.70	82	22.1	1.13	26.4	1.34
Rectum & rectosigmoid	55	14.2	0.90	17.5	1.10	32	8.2	0.67	9.7	0.78
Anus, anal canal, & anorectum	3	0.8	0.23	0.9	0.26	5	1.3	0.27	1.6	0.32
Liver	77	21.9	1.20	27.5	1.46	25	6.9	0.63	8.4	0.75
Gallbladder	3	1.3	0.33	1.6	0.40	8	2.0	0.33	2.5	0.40
Pancreas	41	13.4	0.99	15.6	1.14	41	11.5	0.82	13.5	0.96
Respiratory System	123	42.6	1.83	49.8	2.10	116	33.7	1.44	39.5	1.66
Larynx	13	4.0	0.53	4.9	0.62	2	0.6	0.18	0.8	0.22
Lung & bronchus	105	37.4	1.73	43.5	1.99	111	32.5	1.42	38.1	1.63
Bones & Joints	5	1.1	0.24	1.3	0.27	5	0.8	0.18	1.0	0.21
Soft Tissue (incl. heart)	13	3.3	0.45	3.8	0.53	13	3.1	0.39	3.5	0.45
Skin (excl. basal & sq.)	17	5.2	0.60	6.0	0.69	34	8.1	0.64	9.4	0.74
Melanoma of the skin	14	4.2	0.54	4.9	0.63	31	7.3	0.60	8.4	0.70
Breast (excl. <i>in situ</i>)	2	0.5	0.19	0.6	0.21	456	111.8	2.40	132.5	2.84
Female Genital System	N/A	N/A	N/A	N/A	N/A	183	43.2	1.46	51.4	1.75
Cervix uteri	N/A	N/A	N/A	N/A	N/A	36	7.9	0.60	8.7	0.67
Uterus corpus	N/A	N/A	N/A	N/A	N/A	91	21.3	1.02	26.0	1.25
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	37	8.8	0.67	10.6	0.80
Male Genital System	273	79.3	2.31	96.3	2.75	N/A	N/A	N/A	N/A	N/A
Prostate	236	72.6	2.25	89.2	2.69	N/A	N/A	N/A	N/A	N/A
Testis	32	5.0	0.40	4.9	0.40	N/A	N/A	N/A	N/A	N/A
Penis	5	1.6	0.35	2.0	0.43	N/A	N/A	N/A	N/A	N/A
Urinary System	147	44.1	1.75	52.5	2.05	89	22.7	1.11	27.1	1.32
Bladder (incl. <i>in situ</i>)	51	17.7	1.18	20.9	1.37	19	5.4	0.58	6.5	0.68
Kidney & renal pelvis	95	25.9	1.27	31.1	1.51	68	16.7	0.93	19.8	1.11
Ureter	*	*	*	*	*	2	0.5	0.17	0.5	0.20
Eye & Orbit	2	0.6	0.19	0.7	0.23	3	0.5	0.15	0.5	0.15
Brain & Other CNS	26	6.1	0.59	6.6	0.67	20	4.8	0.50	5.3	0.57
Brain	24	5.6	0.57	6.1	0.64	18	4.4	0.48	4.9	0.55
Endocrine System	31	6.9	0.60	7.9	0.69	112	23.8	1.03	26.1	1.15
Thyroid gland	28	6.2	0.56	7.1	0.64	109	23.3	1.02	25.6	1.14
Lymphomas	74	20.5	1.17	23.7	1.36	65	16.3	0.94	19.0	1.10
Hodgkin lymphoma	14	3.0	0.40	3.4	0.45	10	2.1	0.30	2.2	0.33
Non-Hodgkin lymphoma	60	17.5	1.10	20.3	1.28	55	14.2	0.89	16.7	1.04
Multiple Myeloma	27	8.2	0.76	9.7	0.88	19	5.1	0.54	6.0	0.63
Leukemias	46	11.4	0.83	12.8	0.96	38	8.7	0.67	9.6	0.75
Acute lymphocytic	14	2.2	0.28	2.1	0.28	11	2.0	0.28	1.9	0.28
Chronic lymphocytic	8	2.5	0.42	3.1	0.51	8	2.3	0.36	2.7	0.43
Acute myeloid	14	3.8	0.51	4.3	0.58	11	2.4	0.35	2.8	0.40
Chronic myeloid	5	1.4	0.29	1.6	0.34	4	1.1	0.24	1.2	0.26
Other leukemias	5	1.4	0.32	1.7	0.39	3	0.9	0.22	1.0	0.27
Mesothelioma	4	1.6	0.38	1.9	0.45	*	*	*	*	*
Kaposi Sarcoma	3	0.7	0.19	0.7	0.21	*	*	*	*	*
Ill-Defined & Unknown	44	14.8	1.08	17.2	1.25	40	11.2	0.82	12.9	0.95
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	40	10.8	0.84	11.9	0.95	79	20.1	1.05	22.9	1.20
Breast (<i>in situ</i>)	*	*	*	*	*	94	22.8	1.07	27.5	1.29

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Colorado, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	5	76.9	19.35	97.7	24.49	11	151.0	24.58	180.4	28.97
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	2	34.5	12.16	39.4	13.47
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	4	47.9	13.32	60.3	16.70
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	1	29.1	12.98	36.3	16.24	N/A	N/A	N/A	N/A	N/A
Prostate	1	27.5	12.88	35.0	16.18	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


COLORADO

II-90 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	3,588,561	3,579,830	3,575,324	3,574,561	3,566,022
Non-Hispanic White	2,485,426	2,458,722	2,433,256	2,408,166	2,381,710
Non-Hispanic Black	377,327	380,289	383,833	387,641	392,360
Non-Hispanic Asian/Pacific Islander (NH API)	169,159	172,442	175,491	178,693	181,106
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	9,718	9,690	9,694	9,733	9,765


All Races Population 2015–2019: 17,884,298
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	546,931	558,687	573,050	590,328	601,081
Hispanic White	459,102	468,581	479,012	492,096	499,337
Hispanic Black	66,924	68,579	71,310	74,266	76,893

Hispanic/Latino Population, Census 2010: 479,087
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

CONNECTICUT CANCER REGISTRY

Initial Operation: 1935
 Population-based Data Available: 1935
 Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	119.5	118.8	119.4	118.1	120.8	119.3
Missing Race	0.5	0.5	0.3	0.5	1.0	0.6
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.4	0.6	0.6	1.0	1.0	0.7
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	95.5	Ovary	96.5
Oral Cavity & Pharynx	99.3	Prostate	97.9
Esophagus	97.2	Testis	99.6
Stomach	98.3	Bladder (incl. <i>in situ</i>)	99.0
Colon & Rectum	97.4	Kidney & Renal Pelvis	94.9
Liver	68.9	Brain & Other CNS	90.4
Pancreas	90.9	Brain & Other CNS (non-malig)	51.1
Lung & Bronchus	92.6	Thyroid	99.8
Melanomas of the Skin	99.7	Hodgkin Lymphoma	99.0
Female Breast (excl. <i>in situ</i>)	99.3	Non-Hodgkin Lymphoma	96.8
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	92.7
Cervix Uteri	98.7	Leukemias	85.0
Uterus Corpus & Uterus NOS	99.3		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Connecticut, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	10,808	511.1	2.26	606.2	2.63	10,814	446.2	2.00	519.6	2.27
Oral Cavity & Pharynx	400	18.2	0.42	22.2	0.50	188	7.6	0.26	9.0	0.30
Lip	10	0.5	0.07	0.6	0.08	5	0.2	0.04	0.2	0.04
Tongue	131	5.8	0.24	7.2	0.28	67	2.8	0.16	3.2	0.18
Major salivary gland	33	1.7	0.13	1.9	0.15	24	1.1	0.10	1.2	0.11
Floor of mouth	17	0.8	0.09	0.9	0.10	8	0.3	0.05	0.4	0.06
Gum & other mouth	47	2.2	0.15	2.6	0.17	40	1.5	0.11	1.8	0.13
Nasopharynx	14	0.7	0.09	0.8	0.10	7	0.3	0.06	0.4	0.06
Oropharynx	22	1.0	0.10	1.2	0.12	8	0.3	0.05	0.4	0.06
Hypopharynx	24	1.1	0.10	1.3	0.12	6	0.2	0.04	0.3	0.05
Digestive System	2,003	95.4	0.98	113.3	1.14	1,605	62.8	0.73	73.9	0.84
Esophagus	171	7.9	0.28	9.5	0.33	53	2.0	0.13	2.4	0.15
Stomach	212	10.2	0.32	12.0	0.37	122	4.9	0.21	5.7	0.23
Small intestine	55	2.7	0.17	3.1	0.19	59	2.4	0.15	2.8	0.17
Colon (excl. rectum)	553	26.9	0.53	31.6	0.61	559	21.9	0.43	25.6	0.49
Rectum & rectosigmoid	265	12.9	0.36	15.2	0.42	201	8.2	0.27	9.8	0.32
Anus, anal canal, & anorectum	30	1.4	0.12	1.7	0.14	63	2.5	0.14	3.1	0.17
Liver	242	10.7	0.32	13.3	0.38	66	2.5	0.14	3.0	0.17
Gallbladder	13	0.7	0.08	0.8	0.10	32	1.3	0.10	1.5	0.12
Pancreas	333	15.8	0.40	18.7	0.46	324	12.1	0.31	14.3	0.36
Respiratory System	1,446	68.5	0.82	81.3	0.96	1,468	56.4	0.67	66.9	0.79
Larynx	117	5.3	0.23	6.5	0.27	35	1.4	0.11	1.7	0.13
Lung & bronchus	1,305	62.0	0.78	73.4	0.92	1,419	54.5	0.66	64.5	0.77
Bones & Joints	22	1.2	0.12	1.2	0.12	19	0.9	0.10	1.0	0.10
Soft Tissue (incl. heart)	79	4.1	0.21	4.5	0.23	62	2.7	0.16	3.1	0.18
Skin (excl. basal & sq.)	567	27.6	0.53	32.3	0.61	400	16.8	0.39	19.3	0.44
Melanoma of the skin	521	25.3	0.51	29.6	0.58	370	15.6	0.38	17.9	0.42
Breast (excl. <i>in situ</i>)	33	1.6	0.13	1.9	0.15	3,326	141.2	1.14	165.2	1.30
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,257	51.4	0.68	61.1	0.78
Cervix uteri	N/A	N/A	N/A	N/A	N/A	110	5.6	0.25	6.0	0.26
Uterus corpus	N/A	N/A	N/A	N/A	N/A	739	29.2	0.50	35.6	0.59
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	24	0.9	0.09	1.1	0.10
Ovary	N/A	N/A	N/A	N/A	N/A	243	10.1	0.30	11.8	0.34
Male Genital System	2,939	130.7	1.10	159.8	1.33	N/A	N/A	N/A	N/A	N/A
Prostate	2,808	123.2	1.06	152.0	1.29	N/A	N/A	N/A	N/A	N/A
Testis	105	6.3	0.28	6.3	0.28	N/A	N/A	N/A	N/A	N/A
Penis	20	1.0	0.10	1.2	0.12	N/A	N/A	N/A	N/A	N/A
Urinary System	1,365	66.1	0.82	77.8	0.95	568	22.5	0.44	26.2	0.50
Bladder (incl. <i>in situ</i>)	849	41.6	0.65	48.7	0.75	285	10.7	0.29	12.6	0.34
Kidney & renal pelvis	478	22.5	0.48	26.9	0.55	263	11.0	0.32	12.7	0.35
Ureter	19	1.0	0.10	1.1	0.12	11	0.4	0.06	0.5	0.07
Eye & Orbit	19	0.9	0.10	1.0	0.11	19	0.8	0.09	0.9	0.10
Brain & Other CNS	163	8.3	0.30	9.3	0.33	137	6.3	0.25	6.9	0.27
Brain	156	7.9	0.29	8.8	0.32	129	5.8	0.24	6.4	0.26
Endocrine System	195	10.0	0.33	11.2	0.36	493	25.4	0.53	27.3	0.56
Thyroid gland	177	9.1	0.32	10.3	0.35	478	24.6	0.53	26.5	0.55
Lymphomas	596	29.7	0.56	34.1	0.63	490	20.4	0.43	23.4	0.48
Hodgkin lymphoma	68	3.8	0.21	3.9	0.21	51	2.8	0.18	2.8	0.18
Non-Hodgkin lymphoma	528	25.9	0.52	30.2	0.59	439	17.7	0.39	20.6	0.45
Multiple Myeloma	196	9.4	0.31	11.1	0.36	151	6.0	0.22	7.1	0.26
Leukemias	368	18.4	0.44	21.0	0.49	283	11.6	0.32	13.2	0.36
Acute lymphocytic	30	1.8	0.15	1.7	0.14	23	1.3	0.13	1.2	0.12
Chronic lymphocytic	153	7.3	0.27	8.7	0.32	110	4.1	0.18	4.9	0.21
Acute myeloid	100	5.1	0.23	5.7	0.26	86	3.6	0.18	4.0	0.20
Chronic myeloid	45	2.3	0.16	2.7	0.18	40	1.7	0.12	1.9	0.14
Other leukemias	40	2.0	0.15	2.2	0.16	25	1.0	0.09	1.1	0.10
Mesothelioma	34	1.7	0.13	1.9	0.15	8	0.3	0.05	0.4	0.06
Kaposi Sarcoma	9	0.5	0.08	0.6	0.08	2	0.1	0.02	0.1	0.03
Ill-Defined & Unknown	374	18.7	0.44	21.6	0.50	338	13.0	0.33	14.9	0.37
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	179	9.1	0.32	10.2	0.34	370	16.2	0.39	18.4	0.44
Breast (<i>in situ</i>)	6	0.3	0.06	0.4	0.06	948	42.5	0.64	49.5	0.73

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Connecticut, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	8,899	518.4	2.56	612.8	2.94	8,717	455.8	2.36	530.2	2.64
Oral Cavity & Pharynx	329	18.8	0.48	22.9	0.57	153	7.8	0.30	9.2	0.34
Lip	9	0.6	0.09	0.7	0.10	4	0.2	0.04	0.2	0.05
Tongue	115	6.4	0.28	7.9	0.34	55	2.9	0.19	3.4	0.22
Major salivary gland	26	1.6	0.14	1.8	0.16	18	1.0	0.12	1.1	0.13
Floor of mouth	15	0.8	0.10	1.0	0.12	7	0.4	0.06	0.4	0.07
Gum & other mouth	37	2.1	0.16	2.6	0.19	33	1.5	0.12	1.8	0.14
Nasopharynx	8	0.5	0.09	0.6	0.10	4	0.2	0.05	0.2	0.06
Oropharynx	16	0.9	0.11	1.1	0.13	7	0.3	0.06	0.4	0.07
Hypopharynx	18	1.0	0.11	1.2	0.13	5	0.2	0.05	0.3	0.06
Digestive System	1,580	92.6	1.08	109.6	1.25	1,245	59.4	0.80	70.0	0.92
Esophagus	153	8.7	0.33	10.4	0.38	42	2.0	0.14	2.3	0.16
Stomach	158	9.2	0.34	10.9	0.39	80	3.9	0.21	4.6	0.24
Small intestine	43	2.6	0.19	3.0	0.21	44	2.2	0.16	2.6	0.18
Colon (excl. rectum)	440	26.6	0.59	31.1	0.67	446	21.3	0.49	24.9	0.55
Rectum & rectosigmoid	205	12.6	0.41	14.8	0.47	155	8.0	0.31	9.6	0.36
Anus, anal canal, & anorectum	24	1.4	0.14	1.7	0.16	52	2.5	0.17	3.2	0.20
Liver	162	8.7	0.32	10.8	0.38	42	2.0	0.14	2.3	0.16
Gallbladder	10	0.6	0.09	0.7	0.10	22	1.0	0.10	1.2	0.12
Pancreas	280	16.0	0.44	19.0	0.51	262	11.8	0.34	13.9	0.40
Respiratory System	1,214	69.2	0.91	82.0	1.06	1,272	59.9	0.77	70.8	0.91
Larynx	91	5.1	0.25	6.2	0.29	29	1.5	0.13	1.8	0.15
Lung & bronchus	1,104	63.0	0.87	74.5	1.01	1,232	57.9	0.76	68.4	0.89
Bones & Joints	19	1.5	0.16	1.5	0.16	13	0.9	0.12	0.9	0.12
Soft Tissue (incl. heart)	61	4.0	0.24	4.5	0.26	47	2.7	0.19	3.0	0.20
Skin (excl. basal & sq.)	539	32.6	0.66	37.9	0.74	370	20.6	0.53	23.3	0.57
Melanoma of the skin	497	30.0	0.63	35.0	0.71	346	19.5	0.52	22.0	0.56
Breast (excl. <i>in situ</i>)	27	1.5	0.14	1.9	0.16	2,658	145.7	1.37	170.1	1.53
Female Genital System	N/A	N/A	N/A	N/A	N/A	983	50.9	0.78	60.6	0.89
Cervix uteri	N/A	N/A	N/A	N/A	N/A	71	5.3	0.31	5.5	0.30
Uterus corpus	N/A	N/A	N/A	N/A	N/A	579	28.7	0.56	35.1	0.67
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	17	0.8	0.10	1.0	0.11
Ovary	N/A	N/A	N/A	N/A	N/A	200	10.5	0.36	12.3	0.40
Male Genital System	2,335	127.8	1.22	155.5	1.45	N/A	N/A	N/A	N/A	N/A
Prostate	2,229	118.5	1.15	146.0	1.39	N/A	N/A	N/A	N/A	N/A
Testis	86	8.1	0.41	8.1	0.40	N/A	N/A	N/A	N/A	N/A
Penis	15	0.9	0.11	1.0	0.12	N/A	N/A	N/A	N/A	N/A
Urinary System	1,187	69.5	0.93	81.8	1.07	473	23.1	0.51	26.9	0.57
Bladder (incl. <i>in situ</i>)	770	45.1	0.74	52.7	0.86	253	11.6	0.34	13.6	0.39
Kidney & renal pelvis	384	22.5	0.54	26.8	0.62	204	10.7	0.36	12.4	0.40
Ureter	17	1.0	0.11	1.2	0.13	9	0.4	0.06	0.5	0.07
Eye & Orbit	16	1.0	0.12	1.2	0.13	18	1.0	0.12	1.2	0.13
Brain & Other CNS	133	9.0	0.37	9.9	0.39	111	6.8	0.32	7.4	0.33
Brain	128	8.6	0.36	9.5	0.38	105	6.3	0.30	6.9	0.32
Endocrine System	158	11.0	0.42	12.3	0.45	346	25.5	0.67	27.5	0.68
Thyroid gland	145	10.2	0.41	11.4	0.43	337	24.9	0.66	26.8	0.68
Lymphomas	490	30.7	0.65	35.2	0.72	392	20.6	0.50	23.6	0.56
Hodgkin lymphoma	45	3.7	0.26	3.8	0.26	34	2.8	0.23	2.9	0.23
Non-Hodgkin lymphoma	445	27.0	0.60	31.3	0.67	358	17.7	0.45	20.7	0.51
Multiple Myeloma	149	8.7	0.33	10.2	0.38	105	5.1	0.23	6.1	0.27
Leukemias	307	19.1	0.51	21.8	0.57	236	12.1	0.39	13.7	0.42
Acute lymphocytic	18	1.5	0.18	1.5	0.16	15	1.3	0.16	1.2	0.14
Chronic lymphocytic	140	8.1	0.32	9.6	0.37	100	4.5	0.21	5.4	0.25
Acute myeloid	82	5.1	0.26	5.8	0.29	68	3.5	0.21	4.0	0.23
Chronic myeloid	35	2.3	0.18	2.6	0.20	33	1.8	0.15	2.0	0.16
Other leukemias	33	2.1	0.17	2.3	0.19	20	1.0	0.11	1.1	0.12
Mesothelioma	32	1.9	0.15	2.2	0.17	8	0.4	0.07	0.4	0.07
Kaposi Sarcoma	6	0.5	0.09	0.5	0.10	2	0.1	0.02	0.1	0.02
Ill-Defined & Unknown	317	19.1	0.50	22.0	0.56	286	13.3	0.38	15.3	0.42
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	142	9.5	0.38	10.5	0.40	283	16.2	0.47	18.3	0.51
Breast (<i>in situ</i>)	4	0.3	0.07	0.3	0.07	732	43.6	0.78	50.7	0.86

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Connecticut, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	854	537.4	8.66	647.7	10.23	864	410.8	6.36	482.0	7.36
Oral Cavity & Pharynx	26	15.1	1.40	18.4	1.68	13	5.6	0.72	6.8	0.86
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	5	3.0	0.62	3.7	0.75	2	1.0	0.29	1.2	0.36
Major salivary gland	3	2.2	0.58	2.4	0.64	3	1.2	0.34	1.5	0.40
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	3	1.9	0.48	2.0	0.52	3	1.6	0.39	1.9	0.45
Nasopharynx	2	0.9	0.31	1.0	0.34	1	0.6	0.24	0.6	0.25
Oropharynx	3	1.6	0.45	2.1	0.58	*	*	*	*	*
Hypopharynx	2	1.5	0.47	1.8	0.57	*	*	*	*	*
Digestive System	173	109.7	3.94	132.1	4.65	165	78.7	2.79	93.0	3.25
Esophagus	10	5.8	0.85	7.4	1.06	5	2.5	0.49	3.0	0.58
Stomach	22	16.2	1.61	19.0	1.87	18	8.6	0.93	10.0	1.07
Small intestine	6	3.5	0.66	4.3	0.79	8	3.8	0.61	4.6	0.72
Colon (excl. rectum)	48	30.8	2.10	36.4	2.43	55	26.2	1.61	31.0	1.88
Rectum & rectosigmoid	23	14.2	1.38	16.8	1.61	19	9.3	0.96	10.7	1.09
Anus, anal canal, & anorectum	3	1.6	0.43	2.0	0.54	4	2.1	0.46	2.3	0.51
Liver	26	15.3	1.39	19.4	1.73	9	3.9	0.59	4.9	0.74
Gallbladder	2	0.9	0.32	1.1	0.41	5	2.5	0.49	3.2	0.61
Pancreas	25	16.3	1.56	19.7	1.84	31	14.8	1.22	17.5	1.42
Respiratory System	118	80.5	3.50	95.8	4.07	103	48.8	2.19	58.6	2.59
Larynx	12	7.4	0.98	9.2	1.20	3	1.1	0.32	1.5	0.41
Lung & bronchus	104	72.0	3.34	85.2	3.87	100	47.1	2.15	56.6	2.55
Bones & Joints	2	0.8	0.30	0.8	0.30	2	1.1	0.31	1.2	0.34
Soft Tissue (incl. heart)	7	4.7	0.81	5.1	0.88	7	3.2	0.56	3.6	0.63
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	4	1.7	0.41	1.9	0.46
Melanoma of the skin	2	1.3	0.41	1.4	0.45	2	0.9	0.30	1.1	0.34
Breast (excl. <i>in situ</i>)	4	2.8	0.64	3.3	0.75	280	132.2	3.60	154.9	4.15
Female Genital System	N/A	N/A	N/A	N/A	N/A	113	52.1	2.23	63.0	2.66
Cervix uteri	N/A	N/A	N/A	N/A	N/A	13	6.3	0.79	7.2	0.89
Uterus corpus	N/A	N/A	N/A	N/A	N/A	68	30.7	1.70	38.1	2.07
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	4	2.1	0.46	2.4	0.51
Ovary	N/A	N/A	N/A	N/A	N/A	16	7.7	0.87	9.0	1.00
Male Genital System	319	191.9	5.04	239.0	6.11	N/A	N/A	N/A	N/A	N/A
Prostate	315	189.3	5.01	236.0	6.07	N/A	N/A	N/A	N/A	N/A
Testis	2	0.8	0.30	0.9	0.34	N/A	N/A	N/A	N/A	N/A
Penis	2	1.4	0.45	1.6	0.51	N/A	N/A	N/A	N/A	N/A
Urinary System	73	48.3	2.68	57.0	3.11	37	18.1	1.34	21.0	1.54
Bladder (incl. <i>in situ</i>)	27	20.7	1.89	24.3	2.19	13	6.1	0.78	7.4	0.93
Kidney & renal pelvis	44	25.9	1.82	30.8	2.13	23	11.3	1.07	12.8	1.20
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	10	5.9	0.87	6.5	0.96	7	3.6	0.59	3.8	0.63
Brain	9	5.2	0.81	5.7	0.90	7	3.1	0.55	3.4	0.60
Endocrine System	9	5.3	0.81	6.1	0.92	34	16.5	1.29	18.4	1.42
Thyroid gland	7	4.3	0.73	4.9	0.83	31	14.9	1.22	16.6	1.34
Lymphomas	38	22.9	1.73	26.5	1.99	30	14.9	1.23	16.8	1.38
Hodgkin lymphoma	8	4.5	0.76	4.7	0.79	4	2.1	0.46	2.3	0.49
Non-Hodgkin lymphoma	31	18.4	1.56	21.8	1.83	26	12.8	1.14	14.6	1.29
Multiple Myeloma	29	18.6	1.62	22.1	1.89	25	12.2	1.10	14.4	1.28
Leukemias	21	13.6	1.41	15.3	1.58	19	9.3	0.98	10.5	1.09
Acute lymphocytic	2	1.0	0.32	0.9	0.30	2	0.8	0.29	0.8	0.29
Chronic lymphocytic	4	2.8	0.64	3.4	0.74	4	2.0	0.45	2.4	0.53
Acute myeloid	8	5.4	0.92	6.1	1.03	8	3.9	0.64	4.3	0.69
Chronic myeloid	5	3.0	0.64	3.4	0.74	3	1.6	0.41	1.9	0.46
Other leukemias	2	1.4	0.46	1.5	0.49	2	0.9	0.32	1.1	0.36
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	21	14.8	1.52	17.2	1.75	24	12.4	1.13	13.8	1.26
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	16	10.4	1.23	12.0	1.40	29	13.4	1.14	15.7	1.32
Breast (<i>in situ</i>)	*	*	*	*	*	84	39.6	1.96	46.4	2.27

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Connecticut, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	150	234.9	9.15	279.3	10.80	207	253.2	8.20	294.8	9.55
Oral Cavity & Pharynx	8	11.3	1.84	14.0	2.27	5	6.4	1.33	7.8	1.58
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	3	4.1	1.21	4.9	1.44	2	2.8	0.82	3.5	1.02
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	2	2.9	0.85	4.1	1.20	*	*	*	*	*
Nasopharynx	2	2.1	0.75	2.5	0.90	1	1.5	0.56	1.8	0.70
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	40	64.2	4.81	76.0	5.65	30	41.8	3.59	49.5	4.19
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	6	9.8	1.92	11.1	2.16	5	6.3	1.39	7.4	1.61
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	10	15.8	2.33	18.9	2.77	9	12.2	1.93	14.5	2.25
Rectum & rectosigmoid	5	6.8	1.38	8.4	1.72	5	5.9	1.27	6.8	1.47
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	8	12.4	2.07	14.6	2.43	2	3.3	1.01	4.0	1.21
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	5	9.6	1.98	11.0	2.25	4	6.4	1.48	7.5	1.70
Respiratory System	18	31.4	3.51	38.3	4.19	15	20.7	2.53	24.4	2.97
Larynx	1	2.2	0.95	2.7	1.12	*	*	*	*	*
Lung & bronchus	17	28.2	3.32	34.5	3.97	14	20.4	2.53	24.1	2.95
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	1	1.6	0.60	1.8	0.69
Skin (excl. basal & sq.)	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	*	*	*	*	*	1	1.5	0.66	1.9	0.81
Breast (excl. <i>in situ</i>)	*	*	*	*	*	76	88.8	4.66	104.2	5.47
Female Genital System	N/A	N/A	N/A	N/A	N/A	27	32.0	2.87	37.2	3.35
Cervix uteri	N/A	N/A	N/A	N/A	N/A	3	4.0	1.07	4.5	1.21
Uterus corpus	N/A	N/A	N/A	N/A	N/A	14	15.6	1.90	18.9	2.31
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	7	8.4	1.51	9.2	1.66
Male Genital System	31	50.0	4.21	60.6	5.01	N/A	N/A	N/A	N/A	N/A
Prostate	30	47.7	4.08	58.2	4.87	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	16	24.9	2.96	29.4	3.48	6	7.8	1.44	9.4	1.74
Bladder (incl. <i>in situ</i>)	7	12.6	2.24	15.3	2.67	1	1.5	0.62	1.8	0.73
Kidney & renal pelvis	8	11.7	1.88	13.3	2.16	5	5.8	1.26	7.0	1.51
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	3	4.6	1.20	5.1	1.35	3	3.6	0.94	4.0	1.05
Brain	3	4.4	1.17	4.9	1.32	3	3.2	0.90	3.5	0.98
Endocrine System	6	7.9	1.47	9.2	1.75	22	23.4	2.29	24.8	2.47
Thyroid gland	6	7.1	1.41	8.4	1.69	21	22.8	2.26	24.0	2.43
Lymphomas	10	14.8	2.36	17.3	2.76	9	11.2	1.72	13.2	2.02
Hodgkin lymphoma	2	2.6	0.92	3.0	1.05	2	2.0	0.69	2.2	0.78
Non-Hodgkin lymphoma	8	12.2	2.17	14.3	2.55	7	9.2	1.58	11.0	1.87
Multiple Myeloma	2	2.7	1.02	3.3	1.21	2	2.8	0.91	3.2	1.06
Leukemias	7	10.0	1.85	11.3	2.13	2	2.7	0.86	3.1	0.98
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Chronic lymphocytic	2	3.0	1.07	3.6	1.26	*	*	*	*	*
Acute myeloid	1	1.8	0.77	2.2	0.99	*	*	*	*	*
Chronic myeloid	1	2.6	1.01	3.0	1.18	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	6	8.8	1.82	10.1	2.06	6	7.9	1.56	9.1	1.80
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	3	5.0	1.29	6.2	1.62	10	12.0	1.81	14.1	2.12
Breast (<i>in situ</i>)	*	*	*	*	*	31	34.6	2.84	39.8	3.30

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Connecticut, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	11	240.5	33.76	285.3	38.74	15	296.7	35.17	349.8	40.19
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	2	38.5	11.96	51.8	15.83	2	39.6	12.33	49.6	15.06
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	2	31.4	10.11	42.2	13.40
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	2	31.4	10.11	42.2	13.40
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	6	118.2	23.18	130.6	24.95
Female Genital System	N/A	N/A	N/A	N/A	N/A	1	24.2	9.38	30.2	11.44
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	4	82.9	20.95	96.8	23.83	N/A	N/A	N/A	N/A	N/A
Prostate	3	75.9	19.77	90.9	23.09	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	1	25.3	10.56	30.1	12.35	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Connecticut, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	775	462.2	8.21	550.6	9.59	917	420.7	6.51	489.4	7.58
Oral Cavity & Pharynx	32	17.8	1.54	21.5	1.81	16	7.5	0.89	8.6	1.01
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	6	3.5	0.66	4.3	0.79	6	3.0	0.56	3.5	0.65
Major salivary gland	3	1.7	0.54	1.9	0.61	3	1.3	0.35	1.4	0.39
Floor of mouth	1	0.7	0.31	1.0	0.38	*	*	*	*	*
Gum & other mouth	3	2.1	0.56	2.5	0.63	2	1.2	0.38	1.3	0.42
Nasopharynx	3	1.3	0.38	1.5	0.43	*	*	*	*	*
Oropharynx	3	1.5	0.43	1.7	0.49	*	*	*	*	*
Hypopharynx	3	1.9	0.50	2.4	0.59	*	*	*	*	*
Digestive System	195	114.8	4.06	137.7	4.76	152	74.7	2.85	88.1	3.34
Esophagus	7	4.6	0.82	5.5	0.96	4	2.7	0.59	3.0	0.66
Stomach	24	14.6	1.48	17.2	1.72	19	9.0	0.97	10.6	1.14
Small intestine	4	2.4	0.59	2.8	0.67	6	2.7	0.53	3.1	0.61
Colon (excl. rectum)	50	30.3	2.14	36.0	2.50	44	21.4	1.51	25.0	1.77
Rectum & rectosigmoid	28	15.3	1.42	18.1	1.65	19	8.4	0.90	10.2	1.09
Anus, anal canal, & anorectum	3	1.7	0.51	1.9	0.59	6	2.9	0.53	3.6	0.65
Liver	45	25.2	1.82	31.6	2.21	12	6.3	0.85	7.5	1.00
Gallbladder	1	1.0	0.42	1.1	0.47	4	2.1	0.48	2.5	0.57
Pancreas	21	12.8	1.38	15.1	1.60	24	13.0	1.23	15.4	1.44
Respiratory System	87	59.4	3.11	70.5	3.60	73	38.0	2.08	45.5	2.44
Larynx	11	6.8	0.99	8.1	1.14	3	1.4	0.35	1.7	0.44
Lung & bronchus	73	51.4	2.93	61.0	3.39	67	35.7	2.02	42.8	2.38
Bones & Joints	1	0.4	0.15	0.3	0.13	3	1.2	0.32	1.1	0.32
Soft Tissue (incl. heart)	8	3.9	0.68	4.5	0.78	6	2.3	0.45	2.6	0.52
Skin (excl. basal & sq.)	10	6.8	1.08	7.9	1.23	12	5.6	0.75	6.7	0.90
Melanoma of the skin	8	6.0	1.02	7.0	1.17	9	4.3	0.66	5.2	0.81
Breast (excl. <i>in situ</i>)	2	0.9	0.36	1.0	0.41	279	123.8	3.45	145.0	4.03
Female Genital System	N/A	N/A	N/A	N/A	N/A	121	53.8	2.28	63.2	2.67
Cervix uteri	N/A	N/A	N/A	N/A	N/A	21	8.4	0.84	9.0	0.92
Uterus corpus	N/A	N/A	N/A	N/A	N/A	70	31.3	1.74	37.5	2.08
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	0.8	0.28	0.9	0.32
Ovary	N/A	N/A	N/A	N/A	N/A	19	8.5	0.92	9.9	1.07
Male Genital System	204	119.3	4.07	146.2	4.84	N/A	N/A	N/A	N/A	N/A
Prostate	187	113.2	4.01	139.9	4.78	N/A	N/A	N/A	N/A	N/A
Testis	14	4.7	0.56	4.5	0.54	N/A	N/A	N/A	N/A	N/A
Penis	2	1.4	0.41	1.6	0.48	N/A	N/A	N/A	N/A	N/A
Urinary System	76	48.4	2.73	57.2	3.16	47	22.8	1.56	26.8	1.83
Bladder (incl. <i>in situ</i>)	37	27.2	2.18	31.7	2.49	16	8.7	1.01	10.4	1.18
Kidney & renal pelvis	36	19.2	1.54	23.2	1.84	28	12.5	1.10	14.7	1.29
Ureter	*	*	*	*	*	2	1.1	0.39	1.3	0.44
Eye & Orbit	2	0.9	0.30	1.0	0.36	*	*	*	*	*
Brain & Other CNS	16	7.7	0.99	8.6	1.12	14	6.2	0.79	6.6	0.85
Brain	15	7.1	0.92	7.8	1.04	13	5.9	0.77	6.3	0.83
Endocrine System	19	8.0	0.90	8.9	1.02	81	30.2	1.54	32.5	1.69
Thyroid gland	16	6.9	0.83	7.6	0.94	80	29.7	1.52	32.0	1.68
Lymphomas	52	28.3	1.99	32.9	2.30	53	24.2	1.57	28.0	1.81
Hodgkin lymphoma	11	4.5	0.68	4.9	0.76	9	3.4	0.53	3.5	0.56
Non-Hodgkin lymphoma	41	23.8	1.87	27.9	2.17	44	20.8	1.48	24.5	1.72
Multiple Myeloma	15	10.7	1.35	12.8	1.60	16	8.9	1.02	10.3	1.17
Leukemias	28	13.8	1.33	15.7	1.54	23	10.1	0.99	11.4	1.14
Acute lymphocytic	8	2.5	0.42	2.4	0.41	6	2.0	0.39	2.0	0.41
Chronic lymphocytic	4	2.7	0.67	3.3	0.80	5	2.5	0.53	2.9	0.61
Acute myeloid	8	4.6	0.81	5.4	0.94	8	3.4	0.58	3.8	0.67
Chronic myeloid	4	2.2	0.52	2.6	0.62	3	1.2	0.31	1.4	0.38
Other leukemias	4	1.9	0.48	2.1	0.55	2	1.1	0.34	1.3	0.39
Mesothelioma	1	1.5	0.58	1.7	0.66	*	*	*	*	*
Kaposi Sarcoma	2	0.9	0.36	0.9	0.37	*	*	*	*	*
Ill-Defined & Unknown	26	18.6	1.79	21.4	2.04	20	10.9	1.15	12.5	1.32
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	15	7.6	1.00	8.5	1.12	43	18.7	1.32	21.5	1.54
Breast (<i>in situ</i>)	*	*	*	*	*	91	38.4	1.85	44.7	2.16

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

CONNECTICUT

II-98 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Connecticut, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	606	417.2	8.34	496.1	9.74	723	386.5	6.70	449.1	7.78
Oral Cavity & Pharynx	26	16.6	1.58	20.2	1.86	13	7.4	0.95	8.3	1.07
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	4	2.7	0.61	3.3	0.73	5	3.1	0.62	3.5	0.70
Major salivary gland	3	1.8	0.60	2.0	0.67	2	1.2	0.38	1.3	0.41
Floor of mouth	1	0.7	0.33	0.9	0.39	*	*	*	*	*
Gum & other mouth	3	2.0	0.54	2.3	0.62	2	1.3	0.42	1.4	0.46
Nasopharynx	2	1.3	0.41	1.5	0.47	*	*	*	*	*
Oropharynx	2	1.5	0.48	1.7	0.54	*	*	*	*	*
Hypopharynx	3	1.8	0.51	2.2	0.62	*	*	*	*	*
Digestive System	159	108.5	4.21	130.0	4.94	120	69.2	2.94	81.5	3.45
Esophagus	6	4.2	0.84	4.9	0.95	4	2.7	0.64	3.0	0.71
Stomach	19	13.6	1.54	15.9	1.78	15	8.5	1.02	10.1	1.20
Small intestine	4	2.5	0.65	2.9	0.73	4	2.3	0.52	2.5	0.58
Colon (excl. rectum)	39	27.4	2.17	32.7	2.54	36	20.2	1.57	23.5	1.83
Rectum & rectosigmoid	21	13.3	1.42	15.7	1.65	12	6.3	0.85	7.6	1.03
Anus, anal canal, & anorectum	2	1.7	0.56	2.0	0.65	5	2.6	0.52	3.2	0.65
Liver	38	24.4	1.91	30.5	2.31	10	6.1	0.89	7.3	1.05
Gallbladder	*	*	*	*	*	3	1.6	0.45	1.9	0.53
Pancreas	18	12.6	1.47	14.9	1.71	21	12.8	1.30	15.4	1.54
Respiratory System	76	60.1	3.36	70.9	3.87	61	36.6	2.17	43.8	2.56
Larynx	9	6.6	1.03	7.9	1.20	2	1.2	0.35	1.5	0.44
Lung & bronchus	64	52.3	3.17	61.6	3.65	57	34.8	2.13	41.7	2.50
Bones & Joints	1	0.4	0.17	0.3	0.14	3	1.2	0.35	1.2	0.35
Soft Tissue (incl. heart)	6	3.6	0.69	4.1	0.81	4	2.1	0.47	2.4	0.54
Skin (excl. basal & sq.)	8	6.8	1.17	8.0	1.34	12	6.1	0.84	7.2	1.00
Melanoma of the skin	7	6.0	1.10	7.1	1.27	9	4.7	0.73	5.6	0.89
Breast (excl. <i>in situ</i>)	1	0.8	0.39	0.9	0.43	220	113.4	3.54	132.3	4.13
Female Genital System	N/A	N/A	N/A	N/A	N/A	91	47.2	2.29	55.2	2.68
Cervix uteri	N/A	N/A	N/A	N/A	N/A	15	7.2	0.84	7.7	0.91
Uterus corpus	N/A	N/A	N/A	N/A	N/A	53	27.5	1.76	32.9	2.09
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	1	0.6	0.24	0.7	0.27
Ovary	N/A	N/A	N/A	N/A	N/A	15	7.8	0.95	9.0	1.10
Male Genital System	144	95.5	3.86	117.1	4.61	N/A	N/A	N/A	N/A	N/A
Prostate	130	89.6	3.79	111.0	4.54	N/A	N/A	N/A	N/A	N/A
Testis	12	4.6	0.60	4.4	0.59	N/A	N/A	N/A	N/A	N/A
Penis	2	1.3	0.44	1.6	0.51	N/A	N/A	N/A	N/A	N/A
Urinary System	63	46.2	2.86	54.6	3.32	38	21.7	1.63	25.6	1.91
Bladder (incl. <i>in situ</i>)	31	26.4	2.29	30.7	2.61	15	9.0	1.09	10.8	1.28
Kidney & renal pelvis	29	17.6	1.59	21.2	1.90	22	11.2	1.12	13.2	1.32
Ureter	*	*	*	*	*	2	1.2	0.43	1.3	0.48
Eye & Orbit	2	0.8	0.30	0.9	0.36	*	*	*	*	*
Brain & Other CNS	12	7.1	1.01	7.9	1.15	11	5.5	0.80	6.0	0.88
Brain	11	6.7	0.97	7.4	1.11	10	5.3	0.78	5.7	0.86
Endocrine System	14	7.3	0.94	8.1	1.07	63	27.4	1.58	29.3	1.72
Thyroid gland	13	6.4	0.88	7.0	1.00	62	27.1	1.57	29.0	1.71
Lymphomas	39	24.4	1.96	28.4	2.29	41	21.6	1.58	25.1	1.84
Hodgkin lymphoma	8	3.6	0.64	4.0	0.75	7	3.1	0.55	3.3	0.59
Non-Hodgkin lymphoma	31	20.8	1.86	24.3	2.16	34	18.5	1.49	21.8	1.74
Multiple Myeloma	11	8.7	1.31	10.4	1.54	12	7.4	1.00	8.5	1.14
Leukemias	22	12.3	1.33	14.1	1.56	19	9.8	1.06	11.2	1.22
Acute lymphocytic	6	2.4	0.44	2.2	0.43	4	1.8	0.42	1.9	0.45
Chronic lymphocytic	3	2.2	0.67	2.9	0.82	4	2.4	0.56	2.8	0.64
Acute myeloid	7	4.3	0.84	5.1	0.98	7	3.6	0.64	4.0	0.74
Chronic myeloid	3	1.9	0.52	2.3	0.62	2	1.0	0.32	1.3	0.40
Other leukemias	3	1.5	0.40	1.6	0.46	2	1.0	0.33	1.2	0.39
Mesothelioma	1	1.5	0.60	1.6	0.67	*	*	*	*	*
Kaposi Sarcoma	1	0.9	0.40	1.0	0.42	*	*	*	*	*
Ill-Defined & Unknown	19	15.6	1.73	17.9	1.97	15	9.4	1.13	10.7	1.30
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	12	7.1	1.05	8.1	1.17	36	17.8	1.38	20.4	1.61
Breast (<i>in situ</i>)	*	*	*	*	*	72	35.2	1.89	41.2	2.22

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Connecticut, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	27	163.0	16.37	198.5	19.12	30	139.2	12.41	166.1	14.82
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	7	40.7	7.62	50.7	9.09	6	31.3	6.21	37.8	7.45
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	2	14.7	4.95	16.4	5.47	2	9.8	3.79	11.6	4.41
Rectum & rectosigmoid	1	7.0	3.29	8.5	3.75	1	5.3	2.10	6.4	2.56
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	1	6.3	2.37	9.4	3.57	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	3	18.0	5.66	22.2	6.69	3	14.4	4.31	17.8	5.28
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	2	16.3	5.53	20.0	6.52	2	13.2	4.12	16.4	5.11
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	9	38.7	5.97	47.4	7.34
Female Genital System	N/A	N/A	N/A	N/A	N/A	5	22.2	5.00	26.4	5.95
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2	9.9	3.29	12.4	4.04
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	1	5.2	2.21	6.4	2.71
Male Genital System	9	55.3	9.40	68.5	11.17	N/A	N/A	N/A	N/A	N/A
Prostate	8	53.9	9.36	67.2	11.14	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	1	10.5	4.45	11.8	4.82	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	2	5.3	1.80	5.8	2.04
Thyroid gland	*	*	*	*	*	2	5.3	1.80	5.8	2.04
Lymphomas	2	8.9	3.87	10.4	4.47	1	5.2	2.34	5.1	2.34
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	1	6.7	2.83	7.1	3.06
Breast (<i>in situ</i>)	*	*	*	*	*	3	14.8	3.95	16.6	4.52

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.


N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	942,065	949,989	957,942	966,985	976,668
Non-Hispanic White	605,670	607,061	607,980	609,223	610,944
Non-Hispanic Black	211,146	214,552	217,773	221,455	225,323
Non-Hispanic Asian/Pacific Islander (NH API)	38,405	39,406	40,192	41,403	42,766
Non-Hispanic American Indian/Alaskan Native PRCA (NH AI/AN)	0	0	0	0	0


All Races Population 2015–2019: 4,793,649
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	83,478	85,558	88,549	91,407	94,154
Hispanic White	67,467	69,073	71,333	73,449	75,297
Hispanic Black	11,278	11,607	12,074	12,504	13,115

Hispanic/Latino Population, Census 2010: 73,221
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

DELAWARE CANCER REGISTRY

Initial Operation: 1972
Population-based Data Available: 1980
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	115.2	108.7	102.4	101.5	100.8	105.7
Missing Race	0.1	0.0	0.4	2.7	2.8	1.2
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.1	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.1	0.9	0.8	0.8	1.2	1.0
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.4	Ovary	94.2
Oral Cavity & Pharynx	98.6	Prostate	98.3
Esophagus	98.1	Testis	100.0
Stomach	96.2	Bladder (incl. <i>in situ</i>)	99.0
Colon & Rectum	96.1	Kidney & Renal Pelvis	91.0
Liver	50.1	Brain & Other CNS	85.3
Pancreas	89.0	Brain & Other CNS (non-malig)	48.6
Lung & Bronchus	89.3	Thyroid	99.8
Melanomas of the Skin	99.6	Hodgkin Lymphoma	100.0
Female Breast (excl. <i>in situ</i>)	98.8	Non-Hodgkin Lymphoma	97.1
Female Breast (<i>in situ</i>)	99.9	Multiple Myeloma	89.5
Cervix Uteri	98.5	Leukemias	89.8
Uterus Corpus & Uterus NOS	98.4		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Delaware, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3,081	519.9	4.32	618.1	5.06	2,927	442.5	3.84	515.9	4.36
Oral Cavity & Pharynx	117	19.7	0.85	24.1	1.01	42	6.3	0.46	7.3	0.52
Lip	2	0.3	0.12	0.4	0.13	*	*	*	*	*
Tongue	36	6.1	0.47	7.5	0.56	12	1.8	0.24	2.2	0.28
Major salivary gland	9	1.8	0.28	2.1	0.31	9	1.4	0.23	1.6	0.25
Floor of mouth	5	0.7	0.14	0.9	0.18	2	0.3	0.09	0.4	0.12
Gum & other mouth	11	2.0	0.28	2.3	0.32	6	0.9	0.19	1.0	0.20
Nasopharynx	2	0.4	0.12	0.5	0.14	*	*	*	*	*
Oropharynx	8	1.4	0.22	1.7	0.27	1	0.2	0.07	0.3	0.10
Hypopharynx	6	1.0	0.17	1.2	0.22	1	0.2	0.09	0.2	0.09
Digestive System	570	98.0	1.89	116.6	2.22	445	65.0	1.43	76.9	1.66
Esophagus	49	8.3	0.54	9.9	0.64	12	1.8	0.23	2.1	0.27
Stomach	51	8.9	0.58	10.5	0.67	29	4.2	0.36	5.0	0.43
Small intestine	19	3.2	0.34	3.9	0.40	18	2.8	0.31	3.2	0.35
Colon (excl. rectum)	172	30.4	1.07	35.5	1.23	169	25.1	0.90	29.3	1.03
Rectum & rectosigmoid	66	12.3	0.70	14.3	0.80	49	7.4	0.50	8.9	0.58
Anus, anal canal, & anorectum	11	1.9	0.27	2.3	0.32	15	2.2	0.27	2.7	0.31
Liver	71	11.0	0.60	14.0	0.75	21	3.0	0.29	3.6	0.35
Gallbladder	4	0.7	0.16	0.8	0.18	10	1.4	0.20	1.6	0.24
Pancreas	95	16.1	0.76	19.1	0.89	89	12.5	0.61	14.9	0.72
Respiratory System	449	74.7	1.62	88.7	1.90	427	58.4	1.29	69.8	1.53
Larynx	30	4.9	0.42	6.0	0.50	12	1.7	0.22	2.1	0.28
Lung & bronchus	413	68.7	1.55	81.5	1.82	412	56.3	1.27	67.3	1.50
Bones & Joints	5	1.0	0.21	1.0	0.21	5	0.9	0.19	1.0	0.20
Soft Tissue (incl. heart)	17	3.1	0.35	3.5	0.39	16	2.7	0.32	2.9	0.33
Skin (excl. basal & sq.)	230	40.1	1.22	46.8	1.40	147	23.3	0.91	26.6	1.00
Melanoma of the skin	218	37.9	1.18	44.3	1.36	139	22.0	0.88	25.3	0.98
Breast (excl. <i>in situ</i>)	8	1.3	0.22	1.6	0.26	878	136.2	2.17	158.9	2.46
Female Genital System	N/A	N/A	N/A	N/A	N/A	354	52.8	1.32	62.6	1.52
Cervix uteri	N/A	N/A	N/A	N/A	N/A	41	7.7	0.57	8.2	0.58
Uterus corpus	N/A	N/A	N/A	N/A	N/A	205	29.1	0.95	35.4	1.13
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	11	1.6	0.22	1.9	0.26
Ovary	N/A	N/A	N/A	N/A	N/A	65	9.7	0.57	11.5	0.65
Male Genital System	839	132.0	2.09	162.4	2.54	N/A	N/A	N/A	N/A	N/A
Prostate	811	126.0	2.02	156.2	2.49	N/A	N/A	N/A	N/A	N/A
Testis	23	5.2	0.50	5.3	0.49	N/A	N/A	N/A	N/A	N/A
Penis	3	0.5	0.15	0.6	0.16	N/A	N/A	N/A	N/A	N/A
Urinary System	380	65.4	1.54	76.9	1.79	154	22.5	0.84	26.1	0.96
Bladder (incl. <i>in situ</i>)	233	40.3	1.21	47.2	1.41	72	10.1	0.55	11.7	0.63
Kidney & renal pelvis	138	23.4	0.92	27.8	1.08	78	11.8	0.63	13.8	0.71
Ureter	6	1.0	0.19	1.1	0.22	3	0.4	0.11	0.5	0.13
Eye & Orbit	3	0.5	0.14	0.5	0.14	3	0.6	0.16	0.6	0.15
Brain & Other CNS	38	7.2	0.54	8.1	0.59	31	5.2	0.44	5.7	0.46
Brain	35	6.6	0.52	7.4	0.57	30	4.9	0.42	5.3	0.45
Endocrine System	45	8.6	0.60	9.7	0.65	128	24.5	1.02	26.1	1.05
Thyroid gland	41	7.7	0.56	8.8	0.62	123	23.5	1.00	25.2	1.03
Lymphomas	142	25.8	1.00	29.4	1.12	115	17.6	0.77	20.2	0.86
Hodgkin lymphoma	15	3.2	0.38	3.3	0.39	12	2.4	0.33	2.4	0.32
Non-Hodgkin lymphoma	127	22.6	0.93	26.1	1.05	103	15.2	0.70	17.8	0.80
Multiple Myeloma	47	8.0	0.54	9.5	0.63	44	6.1	0.43	7.5	0.51
Leukemias	94	16.9	0.81	19.1	0.90	57	8.9	0.55	10.0	0.60
Acute lymphocytic	8	1.9	0.30	1.7	0.27	5	1.2	0.24	1.1	0.21
Chronic lymphocytic	31	5.3	0.44	6.3	0.51	18	2.5	0.27	3.0	0.32
Acute myeloid	31	5.5	0.46	6.3	0.51	22	3.4	0.34	3.8	0.37
Chronic myeloid	12	2.2	0.30	2.5	0.33	8	1.3	0.21	1.5	0.24
Other leukemias	11	2.0	0.27	2.3	0.31	4	0.6	0.14	0.7	0.16
Mesothelioma	11	2.0	0.28	2.3	0.31	3	0.5	0.12	0.5	0.14
Kaposi Sarcoma	2	0.5	0.15	0.5	0.15	*	*	*	*	*
Ill-Defined & Unknown	83	14.9	0.75	17.3	0.86	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	37	6.8	0.53	7.7	0.57	75	12.4	0.67	13.9	0.73
Breast (<i>in situ</i>)	*	*	*	*	*	196	30.7	1.04	36.5	1.19

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Delaware, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,377	524.9	5.06	621.8	5.87	2,238	462.0	4.78	536.4	5.33
Oral Cavity & Pharynx	99	22.4	1.08	27.5	1.28	33	6.7	0.57	7.9	0.65
Lip	2	0.5	0.16	0.5	0.18	*	*	*	*	*
Tongue	31	7.1	0.61	8.8	0.72	10	2.0	0.30	2.4	0.36
Major salivary gland	7	1.7	0.32	2.0	0.35	6	1.4	0.28	1.6	0.30
Floor of mouth	4	0.7	0.16	1.0	0.22	2	0.3	0.11	0.4	0.15
Gum & other mouth	9	2.0	0.32	2.3	0.37	4	1.1	0.26	1.1	0.26
Nasopharynx	1	0.4	0.14	0.4	0.16	*	*	*	*	*
Oropharynx	7	1.7	0.30	2.0	0.35	1	0.2	0.09	0.3	0.12
Hypopharynx	5	0.9	0.19	1.2	0.25	1	0.2	0.09	0.2	0.10
Digestive System	428	96.0	2.18	114.2	2.54	326	63.8	1.70	74.8	1.94
Esophagus	45	9.7	0.67	11.6	0.80	11	2.1	0.30	2.4	0.34
Stomach	35	8.0	0.64	9.4	0.74	19	3.7	0.40	4.3	0.47
Small intestine	14	2.9	0.36	3.6	0.44	12	2.7	0.39	3.0	0.42
Colon (excl. rectum)	131	30.3	1.25	35.4	1.43	127	25.5	1.09	29.5	1.23
Rectum & rectosigmoid	49	12.2	0.84	14.3	0.95	35	7.5	0.62	8.8	0.70
Anus, anal canal, & anorectum	7	1.7	0.30	2.1	0.35	13	2.4	0.33	3.0	0.39
Liver	46	9.3	0.64	11.8	0.80	14	2.6	0.32	3.1	0.38
Gallbladder	3	0.7	0.20	0.8	0.21	7	1.2	0.22	1.4	0.25
Pancreas	74	15.8	0.85	18.9	1.00	65	11.8	0.69	14.0	0.80
Respiratory System	372	79.3	1.91	94.3	2.24	354	63.1	1.55	75.7	1.85
Larynx	25	5.4	0.51	6.6	0.61	10	1.9	0.29	2.4	0.35
Lung & bronchus	343	72.9	1.82	86.5	2.14	342	60.8	1.52	72.9	1.81
Bones & Joints	3	0.9	0.25	1.0	0.26	3	0.9	0.25	0.9	0.25
Soft Tissue (incl. heart)	13	3.2	0.43	3.6	0.46	11	3.0	0.44	3.1	0.44
Skin (excl. basal & sq.)	219	50.1	1.60	58.4	1.82	137	30.9	1.31	35.1	1.41
Melanoma of the skin	208	47.7	1.57	55.5	1.78	130	29.4	1.28	33.5	1.38
Breast (excl. <i>in situ</i>)	6	1.3	0.24	1.5	0.28	648	138.2	2.67	160.7	2.98
Female Genital System	N/A	N/A	N/A	N/A	N/A	267	55.4	1.67	65.4	1.88
Cervix uteri	N/A	N/A	N/A	N/A	N/A	28	8.3	0.76	8.7	0.77
Uterus corpus	N/A	N/A	N/A	N/A	N/A	155	30.4	1.19	36.8	1.38
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	7	1.2	0.22	1.4	0.25
Ovary	N/A	N/A	N/A	N/A	N/A	53	10.7	0.72	12.6	0.82
Male Genital System	561	115.3	2.26	140.3	2.72	N/A	N/A	N/A	N/A	N/A
Prostate	539	107.4	2.12	132.3	2.60	N/A	N/A	N/A	N/A	N/A
Testis	19	7.1	0.75	7.2	0.74	N/A	N/A	N/A	N/A	N/A
Penis	2	0.5	0.18	0.6	0.19	N/A	N/A	N/A	N/A	N/A
Urinary System	311	69.1	1.83	81.2	2.12	120	23.4	1.03	27.1	1.15
Bladder (incl. <i>in situ</i>)	200	43.6	1.42	51.2	1.66	61	10.9	0.66	12.8	0.75
Kidney & renal pelvis	103	23.5	1.11	27.9	1.27	56	11.8	0.78	13.7	0.86
Ureter	5	1.2	0.24	1.4	0.27	3	0.5	0.13	0.5	0.15
Eye & Orbit	2	0.4	0.15	0.5	0.17	2	0.8	0.26	0.8	0.24
Brain & Other CNS	30	8.1	0.72	9.0	0.76	23	5.3	0.55	5.9	0.57
Brain	28	7.5	0.69	8.5	0.74	23	5.2	0.54	5.7	0.56
Endocrine System	35	9.7	0.80	10.8	0.85	90	26.1	1.35	27.7	1.37
Thyroid gland	32	8.8	0.76	10.0	0.82	86	25.3	1.33	26.9	1.35
Lymphomas	111	26.2	1.18	30.1	1.32	89	18.5	0.97	21.3	1.06
Hodgkin lymphoma	9	3.0	0.48	3.0	0.47	9	3.0	0.49	3.0	0.46
Non-Hodgkin lymphoma	102	23.1	1.08	27.0	1.23	80	15.5	0.83	18.3	0.95
Multiple Myeloma	32	7.0	0.58	8.2	0.67	26	4.7	0.43	5.7	0.52
Leukemias	75	17.6	0.97	20.2	1.07	42	8.9	0.69	10.0	0.73
Acute lymphocytic	4	1.5	0.34	1.4	0.31	2	1.0	0.29	0.9	0.25
Chronic lymphocytic	26	5.7	0.52	6.8	0.61	15	2.7	0.33	3.2	0.39
Acute myeloid	26	5.8	0.54	6.6	0.60	17	3.5	0.43	3.9	0.45
Chronic myeloid	10	2.6	0.38	2.9	0.42	5	1.1	0.25	1.3	0.27
Other leukemias	9	2.1	0.33	2.4	0.37	3	0.6	0.18	0.7	0.19
Mesothelioma	10	2.3	0.33	2.5	0.36	3	0.6	0.17	0.7	0.18
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	25	6.2	0.61	7.1	0.66	53	12.3	0.84	13.7	0.89
Breast (<i>in situ</i>)	*	*	*	*	*	137	30.1	1.27	35.6	1.44

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

DELAWARE

II-104 Incidence – NH White

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Delaware, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	500	514.1	10.82	620.0	12.77	506	410.3	8.39	482.2	9.67
Oral Cavity & Pharynx	11	11.7	1.66	13.9	1.93	6	5.5	1.01	6.0	1.08
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	3	3.3	0.87	4.0	1.03	1	1.4	0.54	1.5	0.57
Major salivary gland	1	1.4	0.58	1.5	0.63	2	2.0	0.61	2.1	0.63
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	104	110.5	5.12	132.7	6.03	91	74.2	3.57	89.4	4.23
Esophagus	3	3.8	1.03	4.6	1.21	1	0.9	0.37	1.1	0.46
Stomach	10	10.7	1.61	12.7	1.88	7	6.0	1.02	7.2	1.22
Small intestine	4	4.3	1.01	5.1	1.18	5	4.5	0.92	5.3	1.06
Colon (excl. rectum)	32	36.1	3.00	42.5	3.50	32	25.7	2.10	30.7	2.46
Rectum & rectosigmoid	11	12.6	1.75	14.6	2.00	10	7.6	1.11	9.4	1.36
Anus, anal canal, & anorectum	3	2.5	0.70	3.0	0.83	1	1.2	0.46	1.3	0.50
Liver	18	16.8	1.87	21.8	2.35	5	4.1	0.82	5.1	0.99
Gallbladder	*	*	*	*	*	2	1.8	0.54	2.1	0.65
Pancreas	17	17.9	2.06	21.1	2.38	20	16.7	1.72	20.2	2.04
Respiratory System	63	69.4	4.14	82.6	4.83	62	50.2	2.94	59.5	3.42
Larynx	4	4.0	0.99	4.9	1.16	1	0.9	0.36	1.3	0.50
Lung & bronchus	58	63.7	3.96	75.8	4.62	60	48.9	2.91	57.6	3.36
Bones & Joints	*	*	*	*	*	1	1.0	0.41	1.0	0.42
Soft Tissue (incl. heart)	3	3.0	0.84	3.3	0.95	3	2.4	0.63	2.8	0.71
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	1	1.4	0.55	1.6	0.61	1	1.1	0.46	1.2	0.51
Breast (excl. <i>in situ</i>)	2	1.6	0.59	1.9	0.68	174	139.6	4.88	164.1	5.61
Female Genital System	N/A	N/A	N/A	N/A	N/A	62	48.0	2.82	57.3	3.28
Cervix uteri	N/A	N/A	N/A	N/A	N/A	8	7.2	1.17	7.6	1.21
Uterus corpus	N/A	N/A	N/A	N/A	N/A	36	27.1	2.07	33.5	2.49
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	4	2.9	0.65	3.7	0.81
Ovary	N/A	N/A	N/A	N/A	N/A	8	6.2	1.01	7.4	1.17
Male Genital System	199	189.3	6.24	237.8	7.65	N/A	N/A	N/A	N/A	N/A
Prostate	198	188.1	6.22	236.6	7.63	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	51	55.8	3.65	65.0	4.17	26	21.2	1.91	24.9	2.20
Bladder (incl. <i>in situ</i>)	22	25.3	2.55	29.5	2.92	8	7.1	1.13	8.1	1.28
Kidney & renal pelvis	28	29.1	2.53	33.9	2.88	17	13.7	1.52	16.2	1.75
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	4	3.5	0.88	4.1	1.02	5	4.3	0.85	4.6	0.92
Brain	3	2.8	0.78	3.3	0.94	5	3.7	0.79	4.1	0.85
Endocrine System	7	6.7	1.21	7.6	1.37	18	15.7	1.69	16.8	1.77
Thyroid gland	5	5.0	1.04	5.9	1.21	17	14.5	1.63	15.5	1.70
Lymphomas	18	19.3	2.08	21.3	2.27	18	15.5	1.66	17.5	1.84
Hodgkin lymphoma	3	3.5	0.87	3.7	0.91	2	1.9	0.59	1.8	0.57
Non-Hodgkin lymphoma	15	15.8	1.89	17.6	2.08	16	13.6	1.55	15.7	1.75
Multiple Myeloma	13	13.4	1.71	15.8	1.97	16	12.2	1.42	14.8	1.69
Leukemias	10	11.7	1.72	13.1	1.91	10	7.7	1.14	8.9	1.30
Acute lymphocytic	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	3	3.9	1.05	4.6	1.20	2	1.5	0.48	1.8	0.59
Acute myeloid	3	3.7	0.99	4.1	1.06	4	3.0	0.73	3.5	0.84
Chronic myeloid	1	1.5	0.58	1.7	0.66	2	1.8	0.55	2.1	0.64
Other leukemias	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Mesothelioma	1	1.7	0.73	1.9	0.80	*	*	*	*	*
Kaposi Sarcoma	1	1.4	0.52	1.4	0.55	*	*	*	*	*
Ill-Defined & Unknown	9	11.4	1.84	13.5	2.16	12	10.7	1.42	12.2	1.60
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	8	8.0	1.30	8.7	1.42	16	13.3	1.51	15.1	1.68
Breast (<i>in situ</i>)	*	*	*	*	*	43	34.5	2.41	40.8	2.80

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Delaware, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	41	249.1	18.05	287.8	20.90	51	248.8	15.90	286.6	18.36
Oral Cavity & Pharynx	3	17.3	4.41	20.1	5.16	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	10	64.6	9.35	73.3	10.62	6	30.2	5.50	35.6	6.43
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	2	13.4	4.31	14.6	4.76	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	1	7.8	3.00	8.0	3.10	2	10.9	3.33	12.5	3.83
Rectum & rectosigmoid	2	13.8	4.92	15.8	5.55	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	2	11.0	3.52	13.5	4.33	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	2	9.5	3.36	11.0	3.88	1	6.7	2.56	8.3	3.13
Respiratory System	5	33.7	7.67	38.5	8.66	5	25.2	5.44	29.8	6.38
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	4	31.3	7.49	35.7	8.44	4	23.5	5.16	27.9	6.10
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	20	99.6	10.09	115.7	11.69
Female Genital System	N/A	N/A	N/A	N/A	N/A	6	28.5	5.17	34.4	6.28
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	5	21.5	4.54	25.4	5.39
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	11	65.9	8.90	79.7	10.75	N/A	N/A	N/A	N/A	N/A
Prostate	11	65.0	8.86	79.0	10.72	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	3	17.4	4.53	20.5	5.33	2	9.3	3.13	10.1	3.39
Bladder (incl. <i>in situ</i>)	1	8.1	3.09	9.0	3.48	*	*	*	*	*
Kidney & renal pelvis	2	9.3	3.32	11.4	4.04	1	6.1	2.52	6.8	2.80
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	7	29.1	5.17	30.0	5.44
Thyroid gland	*	*	*	*	*	7	29.1	5.17	30.0	5.44
Lymphomas	3	17.5	4.86	20.6	5.83	2	8.1	2.77	10.1	3.47
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	2	9.0	3.10	9.1	3.28	1	7.6	2.93	8.5	3.31
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	9.7	3.45	11.0	3.95	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)	2	8.5	3.07	9.6	3.51	2	9.4	3.16	10.1	3.46
Brain & Other CNS (non-malignant)	2	8.5	3.07	9.6	3.51	2	9.4	3.16	10.1	3.46
Breast (<i>in situ</i>)	*	*	*	*	*	7	35.2	5.95	41.8	7.02

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Delaware, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	91	402.6	21.39	473.1	24.68	101	379.4	18.36	444.1	21.51
Oral Cavity & Pharynx	3	11.4	3.53	13.2	4.04	1	5.8	2.36	7.1	2.86
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	22	97.5	10.27	115.9	11.91	18	79.2	8.98	94.8	10.57
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	3	15.7	4.24	17.7	4.73	2	9.5	3.09	11.7	3.73
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	6	27.9	5.58	32.9	6.45	7	29.7	5.56	35.4	6.53
Rectum & rectosigmoid	3	9.9	2.64	12.0	3.33	2	9.2	2.86	10.8	3.33
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	4	21.6	4.92	25.3	5.58	1	5.5	2.38	6.5	2.72
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	2	11.7	3.99	13.4	4.44	2	11.8	3.80	13.9	4.45
Respiratory System	8	41.1	7.17	47.6	8.11	6	28.7	5.69	32.9	6.42
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	6	36.1	6.79	41.6	7.68	5	25.1	5.33	28.9	6.02
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	1	6.4	2.62	7.3	2.94	2	5.3	2.03	5.6	2.19
Breast (excl. <i>in situ</i>)	*	*	*	*	*	28	102.1	9.22	120.9	10.96
Female Genital System	N/A	N/A	N/A	N/A	N/A	14	51.8	6.62	61.1	7.79
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	6.3	1.93	6.7	2.17
Uterus corpus	N/A	N/A	N/A	N/A	N/A	7	29.5	5.13	36.5	6.25
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	3	9.1	2.74	10.2	3.06
Male Genital System	24	109.1	10.96	131.7	12.74	N/A	N/A	N/A	N/A	N/A
Prostate	22	102.3	10.72	124.4	12.50	N/A	N/A	N/A	N/A	N/A
Testis	2	4.1	1.33	4.2	1.42	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	9	49.9	8.42	59.6	9.78	5	19.4	4.12	22.7	4.81
Bladder (incl. <i>in situ</i>)	5	33.7	7.27	39.6	8.39	2	6.2	2.27	7.0	2.59
Kidney & renal pelvis	4	16.2	4.24	20.0	5.02	3	13.2	3.45	15.7	4.05
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	3	9.3	2.84	10.1	3.16	2	6.5	2.22	6.5	2.29
Brain	2	7.9	2.68	8.5	2.94	2	5.6	2.16	5.8	2.26
Endocrine System	2	3.8	1.38	4.3	1.68	11	28.4	3.97	32.2	4.72
Thyroid gland	1	3.5	1.35	4.1	1.66	10	27.7	3.95	31.5	4.70
Lymphomas	8	28.0	5.36	31.0	6.05	5	20.2	4.60	22.3	5.11
Hodgkin lymphoma	2	4.0	1.39	4.6	1.68	*	*	*	*	*
Non-Hodgkin lymphoma	6	23.9	5.18	26.4	5.81	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	1	7.3	3.08	8.2	3.40	2	8.4	2.99	10.1	3.52
Leukemias	5	17.0	4.21	18.4	4.83	4	12.3	3.02	14.4	3.66
Acute lymphocytic	2	4.4	1.43	3.9	1.44	1	1.9	0.80	1.6	0.64
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	1	5.2	2.43	5.7	2.75	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	3	15.0	4.58	17.7	5.34	2	6.7	2.42	7.9	2.92
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	2	6.9	2.33	7.9	2.74	4	11.0	2.87	12.2	3.23
Breast (<i>in situ</i>)	*	*	*	*	*	8	26.3	4.24	31.8	5.19

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

DELAWARE

II-108 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Delaware, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	61	328.4	21.12	384.2	24.29	73	332.4	18.64	388.6	21.88
Oral Cavity & Pharynx	2	9.7	3.61	10.9	4.07	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	16	83.9	10.35	100.2	12.06	14	75.4	9.43	90.3	11.15
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	3	15.9	4.68	17.8	5.19	1	7.8	3.13	9.8	3.83
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	4	21.4	5.25	25.6	6.15	5	28.3	5.80	33.6	6.81
Rectum & rectosigmoid	3	10.1	2.97	12.6	3.81	2	8.8	3.11	10.3	3.62
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	3	14.6	4.25	17.7	4.97	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	2	12.0	4.49	13.3	4.87	2	12.0	4.04	14.4	4.83
Respiratory System	6	37.3	7.40	43.1	8.33	4	22.8	5.38	26.4	6.11
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	5	33.1	7.00	38.4	7.93	3	20.3	5.16	23.6	5.87
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	1	7.5	3.09	8.7	3.46	1	5.0	2.20	5.4	2.39
Breast (excl. <i>in situ</i>)	*	*	*	*	*	18	79.9	8.91	96.1	10.74
Female Genital System	N/A	N/A	N/A	N/A	N/A	10	48.6	7.13	56.9	8.29
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	6.5	2.20	7.2	2.53
Uterus corpus	N/A	N/A	N/A	N/A	N/A	6	29.2	5.59	35.7	6.75
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	8.5	2.98	9.5	3.30
Male Genital System	14	76.1	10.14	89.1	11.48	N/A	N/A	N/A	N/A	N/A
Prostate	12	68.9	9.80	81.3	11.13	N/A	N/A	N/A	N/A	N/A
Testis	2	4.1	1.47	4.2	1.59	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	6	42.6	8.32	51.2	9.73	3	14.4	3.75	17.0	4.47
Bladder (incl. <i>in situ</i>)	4	30.5	7.34	36.1	8.52	*	*	*	*	*
Kidney & renal pelvis	2	12.1	3.90	15.0	4.70	3	12.2	3.54	14.6	4.22
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	8.8	2.95	9.7	3.33	2	6.6	2.42	6.3	2.40
Brain	2	7.5	2.75	8.1	3.06	2	5.8	2.36	5.7	2.36
Endocrine System	*	*	*	*	*	8	25.2	4.18	28.1	4.90
Thyroid gland	*	*	*	*	*	7	24.3	4.14	27.3	4.86
Lymphomas	5	23.2	5.40	25.9	6.16	4	18.9	4.63	20.7	5.16
Hodgkin lymphoma	1	3.2	1.36	3.6	1.60	*	*	*	*	*
Non-Hodgkin lymphoma	4	19.9	5.23	22.3	5.95	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	1	7.0	3.03	8.3	3.54
Leukemias	4	13.3	3.82	14.7	4.56	4	12.3	3.21	14.0	3.87
Acute lymphocytic	2	4.4	1.57	4.0	1.61	1	2.5	1.01	2.0	0.82
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	13.6	4.87	16.4	5.72	1	6.1	2.49	6.8	2.90
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	2	7.2	2.62	8.3	3.09	3	9.5	2.88	10.3	3.21
Breast (<i>in situ</i>)	*	*	*	*	*	6	22.7	4.35	27.0	5.22

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Delaware, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	8	320.2	62.96	379.9	71.95	7	224.5	45.59	262.0	52.24
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	3	77.3	26.98	88.1	30.86
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	4	150.3	38.58	190.1	46.44	N/A	N/A	N/A	N/A	N/A
Prostate	4	150.3	38.58	190.1	46.44	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

DELAWARE


II-110 Incidence – Hispanic Black

DISTRICT OF COLUMBIA CANCER REGISTRY

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	677,014	687,576	697,079	704,147	708,253
Non-Hispanic White	248,979	254,945	260,987	265,716	269,824
Non-Hispanic Black	324,521	325,644	325,889	325,534	323,111
Non-Hispanic Asian/Pacific Islander (NH API)	29,369	30,736	32,026	32,808	33,579
Non-Hispanic American Indian/Alaskan Native PRCA (NH AI/AN)	0	0	0	0	0


All Races Population 2015–2019: 3,474,069
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	72,338	74,409	76,328	78,217	79,838
Hispanic White	55,140	56,714	58,133	59,482	60,728
Hispanic Black	12,134	12,458	12,812	13,242	13,538

Hispanic/Latino Population, Census 2010: 54,749
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

DISTRICT OF COLUMBIA CANCER REGISTRY

Initial Operation: 1987
Population-based Data Available: 1987
Coverage Area: District of Columbia

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	95.5	96.3	102.5	99.3	98.4	98.4
Missing Race	1.9	2.2	2.7	0.6	1.0	1.7
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.8	0.6	3.1	2.5	2.6	1.9
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.0	Ovary	91.2
Oral Cavity & Pharynx	96.0	Prostate	97.5
Esophagus	90.9	Testis	98.1
Stomach	96.5	Bladder (incl. <i>in situ</i>)	97.6
Colon & Rectum	95.3	Kidney & Renal Pelvis	91.9
Liver	54.1	Brain & Other CNS	86.0
Pancreas	84.0	Brain & Other CNS (non-malig)	41.5
Lung & Bronchus	87.4	Thyroid	99.0
Melanomas of the Skin	99.4	Hodgkin Lymphoma	98.9
Female Breast (excl. <i>in situ</i>)	98.8	Non-Hodgkin Lymphoma	95.9
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	90.9
Cervix Uteri	94.5	Leukemias	87.6
Uterus Corpus & Uterus NOS	98.1		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
District of Columbia, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,359	447.7	5.59	535.7	6.60	1,497	401.2	4.76	472.6	5.57
Oral Cavity & Pharynx	51	16.8	1.08	20.2	1.28	23	6.1	0.58	7.1	0.67
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	17	5.5	0.62	6.7	0.74	5	1.4	0.29	1.6	0.32
Major salivary gland	3	1.2	0.29	1.3	0.31	5	1.3	0.26	1.5	0.30
Floor of mouth	1	0.4	0.16	0.5	0.19	1	0.3	0.11	0.3	0.14
Gum & other mouth	6	1.9	0.36	2.3	0.43	4	1.2	0.26	1.4	0.31
Nasopharynx	4	1.1	0.27	1.4	0.34	2	0.5	0.16	0.6	0.19
Oropharynx	4	1.3	0.31	1.5	0.35	2	0.5	0.17	0.7	0.21
Hypopharynx	5	1.5	0.32	1.8	0.38	*	*	*	*	*
Digestive System	312	102.6	2.67	124.2	3.19	269	71.1	1.99	85.1	2.36
Esophagus	17	6.0	0.66	7.2	0.78	7	1.7	0.30	2.1	0.36
Stomach	30	9.8	0.82	12.0	0.99	21	5.8	0.58	6.8	0.67
Small intestine	10	3.4	0.48	4.1	0.58	12	3.3	0.44	3.9	0.52
Colon (excl. rectum)	83	27.9	1.42	33.0	1.66	88	23.4	1.15	27.5	1.34
Rectum & rectosigmoid	35	11.5	0.89	13.7	1.05	32	8.6	0.70	10.1	0.82
Anus, anal canal, & anorectum	12	3.9	0.51	4.7	0.60	11	3.0	0.42	3.6	0.50
Liver	59	18.0	1.07	23.1	1.35	21	5.5	0.54	6.8	0.67
Gallbladder	2	0.8	0.24	1.0	0.29	4	1.2	0.25	1.4	0.30
Pancreas	51	17.6	1.13	21.0	1.32	55	14.1	0.86	17.2	1.05
Respiratory System	158	54.4	1.99	65.5	2.35	166	43.1	1.52	52.8	1.85
Larynx	15	4.9	0.60	6.1	0.72	5	1.3	0.27	1.7	0.33
Lung & bronchus	141	48.6	1.88	58.4	2.22	158	40.9	1.48	50.1	1.81
Bones & Joints	4	1.5	0.33	1.5	0.33	3	1.0	0.26	1.0	0.25
Soft Tissue (incl. heart)	12	3.8	0.51	4.1	0.56	9	2.5	0.38	2.7	0.41
Skin (excl. basal & sq.)	45	15.2	1.05	17.3	1.19	30	7.6	0.65	8.3	0.71
Melanoma of the skin	42	14.3	1.02	16.3	1.15	26	6.7	0.61	7.3	0.67
Breast (excl. <i>in situ</i>)	6	1.9	0.37	2.1	0.41	494	136.6	2.82	160.5	3.29
Female Genital System	N/A	N/A	N/A	N/A	N/A	203	54.4	1.74	65.2	2.08
Cervix uteri	N/A	N/A	N/A	N/A	N/A	29	7.8	0.67	8.7	0.75
Uterus corpus	N/A	N/A	N/A	N/A	N/A	105	27.6	1.23	34.1	1.50
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	8	2.2	0.37	2.7	0.44
Ovary	N/A	N/A	N/A	N/A	N/A	43	11.7	0.82	13.9	0.97
Male Genital System	428	137.4	3.05	168.7	3.69	N/A	N/A	N/A	N/A	N/A
Prostate	405	131.3	2.99	162.5	3.64	N/A	N/A	N/A	N/A	N/A
Testis	21	5.3	0.53	5.3	0.54	N/A	N/A	N/A	N/A	N/A
Penis	2	0.6	0.22	0.7	0.24	N/A	N/A	N/A	N/A	N/A
Urinary System	115	39.2	1.68	46.7	1.97	60	16.1	0.95	19.0	1.11
Bladder (incl. <i>in situ</i>)	65	23.3	1.32	27.2	1.53	27	7.3	0.63	8.5	0.74
Kidney & renal pelvis	47	14.9	1.00	18.2	1.20	32	8.4	0.68	9.9	0.80
Ureter	1	0.4	0.18	0.5	0.21	*	*	*	*	*
Eye & Orbit	2	0.6	0.21	0.6	0.22	2	0.5	0.17	0.5	0.18
Brain & Other CNS	19	6.0	0.65	6.3	0.68	14	3.6	0.45	4.1	0.51
Brain	18	5.6	0.63	5.9	0.66	13	3.3	0.43	3.8	0.49
Endocrine System	24	7.0	0.66	8.1	0.77	65	16.8	0.98	18.5	1.07
Thyroid gland	20	6.0	0.61	6.9	0.71	62	15.9	0.95	17.5	1.05
Lymphomas	63	20.4	1.19	23.2	1.35	54	14.1	0.88	16.1	1.01
Hodgkin lymphoma	9	2.6	0.41	2.7	0.42	10	2.2	0.33	2.3	0.35
Non-Hodgkin lymphoma	54	17.8	1.11	20.5	1.28	44	11.9	0.82	13.8	0.95
Multiple Myeloma	31	11.2	0.92	13.0	1.06	32	8.6	0.69	10.3	0.82
Leukemias	38	13.0	0.98	14.6	1.09	25	6.9	0.64	7.4	0.68
Acute lymphocytic	6	2.3	0.42	1.9	0.36	4	1.4	0.31	1.2	0.27
Chronic lymphocytic	12	4.2	0.56	5.2	0.67	7	1.8	0.32	2.1	0.36
Acute myeloid	11	3.7	0.52	4.2	0.59	8	2.0	0.35	2.2	0.37
Chronic myeloid	5	1.6	0.34	1.9	0.39	4	1.0	0.23	1.1	0.27
Other leukemias	4	1.1	0.28	1.3	0.32	2	0.7	0.20	0.8	0.23
Mesothelioma	1	0.4	0.18	0.5	0.20	1	0.3	0.13	0.4	0.15
Kaposi Sarcoma	9	2.4	0.37	2.8	0.43	*	*	*	*	*
Ill-Defined & Unknown	40	13.8	1.00	16.3	1.17	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	31	10.7	0.88	12.2	0.99	57	15.7	0.95	18.2	1.10
Breast (<i>in situ</i>)	*	*	*	*	*	136	38.9	1.53	45.5	1.77

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
District of Columbia, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	423	363.8	8.18	427.0	9.56	419	367.5	8.44	425.7	9.81
Oral Cavity & Pharynx	23	19.4	1.86	23.4	2.23	8	6.2	1.05	7.0	1.19
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	9	7.5	1.17	8.9	1.38	3	2.3	0.65	2.5	0.71
Major salivary gland	1	1.2	0.45	1.4	0.52	2	1.2	0.45	1.4	0.50
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	3	2.9	0.72	3.6	0.88	1	1.2	0.49	1.4	0.57
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	1	1.2	0.46	1.5	0.57	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	72	62.3	3.37	74.4	4.03	54	46.1	2.92	54.5	3.47
Esophagus	4	4.1	0.89	4.8	1.04	1	1.4	0.55	1.6	0.63
Stomach	6	5.4	0.97	6.7	1.21	3	2.7	0.72	3.1	0.84
Small intestine	3	2.4	0.66	3.1	0.83	2	2.1	0.60	2.5	0.75
Colon (excl. rectum)	20	17.2	1.78	19.9	2.08	20	17.0	1.76	20.1	2.10
Rectum & rectosigmoid	9	7.5	1.15	8.9	1.37	6	5.3	0.99	6.3	1.19
Anus, anal canal, & anorectum	4	3.4	0.75	4.4	0.98	2	2.0	0.61	2.5	0.75
Liver	7	6.1	1.05	7.6	1.30	1	1.1	0.46	1.3	0.55
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	14	12.8	1.56	14.7	1.80	13	11.4	1.46	13.6	1.74
Respiratory System	30	27.6	2.28	32.5	2.67	31	27.1	2.24	32.0	2.63
Larynx	3	2.9	0.77	3.3	0.87	*	*	*	*	*
Lung & bronchus	27	24.2	2.13	28.6	2.51	30	26.2	2.20	30.7	2.58
Bones & Joints	2	1.5	0.54	1.5	0.54	2	1.9	0.81	1.6	0.65
Soft Tissue (incl. heart)	5	4.6	0.97	4.9	1.00	2	2.5	0.84	2.6	0.82
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	22	16.5	1.69	18.2	1.91
Melanoma of the skin	34	28.6	2.28	32.8	2.62	21	15.3	1.63	16.8	1.83
Breast (excl. <i>in situ</i>)	2	1.5	0.52	1.6	0.57	160	145.7	5.33	171.1	6.31
Female Genital System	N/A	N/A	N/A	N/A	N/A	51	47.0	3.03	56.1	3.64
Cervix uteri	N/A	N/A	N/A	N/A	N/A	6	4.8	0.93	5.5	1.08
Uterus corpus	N/A	N/A	N/A	N/A	N/A	25	23.7	2.15	28.9	2.63
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	1	1.2	0.50	1.4	0.57
Ovary	N/A	N/A	N/A	N/A	N/A	13	12.0	1.54	14.4	1.87
Male Genital System	131	108.0	4.34	129.8	5.21	N/A	N/A	N/A	N/A	N/A
Prostate	114	98.7	4.19	120.1	5.07	N/A	N/A	N/A	N/A	N/A
Testis	15	8.2	1.02	8.4	1.07	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	42	37.8	2.65	44.1	3.08	15	13.8	1.66	15.9	1.91
Bladder (incl. <i>in situ</i>)	29	26.1	2.22	30.2	2.55	6	6.0	1.09	6.8	1.24
Kidney & renal pelvis	12	10.3	1.36	12.4	1.63	8	7.1	1.19	8.2	1.38
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	1	1.3	0.51	1.4	0.53	1	1.1	0.44	1.2	0.49
Brain & Other CNS	9	8.2	1.48	8.3	1.39	6	5.4	1.02	6.0	1.14
Brain	8	8.0	1.47	8.0	1.37	6	5.2	0.99	5.9	1.13
Endocrine System	12	9.0	1.27	10.2	1.43	27	19.8	1.93	21.3	2.10
Thyroid gland	11	7.3	1.05	8.5	1.27	26	18.9	1.88	20.3	2.06
Lymphomas	24	20.2	1.94	23.1	2.23	16	13.6	1.60	15.7	1.87
Hodgkin lymphoma	3	1.7	0.48	1.8	0.55	4	2.5	0.61	2.4	0.59
Non-Hodgkin lymphoma	21	18.5	1.88	21.3	2.16	12	11.1	1.48	13.2	1.77
Multiple Myeloma	8	7.5	1.20	8.8	1.40	6	4.8	0.95	5.8	1.13
Leukemias	14	13.0	1.62	14.8	1.81	9	8.6	1.51	8.5	1.40
Acute lymphocytic	2	2.6	0.79	2.4	0.71	2	2.8	1.02	2.2	0.78
Chronic lymphocytic	5	4.8	0.93	6.1	1.18	3	2.8	0.69	3.1	0.77
Acute myeloid	3	2.8	0.77	3.1	0.82	2	2.2	0.78	2.3	0.76
Chronic myeloid	2	1.9	0.62	2.1	0.68	*	*	*	*	*
Other leukemias	1	1.0	0.40	1.2	0.50	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	2	1.5	0.51	1.8	0.60	*	*	*	*	*
Ill-Defined & Unknown	12	10.5	1.42	12.2	1.65	9	7.2	1.13	8.2	1.29
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	11	9.8	1.36	11.2	1.54	14	12.1	1.53	14.0	1.78
Breast (<i>in situ</i>)	*	*	*	*	*	41	39.1	2.81	45.8	3.32

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
District of Columbia, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	803	511.6	8.36	617.3	9.85	929	426.6	6.50	505.7	7.54
Oral Cavity & Pharynx	25	15.6	1.45	18.8	1.72	13	5.8	0.75	7.0	0.88
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	7	4.7	0.80	5.8	0.97	2	0.8	0.27	0.9	0.32
Major salivary gland	1	0.9	0.37	1.1	0.42	2	1.1	0.32	1.2	0.35
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	2	1.3	0.43	1.5	0.48	3	1.4	0.37	1.6	0.43
Nasopharynx	2	1.5	0.43	1.8	0.51	1	0.7	0.27	0.8	0.31
Oropharynx	2	1.6	0.48	1.9	0.54	1	0.6	0.24	0.8	0.31
Hypopharynx	4	2.3	0.55	2.7	0.64	*	*	*	*	*
Digestive System	210	134.5	4.30	162.8	5.07	188	84.0	2.84	100.9	3.35
Esophagus	12	7.9	1.06	9.6	1.25	5	2.1	0.42	2.5	0.52
Stomach	18	12.1	1.31	14.5	1.53	15	7.1	0.84	8.4	0.98
Small intestine	7	4.5	0.79	5.4	0.92	8	4.1	0.66	4.8	0.76
Colon (excl. rectum)	53	35.8	2.27	42.6	2.64	60	27.3	1.63	32.1	1.89
Rectum & rectosigmoid	22	14.8	1.46	17.1	1.66	21	9.9	1.00	11.7	1.16
Anus, anal canal, & anorectum	8	5.4	0.89	6.1	0.99	8	3.7	0.63	4.5	0.74
Liver	48	27.4	1.83	35.1	2.28	17	7.4	0.83	9.2	1.01
Gallbladder	2	1.2	0.42	1.5	0.50	3	1.3	0.33	1.6	0.41
Pancreas	33	21.1	1.69	25.6	2.00	39	16.3	1.21	20.1	1.47
Respiratory System	120	78.0	3.30	94.0	3.89	127	54.4	2.21	67.0	2.69
Larynx	11	7.1	0.97	8.8	1.18	4	1.9	0.41	2.4	0.51
Lung & bronchus	107	69.9	3.14	83.9	3.68	121	51.7	2.15	63.7	2.62
Bones & Joints	2	1.6	0.49	1.6	0.49	1	0.7	0.27	0.8	0.31
Soft Tissue (incl. heart)	6	4.2	0.78	4.6	0.84	6	2.9	0.55	3.1	0.58
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	3	1.6	0.44	1.8	0.46
Melanoma of the skin	2	1.4	0.44	1.6	0.52	2	0.9	0.33	1.0	0.35
Breast (excl. <i>in situ</i>)	4	2.7	0.63	3.0	0.69	290	138.2	3.78	162.5	4.33
Female Genital System	N/A	N/A	N/A	N/A	N/A	126	58.1	2.41	69.0	2.79
Cervix uteri	N/A	N/A	N/A	N/A	N/A	17	8.6	0.99	9.5	1.06
Uterus corpus	N/A	N/A	N/A	N/A	N/A	67	29.4	1.65	35.9	1.98
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	6	3.0	0.58	3.6	0.67
Ovary	N/A	N/A	N/A	N/A	N/A	24	11.4	1.08	13.6	1.25
Male Genital System	253	154.2	4.48	191.6	5.43	N/A	N/A	N/A	N/A	N/A
Prostate	250	151.5	4.43	189.0	5.40	N/A	N/A	N/A	N/A	N/A
Testis	3	2.2	0.60	2.1	0.58	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	67	43.1	2.44	51.7	2.86	41	18.4	1.33	21.9	1.55
Bladder (incl. <i>in situ</i>)	33	22.0	1.77	26.1	2.06	19	8.4	0.88	10.0	1.03
Kidney & renal pelvis	33	20.2	1.64	24.6	1.94	21	9.5	0.97	11.3	1.12
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	8	5.1	0.85	5.3	0.88	6	3.0	0.55	3.3	0.61
Brain	7	4.4	0.78	4.7	0.82	5	2.4	0.49	2.8	0.56
Endocrine System	8	5.3	0.84	6.5	1.01	25	12.8	1.19	14.3	1.30
Thyroid gland	7	4.4	0.77	5.4	0.93	23	11.8	1.14	13.3	1.24
Lymphomas	28	18.5	1.64	21.3	1.83	29	13.7	1.19	15.6	1.33
Hodgkin lymphoma	3	2.5	0.62	2.6	0.63	4	2.1	0.46	2.3	0.50
Non-Hodgkin lymphoma	24	16.1	1.51	18.7	1.71	24	11.6	1.10	13.3	1.23
Multiple Myeloma	21	14.8	1.50	16.9	1.68	25	11.0	1.02	13.3	1.21
Leukemias	18	12.0	1.31	13.4	1.45	14	6.5	0.81	7.4	0.90
Acute lymphocytic	2	1.2	0.41	0.9	0.31	2	0.9	0.29	0.9	0.30
Chronic lymphocytic	5	3.8	0.76	4.4	0.86	3	1.1	0.31	1.4	0.38
Acute myeloid	7	4.5	0.80	5.1	0.91	5	2.2	0.47	2.4	0.50
Chronic myeloid	2	1.4	0.41	1.7	0.50	3	1.6	0.42	1.8	0.48
Other leukemias	2	1.2	0.42	1.3	0.44	2	0.8	0.28	0.9	0.33
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	6	3.7	0.69	4.0	0.74	*	*	*	*	*
Ill-Defined & Unknown	25	16.5	1.52	19.6	1.76	32	14.5	1.19	16.7	1.35
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	16	11.1	1.28	12.6	1.42	36	17.2	1.33	19.9	1.51
Breast (<i>in situ</i>)	*	*	*	*	*	77	37.7	2.01	44.4	2.30

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
District of Columbia, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	24	310.1	30.16	377.5	36.13	38	274.4	21.31	319.3	25.10
Oral Cavity & Pharynx	2	18.4	6.74	22.8	8.40	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	7	94.9	16.79	115.2	19.96	6	51.9	9.56	61.5	11.39
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	2	20.3	7.39	27.1	9.69	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	1	18.4	7.71	22.5	9.07	2	16.1	5.40	19.0	6.40
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	1	18.3	7.26	20.9	8.18	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	1	23.2	9.16	27.0	10.35	*	*	*	*	*
Respiratory System	3	52.9	13.40	62.9	15.67	3	27.8	7.13	33.8	8.60
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	3	47.9	12.83	57.7	15.12	3	26.7	7.04	32.9	8.55
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	12	82.4	11.14	94.1	13.06
Female Genital System	N/A	N/A	N/A	N/A	N/A	6	42.4	8.15	51.8	10.08
Cervix uteri	N/A	N/A	N/A	N/A	N/A	1	9.0	3.92	10.4	4.49
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2	15.2	4.95	19.8	6.44
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	11.3	3.83	12.8	4.53
Male Genital System	6	74.6	14.27	97.0	18.18	N/A	N/A	N/A	N/A	N/A
Prostate	6	73.6	14.24	96.2	18.16	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	2	20.6	7.41	26.4	9.41	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	3	17.2	4.92	19.9	5.84
Thyroid gland	*	*	*	*	*	3	16.8	4.90	19.5	5.82
Lymphomas	2	18.8	7.63	19.4	7.84	2	17.2	5.44	19.4	6.25
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	2	14.3	4.84	18.5	6.25
Breast (<i>in situ</i>)	*	*	*	*	*	6	40.1	7.72	46.6	9.33

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
District of Columbia, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	60	280.2	19.32	324.8	22.01	75	278.8	15.14	320.2	17.46
Oral Cavity & Pharynx	2	10.2	3.85	11.3	4.13	1	5.2	2.15	5.5	2.29
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	16	77.5	10.26	90.3	11.66	15	62.3	7.58	70.1	8.54
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	4	15.8	4.00	18.8	4.70	1	5.9	2.31	6.4	2.52
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	4	20.2	5.52	23.1	6.16	3	12.6	3.44	13.3	3.62
Rectum & rectosigmoid	2	6.7	2.30	9.0	3.09	3	9.9	2.91	11.3	3.37
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	2	7.7	2.68	10.1	3.43	2	8.2	2.70	10.0	3.23
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	2	19.4	6.19	20.7	6.59	2	10.7	3.47	12.0	3.94
Respiratory System	4	20.4	5.08	24.7	5.98	3	13.0	3.34	16.0	4.04
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	4	19.3	5.01	23.2	5.86	3	11.6	3.18	14.2	3.86
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	2	10.7	4.35	12.3	5.08	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	22	80.2	7.98	92.6	9.30
Female Genital System	N/A	N/A	N/A	N/A	N/A	12	39.1	5.35	47.1	6.48
Cervix uteri	N/A	N/A	N/A	N/A	N/A	4	10.2	2.50	10.9	2.76
Uterus corpus	N/A	N/A	N/A	N/A	N/A	5	18.5	3.77	23.2	4.64
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	3	8.0	2.26	10.1	2.92
Male Genital System	15	67.5	9.12	82.6	10.78	N/A	N/A	N/A	N/A	N/A
Prostate	12	60.9	8.95	75.7	10.61	N/A	N/A	N/A	N/A	N/A
Testis	2	4.8	1.45	4.8	1.42	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	3	15.2	4.81	18.0	5.69	2	8.7	2.62	10.3	3.07
Bladder (incl. <i>in situ</i>)	1	9.8	4.32	11.5	5.09	*	*	*	*	*
Kidney & renal pelvis	2	5.4	2.11	6.5	2.53	1	5.2	2.01	6.6	2.48
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	1	6.1	2.88	6.0	2.89	*	*	*	*	*
Brain	1	6.1	2.88	6.0	2.89	*	*	*	*	*
Endocrine System	2	5.4	1.64	5.3	1.60	7	21.6	3.69	24.9	4.37
Thyroid gland	2	5.1	1.61	4.9	1.57	7	21.3	3.68	24.6	4.36
Lymphomas	7	29.0	6.36	30.6	6.86	5	16.5	3.69	18.0	4.07
Hodgkin lymphoma	2	5.2	2.49	5.0	2.47	*	*	*	*	*
Non-Hodgkin lymphoma	5	23.8	5.86	25.6	6.40	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	2	6.6	2.48	8.5	3.10	1	6.6	2.57	7.5	2.87
Leukemias	5	20.1	5.18	22.9	5.83	1	5.1	2.08	5.0	2.09
Acute lymphocytic	2	5.6	2.61	5.5	3.04	*	*	*	*	*
Chronic lymphocytic	1	7.5	3.49	8.9	3.82	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	1	8.9	4.05	9.5	4.25	2	11.3	3.41	13.2	3.97
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	3	7.7	2.09	8.9	2.50	4	15.2	3.67	16.3	3.92
Breast (<i>in situ</i>)	*	*	*	*	*	10	34.5	4.94	39.7	5.76

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

District of Columbia

II-118 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
District of Columbia, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	57	343.6	24.92	395.7	28.03	65	310.9	18.06	357.6	20.88
Oral Cavity & Pharynx	2	13.7	5.32	15.2	5.66	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	15	96.5	13.56	111.5	15.18	13	70.1	9.12	78.8	10.24
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	3	17.9	4.87	20.9	5.63	1	7.7	2.97	8.2	3.24
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	4	26.6	7.38	30.1	8.11	3	15.5	4.42	16.4	4.66
Rectum & rectosigmoid	2	7.3	2.65	9.8	3.59	2	11.0	3.27	12.5	3.81
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	2	9.8	3.45	12.9	4.41	2	9.9	3.42	12.0	4.05
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	2	26.7	8.59	28.4	9.11	2	12.0	4.12	13.2	4.58
Respiratory System	3	20.2	5.56	24.6	6.59	3	13.2	3.75	16.2	4.52
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	3	18.6	5.45	22.5	6.41	2	11.3	3.50	14.0	4.24
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	2	13.5	5.47	15.5	6.36	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	19	87.9	9.45	102.4	11.12
Female Genital System	N/A	N/A	N/A	N/A	N/A	10	41.5	6.18	50.1	7.57
Cervix uteri	N/A	N/A	N/A	N/A	N/A	3	10.8	2.94	11.0	3.11
Uterus corpus	N/A	N/A	N/A	N/A	N/A	4	18.8	4.34	24.0	5.46
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	3	10.7	3.01	13.5	3.89
Male Genital System	14	81.1	11.62	98.5	13.55	N/A	N/A	N/A	N/A	N/A
Prostate	11	72.8	11.40	89.8	13.33	N/A	N/A	N/A	N/A	N/A
Testis	2	6.2	1.86	6.1	1.83	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	3	19.5	6.24	23.2	7.34	1	5.6	2.16	7.0	2.75
Bladder (incl. <i>in situ</i>)	1	12.6	5.61	14.8	6.58	*	*	*	*	*
Kidney & renal pelvis	2	6.9	2.74	8.4	3.27	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	1	8.2	3.97	8.1	3.97	*	*	*	*	*
Brain	1	8.2	3.97	8.1	3.97	*	*	*	*	*
Endocrine System	2	7.0	2.12	6.7	2.05	7	27.2	4.72	31.4	5.62
Thyroid gland	2	6.7	2.09	6.3	2.01	7	26.8	4.71	31.0	5.60
Lymphomas	7	38.1	8.59	40.2	9.17	4	20.6	4.74	22.4	5.20
Hodgkin lymphoma	2	6.8	3.45	6.7	3.42	*	*	*	*	*
Non-Hodgkin lymphoma	5	31.3	7.87	33.6	8.51	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	1	7.2	2.94	9.3	3.63	1	7.5	3.12	8.5	3.50
Leukemias	5	27.0	7.00	30.4	7.73	1	6.7	2.76	6.6	2.76
Acute lymphocytic	2	7.4	3.24	7.1	3.65	*	*	*	*	*
Chronic lymphocytic	1	10.3	4.88	12.0	5.28	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	2	12.7	4.00	15.0	4.66
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	3	9.6	2.62	11.2	3.15	4	20.0	4.86	21.5	5.19
Breast (<i>in situ</i>)	*	*	*	*	*	10	45.3	6.50	52.4	7.62

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
District of Columbia, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3	94.8	24.97	116.9	30.12	10	244.0	38.23	279.3	43.97
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	2	53.2	18.79	60.8	21.63
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	3	71.2	19.59	77.8	21.56
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	43.5	14.65	52.2	17.41
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1	24.2	10.33	28.6	12.05
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	1	30.3	13.03	38.8	16.21	N/A	N/A	N/A	N/A	N/A
Prostate	1	30.3	13.03	38.8	16.21	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.


N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	20,219,111	20,627,237	20,977,089	21,254,926	21,492,056
Non-Hispanic White	11,355,506	11,481,559	11,565,455	11,614,771	11,669,238
Non-Hispanic Black	3,251,173	3,313,181	3,369,356	3,415,427	3,455,819
Non-Hispanic Asian/Pacific Islander (NH API)	602,857	628,227	650,920	667,812	684,529
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	11,453	11,556	11,469	11,375	11,399


All Races Population 2015–2019: 104,570,419
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	4,951,209	5,144,983	5,331,295	5,496,345	5,621,362
Hispanic White	4,575,915	4,749,909	4,917,585	5,064,736	5,173,635
Hispanic Black	281,037	296,636	311,106	324,723	336,637

Hispanic/Latino Population, Census 2010: 4,223,806
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

FLORIDA CANCER REGISTRY

Initial Operation: 1981
 Population-based Data Available: 1981
 Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	114.1	111.9	110.8	110.4	106.2	110.7
Missing Race	2.0	2.0	1.7	1.7	2.4	1.9
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.4	1.4	1.4	1.6	1.9	1.5
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.3	Ovary	92.1
Oral Cavity & Pharynx	95.1	Prostate	92.9
Esophagus	93.3	Testis	96.7
Stomach	95.5	Bladder (incl. <i>in situ</i>)	96.4
Colon & Rectum	95.6	Kidney & Renal Pelvis	89.4
Liver	67.7	Brain & Other CNS	83.8
Pancreas	85.3	Brain & Other CNS (non-malig)	37.1
Lung & Bronchus	89.0	Thyroid	99.3
Melanomas of the Skin	99.1	Hodgkin Lymphoma	97.9
Female Breast (excl. <i>in situ</i>)	97.6	Non-Hodgkin Lymphoma	97.4
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	95.1
Cervix Uteri	96.6	Leukemias	95.6
Uterus Corpus & Uterus NOS	98.3		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Florida, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	69,346	498.0	0.86	592.8	1.02	65,385	433.4	0.80	506.4	0.91
Oral Cavity & Pharynx	2,992	21.7	0.18	26.8	0.22	1,067	6.9	0.10	8.3	0.12
Lip	59	0.4	0.03	0.5	0.03	18	0.1	0.01	0.1	0.01
Tongue	1,004	7.2	0.10	8.9	0.13	329	2.2	0.06	2.6	0.07
Major salivary gland	216	1.6	0.05	1.9	0.06	136	0.9	0.04	1.1	0.04
Floor of mouth	120	0.9	0.04	1.1	0.04	60	0.4	0.02	0.5	0.03
Gum & other mouth	257	1.9	0.05	2.3	0.06	190	1.2	0.04	1.4	0.05
Nasopharynx	102	0.8	0.04	1.0	0.04	43	0.3	0.02	0.4	0.03
Oropharynx	260	1.9	0.05	2.3	0.07	62	0.4	0.02	0.5	0.03
Hypopharynx	168	1.2	0.04	1.5	0.05	40	0.2	0.02	0.3	0.02
Digestive System	12,795	92.3	0.37	111.1	0.45	9,921	62.3	0.29	73.7	0.34
Esophagus	1,118	7.8	0.11	9.5	0.13	299	1.8	0.05	2.2	0.06
Stomach	1,060	7.7	0.11	9.1	0.13	654	4.2	0.08	4.9	0.09
Small intestine	351	2.6	0.06	3.1	0.07	284	1.9	0.05	2.2	0.06
Colon (excl. rectum)	3,893	28.6	0.21	34.0	0.25	3,810	24.1	0.18	28.2	0.21
Rectum & rectosigmoid	1,664	12.5	0.14	15.1	0.17	1,121	7.6	0.11	9.0	0.12
Anus, anal canal, & anorectum	244	1.8	0.05	2.3	0.07	461	3.0	0.06	3.7	0.08
Liver	1,567	10.8	0.12	13.6	0.16	537	3.2	0.06	4.0	0.08
Gallbladder	104	0.7	0.03	0.9	0.04	186	1.1	0.04	1.3	0.05
Pancreas	2,112	14.9	0.15	17.8	0.18	1,885	11.2	0.12	13.3	0.14
Respiratory System	10,231	71.0	0.32	85.4	0.38	8,750	51.9	0.25	62.2	0.30
Larynx	878	6.2	0.10	7.7	0.12	186	1.2	0.04	1.5	0.05
Lung & bronchus	9,193	63.5	0.30	76.2	0.36	8,468	50.0	0.25	60.0	0.30
Bones & Joints	162	1.5	0.05	1.5	0.05	112	1.0	0.04	1.0	0.04
Soft Tissue (incl. heart)	502	4.0	0.08	4.5	0.09	411	3.1	0.07	3.4	0.08
Skin (excl. basal & sq.)	5,101	37.1	0.24	43.5	0.28	2,958	20.2	0.18	23.3	0.20
Melanoma of the skin	4,690	34.2	0.23	40.1	0.27	2,746	18.9	0.17	21.8	0.19
Breast (excl. <i>in situ</i>)	177	1.3	0.04	1.5	0.05	17,860	122.4	0.43	143.7	0.50
Female Genital System	N/A	N/A	N/A	N/A	N/A	7,353	50.5	0.28	59.6	0.32
Cervix uteri	N/A	N/A	N/A	N/A	N/A	1,068	9.2	0.13	10.0	0.14
Uterus corpus	N/A	N/A	N/A	N/A	N/A	3,832	24.8	0.19	30.3	0.22
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	159	1.0	0.04	1.2	0.05
Ovary	N/A	N/A	N/A	N/A	N/A	1,630	11.1	0.13	13.0	0.15
Male Genital System	15,068	103.8	0.38	126.6	0.47	N/A	N/A	N/A	N/A	N/A
Prostate	14,461	97.9	0.37	120.6	0.45	N/A	N/A	N/A	N/A	N/A
Testis	473	4.9	0.10	4.9	0.10	N/A	N/A	N/A	N/A	N/A
Penis	106	0.8	0.04	0.9	0.04	N/A	N/A	N/A	N/A	N/A
Urinary System	7,581	54.1	0.28	63.9	0.33	3,083	19.2	0.16	22.5	0.19
Bladder (incl. <i>in situ</i>)	4,646	32.4	0.21	38.1	0.25	1,409	8.2	0.10	9.7	0.12
Kidney & renal pelvis	2,763	20.5	0.18	24.4	0.21	1,576	10.4	0.12	12.1	0.14
Ureter	111	0.8	0.03	0.9	0.04	66	0.4	0.02	0.4	0.02
Eye & Orbit	110	0.9	0.04	1.0	0.04	94	0.7	0.03	0.8	0.04
Brain & Other CNS	945	7.7	0.12	8.6	0.13	732	5.5	0.10	6.0	0.10
Brain	894	7.3	0.11	8.1	0.12	676	5.0	0.09	5.5	0.10
Endocrine System	868	7.4	0.12	8.2	0.13	2,266	19.4	0.19	21.1	0.20
Thyroid gland	751	6.4	0.11	7.1	0.12	2,164	18.6	0.19	20.2	0.20
Lymphomas	3,928	30.0	0.22	34.4	0.25	3,258	21.9	0.18	25.2	0.20
Hodgkin lymphoma	372	3.4	0.08	3.6	0.08	318	2.9	0.08	3.0	0.08
Non-Hodgkin lymphoma	3,556	26.6	0.20	30.8	0.23	2,940	19.1	0.17	22.2	0.19
Multiple Myeloma	1,396	9.9	0.12	11.9	0.14	1,114	6.8	0.10	8.1	0.11
Leukemias	2,871	21.7	0.19	24.6	0.21	2,102	14.1	0.15	15.9	0.16
Acute lymphocytic	237	2.4	0.07	2.2	0.07	178	1.7	0.06	1.6	0.05
Chronic lymphocytic	1,079	7.6	0.10	9.0	0.12	748	4.4	0.07	5.3	0.09
Acute myeloid	786	5.8	0.10	6.7	0.11	601	4.1	0.08	4.6	0.09
Chronic myeloid	418	3.2	0.07	3.6	0.08	303	2.1	0.06	2.4	0.06
Other leukemias	351	2.7	0.07	3.1	0.07	273	1.8	0.05	2.1	0.06
Mesothelioma	173	1.2	0.04	1.4	0.05	56	0.3	0.02	0.4	0.02
Kaposi Sarcoma	88	0.8	0.04	0.9	0.04	15	0.1	0.01	0.1	0.01
Ill-Defined & Unknown	4,358	31.7	0.22	37.0	0.25	4,232	27.0	0.20	31.1	0.22
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	1,211	9.6	0.13	10.9	0.14	2,518	17.2	0.16	19.7	0.18
Breast (<i>in situ</i>)	14	0.1	0.01	0.1	0.01	3,964	27.7	0.21	32.8	0.24

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Florida, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	50,395	517.2	1.10	615.3	1.28	45,511	459.1	1.08	536.1	1.22
Oral Cavity & Pharynx	2,347	25.3	0.25	31.5	0.30	797	8.0	0.14	9.6	0.16
Lip	50	0.6	0.04	0.7	0.04	16	0.2	0.02	0.2	0.02
Tongue	825	8.8	0.15	10.9	0.18	257	2.6	0.08	3.1	0.09
Major salivary gland	168	1.7	0.06	2.0	0.07	85	0.9	0.05	1.0	0.05
Floor of mouth	98	1.0	0.05	1.3	0.06	47	0.5	0.03	0.6	0.04
Gum & other mouth	187	2.0	0.07	2.4	0.08	140	1.3	0.05	1.5	0.06
Nasopharynx	56	0.6	0.04	0.8	0.05	24	0.3	0.03	0.3	0.03
Oropharynx	198	2.1	0.07	2.7	0.09	51	0.5	0.03	0.6	0.04
Hypopharynx	128	1.3	0.06	1.7	0.07	30	0.3	0.03	0.4	0.03
Digestive System	8,806	91.0	0.46	109.8	0.55	6,534	60.9	0.37	72.0	0.43
Esophagus	900	8.9	0.14	10.8	0.17	222	1.9	0.06	2.4	0.08
Stomach	639	6.5	0.12	7.8	0.14	329	3.1	0.08	3.6	0.10
Small intestine	237	2.5	0.08	3.0	0.09	181	1.8	0.07	2.1	0.08
Colon (excl. rectum)	2,626	27.8	0.26	33.0	0.30	2,525	23.6	0.23	27.6	0.27
Rectum & rectosigmoid	1,139	13.0	0.19	15.7	0.22	767	8.2	0.15	9.7	0.17
Anus, anal canal, & anorectum	170	1.9	0.07	2.4	0.08	333	3.4	0.09	4.1	0.11
Liver	1,027	10.1	0.15	12.8	0.18	317	2.9	0.08	3.5	0.09
Gallbladder	63	0.6	0.04	0.7	0.04	100	0.9	0.04	1.0	0.05
Pancreas	1,521	14.9	0.18	17.9	0.21	1,289	11.1	0.15	13.1	0.17
Respiratory System	7,843	75.8	0.40	91.5	0.48	7,064	61.0	0.34	73.4	0.41
Larynx	631	6.6	0.12	8.1	0.15	141	1.4	0.06	1.8	0.07
Lung & bronchus	7,097	67.9	0.37	81.8	0.45	6,856	58.9	0.33	70.8	0.40
Bones & Joints	100	1.5	0.08	1.6	0.08	68	1.0	0.06	1.0	0.06
Soft Tissue (incl. heart)	341	4.1	0.11	4.6	0.12	242	2.9	0.10	3.2	0.10
Skin (excl. basal & sq.)	4,710	49.6	0.35	57.9	0.40	2,635	29.3	0.29	33.4	0.32
Melanoma of the skin	4,346	46.1	0.34	53.9	0.39	2,468	27.8	0.29	31.7	0.31
Breast (excl. <i>in situ</i>)	126	1.3	0.05	1.5	0.06	12,102	128.0	0.59	150.1	0.66
Female Genital System	N/A	N/A	N/A	N/A	N/A	4,674	50.6	0.37	59.4	0.42
Cervix uteri	N/A	N/A	N/A	N/A	N/A	564	9.0	0.19	9.6	0.19
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2,445	24.4	0.24	29.7	0.29
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	78	0.8	0.05	0.9	0.05
Ovary	N/A	N/A	N/A	N/A	N/A	1,107	11.7	0.18	13.6	0.20
Male Genital System	9,655	94.6	0.45	114.9	0.54	N/A	N/A	N/A	N/A	N/A
Prostate	9,256	87.2	0.42	107.3	0.52	N/A	N/A	N/A	N/A	N/A
Testis	313	6.5	0.17	6.5	0.17	N/A	N/A	N/A	N/A	N/A
Penis	66	0.7	0.04	0.8	0.05	N/A	N/A	N/A	N/A	N/A
Urinary System	5,857	58.4	0.36	69.0	0.42	2,230	20.4	0.21	23.9	0.24
Bladder (incl. <i>in situ</i>)	3,764	35.7	0.27	42.2	0.32	1,095	9.2	0.13	10.9	0.16
Kidney & renal pelvis	1,956	21.3	0.23	25.3	0.27	1,060	10.5	0.16	12.3	0.18
Ureter	90	0.8	0.04	1.0	0.05	52	0.4	0.03	0.5	0.03
Eye & Orbit	86	1.0	0.05	1.1	0.06	73	0.9	0.05	1.0	0.06
Brain & Other CNS	666	8.6	0.17	9.6	0.18	492	6.0	0.14	6.6	0.14
Brain	638	8.2	0.16	9.1	0.17	462	5.6	0.13	6.1	0.14
Endocrine System	564	7.9	0.17	8.7	0.17	1,252	19.1	0.27	20.5	0.28
Thyroid gland	492	6.9	0.15	7.6	0.16	1,194	18.3	0.27	19.7	0.27
Lymphomas	2,775	30.8	0.29	35.3	0.32	2,209	22.4	0.24	25.8	0.27
Hodgkin lymphoma	212	3.5	0.12	3.6	0.12	179	3.0	0.11	3.1	0.11
Non-Hodgkin lymphoma	2,563	27.3	0.26	31.7	0.30	2,030	19.4	0.21	22.7	0.24
Multiple Myeloma	891	8.8	0.14	10.5	0.16	630	5.6	0.11	6.6	0.12
Leukemias	2,145	23.0	0.24	26.3	0.27	1,468	14.6	0.19	16.6	0.21
Acute lymphocytic	125	2.2	0.10	2.1	0.09	94	1.6	0.08	1.5	0.08
Chronic lymphocytic	865	8.4	0.13	10.0	0.16	587	5.0	0.10	6.0	0.12
Acute myeloid	589	6.2	0.12	7.1	0.14	397	4.0	0.10	4.6	0.11
Chronic myeloid	305	3.3	0.09	3.8	0.10	211	2.2	0.08	2.5	0.08
Other leukemias	260	2.8	0.09	3.3	0.10	180	1.8	0.07	2.1	0.08
Mesothelioma	147	1.4	0.05	1.6	0.06	42	0.4	0.03	0.4	0.03
Kaposi Sarcoma	39	0.6	0.04	0.6	0.05	8	0.1	0.01	0.1	0.01
Ill-Defined & Unknown	3,299	33.5	0.28	39.3	0.32	2,990	28.1	0.26	32.5	0.29
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	827	10.0	0.17	11.3	0.19	1,634	17.3	0.22	19.7	0.24
Breast (<i>in situ</i>)	9	0.1	0.01	0.1	0.02	2,571	28.4	0.28	33.5	0.32

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Florida, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	6,557	464.4	2.69	558.9	3.17	6,730	383.8	2.14	450.5	2.47
Oral Cavity & Pharynx	186	12.6	0.43	15.3	0.51	83	4.6	0.23	5.5	0.27
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	40	2.7	0.20	3.4	0.24	15	0.8	0.10	1.0	0.12
Major salivary gland	15	1.0	0.12	1.2	0.14	20	1.2	0.12	1.3	0.13
Floor of mouth	6	0.4	0.08	0.5	0.10	4	0.2	0.05	0.2	0.06
Gum & other mouth	21	1.5	0.15	1.7	0.17	16	0.9	0.10	1.0	0.12
Nasopharynx	17	1.1	0.12	1.2	0.14	8	0.4	0.07	0.5	0.08
Oropharynx	22	1.4	0.14	1.8	0.17	5	0.2	0.05	0.3	0.06
Hypopharynx	19	1.3	0.14	1.6	0.17	4	0.2	0.05	0.2	0.06
Digestive System	1,430	102.7	1.27	123.4	1.50	1,246	71.5	0.92	85.0	1.08
Esophagus	68	4.8	0.27	5.8	0.32	37	2.0	0.15	2.5	0.19
Stomach	167	12.6	0.46	15.0	0.54	127	7.5	0.30	8.7	0.35
Small intestine	55	4.0	0.25	4.8	0.30	49	2.8	0.18	3.3	0.21
Colon (excl. rectum)	470	34.2	0.74	40.8	0.87	463	26.7	0.57	31.6	0.66
Rectum & rectosigmoid	168	11.7	0.42	14.1	0.50	123	7.0	0.29	8.3	0.34
Anus, anal canal, & anorectum	28	1.9	0.16	2.2	0.19	31	1.8	0.15	2.1	0.17
Liver	186	12.1	0.41	15.2	0.51	77	4.1	0.21	5.1	0.26
Gallbladder	17	1.3	0.15	1.5	0.17	40	2.3	0.17	2.8	0.20
Pancreas	210	15.6	0.51	18.6	0.59	227	13.2	0.40	15.7	0.47
Respiratory System	876	64.0	1.02	77.4	1.20	612	34.5	0.64	41.8	0.76
Larynx	88	6.3	0.31	7.7	0.37	18	0.9	0.10	1.2	0.12
Lung & bronchus	775	56.9	0.96	68.8	1.14	583	32.9	0.62	39.8	0.74
Bones & Joints	17	1.1	0.12	1.1	0.12	15	0.9	0.10	0.9	0.10
Soft Tissue (incl. heart)	50	3.5	0.23	3.9	0.26	64	3.7	0.21	4.0	0.23
Skin (excl. basal & sq.)	37	2.8	0.21	3.2	0.24	32	1.9	0.15	2.1	0.17
Melanoma of the skin	24	1.9	0.18	2.2	0.20	17	1.0	0.11	1.2	0.13
Breast (excl. <i>in situ</i>)	23	1.7	0.17	2.0	0.19	1,982	112.9	1.16	132.5	1.34
Female Genital System	N/A	N/A	N/A	N/A	N/A	997	55.4	0.80	66.0	0.94
Cervix uteri	N/A	N/A	N/A	N/A	N/A	196	11.4	0.37	12.7	0.41
Uterus corpus	N/A	N/A	N/A	N/A	N/A	545	29.4	0.58	36.1	0.69
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	39	2.1	0.16	2.6	0.19
Ovary	N/A	N/A	N/A	N/A	N/A	154	8.7	0.32	10.3	0.37
Male Genital System	2,232	150.7	1.49	187.4	1.81	N/A	N/A	N/A	N/A	N/A
Prostate	2,198	148.3	1.48	184.8	1.79	N/A	N/A	N/A	N/A	N/A
Testis	18	1.2	0.13	1.1	0.12	N/A	N/A	N/A	N/A	N/A
Penis	13	1.0	0.13	1.2	0.15	N/A	N/A	N/A	N/A	N/A
Urinary System	464	34.6	0.75	41.1	0.88	282	16.1	0.44	19.0	0.51
Bladder (incl. <i>in situ</i>)	187	15.3	0.53	17.9	0.61	82	4.9	0.24	5.7	0.28
Kidney & renal pelvis	271	18.9	0.53	22.6	0.63	194	10.9	0.36	12.8	0.42
Ureter	3	0.2	0.05	0.2	0.07	2	0.1	0.04	0.1	0.04
Eye & Orbit	5	0.3	0.06	0.3	0.05	4	0.2	0.05	0.2	0.05
Brain & Other CNS	72	4.8	0.26	5.1	0.28	62	3.5	0.20	3.8	0.22
Brain	66	4.4	0.25	4.7	0.27	56	3.1	0.19	3.5	0.21
Endocrine System	63	4.3	0.25	4.8	0.28	219	12.6	0.39	14.0	0.43
Thyroid gland	46	3.1	0.21	3.6	0.24	200	11.5	0.37	12.9	0.41
Lymphomas	323	22.4	0.58	25.3	0.65	283	16.4	0.44	18.5	0.50
Hodgkin lymphoma	51	3.2	0.21	3.4	0.22	41	2.3	0.17	2.4	0.17
Non-Hodgkin lymphoma	272	19.2	0.54	21.9	0.61	241	14.1	0.41	16.0	0.47
Multiple Myeloma	236	17.8	0.55	21.2	0.64	245	14.1	0.41	16.8	0.48
Leukemias	206	15.2	0.50	17.2	0.56	186	10.8	0.36	12.2	0.40
Acute lymphocytic	25	1.6	0.15	1.5	0.15	18	1.1	0.11	1.1	0.11
Chronic lymphocytic	61	4.6	0.28	5.4	0.32	42	2.5	0.17	2.9	0.20
Acute myeloid	63	4.7	0.28	5.3	0.31	63	3.7	0.21	4.1	0.23
Chronic myeloid	33	2.4	0.20	2.8	0.23	27	1.6	0.14	1.8	0.15
Other leukemias	25	1.9	0.18	2.1	0.20	36	2.0	0.15	2.4	0.18
Mesothelioma	6	0.5	0.09	0.5	0.10	3	0.2	0.05	0.2	0.06
Kaposi Sarcoma	21	1.3	0.14	1.4	0.15	3	0.2	0.05	0.2	0.05
Ill-Defined & Unknown	311	24.2	0.65	28.3	0.75	412	24.3	0.55	27.9	0.62
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	133	9.9	0.40	11.3	0.46	313	18.2	0.47	20.9	0.53
Breast (<i>in situ</i>)	2	0.2	0.05	0.2	0.05	494	27.6	0.57	33.0	0.67

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Florida, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	657	220.2	3.97	259.8	4.65	942	241.4	3.60	279.8	4.13
Oral Cavity & Pharynx	32	10.3	0.83	12.3	0.99	15	3.7	0.44	4.3	0.51
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	7	2.4	0.42	2.9	0.49	5	1.2	0.24	1.4	0.28
Major salivary gland	3	0.9	0.25	1.0	0.29	2	0.5	0.16	0.6	0.20
Floor of mouth	*	*	*	*	*	1	0.3	0.11	0.3	0.13
Gum & other mouth	6	1.9	0.35	2.4	0.43	3	0.9	0.24	1.0	0.27
Nasopharynx	8	2.6	0.41	3.0	0.47	2	0.6	0.17	0.6	0.18
Oropharynx	1	0.4	0.16	0.5	0.19	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	179	59.5	2.05	71.2	2.43	154	40.9	1.52	47.3	1.73
Esophagus	8	2.5	0.41	2.8	0.46	4	0.9	0.22	1.1	0.25
Stomach	20	6.6	0.67	7.9	0.80	15	4.1	0.48	4.8	0.56
Small intestine	3	1.0	0.25	1.2	0.31	2	0.6	0.17	0.7	0.21
Colon (excl. rectum)	45	15.2	1.04	17.9	1.23	55	15.0	0.93	17.0	1.05
Rectum & rectosigmoid	33	10.8	0.86	13.0	1.02	21	5.2	0.53	6.2	0.61
Anus, anal canal, & anorectum	*	*	*	*	*	2	0.5	0.17	0.6	0.18
Liver	36	11.6	0.88	14.3	1.08	15	4.1	0.49	4.9	0.57
Gallbladder	1	0.5	0.18	0.5	0.19	3	0.8	0.22	1.0	0.26
Pancreas	20	7.0	0.74	8.4	0.88	24	6.2	0.58	7.2	0.67
Respiratory System	88	30.5	1.53	36.2	1.79	90	23.2	1.13	27.3	1.31
Larynx	5	1.5	0.34	1.9	0.41	*	*	*	*	*
Lung & bronchus	82	28.5	1.48	33.8	1.73	88	22.7	1.12	26.7	1.30
Bones & Joints	3	1.1	0.28	1.1	0.28	1	0.4	0.15	0.4	0.14
Soft Tissue (incl. heart)	5	1.7	0.35	1.9	0.37	10	2.7	0.39	2.9	0.42
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	6	2.0	0.37	2.2	0.42	4	1.1	0.25	1.2	0.27
Breast (excl. <i>in situ</i>)	2	0.7	0.21	0.8	0.25	318	79.3	2.03	92.9	2.35
Female Genital System	N/A	N/A	N/A	N/A	N/A	128	31.5	1.27	37.4	1.49
Cervix uteri	N/A	N/A	N/A	N/A	N/A	20	5.1	0.52	5.6	0.57
Uterus corpus	N/A	N/A	N/A	N/A	N/A	67	15.8	0.88	19.4	1.07
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	3	0.7	0.19	0.8	0.21
Ovary	N/A	N/A	N/A	N/A	N/A	31	7.8	0.64	9.2	0.75
Male Genital System	128	41.5	1.68	49.9	2.00	N/A	N/A	N/A	N/A	N/A
Prostate	121	39.5	1.64	47.9	1.97	N/A	N/A	N/A	N/A	N/A
Testis	5	1.6	0.31	1.6	0.31	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	52	17.9	1.14	21.0	1.34	26	7.2	0.65	8.3	0.74
Bladder (incl. <i>in situ</i>)	29	10.2	0.89	12.1	1.04	8	2.3	0.37	2.6	0.42
Kidney & renal pelvis	22	7.1	0.70	8.3	0.81	17	4.6	0.51	5.3	0.58
Ureter	1	0.5	0.18	0.5	0.20	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	13	4.3	0.55	4.7	0.61	8	2.3	0.37	2.4	0.37
Brain	11	3.8	0.52	4.3	0.58	8	2.2	0.35	2.2	0.35
Endocrine System	16	4.9	0.56	5.7	0.65	66	17.2	0.96	18.6	1.03
Thyroid gland	15	4.5	0.53	5.3	0.62	63	16.6	0.94	17.9	1.02
Lymphomas	47	15.7	1.05	18.1	1.20	42	11.0	0.78	12.7	0.89
Hodgkin lymphoma	5	1.6	0.33	1.7	0.37	3	1.1	0.26	1.1	0.26
Non-Hodgkin lymphoma	42	14.1	0.99	16.4	1.15	39	9.9	0.73	11.7	0.85
Multiple Myeloma	15	5.4	0.65	6.5	0.76	12	3.0	0.39	3.5	0.46
Leukemias	28	9.4	0.80	10.3	0.88	26	6.6	0.60	7.6	0.68
Acute lymphocytic	5	1.8	0.36	1.6	0.31	3	1.0	0.25	0.9	0.24
Chronic lymphocytic	6	2.1	0.38	2.4	0.44	5	1.2	0.25	1.5	0.31
Acute myeloid	8	2.4	0.40	2.8	0.46	11	3.0	0.41	3.4	0.45
Chronic myeloid	6	1.9	0.36	2.1	0.39	3	0.7	0.18	0.9	0.23
Other leukemias	4	1.2	0.29	1.4	0.34	3	0.7	0.19	0.8	0.23
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	40	14.7	1.10	17.1	1.27	40	10.9	0.79	12.4	0.89
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	19	6.3	0.68	7.4	0.80	50	13.1	0.85	15.1	0.97
Breast (<i>in situ</i>)	*	*	*	*	*	94	23.2	1.09	27.4	1.27

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Florida, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	19	284.8	30.49	346.4	36.30	21	329.3	33.81	365.4	36.30
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	5	74.1	15.18	91.5	18.39	4	53.2	12.17	68.0	15.31
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	1	19.0	7.33	25.4	9.61	2	27.8	9.01	34.8	11.14
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	1	17.5	7.29	21.6	8.86	*	*	*	*	*
Respiratory System	2	28.3	9.12	36.4	11.56	2	27.9	9.67	31.8	10.69
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	2	25.9	8.81	32.8	10.96	2	27.9	9.67	31.8	10.69
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	5	89.4	17.92	97.3	18.90
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	42.5	13.25	41.1	12.45
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1	27.1	10.62	26.2	9.96
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	4	61.5	13.42	80.7	17.36	N/A	N/A	N/A	N/A	N/A
Prostate	4	61.5	13.42	80.7	17.36	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	2	34.7	11.52	39.3	12.70	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	2	28.9	9.98	33.0	11.03	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	1	24.8	9.80	29.1	11.27	2	24.8	9.36	28.1	10.03
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	1	18.9	7.88	20.7	8.50
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	1	16.7	7.01	21.4	8.77	1	23.2	8.87	26.9	10.24
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Florida, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	9,812	423.3	1.94	501.3	2.29	10,811	371.6	1.61	432.9	1.87
Oral Cavity & Pharynx	369	15.2	0.36	18.4	0.43	152	5.1	0.19	6.1	0.22
Lip	6	0.3	0.05	0.3	0.06	*	*	*	*	*
Tongue	112	4.6	0.20	5.6	0.24	48	1.6	0.11	1.9	0.12
Major salivary gland	27	1.1	0.10	1.3	0.12	25	0.8	0.08	1.0	0.09
Floor of mouth	14	0.6	0.07	0.7	0.09	7	0.2	0.04	0.3	0.05
Gum & other mouth	36	1.6	0.12	1.9	0.14	28	0.9	0.08	1.1	0.09
Nasopharynx	18	0.7	0.08	0.8	0.09	6	0.2	0.04	0.3	0.05
Oropharynx	33	1.3	0.10	1.7	0.13	6	0.2	0.04	0.2	0.04
Hypopharynx	17	0.7	0.08	0.9	0.10	5	0.2	0.03	0.2	0.04
Digestive System	2,154	92.8	0.91	110.9	1.08	1,833	62.2	0.65	73.5	0.77
Esophagus	119	5.2	0.22	6.2	0.26	32	1.1	0.08	1.3	0.10
Stomach	214	9.3	0.29	10.9	0.34	171	5.8	0.20	6.8	0.23
Small intestine	49	2.1	0.14	2.5	0.16	47	1.6	0.11	1.9	0.12
Colon (excl. rectum)	685	29.8	0.52	35.3	0.61	707	24.1	0.41	28.2	0.48
Rectum & rectosigmoid	292	12.1	0.32	14.6	0.39	191	6.5	0.21	7.7	0.25
Anus, anal canal, & anorectum	38	1.6	0.11	1.9	0.14	87	2.9	0.14	3.6	0.17
Liver	297	12.4	0.33	15.4	0.40	122	4.1	0.17	4.9	0.20
Gallbladder	21	0.9	0.09	1.1	0.11	39	1.3	0.09	1.6	0.11
Pancreas	324	14.3	0.36	17.0	0.43	317	10.8	0.27	12.7	0.32
Respiratory System	1,261	56.8	0.73	67.3	0.85	888	30.1	0.45	35.8	0.54
Larynx	138	5.9	0.23	7.2	0.28	24	0.8	0.07	1.0	0.09
Lung & bronchus	1,096	49.8	0.68	58.8	0.80	849	28.8	0.44	34.2	0.53
Bones & Joints	38	1.5	0.11	1.6	0.12	27	1.0	0.09	1.0	0.09
Soft Tissue (incl. heart)	96	4.0	0.18	4.5	0.21	88	3.1	0.15	3.5	0.17
Skin (excl. basal & sq.)	179	7.7	0.26	9.0	0.31	170	5.9	0.20	6.7	0.23
Melanoma of the skin	153	6.5	0.24	7.7	0.28	147	5.1	0.19	5.8	0.22
Breast (excl. <i>in situ</i>)	21	0.9	0.09	1.1	0.11	3,107	106.8	0.86	125.7	1.01
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,430	48.9	0.58	57.8	0.69
Cervix uteri	N/A	N/A	N/A	N/A	N/A	269	9.6	0.26	10.5	0.29
Uterus corpus	N/A	N/A	N/A	N/A	N/A	724	24.3	0.41	29.7	0.49
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	37	1.2	0.09	1.5	0.11
Ovary	N/A	N/A	N/A	N/A	N/A	300	10.3	0.27	12.1	0.31
Male Genital System	2,413	102.5	0.95	124.3	1.14	N/A	N/A	N/A	N/A	N/A
Prostate	2,263	96.9	0.93	118.6	1.12	N/A	N/A	N/A	N/A	N/A
Testis	121	4.3	0.18	4.3	0.17	N/A	N/A	N/A	N/A	N/A
Penis	25	1.1	0.10	1.2	0.11	N/A	N/A	N/A	N/A	N/A
Urinary System	1,014	44.9	0.64	53.0	0.75	481	16.4	0.34	19.3	0.39
Bladder (incl. <i>in situ</i>)	516	24.1	0.48	28.2	0.56	181	6.1	0.20	7.2	0.24
Kidney & renal pelvis	473	19.7	0.41	23.4	0.49	286	9.8	0.26	11.5	0.30
Ureter	17	0.8	0.09	0.9	0.10	10	0.3	0.05	0.4	0.06
Eye & Orbit	17	0.7	0.08	0.8	0.09	15	0.5	0.06	0.6	0.07
Brain & Other CNS	180	7.3	0.25	8.2	0.28	159	5.7	0.20	6.1	0.22
Brain	166	6.7	0.24	7.6	0.27	141	5.0	0.19	5.4	0.21
Endocrine System	209	8.2	0.26	9.3	0.29	695	24.8	0.42	27.2	0.46
Thyroid gland	185	7.3	0.24	8.3	0.28	675	24.1	0.42	26.4	0.46
Lymphomas	672	28.3	0.50	32.4	0.57	616	21.3	0.39	24.5	0.44
Hodgkin lymphoma	92	3.6	0.17	3.8	0.18	82	3.0	0.15	3.1	0.15
Non-Hodgkin lymphoma	579	24.7	0.47	28.6	0.54	534	18.3	0.36	21.4	0.42
Multiple Myeloma	207	9.1	0.29	10.8	0.34	193	6.5	0.21	7.8	0.25
Leukemias	406	17.5	0.39	19.4	0.44	357	12.6	0.30	13.9	0.33
Acute lymphocytic	79	3.1	0.16	2.9	0.15	59	2.2	0.13	2.2	0.13
Chronic lymphocytic	100	4.5	0.20	5.3	0.24	79	2.7	0.14	3.2	0.16
Acute myeloid	115	5.0	0.21	5.8	0.25	119	4.2	0.17	4.7	0.19
Chronic myeloid	61	2.6	0.15	3.0	0.17	54	1.9	0.12	2.1	0.13
Other leukemias	51	2.2	0.14	2.5	0.16	46	1.6	0.10	1.8	0.12
Mesothelioma	17	0.8	0.09	0.9	0.10	9	0.3	0.04	0.4	0.05
Kaposi Sarcoma	24	0.9	0.09	1.0	0.10	3	0.1	0.02	0.1	0.03
Ill-Defined & Unknown	534	24.2	0.48	28.2	0.55	589	20.2	0.37	23.1	0.43
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	215	9.1	0.28	10.3	0.32	487	16.7	0.34	19.4	0.39
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.03	733	25.2	0.42	29.8	0.49

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

FLORIDA

II-128 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Florida, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	8,883	406.5	1.96	481.2	2.31	9,826	357.9	1.63	416.9	1.89
Oral Cavity & Pharynx	335	14.7	0.36	17.8	0.44	141	5.0	0.19	6.0	0.23
Lip	6	0.3	0.05	0.3	0.06	*	*	*	*	*
Tongue	105	4.6	0.20	5.6	0.25	45	1.6	0.11	1.9	0.13
Major salivary gland	24	1.1	0.10	1.3	0.12	22	0.8	0.08	1.0	0.09
Floor of mouth	13	0.6	0.07	0.7	0.09	6	0.2	0.04	0.3	0.05
Gum & other mouth	33	1.5	0.12	1.8	0.14	25	0.9	0.08	1.0	0.09
Nasopharynx	16	0.7	0.08	0.8	0.09	6	0.2	0.04	0.3	0.05
Oropharynx	29	1.2	0.10	1.6	0.13	6	0.2	0.04	0.2	0.05
Hypopharynx	15	0.7	0.08	0.9	0.10	5	0.2	0.03	0.2	0.04
Digestive System	1,953	89.2	0.92	106.6	1.09	1,669	59.7	0.66	70.5	0.77
Esophagus	108	5.0	0.22	6.0	0.26	29	1.0	0.08	1.2	0.10
Stomach	191	8.8	0.29	10.4	0.34	152	5.5	0.20	6.4	0.23
Small intestine	44	2.0	0.14	2.3	0.16	41	1.5	0.11	1.7	0.12
Colon (excl. rectum)	618	28.5	0.52	33.8	0.61	647	23.2	0.41	27.2	0.48
Rectum & rectosigmoid	267	11.7	0.33	14.2	0.39	172	6.2	0.21	7.4	0.25
Anus, anal canal, & anorectum	36	1.6	0.12	1.9	0.14	83	2.9	0.14	3.6	0.18
Liver	272	12.1	0.33	14.9	0.41	113	4.0	0.17	4.8	0.20
Gallbladder	18	0.9	0.09	1.0	0.11	34	1.2	0.09	1.4	0.11
Pancreas	294	13.8	0.36	16.3	0.43	292	10.4	0.27	12.2	0.32
Respiratory System	1,172	55.8	0.74	66.1	0.87	822	29.4	0.46	34.9	0.55
Larynx	125	5.7	0.23	7.0	0.28	21	0.8	0.07	0.9	0.09
Lung & bronchus	1,021	49.1	0.70	57.9	0.81	787	28.1	0.45	33.4	0.53
Bones & Joints	35	1.5	0.11	1.5	0.12	24	1.0	0.09	1.0	0.09
Soft Tissue (incl. heart)	86	3.8	0.19	4.3	0.21	80	3.0	0.15	3.3	0.17
Skin (excl. basal & sq.)	163	7.5	0.27	8.7	0.31	156	5.7	0.21	6.5	0.23
Melanoma of the skin	140	6.4	0.24	7.5	0.29	135	5.0	0.19	5.7	0.22
Breast (excl. <i>in situ</i>)	18	0.8	0.09	1.0	0.11	2,817	102.7	0.87	120.9	1.02
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,293	46.9	0.59	55.4	0.69
Cervix uteri	N/A	N/A	N/A	N/A	N/A	241	9.2	0.27	10.1	0.29
Uterus corpus	N/A	N/A	N/A	N/A	N/A	651	23.2	0.41	28.3	0.50
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	33	1.2	0.09	1.4	0.11
Ovary	N/A	N/A	N/A	N/A	N/A	274	10.0	0.27	11.7	0.32
Male Genital System	2,130	95.7	0.94	116.2	1.13	N/A	N/A	N/A	N/A	N/A
Prostate	1,995	90.3	0.92	110.7	1.11	N/A	N/A	N/A	N/A	N/A
Testis	107	4.2	0.18	4.1	0.18	N/A	N/A	N/A	N/A	N/A
Penis	23	1.0	0.10	1.2	0.11	N/A	N/A	N/A	N/A	N/A
Urinary System	920	43.2	0.65	50.9	0.76	430	15.5	0.34	18.2	0.39
Bladder (incl. <i>in situ</i>)	473	23.3	0.49	27.2	0.56	163	5.8	0.20	6.9	0.24
Kidney & renal pelvis	425	18.8	0.41	22.4	0.49	254	9.3	0.26	10.8	0.30
Ureter	15	0.7	0.09	0.9	0.10	9	0.3	0.05	0.4	0.06
Eye & Orbit	17	0.7	0.08	0.8	0.09	14	0.5	0.06	0.6	0.07
Brain & Other CNS	163	7.1	0.25	7.9	0.28	145	5.5	0.21	6.0	0.22
Brain	151	6.6	0.24	7.4	0.27	129	4.9	0.20	5.3	0.21
Endocrine System	193	8.1	0.26	9.2	0.30	648	24.8	0.44	27.1	0.48
Thyroid gland	171	7.2	0.25	8.2	0.28	629	24.0	0.43	26.3	0.47
Lymphomas	621	27.8	0.51	31.9	0.58	560	20.6	0.39	23.6	0.45
Hodgkin lymphoma	86	3.6	0.18	3.8	0.19	74	2.9	0.15	3.0	0.16
Non-Hodgkin lymphoma	535	24.2	0.48	28.1	0.55	487	17.7	0.36	20.6	0.42
Multiple Myeloma	187	8.7	0.29	10.4	0.34	171	6.1	0.21	7.3	0.25
Leukemias	372	17.1	0.40	19.0	0.45	325	12.2	0.31	13.5	0.34
Acute lymphocytic	71	3.1	0.16	2.8	0.15	55	2.3	0.14	2.2	0.13
Chronic lymphocytic	93	4.4	0.21	5.2	0.24	72	2.6	0.14	3.0	0.16
Acute myeloid	107	5.0	0.22	5.7	0.25	109	4.0	0.17	4.5	0.20
Chronic myeloid	56	2.5	0.15	2.9	0.18	48	1.8	0.12	2.0	0.13
Other leukemias	46	2.1	0.14	2.4	0.16	40	1.5	0.10	1.7	0.12
Mesothelioma	15	0.8	0.09	0.9	0.10	8	0.3	0.04	0.4	0.06
Kaposi Sarcoma	21	0.9	0.09	1.0	0.10	2	0.1	0.02	0.1	0.03
Ill-Defined & Unknown	482	23.1	0.48	26.9	0.55	523	18.9	0.37	21.7	0.43
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	190	8.5	0.28	9.7	0.32	435	15.9	0.34	18.3	0.39
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.03	672	24.6	0.43	29.1	0.50

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Florida, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	283	290.2	8.63	346.8	10.20	309	248.0	6.49	293.6	7.68
Oral Cavity & Pharynx	12	10.4	1.40	12.7	1.69	4	3.2	0.75	3.8	0.90
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	1.9	0.64	2.3	0.73	*	*	*	*	*
Major salivary gland	1	1.4	0.55	1.6	0.63	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	2	1.7	0.58	2.0	0.67	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	1	0.9	0.38	1.3	0.52	*	*	*	*	*
Digestive System	66	72.9	4.54	86.7	5.34	56	47.0	2.89	57.0	3.48
Esophagus	4	3.8	0.93	4.4	1.06	1	0.9	0.35	1.2	0.48
Stomach	7	8.7	1.75	10.2	2.05	6	5.3	0.96	6.5	1.18
Small intestine	2	2.8	1.02	3.4	1.26	3	2.2	0.59	2.7	0.73
Colon (excl. rectum)	22	24.2	2.69	28.2	3.10	17	14.6	1.62	17.6	1.95
Rectum & rectosigmoid	7	6.8	1.28	8.2	1.55	6	4.5	0.87	5.4	1.05
Anus, anal canal, & anorectum	*	*	*	*	*	1	1.0	0.36	1.3	0.50
Liver	7	6.8	1.22	8.6	1.51	3	2.8	0.70	3.4	0.85
Gallbladder	1	1.6	0.61	1.8	0.70	2	1.7	0.54	2.0	0.64
Pancreas	12	12.5	1.76	14.9	2.08	12	10.1	1.36	12.0	1.60
Respiratory System	33	33.3	2.83	40.0	3.35	24	21.3	1.98	25.4	2.32
Larynx	6	5.6	1.17	6.8	1.42	2	1.3	0.47	1.7	0.61
Lung & bronchus	26	27.3	2.57	32.6	3.02	22	19.7	1.92	23.3	2.22
Bones & Joints	1	1.2	0.53	1.3	0.60	*	*	*	*	*
Soft Tissue (incl. heart)	5	3.7	0.81	4.3	0.97	4	2.5	0.59	2.8	0.68
Skin (excl. basal & sq.)	2	1.7	0.73	2.2	0.94	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	1	1.2	0.53	1.5	0.64	90	71.4	3.45	85.1	4.10
Female Genital System	N/A	N/A	N/A	N/A	N/A	48	37.5	2.49	44.9	2.96
Cervix uteri	N/A	N/A	N/A	N/A	N/A	11	7.9	1.09	9.0	1.26
Uterus corpus	N/A	N/A	N/A	N/A	N/A	25	20.0	1.83	24.5	2.23
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	1.6	0.52	2.0	0.64
Ovary	N/A	N/A	N/A	N/A	N/A	7	5.6	0.98	6.4	1.12
Male Genital System	90	91.0	4.67	111.0	5.57	N/A	N/A	N/A	N/A	N/A
Prostate	87	88.9	4.63	108.8	5.54	N/A	N/A	N/A	N/A	N/A
Testis	2	1.2	0.39	1.2	0.38	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	18	21.5	2.59	25.4	3.02	13	11.5	1.45	13.1	1.66
Bladder (incl. <i>in situ</i>)	8	10.0	1.83	11.6	2.11	4	4.0	0.88	4.9	1.05
Kidney & renal pelvis	10	11.2	1.82	13.3	2.14	9	7.2	1.12	8.0	1.25
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	6	4.9	1.04	5.3	1.16	5	3.6	0.75	3.7	0.80
Brain	5	4.2	0.99	4.7	1.13	4	3.2	0.70	3.2	0.75
Endocrine System	3	2.5	0.64	2.9	0.74	14	10.3	1.25	11.3	1.40
Thyroid gland	2	1.9	0.57	2.3	0.68	13	9.5	1.20	10.5	1.35
Lymphomas	13	10.9	1.46	12.6	1.71	16	12.3	1.40	14.4	1.66
Hodgkin lymphoma	3	2.0	0.60	2.0	0.60	3	2.3	0.56	2.4	0.61
Non-Hodgkin lymphoma	11	8.9	1.33	10.6	1.60	13	10.1	1.28	12.0	1.54
Multiple Myeloma	8	8.8	1.53	10.7	1.84	7	5.8	0.99	7.1	1.21
Leukemias	10	9.2	1.50	10.4	1.73	11	9.0	1.24	10.6	1.47
Acute lymphocytic	2	1.1	0.39	1.3	0.47	1	1.0	0.39	1.2	0.48
Chronic lymphocytic	2	1.7	0.63	2.0	0.71	2	1.4	0.51	1.7	0.62
Acute myeloid	3	3.1	0.93	3.7	1.07	4	3.5	0.79	3.9	0.89
Chronic myeloid	2	1.5	0.56	1.6	0.59	2	1.7	0.53	2.1	0.67
Other leukemias	2	1.7	0.73	1.9	0.89	2	1.4	0.48	1.6	0.55
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	12	15.4	2.25	18.2	2.65	13	11.3	1.43	13.0	1.64
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	8	8.3	1.53	9.3	1.71	14	11.8	1.46	14.0	1.71
Breast (<i>in situ</i>)	*	*	*	*	*	20	15.9	1.63	18.4	1.89

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.


N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	10,183,353	10,308,442	10,417,031	10,519,389	10,628,020
Non-Hispanic White	5,573,671	5,590,301	5,600,365	5,608,382	5,620,358
Non-Hispanic Black	3,228,564	3,286,127	3,340,699	3,392,551	3,446,528
Non-Hispanic Asian/Pacific Islander (NH API)	420,707	442,564	460,096	475,183	491,262
Non-Hispanic American Indian/Alaskan Native PRCA (NH AI/AN)	0	0	0	0	0


All Races Population 2015–2019: 52,056,235
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	934,064	962,703	988,871	1,015,903	1,042,080
Hispanic White	788,622	811,569	832,700	854,663	875,545
Hispanic Black	97,319	101,043	104,446	107,880	111,518

Hispanic/Latino Population, Census 2010: 853,689
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

GEORGIA CANCER REGISTRY

Initial Operation: 1995
 Population-based Data Available: 1995
 Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	109.9	110.7	111.3	111.4	110.7	110.8
Missing Race	0.1	0.3	0.1	0.3	0.2	0.2
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.3	1.3	1.0	1.2	1.3	1.2
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.2	Ovary	93.2
Oral Cavity & Pharynx	97.6	Prostate	97.3
Esophagus	95.1	Testis	98.9
Stomach	96.0	Bladder (incl. <i>in situ</i>)	97.3
Colon & Rectum	96.2	Kidney & Renal Pelvis	86.8
Liver	50.4	Brain & Other CNS	84.4
Pancreas	83.8	Brain & Other CNS (non-malig)	34.3
Lung & Bronchus	88.5	Thyroid	99.1
Melanomas of the Skin	99.5	Hodgkin Lymphoma	99.0
Female Breast (excl. <i>in situ</i>)	98.9	Non-Hodgkin Lymphoma	96.4
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	87.6
Cervix Uteri	97.2	Leukemias	90.6
Uterus Corpus & Uterus NOS	98.5		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Georgia, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	27,605	531.5	1.48	633.8	1.75	25,858	424.0	1.20	495.6	1.39
Oral Cavity & Pharynx	1,076	19.8	0.28	24.2	0.34	432	7.0	0.15	8.3	0.18
Lip	35	0.7	0.06	0.8	0.07	14	0.2	0.03	0.3	0.03
Tongue	321	5.8	0.15	7.1	0.18	119	1.9	0.08	2.3	0.09
Major salivary gland	104	2.2	0.10	2.6	0.12	70	1.2	0.06	1.3	0.07
Floor of mouth	43	0.8	0.05	1.0	0.07	19	0.3	0.03	0.4	0.04
Gum & other mouth	118	2.3	0.10	2.7	0.11	98	1.6	0.07	1.9	0.09
Nasopharynx	45	0.8	0.06	1.0	0.07	19	0.3	0.03	0.4	0.04
Oropharynx	73	1.3	0.07	1.6	0.08	19	0.3	0.03	0.4	0.04
Hypopharynx	65	1.2	0.07	1.5	0.08	19	0.3	0.03	0.4	0.04
Digestive System	5,223	100.5	0.65	120.6	0.76	4,117	66.8	0.47	79.1	0.56
Esophagus	394	7.4	0.17	9.0	0.21	118	1.9	0.08	2.2	0.09
Stomach	422	8.3	0.19	9.8	0.22	289	4.8	0.13	5.6	0.15
Small intestine	179	3.4	0.12	4.1	0.14	154	2.5	0.09	3.0	0.11
Colon (excl. rectum)	1,624	31.9	0.37	37.9	0.43	1,551	25.4	0.29	29.8	0.34
Rectum & rectosigmoid	817	15.4	0.25	18.5	0.29	573	9.4	0.18	11.2	0.21
Anus, anal canal, & anorectum	108	2.1	0.09	2.4	0.11	151	2.4	0.09	2.9	0.11
Liver	629	11.2	0.21	14.0	0.25	216	3.4	0.10	4.1	0.12
Gallbladder	37	0.8	0.06	0.9	0.07	75	1.2	0.06	1.4	0.07
Pancreas	769	15.2	0.25	18.1	0.30	719	11.6	0.20	13.7	0.23
Respiratory System	4,116	80.2	0.58	96.1	0.69	3,290	51.9	0.41	62.2	0.49
Larynx	337	6.2	0.16	7.6	0.19	84	1.3	0.06	1.6	0.08
Lung & bronchus	3,717	72.8	0.56	87.1	0.66	3,162	49.9	0.40	59.7	0.48
Bones & Joints	56	1.1	0.07	1.2	0.07	47	0.8	0.06	0.9	0.06
Soft Tissue (incl. heart)	196	3.9	0.13	4.4	0.14	160	2.8	0.10	3.0	0.11
Skin (excl. basal & sq.)	1,848	37.2	0.40	43.6	0.47	1,282	21.7	0.28	24.8	0.31
Melanoma of the skin	1,726	34.5	0.39	40.5	0.45	1,210	20.4	0.27	23.4	0.30
Breast (excl. <i>in situ</i>)	73	1.4	0.08	1.7	0.09	7,885	129.2	0.66	151.8	0.77
Female Genital System	N/A	N/A	N/A	N/A	N/A	2,936	47.8	0.40	56.2	0.47
Cervix uteri	N/A	N/A	N/A	N/A	N/A	436	8.0	0.17	8.5	0.18
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,532	23.9	0.28	29.1	0.33
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	49	0.8	0.05	0.9	0.06
Ovary	N/A	N/A	N/A	N/A	N/A	611	10.1	0.19	11.7	0.21
Male Genital System	7,658	138.2	0.73	169.6	0.88	N/A	N/A	N/A	N/A	N/A
Prostate	7,378	132.5	0.71	163.8	0.87	N/A	N/A	N/A	N/A	N/A
Testis	215	4.4	0.13	4.3	0.13	N/A	N/A	N/A	N/A	N/A
Penis	50	1.0	0.07	1.2	0.08	N/A	N/A	N/A	N/A	N/A
Urinary System	2,853	57.7	0.50	68.0	0.59	1,264	20.5	0.26	24.1	0.30
Bladder (incl. <i>in situ</i>)	1,526	32.4	0.39	37.9	0.45	468	7.6	0.16	8.9	0.19
Kidney & renal pelvis	1,249	23.7	0.31	28.2	0.36	752	12.2	0.20	14.3	0.23
Ureter	35	0.8	0.06	0.9	0.07	24	0.4	0.04	0.5	0.04
Eye & Orbit	48	0.9	0.06	1.1	0.07	43	0.7	0.05	0.8	0.06
Brain & Other CNS	350	6.9	0.17	7.6	0.19	294	5.1	0.14	5.5	0.14
Brain	333	6.6	0.17	7.3	0.18	273	4.7	0.13	5.1	0.14
Endocrine System	376	7.3	0.17	8.1	0.19	1,010	18.0	0.26	19.6	0.28
Thyroid gland	329	6.3	0.16	7.2	0.18	967	17.2	0.25	18.7	0.27
Lymphomas	1,228	24.5	0.32	28.0	0.37	1,011	16.9	0.24	19.4	0.27
Hodgkin lymphoma	134	2.6	0.10	2.8	0.11	121	2.2	0.09	2.3	0.09
Non-Hodgkin lymphoma	1,094	21.9	0.31	25.3	0.35	890	14.7	0.22	17.1	0.26
Multiple Myeloma	513	10.2	0.21	12.1	0.24	460	7.5	0.16	8.8	0.18
Leukemias	890	18.2	0.28	20.6	0.32	676	11.5	0.20	12.9	0.22
Acute lymphocytic	84	1.7	0.08	1.5	0.08	67	1.3	0.07	1.2	0.07
Chronic lymphocytic	335	6.8	0.17	8.0	0.20	224	3.6	0.11	4.3	0.13
Acute myeloid	243	5.0	0.15	5.7	0.17	213	3.7	0.11	4.1	0.13
Chronic myeloid	131	2.7	0.11	3.0	0.12	103	1.8	0.08	2.0	0.09
Other leukemias	97	2.1	0.10	2.4	0.11	69	1.2	0.06	1.3	0.07
Mesothelioma	44	1.0	0.07	1.1	0.08	16	0.3	0.03	0.3	0.03
Kaposi Sarcoma	68	1.4	0.08	1.4	0.08	2	0.0	0.01	0.0	0.01
Ill-Defined & Unknown	989	21.0	0.31	24.4	0.36	934	15.6	0.23	17.9	0.26
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	527	10.6	0.21	11.9	0.24	1,096	18.4	0.25	21.0	0.29
Breast (<i>in situ</i>)	12	0.2	0.03	0.3	0.03	1,724	28.1	0.31	33.3	0.36

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Georgia, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	18,831	540.4	1.82	641.3	2.13	17,074	445.6	1.59	519.9	1.81
Oral Cavity & Pharynx	826	23.0	0.37	28.2	0.44	312	8.0	0.21	9.5	0.24
Lip	32	0.9	0.08	1.1	0.09	12	0.3	0.04	0.4	0.05
Tongue	267	7.3	0.20	9.0	0.25	95	2.4	0.12	2.9	0.13
Major salivary gland	82	2.5	0.13	2.9	0.15	42	1.2	0.08	1.3	0.09
Floor of mouth	32	0.9	0.07	1.1	0.09	14	0.3	0.04	0.4	0.05
Gum & other mouth	78	2.3	0.12	2.7	0.14	71	1.8	0.10	2.1	0.11
Nasopharynx	21	0.6	0.06	0.7	0.07	9	0.2	0.04	0.3	0.04
Oropharynx	55	1.4	0.09	1.8	0.11	14	0.3	0.04	0.4	0.05
Hypopharynx	40	1.1	0.08	1.4	0.10	12	0.3	0.04	0.4	0.05
Digestive System	3,380	97.4	0.77	116.4	0.91	2,505	62.8	0.58	74.3	0.67
Esophagus	290	8.1	0.22	9.8	0.26	80	1.9	0.10	2.3	0.12
Stomach	230	6.6	0.20	7.9	0.24	144	3.6	0.14	4.2	0.16
Small intestine	106	3.1	0.14	3.7	0.16	83	2.1	0.11	2.5	0.13
Colon (excl. rectum)	1,048	31.0	0.44	36.6	0.51	950	24.0	0.36	28.1	0.41
Rectum & rectosigmoid	541	15.8	0.31	18.8	0.37	349	9.3	0.23	11.0	0.27
Anus, anal canal, & anorectum	64	1.9	0.11	2.2	0.13	117	3.0	0.13	3.7	0.15
Liver	393	10.4	0.24	13.1	0.30	122	2.9	0.12	3.5	0.14
Gallbladder	20	0.6	0.06	0.7	0.07	38	0.9	0.07	1.1	0.08
Pancreas	519	14.9	0.30	17.7	0.35	440	10.6	0.23	12.6	0.27
Respiratory System	2,964	83.2	0.70	99.7	0.83	2,437	58.1	0.53	69.6	0.64
Larynx	223	6.1	0.19	7.5	0.23	61	1.5	0.09	1.9	0.11
Lung & bronchus	2,698	75.9	0.67	90.7	0.80	2,348	55.8	0.52	66.9	0.62
Bones & Joints	35	1.2	0.09	1.3	0.10	26	0.8	0.08	0.9	0.08
Soft Tissue (incl. heart)	124	3.9	0.16	4.4	0.18	93	2.7	0.13	2.9	0.14
Skin (excl. basal & sq.)	1,785	53.2	0.58	62.3	0.67	1,216	34.9	0.47	39.5	0.51
Melanoma of the skin	1,683	50.0	0.56	58.6	0.65	1,165	33.5	0.46	37.9	0.51
Breast (excl. <i>in situ</i>)	45	1.3	0.09	1.5	0.10	4,969	130.1	0.86	153.2	0.99
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,807	48.2	0.53	56.5	0.61
Cervix uteri	N/A	N/A	N/A	N/A	N/A	232	7.9	0.24	8.3	0.25
Uterus corpus	N/A	N/A	N/A	N/A	N/A	939	23.7	0.36	28.9	0.43
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	21	0.5	0.05	0.6	0.06
Ovary	N/A	N/A	N/A	N/A	N/A	398	10.4	0.24	12.2	0.28
Male Genital System	4,397	118.3	0.82	143.7	0.98	N/A	N/A	N/A	N/A	N/A
Prostate	4,193	110.7	0.78	135.9	0.95	N/A	N/A	N/A	N/A	N/A
Testis	160	6.2	0.22	6.2	0.22	N/A	N/A	N/A	N/A	N/A
Penis	35	1.1	0.08	1.2	0.10	N/A	N/A	N/A	N/A	N/A
Urinary System	2,160	63.4	0.63	74.7	0.73	854	21.6	0.34	25.3	0.39
Bladder (incl. <i>in situ</i>)	1,263	37.6	0.49	44.1	0.57	347	8.4	0.21	9.9	0.24
Kidney & renal pelvis	836	24.0	0.38	28.4	0.45	475	12.4	0.27	14.4	0.30
Ureter	29	0.9	0.07	1.0	0.08	19	0.5	0.05	0.5	0.06
Eye & Orbit	42	1.3	0.09	1.4	0.10	36	1.0	0.08	1.1	0.08
Brain & Other CNS	255	8.1	0.24	9.0	0.25	208	6.0	0.20	6.6	0.21
Brain	243	7.7	0.23	8.5	0.25	194	5.6	0.19	6.1	0.20
Endocrine System	272	8.6	0.24	9.6	0.26	632	20.4	0.38	21.9	0.39
Thyroid gland	246	7.8	0.23	8.7	0.25	609	19.6	0.37	21.1	0.39
Lymphomas	857	26.1	0.41	29.8	0.46	689	18.0	0.32	20.7	0.36
Hodgkin lymphoma	81	2.8	0.14	2.9	0.15	67	2.3	0.13	2.4	0.13
Non-Hodgkin lymphoma	777	23.3	0.39	26.9	0.44	622	15.7	0.29	18.3	0.33
Multiple Myeloma	268	7.8	0.22	9.3	0.26	207	5.1	0.16	6.0	0.19
Leukemias	638	19.5	0.36	22.3	0.40	447	12.0	0.27	13.4	0.29
Acute lymphocytic	41	1.6	0.11	1.5	0.10	35	1.3	0.10	1.2	0.09
Chronic lymphocytic	260	7.5	0.21	9.0	0.25	172	4.2	0.15	4.9	0.17
Acute myeloid	174	5.2	0.18	6.0	0.21	132	3.6	0.15	4.0	0.16
Chronic myeloid	90	2.8	0.14	3.2	0.15	66	1.8	0.11	2.1	0.12
Other leukemias	73	2.3	0.12	2.6	0.14	42	1.1	0.08	1.3	0.09
Mesothelioma	37	1.1	0.09	1.3	0.10	12	0.3	0.04	0.4	0.05
Kaposi Sarcoma	16	0.6	0.07	0.6	0.07	*	*	*	*	*
Ill-Defined & Unknown	731	22.4	0.38	26.0	0.44	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	357	11.2	0.28	12.6	0.30	679	18.3	0.33	20.9	0.36
Breast (<i>in situ</i>)	7	0.2	0.03	0.2	0.04	1,019	27.1	0.40	32.1	0.46

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Georgia, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	7,252	555.9	3.20	671.1	3.76	7,011	400.5	2.21	469.5	2.55
Oral Cavity & Pharynx	193	13.8	0.48	16.7	0.56	94	5.2	0.25	6.2	0.29
Lip	2	0.1	0.04	0.1	0.04	*	*	*	*	*
Tongue	41	2.9	0.22	3.6	0.26	15	0.8	0.10	1.0	0.12
Major salivary gland	17	1.3	0.16	1.5	0.18	23	1.3	0.12	1.5	0.14
Floor of mouth	9	0.6	0.10	0.8	0.12	4	0.2	0.04	0.3	0.06
Gum & other mouth	27	1.9	0.18	2.3	0.21	20	1.2	0.13	1.4	0.15
Nasopharynx	16	1.1	0.13	1.3	0.15	7	0.4	0.07	0.5	0.08
Oropharynx	16	1.1	0.13	1.4	0.15	4	0.2	0.04	0.2	0.06
Hypopharynx	22	1.5	0.16	1.9	0.20	7	0.3	0.06	0.5	0.08
Digestive System	1,478	114.9	1.47	138.7	1.73	1,320	76.6	0.98	91.0	1.14
Esophagus	86	6.6	0.36	8.2	0.42	33	1.8	0.15	2.2	0.18
Stomach	145	11.9	0.49	14.2	0.58	112	6.8	0.30	8.0	0.34
Small intestine	62	4.7	0.29	5.6	0.33	64	3.7	0.21	4.4	0.25
Colon (excl. rectum)	479	38.0	0.86	45.4	1.00	502	29.1	0.60	34.5	0.70
Rectum & rectosigmoid	211	15.7	0.53	19.0	0.62	176	9.8	0.34	11.7	0.40
Anus, anal canal, & anorectum	40	2.8	0.21	3.2	0.23	27	1.5	0.13	1.8	0.16
Liver	173	11.8	0.43	15.1	0.53	67	3.6	0.21	4.4	0.25
Gallbladder	14	1.2	0.16	1.4	0.19	30	1.7	0.15	2.1	0.17
Pancreas	213	17.7	0.60	21.3	0.71	241	14.6	0.44	17.2	0.51
Respiratory System	1,016	83.1	1.29	100.0	1.50	728	42.4	0.73	50.7	0.86
Larynx	103	7.7	0.37	9.4	0.43	20	1.1	0.11	1.4	0.14
Lung & bronchus	898	74.3	1.22	89.4	1.43	694	40.5	0.72	48.5	0.84
Bones & Joints	13	0.9	0.11	0.9	0.12	13	0.7	0.09	0.8	0.10
Soft Tissue (incl. heart)	51	3.7	0.25	4.1	0.28	52	3.0	0.19	3.3	0.21
Skin (excl. basal & sq.)	27	2.1	0.21	2.5	0.24	31	1.8	0.15	2.0	0.17
Melanoma of the skin	11	1.0	0.15	1.2	0.18	13	0.8	0.10	0.9	0.12
Breast (excl. <i>in situ</i>)	24	2.0	0.20	2.4	0.23	2,358	132.1	1.25	154.7	1.44
Female Genital System	N/A	N/A	N/A	N/A	N/A	880	48.5	0.75	57.4	0.88
Cervix uteri	N/A	N/A	N/A	N/A	N/A	143	8.2	0.32	9.0	0.34
Uterus corpus	N/A	N/A	N/A	N/A	N/A	484	25.8	0.54	31.5	0.65
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	24	1.3	0.12	1.6	0.15
Ovary	N/A	N/A	N/A	N/A	N/A	156	9.0	0.33	10.4	0.38
Male Genital System	2,855	207.3	1.88	257.2	2.26	N/A	N/A	N/A	N/A	N/A
Prostate	2,815	204.2	1.87	253.9	2.24	N/A	N/A	N/A	N/A	N/A
Testis	23	1.5	0.14	1.5	0.14	N/A	N/A	N/A	N/A	N/A
Penis	12	1.2	0.17	1.4	0.20	N/A	N/A	N/A	N/A	N/A
Urinary System	549	45.1	0.95	53.5	1.10	342	20.0	0.50	23.6	0.58
Bladder (incl. <i>in situ</i>)	196	18.5	0.65	21.7	0.76	99	6.3	0.29	7.3	0.34
Kidney & renal pelvis	341	25.5	0.67	30.4	0.78	234	13.2	0.40	15.7	0.47
Ureter	4	0.4	0.10	0.5	0.12	2	0.1	0.04	0.2	0.05
Eye & Orbit	4	0.3	0.07	0.3	0.07	4	0.2	0.06	0.2	0.05
Brain & Other CNS	60	4.2	0.26	4.6	0.28	60	3.5	0.20	3.7	0.22
Brain	56	3.9	0.24	4.2	0.27	53	3.1	0.19	3.3	0.20
Endocrine System	63	4.4	0.27	5.0	0.30	228	12.7	0.38	14.2	0.42
Thyroid gland	47	3.4	0.23	3.9	0.27	211	11.7	0.37	13.1	0.41
Lymphomas	272	20.3	0.60	23.0	0.67	241	13.9	0.41	15.8	0.46
Hodgkin lymphoma	40	2.7	0.19	2.8	0.21	42	2.3	0.17	2.4	0.17
Non-Hodgkin lymphoma	232	17.6	0.56	20.2	0.64	199	11.6	0.38	13.4	0.43
Multiple Myeloma	218	18.0	0.60	21.4	0.70	229	13.7	0.42	16.1	0.48
Leukemias	175	14.3	0.54	16.2	0.61	171	10.2	0.36	11.5	0.40
Acute lymphocytic	18	1.1	0.12	1.0	0.12	16	0.9	0.10	0.9	0.10
Chronic lymphocytic	60	5.1	0.33	6.1	0.38	42	2.5	0.18	3.0	0.21
Acute myeloid	51	4.2	0.29	4.7	0.33	65	3.9	0.22	4.3	0.25
Chronic myeloid	29	2.4	0.22	2.7	0.24	28	1.7	0.14	1.9	0.16
Other leukemias	18	1.5	0.18	1.7	0.21	19	1.2	0.12	1.4	0.14
Mesothelioma	5	0.4	0.09	0.5	0.10	2	0.1	0.04	0.1	0.04
Kaposi Sarcoma	47	3.0	0.20	3.0	0.21	2	0.1	0.04	0.1	0.03
Ill-Defined & Unknown	204	18.1	0.63	21.0	0.72	257	15.9	0.46	18.2	0.52
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	126	10.2	0.45	11.7	0.51	330	19.5	0.49	22.2	0.56
Breast (<i>in situ</i>)	4	0.3	0.06	0.3	0.08	572	31.4	0.60	37.3	0.71

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Georgia, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	497	293.6	6.42	346.8	7.50	604	282.5	5.43	328.2	6.29
Oral Cavity & Pharynx	29	15.4	1.34	18.5	1.60	13	5.6	0.74	6.5	0.86
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	6	2.9	0.56	3.7	0.70	4	1.8	0.41	2.2	0.49
Major salivary gland	3	1.4	0.40	1.6	0.46	1	0.5	0.19	0.6	0.22
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	10	5.2	0.78	6.1	0.93	3	1.4	0.41	1.6	0.47
Nasopharynx	6	2.6	0.48	3.0	0.58	2	0.9	0.27	1.0	0.30
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	2	1.5	0.50	1.9	0.61	*	*	*	*	*
Digestive System	149	88.0	3.53	105.0	4.14	106	53.7	2.49	63.6	2.89
Esophagus	5	3.1	0.63	3.7	0.75	3	1.3	0.38	1.6	0.46
Stomach	21	14.2	1.52	16.6	1.75	14	7.0	0.88	8.2	1.02
Small intestine	3	1.7	0.46	1.9	0.52	1	0.8	0.32	0.9	0.36
Colon (excl. rectum)	36	20.9	1.67	25.1	1.98	32	16.3	1.37	19.3	1.60
Rectum & rectosigmoid	29	14.9	1.34	18.3	1.62	18	8.1	0.90	10.1	1.10
Anus, anal canal, & anorectum	1	0.8	0.31	0.8	0.33	*	*	*	*	*
Liver	30	18.0	1.65	21.8	1.95	13	6.9	0.91	8.1	1.06
Gallbladder	2	1.1	0.39	1.4	0.48	2	1.1	0.39	1.2	0.43
Pancreas	14	8.6	1.15	9.9	1.31	13	7.2	0.95	8.4	1.09
Respiratory System	51	33.9	2.35	40.2	2.74	44	23.4	1.69	27.8	1.97
Larynx	3	1.6	0.44	1.9	0.52	*	*	*	*	*
Lung & bronchus	47	31.2	2.27	37.1	2.66	43	22.7	1.66	26.9	1.94
Bones & Joints	2	1.0	0.32	1.2	0.37	3	1.1	0.30	1.0	0.29
Soft Tissue (incl. heart)	6	3.4	0.73	3.9	0.83	4	1.9	0.41	2.0	0.44
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	2	1.4	0.43	1.6	0.50	2	0.7	0.28	0.8	0.30
Breast (excl. <i>in situ</i>)	2	1.2	0.38	1.6	0.50	214	94.9	3.02	110.9	3.53
Female Genital System	N/A	N/A	N/A	N/A	N/A	79	35.0	1.84	41.6	2.17
Cervix uteri	N/A	N/A	N/A	N/A	N/A	14	5.9	0.72	6.6	0.81
Uterus corpus	N/A	N/A	N/A	N/A	N/A	35	14.8	1.15	18.0	1.39
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	1	0.5	0.19	0.6	0.24
Ovary	N/A	N/A	N/A	N/A	N/A	24	11.6	1.11	13.7	1.31
Male Genital System	105	63.4	2.95	75.9	3.46	N/A	N/A	N/A	N/A	N/A
Prostate	101	61.5	2.93	73.9	3.43	N/A	N/A	N/A	N/A	N/A
Testis	4	1.6	0.36	1.5	0.35	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	41	25.4	1.95	30.1	2.29	19	10.5	1.16	12.3	1.33
Bladder (incl. <i>in situ</i>)	22	15.2	1.56	17.9	1.82	7	3.9	0.70	4.6	0.82
Kidney & renal pelvis	16	8.7	1.02	10.5	1.22	10	5.4	0.80	6.2	0.92
Ureter	1	1.1	0.54	1.4	0.61	1	1.0	0.43	1.2	0.49
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	9	5.0	0.84	5.5	0.94	7	3.2	0.58	3.3	0.62
Brain	9	4.8	0.82	5.3	0.93	7	3.1	0.58	3.2	0.61
Endocrine System	20	9.4	0.96	10.3	1.08	50	20.3	1.29	22.1	1.44
Thyroid gland	18	8.4	0.91	9.2	1.02	49	19.7	1.28	21.5	1.42
Lymphomas	28	15.8	1.42	18.3	1.64	24	12.3	1.21	13.9	1.37
Hodgkin lymphoma	3	1.3	0.37	1.3	0.38	3	1.4	0.36	1.5	0.39
Non-Hodgkin lymphoma	26	14.5	1.37	17.0	1.60	21	10.9	1.15	12.4	1.31
Multiple Myeloma	9	5.3	0.85	6.3	0.99	5	2.3	0.49	2.6	0.55
Leukemias	19	10.4	1.14	11.9	1.32	17	8.0	0.92	8.7	1.02
Acute lymphocytic	4	1.9	0.44	1.8	0.46	4	1.6	0.39	1.5	0.38
Chronic lymphocytic	4	2.7	0.64	3.2	0.76	3	1.8	0.47	2.2	0.56
Acute myeloid	6	3.1	0.62	3.6	0.72	6	3.0	0.55	3.2	0.61
Chronic myeloid	4	2.0	0.48	2.4	0.56	1	0.5	0.21	0.6	0.25
Other leukemias	1	0.7	0.31	0.9	0.37	2	1.0	0.34	1.1	0.38
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	20	12.6	1.42	14.6	1.63	17	8.9	1.06	10.2	1.21
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	17	8.8	1.01	9.7	1.13	34	16.5	1.34	18.9	1.53
Breast (<i>in situ</i>)	*	*	*	*	*	54	23.2	1.44	26.6	1.66

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Georgia, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	884	407.5	7.51	475.6	8.56	1,073	400.1	6.15	464.3	7.12
Oral Cavity & Pharynx	23	8.6	0.93	10.9	1.14	12	4.6	0.67	5.5	0.79
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	6	2.4	0.48	3.0	0.58	4	1.9	0.47	2.2	0.54
Major salivary gland	2	0.7	0.23	0.8	0.28	3	1.0	0.30	1.2	0.35
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	3	1.3	0.41	1.6	0.49	3	1.1	0.31	1.3	0.37
Nasopharynx	1	0.6	0.30	0.7	0.35	*	*	*	*	*
Oropharynx	1	0.3	0.15	0.4	0.19	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	200	92.7	3.58	109.2	4.10	176	77.1	2.89	89.8	3.32
Esophagus	12	6.6	1.03	7.7	1.17	2	1.0	0.36	1.2	0.40
Stomach	25	11.3	1.25	13.3	1.45	19	7.3	0.83	8.3	0.95
Small intestine	7	3.1	0.67	3.5	0.73	5	2.6	0.54	3.1	0.64
Colon (excl. rectum)	55	24.2	1.79	28.4	2.04	63	26.8	1.69	31.2	1.95
Rectum & rectosigmoid	32	12.4	1.20	14.8	1.39	27	10.6	1.02	12.5	1.19
Anus, anal canal, & anorectum	2	0.8	0.30	0.9	0.32	6	2.7	0.55	3.1	0.62
Liver	31	14.5	1.39	17.6	1.61	13	6.2	0.82	7.3	0.95
Gallbladder	2	1.1	0.37	1.2	0.41	5	2.2	0.49	2.4	0.53
Pancreas	23	12.3	1.39	14.4	1.60	23	12.1	1.21	13.9	1.37
Respiratory System	76	44.1	2.64	51.4	2.98	73	36.1	2.03	42.7	2.33
Larynx	7	3.5	0.74	4.2	0.84	1	0.4	0.16	0.6	0.22
Lung & bronchus	66	39.9	2.53	46.5	2.86	70	35.3	2.02	41.5	2.31
Bones & Joints	6	1.0	0.20	1.0	0.21	5	1.3	0.31	1.4	0.36
Soft Tissue (incl. heart)	14	4.5	0.71	4.9	0.79	9	2.7	0.44	3.0	0.51
Skin (excl. basal & sq.)	19	8.5	1.11	9.6	1.24	22	8.4	0.91	9.7	1.03
Melanoma of the skin	17	7.2	1.01	8.3	1.15	20	7.3	0.82	8.4	0.94
Breast (excl. <i>in situ</i>)	1	0.6	0.28	0.7	0.31	322	114.8	3.17	134.7	3.72
Female Genital System	N/A	N/A	N/A	N/A	N/A	156	52.4	2.09	61.1	2.45
Cervix uteri	N/A	N/A	N/A	N/A	N/A	43	11.5	0.85	12.5	0.96
Uterus corpus	N/A	N/A	N/A	N/A	N/A	68	24.8	1.48	29.5	1.74
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	3	1.1	0.29	1.3	0.36
Ovary	N/A	N/A	N/A	N/A	N/A	32	10.9	0.97	12.7	1.14
Male Genital System	240	115.1	3.88	136.8	4.44	N/A	N/A	N/A	N/A	N/A
Prostate	211	109.5	3.85	131.1	4.41	N/A	N/A	N/A	N/A	N/A
Testis	26	4.5	0.39	4.4	0.39	N/A	N/A	N/A	N/A	N/A
Penis	3	0.9	0.28	1.1	0.32	N/A	N/A	N/A	N/A	N/A
Urinary System	90	47.8	2.73	55.7	3.11	44	18.3	1.38	21.5	1.61
Bladder (incl. <i>in situ</i>)	37	24.9	2.11	28.6	2.38	11	5.7	0.83	6.7	0.96
Kidney & renal pelvis	52	21.8	1.67	25.9	1.93	31	11.9	1.06	14.1	1.25
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	2	0.6	0.27	0.6	0.31	2	0.5	0.20	0.5	0.23
Brain & Other CNS	24	8.2	1.00	9.1	1.15	19	5.7	0.68	6.2	0.77
Brain	24	8.0	1.00	8.9	1.14	18	5.5	0.68	5.9	0.76
Endocrine System	18	5.4	0.71	6.0	0.79	92	25.1	1.29	27.7	1.48
Thyroid gland	15	4.8	0.68	5.4	0.76	90	24.7	1.29	27.3	1.47
Lymphomas	65	25.0	1.77	28.9	2.04	53	18.9	1.33	21.9	1.54
Hodgkin lymphoma	10	2.4	0.44	2.6	0.48	9	2.0	0.35	2.1	0.39
Non-Hodgkin lymphoma	56	22.6	1.72	26.3	1.99	44	16.9	1.29	19.8	1.49
Multiple Myeloma	18	9.3	1.15	10.8	1.31	17	7.6	0.90	9.0	1.05
Leukemias	52	17.2	1.45	18.7	1.63	37	11.2	1.00	12.1	1.12
Acute lymphocytic	20	3.5	0.42	3.1	0.41	12	2.3	0.34	2.2	0.35
Chronic lymphocytic	7	4.1	0.80	4.8	0.90	5	2.2	0.51	2.7	0.59
Acute myeloid	12	5.3	0.86	6.0	0.98	10	3.6	0.62	4.0	0.68
Chronic myeloid	7	2.6	0.59	2.9	0.68	6	1.6	0.35	1.6	0.36
Other leukemias	5	1.7	0.45	1.9	0.50	4	1.4	0.37	1.6	0.44
Mesothelioma	2	1.2	0.46	1.3	0.49	1	0.6	0.23	0.7	0.27
Kaposi Sarcoma	5	1.2	0.34	1.3	0.38	*	*	*	*	*
Ill-Defined & Unknown	29	16.4	1.68	18.6	1.91	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	23	7.1	0.86	7.9	0.97	47	17.0	1.26	19.4	1.45
Breast (<i>in situ</i>)	*	*	*	*	*	72	24.1	1.37	28.8	1.65

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

GEORGIA

II-138 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Georgia, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	786	416.2	8.10	484.6	9.23	936	403.7	6.61	467.2	7.65
Oral Cavity & Pharynx	21	8.5	0.97	10.8	1.20	11	5.0	0.75	5.8	0.88
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	5	2.4	0.52	3.0	0.62	4	2.0	0.51	2.3	0.59
Major salivary gland	2	0.7	0.25	0.9	0.31	3	1.1	0.33	1.3	0.39
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	3	1.1	0.36	1.4	0.45	3	1.3	0.36	1.5	0.43
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	178	94.3	3.84	110.9	4.40	154	78.1	3.10	90.8	3.57
Esophagus	10	6.6	1.09	7.7	1.25	2	1.1	0.41	1.2	0.44
Stomach	22	11.3	1.32	13.3	1.54	18	8.0	0.94	9.2	1.08
Small intestine	5	2.9	0.70	3.3	0.78	4	2.4	0.54	2.9	0.65
Colon (excl. rectum)	48	24.4	1.91	28.4	2.17	54	26.6	1.79	30.9	2.07
Rectum & rectosigmoid	30	13.4	1.35	15.9	1.55	24	10.9	1.11	12.9	1.29
Anus, anal canal, & anorectum	2	0.9	0.34	1.0	0.37	4	2.3	0.55	2.7	0.62
Liver	28	15.1	1.51	18.2	1.75	12	6.3	0.89	7.4	1.03
Gallbladder	2	0.9	0.35	1.1	0.40	4	2.3	0.55	2.6	0.60
Pancreas	20	11.9	1.44	14.2	1.68	21	12.3	1.30	14.1	1.48
Respiratory System	66	44.5	2.85	51.8	3.22	65	37.6	2.23	44.5	2.57
Larynx	5	3.1	0.75	3.7	0.86	*	*	*	*	*
Lung & bronchus	58	40.7	2.74	47.3	3.09	63	36.7	2.21	43.3	2.54
Bones & Joints	5	1.2	0.23	1.2	0.25	5	1.5	0.36	1.6	0.41
Soft Tissue (incl. heart)	12	4.8	0.80	5.2	0.88	8	2.6	0.45	2.8	0.53
Skin (excl. basal & sq.)	18	9.6	1.26	10.8	1.41	22	9.5	1.03	10.9	1.17
Melanoma of the skin	16	8.1	1.15	9.4	1.30	20	8.1	0.92	9.3	1.06
Breast (excl. <i>in situ</i>)	1	0.7	0.33	0.8	0.36	274	112.8	3.36	131.9	3.94
Female Genital System	N/A	N/A	N/A	N/A	N/A	136	51.9	2.20	60.2	2.58
Cervix uteri	N/A	N/A	N/A	N/A	N/A	39	12.2	0.94	13.1	1.06
Uterus corpus	N/A	N/A	N/A	N/A	N/A	57	23.7	1.55	27.9	1.81
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	3	1.0	0.28	1.3	0.37
Ovary	N/A	N/A	N/A	N/A	N/A	28	10.7	1.00	12.4	1.18
Male Genital System	209	115.2	4.16	136.3	4.74	N/A	N/A	N/A	N/A	N/A
Prostate	181	108.9	4.12	129.9	4.70	N/A	N/A	N/A	N/A	N/A
Testis	25	5.0	0.45	4.9	0.45	N/A	N/A	N/A	N/A	N/A
Penis	3	1.0	0.32	1.2	0.37	N/A	N/A	N/A	N/A	N/A
Urinary System	82	49.9	2.97	58.2	3.39	38	18.3	1.48	21.6	1.72
Bladder (incl. <i>in situ</i>)	33	25.6	2.28	29.4	2.58	10	5.8	0.89	6.7	1.03
Kidney & renal pelvis	47	23.1	1.84	27.4	2.12	27	12.0	1.14	14.2	1.35
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	2	0.7	0.31	0.7	0.36	2	0.5	0.23	0.6	0.27
Brain & Other CNS	22	8.7	1.10	9.7	1.26	17	5.7	0.73	6.1	0.81
Brain	22	8.5	1.09	9.4	1.26	16	5.4	0.72	5.8	0.79
Endocrine System	16	5.6	0.76	6.2	0.85	86	27.5	1.46	30.2	1.65
Thyroid gland	14	4.9	0.73	5.5	0.82	85	27.3	1.46	29.9	1.65
Lymphomas	58	25.4	1.89	29.4	2.18	43	18.3	1.41	21.3	1.64
Hodgkin lymphoma	9	2.7	0.50	2.9	0.55	7	1.9	0.38	2.0	0.41
Non-Hodgkin lymphoma	49	22.7	1.83	26.4	2.11	37	16.4	1.36	19.4	1.58
Multiple Myeloma	15	9.0	1.22	10.4	1.38	13	6.9	0.94	8.2	1.09
Leukemias	47	18.0	1.59	19.5	1.77	33	11.2	1.03	12.1	1.17
Acute lymphocytic	18	3.8	0.47	3.4	0.46	12	2.5	0.35	2.4	0.37
Chronic lymphocytic	7	4.7	0.91	5.4	1.03	4	2.2	0.54	2.7	0.63
Acute myeloid	10	5.1	0.88	5.7	1.01	9	3.6	0.65	4.0	0.73
Chronic myeloid	6	2.5	0.65	2.9	0.74	5	1.6	0.35	1.6	0.37
Other leukemias	5	1.9	0.51	2.1	0.57	4	1.2	0.33	1.5	0.42
Mesothelioma	2	1.3	0.52	1.5	0.55	1	0.6	0.26	0.7	0.31
Kaposi Sarcoma	4	1.3	0.38	1.4	0.43	*	*	*	*	*
Ill-Defined & Unknown	27	17.7	1.86	20.0	2.11	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	21	7.5	0.93	8.4	1.06	42	18.0	1.39	20.7	1.61
Breast (<i>in situ</i>)	*	*	*	*	*	61	23.6	1.46	28.0	1.74

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Georgia, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	65	346.0	22.89	411.0	26.52	101	384.0	19.30	454.1	22.31
Oral Cavity & Pharynx	1	8.9	3.80	10.4	4.31	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	14	77.3	10.94	93.0	12.85	16	68.6	8.74	81.3	10.07
Esophagus	1	8.3	4.01	9.9	4.51	*	*	*	*	*
Stomach	1	7.7	3.77	9.4	4.49	*	*	*	*	*
Small intestine	1	5.4	2.69	6.2	2.93	*	*	*	*	*
Colon (excl. rectum)	5	27.9	6.59	33.7	7.79	6	26.1	5.41	31.0	6.24
Rectum & rectosigmoid	2	7.4	2.60	9.7	3.35	2	9.3	3.18	11.2	3.75
Anus, anal canal, & anorectum	*	*	*	*	*	1	5.9	2.59	6.5	2.77
Liver	1	8.7	3.65	10.5	4.32	1	4.8	2.16	6.2	2.63
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	1	9.5	4.12	11.1	4.83	2	9.2	3.46	10.3	3.78
Respiratory System	7	44.6	8.61	53.5	9.99	6	26.9	5.14	32.1	5.95
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	6	37.3	7.86	45.1	9.24	6	26.3	5.10	31.1	5.87
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	38	137.2	11.11	163.9	12.99
Female Genital System	N/A	N/A	N/A	N/A	N/A	14	55.9	7.49	66.5	8.62
Cervix uteri	N/A	N/A	N/A	N/A	N/A	3	6.8	1.84	8.2	2.35
Uterus corpus	N/A	N/A	N/A	N/A	N/A	8	32.0	5.64	39.1	6.60
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	11.7	3.70	13.7	4.22
Male Genital System	21	115.7	12.79	139.5	14.93	N/A	N/A	N/A	N/A	N/A
Prostate	21	115.3	12.79	139.2	14.92	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	6	35.1	7.63	41.2	8.63	4	20.1	4.67	24.5	5.46
Bladder (incl. <i>in situ</i>)	3	22.7	6.76	26.8	7.65	1	6.9	2.72	8.3	3.23
Kidney & renal pelvis	3	12.3	3.54	14.4	4.01	3	13.2	3.79	16.2	4.41
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	1	6.5	3.01	7.0	3.19	1	4.9	1.97	6.1	2.43
Brain	1	6.5	3.01	7.0	3.19	1	4.9	1.97	6.1	2.43
Endocrine System	*	*	*	*	*	3	8.9	2.59	10.4	3.13
Thyroid gland	*	*	*	*	*	3	8.4	2.55	10.0	3.10
Lymphomas	4	19.0	5.46	22.0	6.17	7	20.1	4.01	21.8	4.41
Hodgkin lymphoma	*	*	*	*	*	2	3.2	1.19	3.1	1.28
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	5	17.0	3.83	18.7	4.22
Multiple Myeloma	3	15.7	4.74	18.9	5.65	4	14.8	3.58	17.3	4.14
Leukemias	2	6.8	2.80	7.2	3.02	2	9.6	3.50	10.1	3.68
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	9.3	4.18	11.4	5.11	2	9.6	3.19	11.4	3.68
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	1	4.5	2.54	4.5	2.64	2	8.8	2.94	10.1	3.31
Breast (<i>in situ</i>)	*	*	*	*	*	8	28.2	4.72	35.3	5.82

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


GEORGIA

II-140 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	1,422,999	1,428,885	1,425,763	1,423,102	1,415,615
Non-Hispanic White	309,095	310,066	309,363	308,946	307,247
Non-Hispanic Black	36,087	37,050	37,341	37,650	37,655
Non-Hispanic Asian/Pacific Islander (NH API)	933,983	934,769	930,371	926,135	919,414
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	0	0	0	0	0


All Races Population 2015–2019: 7,116,364
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	140,259	143,476	145,237	146,909	147,870
Hispanic White	49,302	51,109	51,899	52,723	53,179
Hispanic Black	5,626	5,741	5,884	5,879	5,890

Hispanic/Latino Population, Census 2010: 120,842
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

HAWAII CANCER REGISTRY

Initial Operation: 1960
Population-based Data Available: 1960
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	109.9	112.5	117.1	110.8	111.7	112.4
Missing Race	0.2	1.1	1.2	1.4	1.9	1.2
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.1	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.2	1.3	1.6	1.6	1.2	1.4
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.5	Ovary	94.5
Oral Cavity & Pharynx	98.8	Prostate	97.1
Esophagus	97.4	Testis	99.0
Stomach	96.9	Bladder (incl. <i>in situ</i>)	97.8
Colon & Rectum	96.6	Kidney & Renal Pelvis	93.7
Liver	60.8	Brain & Other CNS	84.3
Pancreas	82.5	Brain & Other CNS (non-malig)	40.1
Lung & Bronchus	88.9	Thyroid	99.4
Melanomas of the Skin	99.9	Hodgkin Lymphoma	99.2
Female Breast (excl. <i>in situ</i>)	99.3	Non-Hodgkin Lymphoma	97.8
Female Breast (<i>in situ</i>)	99.9	Multiple Myeloma	91.0
Cervix Uteri	97.6	Leukemias	94.7
Uterus Corpus & Uterus NOS	99.3		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Hawaii, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3,846	442.3	3.28	523.2	3.82	3,691	402.2	3.11	469.0	3.56
Oral Cavity & Pharynx	161	18.8	0.68	22.6	0.81	70	7.7	0.43	9.1	0.50
Lip	7	0.9	0.16	1.0	0.18	2	0.3	0.07	0.3	0.09
Tongue	53	6.0	0.38	7.3	0.45	26	2.8	0.26	3.3	0.30
Major salivary gland	16	2.0	0.23	2.3	0.26	14	1.6	0.20	1.8	0.23
Floor of mouth	6	0.6	0.12	0.8	0.16	2	0.2	0.07	0.2	0.08
Gum & other mouth	18	2.1	0.23	2.5	0.27	12	1.3	0.17	1.5	0.20
Nasopharynx	15	1.9	0.23	2.2	0.26	6	0.7	0.14	0.9	0.16
Oropharynx	6	0.7	0.14	0.9	0.16	1	0.2	0.06	0.2	0.07
Hypopharynx	11	1.2	0.17	1.5	0.20	2	0.2	0.08	0.3	0.10
Digestive System	888	102.9	1.59	123.5	1.88	639	64.9	1.21	76.3	1.40
Esophagus	54	6.1	0.38	7.3	0.45	15	1.4	0.17	1.8	0.21
Stomach	92	10.7	0.51	12.6	0.60	59	5.8	0.36	6.7	0.41
Small intestine	21	2.5	0.25	3.0	0.29	16	1.7	0.20	2.0	0.23
Colon (excl. rectum)	234	27.6	0.83	33.0	0.98	220	22.3	0.71	26.1	0.82
Rectum & rectosigmoid	152	18.1	0.68	22.0	0.81	99	11.1	0.52	13.0	0.61
Anus, anal canal, & anorectum	9	1.0	0.15	1.2	0.18	12	1.3	0.17	1.6	0.21
Liver	121	13.6	0.56	16.6	0.68	45	4.4	0.30	5.2	0.36
Gallbladder	8	1.0	0.16	1.1	0.18	9	0.8	0.13	1.0	0.16
Pancreas	136	15.6	0.62	18.5	0.72	122	11.8	0.50	13.9	0.58
Respiratory System	508	57.5	1.17	68.0	1.37	378	36.7	0.87	43.5	1.02
Larynx	32	3.4	0.28	4.2	0.34	7	0.7	0.12	0.9	0.15
Lung & bronchus	466	52.9	1.12	62.5	1.31	366	35.5	0.86	42.0	1.01
Bones & Joints	6	0.9	0.16	0.9	0.16	7	0.9	0.16	0.9	0.16
Soft Tissue (incl. heart)	38	4.8	0.36	5.3	0.39	27	3.0	0.27	3.4	0.30
Skin (excl. basal & sq.)	305	35.5	0.94	41.4	1.08	160	17.7	0.66	20.5	0.75
Melanoma of the skin	283	32.9	0.90	38.5	1.04	146	16.4	0.64	19.0	0.72
Breast (excl. <i>in situ</i>)	7	0.8	0.13	1.0	0.16	1,253	140.2	1.86	165.1	2.14
Female Genital System	N/A	N/A	N/A	N/A	N/A	484	55.7	1.19	65.5	1.36
Cervix uteri	N/A	N/A	N/A	N/A	N/A	50	6.8	0.45	7.3	0.47
Uterus corpus	N/A	N/A	N/A	N/A	N/A	294	33.1	0.90	39.6	1.06
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	7	0.8	0.14	0.9	0.16
Ovary	N/A	N/A	N/A	N/A	N/A	80	9.4	0.49	10.9	0.56
Male Genital System	968	106.9	1.58	128.1	1.86	N/A	N/A	N/A	N/A	N/A
Prostate	920	100.3	1.51	121.3	1.81	N/A	N/A	N/A	N/A	N/A
Testis	40	5.7	0.41	5.7	0.41	N/A	N/A	N/A	N/A	N/A
Penis	5	0.6	0.12	0.7	0.15	N/A	N/A	N/A	N/A	N/A
Urinary System	387	45.1	1.05	52.9	1.22	139	14.2	0.56	16.5	0.65
Bladder (incl. <i>in situ</i>)	207	24.0	0.76	28.1	0.88	56	5.3	0.33	6.3	0.38
Kidney & renal pelvis	167	19.5	0.70	23.1	0.81	78	8.5	0.45	9.7	0.51
Ureter	8	1.0	0.15	1.1	0.17	5	0.4	0.08	0.5	0.10
Eye & Orbit	6	0.6	0.12	0.7	0.14	2	0.2	0.09	0.3	0.09
Brain & Other CNS	39	5.0	0.37	5.5	0.40	28	3.4	0.30	3.7	0.32
Brain	37	4.7	0.36	5.2	0.38	24	2.9	0.28	3.2	0.30
Endocrine System	55	7.2	0.45	8.0	0.49	166	22.5	0.81	24.2	0.85
Thyroid gland	48	6.4	0.42	7.1	0.46	161	21.9	0.80	23.6	0.84
Lymphomas	174	20.4	0.71	23.6	0.81	130	13.8	0.57	15.9	0.64
Hodgkin lymphoma	15	2.0	0.24	2.1	0.24	11	1.5	0.21	1.5	0.21
Non-Hodgkin lymphoma	158	18.4	0.67	21.5	0.78	119	12.4	0.53	14.4	0.61
Multiple Myeloma	53	6.0	0.38	7.2	0.45	39	3.9	0.29	4.6	0.34
Leukemias	110	13.2	0.58	15.0	0.65	70	7.7	0.44	8.6	0.47
Acute lymphocytic	13	1.9	0.23	1.8	0.23	11	1.5	0.22	1.5	0.20
Chronic lymphocytic	25	2.7	0.25	3.2	0.30	16	1.5	0.18	1.9	0.22
Acute myeloid	41	5.0	0.36	5.7	0.40	28	3.1	0.27	3.5	0.30
Chronic myeloid	19	2.2	0.24	2.6	0.27	10	1.1	0.16	1.3	0.18
Other leukemias	12	1.5	0.20	1.6	0.22	5	0.5	0.11	0.5	0.11
Mesothelioma	6	0.7	0.13	0.8	0.15	1	0.1	0.06	0.2	0.07
Kaposi Sarcoma	4	0.6	0.13	0.6	0.14	*	*	*	*	*
Ill-Defined & Unknown	131	15.4	0.62	18.0	0.71	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	62	7.7	0.45	8.7	0.50	125	13.6	0.58	15.5	0.64
Breast (<i>in situ</i>)	*	*	*	*	*	307	35.2	0.94	41.9	1.09

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Hawaii, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,339	523.1	7.04	609.9	7.92	921	442.5	7.43	504.3	8.02
Oral Cavity & Pharynx	70	26.8	1.57	32.3	1.83	19	9.8	1.11	11.2	1.22
Lip	4	1.9	0.48	2.2	0.54	1	0.5	0.23	0.6	0.26
Tongue	26	9.5	0.90	11.4	1.06	8	4.2	0.75	4.7	0.81
Major salivary gland	6	2.7	0.53	3.2	0.62	3	1.7	0.46	1.8	0.49
Floor of mouth	3	1.2	0.32	1.4	0.38	*	*	*	*	*
Gum & other mouth	7	2.6	0.47	3.1	0.55	3	1.1	0.34	1.3	0.40
Nasopharynx	1	0.7	0.26	0.8	0.31	*	*	*	*	*
Oropharynx	3	1.2	0.33	1.5	0.37	*	*	*	*	*
Hypopharynx	3	0.9	0.27	1.2	0.33	*	*	*	*	*
Digestive System	222	86.6	2.85	103.1	3.28	131	59.9	2.62	69.4	2.91
Esophagus	16	6.0	0.71	7.2	0.84	6	2.3	0.47	2.8	0.55
Stomach	17	6.2	0.73	7.6	0.86	6	2.7	0.54	3.2	0.61
Small intestine	6	2.4	0.48	2.9	0.56	3	1.5	0.42	1.8	0.49
Colon (excl. rectum)	63	27.0	1.69	31.5	1.89	49	23.6	1.69	26.8	1.85
Rectum & rectosigmoid	36	15.4	1.24	18.3	1.44	21	10.6	1.16	12.2	1.28
Anus, anal canal, & anorectum	6	2.0	0.40	2.3	0.47	7	2.9	0.52	3.7	0.64
Liver	30	9.5	0.83	12.0	1.02	7	2.9	0.57	3.4	0.63
Gallbladder	*	*	*	*	*	2	0.9	0.30	0.9	0.31
Pancreas	34	12.9	1.09	15.1	1.23	23	9.7	1.01	11.3	1.12
Respiratory System	131	48.4	2.04	57.2	2.36	92	39.7	2.02	46.3	2.28
Larynx	16	5.5	0.67	6.7	0.81	3	1.0	0.27	1.3	0.34
Lung & bronchus	111	41.3	1.88	48.7	2.17	87	37.7	1.97	43.8	2.22
Bones & Joints	2	1.0	0.44	1.0	0.39	*	*	*	*	*
Soft Tissue (incl. heart)	9	4.0	0.74	4.4	0.73	5	2.9	0.71	3.1	0.67
Skin (excl. basal & sq.)	254	103.9	3.20	118.9	3.54	119	57.4	2.70	65.0	2.87
Melanoma of the skin	244	99.5	3.12	114.0	3.46	112	54.8	2.65	62.0	2.82
Breast (excl. <i>in situ</i>)	2	0.7	0.23	0.9	0.29	284	139.1	4.24	158.9	4.58
Female Genital System	N/A	N/A	N/A	N/A	N/A	112	53.2	2.53	62.1	2.82
Cervix uteri	N/A	N/A	N/A	N/A	N/A	12	7.7	1.09	8.2	1.11
Uterus corpus	N/A	N/A	N/A	N/A	N/A	55	23.8	1.58	28.9	1.86
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	0.7	0.30	0.9	0.35
Ovary	N/A	N/A	N/A	N/A	N/A	24	12.7	1.29	14.3	1.39
Male Genital System	306	109.8	3.05	130.1	3.51	N/A	N/A	N/A	N/A	N/A
Prostate	290	100.5	2.84	120.6	3.34	N/A	N/A	N/A	N/A	N/A
Testis	14	8.3	1.04	8.3	1.03	N/A	N/A	N/A	N/A	N/A
Penis	2	0.6	0.23	0.7	0.27	N/A	N/A	N/A	N/A	N/A
Urinary System	141	55.7	2.27	64.7	2.57	37	16.5	1.37	19.1	1.50
Bladder (incl. <i>in situ</i>)	85	33.9	1.77	39.3	2.02	20	8.4	0.92	9.8	1.03
Kidney & renal pelvis	53	20.6	1.38	24.1	1.55	16	8.0	1.02	9.0	1.08
Ureter	2	0.8	0.26	0.9	0.28	*	*	*	*	*
Eye & Orbit	4	1.3	0.32	1.6	0.38	1	1.1	0.49	1.1	0.48
Brain & Other CNS	20	10.2	1.24	10.5	1.17	9	5.8	1.03	5.9	0.95
Brain	19	9.8	1.23	10.1	1.15	9	5.5	1.02	5.7	0.94
Endocrine System	14	7.2	0.98	7.6	0.99	26	17.2	1.68	17.6	1.64
Thyroid gland	13	6.7	0.95	7.0	0.96	25	17.1	1.68	17.4	1.63
Lymphomas	59	24.6	1.64	28.0	1.75	34	16.3	1.43	18.2	1.51
Hodgkin lymphoma	6	3.4	0.64	3.4	0.62	4	3.2	0.79	3.1	0.73
Non-Hodgkin lymphoma	53	21.3	1.51	24.6	1.63	30	13.1	1.19	15.1	1.32
Multiple Myeloma	20	7.8	0.84	9.4	1.00	7	3.2	0.57	3.6	0.63
Leukemias	36	14.4	1.19	16.5	1.31	18	9.3	1.12	10.4	1.19
Acute lymphocytic	2	1.1	0.44	1.1	0.40	*	*	*	*	*
Chronic lymphocytic	14	5.1	0.65	6.0	0.76	7	3.3	0.61	3.8	0.70
Acute myeloid	10	4.2	0.65	4.7	0.71	7	3.8	0.77	4.1	0.78
Chronic myeloid	6	2.2	0.44	2.6	0.51	2	1.1	0.33	1.2	0.37
Other leukemias	4	1.9	0.45	2.1	0.47	N/A	N/A	N/A	N/A	N/A
Mesothelioma	1	0.7	0.27	0.8	0.31	*	*	*	*	*
Kaposi Sarcoma	1	0.6	0.25	0.7	0.26	*	*	*	*	*
Ill-Defined & Unknown	47	19.4	1.39	22.4	1.55	25	10.3	1.03	11.8	1.12
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	15	6.9	0.90	7.5	0.94	27	14.8	1.45	16.2	1.50
Breast (<i>in situ</i>)	*	*	*	*	*	54	28.0	1.94	32.0	2.11

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Hawaii, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	59	419.1	27.06	512.9	32.04	31	343.5	29.83	412.6	35.51
Oral Cavity & Pharynx	1	8.0	3.32	10.0	4.12	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	12	84.7	11.95	105.4	14.31	5	64.2	13.74	75.8	16.07
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	1	13.7	5.73	15.9	6.64
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	5	34.0	7.84	42.1	9.40	2	28.8	9.98	34.7	11.83
Rectum & rectosigmoid	1	8.8	3.41	11.0	4.20	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	1	11.1	4.69	13.6	5.38	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	1	8.3	3.27	10.6	4.12	*	*	*	*	*
Respiratory System	6	49.4	10.27	59.2	11.87	2	36.3	10.93	41.0	11.96
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	5	45.8	10.05	54.2	11.51	2	36.3	10.93	41.0	11.96
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	12	126.3	17.52	147.8	20.59
Female Genital System	N/A	N/A	N/A	N/A	N/A	4	41.9	10.36	54.0	13.02
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	3	28.3	8.53	36.4	10.80
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	24	163.8	16.30	205.7	19.63	N/A	N/A	N/A	N/A	N/A
Prostate	23	161.7	16.24	203.9	19.60	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	6	51.0	10.55	58.9	12.08	2	18.8	7.09	22.1	8.20
Bladder (incl. <i>in situ</i>)	4	33.5	8.85	38.8	10.20	*	*	*	*	*
Kidney & renal pelvis	3	16.5	5.66	18.6	6.30	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	3	17.7	4.80	20.3	5.54	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Multiple Myeloma	1	9.1	3.51	11.6	4.41	*	*	*	*	*
Leukemias	2	11.6	4.54	14.2	5.38	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	11.8	4.50	14.1	5.38	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	2	17.4	6.47	19.3	7.13
Breast (<i>in situ</i>)	*	*	*	*	*	2	23.9	7.83	29.7	9.48

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Hawaii, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,190	396.0	3.85	470.6	4.55	2,454	383.7	3.63	450.8	4.22
Oral Cavity & Pharynx	78	14.7	0.76	17.6	0.90	46	7.3	0.51	8.7	0.60
Lip	2	0.4	0.14	0.4	0.14	*	*	*	*	*
Tongue	22	4.1	0.40	5.0	0.48	16	2.5	0.30	3.1	0.35
Major salivary gland	9	1.8	0.27	2.0	0.30	10	1.7	0.25	2.0	0.29
Floor of mouth	2	0.4	0.11	0.6	0.16	1	0.2	0.09	0.2	0.10
Gum & other mouth	10	1.9	0.28	2.2	0.32	9	1.3	0.21	1.5	0.24
Nasopharynx	13	2.5	0.33	3.0	0.38	6	1.0	0.19	1.2	0.23
Oropharynx	2	0.4	0.12	0.4	0.14	*	*	*	*	*
Hypopharynx	8	1.5	0.23	1.8	0.28	1	0.2	0.07	0.2	0.09
Digestive System	596	108.6	2.02	130.8	2.42	455	64.4	1.43	76.1	1.68
Esophagus	34	6.1	0.48	7.4	0.57	8	1.1	0.18	1.4	0.23
Stomach	70	12.5	0.68	14.7	0.80	47	6.4	0.44	7.5	0.51
Small intestine	13	2.4	0.30	2.9	0.36	11	1.7	0.24	2.0	0.28
Colon (excl. rectum)	152	28.0	1.03	33.8	1.24	153	21.7	0.83	25.5	0.97
Rectum & rectosigmoid	104	19.6	0.88	24.0	1.07	69	11.1	0.62	13.1	0.73
Anus, anal canal, & anorectum	2	0.4	0.12	0.5	0.15	4	0.7	0.15	0.8	0.18
Liver	81	14.7	0.74	17.8	0.89	34	4.5	0.36	5.4	0.43
Gallbladder	7	1.2	0.22	1.5	0.26	6	0.9	0.16	1.1	0.20
Pancreas	91	16.4	0.78	19.4	0.92	89	11.9	0.59	14.1	0.70
Respiratory System	342	60.5	1.48	71.9	1.76	252	34.3	1.00	41.0	1.20
Larynx	14	2.3	0.28	2.8	0.35	3	0.5	0.12	0.6	0.16
Lung & bronchus	324	57.2	1.44	68.0	1.71	245	33.5	0.99	39.9	1.18
Bones & Joints	4	0.8	0.19	0.8	0.18	5	1.0	0.20	1.0	0.20
Soft Tissue (incl. heart)	27	5.4	0.47	5.9	0.51	20	3.2	0.34	3.7	0.39
Skin (excl. basal & sq.)	25	4.6	0.42	5.4	0.49	16	2.6	0.30	2.9	0.34
Melanoma of the skin	15	2.9	0.33	3.4	0.39	11	1.7	0.25	1.9	0.28
Breast (excl. <i>in situ</i>)	4	0.7	0.16	0.9	0.20	876	141.4	2.22	168.1	2.61
Female Genital System	N/A	N/A	N/A	N/A	N/A	333	56.7	1.45	67.1	1.68
Cervix uteri	N/A	N/A	N/A	N/A	N/A	32	6.3	0.52	6.8	0.55
Uterus corpus	N/A	N/A	N/A	N/A	N/A	217	36.5	1.15	43.9	1.36
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	4	0.7	0.17	0.8	0.19
Ovary	N/A	N/A	N/A	N/A	N/A	50	8.7	0.57	10.1	0.66
Male Genital System	577	101.4	1.91	122.1	2.29	N/A	N/A	N/A	N/A	N/A
Prostate	552	95.9	1.84	116.5	2.24	N/A	N/A	N/A	N/A	N/A
Testis	20	4.7	0.48	4.7	0.47	N/A	N/A	N/A	N/A	N/A
Penis	3	0.5	0.13	0.6	0.16	N/A	N/A	N/A	N/A	N/A
Urinary System	214	38.7	1.20	45.7	1.42	90	12.9	0.64	15.1	0.74
Bladder (incl. <i>in situ</i>)	105	18.4	0.82	21.6	0.95	31	3.8	0.33	4.6	0.39
Kidney & renal pelvis	100	18.7	0.85	22.3	1.01	55	8.5	0.54	9.9	0.62
Ureter	6	1.0	0.19	1.2	0.22	4	0.4	0.10	0.5	0.12
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	16	3.3	0.37	3.6	0.40	16	2.7	0.32	3.0	0.34
Brain	15	3.1	0.36	3.3	0.39	13	2.3	0.30	2.5	0.31
Endocrine System	38	7.8	0.58	8.8	0.65	125	24.6	1.02	26.9	1.09
Thyroid gland	33	6.8	0.54	7.7	0.61	120	23.8	1.00	26.0	1.08
Lymphomas	97	17.9	0.83	20.8	0.95	85	12.9	0.66	14.8	0.75
Hodgkin lymphoma	7	1.4	0.25	1.5	0.26	5	1.0	0.20	1.1	0.22
Non-Hodgkin lymphoma	91	16.5	0.79	19.3	0.92	80	11.9	0.63	13.7	0.72
Multiple Myeloma	29	5.2	0.44	6.3	0.53	28	4.0	0.35	4.8	0.41
Leukemias	64	12.4	0.71	13.7	0.78	43	6.8	0.50	7.4	0.53
Acute lymphocytic	11	2.4	0.33	2.3	0.32	8	1.7	0.28	1.6	0.26
Chronic lymphocytic	7	1.2	0.20	1.5	0.25	7	0.9	0.15	1.1	0.19
Acute myeloid	28	5.3	0.46	6.0	0.52	19	2.9	0.32	3.3	0.35
Chronic myeloid	11	2.1	0.29	2.4	0.33	6	1.0	0.19	1.1	0.21
Other leukemias	7	1.3	0.23	1.5	0.25	2	0.3	0.10	0.4	0.12
Mesothelioma	3	0.6	0.14	0.7	0.16	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	73	13.1	0.70	15.2	0.81	63	8.5	0.52	9.7	0.58
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	41	7.8	0.56	8.9	0.63	86	12.7	0.65	14.8	0.75
Breast (<i>in situ</i>)	*	*	*	*	*	231	38.2	1.16	46.0	1.38

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Hawaii, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	187	605.4	23.50	713.8	27.52	226	576.4	18.63	670.1	21.50
Oral Cavity & Pharynx	8	20.7	3.98	25.0	4.86	3	5.8	1.66	7.1	2.00
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	4	8.8	2.54	10.9	3.18	1	2.2	0.90	3.1	1.27
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	49	161.3	12.35	194.8	14.75	41	112.3	8.49	131.8	9.83
Esophagus	2	5.3	1.79	6.2	2.03	*	*	*	*	*
Stomach	3	12.8	3.62	15.0	4.22	3	10.9	2.87	12.3	3.30
Small intestine	2	7.8	3.03	9.5	3.60	1	3.6	1.60	4.3	1.86
Colon (excl. rectum)	13	44.2	6.82	53.7	8.27	13	35.0	4.80	41.6	5.61
Rectum & rectosigmoid	8	24.0	4.57	30.2	5.65	7	15.4	2.81	18.0	3.22
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	8	28.1	5.19	33.6	6.11	4	12.8	2.91	14.2	3.18
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	8	24.7	4.45	29.8	5.26	8	21.4	3.64	25.5	4.29
Respiratory System	26	95.7	9.55	109.4	10.83	27	82.4	7.60	96.2	8.74
Larynx	2	4.5	1.57	5.6	1.87	*	*	*	*	*
Lung & bronchus	24	90.1	9.41	102.6	10.65	27	80.0	7.48	93.5	8.61
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	1	3.2	1.36	3.5	1.48	2	3.4	1.26	3.7	1.38
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	5	12.6	3.11	15.4	3.79	6	11.7	2.29	13.7	2.66
Breast (excl. <i>in situ</i>)	*	*	*	*	*	70	165.1	9.39	193.4	10.91
Female Genital System	N/A	N/A	N/A	N/A	N/A	31	76.4	6.67	88.4	7.66
Cervix uteri	N/A	N/A	N/A	N/A	N/A	5	9.5	2.12	10.7	2.43
Uterus corpus	N/A	N/A	N/A	N/A	N/A	16	38.4	4.62	44.8	5.33
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	5	15.9	3.35	17.7	3.72
Male Genital System	40	123.7	10.06	145.9	11.62	N/A	N/A	N/A	N/A	N/A
Prostate	36	114.1	9.61	134.6	11.01	N/A	N/A	N/A	N/A	N/A
Testis	3	4.9	1.25	5.3	1.42	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	21	78.0	8.88	90.6	10.32	10	27.3	4.26	31.1	4.87
Bladder (incl. <i>in situ</i>)	10	46.7	7.30	53.5	8.43	4	9.9	2.47	11.6	2.82
Kidney & renal pelvis	10	29.8	4.98	35.3	5.86	5	15.5	3.21	17.2	3.60
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	3	7.7	2.57	8.8	3.07	2	5.0	1.63	5.3	1.72
Brain	2	7.3	2.56	8.5	3.06	1	3.7	1.48	3.9	1.54
Endocrine System	2	4.1	1.21	4.5	1.39	12	25.2	3.55	27.9	3.99
Thyroid gland	2	2.6	0.95	2.7	1.00	12	25.2	3.55	27.9	3.99
Lymphomas	12	34.2	5.28	39.9	6.14	8	21.4	3.84	25.6	4.56
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	1	4.6	2.01	5.6	2.39	2	5.4	1.93	6.1	2.15
Leukemias	6	20.4	4.54	24.2	5.42	6	14.8	3.05	16.9	3.61
Acute lymphocytic	*	*	*	*	*	2	2.4	0.90	2.3	0.92
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	3	8.9	2.67	9.9	2.90	2	5.1	1.93	6.3	2.39
Chronic myeloid	1	7.3	3.31	9.1	4.19	1	4.2	1.74	4.7	2.01
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	1	5.2	2.36	6.3	2.88	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	7	26.0	5.45	31.0	6.49	6	18.3	3.58	20.7	4.07
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	5	15.4	3.84	17.9	4.58	7	17.1	3.34	19.4	3.86
Breast (<i>in situ</i>)	*	*	*	*	*	16	35.3	4.07	42.4	4.82

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

HAWAII

II-148 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Hawaii, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	106	607.0	29.50	709.0	33.51	113	605.6	27.12	691.6	30.33
Oral Cavity & Pharynx	5	21.6	4.81	26.4	5.74	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	9.4	2.96	12.0	3.65	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	26	143.2	14.22	171.7	16.47	20	111.5	11.99	128.9	13.45
Esophagus	1	7.1	2.97	8.2	3.26	*	*	*	*	*
Stomach	2	10.7	3.90	12.8	4.45	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	8	47.5	8.52	56.3	9.87	6	33.2	6.55	39.0	7.43
Rectum & rectosigmoid	4	17.2	4.31	21.3	5.05	4	21.6	4.82	25.8	5.59
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	4	28.0	6.64	33.2	7.66	2	13.2	4.42	14.4	4.74
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	4	20.2	4.95	24.4	5.78	4	19.1	4.84	22.6	5.55
Respiratory System	15	92.3	12.00	106.5	13.41	13	71.1	9.46	83.9	10.83
Larynx	1	5.4	2.33	6.7	2.79	*	*	*	*	*
Lung & bronchus	13	86.0	11.75	98.7	13.07	13	70.5	9.43	83.0	10.79
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	4	20.1	4.63	24.4	5.54	5	22.5	4.81	25.6	5.37
Breast (excl. <i>in situ</i>)	*	*	*	*	*	34	180.1	14.52	206.0	16.27
Female Genital System	N/A	N/A	N/A	N/A	N/A	16	84.6	10.15	95.2	11.20
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	10.8	3.27	11.6	3.50
Uterus corpus	N/A	N/A	N/A	N/A	N/A	8	43.9	7.38	49.7	8.11
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	14.5	4.62	16.4	5.11
Male Genital System	23	127.8	13.29	149.6	15.03	N/A	N/A	N/A	N/A	N/A
Prostate	21	118.7	12.93	139.6	14.61	N/A	N/A	N/A	N/A	N/A
Testis	2	5.9	1.98	6.1	2.10	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	14	90.7	12.05	103.3	13.42	6	30.4	6.14	34.6	6.89
Bladder (incl. <i>in situ</i>)	7	55.3	10.02	61.9	11.12	3	12.8	3.88	15.2	4.47
Kidney & renal pelvis	6	33.1	6.49	38.9	7.31	3	16.5	4.64	18.0	5.08
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	11.0	3.92	12.4	4.44	1	7.2	3.06	8.0	3.33
Brain	2	10.3	3.86	11.8	4.40	*	*	*	*	*
Endocrine System	*	*	*	*	*	5	24.2	4.91	25.9	5.28
Thyroid gland	*	*	*	*	*	5	24.2	4.91	25.9	5.28
Lymphomas	6	28.2	6.03	32.9	6.88	4	23.0	5.33	26.9	6.05
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	1	8.3	3.80	10.0	4.47	1	7.3	3.21	8.5	3.61
Leukemias	3	20.8	5.65	24.3	6.51	3	18.1	4.89	19.4	5.30
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	2	11.4	4.31	12.5	4.69	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	3	23.4	6.14	26.3	6.77	2	15.3	4.60	17.2	5.13
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	3	17.8	4.92	19.8	5.68	4	22.9	5.46	25.1	5.98
Breast (<i>in situ</i>)	*	*	*	*	*	6	28.4	5.35	34.7	6.32

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Hawaii, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3	268.8	89.31	333.0	105.78	2	158.8	63.83	171.5	68.05
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	1	135.6	65.29	170.9	78.92	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


HAWAII

II-150 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹


Race	2015	2016	2017	2018	2019
All Races	1,652,495	1,684,036	1,719,745	1,752,074	1,789,060
Non-Hispanic White	1,385,913	1,407,204	1,433,320	1,457,207	1,484,389
Non-Hispanic Black	15,484	16,425	17,272	17,995	18,752
Non-Hispanic Asian/Pacific Islander (NH API)	28,549	30,399	31,691	32,544	33,655
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	12,449	12,631	12,649	12,698	12,830

All Races Population 2015–2019: 8,597,410
Distribution of Population by Race Only (excludes Hispanics)


**Hispanic/Latino Population Counts by Year¹**

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	201,713	208,799	215,992	222,587	230,189
Hispanic White	183,273	189,572	195,888	201,809	208,509
Hispanic Black	3,357	3,546	3,714	3,818	4,036

Hispanic/Latino Population, Census 2010: 175,901
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

IDAHO CANCER REGISTRY

Initial Operation: 1969
Population-based Data Available: 1970
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	108.3	105.8	104.0	103.3	107.3	105.7
Missing Race	0.4	0.3	0.9	0.7	1.0	0.7
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.3	1.7	1.3	0.9	1.1	1.4
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	91.7	Ovary	91.2
Oral Cavity & Pharynx	98.4	Prostate	96.7
Esophagus	95.4	Testis	99.6
Stomach	95.7	Bladder (incl. <i>in situ</i>)	96.2
Colon & Rectum	95.1	Kidney & Renal Pelvis	85.4
Liver	45.1	Brain & Other CNS	83.8
Pancreas	78.8	Brain & Other CNS (non-malig)	43.9
Lung & Bronchus	82.1	Thyroid	99.6
Melanomas of the Skin	99.5	Hodgkin Lymphoma	99.5
Female Breast (excl. <i>in situ</i>)	98.5	Non-Hodgkin Lymphoma	96.8
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	85.9
Cervix Uteri	98.1	Leukemias	87.0
Uterus Corpus & Uterus NOS	98.0		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Idaho, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	4,686	486.8	3.27	574.5	3.82	4,193	418.7	2.98	487.3	3.42
Oral Cavity & Pharynx	183	18.4	0.63	22.5	0.76	70	6.8	0.38	8.0	0.44
Lip	25	2.7	0.25	3.2	0.29	6	0.5	0.10	0.6	0.12
Tongue	56	5.6	0.34	6.8	0.41	23	2.2	0.21	2.6	0.25
Major salivary gland	18	1.9	0.21	2.2	0.24	10	1.1	0.16	1.2	0.18
Floor of mouth	7	0.7	0.12	0.8	0.14	3	0.3	0.07	0.4	0.09
Gum & other mouth	16	1.6	0.19	2.0	0.23	13	1.3	0.16	1.5	0.18
Nasopharynx	4	0.4	0.10	0.5	0.11	1	0.1	0.05	0.2	0.06
Oropharynx	12	1.2	0.16	1.5	0.20	2	0.2	0.07	0.3	0.08
Hypopharynx	7	0.6	0.11	0.8	0.14	2	0.2	0.06	0.2	0.08
Digestive System	857	89.7	1.41	107.0	1.66	624	60.7	1.12	71.5	1.30
Esophagus	84	8.6	0.43	10.4	0.52	16	1.5	0.17	1.8	0.21
Stomach	65	6.9	0.39	8.2	0.46	32	3.1	0.25	3.7	0.29
Small intestine	27	2.8	0.25	3.3	0.29	22	2.1	0.20	2.5	0.24
Colon (excl. rectum)	241	26.0	0.77	30.7	0.90	234	23.3	0.70	26.9	0.80
Rectum & rectosigmoid	128	13.5	0.55	16.2	0.65	80	8.0	0.41	9.5	0.48
Anus, anal canal, & anorectum	6	0.6	0.11	0.7	0.14	30	2.9	0.25	3.6	0.30
Liver	96	9.2	0.43	11.5	0.53	32	3.0	0.24	3.6	0.28
Gallbladder	8	0.9	0.14	1.1	0.17	11	1.0	0.13	1.1	0.16
Pancreas	153	16.1	0.60	18.9	0.70	120	11.4	0.48	13.4	0.56
Respiratory System	537	55.8	1.10	65.8	1.29	495	46.7	0.96	55.2	1.12
Larynx	33	3.3	0.26	4.0	0.32	9	0.9	0.13	1.1	0.16
Lung & bronchus	495	51.6	1.06	60.5	1.24	481	45.3	0.94	53.5	1.10
Bones & Joints	9	1.0	0.15	1.1	0.16	8	0.9	0.15	0.9	0.15
Soft Tissue (incl. heart)	32	3.6	0.29	4.0	0.33	31	3.3	0.28	3.6	0.30
Skin (excl. basal & sq.)	352	38.1	0.93	44.4	1.08	237	25.0	0.75	28.3	0.83
Melanoma of the skin	335	36.1	0.91	42.2	1.05	226	23.9	0.74	26.9	0.81
Breast (excl. <i>in situ</i>)	10	1.1	0.16	1.3	0.19	1,287	129.6	1.67	152.0	1.93
Female Genital System	N/A	N/A	N/A	N/A	N/A	481	47.9	1.01	56.7	1.17
Cervix uteri	N/A	N/A	N/A	N/A	N/A	62	7.4	0.44	7.9	0.46
Uterus corpus	N/A	N/A	N/A	N/A	N/A	259	24.7	0.71	30.1	0.85
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	8	0.7	0.12	0.9	0.15
Ovary	N/A	N/A	N/A	N/A	N/A	107	10.6	0.47	12.6	0.55
Male Genital System	1,261	123.2	1.59	148.5	1.90	N/A	N/A	N/A	N/A	N/A
Prostate	1,198	115.5	1.53	140.7	1.85	N/A	N/A	N/A	N/A	N/A
Testis	55	6.8	0.42	6.7	0.41	N/A	N/A	N/A	N/A	N/A
Penis	6	0.7	0.13	0.8	0.15	N/A	N/A	N/A	N/A	N/A
Urinary System	582	62.2	1.18	72.9	1.38	217	20.9	0.65	24.4	0.75
Bladder (incl. <i>in situ</i>)	340	36.5	0.91	42.5	1.05	89	8.2	0.40	9.8	0.47
Kidney & renal pelvis	223	23.5	0.72	27.9	0.85	123	12.1	0.50	14.0	0.57
Ureter	9	1.0	0.15	1.1	0.18	3	0.3	0.08	0.3	0.09
Eye & Orbit	10	1.0	0.14	1.2	0.18	6	0.7	0.13	0.8	0.14
Brain & Other CNS	84	9.1	0.46	10.1	0.50	55	5.8	0.36	6.4	0.39
Brain	80	8.6	0.44	9.7	0.49	52	5.4	0.35	6.0	0.38
Endocrine System	74	8.3	0.44	9.1	0.48	186	21.5	0.73	23.2	0.77
Thyroid gland	67	7.6	0.42	8.3	0.46	180	20.8	0.71	22.4	0.76
Lymphomas	238	25.5	0.76	29.2	0.86	181	18.0	0.61	20.8	0.70
Hodgkin lymphoma	23	2.6	0.25	2.7	0.25	18	2.1	0.22	2.1	0.23
Non-Hodgkin lymphoma	216	22.9	0.72	26.5	0.82	163	15.9	0.57	18.7	0.67
Multiple Myeloma	84	8.9	0.44	10.4	0.52	53	5.0	0.32	6.0	0.37
Leukemias	191	20.9	0.69	23.7	0.78	126	12.8	0.52	14.3	0.58
Acute lymphocytic	21	2.3	0.23	2.2	0.22	11	1.3	0.17	1.1	0.15
Chronic lymphocytic	75	7.9	0.42	9.3	0.49	49	4.7	0.30	5.5	0.35
Acute myeloid	51	5.7	0.37	6.4	0.41	35	3.6	0.28	4.1	0.31
Chronic myeloid	27	2.9	0.26	3.4	0.30	17	1.8	0.20	2.1	0.22
Other leukemias	18	2.0	0.22	2.3	0.25	14	1.4	0.17	1.6	0.20
Mesothelioma	16	1.8	0.20	2.1	0.23	5	0.5	0.10	0.6	0.12
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	88	9.8	0.48	10.9	0.53	180	18.4	0.63	21.0	0.71
Breast (<i>in situ</i>)	1	0.1	0.05	0.2	0.06	226	23.0	0.71	27.1	0.82

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Idaho, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	4,353	493.0	3.44	581.2	4.02	3,841	421.7	3.17	490.5	3.62
Oral Cavity & Pharynx	173	19.2	0.67	23.4	0.81	63	6.7	0.39	7.9	0.46
Lip	23	2.7	0.26	3.2	0.31	5	0.5	0.11	0.6	0.12
Tongue	53	5.8	0.37	7.1	0.44	21	2.2	0.23	2.6	0.27
Major salivary gland	18	2.1	0.23	2.4	0.26	9	1.1	0.17	1.3	0.19
Floor of mouth	7	0.7	0.13	0.9	0.16	3	0.3	0.08	0.4	0.10
Gum & other mouth	15	1.6	0.20	2.0	0.24	12	1.2	0.16	1.4	0.19
Nasopharynx	4	0.4	0.10	0.5	0.12	1	0.1	0.05	0.1	0.06
Oropharynx	11	1.2	0.17	1.5	0.20	2	0.2	0.06	0.2	0.08
Hypopharynx	6	0.7	0.12	0.8	0.15	2	0.2	0.06	0.2	0.07
Digestive System	786	89.5	1.47	106.8	1.74	567	60.0	1.17	70.7	1.35
Esophagus	78	8.7	0.45	10.5	0.54	16	1.6	0.18	1.9	0.22
Stomach	58	6.7	0.40	7.9	0.47	25	2.6	0.24	3.1	0.28
Small intestine	25	2.9	0.26	3.4	0.31	21	2.1	0.22	2.5	0.25
Colon (excl. rectum)	222	26.3	0.81	30.9	0.95	215	23.3	0.74	27.0	0.84
Rectum & rectosigmoid	117	13.5	0.58	16.3	0.69	72	7.9	0.43	9.4	0.51
Anus, anal canal, & anorectum	6	0.6	0.12	0.8	0.15	28	3.0	0.27	3.6	0.32
Liver	81	8.4	0.43	10.5	0.53	27	2.6	0.24	3.2	0.28
Gallbladder	7	0.8	0.14	1.0	0.17	9	0.8	0.13	1.0	0.15
Pancreas	146	16.5	0.63	19.4	0.73	111	11.5	0.50	13.5	0.58
Respiratory System	510	56.9	1.15	67.1	1.35	464	47.1	1.00	55.7	1.17
Larynx	31	3.3	0.27	4.1	0.33	9	1.0	0.15	1.2	0.18
Lung & bronchus	471	52.6	1.11	61.9	1.30	450	45.6	0.98	53.9	1.15
Bones & Joints	8	1.1	0.17	1.1	0.18	7	0.9	0.16	0.9	0.16
Soft Tissue (incl. heart)	29	3.7	0.32	4.1	0.35	28	3.5	0.30	3.8	0.32
Skin (excl. basal & sq.)	347	41.3	1.02	48.1	1.18	228	27.1	0.84	30.5	0.92
Melanoma of the skin	330	39.1	1.00	45.6	1.15	218	26.0	0.83	29.2	0.90
Breast (excl. <i>in situ</i>)	10	1.2	0.18	1.4	0.20	1,180	130.9	1.78	153.5	2.04
Female Genital System	N/A	N/A	N/A	N/A	N/A	434	47.8	1.07	56.5	1.24
Cervix uteri	N/A	N/A	N/A	N/A	N/A	52	7.3	0.47	7.7	0.48
Uterus corpus	N/A	N/A	N/A	N/A	N/A	237	24.9	0.75	30.3	0.90
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	7	0.7	0.12	0.9	0.15
Ovary	N/A	N/A	N/A	N/A	N/A	97	10.6	0.50	12.6	0.58
Male Genital System	1,151	122.1	1.66	147.2	1.97	N/A	N/A	N/A	N/A	N/A
Prostate	1,096	114.1	1.58	139.1	1.91	N/A	N/A	N/A	N/A	N/A
Testis	47	7.1	0.47	7.0	0.46	N/A	N/A	N/A	N/A	N/A
Penis	6	0.7	0.14	0.8	0.15	N/A	N/A	N/A	N/A	N/A
Urinary System	539	62.2	1.23	72.8	1.43	198	20.6	0.67	24.1	0.78
Bladder (incl. <i>in situ</i>)	322	36.9	0.94	43.0	1.09	82	8.2	0.41	9.8	0.49
Kidney & renal pelvis	199	23.0	0.75	27.2	0.88	110	11.8	0.52	13.6	0.59
Ureter	8	1.0	0.16	1.2	0.18	3	0.3	0.08	0.4	0.09
Eye & Orbit	10	1.1	0.16	1.3	0.19	6	0.8	0.15	0.9	0.16
Brain & Other CNS	78	9.6	0.50	10.7	0.55	48	5.8	0.39	6.3	0.42
Brain	74	9.1	0.49	10.1	0.53	46	5.4	0.37	6.0	0.40
Endocrine System	67	8.6	0.49	9.4	0.52	160	21.4	0.79	23.0	0.83
Thyroid gland	60	7.8	0.47	8.6	0.50	154	20.6	0.77	22.2	0.81
Lymphomas	218	25.7	0.80	29.4	0.91	166	18.2	0.66	21.1	0.75
Hodgkin lymphoma	19	2.6	0.27	2.7	0.28	16	2.2	0.25	2.2	0.26
Non-Hodgkin lymphoma	198	23.1	0.76	26.7	0.86	150	16.1	0.61	18.8	0.70
Multiple Myeloma	77	8.8	0.46	10.3	0.53	49	5.0	0.33	5.9	0.38
Leukemias	178	21.4	0.74	24.2	0.83	114	12.6	0.55	14.2	0.61
Acute lymphocytic	16	2.3	0.25	2.1	0.23	8	1.2	0.19	1.0	0.16
Chronic lymphocytic	73	8.4	0.45	9.8	0.52	47	4.9	0.32	5.7	0.38
Acute myeloid	47	5.7	0.38	6.4	0.43	31	3.5	0.29	3.9	0.32
Chronic myeloid	26	3.1	0.28	3.6	0.32	15	1.8	0.21	2.0	0.23
Other leukemias	16	2.0	0.22	2.3	0.26	12	1.3	0.18	1.5	0.20
Mesothelioma	15	1.8	0.21	2.1	0.24	5	0.5	0.11	0.6	0.12
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	78	9.7	0.51	11.0	0.57	162	18.4	0.67	20.9	0.75
Breast (<i>in situ</i>)	*	*	*	*	*	209	23.6	0.77	27.9	0.89

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Idaho, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	21	551.6	76.10	659.2	87.97	10	299.4	47.51	346.9	53.61
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	4	95.0	31.78	113.1	36.58	2	81.4	27.71	97.8	31.50
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	1	26.8	12.41	32.3	14.34	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	3	93.1	33.56	111.0	39.02	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	3	89.5	33.37	106.4	38.73	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	3	74.5	22.98	83.7	25.32
Female Genital System	N/A	N/A	N/A	N/A	N/A	1	32.6	13.37	40.9	16.72
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	10	210.5	40.12	253.1	45.83	N/A	N/A	N/A	N/A	N/A
Prostate	10	210.5	40.12	253.1	45.83	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	1	50.9	28.32	58.8	32.32	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	1	24.8	10.17	27.1	11.41
Thyroid gland	*	*	*	*	*	1	24.8	10.17	27.1	11.41
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Idaho, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	34	341.2	28.73	406.7	33.73	50	322.0	21.27	372.7	24.47
Oral Cavity & Pharynx	*	*	*	*	*	1	9.9	3.85	11.4	4.40
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	7	77.9	14.29	91.6	16.61	9	59.6	9.27	70.2	10.81
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	1	14.0	6.09	17.6	7.51	1	10.3	4.09	12.0	4.68
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	1	14.8	5.97	16.1	6.38	2	13.6	3.93	15.7	4.59
Rectum & rectosigmoid	*	*	*	*	*	1	10.1	4.29	11.4	4.88
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	1	15.6	6.44	18.9	7.71	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	2	12.0	4.13	14.3	4.87
Respiratory System	5	48.7	10.73	59.2	12.48	5	38.9	7.91	44.4	8.94
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	4	43.1	9.78	52.3	11.35	5	38.9	7.91	44.4	8.94
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	17	104.9	11.78	125.7	14.05
Female Genital System	N/A	N/A	N/A	N/A	N/A	5	34.7	6.94	40.3	8.03
Cervix uteri	N/A	N/A	N/A	N/A	N/A	1	10.0	4.02	11.1	4.44
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2	12.6	3.84	15.7	4.80
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	1	7.2	2.97	8.4	3.46
Male Genital System	8	83.1	14.55	100.5	17.14	N/A	N/A	N/A	N/A	N/A
Prostate	7	79.8	14.43	97.3	17.04	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	6	59.1	11.91	73.0	14.45	2	11.5	4.29	12.4	4.53
Bladder (incl. <i>in situ</i>)	3	39.1	10.39	48.2	12.52	*	*	*	*	*
Kidney & renal pelvis	2	19.9	5.82	24.8	7.20	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	2	13.3	5.08	15.4	6.03	4	23.5	5.28	25.7	5.84
Thyroid gland	2	13.3	5.08	15.4	6.03	4	21.0	4.98	23.2	5.55
Lymphomas	2	19.4	6.43	21.9	7.38	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	1	11.8	5.46	12.5	6.01	1	9.6	3.77	9.9	3.90
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	1	10.3	4.31	11.2	4.82	3	15.6	4.48	18.8	5.32
Breast (<i>in situ</i>)	*	*	*	*	*	3	19.1	5.05	22.2	5.87

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Idaho, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	23	417.0	40.76	494.0	47.58	33	538.9	44.52	625.6	51.01
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	7	130.6	23.00	159.3	27.54	6	97.7	19.66	114.8	22.80
Esophagus	1	22.7	9.53	26.9	11.15	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	2	31.3	12.15	39.1	14.96	2	48.5	14.99	57.9	17.65
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	2	31.0	10.29	40.3	12.96	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	1	25.0	10.36	28.2	11.60	*	*	*	*	*
Respiratory System	2	48.8	14.48	55.8	16.40	5	86.4	17.40	96.7	19.41
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	2	46.4	14.28	52.2	15.99	5	86.4	17.40	96.7	19.41
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	11	170.3	24.83	202.2	28.92
Female Genital System	N/A	N/A	N/A	N/A	N/A	4	64.4	15.37	72.2	17.01
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2	36.9	11.35	38.9	11.79
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	6	103.8	20.14	123.7	23.31	N/A	N/A	N/A	N/A	N/A
Prostate	6	93.9	19.27	113.4	22.54	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	3	62.7	16.87	69.2	18.99	2	23.1	8.56	29.9	10.94
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	2	40.4	13.51	45.0	15.44	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	1	25.9	10.32	28.8	11.43
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Idaho, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	183	353.3	13.53	416.4	15.69	217	364.8	12.21	426.3	14.21
Oral Cavity & Pharynx	5	8.2	1.83	10.3	2.18	3	5.9	1.54	6.9	1.79
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	1	2.2	0.98	2.8	1.17	1	1.8	0.76	2.2	0.94
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	46	86.9	6.55	104.0	7.68	34	63.1	5.29	74.5	6.15
Esophagus	3	4.7	1.48	5.5	1.70	*	*	*	*	*
Stomach	4	9.1	2.27	10.7	2.60	4	7.6	1.84	8.9	2.13
Small intestine	*	*	*	*	*	1	1.8	0.73	2.5	1.03
Colon (excl. rectum)	11	21.2	3.25	25.3	3.85	11	21.1	3.02	24.5	3.47
Rectum & rectosigmoid	8	12.4	2.19	15.0	2.66	4	6.0	1.40	7.2	1.68
Anus, anal canal, & anorectum	*	*	*	*	*	2	3.3	1.21	3.9	1.41
Liver	10	17.7	2.74	21.8	3.24	3	6.3	1.79	6.9	1.93
Gallbladder	*	*	*	*	*	2	3.8	1.38	4.7	1.65
Pancreas	5	11.7	2.67	14.2	3.18	5	9.6	2.10	11.5	2.49
Respiratory System	14	36.6	4.78	41.1	5.29	16	37.2	4.43	43.3	5.06
Larynx	1	2.1	0.90	2.6	1.07	*	*	*	*	*
Lung & bronchus	12	33.8	4.64	37.8	5.14	16	36.7	4.40	42.8	5.04
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	2	3.1	1.29	3.7	1.55	2	2.7	0.99	2.9	1.06
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	4	6.6	1.73	7.8	2.01	6	9.0	1.83	10.4	2.11
Breast (excl. <i>in situ</i>)	*	*	*	*	*	64	105.6	6.32	123.8	7.40
Female Genital System	N/A	N/A	N/A	N/A	N/A	30	43.9	3.85	52.7	4.66
Cervix uteri	N/A	N/A	N/A	N/A	N/A	7	8.9	1.48	9.8	1.71
Uterus corpus	N/A	N/A	N/A	N/A	N/A	12	17.9	2.37	22.1	2.94
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	7	10.4	1.97	12.7	2.37
Male Genital System	47	91.2	6.83	108.5	7.95	N/A	N/A	N/A	N/A	N/A
Prostate	40	85.6	6.75	103.0	7.88	N/A	N/A	N/A	N/A	N/A
Testis	6	4.9	0.89	4.7	0.85	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	24	49.7	5.22	59.3	6.06	12	23.0	3.26	26.3	3.70
Bladder (incl. <i>in situ</i>)	9	21.7	3.68	25.3	4.19	3	7.2	2.01	8.0	2.21
Kidney & renal pelvis	15	26.8	3.58	32.7	4.25	9	15.8	2.57	18.4	2.97
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	4	6.5	1.77	6.8	1.92	4	3.7	0.91	4.1	1.10
Brain	4	6.5	1.77	6.8	1.92	3	3.4	0.88	3.9	1.08
Endocrine System	4	5.0	1.16	5.5	1.31	19	22.6	2.53	25.2	2.92
Thyroid gland	4	4.6	1.11	5.0	1.26	19	22.4	2.53	25.0	2.92
Lymphomas	14	22.8	3.31	26.7	3.87	11	18.7	2.90	22.5	3.45
Hodgkin lymphoma	2	2.1	0.62	2.1	0.67	1	2.2	0.99	2.3	1.03
Non-Hodgkin lymphoma	12	20.7	3.25	24.5	3.81	9	16.5	2.73	20.2	3.30
Multiple Myeloma	5	11.1	2.58	13.1	3.02	2	4.3	1.37	5.0	1.57
Leukemias	9	13.3	2.55	15.4	3.10	10	16.8	2.81	19.3	3.23
Acute lymphocytic	4	3.1	0.84	3.2	0.95	2	1.5	0.49	1.4	0.47
Chronic lymphocytic	*	*	*	*	*	2	2.8	1.03	3.5	1.25
Acute myeloid	3	5.4	1.70	6.3	1.99	3	5.7	1.67	6.7	1.93
Chronic myeloid	*	*	*	*	*	1	2.9	1.35	3.4	1.56
Other leukemias	1	2.6	1.34	3.1	1.68	2	3.8	1.41	4.4	1.59
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	5	10.1	2.40	11.6	2.74	3	6.5	1.78	7.4	1.98
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	6	9.3	2.05	9.5	2.15	12	18.3	2.64	21.2	3.05
Breast (<i>in situ</i>)	*	*	*	*	*	10	15.4	2.39	18.3	2.85

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

IDAHO

II-158 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Idaho, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	165	346.9	13.95	409.6	16.20	199	361.7	12.56	422.4	14.62
Oral Cavity & Pharynx	4	8.0	1.91	10.1	2.27	3	6.3	1.65	7.4	1.93
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	1	2.4	1.06	3.0	1.27	1	1.9	0.82	2.4	1.02
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	42	87.2	6.82	104.8	8.02	30	61.2	5.36	72.0	6.22
Esophagus	2	4.7	1.55	5.5	1.77	*	*	*	*	*
Stomach	4	9.6	2.44	11.3	2.81	4	7.2	1.80	8.2	2.04
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	11	21.9	3.46	26.2	4.10	10	21.1	3.15	24.2	3.59
Rectum & rectosigmoid	7	12.1	2.22	14.9	2.74	4	6.2	1.49	7.4	1.78
Anus, anal canal, & anorectum	*	*	*	*	*	2	3.5	1.29	4.2	1.51
Liver	9	17.6	2.85	21.7	3.37	2	6.0	1.81	6.6	1.97
Gallbladder	*	*	*	*	*	2	4.0	1.46	5.0	1.75
Pancreas	5	12.6	2.87	15.3	3.41	4	8.4	1.95	10.3	2.36
Respiratory System	12	35.4	4.91	39.9	5.47	16	39.3	4.69	45.8	5.37
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	11	32.7	4.77	36.6	5.30	16	38.8	4.66	45.2	5.34
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	2	3.1	1.36	3.6	1.61	2	2.8	1.05	3.0	1.13
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	4	7.2	1.87	8.4	2.17	6	9.7	1.97	11.2	2.27
Breast (excl. <i>in situ</i>)	*	*	*	*	*	59	105.3	6.53	123.1	7.62
Female Genital System	N/A	N/A	N/A	N/A	N/A	27	42.5	3.95	51.0	4.78
Cervix uteri	N/A	N/A	N/A	N/A	N/A	6	8.4	1.51	9.2	1.72
Uterus corpus	N/A	N/A	N/A	N/A	N/A	11	17.3	2.39	21.3	2.98
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	6	9.8	2.02	11.8	2.41
Male Genital System	41	85.2	6.79	101.5	7.90	N/A	N/A	N/A	N/A	N/A
Prostate	35	79.9	6.70	96.3	7.83	N/A	N/A	N/A	N/A	N/A
Testis	5	4.5	0.91	4.3	0.86	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	22	49.2	5.52	58.5	6.37	12	23.2	3.37	26.6	3.84
Bladder (incl. <i>in situ</i>)	8	20.8	3.85	24.0	4.35	3	7.7	2.13	8.5	2.35
Kidney & renal pelvis	14	27.1	3.80	33.1	4.50	9	15.6	2.62	18.1	3.04
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	4	6.9	1.90	7.2	2.05	3	3.9	0.99	4.4	1.19
Brain	4	6.9	1.90	7.2	2.05	3	3.7	0.96	4.2	1.18
Endocrine System	4	5.4	1.26	6.0	1.42	16	20.4	2.41	22.7	2.79
Thyroid gland	4	5.0	1.21	5.5	1.37	16	20.1	2.40	22.5	2.79
Lymphomas	13	23.3	3.52	27.5	4.12	10	19.2	3.05	23.1	3.63
Hodgkin lymphoma	2	1.9	0.62	2.0	0.68	1	2.4	1.06	2.5	1.10
Non-Hodgkin lymphoma	11	21.4	3.47	25.5	4.07	9	16.8	2.86	20.6	3.46
Multiple Myeloma	4	11.4	2.73	13.6	3.20	2	4.7	1.47	5.4	1.68
Leukemias	8	13.9	2.71	16.2	3.30	8	15.9	2.81	18.4	3.25
Acute lymphocytic	4	3.5	0.92	3.6	1.04	2	1.3	0.48	1.1	0.45
Chronic lymphocytic	*	*	*	*	*	2	3.1	1.11	3.8	1.35
Acute myeloid	3	5.8	1.82	6.8	2.14	3	5.6	1.71	6.7	1.99
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	1	2.8	1.43	3.3	1.80	N/A	N/A	N/A	N/A	N/A
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	4	9.2	2.41	10.7	2.78	2	5.3	1.66	6.1	1.87
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	4	8.9	2.16	9.3	2.30	10	17.8	2.70	20.5	3.11
Breast (<i>in situ</i>)	*	*	*	*	*	9	15.5	2.50	18.5	2.99

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Idaho, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1	163.3	72.08	166.2	76.63	*	*	*	*	*
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


IDAHO

II-160 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	12,859,585	12,821,709	12,779,893	12,724,685	12,667,017
Non-Hispanic White	8,075,797	8,015,299	7,950,403	7,874,972	7,801,887
Non-Hispanic Black	1,888,832	1,880,340	1,870,706	1,863,423	1,857,317
Non-Hispanic Asian/Pacific Islander (NH API)	725,801	739,231	755,694	767,693	775,576
Non-Hispanic American Indian/Alaskan Native PRCA (NH AI/AN)	0	0	0	0	0


All Races Population 2015–2019: 63,852,889
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	2,143,300	2,160,875	2,177,135	2,192,625	2,206,243
Hispanic White	1,975,804	1,991,630	2,006,115	2,019,391	2,030,281
Hispanic Black	80,022	81,180	82,453	83,920	85,231

Hispanic/Latino Population, Census 2010: 2,027,578
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

ILLINOIS CANCER REGISTRY

Initial Operation: 1985
Population-based Data Available: 1986
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	108.8	110.3	111.0	109.4	108.9	109.7
Missing Race	0.7	0.5	0.4	0.7	1.0	0.7
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.1	2.0	2.0	1.4	0.9	1.7
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.0	Ovary	93.9
Oral Cavity & Pharynx	98.3	Prostate	97.3
Esophagus	96.6	Testis	99.4
Stomach	97.0	Bladder (incl. <i>in situ</i>)	97.7
Colon & Rectum	96.6	Kidney & Renal Pelvis	90.7
Liver	53.7	Brain & Other CNS	88.6
Pancreas	87.1	Brain & Other CNS (non-malig)	40.6
Lung & Bronchus	88.7	Thyroid	99.5
Melanomas of the Skin	99.6	Hodgkin Lymphoma	99.3
Female Breast (excl. <i>in situ</i>)	98.9	Non-Hodgkin Lymphoma	97.1
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	90.0
Cervix Uteri	97.8	Leukemias	88.6
Uterus Corpus & Uterus NOS	98.7		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Illinois, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	34,824	501.4	1.23	595.5	1.44	35,361	443.5	1.09	517.9	1.25
Oral Cavity & Pharynx	1,322	18.4	0.23	22.4	0.28	550	6.8	0.13	8.0	0.15
Lip	49	0.7	0.05	0.9	0.06	16	0.2	0.02	0.2	0.03
Tongue	413	5.7	0.13	6.9	0.15	169	2.1	0.07	2.5	0.09
Major salivary gland	116	1.8	0.08	2.1	0.09	88	1.2	0.06	1.3	0.06
Floor of mouth	55	0.8	0.05	0.9	0.06	27	0.3	0.03	0.4	0.03
Gum & other mouth	151	2.1	0.08	2.6	0.10	112	1.3	0.06	1.6	0.07
Nasopharynx	51	0.7	0.05	0.9	0.05	25	0.3	0.03	0.4	0.03
Oropharynx	85	1.1	0.06	1.4	0.07	22	0.3	0.03	0.3	0.03
Hypopharynx	84	1.2	0.06	1.4	0.07	23	0.3	0.03	0.3	0.03
Digestive System	7,086	102.6	0.56	122.4	0.66	5,815	70.4	0.42	82.9	0.49
Esophagus	576	8.1	0.15	9.8	0.18	164	1.9	0.07	2.3	0.08
Stomach	651	9.6	0.17	11.3	0.20	420	5.2	0.12	6.0	0.13
Small intestine	226	3.3	0.10	3.9	0.12	192	2.4	0.08	2.8	0.09
Colon (excl. rectum)	2,173	32.2	0.32	38.0	0.37	2,183	26.5	0.26	30.9	0.30
Rectum & rectosigmoid	1,075	15.4	0.22	18.5	0.25	758	9.6	0.16	11.3	0.19
Anus, anal canal, & anorectum	107	1.5	0.07	1.8	0.08	187	2.3	0.08	2.8	0.09
Liver	743	10.0	0.17	12.5	0.21	287	3.4	0.09	4.0	0.11
Gallbladder	64	1.0	0.05	1.1	0.06	138	1.7	0.06	1.9	0.07
Pancreas	1,106	16.1	0.22	19.2	0.26	1,058	12.4	0.17	14.7	0.20
Respiratory System	5,248	76.2	0.48	90.6	0.56	4,872	57.6	0.38	68.6	0.44
Larynx	433	6.0	0.13	7.3	0.16	121	1.4	0.06	1.8	0.07
Lung & bronchus	4,739	69.1	0.46	82.0	0.54	4,713	55.7	0.37	66.3	0.44
Bones & Joints	65	1.0	0.06	1.1	0.06	55	0.8	0.05	0.8	0.05
Soft Tissue (incl. heart)	266	4.1	0.11	4.6	0.13	213	2.8	0.09	3.1	0.10
Skin (excl. basal & sq.)	1,977	29.4	0.30	34.4	0.35	1,518	20.3	0.24	22.9	0.27
Melanoma of the skin	1,847	27.4	0.29	32.0	0.34	1,422	19.1	0.23	21.6	0.26
Breast (excl. <i>in situ</i>)	92	1.3	0.06	1.6	0.08	10,477	134.1	0.60	157.4	0.69
Female Genital System	N/A	N/A	N/A	N/A	N/A	4,317	54.1	0.38	64.3	0.44
Cervix uteri	N/A	N/A	N/A	N/A	N/A	517	7.5	0.15	8.2	0.16
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2,435	29.4	0.27	36.0	0.33
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	85	1.0	0.05	1.2	0.06
Ovary	N/A	N/A	N/A	N/A	N/A	845	10.8	0.17	12.5	0.19
Male Genital System	8,907	120.7	0.59	147.5	0.70	N/A	N/A	N/A	N/A	N/A
Prostate	8,452	113.3	0.56	140.1	0.69	N/A	N/A	N/A	N/A	N/A
Testis	388	6.3	0.15	6.2	0.14	N/A	N/A	N/A	N/A	N/A
Penis	54	0.8	0.05	1.0	0.06	N/A	N/A	N/A	N/A	N/A
Urinary System	4,126	61.2	0.44	72.0	0.51	1,819	22.1	0.24	25.9	0.27
Bladder (incl. <i>in situ</i>)	2,305	34.9	0.33	40.9	0.39	763	8.9	0.15	10.5	0.17
Kidney & renal pelvis	1,730	24.9	0.27	29.4	0.32	1,006	12.6	0.18	14.7	0.21
Ureter	54	0.9	0.05	1.0	0.06	33	0.4	0.03	0.5	0.04
Eye & Orbit	54	0.8	0.05	0.9	0.06	52	0.7	0.04	0.8	0.05
Brain & Other CNS	494	7.5	0.15	8.2	0.17	385	5.2	0.12	5.7	0.13
Brain	466	7.0	0.15	7.8	0.16	358	4.8	0.12	5.3	0.13
Endocrine System	567	8.5	0.16	9.5	0.18	1,466	21.4	0.26	23.2	0.27
Thyroid gland	507	7.6	0.15	8.5	0.17	1,409	20.6	0.25	22.4	0.27
Lymphomas	1,756	26.4	0.29	30.2	0.33	1,469	18.6	0.22	21.3	0.25
Hodgkin lymphoma	207	3.2	0.10	3.4	0.11	159	2.4	0.09	2.5	0.09
Non-Hodgkin lymphoma	1,549	23.2	0.27	26.9	0.31	1,310	16.2	0.21	18.8	0.23
Multiple Myeloma	556	8.1	0.16	9.6	0.18	488	5.8	0.12	6.9	0.14
Leukemias	1,132	17.2	0.23	19.5	0.26	817	10.4	0.17	11.6	0.18
Acute lymphocytic	124	2.1	0.08	1.9	0.08	94	1.5	0.07	1.4	0.06
Chronic lymphocytic	375	5.5	0.13	6.6	0.15	257	3.0	0.09	3.6	0.10
Acute myeloid	358	5.5	0.13	6.2	0.15	281	3.6	0.10	4.0	0.11
Chronic myeloid	152	2.3	0.09	2.7	0.10	109	1.4	0.06	1.6	0.07
Other leukemias	123	1.9	0.08	2.2	0.09	75	0.9	0.05	1.1	0.06
Mesothelioma	90	1.4	0.07	1.7	0.08	37	0.4	0.03	0.5	0.04
Kaposi Sarcoma	34	0.5	0.04	0.6	0.04	4	0.0	0.01	0.1	0.01
Ill-Defined & Unknown	1,053	16.1	0.23	18.7	0.26	1,007	11.9	0.17	13.8	0.20
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	642	9.7	0.18	11.0	0.20	1,327	17.2	0.22	19.6	0.24
Breast (<i>in situ</i>)	9	0.1	0.02	0.2	0.02	2,443	32.2	0.30	37.9	0.35

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Illinois, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	26,526	516.9	1.46	611.7	1.70	26,363	462.7	1.35	538.5	1.52
Oral Cavity & Pharynx	1,062	20.2	0.29	24.7	0.34	426	7.3	0.17	8.6	0.19
Lip	42	0.9	0.06	1.0	0.07	13	0.2	0.03	0.3	0.03
Tongue	349	6.6	0.16	8.0	0.19	138	2.4	0.09	2.8	0.11
Major salivary gland	91	1.9	0.09	2.2	0.10	61	1.2	0.07	1.3	0.08
Floor of mouth	47	0.9	0.06	1.1	0.07	22	0.4	0.04	0.4	0.04
Gum & other mouth	108	2.0	0.09	2.5	0.11	89	1.5	0.07	1.7	0.08
Nasopharynx	28	0.6	0.05	0.7	0.06	15	0.3	0.03	0.3	0.04
Oropharynx	69	1.3	0.07	1.6	0.09	16	0.3	0.03	0.3	0.04
Hypopharynx	60	1.1	0.07	1.4	0.08	18	0.3	0.03	0.4	0.04
Digestive System	5,118	100.2	0.65	119.1	0.75	4,104	67.5	0.49	79.3	0.57
Esophagus	478	9.0	0.19	10.9	0.22	126	2.0	0.08	2.4	0.10
Stomach	424	8.3	0.19	9.8	0.22	228	3.8	0.12	4.4	0.13
Small intestine	161	3.2	0.12	3.7	0.13	130	2.2	0.09	2.6	0.11
Colon (excl. rectum)	1,605	32.3	0.37	37.9	0.43	1,606	26.4	0.31	30.7	0.35
Rectum & rectosigmoid	772	15.3	0.26	18.3	0.30	530	9.4	0.19	11.1	0.22
Anus, anal canal, & anorectum	77	1.5	0.08	1.8	0.09	152	2.6	0.10	3.2	0.12
Liver	460	8.4	0.18	10.3	0.22	169	2.7	0.10	3.2	0.11
Gallbladder	41	0.8	0.06	0.9	0.07	87	1.4	0.07	1.6	0.08
Pancreas	841	16.3	0.26	19.4	0.30	765	12.0	0.20	14.2	0.23
Respiratory System	4,162	79.8	0.57	94.8	0.66	3,881	61.9	0.46	73.6	0.54
Larynx	325	6.1	0.15	7.4	0.19	90	1.5	0.07	1.8	0.09
Lung & bronchus	3,782	72.6	0.54	86.0	0.63	3,762	59.9	0.45	71.2	0.53
Bones & Joints	42	1.0	0.07	1.0	0.07	39	0.9	0.07	0.9	0.07
Soft Tissue (incl. heart)	191	4.2	0.14	4.6	0.15	146	2.8	0.11	3.1	0.12
Skin (excl. basal & sq.)	1,842	37.3	0.40	43.5	0.46	1,379	27.4	0.35	30.7	0.38
Melanoma of the skin	1,732	35.1	0.39	40.9	0.44	1,302	26.1	0.35	29.2	0.37
Breast (excl. <i>in situ</i>)	69	1.3	0.07	1.6	0.09	7,707	139.4	0.75	163.3	0.85
Female Genital System	N/A	N/A	N/A	N/A	N/A	3,087	54.3	0.46	64.5	0.53
Cervix uteri	N/A	N/A	N/A	N/A	N/A	307	6.9	0.19	7.4	0.19
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,775	29.8	0.33	36.6	0.40
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	50	0.8	0.05	1.0	0.06
Ovary	N/A	N/A	N/A	N/A	N/A	617	11.0	0.21	12.9	0.24
Male Genital System	6,320	115.8	0.67	140.8	0.80	N/A	N/A	N/A	N/A	N/A
Prostate	6,000	107.3	0.63	132.3	0.77	N/A	N/A	N/A	N/A	N/A
Testis	277	7.6	0.21	7.5	0.20	N/A	N/A	N/A	N/A	N/A
Penis	35	0.7	0.06	0.8	0.06	N/A	N/A	N/A	N/A	N/A
Urinary System	3,361	66.6	0.53	78.1	0.61	1,415	23.5	0.29	27.5	0.34
Bladder (incl. <i>in situ</i>)	2,004	39.6	0.40	46.4	0.47	642	10.0	0.18	11.8	0.21
Kidney & renal pelvis	1,279	25.4	0.33	29.9	0.38	733	12.9	0.22	15.0	0.25
Ureter	48	1.0	0.06	1.1	0.07	28	0.4	0.04	0.5	0.04
Eye & Orbit	44	0.9	0.06	1.0	0.07	47	0.9	0.06	1.0	0.07
Brain & Other CNS	377	8.4	0.20	9.1	0.21	300	6.0	0.17	6.6	0.17
Brain	359	7.9	0.20	8.7	0.21	281	5.6	0.16	6.1	0.17
Endocrine System	426	9.4	0.21	10.5	0.23	1,016	23.0	0.34	24.8	0.35
Thyroid gland	388	8.5	0.20	9.5	0.22	979	22.2	0.34	24.0	0.35
Lymphomas	1,350	27.8	0.35	31.9	0.39	1,112	19.7	0.28	22.4	0.31
Hodgkin lymphoma	138	3.4	0.13	3.5	0.14	110	2.7	0.12	2.8	0.12
Non-Hodgkin lymphoma	1,212	24.4	0.32	28.4	0.37	1,003	16.9	0.25	19.7	0.28
Multiple Myeloma	372	7.3	0.17	8.6	0.20	295	4.7	0.13	5.6	0.15
Leukemias	864	17.9	0.28	20.4	0.31	612	10.8	0.21	12.1	0.23
Acute lymphocytic	67	1.8	0.10	1.7	0.09	51	1.3	0.09	1.2	0.08
Chronic lymphocytic	313	6.1	0.16	7.2	0.18	213	3.3	0.11	4.0	0.12
Acute myeloid	277	5.7	0.16	6.6	0.18	209	3.7	0.12	4.1	0.13
Chronic myeloid	108	2.3	0.10	2.6	0.11	80	1.5	0.08	1.6	0.09
Other leukemias	98	2.0	0.09	2.3	0.11	60	1.0	0.06	1.2	0.07
Mesothelioma	79	1.6	0.08	1.9	0.10	32	0.5	0.04	0.6	0.05
Kaposi Sarcoma	12	0.3	0.04	0.3	0.04	3	0.0	0.01	0.0	0.01
Ill-Defined & Unknown	835	16.9	0.27	19.7	0.31	763	12.0	0.20	13.9	0.23
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	473	10.0	0.21	11.4	0.24	955	17.5	0.27	20.0	0.30
Breast (<i>in situ</i>)	6	0.1	0.02	0.1	0.03	1,711	32.9	0.38	38.4	0.43

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Illinois, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	4,507	553.8	3.84	671.5	4.56	4,853	442.6	2.90	522.8	3.37
Oral Cavity & Pharynx	130	15.4	0.62	19.0	0.75	62	5.5	0.32	6.7	0.38
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	30	3.5	0.29	4.3	0.36	12	1.0	0.14	1.3	0.17
Major salivary gland	13	1.7	0.21	2.0	0.24	16	1.5	0.17	1.7	0.19
Floor of mouth	5	0.6	0.13	0.8	0.15	3	0.2	0.06	0.3	0.08
Gum & other mouth	16	2.1	0.24	2.5	0.28	12	1.0	0.13	1.2	0.16
Nasopharynx	9	1.0	0.15	1.3	0.19	4	0.4	0.09	0.4	0.10
Oropharynx	11	1.3	0.18	1.7	0.22	4	0.3	0.07	0.4	0.09
Hypopharynx	14	1.7	0.21	2.1	0.25	3	0.3	0.07	0.3	0.08
Digestive System	1,012	127.1	1.86	153.1	2.20	976	88.3	1.29	105.5	1.52
Esophagus	57	7.1	0.43	8.6	0.52	28	2.4	0.21	2.9	0.25
Stomach	106	14.0	0.64	16.6	0.74	92	8.5	0.40	10.0	0.47
Small intestine	39	4.9	0.36	5.8	0.42	44	4.1	0.28	4.8	0.33
Colon (excl. rectum)	325	42.4	1.10	50.4	1.28	368	33.4	0.79	39.8	0.93
Rectum & rectosigmoid	133	16.5	0.66	19.9	0.78	114	10.4	0.45	12.5	0.53
Anus, anal canal, & anorectum	20	2.5	0.25	2.9	0.29	22	2.0	0.20	2.4	0.23
Liver	125	13.9	0.58	17.8	0.72	53	4.5	0.28	5.5	0.34
Gallbladder	12	1.6	0.21	1.9	0.26	27	2.4	0.21	2.9	0.25
Pancreas	154	19.5	0.73	23.6	0.86	179	16.0	0.55	19.2	0.65
Respiratory System	749	95.8	1.63	115.5	1.93	735	65.1	1.09	78.4	1.30
Larynx	73	8.8	0.48	10.9	0.58	25	2.1	0.19	2.7	0.24
Lung & bronchus	665	85.7	1.55	103.2	1.83	705	62.5	1.07	75.2	1.27
Bones & Joints	8	0.9	0.15	1.0	0.16	7	0.7	0.12	0.7	0.12
Soft Tissue (incl. heart)	35	4.4	0.34	4.8	0.38	35	3.3	0.25	3.7	0.28
Skin (excl. basal & sq.)	12	1.5	0.20	1.7	0.23	17	1.7	0.18	1.8	0.20
Melanoma of the skin	4	0.5	0.12	0.6	0.14	8	0.8	0.12	0.9	0.13
Breast (excl. <i>in situ</i>)	15	2.0	0.24	2.4	0.28	1,481	136.6	1.63	161.2	1.88
Female Genital System	N/A	N/A	N/A	N/A	N/A	615	55.3	1.02	65.9	1.19
Cervix uteri	N/A	N/A	N/A	N/A	N/A	101	9.9	0.45	11.0	0.49
Uterus corpus	N/A	N/A	N/A	N/A	N/A	335	28.9	0.72	35.6	0.87
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	24	2.2	0.20	2.6	0.24
Ovary	N/A	N/A	N/A	N/A	N/A	105	9.7	0.43	11.3	0.50
Male Genital System	1,556	180.4	2.12	226.3	2.60	N/A	N/A	N/A	N/A	N/A
Prostate	1,533	177.6	2.11	223.4	2.58	N/A	N/A	N/A	N/A	N/A
Testis	13	1.7	0.21	1.6	0.20	N/A	N/A	N/A	N/A	N/A
Penis	6	0.8	0.15	0.9	0.17	N/A	N/A	N/A	N/A	N/A
Urinary System	386	49.2	1.17	58.7	1.37	231	20.9	0.63	24.8	0.73
Bladder (incl. <i>in situ</i>)	146	20.0	0.77	23.6	0.90	70	6.4	0.34	7.5	0.40
Kidney & renal pelvis	234	28.3	0.86	34.1	1.01	155	14.1	0.52	16.7	0.60
Ureter	3	0.4	0.10	0.4	0.13	2	0.2	0.06	0.2	0.07
Eye & Orbit	3	0.3	0.08	0.3	0.09	1	0.2	0.06	0.1	0.05
Brain & Other CNS	45	5.5	0.38	6.1	0.42	35	3.3	0.26	3.5	0.27
Brain	41	5.0	0.36	5.5	0.40	32	3.0	0.25	3.2	0.26
Endocrine System	39	4.8	0.36	5.4	0.40	130	12.7	0.51	14.0	0.55
Thyroid gland	29	3.6	0.31	4.1	0.35	120	11.7	0.49	13.0	0.53
Lymphomas	163	20.5	0.75	23.1	0.83	154	14.7	0.54	16.5	0.60
Hodgkin lymphoma	30	3.3	0.28	3.5	0.29	24	2.4	0.22	2.4	0.23
Non-Hodgkin lymphoma	133	17.2	0.69	19.6	0.78	130	12.3	0.49	14.1	0.55
Multiple Myeloma	119	15.4	0.66	18.4	0.77	138	12.5	0.48	14.9	0.57
Leukemias	108	13.7	0.62	15.7	0.70	94	8.7	0.41	9.9	0.46
Acute lymphocytic	9	1.0	0.15	0.9	0.14	9	0.9	0.14	0.9	0.13
Chronic lymphocytic	36	4.8	0.37	5.7	0.44	25	2.2	0.20	2.6	0.23
Acute myeloid	35	4.5	0.35	5.1	0.40	38	3.5	0.26	4.0	0.29
Chronic myeloid	19	2.2	0.24	2.6	0.27	15	1.3	0.16	1.6	0.19
Other leukemias	9	1.2	0.18	1.4	0.21	8	0.8	0.12	0.9	0.13
Mesothelioma	3	0.5	0.11	0.5	0.14	*	*	*	*	*
Kaposi Sarcoma	12	1.4	0.19	1.4	0.19	*	*	*	*	*
Ill-Defined & Unknown	113	15.2	0.66	18.0	0.78	139	12.9	0.50	15.0	0.57
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	70	8.9	0.49	10.2	0.56	183	17.2	0.58	19.9	0.66
Breast (<i>in situ</i>)	2	0.2	0.07	0.3	0.09	381	34.4	0.81	41.3	0.95

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Illinois, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	904	275.9	4.25	324.6	4.98	1,143	285.1	3.83	332.4	4.46
Oral Cavity & Pharynx	43	12.6	0.88	15.1	1.05	20	5.0	0.51	6.0	0.61
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	9	2.8	0.43	3.3	0.50	5	1.1	0.24	1.4	0.30
Major salivary gland	4	1.2	0.27	1.3	0.30	4	1.0	0.23	1.1	0.25
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	14	3.9	0.48	4.8	0.60	5	1.4	0.27	1.6	0.32
Nasopharynx	9	2.5	0.40	2.9	0.46	4	0.9	0.21	1.1	0.26
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	2	0.7	0.21	0.9	0.25	*	*	*	*	*
Digestive System	261	80.3	2.31	95.8	2.74	191	48.9	1.61	57.6	1.89
Esophagus	10	3.1	0.45	3.8	0.55	4	0.9	0.21	1.1	0.25
Stomach	34	10.5	0.85	12.5	1.00	22	5.7	0.55	6.7	0.65
Small intestine	7	2.4	0.41	2.8	0.47	4	0.9	0.21	1.1	0.25
Colon (excl. rectum)	71	21.4	1.18	25.3	1.38	57	14.7	0.88	17.1	1.03
Rectum & rectosigmoid	47	13.7	0.93	16.7	1.12	32	8.0	0.64	9.5	0.76
Anus, anal canal, & anorectum	1	0.4	0.15	0.5	0.20	2	0.4	0.13	0.5	0.17
Liver	45	13.4	0.94	16.4	1.13	17	4.3	0.48	5.1	0.56
Gallbladder	3	0.8	0.21	0.9	0.25	5	1.5	0.29	1.6	0.32
Pancreas	24	7.5	0.71	9.0	0.84	28	7.2	0.62	8.5	0.73
Respiratory System	121	38.2	1.61	45.2	1.89	87	22.7	1.11	26.7	1.30
Larynx	7	2.2	0.38	2.6	0.45	*	*	*	*	*
Lung & bronchus	112	35.3	1.55	41.8	1.82	84	22.0	1.09	25.9	1.28
Bones & Joints	3	0.9	0.24	1.0	0.26	2	0.5	0.16	0.6	0.19
Soft Tissue (incl. heart)	9	2.6	0.40	2.8	0.45	7	1.8	0.31	2.0	0.33
Skin (excl. basal & sq.)	7	2.3	0.40	2.7	0.46	7	1.6	0.28	1.8	0.32
Melanoma of the skin	4	1.2	0.28	1.5	0.33	5	1.1	0.23	1.3	0.27
Breast (excl. <i>in situ</i>)	3	0.8	0.23	1.0	0.28	431	105.5	2.30	123.5	2.69
Female Genital System	N/A	N/A	N/A	N/A	N/A	158	38.1	1.38	45.5	1.64
Cervix uteri	N/A	N/A	N/A	N/A	N/A	21	5.2	0.51	6.0	0.59
Uterus corpus	N/A	N/A	N/A	N/A	N/A	83	19.7	0.98	24.2	1.20
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	0.5	0.17	0.6	0.19
Ovary	N/A	N/A	N/A	N/A	N/A	37	9.2	0.69	10.8	0.81
Male Genital System	196	57.4	1.89	68.8	2.25	N/A	N/A	N/A	N/A	N/A
Prostate	187	55.0	1.85	66.4	2.21	N/A	N/A	N/A	N/A	N/A
Testis	7	1.9	0.31	1.8	0.30	N/A	N/A	N/A	N/A	N/A
Penis	2	0.5	0.20	0.6	0.23	N/A	N/A	N/A	N/A	N/A
Urinary System	77	24.4	1.29	28.3	1.49	31	8.0	0.66	9.5	0.77
Bladder (incl. <i>in situ</i>)	39	13.3	0.99	15.4	1.14	10	2.7	0.39	3.2	0.45
Kidney & renal pelvis	35	10.4	0.80	12.2	0.94	18	4.6	0.49	5.5	0.58
Ureter	1	0.4	0.17	0.5	0.18	2	0.4	0.16	0.5	0.19
Eye & Orbit	1	0.3	0.14	0.3	0.14	*	*	*	*	*
Brain & Other CNS	13	3.7	0.46	4.1	0.52	11	3.0	0.40	3.2	0.42
Brain	12	3.3	0.44	3.7	0.50	10	2.8	0.39	2.9	0.41
Endocrine System	33	9.1	0.72	10.1	0.81	88	21.4	1.03	23.5	1.14
Thyroid gland	29	8.0	0.68	8.9	0.77	85	20.5	1.01	22.5	1.12
Lymphomas	59	18.2	1.11	20.6	1.26	48	12.2	0.80	13.9	0.91
Hodgkin lymphoma	8	2.2	0.36	2.2	0.38	6	1.6	0.29	1.5	0.29
Non-Hodgkin lymphoma	51	16.0	1.05	18.4	1.20	42	10.6	0.75	12.4	0.87
Multiple Myeloma	16	5.2	0.60	6.1	0.69	11	2.8	0.38	3.3	0.45
Leukemias	35	10.4	0.81	11.7	0.92	23	6.0	0.57	6.4	0.61
Acute lymphocytic	6	1.8	0.34	1.7	0.33	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	6	1.9	0.36	2.3	0.43	4	0.9	0.22	1.0	0.25
Acute myeloid	14	4.1	0.50	4.7	0.58	9	2.2	0.34	2.5	0.39
Chronic myeloid	4	1.3	0.28	1.6	0.34	4	0.9	0.21	1.0	0.25
Other leukemias	4	1.3	0.30	1.4	0.33	*	*	*	*	*
Mesothelioma	2	0.5	0.20	0.6	0.23	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	27	7.3	0.64	8.5	0.73
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	27	7.8	0.69	8.8	0.78	53	13.1	0.82	15.1	0.94
Breast (<i>in situ</i>)	*	*	*	*	*	131	32.2	1.27	38.0	1.50

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Illinois, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,435	372.3	3.77	439.1	4.36	2,705	360.2	3.26	419.2	3.80
Oral Cavity & Pharynx	73	10.8	0.62	12.9	0.73	34	4.7	0.38	5.5	0.44
Lip	4	0.7	0.17	0.8	0.20	2	0.3	0.10	0.3	0.11
Tongue	21	2.9	0.32	3.5	0.37	12	1.7	0.23	2.0	0.27
Major salivary gland	7	1.1	0.20	1.2	0.22	7	0.9	0.17	1.0	0.19
Floor of mouth	*	*	*	*	*	2	0.3	0.09	0.3	0.11
Gum & other mouth	12	1.8	0.26	2.2	0.32	5	0.8	0.17	1.0	0.20
Nasopharynx	4	0.4	0.11	0.6	0.14	2	0.2	0.07	0.2	0.08
Oropharynx	3	0.5	0.13	0.6	0.16	2	0.2	0.06	0.2	0.08
Hypopharynx	7	1.1	0.21	1.3	0.24	*	*	*	*	*
Digestive System	644	100.6	1.97	120.6	2.31	507	74.9	1.56	87.6	1.81
Esophagus	28	4.7	0.43	5.6	0.50	6	1.0	0.19	1.2	0.22
Stomach	83	13.5	0.74	15.8	0.85	74	10.8	0.59	12.6	0.68
Small intestine	16	2.5	0.31	2.9	0.35	12	1.7	0.22	2.0	0.27
Colon (excl. rectum)	156	24.1	0.96	28.6	1.12	139	20.1	0.80	23.4	0.93
Rectum & rectosigmoid	110	15.2	0.72	18.6	0.86	71	9.4	0.52	11.2	0.62
Anus, anal canal, & anorectum	8	1.3	0.22	1.5	0.25	10	1.4	0.21	1.7	0.25
Liver	109	16.6	0.78	20.5	0.94	47	7.4	0.50	8.7	0.59
Gallbladder	8	1.5	0.25	1.8	0.30	18	2.7	0.30	3.1	0.34
Pancreas	83	14.2	0.77	16.9	0.89	84	13.4	0.69	15.6	0.79
Respiratory System	199	36.6	1.27	43.0	1.46	158	25.2	0.94	29.7	1.08
Larynx	24	3.9	0.39	4.7	0.46	4	0.6	0.12	0.7	0.15
Lung & bronchus	166	31.7	1.20	37.1	1.37	152	24.3	0.92	28.6	1.07
Bones & Joints	11	1.0	0.15	1.0	0.16	7	0.8	0.14	0.8	0.15
Soft Tissue (incl. heart)	28	3.6	0.35	3.9	0.39	23	2.6	0.26	2.8	0.29
Skin (excl. basal & sq.)	38	6.0	0.49	6.8	0.55	48	6.1	0.42	7.0	0.48
Melanoma of the skin	31	5.1	0.46	5.8	0.52	42	5.2	0.38	5.9	0.43
Breast (excl. <i>in situ</i>)	5	0.7	0.17	0.9	0.20	796	101.7	1.68	119.4	1.98
Female Genital System	N/A	N/A	N/A	N/A	N/A	424	52.5	1.19	62.2	1.42
Cervix uteri	N/A	N/A	N/A	N/A	N/A	84	9.9	0.50	10.8	0.56
Uterus corpus	N/A	N/A	N/A	N/A	N/A	219	26.9	0.84	32.8	1.03
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	9	1.2	0.19	1.5	0.23
Ovary	N/A	N/A	N/A	N/A	N/A	81	10.4	0.54	12.1	0.63
Male Genital System	648	97.5	1.89	117.1	2.21	N/A	N/A	N/A	N/A	N/A
Prostate	552	88.9	1.85	108.4	2.16	N/A	N/A	N/A	N/A	N/A
Testis	84	6.7	0.33	6.5	0.32	N/A	N/A	N/A	N/A	N/A
Penis	11	1.8	0.27	2.0	0.30	N/A	N/A	N/A	N/A	N/A
Urinary System	259	41.0	1.27	48.2	1.46	125	17.6	0.74	20.7	0.86
Bladder (incl. <i>in situ</i>)	86	16.9	0.89	19.7	1.02	30	5.0	0.43	5.7	0.48
Kidney & renal pelvis	170	23.4	0.88	27.7	1.03	93	12.3	0.60	14.6	0.71
Ureter	2	0.5	0.17	0.6	0.19	1	0.2	0.08	0.3	0.10
Eye & Orbit	5	0.6	0.13	0.7	0.16	3	0.4	0.10	0.4	0.11
Brain & Other CNS	55	6.8	0.46	7.7	0.53	37	4.2	0.33	4.7	0.38
Brain	52	6.5	0.46	7.4	0.52	34	3.9	0.32	4.4	0.37
Endocrine System	62	7.3	0.46	8.2	0.52	211	23.2	0.74	25.6	0.84
Thyroid gland	56	6.7	0.44	7.5	0.50	206	22.7	0.73	25.0	0.83
Lymphomas	168	24.1	0.94	27.6	1.07	141	19.3	0.77	22.3	0.89
Hodgkin lymphoma	29	3.2	0.29	3.5	0.33	18	1.9	0.21	2.0	0.23
Non-Hodgkin lymphoma	139	20.9	0.89	24.1	1.02	123	17.4	0.74	20.4	0.86
Multiple Myeloma	45	7.1	0.52	8.5	0.61	40	6.2	0.46	7.4	0.54
Leukemias	111	13.8	0.68	14.9	0.76	79	9.7	0.53	10.6	0.59
Acute lymphocytic	41	3.4	0.25	3.1	0.25	27	2.4	0.22	2.3	0.23
Chronic lymphocytic	13	2.3	0.32	2.7	0.36	11	1.7	0.25	2.0	0.28
Acute myeloid	30	4.6	0.42	5.1	0.48	25	3.4	0.33	3.8	0.37
Chronic myeloid	17	2.2	0.27	2.5	0.31	10	1.2	0.19	1.5	0.22
Other leukemias	10	1.4	0.22	1.5	0.24	6	0.9	0.17	1.0	0.19
Mesothelioma	6	1.1	0.22	1.3	0.26	3	0.3	0.10	0.4	0.11
Kaposi Sarcoma	9	1.0	0.16	1.1	0.18	*	*	*	*	*
Ill-Defined & Unknown	70	12.7	0.75	14.8	0.87	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	62	8.9	0.58	10.1	0.66	121	15.4	0.66	17.9	0.77
Breast (<i>in situ</i>)	*	*	*	*	*	203	25.3	0.82	29.9	0.97

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

ILLINOIS

II-168 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Illinois, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,280	374.6	3.92	441.6	4.53	2,550	365.3	3.41	425.2	3.96
Oral Cavity & Pharynx	69	11.0	0.65	13.2	0.76	33	4.9	0.40	5.7	0.47
Lip	4	0.7	0.18	0.8	0.21	2	0.3	0.10	0.3	0.12
Tongue	20	3.0	0.34	3.6	0.39	11	1.6	0.23	1.9	0.27
Major salivary gland	7	1.1	0.21	1.3	0.24	7	1.0	0.18	1.1	0.20
Floor of mouth	*	*	*	*	*	2	0.3	0.09	0.3	0.12
Gum & other mouth	11	1.8	0.27	2.2	0.33	5	0.9	0.18	1.1	0.21
Nasopharynx	3	0.4	0.11	0.5	0.14	2	0.2	0.08	0.3	0.09
Oropharynx	3	0.5	0.14	0.7	0.17	2	0.2	0.07	0.2	0.08
Hypopharynx	7	1.2	0.22	1.4	0.25	*	*	*	*	*
Digestive System	609	102.5	2.06	122.9	2.41	474	75.3	1.62	88.1	1.88
Esophagus	28	4.9	0.46	5.9	0.54	6	1.0	0.19	1.2	0.23
Stomach	80	14.0	0.78	16.4	0.90	69	10.8	0.61	12.6	0.71
Small intestine	15	2.5	0.32	2.9	0.36	11	1.6	0.23	2.0	0.27
Colon (excl. rectum)	145	24.0	0.99	28.6	1.16	131	20.3	0.84	23.6	0.97
Rectum & rectosigmoid	101	15.2	0.75	18.6	0.90	66	9.4	0.54	11.1	0.64
Anus, anal canal, & anorectum	8	1.3	0.23	1.5	0.27	9	1.4	0.22	1.7	0.26
Liver	105	17.2	0.83	21.3	0.99	44	7.5	0.53	8.9	0.61
Gallbladder	8	1.5	0.26	1.8	0.31	17	2.7	0.31	3.1	0.36
Pancreas	79	14.7	0.81	17.3	0.94	78	13.3	0.71	15.5	0.81
Respiratory System	185	36.8	1.32	43.2	1.52	152	26.0	0.98	30.7	1.14
Larynx	23	3.9	0.41	4.8	0.48	4	0.5	0.13	0.7	0.16
Lung & bronchus	154	31.8	1.24	37.2	1.42	146	25.2	0.97	29.6	1.12
Bones & Joints	10	1.0	0.16	1.0	0.17	7	0.8	0.14	0.8	0.16
Soft Tissue (incl. heart)	26	3.5	0.35	3.8	0.39	22	2.7	0.27	2.9	0.30
Skin (excl. basal & sq.)	35	5.8	0.49	6.7	0.56	47	6.4	0.44	7.3	0.51
Melanoma of the skin	28	4.8	0.46	5.6	0.52	41	5.5	0.40	6.2	0.46
Breast (excl. <i>in situ</i>)	4	0.7	0.17	0.8	0.20	752	103.2	1.75	121.0	2.06
Female Genital System	N/A	N/A	N/A	N/A	N/A	397	53.0	1.24	62.7	1.47
Cervix uteri	N/A	N/A	N/A	N/A	N/A	79	10.0	0.52	11.0	0.58
Uterus corpus	N/A	N/A	N/A	N/A	N/A	205	27.1	0.87	33.1	1.07
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	8	1.2	0.20	1.4	0.23
Ovary	N/A	N/A	N/A	N/A	N/A	76	10.5	0.57	12.3	0.66
Male Genital System	600	96.7	1.95	115.9	2.27	N/A	N/A	N/A	N/A	N/A
Prostate	509	87.8	1.90	106.9	2.22	N/A	N/A	N/A	N/A	N/A
Testis	79	6.9	0.35	6.7	0.34	N/A	N/A	N/A	N/A	N/A
Penis	11	1.8	0.28	2.1	0.32	N/A	N/A	N/A	N/A	N/A
Urinary System	239	40.7	1.31	47.9	1.51	118	17.9	0.77	21.1	0.90
Bladder (incl. <i>in situ</i>)	79	16.7	0.92	19.5	1.05	28	5.1	0.45	5.8	0.50
Kidney & renal pelvis	157	23.2	0.91	27.5	1.06	88	12.5	0.62	14.8	0.74
Ureter	2	0.6	0.19	0.6	0.20	1	0.2	0.09	0.3	0.11
Eye & Orbit	5	0.6	0.13	0.6	0.16	3	0.4	0.11	0.4	0.11
Brain & Other CNS	52	7.0	0.49	7.9	0.56	35	4.3	0.35	4.8	0.40
Brain	50	6.7	0.48	7.7	0.55	32	4.0	0.34	4.5	0.39
Endocrine System	59	7.4	0.47	8.3	0.53	196	23.4	0.77	25.8	0.87
Thyroid gland	53	6.7	0.45	7.6	0.52	191	22.8	0.76	25.1	0.86
Lymphomas	158	24.3	0.98	27.8	1.12	133	19.7	0.81	22.8	0.93
Hodgkin lymphoma	27	3.3	0.31	3.6	0.35	17	1.9	0.22	2.0	0.24
Non-Hodgkin lymphoma	130	21.0	0.93	24.2	1.06	116	17.8	0.78	20.8	0.90
Multiple Myeloma	43	7.3	0.55	8.7	0.64	38	6.3	0.48	7.5	0.56
Leukemias	107	14.4	0.72	15.5	0.80	75	9.8	0.55	10.7	0.62
Acute lymphocytic	39	3.6	0.27	3.3	0.27	25	2.5	0.23	2.4	0.24
Chronic lymphocytic	12	2.4	0.34	2.8	0.38	10	1.8	0.26	2.1	0.30
Acute myeloid	29	4.6	0.44	5.2	0.50	25	3.5	0.34	3.9	0.39
Chronic myeloid	16	2.3	0.29	2.6	0.33	9	1.2	0.19	1.5	0.23
Other leukemias	10	1.5	0.23	1.6	0.25	6	0.8	0.17	0.9	0.19
Mesothelioma	6	1.1	0.23	1.4	0.28	3	0.4	0.10	0.4	0.12
Kaposi Sarcoma	8	0.9	0.16	1.0	0.18	*	*	*	*	*
Ill-Defined & Unknown	67	12.9	0.79	15.1	0.90	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	59	8.9	0.60	10.1	0.68	116	15.8	0.69	18.3	0.81
Breast (<i>in situ</i>)	*	*	*	*	*	188	25.3	0.85	29.9	1.01

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Illinois, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	35	178.8	14.70	221.8	17.87	41	178.2	13.53	206.6	15.59
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	8	37.6	6.33	48.7	8.07	8	37.3	6.39	43.6	7.35
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	2	10.5	3.47	13.3	4.34	3	13.3	3.71	15.5	4.31
Rectum & rectosigmoid	1	5.2	2.16	6.6	2.80	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	1	5.9	2.61	7.8	3.26	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	1	7.0	2.97	8.8	3.60	1	7.2	2.88	9.0	3.54
Respiratory System	6	38.2	7.42	44.8	8.52	3	14.7	4.12	17.1	4.70
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	6	36.6	7.33	42.2	8.33	3	14.1	4.07	16.6	4.67
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	15	64.8	8.13	76.2	9.41
Female Genital System	N/A	N/A	N/A	N/A	N/A	7	29.6	5.41	34.6	6.32
Cervix uteri	N/A	N/A	N/A	N/A	N/A	1	4.3	1.86	5.3	2.31
Uterus corpus	N/A	N/A	N/A	N/A	N/A	3	13.2	3.49	15.1	4.06
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	1	5.4	2.34	6.4	2.74
Male Genital System	10	53.8	7.95	68.5	9.81	N/A	N/A	N/A	N/A	N/A
Prostate	10	52.3	7.90	67.2	9.78	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	3	17.7	4.54	22.0	5.53	2	7.7	3.05	8.4	3.40
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	2	11.6	3.55	14.6	4.43	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	2	4.9	1.88	5.4	2.10
Thyroid gland	*	*	*	*	*	2	4.9	1.88	5.4	2.10
Lymphomas	1	5.9	2.38	7.1	2.83	2	5.8	2.16	6.4	2.48
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	4	14.7	3.54	17.8	4.29

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


ILLINOIS

II-170 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	6,611,442	6,637,898	6,662,068	6,698,481	6,731,010
Non-Hispanic White	5,345,140	5,341,672	5,337,756	5,337,364	5,337,883
Non-Hispanic Black	659,837	668,693	677,849	690,035	700,534
Non-Hispanic Asian/Pacific Islander (NH API)	151,445	160,619	167,064	176,887	184,116
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	2,346	2,343	2,370	2,427	2,421


All Races Population 2015–2019: 33,340,899
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	437,040	448,816	461,125	475,603	489,687
Hispanic White	391,766	402,106	412,594	425,155	437,081
Hispanic Black	26,084	26,989	28,145	29,280	30,582

Hispanic/Latino Population, Census 2010: 389,707
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

INDIANA CANCER REGISTRY

Initial Operation: 1987
 Population-based Data Available: 1987
 Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	107.9	109.3	108.8	104.2	95.0	105.0
Missing Race	0.5	0.6	0.6	0.5	0.7	0.6
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.2	1.1	1.7	2.4	2.5	1.8
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.0	Ovary	94.1
Oral Cavity & Pharynx	98.2	Prostate	96.9
Esophagus	96.6	Testis	99.1
Stomach	97.6	Bladder (incl. <i>in situ</i>)	97.8
Colon & Rectum	96.7	Kidney & Renal Pelvis	91.1
Liver	57.6	Brain & Other CNS	85.3
Pancreas	88.0	Brain & Other CNS (non-malig)	38.4
Lung & Bronchus	89.4	Thyroid	99.5
Melanomas of the Skin	99.6	Hodgkin Lymphoma	99.1
Female Breast (excl. <i>in situ</i>)	98.8	Non-Hodgkin Lymphoma	97.4
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	91.0
Cervix Uteri	98.2	Leukemias	91.6
Uterus Corpus & Uterus NOS	98.6		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Indiana, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	18,186	497.7	1.70	590.5	1.98	17,813	430.9	1.49	504.3	1.71
Oral Cavity & Pharynx	735	19.4	0.33	23.8	0.40	281	6.7	0.19	8.0	0.21
Lip	25	0.7	0.07	0.8	0.08	8	0.2	0.03	0.2	0.04
Tongue	241	6.3	0.19	7.7	0.22	94	2.3	0.11	2.7	0.13
Major salivary gland	60	1.8	0.10	2.1	0.12	39	1.0	0.07	1.1	0.08
Floor of mouth	30	0.8	0.06	1.0	0.08	14	0.3	0.04	0.4	0.05
Gum & other mouth	73	2.0	0.11	2.4	0.13	58	1.4	0.08	1.6	0.09
Nasopharynx	23	0.6	0.06	0.8	0.07	8	0.2	0.03	0.2	0.04
Oropharynx	41	1.1	0.08	1.3	0.09	13	0.3	0.04	0.4	0.05
Hypopharynx	38	1.0	0.07	1.2	0.09	8	0.2	0.03	0.2	0.04
Digestive System	3,681	101.0	0.77	120.6	0.90	2,883	67.6	0.58	79.8	0.67
Esophagus	367	9.8	0.24	11.9	0.28	80	1.8	0.09	2.2	0.11
Stomach	296	8.2	0.22	9.7	0.26	162	3.9	0.14	4.5	0.16
Small intestine	109	3.1	0.13	3.6	0.16	101	2.5	0.11	2.9	0.13
Colon (excl. rectum)	1,133	31.9	0.44	37.6	0.51	1,139	26.8	0.36	31.3	0.42
Rectum & rectosigmoid	541	15.0	0.30	17.8	0.35	383	9.4	0.22	11.1	0.26
Anus, anal canal, & anorectum	55	1.5	0.09	1.8	0.11	120	2.8	0.12	3.5	0.14
Liver	397	10.0	0.23	12.5	0.28	122	2.7	0.11	3.3	0.14
Gallbladder	21	0.6	0.06	0.7	0.07	55	1.2	0.08	1.5	0.09
Pancreas	567	15.5	0.30	18.6	0.35	516	11.8	0.24	14.0	0.28
Respiratory System	3,215	87.3	0.71	104.3	0.83	2,768	63.0	0.55	75.6	0.65
Larynx	228	5.9	0.18	7.3	0.22	70	1.6	0.09	2.0	0.11
Lung & bronchus	2,951	80.5	0.68	95.9	0.80	2,672	60.8	0.54	72.8	0.64
Bones & Joints	35	1.1	0.08	1.1	0.08	30	0.9	0.07	0.9	0.07
Soft Tissue (incl. heart)	123	3.6	0.15	4.0	0.16	106	2.8	0.12	3.1	0.13
Skin (excl. basal & sq.)	999	28.4	0.41	33.2	0.48	769	20.0	0.33	22.7	0.37
Melanoma of the skin	936	26.5	0.40	31.0	0.46	723	18.9	0.33	21.4	0.36
Breast (excl. <i>in situ</i>)	39	1.1	0.08	1.3	0.10	5,093	124.4	0.81	146.8	0.93
Female Genital System	N/A	N/A	N/A	N/A	N/A	2,146	52.6	0.53	62.1	0.61
Cervix uteri	N/A	N/A	N/A	N/A	N/A	284	8.4	0.23	9.0	0.24
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,212	28.5	0.38	34.7	0.45
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	16	0.4	0.04	0.4	0.05
Ovary	N/A	N/A	N/A	N/A	N/A	400	9.8	0.23	11.4	0.26
Male Genital System	4,136	107.0	0.76	129.9	0.91	N/A	N/A	N/A	N/A	N/A
Prostate	3,910	99.9	0.73	122.6	0.89	N/A	N/A	N/A	N/A	N/A
Testis	186	5.9	0.20	5.9	0.19	N/A	N/A	N/A	N/A	N/A
Penis	33	1.0	0.08	1.1	0.09	N/A	N/A	N/A	N/A	N/A
Urinary System	2,253	63.3	0.61	74.7	0.71	969	23.0	0.34	27.0	0.39
Bladder (incl. <i>in situ</i>)	1,274	36.4	0.47	42.8	0.54	384	8.7	0.20	10.3	0.24
Kidney & renal pelvis	929	25.4	0.38	30.1	0.45	557	13.6	0.27	15.9	0.30
Ureter	32	0.9	0.08	1.1	0.09	18	0.4	0.04	0.5	0.05
Eye & Orbit	35	1.0	0.07	1.1	0.08	31	0.8	0.06	0.9	0.07
Brain & Other CNS	270	7.8	0.22	8.5	0.23	206	5.4	0.17	5.9	0.19
Brain	258	7.4	0.21	8.1	0.23	196	5.1	0.17	5.6	0.18
Endocrine System	250	7.3	0.21	8.1	0.23	636	18.5	0.34	19.8	0.35
Thyroid gland	223	6.5	0.20	7.3	0.22	609	17.7	0.33	19.0	0.35
Lymphomas	877	25.0	0.39	28.7	0.44	714	17.4	0.30	19.9	0.34
Hodgkin lymphoma	98	3.0	0.14	3.1	0.14	76	2.2	0.12	2.3	0.12
Non-Hodgkin lymphoma	779	22.1	0.36	25.6	0.42	638	15.2	0.28	17.6	0.31
Multiple Myeloma	289	8.1	0.22	9.5	0.25	236	5.5	0.16	6.5	0.19
Leukemias	618	17.9	0.33	20.4	0.37	416	10.2	0.23	11.4	0.25
Acute lymphocytic	59	1.8	0.11	1.7	0.10	40	1.2	0.09	1.1	0.08
Chronic lymphocytic	232	6.5	0.20	7.7	0.23	142	3.2	0.12	3.8	0.15
Acute myeloid	186	5.4	0.18	6.2	0.21	143	3.6	0.14	4.0	0.15
Chronic myeloid	78	2.3	0.12	2.6	0.13	51	1.3	0.08	1.4	0.09
Other leukemias	62	1.9	0.11	2.1	0.12	39	1.0	0.07	1.1	0.08
Mesothelioma	47	1.4	0.10	1.7	0.11	18	0.4	0.04	0.5	0.05
Kaposi Sarcoma	8	0.3	0.04	0.3	0.04	*	*	*	*	*
Ill-Defined & Unknown	574	16.6	0.32	19.4	0.37	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	270	7.8	0.22	8.9	0.24	531	13.3	0.27	15.2	0.30
Breast (<i>in situ</i>)	5	0.1	0.03	0.2	0.03	1,084	26.8	0.38	31.8	0.44

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Indiana, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	16,223	503.1	1.82	595.7	2.12	15,796	439.1	1.63	513.2	1.86
Oral Cavity & Pharynx	675	20.4	0.36	24.9	0.43	251	6.9	0.20	8.1	0.23
Lip	23	0.8	0.07	0.9	0.08	7	0.2	0.03	0.2	0.04
Tongue	225	6.7	0.21	8.2	0.25	85	2.4	0.12	2.8	0.14
Major salivary gland	54	1.8	0.11	2.1	0.13	31	0.9	0.08	1.0	0.08
Floor of mouth	28	0.8	0.07	1.0	0.09	13	0.3	0.04	0.4	0.05
Gum & other mouth	67	2.0	0.12	2.5	0.14	53	1.4	0.09	1.6	0.10
Nasopharynx	19	0.6	0.07	0.7	0.08	6	0.2	0.03	0.2	0.04
Oropharynx	37	1.1	0.08	1.4	0.10	11	0.3	0.04	0.4	0.05
Hypopharynx	32	0.9	0.07	1.2	0.09	8	0.2	0.03	0.3	0.04
Digestive System	3,253	101.1	0.82	120.5	0.96	2,525	67.4	0.62	79.3	0.72
Esophagus	342	10.3	0.26	12.5	0.31	68	1.7	0.10	2.1	0.11
Stomach	253	7.9	0.23	9.4	0.27	128	3.4	0.14	4.0	0.16
Small intestine	97	3.1	0.15	3.6	0.17	85	2.4	0.12	2.8	0.14
Colon (excl. rectum)	1,007	32.1	0.47	37.8	0.54	1,015	27.1	0.40	31.6	0.45
Rectum & rectosigmoid	482	15.2	0.32	18.1	0.37	337	9.6	0.25	11.3	0.28
Anus, anal canal, & anorectum	48	1.5	0.10	1.8	0.12	113	3.0	0.13	3.8	0.16
Liver	323	9.2	0.24	11.5	0.29	96	2.4	0.11	2.9	0.14
Gallbladder	18	0.6	0.06	0.7	0.07	46	1.1	0.08	1.4	0.09
Pancreas	509	15.6	0.32	18.7	0.38	454	11.7	0.25	13.9	0.30
Respiratory System	2,948	89.7	0.76	107.1	0.89	2,519	64.8	0.59	77.7	0.70
Larynx	201	5.9	0.19	7.3	0.23	63	1.7	0.10	2.1	0.12
Lung & bronchus	2,714	82.8	0.73	98.6	0.86	2,432	62.5	0.58	74.9	0.69
Bones & Joints	30	1.1	0.09	1.1	0.09	24	0.9	0.08	0.9	0.08
Soft Tissue (incl. heart)	108	3.6	0.16	4.1	0.18	86	2.7	0.14	2.9	0.14
Skin (excl. basal & sq.)	956	31.0	0.46	36.0	0.53	717	22.1	0.39	24.9	0.42
Melanoma of the skin	898	29.0	0.45	33.8	0.51	678	21.0	0.38	23.7	0.41
Breast (excl. <i>in situ</i>)	34	1.1	0.09	1.3	0.10	4,485	125.9	0.88	148.5	1.01
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,896	53.8	0.58	63.5	0.66
Cervix uteri	N/A	N/A	N/A	N/A	N/A	233	8.4	0.26	8.9	0.27
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,075	29.1	0.41	35.4	0.49
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	14	0.3	0.04	0.4	0.05
Ovary	N/A	N/A	N/A	N/A	N/A	360	10.1	0.25	11.9	0.29
Male Genital System	3,521	103.0	0.80	124.6	0.95	N/A	N/A	N/A	N/A	N/A
Prostate	3,324	95.2	0.76	116.7	0.91	N/A	N/A	N/A	N/A	N/A
Testis	162	6.6	0.24	6.5	0.23	N/A	N/A	N/A	N/A	N/A
Penis	28	0.9	0.08	1.1	0.09	N/A	N/A	N/A	N/A	N/A
Urinary System	2,049	64.8	0.66	76.4	0.76	869	23.5	0.37	27.5	0.43
Bladder (incl. <i>in situ</i>)	1,187	37.8	0.50	44.4	0.58	353	9.0	0.22	10.7	0.26
Kidney & renal pelvis	815	25.5	0.41	30.2	0.48	490	13.8	0.29	16.1	0.33
Ureter	31	1.0	0.08	1.2	0.10	17	0.4	0.05	0.5	0.05
Eye & Orbit	33	1.1	0.09	1.2	0.09	30	0.9	0.08	1.0	0.08
Brain & Other CNS	243	8.3	0.25	9.1	0.26	184	5.7	0.20	6.2	0.21
Brain	232	8.0	0.24	8.7	0.26	176	5.4	0.19	5.9	0.20
Endocrine System	222	7.8	0.24	8.5	0.26	546	19.3	0.39	20.6	0.40
Thyroid gland	199	6.9	0.23	7.7	0.25	525	18.6	0.38	19.8	0.39
Lymphomas	787	25.7	0.42	29.5	0.48	640	17.8	0.33	20.4	0.37
Hodgkin lymphoma	83	3.1	0.16	3.2	0.16	63	2.3	0.13	2.3	0.13
Non-Hodgkin lymphoma	704	22.6	0.39	26.2	0.45	577	15.6	0.30	18.1	0.34
Multiple Myeloma	241	7.6	0.23	9.0	0.26	185	4.8	0.16	5.7	0.19
Leukemias	553	18.3	0.36	20.8	0.40	364	10.3	0.25	11.6	0.28
Acute lymphocytic	47	1.9	0.12	1.7	0.11	32	1.2	0.10	1.2	0.09
Chronic lymphocytic	214	6.8	0.21	8.0	0.25	129	3.3	0.13	3.9	0.16
Acute myeloid	164	5.4	0.19	6.2	0.22	125	3.6	0.15	4.0	0.16
Chronic myeloid	70	2.3	0.13	2.7	0.14	44	1.3	0.09	1.4	0.10
Other leukemias	58	2.0	0.12	2.3	0.13	34	0.9	0.07	1.1	0.08
Mesothelioma	44	1.5	0.10	1.7	0.12	16	0.4	0.05	0.5	0.05
Kaposi Sarcoma	3	0.1	0.03	0.1	0.03	*	*	*	*	*
Ill-Defined & Unknown	523	17.0	0.34	19.8	0.39	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	236	8.0	0.24	9.0	0.26	459	13.4	0.29	15.2	0.32
Breast (<i>in situ</i>)	4	0.1	0.03	0.1	0.03	926	26.5	0.41	31.5	0.47

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

INDIANA

II-174 Incidence – NH White

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Indiana, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,329	530.9	6.94	640.8	8.18	1,309	400.4	5.08	474.8	5.93
Oral Cavity & Pharynx	36	13.4	1.05	16.3	1.25	18	5.4	0.58	6.3	0.67
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	9	3.1	0.49	3.8	0.59	4	1.1	0.26	1.4	0.33
Major salivary gland	3	1.2	0.36	1.4	0.42	6	1.7	0.33	1.9	0.37
Floor of mouth	2	0.6	0.20	0.7	0.25	*	*	*	*	*
Gum & other mouth	2	1.0	0.30	1.1	0.34	2	0.6	0.21	0.7	0.22
Nasopharynx	2	0.8	0.26	0.9	0.30	1	0.4	0.16	0.4	0.17
Oropharynx	3	1.0	0.29	1.2	0.34	2	0.5	0.17	0.6	0.20
Hypopharynx	5	1.8	0.38	2.3	0.46	*	*	*	*	*
Digestive System	289	117.4	3.29	141.3	3.87	245	75.6	2.22	90.8	2.62
Esophagus	17	6.4	0.75	7.9	0.90	9	2.5	0.40	3.2	0.49
Stomach	28	11.9	1.07	14.1	1.24	19	6.1	0.64	7.3	0.75
Small intestine	10	3.9	0.59	4.7	0.71	12	3.7	0.49	4.6	0.58
Colon (excl. rectum)	90	38.2	1.92	45.1	2.23	91	28.2	1.36	33.5	1.59
Rectum & rectosigmoid	36	14.4	1.14	17.3	1.34	27	8.4	0.74	9.8	0.86
Anus, anal canal, & anorectum	6	2.2	0.42	2.4	0.46	5	1.5	0.31	1.8	0.36
Liver	48	17.2	1.17	22.1	1.46	16	4.6	0.53	5.7	0.65
Gallbladder	2	1.0	0.31	1.2	0.37	6	1.7	0.34	2.1	0.40
Pancreas	40	17.2	1.29	20.5	1.50	46	13.7	0.94	16.9	1.13
Respiratory System	214	90.2	2.95	108.5	3.45	197	60.8	1.99	73.4	2.36
Larynx	20	7.6	0.81	9.4	0.97	6	1.6	0.31	2.0	0.39
Lung & bronchus	192	81.9	2.82	98.3	3.30	190	58.9	1.97	71.0	2.32
Bones & Joints	4	1.3	0.32	1.3	0.34	2	0.6	0.17	0.6	0.18
Soft Tissue (incl. heart)	8	2.8	0.47	3.2	0.54	13	3.8	0.48	4.3	0.55
Skin (excl. basal & sq.)	5	2.1	0.43	2.4	0.48	6	1.8	0.35	2.0	0.37
Melanoma of the skin	2	1.1	0.31	1.1	0.34	2	0.7	0.22	0.9	0.25
Breast (excl. <i>in situ</i>)	4	2.2	0.50	2.5	0.56	402	122.4	2.80	145.8	3.28
Female Genital System	N/A	N/A	N/A	N/A	N/A	154	45.5	1.68	54.6	1.98
Cervix uteri	N/A	N/A	N/A	N/A	N/A	27	8.2	0.72	9.1	0.80
Uterus corpus	N/A	N/A	N/A	N/A	N/A	89	25.6	1.24	31.6	1.50
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	0.6	0.18	0.7	0.22
Ovary	N/A	N/A	N/A	N/A	N/A	25	7.7	0.71	8.9	0.81
Male Genital System	455	173.9	3.87	215.6	4.65	N/A	N/A	N/A	N/A	N/A
Prostate	447	171.0	3.84	212.4	4.62	N/A	N/A	N/A	N/A	N/A
Testis	4	1.3	0.29	1.4	0.32	N/A	N/A	N/A	N/A	N/A
Penis	3	1.2	0.33	1.4	0.37	N/A	N/A	N/A	N/A	N/A
Urinary System	127	53.1	2.25	63.6	2.63	69	21.5	1.19	25.1	1.37
Bladder (incl. <i>in situ</i>)	50	22.4	1.52	26.9	1.79	22	7.2	0.70	8.4	0.81
Kidney & renal pelvis	77	30.2	1.64	36.2	1.92	45	13.7	0.94	16.1	1.08
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	1	0.3	0.14	0.4	0.16	*	*	*	*	*
Brain & Other CNS	13	4.5	0.59	5.1	0.69	13	4.0	0.50	4.2	0.54
Brain	12	4.1	0.56	4.6	0.65	12	3.6	0.48	3.8	0.51
Endocrine System	11	4.2	0.58	4.7	0.65	40	12.4	0.90	13.3	0.96
Thyroid gland	10	3.6	0.55	4.1	0.62	35	10.9	0.85	11.7	0.90
Lymphomas	49	18.5	1.26	21.1	1.43	41	12.6	0.90	14.3	1.01
Hodgkin lymphoma	8	2.4	0.39	2.4	0.40	7	1.9	0.34	1.9	0.34
Non-Hodgkin lymphoma	41	16.2	1.20	18.6	1.37	34	10.6	0.83	12.3	0.95
Multiple Myeloma	39	16.2	1.24	19.4	1.44	41	12.7	0.91	15.1	1.06
Leukemias	36	14.5	1.16	16.8	1.34	29	9.0	0.77	10.5	0.88
Acute lymphocytic	4	1.0	0.24	1.0	0.26	2	0.6	0.19	0.6	0.20
Chronic lymphocytic	11	4.8	0.68	5.9	0.82	9	2.8	0.44	3.4	0.51
Acute myeloid	13	5.3	0.69	6.0	0.79	11	3.2	0.44	3.7	0.51
Chronic myeloid	6	2.7	0.54	3.1	0.60	4	1.4	0.30	1.6	0.35
Other leukemias	2	0.8	0.25	0.8	0.28	3	1.1	0.27	1.2	0.30
Mesothelioma	2	0.9	0.30	1.0	0.34	*	*	*	*	*
Kaposi Sarcoma	3	1.1	0.28	1.1	0.28	*	*	*	*	*
Ill-Defined & Unknown	32	14.2	1.19	16.6	1.37	37	11.9	0.90	14.0	1.04
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	22	8.7	0.88	10.0	1.01	46	14.3	0.97	16.7	1.12
Breast (<i>in situ</i>)	*	*	*	*	*	102	30.9	1.40	36.8	1.64

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Indiana, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	112	234.2	11.21	274.9	13.02	155	247.3	9.46	285.4	10.96
Oral Cavity & Pharynx	6	10.9	2.35	13.1	2.79	3	5.3	1.34	6.0	1.56
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	1	1.9	0.75	2.1	0.83
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	32	73.3	6.47	85.5	7.43	24	43.5	4.23	51.8	4.95
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	5	11.7	2.65	13.2	2.97	4	7.4	1.74	8.7	2.03
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	8	16.9	2.85	20.0	3.32	5	8.4	1.80	10.3	2.15
Rectum & rectosigmoid	5	9.0	1.99	10.5	2.31	4	7.4	1.72	8.4	1.92
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	6	12.6	2.46	14.6	2.80	2	2.6	0.99	3.3	1.21
Gallbladder	*	*	*	*	*	1	2.8	1.11	3.2	1.26
Pancreas	4	10.6	2.83	12.3	3.24	4	9.2	2.10	10.7	2.43
Respiratory System	14	28.6	3.65	34.6	4.36	14	26.7	3.35	31.6	3.93
Larynx	2	3.1	1.14	3.9	1.37	*	*	*	*	*
Lung & bronchus	12	25.3	3.46	30.6	4.13	13	25.1	3.25	29.9	3.81
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	2	2.3	0.90	2.6	1.05
Skin (excl. basal & sq.)	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	*	*	*	*	*	2	2.2	0.83	2.3	0.90
Breast (excl. <i>in situ</i>)	*	*	*	*	*	58	87.9	5.45	101.9	6.35
Female Genital System	N/A	N/A	N/A	N/A	N/A	16	24.7	2.87	28.1	3.29
Cervix uteri	N/A	N/A	N/A	N/A	N/A	3	3.8	1.02	4.1	1.16
Uterus corpus	N/A	N/A	N/A	N/A	N/A	8	12.7	2.03	14.5	2.32
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	4	6.9	1.60	7.8	1.86
Male Genital System	22	50.0	5.17	59.6	6.02	N/A	N/A	N/A	N/A	N/A
Prostate	20	48.2	5.14	57.8	5.99	N/A	N/A	N/A	N/A	N/A
Testis	1	1.3	0.48	1.2	0.46	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	8	18.7	3.41	22.3	4.03	5	8.7	1.94	9.9	2.18
Bladder (incl. <i>in situ</i>)	6	15.2	3.22	18.0	3.79	2	4.4	1.48	4.9	1.65
Kidney & renal pelvis	2	3.5	1.13	4.3	1.38	2	3.8	1.18	4.3	1.34
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	4	6.2	1.69	7.3	2.08	2	3.5	1.06	3.6	1.17
Brain	4	6.2	1.69	7.3	2.08	2	3.5	1.06	3.6	1.17
Endocrine System	4	5.9	1.28	6.3	1.46	12	15.1	1.97	16.3	2.21
Thyroid gland	4	4.8	1.15	5.1	1.31	12	14.9	1.95	16.1	2.20
Lymphomas	6	12.5	2.69	14.0	3.00	6	9.4	1.82	10.9	2.10
Hodgkin lymphoma	1	1.9	0.98	2.0	1.09	1	1.9	0.74	2.1	0.86
Non-Hodgkin lymphoma	5	10.6	2.50	12.0	2.80	5	7.6	1.67	8.8	1.92
Multiple Myeloma	2	4.3	1.41	5.0	1.61	2	3.5	1.22	3.8	1.37
Leukemias	6	11.4	2.60	12.6	2.95	4	6.1	1.49	7.0	1.75
Acute lymphocytic	2	1.9	0.66	1.6	0.57	*	*	*	*	*
Chronic lymphocytic	1	3.7	1.50	4.3	1.76	1	2.2	0.94	2.7	1.16
Acute myeloid	2	5.0	1.96	5.7	2.23	1	2.0	0.84	2.2	0.97
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	4	7.8	1.99	9.1	2.37	3	6.1	1.66	7.1	1.90
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	2	3.4	1.26	4.0	1.49	7	10.9	1.97	12.8	2.31
Breast (<i>in situ</i>)	*	*	*	*	*	16	25.4	2.97	29.7	3.45

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

INDIANA

II-176 Incidence – NH API

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Indiana, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3	244.9	65.18	288.4	75.72	2	161.9	51.35	204.1	61.22
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Indiana, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	369	319.7	8.58	376.0	9.86	444	334.6	7.71	391.0	9.01
Oral Cavity & Pharynx	11	9.2	1.41	10.9	1.63	6	4.6	0.92	5.5	1.09
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	3	3.1	0.93	3.7	1.07	2	1.5	0.56	1.6	0.62
Major salivary gland	1	0.7	0.28	0.9	0.35	1	0.9	0.35	1.1	0.44
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	1.5	0.63	1.6	0.69	1	0.9	0.39	1.1	0.47
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	93	82.6	4.37	98.8	5.06	76	63.8	3.52	76.0	4.13
Esophagus	7	6.0	1.16	7.1	1.33	2	1.8	0.60	2.2	0.71
Stomach	9	8.6	1.44	10.0	1.64	9	7.6	1.21	8.8	1.40
Small intestine	1	1.2	0.52	1.4	0.60	3	2.1	0.61	2.3	0.67
Colon (excl. rectum)	23	21.5	2.31	25.8	2.70	25	21.4	2.07	25.3	2.41
Rectum & rectosigmoid	15	11.4	1.52	13.7	1.78	10	7.7	1.16	9.2	1.37
Anus, anal canal, & anorectum	*	*	*	*	*	2	1.0	0.38	1.3	0.49
Liver	18	16.3	1.92	19.8	2.22	8	7.2	1.21	8.7	1.44
Gallbladder	*	*	*	*	*	2	1.4	0.53	1.8	0.65
Pancreas	12	11.2	1.61	13.4	1.87	11	9.7	1.39	11.5	1.63
Respiratory System	30	31.9	2.92	36.8	3.24	31	28.9	2.49	34.3	2.89
Larynx	4	3.6	0.87	4.5	1.03	*	*	*	*	*
Lung & bronchus	24	27.3	2.75	31.1	3.02	29	28.1	2.47	33.3	2.86
Bones & Joints	1	0.7	0.31	0.7	0.34	3	1.2	0.37	1.4	0.44
Soft Tissue (incl. heart)	5	3.0	0.71	3.4	0.83	5	3.0	0.69	3.2	0.78
Skin (excl. basal & sq.)	6	4.8	1.04	5.7	1.21	10	7.5	1.14	9.0	1.36
Melanoma of the skin	5	3.8	0.93	4.4	1.08	9	6.1	1.00	7.4	1.21
Breast (excl. <i>in situ</i>)	*	*	*	*	*	128	95.4	4.05	111.9	4.74
Female Genital System	N/A	N/A	N/A	N/A	N/A	72	49.0	2.75	57.4	3.27
Cervix uteri	N/A	N/A	N/A	N/A	N/A	21	12.2	1.26	13.2	1.42
Uterus corpus	N/A	N/A	N/A	N/A	N/A	36	24.6	1.93	30.0	2.38
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	10	7.5	1.15	8.6	1.32
Male Genital System	95	84.1	4.36	101.1	5.09	N/A	N/A	N/A	N/A	N/A
Prostate	79	77.3	4.28	94.3	5.02	N/A	N/A	N/A	N/A	N/A
Testis	15	5.8	0.69	5.7	0.70	N/A	N/A	N/A	N/A	N/A
Penis	1	1.0	0.45	1.1	0.49	N/A	N/A	N/A	N/A	N/A
Urinary System	48	45.2	3.31	53.1	3.82	22	18.0	1.87	21.0	2.17
Bladder (incl. <i>in situ</i>)	17	20.3	2.40	23.6	2.74	5	4.0	0.87	4.8	1.05
Kidney & renal pelvis	30	23.8	2.20	28.1	2.56	17	14.0	1.65	16.2	1.90
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	9	4.7	0.84	5.3	0.99	6	3.2	0.68	3.5	0.77
Brain	8	4.6	0.84	5.2	0.99	5	3.1	0.68	3.4	0.77
Endocrine System	9	5.8	1.04	6.3	1.16	32	18.6	1.55	20.7	1.79
Thyroid gland	7	5.0	0.96	5.4	1.06	31	18.1	1.52	20.1	1.76
Lymphomas	27	20.2	2.05	23.1	2.32	22	17.0	1.75	19.9	2.05
Hodgkin lymphoma	5	2.3	0.47	2.6	0.56	4	2.8	0.66	3.2	0.77
Non-Hodgkin lymphoma	22	17.9	1.99	20.4	2.25	18	14.2	1.62	16.7	1.90
Multiple Myeloma	5	4.7	1.05	5.4	1.17	6	6.0	1.18	6.8	1.31
Leukemias	17	12.0	1.62	13.1	1.81	15	8.1	1.07	8.6	1.21
Acute lymphocytic	6	2.7	0.61	2.7	0.65	6	2.6	0.56	2.5	0.63
Chronic lymphocytic	2	1.7	0.62	2.0	0.69	1	0.9	0.40	1.2	0.50
Acute myeloid	6	5.1	1.12	5.5	1.24	5	3.2	0.71	3.5	0.80
Chronic myeloid	2	1.2	0.45	1.6	0.59	1	0.7	0.27	0.7	0.29
Other leukemias	1	1.3	0.63	1.4	0.71	1	0.7	0.32	0.6	0.31
Mesothelioma	1	1.6	0.66	1.8	0.74	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	9	8.0	1.42	9.1	1.59	11	9.6	1.40	11.4	1.65
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	7	4.5	0.90	5.2	1.05	15	11.1	1.40	13.0	1.64
Breast (<i>in situ</i>)	*	*	*	*	*	35	25.7	2.07	30.5	2.45

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

INDIANA

II-178 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Indiana, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	351	328.5	8.98	386.7	10.33	425	348.9	8.17	407.4	9.55
Oral Cavity & Pharynx	11	9.9	1.51	11.8	1.75	6	4.7	0.96	5.7	1.14
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	3	3.4	0.99	4.0	1.14	2	1.6	0.61	1.8	0.67
Major salivary gland	1	0.8	0.31	1.0	0.39	1	1.0	0.38	1.2	0.48
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	1.6	0.68	1.7	0.74	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	88	84.1	4.55	100.8	5.28	74	67.2	3.74	80.0	4.39
Esophagus	7	6.2	1.22	7.4	1.40	2	2.0	0.64	2.4	0.76
Stomach	9	9.0	1.52	10.5	1.73	9	8.2	1.30	9.5	1.51
Small intestine	1	1.3	0.56	1.5	0.64	3	2.3	0.66	2.5	0.72
Colon (excl. rectum)	21	22.1	2.43	26.4	2.83	24	22.6	2.22	26.9	2.58
Rectum & rectosigmoid	14	11.6	1.58	14.0	1.86	10	8.3	1.25	9.8	1.47
Anus, anal canal, & anorectum	*	*	*	*	*	1	1.0	0.39	1.3	0.50
Liver	17	16.7	2.03	20.2	2.34	8	7.3	1.26	8.9	1.50
Gallbladder	*	*	*	*	*	1	1.4	0.55	1.8	0.68
Pancreas	12	11.3	1.65	13.5	1.94	11	9.9	1.44	11.8	1.69
Respiratory System	29	33.1	3.07	38.1	3.40	30	30.3	2.64	36.0	3.07
Larynx	4	3.7	0.93	4.7	1.10	*	*	*	*	*
Lung & bronchus	23	28.2	2.89	32.1	3.16	28	29.4	2.62	35.0	3.03
Bones & Joints	1	0.6	0.32	0.6	0.32	2	1.3	0.40	1.4	0.48
Soft Tissue (incl. heart)	5	3.2	0.74	3.5	0.87	5	3.1	0.74	3.4	0.84
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	10	8.0	1.21	9.6	1.45
Melanoma of the skin	4	3.0	0.79	3.6	0.94	8	6.4	1.06	7.8	1.29
Breast (excl. <i>in situ</i>)	*	*	*	*	*	122	98.9	4.27	115.7	5.00
Female Genital System	N/A	N/A	N/A	N/A	N/A	68	50.8	2.91	59.5	3.46
Cervix uteri	N/A	N/A	N/A	N/A	N/A	19	12.7	1.34	13.7	1.51
Uterus corpus	N/A	N/A	N/A	N/A	N/A	34	25.3	2.03	31.0	2.52
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	10	8.2	1.24	9.3	1.42
Male Genital System	91	87.4	4.62	105.1	5.38	N/A	N/A	N/A	N/A	N/A
Prostate	75	80.1	4.53	97.7	5.30	N/A	N/A	N/A	N/A	N/A
Testis	14	6.2	0.75	6.1	0.76	N/A	N/A	N/A	N/A	N/A
Penis	1	1.1	0.49	1.2	0.53	N/A	N/A	N/A	N/A	N/A
Urinary System	46	45.6	3.42	53.7	3.94	21	18.4	1.97	21.3	2.28
Bladder (incl. <i>in situ</i>)	16	19.9	2.44	23.2	2.79	4	3.9	0.90	4.7	1.07
Kidney & renal pelvis	29	24.6	2.30	29.0	2.68	16	14.5	1.75	16.6	2.01
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	8	4.8	0.89	5.5	1.05	5	3.2	0.67	3.4	0.76
Brain	8	4.7	0.89	5.4	1.05	5	3.1	0.67	3.4	0.76
Endocrine System	9	6.3	1.13	6.9	1.25	31	19.5	1.66	21.7	1.91
Thyroid gland	7	5.4	1.03	5.9	1.14	30	18.9	1.63	21.0	1.88
Lymphomas	26	21.3	2.18	24.4	2.47	21	17.5	1.86	20.4	2.16
Hodgkin lymphoma	5	2.4	0.51	2.7	0.61	4	3.1	0.72	3.5	0.84
Non-Hodgkin lymphoma	21	18.9	2.12	21.6	2.40	17	14.5	1.71	16.9	1.99
Multiple Myeloma	5	5.1	1.12	5.9	1.26	6	6.5	1.28	7.3	1.41
Leukemias	17	12.8	1.73	14.0	1.93	15	8.9	1.17	9.4	1.31
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	6	2.9	0.61	2.8	0.68
Chronic lymphocytic	2	1.8	0.66	2.1	0.74	1	1.0	0.43	1.3	0.53
Acute myeloid	6	5.4	1.20	5.9	1.32	5	3.5	0.77	3.8	0.87
Chronic myeloid	2	1.3	0.48	1.7	0.63	1	0.8	0.30	0.8	0.32
Other leukemias	*	*	*	*	*	1	0.8	0.35	0.7	0.34
Mesothelioma	1	1.7	0.71	2.0	0.79	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	8	7.7	1.43	8.7	1.61	10	10.1	1.50	12.0	1.76
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	6	4.5	0.94	5.1	1.09	15	11.6	1.49	13.5	1.74
Breast (<i>in situ</i>)	*	*	*	*	*	34	27.2	2.22	32.3	2.63

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Indiana, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3	53.9	16.15	63.7	18.94	6	127.1	28.37	147.5	32.21
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	2	59.7	20.96	68.0	23.18
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


INDIANA

II-180 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	3,122,541	3,133,210	3,143,734	3,149,900	3,159,596
Non-Hispanic White	2,727,830	2,724,355	2,720,040	2,714,237	2,710,101
Non-Hispanic Black	124,939	130,094	136,134	140,687	145,472
Non-Hispanic Asian/Pacific Islander (NH API)	80,990	84,454	87,907	89,777	92,883
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	3,429	3,425	3,357	3,368	3,434


All Races Population 2015–2019: 15,708,981
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	178,561	183,978	189,243	194,626	200,424
Hispanic White	161,832	166,679	171,133	175,762	180,915
Hispanic Black	6,696	6,904	7,323	7,644	7,935

Hispanic/Latino Population, Census 2010: 151,544
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

IOWA CANCER REGISTRY

Initial Operation: 1973
Population-based Data Available: 1973
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	111.5	114.7	115.3	114.5	115.6	114.3
Missing Race	0.4	0.4	0.5	0.6	0.6	0.5
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.5	1.6	1.3	1.6	1.4	1.5
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.8	Ovary	90.8
Oral Cavity & Pharynx	98.7	Prostate	97.1
Esophagus	97.1	Testis	98.8
Stomach	97.2	Bladder (incl. <i>in situ</i>)	97.3
Colon & Rectum	95.7	Kidney & Renal Pelvis	90.0
Liver	48.6	Brain & Other CNS	84.0
Pancreas	83.9	Brain & Other CNS (non-malig)	41.1
Lung & Bronchus	88.0	Thyroid	99.4
Melanomas of the Skin	99.8	Hodgkin Lymphoma	99.8
Female Breast (excl. <i>in situ</i>)	99.0	Non-Hodgkin Lymphoma	97.6
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	92.1
Cervix Uteri	99.3	Leukemias	93.5
Uterus Corpus & Uterus NOS	98.8		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Iowa, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	9,884	535.9	2.47	635.4	2.88	9,226	460.9	2.25	537.6	2.56
Oral Cavity & Pharynx	395	21.1	0.49	25.8	0.59	166	8.0	0.29	9.6	0.34
Lip	39	2.2	0.16	2.6	0.19	10	0.5	0.07	0.6	0.08
Tongue	129	6.7	0.27	8.3	0.33	51	2.5	0.16	3.0	0.19
Major salivary gland	32	1.8	0.15	2.1	0.17	26	1.3	0.12	1.5	0.14
Floor of mouth	17	0.9	0.10	1.1	0.12	6	0.3	0.06	0.4	0.07
Gum & other mouth	45	2.5	0.17	3.0	0.20	41	1.9	0.14	2.2	0.16
Nasopharynx	12	0.6	0.09	0.8	0.10	6	0.3	0.06	0.4	0.07
Oropharynx	19	1.0	0.10	1.3	0.13	4	0.2	0.05	0.3	0.06
Hypopharynx	19	1.0	0.10	1.2	0.13	4	0.2	0.05	0.2	0.05
Digestive System	1,805	98.8	1.07	117.7	1.25	1,458	68.9	0.84	80.5	0.97
Esophagus	189	10.0	0.33	12.1	0.40	44	2.0	0.14	2.4	0.16
Stomach	117	6.3	0.27	7.6	0.31	67	3.3	0.19	3.9	0.22
Small intestine	62	3.4	0.20	4.0	0.23	53	2.6	0.17	3.1	0.19
Colon (excl. rectum)	576	32.6	0.62	38.2	0.72	626	29.4	0.55	33.9	0.62
Rectum & rectosigmoid	267	14.8	0.42	17.7	0.49	164	8.5	0.31	9.9	0.36
Anus, anal canal, & anorectum	29	1.6	0.13	1.9	0.16	59	2.9	0.18	3.5	0.21
Liver	167	8.6	0.31	10.7	0.37	57	2.6	0.16	3.1	0.19
Gallbladder	13	0.7	0.09	0.8	0.10	28	1.2	0.11	1.5	0.13
Pancreas	291	15.8	0.42	18.8	0.50	261	11.8	0.34	13.9	0.39
Respiratory System	1,481	79.2	0.94	94.4	1.11	1,227	56.7	0.74	67.8	0.88
Larynx	112	5.9	0.26	7.2	0.31	26	1.2	0.11	1.5	0.14
Lung & bronchus	1,350	72.2	0.90	86.0	1.05	1,190	54.9	0.73	65.6	0.86
Bones & Joints	18	1.1	0.12	1.1	0.12	13	0.8	0.10	0.8	0.10
Soft Tissue (incl. heart)	64	3.8	0.22	4.2	0.24	48	2.6	0.18	2.9	0.19
Skin (excl. basal & sq.)	644	36.6	0.66	42.3	0.75	526	29.4	0.60	32.9	0.66
Melanoma of the skin	587	33.3	0.63	38.5	0.72	491	27.8	0.59	31.1	0.64
Breast (excl. <i>in situ</i>)	25	1.4	0.13	1.6	0.15	2,631	135.3	1.24	159.3	1.42
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,111	55.5	0.78	66.1	0.91
Cervix uteri	N/A	N/A	N/A	N/A	N/A	119	7.7	0.33	8.1	0.34
Uterus corpus	N/A	N/A	N/A	N/A	N/A	626	30.1	0.56	36.9	0.67
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	15	0.7	0.09	0.9	0.10
Ovary	N/A	N/A	N/A	N/A	N/A	200	9.7	0.32	11.6	0.38
Male Genital System	2,482	127.3	1.17	155.0	1.40	N/A	N/A	N/A	N/A	N/A
Prostate	2,357	119.0	1.12	146.6	1.36	N/A	N/A	N/A	N/A	N/A
Testis	103	7.1	0.32	7.0	0.31	N/A	N/A	N/A	N/A	N/A
Penis	17	1.0	0.11	1.1	0.12	N/A	N/A	N/A	N/A	N/A
Urinary System	1,217	67.0	0.88	79.1	1.02	485	23.0	0.49	27.0	0.56
Bladder (incl. <i>in situ</i>)	696	38.6	0.67	45.2	0.77	194	8.6	0.28	10.1	0.33
Kidney & renal pelvis	495	27.0	0.56	32.2	0.65	274	13.8	0.39	16.1	0.44
Ureter	13	0.7	0.09	0.8	0.10	10	0.4	0.06	0.5	0.08
Eye & Orbit	23	1.3	0.13	1.5	0.14	22	1.1	0.11	1.3	0.13
Brain & Other CNS	138	7.9	0.31	8.8	0.34	112	6.2	0.27	6.7	0.29
Brain	131	7.4	0.30	8.4	0.33	106	5.8	0.26	6.4	0.28
Endocrine System	149	8.8	0.33	9.9	0.37	351	22.1	0.55	23.7	0.57
Thyroid gland	133	7.8	0.31	8.9	0.35	340	21.5	0.54	23.0	0.57
Lymphomas	508	29.0	0.59	33.1	0.66	398	19.8	0.46	22.7	0.52
Hodgkin lymphoma	50	3.1	0.20	3.3	0.21	39	2.4	0.18	2.5	0.18
Non-Hodgkin lymphoma	458	25.9	0.55	29.8	0.63	360	17.4	0.43	20.2	0.49
Multiple Myeloma	167	9.2	0.33	10.9	0.38	125	5.8	0.24	6.8	0.28
Leukemias	394	22.4	0.52	25.4	0.58	256	12.5	0.37	14.1	0.40
Acute lymphocytic	34	2.2	0.17	2.0	0.16	19	1.3	0.13	1.1	0.12
Chronic lymphocytic	161	8.7	0.31	10.4	0.37	100	4.5	0.21	5.3	0.24
Acute myeloid	112	6.4	0.28	7.3	0.31	86	4.3	0.22	4.8	0.24
Chronic myeloid	51	3.0	0.19	3.4	0.21	30	1.5	0.13	1.7	0.14
Other leukemias	35	2.0	0.16	2.3	0.18	22	1.0	0.10	1.2	0.12
Mesothelioma	24	1.3	0.13	1.6	0.15	9	0.4	0.07	0.5	0.08
Kaposi Sarcoma	3	0.2	0.05	0.2	0.05	*	*	*	*	*
Ill-Defined & Unknown	348	19.5	0.48	22.8	0.55	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	185	10.7	0.36	12.1	0.40	358	18.9	0.47	21.5	0.52
Breast (<i>in situ</i>)	3	0.1	0.04	0.2	0.05	554	29.7	0.59	35.0	0.68

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Iowa, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	9,373	539.5	2.57	639.0	2.98	8,752	465.8	2.36	542.8	2.68
Oral Cavity & Pharynx	376	21.5	0.51	26.2	0.61	157	8.1	0.30	9.6	0.35
Lip	38	2.3	0.17	2.7	0.20	10	0.5	0.08	0.6	0.09
Tongue	125	7.0	0.29	8.6	0.35	49	2.5	0.17	3.1	0.20
Major salivary gland	30	1.8	0.15	2.1	0.17	24	1.3	0.12	1.5	0.14
Floor of mouth	16	0.9	0.10	1.1	0.12	6	0.3	0.06	0.4	0.07
Gum & other mouth	42	2.5	0.18	2.9	0.20	40	1.9	0.14	2.2	0.16
Nasopharynx	9	0.5	0.08	0.6	0.09	4	0.2	0.06	0.3	0.06
Oropharynx	19	1.0	0.11	1.3	0.14	4	0.2	0.06	0.3	0.07
Hypopharynx	18	1.0	0.10	1.2	0.13	4	0.2	0.05	0.2	0.06
Digestive System	1,686	97.9	1.10	116.5	1.28	1,376	68.4	0.87	79.9	1.00
Esophagus	184	10.3	0.35	12.4	0.41	42	2.0	0.14	2.4	0.17
Stomach	105	6.0	0.27	7.1	0.31	59	3.0	0.19	3.5	0.21
Small intestine	59	3.4	0.20	4.0	0.24	50	2.6	0.17	3.1	0.20
Colon (excl. rectum)	545	32.8	0.65	38.3	0.74	596	29.4	0.57	33.9	0.64
Rectum & rectosigmoid	250	14.9	0.44	17.7	0.51	154	8.5	0.33	9.9	0.37
Anus, anal canal, & anorectum	26	1.5	0.14	1.8	0.16	57	3.1	0.19	3.7	0.22
Liver	142	7.7	0.30	9.6	0.36	50	2.4	0.16	2.9	0.19
Gallbladder	11	0.6	0.09	0.8	0.10	24	1.1	0.10	1.3	0.12
Pancreas	277	15.8	0.44	18.8	0.51	250	11.8	0.35	13.9	0.40
Respiratory System	1,424	80.0	0.97	95.3	1.14	1,184	57.4	0.77	68.7	0.91
Larynx	106	5.9	0.26	7.2	0.32	25	1.2	0.12	1.6	0.14
Lung & bronchus	1,299	72.9	0.92	86.8	1.09	1,149	55.6	0.75	66.5	0.89
Bones & Joints	16	1.1	0.13	1.1	0.13	12	0.8	0.11	0.9	0.11
Soft Tissue (incl. heart)	60	3.9	0.24	4.3	0.25	44	2.6	0.19	2.9	0.20
Skin (excl. basal & sq.)	618	37.6	0.70	43.3	0.79	504	31.1	0.66	34.7	0.71
Melanoma of the skin	564	34.3	0.67	39.5	0.75	472	29.6	0.65	32.9	0.70
Breast (excl. <i>in situ</i>)	24	1.4	0.13	1.7	0.15	2,503	137.2	1.30	161.5	1.49
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,049	55.7	0.82	66.3	0.94
Cervix uteri	N/A	N/A	N/A	N/A	N/A	104	7.5	0.35	7.9	0.36
Uterus corpus	N/A	N/A	N/A	N/A	N/A	597	30.4	0.58	37.2	0.70
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	14	0.7	0.09	0.8	0.10
Ovary	N/A	N/A	N/A	N/A	N/A	190	9.8	0.34	11.7	0.39
Male Genital System	2,348	127.6	1.21	155.2	1.45	N/A	N/A	N/A	N/A	N/A
Prostate	2,236	118.8	1.15	146.4	1.40	N/A	N/A	N/A	N/A	N/A
Testis	91	7.5	0.36	7.4	0.35	N/A	N/A	N/A	N/A	N/A
Penis	16	1.0	0.11	1.1	0.13	N/A	N/A	N/A	N/A	N/A
Urinary System	1,166	67.9	0.91	80.0	1.06	457	22.9	0.50	26.9	0.58
Bladder (incl. <i>in situ</i>)	674	39.2	0.69	45.8	0.80	189	8.7	0.29	10.3	0.34
Kidney & renal pelvis	467	27.3	0.59	32.5	0.68	252	13.4	0.40	15.8	0.46
Ureter	13	0.8	0.09	0.9	0.11	10	0.5	0.07	0.5	0.08
Eye & Orbit	22	1.4	0.14	1.6	0.15	21	1.2	0.12	1.4	0.14
Brain & Other CNS	132	8.3	0.34	9.2	0.36	105	6.4	0.30	6.9	0.31
Brain	125	7.8	0.32	8.8	0.35	100	6.0	0.29	6.6	0.30
Endocrine System	138	8.9	0.36	10.1	0.39	321	22.6	0.60	24.2	0.62
Thyroid gland	124	8.1	0.34	9.2	0.37	311	22.1	0.59	23.6	0.61
Lymphomas	477	29.2	0.62	33.3	0.69	377	20.0	0.49	22.9	0.54
Hodgkin lymphoma	44	3.1	0.22	3.3	0.22	35	2.5	0.20	2.5	0.19
Non-Hodgkin lymphoma	433	26.0	0.58	30.0	0.65	342	17.5	0.45	20.4	0.51
Multiple Myeloma	158	9.2	0.34	10.8	0.39	116	5.6	0.24	6.6	0.28
Leukemias	370	22.4	0.54	25.6	0.60	240	12.4	0.38	14.0	0.42
Acute lymphocytic	27	2.1	0.19	1.9	0.16	14	1.1	0.14	1.0	0.12
Chronic lymphocytic	156	8.9	0.33	10.6	0.38	97	4.6	0.22	5.4	0.25
Acute myeloid	107	6.4	0.28	7.3	0.32	80	4.2	0.23	4.8	0.25
Chronic myeloid	46	2.9	0.20	3.3	0.22	28	1.5	0.13	1.7	0.15
Other leukemias	34	2.1	0.17	2.4	0.19	21	1.0	0.10	1.2	0.12
Mesothelioma	23	1.3	0.13	1.6	0.15	9	0.4	0.07	0.5	0.08
Kaposi Sarcoma	2	0.1	0.04	0.1	0.04	*	*	*	*	*
Ill-Defined & Unknown	334	19.7	0.49	23.0	0.57	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	172	10.9	0.39	12.3	0.42	337	19.1	0.50	21.7	0.55
Breast (<i>in situ</i>)	3	0.1	0.04	0.2	0.05	521	30.1	0.63	35.4	0.71

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Iowa, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	225	622.1	21.26	757.6	25.09	178	477.9	17.02	561.4	19.82
Oral Cavity & Pharynx	7	17.7	3.71	22.1	4.49	2	5.1	1.75	6.2	2.10
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	3.7	1.49	4.6	1.78	*	*	*	*	*
Major salivary gland	1	3.2	1.64	3.8	1.94	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	1	3.2	1.66	4.2	2.15	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	54	156.9	10.95	189.8	12.83	33	90.0	7.40	107.4	8.72
Esophagus	2	7.1	2.73	9.1	3.44	1	4.1	1.69	5.2	2.00
Stomach	5	14.9	3.29	18.3	3.85	3	5.9	1.67	6.9	1.98
Small intestine	2	5.7	1.88	6.8	2.17	2	5.2	1.85	5.4	1.97
Colon (excl. rectum)	14	47.8	6.56	55.7	7.47	12	36.2	4.90	42.5	5.69
Rectum & rectosigmoid	6	16.6	3.35	20.5	4.00	4	8.3	1.94	10.2	2.42
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	14	33.7	4.47	42.0	5.37	3	5.9	1.60	7.4	2.07
Gallbladder	*	*	*	*	*	2	4.1	1.50	5.4	1.94
Pancreas	7	21.2	4.02	25.8	4.71	5	13.2	2.89	16.3	3.47
Respiratory System	33	104.1	9.10	123.8	10.41	23	70.7	6.88	85.1	8.04
Larynx	3	9.3	2.67	11.3	3.07	*	*	*	*	*
Lung & bronchus	30	94.4	8.69	112.0	9.94	23	68.4	6.75	82.6	7.91
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	1	2.0	0.79	2.3	0.96	1	2.6	1.17	2.5	1.18
Skin (excl. basal & sq.)	*	*	*	*	*	1	4.3	1.80	4.5	1.87
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	50	133.4	8.87	155.8	10.31
Female Genital System	N/A	N/A	N/A	N/A	N/A	21	53.4	5.54	66.2	6.77
Cervix uteri	N/A	N/A	N/A	N/A	N/A	4	9.3	2.11	11.1	2.55
Uterus corpus	N/A	N/A	N/A	N/A	N/A	10	28.5	4.22	35.9	5.14
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	3	7.3	1.94	9.0	2.50
Male Genital System	72	191.6	11.14	242.8	13.50	N/A	N/A	N/A	N/A	N/A
Prostate	71	188.9	11.06	239.9	13.43	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	19	53.1	6.34	65.1	7.67	14	38.3	4.93	43.9	5.60
Bladder (incl. <i>in situ</i>)	7	24.1	4.66	30.4	5.75	2	8.9	2.67	9.8	2.88
Kidney & renal pelvis	11	27.7	4.19	33.4	4.98	11	28.8	4.10	33.5	4.75
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	2.8	0.99	3.0	1.14	3	4.8	1.49	5.3	1.71
Brain	2	2.8	0.99	3.0	1.14	2	4.4	1.42	4.6	1.57
Endocrine System	3	5.1	1.39	5.7	1.67	7	16.3	2.87	17.4	3.10
Thyroid gland	2	3.1	1.14	3.7	1.40	7	14.5	2.66	15.3	2.84
Lymphomas	11	24.6	3.74	28.5	4.33	7	16.4	3.09	18.2	3.47
Hodgkin lymphoma	3	3.7	1.07	3.7	1.09	2	3.6	1.40	3.5	1.37
Non-Hodgkin lymphoma	9	20.9	3.58	24.8	4.19	5	12.8	2.75	14.7	3.19
Multiple Myeloma	6	14.4	3.03	18.3	3.78	6	18.4	3.46	22.4	4.09
Leukemias	7	20.7	4.16	22.5	4.67	5	12.0	2.71	12.9	2.97
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	1	1.8	0.72	1.7	0.77
Chronic lymphocytic	2	6.7	2.38	7.5	2.58	*	*	*	*	*
Acute myeloid	2	7.9	2.70	8.8	3.10	2	4.5	1.56	4.9	1.71
Chronic myeloid	2	3.8	1.68	4.1	2.03	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	5	22.4	4.81	25.9	5.50	4	11.1	2.58	12.5	2.94
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	5	13.9	3.17	16.5	3.69	8	21.7	3.52	25.0	4.08
Breast (<i>in situ</i>)	*	*	*	*	*	12	32.6	4.44	37.9	5.10

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Iowa, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	65	326.5	21.32	388.5	24.88	86	295.5	15.33	345.4	17.83
Oral Cavity & Pharynx	5	20.7	4.83	25.4	5.73	3	9.6	2.82	10.9	3.19
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	8.1	3.06	9.6	3.47	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	1	4.8	1.81	6.0	2.34	1	3.6	1.37	4.3	1.75
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	22	115.2	12.58	137.9	14.70	18	69.7	7.85	83.3	9.15
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	3	16.3	5.16	18.0	5.70	2	8.8	2.87	10.3	3.30
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	4	16.3	4.22	20.4	5.25	6	19.6	3.94	23.3	4.61
Rectum & rectosigmoid	4	18.9	5.51	22.4	6.24	2	7.3	2.25	9.2	2.81
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	6	26.6	5.37	32.7	6.36	2	9.8	3.16	11.9	3.73
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	3	16.5	5.06	19.7	5.93	3	10.6	2.97	12.7	3.45
Respiratory System	10	60.3	9.79	70.0	11.13	8	33.2	5.71	38.8	6.58
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	10	56.9	9.53	65.8	10.81	7	32.2	5.64	37.8	6.51
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	29	94.1	8.17	109.8	9.58
Female Genital System	N/A	N/A	N/A	N/A	N/A	10	29.8	4.39	35.6	5.30
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	6.1	1.91	6.8	2.17
Uterus corpus	N/A	N/A	N/A	N/A	N/A	6	17.0	3.42	21.0	4.20
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	1	4.1	1.60	4.5	1.76
Male Genital System	8	44.3	8.16	53.3	9.51	N/A	N/A	N/A	N/A	N/A
Prostate	8	43.4	8.14	52.4	9.50	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	4	20.8	4.99	25.7	6.04	2	7.6	2.45	8.6	2.81
Bladder (incl. <i>in situ</i>)	2	12.8	4.08	16.0	4.99	*	*	*	*	*
Kidney & renal pelvis	2	7.3	2.78	8.7	3.21	2	5.4	2.07	5.9	2.33
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	1	3.5	1.43	4.3	1.91	*	*	*	*	*
Brain	1	2.8	1.23	3.2	1.54	*	*	*	*	*
Endocrine System	2	4.8	1.73	5.6	2.13	5	14.0	2.90	15.5	3.29
Thyroid gland	2	4.0	1.49	4.5	1.81	5	12.3	2.73	13.2	2.98
Lymphomas	4	20.0	5.18	23.7	6.29	4	13.0	3.40	15.0	3.86
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	3	17.8	5.70	19.8	6.44	1	4.4	1.84	5.2	2.21
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	1	8.5	4.03	9.9	4.66	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	9.6	3.34	12.0	4.15	2	10.0	3.09	11.3	3.43
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	2	11.2	3.74	13.8	4.61	4	12.3	2.91	14.4	3.45
Breast (<i>in situ</i>)	*	*	*	*	*	9	26.3	4.01	32.0	4.96

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Iowa, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	9	940.7	157.35	1143.7	185.91	12	764.8	106.42	898.6	126.29
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	3	260.4	80.35	326.9	96.84	2	175.8	54.89	201.0	64.37
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	1	77.7	33.01	99.7	41.46
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	1	77.7	33.01	99.7	41.46
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	3	214.2	59.19	249.5	70.13
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	97.4	34.95	112.0	40.51
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	2	196.0	71.96	214.8	77.90	N/A	N/A	N/A	N/A	N/A
Prostate	2	179.8	70.12	201.5	76.76	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	1	129.8	54.19	160.0	66.84	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Iowa, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	135	304.6	14.17	359.8	16.31	142	287.6	12.12	335.1	14.09
Oral Cavity & Pharynx	4	9.2	2.49	10.8	2.83	2	4.3	1.68	5.0	1.85
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	34	83.9	7.61	99.2	8.70	23	56.5	5.82	65.9	6.66
Esophagus	2	4.8	1.70	5.7	1.91	*	*	*	*	*
Stomach	3	7.5	2.20	8.9	2.58	3	6.8	1.82	8.1	2.13
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	10	27.2	4.50	31.4	5.04	9	22.4	3.81	25.3	4.23
Rectum & rectosigmoid	4	9.2	2.23	11.4	2.63	3	5.8	1.52	7.1	1.91
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	5	11.7	2.70	14.8	3.23	1	4.5	1.74	5.2	1.99
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	4	9.8	2.72	11.2	3.07	3	7.1	2.20	8.2	2.49
Respiratory System	10	30.3	4.93	35.4	5.55	8	22.3	3.76	26.1	4.30
Larynx	1	4.2	1.86	4.9	2.06	*	*	*	*	*
Lung & bronchus	8	25.8	4.56	30.3	5.15	8	22.0	3.75	25.6	4.27
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	2	3.3	1.25	3.5	1.36	2	3.2	1.17	4.0	1.47
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	1	3.4	1.45	3.9	1.63	2	3.6	1.35	4.5	1.71
Breast (excl. <i>in situ</i>)	*	*	*	*	*	37	72.8	5.75	86.3	6.87
Female Genital System	N/A	N/A	N/A	N/A	N/A	25	46.9	4.67	54.0	5.36
Cervix uteri	N/A	N/A	N/A	N/A	N/A	7	12.9	2.41	13.9	2.68
Uterus corpus	N/A	N/A	N/A	N/A	N/A	11	21.2	3.27	24.7	3.72
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	4	6.5	1.60	7.6	1.90
Male Genital System	30	69.6	6.72	83.9	7.76	N/A	N/A	N/A	N/A	N/A
Prostate	24	63.4	6.60	77.4	7.64	N/A	N/A	N/A	N/A	N/A
Testis	6	5.3	0.99	5.4	1.04	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	16	36.4	4.82	44.3	5.70	6	13.7	2.70	16.5	3.21
Bladder (incl. <i>in situ</i>)	5	15.0	3.31	18.4	3.93	*	*	*	*	*
Kidney & renal pelvis	11	21.5	3.50	25.9	4.13	6	11.8	2.46	14.3	2.92
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	3	4.1	1.35	4.2	1.45	2	4.1	1.28	5.1	1.67
Brain	3	3.8	1.33	4.0	1.45	2	3.8	1.24	4.8	1.65
Endocrine System	6	8.5	1.97	10.3	2.46	13	18.4	2.50	19.5	2.77
Thyroid gland	5	6.7	1.57	8.3	2.03	13	18.4	2.50	19.5	2.77
Lymphomas	11	22.8	3.69	26.5	4.26	8	19.7	3.34	23.4	3.88
Hodgkin lymphoma	2	2.0	0.66	1.9	0.67	1	2.2	0.94	2.8	1.18
Non-Hodgkin lymphoma	9	20.8	3.63	24.6	4.21	7	17.5	3.20	20.6	3.70
Multiple Myeloma	2	3.9	1.64	4.9	2.03	2	3.9	1.41	5.1	1.80
Leukemias	8	12.1	2.59	13.0	2.91	6	8.3	1.79	9.1	2.11
Acute lymphocytic	4	3.3	0.72	2.8	0.62	3	3.5	1.14	3.3	1.24
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	1	3.3	1.52	3.8	1.76	2	3.4	1.19	4.2	1.49
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	5	10.9	2.70	12.5	3.06	3	8.1	2.31	8.8	2.51
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	3	6.8	2.00	7.5	2.18	7	14.1	2.85	15.9	3.20
Breast (<i>in situ</i>)	*	*	*	*	*	10	19.4	2.86	23.0	3.43

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

IOWA

II-188 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Iowa, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	131	317.3	14.83	374.4	17.06	138	300.8	12.77	349.9	14.82
Oral Cavity & Pharynx	4	9.8	2.64	11.5	2.99	2	4.7	1.79	5.4	1.98
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	33	88.1	8.01	104.0	9.15	23	58.0	6.07	67.5	6.93
Esophagus	2	4.8	1.77	5.6	1.98	*	*	*	*	*
Stomach	3	7.9	2.31	9.5	2.71	3	7.0	1.92	8.3	2.25
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	10	28.9	4.76	33.4	5.32	9	23.8	4.04	26.9	4.49
Rectum & rectosigmoid	4	9.9	2.37	12.2	2.80	3	5.1	1.40	6.3	1.76
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	5	12.4	2.85	15.7	3.41	1	4.7	1.84	5.5	2.10
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	3	10.0	2.85	11.3	3.18	3	7.5	2.33	8.7	2.64
Respiratory System	10	31.7	5.19	37.0	5.83	8	22.0	3.86	25.7	4.39
Larynx	1	4.5	1.97	5.2	2.18	*	*	*	*	*
Lung & bronchus	8	27.0	4.80	31.6	5.41	8	21.7	3.85	25.1	4.36
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	2	3.5	1.33	3.8	1.45	2	3.5	1.24	4.3	1.57
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	1	3.6	1.53	4.2	1.73	2	3.8	1.42	4.7	1.80
Breast (excl. <i>in situ</i>)	*	*	*	*	*	37	76.8	6.09	90.9	7.27
Female Genital System	N/A	N/A	N/A	N/A	N/A	24	49.5	4.97	56.9	5.70
Cervix uteri	N/A	N/A	N/A	N/A	N/A	7	13.3	2.55	14.5	2.85
Uterus corpus	N/A	N/A	N/A	N/A	N/A	11	22.8	3.50	26.6	3.99
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	4	7.0	1.71	8.2	2.03
Male Genital System	29	72.0	6.98	86.6	8.06	N/A	N/A	N/A	N/A	N/A
Prostate	23	65.3	6.85	79.6	7.93	N/A	N/A	N/A	N/A	N/A
Testis	6	5.8	1.08	5.9	1.14	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	15	37.5	5.00	45.8	5.94	6	14.7	2.88	17.7	3.42
Bladder (incl. <i>in situ</i>)	5	15.8	3.48	19.4	4.13	*	*	*	*	*
Kidney & renal pelvis	10	21.7	3.59	26.3	4.27	6	12.7	2.63	15.3	3.12
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	3	4.4	1.44	4.6	1.55	2	4.4	1.36	5.4	1.77
Brain	3	4.1	1.42	4.3	1.54	2	4.1	1.32	5.2	1.75
Endocrine System	6	9.1	2.07	11.0	2.59	13	19.6	2.66	20.7	2.95
Thyroid gland	5	7.2	1.66	8.9	2.14	13	19.6	2.66	20.7	2.95
Lymphomas	11	23.6	3.87	27.5	4.46	8	20.9	3.54	24.8	4.12
Hodgkin lymphoma	2	2.2	0.73	2.1	0.73	1	2.3	0.99	2.9	1.25
Non-Hodgkin lymphoma	9	21.4	3.80	25.4	4.40	7	18.6	3.40	21.9	3.93
Multiple Myeloma	2	4.1	1.71	5.2	2.12	2	4.2	1.51	5.5	1.94
Leukemias	8	12.7	2.72	13.5	3.04	6	8.8	1.91	9.6	2.25
Acute lymphocytic	4	3.7	0.80	3.1	0.69	3	3.9	1.24	3.7	1.34
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	1	3.5	1.60	4.1	1.85	2	3.7	1.27	4.5	1.59
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	5	10.8	2.73	12.4	3.12	3	8.2	2.41	8.8	2.58
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	3	6.9	2.10	7.7	2.30	6	13.9	2.86	15.7	3.21
Breast (<i>in situ</i>)	*	*	*	*	*	10	20.4	3.04	24.3	3.64

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Iowa, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	*	*	*	*	*	*	*	*	*	*
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


IOWA

II-190 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	2,910,717	2,912,977	2,910,892	2,912,748	2,912,635
Non-Hispanic White	2,261,497	2,254,900	2,246,987	2,240,420	2,233,672
Non-Hispanic Black	192,858	192,732	192,480	193,094	193,747
Non-Hispanic Asian/Pacific Islander (NH API)	92,512	95,970	96,914	99,026	99,851
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	5,003	5,022	5,016	4,981	4,978


All Races Population 2015–2019: 14,559,969
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	335,464	341,051	346,287	352,043	357,005
Hispanic White	303,565	308,669	313,337	318,099	322,354
Hispanic Black	14,135	14,420	14,645	15,182	15,478

Hispanic/Latino Population, Census 2010: 300,042
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

KANSAS CANCER REGISTRY

Initial Operation: 1968
Population-based Data Available: 1984
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	103.4	102.6	105.3	100.1	101.2	102.5
Missing Race	1.7	1.7	2.8	2.7	2.6	2.3
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.2	0.2	0.3	0.3	0.4	0.3
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	95.5	Ovary	96.0
Oral Cavity & Pharynx	98.0	Prostate	98.5
Esophagus	97.7	Testis	99.8
Stomach	98.6	Bladder (incl. <i>in situ</i>)	99.2
Colon & Rectum	98.3	Kidney & Renal Pelvis	92.6
Liver	62.3	Brain & Other CNS	89.5
Pancreas	89.9	Brain & Other CNS (non-malig)	38.2
Lung & Bronchus	90.8	Thyroid	99.5
Melanomas of the Skin	99.7	Hodgkin Lymphoma	98.9
Female Breast (excl. <i>in situ</i>)	99.5	Non-Hodgkin Lymphoma	97.3
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	92.6
Cervix Uteri	98.6	Leukemias	90.5
Uterus Corpus & Uterus NOS	99.4		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Kansas, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	7,996	496.2	2.55	589.5	2.97	7,625	436.2	2.32	508.1	2.64
Oral Cavity & Pharynx	292	17.7	0.48	21.7	0.57	119	6.6	0.28	7.9	0.33
Lip	11	0.7	0.10	0.9	0.12	5	0.2	0.05	0.3	0.06
Tongue	91	5.5	0.26	6.7	0.32	43	2.4	0.17	2.9	0.20
Major salivary gland	32	2.1	0.17	2.4	0.19	15	0.8	0.10	1.0	0.12
Floor of mouth	10	0.6	0.09	0.7	0.10	7	0.4	0.06	0.4	0.08
Gum & other mouth	32	2.0	0.16	2.4	0.19	21	1.1	0.11	1.3	0.13
Nasopharynx	11	0.7	0.10	0.8	0.11	4	0.3	0.06	0.3	0.07
Oropharynx	16	1.0	0.11	1.2	0.14	5	0.3	0.06	0.3	0.07
Hypopharynx	14	0.8	0.10	1.0	0.12	4	0.2	0.04	0.2	0.06
Digestive System	1,474	91.9	1.10	109.8	1.29	1,147	63.2	0.86	74.5	1.00
Esophagus	133	8.1	0.32	9.8	0.38	35	1.8	0.14	2.2	0.17
Stomach	110	6.8	0.30	8.1	0.35	64	3.4	0.20	4.1	0.23
Small intestine	54	3.3	0.21	4.0	0.25	42	2.5	0.18	2.8	0.20
Colon (excl. rectum)	480	30.9	0.65	36.3	0.75	468	26.0	0.56	30.2	0.64
Rectum & rectosigmoid	226	14.3	0.44	17.1	0.51	154	8.8	0.33	10.5	0.38
Anus, anal canal, & anorectum	19	1.2	0.12	1.4	0.15	43	2.3	0.16	2.9	0.20
Liver	165	9.4	0.34	11.9	0.42	51	2.7	0.17	3.3	0.21
Gallbladder	10	0.6	0.09	0.8	0.11	21	1.1	0.12	1.3	0.13
Pancreas	217	13.5	0.42	16.1	0.49	196	10.5	0.34	12.4	0.40
Respiratory System	1,093	67.7	0.94	80.5	1.10	968	51.2	0.75	61.3	0.89
Larynx	87	5.2	0.26	6.3	0.31	18	1.0	0.10	1.2	0.13
Lung & bronchus	989	61.5	0.90	73.0	1.05	938	49.6	0.74	59.3	0.88
Bones & Joints	16	1.1	0.12	1.1	0.12	16	1.0	0.12	1.0	0.12
Soft Tissue (incl. heart)	66	4.3	0.24	4.9	0.27	52	3.2	0.20	3.5	0.22
Skin (excl. basal & sq.)	559	35.8	0.70	41.9	0.80	405	25.1	0.58	28.1	0.64
Melanoma of the skin	526	33.6	0.67	39.4	0.77	384	24.0	0.57	26.9	0.62
Breast (excl. <i>in situ</i>)	18	1.2	0.13	1.3	0.14	2,303	133.3	1.29	156.6	1.48
Female Genital System	N/A	N/A	N/A	N/A	N/A	873	51.0	0.80	59.9	0.92
Cervix uteri	N/A	N/A	N/A	N/A	N/A	114	8.1	0.35	8.5	0.36
Uterus corpus	N/A	N/A	N/A	N/A	N/A	479	26.8	0.57	32.5	0.67
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	17	1.0	0.11	1.2	0.13
Ovary	N/A	N/A	N/A	N/A	N/A	172	10.0	0.35	11.6	0.40
Male Genital System	2,056	121.3	1.23	147.4	1.47	N/A	N/A	N/A	N/A	N/A
Prostate	1,955	114.0	1.18	140.1	1.43	N/A	N/A	N/A	N/A	N/A
Testis	88	6.3	0.31	6.3	0.30	N/A	N/A	N/A	N/A	N/A
Penis	11	0.7	0.10	0.9	0.12	N/A	N/A	N/A	N/A	N/A
Urinary System	997	63.1	0.92	74.5	1.06	426	23.5	0.53	27.6	0.61
Bladder (incl. <i>in situ</i>)	558	35.7	0.69	41.9	0.80	176	9.2	0.32	10.8	0.37
Kidney & renal pelvis	418	26.1	0.59	31.0	0.68	240	13.8	0.41	16.1	0.47
Ureter	14	0.9	0.11	1.1	0.13	7	0.4	0.06	0.5	0.08
Eye & Orbit	17	1.1	0.13	1.3	0.14	13	0.8	0.10	0.9	0.11
Brain & Other CNS	114	7.4	0.32	8.3	0.35	91	5.6	0.27	6.1	0.29
Brain	109	7.0	0.31	7.9	0.34	85	5.2	0.26	5.7	0.28
Endocrine System	134	8.7	0.35	9.9	0.39	338	22.9	0.58	24.8	0.61
Thyroid gland	122	8.0	0.33	9.1	0.37	330	22.4	0.57	24.3	0.61
Lymphomas	409	26.5	0.60	30.6	0.68	309	17.6	0.46	20.2	0.52
Hodgkin lymphoma	42	2.9	0.20	3.0	0.21	30	2.0	0.17	2.1	0.17
Non-Hodgkin lymphoma	366	23.6	0.57	27.6	0.65	280	15.6	0.43	18.1	0.49
Multiple Myeloma	126	7.9	0.32	9.4	0.38	93	5.1	0.24	6.0	0.28
Leukemias	293	19.0	0.51	21.7	0.57	200	11.5	0.38	12.9	0.41
Acute lymphocytic	25	1.8	0.16	1.6	0.15	18	1.3	0.14	1.1	0.12
Chronic lymphocytic	117	7.3	0.31	8.7	0.36	75	4.0	0.21	4.7	0.25
Acute myeloid	82	5.4	0.27	6.2	0.31	61	3.6	0.21	4.0	0.23
Chronic myeloid	40	2.7	0.20	3.0	0.22	26	1.6	0.14	1.8	0.16
Other leukemias	28	1.9	0.16	2.1	0.18	19	1.1	0.11	1.2	0.13
Mesothelioma	14	0.9	0.11	1.1	0.13	7	0.4	0.07	0.5	0.08
Kaposi Sarcoma	3	0.2	0.05	0.2	0.05	*	*	*	*	*
Ill-Defined & Unknown	315	20.3	0.52	23.7	0.60	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	117	7.6	0.32	8.6	0.36	275	16.2	0.45	18.5	0.51
Breast (<i>in situ</i>)	2	0.2	0.05	0.2	0.05	432	25.7	0.57	30.4	0.66

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Kansas, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	6,903	490.9	2.72	582.1	3.17	6,587	435.2	2.53	506.8	2.87
Oral Cavity & Pharynx	259	18.2	0.52	22.3	0.63	102	6.5	0.31	7.7	0.35
Lip	10	0.7	0.11	0.9	0.12	5	0.3	0.06	0.3	0.07
Tongue	84	5.8	0.30	7.1	0.35	37	2.5	0.19	2.9	0.22
Major salivary gland	29	2.1	0.18	2.4	0.21	11	0.7	0.10	0.8	0.12
Floor of mouth	8	0.6	0.09	0.7	0.11	6	0.4	0.07	0.5	0.08
Gum & other mouth	28	2.0	0.17	2.4	0.21	19	1.1	0.12	1.3	0.14
Nasopharynx	7	0.5	0.09	0.6	0.11	3	0.2	0.06	0.3	0.07
Oropharynx	15	1.0	0.12	1.3	0.15	5	0.3	0.07	0.4	0.08
Hypopharynx	13	0.8	0.10	1.0	0.13	3	0.2	0.04	0.2	0.05
Digestive System	1,256	89.9	1.17	107.3	1.37	979	61.4	0.92	72.2	1.06
Esophagus	121	8.4	0.35	10.1	0.42	32	1.9	0.15	2.3	0.18
Stomach	88	6.2	0.31	7.4	0.36	48	2.9	0.20	3.5	0.23
Small intestine	45	3.2	0.22	3.8	0.26	34	2.3	0.19	2.7	0.21
Colon (excl. rectum)	416	30.7	0.69	36.0	0.80	407	25.7	0.60	29.8	0.68
Rectum & rectosigmoid	196	14.5	0.48	17.2	0.56	130	8.7	0.36	10.3	0.41
Anus, anal canal, & anorectum	16	1.2	0.14	1.4	0.16	38	2.4	0.18	3.0	0.22
Liver	127	8.3	0.34	10.5	0.42	39	2.3	0.17	2.8	0.21
Gallbladder	8	0.6	0.10	0.7	0.11	15	0.9	0.11	1.1	0.13
Pancreas	189	13.3	0.44	15.9	0.52	170	10.2	0.36	12.2	0.42
Respiratory System	979	68.4	1.00	81.2	1.17	872	52.0	0.81	62.4	0.96
Larynx	74	5.1	0.27	6.2	0.32	17	1.0	0.12	1.3	0.14
Lung & bronchus	892	62.4	0.96	73.9	1.12	845	50.3	0.79	60.3	0.94
Bones & Joints	13	1.1	0.14	1.1	0.14	13	1.0	0.13	1.1	0.13
Soft Tissue (incl. heart)	55	4.2	0.26	4.9	0.30	44	3.3	0.23	3.6	0.25
Skin (excl. basal & sq.)	484	36.0	0.76	41.9	0.86	343	25.5	0.66	28.3	0.70
Melanoma of the skin	454	33.7	0.73	39.3	0.83	326	24.5	0.64	27.1	0.69
Breast (excl. <i>in situ</i>)	15	1.2	0.14	1.3	0.15	2,016	135.1	1.42	158.7	1.62
Female Genital System	N/A	N/A	N/A	N/A	N/A	738	50.1	0.87	59.0	1.00
Cervix uteri	N/A	N/A	N/A	N/A	N/A	87	7.7	0.39	8.1	0.39
Uterus corpus	N/A	N/A	N/A	N/A	N/A	411	26.5	0.62	32.3	0.73
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	12	0.7	0.10	0.9	0.12
Ovary	N/A	N/A	N/A	N/A	N/A	147	9.8	0.38	11.5	0.44
Male Genital System	1,707	114.9	1.28	139.4	1.52	N/A	N/A	N/A	N/A	N/A
Prostate	1,626	107.3	1.22	131.8	1.47	N/A	N/A	N/A	N/A	N/A
Testis	69	6.7	0.37	6.6	0.36	N/A	N/A	N/A	N/A	N/A
Penis	10	0.7	0.10	0.8	0.12	N/A	N/A	N/A	N/A	N/A
Urinary System	888	63.9	0.99	75.3	1.14	375	23.6	0.57	27.7	0.66
Bladder (incl. <i>in situ</i>)	508	36.4	0.74	42.8	0.86	159	9.4	0.35	11.0	0.40
Kidney & renal pelvis	359	26.0	0.64	30.8	0.74	207	13.7	0.45	16.0	0.51
Ureter	14	1.0	0.12	1.2	0.14	7	0.4	0.07	0.5	0.08
Eye & Orbit	15	1.2	0.14	1.3	0.15	11	0.8	0.11	0.9	0.12
Brain & Other CNS	104	8.1	0.37	9.1	0.40	79	5.9	0.31	6.4	0.33
Brain	99	7.7	0.36	8.6	0.39	73	5.4	0.30	5.9	0.32
Endocrine System	111	8.8	0.39	9.9	0.43	266	22.4	0.65	24.1	0.68
Thyroid gland	102	8.1	0.37	9.1	0.41	260	21.9	0.64	23.7	0.67
Lymphomas	358	26.9	0.66	31.1	0.74	263	17.3	0.50	19.9	0.56
Hodgkin lymphoma	35	3.0	0.23	3.2	0.24	25	2.2	0.20	2.2	0.20
Non-Hodgkin lymphoma	323	23.9	0.61	27.9	0.70	239	15.1	0.46	17.6	0.52
Multiple Myeloma	106	7.5	0.33	8.9	0.39	73	4.5	0.24	5.3	0.28
Leukemias	259	19.4	0.56	22.2	0.62	168	11.2	0.41	12.5	0.45
Acute lymphocytic	17	1.6	0.18	1.5	0.16	12	1.2	0.16	1.1	0.14
Chronic lymphocytic	108	7.5	0.34	9.1	0.40	65	3.9	0.23	4.7	0.27
Acute myeloid	72	5.4	0.29	6.2	0.33	52	3.5	0.23	3.9	0.25
Chronic myeloid	35	2.8	0.22	3.1	0.24	21	1.5	0.15	1.7	0.17
Other leukemias	27	2.1	0.19	2.4	0.21	17	1.1	0.12	1.2	0.14
Mesothelioma	13	1.0	0.12	1.1	0.14	7	0.4	0.08	0.5	0.09
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	99	7.7	0.36	8.7	0.39	233	16.2	0.50	18.4	0.56
Breast (<i>in situ</i>)	*	*	*	*	*	372	25.9	0.64	30.6	0.73

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Kansas, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	393	517.4	12.59	628.9	14.86	341	413.2	10.27	484.7	11.86
Oral Cavity & Pharynx	11	13.9	1.98	16.9	2.32	5	5.7	1.18	7.0	1.42
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	2.7	0.84	3.1	0.95	2	1.8	0.65	2.3	0.83
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	2	2.0	0.81	2.5	0.96	*	*	*	*	*
Nasopharynx	1	1.6	0.68	1.7	0.73	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	1	1.5	0.59	2.1	0.78	*	*	*	*	*
Digestive System	82	109.6	5.83	134.2	6.93	62	76.9	4.45	92.0	5.24
Esophagus	5	6.2	1.31	8.0	1.62	*	*	*	*	*
Stomach	6	8.4	1.59	10.4	1.92	4	5.1	1.12	6.2	1.32
Small intestine	4	4.5	1.11	5.4	1.28	4	4.5	1.10	5.2	1.24
Colon (excl. rectum)	23	32.4	3.30	38.4	3.82	22	27.8	2.70	33.1	3.17
Rectum & rectosigmoid	9	11.5	1.83	14.1	2.17	8	9.8	1.56	12.2	1.92
Anus, anal canal, & anorectum	1	1.6	0.62	1.8	0.68	2	2.4	0.83	2.7	0.90
Liver	15	17.4	2.12	22.8	2.69	5	4.6	0.93	6.4	1.32
Gallbladder	*	*	*	*	*	1	1.5	0.62	1.8	0.74
Pancreas	14	20.8	2.72	25.0	3.17	13	17.0	2.16	19.5	2.44
Respiratory System	60	79.5	4.94	96.8	5.80	45	53.8	3.69	64.2	4.31
Larynx	5	6.0	1.17	7.8	1.51	*	*	*	*	*
Lung & bronchus	53	72.7	4.79	88.0	5.58	43	51.7	3.61	62.1	4.24
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	4	5.6	1.26	5.5	1.26	2	2.2	0.76	2.3	0.81
Skin (excl. basal & sq.)	2	2.9	1.05	3.4	1.26	2	1.9	0.68	2.2	0.80
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	1	1.8	0.74	2.2	0.86	107	130.4	5.79	152.8	6.66
Female Genital System	N/A	N/A	N/A	N/A	N/A	38	45.4	3.38	53.6	3.91
Cervix uteri	N/A	N/A	N/A	N/A	N/A	5	5.5	1.15	6.4	1.32
Uterus corpus	N/A	N/A	N/A	N/A	N/A	20	22.3	2.31	27.3	2.77
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	2.0	0.74	2.4	0.86
Ovary	N/A	N/A	N/A	N/A	N/A	8	10.5	1.70	11.6	1.85
Male Genital System	134	168.6	6.96	211.9	8.44	N/A	N/A	N/A	N/A	N/A
Prostate	132	165.5	6.90	208.6	8.38	N/A	N/A	N/A	N/A	N/A
Testis	2	2.0	0.63	2.1	0.69	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	38	52.6	4.12	62.7	4.76	16	19.8	2.26	23.0	2.60
Bladder (incl. <i>in situ</i>)	17	26.1	3.04	31.0	3.51	4	5.6	1.24	6.2	1.37
Kidney & renal pelvis	20	26.1	2.76	31.1	3.19	12	14.0	1.88	16.5	2.20
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	3	3.1	0.82	3.3	0.89	3	3.4	0.90	3.5	0.96
Brain	3	3.0	0.81	3.1	0.88	3	2.9	0.82	3.0	0.89
Endocrine System	6	7.0	1.39	8.2	1.59	12	14.8	1.95	16.3	2.11
Thyroid gland	4	5.4	1.22	6.2	1.38	12	14.3	1.92	15.7	2.09
Lymphomas	14	17.0	2.24	19.1	2.54	13	15.4	1.94	17.9	2.23
Hodgkin lymphoma	3	2.9	0.82	2.9	0.82	1	1.4	0.59	1.5	0.62
Non-Hodgkin lymphoma	11	14.1	2.09	16.3	2.41	12	13.9	1.85	16.4	2.14
Multiple Myeloma	11	17.1	2.54	19.8	2.89	12	14.8	1.96	17.5	2.28
Leukemias	12	17.6	2.44	20.1	2.80	12	15.1	1.99	16.5	2.17
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	5	8.0	1.77	9.3	2.04	3	3.9	0.99	4.6	1.16
Acute myeloid	4	5.7	1.35	6.8	1.60	4	5.4	1.23	5.7	1.29
Chronic myeloid	2	2.2	0.83	2.4	0.86	3	3.3	0.93	3.5	1.01
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	12	18.6	2.63	22.2	3.05	10	12.6	1.79	14.8	2.07
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	7	8.5	1.58	10.2	1.86	13	16.9	2.11	19.5	2.41
Breast (<i>in situ</i>)	*	*	*	*	*	21	25.0	2.53	29.8	2.95

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Kansas, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	78	258.8	14.26	308.0	16.81	113	281.4	12.35	328.4	14.39
Oral Cavity & Pharynx	4	15.0	3.71	17.7	4.30	2	3.7	1.40	4.5	1.67
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	1	5.3	2.63	6.0	2.94	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	4.4	1.92	5.2	2.32	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	27	92.4	8.48	109.6	9.92	21	57.3	5.85	67.6	6.80
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	3	11.9	3.57	14.0	4.13	3	6.6	1.92	7.8	2.20
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	8	25.7	4.38	30.1	5.05	8	20.7	3.46	24.4	4.05
Rectum & rectosigmoid	4	11.4	2.55	12.8	2.91	4	10.0	2.47	12.2	2.97
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	6	19.1	3.72	23.4	4.47	2	5.0	1.78	5.9	2.09
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	3	10.8	3.15	12.9	3.71	2	4.9	1.74	5.7	1.93
Respiratory System	10	33.2	4.93	40.9	5.96	14	37.8	4.77	44.7	5.55
Larynx	1	3.6	1.51	4.3	1.82	*	*	*	*	*
Lung & bronchus	9	29.6	4.69	36.5	5.68	14	37.8	4.77	44.7	5.55
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	2	4.0	1.36	4.6	1.57
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	34	81.5	6.44	96.5	7.65
Female Genital System	N/A	N/A	N/A	N/A	N/A	14	33.8	4.10	39.8	4.84
Cervix uteri	N/A	N/A	N/A	N/A	N/A	3	7.3	1.98	8.3	2.28
Uterus corpus	N/A	N/A	N/A	N/A	N/A	9	20.9	3.22	25.1	3.85
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	5.3	1.55	5.8	1.74
Male Genital System	14	46.6	6.07	56.7	7.21	N/A	N/A	N/A	N/A	N/A
Prostate	13	44.8	6.01	55.1	7.17	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	6	20.5	4.04	24.4	4.80	4	10.5	2.54	12.8	3.03
Bladder (incl. <i>in situ</i>)	4	14.5	3.56	17.0	4.16	2	5.0	1.75	6.4	2.20
Kidney & renal pelvis	2	6.0	1.93	7.4	2.38	2	4.7	1.66	5.5	1.91
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	2	5.5	1.67	5.8	1.83	10	19.9	2.86	22.1	3.26
Thyroid gland	2	5.0	1.61	5.5	1.80	9	17.8	2.69	20.0	3.12
Lymphomas	4	15.4	3.68	18.2	4.31	5	12.6	2.59	13.9	2.88
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	2	4.8	1.68	5.8	2.02
Leukemias	3	8.8	2.73	9.9	3.22	2	5.9	1.78	5.7	1.78
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	1	4.2	1.93	4.9	2.33	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	3	11.0	3.10	12.5	3.61	2	6.5	2.14	7.5	2.47
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	2	6.0	2.01	7.1	2.38	6	17.8	3.40	19.7	3.73
Breast (<i>in situ</i>)	*	*	*	*	*	11	27.1	3.81	31.5	4.41

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

KANSAS

II-196 Incidence – NH API

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Kansas, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	305	356.7	10.42	421.2	12.07	353	354.2	9.12	412.1	10.61
Oral Cavity & Pharynx	7	6.5	1.24	7.7	1.45	5	5.7	1.20	6.9	1.42
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	1.6	0.60	2.2	0.78	2	2.4	0.76	2.9	0.89
Major salivary gland	*	*	*	*	*	1	1.4	0.61	1.7	0.73
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	76	88.7	5.11	106.8	6.03	59	65.6	4.11	77.5	4.79
Esophagus	4	5.9	1.47	6.9	1.68	*	*	*	*	*
Stomach	9	10.4	1.76	12.2	2.06	6	6.8	1.30	8.0	1.54
Small intestine	3	4.2	1.14	5.3	1.41	2	2.7	0.88	3.2	1.03
Colon (excl. rectum)	21	25.7	2.83	30.2	3.29	21	24.3	2.56	28.0	2.91
Rectum & rectosigmoid	11	11.4	1.69	13.8	2.02	7	6.7	1.15	8.3	1.45
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	13	14.8	1.99	18.4	2.39	5	6.1	1.31	7.3	1.50
Gallbladder	*	*	*	*	*	3	3.9	1.00	4.8	1.21
Pancreas	9	10.6	1.75	13.2	2.10	7	8.6	1.49	10.2	1.77
Respiratory System	25	37.5	3.70	43.3	4.18	23	30.2	2.96	34.8	3.34
Larynx	4	5.0	1.31	6.0	1.50	*	*	*	*	*
Lung & bronchus	20	31.8	3.45	36.6	3.88	22	28.8	2.91	33.0	3.26
Bones & Joints	*	*	*	*	*	1	0.6	0.25	0.6	0.25
Soft Tissue (incl. heart)	4	2.7	0.75	3.1	0.90	3	2.6	0.74	2.9	0.83
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	6	7.9	1.62	9.3	1.86	7	6.0	1.08	6.8	1.24
Breast (excl. <i>in situ</i>)	*	*	*	*	*	98	96.9	4.63	114.3	5.47
Female Genital System	N/A	N/A	N/A	N/A	N/A	56	53.7	3.42	62.5	4.00
Cervix uteri	N/A	N/A	N/A	N/A	N/A	14	11.6	1.50	12.0	1.59
Uterus corpus	N/A	N/A	N/A	N/A	N/A	27	27.1	2.48	32.6	2.96
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	2.0	0.63	2.5	0.77
Ovary	N/A	N/A	N/A	N/A	N/A	10	9.5	1.45	11.3	1.74
Male Genital System	79	93.3	5.28	111.7	6.12	N/A	N/A	N/A	N/A	N/A
Prostate	66	86.1	5.18	104.0	6.01	N/A	N/A	N/A	N/A	N/A
Testis	12	6.4	0.87	6.6	0.94	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	38	47.1	3.83	55.7	4.43	20	21.1	2.30	24.4	2.65
Bladder (incl. <i>in situ</i>)	11	17.3	2.52	20.5	2.93	6	7.6	1.51	8.7	1.70
Kidney & renal pelvis	26	29.4	2.85	34.8	3.31	14	12.5	1.62	14.7	1.94
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	2	1.4	0.58	1.5	0.68
Brain & Other CNS	6	4.2	0.87	4.9	1.06	7	6.0	1.17	6.4	1.32
Brain	6	4.2	0.87	4.8	1.06	7	5.9	1.17	6.3	1.31
Endocrine System	10	9.0	1.51	10.5	1.76	29	22.2	1.97	24.9	2.28
Thyroid gland	9	8.5	1.48	9.9	1.72	28	22.0	1.96	24.7	2.27
Lymphomas	20	21.4	2.52	24.1	2.86	19	17.7	2.03	20.6	2.37
Hodgkin lymphoma	4	2.5	0.74	2.6	0.80	3	1.6	0.44	1.7	0.50
Non-Hodgkin lymphoma	16	18.8	2.41	21.6	2.74	16	16.1	1.98	18.9	2.31
Multiple Myeloma	6	8.8	1.76	10.2	1.98	4	5.0	1.15	6.0	1.37
Leukemias	13	12.7	1.95	13.6	2.16	11	8.9	1.40	9.9	1.62
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	2	3.2	1.12	3.9	1.34	1	1.5	0.66	1.9	0.80
Acute myeloid	3	3.7	1.10	3.9	1.16	4	3.7	0.98	4.2	1.11
Chronic myeloid	2	2.0	0.72	2.1	0.76	1	1.1	0.47	1.3	0.56
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	12	14.6	2.14	17.8	2.57	8	9.9	1.65	11.2	1.88
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	5	5.3	1.21	5.9	1.33	17	17.6	2.10	20.5	2.44
Breast (<i>in situ</i>)	*	*	*	*	*	17	17.0	1.92	20.2	2.29

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

KANSAS

II-198 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Kansas, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	242	309.3	10.08	365.7	11.70	292	319.5	8.96	373.6	10.47
Oral Cavity & Pharynx	6	6.5	1.31	7.8	1.53	5	5.4	1.18	6.6	1.44
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	1.7	0.65	2.3	0.83	2	2.1	0.69	2.7	0.86
Major salivary gland	*	*	*	*	*	1	1.5	0.65	1.8	0.78
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	62	77.8	4.95	93.4	5.85	49	58.9	4.01	69.8	4.70
Esophagus	4	6.1	1.55	7.0	1.77	*	*	*	*	*
Stomach	8	9.2	1.66	10.8	1.96	5	5.5	1.21	6.5	1.44
Small intestine	2	3.4	1.13	4.2	1.36	2	2.9	0.93	3.4	1.09
Colon (excl. rectum)	17	22.3	2.71	26.3	3.15	17	20.8	2.43	23.9	2.77
Rectum & rectosigmoid	10	11.5	1.77	13.9	2.13	6	6.5	1.18	8.1	1.49
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	9	11.1	1.77	13.9	2.14	4	5.1	1.21	6.2	1.40
Gallbladder	*	*	*	*	*	3	4.0	1.05	4.9	1.27
Pancreas	7	9.5	1.72	11.7	2.06	7	8.5	1.52	10.1	1.82
Respiratory System	22	36.3	3.80	41.7	4.27	20	28.0	2.93	32.3	3.30
Larynx	3	5.2	1.39	6.2	1.60	*	*	*	*	*
Lung & bronchus	17	30.3	3.52	34.7	3.93	19	27.0	2.88	31.0	3.24
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	3	2.4	0.74	2.8	0.90	3	2.5	0.76	2.8	0.85
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	5	6.2	1.50	7.4	1.76	6	5.8	1.12	6.7	1.30
Breast (excl. <i>in situ</i>)	*	*	*	*	*	84	91.2	4.67	108.0	5.54
Female Genital System	N/A	N/A	N/A	N/A	N/A	46	47.1	3.29	55.2	3.89
Cervix uteri	N/A	N/A	N/A	N/A	N/A	11	10.0	1.43	10.3	1.52
Uterus corpus	N/A	N/A	N/A	N/A	N/A	22	23.4	2.35	28.6	2.85
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	1	1.3	0.49	1.5	0.60
Ovary	N/A	N/A	N/A	N/A	N/A	9	9.4	1.51	11.3	1.81
Male Genital System	58	73.0	4.81	88.0	5.61	N/A	N/A	N/A	N/A	N/A
Prostate	49	66.8	4.70	81.3	5.49	N/A	N/A	N/A	N/A	N/A
Testis	9	5.2	0.82	5.5	0.90	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	31	41.1	3.68	48.8	4.29	15	17.7	2.18	20.5	2.52
Bladder (incl. <i>in situ</i>)	8	13.4	2.28	16.1	2.68	4	6.2	1.39	7.2	1.58
Kidney & renal pelvis	23	27.3	2.86	32.3	3.32	11	11.1	1.62	12.9	1.92
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	5	3.7	0.86	4.2	1.05	6	5.8	1.21	6.2	1.36
Brain	5	3.6	0.86	4.1	1.04	6	5.7	1.20	6.1	1.36
Endocrine System	8	8.1	1.49	9.6	1.75	23	20.0	1.95	22.3	2.25
Thyroid gland	7	7.8	1.47	9.2	1.72	23	19.8	1.94	22.1	2.23
Lymphomas	15	19.1	2.55	21.6	2.88	16	15.9	1.98	18.3	2.31
Hodgkin lymphoma	3	2.4	0.77	2.5	0.85	3	1.6	0.47	1.7	0.53
Non-Hodgkin lymphoma	12	16.7	2.43	19.1	2.75	13	14.2	1.93	16.6	2.24
Multiple Myeloma	5	8.2	1.75	9.5	1.99	3	3.8	1.04	4.6	1.23
Leukemias	10	11.2	1.91	12.2	2.11	7	6.8	1.27	7.9	1.52
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	2	1.4	0.48	1.4	0.53
Chronic lymphocytic	2	2.4	0.96	3.0	1.17	*	*	*	*	*
Acute myeloid	3	3.7	1.17	4.0	1.23	2	2.6	0.83	3.0	0.98
Chronic myeloid	2	2.1	0.78	2.3	0.82	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	10	13.4	2.16	16.2	2.58	7	8.4	1.57	9.6	1.78
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	4	5.0	1.26	5.6	1.39	13	15.5	2.07	17.6	2.36
Breast (<i>in situ</i>)	*	*	*	*	*	14	14.4	1.83	17.0	2.16

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Kansas, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2	108.2	40.76	131.0	47.60	4	176.2	45.02	212.1	52.35
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	2	60.7	24.69	78.0	30.48
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


KANSAS

II-200 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	4,429,126	4,440,306	4,455,590	4,464,273	4,472,345
Non-Hispanic White	3,815,887	3,814,847	3,815,582	3,813,636	3,810,526
Non-Hispanic Black	379,636	383,712	389,113	392,450	397,029
Non-Hispanic Asian/Pacific Islander (NH API)	70,384	73,646	76,415	77,565	79,946
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	0	0	0	0	0


All Races Population 2015–2019: 22,261,640
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	153,713	158,466	164,894	170,925	175,127
Hispanic White	135,510	139,616	145,296	150,671	154,371
Hispanic Black	10,933	11,233	11,830	12,212	12,576

Hispanic/Latino Population, Census 2010: 132,836
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

KENTUCKY CANCER REGISTRY

Initial Operation: 1991
Population-based Data Available: 1991
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	112.6	112.5	113.5	113.2	111.5	112.6
Missing Race	0.7	0.6	0.7	0.9	1.3	0.8
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.9	0.8	0.7	0.6	0.4	0.7
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.7	Ovary	90.9
Oral Cavity & Pharynx	98.1	Prostate	97.6
Esophagus	95.6	Testis	99.3
Stomach	96.3	Bladder (incl. <i>in situ</i>)	98.0
Colon & Rectum	96.8	Kidney & Renal Pelvis	90.7
Liver	51.0	Brain & Other CNS	81.7
Pancreas	84.1	Brain & Other CNS (non-malig)	33.0
Lung & Bronchus	87.1	Thyroid	99.3
Melanomas of the Skin	99.5	Hodgkin Lymphoma	99.0
Female Breast (excl. <i>in situ</i>)	98.8	Non-Hodgkin Lymphoma	96.7
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	85.5
Cervix Uteri	98.5	Leukemias	87.5
Uterus Corpus & Uterus NOS	98.9		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Kentucky, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	14,249	563.7	2.18	671.3	2.55	13,749	485.0	1.91	566.7	2.19
Oral Cavity & Pharynx	551	21.1	0.41	25.9	0.50	216	7.6	0.24	9.0	0.28
Lip	33	1.3	0.11	1.6	0.13	12	0.4	0.05	0.5	0.06
Tongue	162	6.1	0.22	7.5	0.27	66	2.4	0.14	2.8	0.16
Major salivary gland	38	1.6	0.12	1.9	0.14	28	1.0	0.09	1.2	0.10
Floor of mouth	23	0.9	0.08	1.1	0.10	10	0.3	0.05	0.4	0.06
Gum & other mouth	56	2.2	0.13	2.7	0.16	42	1.5	0.10	1.7	0.12
Nasopharynx	18	0.7	0.08	0.8	0.09	6	0.2	0.04	0.3	0.05
Oropharynx	31	1.2	0.10	1.5	0.12	8	0.3	0.05	0.3	0.06
Hypopharynx	27	1.0	0.09	1.3	0.11	8	0.3	0.05	0.3	0.05
Digestive System	2,783	110.5	0.97	132.3	1.14	2,191	75.1	0.74	88.8	0.86
Esophagus	248	9.6	0.28	11.5	0.33	55	1.8	0.11	2.2	0.14
Stomach	210	8.5	0.27	10.1	0.32	139	4.8	0.19	5.6	0.22
Small intestine	82	3.3	0.17	3.9	0.19	82	2.9	0.15	3.4	0.17
Colon (excl. rectum)	899	36.5	0.56	43.3	0.66	883	30.5	0.47	35.6	0.54
Rectum & rectosigmoid	456	18.2	0.39	21.7	0.46	303	10.7	0.28	12.8	0.33
Anus, anal canal, & anorectum	43	1.8	0.12	2.1	0.14	96	3.3	0.16	4.1	0.19
Liver	312	11.4	0.30	14.3	0.37	95	3.2	0.15	3.8	0.18
Gallbladder	19	0.8	0.08	0.9	0.10	37	1.3	0.09	1.5	0.11
Pancreas	391	15.5	0.36	18.6	0.43	364	12.0	0.29	14.3	0.34
Respiratory System	2,820	110.1	0.96	132.1	1.13	2,441	80.1	0.74	96.4	0.88
Larynx	213	8.1	0.25	9.9	0.31	76	2.6	0.14	3.2	0.17
Lung & bronchus	2,575	100.8	0.92	120.7	1.08	2,346	76.9	0.72	92.4	0.86
Bones & Joints	26	1.2	0.10	1.2	0.11	18	0.8	0.08	0.8	0.08
Soft Tissue (incl. heart)	92	3.9	0.19	4.4	0.21	65	2.4	0.14	2.7	0.15
Skin (excl. basal & sq.)	883	36.6	0.57	42.8	0.65	667	25.5	0.46	28.8	0.51
Melanoma of the skin	830	34.4	0.55	40.1	0.63	628	24.1	0.45	27.2	0.49
Breast (excl. <i>in situ</i>)	22	0.9	0.09	1.1	0.10	3,616	128.4	0.99	150.9	1.14
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,509	55.0	0.66	64.1	0.75
Cervix uteri	N/A	N/A	N/A	N/A	N/A	223	9.8	0.30	10.3	0.31
Uterus corpus	N/A	N/A	N/A	N/A	N/A	791	27.6	0.45	33.1	0.53
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	20	0.7	0.07	0.8	0.08
Ovary	N/A	N/A	N/A	N/A	N/A	258	9.3	0.27	10.8	0.30
Male Genital System	3,095	115.1	0.95	140.8	1.15	N/A	N/A	N/A	N/A	N/A
Prostate	2,942	108.0	0.92	133.5	1.12	N/A	N/A	N/A	N/A	N/A
Testis	113	5.4	0.23	5.4	0.23	N/A	N/A	N/A	N/A	N/A
Penis	37	1.5	0.11	1.8	0.13	N/A	N/A	N/A	N/A	N/A
Urinary System	1,657	67.5	0.77	79.6	0.89	739	25.6	0.43	30.0	0.50
Bladder (incl. <i>in situ</i>)	905	37.5	0.58	44.1	0.67	286	9.6	0.26	11.3	0.30
Kidney & renal pelvis	711	28.3	0.49	33.5	0.57	432	15.3	0.34	17.9	0.39
Ureter	25	1.0	0.09	1.2	0.11	14	0.5	0.06	0.5	0.06
Eye & Orbit	36	1.4	0.11	1.7	0.13	28	1.0	0.09	1.2	0.10
Brain & Other CNS	207	8.8	0.28	9.6	0.30	163	6.3	0.23	6.8	0.24
Brain	193	8.1	0.27	9.0	0.29	151	5.8	0.22	6.3	0.23
Endocrine System	201	8.4	0.27	9.4	0.30	560	23.7	0.46	25.4	0.49
Thyroid gland	183	7.6	0.26	8.6	0.29	541	22.9	0.46	24.7	0.48
Lymphomas	630	26.1	0.48	30.0	0.54	538	18.9	0.38	21.9	0.43
Hodgkin lymphoma	68	3.1	0.17	3.2	0.17	50	2.2	0.14	2.3	0.15
Non-Hodgkin lymphoma	562	23.1	0.45	26.8	0.51	488	16.7	0.35	19.6	0.40
Multiple Myeloma	219	8.9	0.28	10.5	0.32	164	5.5	0.20	6.5	0.23
Leukemias	492	20.5	0.43	23.4	0.48	361	12.9	0.32	14.7	0.35
Acute lymphocytic	42	1.9	0.13	1.8	0.12	31	1.4	0.11	1.3	0.10
Chronic lymphocytic	202	8.1	0.26	9.7	0.31	127	4.2	0.17	5.0	0.20
Acute myeloid	129	5.4	0.22	6.2	0.25	113	4.1	0.18	4.7	0.20
Chronic myeloid	68	2.9	0.16	3.2	0.18	52	1.9	0.12	2.2	0.14
Other leukemias	52	2.2	0.14	2.5	0.16	38	1.3	0.10	1.6	0.11
Mesothelioma	27	1.1	0.10	1.3	0.12	8	0.3	0.05	0.3	0.05
Kaposi Sarcoma	4	0.2	0.04	0.2	0.05	*	*	*	*	*
Ill-Defined & Unknown	505	21.4	0.44	25.0	0.51	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	263	11.1	0.32	12.5	0.35	558	20.7	0.41	23.5	0.45
Breast (<i>in situ</i>)	2	0.1	0.02	0.1	0.03	734	26.2	0.45	31.0	0.52

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Kentucky, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	13,032	567.0	2.29	674.1	2.68	12,582	491.1	2.04	573.6	2.32
Oral Cavity & Pharynx	514	21.7	0.44	26.7	0.53	202	7.9	0.26	9.4	0.30
Lip	31	1.3	0.11	1.6	0.13	11	0.4	0.06	0.5	0.07
Tongue	152	6.3	0.24	7.7	0.28	62	2.5	0.15	2.9	0.17
Major salivary gland	34	1.6	0.13	1.9	0.14	26	1.1	0.10	1.2	0.11
Floor of mouth	23	0.9	0.09	1.2	0.11	9	0.3	0.05	0.4	0.06
Gum & other mouth	50	2.1	0.14	2.6	0.17	40	1.5	0.11	1.8	0.13
Nasopharynx	16	0.7	0.08	0.8	0.09	6	0.2	0.05	0.3	0.05
Oropharynx	31	1.3	0.11	1.6	0.13	7	0.3	0.05	0.4	0.06
Hypopharynx	24	1.0	0.09	1.2	0.11	7	0.3	0.05	0.3	0.06
Digestive System	2,536	110.8	1.02	132.4	1.19	1,972	74.3	0.77	87.8	0.90
Esophagus	235	10.0	0.30	12.0	0.36	49	1.8	0.12	2.2	0.14
Stomach	189	8.4	0.28	9.9	0.33	118	4.4	0.19	5.2	0.22
Small intestine	73	3.3	0.18	3.8	0.20	72	2.9	0.16	3.3	0.18
Colon (excl. rectum)	820	36.6	0.59	43.3	0.69	806	30.6	0.50	35.7	0.57
Rectum & rectosigmoid	418	18.5	0.42	22.0	0.49	271	10.6	0.30	12.7	0.35
Anus, anal canal, & anorectum	39	1.8	0.13	2.1	0.15	90	3.4	0.17	4.2	0.20
Liver	272	11.0	0.31	13.7	0.38	84	3.1	0.16	3.7	0.18
Gallbladder	17	0.8	0.09	0.9	0.10	33	1.2	0.10	1.4	0.11
Pancreas	361	15.6	0.38	18.8	0.45	326	11.8	0.30	14.0	0.35
Respiratory System	2,642	112.4	1.01	134.9	1.19	2,274	81.7	0.78	98.5	0.93
Larynx	197	8.2	0.27	10.1	0.32	69	2.6	0.15	3.2	0.18
Lung & bronchus	2,415	102.8	0.96	123.3	1.14	2,188	78.4	0.77	94.4	0.91
Bones & Joints	23	1.2	0.11	1.2	0.11	16	0.8	0.09	0.8	0.09
Soft Tissue (incl. heart)	82	3.9	0.20	4.4	0.22	57	2.4	0.15	2.6	0.16
Skin (excl. basal & sq.)	864	39.5	0.62	46.0	0.71	646	27.7	0.51	31.3	0.56
Melanoma of the skin	814	37.1	0.60	43.3	0.69	610	26.3	0.50	29.7	0.55
Breast (excl. <i>in situ</i>)	20	0.9	0.09	1.1	0.11	3,286	128.8	1.05	151.6	1.20
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,377	56.0	0.71	65.3	0.80
Cervix uteri	N/A	N/A	N/A	N/A	N/A	197	10.0	0.33	10.5	0.34
Uterus corpus	N/A	N/A	N/A	N/A	N/A	722	28.0	0.49	33.7	0.57
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	15	0.6	0.07	0.7	0.08
Ovary	N/A	N/A	N/A	N/A	N/A	239	9.6	0.29	11.1	0.33
Male Genital System	2,656	108.7	0.97	132.3	1.16	N/A	N/A	N/A	N/A	N/A
Prostate	2,511	100.8	0.92	124.3	1.12	N/A	N/A	N/A	N/A	N/A
Testis	106	6.1	0.27	6.0	0.26	N/A	N/A	N/A	N/A	N/A
Penis	36	1.6	0.12	1.9	0.15	N/A	N/A	N/A	N/A	N/A
Urinary System	1,560	69.5	0.81	82.0	0.94	677	26.0	0.46	30.3	0.53
Bladder (incl. <i>in situ</i>)	869	39.1	0.61	46.0	0.71	270	9.9	0.28	11.7	0.32
Kidney & renal pelvis	652	28.7	0.52	34.0	0.60	389	15.4	0.37	17.9	0.41
Ureter	23	1.0	0.10	1.2	0.12	13	0.5	0.06	0.5	0.07
Eye & Orbit	35	1.6	0.12	1.8	0.14	27	1.1	0.10	1.3	0.11
Brain & Other CNS	191	9.2	0.31	10.1	0.33	151	6.6	0.25	7.1	0.26
Brain	180	8.6	0.30	9.5	0.32	140	6.0	0.24	6.6	0.25
Endocrine System	187	8.9	0.30	9.9	0.33	501	24.3	0.51	26.0	0.53
Thyroid gland	171	8.1	0.29	9.1	0.31	484	23.6	0.50	25.2	0.52
Lymphomas	581	26.6	0.51	30.5	0.58	499	19.3	0.40	22.4	0.46
Hodgkin lymphoma	59	3.1	0.18	3.2	0.19	44	2.3	0.16	2.3	0.16
Non-Hodgkin lymphoma	522	23.5	0.48	27.3	0.54	454	17.0	0.37	20.0	0.43
Multiple Myeloma	192	8.5	0.28	10.1	0.33	139	5.1	0.20	6.0	0.23
Leukemias	453	20.9	0.45	23.8	0.51	323	12.8	0.33	14.6	0.37
Acute lymphocytic	36	2.0	0.15	1.8	0.14	26	1.4	0.12	1.3	0.11
Chronic lymphocytic	189	8.3	0.28	9.9	0.33	115	4.1	0.18	4.9	0.21
Acute myeloid	118	5.5	0.23	6.2	0.26	102	4.1	0.19	4.6	0.21
Chronic myeloid	62	2.9	0.17	3.3	0.19	46	1.9	0.13	2.2	0.14
Other leukemias	47	2.2	0.15	2.6	0.17	34	1.3	0.10	1.5	0.12
Mesothelioma	25	1.2	0.11	1.4	0.12	8	0.3	0.05	0.4	0.06
Kaposi Sarcoma	3	0.1	0.04	0.2	0.04	*	*	*	*	*
Ill-Defined & Unknown	468	21.6	0.46	25.3	0.53	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	235	11.1	0.34	12.5	0.37	505	21.0	0.44	23.7	0.48
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.03	655	26.0	0.48	30.8	0.55

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Kentucky, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	852	542.1	9.00	655.2	10.58	870	457.2	7.15	537.1	8.22
Oral Cavity & Pharynx	23	13.7	1.36	16.9	1.63	10	5.0	0.74	6.0	0.86
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	7	4.0	0.74	5.1	0.90	2	1.3	0.38	1.5	0.43
Major salivary gland	3	1.9	0.57	2.2	0.64	2	1.1	0.35	1.2	0.38
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	3	1.7	0.50	2.1	0.60	2	0.9	0.32	1.2	0.40
Nasopharynx	2	0.7	0.25	0.9	0.34	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	3	1.4	0.42	1.9	0.54	*	*	*	*	*
Digestive System	186	119.4	4.24	144.8	5.00	168	87.4	3.11	104.7	3.64
Esophagus	11	6.2	0.90	7.6	1.07	5	2.7	0.53	3.2	0.63
Stomach	14	11.0	1.41	13.1	1.66	15	8.0	0.95	9.4	1.10
Small intestine	7	4.8	0.87	5.7	1.02	9	4.5	0.70	5.4	0.82
Colon (excl. rectum)	64	44.1	2.68	52.2	3.09	62	32.8	1.92	38.8	2.23
Rectum & rectosigmoid	24	14.0	1.35	17.2	1.61	22	11.0	1.09	13.4	1.30
Anus, anal canal, & anorectum	3	2.3	0.62	2.5	0.68	5	2.5	0.51	3.0	0.60
Liver	31	17.0	1.46	21.9	1.81	8	4.0	0.64	5.0	0.78
Gallbladder	1	0.8	0.38	1.1	0.47	3	1.7	0.44	2.1	0.52
Pancreas	24	14.8	1.46	18.4	1.76	32	16.4	1.34	19.6	1.57
Respiratory System	151	104.1	4.11	124.5	4.78	143	76.1	2.94	90.7	3.42
Larynx	14	7.8	1.02	10.0	1.27	6	2.9	0.55	3.6	0.67
Lung & bronchus	136	95.2	3.96	113.3	4.59	137	73.1	2.89	87.0	3.35
Bones & Joints	2	1.3	0.44	1.4	0.50	1	0.7	0.28	0.7	0.28
Soft Tissue (incl. heart)	7	4.2	0.79	4.8	0.90	5	2.4	0.51	2.9	0.59
Skin (excl. basal & sq.)	3	2.0	0.54	2.4	0.65	4	2.1	0.49	2.3	0.53
Melanoma of the skin	1	1.0	0.43	1.2	0.52	2	0.9	0.32	1.0	0.35
Breast (excl. <i>in situ</i>)	2	1.1	0.39	1.3	0.45	251	133.2	3.87	155.8	4.43
Female Genital System	N/A	N/A	N/A	N/A	N/A	93	47.8	2.29	56.3	2.62
Cervix uteri	N/A	N/A	N/A	N/A	N/A	15	8.3	0.99	9.1	1.06
Uterus corpus	N/A	N/A	N/A	N/A	N/A	52	25.7	1.65	31.1	1.94
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	4	2.2	0.50	2.6	0.56
Ovary	N/A	N/A	N/A	N/A	N/A	12	6.5	0.87	7.4	0.96
Male Genital System	276	163.7	4.76	204.9	5.74	N/A	N/A	N/A	N/A	N/A
Prostate	272	162.0	4.74	203.1	5.72	N/A	N/A	N/A	N/A	N/A
Testis	2	1.2	0.36	1.3	0.38	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	72	47.7	2.71	56.4	3.14	52	26.8	1.72	32.1	2.01
Bladder (incl. <i>in situ</i>)	25	18.2	1.76	21.5	2.03	12	6.7	0.89	7.9	1.02
Kidney & renal pelvis	46	28.3	2.01	33.6	2.34	39	19.3	1.44	23.4	1.70
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	10	5.3	0.80	5.6	0.87	9	4.4	0.69	4.6	0.72
Brain	9	4.9	0.78	5.2	0.84	7	3.9	0.65	4.1	0.69
Endocrine System	7	4.1	0.71	4.7	0.80	36	18.8	1.44	21.5	1.60
Thyroid gland	6	3.2	0.64	3.8	0.74	35	18.3	1.42	20.9	1.58
Lymphomas	37	22.5	1.79	25.5	2.00	25	14.1	1.29	15.7	1.42
Hodgkin lymphoma	7	4.0	0.69	3.9	0.67	5	2.5	0.54	2.6	0.54
Non-Hodgkin lymphoma	29	18.5	1.65	21.5	1.89	21	11.5	1.17	13.2	1.31
Multiple Myeloma	22	15.4	1.57	18.0	1.79	21	11.3	1.12	13.3	1.30
Leukemias	24	15.3	1.52	17.7	1.73	22	12.0	1.17	13.4	1.29
Acute lymphocytic	1	0.8	0.31	0.7	0.29	*	*	*	*	*
Chronic lymphocytic	8	5.9	1.01	7.0	1.16	9	4.4	0.69	5.3	0.81
Acute myeloid	7	4.1	0.72	4.8	0.85	7	3.8	0.66	4.1	0.70
Chronic myeloid	3	2.1	0.54	2.3	0.58	3	1.8	0.46	2.1	0.52
Other leukemias	4	2.5	0.61	2.9	0.71	N/A	N/A	N/A	N/A	N/A
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	28	20.8	1.92	24.6	2.22	28	15.0	1.31	17.2	1.48
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	17	10.8	1.27	12.1	1.41	41	21.7	1.55	24.9	1.76
Breast (<i>in situ</i>)	*	*	*	*	*	62	32.3	1.89	38.1	2.17

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Kentucky, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	53	238.2	16.18	279.8	18.92	87	278.9	14.16	317.4	16.27
Oral Cavity & Pharynx	3	13.1	3.53	14.9	3.93	2	6.2	2.18	6.8	2.42
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	5.3	2.28	6.2	2.60	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	17	73.3	8.75	90.7	10.77	16	57.4	6.78	67.1	7.86
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	2	5.7	2.04	7.0	2.55	2	7.6	2.51	9.1	2.96
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	3	10.0	2.98	12.3	3.67	5	17.2	3.77	19.7	4.29
Rectum & rectosigmoid	5	21.7	4.79	27.1	5.90	2	8.3	2.46	9.4	2.76
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	4	15.0	3.50	19.1	4.40	2	6.7	2.35	8.0	2.72
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	2	6.3	2.38	7.4	2.73	2	6.4	2.14	7.7	2.57
Respiratory System	8	39.8	6.82	46.4	7.82	9	35.0	5.41	41.6	6.31
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	8	38.3	6.66	44.9	7.68	9	33.3	5.32	39.3	6.17
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	1	3.4	1.29	3.5	1.40
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	25	73.5	6.86	83.3	7.88
Female Genital System	N/A	N/A	N/A	N/A	N/A	11	33.3	4.78	39.1	5.71
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	5.4	1.70	6.0	1.95
Uterus corpus	N/A	N/A	N/A	N/A	N/A	4	12.4	2.82	14.9	3.42
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	3	10.3	2.90	11.9	3.42
Male Genital System	6	32.7	6.44	38.0	7.30	N/A	N/A	N/A	N/A	N/A
Prostate	6	30.8	6.35	36.0	7.19	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	5	23.8	4.98	28.2	5.89	2	8.5	2.61	10.0	3.05
Bladder (incl. <i>in situ</i>)	3	15.4	4.18	18.9	5.08	*	*	*	*	*
Kidney & renal pelvis	2	8.4	2.70	9.3	2.99	1	4.8	1.95	5.5	2.22
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	2	5.3	2.20	5.9	2.53	9	22.7	3.45	25.2	3.97
Thyroid gland	1	4.9	2.15	5.5	2.51	8	21.3	3.34	24.0	3.91
Lymphomas	2	6.9	2.47	7.6	2.78	4	13.4	3.16	14.1	3.48
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	1	8.8	3.55	10.0	4.02	2	6.9	2.64	7.8	2.93
Leukemias	3	14.8	3.99	15.8	4.47	2	6.1	1.87	6.2	1.97
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	11.5	3.82	12.8	4.31	2	7.3	2.54	7.8	2.80
Selected Sites (Non-Malignant or <i>in situ</i>)	2	7.6	2.65	8.7	3.09	4	12.7	2.93	14.1	3.37
Brain & Other CNS (non-malignant)	*	*	*	*	*	8	24.2	3.84	29.4	4.69
Breast (<i>in situ</i>)										

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Kentucky, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	124	311.0	14.67	361.5	16.78	135	316.7	13.36	367.3	15.59
Oral Cavity & Pharynx	4	9.8	2.55	11.1	2.85	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	3.9	1.82	4.1	1.95	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	31	79.3	7.38	94.5	8.63	24	60.9	5.99	72.2	7.06
Esophagus	2	5.0	1.92	5.4	2.02	*	*	*	*	*
Stomach	4	11.1	2.80	13.1	3.31	4	8.6	2.21	9.4	2.47
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	9	21.4	3.78	25.4	4.40	8	17.7	3.16	20.6	3.68
Rectum & rectosigmoid	4	9.6	2.57	10.9	2.91	4	8.6	2.16	10.9	2.71
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	4	9.0	2.38	11.8	3.02	1	2.5	1.08	3.0	1.39
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	5	11.8	2.80	14.1	3.23	4	12.5	2.96	14.4	3.35
Respiratory System	15	44.8	5.72	53.3	6.59	11	32.8	4.75	38.7	5.49
Larynx	1	4.0	1.58	5.0	1.93	*	*	*	*	*
Lung & bronchus	13	39.3	5.40	46.5	6.17	10	31.2	4.66	36.7	5.37
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	2	4.2	1.59	4.5	1.80	*	*	*	*	*
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	2	5.6	1.95	6.4	2.23	2	4.1	1.38	4.7	1.62
Breast (excl. <i>in situ</i>)	*	*	*	*	*	42	96.2	7.10	112.1	8.38
Female Genital System	N/A	N/A	N/A	N/A	N/A	20	42.9	4.62	49.1	5.41
Cervix uteri	N/A	N/A	N/A	N/A	N/A	6	10.7	2.18	11.4	2.44
Uterus corpus	N/A	N/A	N/A	N/A	N/A	9	18.9	2.92	22.3	3.54
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	3	8.2	2.28	9.5	2.64
Male Genital System	27	77.5	7.69	90.1	8.64	N/A	N/A	N/A	N/A	N/A
Prostate	23	72.8	7.55	84.9	8.49	N/A	N/A	N/A	N/A	N/A
Testis	3	3.4	0.84	3.5	0.91	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	14	33.9	4.79	38.7	5.40	6	16.9	3.39	19.1	3.82
Bladder (incl. <i>in situ</i>)	5	18.2	3.82	20.5	4.24	2	8.6	2.59	9.8	2.89
Kidney & renal pelvis	8	14.0	2.63	16.2	3.10	3	6.9	1.94	7.8	2.23
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	3	5.6	1.75	6.1	2.00	2	2.2	0.81	2.1	0.79
Brain	3	4.8	1.70	5.4	1.96	1	2.0	0.80	1.9	0.78
Endocrine System	3	4.2	1.14	4.8	1.39	7	12.0	2.14	13.4	2.53
Thyroid gland	3	4.2	1.14	4.8	1.39	7	11.3	2.08	12.6	2.45
Lymphomas	8	16.1	3.00	18.8	3.52	6	15.4	3.05	18.3	3.62
Hodgkin lymphoma	1	1.8	0.76	1.9	0.88	*	*	*	*	*
Non-Hodgkin lymphoma	7	14.3	2.90	16.9	3.41	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	3	5.8	1.82	7.0	2.16	1	4.3	1.72	5.2	2.03
Leukemias	8	14.0	2.97	14.7	3.24	7	13.2	2.63	14.6	3.02
Acute lymphocytic	3	2.5	0.68	2.2	0.59	3	3.4	1.08	3.1	1.07
Chronic lymphocytic	1	3.7	1.73	4.2	1.93	*	*	*	*	*
Acute myeloid	3	6.2	2.20	6.6	2.39	3	5.8	1.89	6.6	2.13
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	6.7	2.28	7.9	2.66	4	10.9	2.76	12.0	3.05
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	7	12.8	2.62	14.4	3.02	5	9.8	2.06	11.6	2.53
Breast (<i>in situ</i>)	*	*	*	*	*	7	14.9	2.70	18.8	3.45

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

KENTUCKY

II-208 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Kentucky, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	113	314.0	15.46	365.8	17.75	125	327.4	14.21	381.6	16.67
Oral Cavity & Pharynx	4	10.6	2.82	12.0	3.15	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	4.3	2.02	4.6	2.17	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	28	78.8	7.73	94.6	9.10	22	62.0	6.37	73.9	7.52
Esophagus	1	4.8	2.04	5.2	2.15	*	*	*	*	*
Stomach	4	12.3	3.10	14.6	3.66	3	7.9	2.29	8.9	2.60
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	8	21.5	3.97	26.0	4.70	7	18.5	3.41	21.5	3.95
Rectum & rectosigmoid	3	9.7	2.80	11.1	3.19	3	9.0	2.34	11.4	2.93
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	3	8.7	2.41	11.3	3.04	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	4	10.5	2.78	12.7	3.26	4	13.0	3.15	14.9	3.55
Respiratory System	14	47.7	6.25	56.7	7.19	10	33.4	5.02	39.4	5.80
Larynx	1	4.5	1.77	5.7	2.15	*	*	*	*	*
Lung & bronchus	12	41.6	5.88	49.1	6.71	9	31.7	4.92	37.2	5.65
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	2	4.7	1.78	5.1	2.01	*	*	*	*	*
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	2	6.2	2.17	7.2	2.49	2	4.3	1.49	4.9	1.78
Breast (excl. <i>in situ</i>)	*	*	*	*	*	39	97.8	7.45	115.1	8.90
Female Genital System	N/A	N/A	N/A	N/A	N/A	20	46.2	5.03	53.1	5.90
Cervix uteri	N/A	N/A	N/A	N/A	N/A	5	11.2	2.35	12.0	2.64
Uterus corpus	N/A	N/A	N/A	N/A	N/A	9	21.1	3.24	24.9	3.94
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	3	8.4	2.42	9.7	2.77
Male Genital System	23	71.9	7.74	83.8	8.73	N/A	N/A	N/A	N/A	N/A
Prostate	19	66.9	7.58	78.4	8.55	N/A	N/A	N/A	N/A	N/A
Testis	3	3.3	0.89	3.5	0.98	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	13	34.5	5.09	39.1	5.71	6	17.0	3.50	19.3	3.98
Bladder (incl. <i>in situ</i>)	5	18.6	4.07	20.9	4.51	2	9.4	2.82	10.7	3.15
Kidney & renal pelvis	7	14.0	2.77	15.9	3.21	3	6.2	1.77	6.9	2.11
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	3	5.7	1.87	6.1	2.11	2	2.5	0.91	2.3	0.89
Brain	2	4.8	1.82	5.3	2.06	1	2.3	0.90	2.2	0.88
Endocrine System	3	4.7	1.27	5.3	1.56	6	12.5	2.33	14.2	2.79
Thyroid gland	3	4.7	1.27	5.3	1.56	6	11.7	2.26	13.3	2.70
Lymphomas	8	18.0	3.35	20.9	3.94	5	15.9	3.29	19.0	3.90
Hodgkin lymphoma	1	2.0	0.86	2.1	1.00	*	*	*	*	*
Non-Hodgkin lymphoma	7	15.9	3.24	18.8	3.81	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	2	5.0	1.63	6.5	2.09	1	4.1	1.76	4.9	2.07
Leukemias	7	15.0	3.24	15.7	3.53	7	14.5	2.89	16.1	3.32
Acute lymphocytic	3	2.9	0.77	2.5	0.67	3	3.7	1.20	3.3	1.18
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	2	6.7	2.39	7.1	2.60	3	6.4	2.06	7.3	2.33
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	7.2	2.53	8.6	2.96	4	11.9	3.00	13.1	3.32
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	6	12.7	2.71	14.2	3.12	5	10.6	2.26	12.6	2.80
Breast (<i>in situ</i>)	*	*	*	*	*	6	15.2	2.88	19.0	3.66

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Kentucky, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3	134.1	48.08	159.4	53.48	4	209.6	54.32	228.9	58.94
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	2	108.3	39.71	114.8	41.47
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


KENTUCKY

II-210 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	4,666,998	4,681,346	4,673,673	4,664,450	4,658,285
Non-Hispanic White	2,794,947	2,794,301	2,780,282	2,765,874	2,751,820
Non-Hispanic Black	1,524,917	1,531,664	1,533,905	1,534,245	1,534,884
Non-Hispanic Asian/Pacific Islander (NH API)	86,703	88,752	89,357	90,096	91,362
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	3,572	3,554	3,585	3,506	3,506


All Races Population 2015–2019: 23,344,752
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	228,477	234,512	237,810	241,936	247,865
Hispanic White	192,999	197,579	199,689	202,600	207,381
Hispanic Black	23,890	25,041	25,799	26,700	27,696

Hispanic/Latino Population, Census 2010: 192,560
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

LOUISIANA CANCER REGISTRY

Initial Operation: 1974
 Population-based Data Available: 1988
 Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	105.7	106.3	107.3	105.7	108.3	106.7
Missing Race	0.0	0.1	0.1	0.3	0.4	0.2
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.1	1.0	0.9	1.0	1.0	1.0
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.9	Ovary	93.1
Oral Cavity & Pharynx	98.2	Prostate	98.2
Esophagus	97.0	Testis	99.4
Stomach	98.0	Bladder (incl. <i>in situ</i>)	98.5
Colon & Rectum	97.4	Kidney & Renal Pelvis	91.0
Liver	54.1	Brain & Other CNS	86.9
Pancreas	85.7	Brain & Other CNS (non-malig)	41.9
Lung & Bronchus	89.9	Thyroid	99.7
Melanomas of the Skin	99.8	Hodgkin Lymphoma	99.2
Female Breast (excl. <i>in situ</i>)	99.0	Non-Hodgkin Lymphoma	97.4
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	84.1
Cervix Uteri	97.9	Leukemias	91.9
Uterus Corpus & Uterus NOS	98.7		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Louisiana, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	14,106	557.1	2.17	668.2	2.55	12,320	430.1	1.79	503.4	2.05
Oral Cavity & Pharynx	528	20.3	0.41	25.0	0.49	194	6.7	0.22	8.0	0.26
Lip	25	1.0	0.09	1.3	0.11	8	0.3	0.04	0.3	0.05
Tongue	162	6.1	0.22	7.6	0.27	62	2.2	0.13	2.6	0.15
Major salivary gland	37	1.6	0.12	1.8	0.14	24	0.9	0.08	1.0	0.09
Floor of mouth	28	1.1	0.09	1.3	0.11	10	0.4	0.05	0.4	0.06
Gum & other mouth	62	2.4	0.14	2.9	0.17	37	1.3	0.10	1.5	0.11
Nasopharynx	24	1.0	0.09	1.1	0.10	8	0.3	0.05	0.3	0.05
Oropharynx	34	1.3	0.10	1.6	0.12	11	0.4	0.05	0.5	0.06
Hypopharynx	30	1.1	0.09	1.4	0.11	8	0.3	0.05	0.3	0.05
Digestive System	2,849	112.5	0.97	136.3	1.16	2,129	72.4	0.72	85.9	0.84
Esophagus	198	7.6	0.25	9.4	0.30	52	1.7	0.11	2.1	0.13
Stomach	231	9.3	0.28	11.2	0.34	139	4.7	0.18	5.5	0.21
Small intestine	90	3.6	0.17	4.3	0.21	84	3.0	0.15	3.5	0.17
Colon (excl. rectum)	875	35.4	0.55	42.3	0.65	823	28.2	0.45	33.2	0.52
Rectum & rectosigmoid	431	17.3	0.38	20.8	0.45	300	10.6	0.28	12.7	0.33
Anus, anal canal, & anorectum	46	1.8	0.13	2.2	0.15	66	2.3	0.13	2.8	0.15
Liver	436	15.6	0.34	19.9	0.43	119	3.8	0.16	4.7	0.19
Gallbladder	23	0.9	0.09	1.1	0.11	48	1.5	0.10	1.9	0.12
Pancreas	404	16.3	0.37	19.6	0.44	384	12.8	0.30	15.1	0.35
Respiratory System	2,219	87.7	0.86	105.5	1.02	1,671	54.8	0.61	65.9	0.73
Larynx	221	8.4	0.26	10.4	0.32	65	2.1	0.12	2.6	0.15
Lung & bronchus	1,971	78.2	0.81	93.8	0.96	1,586	52.0	0.59	62.5	0.71
Bones & Joints	20	0.9	0.09	0.9	0.09	20	0.8	0.08	0.8	0.08
Soft Tissue (incl. heart)	117	5.0	0.21	5.7	0.24	81	3.0	0.16	3.3	0.17
Skin (excl. basal & sq.)	652	27.6	0.50	32.1	0.57	404	15.1	0.35	17.0	0.38
Melanoma of the skin	587	24.7	0.47	28.8	0.54	363	13.6	0.33	15.3	0.36
Breast (excl. <i>in situ</i>)	33	1.4	0.11	1.6	0.13	3,637	128.6	0.99	151.0	1.13
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,256	44.5	0.58	52.1	0.67
Cervix uteri	N/A	N/A	N/A	N/A	N/A	223	9.2	0.29	9.9	0.30
Uterus corpus	N/A	N/A	N/A	N/A	N/A	606	20.3	0.38	24.7	0.45
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	22	0.7	0.07	0.9	0.09
Ovary	N/A	N/A	N/A	N/A	N/A	256	9.0	0.26	10.5	0.30
Male Genital System	3,901	144.7	1.07	178.4	1.29	N/A	N/A	N/A	N/A	N/A
Prostate	3,760	138.5	1.04	171.9	1.27	N/A	N/A	N/A	N/A	N/A
Testis	107	4.8	0.21	4.8	0.21	N/A	N/A	N/A	N/A	N/A
Penis	28	1.2	0.10	1.4	0.12	N/A	N/A	N/A	N/A	N/A
Urinary System	1,548	63.3	0.74	75.0	0.87	710	24.2	0.42	28.6	0.48
Bladder (incl. <i>in situ</i>)	756	31.7	0.53	37.3	0.62	225	7.5	0.23	8.8	0.27
Kidney & renal pelvis	756	30.1	0.51	35.9	0.59	462	16.0	0.34	18.9	0.40
Ureter	18	0.8	0.08	0.9	0.10	12	0.4	0.05	0.4	0.06
Eye & Orbit	23	1.0	0.09	1.1	0.10	16	0.6	0.07	0.7	0.07
Brain & Other CNS	169	7.1	0.25	7.8	0.27	129	4.8	0.19	5.2	0.21
Brain	158	6.6	0.24	7.3	0.26	122	4.5	0.19	4.9	0.20
Endocrine System	203	8.3	0.27	9.5	0.30	553	22.2	0.44	24.1	0.46
Thyroid gland	182	7.5	0.26	8.6	0.29	538	21.6	0.43	23.5	0.46
Lymphomas	617	25.7	0.48	29.6	0.54	514	18.1	0.37	20.7	0.41
Hodgkin lymphoma	73	3.1	0.17	3.3	0.18	59	2.5	0.15	2.5	0.15
Non-Hodgkin lymphoma	544	22.6	0.45	26.3	0.51	455	15.6	0.34	18.2	0.39
Multiple Myeloma	243	9.9	0.29	11.8	0.34	208	6.9	0.22	8.3	0.26
Leukemias	423	17.9	0.40	20.4	0.45	314	11.0	0.29	12.5	0.32
Acute lymphocytic	34	1.5	0.12	1.4	0.11	28	1.2	0.10	1.1	0.09
Chronic lymphocytic	170	7.0	0.25	8.3	0.29	108	3.6	0.16	4.2	0.18
Acute myeloid	118	5.0	0.21	5.7	0.24	100	3.5	0.16	4.0	0.18
Chronic myeloid	63	2.7	0.16	3.1	0.18	49	1.8	0.12	2.0	0.13
Other leukemias	37	1.7	0.12	1.9	0.14	28	0.9	0.08	1.1	0.09
Mesothelioma	46	2.0	0.13	2.2	0.15	20	0.7	0.07	0.8	0.08
Kaposi Sarcoma	19	0.9	0.09	0.9	0.09	2	0.1	0.02	0.1	0.02
Ill-Defined & Unknown	498	21.0	0.43	24.6	0.50	461	15.6	0.33	18.2	0.38
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	250	10.5	0.31	11.9	0.34	494	17.7	0.37	20.3	0.41
Breast (<i>in situ</i>)	3	0.1	0.03	0.1	0.04	724	25.4	0.44	30.2	0.51

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Louisiana, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	9,686	558.1	2.61	664.7	3.06	8,378	444.7	2.27	519.2	2.59
Oral Cavity & Pharynx	401	22.5	0.52	27.8	0.63	145	7.6	0.29	9.1	0.34
Lip	24	1.4	0.13	1.7	0.16	8	0.4	0.07	0.5	0.08
Tongue	131	7.3	0.29	8.9	0.35	51	2.8	0.18	3.3	0.21
Major salivary gland	28	1.7	0.15	2.0	0.17	14	0.7	0.09	0.9	0.11
Floor of mouth	17	1.0	0.11	1.2	0.13	7	0.4	0.06	0.4	0.08
Gum & other mouth	43	2.5	0.17	3.0	0.21	27	1.4	0.12	1.6	0.14
Nasopharynx	14	0.8	0.10	1.0	0.12	4	0.2	0.05	0.3	0.06
Oropharynx	26	1.4	0.13	1.8	0.16	8	0.4	0.07	0.5	0.08
Hypopharynx	18	1.0	0.10	1.2	0.13	5	0.3	0.06	0.4	0.07
Digestive System	1,818	105.1	1.14	126.3	1.34	1,335	67.9	0.86	80.3	1.00
Esophagus	147	8.2	0.31	10.0	0.37	33	1.6	0.13	1.9	0.15
Stomach	127	7.4	0.30	8.9	0.36	68	3.4	0.19	4.0	0.22
Small intestine	57	3.3	0.20	3.9	0.24	44	2.3	0.16	2.7	0.19
Colon (excl. rectum)	564	33.4	0.65	39.5	0.75	520	26.7	0.54	31.2	0.63
Rectum & rectosigmoid	282	16.8	0.46	20.0	0.54	193	10.6	0.36	12.5	0.41
Anus, anal canal, & anorectum	32	1.9	0.15	2.3	0.18	50	2.6	0.17	3.2	0.21
Liver	244	13.1	0.38	16.5	0.48	72	3.5	0.19	4.3	0.23
Gallbladder	13	0.7	0.10	0.9	0.11	27	1.3	0.11	1.6	0.13
Pancreas	277	16.0	0.44	19.1	0.52	251	12.2	0.35	14.5	0.41
Respiratory System	1,498	85.0	1.01	101.8	1.19	1,224	59.5	0.78	71.6	0.93
Larynx	142	7.8	0.30	9.7	0.37	44	2.2	0.15	2.7	0.19
Lung & bronchus	1,335	75.8	0.95	90.6	1.12	1,165	56.5	0.76	67.9	0.90
Bones & Joints	12	0.9	0.12	0.9	0.11	15	1.0	0.12	1.0	0.12
Soft Tissue (incl. heart)	87	5.5	0.27	6.2	0.30	52	3.1	0.20	3.3	0.21
Skin (excl. basal & sq.)	624	38.1	0.70	44.2	0.80	376	22.2	0.54	24.9	0.59
Melanoma of the skin	569	34.7	0.67	40.3	0.77	345	20.6	0.52	23.0	0.57
Breast (excl. <i>in situ</i>)	22	1.3	0.13	1.5	0.15	2,396	128.3	1.23	151.0	1.41
Female Genital System	N/A	N/A	N/A	N/A	N/A	794	43.7	0.73	51.0	0.83
Cervix uteri	N/A	N/A	N/A	N/A	N/A	125	8.6	0.36	9.1	0.37
Uterus corpus	N/A	N/A	N/A	N/A	N/A	381	19.9	0.48	24.1	0.56
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	9	0.5	0.07	0.6	0.08
Ovary	N/A	N/A	N/A	N/A	N/A	174	9.3	0.33	10.8	0.37
Male Genital System	2,408	130.3	1.22	159.1	1.47	N/A	N/A	N/A	N/A	N/A
Prostate	2,302	122.5	1.17	151.2	1.43	N/A	N/A	N/A	N/A	N/A
Testis	85	6.5	0.32	6.5	0.31	N/A	N/A	N/A	N/A	N/A
Penis	17	1.0	0.11	1.1	0.13	N/A	N/A	N/A	N/A	N/A
Urinary System	1,199	70.4	0.94	83.2	1.09	506	26.0	0.54	30.6	0.62
Bladder (incl. <i>in situ</i>)	630	37.0	0.68	43.7	0.79	173	8.5	0.30	10.0	0.35
Kidney & renal pelvis	539	31.6	0.63	37.4	0.73	317	16.8	0.44	19.7	0.50
Ureter	17	1.0	0.11	1.1	0.13	10	0.5	0.07	0.6	0.08
Eye & Orbit	20	1.3	0.13	1.4	0.14	14	0.8	0.10	0.9	0.11
Brain & Other CNS	131	8.4	0.34	9.2	0.36	100	5.8	0.27	6.3	0.29
Brain	123	7.8	0.33	8.7	0.35	96	5.5	0.27	6.1	0.28
Endocrine System	156	9.8	0.37	11.2	0.40	396	26.1	0.62	28.2	0.64
Thyroid gland	145	9.1	0.35	10.4	0.39	388	25.6	0.61	27.7	0.64
Lymphomas	462	28.2	0.61	32.5	0.68	370	19.5	0.47	22.4	0.53
Hodgkin lymphoma	49	3.4	0.23	3.6	0.23	41	2.9	0.21	2.9	0.21
Non-Hodgkin lymphoma	413	24.8	0.56	28.9	0.64	329	16.6	0.42	19.5	0.49
Multiple Myeloma	136	7.9	0.31	9.4	0.37	99	4.8	0.22	5.8	0.27
Leukemias	315	19.5	0.51	22.2	0.57	231	12.3	0.38	13.9	0.42
Acute lymphocytic	22	1.7	0.17	1.6	0.15	20	1.5	0.15	1.4	0.14
Chronic lymphocytic	137	8.0	0.31	9.5	0.37	86	4.1	0.20	4.9	0.24
Acute myeloid	83	5.1	0.26	5.8	0.29	70	3.7	0.21	4.3	0.23
Chronic myeloid	45	2.9	0.20	3.3	0.22	34	1.9	0.15	2.2	0.17
Other leukemias	28	1.8	0.16	2.0	0.17	20	1.0	0.11	1.2	0.12
Mesothelioma	34	2.0	0.16	2.3	0.18	16	0.8	0.10	1.0	0.11
Kaposi Sarcoma	7	0.5	0.09	0.6	0.10	1	0.1	0.03	0.1	0.03
Ill-Defined & Unknown	355	21.4	0.52	25.0	0.60	309	15.3	0.40	17.9	0.46
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	172	10.8	0.38	12.1	0.42	326	17.8	0.46	20.4	0.52
Breast (<i>in situ</i>)	2	0.1	0.04	0.1	0.04	451	24.4	0.54	28.9	0.62

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Louisiana, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3,940	596.6	4.52	726.0	5.36	3,491	423.1	3.30	497.3	3.80
Oral Cavity & Pharynx	111	16.0	0.72	19.7	0.86	41	5.0	0.36	5.9	0.41
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	26	3.7	0.35	4.6	0.42	9	1.1	0.17	1.3	0.20
Major salivary gland	7	1.1	0.19	1.3	0.22	8	0.9	0.16	1.0	0.17
Floor of mouth	10	1.4	0.21	1.8	0.26	3	0.3	0.09	0.4	0.11
Gum & other mouth	15	2.0	0.25	2.6	0.31	9	1.2	0.18	1.4	0.20
Nasopharynx	8	1.2	0.20	1.4	0.22	2	0.3	0.09	0.3	0.10
Oropharynx	8	1.2	0.19	1.4	0.23	3	0.4	0.09	0.4	0.11
Hypopharynx	11	1.6	0.23	2.0	0.27	2	0.3	0.09	0.3	0.10
Digestive System	922	140.4	2.20	172.0	2.63	717	86.7	1.49	103.1	1.74
Esophagus	47	6.9	0.48	8.6	0.58	19	2.2	0.23	2.7	0.28
Stomach	91	14.7	0.74	17.8	0.87	63	7.8	0.45	9.2	0.52
Small intestine	32	5.1	0.43	6.2	0.51	37	4.7	0.35	5.4	0.40
Colon (excl. rectum)	281	44.2	1.25	53.4	1.48	278	33.9	0.93	40.1	1.09
Rectum & rectosigmoid	132	20.0	0.82	24.4	0.98	96	11.4	0.54	13.8	0.64
Anus, anal canal, & anorectum	13	2.0	0.26	2.3	0.30	14	1.7	0.21	2.0	0.24
Liver	166	21.6	0.79	28.1	0.99	39	4.3	0.32	5.3	0.39
Gallbladder	9	1.5	0.24	1.8	0.27	17	2.0	0.22	2.4	0.27
Pancreas	116	18.6	0.83	22.5	0.98	122	15.0	0.62	17.7	0.72
Respiratory System	669	104.4	1.93	126.6	2.27	404	47.6	1.09	57.5	1.29
Larynx	74	10.8	0.59	13.3	0.71	19	2.2	0.23	2.8	0.28
Lung & bronchus	590	92.8	1.83	112.3	2.15	381	44.9	1.06	54.2	1.25
Bones & Joints	6	1.0	0.19	1.0	0.19	5	0.6	0.12	0.6	0.13
Soft Tissue (incl. heart)	25	3.8	0.36	4.3	0.41	26	3.2	0.29	3.5	0.31
Skin (excl. basal & sq.)	12	2.2	0.29	2.4	0.33	15	2.0	0.23	2.2	0.26
Melanoma of the skin	5	0.9	0.19	1.0	0.21	7	1.0	0.16	1.1	0.18
Breast (excl. <i>in situ</i>)	10	1.6	0.25	1.9	0.28	1,112	135.7	1.88	159.0	2.15
Female Genital System	N/A	N/A	N/A	N/A	N/A	407	48.5	1.11	57.2	1.28
Cervix uteri	N/A	N/A	N/A	N/A	N/A	83	10.8	0.55	11.8	0.58
Uterus corpus	N/A	N/A	N/A	N/A	N/A	200	22.7	0.74	27.7	0.88
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	12	1.5	0.19	1.8	0.23
Ovary	N/A	N/A	N/A	N/A	N/A	71	8.5	0.46	9.9	0.53
Male Genital System	1,357	194.6	2.50	242.7	3.02	N/A	N/A	N/A	N/A	N/A
Prostate	1,333	190.8	2.47	238.6	3.00	N/A	N/A	N/A	N/A	N/A
Testis	12	1.8	0.24	1.8	0.24	N/A	N/A	N/A	N/A	N/A
Penis	10	1.7	0.25	2.0	0.29	N/A	N/A	N/A	N/A	N/A
Urinary System	301	47.5	1.30	56.9	1.52	183	22.0	0.75	26.2	0.88
Bladder (incl. <i>in situ</i>)	107	17.8	0.82	21.2	0.96	47	5.9	0.39	6.9	0.46
Kidney & renal pelvis	189	28.8	0.99	34.6	1.15	129	15.3	0.62	18.3	0.73
Ureter	*	*	*	*	*	1	0.2	0.07	0.2	0.08
Eye & Orbit	2	0.3	0.09	0.3	0.10	2	0.2	0.07	0.2	0.07
Brain & Other CNS	32	4.8	0.40	5.4	0.45	22	2.8	0.27	2.9	0.28
Brain	30	4.5	0.39	5.0	0.43	20	2.5	0.25	2.6	0.27
Endocrine System	35	5.2	0.41	6.1	0.47	122	15.3	0.64	16.9	0.69
Thyroid gland	27	4.0	0.36	4.6	0.41	116	14.5	0.62	16.0	0.67
Lymphomas	124	19.3	0.82	22.0	0.92	120	14.9	0.62	16.8	0.69
Hodgkin lymphoma	20	2.9	0.29	3.0	0.31	16	2.1	0.23	2.1	0.24
Non-Hodgkin lymphoma	104	16.4	0.76	19.0	0.87	104	12.8	0.58	14.7	0.65
Multiple Myeloma	97	16.1	0.77	19.1	0.90	104	12.5	0.57	15.0	0.66
Leukemias	92	14.6	0.72	16.7	0.82	70	8.7	0.47	9.8	0.53
Acute lymphocytic	10	1.3	0.19	1.2	0.19	6	0.7	0.13	0.6	0.12
Chronic lymphocytic	29	4.8	0.42	5.7	0.49	19	2.3	0.25	2.7	0.28
Acute myeloid	29	4.8	0.42	5.4	0.47	26	3.3	0.29	3.7	0.32
Chronic myeloid	16	2.5	0.29	3.0	0.34	13	1.5	0.20	1.8	0.23
Other leukemias	7	1.3	0.23	1.4	0.25	7	0.8	0.15	1.0	0.17
Mesothelioma	10	1.9	0.29	2.2	0.33	4	0.5	0.12	0.6	0.13
Kaposi Sarcoma	11	1.7	0.24	1.7	0.25	*	*	*	*	*
Ill-Defined & Unknown	124	21.2	0.91	25.0	1.05	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	65	10.6	0.62	12.1	0.70	148	18.5	0.70	21.2	0.79
Breast (<i>in situ</i>)	*	*	*	*	*	245	28.9	0.85	34.6	1.00

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Louisiana, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	126	329.7	14.06	399.4	16.64	124	290.0	12.13	336.7	13.91
Oral Cavity & Pharynx	4	9.1	2.11	11.0	2.54	3	6.9	1.88	8.2	2.19
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	1	3.0	1.31	3.7	1.57
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	3.1	1.35	3.6	1.59	*	*	*	*	*
Nasopharynx	2	3.5	1.23	4.1	1.47	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	43	107.4	7.76	132.5	9.34	22	53.7	5.39	63.6	6.25
Esophagus	1	2.9	1.10	4.0	1.50	*	*	*	*	*
Stomach	4	9.3	2.08	11.7	2.59	2	4.2	1.55	4.8	1.72
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	9	24.3	3.86	29.1	4.54	7	16.1	2.88	19.6	3.43
Rectum & rectosigmoid	7	19.2	3.36	23.5	4.03	5	11.4	2.51	13.8	2.96
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	14	33.9	4.19	42.4	5.10	3	7.1	1.92	8.1	2.16
Gallbladder	*	*	*	*	*	1	2.8	1.20	3.4	1.38
Pancreas	4	8.9	2.22	11.6	2.82	3	7.3	2.05	8.7	2.39
Respiratory System	20	55.3	5.90	67.9	7.04	15	37.3	4.58	42.8	5.14
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	19	52.2	5.75	64.5	6.90	14	35.7	4.47	41.0	5.03
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	1	3.4	1.49	3.9	1.62	*	*	*	*	*
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Melanoma of the skin	1	2.7	1.12	3.4	1.38	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	38	85.3	6.36	99.9	7.37
Female Genital System	N/A	N/A	N/A	N/A	N/A	13	28.7	3.64	34.5	4.33
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	5.5	1.65	6.2	1.84
Uterus corpus	N/A	N/A	N/A	N/A	N/A	6	13.3	2.45	16.4	2.99
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	3	7.0	1.74	8.5	2.12
Male Genital System	24	61.7	6.07	75.6	7.24	N/A	N/A	N/A	N/A	N/A
Prostate	22	57.2	5.88	70.8	7.05	N/A	N/A	N/A	N/A	N/A
Testis	2	3.1	1.10	3.1	1.10	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	9	23.2	3.78	27.9	4.39	3	8.7	2.21	10.3	2.57
Bladder (incl. <i>in situ</i>)	5	13.1	2.91	15.6	3.35	2	4.1	1.53	4.8	1.76
Kidney & renal pelvis	4	9.7	2.37	11.7	2.77	2	4.5	1.60	5.5	1.88
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	3.9	1.48	4.5	1.71	2	4.1	1.54	4.9	1.81
Brain	*	*	*	*	*	1	3.8	1.50	4.6	1.77
Endocrine System	2	6.6	1.99	6.8	2.09	13	27.8	3.56	29.7	3.80
Thyroid gland	2	5.2	1.72	5.6	1.88	12	26.5	3.47	28.3	3.72
Lymphomas	8	21.7	3.55	25.7	4.15	5	11.4	2.39	13.3	2.75
Hodgkin lymphoma	1	2.4	0.98	2.5	1.03	*	*	*	*	*
Non-Hodgkin lymphoma	7	19.3	3.41	23.2	4.02	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	2	7.6	2.40	9.3	2.85	2	4.4	1.63	5.3	1.94
Leukemias	3	10.0	2.65	11.2	2.96	3	7.7	1.99	8.4	2.17
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	2	5.7	2.16	6.4	2.39	1	3.9	1.52	4.5	1.72
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	4	11.9	2.97	13.6	3.34	4	9.3	2.30	10.9	2.67
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	4	9.7	2.37	11.2	2.74	5	12.5	2.52	13.8	2.77
Breast (<i>in situ</i>)	*	*	*	*	*	7	14.1	2.51	17.3	3.00

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Louisiana, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	6	304.5	59.38	352.2	67.10	5	244.4	48.53	305.7	59.57
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	1	60.2	23.31	78.3	29.72
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	2	68.0	24.21	86.9	30.82
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	2	68.0	24.21	86.9	30.82
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	2	81.6	29.55	96.7	34.45	N/A	N/A	N/A	N/A	N/A
Prostate	1	72.0	27.97	86.9	33.02	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Louisiana, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	261	310.8	9.15	371.2	10.79	268	304.0	8.42	354.9	9.89
Oral Cavity & Pharynx	9	9.6	1.54	11.6	1.84	4	4.9	1.06	5.9	1.28
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	4	4.2	1.00	5.1	1.20	*	*	*	*	*
Major salivary gland	*	*	*	*	*	2	1.7	0.61	1.9	0.72
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	57	67.1	4.20	81.4	5.02	47	53.5	3.55	64.0	4.24
Esophagus	2	2.9	0.92	3.6	1.12	*	*	*	*	*
Stomach	9	10.6	1.72	12.4	2.01	6	6.5	1.25	7.7	1.47
Small intestine	*	*	*	*	*	2	2.3	0.78	2.5	0.84
Colon (excl. rectum)	17	19.6	2.28	23.5	2.70	14	16.0	1.92	18.7	2.25
Rectum & rectosigmoid	9	9.4	1.49	11.4	1.78	5	5.8	1.13	7.5	1.45
Anus, anal canal, & anorectum	*	*	*	*	*	2	2.3	0.74	2.8	0.90
Liver	10	10.9	1.57	14.0	1.99	5	4.9	1.05	6.3	1.33
Gallbladder	*	*	*	*	*	2	2.4	0.77	2.9	0.93
Pancreas	7	9.2	1.65	10.9	1.90	7	8.0	1.41	9.2	1.61
Respiratory System	23	29.1	2.88	34.6	3.35	21	25.4	2.49	30.9	3.01
Larynx	3	4.3	1.11	5.1	1.29	*	*	*	*	*
Lung & bronchus	19	23.7	2.60	28.4	3.04	20	24.1	2.42	29.4	2.94
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	2	2.3	0.73	2.6	0.82	2	2.1	0.66	2.2	0.71
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	4	5.6	1.25	6.5	1.47	4	4.1	0.96	4.6	1.09
Breast (excl. <i>in situ</i>)	*	*	*	*	*	80	91.7	4.63	108.3	5.49
Female Genital System	N/A	N/A	N/A	N/A	N/A	35	39.2	2.98	45.0	3.46
Cervix uteri	N/A	N/A	N/A	N/A	N/A	11	12.0	1.62	12.3	1.70
Uterus corpus	N/A	N/A	N/A	N/A	N/A	15	16.4	1.93	20.1	2.38
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	6	6.5	1.21	7.4	1.39
Male Genital System	78	94.1	5.04	114.4	5.99	N/A	N/A	N/A	N/A	N/A
Prostate	70	88.2	4.94	108.6	5.91	N/A	N/A	N/A	N/A	N/A
Testis	7	5.1	0.89	4.8	0.84	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	30	40.3	3.48	47.4	4.05	12	14.5	1.90	16.3	2.14
Bladder (incl. <i>in situ</i>)	11	16.1	2.32	19.0	2.70	2	2.9	0.88	3.1	0.94
Kidney & renal pelvis	19	23.7	2.57	28.0	2.99	9	10.6	1.61	12.1	1.83
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	4	4.1	0.94	4.6	1.10	5	4.8	1.02	5.1	1.11
Brain	4	3.7	0.90	4.2	1.07	4	4.4	0.97	4.6	1.07
Endocrine System	6	6.5	1.23	7.4	1.41	19	19.5	2.06	21.6	2.33
Thyroid gland	6	6.2	1.21	7.1	1.39	18	19.1	2.03	21.1	2.30
Lymphomas	19	19.7	2.18	22.7	2.54	15	17.4	2.04	20.2	2.36
Hodgkin lymphoma	3	2.5	0.72	2.8	0.80	1	1.2	0.51	1.3	0.56
Non-Hodgkin lymphoma	16	17.2	2.06	20.0	2.41	14	16.2	1.97	18.9	2.29
Multiple Myeloma	6	7.1	1.33	8.6	1.59	3	3.6	0.94	4.4	1.14
Leukemias	9	8.6	1.43	10.1	1.71	9	9.6	1.48	10.6	1.67
Acute lymphocytic	1	1.1	0.43	1.1	0.44	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	2	2.6	0.82	3.3	1.03	3	3.1	0.87	3.7	1.03
Acute myeloid	3	3.1	0.89	3.6	1.04	2	2.5	0.76	2.7	0.84
Chronic myeloid	*	*	*	*	*	2	1.9	0.69	2.1	0.77
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	1	1.5	0.66	1.8	0.74	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	10	12.9	1.98	15.0	2.29	10	11.7	1.69	13.8	1.98
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	6	7.4	1.43	8.2	1.61	11	12.2	1.67	14.3	1.97
Breast (<i>in situ</i>)	*	*	*	*	*	18	20.3	2.19	24.5	2.63

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

LOUISIANA

II-218 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Louisiana, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	216	289.9	9.32	345.8	11.01	226	291.6	8.79	340.9	10.35
Oral Cavity & Pharynx	8	9.4	1.60	11.4	1.92	4	5.0	1.13	6.0	1.37
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	4	4.5	1.11	5.5	1.32	*	*	*	*	*
Major salivary gland	*	*	*	*	*	2	1.9	0.69	2.2	0.81
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	47	62.5	4.29	75.5	5.12	40	51.9	3.72	61.7	4.43
Esophagus	2	3.2	1.02	4.0	1.23	*	*	*	*	*
Stomach	7	9.9	1.74	11.4	2.01	5	6.0	1.27	7.0	1.48
Small intestine	*	*	*	*	*	1	1.7	0.70	1.9	0.77
Colon (excl. rectum)	14	18.6	2.35	22.4	2.79	13	16.6	2.07	19.4	2.44
Rectum & rectosigmoid	6	8.0	1.46	9.6	1.74	4	5.5	1.17	6.9	1.49
Anus, anal canal, & anorectum	*	*	*	*	*	1	1.9	0.71	2.2	0.84
Liver	8	9.7	1.59	12.2	1.99	4	4.6	1.10	5.7	1.36
Gallbladder	*	*	*	*	*	2	2.5	0.83	3.0	1.01
Pancreas	6	8.5	1.65	10.0	1.92	6	8.5	1.54	9.7	1.76
Respiratory System	19	27.1	2.92	32.2	3.40	18	25.2	2.65	30.5	3.19
Larynx	3	4.9	1.24	5.7	1.44	*	*	*	*	*
Lung & bronchus	15	21.2	2.59	25.4	3.02	17	23.7	2.56	28.9	3.10
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	2	2.2	0.78	2.5	0.91	2	1.8	0.65	2.0	0.72
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	4	6.0	1.38	7.0	1.60	3	4.3	1.04	4.7	1.18
Breast (excl. <i>in situ</i>)	*	*	*	*	*	67	87.3	4.82	103.4	5.74
Female Genital System	N/A	N/A	N/A	N/A	N/A	28	35.8	3.05	41.5	3.57
Cervix uteri	N/A	N/A	N/A	N/A	N/A	8	9.3	1.52	9.8	1.65
Uterus corpus	N/A	N/A	N/A	N/A	N/A	12	15.4	2.00	18.7	2.45
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	6	7.0	1.35	8.1	1.57
Male Genital System	62	83.9	5.03	102.2	6.00	N/A	N/A	N/A	N/A	N/A
Prostate	55	78.3	4.92	96.6	5.91	N/A	N/A	N/A	N/A	N/A
Testis	6	4.8	0.93	4.5	0.89	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	25	36.9	3.49	43.8	4.10	9	13.0	1.92	14.8	2.19
Bladder (incl. <i>in situ</i>)	10	16.1	2.41	19.1	2.83	2	2.3	0.83	2.6	0.91
Kidney & renal pelvis	15	20.4	2.49	24.3	2.92	7	9.8	1.65	11.2	1.90
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	4	4.2	1.01	4.6	1.17	4	4.9	1.11	5.1	1.19
Brain	3	3.6	0.96	4.1	1.13	4	4.4	1.05	4.6	1.13
Endocrine System	5	6.5	1.32	7.3	1.50	17	20.0	2.22	22.1	2.52
Thyroid gland	5	6.1	1.29	6.8	1.47	16	19.4	2.19	21.6	2.49
Lymphomas	17	20.7	2.37	23.8	2.76	13	17.1	2.14	19.9	2.49
Hodgkin lymphoma	3	2.8	0.81	3.0	0.91	*	*	*	*	*
Non-Hodgkin lymphoma	15	17.9	2.23	20.8	2.61	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	5	7.2	1.44	8.7	1.71	2	3.3	0.95	4.0	1.17
Leukemias	7	8.0	1.45	9.3	1.73	8	9.5	1.56	10.2	1.73
Acute lymphocytic	1	1.3	0.51	1.3	0.51	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	1	1.7	0.69	2.2	0.88	2	2.7	0.87	3.2	1.02
Acute myeloid	3	3.3	0.97	3.8	1.15	2	2.5	0.82	2.8	0.93
Chronic myeloid	*	*	*	*	*	1	1.9	0.72	2.0	0.79
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	8	11.7	1.95	13.7	2.27	8	10.8	1.72	12.6	2.02
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	6	7.3	1.48	7.8	1.64	9	12.0	1.77	14.0	2.09
Breast (<i>in situ</i>)	*	*	*	*	*	16	20.6	2.35	24.9	2.85

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Louisiana, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	15	244.2	32.99	289.8	38.39	15	197.4	23.75	232.8	27.71
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	2	39.3	13.04	45.7	14.63	3	43.2	11.13	51.8	13.11
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	1	25.9	11.20	28.6	12.25	1	15.6	6.66	20.0	8.24
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	1	25.9	11.20	28.6	12.25	1	15.6	6.66	20.0	8.24
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	5	57.6	11.97	69.2	14.31
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	26.2	8.43	29.3	9.44
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1	18.7	7.15	22.1	8.35
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	6	93.0	18.60	114.1	21.85	N/A	N/A	N/A	N/A	N/A
Prostate	6	91.4	18.53	112.7	21.80	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	1	32.3	14.53	38.6	17.27	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	1	16.4	6.73	18.6	7.65

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


LOUISIANA

II-220 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	1,329,098	1,332,348	1,335,743	1,340,123	1,345,770
Non-Hispanic White	1,258,854	1,259,577	1,260,993	1,263,248	1,265,658
Non-Hispanic Black	22,457	23,483	24,225	25,159	26,465
Non-Hispanic Asian/Pacific Islander (NH API)	17,082	17,832	18,171	18,559	19,148
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	5,479	5,524	5,505	5,507	5,564


All Races Population 2015–2019: 6,683,082
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	20,640	21,325	22,132	22,888	24,098
Hispanic White	18,044	18,633	19,289	19,947	21,005
Hispanic Black	1,349	1,366	1,445	1,499	1,602

Hispanic/Latino Population, Census 2010: 16,935
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

MAINE CANCER REGISTRY

Initial Operation: 1983
Population-based Data Available: 1983
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	111.4	112.5	110.3	107.7	109.9	110.4
Missing Race	0.5	0.3	0.7	1.2	0.8	0.7
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.0	2.0	2.1	2.3	2.1	2.1
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.1	Ovary	92.9
Oral Cavity & Pharynx	97.6	Prostate	95.8
Esophagus	96.4	Testis	99.1
Stomach	96.4	Bladder (incl. <i>in situ</i>)	97.5
Colon & Rectum	95.4	Kidney & Renal Pelvis	88.0
Liver	59.6	Brain & Other CNS	84.0
Pancreas	85.8	Brain & Other CNS (non-malig)	55.7
Lung & Bronchus	83.5	Thyroid	99.6
Melanomas of the Skin	99.5	Hodgkin Lymphoma	98.6
Female Breast (excl. <i>in situ</i>)	98.6	Non-Hodgkin Lymphoma	96.2
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	83.8
Cervix Uteri	99.5	Leukemias	86.7
Uterus Corpus & Uterus NOS	98.4		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Maine, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	4,659	506.4	3.45	600.3	4.01	4,530	458.0	3.23	532.9	3.64
Oral Cavity & Pharynx	194	20.9	0.70	25.6	0.84	77	7.5	0.41	8.9	0.47
Lip	16	1.9	0.22	2.2	0.25	6	0.5	0.10	0.7	0.12
Tongue	58	6.0	0.37	7.4	0.44	20	2.0	0.21	2.4	0.24
Major salivary gland	13	1.5	0.19	1.7	0.22	7	0.8	0.14	0.9	0.16
Floor of mouth	10	1.0	0.15	1.3	0.19	4	0.4	0.10	0.5	0.11
Gum & other mouth	19	2.1	0.23	2.5	0.26	16	1.5	0.17	1.7	0.20
Nasopharynx	7	0.8	0.15	1.0	0.17	3	0.4	0.09	0.4	0.10
Oropharynx	10	1.1	0.16	1.3	0.19	3	0.3	0.09	0.4	0.10
Hypopharynx	12	1.2	0.17	1.5	0.20	3	0.3	0.09	0.4	0.10
Digestive System	834	92.3	1.49	109.8	1.73	667	64.2	1.17	75.7	1.34
Esophagus	111	11.9	0.52	14.4	0.62	26	2.3	0.21	2.8	0.25
Stomach	68	7.5	0.42	8.8	0.49	42	3.9	0.28	4.7	0.33
Small intestine	28	3.1	0.27	3.7	0.32	28	2.7	0.24	3.3	0.29
Colon (excl. rectum)	229	26.1	0.80	30.9	0.93	254	25.0	0.74	28.9	0.83
Rectum & rectosigmoid	117	13.5	0.59	16.1	0.68	78	8.1	0.43	9.6	0.50
Anus, anal canal, & anorectum	15	1.6	0.20	1.9	0.23	28	2.6	0.23	3.3	0.28
Liver	86	8.7	0.43	10.6	0.52	23	2.1	0.20	2.5	0.24
Gallbladder	4	0.5	0.11	0.6	0.12	13	1.2	0.16	1.4	0.18
Pancreas	137	15.0	0.59	17.7	0.69	127	11.6	0.48	13.9	0.56
Respiratory System	780	82.4	1.36	98.9	1.61	740	68.9	1.17	81.7	1.37
Larynx	51	5.3	0.34	6.5	0.41	20	1.8	0.19	2.3	0.24
Lung & bronchus	719	75.9	1.30	91.0	1.54	715	66.5	1.15	78.7	1.34
Bones & Joints	7	1.2	0.20	1.1	0.18	7	0.9	0.17	0.9	0.16
Soft Tissue (incl. heart)	29	3.7	0.33	4.1	0.34	25	2.9	0.28	3.1	0.29
Skin (excl. basal & sq.)	282	31.7	0.88	37.0	1.00	251	27.9	0.85	31.6	0.92
Melanoma of the skin	259	29.1	0.84	34.1	0.96	232	25.9	0.82	29.4	0.89
Breast (excl. <i>in situ</i>)	13	1.4	0.18	1.6	0.20	1,241	128.2	1.74	149.7	1.96
Female Genital System	N/A	N/A	N/A	N/A	N/A	548	54.8	1.11	65.1	1.28
Cervix uteri	N/A	N/A	N/A	N/A	N/A	40	5.4	0.41	5.7	0.42
Uterus corpus	N/A	N/A	N/A	N/A	N/A	329	31.2	0.81	38.3	0.97
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	9	0.9	0.14	1.1	0.16
Ovary	N/A	N/A	N/A	N/A	N/A	81	8.8	0.47	10.0	0.51
Male Genital System	1,048	106.0	1.52	128.2	1.80	N/A	N/A	N/A	N/A	N/A
Prostate	990	97.0	1.41	119.1	1.71	N/A	N/A	N/A	N/A	N/A
Testis	44	7.4	0.51	7.4	0.50	N/A	N/A	N/A	N/A	N/A
Penis	12	1.3	0.18	1.5	0.20	N/A	N/A	N/A	N/A	N/A
Urinary System	636	69.7	1.28	82.4	1.49	250	24.1	0.72	28.3	0.82
Bladder (incl. <i>in situ</i>)	410	44.9	1.02	52.9	1.19	124	11.6	0.48	13.6	0.56
Kidney & renal pelvis	212	23.2	0.75	27.7	0.87	119	12.0	0.52	14.0	0.59
Ureter	7	0.8	0.14	1.0	0.16	4	0.4	0.09	0.4	0.10
Eye & Orbit	8	1.0	0.16	1.1	0.18	6	0.7	0.14	0.7	0.14
Brain & Other CNS	72	9.1	0.50	10.0	0.54	54	6.5	0.43	6.9	0.43
Brain	70	8.8	0.50	9.7	0.53	51	6.1	0.41	6.5	0.42
Endocrine System	74	9.1	0.50	10.2	0.54	163	21.7	0.81	23.3	0.84
Thyroid gland	68	8.3	0.48	9.4	0.52	155	20.7	0.79	22.3	0.82
Lymphomas	251	29.2	0.86	33.6	0.97	181	18.2	0.64	21.0	0.72
Hodgkin lymphoma	22	3.1	0.31	3.3	0.32	19	2.6	0.28	2.7	0.28
Non-Hodgkin lymphoma	229	26.1	0.81	30.4	0.91	162	15.7	0.58	18.3	0.66
Multiple Myeloma	70	7.6	0.42	9.0	0.49	52	4.7	0.30	5.6	0.35
Leukemias	164	19.1	0.70	21.8	0.78	109	11.5	0.53	12.8	0.56
Acute lymphocytic	11	1.9	0.26	1.7	0.23	10	1.6	0.24	1.5	0.21
Chronic lymphocytic	73	7.8	0.42	9.3	0.50	48	4.4	0.29	5.2	0.34
Acute myeloid	47	5.5	0.37	6.2	0.41	31	3.4	0.29	3.7	0.31
Chronic myeloid	17	1.9	0.22	2.2	0.25	11	1.2	0.17	1.3	0.19
Other leukemias	17	2.0	0.23	2.4	0.26	9	0.9	0.15	1.0	0.16
Mesothelioma	21	2.5	0.25	2.8	0.28	5	0.5	0.10	0.5	0.11
Kaposi Sarcoma	2	0.2	0.08	0.2	0.08	*	*	*	*	*
Ill-Defined & Unknown	172	19.5	0.69	22.7	0.79	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	52	6.5	0.43	7.4	0.47	92	10.5	0.53	11.8	0.57
Breast (<i>in situ</i>)	*	*	*	*	*	266	28.1	0.82	33.2	0.94

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Maine, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	4,530	506.1	3.51	599.7	4.06	4,410	459.0	3.30	534.1	3.71
Oral Cavity & Pharynx	189	21.0	0.71	25.6	0.85	76	7.7	0.42	9.1	0.48
Lip	15	1.8	0.22	2.1	0.25	5	0.5	0.09	0.6	0.11
Tongue	57	6.0	0.37	7.5	0.45	20	2.1	0.22	2.4	0.25
Major salivary gland	13	1.5	0.19	1.7	0.22	7	0.8	0.15	0.9	0.16
Floor of mouth	10	1.1	0.16	1.4	0.20	4	0.4	0.10	0.5	0.12
Gum & other mouth	18	2.1	0.23	2.5	0.27	16	1.5	0.18	1.7	0.20
Nasopharynx	6	0.7	0.14	0.9	0.16	3	0.4	0.10	0.4	0.11
Oropharynx	10	1.1	0.16	1.3	0.19	3	0.4	0.10	0.4	0.11
Hypopharynx	11	1.2	0.17	1.5	0.20	3	0.4	0.09	0.4	0.11
Digestive System	809	92.0	1.51	109.4	1.75	651	64.4	1.19	75.8	1.37
Esophagus	108	11.9	0.53	14.4	0.63	26	2.4	0.22	2.9	0.26
Stomach	66	7.4	0.43	8.7	0.49	41	3.9	0.28	4.6	0.33
Small intestine	28	3.2	0.28	3.7	0.33	27	2.7	0.25	3.3	0.29
Colon (excl. rectum)	222	26.1	0.82	30.8	0.94	250	25.3	0.76	29.2	0.85
Rectum & rectosigmoid	113	13.5	0.60	16.1	0.69	75	8.0	0.44	9.5	0.51
Anus, anal canal, & anorectum	14	1.7	0.21	2.0	0.24	28	2.7	0.24	3.3	0.29
Liver	81	8.4	0.43	10.3	0.52	22	2.0	0.20	2.4	0.23
Gallbladder	4	0.5	0.11	0.6	0.12	12	1.2	0.16	1.3	0.17
Pancreas	134	15.0	0.60	17.8	0.70	124	11.7	0.49	13.9	0.57
Respiratory System	763	82.6	1.38	99.2	1.63	727	69.5	1.19	82.4	1.39
Larynx	50	5.4	0.35	6.6	0.42	19	1.9	0.20	2.3	0.24
Lung & bronchus	703	76.0	1.32	91.1	1.56	703	67.0	1.17	79.3	1.36
Bones & Joints	7	1.1	0.20	1.1	0.19	6	0.9	0.18	0.9	0.17
Soft Tissue (incl. heart)	29	3.8	0.34	4.1	0.36	23	2.8	0.28	3.0	0.29
Skin (excl. basal & sq.)	261	30.3	0.88	35.3	1.00	229	26.2	0.84	29.7	0.91
Melanoma of the skin	239	27.7	0.84	32.4	0.96	211	24.3	0.81	27.7	0.88
Breast (excl. <i>in situ</i>)	13	1.4	0.18	1.7	0.21	1,210	128.7	1.78	150.2	2.00
Female Genital System	N/A	N/A	N/A	N/A	N/A	536	55.1	1.14	65.7	1.31
Cervix uteri	N/A	N/A	N/A	N/A	N/A	37	5.3	0.42	5.6	0.42
Uterus corpus	N/A	N/A	N/A	N/A	N/A	323	31.6	0.83	38.7	0.99
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	9	0.9	0.14	1.0	0.16
Ovary	N/A	N/A	N/A	N/A	N/A	80	8.8	0.48	10.1	0.52
Male Genital System	1,021	106.0	1.54	128.1	1.82	N/A	N/A	N/A	N/A	N/A
Prostate	964	96.7	1.43	118.6	1.73	N/A	N/A	N/A	N/A	N/A
Testis	43	7.8	0.55	7.7	0.53	N/A	N/A	N/A	N/A	N/A
Penis	12	1.3	0.18	1.5	0.21	N/A	N/A	N/A	N/A	N/A
Urinary System	624	70.1	1.30	82.9	1.51	247	24.5	0.74	28.7	0.84
Bladder (incl. <i>in situ</i>)	403	45.2	1.04	53.3	1.21	123	11.7	0.49	13.8	0.57
Kidney & renal pelvis	208	23.3	0.76	27.9	0.89	117	12.2	0.54	14.3	0.61
Ureter	7	0.8	0.14	1.0	0.17	4	0.4	0.09	0.4	0.10
Eye & Orbit	8	0.9	0.16	1.1	0.18	5	0.6	0.13	0.7	0.14
Brain & Other CNS	71	9.2	0.52	10.2	0.55	53	6.7	0.45	7.1	0.45
Brain	69	9.0	0.51	9.9	0.55	50	6.2	0.43	6.7	0.44
Endocrine System	72	9.3	0.52	10.4	0.56	159	22.1	0.85	23.7	0.87
Thyroid gland	66	8.5	0.50	9.6	0.54	151	21.1	0.83	22.7	0.85
Lymphomas	244	29.2	0.88	33.7	0.98	177	18.3	0.66	21.1	0.73
Hodgkin lymphoma	22	3.2	0.33	3.4	0.33	19	2.7	0.30	2.9	0.30
Non-Hodgkin lymphoma	222	26.0	0.82	30.3	0.93	157	15.6	0.59	18.2	0.67
Multiple Myeloma	68	7.6	0.43	9.0	0.50	51	4.7	0.31	5.6	0.36
Leukemias	161	19.4	0.72	22.1	0.80	107	11.7	0.55	13.0	0.58
Acute lymphocytic	10	1.9	0.28	1.7	0.24	10	1.7	0.26	1.5	0.23
Chronic lymphocytic	71	7.8	0.43	9.4	0.51	47	4.4	0.30	5.3	0.35
Acute myeloid	47	5.6	0.38	6.4	0.43	31	3.4	0.30	3.8	0.32
Chronic myeloid	16	2.0	0.22	2.3	0.26	11	1.2	0.18	1.4	0.19
Other leukemias	17	2.1	0.24	2.4	0.26	9	0.9	0.16	1.0	0.16
Mesothelioma	21	2.5	0.25	2.9	0.28	5	0.5	0.10	0.5	0.11
Kaposi Sarcoma	1	0.2	0.08	0.2	0.08	*	*	*	*	*
Ill-Defined & Unknown	168	19.5	0.70	22.8	0.80	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	50	6.4	0.43	7.2	0.47	89	10.5	0.55	11.8	0.58
Breast (<i>in situ</i>)	*	*	*	*	*	261	28.5	0.84	33.6	0.96

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Maine, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	29	429.4	40.87	511.7	46.98	18	301.1	33.85	354.2	40.53
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	7	87.5	16.31	106.7	19.24	3	54.6	13.88	69.4	17.68
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	2	28.7	11.12	31.2	11.70	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	2	22.0	7.03	29.1	9.37	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	4	55.9	14.22	69.5	16.90	1	27.3	11.85	29.9	13.22
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	4	51.3	13.84	63.4	16.31	1	27.3	11.85	29.9	13.22
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	5	79.4	16.34	91.6	19.39
Female Genital System	N/A	N/A	N/A	N/A	N/A	3	55.6	14.59	66.1	17.65
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1	24.1	10.20	30.9	12.74
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	9	155.1	26.02	182.5	29.03	N/A	N/A	N/A	N/A	N/A
Prostate	9	155.1	26.02	182.5	29.03	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	3	52.2	15.67	62.6	18.73	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	1	30.1	13.55	35.7	16.12	*	*	*	*	*
Kidney & renal pelvis	2	22.1	7.88	26.9	9.54	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	1	15.4	6.55	16.8	7.71
Thyroid gland	*	*	*	*	*	1	15.4	6.55	16.8	7.71
Lymphomas	2	31.7	12.00	35.9	13.26	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	1	14.4	6.62	17.7	7.87	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	1	30.1	11.80	33.9	13.18

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Maine, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	16	300.8	37.13	348.5	42.22	22	224.0	22.17	260.3	25.68
Oral Cavity & Pharynx	1	15.9	6.52	20.9	8.59	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	6	116.9	23.45	134.5	26.41	5	50.9	10.41	62.3	12.62
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	1	27.6	11.24	32.0	12.66	2	20.7	6.76	25.0	8.11
Rectum & rectosigmoid	1	17.8	7.30	21.8	8.92	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	2	40.5	13.86	47.7	15.98	2	22.3	6.88	27.4	8.51
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	2	40.5	13.86	47.7	15.98	2	22.3	6.88	27.4	8.51
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	7	69.6	11.95	81.4	13.92
Female Genital System	N/A	N/A	N/A	N/A	N/A	3	23.9	6.71	26.7	7.58
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1	10.1	4.12	13.7	5.61
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	2	26.4	8.45	34.5	11.04	N/A	N/A	N/A	N/A	N/A
Prostate	2	24.4	8.20	32.6	10.87	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	1	25.3	11.41	28.9	12.92	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	2	15.1	5.35	16.5	5.90

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Maine, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	13	470.4	62.37	590.0	75.60	16	569.1	65.13	662.8	74.02
Oral Cavity & Pharynx	1	57.2	23.00	69.9	27.59	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	3	107.8	28.20	134.2	33.93	2	79.7	24.06	98.0	28.86
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	1	31.8	13.16	43.4	17.89
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	3	103.4	29.76	135.7	37.29	4	144.9	31.97	176.3	38.00
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	3	103.4	29.76	135.7	37.29	4	138.3	31.29	167.7	37.02
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	5	183.9	36.55	214.8	41.56
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	3	106.5	29.59	133.4	35.73	N/A	N/A	N/A	N/A	N/A
Prostate	3	106.5	29.59	133.4	35.73	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Maine, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	18	270.7	30.61	318.4	35.36	21	261.3	26.18	305.5	30.57
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	5	72.4	15.87	86.1	18.46	3	48.4	12.04	57.6	14.14
Esophagus	1	19.8	8.37	22.3	9.27	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	2	38.8	12.28	45.7	14.07	2	25.8	8.27	29.5	9.44
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	2	38.8	12.28	45.7	14.07	2	25.8	8.27	29.5	9.44
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	8	91.9	15.36	107.7	18.00
Female Genital System	N/A	N/A	N/A	N/A	N/A	3	30.6	8.67	35.3	10.08
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2	20.9	7.09	26.0	8.75
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	4	56.6	13.94	67.7	16.16	N/A	N/A	N/A	N/A	N/A
Prostate	3	53.9	13.81	65.0	16.05	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	3	41.6	12.20	46.8	13.59	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	2	35.0	11.53	39.1	12.72	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	1	14.7	5.67	16.0	6.31
Thyroid gland	*	*	*	*	*	1	13.1	5.43	14.4	6.12
Lymphomas	1	18.2	8.10	20.0	8.75	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	1	16.1	6.84	18.9	7.93
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

MAINE

II-228 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Maine, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	14	256.8	33.12	298.8	37.74	19	257.4	27.49	299.6	32.00
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	3	63.8	16.80	74.9	19.21	3	49.1	13.03	57.4	15.03
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	2	39.5	13.72	45.5	15.42	2	29.0	9.34	33.3	10.66
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	2	39.5	13.72	45.5	15.42	2	29.0	9.34	33.3	10.66
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	7	89.8	16.08	104.8	18.73
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	32.0	9.51	37.7	11.20
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2	23.6	8.03	29.2	9.85
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	3	46.6	13.94	55.6	16.01	N/A	N/A	N/A	N/A	N/A
Prostate	2	45.0	13.85	54.1	15.94	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	2	46.2	14.23	51.8	15.75	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	2	41.6	13.81	46.2	15.14	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	1	16.5	6.38	18.0	7.11
Thyroid gland	*	*	*	*	*	1	14.7	6.13	16.3	6.90
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Maine, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	*	*	*	*	*	*	*	*	*	*
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


MAINE

II-230 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	5,988,528	6,007,014	6,028,186	6,042,153	6,054,954
Non-Hispanic White	3,181,503	3,160,162	3,138,533	3,116,185	3,093,120
Non-Hispanic Black	1,822,606	1,835,787	1,850,269	1,861,850	1,874,084
Non-Hispanic Asian/Pacific Islander (NH API)	402,344	410,785	419,975	425,499	431,423
Non-Hispanic American Indian/Alaskan Native PRCA (NH AI/AN)	0	0	0	0	0


All Races Population 2015–2019: 30,120,835
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	564,266	582,352	601,426	620,598	638,293
Hispanic White	459,830	474,389	489,335	504,428	517,989
Hispanic Black	68,810	71,063	73,619	76,093	78,858

Hispanic/Latino Population, Census 2010: 470,632
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

MARYLAND CANCER REGISTRY

Initial Operation: 1982
Population-based Data Available: 1992
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	109.3	108.3	108.1	105.7	105.6	107.4
Missing Race	0.2	0.3	0.3	0.3	0.4	0.3
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.2	0.7	0.4	1.4	0.4	0.6
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.8	3.2	3.7	3.1	2.9	3.1
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.3	Ovary	92.2
Oral Cavity & Pharynx	97.6	Prostate	96.7
Esophagus	93.6	Testis	98.6
Stomach	95.5	Bladder (incl. <i>in situ</i>)	96.1
Colon & Rectum	94.8	Kidney & Renal Pelvis	90.2
Liver	53.0	Brain & Other CNS	84.7
Pancreas	85.5	Brain & Other CNS (non-malig)	44.1
Lung & Bronchus	86.9	Thyroid	99.1
Melanomas of the Skin	99.2	Hodgkin Lymphoma	97.8
Female Breast (excl. <i>in situ</i>)	98.2	Non-Hodgkin Lymphoma	95.1
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	86.0
Cervix Uteri	96.3	Leukemias	82.2
Uterus Corpus & Uterus NOS	98.2		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Maryland, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	16,139	494.8	1.79	590.0	2.10	16,376	428.0	1.54	499.7	1.76
Oral Cavity & Pharynx	589	17.2	0.33	21.2	0.39	241	6.2	0.18	7.3	0.21
Lip	15	0.4	0.05	0.5	0.06	9	0.2	0.03	0.3	0.04
Tongue	202	5.8	0.19	7.2	0.23	76	1.9	0.10	2.3	0.12
Major salivary gland	48	1.6	0.10	1.8	0.12	37	1.0	0.08	1.1	0.08
Floor of mouth	19	0.5	0.06	0.7	0.07	9	0.2	0.03	0.3	0.04
Gum & other mouth	65	2.0	0.11	2.4	0.13	53	1.3	0.08	1.6	0.10
Nasopharynx	22	0.7	0.07	0.8	0.08	10	0.3	0.04	0.3	0.05
Oropharynx	43	1.2	0.09	1.5	0.10	11	0.3	0.04	0.3	0.05
Hypopharynx	37	1.1	0.08	1.3	0.10	9	0.2	0.03	0.3	0.04
Digestive System	3,043	93.9	0.78	112.1	0.92	2,582	65.9	0.59	77.8	0.69
Esophagus	237	7.3	0.22	8.7	0.26	77	1.9	0.10	2.3	0.12
Stomach	284	8.9	0.24	10.5	0.28	207	5.4	0.17	6.3	0.20
Small intestine	100	3.0	0.14	3.6	0.16	89	2.3	0.11	2.7	0.13
Colon (excl. rectum)	867	27.6	0.43	32.5	0.50	945	24.4	0.36	28.5	0.42
Rectum & rectosigmoid	406	12.4	0.28	14.8	0.33	320	8.4	0.22	10.0	0.25
Anus, anal canal, & anorectum	51	1.6	0.10	1.9	0.12	89	2.2	0.11	2.7	0.13
Liver	410	11.5	0.26	14.4	0.32	148	3.7	0.14	4.4	0.16
Gallbladder	25	0.8	0.08	0.9	0.09	47	1.2	0.08	1.4	0.09
Pancreas	503	15.6	0.32	18.6	0.38	487	12.2	0.25	14.4	0.29
Respiratory System	2,090	65.1	0.66	77.4	0.77	2,096	51.9	0.52	61.9	0.61
Larynx	158	4.7	0.17	5.7	0.21	43	1.1	0.07	1.3	0.09
Lung & bronchus	1,891	59.2	0.63	70.1	0.73	2,027	50.2	0.51	59.9	0.60
Bones & Joints	37	1.3	0.10	1.3	0.10	28	0.9	0.08	0.9	0.08
Soft Tissue (incl. heart)	122	4.0	0.17	4.5	0.18	99	2.8	0.13	3.1	0.14
Skin (excl. basal & sq.)	1,102	35.2	0.49	41.2	0.56	757	20.6	0.34	23.5	0.39
Melanoma of the skin	1,040	33.1	0.47	38.7	0.54	713	19.4	0.34	22.2	0.38
Breast (excl. <i>in situ</i>)	51	1.6	0.11	1.9	0.12	5,054	133.7	0.87	156.7	0.99
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,991	51.1	0.53	60.8	0.61
Cervix uteri	N/A	N/A	N/A	N/A	N/A	225	6.7	0.21	7.2	0.22
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,099	27.1	0.38	33.2	0.45
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	43	1.1	0.08	1.3	0.09
Ovary	N/A	N/A	N/A	N/A	N/A	409	10.6	0.24	12.6	0.28
Male Genital System	4,812	138.0	0.91	170.1	1.11	N/A	N/A	N/A	N/A	N/A
Prostate	4,657	132.7	0.89	164.6	1.09	N/A	N/A	N/A	N/A	N/A
Testis	127	4.4	0.18	4.4	0.18	N/A	N/A	N/A	N/A	N/A
Penis	20	0.7	0.07	0.8	0.08	N/A	N/A	N/A	N/A	N/A
Urinary System	1,634	52.1	0.59	61.4	0.69	779	19.9	0.33	23.3	0.38
Bladder (incl. <i>in situ</i>)	892	29.3	0.45	34.4	0.52	312	7.7	0.20	9.1	0.23
Kidney & renal pelvis	696	21.2	0.37	25.2	0.43	445	11.6	0.25	13.5	0.29
Ureter	22	0.7	0.07	0.8	0.08	13	0.3	0.04	0.4	0.05
Eye & Orbit	17	0.6	0.07	0.6	0.07	18	0.5	0.06	0.6	0.06
Brain & Other CNS	230	7.5	0.23	8.2	0.24	180	5.1	0.18	5.6	0.19
Brain	216	7.0	0.22	7.7	0.24	168	4.7	0.17	5.2	0.18
Endocrine System	239	7.6	0.23	8.5	0.25	678	20.5	0.36	22.1	0.38
Thyroid gland	209	6.7	0.21	7.5	0.23	646	19.5	0.35	21.1	0.37
Lymphomas	765	24.6	0.41	28.3	0.46	645	17.3	0.31	19.8	0.35
Hodgkin lymphoma	87	2.9	0.14	3.1	0.15	75	2.4	0.13	2.5	0.13
Non-Hodgkin lymphoma	678	21.7	0.38	25.2	0.44	570	14.9	0.29	17.3	0.33
Multiple Myeloma	296	9.4	0.25	11.1	0.29	277	7.0	0.19	8.3	0.22
Leukemias	485	15.8	0.33	17.9	0.37	364	9.8	0.24	11.0	0.26
Acute lymphocytic	47	1.7	0.11	1.5	0.10	41	1.4	0.10	1.3	0.09
Chronic lymphocytic	166	5.3	0.19	6.3	0.22	112	2.8	0.12	3.3	0.14
Acute myeloid	147	4.8	0.18	5.5	0.20	121	3.3	0.14	3.7	0.15
Chronic myeloid	62	2.0	0.12	2.3	0.13	53	1.4	0.09	1.6	0.10
Other leukemias	62	2.0	0.12	2.3	0.14	38	1.0	0.07	1.1	0.08
Mesothelioma	35	1.2	0.09	1.4	0.11	15	0.4	0.04	0.4	0.05
Kaposi Sarcoma	18	0.6	0.07	0.6	0.07	3	0.1	0.02	0.1	0.02
Ill-Defined & Unknown	574	19.0	0.36	22.3	0.42	569	14.3	0.27	16.5	0.31
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	274	8.8	0.25	10.0	0.27	592	15.7	0.30	18.1	0.34
Breast (<i>in situ</i>)	5	0.2	0.03	0.2	0.04	1,128	30.2	0.42	35.6	0.48

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Maryland, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	10,737	515.5	2.30	611.6	2.67	10,499	463.0	2.14	538.5	2.41
Oral Cavity & Pharynx	446	20.6	0.45	25.5	0.55	168	7.1	0.26	8.4	0.30
Lip	13	0.6	0.08	0.7	0.09	8	0.3	0.05	0.4	0.06
Tongue	166	7.5	0.27	9.4	0.33	60	2.6	0.16	3.0	0.18
Major salivary gland	34	1.7	0.14	2.0	0.16	19	0.9	0.10	1.0	0.11
Floor of mouth	14	0.6	0.08	0.8	0.10	7	0.3	0.05	0.4	0.06
Gum & other mouth	45	2.1	0.14	2.5	0.17	37	1.5	0.11	1.7	0.13
Nasopharynx	10	0.5	0.07	0.6	0.08	3	0.1	0.04	0.2	0.04
Oropharynx	31	1.4	0.12	1.8	0.14	8	0.4	0.06	0.4	0.07
Hypopharynx	22	1.0	0.09	1.2	0.12	6	0.2	0.05	0.3	0.06
Digestive System	1,889	91.4	0.97	108.7	1.13	1,522	63.7	0.77	74.7	0.88
Esophagus	191	9.0	0.30	10.7	0.35	53	2.1	0.13	2.5	0.16
Stomach	154	7.4	0.28	8.8	0.32	86	3.6	0.18	4.2	0.21
Small intestine	55	2.6	0.16	3.2	0.19	44	1.9	0.14	2.3	0.16
Colon (excl. rectum)	539	26.9	0.54	31.6	0.62	593	25.2	0.49	29.1	0.55
Rectum & rectosigmoid	262	13.1	0.38	15.5	0.44	190	8.5	0.29	10.1	0.34
Anus, anal canal, & anorectum	31	1.5	0.12	1.8	0.15	63	2.7	0.16	3.2	0.19
Liver	211	9.3	0.29	11.6	0.36	74	3.1	0.17	3.6	0.19
Gallbladder	13	0.7	0.08	0.7	0.09	22	0.8	0.08	1.0	0.10
Pancreas	328	15.6	0.40	18.5	0.46	287	11.4	0.31	13.4	0.36
Respiratory System	1,465	69.1	0.83	82.1	0.97	1,460	58.1	0.70	69.2	0.82
Larynx	104	4.8	0.21	5.9	0.26	27	1.1	0.10	1.4	0.12
Lung & bronchus	1,335	63.0	0.79	74.7	0.92	1,415	56.1	0.68	66.8	0.81
Bones & Joints	23	1.4	0.14	1.4	0.13	18	1.1	0.12	1.1	0.12
Soft Tissue (incl. heart)	78	4.3	0.22	4.8	0.24	58	2.9	0.18	3.1	0.19
Skin (excl. basal & sq.)	1,059	52.7	0.75	61.4	0.86	714	34.6	0.62	39.2	0.68
Melanoma of the skin	1,009	50.1	0.73	58.5	0.83	685	33.4	0.61	37.8	0.66
Breast (excl. <i>in situ</i>)	31	1.5	0.12	1.8	0.14	3,114	141.1	1.20	165.0	1.36
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,230	53.7	0.72	63.8	0.83
Cervix uteri	N/A	N/A	N/A	N/A	N/A	114	6.5	0.29	6.9	0.30
Uterus corpus	N/A	N/A	N/A	N/A	N/A	683	28.4	0.51	34.7	0.60
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	18	0.7	0.08	0.9	0.09
Ovary	N/A	N/A	N/A	N/A	N/A	268	11.9	0.34	14.0	0.39
Male Genital System	2,744	123.3	1.08	150.5	1.30	N/A	N/A	N/A	N/A	N/A
Prostate	2,631	115.6	1.03	142.7	1.25	N/A	N/A	N/A	N/A	N/A
Testis	97	6.8	0.32	6.8	0.31	N/A	N/A	N/A	N/A	N/A
Penis	12	0.6	0.08	0.7	0.09	N/A	N/A	N/A	N/A	N/A
Urinary System	1,194	58.4	0.78	68.8	0.90	499	20.9	0.44	24.4	0.50
Bladder (incl. <i>in situ</i>)	710	34.6	0.59	40.7	0.69	220	8.6	0.27	10.2	0.32
Kidney & renal pelvis	452	22.2	0.49	26.1	0.56	264	11.7	0.34	13.5	0.38
Ureter	16	0.8	0.09	0.9	0.10	10	0.4	0.05	0.5	0.07
Eye & Orbit	15	0.8	0.10	0.9	0.11	16	0.8	0.10	0.9	0.10
Brain & Other CNS	160	8.9	0.33	9.7	0.35	125	6.2	0.27	6.8	0.28
Brain	152	8.3	0.32	9.2	0.34	118	5.8	0.26	6.4	0.27
Endocrine System	162	9.0	0.33	10.0	0.36	407	23.5	0.55	25.1	0.57
Thyroid gland	148	8.2	0.32	9.2	0.34	390	22.5	0.54	24.2	0.56
Lymphomas	528	26.8	0.54	31.0	0.61	419	18.8	0.43	21.5	0.48
Hodgkin lymphoma	50	3.1	0.20	3.3	0.21	41	2.6	0.19	2.6	0.19
Non-Hodgkin lymphoma	478	23.7	0.50	27.7	0.57	379	16.2	0.39	18.8	0.44
Multiple Myeloma	160	7.7	0.28	9.2	0.33	126	5.1	0.21	6.0	0.24
Leukemias	341	17.6	0.44	20.1	0.49	238	10.5	0.33	11.9	0.35
Acute lymphocytic	24	1.7	0.16	1.5	0.14	22	1.4	0.14	1.3	0.13
Chronic lymphocytic	131	6.3	0.25	7.5	0.30	86	3.4	0.17	4.0	0.20
Acute myeloid	98	5.0	0.23	5.7	0.26	74	3.3	0.18	3.8	0.20
Chronic myeloid	42	2.2	0.16	2.5	0.18	32	1.4	0.12	1.7	0.14
Other leukemias	45	2.4	0.16	2.7	0.18	24	1.0	0.10	1.2	0.11
Mesothelioma	30	1.5	0.13	1.8	0.14	11	0.5	0.06	0.6	0.07
Kaposi Sarcoma	3	0.2	0.06	0.2	0.06	*	*	*	*	*
Ill-Defined & Unknown	408	20.3	0.46	23.7	0.53	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	175	9.2	0.33	10.4	0.36	344	15.6	0.40	18.0	0.45
Breast (<i>in situ</i>)	2	0.1	0.04	0.1	0.04	646	30.5	0.57	35.8	0.65

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Maryland, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	4,317	523.2	3.78	631.3	4.45	4,514	406.7	2.78	478.6	3.21
Oral Cavity & Pharynx	107	12.6	0.57	15.3	0.68	55	4.9	0.31	5.8	0.35
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	26	3.0	0.28	3.7	0.33	12	1.0	0.13	1.2	0.16
Major salivary gland	10	1.3	0.19	1.5	0.22	14	1.3	0.16	1.5	0.17
Floor of mouth	4	0.4	0.11	0.5	0.13	1	0.1	0.05	0.1	0.05
Gum & other mouth	13	1.6	0.21	2.0	0.25	11	1.0	0.14	1.1	0.16
Nasopharynx	7	0.8	0.14	0.9	0.16	5	0.5	0.10	0.5	0.11
Oropharynx	11	1.3	0.18	1.6	0.22	2	0.2	0.06	0.2	0.07
Hypopharynx	12	1.5	0.20	1.8	0.24	2	0.2	0.06	0.3	0.07
Digestive System	892	110.5	1.76	132.8	2.07	834	75.0	1.19	89.5	1.40
Esophagus	38	4.9	0.38	5.9	0.45	21	1.8	0.18	2.2	0.22
Stomach	83	10.9	0.57	12.9	0.66	88	8.0	0.39	9.4	0.45
Small intestine	39	4.8	0.36	5.7	0.43	39	3.6	0.26	4.2	0.30
Colon (excl. rectum)	260	33.8	1.00	39.8	1.15	287	26.1	0.71	30.9	0.82
Rectum & rectosigmoid	103	12.5	0.58	14.9	0.68	94	8.5	0.40	10.0	0.47
Anus, anal canal, & anorectum	19	2.2	0.24	2.5	0.26	22	1.9	0.18	2.3	0.22
Liver	159	16.9	0.63	21.6	0.78	56	4.7	0.29	5.8	0.35
Gallbladder	9	1.3	0.20	1.4	0.22	19	1.7	0.18	2.0	0.21
Pancreas	141	17.9	0.72	21.5	0.84	164	14.9	0.53	17.8	0.63
Respiratory System	525	68.3	1.42	81.5	1.66	545	48.7	0.96	58.4	1.13
Larynx	47	5.9	0.41	7.2	0.49	15	1.3	0.15	1.6	0.18
Lung & bronchus	468	61.2	1.35	72.9	1.57	525	46.9	0.94	56.3	1.11
Bones & Joints	10	1.2	0.18	1.3	0.18	7	0.7	0.12	0.8	0.13
Soft Tissue (incl. heart)	31	3.9	0.33	4.3	0.36	30	2.8	0.24	3.1	0.25
Skin (excl. basal & sq.)	20	2.7	0.28	3.0	0.32	18	1.7	0.18	1.9	0.21
Melanoma of the skin	10	1.4	0.21	1.6	0.23	8	0.7	0.11	0.8	0.13
Breast (excl. <i>in situ</i>)	18	2.4	0.27	2.8	0.31	1,493	134.0	1.59	157.4	1.83
Female Genital System	N/A	N/A	N/A	N/A	N/A	571	49.3	0.95	59.3	1.12
Cervix uteri	N/A	N/A	N/A	N/A	N/A	75	7.0	0.37	7.8	0.40
Uterus corpus	N/A	N/A	N/A	N/A	N/A	320	26.7	0.69	33.0	0.83
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	22	1.9	0.18	2.3	0.22
Ovary	N/A	N/A	N/A	N/A	N/A	100	8.9	0.41	10.6	0.48
Male Genital System	1,742	197.4	2.23	245.8	2.70	N/A	N/A	N/A	N/A	N/A
Prostate	1,724	195.1	2.22	243.4	2.69	N/A	N/A	N/A	N/A	N/A
Testis	11	1.3	0.17	1.3	0.17	N/A	N/A	N/A	N/A	N/A
Penis	6	0.8	0.16	1.0	0.19	N/A	N/A	N/A	N/A	N/A
Urinary System	351	44.9	1.14	53.3	1.33	230	21.0	0.64	24.6	0.73
Bladder (incl. <i>in situ</i>)	140	19.6	0.79	23.1	0.92	75	7.0	0.37	8.2	0.43
Kidney & renal pelvis	201	24.0	0.80	28.6	0.93	150	13.6	0.51	15.9	0.58
Ureter	3	0.5	0.13	0.6	0.15	2	0.1	0.05	0.2	0.06
Eye & Orbit	1	0.2	0.07	0.2	0.08	1	0.1	0.05	0.1	0.05
Brain & Other CNS	40	4.8	0.36	5.3	0.39	35	3.4	0.26	3.6	0.28
Brain	37	4.5	0.34	4.9	0.38	32	3.0	0.25	3.3	0.27
Endocrine System	46	5.5	0.38	6.3	0.42	148	14.2	0.53	15.4	0.57
Thyroid gland	36	4.3	0.33	4.9	0.38	137	13.2	0.52	14.3	0.55
Lymphomas	166	20.0	0.73	22.8	0.82	163	15.1	0.54	17.3	0.61
Hodgkin lymphoma	27	3.1	0.28	3.3	0.29	26	2.6	0.23	2.7	0.24
Non-Hodgkin lymphoma	139	16.8	0.67	19.5	0.77	137	12.5	0.49	14.6	0.56
Multiple Myeloma	121	16.0	0.69	18.8	0.80	133	11.9	0.48	14.2	0.56
Leukemias	98	12.6	0.60	14.2	0.68	92	8.7	0.41	9.7	0.46
Acute lymphocytic	9	1.0	0.15	0.9	0.14	9	1.0	0.15	0.9	0.14
Chronic lymphocytic	27	3.7	0.34	4.4	0.39	22	2.0	0.20	2.3	0.23
Acute myeloid	35	4.4	0.35	5.0	0.40	35	3.2	0.25	3.7	0.28
Chronic myeloid	15	1.8	0.23	2.1	0.26	15	1.4	0.17	1.6	0.19
Other leukemias	13	1.6	0.21	1.8	0.24	11	1.0	0.14	1.2	0.16
Mesothelioma	3	0.5	0.13	0.6	0.15	3	0.2	0.06	0.3	0.07
Kaposi Sarcoma	12	1.5	0.19	1.5	0.20	2	0.2	0.06	0.2	0.06
Ill-Defined & Unknown	131	18.2	0.76	21.4	0.88	156	14.8	0.54	17.1	0.62
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	72	9.4	0.53	10.7	0.59	178	16.5	0.57	19.0	0.64
Breast (<i>in situ</i>)	3	0.3	0.08	0.4	0.10	366	32.2	0.77	38.3	0.90

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Maryland, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	524	277.1	5.58	325.6	6.50	673	286.5	5.01	332.3	5.78
Oral Cavity & Pharynx	21	10.5	1.03	12.7	1.25	11	4.5	0.62	5.2	0.72
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	6	3.0	0.55	3.7	0.67	3	1.1	0.31	1.2	0.34
Major salivary gland	2	0.9	0.30	1.1	0.35	2	0.8	0.27	1.0	0.32
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	5	2.6	0.52	3.1	0.63	2	1.0	0.31	1.3	0.38
Nasopharynx	4	1.8	0.42	2.1	0.49	2	0.8	0.26	0.9	0.28
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	2	1.0	0.35	1.2	0.41	*	*	*	*	*
Digestive System	142	75.0	2.90	88.5	3.40	113	49.8	2.13	58.6	2.49
Esophagus	4	2.2	0.49	2.6	0.57	3	1.2	0.33	1.4	0.39
Stomach	23	12.4	1.21	14.4	1.39	17	7.2	0.80	8.6	0.95
Small intestine	4	1.8	0.42	2.1	0.49	3	1.5	0.37	1.6	0.40
Colon (excl. rectum)	39	20.7	1.52	24.4	1.78	30	13.1	1.09	15.3	1.27
Rectum & rectosigmoid	22	11.0	1.08	13.2	1.29	21	8.7	0.87	10.4	1.03
Anus, anal canal, & anorectum	*	*	*	*	*	1	0.5	0.22	0.6	0.25
Liver	23	12.0	1.14	14.5	1.35	10	4.6	0.65	5.3	0.75
Gallbladder	1	0.8	0.31	0.9	0.36	3	1.4	0.37	1.6	0.42
Pancreas	18	10.2	1.10	11.9	1.28	18	8.3	0.88	9.6	1.01
Respiratory System	65	35.7	2.03	42.1	2.37	54	23.6	1.47	28.0	1.72
Larynx	3	1.8	0.47	2.2	0.55	*	*	*	*	*
Lung & bronchus	60	32.7	1.94	38.6	2.27	53	23.2	1.45	27.5	1.71
Bones & Joints	1	0.8	0.31	0.9	0.34	*	*	*	*	*
Soft Tissue (incl. heart)	4	2.0	0.47	2.1	0.49	4	1.9	0.41	2.1	0.45
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	4	2.2	0.50	2.4	0.56	1	0.6	0.25	0.8	0.29
Breast (excl. <i>in situ</i>)	1	0.6	0.25	0.7	0.29	243	100.1	2.91	117.1	3.39
Female Genital System	N/A	N/A	N/A	N/A	N/A	87	36.2	1.76	42.7	2.06
Cervix uteri	N/A	N/A	N/A	N/A	N/A	10	4.2	0.59	4.8	0.67
Uterus corpus	N/A	N/A	N/A	N/A	N/A	46	18.8	1.26	22.6	1.51
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	22	9.4	0.90	10.8	1.03
Male Genital System	133	67.7	2.70	82.2	3.23	N/A	N/A	N/A	N/A	N/A
Prostate	128	65.0	2.65	79.3	3.18	N/A	N/A	N/A	N/A	N/A
Testis	4	2.0	0.45	2.0	0.45	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	45	25.4	1.74	29.4	2.01	23	10.0	0.95	11.6	1.10
Bladder (incl. <i>in situ</i>)	25	14.4	1.34	16.5	1.53	10	4.5	0.65	5.3	0.76
Kidney & renal pelvis	18	9.1	0.97	10.8	1.15	11	4.8	0.65	5.7	0.76
Ureter	2	1.3	0.41	1.4	0.46	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	12	6.0	0.81	6.5	0.88	8	3.4	0.57	3.7	0.61
Brain	10	4.9	0.71	5.4	0.79	7	3.0	0.53	3.2	0.56
Endocrine System	19	9.1	0.96	10.1	1.08	62	25.9	1.49	28.1	1.62
Thyroid gland	16	7.9	0.90	8.5	0.99	58	24.4	1.44	26.5	1.57
Lymphomas	31	16.7	1.37	18.8	1.55	28	12.6	1.07	14.2	1.20
Hodgkin lymphoma	5	2.7	0.52	2.6	0.51	3	1.2	0.34	1.2	0.34
Non-Hodgkin lymphoma	26	14.0	1.27	16.2	1.46	26	11.4	1.02	13.0	1.15
Multiple Myeloma	8	3.9	0.64	4.8	0.78	8	3.2	0.53	3.9	0.63
Leukemias	20	10.7	1.11	11.9	1.24	12	5.6	0.72	6.1	0.79
Acute lymphocytic	3	1.6	0.41	1.6	0.42	3	1.3	0.35	1.2	0.34
Chronic lymphocytic	3	1.8	0.46	2.1	0.54	*	*	*	*	*
Acute myeloid	9	5.1	0.77	5.9	0.89	5	2.1	0.46	2.4	0.50
Chronic myeloid	2	1.1	0.34	1.2	0.35	3	1.4	0.35	1.6	0.40
Other leukemias	2	1.1	0.37	1.1	0.38	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	15	9.5	1.13	10.7	1.28	17	8.1	0.89	9.1	1.00
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	13	7.2	0.93	8.0	1.04	34	14.8	1.15	17.1	1.32
Breast (<i>in situ</i>)	*	*	*	*	*	70	28.7	1.54	33.0	1.77

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Maryland, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	446	284.6	7.16	335.4	8.25	587	299.7	5.98	346.3	6.91
Oral Cavity & Pharynx	12	7.2	1.11	8.4	1.25	7	3.4	0.63	4.1	0.76
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	3	2.1	0.57	2.4	0.65	1	0.6	0.24	0.9	0.34
Major salivary gland	1	0.6	0.25	0.8	0.33	1	0.8	0.34	0.9	0.39
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	0.8	0.39	0.9	0.40	3	1.4	0.39	1.6	0.46
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	1	0.7	0.35	0.9	0.43	*	*	*	*	*
Digestive System	107	66.5	3.37	79.6	3.92	98	56.1	2.73	65.1	3.13
Esophagus	4	2.0	0.51	2.6	0.64	*	*	*	*	*
Stomach	22	14.1	1.58	16.6	1.81	16	9.4	1.13	10.4	1.26
Small intestine	2	1.5	0.50	1.6	0.54	2	0.9	0.31	1.2	0.39
Colon (excl. rectum)	25	13.8	1.44	16.7	1.69	30	16.2	1.44	19.0	1.66
Rectum & rectosigmoid	16	8.1	1.03	9.6	1.21	13	6.5	0.86	7.6	1.00
Anus, anal canal, & anorectum	*	*	*	*	*	2	1.5	0.45	1.8	0.53
Liver	16	11.2	1.45	13.4	1.68	7	4.7	0.81	5.4	0.93
Gallbladder	*	*	*	*	*	4	2.2	0.54	2.6	0.63
Pancreas	14	11.5	1.55	13.8	1.81	15	9.8	1.19	11.2	1.35
Respiratory System	28	22.3	2.14	26.1	2.45	32	19.5	1.65	23.3	1.93
Larynx	3	2.4	0.71	2.8	0.83	*	*	*	*	*
Lung & bronchus	23	18.8	1.98	21.9	2.26	30	18.7	1.62	22.4	1.89
Bones & Joints	2	0.8	0.28	0.8	0.29	2	0.7	0.25	0.7	0.28
Soft Tissue (incl. heart)	7	3.6	0.78	3.8	0.85	5	2.3	0.51	2.4	0.54
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	13	6.3	0.84	7.1	0.96
Melanoma of the skin	8	6.1	1.13	6.9	1.25	10	5.2	0.78	5.9	0.88
Breast (excl. <i>in situ</i>)	*	*	*	*	*	174	88.2	3.20	102.6	3.71
Female Genital System	N/A	N/A	N/A	N/A	N/A	91	44.3	2.25	51.3	2.60
Cervix uteri	N/A	N/A	N/A	N/A	N/A	22	9.2	0.94	9.7	1.02
Uterus corpus	N/A	N/A	N/A	N/A	N/A	44	21.5	1.55	25.7	1.84
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	3	1.4	0.42	1.7	0.51
Ovary	N/A	N/A	N/A	N/A	N/A	16	8.2	1.01	9.4	1.15
Male Genital System	135	89.3	3.99	108.4	4.66	N/A	N/A	N/A	N/A	N/A
Prostate	119	84.2	3.93	103.1	4.61	N/A	N/A	N/A	N/A	N/A
Testis	14	4.2	0.56	4.2	0.57	N/A	N/A	N/A	N/A	N/A
Penis	2	0.8	0.36	0.9	0.42	N/A	N/A	N/A	N/A	N/A
Urinary System	37	26.2	2.26	30.8	2.59	24	12.7	1.26	15.1	1.48
Bladder (incl. <i>in situ</i>)	14	12.3	1.68	13.9	1.85	6	3.9	0.76	4.6	0.89
Kidney & renal pelvis	22	12.9	1.45	15.8	1.75	17	8.3	0.97	9.8	1.14
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	15	6.1	0.84	6.8	0.96	11	5.0	0.75	5.5	0.85
Brain	15	5.8	0.83	6.5	0.95	10	4.6	0.70	5.1	0.81
Endocrine System	10	4.7	0.83	5.1	0.91	56	22.6	1.43	25.0	1.62
Thyroid gland	8	3.1	0.61	3.4	0.66	54	22.1	1.42	24.3	1.61
Lymphomas	35	20.4	1.89	23.5	2.16	28	14.7	1.35	17.0	1.55
Hodgkin lymphoma	4	1.6	0.42	1.6	0.46	5	1.9	0.40	2.1	0.44
Non-Hodgkin lymphoma	31	18.9	1.84	21.9	2.11	23	12.7	1.29	14.9	1.49
Multiple Myeloma	7	4.7	0.94	5.5	1.09	9	4.7	0.75	5.8	0.92
Leukemias	20	10.0	1.29	10.8	1.42	18	7.7	0.89	8.2	0.99
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	7	2.5	0.46	2.4	0.47
Chronic lymphocytic	3	2.0	0.65	2.4	0.74	1	0.9	0.35	1.0	0.40
Acute myeloid	4	2.9	0.78	3.2	0.84	6	2.6	0.51	2.9	0.58
Chronic myeloid	3	0.9	0.25	1.0	0.29	1	0.6	0.25	0.7	0.30
Other leukemias	*	*	*	*	*	2	1.0	0.37	1.1	0.42
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	2	1.0	0.45	1.1	0.49	*	*	*	*	*
Ill-Defined & Unknown	17	13.6	1.75	15.6	1.98	20	11.0	1.21	12.6	1.39
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	11	5.5	0.89	6.1	0.99	27	14.0	1.29	16.2	1.49
Breast (<i>in situ</i>)	*	*	*	*	*	39	18.1	1.36	21.5	1.62

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

MARYLAND

II-238 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Maryland, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	308	240.0	7.15	282.5	8.23	398	246.4	5.91	286.1	6.85
Oral Cavity & Pharynx	8	5.6	1.02	6.5	1.16	5	3.2	0.65	3.8	0.80
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	3	1.7	0.55	2.0	0.63	1	0.7	0.27	0.9	0.38
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	0.6	0.30	0.7	0.34	2	1.0	0.37	1.2	0.43
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	76	57.9	3.42	69.0	3.96	69	47.6	2.74	55.3	3.14
Esophagus	2	1.2	0.44	1.6	0.54	*	*	*	*	*
Stomach	15	12.0	1.59	14.1	1.82	11	8.0	1.15	8.9	1.28
Small intestine	1	1.2	0.51	1.3	0.55	1	0.8	0.33	1.0	0.41
Colon (excl. rectum)	17	11.1	1.37	13.5	1.63	20	13.3	1.41	15.5	1.62
Rectum & rectosigmoid	12	7.3	1.09	8.7	1.26	9	5.1	0.82	6.0	0.97
Anus, anal canal, & anorectum	*	*	*	*	*	2	1.3	0.46	1.6	0.54
Liver	12	10.3	1.51	12.3	1.75	5	4.2	0.86	4.8	0.97
Gallbladder	*	*	*	*	*	2	1.7	0.52	2.1	0.62
Pancreas	11	10.4	1.60	12.3	1.84	12	9.1	1.24	10.5	1.41
Respiratory System	21	19.9	2.20	23.4	2.53	23	16.3	1.62	19.8	1.91
Larynx	2	2.2	0.76	2.6	0.88	*	*	*	*	*
Lung & bronchus	17	17.0	2.04	19.8	2.34	22	15.7	1.59	19.0	1.88
Bones & Joints	2	0.5	0.19	0.4	0.16	*	*	*	*	*
Soft Tissue (incl. heart)	6	3.2	0.77	3.5	0.85	2	1.6	0.50	1.7	0.54
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	10	6.0	0.90	6.9	1.03
Melanoma of the skin	7	6.5	1.25	7.3	1.40	9	5.4	0.86	6.2	0.99
Breast (excl. <i>in situ</i>)	*	*	*	*	*	112	68.0	3.06	78.9	3.54
Female Genital System	N/A	N/A	N/A	N/A	N/A	66	39.1	2.29	45.6	2.68
Cervix uteri	N/A	N/A	N/A	N/A	N/A	16	8.1	0.96	8.5	1.05
Uterus corpus	N/A	N/A	N/A	N/A	N/A	31	18.1	1.52	21.9	1.83
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	1.2	0.41	1.5	0.52
Ovary	N/A	N/A	N/A	N/A	N/A	11	7.4	1.07	8.4	1.21
Male Genital System	85	68.5	3.80	82.9	4.43	N/A	N/A	N/A	N/A	N/A
Prostate	76	65.0	3.75	79.3	4.39	N/A	N/A	N/A	N/A	N/A
Testis	8	3.0	0.55	3.0	0.55	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	25	22.2	2.26	26.2	2.60	15	10.0	1.22	12.0	1.46
Bladder (incl. <i>in situ</i>)	10	10.8	1.71	12.1	1.89	4	3.6	0.79	4.2	0.92
Kidney & renal pelvis	15	10.5	1.41	12.9	1.70	10	6.1	0.91	7.4	1.10
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	11	5.7	0.92	6.5	1.05	8	4.8	0.82	5.4	0.95
Brain	11	5.5	0.91	6.3	1.04	7	4.3	0.77	4.9	0.89
Endocrine System	6	3.8	0.84	4.2	0.92	39	19.4	1.46	21.5	1.66
Thyroid gland	5	2.4	0.56	2.6	0.62	38	18.9	1.44	20.9	1.64
Lymphomas	26	19.0	1.99	22.0	2.28	19	11.4	1.27	13.2	1.47
Hodgkin lymphoma	3	1.5	0.45	1.6	0.49	3	1.2	0.34	1.3	0.35
Non-Hodgkin lymphoma	23	17.5	1.94	20.4	2.23	16	10.1	1.22	12.0	1.43
Multiple Myeloma	4	3.9	0.95	4.6	1.11	5	3.5	0.70	4.5	0.88
Leukemias	15	9.3	1.37	10.0	1.50	11	5.6	0.83	6.0	0.93
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	4	1.6	0.35	1.5	0.36
Chronic lymphocytic	2	2.0	0.70	2.3	0.80	*	*	*	*	*
Acute myeloid	4	2.8	0.81	3.1	0.86	4	2.0	0.50	2.3	0.58
Chronic myeloid	2	0.6	0.23	0.7	0.27	*	*	*	*	*
Other leukemias	*	*	*	*	*	1	0.9	0.39	0.9	0.43
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	12	11.8	1.74	13.5	1.97	13	9.1	1.21	10.5	1.40
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	7	4.0	0.83	4.4	0.89	18	11.8	1.31	13.6	1.51
Breast (<i>in situ</i>)	*	*	*	*	*	25	14.0	1.29	16.6	1.54

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Maryland, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	29	235.9	30.12	278.2	34.73	40	196.4	16.23	226.5	18.62
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	5	64.4	18.85	74.0	20.79	6	35.4	7.54	40.5	8.57
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	2	19.9	7.00	22.9	7.66	2	14.2	5.31	16.4	6.23
Rectum & rectosigmoid	*	*	*	*	*	1	5.7	2.51	6.1	2.67
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	2	17.7	8.33	21.1	10.30	4	22.8	5.80	27.1	6.61
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	2	16.8	8.28	19.8	10.21	4	22.1	5.76	26.3	6.56
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	14	65.4	9.16	76.4	10.73
Female Genital System	N/A	N/A	N/A	N/A	N/A	5	24.1	5.57	26.6	6.00
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	5.3	1.80	5.7	1.99
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2	15.0	4.76	16.5	5.08
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	13	91.1	15.22	111.5	18.41	N/A	N/A	N/A	N/A	N/A
Prostate	12	88.6	15.18	109.2	18.38	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	3	34.1	13.83	39.2	15.91	2	13.6	4.73	15.2	5.14
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	2	17.3	8.91	20.9	11.00	2	9.4	3.69	10.8	4.11
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	2	8.3	2.52	9.2	2.85
Thyroid gland	*	*	*	*	*	2	8.3	2.52	9.2	2.85
Lymphomas	*	*	*	*	*	2	7.7	3.69	9.4	4.65
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	1	5.3	2.04	6.6	2.60
Leukemias	1	6.1	3.75	6.7	4.33	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	2	6.6	2.46	8.0	2.98
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	1	6.5	2.89	7.4	3.17
Breast (<i>in situ</i>)	*	*	*	*	*	2	10.9	3.61	13.3	4.23

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


MARYLAND

II-240 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	6,797,484	6,827,280	6,863,560	6,885,720	6,894,883
Non-Hispanic White	5,062,923	5,041,626	5,022,096	4,997,218	4,968,216
Non-Hispanic Black	503,492	514,643	526,016	535,304	543,751
Non-Hispanic Asian/Pacific Islander (NH API)	457,097	474,151	492,038	503,841	516,897
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	8,085	8,093	8,135	8,182	8,148


All Races Population 2015–2019: 34,268,927
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	758,599	781,399	807,861	833,650	850,345
Hispanic White	602,051	619,666	640,292	660,525	672,197
Hispanic Black	120,141	124,241	129,079	133,656	137,432

Hispanic/Latino Population, Census 2010: 627,654
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

MASSACHUSETTS CANCER REGISTRY

Initial Operation: 1982
Population-based Data Available: 1982
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	112.0	113.6	110.7	104.9	105.2	109.3
Missing Race	1.8	1.5	2.2	1.4	1.5	1.7
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.2	1.7	1.6	1.7	4.9	2.4
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.6	Ovary	94.4
Oral Cavity & Pharynx	98.3	Prostate	96.8
Esophagus	96.1	Testis	99.8
Stomach	96.7	Bladder (incl. <i>in situ</i>)	97.5
Colon & Rectum	96.6	Kidney & Renal Pelvis	92.4
Liver	52.2	Brain & Other CNS	88.8
Pancreas	86.3	Brain & Other CNS (non-malig)	54.7
Lung & Bronchus	87.4	Thyroid	99.5
Melanomas of the Skin	99.4	Hodgkin Lymphoma	99.5
Female Breast (excl. <i>in situ</i>)	99.1	Non-Hodgkin Lymphoma	97.1
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	92.2
Cervix Uteri	98.5	Leukemias	86.8
Uterus Corpus & Uterus NOS	98.9		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Massachusetts, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	18,814	484.9	1.62	575.8	1.89	19,733	438.2	1.45	510.9	1.65
Oral Cavity & Pharynx	715	17.7	0.30	21.7	0.37	305	6.6	0.17	7.8	0.20
Lip	18	0.5	0.05	0.6	0.06	12	0.2	0.03	0.3	0.04
Tongue	225	5.5	0.17	6.8	0.20	93	2.0	0.10	2.4	0.11
Major salivary gland	61	1.6	0.10	1.9	0.11	43	1.0	0.07	1.1	0.08
Floor of mouth	35	0.8	0.06	1.1	0.08	16	0.3	0.04	0.4	0.05
Gum & other mouth	72	1.9	0.10	2.2	0.12	62	1.3	0.08	1.5	0.09
Nasopharynx	30	0.8	0.07	0.9	0.08	13	0.3	0.04	0.4	0.04
Oropharynx	49	1.1	0.07	1.4	0.09	8	0.2	0.03	0.2	0.03
Hypopharynx	40	1.0	0.07	1.2	0.09	11	0.2	0.03	0.3	0.04
Digestive System	3,648	95.1	0.72	113.1	0.84	2,887	61.6	0.53	72.2	0.61
Esophagus	359	9.2	0.22	11.0	0.26	107	2.2	0.10	2.6	0.12
Stomach	339	8.9	0.22	10.5	0.26	209	4.5	0.15	5.2	0.17
Small intestine	104	2.8	0.12	3.2	0.14	87	1.9	0.09	2.2	0.11
Colon (excl. rectum)	959	25.8	0.38	30.2	0.44	1,013	21.7	0.32	25.2	0.36
Rectum & rectosigmoid	471	12.4	0.26	14.7	0.30	357	8.0	0.20	9.4	0.23
Anus, anal canal, & anorectum	66	1.7	0.10	2.0	0.11	109	2.3	0.10	2.8	0.12
Liver	463	11.3	0.24	14.0	0.29	126	2.6	0.11	3.1	0.13
Gallbladder	32	0.9	0.07	1.0	0.08	66	1.4	0.08	1.6	0.09
Pancreas	614	15.9	0.29	19.0	0.35	581	12.0	0.23	14.1	0.27
Respiratory System	2,668	69.1	0.61	82.1	0.72	2,896	60.1	0.51	71.5	0.60
Larynx	199	4.9	0.16	6.0	0.19	53	1.1	0.07	1.4	0.09
Lung & bronchus	2,432	63.2	0.59	75.0	0.69	2,816	58.3	0.50	69.5	0.59
Bones & Joints	38	1.1	0.08	1.1	0.08	30	0.8	0.07	0.8	0.07
Soft Tissue (incl. heart)	138	3.8	0.15	4.2	0.16	108	2.6	0.12	2.9	0.13
Skin (excl. basal & sq.)	1,056	28.3	0.40	33.0	0.46	831	19.0	0.31	21.8	0.34
Melanoma of the skin	970	25.9	0.38	30.3	0.44	773	17.8	0.30	20.4	0.33
Breast (excl. <i>in situ</i>)	54	1.4	0.09	1.7	0.10	6,026	137.7	0.82	161.0	0.94
Female Genital System	N/A	N/A	N/A	N/A	N/A	2,307	50.4	0.49	60.3	0.57
Cervix uteri	N/A	N/A	N/A	N/A	N/A	203	5.4	0.18	5.8	0.18
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,350	28.6	0.36	35.1	0.43
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	38	0.8	0.06	1.0	0.07
Ovary	N/A	N/A	N/A	N/A	N/A	452	10.0	0.22	11.9	0.25
Male Genital System	4,921	118.3	0.77	145.3	0.93	N/A	N/A	N/A	N/A	N/A
Prostate	4,697	111.6	0.75	138.5	0.91	N/A	N/A	N/A	N/A	N/A
Testis	186	5.6	0.19	5.6	0.18	N/A	N/A	N/A	N/A	N/A
Penis	31	0.9	0.07	1.0	0.08	N/A	N/A	N/A	N/A	N/A
Urinary System	2,281	60.5	0.58	71.1	0.67	1,004	21.3	0.31	25.1	0.36
Bladder (incl. <i>in situ</i>)	1,383	37.3	0.46	43.6	0.53	501	10.3	0.21	12.2	0.25
Kidney & renal pelvis	847	21.8	0.35	25.9	0.40	470	10.3	0.22	12.2	0.25
Ureter	29	0.8	0.07	1.0	0.08	21	0.4	0.04	0.5	0.05
Eye & Orbit	34	0.9	0.07	1.0	0.08	29	0.7	0.06	0.8	0.07
Brain & Other CNS	298	8.2	0.22	9.1	0.24	245	6.0	0.18	6.5	0.19
Brain	286	7.8	0.21	8.7	0.23	232	5.6	0.17	6.2	0.18
Endocrine System	390	10.7	0.25	11.9	0.27	988	26.1	0.39	28.2	0.40
Thyroid gland	358	9.7	0.24	10.9	0.26	958	25.3	0.38	27.4	0.40
Lymphomas	986	26.6	0.39	30.5	0.44	806	18.1	0.30	20.8	0.33
Hodgkin lymphoma	109	3.1	0.14	3.3	0.14	95	2.6	0.12	2.7	0.12
Non-Hodgkin lymphoma	877	23.4	0.36	27.2	0.41	711	15.5	0.27	18.1	0.31
Multiple Myeloma	316	8.3	0.21	9.8	0.25	251	5.2	0.15	6.3	0.18
Leukemias	600	16.4	0.31	18.6	0.34	439	9.9	0.22	11.1	0.24
Acute lymphocytic	52	1.7	0.11	1.5	0.10	46	1.4	0.10	1.3	0.09
Chronic lymphocytic	214	5.6	0.17	6.6	0.21	148	3.0	0.11	3.6	0.13
Acute myeloid	182	5.0	0.17	5.7	0.19	144	3.2	0.13	3.7	0.14
Chronic myeloid	83	2.3	0.12	2.6	0.13	56	1.3	0.08	1.5	0.09
Other leukemias	70	1.9	0.10	2.2	0.12	44	0.9	0.07	1.1	0.07
Mesothelioma	60	1.7	0.10	2.0	0.11	21	0.4	0.04	0.5	0.05
Kaposi Sarcoma	19	0.5	0.06	0.6	0.06	4	0.1	0.02	0.1	0.02
Ill-Defined & Unknown	591	16.3	0.31	18.9	0.35	559	11.4	0.22	13.2	0.26
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	274	7.5	0.21	8.4	0.23	540	12.5	0.25	14.3	0.28
Breast (<i>in situ</i>)	7	0.2	0.04	0.2	0.04	1,568	37.3	0.44	43.6	0.50

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Massachusetts, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	15,811	484.5	1.78	574.1	2.06	16,643	448.0	1.65	522.1	1.86
Oral Cavity & Pharynx	617	18.3	0.34	22.5	0.41	255	6.6	0.20	7.9	0.23
Lip	17	0.5	0.06	0.6	0.07	11	0.3	0.04	0.3	0.04
Tongue	198	5.8	0.19	7.1	0.23	81	2.2	0.11	2.5	0.13
Major salivary gland	50	1.6	0.10	1.8	0.12	33	0.9	0.08	1.1	0.09
Floor of mouth	28	0.8	0.07	1.0	0.09	15	0.4	0.04	0.5	0.05
Gum & other mouth	64	2.0	0.11	2.4	0.13	51	1.2	0.08	1.5	0.10
Nasopharynx	17	0.6	0.06	0.7	0.07	8	0.2	0.04	0.3	0.04
Oropharynx	44	1.2	0.09	1.6	0.11	6	0.2	0.03	0.2	0.03
Hypopharynx	33	0.9	0.07	1.2	0.09	11	0.2	0.03	0.3	0.04
Digestive System	2,986	92.4	0.78	109.6	0.91	2,388	60.4	0.58	70.8	0.67
Esophagus	325	9.7	0.25	11.7	0.29	95	2.3	0.11	2.8	0.13
Stomach	249	7.7	0.22	9.1	0.26	146	3.7	0.15	4.3	0.16
Small intestine	84	2.7	0.14	3.1	0.15	71	1.8	0.10	2.2	0.12
Colon (excl. rectum)	799	25.6	0.42	29.9	0.48	864	22.0	0.35	25.6	0.40
Rectum & rectosigmoid	389	12.4	0.29	14.7	0.34	292	8.0	0.22	9.4	0.25
Anus, anal canal, & anorectum	56	1.7	0.11	2.1	0.13	93	2.4	0.12	2.9	0.14
Liver	334	9.6	0.24	11.8	0.29	87	2.1	0.11	2.6	0.13
Gallbladder	24	0.8	0.07	0.9	0.08	49	1.2	0.08	1.4	0.09
Pancreas	529	16.1	0.32	19.1	0.38	495	12.0	0.25	14.1	0.29
Respiratory System	2,328	70.3	0.67	83.5	0.78	2,602	63.6	0.57	75.7	0.67
Larynx	165	4.8	0.17	5.9	0.21	46	1.2	0.08	1.4	0.10
Lung & bronchus	2,132	64.4	0.64	76.4	0.75	2,534	61.8	0.56	73.6	0.66
Bones & Joints	31	1.2	0.10	1.2	0.10	21	0.7	0.08	0.8	0.08
Soft Tissue (incl. heart)	113	3.8	0.17	4.3	0.18	86	2.7	0.14	2.9	0.14
Skin (excl. basal & sq.)	947	30.4	0.46	35.2	0.52	724	20.8	0.37	23.7	0.41
Melanoma of the skin	873	28.0	0.44	32.5	0.50	676	19.6	0.36	22.3	0.39
Breast (excl. <i>in situ</i>)	45	1.4	0.10	1.7	0.11	5,108	143.0	0.95	167.2	1.07
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,889	49.9	0.54	59.8	0.63
Cervix uteri	N/A	N/A	N/A	N/A	N/A	134	4.7	0.19	5.0	0.20
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,124	28.7	0.40	35.3	0.48
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	29	0.7	0.06	0.9	0.07
Ovary	N/A	N/A	N/A	N/A	N/A	376	10.2	0.25	12.0	0.28
Male Genital System	3,953	112.9	0.83	138.1	0.99	N/A	N/A	N/A	N/A	N/A
Prostate	3,763	105.0	0.78	130.1	0.96	N/A	N/A	N/A	N/A	N/A
Testis	160	7.0	0.25	6.9	0.24	N/A	N/A	N/A	N/A	N/A
Penis	25	0.8	0.07	0.9	0.08	N/A	N/A	N/A	N/A	N/A
Urinary System	2,019	63.0	0.65	74.0	0.74	865	21.9	0.35	25.8	0.40
Bladder (incl. <i>in situ</i>)	1,253	39.1	0.51	45.8	0.58	448	10.9	0.24	12.9	0.28
Kidney & renal pelvis	720	22.4	0.39	26.5	0.45	388	10.3	0.25	12.1	0.28
Ureter	26	0.9	0.08	1.0	0.09	19	0.5	0.05	0.5	0.05
Eye & Orbit	30	1.0	0.08	1.1	0.09	26	0.8	0.07	0.9	0.08
Brain & Other CNS	252	8.6	0.26	9.6	0.27	206	6.4	0.21	6.9	0.22
Brain	243	8.2	0.25	9.2	0.27	197	6.0	0.21	6.6	0.22
Endocrine System	313	11.0	0.29	12.2	0.31	731	25.7	0.45	27.6	0.47
Thyroid gland	289	10.0	0.28	11.3	0.30	710	25.0	0.45	26.9	0.46
Lymphomas	837	27.3	0.44	31.3	0.49	678	18.7	0.34	21.3	0.38
Hodgkin lymphoma	84	3.2	0.16	3.4	0.17	76	2.9	0.16	2.9	0.15
Non-Hodgkin lymphoma	752	24.0	0.41	27.9	0.46	603	15.7	0.30	18.4	0.34
Multiple Myeloma	251	7.7	0.22	9.1	0.26	187	4.6	0.16	5.5	0.18
Leukemias	508	16.7	0.35	19.0	0.38	368	10.0	0.25	11.3	0.27
Acute lymphocytic	34	1.5	0.12	1.4	0.11	33	1.4	0.12	1.3	0.10
Chronic lymphocytic	192	5.9	0.20	7.0	0.23	130	3.1	0.13	3.8	0.15
Acute myeloid	155	5.1	0.19	5.8	0.21	121	3.3	0.14	3.7	0.15
Chronic myeloid	68	2.3	0.13	2.6	0.14	46	1.3	0.09	1.5	0.10
Other leukemias	58	1.9	0.12	2.2	0.13	38	0.9	0.07	1.1	0.08
Mesothelioma	56	1.8	0.11	2.1	0.13	19	0.5	0.05	0.5	0.06
Kaposi Sarcoma	9	0.3	0.05	0.4	0.05	2	0.0	0.01	0.0	0.02
Ill-Defined & Unknown	518	16.6	0.33	19.3	0.38	487	11.6	0.25	13.5	0.28
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	221	7.5	0.24	8.4	0.26	421	12.0	0.28	13.8	0.31
Breast (<i>in situ</i>)	6	0.2	0.04	0.2	0.04	1,294	38.6	0.51	45.0	0.57

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Massachusetts, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,007	479.4	7.21	581.1	8.50	1,013	388.1	5.55	453.0	6.40
Oral Cavity & Pharynx	26	12.4	1.17	14.7	1.34	13	4.7	0.60	5.7	0.72
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	7	3.7	0.67	4.2	0.74	1	0.5	0.20	0.6	0.24
Major salivary gland	3	1.5	0.41	1.6	0.45	4	1.4	0.33	1.6	0.38
Floor of mouth	2	1.0	0.35	1.2	0.40	*	*	*	*	*
Gum & other mouth	3	1.5	0.41	1.8	0.47	4	1.4	0.32	1.8	0.40
Nasopharynx	2	0.8	0.31	0.9	0.35	*	*	*	*	*
Oropharynx	2	0.8	0.28	1.0	0.33	*	*	*	*	*
Hypopharynx	2	0.9	0.31	1.1	0.37	*	*	*	*	*
Digestive System	232	113.0	3.54	136.1	4.16	190	73.8	2.44	86.6	2.83
Esophagus	13	6.6	0.87	8.0	1.01	5	2.1	0.41	2.6	0.49
Stomach	29	15.2	1.36	18.1	1.58	24	9.5	0.87	11.1	1.01
Small intestine	9	4.3	0.65	5.1	0.76	8	3.1	0.49	3.8	0.59
Colon (excl. rectum)	62	31.1	1.89	37.5	2.23	57	22.4	1.36	26.0	1.56
Rectum & rectosigmoid	27	12.2	1.11	14.5	1.30	21	8.1	0.80	9.6	0.94
Anus, anal canal, & anorectum	3	1.5	0.38	1.8	0.44	5	2.1	0.41	2.5	0.47
Liver	36	16.0	1.25	19.9	1.52	12	4.4	0.58	5.3	0.69
Gallbladder	3	1.6	0.44	1.8	0.50	8	3.1	0.50	3.7	0.58
Pancreas	36	17.8	1.42	21.5	1.66	35	14.0	1.08	16.1	1.23
Respiratory System	113	58.1	2.62	69.9	3.05	106	39.9	1.77	48.5	2.12
Larynx	10	4.8	0.71	5.9	0.84	4	1.3	0.31	1.7	0.39
Lung & bronchus	101	52.6	2.51	63.2	2.92	101	38.1	1.73	46.3	2.07
Bones & Joints	2	0.7	0.22	0.8	0.27	3	1.1	0.30	1.1	0.30
Soft Tissue (incl. heart)	8	4.0	0.67	4.3	0.74	7	2.8	0.46	3.0	0.50
Skin (excl. basal & sq.)	4	1.7	0.40	2.0	0.48	4	1.5	0.35	1.6	0.38
Melanoma of the skin	*	*	*	*	*	1	0.6	0.23	0.6	0.24
Breast (excl. <i>in situ</i>)	5	2.4	0.53	2.8	0.61	319	122.4	3.12	141.2	3.55
Female Genital System	N/A	N/A	N/A	N/A	N/A	138	51.7	2.01	62.1	2.38
Cervix uteri	N/A	N/A	N/A	N/A	N/A	23	9.1	0.86	10.3	0.96
Uterus corpus	N/A	N/A	N/A	N/A	N/A	76	28.0	1.47	34.5	1.78
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	4	1.5	0.33	1.9	0.41
Ovary	N/A	N/A	N/A	N/A	N/A	23	8.7	0.83	10.1	0.95
Male Genital System	394	179.4	4.30	224.4	5.20	N/A	N/A	N/A	N/A	N/A
Prostate	389	177.3	4.27	222.0	5.17	N/A	N/A	N/A	N/A	N/A
Testis	2	0.9	0.26	0.9	0.25	N/A	N/A	N/A	N/A	N/A
Penis	2	0.9	0.34	1.0	0.37	N/A	N/A	N/A	N/A	N/A
Urinary System	75	36.9	2.04	43.5	2.35	46	17.5	1.17	20.8	1.38
Bladder (incl. <i>in situ</i>)	27	15.4	1.41	18.1	1.61	15	6.0	0.70	7.1	0.82
Kidney & renal pelvis	46	21.0	1.46	24.9	1.69	29	10.9	0.92	13.0	1.08
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	11	4.4	0.63	4.9	0.71	11	4.3	0.59	4.5	0.62
Brain	10	3.9	0.60	4.5	0.68	10	4.0	0.57	4.2	0.60
Endocrine System	12	4.9	0.66	5.5	0.74	52	19.6	1.23	21.7	1.35
Thyroid gland	10	4.1	0.61	4.6	0.68	50	18.7	1.21	20.7	1.32
Lymphomas	40	17.5	1.31	20.4	1.52	41	15.8	1.12	18.1	1.27
Hodgkin lymphoma	7	3.1	0.53	3.3	0.58	6	2.3	0.43	2.4	0.44
Non-Hodgkin lymphoma	32	14.4	1.20	17.0	1.40	35	13.4	1.03	15.7	1.19
Multiple Myeloma	31	15.5	1.32	18.5	1.54	36	14.1	1.08	16.7	1.25
Leukemias	25	12.0	1.14	13.9	1.31	20	7.9	0.79	8.7	0.87
Acute lymphocytic	3	1.3	0.34	1.1	0.32	3	1.0	0.28	0.9	0.24
Chronic lymphocytic	6	2.8	0.55	3.4	0.66	5	2.1	0.41	2.4	0.47
Acute myeloid	7	3.5	0.64	4.0	0.72	5	1.9	0.39	2.1	0.43
Chronic myeloid	4	2.0	0.45	2.4	0.53	4	1.6	0.35	1.8	0.41
Other leukemias	5	2.4	0.52	3.0	0.62	3	1.3	0.32	1.4	0.36
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	5	2.8	0.58	3.0	0.63	*	*	*	*	*
Ill-Defined & Unknown	24	12.8	1.27	15.2	1.48	26	10.3	0.92	12.0	1.06
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	17	8.3	0.95	9.3	1.05	44	16.4	1.13	19.3	1.32
Breast (<i>in situ</i>)	*	*	*	*	*	90	34.2	1.64	40.2	1.90

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Massachusetts, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	543	310.5	6.22	364.7	7.23	650	291.4	5.25	337.4	6.10
Oral Cavity & Pharynx	25	12.7	1.18	15.1	1.40	14	6.0	0.74	7.1	0.88
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	6	3.0	0.57	3.4	0.64	5	2.1	0.45	2.6	0.55
Major salivary gland	2	1.1	0.33	1.4	0.40	2	0.6	0.21	0.7	0.27
Floor of mouth	1	0.7	0.28	0.8	0.34	*	*	*	*	*
Gum & other mouth	2	1.1	0.35	1.3	0.43	2	1.0	0.29	1.1	0.33
Nasopharynx	11	5.2	0.73	6.2	0.87	4	1.5	0.36	1.7	0.41
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	2	1.2	0.43	1.4	0.49	*	*	*	*	*
Digestive System	163	94.4	3.44	111.8	4.02	107	52.6	2.33	61.4	2.70
Esophagus	8	4.8	0.78	5.8	0.93	2	0.8	0.29	0.9	0.32
Stomach	24	15.1	1.43	17.3	1.61	13	6.4	0.81	7.3	0.93
Small intestine	3	1.7	0.45	2.0	0.54	*	*	*	*	*
Colon (excl. rectum)	34	20.3	1.62	24.1	1.89	34	16.6	1.30	19.2	1.50
Rectum & rectosigmoid	23	12.0	1.15	14.3	1.37	17	7.8	0.88	9.2	1.03
Anus, anal canal, & anorectum	*	*	*	*	*	1	0.5	0.23	0.7	0.28
Liver	40	22.4	1.66	27.0	1.96	11	5.6	0.76	6.7	0.90
Gallbladder	3	1.7	0.48	2.0	0.55	2	0.7	0.26	0.9	0.31
Pancreas	16	9.6	1.11	11.3	1.28	16	8.1	0.93	9.5	1.09
Respiratory System	90	55.2	2.72	65.4	3.17	60	30.4	1.80	35.7	2.09
Larynx	3	1.8	0.48	2.2	0.57	*	*	*	*	*
Lung & bronchus	84	52.1	2.65	61.9	3.08	58	29.7	1.78	34.8	2.06
Bones & Joints	2	0.9	0.29	1.0	0.32	3	1.3	0.33	1.3	0.36
Soft Tissue (incl. heart)	5	2.7	0.58	3.1	0.66	4	1.5	0.37	1.5	0.37
Skin (excl. basal & sq.)	3	1.6	0.45	1.9	0.50	4	1.5	0.37	1.7	0.41
Melanoma of the skin	2	0.8	0.32	0.9	0.34	2	0.8	0.28	0.9	0.30
Breast (excl. <i>in situ</i>)	2	1.0	0.37	1.2	0.43	223	96.8	2.96	112.2	3.45
Female Genital System	N/A	N/A	N/A	N/A	N/A	82	35.4	1.79	41.9	2.13
Cervix uteri	N/A	N/A	N/A	N/A	N/A	11	4.2	0.59	4.9	0.69
Uterus corpus	N/A	N/A	N/A	N/A	N/A	42	18.1	1.28	21.8	1.53
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	1	0.7	0.28	0.8	0.30
Ovary	N/A	N/A	N/A	N/A	N/A	21	9.3	0.92	11.0	1.09
Male Genital System	100	57.9	2.69	69.9	3.18	N/A	N/A	N/A	N/A	N/A
Prostate	95	56.0	2.66	67.9	3.15	N/A	N/A	N/A	N/A	N/A
Testis	3	1.1	0.29	1.1	0.29	N/A	N/A	N/A	N/A	N/A
Penis	1	0.7	0.29	0.9	0.37	N/A	N/A	N/A	N/A	N/A
Urinary System	44	26.1	1.83	30.3	2.11	18	8.8	0.95	10.4	1.11
Bladder (incl. <i>in situ</i>)	23	14.7	1.43	16.8	1.62	7	3.5	0.62	4.2	0.72
Kidney & renal pelvis	20	10.3	1.08	12.2	1.28	10	4.6	0.67	5.5	0.79
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	13	5.7	0.74	6.3	0.83	7	3.0	0.51	3.0	0.52
Brain	12	5.4	0.71	5.9	0.80	6	2.4	0.46	2.5	0.49
Endocrine System	25	11.2	1.04	12.3	1.15	70	27.3	1.49	30.3	1.69
Thyroid gland	22	9.6	0.95	10.5	1.06	68	26.5	1.46	29.6	1.67
Lymphomas	29	15.8	1.37	18.1	1.57	24	10.2	0.98	11.8	1.13
Hodgkin lymphoma	4	1.7	0.40	1.8	0.44	3	0.9	0.24	1.0	0.27
Non-Hodgkin lymphoma	25	14.1	1.30	16.3	1.51	21	9.3	0.95	10.8	1.10
Multiple Myeloma	7	3.9	0.71	4.6	0.82	7	3.2	0.57	3.8	0.67
Leukemias	19	9.6	1.04	10.3	1.13	14	6.2	0.77	6.8	0.85
Acute lymphocytic	4	1.9	0.42	1.6	0.36	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	3	1.4	0.41	1.8	0.49	2	1.2	0.37	1.5	0.42
Acute myeloid	7	3.7	0.66	3.9	0.71	6	2.7	0.52	3.0	0.57
Chronic myeloid	3	1.6	0.43	1.8	0.48	1	0.6	0.23	0.7	0.27
Other leukemias	2	1.1	0.35	1.2	0.41	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	17	11.0	1.25	12.7	1.43	13	6.9	0.86	7.9	0.99
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	11	5.4	0.76	6.0	0.85	22	10.0	0.99	11.3	1.12
Breast (<i>in situ</i>)	*	*	*	*	*	75	32.5	1.70	38.1	2.00

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Massachusetts, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	10	219.2	31.22	270.3	37.66	11	246.1	34.16	287.3	38.53
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	1	26.6	10.18	36.1	13.66	3	54.2	15.41	66.8	18.79
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	1	23.5	9.70	28.1	11.56
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	2	51.1	16.73	55.8	17.78	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	2	51.1	16.73	55.8	17.78	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	3	69.4	17.79	82.8	20.36
Female Genital System	N/A	N/A	N/A	N/A	N/A	1	32.2	12.60	38.1	14.56
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	3	63.7	16.14	80.1	20.06	N/A	N/A	N/A	N/A	N/A
Prostate	2	39.7	12.01	55.6	16.78	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	1	24.6	10.27	31.2	12.83	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	1	28.9	12.63	30.0	12.34
Thyroid gland	*	*	*	*	*	1	28.9	12.63	30.0	12.34
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	2	41.8	14.59	48.3	16.36

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Massachusetts, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	826	374.3	6.51	445.1	7.59	953	315.1	4.78	367.7	5.58
Oral Cavity & Pharynx	31	13.6	1.20	16.7	1.44	16	5.8	0.68	6.8	0.78
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	9	4.0	0.69	5.0	0.82	4	1.7	0.38	1.9	0.43
Major salivary gland	3	1.4	0.39	1.6	0.44	3	1.0	0.27	1.1	0.31
Floor of mouth	2	0.8	0.24	1.1	0.33	*	*	*	*	*
Gum & other mouth	2	0.9	0.33	1.0	0.38	4	1.4	0.34	1.6	0.40
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	1	0.6	0.27	0.8	0.33	*	*	*	*	*
Hypopharynx	3	1.5	0.42	1.8	0.47	*	*	*	*	*
Digestive System	197	91.7	3.26	109.5	3.80	154	55.4	2.09	65.0	2.43
Esophagus	9	3.9	0.65	4.8	0.77	2	1.0	0.30	1.1	0.34
Stomach	29	13.9	1.30	16.2	1.49	22	7.4	0.75	8.7	0.87
Small intestine	5	2.4	0.51	2.9	0.60	6	2.0	0.40	2.4	0.46
Colon (excl. rectum)	47	22.4	1.64	26.3	1.88	43	15.1	1.08	17.6	1.25
Rectum & rectosigmoid	23	9.6	0.99	11.4	1.16	20	6.8	0.70	7.9	0.81
Anus, anal canal, & anorectum	4	1.5	0.38	1.8	0.46	7	2.2	0.40	2.6	0.47
Liver	41	18.1	1.38	22.7	1.66	13	5.0	0.64	6.0	0.76
Gallbladder	2	1.2	0.43	1.3	0.45	6	2.1	0.38	2.5	0.46
Pancreas	22	11.0	1.17	13.2	1.37	23	9.2	0.89	10.9	1.04
Respiratory System	91	49.4	2.55	58.4	2.94	70	26.3	1.46	31.6	1.72
Larynx	14	6.7	0.87	8.3	1.04	2	0.5	0.19	0.7	0.23
Lung & bronchus	75	42.0	2.38	49.4	2.73	67	25.3	1.44	30.4	1.70
Bones & Joints	3	0.7	0.19	0.7	0.21	3	0.8	0.23	0.7	0.23
Soft Tissue (incl. heart)	7	2.4	0.49	2.6	0.54	8	2.4	0.40	2.6	0.45
Skin (excl. basal & sq.)	9	3.9	0.69	4.5	0.78	11	3.6	0.51	4.3	0.61
Melanoma of the skin	6	3.1	0.63	3.6	0.72	9	2.9	0.46	3.4	0.54
Breast (excl. <i>in situ</i>)	3	1.3	0.40	1.5	0.47	287	92.3	2.53	108.2	2.96
Female Genital System	N/A	N/A	N/A	N/A	N/A	143	45.8	1.78	54.3	2.12
Cervix uteri	N/A	N/A	N/A	N/A	N/A	27	8.0	0.71	8.6	0.79
Uterus corpus	N/A	N/A	N/A	N/A	N/A	76	24.8	1.32	30.2	1.59
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	3	1.2	0.32	1.5	0.37
Ovary	N/A	N/A	N/A	N/A	N/A	23	7.2	0.70	8.5	0.83
Male Genital System	235	103.7	3.29	127.9	3.94	N/A	N/A	N/A	N/A	N/A
Prostate	219	99.9	3.26	124.0	3.91	N/A	N/A	N/A	N/A	N/A
Testis	13	2.7	0.34	2.6	0.34	N/A	N/A	N/A	N/A	N/A
Penis	3	1.0	0.30	1.2	0.37	N/A	N/A	N/A	N/A	N/A
Urinary System	77	36.2	2.05	42.2	2.35	44	16.1	1.14	18.8	1.32
Bladder (incl. <i>in situ</i>)	36	20.1	1.64	23.2	1.86	14	5.8	0.72	6.7	0.83
Kidney & renal pelvis	40	15.6	1.21	18.3	1.41	29	10.1	0.88	11.8	1.02
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	1	0.5	0.23	0.5	0.26	*	*	*	*	*
Brain & Other CNS	16	5.7	0.73	6.1	0.81	14	4.3	0.54	4.6	0.59
Brain	16	5.6	0.72	6.0	0.80	13	3.9	0.51	4.2	0.57
Endocrine System	25	7.9	0.79	9.1	0.93	94	26.0	1.24	29.0	1.41
Thyroid gland	22	7.2	0.75	8.4	0.88	92	25.2	1.22	28.1	1.39
Lymphomas	63	25.6	1.66	29.6	1.93	47	15.3	1.05	17.7	1.23
Hodgkin lymphoma	11	3.0	0.49	3.2	0.56	9	2.3	0.35	2.5	0.40
Non-Hodgkin lymphoma	52	22.5	1.59	26.4	1.85	38	12.9	0.99	15.2	1.16
Multiple Myeloma	17	8.2	0.98	9.7	1.12	15	5.6	0.66	6.7	0.78
Leukemias	30	10.9	1.04	11.9	1.16	25	8.1	0.77	9.1	0.88
Acute lymphocytic	9	2.1	0.34	1.9	0.33	6	1.5	0.28	1.4	0.28
Chronic lymphocytic	5	2.1	0.46	2.5	0.54	4	1.6	0.37	2.0	0.44
Acute myeloid	9	4.1	0.70	4.6	0.79	9	2.9	0.46	3.3	0.53
Chronic myeloid	4	1.4	0.33	1.5	0.37	4	1.5	0.35	1.8	0.41
Other leukemias	3	1.3	0.38	1.4	0.42	2	0.6	0.22	0.6	0.24
Mesothelioma	2	1.1	0.41	1.3	0.47	*	*	*	*	*
Kaposi Sarcoma	2	0.7	0.22	0.8	0.26	*	*	*	*	*
Ill-Defined & Unknown	18	10.7	1.26	12.0	1.41	17	6.6	0.75	7.5	0.86
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	17	6.3	0.79	7.3	0.91	36	11.4	0.89	13.2	1.04
Breast (<i>in situ</i>)	*	*	*	*	*	80	25.3	1.30	30.1	1.54

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

MASSACHUSETTS

II-248 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Massachusetts, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	549	316.1	6.76	375.2	7.87	673	282.7	5.11	329.3	5.94
Oral Cavity & Pharynx	20	10.9	1.20	13.5	1.45	12	5.6	0.77	6.4	0.88
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	6	3.3	0.69	4.1	0.84	3	1.8	0.45	2.0	0.50
Major salivary gland	2	1.3	0.45	1.5	0.51	1	0.6	0.27	0.7	0.30
Floor of mouth	2	0.7	0.26	1.0	0.35	*	*	*	*	*
Gum & other mouth	1	0.7	0.33	0.8	0.37	3	1.4	0.39	1.7	0.46
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	2	0.9	0.36	1.1	0.40	*	*	*	*	*
Digestive System	139	82.6	3.50	98.4	4.06	110	49.9	2.23	58.2	2.58
Esophagus	6	3.2	0.65	4.0	0.81	2	0.9	0.33	1.0	0.37
Stomach	20	12.4	1.39	14.3	1.57	16	6.9	0.81	8.1	0.94
Small intestine	3	1.9	0.51	2.3	0.60	4	2.0	0.45	2.3	0.51
Colon (excl. rectum)	33	20.0	1.75	23.4	2.01	31	13.4	1.13	15.7	1.32
Rectum & rectosigmoid	17	8.9	1.09	10.4	1.26	14	5.7	0.70	6.7	0.83
Anus, anal canal, & anorectum	3	1.2	0.37	1.5	0.46	4	1.7	0.38	2.1	0.47
Liver	30	16.7	1.50	21.0	1.80	10	5.1	0.74	6.0	0.86
Gallbladder	2	1.5	0.53	1.6	0.56	5	1.9	0.40	2.4	0.50
Pancreas	16	10.5	1.29	12.6	1.51	17	8.6	0.98	10.1	1.13
Respiratory System	70	48.6	2.85	57.6	3.29	55	26.0	1.63	31.2	1.92
Larynx	11	6.3	0.95	7.9	1.15	2	0.6	0.22	0.7	0.26
Lung & bronchus	59	41.9	2.68	49.2	3.08	53	25.1	1.61	30.2	1.89
Bones & Joints	2	0.5	0.18	0.6	0.20	2	0.7	0.25	0.7	0.26
Soft Tissue (incl. heart)	4	1.9	0.46	2.1	0.52	5	1.8	0.39	2.0	0.44
Skin (excl. basal & sq.)	6	3.3	0.70	3.8	0.81	9	3.6	0.57	4.4	0.69
Melanoma of the skin	4	2.6	0.63	3.1	0.74	7	3.0	0.52	3.5	0.61
Breast (excl. <i>in situ</i>)	2	1.2	0.43	1.4	0.49	205	83.7	2.71	98.6	3.19
Female Genital System	N/A	N/A	N/A	N/A	N/A	100	40.7	1.90	47.9	2.24
Cervix uteri	N/A	N/A	N/A	N/A	N/A	19	7.2	0.76	7.6	0.83
Uterus corpus	N/A	N/A	N/A	N/A	N/A	52	21.3	1.38	25.7	1.65
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	3	1.1	0.32	1.3	0.38
Ovary	N/A	N/A	N/A	N/A	N/A	17	6.7	0.77	7.9	0.91
Male Genital System	128	70.8	3.05	87.5	3.65	N/A	N/A	N/A	N/A	N/A
Prostate	120	68.3	3.02	84.8	3.63	N/A	N/A	N/A	N/A	N/A
Testis	7	2.0	0.33	1.9	0.33	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	54	32.8	2.22	38.3	2.53	29	13.8	1.20	15.9	1.37
Bladder (incl. <i>in situ</i>)	27	18.5	1.77	21.5	2.01	10	5.1	0.76	5.9	0.87
Kidney & renal pelvis	26	13.6	1.30	15.9	1.50	19	8.5	0.92	9.8	1.05
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	12	5.2	0.77	5.6	0.86	10	3.9	0.59	4.0	0.62
Brain	12	5.1	0.76	5.4	0.85	9	3.4	0.55	3.6	0.58
Endocrine System	17	7.1	0.87	8.1	1.01	62	21.1	1.23	23.2	1.39
Thyroid gland	16	6.4	0.82	7.3	0.95	59	20.3	1.21	22.4	1.37
Lymphomas	46	23.8	1.80	27.7	2.10	35	14.5	1.16	16.8	1.34
Hodgkin lymphoma	8	3.2	0.58	3.4	0.67	7	2.1	0.39	2.3	0.44
Non-Hodgkin lymphoma	38	20.6	1.70	24.3	1.99	28	12.4	1.09	14.4	1.27
Multiple Myeloma	11	6.7	1.02	7.8	1.16	10	4.7	0.68	5.6	0.79
Leukemias	20	8.7	1.00	9.6	1.12	17	6.8	0.80	7.7	0.91
Acute lymphocytic	5	1.4	0.27	1.1	0.24	4	1.4	0.32	1.3	0.32
Chronic lymphocytic	3	1.6	0.44	2.0	0.53	3	1.5	0.39	1.8	0.46
Acute myeloid	6	3.3	0.68	3.8	0.78	5	2.3	0.47	2.6	0.54
Chronic myeloid	3	1.1	0.30	1.3	0.35	2	1.0	0.31	1.3	0.38
Other leukemias	3	1.3	0.41	1.4	0.43	1	0.6	0.25	0.7	0.28
Mesothelioma	1	1.1	0.46	1.3	0.52	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	13	10.1	1.38	11.3	1.55	11	5.1	0.73	5.9	0.85
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	11	5.3	0.81	6.1	0.94	24	9.7	0.93	11.1	1.08
Breast (<i>in situ</i>)	*	*	*	*	*	56	22.0	1.35	26.4	1.61

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Massachusetts, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	99	299.4	14.81	356.1	17.16	104	216.0	9.93	255.7	11.75
Oral Cavity & Pharynx	4	10.9	2.61	14.3	3.28	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	1	3.6	1.77	4.7	2.13	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	23	72.0	7.47	84.2	8.49	20	42.6	4.50	52.7	5.49
Esophagus	2	5.1	1.99	5.9	2.17	*	*	*	*	*
Stomach	3	11.5	3.16	13.2	3.50	2	4.8	1.51	6.2	1.93
Small intestine	1	3.4	1.51	4.2	1.78	*	*	*	*	*
Colon (excl. rectum)	7	22.8	4.16	26.6	4.76	6	13.6	2.61	16.2	3.07
Rectum & rectosigmoid	*	*	*	*	*	3	5.2	1.50	6.5	1.83
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	5	13.2	2.93	16.1	3.47	2	3.2	1.16	4.2	1.49
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	2	5.4	1.83	6.6	2.15	4	8.3	1.99	10.1	2.43
Respiratory System	9	34.2	5.40	39.1	6.06	6	14.2	2.60	17.1	3.07
Larynx	1	3.7	1.62	4.3	1.83	*	*	*	*	*
Lung & bronchus	8	28.6	5.03	32.7	5.65	6	14.2	2.60	17.1	3.07
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	1	2.1	0.88	2.3	1.03
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	34	71.1	5.65	82.1	6.52
Female Genital System	N/A	N/A	N/A	N/A	N/A	14	27.7	3.47	34.4	4.33
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	3.4	1.19	3.9	1.41
Uterus corpus	N/A	N/A	N/A	N/A	N/A	8	16.9	2.70	21.6	3.45
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	1	2.8	1.12	3.5	1.42
Male Genital System	34	99.9	8.20	124.4	9.89	N/A	N/A	N/A	N/A	N/A
Prostate	33	97.3	8.09	121.4	9.76	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	7	21.0	3.79	24.6	4.34	5	10.7	2.29	13.0	2.75
Bladder (incl. <i>in situ</i>)	4	12.1	3.09	13.7	3.44	1	3.4	1.34	4.0	1.57
Kidney & renal pelvis	4	8.8	2.20	10.9	2.65	3	7.3	1.86	9.0	2.25
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	1	1.7	0.74	2.2	0.98
Brain	*	*	*	*	*	1	1.7	0.74	2.2	0.98
Endocrine System	3	5.3	1.53	6.3	1.86	8	14.3	2.36	16.4	2.76
Thyroid gland	2	5.0	1.51	6.0	1.85	8	14.3	2.36	16.4	2.76
Lymphomas	6	16.8	3.61	19.4	4.16	4	9.8	2.21	11.0	2.50
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	3	8.4	2.22	10.2	2.64	2	5.2	1.69	5.9	1.89
Leukemias	4	12.6	3.28	13.6	3.59	4	7.2	1.81	8.3	2.14
Acute lymphocytic	1	2.5	1.32	2.6	1.49	*	*	*	*	*
Chronic lymphocytic	1	4.1	1.77	4.6	1.93	*	*	*	*	*
Acute myeloid	1	4.9	2.17	4.9	2.25	2	3.2	1.15	3.9	1.42
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	7.3	2.58	8.2	2.84	2	5.8	1.76	6.2	1.93
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	2	4.9	1.71	5.2	1.82	4	7.4	1.73	8.4	1.99
Breast (<i>in situ</i>)	*	*	*	*	*	9	19.6	3.04	23.1	3.52

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.


N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	9,934,483	9,954,117	9,976,752	9,987,286	9,984,795
Non-Hispanic White	7,604,621	7,596,932	7,593,504	7,582,182	7,562,401
Non-Hispanic Black	1,451,144	1,452,397	1,454,778	1,456,965	1,458,479
Non-Hispanic Asian/Pacific Islander (NH API)	322,017	335,879	348,202	356,283	359,646
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	38,726	38,895	39,006	38,966	39,347


All Races Population 2015–2019: 49,837,433
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	486,925	498,873	509,922	521,419	533,351
Hispanic White	422,501	432,965	442,278	452,316	462,473
Hispanic Black	38,235	39,115	40,111	41,048	42,174

Hispanic/Latino Population, Census 2010: 436,358
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

MICHIGAN CANCER REGISTRY

Initial Operation: 1981
Population-based Data Available: 1985
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	103.6	106.4	103.1	101.2	98.1	102.5
Missing Race	0.6	1.3	1.7	1.5	2.4	1.5
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.2	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.5	2.2	2.2	1.3	1.2	1.7
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.0	Ovary	93.3
Oral Cavity & Pharynx	98.1	Prostate	97.8
Esophagus	94.7	Testis	99.3
Stomach	96.5	Bladder (incl. <i>in situ</i>)	98.0
Colon & Rectum	96.1	Kidney & Renal Pelvis	92.3
Liver	58.4	Brain & Other CNS	87.6
Pancreas	84.8	Brain & Other CNS (non-malig)	43.1
Lung & Bronchus	88.9	Thyroid	99.6
Melanomas of the Skin	99.4	Hodgkin Lymphoma	98.7
Female Breast (excl. <i>in situ</i>)	98.7	Non-Hodgkin Lymphoma	96.9
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	92.9
Cervix Uteri	98.3	Leukemias	91.1
Uterus Corpus & Uterus NOS	98.7		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Michigan, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	28,709	485.0	1.32	576.7	1.54	27,500	420.9	1.18	491.5	1.35
Oral Cavity & Pharynx	1,080	17.8	0.25	21.7	0.30	448	6.7	0.15	8.0	0.17
Lip	33	0.6	0.05	0.7	0.05	14	0.2	0.02	0.2	0.03
Tongue	362	5.9	0.14	7.2	0.17	132	2.0	0.08	2.4	0.09
Major salivary gland	79	1.4	0.07	1.7	0.08	63	1.0	0.06	1.1	0.06
Floor of mouth	49	0.8	0.05	1.0	0.06	28	0.4	0.04	0.5	0.04
Gum & other mouth	112	1.9	0.08	2.3	0.10	100	1.4	0.07	1.7	0.08
Nasopharynx	37	0.6	0.05	0.8	0.06	13	0.2	0.03	0.2	0.03
Oropharynx	68	1.1	0.06	1.3	0.07	19	0.3	0.03	0.3	0.04
Hypopharynx	66	1.1	0.06	1.3	0.07	15	0.2	0.03	0.3	0.03
Digestive System	5,450	92.9	0.58	110.8	0.68	4,354	64.3	0.45	75.7	0.52
Esophagus	559	9.2	0.18	11.2	0.21	147	2.1	0.08	2.5	0.09
Stomach	457	7.9	0.17	9.3	0.20	271	4.0	0.11	4.7	0.13
Small intestine	171	3.0	0.11	3.5	0.12	148	2.3	0.09	2.7	0.10
Colon (excl. rectum)	1,609	28.4	0.33	33.4	0.38	1,639	24.5	0.28	28.5	0.32
Rectum & rectosigmoid	755	13.1	0.22	15.6	0.26	546	8.5	0.17	10.1	0.20
Anus, anal canal, & anorectum	79	1.4	0.07	1.7	0.08	154	2.3	0.09	2.8	0.10
Liver	580	9.0	0.17	11.2	0.21	213	3.0	0.10	3.6	0.11
Gallbladder	38	0.7	0.05	0.8	0.06	86	1.2	0.06	1.5	0.07
Pancreas	920	15.5	0.24	18.5	0.28	860	12.2	0.19	14.5	0.22
Respiratory System	4,519	75.4	0.52	90.4	0.61	4,123	58.5	0.42	70.0	0.49
Larynx	357	5.7	0.14	7.0	0.17	97	1.4	0.07	1.7	0.08
Lung & bronchus	4,104	68.7	0.49	82.1	0.58	3,988	56.5	0.41	67.6	0.48
Bones & Joints	57	1.1	0.07	1.2	0.07	37	0.7	0.05	0.7	0.05
Soft Tissue (incl. heart)	198	3.7	0.12	4.1	0.13	162	2.7	0.10	3.0	0.11
Skin (excl. basal & sq.)	1,564	27.7	0.32	32.3	0.37	1,158	19.3	0.27	21.8	0.29
Melanoma of the skin	1,407	24.8	0.31	29.0	0.35	1,048	17.6	0.26	19.9	0.28
Breast (excl. <i>in situ</i>)	80	1.4	0.07	1.6	0.08	7,950	124.3	0.65	145.5	0.74
Female Genital System	N/A	N/A	N/A	N/A	N/A	3,365	51.6	0.42	61.2	0.48
Cervix uteri	N/A	N/A	N/A	N/A	N/A	354	6.9	0.17	7.3	0.18
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,932	28.2	0.30	34.4	0.36
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	59	0.9	0.05	1.1	0.06
Ovary	N/A	N/A	N/A	N/A	N/A	629	9.8	0.18	11.5	0.21
Male Genital System	7,449	117.5	0.63	143.7	0.75	N/A	N/A	N/A	N/A	N/A
Prostate	7,118	110.6	0.60	136.6	0.73	N/A	N/A	N/A	N/A	N/A
Testis	275	5.9	0.16	5.9	0.16	N/A	N/A	N/A	N/A	N/A
Penis	43	0.8	0.06	0.9	0.06	N/A	N/A	N/A	N/A	N/A
Urinary System	3,447	60.0	0.47	70.6	0.55	1,433	21.1	0.26	24.7	0.30
Bladder (incl. <i>in situ</i>)	2,057	36.1	0.37	42.4	0.42	650	9.1	0.16	10.8	0.19
Kidney & renal pelvis	1,301	22.4	0.29	26.4	0.33	733	11.2	0.19	13.1	0.22
Ureter	41	0.7	0.05	0.9	0.06	30	0.4	0.04	0.5	0.04
Eye & Orbit	58	1.0	0.06	1.2	0.07	41	0.7	0.05	0.7	0.05
Brain & Other CNS	412	7.6	0.17	8.4	0.19	315	5.3	0.14	5.8	0.15
Brain	392	7.2	0.17	8.0	0.18	294	4.9	0.13	5.4	0.14
Endocrine System	378	7.1	0.17	7.8	0.18	989	18.7	0.28	20.1	0.29
Thyroid gland	332	6.2	0.16	6.9	0.17	949	18.0	0.27	19.4	0.28
Lymphomas	1,463	26.3	0.32	30.1	0.36	1,192	18.4	0.25	21.1	0.28
Hodgkin lymphoma	137	2.7	0.11	2.8	0.11	117	2.3	0.10	2.3	0.10
Non-Hodgkin lymphoma	1,326	23.5	0.30	27.2	0.34	1,075	16.1	0.23	18.8	0.26
Multiple Myeloma	489	8.5	0.18	10.0	0.21	378	5.5	0.13	6.5	0.15
Leukemias	991	17.7	0.26	20.3	0.29	684	10.5	0.19	11.9	0.21
Acute lymphocytic	82	1.7	0.08	1.6	0.08	61	1.2	0.07	1.1	0.07
Chronic lymphocytic	366	6.2	0.15	7.4	0.18	229	3.2	0.10	3.8	0.11
Acute myeloid	306	5.5	0.15	6.3	0.16	238	3.7	0.11	4.2	0.12
Chronic myeloid	133	2.4	0.10	2.7	0.11	98	1.6	0.07	1.8	0.08
Other leukemias	105	1.9	0.09	2.2	0.10	58	0.9	0.05	1.0	0.06
Mesothelioma	86	1.6	0.08	1.8	0.09	27	0.4	0.03	0.5	0.04
Kaposi Sarcoma	17	0.4	0.04	0.4	0.04	4	0.1	0.01	0.1	0.01
Ill-Defined & Unknown	969	17.3	0.26	20.2	0.29	840	12.2	0.19	14.1	0.22
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	433	8.0	0.18	8.9	0.19	883	14.1	0.22	16.1	0.25
Breast (<i>in situ</i>)	9	0.2	0.02	0.2	0.03	1,916	30.7	0.33	36.1	0.38

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Michigan, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	23,841	478.0	1.43	566.8	1.66	22,839	427.1	1.34	497.3	1.51
Oral Cavity & Pharynx	935	18.4	0.28	22.4	0.33	381	6.9	0.17	8.2	0.19
Lip	30	0.6	0.05	0.7	0.06	13	0.2	0.03	0.3	0.03
Tongue	324	6.3	0.16	7.7	0.19	115	2.2	0.10	2.6	0.11
Major salivary gland	66	1.4	0.08	1.6	0.09	51	1.0	0.06	1.1	0.07
Floor of mouth	44	0.8	0.06	1.0	0.07	24	0.4	0.04	0.5	0.05
Gum & other mouth	95	1.9	0.09	2.3	0.11	88	1.5	0.07	1.8	0.09
Nasopharynx	26	0.5	0.05	0.6	0.06	9	0.2	0.03	0.2	0.03
Oropharynx	59	1.1	0.07	1.4	0.08	16	0.3	0.03	0.3	0.04
Hypopharynx	52	1.0	0.06	1.2	0.08	11	0.2	0.03	0.2	0.03
Digestive System	4,398	89.0	0.62	105.9	0.72	3,479	62.1	0.49	72.6	0.56
Esophagus	498	9.7	0.20	11.7	0.24	121	2.1	0.09	2.5	0.10
Stomach	349	7.0	0.17	8.3	0.20	193	3.4	0.12	4.0	0.13
Small intestine	130	2.7	0.11	3.2	0.13	113	2.1	0.09	2.5	0.11
Colon (excl. rectum)	1,310	27.5	0.35	32.2	0.40	1,331	23.9	0.31	27.7	0.35
Rectum & rectosigmoid	612	12.7	0.24	15.2	0.28	439	8.4	0.19	9.9	0.22
Anus, anal canal, & anorectum	61	1.3	0.08	1.5	0.09	137	2.5	0.10	3.1	0.12
Liver	411	7.6	0.17	9.5	0.21	148	2.5	0.10	3.0	0.11
Gallbladder	28	0.6	0.05	0.7	0.06	64	1.1	0.06	1.3	0.07
Pancreas	764	15.1	0.25	18.0	0.30	693	11.7	0.21	13.9	0.24
Respiratory System	3,839	75.0	0.56	89.8	0.66	3,487	59.2	0.46	70.9	0.54
Larynx	288	5.4	0.15	6.7	0.18	73	1.3	0.07	1.6	0.09
Lung & bronchus	3,503	68.6	0.53	82.0	0.63	3,384	57.4	0.45	68.6	0.53
Bones & Joints	47	1.2	0.08	1.2	0.08	30	0.7	0.06	0.7	0.06
Soft Tissue (incl. heart)	156	3.5	0.13	3.9	0.14	127	2.7	0.11	2.9	0.12
Skin (excl. basal & sq.)	1,425	30.0	0.37	35.0	0.42	1,026	21.5	0.32	24.1	0.35
Melanoma of the skin	1,292	27.2	0.35	31.7	0.40	937	19.9	0.31	22.3	0.33
Breast (excl. <i>in situ</i>)	65	1.3	0.08	1.6	0.09	6,626	127.1	0.74	148.5	0.84
Female Genital System	N/A	N/A	N/A	N/A	N/A	2,796	52.4	0.47	62.2	0.54
Cervix uteri	N/A	N/A	N/A	N/A	N/A	267	6.8	0.20	7.1	0.20
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,620	28.8	0.34	35.2	0.40
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	43	0.8	0.05	0.9	0.06
Ovary	N/A	N/A	N/A	N/A	N/A	530	10.1	0.21	11.9	0.24
Male Genital System	5,809	108.6	0.66	132.2	0.79	N/A	N/A	N/A	N/A	N/A
Prostate	5,520	100.6	0.62	124.1	0.75	N/A	N/A	N/A	N/A	N/A
Testis	240	6.9	0.21	6.9	0.20	N/A	N/A	N/A	N/A	N/A
Penis	37	0.8	0.06	0.9	0.07	N/A	N/A	N/A	N/A	N/A
Urinary System	3,027	62.0	0.52	72.9	0.60	1,207	21.4	0.29	25.1	0.33
Bladder (incl. <i>in situ</i>)	1,875	38.4	0.41	45.1	0.47	572	9.6	0.18	11.3	0.22
Kidney & renal pelvis	1,073	22.0	0.31	26.0	0.36	592	11.1	0.22	12.9	0.24
Ureter	39	0.8	0.06	0.9	0.07	27	0.5	0.04	0.5	0.05
Eye & Orbit	52	1.1	0.07	1.3	0.08	38	0.8	0.06	0.9	0.06
Brain & Other CNS	367	8.4	0.21	9.2	0.22	273	5.7	0.17	6.3	0.17
Brain	351	8.0	0.20	8.8	0.21	256	5.3	0.16	5.9	0.17
Endocrine System	327	7.6	0.20	8.4	0.21	807	19.9	0.33	21.2	0.34
Thyroid gland	291	6.7	0.19	7.5	0.20	778	19.2	0.33	20.5	0.34
Lymphomas	1,247	26.7	0.35	30.6	0.39	1,007	18.9	0.28	21.7	0.31
Hodgkin lymphoma	111	2.8	0.12	2.9	0.13	92	2.4	0.12	2.4	0.12
Non-Hodgkin lymphoma	1,136	23.9	0.33	27.7	0.37	914	16.5	0.26	19.3	0.29
Multiple Myeloma	377	7.7	0.18	9.1	0.21	265	4.6	0.13	5.4	0.15
Leukemias	849	18.1	0.29	20.7	0.32	566	10.6	0.21	12.0	0.23
Acute lymphocytic	64	1.7	0.10	1.6	0.09	48	1.3	0.09	1.2	0.08
Chronic lymphocytic	316	6.3	0.16	7.5	0.19	192	3.2	0.11	3.8	0.13
Acute myeloid	269	5.7	0.16	6.6	0.18	199	3.7	0.12	4.2	0.14
Chronic myeloid	110	2.4	0.11	2.7	0.12	79	1.6	0.08	1.8	0.09
Other leukemias	91	2.0	0.10	2.3	0.11	48	0.9	0.06	1.0	0.07
Mesothelioma	81	1.7	0.09	2.0	0.10	24	0.4	0.04	0.5	0.05
Kaposi Sarcoma	8	0.2	0.03	0.2	0.03	2	0.0	0.01	0.0	0.01
Ill-Defined & Unknown	832	17.5	0.28	20.3	0.32	698	12.1	0.21	14.0	0.24
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	356	8.0	0.20	8.9	0.21	709	13.9	0.25	15.8	0.27
Breast (<i>in situ</i>)	8	0.2	0.03	0.2	0.03	1,525	30.4	0.37	35.7	0.42

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Michigan, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3,320	527.4	4.28	636.7	5.05	3,305	404.2	3.23	478.0	3.75
Oral Cavity & Pharynx	97	15.1	0.71	18.2	0.84	44	5.3	0.37	6.4	0.43
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	21	3.2	0.32	3.9	0.38	11	1.3	0.18	1.6	0.22
Major salivary gland	9	1.3	0.20	1.6	0.24	9	1.1	0.17	1.3	0.20
Floor of mouth	4	0.6	0.13	0.7	0.17	2	0.3	0.08	0.3	0.10
Gum & other mouth	10	1.6	0.24	1.9	0.28	7	0.8	0.15	1.0	0.17
Nasopharynx	7	1.1	0.19	1.3	0.22	2	0.2	0.08	0.3	0.09
Oropharynx	8	1.2	0.20	1.4	0.23	3	0.3	0.08	0.4	0.10
Hypopharynx	12	2.0	0.27	2.3	0.31	3	0.4	0.11	0.5	0.12
Digestive System	774	124.5	2.10	150.0	2.47	664	79.5	1.42	95.8	1.68
Esophagus	41	6.4	0.46	7.9	0.56	22	2.5	0.25	3.2	0.30
Stomach	77	13.4	0.71	15.7	0.82	56	6.7	0.41	8.0	0.48
Small intestine	34	5.4	0.44	6.5	0.52	29	3.4	0.29	4.1	0.35
Colon (excl. rectum)	227	37.8	1.17	44.9	1.37	239	29.3	0.87	34.7	1.01
Rectum & rectosigmoid	102	16.1	0.74	19.4	0.88	75	9.1	0.48	11.0	0.57
Anus, anal canal, & anorectum	15	2.4	0.28	2.8	0.32	13	1.6	0.20	1.9	0.24
Liver	121	17.2	0.73	21.9	0.90	45	5.1	0.35	6.3	0.42
Gallbladder	8	1.5	0.24	1.7	0.28	17	2.0	0.22	2.5	0.27
Pancreas	121	19.9	0.85	23.8	0.99	131	15.6	0.62	19.0	0.75
Respiratory System	545	90.0	1.81	108.1	2.12	500	59.7	1.22	72.0	1.45
Larynx	57	8.9	0.55	10.9	0.66	19	2.2	0.23	2.7	0.28
Lung & bronchus	482	80.2	1.72	96.1	2.01	475	56.8	1.19	68.5	1.41
Bones & Joints	4	0.6	0.14	0.6	0.14	5	0.6	0.13	0.6	0.13
Soft Tissue (incl. heart)	28	4.7	0.41	5.2	0.45	25	3.1	0.28	3.5	0.32
Skin (excl. basal & sq.)	11	1.9	0.26	2.1	0.29	17	2.1	0.24	2.4	0.26
Melanoma of the skin	5	0.9	0.18	1.0	0.21	7	0.8	0.15	0.9	0.16
Breast (excl. <i>in situ</i>)	12	2.0	0.27	2.4	0.31	964	119.7	1.77	141.0	2.05
Female Genital System	N/A	N/A	N/A	N/A	N/A	396	48.0	1.11	56.9	1.29
Cervix uteri	N/A	N/A	N/A	N/A	N/A	55	7.4	0.46	8.1	0.49
Uterus corpus	N/A	N/A	N/A	N/A	N/A	224	26.1	0.80	31.8	0.96
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	13	1.6	0.20	1.9	0.24
Ovary	N/A	N/A	N/A	N/A	N/A	67	8.3	0.46	9.7	0.54
Male Genital System	1,107	165.7	2.32	206.9	2.82	N/A	N/A	N/A	N/A	N/A
Prostate	1,093	163.6	2.30	204.5	2.81	N/A	N/A	N/A	N/A	N/A
Testis	9	1.4	0.21	1.5	0.22	N/A	N/A	N/A	N/A	N/A
Penis	4	0.7	0.16	0.8	0.20	N/A	N/A	N/A	N/A	N/A
Urinary System	288	47.6	1.31	56.5	1.53	172	20.7	0.73	24.6	0.85
Bladder (incl. <i>in situ</i>)	116	20.9	0.90	24.6	1.05	60	7.4	0.43	8.7	0.51
Kidney & renal pelvis	164	25.6	0.93	30.5	1.08	106	12.7	0.57	15.1	0.66
Ureter	2	0.3	0.10	0.3	0.11	2	0.2	0.08	0.2	0.09
Eye & Orbit	3	0.3	0.09	0.4	0.10	2	0.2	0.08	0.2	0.08
Brain & Other CNS	28	4.1	0.36	4.6	0.41	25	3.2	0.29	3.4	0.31
Brain	25	3.7	0.35	4.1	0.39	22	2.8	0.27	3.0	0.29
Endocrine System	26	4.1	0.38	4.7	0.43	101	13.3	0.61	14.7	0.66
Thyroid gland	20	3.3	0.34	3.8	0.38	94	12.3	0.59	13.7	0.64
Lymphomas	133	21.6	0.87	24.4	0.97	122	15.2	0.63	17.4	0.71
Hodgkin lymphoma	19	3.0	0.31	3.1	0.32	17	2.2	0.24	2.3	0.25
Non-Hodgkin lymphoma	114	18.6	0.81	21.4	0.92	105	13.0	0.58	15.2	0.67
Multiple Myeloma	87	14.8	0.74	17.6	0.86	98	12.2	0.57	14.4	0.65
Leukemias	77	13.0	0.69	14.7	0.78	73	9.2	0.49	10.4	0.55
Acute lymphocytic	7	0.9	0.15	0.8	0.14	5	0.7	0.14	0.7	0.13
Chronic lymphocytic	26	4.6	0.42	5.4	0.48	20	2.5	0.25	2.9	0.29
Acute myeloid	21	3.7	0.37	4.0	0.41	27	3.5	0.31	3.9	0.34
Chronic myeloid	14	2.2	0.28	2.5	0.31	13	1.6	0.21	1.8	0.23
Other leukemias	9	1.7	0.26	1.9	0.29	7	0.9	0.15	1.0	0.18
Mesothelioma	2	0.5	0.14	0.5	0.16	2	0.2	0.08	0.3	0.09
Kaposi Sarcoma	7	1.1	0.20	1.2	0.20	*	*	*	*	*
Ill-Defined & Unknown	91	15.7	0.77	18.7	0.90	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	51	8.5	0.55	9.7	0.62	126	16.3	0.66	18.4	0.74
Breast (<i>in situ</i>)	1	0.2	0.07	0.2	0.09	277	34.1	0.94	40.6	1.10

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Michigan, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	298	242.1	6.62	282.6	7.69	392	258.0	6.00	300.7	7.02
Oral Cavity & Pharynx	12	8.7	1.14	10.2	1.35	9	6.0	0.92	7.1	1.09
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	4	3.1	0.69	3.7	0.83	1	0.9	0.35	1.1	0.44
Major salivary gland	1	0.8	0.31	0.8	0.34	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	1.2	0.45	1.3	0.51	3	1.7	0.49	2.1	0.60
Nasopharynx	2	1.5	0.43	1.7	0.50	2	1.1	0.38	1.2	0.44
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	79	64.9	3.46	76.9	4.06	66	48.1	2.74	56.5	3.21
Esophagus	3	2.8	0.72	3.3	0.84	1	0.9	0.37	1.0	0.42
Stomach	13	10.9	1.47	12.7	1.69	8	6.4	1.02	7.4	1.18
Small intestine	2	1.8	0.57	1.9	0.61	1	0.9	0.38	1.0	0.43
Colon (excl. rectum)	19	15.5	1.70	18.3	1.99	23	16.8	1.63	19.5	1.90
Rectum & rectosigmoid	12	9.1	1.26	11.0	1.52	12	7.8	1.05	9.3	1.25
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	13	10.6	1.38	12.6	1.62	6	4.2	0.79	5.0	0.92
Gallbladder	*	*	*	*	*	2	1.6	0.49	1.9	0.60
Pancreas	10	8.1	1.20	9.8	1.44	8	6.4	1.02	7.5	1.19
Respiratory System	36	32.0	2.49	37.7	2.91	34	25.9	2.05	30.4	2.38
Larynx	3	1.9	0.55	2.4	0.68	*	*	*	*	*
Lung & bronchus	32	28.6	2.39	33.7	2.78	33	25.1	2.02	29.5	2.35
Bones & Joints	2	1.8	0.57	2.0	0.64	*	*	*	*	*
Soft Tissue (incl. heart)	5	2.8	0.60	3.0	0.69	3	1.8	0.48	2.2	0.57
Skin (excl. basal & sq.)	4	3.1	0.81	3.6	0.92	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	1	1.3	0.54	1.4	0.61	3	1.8	0.49	2.1	0.59
Breast (excl. <i>in situ</i>)	*	*	*	*	*	141	89.1	3.43	104.3	4.04
Female Genital System	N/A	N/A	N/A	N/A	N/A	53	32.5	2.02	38.3	2.40
Cervix uteri	N/A	N/A	N/A	N/A	N/A	7	4.1	0.72	4.5	0.80
Uterus corpus	N/A	N/A	N/A	N/A	N/A	26	16.2	1.44	19.7	1.75
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	1.1	0.39	1.3	0.44
Ovary	N/A	N/A	N/A	N/A	N/A	13	7.6	0.96	8.9	1.14
Male Genital System	69	56.2	3.15	66.6	3.68	N/A	N/A	N/A	N/A	N/A
Prostate	63	52.2	3.07	62.6	3.61	N/A	N/A	N/A	N/A	N/A
Testis	6	3.0	0.57	2.8	0.55	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	27	22.7	2.08	26.1	2.40	8	5.6	0.95	6.5	1.09
Bladder (incl. <i>in situ</i>)	13	12.3	1.59	14.2	1.84	3	2.6	0.68	3.0	0.77
Kidney & renal pelvis	12	9.7	1.30	11.2	1.50	4	2.7	0.62	3.1	0.72
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	5	4.0	0.84	4.4	0.92	5	3.0	0.63	3.1	0.67
Brain	5	4.0	0.84	4.4	0.92	4	2.7	0.60	2.8	0.63
Endocrine System	11	7.3	1.04	8.1	1.18	32	18.3	1.46	20.5	1.67
Thyroid gland	8	5.5	0.91	6.2	1.04	31	17.4	1.41	19.6	1.63
Lymphomas	21	17.2	1.77	19.8	2.04	16	10.6	1.22	12.2	1.40
Hodgkin lymphoma	1	0.6	0.26	0.6	0.25	3	1.4	0.39	1.4	0.39
Non-Hodgkin lymphoma	20	16.6	1.75	19.2	2.03	14	9.3	1.16	10.8	1.35
Multiple Myeloma	4	3.8	0.82	4.1	0.89	3	1.8	0.53	2.2	0.62
Leukemias	12	9.3	1.27	10.3	1.43	8	4.8	0.80	5.5	0.91
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	3	2.0	0.59	2.6	0.74	2	1.1	0.39	1.3	0.46
Acute myeloid	5	4.2	0.89	4.7	1.00	2	1.4	0.41	1.7	0.49
Chronic myeloid	1	1.1	0.46	1.2	0.49	1	0.8	0.35	1.0	0.43
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	8	6.9	1.10	7.8	1.26	10	7.5	1.08	8.6	1.25
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	8	6.5	1.08	7.2	1.21	17	11.7	1.31	13.5	1.52
Breast (<i>in situ</i>)	*	*	*	*	*	47	29.8	1.98	34.3	2.29

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Michigan, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	99	527.6	25.33	636.3	29.73	107	528.6	23.84	615.5	27.07
Oral Cavity & Pharynx	4	21.4	5.31	26.2	6.30	3	16.3	4.34	18.3	4.81
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	1	8.2	3.93	9.5	4.42	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	26	135.5	12.82	163.6	15.01	19	92.8	9.94	109.6	11.43
Esophagus	3	12.4	3.56	15.5	4.34	*	*	*	*	*
Stomach	1	7.7	2.96	8.6	3.26	1	5.4	2.26	6.4	2.63
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	7	40.6	7.37	47.3	8.34	5	21.6	4.74	25.7	5.46
Rectum & rectosigmoid	3	19.1	4.90	21.6	5.35	3	15.4	4.14	16.8	4.36
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	4	19.4	4.70	25.3	5.98	2	9.8	3.42	11.9	4.14
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	4	23.6	5.43	28.2	6.35	5	23.6	4.95	28.1	5.71
Respiratory System	23	124.0	12.27	151.6	14.67	25	118.6	11.18	141.0	13.00
Larynx	3	10.8	3.05	14.5	4.04	*	*	*	*	*
Lung & bronchus	20	112.5	11.86	135.9	14.06	24	115.8	11.08	137.1	12.85
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	2	12.6	4.28	15.6	5.27	1	6.2	2.44	7.6	2.88
Breast (excl. <i>in situ</i>)	*	*	*	*	*	24	117.6	11.11	139.6	12.82
Female Genital System	N/A	N/A	N/A	N/A	N/A	14	68.4	8.67	77.2	9.47
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	12.2	3.77	13.3	4.11
Uterus corpus	N/A	N/A	N/A	N/A	N/A	8	37.9	6.36	43.2	6.96
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	11.8	3.82	12.4	3.98
Male Genital System	17	86.1	9.75	105.8	11.61	N/A	N/A	N/A	N/A	N/A
Prostate	16	81.4	9.51	100.9	11.40	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	11	57.1	8.41	69.4	9.83	6	27.1	5.35	32.3	6.24
Bladder (incl. <i>in situ</i>)	4	27.0	6.50	31.2	7.28	2	9.5	3.04	12.2	3.79
Kidney & renal pelvis	7	30.1	5.34	38.3	6.61	3	16.0	4.13	18.2	4.57
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	4	22.6	5.28	22.3	5.16
Thyroid gland	*	*	*	*	*	4	22.6	5.28	22.3	5.16
Lymphomas	4	24.9	5.63	28.5	6.33	4	18.9	4.42	22.3	5.12
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	2	15.1	4.62	17.6	5.30	*	*	*	*	*
Leukemias	2	11.5	3.46	13.9	4.07	2	12.7	3.82	13.9	4.14
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	1	5.9	2.55	6.9	2.90	1	6.9	2.90	7.6	3.23
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	4	23.1	5.33	26.8	6.01	3	13.2	3.81	15.6	4.50
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	1	8.5	3.31	8.9	3.37	4	22.5	5.08	25.7	5.61
Breast (<i>in situ</i>)	*	*	*	*	*	7	29.8	5.36	35.9	6.29

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Michigan, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	463	329.9	7.59	390.7	8.82	472	288.6	6.23	338.3	7.29
Oral Cavity & Pharynx	15	9.9	1.24	12.1	1.48	6	3.5	0.70	4.2	0.82
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	7	4.6	0.84	5.6	1.01	2	1.5	0.46	1.8	0.53
Major salivary gland	1	0.8	0.35	0.8	0.36	1	0.7	0.31	0.9	0.36
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	0.8	0.32	1.0	0.40	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	121	88.8	3.97	106.5	4.63	90	59.0	2.91	70.3	3.44
Esophagus	8	5.5	0.98	6.8	1.17	2	1.3	0.46	1.5	0.53
Stomach	12	10.9	1.53	12.1	1.67	10	6.4	0.95	7.4	1.10
Small intestine	3	2.0	0.62	2.3	0.72	2	1.2	0.38	1.4	0.46
Colon (excl. rectum)	31	22.0	1.96	26.5	2.32	28	17.8	1.58	21.5	1.89
Rectum & rectosigmoid	16	10.9	1.33	13.3	1.58	12	7.0	0.95	8.2	1.12
Anus, anal canal, & anorectum	1	1.0	0.40	1.1	0.46	2	1.1	0.36	1.4	0.46
Liver	24	17.3	1.69	21.1	1.98	11	7.4	1.06	8.9	1.25
Gallbladder	1	1.4	0.56	1.6	0.64	3	2.1	0.60	2.4	0.68
Pancreas	18	13.6	1.60	16.3	1.85	16	11.3	1.31	13.5	1.54
Respiratory System	41	34.6	2.61	40.6	2.99	49	34.3	2.29	40.8	2.68
Larynx	4	2.5	0.65	3.0	0.76	2	1.4	0.48	1.7	0.56
Lung & bronchus	36	30.8	2.48	36.0	2.84	46	32.2	2.22	38.3	2.59
Bones & Joints	2	1.3	0.41	1.4	0.45	*	*	*	*	*
Soft Tissue (incl. heart)	6	3.2	0.69	3.5	0.78	4	2.0	0.50	2.1	0.53
Skin (excl. basal & sq.)	8	5.5	0.97	6.8	1.17	10	6.3	0.92	7.4	1.07
Melanoma of the skin	6	4.3	0.87	5.4	1.06	8	4.6	0.77	5.5	0.91
Breast (excl. <i>in situ</i>)	*	*	*	*	*	124	73.5	3.06	87.4	3.63
Female Genital System	N/A	N/A	N/A	N/A	N/A	70	40.0	2.23	46.3	2.60
Cervix uteri	N/A	N/A	N/A	N/A	N/A	16	8.2	0.93	8.7	1.02
Uterus corpus	N/A	N/A	N/A	N/A	N/A	34	20.1	1.59	24.0	1.90
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	1	0.6	0.26	0.6	0.28
Ovary	N/A	N/A	N/A	N/A	N/A	12	6.9	0.93	8.0	1.10
Male Genital System	111	78.3	3.66	94.6	4.29	N/A	N/A	N/A	N/A	N/A
Prostate	97	73.2	3.60	89.5	4.24	N/A	N/A	N/A	N/A	N/A
Testis	13	4.6	0.59	4.4	0.57	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	57	42.2	2.76	49.5	3.19	25	15.5	1.46	18.0	1.69
Bladder (incl. <i>in situ</i>)	24	20.2	2.01	24.0	2.34	5	3.8	0.77	4.5	0.89
Kidney & renal pelvis	32	21.2	1.84	24.7	2.12	19	11.5	1.23	13.3	1.43
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	1	0.5	0.28	0.5	0.34	*	*	*	*	*
Brain & Other CNS	7	3.9	0.78	4.3	0.87	8	4.7	0.81	5.0	0.88
Brain	6	3.7	0.77	4.1	0.86	7	4.0	0.75	4.3	0.82
Endocrine System	9	5.2	0.84	5.9	0.98	29	13.9	1.19	15.0	1.32
Thyroid gland	8	4.3	0.76	4.8	0.88	27	13.0	1.15	14.2	1.29
Lymphomas	32	21.0	1.86	24.0	2.12	22	13.9	1.40	16.0	1.61
Hodgkin lymphoma	4	1.8	0.46	1.9	0.48	3	1.6	0.43	1.6	0.46
Non-Hodgkin lymphoma	28	19.1	1.80	22.1	2.06	19	12.4	1.33	14.4	1.55
Multiple Myeloma	11	7.6	1.09	9.2	1.30	6	3.8	0.73	4.6	0.89
Leukemias	23	12.3	1.36	13.4	1.50	13	6.4	0.86	7.2	1.01
Acute lymphocytic	8	2.9	0.48	2.8	0.52	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	3	2.1	0.64	2.4	0.71	2	1.0	0.39	1.4	0.49
Acute myeloid	8	4.9	0.93	5.5	1.02	6	2.8	0.56	3.3	0.67
Chronic myeloid	3	1.4	0.40	1.6	0.46	1	0.9	0.37	1.0	0.39
Other leukemias	2	1.0	0.43	1.1	0.46	*	*	*	*	*
Mesothelioma	2	1.4	0.51	1.6	0.59	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	16	13.1	1.60	15.3	1.85	16	10.8	1.26	12.8	1.48
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	9	5.9	1.01	6.7	1.16	17	10.0	1.14	11.8	1.36
Breast (<i>in situ</i>)	*	*	*	*	*	38	22.6	1.70	26.2	1.96

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

MICHIGAN

II-258 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Michigan, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	386	301.8	7.55	357.4	8.77	408	278.1	6.43	326.1	7.53
Oral Cavity & Pharynx	13	9.3	1.25	11.3	1.49	5	3.8	0.76	4.5	0.89
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	5	3.8	0.78	4.6	0.95	2	1.7	0.51	2.0	0.59
Major salivary gland	1	0.8	0.37	0.8	0.38	1	0.7	0.32	0.8	0.37
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	0.8	0.33	1.0	0.43	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	105	85.3	4.06	102.3	4.74	76	55.9	2.98	66.7	3.52
Esophagus	6	4.9	0.95	5.9	1.13	2	1.4	0.51	1.6	0.58
Stomach	11	11.1	1.61	12.2	1.76	7	5.1	0.86	6.0	1.01
Small intestine	2	1.6	0.58	1.9	0.68	1	0.8	0.35	1.0	0.42
Colon (excl. rectum)	26	20.6	1.97	25.1	2.35	25	18.2	1.68	21.8	2.00
Rectum & rectosigmoid	15	11.2	1.40	13.6	1.66	10	6.7	0.99	7.8	1.16
Anus, anal canal, & anorectum	1	1.0	0.42	1.2	0.50	1	0.9	0.36	1.2	0.45
Liver	21	16.6	1.76	20.1	2.04	9	6.7	1.07	8.0	1.26
Gallbladder	*	*	*	*	*	2	2.2	0.65	2.5	0.74
Pancreas	15	13.0	1.64	15.5	1.89	14	10.6	1.32	12.7	1.56
Respiratory System	35	32.1	2.60	37.9	3.00	42	32.6	2.35	39.0	2.75
Larynx	3	2.6	0.69	3.2	0.82	2	1.6	0.53	1.9	0.62
Lung & bronchus	30	28.2	2.46	33.2	2.82	39	30.6	2.27	36.6	2.66
Bones & Joints	2	1.1	0.41	1.2	0.44	*	*	*	*	*
Soft Tissue (incl. heart)	4	2.6	0.64	2.9	0.73	3	1.4	0.41	1.4	0.44
Skin (excl. basal & sq.)	7	5.2	0.98	6.5	1.19	8	5.4	0.90	6.3	1.04
Melanoma of the skin	5	4.0	0.87	5.1	1.07	6	4.3	0.79	5.1	0.93
Breast (excl. <i>in situ</i>)	*	*	*	*	*	112	74.1	3.24	88.0	3.84
Female Genital System	N/A	N/A	N/A	N/A	N/A	60	38.9	2.33	45.0	2.71
Cervix uteri	N/A	N/A	N/A	N/A	N/A	13	7.4	0.95	7.9	1.04
Uterus corpus	N/A	N/A	N/A	N/A	N/A	30	19.7	1.65	23.6	1.98
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	10	6.7	0.97	7.8	1.14
Male Genital System	84	64.5	3.43	77.9	4.03	N/A	N/A	N/A	N/A	N/A
Prostate	73	59.6	3.36	72.9	3.97	N/A	N/A	N/A	N/A	N/A
Testis	11	4.4	0.62	4.3	0.60	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	49	38.9	2.74	45.9	3.18	21	14.5	1.46	16.8	1.70
Bladder (incl. <i>in situ</i>)	22	20.0	2.06	23.8	2.40	5	3.6	0.78	4.3	0.91
Kidney & renal pelvis	26	18.3	1.75	21.4	2.04	16	10.7	1.22	12.2	1.42
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	6	3.4	0.75	3.8	0.84	7	4.7	0.87	5.0	0.94
Brain	5	3.2	0.74	3.7	0.83	6	3.9	0.79	4.1	0.86
Endocrine System	9	5.1	0.87	5.8	1.01	24	13.0	1.22	13.8	1.33
Thyroid gland	7	4.3	0.79	4.8	0.91	23	12.2	1.18	13.0	1.30
Lymphomas	27	20.1	1.91	22.9	2.16	18	12.8	1.41	14.9	1.64
Hodgkin lymphoma	3	1.8	0.49	1.8	0.51	3	1.5	0.45	1.6	0.49
Non-Hodgkin lymphoma	24	18.3	1.84	21.1	2.10	16	11.4	1.34	13.4	1.57
Multiple Myeloma	10	7.4	1.14	8.9	1.35	5	3.5	0.73	4.4	0.90
Leukemias	19	11.5	1.39	12.6	1.53	12	6.3	0.89	7.0	1.03
Acute lymphocytic	7	2.8	0.51	2.8	0.56	4	1.5	0.36	1.5	0.39
Chronic lymphocytic	2	1.7	0.63	1.8	0.68	1	1.0	0.42	1.3	0.51
Acute myeloid	7	4.8	0.95	5.5	1.06	6	3.1	0.62	3.6	0.74
Chronic myeloid	2	1.2	0.37	1.4	0.45	*	*	*	*	*
Other leukemias	1	1.1	0.46	1.1	0.50	*	*	*	*	*
Mesothelioma	1	1.1	0.50	1.4	0.58	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	14	12.3	1.61	14.2	1.83	14	10.2	1.27	12.1	1.50
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	7	4.9	0.95	5.5	1.09	13	8.4	1.10	9.9	1.30
Breast (<i>in situ</i>)	*	*	*	*	*	31	21.3	1.76	24.4	2.01

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Michigan, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	16	451.8	137.90	551.3	172.16	15	173.1	22.92	206.5	27.04
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	1	157.3	101.40	189.2	125.19	3	36.2	11.61	45.4	14.49
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	2	21.2	7.77	23.8	8.56
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	2	21.2	7.77	23.8	8.56
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	3	28.5	7.71	34.8	9.55
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	20.7	6.87	24.1	7.96
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	7	209.6	91.59	263.0	116.18	N/A	N/A	N/A	N/A	N/A
Prostate	7	209.6	91.59	263.0	116.18	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	2	15.6	5.81	19.2	7.44	2	22.4	7.90	25.6	8.88
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	2	15.6	5.81	19.2	7.44	1	16.0	6.46	18.8	7.46
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	2	21.4	9.75	26.9	12.31
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

MICHIGAN


II-260 Incidence – Hispanic Black

METROPOLITAN DETROIT CANCER REGISTRY

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	3,874,792	3,880,727	3,885,219	3,885,429	3,880,208
Non-Hispanic White	2,518,108	2,511,177	2,503,136	2,492,791	2,479,629
Non-Hispanic Black	982,010	980,863	980,942	981,011	981,224
Non-Hispanic Asian/Pacific Islander (NH API)	187,471	197,222	205,793	212,012	215,445
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	0	0	0	0	0


All Races Population 2015–2019: 19,406,375
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	171,262	175,517	179,338	183,507	187,833
Hispanic White	148,697	152,656	155,998	159,753	163,482
Hispanic Black	14,899	15,093	15,448	15,671	16,105

Hispanic/Latino Population, Census 2010: 156,275
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

METROPOLITAN DETROIT CANCER REGISTRY

Initial Operation: 1973
Population-based Data Available: 1973
Coverage Area: County

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	113.8	116.1	112.8	112.2	111.8	113.3
Missing Race	0.1	0.2	0.2	0.3	2.3	0.6
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.3	1.4	1.3	1.6	1.3	1.4
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	95.0	Ovary	94.8
Oral Cavity & Pharynx	99.0	Prostate	98.6
Esophagus	96.7	Testis	99.2
Stomach	97.0	Bladder (incl. <i>in situ</i>)	98.3
Colon & Rectum	96.7	Kidney & Renal Pelvis	92.4
Liver	55.7	Brain & Other CNS	89.2
Pancreas	86.7	Brain & Other CNS (non-malig)	40.7
Lung & Bronchus	90.3	Thyroid	99.7
Melanomas of the Skin	99.7	Hodgkin Lymphoma	99.5
Female Breast (excl. <i>in situ</i>)	99.0	Non-Hodgkin Lymphoma	98.3
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	93.8
Cervix Uteri	99.1	Leukemias	95.6
Uterus Corpus & Uterus NOS	98.9		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Metropolitan Detroit, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	11,741	539.9	2.30	642.5	2.68	11,604	455.1	1.96	532.2	2.24
Oral Cavity & Pharynx	430	18.9	0.42	23.1	0.50	178	6.7	0.23	8.1	0.27
Lip	10	0.5	0.07	0.6	0.08	4	0.1	0.03	0.2	0.04
Tongue	138	5.9	0.23	7.3	0.28	49	1.8	0.12	2.2	0.14
Major salivary gland	31	1.5	0.13	1.8	0.14	28	1.1	0.10	1.3	0.11
Floor of mouth	17	0.7	0.08	0.9	0.10	12	0.4	0.06	0.5	0.07
Gum & other mouth	43	2.0	0.14	2.3	0.16	37	1.4	0.10	1.6	0.12
Nasopharynx	19	0.9	0.09	1.0	0.11	7	0.3	0.05	0.3	0.05
Oropharynx	27	1.1	0.10	1.4	0.12	7	0.2	0.04	0.3	0.05
Hypopharynx	29	1.4	0.12	1.6	0.13	8	0.3	0.05	0.4	0.06
Digestive System	2,294	106.1	1.02	126.7	1.20	1,926	72.7	0.76	86.0	0.89
Esophagus	202	9.1	0.30	11.0	0.35	62	2.3	0.13	2.7	0.16
Stomach	192	9.2	0.31	10.8	0.35	132	5.0	0.20	5.8	0.23
Small intestine	75	3.5	0.19	4.1	0.21	67	2.6	0.15	3.1	0.17
Colon (excl. rectum)	680	32.5	0.57	38.3	0.66	712	27.1	0.47	31.8	0.54
Rectum & rectosigmoid	312	14.3	0.37	17.2	0.44	246	9.7	0.29	11.5	0.33
Anus, anal canal, & anorectum	38	1.8	0.13	2.1	0.15	60	2.2	0.13	2.8	0.16
Liver	265	11.1	0.32	13.9	0.39	97	3.5	0.16	4.3	0.19
Gallbladder	16	0.8	0.09	0.9	0.10	40	1.5	0.11	1.8	0.13
Pancreas	386	17.8	0.42	21.2	0.49	383	14.1	0.33	16.8	0.39
Respiratory System	1,729	80.1	0.89	95.4	1.04	1,705	63.1	0.70	75.2	0.82
Larynx	143	6.2	0.24	7.6	0.29	40	1.5	0.11	1.8	0.13
Lung & bronchus	1,563	72.8	0.85	86.5	0.99	1,650	60.9	0.68	72.7	0.81
Bones & Joints	24	1.2	0.12	1.3	0.12	15	0.7	0.09	0.7	0.09
Soft Tissue (incl. heart)	83	4.2	0.21	4.7	0.23	72	3.1	0.17	3.4	0.18
Skin (excl. basal & sq.)	560	26.9	0.52	31.5	0.60	412	17.2	0.40	19.6	0.44
Melanoma of the skin	495	23.7	0.49	27.9	0.57	365	15.3	0.37	17.4	0.41
Breast (excl. <i>in situ</i>)	33	1.6	0.13	1.9	0.15	3,363	134.8	1.08	157.8	1.23
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,395	54.4	0.68	64.8	0.78
Cervix uteri	N/A	N/A	N/A	N/A	N/A	138	6.6	0.26	7.0	0.27
Uterus corpus	N/A	N/A	N/A	N/A	N/A	802	30.0	0.49	36.8	0.59
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	20	0.7	0.08	0.9	0.09
Ovary	N/A	N/A	N/A	N/A	N/A	270	10.8	0.30	12.7	0.35
Male Genital System	3,250	139.9	1.13	171.3	1.36	N/A	N/A	N/A	N/A	N/A
Prostate	3,129	133.4	1.10	164.6	1.33	N/A	N/A	N/A	N/A	N/A
Testis	100	5.5	0.25	5.5	0.25	N/A	N/A	N/A	N/A	N/A
Penis	16	0.8	0.09	0.9	0.11	N/A	N/A	N/A	N/A	N/A
Urinary System	1,319	62.7	0.80	73.8	0.92	566	21.4	0.41	25.1	0.48
Bladder (incl. <i>in situ</i>)	770	37.4	0.62	43.8	0.72	264	9.7	0.27	11.3	0.32
Kidney & renal pelvis	512	23.6	0.48	27.9	0.56	286	11.1	0.30	13.1	0.35
Ureter	16	0.8	0.09	0.9	0.11	9	0.3	0.05	0.4	0.06
Eye & Orbit	20	1.0	0.10	1.1	0.11	16	0.6	0.08	0.7	0.08
Brain & Other CNS	152	7.5	0.28	8.3	0.30	119	5.1	0.22	5.6	0.23
Brain	145	7.1	0.27	7.9	0.30	109	4.6	0.21	5.1	0.22
Endocrine System	172	8.4	0.30	9.4	0.32	471	22.1	0.47	23.9	0.50
Thyroid gland	155	7.5	0.28	8.5	0.31	454	21.3	0.47	23.1	0.49
Lymphomas	603	29.3	0.55	33.5	0.62	503	20.1	0.42	23.1	0.47
Hodgkin lymphoma	62	3.3	0.19	3.4	0.19	49	2.5	0.17	2.6	0.16
Non-Hodgkin lymphoma	541	26.0	0.52	30.1	0.59	453	17.6	0.38	20.5	0.44
Multiple Myeloma	211	9.9	0.32	11.8	0.37	186	7.1	0.24	8.3	0.28
Leukemias	435	21.1	0.47	24.2	0.53	309	12.1	0.32	13.9	0.36
Acute lymphocytic	34	1.8	0.14	1.7	0.13	20	1.0	0.11	1.0	0.10
Chronic lymphocytic	176	8.1	0.28	9.7	0.33	115	4.2	0.18	5.0	0.21
Acute myeloid	121	6.1	0.25	6.9	0.28	104	4.1	0.19	4.7	0.21
Chronic myeloid	64	3.1	0.18	3.6	0.20	47	1.9	0.13	2.2	0.15
Other leukemias	40	2.0	0.14	2.3	0.16	24	0.9	0.09	1.0	0.10
Mesothelioma	31	1.6	0.13	1.9	0.15	12	0.4	0.06	0.5	0.07
Kaposi Sarcoma	12	0.7	0.09	0.7	0.09	3	0.1	0.03	0.1	0.03
Ill-Defined & Unknown	383	18.8	0.44	21.9	0.51	354	13.2	0.33	15.3	0.37
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	193	9.6	0.32	10.7	0.35	439	17.6	0.39	20.1	0.44
Breast (<i>in situ</i>)	3	0.1	0.04	0.2	0.04	862	35.1	0.56	41.4	0.64

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Metropolitan Detroit, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	8,637	540.1	2.69	640.2	3.12	8,418	473.4	2.43	551.1	2.75
Oral Cavity & Pharynx	336	20.0	0.51	24.6	0.61	134	7.2	0.29	8.6	0.34
Lip	10	0.6	0.09	0.7	0.10	3	0.2	0.04	0.2	0.05
Tongue	114	6.6	0.29	8.2	0.35	39	2.1	0.16	2.5	0.18
Major salivary gland	24	1.6	0.15	1.8	0.17	19	1.1	0.12	1.2	0.13
Floor of mouth	13	0.8	0.10	0.9	0.12	9	0.5	0.08	0.6	0.09
Gum & other mouth	34	2.1	0.16	2.5	0.19	29	1.6	0.14	1.8	0.15
Nasopharynx	10	0.6	0.09	0.8	0.11	5	0.3	0.06	0.3	0.07
Oropharynx	19	1.1	0.12	1.4	0.14	5	0.2	0.05	0.3	0.06
Hypopharynx	21	1.3	0.13	1.5	0.15	5	0.3	0.06	0.3	0.07
Digestive System	1,588	99.8	1.16	118.8	1.35	1,304	69.3	0.90	81.4	1.03
Esophagus	163	9.9	0.36	12.0	0.42	42	2.1	0.15	2.5	0.18
Stomach	123	7.9	0.33	9.3	0.38	81	4.3	0.22	4.9	0.25
Small intestine	47	3.0	0.20	3.5	0.23	43	2.4	0.17	2.8	0.20
Colon (excl. rectum)	472	30.6	0.65	36.0	0.75	491	26.2	0.55	30.5	0.63
Rectum & rectosigmoid	220	13.9	0.44	16.6	0.51	167	9.5	0.35	11.3	0.40
Anus, anal canal, & anorectum	24	1.5	0.14	1.8	0.17	47	2.5	0.17	3.1	0.21
Liver	154	9.0	0.33	11.1	0.40	55	2.8	0.18	3.4	0.21
Gallbladder	10	0.6	0.09	0.7	0.10	25	1.3	0.12	1.5	0.13
Pancreas	279	17.3	0.48	20.6	0.56	261	13.3	0.38	15.7	0.44
Respiratory System	1,275	79.0	1.02	94.0	1.19	1,261	65.0	0.84	77.4	0.99
Larynx	96	5.6	0.26	6.9	0.32	26	1.4	0.13	1.7	0.15
Lung & bronchus	1,162	72.3	0.98	85.8	1.14	1,225	63.0	0.82	75.0	0.97
Bones & Joints	18	1.3	0.15	1.4	0.15	9	0.7	0.11	0.7	0.11
Soft Tissue (incl. heart)	57	4.0	0.24	4.4	0.27	46	2.9	0.21	3.1	0.21
Skin (excl. basal & sq.)	531	34.6	0.69	40.5	0.79	380	23.6	0.58	26.6	0.63
Melanoma of the skin	477	30.9	0.66	36.3	0.75	345	21.6	0.56	24.4	0.60
Breast (excl. <i>in situ</i>)	23	1.5	0.14	1.8	0.17	2,431	140.9	1.35	164.3	1.52
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,010	56.6	0.84	67.5	0.97
Cervix uteri	N/A	N/A	N/A	N/A	N/A	88	6.5	0.33	6.9	0.33
Uterus corpus	N/A	N/A	N/A	N/A	N/A	590	31.6	0.61	38.8	0.73
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	11	0.6	0.08	0.7	0.09
Ovary	N/A	N/A	N/A	N/A	N/A	198	11.4	0.38	13.3	0.43
Male Genital System	2,204	129.0	1.27	157.0	1.51	N/A	N/A	N/A	N/A	N/A
Prostate	2,103	120.6	1.21	148.4	1.46	N/A	N/A	N/A	N/A	N/A
Testis	85	7.3	0.36	7.3	0.36	N/A	N/A	N/A	N/A	N/A
Penis	11	0.8	0.10	0.9	0.12	N/A	N/A	N/A	N/A	N/A
Urinary System	1,054	67.4	0.96	79.2	1.10	413	21.9	0.50	25.7	0.58
Bladder (incl. <i>in situ</i>)	659	42.4	0.76	49.7	0.88	209	10.6	0.34	12.4	0.39
Kidney & renal pelvis	367	23.1	0.56	27.3	0.65	192	10.6	0.36	12.5	0.41
Ureter	14	1.0	0.12	1.1	0.13	7	0.4	0.06	0.4	0.07
Eye & Orbit	17	1.1	0.13	1.3	0.14	13	0.8	0.10	0.9	0.11
Brain & Other CNS	123	8.5	0.36	9.4	0.38	91	5.6	0.28	6.2	0.30
Brain	119	8.1	0.35	9.1	0.38	85	5.2	0.27	5.8	0.29
Endocrine System	134	9.5	0.38	10.5	0.41	345	25.1	0.64	27.0	0.66
Thyroid gland	125	8.8	0.37	9.8	0.40	335	24.4	0.63	26.3	0.65
Lymphomas	466	31.1	0.67	35.5	0.74	378	21.5	0.52	24.6	0.58
Hodgkin lymphoma	44	3.5	0.25	3.6	0.25	33	2.8	0.22	2.8	0.22
Non-Hodgkin lymphoma	422	27.5	0.62	31.9	0.70	345	18.7	0.47	21.9	0.54
Multiple Myeloma	136	8.6	0.34	10.2	0.40	103	5.4	0.25	6.3	0.28
Leukemias	347	22.9	0.57	26.3	0.64	233	12.9	0.40	14.8	0.44
Acute lymphocytic	24	2.0	0.19	1.9	0.18	14	1.2	0.15	1.1	0.13
Chronic lymphocytic	142	8.7	0.34	10.5	0.40	90	4.5	0.22	5.4	0.26
Acute myeloid	99	6.6	0.31	7.6	0.34	77	4.3	0.23	4.9	0.26
Chronic myeloid	51	3.4	0.22	3.9	0.25	34	2.0	0.16	2.3	0.18
Other leukemias	31	2.1	0.17	2.4	0.20	17	0.9	0.11	1.1	0.12
Mesothelioma	28	2.0	0.17	2.3	0.19	9	0.5	0.08	0.6	0.09
Kaposi Sarcoma	5	0.4	0.08	0.4	0.09	1	0.1	0.03	0.1	0.03
Ill-Defined & Unknown	295	19.5	0.52	22.6	0.60	256	13.3	0.39	15.2	0.44
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	143	9.9	0.39	11.1	0.42	314	17.8	0.48	20.5	0.53
Breast (<i>in situ</i>)	2	0.2	0.05	0.2	0.05	597	35.8	0.69	42.2	0.79

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Metropolitan Detroit, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,496	566.7	5.29	682.4	6.22	2,604	431.3	3.89	510.0	4.51
Oral Cavity & Pharynx	73	16.5	0.90	19.8	1.05	34	5.4	0.42	6.7	0.52
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	16	3.4	0.40	4.2	0.47	8	1.3	0.21	1.6	0.25
Major salivary gland	6	1.3	0.25	1.6	0.30	7	1.2	0.20	1.4	0.24
Floor of mouth	4	0.8	0.19	1.1	0.24	2	0.2	0.08	0.3	0.11
Gum & other mouth	7	1.7	0.30	2.0	0.34	4	0.7	0.15	0.8	0.18
Nasopharynx	6	1.3	0.26	1.5	0.29	1	0.2	0.07	0.3	0.10
Oropharynx	7	1.5	0.27	1.8	0.32	2	0.3	0.09	0.3	0.11
Hypopharynx	8	2.0	0.32	2.2	0.36	3	0.5	0.14	0.6	0.16
Digestive System	593	136.2	2.61	163.8	3.06	523	84.1	1.69	101.5	2.00
Esophagus	31	7.0	0.58	8.5	0.69	17	2.6	0.29	3.3	0.36
Stomach	56	13.7	0.85	16.0	0.98	40	6.5	0.47	7.7	0.55
Small intestine	25	5.9	0.55	7.0	0.64	23	3.5	0.34	4.3	0.41
Colon (excl. rectum)	177	42.6	1.49	50.4	1.73	190	31.3	1.04	37.2	1.22
Rectum & rectosigmoid	78	17.5	0.92	21.1	1.08	62	10.2	0.59	12.3	0.70
Anus, anal canal, & anorectum	12	2.9	0.38	3.4	0.43	12	1.9	0.25	2.4	0.31
Liver	94	19.0	0.91	24.2	1.13	34	5.1	0.40	6.3	0.49
Gallbladder	6	1.5	0.30	1.8	0.34	13	2.1	0.26	2.6	0.32
Pancreas	91	20.9	1.02	25.0	1.19	104	16.7	0.75	20.3	0.90
Respiratory System	396	93.0	2.19	111.2	2.55	387	62.2	1.45	75.1	1.72
Larynx	42	9.5	0.68	11.5	0.80	12	2.0	0.26	2.4	0.31
Lung & bronchus	349	82.5	2.06	98.6	2.41	370	59.4	1.42	71.7	1.68
Bones & Joints	3	0.6	0.17	0.6	0.17	4	0.8	0.18	0.8	0.17
Soft Tissue (incl. heart)	21	5.0	0.51	5.5	0.56	21	3.5	0.35	4.0	0.39
Skin (excl. basal & sq.)	7	1.6	0.28	2.0	0.33	14	2.4	0.30	2.6	0.32
Melanoma of the skin	3	0.7	0.19	0.8	0.22	5	0.8	0.17	0.9	0.19
Breast (excl. <i>in situ</i>)	9	2.2	0.33	2.6	0.38	766	129.2	2.15	151.9	2.47
Female Genital System	N/A	N/A	N/A	N/A	N/A	309	50.9	1.33	60.5	1.55
Cervix uteri	N/A	N/A	N/A	N/A	N/A	40	7.3	0.53	8.0	0.57
Uterus corpus	N/A	N/A	N/A	N/A	N/A	175	27.7	0.96	33.7	1.15
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	8	1.3	0.22	1.6	0.26
Ovary	N/A	N/A	N/A	N/A	N/A	55	9.3	0.57	10.9	0.66
Male Genital System	833	178.4	2.87	222.1	3.49	N/A	N/A	N/A	N/A	N/A
Prostate	822	175.8	2.85	219.2	3.46	N/A	N/A	N/A	N/A	N/A
Testis	7	1.5	0.27	1.6	0.28	N/A	N/A	N/A	N/A	N/A
Penis	4	0.9	0.23	1.1	0.27	N/A	N/A	N/A	N/A	N/A
Urinary System	209	49.4	1.59	58.7	1.85	132	21.7	0.87	25.7	1.01
Bladder (incl. <i>in situ</i>)	84	21.4	1.09	25.2	1.26	48	7.8	0.52	9.2	0.60
Kidney & renal pelvis	120	26.7	1.13	31.9	1.32	81	13.3	0.68	15.8	0.79
Ureter	1	0.3	0.13	0.4	0.14	1	0.3	0.10	0.3	0.11
Eye & Orbit	2	0.5	0.14	0.5	0.15	2	0.3	0.11	0.3	0.11
Brain & Other CNS	19	4.3	0.45	4.7	0.50	20	3.6	0.37	3.9	0.39
Brain	17	3.8	0.43	4.2	0.48	18	3.1	0.34	3.4	0.36
Endocrine System	25	5.7	0.53	6.5	0.60	82	14.8	0.75	16.5	0.82
Thyroid gland	19	4.5	0.48	5.1	0.54	76	13.9	0.73	15.4	0.79
Lymphomas	100	23.5	1.09	26.5	1.21	96	16.5	0.77	18.9	0.87
Hodgkin lymphoma	15	3.5	0.41	3.6	0.42	13	2.4	0.31	2.5	0.31
Non-Hodgkin lymphoma	85	20.0	1.01	22.9	1.14	83	14.1	0.71	16.4	0.81
Multiple Myeloma	66	16.1	0.92	19.0	1.07	78	13.0	0.68	15.4	0.78
Leukemias	61	14.9	0.89	16.8	0.99	57	9.7	0.59	11.0	0.66
Acute lymphocytic	4	0.9	0.20	0.8	0.19	4	0.7	0.17	0.6	0.15
Chronic lymphocytic	23	5.8	0.57	6.8	0.65	16	2.7	0.30	3.2	0.36
Acute myeloid	17	4.2	0.47	4.7	0.52	20	3.5	0.36	3.9	0.39
Chronic myeloid	10	2.3	0.34	2.6	0.37	11	1.9	0.26	2.2	0.30
Other leukemias	6	1.6	0.30	1.8	0.34	5	0.9	0.17	1.0	0.20
Mesothelioma	2	0.6	0.20	0.7	0.23	2	0.3	0.11	0.4	0.12
Kaposi Sarcoma	6	1.5	0.28	1.6	0.29	*	*	*	*	*
Ill-Defined & Unknown	69	16.7	0.94	19.8	1.09	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	39	9.3	0.69	10.6	0.77	103	17.9	0.81	20.2	0.90
Breast (<i>in situ</i>)	*	*	*	*	*	214	35.8	1.12	42.3	1.30

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Metropolitan Detroit, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	199	253.2	8.46	295.5	9.84	237	254.8	7.61	296.7	8.91
Oral Cavity & Pharynx	9	10.0	1.55	12.0	1.87	5	5.7	1.16	6.9	1.39
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	3	3.2	0.89	4.0	1.11	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	1.7	0.69	2.1	0.82	2	2.6	0.77	3.2	0.94
Nasopharynx	2	1.8	0.59	2.0	0.67	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	44	57.0	4.07	67.4	4.76	41	48.3	3.50	56.8	4.11
Esophagus	2	3.0	0.99	3.4	1.10	1	1.7	0.64	1.9	0.73
Stomach	7	9.8	1.72	11.7	2.03	5	6.7	1.39	7.9	1.62
Small intestine	1	1.7	0.65	1.8	0.70	*	*	*	*	*
Colon (excl. rectum)	11	14.7	2.09	17.3	2.42	13	15.5	1.98	18.0	2.30
Rectum & rectosigmoid	5	6.3	1.28	7.7	1.54	7	7.8	1.34	9.2	1.58
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	7	8.1	1.49	9.9	1.77	4	4.4	1.05	5.2	1.23
Gallbladder	*	*	*	*	*	2	1.7	0.62	2.2	0.78
Pancreas	5	6.4	1.37	7.6	1.62	5	6.1	1.28	7.1	1.50
Respiratory System	25	34.6	3.25	41.0	3.84	19	22.8	2.46	26.5	2.85
Larynx	2	2.2	0.74	2.6	0.87	*	*	*	*	*
Lung & bronchus	22	31.2	3.11	37.1	3.67	18	22.0	2.42	25.6	2.81
Bones & Joints	2	2.3	0.82	2.6	0.93	*	*	*	*	*
Soft Tissue (incl. heart)	3	2.7	0.73	2.9	0.80	2	2.4	0.72	2.6	0.79
Skin (excl. basal & sq.)	3	3.7	1.18	4.3	1.35	2	1.6	0.60	1.7	0.66
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	81	82.8	4.19	97.6	4.96
Female Genital System	N/A	N/A	N/A	N/A	N/A	34	34.1	2.67	40.2	3.17
Cervix uteri	N/A	N/A	N/A	N/A	N/A	3	2.9	0.85	3.1	0.93
Uterus corpus	N/A	N/A	N/A	N/A	N/A	17	17.5	1.89	21.4	2.33
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	9	9.1	1.34	10.5	1.58
Male Genital System	52	66.2	4.28	77.9	4.98	N/A	N/A	N/A	N/A	N/A
Prostate	48	62.1	4.18	73.7	4.89	N/A	N/A	N/A	N/A	N/A
Testis	3	2.9	0.74	2.8	0.72	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	20	25.0	2.66	28.6	3.05	4	4.9	1.16	5.6	1.33
Bladder (incl. <i>in situ</i>)	9	12.4	1.97	14.2	2.26	2	3.0	0.97	3.3	1.09
Kidney & renal pelvis	10	11.8	1.74	13.4	1.99	2	1.9	0.65	2.3	0.76
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	5	6.2	1.31	6.5	1.40	3	2.5	0.71	2.5	0.72
Brain	5	6.2	1.31	6.5	1.40	3	2.5	0.71	2.5	0.72
Endocrine System	7	7.5	1.29	8.4	1.46	23	21.9	2.05	24.2	2.32
Thyroid gland	5	5.6	1.11	6.2	1.25	23	21.0	1.98	23.2	2.24
Lymphomas	15	17.4	2.14	20.7	2.54	10	11.2	1.62	13.0	1.87
Hodgkin lymphoma	*	*	*	*	*	1	1.5	0.58	1.5	0.58
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	9	9.7	1.51	11.5	1.78
Multiple Myeloma	3	4.0	1.06	4.3	1.12	2	3.1	0.92	3.5	1.04
Leukemias	7	9.8	1.72	11.1	1.98	5	5.0	1.04	6.0	1.25
Acute lymphocytic	1	1.5	0.56	1.3	0.49	*	*	*	*	*
Chronic lymphocytic	2	2.2	0.76	2.8	0.97	1	1.3	0.54	1.6	0.65
Acute myeloid	3	4.3	1.21	4.9	1.42	2	1.7	0.57	2.1	0.73
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	4	5.6	1.26	6.6	1.48	6	7.3	1.38	8.2	1.58
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	4	5.5	1.26	5.9	1.38	10	11.7	1.72	13.2	1.95
Breast (<i>in situ</i>)	*	*	*	*	*	28	28.1	2.41	32.3	2.79

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Metropolitan Detroit, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	226	467.5	15.36	552.9	17.79	257	431.6	12.64	501.7	14.64
Oral Cavity & Pharynx	8	13.9	2.47	16.5	2.86	4	6.2	1.51	7.3	1.76
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	4	6.4	1.52	7.8	1.85	*	*	*	*	*
Major salivary gland	*	*	*	*	*	2	2.4	0.89	2.5	0.96
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	53	111.6	7.50	133.5	8.69	46	81.9	5.63	96.6	6.59
Esophagus	3	7.0	1.86	8.2	2.16	1	2.6	1.08	3.0	1.22
Stomach	5	14.0	2.92	16.1	3.28	5	7.9	1.67	9.6	2.02
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	15	32.0	4.05	37.8	4.68	14	25.9	3.25	30.1	3.74
Rectum & rectosigmoid	7	13.7	2.55	16.0	2.89	7	10.7	1.91	12.0	2.18
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	9	16.3	2.69	20.7	3.24	4	7.3	1.70	9.0	2.04
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	9	19.4	3.15	23.1	3.63	10	17.9	2.66	21.3	3.11
Respiratory System	21	53.2	5.50	62.4	6.31	25	48.5	4.52	56.9	5.19
Larynx	2	3.4	1.24	4.3	1.52	*	*	*	*	*
Lung & bronchus	19	47.8	5.27	55.8	6.03	24	46.3	4.39	54.3	5.05
Bones & Joints	2	3.1	1.12	3.3	1.22	*	*	*	*	*
Soft Tissue (incl. heart)	2	4.4	1.57	5.0	1.78	3	3.9	1.12	4.0	1.20
Skin (excl. basal & sq.)	5	8.7	1.97	10.1	2.26	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	3	5.2	1.50	6.3	1.79	5	8.5	1.71	10.0	2.01
Breast (excl. <i>in situ</i>)	*	*	*	*	*	72	116.3	6.39	136.9	7.51
Female Genital System	N/A	N/A	N/A	N/A	N/A	33	51.6	4.21	60.2	4.93
Cervix uteri	N/A	N/A	N/A	N/A	N/A	7	9.0	1.57	9.5	1.72
Uterus corpus	N/A	N/A	N/A	N/A	N/A	16	25.4	2.98	30.8	3.58
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	6	9.1	1.78	10.4	2.05
Male Genital System	54	110.8	7.38	134.2	8.64	N/A	N/A	N/A	N/A	N/A
Prostate	50	106.3	7.29	129.5	8.55	N/A	N/A	N/A	N/A	N/A
Testis	3	3.9	0.96	4.1	1.03	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	27	59.8	5.69	69.7	6.54	12	22.5	3.00	25.6	3.40
Bladder (incl. <i>in situ</i>)	13	32.7	4.39	38.3	5.05	3	6.8	1.77	7.8	1.97
Kidney & renal pelvis	13	26.2	3.56	30.5	4.10	9	15.6	2.43	17.8	2.76
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	3	5.7	1.58	6.4	1.78	4	7.1	1.75	7.6	1.88
Brain	3	5.5	1.57	6.2	1.77	3	5.8	1.57	6.2	1.69
Endocrine System	5	7.8	1.64	8.9	1.91	18	23.5	2.58	24.9	2.79
Thyroid gland	5	7.4	1.61	8.6	1.89	17	22.7	2.54	24.0	2.75
Lymphomas	18	35.8	4.21	41.1	4.81	13	22.9	2.97	26.5	3.42
Hodgkin lymphoma	2	2.7	1.01	2.9	1.07	2	3.3	1.07	3.7	1.22
Non-Hodgkin lymphoma	16	33.1	4.09	38.3	4.69	11	19.6	2.77	22.8	3.19
Multiple Myeloma	5	8.7	1.85	10.9	2.28	2	4.1	1.22	5.0	1.50
Leukemias	12	18.2	2.80	20.2	3.17	7	11.3	2.01	12.7	2.31
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	1	1.7	0.71	1.9	0.82
Chronic lymphocytic	2	4.3	1.39	5.3	1.69	2	4.0	1.32	4.8	1.54
Acute myeloid	2	4.5	1.54	5.0	1.70	3	4.4	1.20	4.7	1.34
Chronic myeloid	2	3.7	1.32	4.3	1.53	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	9	22.4	3.60	26.7	4.24	11	20.1	2.87	23.4	3.32
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	4	8.0	2.07	8.9	2.35	8	12.7	2.03	15.4	2.48
Breast (<i>in situ</i>)	*	*	*	*	*	17	29.3	3.30	33.4	3.72

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Metropolitan Detroit

II-268 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Metropolitan Detroit, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	194	437.7	15.37	518.5	17.85	232	434.5	13.31	505.2	15.43
Oral Cavity & Pharynx	7	13.5	2.54	16.2	2.96	4	6.7	1.67	7.9	1.94
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	3	5.7	1.47	7.1	1.81	*	*	*	*	*
Major salivary gland	*	*	*	*	*	1	2.4	0.97	2.6	1.05
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	48	107.2	7.54	128.5	8.79	41	80.7	5.87	95.2	6.87
Esophagus	3	6.9	1.86	8.0	2.13	1	2.8	1.18	3.2	1.33
Stomach	5	13.6	2.98	15.5	3.33	4	7.2	1.65	8.8	2.02
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	13	28.8	3.91	34.3	4.57	13	26.9	3.46	31.0	3.96
Rectum & rectosigmoid	6	11.5	2.33	13.8	2.72	6	10.5	2.02	11.9	2.31
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	8	16.7	2.83	21.1	3.42	4	7.1	1.74	8.8	2.12
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	8	19.7	3.31	23.3	3.80	8	17.1	2.73	20.4	3.20
Respiratory System	19	50.7	5.55	59.9	6.41	23	48.7	4.76	57.0	5.46
Larynx	2	3.7	1.34	4.7	1.64	*	*	*	*	*
Lung & bronchus	16	44.8	5.29	52.7	6.09	22	46.2	4.62	54.2	5.31
Bones & Joints	2	3.1	1.17	3.2	1.26	*	*	*	*	*
Soft Tissue (incl. heart)	2	3.8	1.43	4.4	1.69	2	3.4	1.08	3.4	1.12
Skin (excl. basal & sq.)	4	8.6	2.07	10.3	2.41	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	2	4.9	1.56	6.1	1.90	5	8.5	1.80	10.1	2.14
Breast (excl. <i>in situ</i>)	*	*	*	*	*	65	118.1	6.78	139.4	7.98
Female Genital System	N/A	N/A	N/A	N/A	N/A	31	53.7	4.51	62.6	5.28
Cervix uteri	N/A	N/A	N/A	N/A	N/A	6	8.7	1.64	9.0	1.76
Uterus corpus	N/A	N/A	N/A	N/A	N/A	15	26.3	3.17	32.0	3.83
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	6	10.1	1.97	11.6	2.28
Male Genital System	42	93.7	7.03	113.4	8.25	N/A	N/A	N/A	N/A	N/A
Prostate	38	88.9	6.92	108.4	8.14	N/A	N/A	N/A	N/A	N/A
Testis	3	4.1	1.05	4.3	1.13	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	25	61.4	5.96	71.4	6.83	11	22.1	3.09	25.2	3.51
Bladder (incl. <i>in situ</i>)	13	34.2	4.63	39.9	5.31	3	7.0	1.87	8.1	2.10
Kidney & renal pelvis	12	26.2	3.68	30.6	4.24	8	15.1	2.46	17.1	2.81
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	5.0	1.61	5.8	1.83	3	6.7	1.79	7.2	1.92
Brain	2	5.0	1.61	5.8	1.83	3	5.2	1.56	5.6	1.69
Endocrine System	5	8.2	1.75	9.4	2.03	16	23.8	2.76	24.8	2.93
Thyroid gland	5	7.8	1.71	9.0	2.01	15	23.0	2.72	24.0	2.89
Lymphomas	16	34.2	4.25	39.5	4.87	12	23.3	3.14	27.0	3.63
Hodgkin lymphoma	2	2.8	1.08	3.0	1.15	2	3.2	1.14	3.7	1.32
Non-Hodgkin lymphoma	14	31.4	4.11	36.5	4.73	10	20.0	2.92	23.2	3.38
Multiple Myeloma	4	7.5	1.82	9.2	2.20	2	4.5	1.33	5.5	1.63
Leukemias	9	16.8	2.84	18.7	3.22	7	11.5	2.10	13.1	2.43
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	1	1.5	0.63	1.6	0.75
Chronic lymphocytic	2	3.6	1.37	4.4	1.63	2	3.9	1.35	4.8	1.60
Acute myeloid	2	4.7	1.65	5.3	1.82	3	4.9	1.33	5.3	1.48
Chronic myeloid	2	3.2	1.27	3.8	1.50	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	8	20.8	3.55	24.8	4.19	10	19.8	2.95	23.3	3.45
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	3	7.3	2.03	8.1	2.29	7	10.8	1.93	12.9	2.35
Breast (<i>in situ</i>)	*	*	*	*	*	16	30.1	3.52	34.5	4.00

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Metropolitan Detroit, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	18	3259.3	1497.70	3969.6	1869.90	13	355.5	49.38	416.4	57.53
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	3	1669.5	1133.20	2009.1	1393.90	2	62.6	23.03	75.0	28.23
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	2	83.5	35.48	95.5	39.50	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	2	93.9	35.43	103.3	37.95	1	41.5	16.63	48.1	18.72
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	2	93.9	35.43	103.3	37.95	1	41.5	16.63	48.1	18.72
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	4	81.6	20.74	96.5	24.75
Female Genital System	N/A	N/A	N/A	N/A	N/A	1	27.7	11.86	32.6	13.90
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	6	291.0	60.43	347.6	69.05	N/A	N/A	N/A	N/A	N/A
Prostate	6	291.0	60.43	347.6	69.05	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	1	1011.4	975.49	1282.8	1242.80	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	1	64.4	32.22	72.3	36.11	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Multiple Myeloma	1	34.3	14.26	46.5	19.28	*	*	*	*	*
Leukemias	1	17.1	7.82	17.8	8.81	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	2	52.4	22.34	65.1	27.72
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.


N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	5,484,002	5,525,360	5,569,283	5,608,762	5,640,053
Non-Hispanic White	4,496,358	4,502,600	4,511,428	4,517,157	4,519,115
Non-Hispanic Black	360,278	377,648	394,656	411,243	426,820
Non-Hispanic Asian/Pacific Islander (NH API)	276,829	286,864	295,524	303,490	310,380
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	37,973	38,091	38,372	38,665	38,748


All Races Population 2015–2019: 27,827,460
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	284,102	291,460	300,490	309,182	315,863
Hispanic White	245,298	251,284	258,473	265,564	271,278
Hispanic Black	15,043	15,607	16,331	16,862	17,333

Hispanic/Latino Population, Census 2010: 250,258
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

MINNESOTA CANCER REGISTRY

Initial Operation: 1988
Population-based Data Available: 1988
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	118.9	118.3	121.2	120.5	110.0	117.8
Missing Race	0.4	0.3	0.6	0.8	1.1	0.6
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.3	0.8	0.7	0.6	0.5	1.0
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.9	Ovary	94.2
Oral Cavity & Pharynx	99.2	Prostate	98.0
Esophagus	98.1	Testis	99.5
Stomach	97.8	Bladder (incl. <i>in situ</i>)	98.3
Colon & Rectum	96.3	Kidney & Renal Pelvis	91.4
Liver	53.5	Brain & Other CNS	88.1
Pancreas	88.8	Brain & Other CNS (non-malig)	51.9
Lung & Bronchus	88.5	Thyroid	99.5
Melanomas of the Skin	99.9	Hodgkin Lymphoma	99.5
Female Breast (excl. <i>in situ</i>)	99.2	Non-Hodgkin Lymphoma	98.1
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	94.0
Cervix Uteri	98.2	Leukemias	94.0
Uterus Corpus & Uterus NOS	99.2		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Minnesota, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	15,995	508.2	1.85	601.1	2.14	15,258	447.7	1.68	520.9	1.91
Oral Cavity & Pharynx	573	17.6	0.34	21.4	0.40	263	7.4	0.21	8.8	0.25
Lip	43	1.5	0.10	1.7	0.12	19	0.5	0.06	0.6	0.06
Tongue	187	5.7	0.19	6.9	0.23	76	2.2	0.11	2.6	0.13
Major salivary gland	42	1.4	0.10	1.6	0.11	39	1.2	0.09	1.3	0.10
Floor of mouth	27	0.8	0.07	1.0	0.09	16	0.5	0.05	0.5	0.06
Gum & other mouth	56	1.8	0.11	2.1	0.13	59	1.6	0.10	1.9	0.11
Nasopharynx	21	0.7	0.07	0.8	0.08	7	0.2	0.04	0.3	0.04
Oropharynx	32	0.9	0.07	1.2	0.09	8	0.2	0.03	0.3	0.04
Hypopharynx	29	0.9	0.08	1.1	0.09	8	0.2	0.03	0.3	0.04
Digestive System	2,885	92.8	0.79	110.0	0.92	2,267	64.2	0.62	75.2	0.72
Esophagus	268	8.3	0.23	10.0	0.28	71	2.0	0.11	2.4	0.13
Stomach	233	7.5	0.23	8.9	0.26	123	3.5	0.15	4.1	0.17
Small intestine	98	3.1	0.14	3.7	0.17	79	2.3	0.12	2.7	0.14
Colon (excl. rectum)	862	28.6	0.45	33.4	0.51	871	24.8	0.39	28.6	0.44
Rectum & rectosigmoid	414	13.3	0.30	15.8	0.35	263	7.9	0.22	9.3	0.26
Anus, anal canal, & anorectum	33	1.0	0.08	1.2	0.10	79	2.2	0.11	2.7	0.14
Liver	302	9.1	0.24	11.1	0.29	104	2.9	0.13	3.4	0.15
Gallbladder	22	0.7	0.07	0.9	0.08	46	1.3	0.09	1.5	0.10
Pancreas	478	15.3	0.32	18.2	0.38	451	12.5	0.27	14.7	0.31
Respiratory System	2,062	65.6	0.66	77.8	0.77	1,949	53.9	0.56	64.0	0.65
Larynx	142	4.3	0.17	5.3	0.20	38	1.0	0.08	1.3	0.09
Lung & bronchus	1,884	60.2	0.64	71.3	0.74	1,893	52.3	0.55	62.1	0.64
Bones & Joints	33	1.1	0.09	1.2	0.09	20	0.7	0.07	0.7	0.07
Soft Tissue (incl. heart)	114	3.9	0.17	4.3	0.18	91	2.9	0.14	3.1	0.15
Skin (excl. basal & sq.)	1,335	43.7	0.55	50.9	0.63	1,040	33.1	0.48	37.2	0.52
Melanoma of the skin	1,234	40.3	0.53	46.9	0.60	980	31.3	0.47	35.2	0.51
Breast (excl. <i>in situ</i>)	30	1.0	0.08	1.2	0.10	4,539	135.7	0.93	159.0	1.07
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,834	53.2	0.58	63.3	0.67
Cervix uteri	N/A	N/A	N/A	N/A	N/A	160	5.6	0.21	6.0	0.21
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,080	30.3	0.43	37.0	0.51
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	19	0.5	0.06	0.6	0.07
Ovary	N/A	N/A	N/A	N/A	N/A	336	9.9	0.25	11.6	0.29
Male Genital System	4,090	121.5	0.87	148.2	1.04	N/A	N/A	N/A	N/A	N/A
Prostate	3,862	113.2	0.84	139.7	1.01	N/A	N/A	N/A	N/A	N/A
Testis	188	7.0	0.23	7.0	0.23	N/A	N/A	N/A	N/A	N/A
Penis	29	1.0	0.08	1.1	0.10	N/A	N/A	N/A	N/A	N/A
Urinary System	1,911	62.1	0.65	73.0	0.75	746	21.2	0.36	24.8	0.41
Bladder (incl. <i>in situ</i>)	1,095	36.1	0.50	42.2	0.58	331	9.0	0.23	10.6	0.27
Kidney & renal pelvis	776	24.6	0.41	29.2	0.47	393	11.5	0.27	13.4	0.31
Ureter	21	0.7	0.07	0.8	0.08	12	0.3	0.04	0.4	0.05
Eye & Orbit	24	0.8	0.07	0.9	0.08	24	0.7	0.07	0.8	0.08
Brain & Other CNS	248	8.4	0.24	9.2	0.26	180	5.8	0.20	6.3	0.21
Brain	237	7.9	0.24	8.8	0.26	168	5.3	0.19	5.8	0.20
Endocrine System	230	7.7	0.23	8.7	0.26	519	18.1	0.37	19.4	0.38
Thyroid gland	208	7.0	0.22	7.9	0.25	502	17.6	0.36	18.8	0.38
Lymphomas	899	29.8	0.46	34.2	0.52	673	19.7	0.35	22.6	0.39
Hodgkin lymphoma	94	3.4	0.16	3.5	0.16	71	2.5	0.14	2.6	0.14
Non-Hodgkin lymphoma	805	26.5	0.43	30.7	0.49	602	17.1	0.32	20.0	0.37
Multiple Myeloma	269	8.6	0.24	10.2	0.28	181	5.1	0.17	6.0	0.20
Leukemias	649	21.6	0.39	24.6	0.44	412	12.1	0.28	13.6	0.30
Acute lymphocytic	50	1.9	0.12	1.7	0.11	43	1.6	0.11	1.5	0.10
Chronic lymphocytic	272	8.8	0.24	10.3	0.28	144	3.9	0.15	4.6	0.17
Acute myeloid	185	6.2	0.21	7.1	0.23	138	4.1	0.16	4.6	0.18
Chronic myeloid	84	2.9	0.14	3.3	0.16	57	1.7	0.10	1.9	0.12
Other leukemias	58	2.0	0.12	2.3	0.13	30	0.8	0.07	0.9	0.08
Mesothelioma	57	2.0	0.12	2.3	0.14	18	0.5	0.06	0.6	0.06
Kaposi Sarcoma	9	0.3	0.05	0.3	0.05	*	*	*	*	*
Ill-Defined & Unknown	578	19.7	0.37	22.7	0.43	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	248	8.3	0.24	9.3	0.27	440	13.5	0.30	15.3	0.33
Breast (<i>in situ</i>)	4	0.1	0.03	0.1	0.03	973	29.9	0.45	35.4	0.51

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Minnesota, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	14,634	509.0	1.94	601.2	2.24	13,917	452.9	1.81	526.1	2.04
Oral Cavity & Pharynx	527	17.9	0.36	21.7	0.43	238	7.4	0.22	8.8	0.26
Lip	42	1.6	0.11	1.8	0.12	19	0.6	0.06	0.7	0.07
Tongue	176	5.9	0.21	7.2	0.25	70	2.2	0.13	2.6	0.14
Major salivary gland	38	1.4	0.10	1.6	0.12	33	1.1	0.09	1.3	0.10
Floor of mouth	25	0.8	0.08	1.0	0.09	14	0.4	0.05	0.5	0.06
Gum & other mouth	52	1.8	0.12	2.1	0.13	55	1.6	0.10	1.9	0.12
Nasopharynx	11	0.4	0.05	0.4	0.06	4	0.2	0.03	0.2	0.04
Oropharynx	30	0.9	0.08	1.2	0.10	7	0.2	0.04	0.3	0.05
Hypopharynx	26	0.9	0.08	1.0	0.09	6	0.2	0.03	0.2	0.04
Digestive System	2,555	89.8	0.82	106.4	0.95	2,020	62.2	0.65	72.8	0.74
Esophagus	251	8.4	0.25	10.2	0.29	65	1.9	0.11	2.3	0.13
Stomach	197	6.9	0.23	8.2	0.26	98	3.1	0.14	3.6	0.17
Small intestine	88	3.1	0.15	3.7	0.18	72	2.3	0.13	2.7	0.15
Colon (excl. rectum)	785	28.6	0.47	33.4	0.54	799	24.7	0.41	28.5	0.46
Rectum & rectosigmoid	365	13.0	0.32	15.4	0.37	231	7.6	0.24	9.1	0.27
Anus, anal canal, & anorectum	30	1.0	0.09	1.2	0.10	72	2.2	0.12	2.7	0.15
Liver	222	7.2	0.22	8.9	0.27	77	2.3	0.12	2.7	0.14
Gallbladder	19	0.7	0.07	0.8	0.08	38	1.1	0.08	1.3	0.10
Pancreas	442	15.3	0.33	18.2	0.39	412	12.2	0.28	14.4	0.32
Respiratory System	1,893	64.9	0.68	77.0	0.80	1,794	53.6	0.58	63.6	0.68
Larynx	128	4.2	0.17	5.1	0.21	34	1.0	0.08	1.2	0.10
Lung & bronchus	1,736	59.6	0.66	70.6	0.76	1,745	52.1	0.57	61.7	0.67
Bones & Joints	27	1.1	0.10	1.2	0.10	19	0.8	0.08	0.8	0.08
Soft Tissue (incl. heart)	100	3.9	0.18	4.3	0.19	81	3.0	0.16	3.2	0.16
Skin (excl. basal & sq.)	1,289	46.7	0.60	54.2	0.68	993	36.7	0.55	41.0	0.59
Melanoma of the skin	1,195	43.3	0.58	50.2	0.66	940	35.0	0.54	39.0	0.58
Breast (excl. <i>in situ</i>)	28	1.0	0.08	1.1	0.10	4,186	139.1	1.01	162.9	1.15
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,656	53.1	0.61	63.3	0.71
Cervix uteri	N/A	N/A	N/A	N/A	N/A	124	5.3	0.22	5.5	0.23
Uterus corpus	N/A	N/A	N/A	N/A	N/A	987	30.3	0.45	37.2	0.54
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	16	0.5	0.06	0.6	0.07
Ovary	N/A	N/A	N/A	N/A	N/A	306	10.1	0.27	11.8	0.31
Male Genital System	3,734	121.1	0.91	147.5	1.09	N/A	N/A	N/A	N/A	N/A
Prostate	3,531	111.9	0.86	138.1	1.05	N/A	N/A	N/A	N/A	N/A
Testis	168	7.9	0.28	7.9	0.28	N/A	N/A	N/A	N/A	N/A
Penis	27	1.0	0.09	1.1	0.10	N/A	N/A	N/A	N/A	N/A
Urinary System	1,783	62.8	0.68	73.8	0.79	683	21.2	0.38	24.7	0.43
Bladder (incl. <i>in situ</i>)	1,046	37.0	0.52	43.3	0.60	309	9.1	0.24	10.7	0.28
Kidney & renal pelvis	699	24.4	0.43	28.9	0.50	354	11.5	0.29	13.3	0.32
Ureter	20	0.7	0.07	0.8	0.08	12	0.3	0.04	0.4	0.05
Eye & Orbit	23	0.9	0.08	1.0	0.09	22	0.7	0.07	0.9	0.08
Brain & Other CNS	228	8.9	0.27	9.8	0.29	164	6.1	0.23	6.6	0.23
Brain	217	8.4	0.27	9.3	0.28	153	5.6	0.22	6.1	0.23
Endocrine System	205	7.9	0.26	8.9	0.28	445	18.6	0.41	19.8	0.43
Thyroid gland	187	7.2	0.25	8.2	0.27	430	18.0	0.41	19.2	0.42
Lymphomas	819	30.2	0.49	34.5	0.55	611	19.8	0.38	22.7	0.42
Hodgkin lymphoma	83	3.6	0.18	3.7	0.19	62	2.7	0.16	2.8	0.16
Non-Hodgkin lymphoma	736	26.6	0.45	30.8	0.51	549	17.1	0.34	19.9	0.39
Multiple Myeloma	235	8.2	0.24	9.6	0.28	161	4.9	0.18	5.8	0.21
Leukemias	597	21.9	0.41	25.0	0.46	370	12.0	0.29	13.5	0.32
Acute lymphocytic	36	1.7	0.13	1.6	0.12	31	1.5	0.12	1.4	0.11
Chronic lymphocytic	258	9.0	0.26	10.6	0.30	134	3.9	0.16	4.6	0.18
Acute myeloid	171	6.2	0.22	7.1	0.25	127	4.2	0.17	4.7	0.19
Chronic myeloid	77	2.9	0.15	3.3	0.17	51	1.7	0.11	1.9	0.12
Other leukemias	55	2.1	0.13	2.4	0.14	27	0.8	0.07	0.9	0.08
Mesothelioma	55	2.1	0.13	2.4	0.14	17	0.5	0.06	0.6	0.07
Kaposi Sarcoma	3	0.1	0.03	0.1	0.03	*	*	*	*	*
Ill-Defined & Unknown	534	19.6	0.39	22.6	0.44	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	219	8.3	0.26	9.3	0.28	391	13.6	0.33	15.4	0.36
Breast (<i>in situ</i>)	3	0.1	0.03	0.1	0.04	888	30.8	0.49	36.3	0.56

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Minnesota, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	574	546.2	11.98	663.0	14.02	466	398.1	8.88	472.1	10.46
Oral Cavity & Pharynx	16	13.9	1.86	16.6	2.16	10	8.3	1.23	9.8	1.48
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	4	3.9	0.98	4.5	1.09	3	2.5	0.77	3.2	0.94
Major salivary gland	1	1.8	0.87	2.2	1.00	2	1.2	0.40	1.3	0.47
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	2	1.4	0.62	1.6	0.72	3	2.2	0.66	2.6	0.78
Nasopharynx	2	1.4	0.40	1.5	0.47	*	*	*	*	*
Oropharynx	1	1.4	0.62	1.5	0.64	*	*	*	*	*
Hypopharynx	1	1.5	0.66	1.9	0.83	*	*	*	*	*
Digestive System	132	129.4	5.95	154.8	6.91	86	76.9	3.98	92.8	4.73
Esophagus	6	6.3	1.40	7.4	1.54	4	3.1	0.76	3.7	0.89
Stomach	12	10.6	1.65	12.8	1.97	7	6.0	1.11	7.6	1.36
Small intestine	4	3.6	0.96	4.2	1.09	2	2.0	0.62	2.5	0.74
Colon (excl. rectum)	35	33.7	3.04	40.3	3.53	26	22.4	2.12	27.0	2.51
Rectum & rectosigmoid	17	17.2	2.21	20.2	2.54	10	8.1	1.22	9.6	1.44
Anus, anal canal, & anorectum	1	1.1	0.44	1.3	0.51	2	2.4	0.75	2.8	0.85
Liver	33	31.0	2.83	38.0	3.34	10	9.2	1.39	11.4	1.68
Gallbladder	*	*	*	*	*	3	2.7	0.79	3.2	0.93
Pancreas	16	17.2	2.17	20.3	2.50	14	13.3	1.72	16.0	2.02
Respiratory System	79	82.4	4.86	100.4	5.65	57	54.3	3.42	66.3	4.08
Larynx	7	6.0	1.14	7.7	1.39	3	3.2	0.83	4.1	1.03
Lung & bronchus	70	75.2	4.71	91.5	5.46	53	49.8	3.27	60.9	3.90
Bones & Joints	2	0.8	0.26	0.7	0.23	*	*	*	*	*
Soft Tissue (incl. heart)	4	2.5	0.72	2.6	0.80	4	2.4	0.65	2.6	0.75
Skin (excl. basal & sq.)	4	2.8	0.73	3.6	0.89	4	2.9	0.70	3.2	0.78
Melanoma of the skin	*	*	*	*	*	2	1.5	0.52	1.7	0.59
Breast (excl. <i>in situ</i>)	1	1.1	0.46	1.3	0.53	131	105.6	4.39	124.9	5.19
Female Genital System	N/A	N/A	N/A	N/A	N/A	65	56.2	3.35	67.8	3.98
Cervix uteri	N/A	N/A	N/A	N/A	N/A	12	9.2	1.27	10.5	1.46
Uterus corpus	N/A	N/A	N/A	N/A	N/A	37	32.9	2.56	40.8	3.10
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	1.6	0.62	2.1	0.77
Ovary	N/A	N/A	N/A	N/A	N/A	9	8.4	1.35	9.7	1.56
Male Genital System	184	172.2	6.48	216.8	7.77	N/A	N/A	N/A	N/A	N/A
Prostate	180	169.3	6.44	213.4	7.73	N/A	N/A	N/A	N/A	N/A
Testis	3	1.7	0.48	2.0	0.57	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	54	51.6	3.70	61.5	4.27	27	24.8	2.29	29.3	2.67
Bladder (incl. <i>in situ</i>)	19	22.3	2.71	26.0	3.04	9	9.4	1.50	11.2	1.77
Kidney & renal pelvis	34	28.3	2.49	34.4	2.95	16	13.6	1.61	16.1	1.87
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	7	5.0	0.99	5.4	1.07	5	3.1	0.72	3.5	0.81
Brain	7	4.8	0.98	5.2	1.07	4	2.9	0.71	3.3	0.80
Endocrine System	9	6.6	1.15	7.9	1.38	21	14.1	1.47	15.3	1.64
Thyroid gland	7	5.9	1.13	7.2	1.35	21	13.8	1.45	14.8	1.62
Lymphomas	28	24.0	2.44	28.1	2.86	19	16.7	1.88	18.8	2.11
Hodgkin lymphoma	5	2.8	0.57	2.9	0.62	3	1.7	0.56	1.8	0.58
Non-Hodgkin lymphoma	23	21.2	2.37	25.1	2.79	16	14.9	1.79	17.0	2.03
Multiple Myeloma	17	15.5	1.99	19.5	2.39	9	8.7	1.42	10.5	1.68
Leukemias	15	13.9	1.98	15.9	2.25	12	9.2	1.32	9.9	1.48
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	4	3.6	0.95	4.3	1.11	2	1.7	0.59	2.2	0.75
Acute myeloid	6	5.9	1.31	6.7	1.47	3	2.5	0.76	2.8	0.87
Chronic myeloid	3	2.6	0.94	2.8	1.05	3	2.2	0.60	2.3	0.66
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	4	3.3	0.90	3.5	0.95	*	*	*	*	*
Ill-Defined & Unknown	16	20.1	2.61	23.2	2.97	15	14.1	1.79	16.5	2.06
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	10	7.6	1.26	9.0	1.50	16	12.3	1.49	14.5	1.76
Breast (<i>in situ</i>)	*	*	*	*	*	30	22.6	1.91	28.5	2.39

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Minnesota, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	244	317.1	10.06	371.5	11.64	313	297.1	7.98	341.8	9.23
Oral Cavity & Pharynx	12	13.2	1.87	16.2	2.27	5	4.2	0.91	5.1	1.10
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	2.4	0.85	2.9	1.02	*	*	*	*	*
Major salivary gland	1	1.4	0.52	1.8	0.71	2	1.8	0.59	2.1	0.71
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	5	5.0	1.09	5.8	1.26	2	1.5	0.50	1.9	0.65
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	1	1.9	0.85	2.3	1.00	*	*	*	*	*
Digestive System	84	105.6	5.65	126.5	6.65	65	71.3	4.17	82.6	4.79
Esophagus	4	5.2	1.24	6.4	1.50	1	1.4	0.54	1.6	0.64
Stomach	11	14.2	2.10	17.2	2.51	10	10.4	1.60	11.8	1.82
Small intestine	2	2.0	0.77	2.2	0.83	1	1.0	0.42	1.1	0.45
Colon (excl. rectum)	17	19.8	2.36	23.4	2.76	16	17.1	2.03	20.1	2.37
Rectum & rectosigmoid	15	15.9	2.02	19.2	2.41	9	9.1	1.40	10.6	1.64
Anus, anal canal, & anorectum	*	*	*	*	*	1	1.4	0.56	1.7	0.67
Liver	22	26.4	2.71	32.5	3.26	9	10.7	1.66	12.6	1.90
Gallbladder	*	*	*	*	*	3	3.1	0.92	3.6	1.03
Pancreas	8	13.5	2.32	15.7	2.64	9	10.6	1.67	12.1	1.88
Respiratory System	36	56.8	4.54	66.0	5.17	32	36.1	2.97	42.7	3.46
Larynx	1	3.0	1.16	3.2	1.24	*	*	*	*	*
Lung & bronchus	34	53.1	4.37	62.0	4.99	31	35.3	2.95	41.8	3.43
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	2	2.0	0.67	2.2	0.73	2	1.4	0.50	1.3	0.50
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	3	3.2	0.85	3.5	0.92
Melanoma of the skin	2	1.8	0.68	2.0	0.76	1	1.6	0.64	1.8	0.71
Breast (excl. <i>in situ</i>)	*	*	*	*	*	94	82.9	3.97	96.1	4.69
Female Genital System	N/A	N/A	N/A	N/A	N/A	44	36.3	2.60	41.2	3.01
Cervix uteri	N/A	N/A	N/A	N/A	N/A	10	8.1	1.23	9.0	1.40
Uterus corpus	N/A	N/A	N/A	N/A	N/A	21	17.2	1.78	19.4	2.05
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	9	7.0	1.08	8.2	1.30
Male Genital System	38	52.6	4.18	61.8	4.79	N/A	N/A	N/A	N/A	N/A
Prostate	33	49.4	4.11	58.7	4.73	N/A	N/A	N/A	N/A	N/A
Testis	4	2.2	0.49	2.0	0.45	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	16	22.7	2.81	26.9	3.28	7	8.1	1.41	9.4	1.62
Bladder (incl. <i>in situ</i>)	7	11.4	2.13	13.4	2.46	4	4.2	1.04	5.0	1.20
Kidney & renal pelvis	9	10.2	1.71	12.3	2.04	4	3.9	0.95	4.5	1.09
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	5	3.8	0.94	4.0	1.01	3	2.2	0.62	2.4	0.70
Brain	4	3.7	0.93	3.9	1.01	3	2.2	0.62	2.4	0.70
Endocrine System	6	4.9	1.00	5.4	1.13	24	18.3	1.77	19.7	1.98
Thyroid gland	4	3.3	0.74	3.5	0.83	24	17.9	1.75	19.2	1.96
Lymphomas	16	20.2	2.50	23.0	2.83	11	10.2	1.47	12.0	1.73
Hodgkin lymphoma	2	1.3	0.60	1.5	0.68	2	1.4	0.51	1.5	0.55
Non-Hodgkin lymphoma	15	18.9	2.42	21.5	2.75	9	8.8	1.38	10.5	1.64
Multiple Myeloma	4	5.1	1.31	6.3	1.57	5	5.1	1.08	6.1	1.28
Leukemias	11	9.8	1.59	10.1	1.74	8	5.9	1.00	6.5	1.16
Acute lymphocytic	5	3.0	0.61	2.6	0.56	3	2.1	0.55	2.0	0.56
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	4	4.4	1.14	4.9	1.30	3	2.2	0.63	2.5	0.73
Chronic myeloid	1	1.5	0.75	1.5	0.80	1	1.1	0.48	1.3	0.58
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	10	15.6	2.40	18.2	2.79	9	11.2	1.76	12.5	1.96
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	9	8.5	1.46	9.6	1.69	15	14.5	1.76	17.2	2.08
Breast (<i>in situ</i>)	*	*	*	*	*	25	22.3	2.05	26.4	2.45

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Minnesota, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	87	644.1	33.16	759.1	38.11	98	622.7	29.73	733.4	34.33
Oral Cavity & Pharynx	4	27.6	6.60	32.4	7.69	2	12.2	4.02	14.4	4.60
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	20	143.1	15.51	169.5	17.85	20	124.2	13.14	150.1	15.54
Esophagus	2	9.5	3.65	12.0	4.45	1	5.6	2.31	7.8	3.21
Stomach	1	10.6	4.31	12.3	4.76	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	5	43.7	9.01	50.6	10.33	7	47.4	8.18	55.6	9.40
Rectum & rectosigmoid	4	26.0	6.60	30.4	7.52	2	12.5	4.41	14.3	4.95
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	4	26.5	5.98	34.3	7.43	3	15.0	4.29	18.5	5.15
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	4	28.3	6.64	34.1	7.92
Respiratory System	20	162.8	17.27	190.5	19.55	28	172.4	15.33	210.0	18.13
Larynx	2	12.6	4.72	14.4	5.19	*	*	*	*	*
Lung & bronchus	19	150.1	16.61	176.1	18.85	28	171.5	15.31	208.7	18.09
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Melanoma of the skin	1	9.2	4.05	11.1	4.73	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	16	95.5	11.34	112.6	13.01
Female Genital System	N/A	N/A	N/A	N/A	N/A	10	67.3	9.99	74.4	10.81
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	14.3	4.48	14.7	4.45
Uterus corpus	N/A	N/A	N/A	N/A	N/A	3	23.5	5.93	25.8	6.37
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	3	20.7	5.53	25.0	6.54
Male Genital System	15	111.2	13.72	133.6	15.93	N/A	N/A	N/A	N/A	N/A
Prostate	14	102.0	13.26	124.9	15.58	N/A	N/A	N/A	N/A	N/A
Testis	1	9.2	3.53	8.7	3.32	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	11	82.5	11.53	95.5	13.11	6	40.4	7.47	47.1	8.60
Bladder (incl. <i>in situ</i>)	3	23.6	6.41	27.6	7.33	2	11.4	4.26	13.3	4.97
Kidney & renal pelvis	8	57.1	9.41	66.4	10.76	5	29.0	6.14	33.8	7.02
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	1	9.4	3.69	10.2	4.03	1	5.1	2.11	6.1	2.58
Brain	1	9.4	3.69	10.2	4.03	*	*	*	*	*
Endocrine System	*	*	*	*	*	3	19.9	4.91	21.0	5.17
Thyroid gland	*	*	*	*	*	3	18.4	4.68	19.4	4.91
Lymphomas	3	20.8	5.29	26.1	6.56	3	22.1	6.05	25.5	6.93
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	2	11.9	4.27	14.7	5.07	*	*	*	*	*
Leukemias	3	23.2	6.46	26.5	7.44	2	15.4	4.90	18.2	5.89
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	1	10.1	4.28	10.5	4.49	1	8.4	3.69	10.3	4.47
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	3	24.6	7.23	29.0	8.50	3	28.6	7.62	32.9	8.83
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	2	15.9	5.15	17.4	5.55	2	14.4	4.27	16.5	4.85
Breast (<i>in situ</i>)	*	*	*	*	*	3	17.4	4.70	21.0	5.46

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Minnesota, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	250	393.3	13.56	463.0	15.55	286	388.8	11.81	453.1	13.65
Oral Cavity & Pharynx	5	6.1	1.51	7.5	1.78	4	5.9	1.53	6.9	1.78
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	1	1.9	0.89	2.2	0.98
Major salivary gland	*	*	*	*	*	1	1.1	0.49	1.3	0.63
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	1	1.5	0.83	1.6	0.87	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	64	105.5	7.15	125.7	8.27	51	84.2	5.90	98.0	6.75
Esophagus	2	3.4	1.21	4.4	1.50	*	*	*	*	*
Stomach	9	15.9	2.83	18.3	3.23	6	9.4	1.94	10.9	2.23
Small intestine	2	2.9	1.07	3.6	1.31	2	2.4	0.88	2.9	1.03
Colon (excl. rectum)	12	20.3	3.24	23.5	3.70	16	25.0	3.18	29.2	3.66
Rectum & rectosigmoid	10	13.4	2.42	15.8	2.82	7	10.2	1.91	11.6	2.16
Anus, anal canal, & anorectum	*	*	*	*	*	1	2.6	1.06	3.2	1.28
Liver	15	25.0	3.50	30.6	4.05	4	7.4	1.84	8.7	2.08
Gallbladder	*	*	*	*	*	2	3.9	1.39	4.5	1.55
Pancreas	8	14.1	2.61	16.8	2.99	9	16.6	2.78	18.9	3.13
Respiratory System	19	35.8	4.29	42.3	4.89	19	34.3	3.89	40.4	4.48
Larynx	2	3.1	1.16	3.9	1.41	*	*	*	*	*
Lung & bronchus	16	31.1	4.04	36.7	4.59	19	34.0	3.88	40.0	4.47
Bones & Joints	1	1.4	0.64	1.4	0.66	*	*	*	*	*
Soft Tissue (incl. heart)	4	4.4	1.27	5.2	1.54	2	2.1	0.78	2.3	0.85
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	5	8.0	1.89	9.4	2.18	7	7.4	1.34	8.5	1.59
Breast (excl. <i>in situ</i>)	*	*	*	*	*	80	103.4	5.77	121.4	6.73
Female Genital System	N/A	N/A	N/A	N/A	N/A	42	52.2	4.01	62.7	4.81
Cervix uteri	N/A	N/A	N/A	N/A	N/A	8	9.7	1.71	10.7	1.92
Uterus corpus	N/A	N/A	N/A	N/A	N/A	23	27.9	2.87	34.2	3.50
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	6	7.9	1.62	9.5	1.92
Male Genital System	59	97.3	6.71	116.1	7.70	N/A	N/A	N/A	N/A	N/A
Prostate	49	91.0	6.62	109.7	7.62	N/A	N/A	N/A	N/A	N/A
Testis	9	4.8	0.73	4.8	0.73	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	29	49.0	4.85	56.7	5.51	14	18.7	2.59	21.3	2.95
Bladder (incl. <i>in situ</i>)	9	23.2	3.69	26.2	4.12	3	4.4	1.32	5.1	1.51
Kidney & renal pelvis	19	25.0	3.05	29.7	3.58	11	14.2	2.23	16.2	2.53
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	5	4.8	1.21	5.3	1.41	6	5.7	1.39	5.8	1.46
Brain	5	4.6	1.20	5.2	1.40	5	5.5	1.38	5.6	1.45
Endocrine System	7	7.4	1.51	8.2	1.68	18	16.9	1.91	19.5	2.27
Thyroid gland	7	7.0	1.49	7.8	1.66	18	16.8	1.90	19.3	2.26
Lymphomas	22	31.8	3.79	37.4	4.38	19	26.6	3.27	30.5	3.68
Hodgkin lymphoma	3	2.3	0.67	2.5	0.81	3	3.3	1.17	3.5	1.27
Non-Hodgkin lymphoma	19	29.5	3.73	34.9	4.31	16	23.3	3.05	27.0	3.46
Multiple Myeloma	8	13.4	2.54	16.0	2.89	2	4.4	1.38	5.3	1.62
Leukemias	14	13.4	2.21	14.7	2.47	10	11.4	1.98	12.7	2.26
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	2	3.4	1.26	4.1	1.48	1	2.4	0.97	3.1	1.21
Acute myeloid	3	4.6	1.45	5.1	1.60	4	5.4	1.54	5.9	1.70
Chronic myeloid	1	0.9	0.40	1.2	0.56	1	1.4	0.56	1.6	0.68
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	5	10.6	2.57	12.1	2.86	8	12.6	2.34	14.9	2.73
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	4	5.7	1.51	6.6	1.69	12	14.3	2.18	16.2	2.48
Breast (<i>in situ</i>)	*	*	*	*	*	21	27.8	3.00	33.5	3.57

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

MINNESOTA

II-278 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Minnesota, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	223	400.6	14.55	471.4	16.65	250	377.1	12.16	438.3	14.03
Oral Cavity & Pharynx	5	6.9	1.69	8.5	2.00	3	5.4	1.54	6.1	1.74
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	1	1.7	0.94	1.9	0.98	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	55	102.2	7.46	122.0	8.64	45	79.8	5.96	92.7	6.81
Esophagus	2	3.8	1.35	4.9	1.67	*	*	*	*	*
Stomach	9	16.3	3.00	18.7	3.41	5	8.3	1.88	9.6	2.18
Small intestine	2	3.3	1.20	4.1	1.47	2	2.6	0.97	3.2	1.13
Colon (excl. rectum)	9	17.6	3.23	20.5	3.73	13	22.6	3.09	26.4	3.59
Rectum & rectosigmoid	8	13.3	2.62	15.6	3.04	6	10.0	1.98	11.3	2.23
Anus, anal canal, & anorectum	*	*	*	*	*	1	2.8	1.13	3.4	1.36
Liver	12	24.5	3.71	29.7	4.27	3	6.8	1.88	7.7	2.08
Gallbladder	*	*	*	*	*	2	3.7	1.41	4.2	1.54
Pancreas	7	13.2	2.55	15.9	2.96	7	16.1	2.88	18.4	3.25
Respiratory System	18	38.4	4.73	45.3	5.38	17	34.1	4.08	40.0	4.68
Larynx	2	3.4	1.29	4.3	1.58	*	*	*	*	*
Lung & bronchus	15	33.3	4.45	39.1	5.04	16	33.7	4.07	39.5	4.67
Bones & Joints	1	1.4	0.69	1.4	0.72	*	*	*	*	*
Soft Tissue (incl. heart)	3	4.2	1.36	4.8	1.64	2	2.3	0.86	2.5	0.94
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	5	8.6	2.07	10.1	2.37	7	8.2	1.49	9.4	1.77
Breast (excl. <i>in situ</i>)	*	*	*	*	*	72	103.2	6.06	121.1	7.07
Female Genital System	N/A	N/A	N/A	N/A	N/A	35	47.7	4.00	57.3	4.80
Cervix uteri	N/A	N/A	N/A	N/A	N/A	6	8.5	1.69	9.3	1.89
Uterus corpus	N/A	N/A	N/A	N/A	N/A	19	26.2	2.91	32.0	3.56
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	5	7.9	1.73	9.5	2.04
Male Genital System	53	98.5	7.14	117.5	8.18	N/A	N/A	N/A	N/A	N/A
Prostate	44	92.1	7.04	111.0	8.09	N/A	N/A	N/A	N/A	N/A
Testis	8	4.6	0.75	4.6	0.75	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	27	51.4	5.24	59.6	5.96	12	16.6	2.45	19.4	2.86
Bladder (incl. <i>in situ</i>)	9	24.2	3.96	27.3	4.41	3	4.4	1.36	5.1	1.57
Kidney & renal pelvis	18	26.4	3.33	31.5	3.91	9	12.2	2.04	14.3	2.39
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	5	5.0	1.33	5.7	1.56	5	6.1	1.52	6.1	1.59
Brain	5	5.0	1.33	5.7	1.56	5	5.9	1.50	5.9	1.58
Endocrine System	6	7.6	1.66	8.5	1.84	15	15.9	1.96	18.1	2.29
Thyroid gland	6	7.1	1.63	8.1	1.82	15	15.7	1.95	17.9	2.28
Lymphomas	19	32.9	4.13	38.9	4.77	17	26.6	3.43	30.4	3.85
Hodgkin lymphoma	2	2.1	0.71	2.4	0.88	3	3.7	1.28	3.9	1.40
Non-Hodgkin lymphoma	17	30.8	4.07	36.6	4.69	14	23.0	3.18	26.5	3.58
Multiple Myeloma	7	13.3	2.76	15.5	3.08	2	4.1	1.40	4.8	1.61
Leukemias	12	14.1	2.43	15.3	2.69	10	12.1	2.15	13.3	2.44
Acute lymphocytic	6	4.2	1.07	4.0	1.06	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	2	3.5	1.37	4.2	1.60	1	2.4	1.04	3.0	1.27
Acute myeloid	3	5.2	1.62	5.7	1.78	3	5.8	1.67	6.2	1.84
Chronic myeloid	*	*	*	*	*	1	1.4	0.61	1.6	0.75
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	5	11.6	2.86	13.2	3.17	6	12.0	2.45	14.0	2.81
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	4	5.7	1.64	6.6	1.82	11	14.4	2.24	16.4	2.56
Breast (<i>in situ</i>)	*	*	*	*	*	19	27.0	3.11	32.4	3.69

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Minnesota, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	5	160.3	39.89	191.5	46.54	7	284.6	66.31	337.4	78.62
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	2	79.2	31.32	92.3	35.08	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	2	54.8	19.05	64.0	22.16
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	1	48.3	20.54	58.5	24.73	N/A	N/A	N/A	N/A	N/A
Prostate	1	46.0	20.42	56.4	24.63	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


MINNESOTA

II-280 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	2,990,231	2,990,595	2,990,674	2,982,879	2,978,227
Non-Hispanic White	1,721,479	1,716,688	1,711,570	1,701,770	1,696,105
Non-Hispanic Black	1,129,543	1,132,447	1,133,940	1,132,865	1,131,597
Non-Hispanic Asian/Pacific Islander (NH API)	33,642	33,824	34,367	35,067	35,645
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	8,317	8,252	8,312	8,324	8,340


All Races Population 2015–2019: 14,932,606
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	90,531	92,582	95,606	97,966	99,492
Hispanic White	74,071	75,377	77,824	79,601	80,818
Hispanic Black	11,102	11,650	11,990	12,397	12,659

Hispanic/Latino Population, Census 2010: 81,481
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

MISSISSIPPI CANCER REGISTRY

Initial Operation: 1996
Population-based Data Available: 2003
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	103.3	107.5	107.9	107.9	104.1	106.1
Missing Race	0.0	0.0	0.0	0.0	0.0	0.0
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.2	0.8	0.5	0.7	0.6	0.8
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.3	Ovary	92.7
Oral Cavity & Pharynx	97.8	Prostate	97.8
Esophagus	96.1	Testis	99.6
Stomach	97.6	Bladder (incl. <i>in situ</i>)	98.4
Colon & Rectum	97.4	Kidney & Renal Pelvis	89.3
Liver	58.3	Brain & Other CNS	85.7
Pancreas	84.7	Brain & Other CNS (non-malig)	40.3
Lung & Bronchus	91.8	Thyroid	99.7
Melanomas of the Skin	99.6	Hodgkin Lymphoma	98.6
Female Breast (excl. <i>in situ</i>)	98.5	Non-Hodgkin Lymphoma	97.0
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	91.4
Cervix Uteri	98.3	Leukemias	88.3
Uterus Corpus & Uterus NOS	98.6		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Mississippi, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	9,025	551.7	2.68	661.9	3.17	7,899	420.3	2.18	493.2	2.51
Oral Cavity & Pharynx	338	20.2	0.51	24.8	0.61	130	6.7	0.27	8.1	0.32
Lip	11	0.7	0.09	0.8	0.11	1	0.1	0.03	0.1	0.03
Tongue	86	5.0	0.25	6.2	0.30	35	1.8	0.14	2.2	0.17
Major salivary gland	28	1.9	0.16	2.1	0.19	22	1.1	0.11	1.4	0.13
Floor of mouth	16	0.9	0.10	1.1	0.13	6	0.3	0.06	0.4	0.07
Gum & other mouth	42	2.5	0.18	3.1	0.22	24	1.2	0.11	1.5	0.14
Nasopharynx	17	1.1	0.12	1.3	0.14	7	0.3	0.06	0.4	0.07
Oropharynx	29	1.7	0.15	2.1	0.18	7	0.3	0.06	0.4	0.07
Hypopharynx	27	1.6	0.14	1.9	0.17	7	0.4	0.06	0.5	0.08
Digestive System	1,829	112.7	1.22	136.1	1.45	1,460	75.4	0.91	89.8	1.06
Esophagus	140	8.3	0.32	10.3	0.39	35	1.7	0.13	2.1	0.16
Stomach	136	8.5	0.34	10.2	0.40	100	5.2	0.24	6.2	0.28
Small intestine	60	3.8	0.22	4.5	0.26	58	3.1	0.19	3.6	0.22
Colon (excl. rectum)	634	39.8	0.73	47.6	0.86	610	31.6	0.59	37.4	0.69
Rectum & rectosigmoid	268	16.5	0.47	20.0	0.55	187	10.1	0.34	12.0	0.40
Anus, anal canal, & anorectum	23	1.5	0.15	1.8	0.17	49	2.6	0.17	3.2	0.20
Liver	221	12.5	0.39	15.9	0.48	72	3.6	0.19	4.4	0.23
Gallbladder	11	0.7	0.09	0.8	0.11	24	1.2	0.11	1.5	0.13
Pancreas	261	16.3	0.47	19.5	0.55	240	12.0	0.35	14.3	0.42
Respiratory System	1,672	101.9	1.15	122.6	1.36	1,205	59.9	0.78	72.2	0.94
Larynx	137	7.9	0.31	10.0	0.39	33	1.7	0.13	2.1	0.16
Lung & bronchus	1,516	92.8	1.10	111.3	1.30	1,162	57.6	0.77	69.5	0.92
Bones & Joints	15	1.0	0.12	1.1	0.13	12	0.7	0.10	0.8	0.10
Soft Tissue (incl. heart)	59	3.9	0.23	4.4	0.26	47	2.8	0.18	3.0	0.20
Skin (excl. basal & sq.)	406	26.5	0.61	30.8	0.70	259	14.8	0.43	16.8	0.47
Melanoma of the skin	380	24.6	0.58	28.7	0.67	244	14.0	0.41	15.9	0.46
Breast (excl. <i>in situ</i>)	19	1.2	0.13	1.4	0.15	2,280	123.5	1.20	145.2	1.38
Female Genital System	N/A	N/A	N/A	N/A	N/A	854	46.7	0.74	54.6	0.85
Cervix uteri	N/A	N/A	N/A	N/A	N/A	144	9.3	0.36	9.9	0.37
Uterus corpus	N/A	N/A	N/A	N/A	N/A	441	22.9	0.50	27.8	0.60
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	20	1.0	0.11	1.2	0.13
Ovary	N/A	N/A	N/A	N/A	N/A	159	8.6	0.32	10.0	0.36
Male Genital System	2,453	140.9	1.31	173.5	1.59	N/A	N/A	N/A	N/A	N/A
Prostate	2,381	135.6	1.28	168.2	1.56	N/A	N/A	N/A	N/A	N/A
Testis	55	4.1	0.25	4.0	0.24	N/A	N/A	N/A	N/A	N/A
Penis	14	0.9	0.11	1.1	0.13	N/A	N/A	N/A	N/A	N/A
Urinary System	973	61.6	0.91	73.0	1.07	458	23.8	0.51	28.1	0.60
Bladder (incl. <i>in situ</i>)	465	30.1	0.64	35.5	0.75	146	7.3	0.27	8.7	0.32
Kidney & renal pelvis	492	30.4	0.63	36.2	0.74	302	16.1	0.43	18.9	0.49
Ureter	10	0.7	0.10	0.8	0.12	6	0.3	0.05	0.3	0.06
Eye & Orbit	16	1.1	0.12	1.2	0.14	15	0.8	0.10	0.9	0.11
Brain & Other CNS	102	6.6	0.30	7.4	0.33	87	5.1	0.25	5.4	0.26
Brain	98	6.3	0.29	7.1	0.32	81	4.7	0.24	5.0	0.25
Endocrine System	85	5.6	0.28	6.3	0.31	236	14.7	0.44	15.9	0.47
Thyroid gland	74	4.9	0.26	5.6	0.29	224	14.0	0.43	15.2	0.46
Lymphomas	358	23.3	0.57	26.6	0.64	298	16.1	0.43	18.5	0.48
Hodgkin lymphoma	40	2.8	0.20	2.9	0.21	33	2.1	0.17	2.2	0.17
Non-Hodgkin lymphoma	318	20.6	0.53	23.7	0.61	265	14.0	0.39	16.2	0.45
Multiple Myeloma	164	10.2	0.37	12.1	0.43	149	7.6	0.28	9.0	0.33
Leukemias	236	15.4	0.46	17.5	0.52	176	9.5	0.33	10.7	0.37
Acute lymphocytic	22	1.5	0.14	1.4	0.14	16	1.0	0.12	1.0	0.11
Chronic lymphocytic	81	5.0	0.26	6.1	0.31	51	2.5	0.16	3.0	0.19
Acute myeloid	73	4.8	0.26	5.4	0.29	63	3.5	0.20	3.9	0.22
Chronic myeloid	37	2.5	0.19	2.8	0.21	27	1.5	0.13	1.7	0.15
Other leukemias	23	1.5	0.15	1.8	0.17	19	1.0	0.10	1.2	0.12
Mesothelioma	20	1.4	0.14	1.6	0.16	7	0.4	0.07	0.4	0.08
Kaposi Sarcoma	8	0.6	0.10	0.6	0.10	*	*	*	*	*
Ill-Defined & Unknown	269	17.6	0.49	20.7	0.58	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	129	8.5	0.35	9.7	0.39	267	14.7	0.41	16.9	0.47
Breast (<i>in situ</i>)	*	*	*	*	*	458	24.6	0.53	29.4	0.62

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Mississippi, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	6,006	539.7	3.21	642.8	3.77	5,243	434.1	2.83	507.3	3.23
Oral Cavity & Pharynx	247	21.9	0.65	27.1	0.78	93	7.4	0.36	9.0	0.43
Lip	10	0.9	0.13	1.1	0.16	1	0.1	0.05	0.1	0.05
Tongue	68	6.0	0.33	7.5	0.41	30	2.4	0.21	2.9	0.24
Major salivary gland	19	1.8	0.19	2.1	0.22	13	1.1	0.13	1.3	0.16
Floor of mouth	10	0.9	0.12	1.1	0.15	5	0.4	0.08	0.4	0.09
Gum & other mouth	30	2.7	0.23	3.3	0.27	15	1.2	0.14	1.4	0.17
Nasopharynx	9	0.8	0.13	1.0	0.15	3	0.3	0.07	0.3	0.08
Oropharynx	20	1.8	0.18	2.2	0.22	5	0.4	0.08	0.5	0.10
Hypopharynx	16	1.4	0.15	1.7	0.19	4	0.3	0.07	0.4	0.10
Digestive System	1,166	105.7	1.43	126.9	1.69	896	70.3	1.10	83.1	1.28
Esophagus	94	8.2	0.39	10.0	0.47	20	1.5	0.15	1.8	0.18
Stomach	72	6.6	0.36	7.8	0.42	50	4.0	0.27	4.7	0.31
Small intestine	34	3.1	0.25	3.7	0.29	33	2.7	0.22	3.1	0.25
Colon (excl. rectum)	388	36.1	0.85	42.6	0.98	375	29.3	0.71	34.3	0.81
Rectum & rectosigmoid	172	15.9	0.57	19.2	0.67	119	10.1	0.44	12.0	0.51
Anus, anal canal, & anorectum	17	1.6	0.18	1.9	0.21	38	3.1	0.24	3.8	0.28
Liver	156	13.1	0.48	16.6	0.60	48	3.7	0.24	4.4	0.29
Gallbladder	6	0.6	0.11	0.7	0.12	13	1.0	0.13	1.2	0.15
Pancreas	175	15.7	0.54	18.7	0.64	143	10.5	0.40	12.6	0.48
Respiratory System	1,123	98.2	1.34	117.7	1.59	894	66.9	1.03	80.6	1.23
Larynx	77	6.6	0.34	8.3	0.43	22	1.8	0.18	2.3	0.22
Lung & bronchus	1,033	90.4	1.28	108.0	1.52	863	64.3	1.00	77.6	1.21
Bones & Joints	10	1.0	0.15	1.1	0.15	8	0.8	0.14	0.8	0.13
Soft Tissue (incl. heart)	42	4.2	0.30	4.8	0.33	27	2.5	0.23	2.7	0.24
Skin (excl. basal & sq.)	394	37.4	0.87	43.6	1.00	248	23.3	0.71	26.3	0.77
Melanoma of the skin	371	35.2	0.85	41.0	0.97	238	22.5	0.70	25.4	0.76
Breast (excl. <i>in situ</i>)	11	1.0	0.14	1.2	0.16	1,450	122.1	1.52	143.6	1.74
Female Genital System	N/A	N/A	N/A	N/A	N/A	538	48.0	0.99	55.7	1.11
Cervix uteri	N/A	N/A	N/A	N/A	N/A	85	9.5	0.49	10.1	0.50
Uterus corpus	N/A	N/A	N/A	N/A	N/A	268	22.6	0.65	27.3	0.76
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	9	0.7	0.11	0.9	0.13
Ovary	N/A	N/A	N/A	N/A	N/A	111	9.6	0.43	11.0	0.48
Male Genital System	1,391	118.2	1.45	143.5	1.74	N/A	N/A	N/A	N/A	N/A
Prostate	1,339	111.7	1.39	136.9	1.70	N/A	N/A	N/A	N/A	N/A
Testis	41	5.5	0.39	5.3	0.37	N/A	N/A	N/A	N/A	N/A
Penis	10	0.9	0.14	1.1	0.16	N/A	N/A	N/A	N/A	N/A
Urinary System	732	66.9	1.14	79.3	1.33	295	23.4	0.64	27.7	0.74
Bladder (incl. <i>in situ</i>)	386	35.0	0.81	41.3	0.96	109	8.0	0.35	9.6	0.42
Kidney & renal pelvis	336	30.9	0.78	36.8	0.91	178	14.8	0.53	17.4	0.60
Ureter	8	0.8	0.13	0.9	0.15	5	0.3	0.07	0.4	0.09
Eye & Orbit	15	1.4	0.17	1.6	0.19	13	1.1	0.15	1.3	0.17
Brain & Other CNS	78	7.8	0.41	8.7	0.45	65	6.4	0.38	6.7	0.38
Brain	75	7.6	0.41	8.4	0.44	61	5.9	0.36	6.3	0.37
Endocrine System	64	6.6	0.39	7.4	0.42	160	17.3	0.65	18.6	0.67
Thyroid gland	56	5.8	0.36	6.5	0.40	155	16.7	0.63	17.9	0.66
Lymphomas	259	24.7	0.71	28.4	0.80	208	17.0	0.55	19.7	0.63
Hodgkin lymphoma	23	2.6	0.25	2.8	0.26	19	2.1	0.23	2.2	0.23
Non-Hodgkin lymphoma	236	22.1	0.66	25.6	0.76	190	14.9	0.51	17.5	0.58
Multiple Myeloma	83	7.5	0.38	8.8	0.44	61	4.6	0.27	5.4	0.32
Leukemias	175	16.7	0.58	18.9	0.65	124	10.3	0.44	11.5	0.48
Acute lymphocytic	15	1.7	0.21	1.6	0.19	12	1.4	0.19	1.3	0.17
Chronic lymphocytic	60	5.4	0.32	6.4	0.38	39	2.8	0.21	3.4	0.25
Acute myeloid	56	5.3	0.32	6.0	0.36	41	3.6	0.26	4.0	0.28
Chronic myeloid	26	2.6	0.24	3.0	0.26	17	1.5	0.17	1.6	0.18
Other leukemias	17	1.6	0.18	1.9	0.21	14	1.1	0.14	1.3	0.16
Mesothelioma	16	1.6	0.18	1.8	0.20	6	0.4	0.09	0.5	0.10
Kaposi Sarcoma	2	0.2	0.07	0.2	0.07	*	*	*	*	*
Ill-Defined & Unknown	199	18.6	0.60	21.8	0.70	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	88	8.8	0.43	9.9	0.48	167	14.4	0.53	16.5	0.59
Breast (<i>in situ</i>)	*	*	*	*	*	269	23.0	0.66	27.4	0.77

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

MISSISSIPPI

II-284 Incidence – NH White

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Mississippi, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,893	600.1	5.38	728.7	6.35	2,518	410.0	3.76	483.8	4.36
Oral Cavity & Pharynx	86	16.6	0.84	20.3	1.00	35	5.3	0.41	6.5	0.50
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	16	3.2	0.36	3.8	0.42	4	0.6	0.15	0.8	0.17
Major salivary gland	8	1.8	0.30	2.0	0.33	8	1.2	0.19	1.4	0.23
Floor of mouth	5	1.0	0.21	1.3	0.25	1	0.2	0.07	0.3	0.10
Gum & other mouth	11	2.2	0.31	2.8	0.38	8	1.3	0.21	1.6	0.25
Nasopharynx	7	1.4	0.24	1.6	0.28	3	0.5	0.13	0.6	0.15
Oropharynx	9	1.6	0.25	2.0	0.30	2	0.2	0.08	0.3	0.10
Hypopharynx	11	2.1	0.31	2.7	0.37	3	0.5	0.12	0.6	0.15
Digestive System	626	132.9	2.57	161.7	3.04	531	86.6	1.73	103.7	2.03
Esophagus	45	8.8	0.63	11.1	0.77	13	2.0	0.26	2.5	0.31
Stomach	60	13.5	0.85	16.4	1.00	47	7.6	0.52	9.1	0.61
Small intestine	26	5.5	0.52	6.6	0.60	24	4.0	0.38	4.6	0.43
Colon (excl. rectum)	235	51.1	1.61	61.8	1.91	225	36.5	1.12	43.8	1.32
Rectum & rectosigmoid	89	18.4	0.93	22.6	1.12	64	10.2	0.59	12.3	0.69
Anus, anal canal, & anorectum	7	1.3	0.24	1.5	0.26	11	1.8	0.25	2.2	0.29
Liver	57	10.5	0.66	13.4	0.82	20	3.2	0.33	3.8	0.39
Gallbladder	5	0.9	0.19	1.1	0.23	10	1.6	0.24	2.0	0.28
Pancreas	82	18.2	0.98	21.7	1.13	93	15.6	0.75	18.5	0.87
Respiratory System	536	115.7	2.42	140.4	2.86	296	47.5	1.28	57.6	1.51
Larynx	60	11.5	0.72	14.5	0.87	11	1.6	0.23	2.0	0.28
Lung & bronchus	472	103.2	2.31	124.8	2.71	284	45.7	1.25	55.3	1.48
Bones & Joints	5	1.0	0.22	1.0	0.22	4	0.7	0.15	0.7	0.16
Soft Tissue (incl. heart)	15	3.4	0.41	3.7	0.45	19	3.3	0.34	3.6	0.37
Skin (excl. basal & sq.)	9	1.9	0.30	2.1	0.33	10	1.6	0.23	1.8	0.26
Melanoma of the skin	6	1.2	0.25	1.4	0.28	5	0.8	0.17	1.0	0.20
Breast (excl. <i>in situ</i>)	8	1.9	0.32	2.2	0.37	794	129.3	2.11	152.2	2.44
Female Genital System	N/A	N/A	N/A	N/A	N/A	299	47.9	1.28	56.4	1.47
Cervix uteri	N/A	N/A	N/A	N/A	N/A	56	9.6	0.59	10.4	0.63
Uterus corpus	N/A	N/A	N/A	N/A	N/A	165	25.5	0.91	31.0	1.09
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	10	1.6	0.23	2.0	0.28
Ovary	N/A	N/A	N/A	N/A	N/A	44	7.3	0.50	8.6	0.58
Male Genital System	1,030	200.5	2.99	250.0	3.60	N/A	N/A	N/A	N/A	N/A
Prostate	1,014	197.2	2.96	246.6	3.58	N/A	N/A	N/A	N/A	N/A
Testis	10	2.1	0.30	2.0	0.28	N/A	N/A	N/A	N/A	N/A
Penis	4	1.0	0.23	1.2	0.26	N/A	N/A	N/A	N/A	N/A
Urinary System	230	50.8	1.62	60.4	1.89	156	25.6	0.94	30.1	1.09
Bladder (incl. <i>in situ</i>)	75	18.1	1.02	21.6	1.20	37	6.0	0.46	7.2	0.54
Kidney & renal pelvis	152	31.8	1.24	37.8	1.44	117	19.2	0.82	22.5	0.94
Ureter	2	0.3	0.13	0.4	0.16	*	*	*	*	*
Eye & Orbit	2	0.3	0.12	0.3	0.12	2	0.3	0.09	0.3	0.11
Brain & Other CNS	22	4.2	0.42	4.6	0.46	19	3.2	0.33	3.4	0.36
Brain	20	3.8	0.40	4.3	0.44	17	2.8	0.31	3.0	0.33
Endocrine System	19	3.8	0.41	4.4	0.47	66	11.0	0.62	12.1	0.67
Thyroid gland	15	3.2	0.38	3.7	0.44	61	10.1	0.59	11.1	0.64
Lymphomas	92	19.7	0.97	22.0	1.08	83	13.8	0.70	15.7	0.78
Hodgkin lymphoma	16	3.1	0.36	3.2	0.36	13	2.1	0.27	2.2	0.28
Non-Hodgkin lymphoma	76	16.5	0.90	18.8	1.02	70	11.7	0.64	13.5	0.73
Multiple Myeloma	79	17.4	0.94	20.7	1.10	87	14.2	0.71	16.9	0.82
Leukemias	57	12.7	0.81	14.3	0.91	50	8.3	0.54	9.5	0.61
Acute lymphocytic	6	1.1	0.21	1.0	0.20	4	0.7	0.16	0.7	0.15
Chronic lymphocytic	20	4.4	0.47	5.3	0.55	12	2.0	0.26	2.4	0.31
Acute myeloid	16	3.5	0.43	3.9	0.48	21	3.5	0.35	4.0	0.39
Chronic myeloid	11	2.5	0.37	2.8	0.41	8	1.4	0.22	1.5	0.24
Other leukemias	5	1.2	0.26	1.3	0.28	5	0.8	0.17	1.0	0.19
Mesothelioma	4	1.0	0.25	1.1	0.27	1	0.2	0.09	0.2	0.10
Kaposi Sarcoma	6	1.3	0.24	1.2	0.23	*	*	*	*	*
Ill-Defined & Unknown	67	15.3	0.91	18.1	1.05	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	38	8.5	0.67	9.8	0.76	93	15.4	0.73	17.9	0.84
Breast (<i>in situ</i>)	*	*	*	*	*	181	28.4	0.97	34.3	1.15

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Mississippi, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	37	288.1	22.94	349.2	27.06	56	319.9	20.03	369.3	22.93
Oral Cavity & Pharynx	2	10.2	3.62	12.6	4.49	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	11	88.8	13.01	107.3	15.25	11	66.2	9.26	80.2	11.04
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	1	9.1	4.03	11.9	5.01	1	11.2	4.42	13.2	5.16
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	3	23.5	6.91	29.4	8.26	3	15.8	4.09	20.1	5.06
Rectum & rectosigmoid	2	16.4	5.22	19.2	5.93	1	7.6	3.02	9.5	3.78
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	2	19.7	6.09	24.2	7.36	1	7.8	3.32	9.2	3.90
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	1	13.1	5.56	14.1	5.90	2	10.5	3.67	12.6	4.35
Respiratory System	4	37.9	8.86	44.7	10.16	8	52.9	8.91	60.7	10.12
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	4	37.9	8.86	44.7	10.16	7	48.4	8.47	56.0	9.68
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	15	81.5	9.76	95.8	11.31
Female Genital System	N/A	N/A	N/A	N/A	N/A	7	41.5	7.04	47.7	8.06
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	14.9	4.44	16.3	4.83
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2	11.8	3.67	14.5	4.53
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	9.6	3.29	11.0	3.72
Male Genital System	9	59.5	9.59	76.6	12.04	N/A	N/A	N/A	N/A	N/A
Prostate	8	54.4	9.06	71.1	11.51	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	2	21.7	6.82	24.6	7.64	2	14.4	4.27	15.8	4.61
Bladder (incl. <i>in situ</i>)	1	14.5	5.67	16.5	6.44	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	2	12.6	4.07	13.3	4.27
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	1	8.3	3.16	8.5	3.24
Brain	*	*	*	*	*	1	8.3	3.16	8.5	3.24
Endocrine System	1	10.3	4.08	10.6	4.23	4	23.3	5.10	24.2	5.29
Thyroid gland	1	10.3	4.08	10.6	4.23	4	20.7	4.76	22.1	5.07
Lymphomas	2	13.9	4.60	16.2	5.27	3	14.3	4.09	17.1	4.89
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	1	9.9	4.39	12.7	5.50	*	*	*	*	*
Leukemias	2	10.3	3.74	13.0	4.67	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	1	11.5	5.01	13.5	5.75	1	7.2	3.09	8.2	3.50
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	3	17.4	4.72	20.2	5.35
Breast (<i>in situ</i>)	*	*	*	*	*	4	23.7	5.15	27.9	6.00

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

MISSISSIPPI

II-286 Incidence – NH API

Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Mississippi, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	14	587.9	79.67	692.6	93.16	16	488.4	55.47	583.7	65.91
Oral Cavity & Pharynx	1	54.8	22.34	62.9	24.85	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	7	289.6	55.95	346.7	66.10	7	214.0	36.15	257.9	43.44
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	2	66.4	25.48	80.7	30.43	3	104.3	25.95	123.6	30.43
Rectum & rectosigmoid	1	64.6	28.41	71.9	33.63	1	34.7	13.26	41.5	16.34
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	2	86.9	31.62	103.8	36.19	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	3	74.6	20.19	94.7	25.47
Female Genital System	N/A	N/A	N/A	N/A	N/A	1	48.8	18.70	55.5	21.23
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	2	83.0	28.69	101.4	34.17	N/A	N/A	N/A	N/A	N/A
Prostate	2	79.1	28.42	97.2	33.91	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	1	48.2	19.19	53.4	21.34	1	40.5	15.49	48.9	18.72
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	1	44.3	18.79	49.2	20.92	1	40.5	15.49	48.9	18.72
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	1	34.4	14.30	38.9	16.26
Thyroid gland	*	*	*	*	*	1	34.4	14.30	38.9	16.26
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Mississippi, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	59	206.8	13.50	250.0	16.17	56	206.8	13.08	241.2	15.44
Oral Cavity & Pharynx	2	6.2	2.13	7.7	2.67	1	3.2	1.38	3.5	1.63
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	17	54.9	6.63	67.0	8.04	12	48.3	6.60	58.9	7.98
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	1	3.0	1.31	3.8	1.72	1	4.3	1.68	5.0	2.03
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	6	18.0	3.62	22.1	4.48	3	13.4	3.37	17.0	4.24
Rectum & rectosigmoid	4	12.6	3.31	15.0	3.88	1	4.9	2.10	5.7	2.46
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	3	11.4	3.06	14.1	3.70	2	7.1	2.69	8.3	3.09
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	1	6.0	2.45	7.2	2.88	2	8.9	3.09	10.2	3.49
Respiratory System	6	22.6	4.59	27.8	5.53	6	27.0	5.25	31.6	6.06
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	5	21.8	4.55	27.0	5.50	5	26.1	5.19	30.5	5.97
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	1	3.2	1.74	3.5	1.96	*	*	*	*	*
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Melanoma of the skin	2	6.9	2.64	7.8	3.07	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	14	49.6	6.13	57.2	7.25
Female Genital System	N/A	N/A	N/A	N/A	N/A	7	25.4	4.31	29.6	5.19
Cervix uteri	N/A	N/A	N/A	N/A	N/A	1	3.7	1.43	3.9	1.60
Uterus corpus	N/A	N/A	N/A	N/A	N/A	5	16.1	3.44	18.8	4.15
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	1	5.5	2.15	6.8	2.67
Male Genital System	15	59.7	7.50	71.3	8.83	N/A	N/A	N/A	N/A	N/A
Prostate	12	53.8	7.30	65.1	8.62	N/A	N/A	N/A	N/A	N/A
Testis	3	4.0	1.14	4.0	1.17	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	6	21.5	4.39	27.2	5.44	3	11.4	3.05	13.9	3.73
Bladder (incl. <i>in situ</i>)	2	9.1	3.04	11.3	3.70	*	*	*	*	*
Kidney & renal pelvis	3	9.4	2.37	12.7	3.28	2	9.2	2.77	10.8	3.24
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	1	3.8	1.54	4.4	1.91
Brain	*	*	*	*	*	1	3.5	1.51	4.1	1.90
Endocrine System	*	*	*	*	*	4	12.1	3.07	13.2	3.37
Thyroid gland	*	*	*	*	*	3	11.4	2.99	12.1	3.20
Lymphomas	3	9.7	2.95	11.4	3.46	3	11.5	3.28	12.7	3.64
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	2	5.2	1.98	5.6	2.20	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	7.1	2.65	8.9	3.25	2	5.5	1.95	6.4	2.41
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	3	9.3	2.71	9.8	2.90
Breast (<i>in situ</i>)	*	*	*	*	*	2	7.9	2.48	9.1	2.91

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

MISSISSIPPI

II-288 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Mississippi, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	53	227.5	15.88	275.8	19.08	49	224.5	15.19	262.6	18.05
Oral Cavity & Pharynx	2	6.9	2.53	8.7	3.18	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	15	59.0	7.67	72.8	9.39	10	49.4	7.47	60.0	9.03
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	1	3.7	1.63	4.6	2.13	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	6	20.4	4.36	25.0	5.35	3	13.4	3.86	16.4	4.72
Rectum & rectosigmoid	3	13.5	3.81	16.1	4.50	1	6.1	2.64	7.2	3.10
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	3	11.0	3.31	14.0	4.14	1	8.1	3.26	9.2	3.65
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	1	7.9	3.10	9.3	3.62
Respiratory System	5	24.9	5.37	31.3	6.57	5	27.9	6.00	32.6	6.91
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	5	24.4	5.35	30.7	6.54	5	27.9	6.00	32.6	6.91
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	1	4.0	2.13	4.3	2.40	*	*	*	*	*
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Melanoma of the skin	2	8.4	3.25	9.6	3.79	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	12	53.3	7.05	62.7	8.53
Female Genital System	N/A	N/A	N/A	N/A	N/A	7	27.5	4.97	31.8	5.99
Cervix uteri	N/A	N/A	N/A	N/A	N/A	1	3.7	1.53	3.5	1.45
Uterus corpus	N/A	N/A	N/A	N/A	N/A	4	18.0	4.02	21.1	4.92
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	1	5.9	2.49	7.2	3.09
Male Genital System	13	65.3	8.81	78.3	10.42	N/A	N/A	N/A	N/A	N/A
Prostate	11	59.8	8.65	72.5	10.24	N/A	N/A	N/A	N/A	N/A
Testis	2	4.5	1.32	4.4	1.34	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	5	22.8	5.17	28.5	6.31	3	12.4	3.54	15.6	4.44
Bladder (incl. <i>in situ</i>)	2	11.3	3.76	14.1	4.59	*	*	*	*	*
Kidney & renal pelvis	2	7.9	2.41	10.4	3.30	2	9.6	3.14	11.5	3.76
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	1	4.8	1.96	5.6	2.45
Brain	*	*	*	*	*	1	4.4	1.92	5.2	2.43
Endocrine System	*	*	*	*	*	3	14.3	3.73	15.7	4.13
Thyroid gland	*	*	*	*	*	3	13.4	3.63	14.3	3.90
Lymphomas	3	10.8	3.45	12.4	3.99	3	14.5	4.10	16.0	4.57
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	2	6.4	2.46	7.0	2.75	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	1	6.8	2.91	8.4	3.59	2	7.0	2.46	8.1	3.05
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	2	9.2	3.08	10.2	3.41
Breast (<i>in situ</i>)	*	*	*	*	*	2	8.3	2.87	9.6	3.39

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Mississippi, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2	54.7	16.80	66.2	20.25	4	99.6	24.55	111.5	27.16
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


MISSISSIPPI

II-290 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	6,075,411	6,091,384	6,111,382	6,125,986	6,140,475
Non-Hispanic White	4,920,883	4,923,210	4,927,014	4,927,568	4,927,910
Non-Hispanic Black	744,870	748,433	752,126	755,137	757,253
Non-Hispanic Asian/Pacific Islander (NH API)	134,929	138,128	143,254	146,975	151,705
Non-Hispanic American Indian/Alaskan Native PRCA (NH AI/AN)	0	0	0	0	0


All Races Population 2015–2019: 30,544,638
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	242,346	248,916	255,932	262,910	269,836
Hispanic White	212,069	217,412	223,170	228,790	234,294
Hispanic Black	15,723	16,318	16,727	17,425	18,084

Hispanic/Latino Population, Census 2010: 212,470
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

MISSOURI CANCER REGISTRY

Initial Operation: 1972
Population-based Data Available: 1985
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	105.7	103.8	107.5	102.7	101.3	104.2
Missing Race	0.2	0.2	0.4	0.4	0.3	0.3
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.5	2.3	2.4	2.4	2.4	2.4
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.1	Ovary	92.0
Oral Cavity & Pharynx	97.6	Prostate	96.8
Esophagus	92.8	Testis	99.1
Stomach	96.1	Bladder (incl. <i>in situ</i>)	97.6
Colon & Rectum	95.7	Kidney & Renal Pelvis	88.3
Liver	53.1	Brain & Other CNS	85.1
Pancreas	83.2	Brain & Other CNS (non-malig)	36.0
Lung & Bronchus	85.2	Thyroid	99.2
Melanomas of the Skin	98.9	Hodgkin Lymphoma	97.8
Female Breast (excl. <i>in situ</i>)	98.4	Non-Hodgkin Lymphoma	95.8
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	88.7
Cervix Uteri	97.9	Leukemias	88.7
Uterus Corpus & Uterus NOS	98.3		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Missouri, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	17,131	484.5	1.70	576.6	1.99	17,185	433.6	1.54	507.7	1.76
Oral Cavity & Pharynx	712	19.7	0.34	24.2	0.41	263	6.4	0.18	7.7	0.22
Lip	21	0.6	0.06	0.7	0.07	10	0.2	0.03	0.3	0.04
Tongue	232	6.3	0.19	7.8	0.23	80	2.0	0.10	2.4	0.12
Major salivary gland	55	1.6	0.10	1.9	0.12	33	0.8	0.07	1.0	0.08
Floor of mouth	25	0.7	0.06	0.8	0.08	13	0.3	0.04	0.4	0.05
Gum & other mouth	73	2.1	0.11	2.5	0.13	57	1.3	0.08	1.6	0.09
Nasopharynx	22	0.6	0.06	0.8	0.07	12	0.3	0.04	0.4	0.05
Oropharynx	52	1.4	0.09	1.7	0.11	10	0.2	0.03	0.3	0.04
Hypopharynx	42	1.1	0.08	1.4	0.10	9	0.2	0.03	0.3	0.04
Digestive System	3,413	97.2	0.76	116.3	0.90	2,712	65.8	0.58	77.7	0.68
Esophagus	320	8.9	0.23	10.7	0.27	83	1.9	0.10	2.3	0.12
Stomach	257	7.4	0.21	8.8	0.25	147	3.6	0.14	4.2	0.16
Small intestine	98	2.8	0.13	3.3	0.15	93	2.3	0.11	2.8	0.13
Colon (excl. rectum)	1,059	31.2	0.44	36.6	0.51	1,074	26.1	0.37	30.4	0.42
Rectum & rectosigmoid	491	14.1	0.29	16.9	0.35	341	8.7	0.22	10.4	0.26
Anus, anal canal, & anorectum	51	1.5	0.10	1.8	0.11	120	2.9	0.12	3.6	0.15
Liver	401	10.4	0.24	13.1	0.30	130	3.0	0.12	3.7	0.15
Gallbladder	30	0.9	0.07	1.0	0.08	47	1.1	0.07	1.3	0.09
Pancreas	535	15.2	0.30	18.1	0.35	479	11.2	0.24	13.3	0.28
Respiratory System	3,121	87.1	0.71	104.3	0.84	2,754	64.3	0.56	77.4	0.67
Larynx	229	6.2	0.19	7.7	0.23	68	1.7	0.09	2.1	0.11
Lung & bronchus	2,853	79.8	0.68	95.3	0.81	2,664	62.1	0.55	74.7	0.65
Bones & Joints	35	1.1	0.08	1.1	0.09	26	0.8	0.07	0.8	0.07
Soft Tissue (incl. heart)	126	3.8	0.16	4.3	0.17	96	2.6	0.13	2.9	0.13
Skin (excl. basal & sq.)	843	24.9	0.39	29.0	0.45	596	16.6	0.32	18.6	0.35
Melanoma of the skin	791	23.3	0.38	27.2	0.44	565	15.8	0.31	17.7	0.34
Breast (excl. <i>in situ</i>)	42	1.3	0.09	1.5	0.10	5,105	132.0	0.86	155.2	0.99
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,977	50.9	0.53	60.0	0.61
Cervix uteri	N/A	N/A	N/A	N/A	N/A	266	8.4	0.24	9.0	0.25
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,097	27.0	0.38	32.8	0.45
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	38	0.9	0.07	1.1	0.08
Ovary	N/A	N/A	N/A	N/A	N/A	366	9.5	0.23	11.0	0.26
Male Genital System	3,840	102.2	0.76	125.0	0.91	N/A	N/A	N/A	N/A	N/A
Prostate	3,649	95.6	0.72	118.3	0.88	N/A	N/A	N/A	N/A	N/A
Testis	157	5.6	0.20	5.5	0.20	N/A	N/A	N/A	N/A	N/A
Penis	25	0.7	0.07	0.9	0.08	N/A	N/A	N/A	N/A	N/A
Urinary System	2,091	60.6	0.61	71.5	0.71	927	22.6	0.34	26.6	0.40
Bladder (incl. <i>in situ</i>)	1,141	33.3	0.45	39.1	0.52	346	8.0	0.20	9.5	0.23
Kidney & renal pelvis	902	25.9	0.40	30.7	0.46	549	13.8	0.28	16.3	0.32
Ureter	30	0.9	0.07	1.0	0.08	21	0.5	0.05	0.6	0.06
Eye & Orbit	38	1.1	0.08	1.3	0.09	31	0.8	0.07	0.9	0.08
Brain & Other CNS	256	7.8	0.22	8.6	0.24	209	5.8	0.19	6.3	0.20
Brain	245	7.4	0.22	8.3	0.24	196	5.5	0.18	5.9	0.19
Endocrine System	223	6.9	0.21	7.8	0.23	593	18.1	0.35	19.6	0.37
Thyroid gland	201	6.2	0.20	7.0	0.22	570	17.5	0.34	18.9	0.36
Lymphomas	844	25.0	0.39	28.7	0.45	705	17.8	0.31	20.5	0.35
Hodgkin lymphoma	89	2.9	0.14	3.0	0.14	76	2.3	0.12	2.5	0.13
Non-Hodgkin lymphoma	755	22.1	0.37	25.7	0.42	629	15.5	0.28	18.1	0.33
Multiple Myeloma	288	8.2	0.22	9.8	0.26	221	5.3	0.16	6.3	0.19
Leukemias	607	18.2	0.34	20.8	0.38	413	10.6	0.24	12.0	0.27
Acute lymphocytic	50	1.7	0.11	1.6	0.10	39	1.3	0.09	1.2	0.09
Chronic lymphocytic	224	6.4	0.20	7.6	0.23	136	3.2	0.13	3.8	0.15
Acute myeloid	177	5.3	0.18	6.1	0.21	134	3.5	0.14	3.9	0.15
Chronic myeloid	77	2.3	0.12	2.7	0.14	50	1.4	0.09	1.5	0.10
Other leukemias	79	2.4	0.12	2.8	0.14	55	1.3	0.08	1.5	0.09
Mesothelioma	40	1.2	0.09	1.4	0.10	15	0.4	0.04	0.4	0.05
Kaposi Sarcoma	9	0.3	0.05	0.3	0.05	*	*	*	*	*
Ill-Defined & Unknown	604	17.9	0.33	20.9	0.38	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	302	9.2	0.24	10.4	0.27	653	17.2	0.31	19.7	0.35
Breast (<i>in situ</i>)	2	0.1	0.02	0.1	0.02	1,036	27.0	0.39	32.1	0.45

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Missouri, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	15,039	484.7	1.82	575.8	2.12	14,939	439.5	1.69	513.7	1.93
Oral Cavity & Pharynx	649	20.6	0.37	25.3	0.45	237	6.7	0.20	8.1	0.24
Lip	21	0.7	0.07	0.8	0.08	9	0.2	0.04	0.3	0.04
Tongue	218	6.9	0.21	8.5	0.26	73	2.1	0.12	2.6	0.14
Major salivary gland	49	1.7	0.11	2.0	0.13	29	0.9	0.08	1.0	0.09
Floor of mouth	23	0.7	0.07	0.9	0.08	12	0.3	0.04	0.4	0.05
Gum & other mouth	65	2.1	0.12	2.5	0.14	52	1.4	0.09	1.6	0.10
Nasopharynx	16	0.5	0.06	0.6	0.07	9	0.3	0.04	0.3	0.05
Oropharynx	45	1.4	0.10	1.7	0.12	9	0.3	0.04	0.3	0.05
Hypopharynx	36	1.1	0.08	1.3	0.10	9	0.2	0.04	0.3	0.05
Digestive System	2,918	94.9	0.81	113.2	0.95	2,293	64.1	0.62	75.5	0.72
Esophagus	293	9.3	0.25	11.2	0.29	68	1.8	0.10	2.2	0.12
Stomach	208	6.8	0.22	8.0	0.25	112	3.2	0.14	3.7	0.16
Small intestine	79	2.6	0.13	3.1	0.16	76	2.2	0.12	2.6	0.14
Colon (excl. rectum)	919	30.9	0.47	36.2	0.54	930	26.0	0.40	30.2	0.45
Rectum & rectosigmoid	428	14.2	0.32	17.0	0.37	284	8.6	0.24	10.1	0.28
Anus, anal canal, & anorectum	43	1.4	0.10	1.7	0.12	108	3.1	0.14	3.8	0.17
Liver	312	9.2	0.24	11.7	0.30	101	2.7	0.13	3.3	0.15
Gallbladder	24	0.8	0.07	0.9	0.08	37	1.0	0.07	1.1	0.09
Pancreas	461	14.8	0.32	17.6	0.37	407	10.9	0.25	12.9	0.29
Respiratory System	2,760	86.8	0.75	103.9	0.89	2,434	65.4	0.61	78.6	0.72
Larynx	196	6.1	0.20	7.5	0.24	59	1.7	0.10	2.1	0.12
Lung & bronchus	2,530	79.7	0.72	95.1	0.85	2,356	63.1	0.59	75.8	0.71
Bones & Joints	31	1.2	0.10	1.2	0.10	23	0.8	0.08	0.9	0.08
Soft Tissue (incl. heart)	106	3.8	0.17	4.2	0.19	77	2.5	0.13	2.7	0.14
Skin (excl. basal & sq.)	812	27.4	0.44	31.9	0.51	571	19.0	0.38	21.2	0.41
Melanoma of the skin	763	25.7	0.43	30.0	0.49	544	18.3	0.37	20.4	0.40
Breast (excl. <i>in situ</i>)	35	1.2	0.09	1.4	0.11	4,420	133.4	0.95	156.8	1.08
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,709	51.7	0.59	60.9	0.67
Cervix uteri	N/A	N/A	N/A	N/A	N/A	216	8.4	0.27	8.9	0.28
Uterus corpus	N/A	N/A	N/A	N/A	N/A	954	27.4	0.42	33.3	0.49
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	30	0.8	0.07	1.0	0.08
Ovary	N/A	N/A	N/A	N/A	N/A	320	9.7	0.26	11.3	0.29
Male Genital System	3,253	98.7	0.79	120.2	0.95	N/A	N/A	N/A	N/A	N/A
Prostate	3,084	91.4	0.75	112.8	0.92	N/A	N/A	N/A	N/A	N/A
Testis	139	6.2	0.24	6.1	0.23	N/A	N/A	N/A	N/A	N/A
Penis	23	0.8	0.07	0.9	0.09	N/A	N/A	N/A	N/A	N/A
Urinary System	1,887	61.9	0.65	72.9	0.76	805	22.8	0.37	26.8	0.43
Bladder (incl. <i>in situ</i>)	1,053	34.4	0.48	40.4	0.56	308	8.2	0.21	9.7	0.25
Kidney & renal pelvis	788	25.9	0.43	30.8	0.50	469	13.9	0.30	16.2	0.34
Ureter	28	0.9	0.08	1.1	0.09	20	0.5	0.05	0.6	0.06
Eye & Orbit	35	1.2	0.09	1.4	0.11	29	0.9	0.08	1.0	0.09
Brain & Other CNS	231	8.3	0.25	9.2	0.27	189	6.3	0.22	6.8	0.23
Brain	222	7.9	0.25	8.8	0.27	179	5.9	0.21	6.4	0.22
Endocrine System	199	7.3	0.24	8.2	0.26	509	18.9	0.40	20.4	0.41
Thyroid gland	184	6.7	0.23	7.5	0.25	490	18.3	0.39	19.8	0.41
Lymphomas	756	25.7	0.43	29.6	0.49	622	18.2	0.34	21.0	0.39
Hodgkin lymphoma	75	3.0	0.16	3.1	0.16	62	2.4	0.14	2.5	0.14
Non-Hodgkin lymphoma	681	22.7	0.40	26.5	0.46	560	15.9	0.31	18.5	0.36
Multiple Myeloma	234	7.6	0.23	9.0	0.27	165	4.5	0.16	5.3	0.19
Leukemias	545	18.7	0.37	21.4	0.41	364	11.0	0.27	12.3	0.30
Acute lymphocytic	41	1.7	0.12	1.6	0.11	32	1.3	0.11	1.2	0.10
Chronic lymphocytic	204	6.6	0.21	7.9	0.25	122	3.3	0.14	4.0	0.16
Acute myeloid	161	5.5	0.20	6.3	0.23	116	3.5	0.15	4.0	0.17
Chronic myeloid	67	2.3	0.13	2.7	0.15	44	1.4	0.10	1.6	0.11
Other leukemias	73	2.5	0.14	2.9	0.15	50	1.4	0.09	1.6	0.10
Mesothelioma	37	1.3	0.10	1.4	0.11	14	0.4	0.05	0.5	0.06
Kaposi Sarcoma	6	0.2	0.05	0.3	0.05	*	*	*	*	*
Ill-Defined & Unknown	545	18.2	0.36	21.3	0.41	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	260	9.3	0.27	10.4	0.29	544	16.8	0.34	19.2	0.38
Breast (<i>in situ</i>)	2	0.1	0.02	0.1	0.02	861	26.5	0.43	31.5	0.49

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Missouri, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,621	535.7	6.30	648.4	7.44	1,704	427.4	4.74	505.9	5.51
Oral Cavity & Pharynx	47	14.5	0.99	17.9	1.18	19	4.8	0.49	5.7	0.58
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	9	2.7	0.41	3.5	0.51	5	1.3	0.26	1.6	0.32
Major salivary gland	4	1.2	0.30	1.4	0.35	4	0.9	0.22	1.1	0.26
Floor of mouth	1	0.5	0.19	0.6	0.23	*	*	*	*	*
Gum & other mouth	5	1.5	0.31	2.0	0.38	3	0.8	0.20	0.9	0.23
Nasopharynx	4	1.3	0.30	1.5	0.34	2	0.3	0.12	0.4	0.15
Oropharynx	5	1.7	0.35	2.1	0.41	*	*	*	*	*
Hypopharynx	6	1.7	0.34	2.1	0.41	*	*	*	*	*
Digestive System	383	128.2	3.10	155.7	3.68	331	83.0	2.08	99.3	2.45
Esophagus	20	6.6	0.70	8.0	0.82	13	3.0	0.39	3.8	0.48
Stomach	37	13.3	1.03	15.8	1.20	26	6.6	0.59	7.8	0.69
Small intestine	16	5.2	0.61	6.4	0.74	14	3.6	0.44	4.4	0.52
Colon (excl. rectum)	105	36.5	1.69	43.8	1.98	114	29.1	1.24	34.4	1.45
Rectum & rectosigmoid	44	14.4	1.02	17.6	1.22	42	10.2	0.73	12.4	0.86
Anus, anal canal, & anorectum	7	2.3	0.40	2.7	0.45	9	2.3	0.35	2.8	0.41
Liver	70	20.8	1.17	26.5	1.44	21	4.9	0.49	6.0	0.60
Gallbladder	4	1.7	0.38	1.9	0.43	8	2.0	0.33	2.5	0.39
Pancreas	62	21.6	1.30	26.2	1.54	62	15.6	0.90	18.7	1.07
Respiratory System	304	105.5	2.88	127.3	3.37	266	65.6	1.84	79.6	2.20
Larynx	28	8.9	0.80	11.0	0.96	8	1.9	0.31	2.5	0.38
Lung & bronchus	272	95.6	2.75	114.9	3.22	255	63.1	1.81	76.5	2.15
Bones & Joints	3	0.8	0.23	0.9	0.25	2	0.5	0.17	0.6	0.18
Soft Tissue (incl. heart)	13	4.1	0.53	4.6	0.58	15	3.6	0.43	4.0	0.48
Skin (excl. basal & sq.)	5	1.8	0.39	1.9	0.42	4	1.1	0.25	1.3	0.27
Melanoma of the skin	3	1.0	0.30	1.2	0.35	2	0.6	0.18	0.6	0.19
Breast (excl. <i>in situ</i>)	6	2.1	0.41	2.5	0.48	523	133.0	2.67	156.4	3.07
Female Genital System	N/A	N/A	N/A	N/A	N/A	194	48.0	1.58	57.0	1.84
Cervix uteri	N/A	N/A	N/A	N/A	N/A	36	9.4	0.72	10.4	0.78
Uterus corpus	N/A	N/A	N/A	N/A	N/A	107	25.7	1.14	31.3	1.36
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	8	1.8	0.30	2.2	0.36
Ovary	N/A	N/A	N/A	N/A	N/A	29	7.5	0.63	8.8	0.73
Male Genital System	486	150.3	3.20	188.0	3.89	N/A	N/A	N/A	N/A	N/A
Prostate	476	146.9	3.17	184.5	3.85	N/A	N/A	N/A	N/A	N/A
Testis	7	2.2	0.38	2.2	0.38	N/A	N/A	N/A	N/A	N/A
Penis	2	0.7	0.27	0.8	0.29	N/A	N/A	N/A	N/A	N/A
Urinary System	147	50.5	1.97	60.1	2.30	94	23.3	1.10	27.6	1.28
Bladder (incl. <i>in situ</i>)	56	20.8	1.32	24.7	1.53	28	7.0	0.60	8.3	0.71
Kidney & renal pelvis	88	28.9	1.44	34.4	1.68	63	15.7	0.90	18.5	1.05
Ureter	1	0.4	0.17	0.5	0.19	*	*	*	*	*
Eye & Orbit	2	0.5	0.18	0.5	0.18	*	*	*	*	*
Brain & Other CNS	15	4.8	0.58	5.2	0.64	13	3.4	0.42	3.6	0.45
Brain	14	4.6	0.57	5.0	0.64	12	3.0	0.40	3.1	0.42
Endocrine System	13	4.0	0.51	4.5	0.58	47	12.1	0.81	13.7	0.90
Thyroid gland	8	2.6	0.42	3.0	0.48	44	11.3	0.78	12.8	0.87
Lymphomas	59	19.3	1.18	21.9	1.33	61	15.2	0.89	17.6	1.02
Hodgkin lymphoma	9	2.7	0.40	2.7	0.42	10	2.7	0.38	2.8	0.39
Non-Hodgkin lymphoma	50	16.6	1.11	19.2	1.27	50	12.5	0.81	14.8	0.94
Multiple Myeloma	48	17.3	1.19	20.7	1.38	49	12.5	0.82	14.8	0.95
Leukemias	42	14.6	1.06	16.7	1.21	35	8.8	0.68	10.0	0.77
Acute lymphocytic	4	1.0	0.24	0.9	0.23	4	0.9	0.20	0.8	0.20
Chronic lymphocytic	16	5.8	0.69	6.9	0.81	11	2.6	0.37	3.2	0.44
Acute myeloid	12	3.8	0.53	4.3	0.60	13	3.3	0.41	3.8	0.47
Chronic myeloid	7	2.3	0.41	2.6	0.46	4	1.1	0.25	1.1	0.26
Other leukemias	5	1.7	0.37	2.0	0.44	4	0.9	0.22	1.1	0.26
Mesothelioma	2	0.9	0.30	1.0	0.34	*	*	*	*	*
Kaposi Sarcoma	3	0.8	0.23	0.9	0.24	*	*	*	*	*
Ill-Defined & Unknown	43	15.6	1.14	18.3	1.31	48	12.2	0.81	14.3	0.93
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	27	8.9	0.81	10.2	0.92	79	20.5	1.06	23.7	1.20
Breast (<i>in situ</i>)	*	*	*	*	*	132	33.4	1.33	39.5	1.54

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Missouri, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	119	261.2	11.29	306.4	13.19	182	283.2	9.75	330.5	11.37
Oral Cavity & Pharynx	4	9.1	2.02	10.8	2.39	2	4.6	1.40	5.5	1.65
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	35	77.1	6.10	91.0	7.17	34	56.0	4.46	66.1	5.22
Esophagus	1	2.5	1.11	3.5	1.50	*	*	*	*	*
Stomach	4	9.3	2.15	10.5	2.46	5	8.5	1.74	9.9	2.02
Small intestine	2	3.7	1.36	4.4	1.57	*	*	*	*	*
Colon (excl. rectum)	9	21.4	3.29	25.0	3.85	10	17.2	2.48	20.1	2.89
Rectum & rectosigmoid	4	9.4	2.25	11.1	2.63	6	9.7	1.77	11.4	2.06
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	8	16.9	2.77	19.8	3.23	4	6.8	1.58	8.0	1.81
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	4	8.5	1.94	10.3	2.31	3	5.1	1.44	5.9	1.65
Respiratory System	20	48.9	5.11	57.5	5.93	19	31.8	3.41	38.5	4.08
Larynx	1	3.1	1.23	3.8	1.48	*	*	*	*	*
Lung & bronchus	18	42.6	4.75	50.3	5.53	19	31.5	3.40	38.3	4.07
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	*	*	*	*	*	1	1.7	0.65	2.1	0.81
Breast (excl. <i>in situ</i>)	*	*	*	*	*	66	98.8	5.60	116.0	6.58
Female Genital System	N/A	N/A	N/A	N/A	N/A	22	32.0	3.14	36.7	3.63
Cervix uteri	N/A	N/A	N/A	N/A	N/A	5	6.8	1.38	7.5	1.54
Uterus corpus	N/A	N/A	N/A	N/A	N/A	10	14.5	2.09	17.2	2.51
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	5	7.3	1.52	8.4	1.76
Male Genital System	22	48.9	4.91	58.2	5.74	N/A	N/A	N/A	N/A	N/A
Prostate	21	47.6	4.85	56.8	5.68	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	9	20.5	3.20	24.6	3.83	6	11.3	2.13	13.3	2.48
Bladder (incl. <i>in situ</i>)	5	12.6	2.65	15.2	3.13	3	6.5	1.71	7.7	1.98
Kidney & renal pelvis	4	7.6	1.76	9.0	2.14	3	4.2	1.15	5.0	1.37
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	3.4	1.21	4.0	1.42	1	1.6	0.65	1.7	0.70
Brain	2	3.2	1.18	3.8	1.40	*	*	*	*	*
Endocrine System	4	7.7	1.74	8.4	1.94	12	16.3	2.18	17.5	2.39
Thyroid gland	4	5.9	1.45	6.5	1.65	12	16.1	2.17	17.3	2.38
Lymphomas	9	15.8	2.40	18.8	2.92	7	10.0	1.78	11.6	2.08
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	3	6.6	1.89	7.8	2.21	1	2.4	0.95	2.8	1.07
Leukemias	4	6.9	1.69	7.3	1.89	4	5.5	1.32	5.5	1.34
Acute lymphocytic	1	2.0	0.75	1.7	0.69	1	2.0	0.77	1.7	0.68
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	1	2.2	0.85	2.4	0.93
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	4	9.7	2.36	10.8	2.64	5	8.4	1.81	9.9	2.12
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	3	6.9	1.75	8.4	2.10	10	14.3	2.14	16.7	2.49
Breast (<i>in situ</i>)	*	*	*	*	*	21	30.5	3.03	36.5	3.61

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Missouri, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	187	272.6	9.95	319.5	11.48	214	278.1	8.99	324.1	10.49
Oral Cavity & Pharynx	5	7.8	1.67	8.9	1.86	2	3.3	1.02	4.0	1.21
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	2.4	0.87	3.0	1.06	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	48	71.2	5.11	83.3	5.87	33	47.0	3.82	55.2	4.45
Esophagus	4	5.5	1.37	6.6	1.61	*	*	*	*	*
Stomach	5	7.4	1.65	9.0	1.96	3	3.7	1.06	4.5	1.28
Small intestine	*	*	*	*	*	1	1.3	0.53	1.7	0.70
Colon (excl. rectum)	14	20.6	2.77	23.3	3.08	12	16.7	2.27	19.3	2.60
Rectum & rectosigmoid	8	11.7	1.97	14.1	2.35	5	6.7	1.40	7.8	1.62
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	7	10.4	2.00	12.9	2.35	3	3.9	1.12	4.4	1.28
Gallbladder	1	2.2	0.96	2.4	1.06	1	1.9	0.80	2.2	0.91
Pancreas	4	7.4	1.76	7.9	1.87	4	5.4	1.32	6.4	1.55
Respiratory System	20	34.3	3.75	40.8	4.32	21	32.2	3.26	38.2	3.79
Larynx	1	2.1	0.86	2.7	1.09	*	*	*	*	*
Lung & bronchus	18	31.5	3.62	37.1	4.14	20	31.4	3.23	37.2	3.74
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	3	3.0	0.91	3.2	1.04	2	2.4	0.82	2.6	0.91
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	3	5.5	1.48	6.4	1.69	2	2.3	0.78	2.6	0.90
Breast (excl. <i>in situ</i>)	*	*	*	*	*	60	77.1	4.68	89.5	5.44
Female Genital System	N/A	N/A	N/A	N/A	N/A	30	35.7	3.04	42.7	3.67
Cervix uteri	N/A	N/A	N/A	N/A	N/A	5	5.5	1.13	6.2	1.32
Uterus corpus	N/A	N/A	N/A	N/A	N/A	16	18.3	2.13	22.2	2.61
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	7	8.8	1.60	10.4	1.89
Male Genital System	45	65.0	4.80	78.0	5.62	N/A	N/A	N/A	N/A	N/A
Prostate	36	59.1	4.71	72.1	5.54	N/A	N/A	N/A	N/A	N/A
Testis	8	5.7	0.92	5.6	0.92	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	23	35.1	3.58	41.6	4.15	13	18.5	2.39	22.2	2.83
Bladder (incl. <i>in situ</i>)	10	16.3	2.58	19.3	2.98	3	3.7	1.06	4.5	1.27
Kidney & renal pelvis	13	18.6	2.47	22.0	2.88	9	13.1	1.99	15.7	2.36
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	6	4.9	0.96	5.2	1.11	4	3.3	0.86	3.6	1.00
Brain	5	4.6	0.93	4.9	1.08	4	3.3	0.86	3.6	1.00
Endocrine System	3	3.8	1.06	4.3	1.21	18	18.6	2.04	20.1	2.30
Thyroid gland	3	2.6	0.78	3.1	0.93	18	17.9	2.01	19.5	2.27
Lymphomas	11	15.8	2.40	17.6	2.69	11	14.4	2.09	16.9	2.44
Hodgkin lymphoma	2	2.4	0.83	2.6	0.89	2	1.8	0.64	2.1	0.76
Non-Hodgkin lymphoma	9	13.3	2.26	15.0	2.53	9	12.6	1.99	14.8	2.32
Multiple Myeloma	2	2.9	0.99	3.4	1.20	4	5.6	1.34	6.7	1.56
Leukemias	9	10.5	1.74	12.0	2.04	7	8.0	1.54	8.5	1.66
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	1	1.0	0.42	1.0	0.46
Chronic lymphocytic	1	1.7	0.77	2.3	0.98	2	2.9	1.05	3.1	1.11
Acute myeloid	2	3.0	1.06	3.4	1.18	2	2.5	0.79	2.6	0.86
Chronic myeloid	2	2.4	0.87	2.9	1.05	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	6	10.0	2.09	11.2	2.35	6	8.1	1.60	9.4	1.86
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	5	7.3	1.61	8.0	1.82	11	14.0	1.96	16.2	2.32
Breast (<i>in situ</i>)	*	*	*	*	*	13	17.6	2.24	21.0	2.65

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

MISSOURI

II-298 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Missouri, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	136	223.9	9.55	261.2	10.97	166	243.7	8.88	285.8	10.41
Oral Cavity & Pharynx	4	6.5	1.60	7.6	1.81	2	3.7	1.11	4.4	1.33
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	35	59.9	5.01	69.8	5.73	25	39.4	3.66	46.7	4.30
Esophagus	3	5.7	1.48	6.7	1.73	*	*	*	*	*
Stomach	4	7.6	1.78	9.2	2.11	2	2.7	0.98	3.1	1.15
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	9	16.8	2.73	18.8	3.01	10	14.9	2.25	17.4	2.61
Rectum & rectosigmoid	6	8.4	1.74	10.1	2.06	4	5.5	1.30	6.5	1.55
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	5	9.8	2.08	12.0	2.41	1	2.2	0.88	2.5	1.01
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	3	5.6	1.64	6.0	1.72	3	4.8	1.30	5.8	1.54
Respiratory System	16	30.6	3.76	36.0	4.28	18	29.8	3.27	35.8	3.85
Larynx	1	2.0	0.91	2.6	1.14	*	*	*	*	*
Lung & bronchus	14	27.9	3.62	32.6	4.09	17	29.2	3.24	35.1	3.81
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	3	3.0	0.98	3.2	1.12	2	2.3	0.87	2.6	0.98
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	3	5.1	1.49	6.0	1.72	2	2.1	0.79	2.4	0.92
Breast (excl. <i>in situ</i>)	*	*	*	*	*	47	69.3	4.70	80.5	5.46
Female Genital System	N/A	N/A	N/A	N/A	N/A	23	30.6	2.99	37.0	3.63
Cervix uteri	N/A	N/A	N/A	N/A	N/A	3	4.1	1.06	4.9	1.28
Uterus corpus	N/A	N/A	N/A	N/A	N/A	13	16.5	2.14	20.1	2.64
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	5	7.6	1.58	8.9	1.84
Male Genital System	31	48.8	4.36	58.0	5.07	N/A	N/A	N/A	N/A	N/A
Prostate	24	43.4	4.26	52.7	4.98	N/A	N/A	N/A	N/A	N/A
Testis	7	5.4	0.95	5.3	0.95	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	17	27.8	3.32	32.7	3.83	10	16.8	2.42	20.1	2.85
Bladder (incl. <i>in situ</i>)	7	13.0	2.39	15.3	2.74	2	3.9	1.15	4.8	1.39
Kidney & renal pelvis	10	14.6	2.29	17.1	2.65	7	11.1	1.95	13.1	2.28
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	3	3.1	0.79	3.2	0.92	3	2.5	0.77	2.7	0.89
Brain	3	2.9	0.78	3.1	0.91	3	2.5	0.77	2.7	0.89
Endocrine System	2	2.7	0.95	3.0	1.09	13	14.9	1.95	16.2	2.21
Thyroid gland	1	1.4	0.53	1.6	0.66	12	14.4	1.93	15.9	2.20
Lymphomas	9	14.3	2.38	15.9	2.65	9	14.0	2.17	16.4	2.53
Hodgkin lymphoma	2	2.6	0.90	2.7	0.98	2	1.7	0.67	2.0	0.77
Non-Hodgkin lymphoma	7	11.7	2.20	13.1	2.46	8	12.2	2.06	14.4	2.40
Multiple Myeloma	2	2.3	0.90	2.8	1.12	3	4.0	1.16	4.9	1.38
Leukemias	6	8.6	1.75	9.8	2.04	4	5.9	1.40	6.2	1.51
Acute lymphocytic	2	1.9	0.59	1.8	0.63	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	2	3.2	1.16	3.7	1.30	2	2.6	0.86	2.8	0.95
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	4	8.6	2.02	9.8	2.30	4	6.9	1.55	8.1	1.82
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	3	5.0	1.40	5.9	1.66	8	12.1	1.97	14.4	2.37
Breast (<i>in situ</i>)	*	*	*	*	*	10	14.0	2.07	17.1	2.52

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Missouri, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	5	184.7	45.31	218.8	52.39	7	194.6	35.49	228.5	41.45
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	2	46.8	17.03	57.5	21.39	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	1	41.5	16.18	51.7	20.58	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	3	64.3	18.59	79.2	22.95
Female Genital System	N/A	N/A	N/A	N/A	N/A	1	37.4	16.38	47.6	20.19
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	2	74.5	25.42	89.1	30.03	N/A	N/A	N/A	N/A	N/A
Prostate	2	69.3	24.88	82.6	29.32	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	1	21.5	8.15	17.7	6.74
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


MISSOURI

II-300 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	1,031,495	1,042,137	1,053,862	1,061,818	1,070,123
Non-Hispanic White	907,606	915,217	923,166	929,008	934,928
Non-Hispanic Black	8,263	8,602	8,989	9,123	9,475
Non-Hispanic Asian/Pacific Islander (NH API)	10,082	10,654	11,071	11,371	12,057
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	57,943	58,358	58,917	58,859	59,039


All Races Population 2015–2019: 5,259,435
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	37,089	38,596	40,827	42,313	43,494
Hispanic White	29,328	30,532	32,202	33,334	34,278
Hispanic Black	958	995	1,065	1,138	1,162

Hispanic/Latino Population, Census 2010: 28,565
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

MONTANA CANCER REGISTRY

Initial Operation: 1979
Population-based Data Available: 1979
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	109.8	113.6	111.6	104.8	110.4	110.0
Missing Race	0.4	0.6	1.2	1.3	1.6	1.0
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.1	1.2	1.5	1.8	1.9	1.7
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.2	Ovary	89.8
Oral Cavity & Pharynx	97.5	Prostate	96.2
Esophagus	96.0	Testis	97.8
Stomach	96.2	Bladder (incl. <i>in situ</i>)	98.0
Colon & Rectum	95.9	Kidney & Renal Pelvis	89.8
Liver	51.1	Brain & Other CNS	80.2
Pancreas	83.3	Brain & Other CNS (non-malig)	41.2
Lung & Bronchus	87.0	Thyroid	99.9
Melanomas of the Skin	99.7	Hodgkin Lymphoma	98.5
Female Breast (excl. <i>in situ</i>)	98.5	Non-Hodgkin Lymphoma	97.5
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	93.0
Cervix Uteri	97.4	Leukemias	90.6
Uterus Corpus & Uterus NOS	98.8		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Montana, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3,465	503.8	3.98	596.0	4.63	2,990	436.3	3.76	507.7	4.26
Oral Cavity & Pharynx	119	17.2	0.74	20.9	0.88	48	6.9	0.46	8.2	0.54
Lip	4	0.7	0.15	0.8	0.17	2	0.3	0.09	0.3	0.10
Tongue	39	5.6	0.42	6.8	0.50	17	2.4	0.28	2.9	0.32
Major salivary gland	10	1.4	0.21	1.6	0.24	6	0.9	0.17	1.1	0.20
Floor of mouth	5	0.7	0.14	0.8	0.16	2	0.2	0.07	0.3	0.10
Gum & other mouth	15	2.2	0.27	2.6	0.31	8	1.1	0.18	1.3	0.21
Nasopharynx	3	0.4	0.12	0.5	0.13	*	*	*	*	*
Oropharynx	7	1.1	0.19	1.3	0.22	3	0.5	0.13	0.6	0.15
Hypopharynx	6	0.8	0.16	1.1	0.20	2	0.3	0.09	0.3	0.11
Digestive System	604	89.7	1.70	106.9	1.99	422	59.9	1.36	70.0	1.56
Esophagus	57	8.3	0.51	9.9	0.60	12	1.6	0.22	2.0	0.25
Stomach	45	6.8	0.47	8.0	0.55	23	3.4	0.33	3.9	0.38
Small intestine	20	2.8	0.30	3.4	0.34	14	1.9	0.25	2.3	0.28
Colon (excl. rectum)	185	28.4	0.97	33.5	1.13	162	23.3	0.86	26.8	0.97
Rectum & rectosigmoid	97	14.7	0.70	17.7	0.83	54	8.3	0.53	9.8	0.61
Anus, anal canal, & anorectum	8	1.2	0.20	1.4	0.24	20	2.8	0.30	3.5	0.36
Liver	66	8.7	0.49	10.8	0.61	19	2.6	0.27	3.1	0.32
Gallbladder	4	0.6	0.14	0.8	0.17	8	1.1	0.17	1.2	0.20
Pancreas	96	14.0	0.66	16.6	0.77	81	11.1	0.57	13.0	0.66
Respiratory System	385	55.3	1.30	65.4	1.52	389	51.4	1.20	61.4	1.41
Larynx	26	3.7	0.34	4.5	0.40	6	0.9	0.17	1.0	0.19
Lung & bronchus	350	50.4	1.24	59.5	1.45	379	50.1	1.18	59.7	1.39
Bones & Joints	9	1.5	0.23	1.6	0.25	7	1.3	0.23	1.3	0.22
Soft Tissue (incl. heart)	20	3.1	0.33	3.6	0.37	19	3.1	0.34	3.3	0.35
Skin (excl. basal & sq.)	246	37.8	1.12	43.7	1.28	172	27.1	0.98	30.7	1.08
Melanoma of the skin	218	33.6	1.06	38.8	1.20	156	25.0	0.95	28.2	1.04
Breast (excl. <i>in situ</i>)	8	1.2	0.20	1.5	0.23	921	137.0	2.14	160.4	2.44
Female Genital System	N/A	N/A	N/A	N/A	N/A	329	48.0	1.25	56.7	1.44
Cervix uteri	N/A	N/A	N/A	N/A	N/A	38	7.0	0.54	7.5	0.56
Uterus corpus	N/A	N/A	N/A	N/A	N/A	185	25.5	0.88	31.0	1.04
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	70	10.5	0.59	12.3	0.67
Male Genital System	1,038	140.0	2.01	169.4	2.40	N/A	N/A	N/A	N/A	N/A
Prostate	992	130.7	1.91	160.1	2.32	N/A	N/A	N/A	N/A	N/A
Testis	37	7.8	0.58	7.6	0.56	N/A	N/A	N/A	N/A	N/A
Penis	7	1.1	0.20	1.3	0.22	N/A	N/A	N/A	N/A	N/A
Urinary System	423	62.6	1.41	73.8	1.64	156	22.1	0.83	25.7	0.94
Bladder (incl. <i>in situ</i>)	260	38.4	1.10	45.3	1.28	74	10.0	0.54	11.8	0.63
Kidney & renal pelvis	155	23.0	0.86	27.1	0.99	79	11.6	0.62	13.4	0.69
Ureter	5	0.8	0.16	0.9	0.18	2	0.3	0.09	0.3	0.11
Eye & Orbit	6	1.0	0.18	1.1	0.20	7	1.2	0.20	1.3	0.23
Brain & Other CNS	50	8.2	0.55	9.2	0.59	42	6.6	0.49	7.4	0.52
Brain	47	7.8	0.53	8.7	0.58	40	6.2	0.46	7.0	0.51
Endocrine System	55	9.5	0.60	10.5	0.65	113	20.5	0.91	21.9	0.94
Thyroid gland	50	8.5	0.57	9.5	0.62	108	19.7	0.89	21.1	0.93
Lymphomas	154	23.9	0.90	27.2	1.01	118	17.1	0.74	19.7	0.83
Hodgkin lymphoma	14	2.6	0.33	2.6	0.32	13	2.4	0.31	2.5	0.31
Non-Hodgkin lymphoma	140	21.3	0.84	24.6	0.95	105	14.7	0.67	17.2	0.77
Multiple Myeloma	60	8.8	0.52	10.3	0.61	42	5.7	0.41	6.8	0.48
Leukemias	133	20.4	0.82	23.5	0.93	74	10.6	0.58	12.1	0.64
Acute lymphocytic	9	1.7	0.27	1.5	0.24	5	1.0	0.21	0.9	0.18
Chronic lymphocytic	63	9.1	0.53	11.0	0.63	34	4.4	0.35	5.4	0.42
Acute myeloid	28	4.3	0.37	4.9	0.42	18	2.6	0.29	3.1	0.33
Chronic myeloid	17	2.8	0.31	3.1	0.34	9	1.4	0.23	1.6	0.24
Other leukemias	17	2.5	0.29	3.0	0.33	7	1.1	0.19	1.2	0.20
Mesothelioma	13	2.1	0.27	2.5	0.31	4	0.5	0.13	0.6	0.15
Kaposi Sarcoma	1	0.2	0.10	0.2	0.10	*	*	*	*	*
Ill-Defined & Unknown	140	21.2	0.82	24.6	0.95	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	61	10.0	0.60	11.2	0.66	113	17.2	0.77	19.7	0.85
Breast (<i>in situ</i>)	*	*	*	*	*	166	25.0	0.93	29.5	1.06

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Montana, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3,211	496.0	4.08	586.6	4.74	2,750	432.3	3.92	502.7	4.43
Oral Cavity & Pharynx	111	17.2	0.77	20.9	0.91	45	6.8	0.48	8.1	0.56
Lip	4	0.7	0.16	0.9	0.19	2	0.3	0.09	0.3	0.10
Tongue	38	5.8	0.44	7.0	0.52	16	2.5	0.30	3.0	0.35
Major salivary gland	9	1.4	0.22	1.7	0.25	6	0.9	0.18	1.1	0.21
Floor of mouth	4	0.6	0.15	0.7	0.17	2	0.2	0.07	0.3	0.10
Gum & other mouth	14	2.2	0.27	2.6	0.32	7	1.1	0.18	1.2	0.21
Nasopharynx	2	0.3	0.10	0.4	0.12	*	*	*	*	*
Oropharynx	7	1.1	0.20	1.4	0.24	3	0.5	0.13	0.6	0.16
Hypopharynx	5	0.7	0.15	0.9	0.19	2	0.3	0.09	0.3	0.10
Digestive System	550	87.0	1.73	103.5	2.03	388	59.1	1.41	68.9	1.61
Esophagus	54	8.2	0.52	9.8	0.61	12	1.7	0.22	2.0	0.26
Stomach	40	6.6	0.48	7.7	0.55	20	3.2	0.33	3.7	0.38
Small intestine	18	2.8	0.30	3.3	0.35	13	2.0	0.27	2.3	0.30
Colon (excl. rectum)	169	27.6	0.99	32.5	1.15	150	23.2	0.90	26.7	1.01
Rectum & rectosigmoid	87	14.4	0.72	17.3	0.85	49	8.2	0.56	9.5	0.63
Anus, anal canal, & anorectum	8	1.3	0.22	1.6	0.26	20	3.0	0.32	3.6	0.38
Liver	55	7.7	0.48	9.6	0.59	16	2.3	0.26	2.7	0.31
Gallbladder	4	0.6	0.15	0.7	0.17	7	0.9	0.16	1.0	0.18
Pancreas	89	13.8	0.68	16.4	0.79	77	11.1	0.59	13.0	0.68
Respiratory System	359	54.5	1.33	64.3	1.55	354	49.9	1.22	59.6	1.44
Larynx	24	3.6	0.35	4.4	0.41	6	0.9	0.18	1.0	0.20
Lung & bronchus	327	49.7	1.26	58.5	1.47	346	48.6	1.20	58.1	1.42
Bones & Joints	8	1.5	0.24	1.7	0.26	6	1.2	0.24	1.2	0.23
Soft Tissue (incl. heart)	18	3.2	0.34	3.6	0.38	16	2.9	0.35	3.1	0.36
Skin (excl. basal & sq.)	226	37.1	1.16	42.9	1.31	156	26.7	1.03	30.3	1.12
Melanoma of the skin	200	33.0	1.09	38.1	1.24	141	24.6	1.00	27.8	1.08
Breast (excl. <i>in situ</i>)	8	1.3	0.21	1.5	0.24	851	137.0	2.25	160.2	2.55
Female Genital System	N/A	N/A	N/A	N/A	N/A	300	46.7	1.29	55.4	1.48
Cervix uteri	N/A	N/A	N/A	N/A	N/A	33	6.7	0.56	7.2	0.58
Uterus corpus	N/A	N/A	N/A	N/A	N/A	170	24.8	0.90	30.3	1.07
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	64	10.4	0.62	12.1	0.70
Male Genital System	961	137.4	2.06	166.3	2.45	N/A	N/A	N/A	N/A	N/A
Prostate	918	127.8	1.94	156.7	2.36	N/A	N/A	N/A	N/A	N/A
Testis	33	8.1	0.64	7.9	0.61	N/A	N/A	N/A	N/A	N/A
Penis	7	1.2	0.20	1.3	0.23	N/A	N/A	N/A	N/A	N/A
Urinary System	397	61.8	1.44	72.9	1.67	145	21.8	0.85	25.4	0.97
Bladder (incl. <i>in situ</i>)	251	39.0	1.13	45.9	1.32	71	10.4	0.57	12.3	0.66
Kidney & renal pelvis	139	21.6	0.86	25.5	0.99	70	11.0	0.62	12.7	0.70
Ureter	5	0.8	0.16	0.9	0.19	2	0.3	0.09	0.3	0.11
Eye & Orbit	6	1.0	0.20	1.1	0.21	7	1.3	0.22	1.4	0.25
Brain & Other CNS	47	8.5	0.59	9.4	0.63	39	6.8	0.52	7.6	0.56
Brain	45	8.0	0.57	8.9	0.61	37	6.4	0.50	7.2	0.54
Endocrine System	52	9.8	0.64	10.9	0.69	102	20.7	0.98	22.1	1.01
Thyroid gland	47	8.8	0.61	9.8	0.66	97	19.8	0.96	21.2	0.99
Lymphomas	143	23.7	0.93	27.1	1.04	111	17.3	0.78	19.9	0.87
Hodgkin lymphoma	12	2.6	0.35	2.6	0.34	12	2.4	0.33	2.5	0.33
Non-Hodgkin lymphoma	131	21.1	0.86	24.4	0.98	99	14.8	0.70	17.4	0.81
Multiple Myeloma	56	8.6	0.53	10.1	0.62	39	5.7	0.42	6.8	0.49
Leukemias	124	20.2	0.85	23.3	0.96	70	10.9	0.62	12.4	0.68
Acute lymphocytic	7	1.5	0.27	1.4	0.25	5	1.1	0.24	1.0	0.21
Chronic lymphocytic	60	9.3	0.56	11.2	0.66	34	4.7	0.37	5.7	0.44
Acute myeloid	26	4.2	0.38	4.8	0.43	17	2.7	0.31	3.1	0.35
Chronic myeloid	14	2.5	0.31	2.8	0.34	9	1.5	0.25	1.6	0.26
Other leukemias	16	2.7	0.31	3.1	0.35	6	0.9	0.18	1.0	0.19
Mesothelioma	13	2.2	0.28	2.5	0.32	3	0.5	0.12	0.5	0.14
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	55	9.9	0.63	11.0	0.68	104	17.2	0.81	19.7	0.90
Breast (<i>in situ</i>)	*	*	*	*	*	155	25.4	0.98	29.9	1.12

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Montana, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	10	487.2	78.74	573.3	89.52	4	176.1	40.04	208.4	48.19
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	2	114.0	40.11	130.5	44.39	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	1	55.4	22.77	76.0	31.11
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	4	199.4	45.85	244.3	54.83	N/A	N/A	N/A	N/A	N/A
Prostate	4	192.5	45.33	238.5	54.52	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Montana, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	8	231.7	39.44	284.1	47.87	16	288.8	33.40	323.7	37.11
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	3	77.9	23.37	92.6	27.16	2	36.0	12.46	39.8	13.73
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	2	30.7	11.21	34.4	12.30
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	1	26.9	10.54	30.3	11.62
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	6	94.7	18.16	111.0	21.10
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	38.0	11.07	44.1	12.88
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1	18.6	7.66	23.9	9.76
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	1	44.5	17.39	58.2	22.49	N/A	N/A	N/A	N/A	N/A
Prostate	1	44.5	17.39	58.2	22.49	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	1	17.8	7.30	19.9	8.29
Thyroid gland	*	*	*	*	*	1	17.8	7.30	19.9	8.29
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	1	28.2	11.94	29.8	12.58
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	2	30.4	9.72	36.2	11.60

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Montana, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	119	611.4	28.23	722.5	32.43	128	544.6	22.71	634.9	25.97
Oral Cavity & Pharynx	4	18.5	4.05	22.3	4.82	2	8.9	3.19	10.5	3.60
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	29	156.3	14.80	185.4	17.07	22	92.1	9.28	109.8	10.72
Esophagus	2	9.2	3.40	11.2	4.00	*	*	*	*	*
Stomach	4	16.8	4.51	21.2	5.67	2	7.6	2.66	8.9	3.02
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	9	51.6	9.21	60.9	10.74	9	34.8	5.52	41.9	6.50
Rectum & rectosigmoid	5	23.2	5.30	27.2	5.90	4	17.0	4.04	20.5	4.72
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	5	24.0	5.37	28.6	6.06	2	7.1	2.45	9.1	3.05
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	4	22.0	5.24	25.5	5.88	2	10.3	3.17	12.3	3.63
Respiratory System	16	83.4	10.32	101.2	11.91	20	93.5	10.03	109.8	11.54
Larynx	2	6.2	2.08	9.1	3.02	*	*	*	*	*
Lung & bronchus	14	74.6	9.98	88.9	11.37	19	90.3	9.89	106.0	11.38
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	2	7.2	2.55	8.5	3.08
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Melanoma of the skin	1	8.0	3.29	9.5	3.82	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	39	161.8	12.09	191.3	13.98
Female Genital System	N/A	N/A	N/A	N/A	N/A	15	61.1	7.26	71.2	8.31
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	9.1	2.80	9.4	2.90
Uterus corpus	N/A	N/A	N/A	N/A	N/A	8	29.0	4.83	35.1	5.71
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	3	14.5	3.75	16.6	4.21
Male Genital System	31	152.8	13.65	185.5	16.10	N/A	N/A	N/A	N/A	N/A
Prostate	29	144.7	13.41	177.2	15.90	N/A	N/A	N/A	N/A	N/A
Testis	2	6.6	2.32	6.3	2.15	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	14	75.8	10.28	88.0	11.67	7	34.3	5.83	37.4	6.31
Bladder (incl. <i>in situ</i>)	4	25.9	7.01	31.2	8.19	1	5.7	2.39	6.5	2.69
Kidney & renal pelvis	10	49.9	7.53	56.8	8.31	6	27.3	5.16	29.5	5.51
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	1	8.2	3.45	9.5	3.90	1	3.4	1.39	3.9	1.63
Brain	1	7.4	3.36	8.5	3.76	*	*	*	*	*
Endocrine System	2	7.2	2.60	8.1	2.91	6	21.9	4.22	24.7	4.70
Thyroid gland	2	7.2	2.60	8.1	2.91	6	21.3	4.18	23.9	4.63
Lymphomas	6	30.3	6.32	33.4	6.87	3	13.2	3.58	14.3	3.87
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	2	11.7	3.88	14.1	4.51	2	6.0	2.23	7.6	2.71
Leukemias	4	20.6	5.23	22.0	5.58	2	7.8	2.47	9.3	2.92
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	1	6.5	2.82	6.5	2.81	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	5	29.9	6.68	33.4	7.32	5	25.4	5.20	28.3	5.80
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	2	8.4	2.89	9.4	3.21	4	15.5	3.80	16.0	3.88
Breast (<i>in situ</i>)	*	*	*	*	*	6	24.3	4.76	28.9	5.49

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Montana, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	40	380.2	29.90	447.3	34.23	40	319.7	23.84	374.7	27.50
Oral Cavity & Pharynx	2	14.2	4.85	16.9	5.77	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	10	91.2	14.38	109.6	16.75	5	40.2	8.44	49.6	10.22
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	2	26.4	8.17	30.1	9.17	1	8.5	3.56	11.0	4.51
Rectum & rectosigmoid	2	24.2	7.69	29.5	8.90	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	2	16.2	5.66	20.3	6.93	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	1	10.5	4.44	13.4	5.60
Respiratory System	2	22.1	7.55	26.2	8.67	4	36.5	8.83	41.5	9.79
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	2	20.7	7.43	24.1	8.42	4	35.3	8.74	40.5	9.74
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	1	10.5	4.72	14.3	6.12	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	*	*	*	*	*	2	12.1	4.07	15.6	5.23
Breast (excl. <i>in situ</i>)	*	*	*	*	*	13	104.3	13.62	122.2	15.66
Female Genital System	N/A	N/A	N/A	N/A	N/A	6	42.3	8.46	49.5	9.76
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	3	24.9	6.51	29.7	7.64
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	1	9.5	3.96	11.6	4.77
Male Genital System	9	89.8	14.79	105.9	16.93	N/A	N/A	N/A	N/A	N/A
Prostate	8	86.6	14.70	102.9	16.86	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	6	66.2	13.03	77.2	14.67	1	12.6	4.88	14.8	5.66
Bladder (incl. <i>in situ</i>)	3	31.2	9.17	36.8	10.34	*	*	*	*	*
Kidney & renal pelvis	3	35.0	9.25	40.4	10.41	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	1	7.5	3.32	9.4	4.17	1	6.0	2.75	6.1	3.01
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	2	12.4	4.48	13.7	4.94
Thyroid gland	*	*	*	*	*	2	12.4	4.48	13.7	4.94
Lymphomas	2	17.7	5.88	20.6	6.71	2	11.7	3.74	14.6	4.82
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	2	17.3	6.19	19.2	7.07	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	21.9	8.12	23.2	8.51	2	15.4	5.72	17.8	6.43
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	2	14.6	5.92	16.9	6.88	2	12.4	4.26	14.8	5.14
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

MONTANA

II-308 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Montana, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	38	414.5	33.45	486.5	38.14	38	341.9	26.14	402.2	30.33
Oral Cavity & Pharynx	1	13.1	5.13	15.9	6.12	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	9	100.4	15.92	121.2	18.65	5	46.0	9.59	56.8	11.62
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	2	30.5	9.39	34.7	10.51	1	9.9	4.12	12.8	5.23
Rectum & rectosigmoid	2	23.5	7.77	29.4	9.27	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	2	18.7	6.44	23.2	7.86	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	1	11.7	4.92	15.0	6.21
Respiratory System	2	23.8	8.54	27.6	9.59	3	32.6	8.87	37.1	9.82
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	2	23.8	8.54	27.6	9.59	3	31.1	8.75	35.8	9.75
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	*	*	*	*	*	2	12.5	4.44	16.3	5.81
Breast (excl. <i>in situ</i>)	*	*	*	*	*	13	117.4	15.34	138.2	17.76
Female Genital System	N/A	N/A	N/A	N/A	N/A	5	39.7	8.41	47.3	10.02
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	3	24.1	6.64	29.5	8.08
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	8	93.4	16.11	110.1	18.41	N/A	N/A	N/A	N/A	N/A
Prostate	7	89.5	15.99	106.4	18.32	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	6	76.1	15.00	88.6	16.82	1	14.3	5.56	16.8	6.47
Bladder (incl. <i>in situ</i>)	3	35.9	10.58	42.2	11.87	*	*	*	*	*
Kidney & renal pelvis	3	40.2	10.64	46.4	11.92	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	1	8.7	3.84	10.9	4.80	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	2	14.5	5.21	16.1	5.74
Thyroid gland	*	*	*	*	*	2	14.5	5.21	16.1	5.74
Lymphomas	2	19.9	6.82	23.3	7.76	2	12.1	4.06	15.0	5.19
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	2	20.5	7.14	22.4	8.02	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	1	22.8	9.07	24.1	9.47	2	17.5	6.51	20.3	7.33
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	2	16.7	6.67	19.2	7.74	2	14.7	4.98	17.3	5.98
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Montana, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	*	*	*	*	*	*	*	*	*	*
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


MONTANA

II-310 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	1,892,059	1,906,483	1,916,998	1,925,512	1,932,571
Non-Hispanic White	1,530,724	1,532,528	1,532,335	1,530,736	1,529,733
Non-Hispanic Black	100,524	103,034	104,535	106,598	108,265
Non-Hispanic Asian/Pacific Islander (NH API)	47,245	50,716	52,843	54,752	55,813
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	13,739	13,840	13,991	14,073	14,093


All Races Population 2015–2019: 9,573,623
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	196,521	202,978	209,886	215,879	221,125
Hispanic White	173,697	179,021	184,880	189,571	193,997
Hispanic Black	6,665	6,996	7,311	7,660	7,898

Hispanic/Latino Population, Census 2010: 167,405
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

NEBRASKA CANCER REGISTRY

Initial Operation: 1987
Population-based Data Available: 1987
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	110.3	110.1	111.6	106.1	102.3	108.1
Missing Race	0.7	0.2	0.6	1.0	2.6	1.0
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.2	1.4	1.3	1.3	2.2	1.5
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	95.2	Ovary	92.5
Oral Cavity & Pharynx	98.6	Prostate	97.8
Esophagus	95.2	Testis	99.4
Stomach	97.0	Bladder (incl. <i>in situ</i>)	98.2
Colon & Rectum	96.7	Kidney & Renal Pelvis	93.5
Liver	61.8	Brain & Other CNS	83.9
Pancreas	88.6	Brain & Other CNS (non-malig)	45.9
Lung & Bronchus	91.3	Thyroid	99.5
Melanomas of the Skin	99.9	Hodgkin Lymphoma	98.5
Female Breast (excl. <i>in situ</i>)	98.8	Non-Hodgkin Lymphoma	96.4
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	92.2
Cervix Uteri	98.3	Leukemias	93.6
Uterus Corpus & Uterus NOS	99.0		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Nebraska, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	5,404	510.1	3.18	605.1	3.71	5,054	443.3	2.90	515.1	3.30
Oral Cavity & Pharynx	203	18.8	0.61	22.9	0.73	84	7.0	0.36	8.4	0.42
Lip	18	1.8	0.19	2.1	0.22	6	0.5	0.09	0.6	0.12
Tongue	61	5.5	0.32	6.7	0.39	27	2.3	0.21	2.7	0.24
Major salivary gland	17	1.7	0.19	2.0	0.22	11	0.8	0.12	1.0	0.14
Floor of mouth	7	0.7	0.12	0.8	0.14	4	0.3	0.08	0.4	0.09
Gum & other mouth	23	2.1	0.20	2.6	0.24	21	1.7	0.17	2.0	0.20
Nasopharynx	6	0.6	0.11	0.7	0.13	3	0.2	0.07	0.3	0.07
Oropharynx	11	1.0	0.13	1.3	0.17	4	0.3	0.07	0.4	0.08
Hypopharynx	12	1.1	0.14	1.3	0.17	2	0.2	0.06	0.2	0.07
Digestive System	973	93.2	1.37	110.6	1.60	809	67.8	1.10	79.6	1.28
Esophagus	91	8.4	0.40	10.1	0.48	23	1.8	0.17	2.2	0.21
Stomach	79	7.6	0.39	9.0	0.46	40	3.4	0.24	4.0	0.29
Small intestine	26	2.5	0.23	2.9	0.26	28	2.5	0.21	2.9	0.24
Colon (excl. rectum)	323	31.5	0.80	37.0	0.93	341	28.4	0.71	32.8	0.81
Rectum & rectosigmoid	150	14.7	0.55	17.4	0.64	109	9.8	0.43	11.5	0.50
Anus, anal canal, & anorectum	11	1.1	0.15	1.3	0.17	30	2.5	0.21	3.1	0.26
Liver	83	7.4	0.37	9.2	0.46	29	2.4	0.21	2.9	0.24
Gallbladder	8	0.8	0.13	0.9	0.15	17	1.4	0.15	1.7	0.18
Pancreas	157	14.9	0.55	17.7	0.64	139	11.4	0.44	13.5	0.52
Respiratory System	708	66.5	1.14	79.4	1.34	633	51.8	0.94	61.7	1.11
Larynx	51	4.6	0.29	5.7	0.36	13	1.1	0.14	1.3	0.17
Lung & bronchus	650	61.2	1.10	72.9	1.29	612	50.0	0.92	59.6	1.09
Bones & Joints	9	0.9	0.13	0.9	0.14	8	0.8	0.13	0.8	0.13
Soft Tissue (incl. heart)	42	4.4	0.31	4.8	0.34	29	2.8	0.24	3.0	0.25
Skin (excl. basal & sq.)	356	35.5	0.86	40.8	0.98	297	28.5	0.77	31.8	0.84
Melanoma of the skin	329	32.7	0.83	37.7	0.94	280	27.0	0.75	30.1	0.82
Breast (excl. <i>in situ</i>)	18	1.6	0.18	2.0	0.21	1,474	131.8	1.60	154.7	1.83
Female Genital System	N/A	N/A	N/A	N/A	N/A	564	50.4	0.99	59.2	1.13
Cervix uteri	N/A	N/A	N/A	N/A	N/A	71	7.7	0.43	8.2	0.44
Uterus corpus	N/A	N/A	N/A	N/A	N/A	321	27.4	0.71	33.3	0.84
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	5	0.5	0.10	0.6	0.11
Ovary	N/A	N/A	N/A	N/A	N/A	103	9.3	0.43	10.8	0.48
Male Genital System	1,521	135.9	1.60	165.8	1.91	N/A	N/A	N/A	N/A	N/A
Prostate	1,447	127.9	1.54	157.7	1.87	N/A	N/A	N/A	N/A	N/A
Testis	62	6.8	0.39	6.7	0.38	N/A	N/A	N/A	N/A	N/A
Penis	10	1.0	0.15	1.2	0.17	N/A	N/A	N/A	N/A	N/A
Urinary System	637	61.3	1.11	72.2	1.29	268	22.6	0.64	26.3	0.73
Bladder (incl. <i>in situ</i>)	364	35.4	0.85	41.5	0.98	110	8.6	0.38	10.2	0.44
Kidney & renal pelvis	258	24.4	0.70	29.0	0.81	149	13.2	0.50	15.3	0.57
Ureter	9	0.9	0.14	1.0	0.16	5	0.4	0.09	0.5	0.10
Eye & Orbit	12	1.1	0.15	1.3	0.17	9	0.8	0.12	0.9	0.13
Brain & Other CNS	81	8.0	0.41	8.9	0.45	67	6.4	0.36	6.8	0.38
Brain	75	7.3	0.39	8.2	0.43	63	6.0	0.35	6.4	0.37
Endocrine System	88	8.8	0.43	9.8	0.47	234	24.5	0.74	26.4	0.78
Thyroid gland	79	7.9	0.41	8.9	0.45	227	23.8	0.73	25.6	0.77
Lymphomas	276	27.0	0.74	31.1	0.84	227	19.6	0.60	22.6	0.68
Hodgkin lymphoma	31	3.3	0.27	3.4	0.28	23	2.3	0.23	2.5	0.23
Non-Hodgkin lymphoma	244	23.7	0.69	27.7	0.80	205	17.2	0.56	20.1	0.64
Multiple Myeloma	84	8.1	0.41	9.6	0.47	57	4.6	0.28	5.5	0.33
Leukemias	192	18.8	0.62	21.5	0.70	122	10.7	0.45	11.9	0.49
Acute lymphocytic	20	2.1	0.21	2.0	0.20	12	1.3	0.17	1.1	0.14
Chronic lymphocytic	73	6.9	0.37	8.3	0.44	36	2.9	0.23	3.5	0.26
Acute myeloid	55	5.4	0.33	6.2	0.38	44	3.8	0.26	4.3	0.30
Chronic myeloid	23	2.3	0.22	2.6	0.25	17	1.6	0.18	1.8	0.19
Other leukemias	21	2.1	0.21	2.4	0.23	12	1.0	0.14	1.2	0.15
Mesothelioma	9	1.0	0.14	1.1	0.17	4	0.4	0.08	0.4	0.09
Kaposi Sarcoma	1	0.2	0.07	0.2	0.06	*	*	*	*	*
Ill-Defined & Unknown	194	19.0	0.62	22.2	0.72	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	76	7.6	0.40	8.5	0.44	149	13.7	0.52	15.5	0.58
Breast (<i>in situ</i>)	2	0.2	0.07	0.2	0.07	311	28.9	0.76	34.0	0.88

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Nebraska, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	4,887	511.9	3.37	606.1	3.92	4,559	448.9	3.14	520.4	3.55
Oral Cavity & Pharynx	189	19.6	0.66	23.9	0.79	79	7.4	0.40	8.8	0.46
Lip	17	1.9	0.21	2.2	0.24	6	0.5	0.10	0.7	0.12
Tongue	58	5.8	0.36	7.2	0.43	25	2.5	0.24	3.0	0.27
Major salivary gland	16	1.8	0.21	2.0	0.23	10	0.9	0.13	1.1	0.16
Floor of mouth	6	0.6	0.12	0.8	0.14	4	0.3	0.08	0.4	0.10
Gum & other mouth	21	2.2	0.22	2.6	0.26	20	1.8	0.19	2.1	0.22
Nasopharynx	5	0.6	0.12	0.7	0.14	2	0.2	0.07	0.3	0.08
Oropharynx	10	1.0	0.14	1.3	0.18	4	0.3	0.07	0.4	0.09
Hypopharynx	11	1.2	0.16	1.4	0.19	2	0.2	0.07	0.3	0.08
Digestive System	859	91.3	1.44	108.1	1.67	720	66.6	1.16	77.9	1.34
Esophagus	87	8.8	0.44	10.7	0.52	21	1.8	0.18	2.2	0.22
Stomach	65	6.9	0.39	8.1	0.46	33	3.0	0.24	3.5	0.28
Small intestine	23	2.5	0.24	2.9	0.27	25	2.4	0.23	2.9	0.26
Colon (excl. rectum)	293	31.6	0.85	37.1	0.98	312	28.6	0.76	32.9	0.86
Rectum & rectosigmoid	132	14.7	0.59	17.2	0.68	95	9.6	0.47	11.3	0.53
Anus, anal canal, & anorectum	10	1.0	0.15	1.3	0.18	28	2.7	0.24	3.3	0.28
Liver	61	6.0	0.35	7.5	0.43	18	1.7	0.19	2.0	0.22
Gallbladder	6	0.7	0.13	0.7	0.14	15	1.3	0.15	1.5	0.18
Pancreas	144	15.1	0.58	17.8	0.67	125	11.2	0.46	13.3	0.54
Respiratory System	656	67.2	1.20	80.3	1.41	581	52.0	0.99	61.8	1.17
Larynx	46	4.5	0.31	5.6	0.38	11	1.1	0.15	1.3	0.17
Lung & bronchus	604	61.9	1.15	73.8	1.35	563	50.2	0.97	59.8	1.15
Bones & Joints	7	0.9	0.15	0.9	0.15	7	0.8	0.15	0.8	0.14
Soft Tissue (incl. heart)	36	4.2	0.32	4.7	0.36	24	2.6	0.25	2.8	0.27
Skin (excl. basal & sq.)	340	38.3	0.96	43.8	1.08	278	31.4	0.89	34.6	0.96
Melanoma of the skin	315	35.4	0.92	40.6	1.04	264	29.9	0.88	33.1	0.94
Breast (excl. <i>in situ</i>)	16	1.7	0.19	2.0	0.23	1,340	134.5	1.74	157.7	1.98
Female Genital System	N/A	N/A	N/A	N/A	N/A	512	51.4	1.08	60.4	1.23
Cervix uteri	N/A	N/A	N/A	N/A	N/A	59	7.6	0.47	8.1	0.48
Uterus corpus	N/A	N/A	N/A	N/A	N/A	293	27.9	0.77	33.9	0.91
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	5	0.5	0.11	0.5	0.12
Ovary	N/A	N/A	N/A	N/A	N/A	95	9.8	0.47	11.3	0.53
Male Genital System	1,353	133.3	1.66	162.5	1.99	N/A	N/A	N/A	N/A	N/A
Prostate	1,287	124.4	1.59	153.5	1.93	N/A	N/A	N/A	N/A	N/A
Testis	54	7.6	0.47	7.5	0.46	N/A	N/A	N/A	N/A	N/A
Penis	10	1.0	0.15	1.2	0.18	N/A	N/A	N/A	N/A	N/A
Urinary System	587	62.2	1.18	73.2	1.36	239	22.2	0.67	26.0	0.77
Bladder (incl. <i>in situ</i>)	344	36.3	0.89	42.6	1.03	103	8.7	0.40	10.3	0.46
Kidney & renal pelvis	228	24.3	0.75	28.8	0.86	129	12.8	0.53	14.8	0.60
Ureter	9	1.0	0.15	1.1	0.17	5	0.4	0.09	0.5	0.11
Eye & Orbit	11	1.2	0.17	1.4	0.19	8	0.9	0.15	1.0	0.16
Brain & Other CNS	73	8.3	0.45	9.3	0.49	59	6.7	0.41	7.0	0.42
Brain	67	7.6	0.43	8.6	0.47	56	6.3	0.40	6.7	0.41
Endocrine System	78	9.2	0.49	10.2	0.52	199	25.0	0.83	26.8	0.87
Thyroid gland	70	8.2	0.46	9.2	0.50	193	24.4	0.82	26.1	0.86
Lymphomas	249	27.5	0.80	31.5	0.90	203	19.4	0.64	22.4	0.72
Hodgkin lymphoma	27	3.6	0.31	3.7	0.32	18	2.2	0.25	2.3	0.25
Non-Hodgkin lymphoma	222	23.9	0.74	27.8	0.84	186	17.2	0.59	20.1	0.68
Multiple Myeloma	74	7.9	0.42	9.2	0.49	47	4.1	0.28	4.9	0.33
Leukemias	171	18.8	0.66	21.5	0.74	108	10.6	0.48	11.8	0.52
Acute lymphocytic	15	2.0	0.24	1.8	0.22	8	1.2	0.19	1.0	0.16
Chronic lymphocytic	68	7.1	0.40	8.5	0.46	34	3.0	0.24	3.6	0.28
Acute myeloid	51	5.5	0.35	6.3	0.40	40	3.8	0.28	4.3	0.31
Chronic myeloid	20	2.2	0.23	2.6	0.26	15	1.6	0.19	1.8	0.20
Other leukemias	18	2.0	0.22	2.3	0.24	10	1.0	0.15	1.1	0.16
Mesothelioma	9	1.0	0.15	1.1	0.17	4	0.4	0.09	0.5	0.10
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	67	7.8	0.44	8.7	0.48	127	13.2	0.55	14.9	0.61
Breast (<i>in situ</i>)	2	0.2	0.07	0.2	0.07	279	29.4	0.83	34.5	0.95

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Nebraska, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	196	582.4	20.31	703.8	23.89	168	434.7	15.45	516.3	18.20
Oral Cavity & Pharynx	6	16.2	3.11	19.5	3.70	1	3.3	1.27	4.2	1.59
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	4.0	1.43	4.5	1.60	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	42	126.1	9.45	151.7	11.09	32	84.9	6.91	101.4	8.16
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	5	13.4	3.02	16.5	3.57	3	7.6	2.06	8.6	2.33
Small intestine	2	5.7	1.90	6.8	2.22	1	3.1	1.29	3.1	1.33
Colon (excl. rectum)	11	35.2	5.11	41.5	5.90	10	28.3	4.03	34.0	4.76
Rectum & rectosigmoid	6	16.5	3.19	20.1	3.83	3	8.3	2.12	10.2	2.59
Anus, anal canal, & anorectum	*	*	*	*	*	1	2.6	1.07	3.6	1.46
Liver	8	20.7	3.59	26.3	4.41	3	7.3	1.93	9.1	2.37
Gallbladder	*	*	*	*	*	1	3.7	1.41	4.4	1.69
Pancreas	7	21.9	4.11	26.3	4.80	7	19.0	3.40	22.8	4.02
Respiratory System	26	83.0	7.93	101.4	9.41	26	68.2	6.23	83.6	7.49
Larynx	3	8.2	2.32	9.7	2.67	*	*	*	*	*
Lung & bronchus	23	74.3	7.56	91.2	9.01	25	66.1	6.15	80.7	7.38
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	2	4.9	1.84	5.3	2.03	1	3.7	1.47	4.0	1.57
Skin (excl. basal & sq.)	*	*	*	*	*	1	3.7	1.43	4.0	1.56
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	47	122.3	8.20	146.9	9.74
Female Genital System	N/A	N/A	N/A	N/A	N/A	16	39.2	4.56	46.3	5.36
Cervix uteri	N/A	N/A	N/A	N/A	N/A	4	9.8	2.29	10.8	2.54
Uterus corpus	N/A	N/A	N/A	N/A	N/A	8	19.4	3.18	23.6	3.82
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	5.9	1.84	6.7	2.13
Male Genital System	67	192.4	11.40	239.2	13.66	N/A	N/A	N/A	N/A	N/A
Prostate	66	190.6	11.36	237.6	13.64	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	21	64.0	6.76	77.1	7.87	11	28.3	4.00	32.6	4.60
Bladder (incl. <i>in situ</i>)	7	24.2	4.54	27.8	5.11	3	7.8	2.21	8.7	2.44
Kidney & renal pelvis	15	39.8	5.01	49.3	5.98	8	19.6	3.26	22.7	3.80
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	3.4	1.10	3.3	1.12	2	5.2	1.63	5.5	1.77
Brain	2	3.1	1.06	3.0	1.08	2	4.7	1.59	5.1	1.74
Endocrine System	2	8.0	2.51	8.7	2.71	8	18.2	3.04	20.8	3.47
Thyroid gland	2	6.7	2.29	7.4	2.50	7	16.5	2.87	19.1	3.31
Lymphomas	8	21.3	3.82	25.2	4.50	10	22.2	3.30	25.6	3.80
Hodgkin lymphoma	*	*	*	*	*	3	6.5	1.63	6.9	1.75
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	6	15.7	2.87	18.7	3.37
Multiple Myeloma	6	19.7	3.84	22.3	4.30	5	13.6	2.86	15.8	3.29
Leukemias	6	17.6	3.46	20.6	4.00	4	9.8	2.28	11.0	2.57
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	2	5.9	1.93	7.4	2.29	*	*	*	*	*
Acute myeloid	2	4.8	1.88	5.5	2.23	2	3.4	1.25	4.3	1.57
Chronic myeloid	1	3.3	1.51	3.9	1.68	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	4	16.6	4.00	19.8	4.67	4	10.3	2.34	12.6	2.87
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	1	3.6	1.67	3.9	1.85	9	22.1	3.40	25.4	3.93
Breast (<i>in situ</i>)	*	*	*	*	*	12	32.2	4.18	38.9	4.99

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Nebraska, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	40	314.2	24.82	365.3	28.34	55	286.6	18.33	333.6	21.36
Oral Cavity & Pharynx	2	9.1	3.24	11.2	4.10	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	15	112.3	14.55	132.0	16.70	12	72.5	9.75	84.5	11.30
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	2	17.7	5.92	20.8	6.77	1	5.6	2.29	7.4	3.01
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	3	26.7	7.79	30.9	8.80	3	18.2	4.91	19.8	5.32
Rectum & rectosigmoid	2	11.4	3.86	13.5	4.59	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	4	32.1	7.58	38.6	8.92	2	10.2	3.64	12.3	4.35
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	3	17.1	4.93	19.6	5.61
Respiratory System	6	60.6	11.32	68.3	12.55	6	38.5	7.41	45.8	8.61
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	6	56.7	10.94	64.0	12.17	5	32.3	6.81	38.4	7.91
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	15	68.9	8.28	80.1	9.78
Female Genital System	N/A	N/A	N/A	N/A	N/A	5	23.0	4.78	26.9	5.62
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	3	15.1	3.88	18.1	4.68
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	7	54.6	10.13	66.2	11.91	N/A	N/A	N/A	N/A	N/A
Prostate	6	53.7	10.11	65.2	11.89	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	2	19.1	6.98	22.4	7.94	1	8.7	3.54	10.4	4.17
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	1	5.1	2.13	5.6	2.49	6	23.9	4.44	27.9	5.42
Thyroid gland	1	5.1	2.13	5.6	2.49	6	23.9	4.44	27.9	5.42
Lymphomas	3	19.1	6.65	21.1	7.37	3	13.9	4.07	15.2	4.50
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	1	9.0	4.03	10.3	4.66	2	11.9	3.99	13.6	4.57
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	1	11.6	5.64	12.7	6.27	1	7.1	2.79	9.2	3.60
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	1	7.5	3.28	9.7	4.25	3	18.9	4.77	22.1	5.58
Breast (<i>in situ</i>)	*	*	*	*	*	6	29.1	5.60	31.8	6.21

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Nebraska, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	23	506.2	50.54	606.9	59.29	27	516.7	50.76	601.6	57.96
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	7	153.5	26.79	193.4	32.98	6	97.2	18.78	117.7	22.15
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	2	44.8	15.91	53.7	18.66	2	30.4	11.10	38.6	13.29
Rectum & rectosigmoid	1	21.8	8.90	30.2	12.36	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	2	42.7	13.18	56.0	16.97	1	18.5	7.69	23.6	9.64
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	3	71.4	20.34	85.1	23.22	4	82.3	21.80	95.9	24.52
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	2	61.5	19.00	73.4	21.67	4	82.3	21.80	95.9	24.52
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	7	126.5	24.84	150.8	29.16
Female Genital System	N/A	N/A	N/A	N/A	N/A	3	55.0	17.98	61.5	20.07
Cervix uteri	N/A	N/A	N/A	N/A	N/A	1	20.6	8.43	21.6	8.91
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	3	71.8	19.48	85.1	22.39	N/A	N/A	N/A	N/A	N/A
Prostate	3	67.3	18.96	80.2	21.85	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	4	73.1	18.13	91.6	22.17	2	36.9	10.80	44.4	12.86
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	3	64.5	15.95	83.0	20.45	2	34.3	10.47	40.6	12.31
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	1	20.0	7.68	20.5	7.96
Thyroid gland	*	*	*	*	*	1	16.9	7.02	16.6	6.95
Lymphomas	1	24.4	11.59	27.0	13.13	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	2	28.9	10.93	29.4	11.52	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	2	49.3	19.40	52.8	20.86
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	1	41.9	26.16	53.6	33.38	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Nebraska, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	166	345.6	14.18	410.4	16.43	195	370.0	13.25	432.2	15.44
Oral Cavity & Pharynx	4	7.7	2.16	9.2	2.47	1	2.9	1.22	3.7	1.50
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	43	94.9	7.62	112.5	8.74	33	70.2	6.09	83.8	7.13
Esophagus	1	2.8	1.20	3.5	1.42	*	*	*	*	*
Stomach	6	12.6	2.80	14.7	3.25	3	7.9	2.18	8.9	2.46
Small intestine	*	*	*	*	*	1	3.2	1.35	3.6	1.47
Colon (excl. rectum)	12	27.7	4.29	31.7	4.79	11	23.9	3.54	28.9	4.19
Rectum & rectosigmoid	7	12.1	2.22	15.1	2.67	6	9.9	2.02	12.1	2.43
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	7	14.5	2.91	17.9	3.40	4	9.0	2.20	10.9	2.59
Gallbladder	2	4.5	1.76	5.5	2.11	*	*	*	*	*
Pancreas	5	12.4	2.95	14.0	3.25	4	7.8	2.05	9.4	2.44
Respiratory System	14	36.1	4.86	42.1	5.48	15	37.8	4.72	45.0	5.50
Larynx	1	2.5	1.16	3.1	1.36	*	*	*	*	*
Lung & bronchus	12	33.2	4.70	38.4	5.28	14	35.9	4.60	43.0	5.38
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	3	3.5	1.27	3.7	1.38	3	3.7	1.18	3.7	1.28
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	2	2.8	1.21	3.5	1.53	5	7.1	1.60	8.6	1.97
Breast (excl. <i>in situ</i>)	*	*	*	*	*	55	103.3	6.82	121.2	7.98
Female Genital System	N/A	N/A	N/A	N/A	N/A	26	43.5	4.10	51.3	4.92
Cervix uteri	N/A	N/A	N/A	N/A	N/A	6	10.4	2.16	10.8	2.33
Uterus corpus	N/A	N/A	N/A	N/A	N/A	14	23.3	2.90	28.3	3.58
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	4	6.7	1.59	8.1	1.97
Male Genital System	45	97.1	7.43	117.3	8.68	N/A	N/A	N/A	N/A	N/A
Prostate	38	91.2	7.36	111.1	8.60	N/A	N/A	N/A	N/A	N/A
Testis	6	5.1	0.95	5.1	0.97	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	17	36.0	4.51	43.3	5.33	11	24.2	3.58	27.7	4.04
Bladder (incl. <i>in situ</i>)	7	17.5	3.37	21.7	4.06	3	7.9	2.21	8.8	2.42
Kidney & renal pelvis	10	18.4	3.00	21.6	3.46	8	16.0	2.80	18.4	3.21
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	4	7.0	1.91	7.9	2.18	5	6.6	1.68	7.1	1.86
Brain	4	6.1	1.79	6.9	2.07	4	6.0	1.63	6.4	1.79
Endocrine System	5	7.4	1.72	8.7	2.00	18	24.0	2.80	25.8	3.13
Thyroid gland	5	7.0	1.71	8.3	1.99	17	23.8	2.79	25.6	3.12
Lymphomas	11	20.8	3.41	24.9	4.05	8	15.2	2.70	18.1	3.14
Hodgkin lymphoma	2	2.1	0.77	2.3	0.90	*	*	*	*	*
Non-Hodgkin lymphoma	9	18.7	3.32	22.6	3.95	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	3	6.3	2.00	7.5	2.35	3	8.1	2.25	9.7	2.62
Leukemias	9	13.3	2.63	15.1	3.02	6	7.3	1.65	7.6	1.81
Acute lymphocytic	4	3.6	1.00	3.6	1.07	3	2.9	0.90	2.6	0.86
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	2	2.7	1.18	2.9	1.28	1	2.6	1.17	2.9	1.31
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	2	3.5	1.58	3.9	1.76	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	5	10.6	2.50	12.5	2.93	5	12.0	2.57	14.5	3.06
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	3	6.1	1.72	7.0	1.94	8	14.6	2.71	16.5	3.04
Breast (<i>in situ</i>)	*	*	*	*	*	9	15.6	2.50	18.7	2.97

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

NEBRASKA

II-318 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Nebraska, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	146	332.5	14.50	393.3	16.75	175	363.7	13.66	424.1	15.89
Oral Cavity & Pharynx	3	8.0	2.34	9.5	2.65	1	3.0	1.29	3.7	1.60
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	36	86.7	7.57	103.1	8.70	29	68.1	6.25	80.7	7.27
Esophagus	1	2.6	1.24	3.3	1.45	*	*	*	*	*
Stomach	5	12.1	2.81	14.0	3.27	3	8.2	2.32	9.2	2.61
Small intestine	*	*	*	*	*	1	3.3	1.44	3.7	1.58
Colon (excl. rectum)	10	24.2	4.12	28.4	4.71	9	21.2	3.45	25.4	4.05
Rectum & rectosigmoid	7	12.8	2.41	16.1	2.90	5	9.8	2.11	11.7	2.50
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	6	13.1	2.89	15.7	3.27	3	8.7	2.24	10.5	2.65
Gallbladder	1	4.5	1.86	5.4	2.21	*	*	*	*	*
Pancreas	4	11.9	3.11	13.3	3.38	3	8.1	2.18	9.6	2.57
Respiratory System	13	36.4	5.04	42.5	5.69	14	39.2	4.98	46.8	5.81
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	12	34.5	4.97	39.9	5.57	14	37.2	4.84	44.6	5.67
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	3	3.9	1.41	4.1	1.54	3	4.0	1.27	4.0	1.37
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	2	3.1	1.31	3.8	1.66	4	5.8	1.38	7.1	1.78
Breast (excl. <i>in situ</i>)	*	*	*	*	*	50	103.4	7.08	121.4	8.29
Female Genital System	N/A	N/A	N/A	N/A	N/A	23	41.7	4.21	49.0	5.02
Cervix uteri	N/A	N/A	N/A	N/A	N/A	5	9.8	2.18	10.3	2.37
Uterus corpus	N/A	N/A	N/A	N/A	N/A	12	21.8	2.96	26.2	3.62
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	4	6.9	1.69	8.4	2.09
Male Genital System	38	89.5	7.45	107.3	8.63	N/A	N/A	N/A	N/A	N/A
Prostate	32	83.8	7.37	101.4	8.55	N/A	N/A	N/A	N/A	N/A
Testis	5	4.8	0.97	4.7	0.94	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	16	36.1	4.71	43.2	5.52	10	24.8	3.76	28.4	4.26
Bladder (incl. <i>in situ</i>)	7	17.6	3.49	21.7	4.17	3	8.5	2.38	9.6	2.61
Kidney & renal pelvis	9	18.5	3.17	21.5	3.63	7	16.0	2.89	18.4	3.33
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	4	6.9	2.01	7.8	2.31	4	7.0	1.80	7.6	2.00
Brain	3	6.1	1.89	7.0	2.18	4	6.3	1.75	6.8	1.93
Endocrine System	5	7.5	1.83	8.6	2.08	15	22.4	2.83	23.6	3.10
Thyroid gland	4	7.0	1.81	8.2	2.07	15	22.2	2.83	23.5	3.10
Lymphomas	10	21.0	3.62	24.9	4.27	7	15.1	2.79	17.9	3.24
Hodgkin lymphoma	1	1.5	0.64	1.5	0.72	*	*	*	*	*
Non-Hodgkin lymphoma	9	19.5	3.56	23.4	4.21	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	2	6.5	2.15	7.7	2.51	3	7.1	2.16	8.6	2.53
Leukemias	8	13.0	2.75	14.5	3.14	5	7.3	1.74	7.4	1.89
Acute lymphocytic	4	3.9	1.09	3.8	1.16	3	3.0	0.97	2.7	0.94
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	2	2.9	1.29	3.2	1.40	1	2.6	1.24	2.9	1.39
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	1	3.3	1.71	3.6	1.87	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	5	11.6	2.71	13.6	3.16	5	12.1	2.71	14.6	3.22
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	3	6.2	1.85	7.3	2.08	7	15.4	2.90	17.2	3.24
Breast (<i>in situ</i>)	*	*	*	*	*	9	16.4	2.68	19.6	3.18

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Nebraska, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2	132.4	50.66	165.3	63.27	*	*	*	*	*
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


NEBRASKA

II-320 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	2,868,531	2,919,555	2,972,097	3,030,725	3,090,771
Non-Hispanic White	1,504,005	1,509,587	1,515,110	1,526,887	1,537,577
Non-Hispanic Black	268,560	281,431	294,869	307,477	319,034
Non-Hispanic Asian/Pacific Islander (NH API)	263,334	272,714	282,509	291,209	302,512
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	28,374	28,740	29,218	29,811	30,134


All Races Population 2015–2019: 14,881,679
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	804,258	827,083	850,391	875,341	901,514
Hispanic White	724,839	744,243	763,945	784,849	806,504
Hispanic Black	31,538	33,073	34,833	36,758	38,707

Hispanic/Latino Population, Census 2010: 716,501
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

NEVADA CANCER REGISTRY

Initial Operation: 1979
 Population-based Data Available: 1995
 Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	No	Yes	Yes	No	No	No
Completeness of Case Ascertainment	87.9	92.8	94.2	86.3	76.7	87.6
Missing Race	0.3	0.3	1.2	1.6	3.2	1.3
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.2	0.0	0.8	1.0	0.7	0.6
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.5	2.6	2.0	2.1	4.1	2.7
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.9	Ovary	91.5
Oral Cavity & Pharynx	96.9	Prostate	95.6
Esophagus	93.5	Testis	97.8
Stomach	95.8	Bladder (incl. <i>in situ</i>)	97.4
Colon & Rectum	94.7	Kidney & Renal Pelvis	89.5
Liver	59.1	Brain & Other CNS	84.7
Pancreas	84.7	Brain & Other CNS (non-malig)	36.7
Lung & Bronchus	87.4	Thyroid	99.5
Melanomas of the Skin	98.7	Hodgkin Lymphoma	98.3
Female Breast (excl. <i>in situ</i>)	98.2	Non-Hodgkin Lymphoma	96.6
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	89.6
Cervix Uteri	96.9	Leukemias	91.2
Uterus Corpus & Uterus NOS	98.3		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Nevada, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	6,712	394.4	2.21	467.0	2.60	6,477	367.2	2.09	428.5	2.41
Oral Cavity & Pharynx	272	15.5	0.43	18.8	0.52	104	5.7	0.26	6.8	0.30
Lip	12	0.8	0.10	0.9	0.12	4	0.2	0.05	0.3	0.06
Tongue	98	5.5	0.25	6.6	0.30	36	2.0	0.15	2.3	0.18
Major salivary gland	26	1.7	0.15	2.0	0.17	13	0.8	0.10	0.9	0.11
Floor of mouth	7	0.4	0.06	0.5	0.08	6	0.3	0.06	0.4	0.07
Gum & other mouth	22	1.3	0.13	1.5	0.15	16	0.9	0.10	1.0	0.12
Nasopharynx	11	0.7	0.10	0.8	0.11	7	0.4	0.07	0.4	0.08
Oropharynx	20	1.1	0.11	1.4	0.14	5	0.3	0.05	0.3	0.07
Hypopharynx	11	0.6	0.08	0.7	0.10	4	0.2	0.05	0.2	0.06
Digestive System	1,398	82.2	1.01	98.8	1.20	1,009	56.3	0.81	66.7	0.95
Esophagus	130	7.4	0.30	9.0	0.36	26	1.4	0.13	1.7	0.15
Stomach	106	6.2	0.28	7.5	0.33	62	3.5	0.21	4.2	0.24
Small intestine	32	1.9	0.16	2.3	0.18	26	1.4	0.13	1.7	0.15
Colon (excl. rectum)	431	26.2	0.58	31.0	0.68	389	22.1	0.51	25.9	0.59
Rectum & rectosigmoid	214	12.4	0.39	15.1	0.47	136	7.7	0.30	9.2	0.36
Anus, anal canal, & anorectum	23	1.4	0.13	1.6	0.16	35	1.8	0.14	2.3	0.18
Liver	169	9.3	0.33	11.6	0.41	59	3.2	0.19	3.9	0.23
Gallbladder	11	0.6	0.09	0.8	0.11	20	1.1	0.12	1.3	0.13
Pancreas	220	13.0	0.40	15.6	0.48	199	10.9	0.35	12.9	0.41
Respiratory System	872	51.4	0.80	60.7	0.94	882	47.6	0.73	56.2	0.86
Larynx	61	3.5	0.20	4.1	0.24	16	0.8	0.10	1.1	0.12
Lung & bronchus	794	46.9	0.77	55.4	0.90	857	46.2	0.72	54.6	0.85
Bones & Joints	19	1.2	0.13	1.3	0.13	13	0.9	0.11	0.9	0.11
Soft Tissue (incl. heart)	63	3.9	0.22	4.3	0.25	50	3.0	0.20	3.3	0.21
Skin (excl. basal & sq.)	372	22.5	0.54	26.3	0.62	239	13.7	0.41	16.0	0.47
Melanoma of the skin	355	21.5	0.53	25.2	0.61	225	12.8	0.39	15.1	0.46
Breast (excl. <i>in situ</i>)	22	1.3	0.13	1.6	0.15	1,929	109.4	1.15	128.3	1.32
Female Genital System	N/A	N/A	N/A	N/A	N/A	782	44.7	0.74	52.3	0.85
Cervix uteri	N/A	N/A	N/A	N/A	N/A	130	8.5	0.34	9.0	0.36
Uterus corpus	N/A	N/A	N/A	N/A	N/A	390	21.2	0.50	25.7	0.59
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	20	1.1	0.11	1.3	0.14
Ovary	N/A	N/A	N/A	N/A	N/A	175	10.1	0.35	11.8	0.40
Male Genital System	1,679	93.1	1.04	113.0	1.25	N/A	N/A	N/A	N/A	N/A
Prostate	1,582	86.4	1.00	106.2	1.21	N/A	N/A	N/A	N/A	N/A
Testis	81	5.5	0.28	5.5	0.27	N/A	N/A	N/A	N/A	N/A
Penis	14	1.0	0.12	1.1	0.14	N/A	N/A	N/A	N/A	N/A
Urinary System	813	48.9	0.79	57.5	0.92	349	19.3	0.47	22.8	0.55
Bladder (incl. <i>in situ</i>)	478	29.3	0.62	34.3	0.72	154	8.4	0.31	10.0	0.37
Kidney & renal pelvis	323	18.8	0.48	22.3	0.56	186	10.4	0.35	12.2	0.41
Ureter	6	0.4	0.07	0.5	0.09	7	0.4	0.07	0.4	0.08
Eye & Orbit	16	1.0	0.11	1.1	0.13	10	0.6	0.09	0.6	0.09
Brain & Other CNS	110	6.9	0.30	7.6	0.33	84	5.0	0.25	5.5	0.27
Brain	107	6.7	0.30	7.3	0.32	80	4.7	0.24	5.2	0.26
Endocrine System	120	7.3	0.31	8.2	0.34	330	21.2	0.53	22.9	0.57
Thyroid gland	108	6.6	0.29	7.4	0.32	321	20.5	0.53	22.3	0.56
Lymphomas	315	19.4	0.50	22.2	0.57	241	13.8	0.41	15.9	0.46
Hodgkin lymphoma	28	1.9	0.16	2.0	0.17	29	1.9	0.16	2.0	0.17
Non-Hodgkin lymphoma	287	17.5	0.47	20.2	0.54	212	11.9	0.37	13.9	0.43
Multiple Myeloma	101	6.0	0.27	7.1	0.32	68	3.8	0.21	4.5	0.25
Leukemias	232	14.5	0.44	16.1	0.48	159	9.4	0.34	10.5	0.38
Acute lymphocytic	28	2.0	0.17	1.8	0.15	23	1.6	0.15	1.5	0.14
Chronic lymphocytic	72	4.2	0.23	5.1	0.27	44	2.5	0.17	2.9	0.20
Acute myeloid	70	4.4	0.24	4.9	0.27	50	2.9	0.19	3.4	0.21
Chronic myeloid	26	1.6	0.15	1.8	0.16	18	1.1	0.11	1.2	0.13
Other leukemias	37	2.3	0.18	2.6	0.19	23	1.4	0.13	1.5	0.14
Mesothelioma	17	1.1	0.13	1.3	0.15	6	0.4	0.07	0.4	0.08
Kaposi Sarcoma	10	0.7	0.10	0.7	0.10	*	*	*	*	*
Ill-Defined & Unknown	281	17.5	0.48	20.4	0.56	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	130	8.2	0.33	9.4	0.38	278	16.0	0.44	18.6	0.50
Breast (<i>in situ</i>)	3	0.2	0.05	0.2	0.05	363	20.2	0.49	24.1	0.57

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Nevada, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	4,958	423.5	2.82	500.7	3.27	4,461	399.5	2.85	465.6	3.23
Oral Cavity & Pharynx	224	18.6	0.58	22.7	0.70	78	6.7	0.36	8.0	0.42
Lip	11	1.0	0.14	1.2	0.17	3	0.3	0.08	0.4	0.09
Tongue	83	6.8	0.35	8.3	0.42	28	2.4	0.22	2.8	0.25
Major salivary gland	22	2.0	0.20	2.3	0.23	8	0.8	0.14	0.9	0.15
Floor of mouth	5	0.4	0.09	0.5	0.11	4	0.4	0.09	0.5	0.10
Gum & other mouth	18	1.5	0.17	1.8	0.19	13	1.1	0.14	1.3	0.17
Nasopharynx	7	0.6	0.12	0.7	0.13	3	0.2	0.06	0.3	0.08
Oropharynx	17	1.3	0.15	1.6	0.18	3	0.2	0.06	0.3	0.08
Hypopharynx	8	0.6	0.10	0.8	0.13	3	0.3	0.07	0.3	0.08
Digestive System	949	80.5	1.22	96.9	1.44	663	56.7	1.03	67.1	1.20
Esophagus	101	8.2	0.37	9.9	0.45	20	1.6	0.17	1.9	0.20
Stomach	66	5.5	0.31	6.6	0.37	27	2.4	0.21	2.8	0.25
Small intestine	23	2.1	0.20	2.4	0.23	19	1.7	0.18	2.0	0.21
Colon (excl. rectum)	296	26.2	0.71	31.1	0.83	260	22.7	0.66	26.5	0.76
Rectum & rectosigmoid	138	12.1	0.48	14.6	0.57	93	8.4	0.41	10.0	0.48
Anus, anal canal, & anorectum	17	1.5	0.17	1.8	0.20	28	2.3	0.21	2.9	0.25
Liver	100	7.8	0.36	9.9	0.45	32	2.7	0.22	3.2	0.26
Gallbladder	6	0.5	0.09	0.6	0.11	11	1.0	0.13	1.1	0.16
Pancreas	160	13.4	0.49	16.0	0.58	135	10.9	0.43	13.0	0.51
Respiratory System	685	56.1	0.99	66.6	1.17	687	54.6	0.96	64.7	1.13
Larynx	49	4.0	0.26	4.8	0.31	12	1.0	0.13	1.3	0.17
Lung & bronchus	625	51.2	0.94	60.7	1.11	669	53.2	0.94	62.9	1.11
Bones & Joints	11	1.3	0.19	1.3	0.19	8	1.0	0.18	1.0	0.17
Soft Tissue (incl. heart)	40	3.9	0.29	4.3	0.32	30	3.0	0.27	3.3	0.28
Skin (excl. basal & sq.)	354	31.8	0.79	37.0	0.91	216	20.8	0.68	24.1	0.76
Melanoma of the skin	340	30.6	0.78	35.7	0.89	206	19.8	0.67	23.0	0.75
Breast (excl. <i>in situ</i>)	15	1.4	0.17	1.6	0.19	1,310	118.5	1.56	138.9	1.78
Female Genital System	N/A	N/A	N/A	N/A	N/A	499	46.1	0.99	54.2	1.12
Cervix uteri	N/A	N/A	N/A	N/A	N/A	71	8.8	0.50	9.2	0.50
Uterus corpus	N/A	N/A	N/A	N/A	N/A	253	21.6	0.64	26.4	0.77
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	12	1.0	0.14	1.2	0.16
Ovary	N/A	N/A	N/A	N/A	N/A	112	10.3	0.47	12.1	0.53
Male Genital System	1,175	94.1	1.28	113.8	1.52	N/A	N/A	N/A	N/A	N/A
Prostate	1,114	86.0	1.18	105.7	1.45	N/A	N/A	N/A	N/A	N/A
Testis	49	7.0	0.46	6.8	0.44	N/A	N/A	N/A	N/A	N/A
Penis	10	1.0	0.14	1.1	0.16	N/A	N/A	N/A	N/A	N/A
Urinary System	643	55.0	1.01	64.7	1.17	248	20.8	0.62	24.6	0.72
Bladder (incl. <i>in situ</i>)	406	34.4	0.79	40.4	0.92	124	10.0	0.41	11.9	0.49
Kidney & renal pelvis	225	19.6	0.62	23.1	0.71	117	10.1	0.44	12.0	0.51
Ureter	6	0.5	0.10	0.7	0.12	6	0.5	0.09	0.5	0.10
Eye & Orbit	13	1.3	0.18	1.5	0.19	8	0.8	0.14	0.9	0.14
Brain & Other CNS	81	8.5	0.46	9.2	0.47	60	6.2	0.40	6.8	0.41
Brain	79	8.2	0.45	8.9	0.46	58	5.8	0.38	6.5	0.40
Endocrine System	86	8.8	0.46	9.8	0.49	178	21.6	0.77	23.1	0.80
Thyroid gland	77	7.8	0.43	8.8	0.46	172	20.8	0.76	22.3	0.78
Lymphomas	220	20.4	0.65	23.3	0.73	163	14.8	0.56	17.0	0.62
Hodgkin lymphoma	16	2.1	0.24	2.1	0.24	19	2.6	0.29	2.6	0.28
Non-Hodgkin lymphoma	204	18.3	0.60	21.2	0.68	145	12.2	0.48	14.4	0.55
Multiple Myeloma	64	5.3	0.31	6.3	0.36	42	3.6	0.26	4.2	0.30
Leukemias	170	16.3	0.60	18.2	0.64	107	10.4	0.49	11.5	0.52
Acute lymphocytic	14	2.3	0.28	2.0	0.24	11	1.8	0.25	1.6	0.22
Chronic lymphocytic	60	4.9	0.29	6.0	0.35	34	2.9	0.23	3.4	0.26
Acute myeloid	50	4.8	0.32	5.4	0.35	34	3.2	0.26	3.7	0.29
Chronic myeloid	19	1.8	0.19	2.0	0.22	12	1.1	0.15	1.3	0.18
Other leukemias	26	2.6	0.24	2.8	0.25	15	1.4	0.18	1.6	0.19
Mesothelioma	13	1.3	0.16	1.4	0.18	4	0.4	0.08	0.4	0.10
Kaposi Sarcoma	3	0.4	0.10	0.4	0.10	*	*	*	*	*
Ill-Defined & Unknown	212	18.5	0.59	21.7	0.68	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	93	8.9	0.44	10.2	0.49	173	15.9	0.58	18.3	0.65
Breast (<i>in situ</i>)	2	0.2	0.05	0.2	0.06	225	20.2	0.65	23.9	0.74

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Nevada, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	479	395.5	8.51	473.3	10.02	471	336.7	7.10	397.2	8.32
Oral Cavity & Pharynx	15	11.3	1.35	13.8	1.62	7	4.6	0.80	5.6	0.97
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	4	3.5	0.77	4.2	0.91	2	1.4	0.44	1.7	0.56
Major salivary gland	2	1.4	0.49	1.7	0.57	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	2	1.2	0.44	1.5	0.52	*	*	*	*	*
Nasopharynx	1	1.0	0.40	1.0	0.42	1	0.8	0.33	0.8	0.34
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	113	93.9	4.16	113.3	4.94	85	60.9	3.01	72.5	3.56
Esophagus	7	5.3	0.99	6.7	1.21	1	0.9	0.36	1.1	0.44
Stomach	8	6.7	1.12	7.9	1.29	7	5.1	0.91	5.9	1.04
Small intestine	4	3.2	0.75	3.6	0.85	3	2.2	0.57	2.6	0.66
Colon (excl. rectum)	37	31.5	2.42	37.5	2.85	34	24.0	1.89	29.0	2.26
Rectum & rectosigmoid	14	11.6	1.43	14.1	1.72	9	6.6	1.00	7.4	1.12
Anus, anal canal, & anorectum	2	1.5	0.48	1.8	0.56	2	1.5	0.47	1.9	0.58
Liver	17	12.8	1.50	16.4	1.86	5	3.1	0.62	4.0	0.81
Gallbladder	*	*	*	*	*	2	1.8	0.54	2.2	0.64
Pancreas	20	16.5	1.76	19.8	2.08	17	12.3	1.35	14.5	1.58
Respiratory System	63	55.1	3.28	64.4	3.77	62	44.7	2.62	53.6	3.11
Larynx	4	3.5	0.81	3.9	0.89	2	1.4	0.49	1.7	0.57
Lung & bronchus	57	50.5	3.15	59.2	3.63	59	42.7	2.55	51.4	3.04
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	6	4.2	0.82	4.8	0.94	5	3.8	0.74	4.1	0.82
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	1	1.3	0.57	1.5	0.65	2	1.5	0.51	1.6	0.55
Breast (excl. <i>in situ</i>)	3	2.1	0.63	2.6	0.78	150	107.1	3.99	125.9	4.65
Female Genital System	N/A	N/A	N/A	N/A	N/A	59	42.0	2.49	49.6	2.92
Cervix uteri	N/A	N/A	N/A	N/A	N/A	12	8.4	1.12	9.0	1.20
Uterus corpus	N/A	N/A	N/A	N/A	N/A	28	19.1	1.66	23.0	1.98
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	3	1.9	0.53	2.4	0.67
Ovary	N/A	N/A	N/A	N/A	N/A	14	10.1	1.25	12.1	1.48
Male Genital System	152	119.8	4.54	148.7	5.51	N/A	N/A	N/A	N/A	N/A
Prostate	149	117.5	4.50	146.0	5.47	N/A	N/A	N/A	N/A	N/A
Testis	2	1.4	0.46	1.5	0.47	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	47	39.0	2.67	45.8	3.09	24	17.2	1.62	20.9	1.96
Bladder (incl. <i>in situ</i>)	19	18.1	1.94	20.9	2.23	8	6.0	0.98	7.2	1.17
Kidney & renal pelvis	27	20.9	1.83	24.9	2.14	16	11.2	1.30	13.7	1.58
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	6	4.6	0.91	5.0	1.01	6	4.3	0.78	4.8	0.89
Brain	6	4.4	0.90	4.8	0.99	6	3.9	0.74	4.3	0.84
Endocrine System	3	2.2	0.56	2.6	0.66	13	8.7	1.11	9.7	1.24
Thyroid gland	3	1.8	0.51	2.1	0.60	12	8.2	1.08	9.2	1.21
Lymphomas	20	16.5	1.76	18.8	2.00	17	11.7	1.32	13.5	1.52
Hodgkin lymphoma	3	2.0	0.56	2.0	0.59	3	1.7	0.46	2.0	0.55
Non-Hodgkin lymphoma	17	14.6	1.67	16.8	1.91	14	10.0	1.23	11.5	1.42
Multiple Myeloma	16	13.6	1.61	16.0	1.86	9	6.6	1.01	7.9	1.21
Leukemias	13	10.9	1.42	12.2	1.61	10	7.6	1.09	8.8	1.26
Acute lymphocytic	1	0.9	0.35	0.8	0.30	*	*	*	*	*
Chronic lymphocytic	3	3.2	0.82	3.8	0.97	3	2.2	0.61	2.7	0.73
Acute myeloid	5	3.8	0.84	4.3	0.95	4	2.8	0.65	3.3	0.79
Chronic myeloid	2	1.2	0.43	1.4	0.48	2	1.4	0.48	1.5	0.50
Other leukemias	2	1.7	0.57	2.0	0.65	N/A	N/A	N/A	N/A	N/A
Mesothelioma	1	1.1	0.48	1.4	0.60	*	*	*	*	*
Kaposi Sarcoma	2	1.4	0.43	1.5	0.46	*	*	*	*	*
Ill-Defined & Unknown	18	17.6	2.01	19.9	2.25	19	13.9	1.48	16.3	1.73
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	10	8.9	1.33	10.4	1.54	28	20.0	1.74	23.7	2.05
Breast (<i>in situ</i>)	*	*	*	*	*	29	20.3	1.73	24.2	2.04

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Nevada, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	357	254.4	6.32	299.2	7.36	538	276.7	5.52	322.1	6.31
Oral Cavity & Pharynx	9	6.5	1.03	7.7	1.21	8	3.7	0.62	4.4	0.72
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	1.8	0.58	2.1	0.65	3	1.3	0.36	1.5	0.42
Major salivary gland	*	*	*	*	*	1	0.6	0.26	0.7	0.28
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	1.0	0.47	1.2	0.55	*	*	*	*	*
Nasopharynx	1	0.8	0.34	1.0	0.42	2	0.9	0.32	1.0	0.35
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	109	79.6	3.57	94.0	4.18	87	45.2	2.25	53.1	2.61
Esophagus	5	3.9	0.81	4.7	0.95	*	*	*	*	*
Stomach	12	8.1	1.10	9.9	1.33	10	5.0	0.76	5.9	0.88
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	31	23.2	1.98	27.0	2.30	35	18.5	1.44	21.5	1.65
Rectum & rectosigmoid	25	17.2	1.60	20.4	1.88	8	4.1	0.66	5.0	0.79
Anus, anal canal, & anorectum	*	*	*	*	*	1	0.5	0.23	0.7	0.27
Liver	17	12.4	1.44	14.7	1.68	8	4.0	0.66	4.6	0.75
Gallbladder	1	0.9	0.37	1.2	0.46	1	0.7	0.30	0.8	0.35
Pancreas	12	8.1	1.09	9.4	1.26	16	8.0	0.94	9.5	1.11
Respiratory System	52	37.3	2.45	44.0	2.85	57	27.5	1.69	32.8	1.99
Larynx	2	1.0	0.36	1.2	0.44	*	*	*	*	*
Lung & bronchus	49	35.8	2.40	42.1	2.80	56	27.2	1.69	32.4	1.98
Bones & Joints	2	1.4	0.47	1.4	0.47	*	*	*	*	*
Soft Tissue (incl. heart)	5	3.4	0.70	3.7	0.77	5	2.8	0.57	3.1	0.63
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	3	1.9	0.55	2.2	0.63	3	1.4	0.40	1.6	0.44
Breast (excl. <i>in situ</i>)	1	1.0	0.38	1.2	0.45	185	92.9	3.14	109.5	3.64
Female Genital System	N/A	N/A	N/A	N/A	N/A	75	38.6	2.06	44.9	2.35
Cervix uteri	N/A	N/A	N/A	N/A	N/A	13	6.9	0.89	7.6	0.96
Uterus corpus	N/A	N/A	N/A	N/A	N/A	37	18.2	1.38	21.9	1.62
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	3	1.5	0.41	1.7	0.46
Ovary	N/A	N/A	N/A	N/A	N/A	19	10.5	1.11	12.0	1.25
Male Genital System	82	54.6	2.83	65.7	3.36	N/A	N/A	N/A	N/A	N/A
Prostate	79	52.1	2.74	63.1	3.28	N/A	N/A	N/A	N/A	N/A
Testis	3	2.0	0.55	2.0	0.53	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	33	23.7	1.96	28.4	2.32	21	11.0	1.11	13.0	1.29
Bladder (incl. <i>in situ</i>)	14	10.8	1.38	12.9	1.62	6	3.3	0.63	4.0	0.74
Kidney & renal pelvis	18	12.8	1.39	15.5	1.66	15	7.3	0.89	8.5	1.02
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	4	2.7	0.65	2.8	0.67	4	2.4	0.57	2.6	0.58
Brain	3	2.1	0.56	2.2	0.58	4	2.4	0.57	2.6	0.58
Endocrine System	10	6.8	0.98	7.7	1.10	41	23.6	1.68	25.3	1.77
Thyroid gland	9	6.2	0.95	7.0	1.06	40	22.9	1.65	24.5	1.75
Lymphomas	19	13.8	1.44	16.0	1.66	19	10.0	1.06	11.5	1.19
Hodgkin lymphoma	1	1.0	0.40	0.9	0.36	1	0.8	0.33	0.8	0.34
Non-Hodgkin lymphoma	18	12.8	1.38	15.1	1.62	18	9.2	1.00	10.7	1.14
Multiple Myeloma	4	2.5	0.58	3.0	0.68	6	2.9	0.56	3.5	0.66
Leukemias	10	7.7	1.12	8.4	1.21	11	6.0	0.88	6.6	0.94
Acute lymphocytic	1	1.0	0.40	0.9	0.36	2	1.2	0.44	1.2	0.40
Chronic lymphocytic	1	1.0	0.40	1.2	0.46	1	0.7	0.29	0.8	0.30
Acute myeloid	5	3.6	0.79	4.1	0.87	4	2.1	0.52	2.5	0.58
Chronic myeloid	*	*	*	*	*	2	1.0	0.31	1.3	0.38
Other leukemias	N/A	N/A	N/A	N/A	N/A	1	0.8	0.35	0.9	0.37
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	13	10.6	1.42	12.0	1.59	14	7.3	0.91	8.6	1.06
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	10	7.0	1.03	7.9	1.16	25	13.1	1.21	15.0	1.36
Breast (<i>in situ</i>)	*	*	*	*	*	49	23.8	1.56	28.6	1.85

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Nevada, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	52	353.1	23.15	419.9	27.06	58	337.5	20.48	394.0	23.44
Oral Cavity & Pharynx	2	15.7	4.73	17.9	5.19	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	13	79.7	10.26	96.0	12.10	11	64.8	8.84	78.6	10.54
Esophagus	1	6.6	2.71	8.7	3.54	*	*	*	*	*
Stomach	1	7.6	3.13	8.8	3.60	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	4	30.0	6.77	33.4	7.39	2	12.7	3.75	16.2	4.71
Rectum & rectosigmoid	2	9.3	3.38	11.8	4.18	1	6.6	2.59	9.0	3.44
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	3	18.0	4.57	23.2	5.81	2	12.8	3.94	15.6	4.78
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	2	15.0	4.43	17.0	4.99
Respiratory System	5	35.5	7.32	42.0	8.54	6	33.5	6.50	38.9	7.45
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	5	30.4	6.70	36.4	7.88	5	31.1	6.26	36.0	7.16
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	18	103.7	11.42	120.2	12.95
Female Genital System	N/A	N/A	N/A	N/A	N/A	8	44.4	7.28	52.4	8.34
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	12.2	4.01	13.5	4.33
Uterus corpus	N/A	N/A	N/A	N/A	N/A	3	17.9	4.49	22.0	5.36
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	9.4	3.38	10.4	3.70
Male Genital System	15	89.8	11.20	111.7	13.63	N/A	N/A	N/A	N/A	N/A
Prostate	14	82.9	10.76	104.7	13.26	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	7	53.8	9.61	63.5	11.34	4	21.4	5.08	24.5	5.68
Bladder (incl. <i>in situ</i>)	3	23.6	6.31	29.2	7.74	*	*	*	*	*
Kidney & renal pelvis	4	30.3	7.25	34.3	8.30	3	16.6	4.54	18.3	4.93
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	1	7.9	3.31	9.2	3.77	2	14.5	4.28	16.0	4.65
Thyroid gland	*	*	*	*	*	2	14.5	4.28	16.0	4.65
Lymphomas	2	18.5	5.91	21.3	6.63	2	11.9	4.03	12.7	4.25
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	1	11.4	4.54	12.6	5.05	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	18.9	5.80	21.4	6.63	3	18.0	4.95	21.1	5.72
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	2	14.4	4.44	16.0	4.88
Breast (<i>in situ</i>)	*	*	*	*	*	3	18.3	4.64	22.5	5.52

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Nevada, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	688	279.7	5.36	328.8	6.20	839	284.0	4.67	329.4	5.42
Oral Cavity & Pharynx	18	7.7	0.92	8.9	1.04	9	3.2	0.52	3.7	0.60
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	5	2.3	0.52	2.6	0.57	3	0.9	0.24	1.0	0.28
Major salivary gland	1	0.7	0.30	0.9	0.38	2	0.7	0.22	0.7	0.24
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	0.7	0.27	0.7	0.28	1	0.6	0.26	0.7	0.30
Nasopharynx	2	0.4	0.15	0.4	0.17	*	*	*	*	*
Oropharynx	1	0.7	0.30	0.8	0.35	*	*	*	*	*
Hypopharynx	1	0.7	0.27	0.8	0.30	*	*	*	*	*
Digestive System	178	74.2	2.78	88.7	3.25	140	52.4	2.11	61.8	2.46
Esophagus	11	4.8	0.74	5.9	0.88	3	1.2	0.33	1.4	0.40
Stomach	16	7.3	0.93	8.5	1.08	17	5.8	0.68	6.9	0.79
Small intestine	3	1.2	0.35	1.4	0.40	2	0.7	0.23	0.8	0.27
Colon (excl. rectum)	52	21.4	1.47	25.3	1.71	48	17.5	1.20	20.4	1.40
Rectum & rectosigmoid	29	10.9	1.01	13.3	1.20	19	6.3	0.67	7.6	0.81
Anus, anal canal, & anorectum	2	0.9	0.30	1.2	0.40	3	0.8	0.24	1.1	0.31
Liver	29	11.9	1.11	14.7	1.31	12	4.9	0.68	5.9	0.80
Gallbladder	2	1.1	0.34	1.2	0.37	5	1.9	0.42	2.2	0.48
Pancreas	24	10.4	1.06	12.3	1.22	26	11.0	1.01	12.8	1.17
Respiratory System	54	27.0	1.78	31.2	2.02	62	25.5	1.53	30.0	1.77
Larynx	5	2.8	0.58	3.2	0.64	*	*	*	*	*
Lung & bronchus	46	23.4	1.67	27.1	1.89	59	24.6	1.51	28.9	1.75
Bones & Joints	4	0.8	0.18	0.8	0.19	4	1.1	0.28	1.2	0.31
Soft Tissue (incl. heart)	12	3.7	0.55	4.0	0.61	7	2.1	0.38	2.4	0.44
Skin (excl. basal & sq.)	9	3.4	0.60	3.8	0.67	13	4.4	0.57	5.1	0.68
Melanoma of the skin	7	2.9	0.56	3.2	0.62	12	3.9	0.54	4.6	0.63
Breast (excl. <i>in situ</i>)	2	0.9	0.32	1.1	0.38	237	77.7	2.38	90.8	2.78
Female Genital System	N/A	N/A	N/A	N/A	N/A	124	38.4	1.62	44.4	1.89
Cervix uteri	N/A	N/A	N/A	N/A	N/A	29	7.9	0.68	8.3	0.73
Uterus corpus	N/A	N/A	N/A	N/A	N/A	59	18.7	1.13	22.4	1.36
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	3	0.9	0.26	1.1	0.32
Ovary	N/A	N/A	N/A	N/A	N/A	25	8.0	0.75	9.3	0.88
Male Genital System	178	70.5	2.61	85.4	3.09	N/A	N/A	N/A	N/A	N/A
Prostate	150	64.1	2.55	78.7	3.02	N/A	N/A	N/A	N/A	N/A
Testis	24	5.0	0.47	5.1	0.48	N/A	N/A	N/A	N/A	N/A
Penis	3	1.2	0.34	1.4	0.42	N/A	N/A	N/A	N/A	N/A
Urinary System	72	32.4	1.89	38.1	2.19	47	17.1	1.18	20.0	1.37
Bladder (incl. <i>in situ</i>)	29	16.0	1.44	18.5	1.65	14	6.0	0.75	6.9	0.85
Kidney & renal pelvis	42	16.2	1.22	19.2	1.44	33	10.8	0.89	12.7	1.05
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	1	0.3	0.12	0.3	0.14	*	*	*	*	*
Brain & Other CNS	16	5.2	0.66	5.9	0.75	11	3.6	0.53	4.1	0.61
Brain	16	5.2	0.66	5.8	0.74	11	3.5	0.52	4.0	0.61
Endocrine System	17	5.0	0.59	5.4	0.67	90	24.2	1.18	27.0	1.35
Thyroid gland	16	4.7	0.58	5.2	0.66	88	23.9	1.17	26.7	1.34
Lymphomas	45	15.9	1.22	18.2	1.40	34	12.0	0.99	13.7	1.13
Hodgkin lymphoma	7	1.9	0.39	1.9	0.41	5	1.3	0.27	1.3	0.29
Non-Hodgkin lymphoma	38	14.0	1.16	16.3	1.34	29	10.7	0.95	12.4	1.09
Multiple Myeloma	16	7.3	0.92	8.7	1.07	9	3.6	0.56	4.3	0.66
Leukemias	33	10.7	0.97	11.4	1.07	27	8.4	0.80	9.2	0.89
Acute lymphocytic	11	2.3	0.36	2.2	0.36	9	2.1	0.34	2.1	0.36
Chronic lymphocytic	4	2.1	0.50	2.5	0.56	4	1.7	0.40	1.9	0.45
Acute myeloid	8	3.0	0.53	3.2	0.59	8	2.7	0.45	3.1	0.53
Chronic myeloid	4	1.4	0.33	1.4	0.35	2	0.6	0.19	0.6	0.22
Other leukemias	6	2.0	0.41	2.2	0.48	4	1.4	0.34	1.5	0.37
Mesothelioma	2	0.9	0.29	1.0	0.33	*	*	*	*	*
Kaposi Sarcoma	4	0.9	0.21	1.0	0.24	*	*	*	*	*
Ill-Defined & Unknown	28	12.9	1.23	14.9	1.41	23	9.7	0.95	11.1	1.09
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	14	4.9	0.66	5.6	0.77	43	14.2	1.04	16.6	1.22
Breast (<i>in situ</i>)	*	*	*	*	*	49	15.6	1.03	19.0	1.25

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

NEVADA

II-328 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Nevada, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	641	281.1	5.55	330.2	6.42	782	287.9	4.88	334.4	5.67
Oral Cavity & Pharynx	16	7.5	0.92	8.7	1.06	8	3.3	0.55	3.8	0.63
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	4	1.8	0.45	2.1	0.50	2	0.8	0.24	0.9	0.27
Major salivary gland	1	0.8	0.32	1.0	0.40	2	0.7	0.23	0.8	0.25
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	0.7	0.29	0.7	0.30	1	0.6	0.27	0.8	0.32
Nasopharynx	2	0.5	0.17	0.5	0.18	*	*	*	*	*
Oropharynx	1	0.7	0.32	0.9	0.38	*	*	*	*	*
Hypopharynx	1	0.7	0.29	0.8	0.33	*	*	*	*	*
Digestive System	167	75.5	2.91	90.1	3.39	129	52.1	2.17	61.6	2.54
Esophagus	10	5.0	0.79	6.2	0.94	3	1.2	0.35	1.5	0.42
Stomach	15	7.3	0.96	8.5	1.11	16	5.9	0.71	7.0	0.83
Small intestine	3	1.1	0.35	1.3	0.40	2	0.7	0.24	0.8	0.27
Colon (excl. rectum)	48	21.3	1.53	25.3	1.78	43	16.8	1.22	19.7	1.42
Rectum & rectosigmoid	27	10.9	1.04	13.3	1.24	18	6.4	0.70	7.7	0.85
Anus, anal canal, & anorectum	2	1.0	0.33	1.3	0.43	2	0.8	0.22	1.1	0.32
Liver	27	12.2	1.16	15.0	1.37	11	5.1	0.71	6.1	0.84
Gallbladder	2	1.2	0.37	1.3	0.40	5	2.0	0.45	2.3	0.51
Pancreas	23	10.9	1.13	12.9	1.30	24	10.8	1.04	12.7	1.21
Respiratory System	51	27.2	1.85	31.3	2.08	59	26.2	1.60	30.9	1.86
Larynx	5	2.7	0.59	3.0	0.65	*	*	*	*	*
Lung & bronchus	44	23.7	1.73	27.3	1.95	56	25.2	1.58	29.6	1.83
Bones & Joints	3	0.8	0.19	0.8	0.21	4	1.1	0.29	1.2	0.33
Soft Tissue (incl. heart)	11	3.8	0.58	4.2	0.65	7	2.3	0.41	2.6	0.47
Skin (excl. basal & sq.)	8	3.7	0.64	4.1	0.72	13	4.7	0.62	5.6	0.73
Melanoma of the skin	7	3.1	0.60	3.5	0.66	12	4.2	0.58	5.0	0.68
Breast (excl. <i>in situ</i>)	2	0.9	0.35	1.1	0.41	221	79.0	2.49	92.4	2.91
Female Genital System	N/A	N/A	N/A	N/A	N/A	114	38.8	1.69	44.9	1.98
Cervix uteri	N/A	N/A	N/A	N/A	N/A	27	8.3	0.73	8.7	0.78
Uterus corpus	N/A	N/A	N/A	N/A	N/A	53	18.5	1.18	22.3	1.41
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	0.9	0.28	1.1	0.34
Ovary	N/A	N/A	N/A	N/A	N/A	24	8.4	0.80	9.7	0.93
Male Genital System	159	68.4	2.67	82.8	3.15	N/A	N/A	N/A	N/A	N/A
Prostate	134	61.9	2.59	75.9	3.07	N/A	N/A	N/A	N/A	N/A
Testis	22	5.1	0.50	5.2	0.51	N/A	N/A	N/A	N/A	N/A
Penis	3	1.2	0.36	1.4	0.44	N/A	N/A	N/A	N/A	N/A
Urinary System	68	32.7	1.96	38.4	2.27	45	17.6	1.25	20.6	1.44
Bladder (incl. <i>in situ</i>)	27	15.5	1.45	18.0	1.67	14	6.2	0.80	7.3	0.91
Kidney & renal pelvis	40	16.9	1.30	20.1	1.53	31	11.1	0.94	13.0	1.10
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	1	0.3	0.13	0.3	0.15	*	*	*	*	*
Brain & Other CNS	15	5.1	0.65	5.8	0.74	11	3.8	0.56	4.4	0.66
Brain	15	5.1	0.65	5.7	0.74	10	3.8	0.56	4.3	0.65
Endocrine System	16	4.8	0.59	5.3	0.67	84	25.0	1.26	27.9	1.44
Thyroid gland	15	4.6	0.58	5.0	0.66	83	24.7	1.25	27.5	1.43
Lymphomas	44	16.9	1.31	19.3	1.49	32	12.0	1.02	13.7	1.17
Hodgkin lymphoma	7	2.0	0.42	2.1	0.44	5	1.3	0.29	1.4	0.31
Non-Hodgkin lymphoma	37	14.8	1.24	17.2	1.43	27	10.6	0.98	12.3	1.12
Multiple Myeloma	16	7.8	0.98	9.2	1.14	9	3.6	0.58	4.4	0.68
Leukemias	31	10.9	1.01	11.6	1.11	23	8.1	0.81	8.9	0.92
Acute lymphocytic	9	2.1	0.31	1.9	0.29	8	2.2	0.36	2.2	0.39
Chronic lymphocytic	4	2.2	0.53	2.6	0.60	3	1.6	0.41	1.8	0.45
Acute myeloid	8	3.1	0.57	3.3	0.62	7	2.5	0.45	2.9	0.53
Chronic myeloid	4	1.5	0.36	1.5	0.38	2	0.6	0.20	0.6	0.24
Other leukemias	6	2.1	0.44	2.3	0.51	3	1.3	0.35	1.4	0.38
Mesothelioma	2	0.9	0.31	1.1	0.35	*	*	*	*	*
Kaposi Sarcoma	4	1.0	0.23	1.1	0.26	*	*	*	*	*
Ill-Defined & Unknown	26	12.9	1.27	15.0	1.46	21	9.6	0.99	11.1	1.13
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	13	4.8	0.68	5.6	0.80	38	14.0	1.07	16.3	1.25
Breast (<i>in situ</i>)	*	*	*	*	*	45	15.7	1.08	19.0	1.30

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Nevada, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	6	122.4	32.06	141.9	36.75	9	100.7	18.43	115.3	20.74
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	2	35.1	12.11	39.2	13.33
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	2	29.0	10.34	33.0	11.63
Female Genital System	N/A	N/A	N/A	N/A	N/A	1	11.5	4.53	13.6	5.52
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	1	13.8	5.75	19.4	8.02	N/A	N/A	N/A	N/A	N/A
Prostate	1	13.8	5.75	19.4	8.02	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


NEVADA

II-330 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	1,337,480	1,343,694	1,350,395	1,355,064	1,360,783
Non-Hispanic White	1,228,023	1,229,418	1,231,828	1,232,538	1,233,985
Non-Hispanic Black	20,440	21,501	22,393	23,388	24,437
Non-Hispanic Asian/Pacific Islander (NH API)	39,729	41,115	41,900	42,513	43,444
Non-Hispanic American Indian/Alaskan Native PRCA (NH AI/AN)	0	0	0	0	0


All Races Population 2015–2019: 6,747,416
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	45,608	47,952	50,529	52,852	55,137
Hispanic White	39,618	41,493	43,582	45,486	47,355
Hispanic Black	3,990	4,328	4,671	4,977	5,319

Hispanic/Latino Population, Census 2010: 36,704
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

NEW HAMPSHIRE CANCER REGISTRY

Initial Operation: 1986
Population-based Data Available: 1987
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	113.4	111.4	108.0	113.3	119.0	113.0
Missing Race	0.9	1.5	1.3	1.2	1.4	1.3
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.2	1.5	1.5	1.4	1.2	1.4
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.4	Ovary	93.5
Oral Cavity & Pharynx	97.8	Prostate	96.2
Esophagus	97.6	Testis	99.1
Stomach	96.7	Bladder (incl. <i>in situ</i>)	97.9
Colon & Rectum	96.8	Kidney & Renal Pelvis	91.1
Liver	55.0	Brain & Other CNS	92.2
Pancreas	87.3	Brain & Other CNS (non-malig)	39.8
Lung & Bronchus	85.0	Thyroid	99.4
Melanomas of the Skin	99.6	Hodgkin Lymphoma	98.2
Female Breast (excl. <i>in situ</i>)	98.9	Non-Hodgkin Lymphoma	96.4
Female Breast (<i>in situ</i>)	99.9	Multiple Myeloma	91.6
Cervix Uteri	97.5	Leukemias	85.3
Uterus Corpus & Uterus NOS	99.3		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Hampshire, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	4,451	517.0	3.61	612.1	4.17	4,245	460.3	3.32	535.6	3.74
Oral Cavity & Pharynx	161	17.9	0.66	21.9	0.78	63	6.6	0.39	7.9	0.45
Lip	4	0.5	0.12	0.6	0.14	3	0.3	0.09	0.4	0.10
Tongue	55	6.1	0.39	7.4	0.45	21	2.3	0.23	2.7	0.26
Major salivary gland	10	1.3	0.19	1.4	0.21	5	0.6	0.12	0.7	0.13
Floor of mouth	7	0.7	0.12	0.9	0.15	4	0.4	0.10	0.5	0.12
Gum & other mouth	13	1.5	0.19	1.8	0.23	11	1.1	0.15	1.3	0.18
Nasopharynx	5	0.6	0.13	0.7	0.14	2	0.2	0.06	0.2	0.07
Oropharynx	12	1.2	0.16	1.5	0.20	3	0.4	0.09	0.4	0.10
Hypopharynx	11	1.2	0.17	1.5	0.20	3	0.3	0.08	0.4	0.10
Digestive System	798	93.8	1.55	111.0	1.79	579	61.7	1.20	71.7	1.35
Esophagus	103	11.6	0.53	14.0	0.63	23	2.2	0.21	2.7	0.26
Stomach	66	7.8	0.45	9.2	0.52	32	3.6	0.29	4.1	0.33
Small intestine	26	3.1	0.28	3.6	0.32	18	2.1	0.23	2.4	0.26
Colon (excl. rectum)	219	27.2	0.86	31.4	0.96	217	23.3	0.74	26.8	0.83
Rectum & rectosigmoid	119	14.2	0.61	16.8	0.70	74	8.3	0.45	9.7	0.51
Anus, anal canal, & anorectum	12	1.3	0.18	1.6	0.22	25	2.5	0.23	3.1	0.28
Liver	77	8.3	0.44	10.2	0.53	21	2.1	0.21	2.5	0.25
Gallbladder	5	0.6	0.13	0.7	0.14	12	1.3	0.17	1.5	0.19
Pancreas	126	14.3	0.59	17.1	0.69	114	11.8	0.51	13.8	0.59
Respiratory System	619	71.8	1.34	85.5	1.56	623	62.7	1.15	74.8	1.35
Larynx	47	5.2	0.35	6.4	0.42	11	1.0	0.14	1.3	0.18
Lung & bronchus	562	65.3	1.28	77.6	1.49	606	61.0	1.14	72.8	1.33
Bones & Joints	8	1.0	0.18	1.0	0.17	6	0.9	0.17	0.9	0.16
Soft Tissue (incl. heart)	32	4.3	0.35	4.8	0.38	24	2.9	0.29	3.2	0.30
Skin (excl. basal & sq.)	342	41.0	1.03	48.0	1.18	246	27.8	0.84	31.7	0.92
Melanoma of the skin	325	38.7	1.00	45.4	1.15	235	26.7	0.83	30.5	0.91
Breast (excl. <i>in situ</i>)	10	1.1	0.17	1.3	0.19	1,297	142.2	1.86	166.7	2.11
Female Genital System	N/A	N/A	N/A	N/A	N/A	495	51.8	1.09	61.9	1.26
Cervix uteri	N/A	N/A	N/A	N/A	N/A	40	5.3	0.40	5.7	0.41
Uterus corpus	N/A	N/A	N/A	N/A	N/A	292	29.6	0.81	36.1	0.96
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	11	1.2	0.16	1.4	0.19
Ovary	N/A	N/A	N/A	N/A	N/A	92	9.6	0.47	11.4	0.54
Male Genital System	1,151	122.8	1.68	149.9	2.00	N/A	N/A	N/A	N/A	N/A
Prostate	1,094	114.1	1.59	141.1	1.93	N/A	N/A	N/A	N/A	N/A
Testis	45	7.2	0.49	7.1	0.48	N/A	N/A	N/A	N/A	N/A
Penis	7	0.9	0.16	1.1	0.18	N/A	N/A	N/A	N/A	N/A
Urinary System	579	69.6	1.34	81.5	1.54	232	24.4	0.75	28.5	0.85
Bladder (incl. <i>in situ</i>)	370	45.0	1.08	52.6	1.25	124	12.6	0.52	14.9	0.60
Kidney & renal pelvis	197	23.0	0.77	27.1	0.88	100	11.0	0.51	12.7	0.58
Ureter	8	1.0	0.16	1.2	0.19	4	0.4	0.10	0.5	0.11
Eye & Orbit	7	0.9	0.17	1.0	0.17	6	0.7	0.13	0.8	0.15
Brain & Other CNS	69	8.8	0.50	9.6	0.53	53	6.5	0.42	7.1	0.44
Brain	66	8.3	0.48	9.2	0.51	51	6.1	0.41	6.8	0.43
Endocrine System	64	8.2	0.48	9.2	0.52	159	21.7	0.81	23.2	0.83
Thyroid gland	54	6.9	0.44	7.8	0.48	154	21.2	0.80	22.6	0.82
Lymphomas	230	28.6	0.88	32.8	0.98	184	20.7	0.71	23.5	0.79
Hodgkin lymphoma	24	3.6	0.33	3.7	0.33	19	2.8	0.30	2.9	0.30
Non-Hodgkin lymphoma	206	25.0	0.81	29.1	0.92	164	17.9	0.65	20.5	0.73
Multiple Myeloma	63	7.6	0.44	8.8	0.51	44	4.4	0.30	5.3	0.36
Leukemias	144	17.8	0.69	20.4	0.77	87	9.9	0.50	11.0	0.54
Acute lymphocytic	10	1.6	0.23	1.5	0.21	8	1.4	0.23	1.3	0.20
Chronic lymphocytic	58	6.9	0.42	8.2	0.49	29	2.9	0.25	3.4	0.29
Acute myeloid	42	5.2	0.37	5.9	0.42	29	3.3	0.29	3.6	0.31
Chronic myeloid	18	2.2	0.25	2.5	0.27	13	1.4	0.18	1.6	0.21
Other leukemias	16	1.9	0.22	2.2	0.26	9	1.0	0.15	1.1	0.16
Mesothelioma	14	1.9	0.23	2.1	0.26	3	0.3	0.08	0.3	0.09
Kaposi Sarcoma	2	0.2	0.08	0.3	0.09	*	*	*	*	*
Ill-Defined & Unknown	159	19.8	0.73	22.9	0.83	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	71	9.0	0.50	10.1	0.55	141	15.9	0.63	18.1	0.70
Breast (<i>in situ</i>)	*	*	*	*	*	303	34.5	0.94	40.3	1.05

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Hampshire, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	4,262	517.2	3.70	612.2	4.27	4,077	463.9	3.44	539.6	3.86
Oral Cavity & Pharynx	157	18.3	0.68	22.4	0.81	61	6.7	0.41	8.0	0.47
Lip	4	0.5	0.12	0.6	0.14	3	0.3	0.09	0.4	0.10
Tongue	54	6.3	0.40	7.6	0.47	21	2.4	0.25	2.8	0.28
Major salivary gland	9	1.3	0.20	1.5	0.22	5	0.6	0.13	0.7	0.14
Floor of mouth	7	0.7	0.12	0.9	0.15	4	0.5	0.10	0.5	0.12
Gum & other mouth	13	1.6	0.20	1.9	0.24	11	1.1	0.16	1.4	0.19
Nasopharynx	4	0.5	0.12	0.7	0.14	1	0.1	0.05	0.1	0.06
Oropharynx	11	1.2	0.16	1.5	0.20	3	0.3	0.08	0.4	0.10
Hypopharynx	11	1.2	0.17	1.5	0.21	3	0.3	0.08	0.4	0.10
Digestive System	763	93.8	1.59	111.0	1.83	561	62.5	1.24	72.6	1.40
Esophagus	101	11.9	0.55	14.3	0.65	23	2.3	0.22	2.8	0.26
Stomach	60	7.4	0.45	8.8	0.52	31	3.7	0.31	4.2	0.34
Small intestine	25	3.1	0.29	3.7	0.33	18	2.1	0.24	2.5	0.27
Colon (excl. rectum)	210	27.5	0.89	31.7	1.00	210	23.6	0.77	27.1	0.86
Rectum & rectosigmoid	111	13.9	0.62	16.5	0.71	72	8.4	0.47	9.9	0.53
Anus, anal canal, & anorectum	12	1.4	0.19	1.7	0.23	24	2.6	0.24	3.2	0.29
Liver	73	8.1	0.44	10.0	0.53	19	2.0	0.21	2.4	0.25
Gallbladder	5	0.6	0.13	0.7	0.14	11	1.3	0.18	1.5	0.20
Pancreas	122	14.5	0.61	17.3	0.71	112	12.1	0.53	14.1	0.61
Respiratory System	601	72.4	1.37	86.2	1.60	607	63.4	1.18	75.8	1.39
Larynx	45	5.1	0.36	6.3	0.43	11	1.1	0.15	1.4	0.19
Lung & bronchus	547	65.9	1.31	78.3	1.52	591	61.7	1.17	73.7	1.37
Bones & Joints	7	1.1	0.19	1.1	0.18	5	0.7	0.16	0.7	0.15
Soft Tissue (incl. heart)	31	4.3	0.37	4.8	0.39	22	2.9	0.30	3.2	0.31
Skin (excl. basal & sq.)	318	39.8	1.04	46.6	1.19	225	27.0	0.86	30.7	0.94
Melanoma of the skin	301	37.5	1.01	44.0	1.15	215	25.9	0.85	29.5	0.92
Breast (excl. <i>in situ</i>)	9	1.1	0.17	1.3	0.20	1,250	144.4	1.94	169.1	2.19
Female Genital System	N/A	N/A	N/A	N/A	N/A	475	52.1	1.13	62.2	1.30
Cervix uteri	N/A	N/A	N/A	N/A	N/A	36	5.2	0.41	5.5	0.42
Uterus corpus	N/A	N/A	N/A	N/A	N/A	282	29.8	0.83	36.4	0.98
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	11	1.2	0.17	1.4	0.20
Ovary	N/A	N/A	N/A	N/A	N/A	89	9.7	0.49	11.5	0.56
Male Genital System	1,094	121.8	1.71	148.6	2.04	N/A	N/A	N/A	N/A	N/A
Prostate	1,042	112.8	1.61	139.5	1.96	N/A	N/A	N/A	N/A	N/A
Testis	42	7.5	0.54	7.5	0.52	N/A	N/A	N/A	N/A	N/A
Penis	6	0.9	0.16	1.0	0.18	N/A	N/A	N/A	N/A	N/A
Urinary System	564	70.6	1.38	82.7	1.58	225	24.7	0.77	28.8	0.87
Bladder (incl. <i>in situ</i>)	362	45.7	1.11	53.4	1.28	122	12.9	0.54	15.2	0.62
Kidney & renal pelvis	190	23.4	0.80	27.6	0.91	95	11.0	0.53	12.7	0.59
Ureter	8	1.0	0.17	1.2	0.19	4	0.4	0.10	0.5	0.11
Eye & Orbit	7	0.9	0.17	1.0	0.18	6	0.7	0.14	0.8	0.15
Brain & Other CNS	65	8.9	0.52	9.7	0.54	51	6.7	0.45	7.3	0.47
Brain	62	8.4	0.51	9.2	0.53	49	6.3	0.43	6.9	0.45
Endocrine System	59	8.1	0.50	9.1	0.54	148	21.9	0.86	23.3	0.88
Thyroid gland	51	7.0	0.46	7.9	0.50	144	21.3	0.85	22.7	0.87
Lymphomas	221	28.9	0.91	33.1	1.02	175	20.7	0.74	23.4	0.81
Hodgkin lymphoma	23	3.7	0.36	3.9	0.36	18	2.8	0.31	2.9	0.31
Non-Hodgkin lymphoma	198	25.2	0.84	29.3	0.95	158	17.9	0.67	20.6	0.75
Multiple Myeloma	60	7.6	0.45	8.8	0.52	42	4.3	0.31	5.2	0.37
Leukemias	139	17.9	0.71	20.7	0.80	84	10.1	0.53	11.2	0.56
Acute lymphocytic	10	1.6	0.25	1.5	0.23	8	1.4	0.25	1.3	0.21
Chronic lymphocytic	57	7.0	0.43	8.3	0.50	28	2.9	0.26	3.4	0.30
Acute myeloid	40	5.2	0.38	5.9	0.43	28	3.4	0.31	3.8	0.33
Chronic myeloid	17	2.2	0.25	2.6	0.28	12	1.4	0.18	1.6	0.21
Other leukemias	16	2.0	0.23	2.3	0.27	8	1.0	0.16	1.1	0.17
Mesothelioma	14	1.9	0.23	2.1	0.26	3	0.3	0.08	0.4	0.10
Kaposi Sarcoma	2	0.2	0.07	0.2	0.09	*	*	*	*	*
Ill-Defined & Unknown	151	19.5	0.74	22.7	0.84	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	67	9.1	0.52	10.2	0.57	133	15.8	0.65	18.1	0.72
Breast (<i>in situ</i>)	*	*	*	*	*	294	35.3	0.98	41.2	1.10

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Hampshire, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	29	357.0	34.07	441.6	40.81	19	293.6	33.33	338.4	37.90
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	5	69.9	16.34	86.1	19.10	3	48.8	12.42	60.0	15.21
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	2	19.3	7.54	23.3	8.76	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	3	40.0	10.81	48.5	12.60	2	42.1	14.96	47.1	16.76
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	3	31.3	9.10	38.2	10.87	2	39.4	14.72	44.9	16.61
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	6	95.7	18.46	111.5	21.05
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	22.5	8.19	27.9	10.19
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	12	153.2	22.52	198.0	28.00	N/A	N/A	N/A	N/A	N/A
Prostate	12	153.2	22.52	198.0	28.00	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	2	24.4	10.00	28.3	11.46	2	28.3	11.18	32.4	12.42
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	1	13.4	5.75	16.1	6.80	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	16.5	6.12	19.3	7.21	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	2	26.8	9.64	31.3	10.97
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Hampshire, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	30	222.8	20.16	257.9	23.21	41	225.2	16.85	261.8	19.58
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	7	47.2	8.63	55.1	10.02	5	34.4	7.42	39.1	8.38
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	2	11.1	4.18	12.5	4.60	2	12.1	4.52	14.1	5.21
Rectum & rectosigmoid	2	14.3	4.76	17.0	5.51	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	1	8.1	3.53	9.2	4.01	1	7.3	3.27	8.3	3.70
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	5	43.9	9.86	51.3	11.46	5	32.3	7.09	38.4	8.38
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	4	39.2	9.34	45.4	10.73	5	32.3	7.09	38.4	8.38
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	15	74.8	8.85	86.9	10.35
Female Genital System	N/A	N/A	N/A	N/A	N/A	5	26.0	5.12	31.2	6.14
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	3	13.7	3.58	16.5	4.34
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	1	5.8	2.39	7.1	2.92
Male Genital System	6	44.7	8.71	53.7	10.24	N/A	N/A	N/A	N/A	N/A
Prostate	5	40.1	8.26	49.3	9.87	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	2	15.1	4.87	18.8	6.10	1	8.7	3.80	9.3	4.08
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	1	7.5	3.15	8.8	3.69	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	1	8.3	3.59	9.8	4.16	2	11.7	3.51	13.1	3.93
Thyroid gland	*	*	*	*	*	2	11.7	3.51	13.1	3.93
Lymphomas	1	9.7	4.12	10.2	4.29	2	10.7	3.73	12.9	4.50
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	2	13.4	6.02	14.3	6.51	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	1	13.4	5.54	14.9	6.20	2	13.4	4.24	14.9	4.70
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	1	12.2	5.11	14.7	6.08	2	9.9	3.44	11.5	3.92
Breast (<i>in situ</i>)	*	*	*	*	*	3	14.8	3.94	17.2	4.58

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Hampshire, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	52	405.5	28.79	478.0	33.00	55	340.0	21.97	393.3	25.32
Oral Cavity & Pharynx	1	7.6	3.20	10.2	4.28	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	13	102.8	14.48	119.7	16.50	5	33.0	6.95	39.0	8.16
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	3	27.5	8.09	31.7	9.09	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	2	17.6	6.53	19.3	7.11	2	13.3	4.17	15.6	4.95
Rectum & rectosigmoid	3	19.6	6.11	22.2	6.82	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	1	10.0	4.20	11.8	4.74	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	5	36.9	7.99	46.5	9.80	5	36.5	7.67	42.3	8.72
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	4	28.5	6.60	36.3	8.37	5	35.6	7.61	41.0	8.61
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	1	15.7	6.29	17.9	6.92	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	*	*	*	*	*	2	12.8	4.88	14.2	5.36
Breast (excl. <i>in situ</i>)	*	*	*	*	*	19	121.1	13.07	141.2	15.09
Female Genital System	N/A	N/A	N/A	N/A	N/A	7	42.9	7.96	49.0	9.04
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	9.2	2.92	8.7	2.83
Uterus corpus	N/A	N/A	N/A	N/A	N/A	3	18.2	5.16	22.0	6.16
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	14	114.0	15.10	135.8	17.39	N/A	N/A	N/A	N/A	N/A
Prostate	12	105.9	14.89	127.9	17.22	N/A	N/A	N/A	N/A	N/A
Testis	2	6.2	2.12	5.7	1.94	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	4	38.1	9.42	43.5	10.41	3	17.8	5.24	21.3	6.15
Bladder (incl. <i>in situ</i>)	2	24.9	8.37	27.9	9.05	*	*	*	*	*
Kidney & renal pelvis	2	13.3	4.33	15.6	5.14	2	16.0	4.93	19.4	5.86
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	1	4.8	2.03	5.3	2.36	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	2	15.2	5.23	17.3	6.04	5	21.6	4.41	22.2	4.68
Thyroid gland	2	10.6	4.36	11.9	5.08	5	20.7	4.31	21.0	4.52
Lymphomas	3	23.5	7.08	26.5	7.85	3	18.3	5.16	20.7	5.81
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	1	11.9	5.55	14.0	6.23	*	*	*	*	*
Leukemias	2	15.9	6.22	17.7	6.67	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	14.7	5.48	18.7	6.78	2	12.7	4.28	15.3	5.22
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	3	18.3	5.03	21.2	5.81
Breast (<i>in situ</i>)	*	*	*	*	*	4	26.0	5.89	29.9	6.74

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

NEW HAMPSHIRE

II-338 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Hampshire, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	41	370.9	29.46	436.7	33.65	45	314.3	22.39	360.1	25.58
Oral Cavity & Pharynx	1	8.7	3.64	11.7	4.87	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	10	92.4	14.82	106.7	16.74	4	27.9	6.74	32.0	7.66
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	2	23.3	8.40	25.9	9.16	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	2	19.0	7.29	21.2	7.98	2	11.7	4.02	13.0	4.51
Rectum & rectosigmoid	2	16.7	5.75	18.5	6.27	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	1	8.8	3.92	10.7	4.58	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	4	36.5	8.64	45.8	10.48	4	34.1	7.86	39.2	8.93
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	4	28.4	7.12	36.3	9.00	4	34.1	7.86	39.2	8.93
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	*	*	*	*	*	1	10.6	4.63	11.5	5.08
Breast (excl. <i>in situ</i>)	*	*	*	*	*	17	121.1	13.73	141.3	15.89
Female Genital System	N/A	N/A	N/A	N/A	N/A	5	38.9	8.14	43.8	9.06
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	9.3	3.13	9.0	3.06
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2	14.9	5.02	18.3	5.97
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	11	97.7	14.62	116.9	16.93	N/A	N/A	N/A	N/A	N/A
Prostate	9	88.7	14.32	108.1	16.68	N/A	N/A	N/A	N/A	N/A
Testis	2	6.6	2.41	6.1	2.18	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	4	40.1	10.48	45.3	11.52	2	16.1	5.43	18.7	6.20
Bladder (incl. <i>in situ</i>)	2	28.0	9.40	31.4	10.16	*	*	*	*	*
Kidney & renal pelvis	2	12.1	4.64	13.9	5.42	2	14.2	5.07	16.6	5.84
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	1	11.4	5.13	12.6	5.74	4	20.5	4.57	21.2	4.88
Thyroid gland	*	*	*	*	*	4	19.4	4.44	19.8	4.69
Lymphomas	2	19.9	6.94	22.6	7.63	2	13.8	4.82	15.7	5.37
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	1	13.5	6.26	15.8	7.02	*	*	*	*	*
Leukemias	2	18.1	7.00	20.1	7.52	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	1	12.9	4.97	16.9	6.41	1	9.2	4.02	10.6	4.70
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	3	18.3	5.38	20.6	6.07
Breast (<i>in situ</i>)	*	*	*	*	*	3	22.5	5.99	26.4	6.90

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Hampshire, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2	246.9	88.61	295.1	108.16	*	*	*	*	*
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.


N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	8,870,312	8,873,584	8,888,147	8,891,730	8,891,258
Non-Hispanic White	5,092,112	5,047,415	5,004,264	4,962,266	4,918,641
Non-Hispanic Black	1,189,964	1,190,673	1,192,496	1,193,548	1,196,384
Non-Hispanic Asian/Pacific Islander (NH API)	848,783	866,858	888,476	900,653	912,249
Non-Hispanic American Indian/Alaskan Native PRCA (NH AI/AN)	0	0	0	0	0


All Races Population 2015–2019: 44,415,031
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	1,722,071	1,751,284	1,785,444	1,817,704	1,846,291
Hispanic White	1,457,062	1,480,262	1,506,999	1,531,410	1,551,545
Hispanic Black	193,967	198,247	203,650	209,397	215,566

Hispanic/Latino Population, Census 2010: 1,555,144
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

NEW JERSEY CANCER REGISTRY

Initial Operation: 1979
 Population-based Data Available: 1979
 Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	115.0	114.6	115.5	116.6	115.2	115.4
Missing Race	1.1	1.1	1.5	1.9	2.4	1.6
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.7	1.2	1.2	1.0	0.9	1.2
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.3	Ovary	94.3
Oral Cavity & Pharynx	97.7	Prostate	97.8
Esophagus	96.2	Testis	99.7
Stomach	96.8	Bladder (incl. <i>in situ</i>)	98.3
Colon & Rectum	96.6	Kidney & Renal Pelvis	92.3
Liver	59.5	Brain & Other CNS	86.2
Pancreas	86.3	Brain & Other CNS (non-malig)	38.5
Lung & Bronchus	89.2	Thyroid	99.5
Melanomas of the Skin	99.1	Hodgkin Lymphoma	98.7
Female Breast (excl. <i>in situ</i>)	98.8	Non-Hodgkin Lymphoma	96.8
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	91.3
Cervix Uteri	97.4	Leukemias	91.2
Uterus Corpus & Uterus NOS	98.6		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Jersey, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	26,721	536.3	1.50	636.0	1.75	26,752	459.4	1.30	534.9	1.48
Oral Cavity & Pharynx	900	17.3	0.26	21.2	0.32	382	6.4	0.15	7.6	0.18
Lip	23	0.5	0.05	0.6	0.05	13	0.2	0.03	0.3	0.03
Tongue	290	5.5	0.15	6.8	0.18	117	1.9	0.08	2.3	0.10
Major salivary gland	88	1.8	0.09	2.2	0.10	67	1.2	0.07	1.4	0.08
Floor of mouth	35	0.7	0.05	0.8	0.06	13	0.2	0.03	0.3	0.03
Gum & other mouth	107	2.2	0.10	2.6	0.11	83	1.4	0.07	1.6	0.08
Nasopharynx	37	0.7	0.06	0.9	0.06	15	0.3	0.03	0.3	0.04
Oropharynx	51	1.0	0.06	1.2	0.08	16	0.2	0.03	0.3	0.04
Hypopharynx	45	0.9	0.06	1.1	0.07	12	0.2	0.02	0.2	0.03
Digestive System	5,078	102.4	0.66	121.8	0.77	4,205	69.2	0.49	81.3	0.57
Esophagus	379	7.5	0.18	9.0	0.21	109	1.7	0.07	2.1	0.09
Stomach	511	10.4	0.21	12.3	0.25	349	5.9	0.15	6.8	0.17
Small intestine	156	3.1	0.11	3.7	0.13	139	2.3	0.09	2.7	0.11
Colon (excl. rectum)	1,504	30.9	0.36	36.4	0.42	1,543	25.6	0.30	29.8	0.34
Rectum & rectosigmoid	745	14.9	0.25	17.8	0.29	554	9.4	0.18	11.1	0.21
Anus, anal canal, & anorectum	75	1.5	0.08	1.8	0.09	130	2.1	0.08	2.6	0.10
Liver	564	10.7	0.21	13.2	0.25	190	3.0	0.10	3.6	0.12
Gallbladder	45	1.0	0.07	1.1	0.07	90	1.4	0.07	1.7	0.08
Pancreas	817	16.6	0.27	19.7	0.31	827	13.2	0.21	15.6	0.25
Respiratory System	3,158	64.6	0.53	76.2	0.61	3,234	51.9	0.42	61.5	0.49
Larynx	255	5.0	0.14	6.1	0.17	61	1.0	0.06	1.2	0.07
Lung & bronchus	2,846	58.5	0.50	68.8	0.58	3,134	50.3	0.41	59.5	0.48
Bones & Joints	59	1.3	0.08	1.4	0.08	48	1.0	0.07	1.0	0.07
Soft Tissue (incl. heart)	201	4.3	0.14	4.8	0.15	157	2.9	0.11	3.2	0.12
Skin (excl. basal & sq.)	1,493	30.9	0.37	36.2	0.42	1,073	18.9	0.27	21.8	0.30
Melanoma of the skin	1,374	28.3	0.35	33.3	0.40	990	17.4	0.26	20.2	0.29
Breast (excl. <i>in situ</i>)	73	1.5	0.08	1.8	0.09	7,906	138.9	0.72	162.4	0.82
Female Genital System	N/A	N/A	N/A	N/A	N/A	3,365	57.3	0.46	68.2	0.53
Cervix uteri	N/A	N/A	N/A	N/A	N/A	384	7.7	0.18	8.4	0.19
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,886	30.8	0.32	37.9	0.39
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	87	1.5	0.07	1.7	0.08
Ovary	N/A	N/A	N/A	N/A	N/A	672	11.7	0.21	13.6	0.24
Male Genital System	7,780	147.3	0.76	179.9	0.92	N/A	N/A	N/A	N/A	N/A
Prostate	7,475	140.1	0.74	172.6	0.90	N/A	N/A	N/A	N/A	N/A
Testis	251	6.0	0.17	6.0	0.17	N/A	N/A	N/A	N/A	N/A
Penis	41	0.8	0.06	1.0	0.07	N/A	N/A	N/A	N/A	N/A
Urinary System	3,086	63.6	0.52	74.6	0.61	1,355	22.2	0.28	26.1	0.32
Bladder (incl. <i>in situ</i>)	1,847	38.7	0.41	45.2	0.47	662	10.4	0.19	12.3	0.22
Kidney & renal pelvis	1,166	23.3	0.31	27.6	0.36	652	11.1	0.20	13.0	0.23
Ureter	42	0.9	0.06	1.0	0.07	27	0.4	0.04	0.5	0.04
Eye & Orbit	32	0.7	0.06	0.8	0.06	35	0.6	0.05	0.7	0.05
Brain & Other CNS	369	7.8	0.19	8.6	0.20	312	5.9	0.15	6.4	0.16
Brain	353	7.5	0.18	8.3	0.20	293	5.5	0.15	6.0	0.16
Endocrine System	495	10.4	0.22	11.7	0.24	1,361	28.0	0.35	30.3	0.37
Thyroid gland	448	9.4	0.20	10.6	0.22	1,314	27.2	0.35	29.3	0.36
Lymphomas	1,431	30.1	0.36	34.4	0.41	1,214	21.2	0.28	24.2	0.31
Hodgkin lymphoma	159	3.5	0.13	3.8	0.13	133	2.9	0.12	3.0	0.12
Non-Hodgkin lymphoma	1,272	26.6	0.34	30.7	0.39	1,081	18.3	0.26	21.2	0.29
Multiple Myeloma	479	9.7	0.20	11.5	0.24	393	6.4	0.15	7.6	0.17
Leukemias	971	20.6	0.30	23.4	0.34	701	12.2	0.21	13.7	0.23
Acute lymphocytic	92	2.2	0.10	2.0	0.10	72	1.6	0.09	1.5	0.08
Chronic lymphocytic	396	8.0	0.18	9.6	0.22	270	4.3	0.12	5.1	0.14
Acute myeloid	248	5.3	0.15	6.0	0.17	202	3.5	0.12	4.0	0.13
Chronic myeloid	126	2.8	0.11	3.1	0.12	83	1.5	0.07	1.7	0.08
Other leukemias	109	2.3	0.10	2.7	0.12	74	1.2	0.07	1.4	0.07
Mesothelioma	80	1.8	0.09	2.0	0.10	35	0.6	0.05	0.7	0.05
Kaposi Sarcoma	31	0.7	0.06	0.7	0.06	6	0.1	0.02	0.1	0.02
Ill-Defined & Unknown	1,003	21.4	0.31	24.8	0.35	970	15.5	0.23	17.9	0.26
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	496	10.5	0.22	11.9	0.24	991	17.4	0.26	20.0	0.29
Breast (<i>in situ</i>)	8	0.2	0.03	0.2	0.03	2,277	41.4	0.40	48.5	0.46

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Jersey, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	19,302	561.9	1.87	663.7	2.16	19,066	494.4	1.72	574.6	1.93
Oral Cavity & Pharynx	675	19.1	0.34	23.4	0.41	272	6.8	0.20	8.0	0.23
Lip	20	0.6	0.06	0.7	0.07	10	0.2	0.04	0.3	0.04
Tongue	228	6.4	0.20	7.9	0.24	86	2.2	0.11	2.6	0.13
Major salivary gland	71	2.2	0.12	2.5	0.13	42	1.1	0.09	1.3	0.09
Floor of mouth	27	0.7	0.06	0.9	0.08	11	0.3	0.04	0.3	0.04
Gum & other mouth	70	2.0	0.11	2.4	0.13	61	1.4	0.09	1.7	0.10
Nasopharynx	18	0.6	0.06	0.7	0.07	7	0.2	0.04	0.2	0.04
Oropharynx	37	1.0	0.08	1.3	0.09	13	0.3	0.04	0.4	0.05
Hypopharynx	30	0.8	0.07	1.0	0.08	8	0.2	0.03	0.2	0.04
Digestive System	3,514	102.2	0.80	121.3	0.92	2,846	68.0	0.60	79.8	0.69
Esophagus	309	8.7	0.23	10.5	0.27	77	1.7	0.09	2.1	0.11
Stomach	314	9.0	0.23	10.7	0.27	177	4.3	0.15	5.0	0.17
Small intestine	105	3.1	0.14	3.6	0.16	89	2.2	0.11	2.6	0.13
Colon (excl. rectum)	1,051	31.4	0.45	36.8	0.51	1,085	26.2	0.38	30.3	0.43
Rectum & rectosigmoid	509	15.2	0.31	18.0	0.36	382	9.8	0.24	11.6	0.28
Anus, anal canal, & anorectum	55	1.5	0.10	1.9	0.11	95	2.4	0.11	2.9	0.14
Liver	336	9.2	0.23	11.3	0.28	111	2.5	0.11	3.0	0.13
Gallbladder	27	0.8	0.07	0.9	0.08	50	1.1	0.07	1.3	0.09
Pancreas	609	17.5	0.33	20.7	0.38	589	13.3	0.25	15.7	0.30
Respiratory System	2,435	69.8	0.65	82.4	0.75	2,583	59.6	0.54	70.5	0.63
Larynx	182	5.1	0.17	6.2	0.21	41	1.0	0.07	1.2	0.09
Lung & bronchus	2,216	63.6	0.62	74.8	0.72	2,513	57.9	0.53	68.5	0.62
Bones & Joints	41	1.6	0.12	1.6	0.11	28	1.0	0.09	1.0	0.09
Soft Tissue (incl. heart)	142	4.5	0.18	5.1	0.20	102	2.9	0.14	3.2	0.15
Skin (excl. basal & sq.)	1,375	41.5	0.52	48.4	0.59	964	27.1	0.43	31.0	0.47
Melanoma of the skin	1,277	38.4	0.50	44.9	0.57	901	25.5	0.41	29.1	0.45
Breast (excl. <i>in situ</i>)	55	1.6	0.10	1.9	0.12	5,486	148.8	0.97	173.6	1.08
Female Genital System	N/A	N/A	N/A	N/A	N/A	2,294	59.0	0.59	70.4	0.68
Cervix uteri	N/A	N/A	N/A	N/A	N/A	199	6.9	0.24	7.4	0.24
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,333	32.7	0.42	40.2	0.50
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	48	1.2	0.08	1.4	0.09
Ovary	N/A	N/A	N/A	N/A	N/A	463	12.2	0.27	14.2	0.31
Male Genital System	5,097	139.8	0.90	170.0	1.07	N/A	N/A	N/A	N/A	N/A
Prostate	4,886	130.6	0.85	160.6	1.03	N/A	N/A	N/A	N/A	N/A
Testis	179	8.3	0.29	8.3	0.28	N/A	N/A	N/A	N/A	N/A
Penis	23	0.7	0.07	0.8	0.08	N/A	N/A	N/A	N/A	N/A
Urinary System	2,407	70.5	0.66	82.6	0.76	1,015	24.2	0.36	28.5	0.41
Bladder (incl. <i>in situ</i>)	1,516	44.1	0.52	51.6	0.60	533	12.0	0.24	14.2	0.28
Kidney & renal pelvis	834	24.7	0.40	29.2	0.46	450	11.6	0.26	13.5	0.29
Ureter	33	1.0	0.08	1.1	0.09	21	0.5	0.05	0.5	0.05
Eye & Orbit	25	0.8	0.08	0.9	0.08	27	0.8	0.08	0.9	0.08
Brain & Other CNS	269	9.0	0.26	9.9	0.27	227	6.9	0.22	7.5	0.23
Brain	258	8.6	0.25	9.4	0.27	213	6.4	0.21	7.0	0.22
Endocrine System	358	12.4	0.31	13.8	0.33	863	31.0	0.51	33.3	0.52
Thyroid gland	330	11.4	0.30	12.7	0.32	837	30.2	0.50	32.4	0.52
Lymphomas	1,051	33.0	0.48	37.6	0.53	881	23.2	0.38	26.5	0.42
Hodgkin lymphoma	105	4.1	0.19	4.3	0.19	81	3.2	0.17	3.3	0.17
Non-Hodgkin lymphoma	947	28.9	0.44	33.3	0.49	800	19.9	0.34	23.2	0.38
Multiple Myeloma	306	8.8	0.23	10.5	0.27	221	5.2	0.16	6.1	0.19
Leukemias	708	21.9	0.38	25.0	0.42	504	12.9	0.28	14.6	0.30
Acute lymphocytic	46	2.0	0.14	1.9	0.12	34	1.5	0.12	1.3	0.10
Chronic lymphocytic	309	8.9	0.23	10.6	0.27	214	4.9	0.16	5.8	0.18
Acute myeloid	183	5.6	0.19	6.5	0.22	144	3.8	0.15	4.2	0.16
Chronic myeloid	89	2.8	0.14	3.2	0.15	56	1.5	0.10	1.7	0.10
Other leukemias	81	2.5	0.13	2.9	0.14	56	1.3	0.09	1.5	0.10
Mesothelioma	72	2.2	0.12	2.5	0.13	27	0.6	0.06	0.7	0.07
Kaposi Sarcoma	12	0.4	0.06	0.5	0.06	3	0.1	0.02	0.1	0.02
Ill-Defined & Unknown	760	22.7	0.38	26.4	0.43	722	16.3	0.29	18.9	0.33
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	338	10.9	0.28	12.4	0.31	676	18.2	0.34	20.8	0.37
Breast (<i>in situ</i>)	6	0.2	0.03	0.2	0.04	1,518	44.6	0.55	52.0	0.61

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Jersey, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,952	565.6	4.88	681.7	5.76	3,056	428.1	3.53	503.3	4.08
Oral Cavity & Pharynx	79	14.1	0.74	17.3	0.89	36	5.1	0.39	6.0	0.44
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	20	3.6	0.37	4.4	0.45	9	1.3	0.19	1.5	0.23
Major salivary gland	7	1.2	0.22	1.4	0.25	9	1.3	0.21	1.4	0.22
Floor of mouth	4	0.7	0.18	0.9	0.21	*	*	*	*	*
Gum & other mouth	8	1.5	0.25	1.8	0.29	7	0.9	0.16	1.1	0.19
Nasopharynx	8	1.3	0.21	1.6	0.26	3	0.5	0.13	0.5	0.13
Oropharynx	6	1.1	0.21	1.3	0.24	2	0.2	0.07	0.3	0.10
Hypopharynx	8	1.4	0.22	1.7	0.28	2	0.3	0.09	0.4	0.11
Digestive System	608	119.3	2.27	143.3	2.67	584	81.4	1.53	96.6	1.79
Esophagus	30	6.0	0.51	7.2	0.60	17	2.3	0.25	2.8	0.31
Stomach	67	14.4	0.83	17.0	0.96	63	9.0	0.51	10.5	0.59
Small intestine	24	4.7	0.45	5.7	0.53	27	3.7	0.33	4.4	0.38
Colon (excl. rectum)	197	39.4	1.32	46.8	1.54	212	29.9	0.93	35.2	1.08
Rectum & rectosigmoid	72	13.8	0.77	16.5	0.90	62	8.7	0.50	10.3	0.59
Anus, anal canal, & anorectum	10	1.8	0.26	2.1	0.30	13	1.7	0.22	2.1	0.26
Liver	87	14.9	0.74	19.0	0.92	27	3.6	0.31	4.5	0.38
Gallbladder	8	1.7	0.28	2.0	0.33	15	2.2	0.25	2.5	0.29
Pancreas	88	17.5	0.88	21.1	1.04	113	15.6	0.67	18.5	0.78
Respiratory System	344	70.7	1.79	84.1	2.08	344	46.9	1.15	56.7	1.37
Larynx	34	6.3	0.51	7.8	0.61	13	1.7	0.21	2.1	0.26
Lung & bronchus	305	63.4	1.70	75.1	1.97	328	44.8	1.12	54.1	1.34
Bones & Joints	5	1.0	0.20	1.1	0.22	6	1.0	0.18	1.0	0.18
Soft Tissue (incl. heart)	21	3.9	0.40	4.3	0.44	22	3.2	0.31	3.6	0.34
Skin (excl. basal & sq.)	12	2.4	0.32	2.7	0.36	16	2.3	0.26	2.6	0.29
Melanoma of the skin	6	1.3	0.24	1.5	0.28	8	1.1	0.18	1.3	0.21
Breast (excl. <i>in situ</i>)	11	2.1	0.29	2.4	0.34	967	136.0	1.99	159.4	2.30
Female Genital System	N/A	N/A	N/A	N/A	N/A	424	57.9	1.28	69.5	1.51
Cervix uteri	N/A	N/A	N/A	N/A	N/A	67	9.9	0.55	11.1	0.61
Uterus corpus	N/A	N/A	N/A	N/A	N/A	229	29.9	0.90	37.2	1.10
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	23	3.2	0.30	3.7	0.35
Ovary	N/A	N/A	N/A	N/A	N/A	71	10.2	0.55	11.8	0.63
Male Genital System	1,193	216.9	2.93	268.5	3.54	N/A	N/A	N/A	N/A	N/A
Prostate	1,177	214.0	2.91	265.5	3.52	N/A	N/A	N/A	N/A	N/A
Testis	11	2.0	0.27	1.9	0.26	N/A	N/A	N/A	N/A	N/A
Penis	4	0.7	0.18	0.9	0.21	N/A	N/A	N/A	N/A	N/A
Urinary System	246	48.7	1.46	57.8	1.70	140	19.6	0.75	23.1	0.88
Bladder (incl. <i>in situ</i>)	100	22.0	1.03	25.8	1.19	51	7.2	0.46	8.4	0.53
Kidney & renal pelvis	140	25.6	1.00	30.7	1.18	85	11.8	0.58	13.9	0.68
Ureter	2	0.6	0.16	0.6	0.19	2	0.2	0.08	0.3	0.09
Eye & Orbit	1	0.2	0.10	0.2	0.11	1	0.2	0.09	0.2	0.08
Brain & Other CNS	28	5.1	0.45	5.7	0.50	26	3.9	0.35	4.3	0.37
Brain	27	4.9	0.44	5.4	0.49	24	3.6	0.33	3.9	0.36
Endocrine System	27	5.1	0.45	5.8	0.51	114	16.8	0.72	18.7	0.78
Thyroid gland	22	4.0	0.40	4.6	0.46	104	15.4	0.69	17.0	0.75
Lymphomas	111	21.5	0.95	24.6	1.08	103	15.0	0.67	16.9	0.75
Hodgkin lymphoma	15	2.7	0.31	2.9	0.33	17	2.6	0.29	2.7	0.29
Non-Hodgkin lymphoma	96	18.8	0.90	21.7	1.02	86	12.4	0.61	14.2	0.69
Multiple Myeloma	93	18.7	0.91	22.4	1.07	100	14.0	0.64	16.6	0.74
Leukemias	71	14.3	0.79	16.3	0.90	63	9.0	0.52	10.3	0.58
Acute lymphocytic	5	0.9	0.19	0.8	0.17	8	1.3	0.20	1.3	0.20
Chronic lymphocytic	25	5.4	0.51	6.3	0.59	16	2.2	0.25	2.6	0.30
Acute myeloid	22	4.4	0.43	5.0	0.49	21	3.2	0.31	3.5	0.34
Chronic myeloid	13	2.4	0.31	2.7	0.36	9	1.2	0.19	1.4	0.22
Other leukemias	7	1.2	0.23	1.5	0.27	9	1.2	0.19	1.5	0.22
Mesothelioma	3	0.7	0.19	0.8	0.22	3	0.4	0.11	0.4	0.12
Kaposi Sarcoma	8	1.4	0.23	1.5	0.25	2	0.3	0.10	0.4	0.11
Ill-Defined & Unknown	91	19.5	0.96	22.8	1.11	103	14.9	0.67	17.0	0.75
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	57	11.2	0.70	12.9	0.79	117	16.8	0.71	19.2	0.80
Breast (<i>in situ</i>)	2	0.3	0.11	0.3	0.12	276	38.2	1.05	45.5	1.22

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Jersey, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,131	288.8	4.00	338.3	4.65	1,385	294.8	3.61	341.6	4.17
Oral Cavity & Pharynx	56	13.1	0.80	15.8	0.96	24	5.1	0.47	5.8	0.54
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	17	3.9	0.44	4.7	0.52	8	1.6	0.26	1.9	0.31
Major salivary gland	4	1.0	0.22	1.2	0.27	4	0.9	0.19	1.0	0.22
Floor of mouth	1	0.3	0.12	0.3	0.14	*	*	*	*	*
Gum & other mouth	18	4.3	0.46	5.2	0.55	7	1.6	0.28	1.8	0.31
Nasopharynx	6	1.2	0.23	1.4	0.27	2	0.4	0.12	0.4	0.13
Oropharynx	2	0.4	0.16	0.5	0.18	*	*	*	*	*
Hypopharynx	3	0.7	0.20	0.9	0.24	*	*	*	*	*
Digestive System	296	75.6	2.06	90.0	2.42	219	49.1	1.52	57.7	1.77
Esophagus	13	3.4	0.43	4.1	0.50	6	1.3	0.24	1.5	0.28
Stomach	42	10.9	0.79	12.9	0.92	33	7.3	0.58	8.6	0.67
Small intestine	7	1.7	0.30	1.9	0.34	5	1.0	0.21	1.2	0.25
Colon (excl. rectum)	71	17.8	0.97	20.9	1.14	68	15.3	0.85	18.1	0.99
Rectum & rectosigmoid	55	13.6	0.86	16.3	1.02	35	7.5	0.58	8.9	0.69
Anus, anal canal, & anorectum	*	*	*	*	*	4	0.8	0.18	0.9	0.22
Liver	50	12.9	0.87	15.7	1.04	15	3.7	0.43	4.2	0.49
Gallbladder	3	0.8	0.22	0.9	0.25	7	1.5	0.27	1.8	0.31
Pancreas	35	9.3	0.74	11.0	0.87	32	7.4	0.60	8.8	0.70
Respiratory System	133	36.2	1.48	42.6	1.72	94	21.4	1.01	25.2	1.18
Larynx	8	1.9	0.31	2.2	0.37	1	0.3	0.11	0.3	0.13
Lung & bronchus	120	33.2	1.42	39.1	1.66	91	20.6	0.99	24.3	1.16
Bones & Joints	4	0.8	0.20	0.9	0.20	4	0.9	0.20	0.8	0.19
Soft Tissue (incl. heart)	12	3.2	0.42	3.5	0.47	9	1.9	0.30	2.1	0.33
Skin (excl. basal & sq.)	8	1.9	0.31	2.2	0.36	5	1.2	0.25	1.4	0.28
Melanoma of the skin	5	1.2	0.25	1.5	0.30	3	0.7	0.18	0.8	0.21
Breast (excl. <i>in situ</i>)	3	0.8	0.20	0.9	0.24	516	106.1	2.12	123.8	2.47
Female Genital System	N/A	N/A	N/A	N/A	N/A	197	40.1	1.30	48.0	1.55
Cervix uteri	N/A	N/A	N/A	N/A	N/A	26	5.4	0.48	6.1	0.55
Uterus corpus	N/A	N/A	N/A	N/A	N/A	103	20.3	0.91	25.1	1.11
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	4	0.9	0.20	1.0	0.23
Ovary	N/A	N/A	N/A	N/A	N/A	53	11.0	0.69	12.8	0.80
Male Genital System	277	69.4	1.93	83.1	2.27	N/A	N/A	N/A	N/A	N/A
Prostate	265	66.6	1.89	80.2	2.24	N/A	N/A	N/A	N/A	N/A
Testis	10	2.2	0.32	2.3	0.33	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	98	25.9	1.22	30.0	1.41	44	10.1	0.69	11.7	0.80
Bladder (incl. <i>in situ</i>)	48	13.8	0.93	15.9	1.06	14	3.5	0.42	4.0	0.48
Kidney & renal pelvis	46	11.2	0.77	13.0	0.89	27	5.8	0.51	6.8	0.59
Ureter	3	0.7	0.20	0.8	0.23	2	0.6	0.18	0.7	0.21
Eye & Orbit	*	*	*	*	*	1	0.3	0.12	0.3	0.12
Brain & Other CNS	22	5.3	0.52	5.6	0.55	18	4.1	0.44	4.4	0.47
Brain	21	5.0	0.51	5.3	0.54	17	3.9	0.43	4.1	0.46
Endocrine System	44	9.9	0.68	10.8	0.75	118	24.1	1.00	25.6	1.07
Thyroid gland	39	8.6	0.63	9.3	0.69	114	23.2	0.98	24.7	1.05
Lymphomas	68	17.3	0.98	19.6	1.11	54	11.9	0.74	13.5	0.84
Hodgkin lymphoma	8	1.8	0.30	2.0	0.33	8	1.9	0.30	1.9	0.31
Non-Hodgkin lymphoma	60	15.5	0.93	17.6	1.06	46	9.9	0.67	11.6	0.78
Multiple Myeloma	21	5.2	0.54	6.1	0.63	15	3.3	0.39	3.9	0.45
Leukemias	44	11.3	0.79	12.3	0.87	29	6.6	0.56	7.3	0.61
Acute lymphocytic	9	2.0	0.31	1.8	0.28	7	1.7	0.28	1.5	0.26
Chronic lymphocytic	8	2.2	0.36	2.6	0.41	5	1.3	0.25	1.5	0.28
Acute myeloid	14	3.7	0.46	4.1	0.51	12	2.6	0.35	3.0	0.40
Chronic myeloid	8	1.9	0.31	2.1	0.35	3	0.7	0.18	0.9	0.22
Other leukemias	6	1.5	0.31	1.7	0.35	2	0.4	0.14	0.4	0.15
Mesothelioma	1	0.3	0.13	0.4	0.16	1	0.2	0.10	0.3	0.12
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	44	12.3	0.88	14.2	1.01	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	32	7.7	0.64	8.5	0.71	53	11.4	0.71	13.2	0.82
Breast (<i>in situ</i>)	*	*	*	*	*	199	40.7	1.30	47.3	1.51

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Jersey, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,619	426.9	4.02	505.7	4.68	2,911	376.0	3.19	436.5	3.69
Oral Cavity & Pharynx	81	12.2	0.65	14.9	0.78	45	5.7	0.39	6.7	0.46
Lip	2	0.3	0.11	0.3	0.13	2	0.3	0.09	0.3	0.10
Tongue	23	3.5	0.36	4.3	0.42	12	1.6	0.20	1.9	0.25
Major salivary gland	6	1.0	0.20	1.2	0.23	12	1.5	0.19	1.7	0.22
Floor of mouth	3	0.4	0.13	0.5	0.15	1	0.2	0.08	0.2	0.09
Gum & other mouth	10	1.6	0.25	1.9	0.29	7	1.0	0.17	1.1	0.19
Nasopharynx	5	0.7	0.14	0.9	0.17	3	0.4	0.10	0.4	0.11
Oropharynx	7	1.0	0.18	1.2	0.22	1	0.2	0.07	0.2	0.09
Hypopharynx	4	0.6	0.16	0.8	0.19	*	*	*	*	*
Digestive System	613	101.9	1.98	121.4	2.32	515	70.2	1.42	82.3	1.65
Esophagus	25	4.1	0.40	5.1	0.48	9	1.3	0.19	1.5	0.23
Stomach	84	14.6	0.77	17.3	0.90	71	9.5	0.52	11.0	0.59
Small intestine	18	2.9	0.33	3.5	0.39	16	2.2	0.25	2.5	0.29
Colon (excl. rectum)	170	28.7	1.06	33.8	1.23	162	22.2	0.80	25.6	0.92
Rectum & rectosigmoid	94	14.4	0.72	17.2	0.84	62	7.9	0.46	9.5	0.55
Anus, anal canal, & anorectum	8	1.3	0.22	1.5	0.26	17	2.2	0.24	2.6	0.29
Liver	87	13.5	0.69	16.9	0.84	36	5.1	0.39	6.1	0.46
Gallbladder	7	1.3	0.24	1.5	0.27	18	2.4	0.26	2.9	0.31
Pancreas	81	14.2	0.76	16.7	0.87	90	12.8	0.62	15.1	0.72
Respiratory System	234	43.4	1.35	50.8	1.55	203	28.6	0.92	33.9	1.08
Larynx	30	5.1	0.44	6.1	0.52	6	0.8	0.14	0.9	0.17
Lung & bronchus	196	37.2	1.26	43.5	1.45	193	27.2	0.90	32.3	1.05
Bones & Joints	9	1.0	0.17	1.1	0.18	9	1.0	0.16	1.1	0.17
Soft Tissue (incl. heart)	22	2.9	0.30	3.2	0.33	22	2.8	0.27	3.0	0.29
Skin (excl. basal & sq.)	32	5.4	0.46	6.2	0.53	33	4.3	0.34	4.9	0.39
Melanoma of the skin	25	4.3	0.41	4.9	0.47	26	3.4	0.31	3.9	0.35
Breast (excl. <i>in situ</i>)	3	0.5	0.14	0.6	0.16	875	110.3	1.70	129.1	1.99
Female Genital System	N/A	N/A	N/A	N/A	N/A	421	52.5	1.17	61.5	1.37
Cervix uteri	N/A	N/A	N/A	N/A	N/A	90	10.9	0.52	11.7	0.57
Uterus corpus	N/A	N/A	N/A	N/A	N/A	205	25.3	0.81	30.9	0.98
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	11	1.4	0.20	1.6	0.22
Ovary	N/A	N/A	N/A	N/A	N/A	80	10.1	0.51	11.6	0.60
Male Genital System	813	131.3	2.20	159.1	2.59	N/A	N/A	N/A	N/A	N/A
Prostate	757	124.6	2.15	152.2	2.55	N/A	N/A	N/A	N/A	N/A
Testis	42	4.3	0.30	4.1	0.29	N/A	N/A	N/A	N/A	N/A
Penis	13	2.2	0.29	2.5	0.34	N/A	N/A	N/A	N/A	N/A
Urinary System	262	44.6	1.33	52.6	1.54	131	17.5	0.70	20.6	0.82
Bladder (incl. <i>in situ</i>)	124	24.0	1.03	28.1	1.18	43	6.2	0.43	7.3	0.50
Kidney & renal pelvis	134	19.5	0.81	23.4	0.95	86	10.9	0.54	12.8	0.63
Ureter	4	0.8	0.19	0.9	0.22	2	0.3	0.09	0.3	0.10
Eye & Orbit	4	0.6	0.15	0.7	0.17	4	0.5	0.12	0.5	0.13
Brain & Other CNS	46	6.4	0.46	7.2	0.52	37	4.4	0.33	4.8	0.37
Brain	44	6.2	0.45	6.9	0.51	36	4.3	0.33	4.7	0.36
Endocrine System	58	7.2	0.45	8.2	0.52	237	27.5	0.81	30.0	0.89
Thyroid gland	51	6.4	0.42	7.3	0.49	229	26.6	0.79	28.9	0.87
Lymphomas	179	27.2	0.98	31.2	1.13	154	20.0	0.74	22.9	0.84
Hodgkin lymphoma	28	3.4	0.30	3.7	0.33	25	2.9	0.27	3.0	0.28
Non-Hodgkin lymphoma	151	23.8	0.94	27.5	1.08	129	17.1	0.69	19.9	0.80
Multiple Myeloma	52	8.8	0.59	10.6	0.69	51	6.8	0.44	8.2	0.52
Leukemias	107	15.7	0.74	17.3	0.83	80	10.2	0.52	11.1	0.58
Acute lymphocytic	31	3.3	0.27	3.1	0.26	22	2.3	0.23	2.3	0.23
Chronic lymphocytic	22	3.9	0.40	4.5	0.46	16	2.4	0.27	2.7	0.31
Acute myeloid	27	4.2	0.39	4.8	0.44	23	3.0	0.29	3.3	0.32
Chronic myeloid	13	2.0	0.26	2.1	0.29	12	1.6	0.21	1.8	0.24
Other leukemias	14	2.4	0.31	2.7	0.35	7	0.9	0.16	0.9	0.17
Mesothelioma	4	0.7	0.17	0.9	0.21	4	0.6	0.13	0.6	0.14
Kaposi Sarcoma	9	1.4	0.23	1.5	0.25	1	0.2	0.07	0.2	0.08
Ill-Defined & Unknown	88	15.6	0.80	18.2	0.93	90	12.9	0.62	14.9	0.72
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	56	8.2	0.53	9.1	0.61	127	16.1	0.66	18.4	0.75
Breast (<i>in situ</i>)	*	*	*	*	*	253	31.0	0.89	36.5	1.04

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

NEW JERSEY

II-348 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Jersey, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,260	426.1	4.30	504.4	5.01	2,568	382.5	3.44	443.3	3.98
Oral Cavity & Pharynx	74	12.8	0.72	15.7	0.86	39	5.7	0.42	6.8	0.50
Lip	2	0.3	0.12	0.4	0.15	2	0.3	0.10	0.4	0.11
Tongue	20	3.7	0.40	4.5	0.46	11	1.6	0.22	2.0	0.27
Major salivary gland	6	1.1	0.22	1.3	0.26	10	1.5	0.21	1.7	0.24
Floor of mouth	2	0.4	0.14	0.5	0.16	1	0.2	0.09	0.3	0.10
Gum & other mouth	9	1.7	0.27	2.0	0.32	6	0.9	0.17	1.1	0.20
Nasopharynx	5	0.7	0.14	0.8	0.18	3	0.4	0.11	0.5	0.13
Oropharynx	6	0.9	0.19	1.2	0.24	1	0.2	0.08	0.3	0.10
Hypopharynx	4	0.7	0.17	0.8	0.21	*	*	*	*	*
Digestive System	556	106.3	2.17	126.8	2.54	457	71.5	1.53	83.6	1.77
Esophagus	23	4.4	0.44	5.4	0.53	8	1.3	0.21	1.6	0.25
Stomach	77	15.2	0.83	18.0	0.98	63	9.6	0.55	11.1	0.64
Small intestine	16	3.0	0.37	3.6	0.43	12	1.9	0.25	2.1	0.28
Colon (excl. rectum)	154	29.9	1.16	35.2	1.34	146	22.9	0.87	26.3	0.99
Rectum & rectosigmoid	83	14.7	0.78	17.6	0.92	55	8.0	0.49	9.6	0.59
Anus, anal canal, & anorectum	7	1.3	0.24	1.6	0.28	15	2.3	0.27	2.8	0.32
Liver	79	14.1	0.75	17.6	0.91	30	4.9	0.41	5.8	0.48
Gallbladder	6	1.3	0.25	1.5	0.28	16	2.4	0.28	2.9	0.33
Pancreas	75	15.2	0.84	17.8	0.96	83	13.4	0.67	15.7	0.78
Respiratory System	215	45.5	1.48	53.3	1.69	184	29.6	0.99	35.1	1.16
Larynx	28	5.3	0.48	6.4	0.57	5	0.7	0.14	0.8	0.18
Lung & bronchus	180	39.0	1.38	45.6	1.58	176	28.3	0.97	33.4	1.14
Bones & Joints	8	1.1	0.19	1.2	0.20	8	1.1	0.17	1.1	0.18
Soft Tissue (incl. heart)	19	2.9	0.32	3.1	0.34	19	2.7	0.28	2.9	0.31
Skin (excl. basal & sq.)	28	5.6	0.51	6.4	0.58	29	4.4	0.37	5.0	0.42
Melanoma of the skin	22	4.4	0.45	5.1	0.51	24	3.5	0.33	4.0	0.38
Breast (excl. <i>in situ</i>)	2	0.5	0.15	0.6	0.17	776	112.9	1.84	131.6	2.14
Female Genital System	N/A	N/A	N/A	N/A	N/A	367	52.9	1.26	62.1	1.47
Cervix uteri	N/A	N/A	N/A	N/A	N/A	77	10.8	0.56	11.7	0.61
Uterus corpus	N/A	N/A	N/A	N/A	N/A	180	25.6	0.87	31.2	1.05
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	9	1.3	0.20	1.5	0.23
Ovary	N/A	N/A	N/A	N/A	N/A	69	10.0	0.55	11.6	0.64
Male Genital System	646	120.5	2.26	145.8	2.66	N/A	N/A	N/A	N/A	N/A
Prostate	598	113.8	2.21	138.9	2.61	N/A	N/A	N/A	N/A	N/A
Testis	36	4.3	0.32	4.1	0.31	N/A	N/A	N/A	N/A	N/A
Penis	11	2.2	0.32	2.6	0.37	N/A	N/A	N/A	N/A	N/A
Urinary System	232	45.6	1.44	53.8	1.67	115	17.7	0.75	20.8	0.88
Bladder (incl. <i>in situ</i>)	110	24.5	1.11	28.7	1.28	39	6.4	0.47	7.5	0.54
Kidney & renal pelvis	118	20.0	0.88	23.9	1.04	74	10.8	0.58	12.7	0.67
Ureter	3	0.8	0.21	1.0	0.24	2	0.3	0.10	0.3	0.11
Eye & Orbit	3	0.6	0.17	0.7	0.19	4	0.5	0.13	0.6	0.14
Brain & Other CNS	38	6.1	0.48	6.9	0.54	31	4.4	0.36	4.8	0.40
Brain	37	5.9	0.47	6.7	0.54	30	4.3	0.35	4.7	0.39
Endocrine System	51	7.4	0.48	8.5	0.56	205	27.7	0.87	30.4	0.97
Thyroid gland	45	6.5	0.45	7.4	0.53	198	26.7	0.86	29.2	0.95
Lymphomas	157	27.7	1.07	31.8	1.23	135	20.3	0.80	23.1	0.91
Hodgkin lymphoma	24	3.4	0.33	3.6	0.36	21	2.9	0.29	3.0	0.30
Non-Hodgkin lymphoma	133	24.3	1.02	28.2	1.17	114	17.3	0.74	20.1	0.86
Multiple Myeloma	47	9.3	0.64	11.1	0.75	44	6.7	0.46	8.1	0.55
Leukemias	94	16.1	0.80	17.7	0.89	71	10.6	0.57	11.5	0.63
Acute lymphocytic	27	3.4	0.30	3.2	0.29	18	2.4	0.25	2.3	0.25
Chronic lymphocytic	19	3.8	0.42	4.4	0.48	14	2.4	0.28	2.7	0.32
Acute myeloid	26	4.6	0.43	5.2	0.49	21	3.2	0.32	3.6	0.36
Chronic myeloid	11	2.0	0.29	2.2	0.32	11	1.6	0.22	1.8	0.25
Other leukemias	11	2.3	0.32	2.6	0.37	7	1.0	0.18	1.0	0.19
Mesothelioma	4	0.7	0.17	0.8	0.21	3	0.5	0.13	0.6	0.15
Kaposi Sarcoma	8	1.5	0.26	1.7	0.29	*	*	*	*	*
Ill-Defined & Unknown	77	15.8	0.87	18.5	1.01	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	50	8.4	0.58	9.4	0.66	108	15.8	0.69	18.1	0.80
Breast (<i>in situ</i>)	*	*	*	*	*	221	31.3	0.96	36.8	1.12

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Jersey, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	103	172.0	8.29	205.6	9.66	136	178.4	7.18	210.5	8.45
Oral Cavity & Pharynx	3	4.4	1.21	5.5	1.49	3	3.2	0.94	3.6	1.06
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	23	39.2	4.04	47.0	4.72	26	38.4	3.52	46.1	4.16
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	3	7.1	1.92	7.9	2.08	3	4.2	1.14	5.0	1.34
Small intestine	*	*	*	*	*	2	2.1	0.78	2.6	0.95
Colon (excl. rectum)	5	9.2	1.97	10.7	2.27	9	12.7	2.01	15.0	2.35
Rectum & rectosigmoid	4	6.8	1.62	8.1	1.91	3	3.5	1.02	4.2	1.22
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	4	7.5	1.68	9.3	2.02	4	5.1	1.26	6.4	1.55
Gallbladder	*	*	*	*	*	2	2.4	0.89	2.9	1.05
Pancreas	3	4.7	1.27	6.0	1.58	3	4.9	1.30	5.9	1.51
Respiratory System	9	19.4	3.08	21.9	3.42	8	11.4	1.92	14.1	2.32
Larynx	1	2.9	1.22	3.0	1.27	*	*	*	*	*
Lung & bronchus	8	16.5	2.82	18.8	3.18	7	10.6	1.86	13.2	2.26
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	1	1.8	0.81	2.2	0.94	2	2.7	0.83	3.3	1.01
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	42	55.0	3.97	64.9	4.66
Female Genital System	N/A	N/A	N/A	N/A	N/A	20	25.5	2.64	30.5	3.15
Cervix uteri	N/A	N/A	N/A	N/A	N/A	7	7.9	1.41	9.0	1.64
Uterus corpus	N/A	N/A	N/A	N/A	N/A	10	12.6	1.90	15.6	2.31
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	3	3.3	0.90	3.8	1.05
Male Genital System	37	62.4	4.96	76.6	5.86	N/A	N/A	N/A	N/A	N/A
Prostate	36	61.1	4.93	75.1	5.82	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	7	12.3	2.30	14.5	2.64	4	5.3	1.27	6.4	1.53
Bladder (incl. <i>in situ</i>)	3	6.3	1.74	7.2	1.95	1	2.1	0.83	2.6	1.01
Kidney & renal pelvis	4	6.0	1.50	7.3	1.77	2	3.2	0.96	3.8	1.15
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	3	4.7	1.31	5.0	1.41	3	3.1	0.79	3.0	0.81
Brain	3	4.6	1.30	4.8	1.41	3	3.1	0.79	3.0	0.81
Endocrine System	2	1.9	0.63	2.1	0.74	11	11.8	1.68	12.6	1.83
Thyroid gland	2	1.7	0.62	2.0	0.74	10	11.7	1.67	12.5	1.83
Lymphomas	7	9.5	1.75	11.0	2.06	9	10.3	1.64	12.4	1.99
Hodgkin lymphoma	2	1.8	0.68	2.0	0.78	2	2.3	0.67	2.5	0.75
Non-Hodgkin lymphoma	5	7.7	1.62	9.0	1.91	6	8.0	1.50	9.9	1.84
Multiple Myeloma	2	3.7	1.20	4.7	1.49	3	3.8	1.10	4.6	1.31
Leukemias	3	4.3	1.20	5.1	1.43	2	2.2	0.70	2.3	0.76
Acute lymphocytic	*	*	*	*	*	1	1.0	0.40	1.0	0.47
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	4	5.8	1.43	7.0	1.70	2	2.9	0.96	3.4	1.13
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	3	3.7	1.15	4.1	1.30	6	7.9	1.57	9.0	1.78
Breast (<i>in situ</i>)	*	*	*	*	*	13	15.6	2.00	18.4	2.37

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.


N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	2,090,071	2,092,555	2,092,844	2,093,754	2,099,634
Non-Hispanic White	812,145	805,616	798,249	789,907	786,295
Non-Hispanic Black	44,653	45,230	45,762	46,407	47,714
Non-Hispanic Asian/Pacific Islander (NH API)	35,407	35,864	36,268	36,877	37,808
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	182,879	183,510	184,087	182,959	183,456


All Races Population 2015–2019: 10,468,858
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	1,010,088	1,017,456	1,023,515	1,032,594	1,039,266
Hispanic White	934,132	939,411	943,802	949,054	954,373
Hispanic Black	17,700	18,092	18,416	18,950	19,537

Hispanic/Latino Population, Census 2010: 953,403
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

NEW MEXICO CANCER REGISTRY

Initial Operation: 1966
 Population-based Data Available: 1969
 Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	96.4	94.5	93.4	89.4	104.5	95.6
Missing Race	0.9	0.8	1.4	1.8	2.8	1.5
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.1	0.0	0.0	0.4	0.3	0.2
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	3.6	1.4	1.3	1.3	1.5	1.8
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.0	Ovary	94.6
Oral Cavity & Pharynx	97.9	Prostate	96.8
Esophagus	94.9	Testis	99.0
Stomach	96.0	Bladder (incl. <i>in situ</i>)	97.2
Colon & Rectum	96.5	Kidney & Renal Pelvis	92.3
Liver	61.9	Brain & Other CNS	88.8
Pancreas	85.7	Brain & Other CNS (non-malig)	57.2
Lung & Bronchus	87.3	Thyroid	99.6
Melanomas of the Skin	99.4	Hodgkin Lymphoma	97.0
Female Breast (excl. <i>in situ</i>)	98.6	Non-Hodgkin Lymphoma	97.2
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	93.3
Cervix Uteri	98.6	Leukemias	94.9
Uterus Corpus & Uterus NOS	98.9		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Mexico, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	4,783	389.5	2.59	462.3	3.03	4,845	365.5	2.45	427.4	2.80
Oral Cavity & Pharynx	169	13.8	0.49	16.7	0.58	63	4.6	0.27	5.5	0.31
Lip	10	0.9	0.13	1.0	0.15	4	0.3	0.06	0.3	0.07
Tongue	54	4.3	0.27	5.2	0.32	21	1.5	0.15	1.8	0.18
Major salivary gland	19	1.7	0.18	1.9	0.20	9	0.8	0.12	0.9	0.13
Floor of mouth	5	0.4	0.08	0.5	0.10	3	0.2	0.05	0.3	0.06
Gum & other mouth	18	1.5	0.16	1.7	0.19	11	0.8	0.11	0.9	0.13
Nasopharynx	8	0.7	0.11	0.8	0.13	*	*	*	*	*
Oropharynx	12	1.0	0.13	1.2	0.15	3	0.2	0.05	0.2	0.06
Hypopharynx	8	0.7	0.11	0.8	0.13	2	0.2	0.04	0.2	0.06
Digestive System	1,087	88.9	1.24	107.0	1.47	816	59.4	0.96	70.4	1.12
Esophagus	83	6.6	0.33	8.0	0.40	19	1.3	0.13	1.6	0.16
Stomach	94	7.9	0.37	9.3	0.44	71	5.3	0.29	6.3	0.34
Small intestine	24	2.0	0.18	2.3	0.22	21	1.6	0.16	1.8	0.18
Colon (excl. rectum)	286	23.9	0.65	28.6	0.77	288	21.3	0.58	25.0	0.67
Rectum & rectosigmoid	161	13.7	0.50	16.4	0.59	107	8.1	0.37	9.8	0.43
Anus, anal canal, & anorectum	13	1.1	0.14	1.4	0.17	25	1.7	0.16	2.1	0.19
Liver	190	14.7	0.49	18.4	0.61	64	4.5	0.26	5.3	0.30
Gallbladder	10	0.9	0.12	1.0	0.14	20	1.4	0.15	1.7	0.17
Pancreas	166	13.4	0.48	16.0	0.56	146	10.3	0.39	12.1	0.46
Respiratory System	556	44.9	0.87	53.3	1.02	489	33.8	0.70	40.1	0.82
Larynx	46	3.5	0.24	4.4	0.29	10	0.7	0.10	0.8	0.12
Lung & bronchus	500	40.5	0.83	47.9	0.97	470	32.5	0.68	38.5	0.80
Bones & Joints	11	1.0	0.14	1.1	0.15	11	0.9	0.13	1.0	0.14
Soft Tissue (incl. heart)	43	3.7	0.26	4.2	0.29	30	2.5	0.21	2.8	0.23
Skin (excl. basal & sq.)	277	23.1	0.64	27.1	0.74	192	14.5	0.49	16.9	0.56
Melanoma of the skin	253	21.0	0.61	24.6	0.70	177	13.3	0.47	15.6	0.53
Breast (excl. <i>in situ</i>)	14	1.2	0.15	1.4	0.17	1,511	114.4	1.38	135.6	1.60
Female Genital System	N/A	N/A	N/A	N/A	N/A	624	48.2	0.91	56.6	1.04
Cervix uteri	N/A	N/A	N/A	N/A	N/A	87	8.4	0.42	8.9	0.43
Uterus corpus	N/A	N/A	N/A	N/A	N/A	322	23.7	0.62	28.7	0.73
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	12	0.8	0.11	1.0	0.13
Ovary	N/A	N/A	N/A	N/A	N/A	136	10.4	0.41	12.1	0.48
Male Genital System	1,195	91.8	1.22	111.2	1.46	N/A	N/A	N/A	N/A	N/A
Prostate	1,119	84.2	1.15	103.6	1.40	N/A	N/A	N/A	N/A	N/A
Testis	62	6.4	0.37	6.3	0.36	N/A	N/A	N/A	N/A	N/A
Penis	12	1.0	0.14	1.2	0.16	N/A	N/A	N/A	N/A	N/A
Urinary System	543	45.1	0.89	53.2	1.04	245	18.4	0.55	21.3	0.62
Bladder (incl. <i>in situ</i>)	278	22.8	0.62	26.9	0.73	92	6.5	0.31	7.6	0.36
Kidney & renal pelvis	253	21.4	0.62	25.2	0.72	146	11.4	0.44	13.2	0.50
Ureter	7	0.6	0.10	0.6	0.11	4	0.3	0.06	0.3	0.07
Eye & Orbit	7	0.7	0.11	0.7	0.12	6	0.5	0.09	0.5	0.10
Brain & Other CNS	73	6.3	0.34	7.1	0.38	59	4.8	0.29	5.2	0.31
Brain	71	6.1	0.33	6.8	0.37	55	4.4	0.27	4.9	0.30
Endocrine System	102	9.2	0.42	10.4	0.47	252	23.0	0.68	25.1	0.72
Thyroid gland	94	8.4	0.40	9.6	0.45	248	22.7	0.67	24.7	0.71
Lymphomas	232	19.7	0.59	22.7	0.68	190	14.0	0.47	16.4	0.54
Hodgkin lymphoma	30	2.8	0.23	3.0	0.25	17	1.5	0.17	1.6	0.17
Non-Hodgkin lymphoma	202	16.9	0.55	19.8	0.63	173	12.5	0.44	14.8	0.51
Multiple Myeloma	90	7.5	0.36	8.9	0.42	61	4.4	0.26	5.2	0.30
Leukemias	192	16.6	0.55	18.7	0.61	136	10.6	0.42	11.7	0.46
Acute lymphocytic	22	2.2	0.21	2.0	0.19	18	1.8	0.19	1.6	0.17
Chronic lymphocytic	71	5.8	0.32	6.9	0.37	48	3.3	0.22	3.9	0.26
Acute myeloid	52	4.5	0.28	5.1	0.32	38	2.9	0.22	3.3	0.24
Chronic myeloid	27	2.3	0.21	2.7	0.23	21	1.8	0.18	1.9	0.19
Other leukemias	21	1.8	0.18	2.1	0.21	11	0.8	0.12	0.9	0.13
Mesothelioma	12	1.0	0.13	1.2	0.15	4	0.3	0.07	0.3	0.08
Kaposi Sarcoma	5	0.5	0.10	0.5	0.10	*	*	*	*	*
Ill-Defined & Unknown	173	14.6	0.51	17.0	0.59	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	66	5.8	0.33	6.5	0.37	132	10.6	0.44	12.0	0.48
Breast (<i>in situ</i>)	2	0.1	0.04	0.1	0.05	235	17.9	0.55	21.5	0.64

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Mexico, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,755	412.1	3.77	488.8	4.36	2,596	381.4	3.78	445.7	4.22
Oral Cavity & Pharynx	112	17.6	0.81	21.4	0.95	36	5.0	0.41	6.0	0.48
Lip	7	1.2	0.22	1.3	0.24	2	0.2	0.07	0.3	0.09
Tongue	37	5.7	0.46	7.0	0.55	13	1.8	0.24	2.3	0.30
Major salivary gland	12	1.9	0.25	2.2	0.29	4	0.7	0.18	0.8	0.19
Floor of mouth	4	0.6	0.14	0.7	0.17	1	0.2	0.07	0.2	0.09
Gum & other mouth	11	1.6	0.23	1.9	0.27	7	0.8	0.15	1.0	0.17
Nasopharynx	3	0.5	0.14	0.6	0.17	*	*	*	*	*
Oropharynx	9	1.3	0.22	1.6	0.26	1	0.2	0.07	0.2	0.10
Hypopharynx	5	0.8	0.16	1.0	0.20	1	0.2	0.07	0.2	0.09
Digestive System	506	76.0	1.61	91.5	1.90	376	51.6	1.32	60.9	1.50
Esophagus	56	7.8	0.49	9.5	0.59	11	1.4	0.19	1.7	0.23
Stomach	32	4.8	0.40	5.7	0.47	21	3.0	0.32	3.5	0.37
Small intestine	11	1.6	0.24	1.9	0.26	10	1.4	0.23	1.7	0.25
Colon (excl. rectum)	143	22.6	0.91	27.0	1.06	137	19.5	0.83	22.6	0.93
Rectum & rectosigmoid	75	12.0	0.67	14.4	0.79	50	7.5	0.53	9.0	0.61
Anus, anal canal, & anorectum	9	1.4	0.23	1.8	0.28	18	2.5	0.29	3.0	0.34
Liver	61	8.3	0.49	10.4	0.62	20	2.5	0.28	3.1	0.33
Gallbladder	3	0.5	0.13	0.5	0.14	7	0.9	0.18	1.1	0.20
Pancreas	90	13.2	0.66	15.7	0.77	81	10.2	0.54	12.2	0.63
Respiratory System	363	51.1	1.25	60.8	1.47	322	40.5	1.06	48.4	1.26
Larynx	25	3.6	0.34	4.4	0.41	6	0.8	0.16	1.0	0.19
Lung & bronchus	333	46.9	1.19	55.6	1.40	312	39.1	1.03	46.7	1.23
Bones & Joints	5	1.1	0.25	1.2	0.24	5	1.0	0.24	1.0	0.22
Soft Tissue (incl. heart)	19	3.2	0.37	3.7	0.40	14	2.5	0.34	2.7	0.35
Skin (excl. basal & sq.)	241	37.5	1.16	43.8	1.32	153	24.4	1.01	28.0	1.10
Melanoma of the skin	223	34.8	1.13	40.6	1.28	145	23.1	0.99	26.5	1.07
Breast (excl. <i>in situ</i>)	9	1.3	0.21	1.6	0.24	840	123.7	2.15	146.6	2.44
Female Genital System	N/A	N/A	N/A	N/A	N/A	307	46.8	1.35	55.1	1.52
Cervix uteri	N/A	N/A	N/A	N/A	N/A	33	8.0	0.69	8.3	0.68
Uterus corpus	N/A	N/A	N/A	N/A	N/A	165	23.3	0.90	28.5	1.06
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	5	0.6	0.13	0.7	0.16
Ovary	N/A	N/A	N/A	N/A	N/A	68	10.0	0.61	11.7	0.68
Male Genital System	685	95.4	1.73	115.7	2.06	N/A	N/A	N/A	N/A	N/A
Prostate	657	87.8	1.59	108.2	1.95	N/A	N/A	N/A	N/A	N/A
Testis	22	6.6	0.65	6.4	0.62	N/A	N/A	N/A	N/A	N/A
Penis	5	0.8	0.17	0.9	0.19	N/A	N/A	N/A	N/A	N/A
Urinary System	311	45.5	1.21	54.0	1.42	119	16.1	0.73	18.7	0.82
Bladder (incl. <i>in situ</i>)	198	28.1	0.92	33.2	1.09	61	7.6	0.45	8.9	0.53
Kidney & renal pelvis	106	16.3	0.77	19.4	0.89	53	7.9	0.56	9.1	0.60
Ureter	5	0.7	0.16	0.9	0.18	3	0.4	0.10	0.4	0.11
Eye & Orbit	5	0.9	0.21	0.9	0.21	4	0.5	0.13	0.6	0.15
Brain & Other CNS	43	7.8	0.59	8.8	0.63	32	5.6	0.51	6.1	0.52
Brain	43	7.7	0.59	8.7	0.63	31	5.1	0.48	5.6	0.50
Endocrine System	54	10.8	0.72	12.1	0.77	99	21.8	1.10	23.7	1.14
Thyroid gland	50	9.9	0.70	11.2	0.75	96	21.4	1.09	23.3	1.13
Lymphomas	130	21.5	0.92	24.6	1.02	101	14.9	0.75	17.3	0.83
Hodgkin lymphoma	16	4.0	0.48	4.1	0.48	8	1.9	0.34	2.0	0.34
Non-Hodgkin lymphoma	114	17.5	0.79	20.5	0.90	93	13.0	0.67	15.2	0.75
Multiple Myeloma	49	7.3	0.49	8.5	0.57	28	3.5	0.32	4.3	0.38
Leukemias	108	18.1	0.86	20.5	0.93	79	12.6	0.74	13.8	0.76
Acute lymphocytic	7	2.2	0.40	1.9	0.33	7	2.1	0.40	1.8	0.33
Chronic lymphocytic	48	7.1	0.49	8.5	0.57	31	4.0	0.34	4.7	0.39
Acute myeloid	29	4.7	0.43	5.3	0.47	22	3.2	0.35	3.7	0.39
Chronic myeloid	14	2.4	0.32	2.7	0.34	12	2.2	0.33	2.4	0.33
Other leukemias	11	1.7	0.25	2.1	0.29	7	1.1	0.20	1.2	0.22
Mesothelioma	7	1.0	0.17	1.2	0.20	1	0.1	0.06	0.2	0.07
Kaposi Sarcoma	2	0.4	0.16	0.4	0.15	*	*	*	*	*
Ill-Defined & Unknown	104	15.6	0.72	18.2	0.83	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	33	6.2	0.54	6.8	0.57	63	10.3	0.66	11.5	0.71
Breast (<i>in situ</i>)	1	0.2	0.07	0.2	0.10	129	20.1	0.90	23.9	1.02

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Mexico, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	93	385.0	19.12	462.6	22.44	63	313.1	18.18	374.1	21.31
Oral Cavity & Pharynx	2	6.8	2.26	8.7	2.77	1	5.4	2.24	6.7	2.74
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	19	80.8	8.95	98.3	10.67	10	50.2	7.33	60.9	8.70
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	2	9.4	2.93	11.5	3.39	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	5	22.4	4.87	26.2	5.70	4	17.9	4.34	21.5	5.09
Rectum & rectosigmoid	1	4.5	1.71	6.1	2.30	1	6.8	2.66	8.6	3.31
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	4	15.2	3.50	19.2	4.25	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	3	12.7	3.66	15.0	4.28	2	9.6	3.31	10.9	3.68
Respiratory System	12	58.4	7.83	66.9	8.80	9	40.4	6.30	49.6	7.59
Larynx	1	4.2	1.74	5.4	2.22	*	*	*	*	*
Lung & bronchus	11	53.3	7.58	60.5	8.45	8	39.7	6.26	48.5	7.51
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	22	113.8	11.09	134.0	12.82
Female Genital System	N/A	N/A	N/A	N/A	N/A	5	25.8	5.24	31.0	6.15
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	4	16.3	3.94	21.1	5.01
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	35	132.2	10.57	166.3	12.90	N/A	N/A	N/A	N/A	N/A
Prostate	35	129.6	10.46	163.8	12.82	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	8	35.9	6.24	41.4	7.07	3	12.5	3.55	15.1	4.24
Bladder (incl. <i>in situ</i>)	2	13.2	4.25	14.5	4.70	1	7.6	2.92	8.9	3.40
Kidney & renal pelvis	5	22.7	4.58	26.9	5.28	1	4.9	2.02	6.1	2.53
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	3	16.9	4.39	19.2	4.88
Thyroid gland	*	*	*	*	*	3	15.4	4.26	17.1	4.64
Lymphomas	4	15.2	3.63	16.6	3.91	3	11.9	3.39	14.8	4.14
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	2	10.1	3.28	11.4	3.63	2	9.0	3.10	11.2	3.78
Leukemias	3	11.8	3.10	14.4	3.73	2	10.9	3.37	12.9	3.95
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	4	19.4	4.83	22.6	5.65	3	12.9	3.66	14.8	4.15
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	1	5.0	2.00	6.1	2.35	2	9.9	3.21	11.7	3.74
Breast (<i>in situ</i>)	*	*	*	*	*	3	13.3	3.75	16.1	4.37

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Mexico, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	51	337.5	22.05	401.4	25.92	64	288.9	16.55	337.7	19.07
Oral Cavity & Pharynx	3	20.1	4.98	24.1	5.96	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	12	78.6	10.76	96.1	12.94	9	42.3	6.37	51.3	7.59
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	2	10.7	3.96	14.2	5.20	1	6.4	2.50	7.8	2.99
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	3	21.1	5.93	25.5	7.04	3	15.5	3.88	19.1	4.69
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	3	19.1	5.09	23.8	6.17	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	2	12.2	4.24	14.9	5.09	1	4.8	2.03	5.9	2.45
Respiratory System	4	31.4	7.08	37.4	8.29	7	34.2	5.82	41.2	6.88
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	3	25.0	6.39	29.6	7.45	7	34.2	5.82	41.2	6.88
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	1	5.3	2.21	6.1	2.50
Melanoma of the skin	1	7.0	2.87	8.5	3.48	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	21	88.2	8.88	105.1	10.46
Female Genital System	N/A	N/A	N/A	N/A	N/A	7	31.0	5.20	37.9	6.29
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	8.3	2.80	10.0	3.34
Uterus corpus	N/A	N/A	N/A	N/A	N/A	5	18.3	3.87	22.8	4.79
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	13	87.1	11.07	106.6	13.33	N/A	N/A	N/A	N/A	N/A
Prostate	13	84.5	10.92	104.4	13.24	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	5	35.9	7.48	41.4	8.49	2	11.0	3.39	12.2	3.78
Bladder (incl. <i>in situ</i>)	3	22.8	6.29	25.3	6.93	*	*	*	*	*
Kidney & renal pelvis	2	13.2	4.05	16.1	4.91	1	6.9	2.67	7.4	2.87
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	7	30.6	5.35	32.6	5.64
Thyroid gland	*	*	*	*	*	7	30.6	5.35	32.6	5.64
Lymphomas	4	28.0	6.23	32.7	7.20	3	14.3	3.79	16.7	4.35
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	1	5.3	2.21	6.1	2.52
Leukemias	3	20.6	5.81	22.9	6.49	2	7.4	2.70	8.4	3.03
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	1	5.4	2.26	6.2	2.59
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	11.9	3.90	13.9	4.53	2	12.8	3.97	13.2	4.01
Selected Sites (Non-Malignant or <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS (non-malignant)	*	*	*	*	*	2	10.3	3.07	12.5	3.68
Breast (<i>in situ</i>)	*	*	*	*	*	4	17.9	3.96	21.8	4.76

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Mexico, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	222	321.6	10.21	376.9	11.83	280	301.9	8.22	349.8	9.42
Oral Cavity & Pharynx	5	6.2	1.36	7.6	1.63	2	1.7	0.58	2.2	0.74
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	1	1.6	0.70	2.1	0.87	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	75	109.9	6.00	130.8	7.02	69	73.8	4.07	87.3	4.75
Esophagus	2	3.3	1.06	4.0	1.27	*	*	*	*	*
Stomach	11	16.7	2.35	19.3	2.69	9	9.4	1.46	10.8	1.66
Small intestine	2	2.1	0.79	2.5	0.91	2	1.8	0.62	2.3	0.76
Colon (excl. rectum)	18	26.8	2.98	32.1	3.52	25	26.7	2.45	31.9	2.89
Rectum & rectosigmoid	12	16.3	2.21	19.5	2.59	8	8.8	1.39	10.3	1.62
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	15	20.1	2.38	24.7	2.85	9	9.1	1.41	10.6	1.62
Gallbladder	2	4.2	1.34	4.8	1.51	3	3.7	0.91	4.3	1.03
Pancreas	8	13.0	2.20	15.2	2.54	6	6.6	1.24	7.7	1.45
Respiratory System	11	18.6	2.60	21.5	2.97	10	11.0	1.61	12.7	1.85
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	9	16.0	2.45	18.3	2.80	9	10.3	1.55	11.9	1.79
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	3	4.5	1.22	4.9	1.37	3	3.7	0.93	4.0	1.01
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	3	4.3	1.27	5.2	1.49	5	5.3	1.08	5.9	1.19
Breast (excl. <i>in situ</i>)	*	*	*	*	*	69	73.0	4.01	86.1	4.66
Female Genital System	N/A	N/A	N/A	N/A	N/A	51	54.5	3.47	62.8	3.95
Cervix uteri	N/A	N/A	N/A	N/A	N/A	7	7.4	1.30	7.9	1.39
Uterus corpus	N/A	N/A	N/A	N/A	N/A	27	28.5	2.49	33.3	2.87
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	1	1.6	0.61	1.6	0.62
Ovary	N/A	N/A	N/A	N/A	N/A	11	12.1	1.65	14.1	1.90
Male Genital System	44	62.2	4.48	72.7	5.18	N/A	N/A	N/A	N/A	N/A
Prostate	35	53.2	4.25	63.9	4.99	N/A	N/A	N/A	N/A	N/A
Testis	8	8.7	1.40	8.5	1.35	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	38	54.1	4.14	63.8	4.81	17	19.2	2.10	22.6	2.45
Bladder (incl. <i>in situ</i>)	5	8.3	1.76	10.1	2.11	3	3.5	0.89	4.2	1.07
Kidney & renal pelvis	33	45.4	3.73	53.3	4.31	14	15.7	1.91	18.4	2.20
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	3	4.5	1.16	5.0	1.32	4	4.8	1.03	4.7	1.02
Brain	3	4.5	1.16	5.0	1.32	4	4.0	0.95	3.9	0.95
Endocrine System	6	6.7	1.25	8.0	1.50	16	16.7	1.91	18.6	2.11
Thyroid gland	5	5.6	1.15	6.8	1.40	15	15.9	1.87	17.6	2.06
Lymphomas	9	13.5	2.17	15.8	2.52	11	12.5	1.69	14.7	1.95
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	7	10.6	1.85	12.4	2.14	6	6.2	1.19	7.1	1.34
Leukemias	8	10.4	1.75	11.4	1.91	7	7.8	1.32	8.3	1.39
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	3	2.9	0.78	3.0	0.81
Chronic lymphocytic	1	2.2	0.91	2.3	0.97	*	*	*	*	*
Acute myeloid	2	3.2	0.98	3.6	1.08	1	1.4	0.55	1.7	0.65
Chronic myeloid	1	1.5	0.65	1.9	0.78	2	2.3	0.74	2.3	0.75
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	8	12.8	2.06	14.4	2.30	8	9.3	1.50	10.3	1.67
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	5	7.3	1.52	8.1	1.66	12	12.9	1.70	14.7	1.92
Breast (<i>in situ</i>)	*	*	*	*	*	8	8.2	1.33	9.8	1.56

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Mexico, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,566	351.6	4.08	417.9	4.80	1,773	352.3	3.80	411.6	4.40
Oral Cavity & Pharynx	45	9.9	0.68	12.0	0.81	22	4.4	0.43	5.2	0.49
Lip	2	0.4	0.15	0.5	0.18	*	*	*	*	*
Tongue	15	3.2	0.38	3.9	0.45	6	1.2	0.21	1.5	0.26
Major salivary gland	5	1.1	0.23	1.2	0.26	4	0.8	0.18	0.8	0.20
Floor of mouth	*	*	*	*	*	1	0.2	0.10	0.3	0.11
Gum & other mouth	5	1.2	0.24	1.4	0.29	5	1.0	0.21	1.1	0.22
Nasopharynx	3	0.5	0.16	0.7	0.19	*	*	*	*	*
Oropharynx	3	0.7	0.17	0.9	0.21	*	*	*	*	*
Hypopharynx	3	0.7	0.18	0.8	0.21	*	*	*	*	*
Digestive System	467	104.8	2.22	126.3	2.64	345	68.0	1.66	80.8	1.95
Esophagus	24	5.6	0.52	6.6	0.61	6	1.1	0.21	1.4	0.25
Stomach	46	10.8	0.73	12.7	0.85	38	7.6	0.56	9.0	0.66
Small intestine	11	2.3	0.33	2.8	0.39	9	1.7	0.26	2.0	0.30
Colon (excl. rectum)	114	25.7	1.10	30.8	1.31	116	23.0	0.97	27.3	1.14
Rectum & rectosigmoid	71	15.9	0.87	19.1	1.02	46	9.0	0.61	10.9	0.72
Anus, anal canal, & anorectum	4	0.8	0.19	1.0	0.23	6	1.0	0.19	1.3	0.24
Liver	106	22.7	1.01	28.3	1.24	34	6.6	0.52	7.8	0.61
Gallbladder	4	1.1	0.23	1.3	0.28	9	1.7	0.26	2.1	0.31
Pancreas	62	14.1	0.82	17.0	0.97	56	11.0	0.67	13.0	0.78
Respiratory System	161	38.5	1.39	45.8	1.64	139	27.8	1.07	32.5	1.23
Larynx	18	4.1	0.44	5.0	0.53	3	0.5	0.15	0.6	0.18
Lung & bronchus	139	33.6	1.31	39.9	1.54	132	26.3	1.04	30.8	1.20
Bones & Joints	5	1.0	0.21	1.1	0.23	5	1.0	0.20	1.1	0.21
Soft Tissue (incl. heart)	19	4.2	0.44	4.8	0.51	11	2.2	0.30	2.5	0.34
Skin (excl. basal & sq.)	26	5.9	0.53	6.9	0.61	27	5.2	0.45	6.2	0.54
Melanoma of the skin	20	4.5	0.46	5.3	0.54	23	4.3	0.41	5.2	0.49
Breast (excl. <i>in situ</i>)	4	1.0	0.22	1.2	0.26	537	106.4	2.09	126.2	2.45
Female Genital System	N/A	N/A	N/A	N/A	N/A	245	48.6	1.41	56.9	1.63
Cervix uteri	N/A	N/A	N/A	N/A	N/A	43	9.2	0.64	9.7	0.67
Uterus corpus	N/A	N/A	N/A	N/A	N/A	117	22.6	0.95	27.4	1.14
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	5	0.9	0.19	1.1	0.23
Ovary	N/A	N/A	N/A	N/A	N/A	54	10.7	0.66	12.6	0.77
Male Genital System	368	79.6	1.90	96.3	2.27	N/A	N/A	N/A	N/A	N/A
Prostate	331	71.9	1.81	88.4	2.19	N/A	N/A	N/A	N/A	N/A
Testis	31	6.0	0.49	5.9	0.48	N/A	N/A	N/A	N/A	N/A
Penis	7	1.7	0.30	2.0	0.35	N/A	N/A	N/A	N/A	N/A
Urinary System	177	40.0	1.38	47.5	1.62	102	20.4	0.92	23.9	1.06
Bladder (incl. <i>in situ</i>)	68	16.2	0.90	19.3	1.07	25	5.1	0.46	6.0	0.53
Kidney & renal pelvis	105	23.0	1.03	27.2	1.20	75	14.9	0.78	17.4	0.91
Ureter	2	0.4	0.15	0.5	0.17	*	*	*	*	*
Eye & Orbit	2	0.4	0.14	0.4	0.15	2	0.4	0.12	0.5	0.14
Brain & Other CNS	24	5.3	0.50	5.9	0.55	21	4.1	0.40	4.5	0.45
Brain	23	5.0	0.48	5.6	0.54	19	3.7	0.38	4.2	0.44
Endocrine System	39	8.5	0.62	9.7	0.70	124	25.1	1.03	27.4	1.11
Thyroid gland	36	7.8	0.59	8.9	0.68	122	24.9	1.02	27.1	1.11
Lymphomas	78	17.6	0.91	20.4	1.05	67	13.3	0.73	15.5	0.85
Hodgkin lymphoma	11	2.3	0.32	2.5	0.35	7	1.4	0.24	1.5	0.26
Non-Hodgkin lymphoma	67	15.3	0.86	17.8	0.99	60	11.9	0.69	14.0	0.81
Multiple Myeloma	30	7.1	0.59	8.4	0.69	24	4.9	0.45	5.7	0.52
Leukemias	61	13.7	0.81	15.1	0.90	41	8.3	0.58	9.0	0.64
Acute lymphocytic	12	2.3	0.30	2.1	0.29	8	1.6	0.25	1.5	0.24
Chronic lymphocytic	13	3.2	0.41	3.6	0.46	11	2.2	0.30	2.5	0.35
Acute myeloid	19	4.3	0.46	5.0	0.52	13	2.6	0.33	3.0	0.37
Chronic myeloid	10	2.2	0.32	2.5	0.37	6	1.3	0.24	1.4	0.25
Other leukemias	7	1.6	0.29	1.8	0.33	3	0.6	0.16	0.6	0.17
Mesothelioma	4	1.1	0.24	1.3	0.27	2	0.5	0.14	0.6	0.17
Kaposi Sarcoma	2	0.4	0.14	0.5	0.15	*	*	*	*	*
Ill-Defined & Unknown	52	12.3	0.79	14.4	0.91	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	25	5.6	0.51	6.3	0.58	51	10.4	0.66	11.7	0.74
Breast (<i>in situ</i>)	*	*	*	*	*	88	17.1	0.83	20.7	0.99

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

NEW MEXICO

II-358 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Mexico, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,503	354.0	4.19	420.9	4.93	1,705	356.3	3.92	416.0	4.53
Oral Cavity & Pharynx	44	10.3	0.71	12.4	0.84	21	4.5	0.44	5.2	0.50
Lip	2	0.5	0.16	0.6	0.19	*	*	*	*	*
Tongue	15	3.4	0.40	4.1	0.48	6	1.2	0.21	1.4	0.27
Major salivary gland	4	1.1	0.23	1.2	0.26	3	0.8	0.19	0.8	0.20
Floor of mouth	*	*	*	*	*	1	0.3	0.10	0.3	0.11
Gum & other mouth	5	1.2	0.25	1.4	0.30	5	1.1	0.22	1.1	0.23
Nasopharynx	3	0.6	0.16	0.7	0.20	*	*	*	*	*
Oropharynx	3	0.7	0.18	0.8	0.22	*	*	*	*	*
Hypopharynx	3	0.7	0.19	0.8	0.22	*	*	*	*	*
Digestive System	452	106.4	2.29	128.1	2.73	331	68.5	1.71	81.2	2.00
Esophagus	24	5.7	0.54	6.7	0.63	5	1.1	0.22	1.3	0.26
Stomach	45	11.0	0.75	13.0	0.88	36	7.4	0.57	8.8	0.66
Small intestine	10	2.3	0.33	2.8	0.40	8	1.6	0.26	1.9	0.30
Colon (excl. rectum)	110	26.1	1.14	31.3	1.35	113	23.3	1.00	27.7	1.17
Rectum & rectosigmoid	68	16.1	0.90	19.3	1.06	43	9.0	0.62	10.8	0.74
Anus, anal canal, & anorectum	4	0.9	0.20	1.0	0.24	6	1.1	0.20	1.3	0.25
Liver	102	22.9	1.04	28.5	1.28	33	6.8	0.53	8.0	0.63
Gallbladder	4	1.1	0.24	1.3	0.29	9	1.8	0.27	2.1	0.32
Pancreas	60	14.3	0.84	17.2	1.00	54	11.2	0.69	13.1	0.80
Respiratory System	155	38.6	1.42	46.0	1.68	135	28.0	1.09	32.7	1.27
Larynx	18	4.1	0.45	5.1	0.54	3	0.5	0.15	0.7	0.18
Lung & bronchus	134	33.8	1.34	40.1	1.57	128	26.5	1.06	31.1	1.23
Bones & Joints	5	1.1	0.22	1.1	0.24	5	1.1	0.21	1.1	0.22
Soft Tissue (incl. heart)	18	4.3	0.46	4.9	0.52	11	2.3	0.31	2.6	0.35
Skin (excl. basal & sq.)	24	5.8	0.54	6.8	0.62	27	5.4	0.47	6.5	0.56
Melanoma of the skin	19	4.5	0.47	5.3	0.55	23	4.5	0.43	5.4	0.51
Breast (excl. <i>in situ</i>)	4	1.0	0.23	1.2	0.27	522	109.0	2.17	129.1	2.54
Female Genital System	N/A	N/A	N/A	N/A	N/A	232	48.4	1.45	56.7	1.67
Cervix uteri	N/A	N/A	N/A	N/A	N/A	41	9.3	0.66	9.8	0.69
Uterus corpus	N/A	N/A	N/A	N/A	N/A	109	22.2	0.96	26.9	1.16
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	5	1.0	0.20	1.2	0.24
Ovary	N/A	N/A	N/A	N/A	N/A	52	10.8	0.68	12.7	0.79
Male Genital System	348	78.8	1.94	95.4	2.31	N/A	N/A	N/A	N/A	N/A
Prostate	313	71.0	1.84	87.4	2.23	N/A	N/A	N/A	N/A	N/A
Testis	29	6.2	0.52	6.0	0.51	N/A	N/A	N/A	N/A	N/A
Penis	6	1.6	0.30	1.9	0.35	N/A	N/A	N/A	N/A	N/A
Urinary System	170	40.4	1.42	48.0	1.67	96	20.0	0.93	23.4	1.08
Bladder (incl. <i>in situ</i>)	66	16.4	0.93	19.6	1.10	24	5.1	0.47	5.9	0.54
Kidney & renal pelvis	101	23.2	1.06	27.5	1.24	69	14.5	0.79	17.0	0.92
Ureter	2	0.4	0.15	0.5	0.18	*	*	*	*	*
Eye & Orbit	2	0.4	0.14	0.5	0.16	2	0.4	0.13	0.5	0.15
Brain & Other CNS	24	5.5	0.52	6.1	0.58	21	4.3	0.42	4.7	0.47
Brain	22	5.2	0.50	5.7	0.56	19	3.9	0.41	4.4	0.46
Endocrine System	37	8.4	0.63	9.6	0.72	116	25.1	1.06	27.4	1.15
Thyroid gland	34	7.7	0.61	8.9	0.69	115	24.8	1.05	27.1	1.14
Lymphomas	76	18.0	0.94	20.8	1.09	65	13.4	0.75	15.7	0.88
Hodgkin lymphoma	11	2.3	0.33	2.6	0.36	7	1.4	0.25	1.5	0.27
Non-Hodgkin lymphoma	65	15.7	0.89	18.2	1.02	58	12.0	0.71	14.2	0.83
Multiple Myeloma	30	7.2	0.61	8.6	0.71	24	5.0	0.47	5.8	0.54
Leukemias	58	13.9	0.84	15.3	0.93	41	8.6	0.61	9.4	0.66
Acute lymphocytic	12	2.4	0.32	2.2	0.31	8	1.8	0.28	1.6	0.26
Chronic lymphocytic	12	3.2	0.41	3.6	0.47	11	2.2	0.30	2.6	0.36
Acute myeloid	18	4.4	0.47	5.1	0.54	13	2.7	0.34	3.1	0.39
Chronic myeloid	9	2.2	0.33	2.5	0.38	5	1.2	0.24	1.3	0.26
Other leukemias	7	1.7	0.30	1.9	0.34	3	0.7	0.17	0.7	0.18
Mesothelioma	4	1.1	0.25	1.3	0.28	2	0.5	0.15	0.6	0.18
Kaposi Sarcoma	2	0.4	0.13	0.4	0.15	*	*	*	*	*
Ill-Defined & Unknown	49	12.3	0.80	14.4	0.93	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	24	5.7	0.53	6.4	0.60	49	10.6	0.69	11.9	0.76
Breast (<i>in situ</i>)	*	*	*	*	*	85	17.3	0.86	21.0	1.02

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Mexico, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2	62.3	21.92	75.6	26.16	3	50.1	14.58	61.8	18.14
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


NEW MEXICO

II-360 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	19,657,321	19,636,391	19,593,849	19,544,098	19,463,131
Non-Hispanic White	11,244,019	11,165,419	11,088,998	11,013,650	10,923,550
Non-Hispanic Black	2,968,316	2,962,779	2,953,048	2,941,357	2,928,902
Non-Hispanic Asian/Pacific Islander (NH API)	1,708,923	1,744,591	1,771,071	1,788,621	1,804,319
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	28,474	28,494	28,576	28,529	28,492


All Races Population 2015–2019: 97,894,790
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	3,664,508	3,691,992	3,709,063	3,728,743	3,734,867
Hispanic White	2,780,363	2,796,561	2,806,303	2,818,485	2,820,232
Hispanic Black	663,352	672,232	678,195	684,294	687,271

Hispanic/Latino Population, Census 2010: 3,416,922
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

NEW YORK CANCER REGISTRY

Initial Operation: 1940
Population-based Data Available: 1976
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	119.0	120.4	120.0	117.4	119.9	119.3
Missing Race	0.4	0.5	0.5	0.9	1.2	0.7
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.1	0.8	1.1	0.9	0.8	0.9
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.5	Ovary	94.1
Oral Cavity & Pharynx	98.5	Prostate	98.1
Esophagus	97.6	Testis	99.6
Stomach	97.6	Bladder (incl. <i>in situ</i>)	98.4
Colon & Rectum	96.8	Kidney & Renal Pelvis	91.4
Liver	57.2	Brain & Other CNS	86.8
Pancreas	87.3	Brain & Other CNS (non-malig)	38.3
Lung & Bronchus	90.4	Thyroid	99.8
Melanomas of the Skin	99.7	Hodgkin Lymphoma	99.4
Female Breast (excl. <i>in situ</i>)	99.2	Non-Hodgkin Lymphoma	98.0
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	93.3
Cervix Uteri	98.5	Leukemias	94.0
Uterus Corpus & Uterus NOS	98.8		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New York, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	57,760	529.3	1.01	627.6	1.18	58,284	457.1	0.88	532.4	1.00
Oral Cavity & Pharynx	1,892	17.0	0.18	20.6	0.21	880	6.8	0.11	8.0	0.12
Lip	61	0.6	0.03	0.7	0.04	33	0.2	0.02	0.3	0.02
Tongue	595	5.2	0.10	6.4	0.12	266	2.0	0.06	2.4	0.07
Major salivary gland	177	1.7	0.06	2.0	0.07	146	1.2	0.05	1.4	0.05
Floor of mouth	77	0.7	0.04	0.8	0.04	39	0.3	0.02	0.4	0.03
Gum & other mouth	215	2.0	0.06	2.4	0.07	181	1.4	0.05	1.6	0.05
Nasopharynx	123	1.2	0.05	1.3	0.05	53	0.4	0.03	0.5	0.03
Oropharynx	112	1.0	0.04	1.2	0.05	32	0.2	0.02	0.3	0.02
Hypopharynx	115	1.0	0.04	1.2	0.05	34	0.3	0.02	0.3	0.02
Digestive System	11,064	102.1	0.44	121.4	0.52	9,223	69.2	0.33	81.2	0.38
Esophagus	828	7.5	0.12	9.0	0.14	272	2.0	0.05	2.4	0.06
Stomach	1,205	11.2	0.15	13.3	0.17	836	6.4	0.10	7.5	0.12
Small intestine	350	3.2	0.08	3.8	0.09	315	2.4	0.06	2.9	0.07
Colon (excl. rectum)	3,101	29.3	0.24	34.4	0.28	3,235	24.4	0.20	28.3	0.23
Rectum & rectosigmoid	1,512	14.0	0.17	16.7	0.19	1,125	8.9	0.12	10.5	0.14
Anus, anal canal, & anorectum	208	1.9	0.06	2.3	0.07	323	2.4	0.06	3.0	0.07
Liver	1,360	11.8	0.15	14.5	0.18	448	3.3	0.07	3.9	0.08
Gallbladder	114	1.1	0.05	1.3	0.05	235	1.7	0.05	2.0	0.06
Pancreas	1,771	16.4	0.18	19.4	0.21	1,781	12.9	0.14	15.1	0.16
Respiratory System	7,624	70.2	0.37	83.3	0.43	7,580	55.4	0.29	65.9	0.34
Larynx	587	5.2	0.10	6.4	0.12	156	1.2	0.04	1.4	0.05
Lung & bronchus	6,901	63.7	0.35	75.5	0.41	7,334	53.5	0.28	63.7	0.34
Bones & Joints	136	1.4	0.05	1.4	0.06	100	1.0	0.04	1.0	0.04
Soft Tissue (incl. heart)	448	4.4	0.09	4.9	0.10	359	3.1	0.08	3.4	0.08
Skin (excl. basal & sq.)	2,737	26.0	0.23	30.3	0.26	1,978	15.9	0.17	18.3	0.19
Melanoma of the skin	2,471	23.4	0.21	27.3	0.25	1,790	14.5	0.16	16.6	0.18
Breast (excl. <i>in situ</i>)	166	1.5	0.05	1.8	0.06	16,819	135.8	0.49	158.8	0.55
Female Genital System	N/A	N/A	N/A	N/A	N/A	7,198	56.4	0.31	67.0	0.36
Cervix uteri	N/A	N/A	N/A	N/A	N/A	841	7.7	0.12	8.4	0.13
Uterus corpus	N/A	N/A	N/A	N/A	N/A	4,065	30.7	0.22	37.5	0.27
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	133	1.0	0.04	1.2	0.05
Ovary	N/A	N/A	N/A	N/A	N/A	1,447	11.6	0.14	13.5	0.16
Male Genital System	15,942	138.0	0.50	168.6	0.60	N/A	N/A	N/A	N/A	N/A
Prostate	15,242	130.7	0.48	161.2	0.59	N/A	N/A	N/A	N/A	N/A
Testis	580	6.1	0.12	6.1	0.11	N/A	N/A	N/A	N/A	N/A
Penis	93	0.9	0.04	1.0	0.05	N/A	N/A	N/A	N/A	N/A
Urinary System	6,834	63.9	0.35	75.3	0.41	2,920	21.9	0.19	25.8	0.22
Bladder (incl. <i>in situ</i>)	4,062	38.5	0.28	45.1	0.32	1,384	10.0	0.12	11.8	0.14
Kidney & renal pelvis	2,624	24.0	0.22	28.6	0.25	1,449	11.3	0.14	13.3	0.16
Ureter	85	0.8	0.04	0.9	0.05	55	0.4	0.02	0.5	0.03
Eye & Orbit	103	1.0	0.04	1.1	0.05	103	0.9	0.04	0.9	0.04
Brain & Other CNS	792	7.7	0.13	8.5	0.14	637	5.5	0.10	5.9	0.11
Brain	745	7.2	0.12	8.0	0.13	591	5.0	0.10	5.5	0.10
Endocrine System	1,178	11.5	0.15	12.8	0.17	3,089	28.9	0.24	31.3	0.25
Thyroid gland	1,054	10.3	0.15	11.5	0.16	2,972	27.9	0.24	30.1	0.25
Lymphomas	3,064	29.3	0.24	33.6	0.27	2,635	20.9	0.19	23.9	0.21
Hodgkin lymphoma	343	3.5	0.09	3.7	0.09	290	2.8	0.08	2.9	0.08
Non-Hodgkin lymphoma	2,721	25.8	0.23	29.9	0.26	2,345	18.1	0.17	21.1	0.20
Multiple Myeloma	1,087	10.1	0.14	11.9	0.16	919	6.9	0.10	8.1	0.12
Leukemias	2,175	20.9	0.20	23.8	0.23	1,576	12.3	0.14	14.0	0.16
Acute lymphocytic	175	1.9	0.07	1.8	0.06	136	1.4	0.06	1.3	0.05
Chronic lymphocytic	914	8.4	0.13	10.0	0.15	598	4.3	0.08	5.1	0.10
Acute myeloid	587	5.7	0.11	6.5	0.12	475	3.7	0.08	4.2	0.09
Chronic myeloid	271	2.6	0.07	3.0	0.08	209	1.7	0.05	1.9	0.06
Other leukemias	227	2.2	0.07	2.5	0.07	158	1.2	0.05	1.4	0.05
Mesothelioma	130	1.3	0.05	1.5	0.06	53	0.4	0.03	0.5	0.03
Kaposi Sarcoma	120	1.2	0.05	1.3	0.05	17	0.1	0.01	0.1	0.01
Ill-Defined & Unknown	2,268	21.9	0.21	25.4	0.24	2,197	15.9	0.16	18.4	0.18
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	1,152	11.1	0.15	12.6	0.17	2,403	19.3	0.18	22.1	0.20
Breast (<i>in situ</i>)	21	0.2	0.02	0.2	0.02	5,073	42.9	0.28	50.1	0.32

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New York, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	40,845	555.2	1.27	656.5	1.47	40,027	493.3	1.18	573.6	1.33
Oral Cavity & Pharynx	1,384	18.6	0.23	22.6	0.28	607	7.2	0.14	8.6	0.16
Lip	54	0.7	0.05	0.9	0.05	28	0.3	0.03	0.4	0.03
Tongue	475	6.3	0.13	7.7	0.16	199	2.4	0.08	2.9	0.09
Major salivary gland	131	1.9	0.08	2.2	0.09	92	1.2	0.06	1.3	0.06
Floor of mouth	59	0.8	0.05	1.0	0.06	30	0.4	0.03	0.4	0.04
Gum & other mouth	146	2.0	0.08	2.4	0.09	123	1.4	0.06	1.6	0.07
Nasopharynx	41	0.6	0.04	0.7	0.05	18	0.2	0.03	0.3	0.03
Oropharynx	79	1.0	0.05	1.3	0.06	24	0.3	0.03	0.3	0.03
Hypopharynx	75	1.0	0.05	1.2	0.06	22	0.2	0.02	0.3	0.03
Digestive System	7,138	97.6	0.53	115.7	0.62	5,836	66.7	0.41	78.1	0.47
Esophagus	643	8.5	0.15	10.2	0.18	195	2.1	0.07	2.5	0.08
Stomach	660	9.0	0.16	10.7	0.19	402	4.6	0.11	5.5	0.13
Small intestine	231	3.2	0.10	3.8	0.11	197	2.4	0.08	2.8	0.09
Colon (excl. rectum)	2,086	29.3	0.30	34.3	0.34	2,166	24.9	0.25	28.7	0.29
Rectum & rectosigmoid	987	13.9	0.21	16.5	0.24	718	8.9	0.16	10.5	0.18
Anus, anal canal, & anorectum	128	1.7	0.07	2.1	0.08	229	2.7	0.08	3.3	0.10
Liver	682	8.7	0.15	10.7	0.18	203	2.3	0.07	2.7	0.09
Gallbladder	55	0.8	0.05	0.9	0.05	109	1.2	0.05	1.4	0.06
Pancreas	1,265	17.0	0.22	20.2	0.26	1,208	13.1	0.18	15.4	0.20
Respiratory System	5,618	74.9	0.46	88.9	0.53	5,828	64.7	0.39	76.9	0.46
Larynx	410	5.4	0.12	6.6	0.15	104	1.2	0.06	1.5	0.07
Lung & bronchus	5,116	68.1	0.43	80.7	0.51	5,661	62.6	0.38	74.5	0.45
Bones & Joints	88	1.5	0.07	1.6	0.08	63	1.0	0.06	1.0	0.06
Soft Tissue (incl. heart)	296	4.4	0.12	5.0	0.13	225	3.1	0.10	3.4	0.10
Skin (excl. basal & sq.)	2,574	36.2	0.33	42.2	0.38	1,807	24.0	0.27	27.2	0.30
Melanoma of the skin	2,351	33.1	0.32	38.5	0.36	1,665	22.2	0.26	25.3	0.29
Breast (excl. <i>in situ</i>)	121	1.6	0.07	1.9	0.08	11,337	146.2	0.66	170.8	0.74
Female Genital System	N/A	N/A	N/A	N/A	N/A	4,648	57.4	0.40	68.4	0.46
Cervix uteri	N/A	N/A	N/A	N/A	N/A	402	6.4	0.15	6.9	0.16
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2,694	32.1	0.29	39.3	0.35
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	61	0.7	0.04	0.8	0.05
Ovary	N/A	N/A	N/A	N/A	N/A	973	12.3	0.19	14.4	0.21
Male Genital System	10,396	133.5	0.60	162.3	0.72	N/A	N/A	N/A	N/A	N/A
Prostate	9,896	124.1	0.57	152.8	0.69	N/A	N/A	N/A	N/A	N/A
Testis	430	8.4	0.19	8.3	0.18	N/A	N/A	N/A	N/A	N/A
Penis	51	0.7	0.05	0.9	0.05	N/A	N/A	N/A	N/A	N/A
Urinary System	5,392	73.7	0.46	86.7	0.53	2,167	25.0	0.25	29.3	0.29
Bladder (incl. <i>in situ</i>)	3,399	46.1	0.36	54.0	0.42	1,117	12.2	0.17	14.4	0.20
Kidney & renal pelvis	1,872	26.0	0.28	30.8	0.32	986	12.1	0.18	14.2	0.21
Ureter	72	1.0	0.05	1.1	0.06	43	0.5	0.03	0.5	0.04
Eye & Orbit	81	1.2	0.06	1.3	0.07	82	1.1	0.06	1.3	0.06
Brain & Other CNS	567	8.8	0.17	9.7	0.18	454	6.5	0.15	7.0	0.15
Brain	538	8.3	0.17	9.2	0.18	424	6.0	0.14	6.5	0.15
Endocrine System	804	12.8	0.21	14.3	0.23	1,835	30.3	0.34	32.5	0.35
Thyroid gland	729	11.7	0.20	13.0	0.22	1,769	29.4	0.33	31.5	0.34
Lymphomas	2,192	31.6	0.31	36.3	0.35	1,842	22.9	0.25	26.2	0.28
Hodgkin lymphoma	220	3.8	0.12	4.0	0.12	182	3.1	0.11	3.2	0.11
Non-Hodgkin lymphoma	1,972	27.8	0.29	32.3	0.33	1,660	19.7	0.23	23.0	0.26
Multiple Myeloma	665	9.0	0.16	10.6	0.19	493	5.6	0.12	6.6	0.14
Leukemias	1,648	23.3	0.27	26.9	0.30	1,140	13.6	0.19	15.6	0.21
Acute lymphocytic	88	1.7	0.08	1.6	0.08	73	1.4	0.08	1.3	0.07
Chronic lymphocytic	784	10.5	0.17	12.5	0.20	502	5.5	0.11	6.5	0.13
Acute myeloid	421	6.0	0.14	6.9	0.15	323	3.9	0.10	4.4	0.11
Chronic myeloid	190	2.8	0.09	3.2	0.10	140	1.7	0.07	2.0	0.08
Other leukemias	164	2.3	0.08	2.7	0.10	102	1.2	0.06	1.4	0.06
Mesothelioma	110	1.5	0.07	1.8	0.08	39	0.5	0.03	0.5	0.04
Kaposi Sarcoma	48	0.7	0.05	0.8	0.05	9	0.1	0.01	0.1	0.01
Ill-Defined & Unknown	1,724	24.1	0.27	27.9	0.30	1,613	17.4	0.21	20.1	0.23
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	790	11.9	0.20	13.4	0.22	1,576	20.1	0.24	23.0	0.27
Breast (<i>in situ</i>)	13	0.2	0.02	0.2	0.03	3,183	44.6	0.38	51.9	0.42

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New York, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	7,276	543.1	2.96	654.1	3.49	7,542	408.7	2.15	479.9	2.48
Oral Cavity & Pharynx	161	11.9	0.43	14.2	0.51	95	5.1	0.24	6.0	0.28
Lip	2	0.1	0.04	0.1	0.05	*	*	*	*	*
Tongue	38	2.7	0.20	3.3	0.24	20	1.0	0.11	1.3	0.13
Major salivary gland	15	1.1	0.13	1.3	0.15	23	1.3	0.13	1.5	0.14
Floor of mouth	6	0.5	0.08	0.6	0.11	3	0.2	0.04	0.2	0.05
Gum & other mouth	21	1.6	0.17	1.9	0.19	20	1.1	0.11	1.3	0.13
Nasopharynx	15	1.1	0.13	1.2	0.15	6	0.3	0.06	0.4	0.07
Oropharynx	13	1.0	0.12	1.2	0.15	5	0.2	0.05	0.3	0.06
Hypopharynx	19	1.4	0.15	1.7	0.18	7	0.4	0.07	0.5	0.08
Digestive System	1,509	116.0	1.39	138.6	1.63	1,461	77.7	0.93	92.2	1.08
Esophagus	72	5.6	0.31	6.7	0.36	43	2.2	0.16	2.7	0.19
Stomach	183	14.9	0.51	17.4	0.59	164	8.9	0.32	10.3	0.36
Small intestine	62	4.7	0.28	5.6	0.33	66	3.6	0.20	4.2	0.23
Colon (excl. rectum)	421	33.1	0.75	39.1	0.87	498	26.5	0.54	31.4	0.63
Rectum & rectosigmoid	190	14.4	0.49	17.1	0.57	153	8.3	0.31	9.9	0.36
Anus, anal canal, & anorectum	40	2.9	0.21	3.3	0.24	42	2.3	0.16	2.7	0.19
Liver	226	15.7	0.48	19.7	0.59	80	4.0	0.20	5.0	0.25
Gallbladder	25	2.1	0.19	2.4	0.22	54	2.8	0.17	3.4	0.21
Pancreas	222	17.2	0.54	20.6	0.63	275	14.5	0.40	17.1	0.46
Respiratory System	864	66.8	1.06	80.1	1.24	814	42.2	0.67	51.0	0.80
Larynx	80	6.0	0.31	7.3	0.37	25	1.2	0.11	1.6	0.14
Lung & bronchus	770	59.7	1.00	71.6	1.18	779	40.4	0.66	48.8	0.78
Bones & Joints	17	1.2	0.14	1.2	0.14	12	0.8	0.10	0.8	0.10
Soft Tissue (incl. heart)	52	4.0	0.26	4.4	0.28	56	3.3	0.20	3.6	0.22
Skin (excl. basal & sq.)	28	2.3	0.20	2.5	0.22	38	2.1	0.16	2.4	0.17
Melanoma of the skin	11	0.9	0.13	1.1	0.15	18	1.0	0.10	1.1	0.12
Breast (excl. <i>in situ</i>)	25	2.0	0.19	2.4	0.22	2,312	127.7	1.22	149.2	1.39
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,110	59.0	0.81	70.6	0.95
Cervix uteri	N/A	N/A	N/A	N/A	N/A	170	9.8	0.34	11.1	0.38
Uterus corpus	N/A	N/A	N/A	N/A	N/A	639	32.8	0.59	40.2	0.71
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	46	2.4	0.16	2.9	0.19
Ovary	N/A	N/A	N/A	N/A	N/A	171	9.3	0.33	10.9	0.37
Male Genital System	2,948	209.3	1.79	259.9	2.17	N/A	N/A	N/A	N/A	N/A
Prostate	2,907	206.3	1.78	256.7	2.15	N/A	N/A	N/A	N/A	N/A
Testis	26	1.9	0.17	1.9	0.16	N/A	N/A	N/A	N/A	N/A
Penis	12	1.0	0.13	1.2	0.15	N/A	N/A	N/A	N/A	N/A
Urinary System	577	44.6	0.86	53.2	1.01	330	17.5	0.44	20.8	0.51
Bladder (incl. <i>in situ</i>)	234	19.3	0.59	22.9	0.69	115	6.1	0.26	7.1	0.30
Kidney & renal pelvis	334	24.5	0.62	29.5	0.73	206	11.0	0.35	13.1	0.41
Ureter	2	0.2	0.06	0.2	0.07	3	0.2	0.04	0.2	0.05
Eye & Orbit	6	0.4	0.08	0.4	0.08	4	0.2	0.06	0.2	0.06
Brain & Other CNS	69	5.2	0.29	5.6	0.31	57	3.4	0.20	3.6	0.21
Brain	62	4.6	0.27	5.1	0.29	51	3.0	0.19	3.2	0.20
Endocrine System	78	5.9	0.30	6.5	0.33	276	16.2	0.45	18.0	0.49
Thyroid gland	61	4.6	0.27	5.2	0.30	256	15.0	0.43	16.7	0.47
Lymphomas	300	22.6	0.61	25.9	0.68	295	16.6	0.44	18.8	0.49
Hodgkin lymphoma	45	3.3	0.22	3.5	0.23	46	2.8	0.19	2.9	0.19
Non-Hodgkin lymphoma	255	19.4	0.56	22.4	0.64	249	13.8	0.40	15.9	0.45
Multiple Myeloma	222	17.3	0.54	20.6	0.63	250	13.3	0.38	15.8	0.45
Leukemias	165	13.0	0.47	14.8	0.53	169	9.4	0.33	10.6	0.37
Acute lymphocytic	17	1.3	0.14	1.2	0.13	15	1.0	0.12	0.9	0.11
Chronic lymphocytic	44	3.5	0.25	4.2	0.29	40	2.1	0.15	2.5	0.18
Acute myeloid	56	4.4	0.27	5.0	0.31	59	3.3	0.20	3.7	0.22
Chronic myeloid	24	1.9	0.18	2.2	0.21	28	1.6	0.14	1.8	0.15
Other leukemias	24	1.9	0.18	2.2	0.20	27	1.5	0.13	1.7	0.15
Mesothelioma	7	0.6	0.11	0.7	0.13	3	0.2	0.04	0.2	0.05
Kaposi Sarcoma	32	2.3	0.19	2.5	0.20	3	0.1	0.04	0.2	0.05
Ill-Defined & Unknown	216	17.6	0.56	20.5	0.64	258	13.8	0.39	16.1	0.45
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	132	10.2	0.41	11.8	0.47	311	17.3	0.45	19.9	0.51
Breast (<i>in situ</i>)	4	0.3	0.07	0.3	0.08	718	39.3	0.67	46.7	0.78

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New York, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3,050	364.3	3.06	428.5	3.53	3,450	350.3	2.72	406.6	3.12
Oral Cavity & Pharynx	136	15.6	0.62	18.3	0.71	77	7.8	0.41	9.1	0.47
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	28	3.2	0.28	3.8	0.32	21	2.2	0.22	2.5	0.25
Major salivary gland	11	1.3	0.18	1.5	0.20	11	1.1	0.15	1.3	0.17
Floor of mouth	3	0.3	0.08	0.4	0.11	2	0.2	0.06	0.2	0.07
Gum & other mouth	22	2.5	0.25	3.1	0.30	16	1.7	0.19	2.0	0.22
Nasopharynx	52	5.8	0.37	6.7	0.42	22	2.2	0.21	2.5	0.24
Oropharynx	3	0.4	0.12	0.5	0.13	*	*	*	*	*
Hypopharynx	7	0.9	0.15	1.1	0.18	*	*	*	*	*
Digestive System	884	104.7	1.63	125.1	1.91	618	64.3	1.18	75.6	1.37
Esophagus	40	4.7	0.34	5.6	0.40	11	1.2	0.16	1.4	0.18
Stomach	168	20.0	0.72	24.0	0.84	100	10.3	0.47	12.1	0.55
Small intestine	15	1.8	0.21	2.1	0.25	13	1.3	0.16	1.5	0.19
Colon (excl. rectum)	198	23.4	0.77	28.0	0.90	175	18.4	0.63	21.5	0.73
Rectum & rectosigmoid	128	15.0	0.61	17.9	0.72	94	9.5	0.44	11.3	0.52
Anus, anal canal, & anorectum	4	0.5	0.11	0.6	0.13	4	0.4	0.09	0.5	0.11
Liver	172	19.6	0.69	23.7	0.82	58	6.0	0.36	7.1	0.42
Gallbladder	11	1.4	0.20	1.6	0.23	18	1.9	0.20	2.2	0.24
Pancreas	94	11.6	0.56	13.7	0.65	90	9.5	0.46	11.2	0.53
Respiratory System	493	60.9	1.27	72.1	1.48	357	36.8	0.89	43.8	1.04
Larynx	24	2.8	0.27	3.5	0.32	3	0.3	0.08	0.4	0.10
Lung & bronchus	461	57.1	1.24	67.5	1.43	348	35.8	0.88	42.7	1.03
Bones & Joints	9	1.1	0.17	1.1	0.17	7	0.8	0.14	0.8	0.13
Soft Tissue (incl. heart)	31	3.7	0.31	4.1	0.34	22	2.2	0.22	2.4	0.23
Skin (excl. basal & sq.)	20	2.5	0.26	2.9	0.29	19	2.0	0.21	2.2	0.23
Melanoma of the skin	13	1.6	0.21	1.9	0.23	11	1.1	0.15	1.3	0.17
Breast (excl. <i>in situ</i>)	7	1.0	0.16	1.1	0.18	1,061	106.3	1.48	123.8	1.71
Female Genital System	N/A	N/A	N/A	N/A	N/A	453	45.0	0.96	53.1	1.12
Cervix uteri	N/A	N/A	N/A	N/A	N/A	81	8.2	0.41	9.3	0.47
Uterus corpus	N/A	N/A	N/A	N/A	N/A	229	22.3	0.67	26.9	0.80
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	5	0.5	0.10	0.6	0.12
Ovary	N/A	N/A	N/A	N/A	N/A	109	11.0	0.48	12.7	0.55
Male Genital System	599	68.9	1.30	82.9	1.53	N/A	N/A	N/A	N/A	N/A
Prostate	571	65.7	1.27	79.6	1.51	N/A	N/A	N/A	N/A	N/A
Testis	21	2.3	0.23	2.3	0.23	N/A	N/A	N/A	N/A	N/A
Penis	5	0.7	0.13	0.8	0.15	N/A	N/A	N/A	N/A	N/A
Urinary System	262	31.9	0.91	37.6	1.06	106	10.8	0.48	12.8	0.56
Bladder (incl. <i>in situ</i>)	138	17.6	0.69	20.6	0.80	37	3.9	0.30	4.6	0.34
Kidney & renal pelvis	116	13.3	0.57	15.8	0.66	65	6.5	0.37	7.7	0.43
Ureter	5	0.6	0.13	0.8	0.15	3	0.4	0.09	0.4	0.11
Eye & Orbit	3	0.3	0.09	0.4	0.10	3	0.3	0.09	0.3	0.09
Brain & Other CNS	46	5.4	0.36	5.9	0.39	35	3.7	0.29	4.1	0.31
Brain	43	5.0	0.35	5.5	0.38	32	3.4	0.27	3.8	0.30
Endocrine System	136	15.4	0.60	17.0	0.66	386	38.4	0.89	41.9	0.96
Thyroid gland	124	14.0	0.57	15.4	0.63	372	37.0	0.87	40.2	0.94
Lymphomas	166	20.2	0.72	22.9	0.81	125	12.9	0.52	14.8	0.60
Hodgkin lymphoma	16	1.9	0.22	2.0	0.22	13	1.4	0.17	1.4	0.17
Non-Hodgkin lymphoma	150	18.2	0.69	20.9	0.78	112	11.5	0.50	13.4	0.57
Multiple Myeloma	51	6.1	0.39	7.3	0.46	31	3.1	0.25	3.7	0.30
Leukemias	97	12.1	0.57	13.4	0.62	69	7.2	0.40	8.1	0.44
Acute lymphocytic	13	1.7	0.21	1.5	0.19	11	1.4	0.19	1.3	0.17
Chronic lymphocytic	18	2.1	0.24	2.5	0.27	10	1.0	0.15	1.2	0.17
Acute myeloid	37	4.8	0.36	5.3	0.39	28	2.9	0.25	3.3	0.28
Chronic myeloid	15	1.8	0.22	2.1	0.25	10	1.1	0.15	1.3	0.17
Other leukemias	13	1.7	0.22	2.0	0.25	9	0.9	0.14	1.1	0.16
Mesothelioma	4	0.6	0.12	0.6	0.13	2	0.2	0.07	0.3	0.08
Kaposi Sarcoma	4	0.5	0.11	0.5	0.11	*	*	*	*	*
Ill-Defined & Unknown	101	13.5	0.62	15.4	0.70	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	85	9.9	0.50	11.5	0.57	158	16.2	0.59	18.8	0.67
Breast (<i>in situ</i>)	2	0.2	0.07	0.2	0.08	441	44.6	0.96	51.5	1.10

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New York, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	61	441.6	26.28	524.6	30.54	67	407.0	22.87	472.3	25.93
Oral Cavity & Pharynx	4	24.0	5.49	31.2	7.01	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	10.1	3.68	12.9	4.57	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	12	80.4	10.91	98.2	13.05	12	72.5	9.52	85.9	10.96
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	1	10.2	4.00	12.6	4.82	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	2	16.0	4.93	19.7	6.00	5	31.3	6.36	36.6	7.21
Rectum & rectosigmoid	2	13.1	4.73	14.3	5.09	1	6.5	2.80	8.3	3.39
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	3	16.4	4.49	21.7	5.81	1	6.2	2.58	8.0	3.28
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	2	12.8	4.13	14.3	4.54
Respiratory System	8	66.3	10.80	76.4	12.23	12	64.3	8.55	79.7	10.50
Larynx	*	*	*	*	*	1	7.6	2.92	9.8	3.72
Lung & bronchus	7	58.8	10.20	67.2	11.48	10	55.7	7.97	68.6	9.73
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	*	*	*	*	*	1	9.3	3.59	9.5	3.62
Breast (excl. <i>in situ</i>)	*	*	*	*	*	17	108.4	12.30	120.7	13.31
Female Genital System	N/A	N/A	N/A	N/A	N/A	9	51.8	8.05	61.8	9.36
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	12.4	4.23	13.3	4.45
Uterus corpus	N/A	N/A	N/A	N/A	N/A	4	24.1	5.43	29.3	6.42
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	10.7	3.45	13.6	4.32
Male Genital System	17	115.3	13.01	140.1	15.47	N/A	N/A	N/A	N/A	N/A
Prostate	16	112.4	12.84	136.6	15.28	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	9	67.6	10.44	78.8	11.94	5	32.8	6.42	38.2	7.38
Bladder (incl. <i>in situ</i>)	4	27.5	6.73	32.0	7.70	*	*	*	*	*
Kidney & renal pelvis	5	37.8	7.64	44.1	8.72	4	27.2	5.88	31.4	6.73
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	3	20.9	5.35	23.2	5.85
Thyroid gland	*	*	*	*	*	3	20.9	5.35	23.2	5.85
Lymphomas	2	14.3	4.49	17.4	5.28	2	16.0	4.74	17.3	5.02
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	2	14.8	4.78	16.6	5.31	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	3	20.7	5.78	24.6	6.73	1	8.6	3.30	9.9	3.77
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	2	11.5	3.48	14.4	4.35
Breast (<i>in situ</i>)	*	*	*	*	*	4	22.9	5.36	27.5	6.34

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New York, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	5,967	437.2	2.66	518.9	3.12	6,729	376.9	2.08	439.3	2.41
Oral Cavity & Pharynx	195	13.8	0.46	16.6	0.55	93	5.2	0.24	6.1	0.29
Lip	4	0.3	0.07	0.3	0.08	3	0.2	0.05	0.2	0.06
Tongue	49	3.4	0.23	4.1	0.27	24	1.3	0.12	1.6	0.15
Major salivary gland	18	1.1	0.13	1.3	0.15	18	1.0	0.11	1.1	0.12
Floor of mouth	8	0.6	0.10	0.7	0.12	3	0.2	0.05	0.2	0.06
Gum & other mouth	24	1.8	0.17	2.1	0.20	20	1.1	0.12	1.3	0.13
Nasopharynx	14	1.0	0.12	1.2	0.14	6	0.3	0.06	0.4	0.07
Oropharynx	16	1.2	0.14	1.4	0.17	2	0.1	0.04	0.2	0.04
Hypopharynx	14	1.1	0.14	1.3	0.16	3	0.2	0.05	0.2	0.05
Digestive System	1,457	108.0	1.33	129.1	1.57	1,243	71.0	0.91	83.5	1.07
Esophagus	69	5.3	0.30	6.4	0.36	22	1.3	0.12	1.5	0.14
Stomach	186	14.1	0.49	16.5	0.56	165	9.5	0.33	11.0	0.39
Small intestine	40	3.0	0.22	3.5	0.25	36	2.1	0.15	2.4	0.18
Colon (excl. rectum)	375	28.2	0.68	33.2	0.80	372	21.3	0.50	25.0	0.58
Rectum & rectosigmoid	191	13.5	0.46	16.1	0.54	146	8.1	0.30	9.6	0.36
Anus, anal canal, & anorectum	34	2.3	0.18	2.8	0.22	47	2.6	0.17	3.1	0.21
Liver	269	19.1	0.55	23.8	0.66	103	5.8	0.26	7.0	0.31
Gallbladder	22	1.6	0.17	2.0	0.19	53	3.0	0.19	3.6	0.22
Pancreas	184	14.2	0.49	17.0	0.58	199	11.5	0.37	13.5	0.43
Respiratory System	616	49.4	0.93	58.4	1.08	554	31.6	0.61	37.8	0.72
Larynx	69	5.2	0.29	6.3	0.35	22	1.2	0.11	1.5	0.14
Lung & bronchus	528	43.1	0.88	50.8	1.02	521	29.8	0.59	35.7	0.70
Bones & Joints	21	1.2	0.12	1.2	0.13	16	0.9	0.10	0.9	0.10
Soft Tissue (incl. heart)	61	3.9	0.24	4.3	0.27	53	2.9	0.18	3.2	0.20
Skin (excl. basal & sq.)	69	5.2	0.29	6.0	0.34	68	3.9	0.21	4.4	0.24
Melanoma of the skin	54	4.1	0.26	4.7	0.30	54	3.1	0.19	3.5	0.21
Breast (excl. <i>in situ</i>)	12	0.9	0.12	1.1	0.14	1,966	109.4	1.11	128.6	1.30
Female Genital System	N/A	N/A	N/A	N/A	N/A	913	50.4	0.75	59.2	0.88
Cervix uteri	N/A	N/A	N/A	N/A	N/A	173	9.6	0.33	10.5	0.36
Uterus corpus	N/A	N/A	N/A	N/A	N/A	463	25.3	0.53	30.7	0.64
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	21	1.2	0.12	1.4	0.14
Ovary	N/A	N/A	N/A	N/A	N/A	179	9.9	0.34	11.5	0.39
Male Genital System	1,742	125.0	1.40	152.6	1.67	N/A	N/A	N/A	N/A	N/A
Prostate	1,623	118.5	1.37	145.8	1.65	N/A	N/A	N/A	N/A	N/A
Testis	94	4.6	0.22	4.6	0.21	N/A	N/A	N/A	N/A	N/A
Penis	22	1.7	0.17	2.0	0.19	N/A	N/A	N/A	N/A	N/A
Urinary System	547	42.1	0.85	49.6	0.99	294	16.6	0.44	19.5	0.51
Bladder (incl. <i>in situ</i>)	262	22.2	0.64	26.0	0.74	105	6.1	0.27	7.2	0.32
Kidney & renal pelvis	275	19.1	0.54	22.6	0.63	180	10.0	0.34	11.7	0.39
Ureter	5	0.4	0.09	0.5	0.10	4	0.3	0.06	0.3	0.06
Eye & Orbit	9	0.7	0.10	0.7	0.12	12	0.7	0.09	0.8	0.10
Brain & Other CNS	104	6.6	0.31	7.2	0.34	86	4.7	0.23	5.1	0.25
Brain	96	6.2	0.30	6.8	0.33	80	4.4	0.22	4.8	0.24
Endocrine System	143	8.6	0.33	9.7	0.38	530	28.8	0.56	31.5	0.62
Thyroid gland	124	7.5	0.31	8.5	0.35	513	27.9	0.56	30.5	0.61
Lymphomas	374	26.3	0.64	30.1	0.74	351	19.7	0.47	22.6	0.55
Hodgkin lymphoma	57	3.3	0.21	3.5	0.22	46	2.5	0.16	2.6	0.17
Non-Hodgkin lymphoma	317	23.0	0.61	26.6	0.70	304	17.2	0.45	20.0	0.52
Multiple Myeloma	140	10.6	0.42	12.7	0.49	136	7.7	0.30	9.2	0.36
Leukemias	237	16.4	0.51	18.2	0.57	179	9.9	0.33	11.0	0.37
Acute lymphocytic	55	3.0	0.18	2.8	0.18	36	1.9	0.14	1.8	0.14
Chronic lymphocytic	52	4.2	0.27	4.9	0.31	35	2.1	0.16	2.4	0.18
Acute myeloid	70	5.1	0.29	5.7	0.33	62	3.4	0.20	3.9	0.22
Chronic myeloid	37	2.5	0.20	2.8	0.22	27	1.5	0.13	1.7	0.15
Other leukemias	24	1.7	0.16	1.9	0.19	18	1.0	0.11	1.2	0.13
Mesothelioma	8	0.7	0.11	0.8	0.13	9	0.5	0.07	0.6	0.09
Kaposi Sarcoma	32	2.1	0.17	2.3	0.20	4	0.3	0.06	0.3	0.06
Ill-Defined & Unknown	199	15.7	0.53	18.2	0.61	224	12.9	0.39	14.9	0.45
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	126	8.6	0.36	9.7	0.41	322	18.0	0.45	20.6	0.52
Breast (<i>in situ</i>)	2	0.2	0.05	0.2	0.06	673	37.3	0.65	44.0	0.76

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

NEW YORK

II-368 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New York, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	4,492	428.9	3.01	507.3	3.52	5,160	378.0	2.38	440.2	2.76
Oral Cavity & Pharynx	152	13.9	0.53	16.7	0.62	71	5.2	0.28	6.1	0.32
Lip	3	0.3	0.08	0.3	0.09	3	0.2	0.06	0.3	0.07
Tongue	39	3.4	0.26	4.1	0.31	19	1.3	0.14	1.6	0.17
Major salivary gland	13	1.1	0.14	1.3	0.16	12	0.9	0.11	1.0	0.13
Floor of mouth	6	0.6	0.11	0.7	0.13	3	0.2	0.06	0.3	0.07
Gum & other mouth	19	1.9	0.20	2.2	0.23	15	1.1	0.13	1.3	0.15
Nasopharynx	10	0.9	0.13	1.1	0.16	5	0.4	0.07	0.4	0.08
Oropharynx	12	1.2	0.16	1.4	0.19	2	0.2	0.05	0.2	0.05
Hypopharynx	12	1.2	0.17	1.4	0.19	2	0.2	0.05	0.2	0.06
Digestive System	1,136	109.6	1.53	130.8	1.80	960	71.5	1.04	84.1	1.22
Esophagus	55	5.5	0.35	6.6	0.41	17	1.3	0.14	1.5	0.16
Stomach	148	14.6	0.56	17.2	0.66	131	9.8	0.39	11.4	0.45
Small intestine	30	2.9	0.25	3.3	0.28	26	2.0	0.17	2.3	0.20
Colon (excl. rectum)	285	27.9	0.78	32.8	0.90	285	21.3	0.57	24.9	0.66
Rectum & rectosigmoid	145	13.3	0.52	15.8	0.61	114	8.3	0.35	9.9	0.42
Anus, anal canal, & anorectum	25	2.2	0.20	2.7	0.24	35	2.5	0.19	3.0	0.23
Liver	213	19.7	0.63	24.5	0.77	79	5.9	0.30	7.0	0.35
Gallbladder	17	1.7	0.19	2.0	0.22	39	2.9	0.21	3.4	0.25
Pancreas	147	14.8	0.57	17.7	0.67	157	11.7	0.42	13.8	0.50
Respiratory System	482	50.3	1.07	59.4	1.24	449	33.3	0.71	39.9	0.84
Larynx	52	5.2	0.34	6.3	0.40	18	1.2	0.13	1.6	0.17
Lung & bronchus	413	43.7	1.00	51.6	1.16	423	31.5	0.69	37.6	0.82
Bones & Joints	15	1.2	0.14	1.2	0.14	11	0.8	0.11	0.8	0.11
Soft Tissue (incl. heart)	46	3.9	0.27	4.3	0.30	41	2.9	0.21	3.2	0.23
Skin (excl. basal & sq.)	60	5.9	0.36	6.9	0.42	58	4.2	0.25	4.9	0.29
Melanoma of the skin	48	4.7	0.32	5.5	0.37	46	3.4	0.22	3.9	0.26
Breast (excl. <i>in situ</i>)	9	0.9	0.14	1.1	0.16	1,484	108.2	1.27	127.1	1.48
Female Genital System	N/A	N/A	N/A	N/A	N/A	678	49.0	0.85	57.5	0.99
Cervix uteri	N/A	N/A	N/A	N/A	N/A	124	9.1	0.37	9.8	0.40
Uterus corpus	N/A	N/A	N/A	N/A	N/A	344	24.6	0.60	29.8	0.72
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	15	1.1	0.13	1.3	0.15
Ovary	N/A	N/A	N/A	N/A	N/A	136	9.8	0.38	11.4	0.44
Male Genital System	1,208	112.8	1.52	137.1	1.81	N/A	N/A	N/A	N/A	N/A
Prostate	1,114	106.0	1.48	130.0	1.78	N/A	N/A	N/A	N/A	N/A
Testis	74	4.8	0.25	4.7	0.25	N/A	N/A	N/A	N/A	N/A
Penis	18	1.8	0.20	2.1	0.23	N/A	N/A	N/A	N/A	N/A
Urinary System	422	42.5	0.97	49.9	1.13	220	16.3	0.50	19.1	0.58
Bladder (incl. <i>in situ</i>)	204	22.6	0.74	26.5	0.85	79	6.0	0.30	7.1	0.36
Kidney & renal pelvis	210	18.9	0.61	22.3	0.71	135	9.8	0.38	11.5	0.44
Ureter	4	0.4	0.10	0.5	0.12	3	0.3	0.07	0.3	0.07
Eye & Orbit	6	0.6	0.11	0.6	0.12	9	0.7	0.10	0.8	0.11
Brain & Other CNS	83	6.9	0.36	7.6	0.40	68	4.9	0.27	5.4	0.30
Brain	77	6.5	0.35	7.1	0.39	63	4.5	0.26	5.0	0.29
Endocrine System	109	8.5	0.37	9.5	0.42	408	29.1	0.65	31.9	0.71
Thyroid gland	95	7.4	0.35	8.3	0.40	396	28.3	0.64	31.0	0.70
Lymphomas	289	26.6	0.74	30.4	0.84	275	20.2	0.55	23.3	0.63
Hodgkin lymphoma	42	3.2	0.23	3.5	0.25	36	2.6	0.19	2.7	0.20
Non-Hodgkin lymphoma	247	23.3	0.70	27.0	0.81	239	17.6	0.52	20.6	0.60
Multiple Myeloma	101	9.9	0.46	11.8	0.54	99	7.4	0.33	8.8	0.40
Leukemias	188	17.0	0.59	18.7	0.65	146	10.7	0.40	11.8	0.44
Acute lymphocytic	47	3.4	0.22	3.2	0.22	31	2.2	0.18	2.1	0.18
Chronic lymphocytic	38	4.0	0.31	4.7	0.35	28	2.1	0.18	2.5	0.21
Acute myeloid	57	5.3	0.33	6.0	0.38	51	3.7	0.23	4.2	0.26
Chronic myeloid	30	2.7	0.23	3.0	0.26	22	1.6	0.15	1.8	0.17
Other leukemias	17	1.6	0.18	1.9	0.21	14	1.0	0.12	1.2	0.14
Mesothelioma	6	0.7	0.12	0.8	0.15	6	0.4	0.08	0.5	0.09
Kaposi Sarcoma	22	1.9	0.19	2.1	0.22	3	0.2	0.06	0.3	0.07
Ill-Defined & Unknown	156	16.1	0.61	18.7	0.70	172	12.9	0.45	14.8	0.51
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	95	8.5	0.41	9.5	0.46	237	17.4	0.51	19.9	0.58
Breast (<i>in situ</i>)	*	*	*	*	*	510	37.0	0.74	43.7	0.87

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New York, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	920	391.4	6.06	469.9	7.14	1,055	325.6	4.56	383.0	5.32
Oral Cavity & Pharynx	27	11.7	1.04	14.1	1.24	14	4.4	0.53	5.2	0.62
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	6	2.9	0.53	3.4	0.61	3	0.8	0.24	1.0	0.27
Major salivary gland	3	1.0	0.29	1.2	0.35	4	1.2	0.27	1.4	0.32
Floor of mouth	1	0.5	0.22	0.6	0.25	*	*	*	*	*
Gum & other mouth	3	1.2	0.33	1.5	0.40	3	1.0	0.26	1.2	0.29
Nasopharynx	3	1.0	0.29	1.4	0.38	*	*	*	*	*
Oropharynx	2	0.8	0.30	0.9	0.34	*	*	*	*	*
Hypopharynx	2	1.0	0.33	1.1	0.36	*	*	*	*	*
Digestive System	225	96.5	3.02	116.6	3.58	202	63.7	2.04	75.5	2.40
Esophagus	11	4.7	0.66	5.7	0.79	4	1.3	0.29	1.5	0.35
Stomach	25	11.1	1.03	13.2	1.21	22	7.2	0.70	8.4	0.80
Small intestine	8	3.5	0.56	4.2	0.65	7	2.1	0.37	2.4	0.42
Colon (excl. rectum)	60	26.6	1.61	32.3	1.93	59	18.8	1.11	22.2	1.30
Rectum & rectosigmoid	31	13.0	1.09	15.5	1.28	22	6.6	0.64	7.8	0.75
Anus, anal canal, & anorectum	8	3.4	0.56	3.9	0.65	9	2.9	0.43	3.4	0.50
Liver	40	15.9	1.18	19.9	1.44	18	5.3	0.57	6.6	0.70
Gallbladder	3	1.2	0.35	1.4	0.40	11	3.5	0.47	4.2	0.57
Pancreas	27	12.0	1.07	14.4	1.27	34	10.9	0.86	12.9	1.00
Respiratory System	99	45.3	2.14	53.5	2.48	80	25.4	1.29	30.6	1.53
Larynx	10	4.1	0.61	5.0	0.72	3	1.0	0.25	1.2	0.30
Lung & bronchus	87	40.5	2.04	47.8	2.36	75	23.9	1.26	28.7	1.49
Bones & Joints	3	0.9	0.24	0.9	0.24	3	0.8	0.22	0.8	0.23
Soft Tissue (incl. heart)	11	3.8	0.55	4.3	0.63	9	2.5	0.38	2.8	0.43
Skin (excl. basal & sq.)	5	2.2	0.46	2.5	0.53	4	1.4	0.31	1.5	0.34
Melanoma of the skin	3	1.5	0.40	1.6	0.44	3	0.9	0.26	1.1	0.29
Breast (excl. <i>in situ</i>)	3	1.2	0.34	1.4	0.39	350	106.5	2.58	126.0	3.03
Female Genital System	N/A	N/A	N/A	N/A	N/A	147	44.7	1.67	53.3	1.98
Cervix uteri	N/A	N/A	N/A	N/A	N/A	27	8.4	0.73	9.5	0.82
Uterus corpus	N/A	N/A	N/A	N/A	N/A	76	22.6	1.18	27.9	1.44
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	5	1.4	0.31	1.7	0.36
Ovary	N/A	N/A	N/A	N/A	N/A	28	8.8	0.75	10.0	0.85
Male Genital System	309	127.6	3.39	157.3	4.07	N/A	N/A	N/A	N/A	N/A
Prostate	298	123.9	3.35	153.4	4.03	N/A	N/A	N/A	N/A	N/A
Testis	7	2.2	0.37	2.1	0.37	N/A	N/A	N/A	N/A	N/A
Penis	3	1.4	0.37	1.7	0.44	N/A	N/A	N/A	N/A	N/A
Urinary System	74	33.6	1.84	39.9	2.15	46	14.7	0.98	17.1	1.14
Bladder (incl. <i>in situ</i>)	37	18.0	1.39	21.4	1.62	17	5.8	0.63	6.6	0.72
Kidney & renal pelvis	36	14.8	1.16	17.8	1.37	27	8.1	0.71	9.6	0.83
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	1	0.4	0.15	0.4	0.17
Brain & Other CNS	14	5.3	0.69	5.8	0.76	13	3.9	0.50	4.2	0.55
Brain	13	5.0	0.67	5.5	0.74	12	3.7	0.49	3.9	0.53
Endocrine System	15	6.1	0.72	6.9	0.82	60	17.9	1.05	19.8	1.16
Thyroid gland	13	5.2	0.67	5.9	0.76	56	16.9	1.02	18.6	1.13
Lymphomas	48	19.6	1.33	22.6	1.53	47	14.5	0.96	16.6	1.10
Hodgkin lymphoma	9	2.9	0.46	3.1	0.50	6	1.8	0.33	1.8	0.34
Non-Hodgkin lymphoma	39	16.7	1.25	19.5	1.45	41	12.7	0.90	14.8	1.05
Multiple Myeloma	28	12.0	1.07	14.6	1.27	24	7.7	0.72	9.1	0.83
Leukemias	29	12.0	1.06	13.4	1.18	21	6.3	0.63	7.3	0.73
Acute lymphocytic	3	1.0	0.25	0.9	0.23	2	0.4	0.15	0.4	0.15
Chronic lymphocytic	8	3.4	0.58	4.1	0.67	5	1.4	0.30	1.7	0.36
Acute myeloid	9	4.0	0.63	4.4	0.69	9	2.8	0.41	3.2	0.47
Chronic myeloid	4	1.5	0.35	1.7	0.41	3	0.9	0.23	1.0	0.28
Other leukemias	5	2.1	0.45	2.4	0.51	3	0.9	0.23	1.0	0.26
Mesothelioma	1	0.7	0.28	0.7	0.29	1	0.3	0.14	0.4	0.18
Kaposi Sarcoma	4	1.1	0.27	1.4	0.34	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	15	6.0	0.73	7.2	0.88	45	14.2	0.95	16.5	1.10
Breast (<i>in situ</i>)	*	*	*	*	*	105	32.1	1.42	37.7	1.66

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.


N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	10,037,218	10,161,802	10,275,758	10,391,358	10,501,384
Non-Hispanic White	6,501,826	6,552,738	6,592,887	6,635,208	6,675,690
Non-Hispanic Black	2,218,090	2,245,717	2,272,121	2,298,538	2,323,474
Non-Hispanic Asian/Pacific Islander (NH API)	296,455	312,980	329,570	341,725	355,194
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	15,590	15,811	15,935	15,998	16,107


All Races Population 2015–2019: 51,367,520
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	900,391	929,010	958,955	992,905	1,023,296
Hispanic White	745,695	767,190	789,905	816,537	840,372
Hispanic Black	88,359	92,991	97,559	102,104	106,323

Hispanic/Latino Population, Census 2010: 800,120
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

NORTH CAROLINA CANCER REGISTRY

Initial Operation: 1987
Population-based Data Available: 1990
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	110.8	110.7	110.5	108.7	107.4	109.6
Missing Race	0.4	1.0	1.3	1.1	1.3	1.0
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.2	0.1	0.1	0.1	0.0	0.1
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.8	0.6	0.6	0.7	0.8	0.7
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.5	Ovary	93.5
Oral Cavity & Pharynx	97.8	Prostate	97.5
Esophagus	95.7	Testis	99.6
Stomach	96.9	Bladder (incl. <i>in situ</i>)	97.8
Colon & Rectum	96.2	Kidney & Renal Pelvis	88.3
Liver	52.8	Brain & Other CNS	87.1
Pancreas	87.4	Brain & Other CNS (non-malig)	39.3
Lung & Bronchus	87.6	Thyroid	99.4
Melanomas of the Skin	99.6	Hodgkin Lymphoma	98.7
Female Breast (excl. <i>in situ</i>)	98.9	Non-Hodgkin Lymphoma	96.4
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	90.3
Cervix Uteri	97.4	Leukemias	91.3
Uterus Corpus & Uterus NOS	99.0		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
North Carolina, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	29,778	521.8	1.39	621.9	1.64	28,635	434.6	1.18	508.2	1.36
Oral Cavity & Pharynx	1,142	19.4	0.26	23.7	0.32	459	6.9	0.15	8.1	0.17
Lip	35	0.7	0.05	0.8	0.06	14	0.2	0.03	0.3	0.03
Tongue	368	6.2	0.15	7.6	0.18	135	2.0	0.08	2.4	0.09
Major salivary gland	93	1.7	0.08	2.0	0.10	63	1.0	0.06	1.1	0.06
Floor of mouth	48	0.8	0.05	1.0	0.07	23	0.3	0.03	0.4	0.04
Gum & other mouth	117	2.1	0.09	2.5	0.10	103	1.5	0.07	1.8	0.08
Nasopharynx	40	0.7	0.05	0.8	0.06	17	0.3	0.03	0.3	0.03
Oropharynx	77	1.3	0.07	1.6	0.08	20	0.3	0.03	0.4	0.04
Hypopharynx	64	1.1	0.06	1.3	0.07	14	0.2	0.02	0.2	0.03
Digestive System	5,358	94.4	0.59	113.2	0.70	4,305	63.9	0.45	75.4	0.52
Esophagus	421	7.2	0.16	8.8	0.19	112	1.6	0.07	1.9	0.08
Stomach	479	8.6	0.18	10.1	0.21	304	4.6	0.12	5.3	0.14
Small intestine	195	3.5	0.11	4.1	0.13	182	2.8	0.09	3.2	0.11
Colon (excl. rectum)	1,576	28.5	0.33	33.7	0.39	1,582	23.7	0.27	27.7	0.31
Rectum & rectosigmoid	731	12.9	0.22	15.5	0.26	527	8.2	0.16	9.6	0.19
Anus, anal canal, & anorectum	87	1.6	0.08	1.8	0.09	179	2.7	0.09	3.2	0.11
Liver	707	11.5	0.20	14.6	0.25	203	2.9	0.09	3.5	0.11
Gallbladder	42	0.8	0.05	0.9	0.06	87	1.2	0.06	1.5	0.07
Pancreas	855	15.2	0.24	18.0	0.28	817	11.8	0.19	13.9	0.22
Respiratory System	4,887	85.4	0.56	102.0	0.66	4,051	57.6	0.41	68.9	0.49
Larynx	387	6.5	0.15	8.0	0.18	106	1.5	0.07	1.9	0.08
Lung & bronchus	4,434	77.7	0.54	92.7	0.63	3,910	55.5	0.40	66.4	0.48
Bones & Joints	55	1.1	0.07	1.1	0.07	44	0.8	0.06	0.8	0.06
Soft Tissue (incl. heart)	206	3.9	0.12	4.3	0.14	168	2.8	0.10	3.1	0.11
Skin (excl. basal & sq.)	2,026	37.3	0.38	43.5	0.44	1,367	22.0	0.27	25.0	0.31
Melanoma of the skin	1,888	34.5	0.37	40.4	0.42	1,281	20.6	0.27	23.5	0.30
Breast (excl. <i>in situ</i>)	71	1.3	0.07	1.5	0.08	8,988	137.8	0.67	162.0	0.77
Female Genital System	N/A	N/A	N/A	N/A	N/A	3,176	48.4	0.40	57.2	0.46
Cervix uteri	N/A	N/A	N/A	N/A	N/A	388	7.0	0.16	7.5	0.17
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,722	25.1	0.28	30.5	0.33
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	57	0.9	0.05	1.0	0.06
Ovary	N/A	N/A	N/A	N/A	N/A	628	9.8	0.18	11.4	0.21
Male Genital System	7,886	129.4	0.67	158.9	0.81	N/A	N/A	N/A	N/A	N/A
Prostate	7,569	122.9	0.65	152.4	0.79	N/A	N/A	N/A	N/A	N/A
Testis	250	5.2	0.15	5.2	0.15	N/A	N/A	N/A	N/A	N/A
Penis	52	0.9	0.06	1.1	0.07	N/A	N/A	N/A	N/A	N/A
Urinary System	3,316	60.0	0.48	70.8	0.56	1,438	21.2	0.26	24.9	0.30
Bladder (incl. <i>in situ</i>)	1,836	34.0	0.37	39.9	0.42	586	8.4	0.16	9.9	0.19
Kidney & renal pelvis	1,404	24.5	0.30	29.2	0.35	810	12.2	0.20	14.3	0.23
Ureter	43	0.8	0.06	1.0	0.07	26	0.4	0.03	0.4	0.04
Eye & Orbit	49	0.9	0.06	1.0	0.06	47	0.8	0.05	0.9	0.06
Brain & Other CNS	406	7.6	0.17	8.3	0.19	317	5.2	0.14	5.7	0.14
Brain	384	7.2	0.17	7.9	0.18	298	4.9	0.13	5.4	0.14
Endocrine System	365	6.8	0.16	7.6	0.18	994	17.9	0.26	19.2	0.27
Thyroid gland	320	6.0	0.15	6.7	0.17	955	17.2	0.26	18.5	0.27
Lymphomas	1,330	24.5	0.31	28.1	0.35	1,098	16.9	0.23	19.4	0.26
Hodgkin lymphoma	146	2.8	0.11	3.0	0.11	120	2.2	0.09	2.3	0.09
Non-Hodgkin lymphoma	1,184	21.7	0.29	25.1	0.33	978	14.7	0.21	17.1	0.25
Multiple Myeloma	531	9.4	0.19	11.2	0.22	454	6.6	0.14	7.8	0.17
Leukemias	1,015	18.9	0.27	21.5	0.31	710	11.0	0.19	12.4	0.21
Acute lymphocytic	90	1.8	0.09	1.7	0.08	67	1.3	0.07	1.2	0.07
Chronic lymphocytic	405	7.3	0.17	8.6	0.20	257	3.7	0.10	4.3	0.12
Acute myeloid	285	5.4	0.15	6.1	0.16	214	3.3	0.10	3.8	0.12
Chronic myeloid	145	2.8	0.11	3.1	0.12	107	1.7	0.08	1.9	0.08
Other leukemias	90	1.7	0.08	2.0	0.09	66	1.0	0.06	1.1	0.06
Mesothelioma	59	1.1	0.07	1.3	0.08	19	0.3	0.03	0.3	0.03
Kaposi Sarcoma	23	0.5	0.05	0.5	0.05	1	0.0	0.01	0.0	0.01
Ill-Defined & Unknown	1,054	19.9	0.28	23.2	0.33	998	14.7	0.21	17.0	0.24
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	519	9.8	0.20	11.0	0.22	1,098	17.2	0.24	19.7	0.27
Breast (<i>in situ</i>)	6	0.1	0.02	0.1	0.02	1,932	29.9	0.31	35.3	0.36

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
North Carolina, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	22,458	519.6	1.60	616.9	1.87	21,405	447.6	1.44	522.1	1.64
Oral Cavity & Pharynx	931	21.2	0.32	26.0	0.39	366	7.5	0.18	8.9	0.21
Lip	33	0.8	0.06	0.9	0.07	13	0.3	0.03	0.3	0.04
Tongue	319	7.2	0.18	8.8	0.22	113	2.4	0.10	2.8	0.12
Major salivary gland	73	1.8	0.10	2.1	0.11	43	1.0	0.07	1.1	0.08
Floor of mouth	39	0.9	0.07	1.1	0.08	19	0.4	0.04	0.4	0.05
Gum & other mouth	90	2.1	0.10	2.5	0.12	83	1.6	0.08	1.9	0.10
Nasopharynx	23	0.6	0.05	0.7	0.06	11	0.2	0.03	0.3	0.04
Oropharynx	60	1.3	0.08	1.7	0.10	17	0.4	0.04	0.4	0.05
Hypopharynx	45	1.0	0.07	1.2	0.08	10	0.2	0.03	0.2	0.03
Digestive System	3,887	90.6	0.67	108.4	0.79	3,019	60.6	0.51	71.2	0.59
Esophagus	346	7.8	0.19	9.4	0.23	80	1.5	0.08	1.8	0.09
Stomach	304	7.1	0.19	8.4	0.22	173	3.4	0.12	4.0	0.14
Small intestine	136	3.2	0.13	3.8	0.15	120	2.5	0.11	2.9	0.12
Colon (excl. rectum)	1,148	27.6	0.38	32.5	0.44	1,129	22.9	0.32	26.6	0.36
Rectum & rectosigmoid	542	13.1	0.26	15.6	0.30	379	8.2	0.20	9.6	0.23
Anus, anal canal, & anorectum	63	1.5	0.09	1.8	0.10	147	3.0	0.12	3.6	0.14
Liver	492	10.7	0.22	13.5	0.27	135	2.6	0.10	3.1	0.12
Gallbladder	25	0.6	0.05	0.7	0.06	50	1.0	0.06	1.1	0.07
Pancreas	635	14.6	0.27	17.4	0.31	574	10.9	0.21	12.9	0.25
Respiratory System	3,778	85.3	0.64	101.9	0.75	3,244	61.4	0.49	73.5	0.59
Larynx	276	6.2	0.17	7.6	0.21	81	1.6	0.08	2.0	0.10
Lung & bronchus	3,452	77.9	0.61	92.9	0.72	3,141	59.2	0.48	70.9	0.58
Bones & Joints	38	1.1	0.08	1.1	0.08	33	1.0	0.08	1.0	0.08
Soft Tissue (incl. heart)	153	3.9	0.15	4.4	0.16	114	2.6	0.12	3.0	0.13
Skin (excl. basal & sq.)	1,898	45.9	0.49	53.6	0.56	1,254	28.9	0.39	32.7	0.42
Melanoma of the skin	1,779	43.0	0.47	50.1	0.54	1,188	27.5	0.38	31.2	0.41
Breast (excl. <i>in situ</i>)	50	1.2	0.08	1.4	0.09	6,636	140.7	0.81	165.4	0.93
Female Genital System	N/A	N/A	N/A	N/A	N/A	2,283	48.6	0.48	57.3	0.55
Cervix uteri	N/A	N/A	N/A	N/A	N/A	240	6.6	0.20	7.0	0.21
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,238	24.9	0.33	30.4	0.39
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	33	0.7	0.06	0.8	0.06
Ovary	N/A	N/A	N/A	N/A	N/A	479	10.4	0.22	12.0	0.25
Male Genital System	5,315	115.2	0.73	140.4	0.87	N/A	N/A	N/A	N/A	N/A
Prostate	5,065	107.3	0.69	132.4	0.84	N/A	N/A	N/A	N/A	N/A
Testis	199	6.7	0.22	6.6	0.21	N/A	N/A	N/A	N/A	N/A
Penis	39	0.9	0.07	1.1	0.08	N/A	N/A	N/A	N/A	N/A
Urinary System	2,709	63.7	0.56	75.1	0.66	1,066	21.2	0.30	25.0	0.35
Bladder (incl. <i>in situ</i>)	1,603	37.7	0.43	44.3	0.50	470	8.9	0.19	10.6	0.22
Kidney & renal pelvis	1,040	24.4	0.35	29.0	0.41	565	11.7	0.23	13.7	0.26
Ureter	39	0.9	0.07	1.1	0.08	22	0.4	0.04	0.5	0.05
Eye & Orbit	42	1.0	0.07	1.2	0.08	41	1.0	0.07	1.1	0.08
Brain & Other CNS	320	8.4	0.22	9.2	0.23	255	6.0	0.18	6.6	0.19
Brain	305	8.0	0.21	8.8	0.23	243	5.7	0.17	6.3	0.18
Endocrine System	283	7.5	0.21	8.4	0.23	702	19.3	0.34	20.5	0.35
Thyroid gland	257	6.8	0.20	7.6	0.21	677	18.6	0.34	19.8	0.35
Lymphomas	1,032	25.3	0.37	29.1	0.41	839	17.6	0.29	20.2	0.32
Hodgkin lymphoma	97	2.8	0.13	2.9	0.14	79	2.4	0.12	2.4	0.12
Non-Hodgkin lymphoma	936	22.5	0.34	26.1	0.39	759	15.2	0.26	17.8	0.30
Multiple Myeloma	329	7.6	0.19	9.0	0.23	258	4.9	0.14	5.9	0.17
Leukemias	798	19.7	0.32	22.5	0.36	537	11.4	0.23	12.8	0.25
Acute lymphocytic	54	1.8	0.11	1.7	0.10	46	1.4	0.10	1.3	0.09
Chronic lymphocytic	340	7.8	0.19	9.3	0.23	207	3.9	0.13	4.6	0.15
Acute myeloid	220	5.4	0.17	6.2	0.19	158	3.3	0.12	3.8	0.14
Chronic myeloid	109	2.8	0.12	3.2	0.14	76	1.7	0.09	1.9	0.10
Other leukemias	75	1.9	0.10	2.2	0.11	51	1.1	0.07	1.2	0.08
Mesothelioma	51	1.2	0.08	1.4	0.09	16	0.3	0.04	0.4	0.04
Kaposi Sarcoma	9	0.3	0.04	0.3	0.04	*	*	*	*	*
Ill-Defined & Unknown	834	20.3	0.32	23.7	0.37	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & other CNS (non-malig)	382	9.9	0.24	11.1	0.26	788	17.1	0.29	19.5	0.32
Breast (<i>in situ</i>)	4	0.1	0.02	0.1	0.02	1,369	29.8	0.38	35.1	0.44

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
North Carolina, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	5,625	553.0	3.52	668.4	4.16	5,411	405.2	2.53	477.0	2.92
Oral Cavity & Pharynx	157	14.4	0.54	17.7	0.65	67	4.9	0.28	5.9	0.33
Lip	2	0.1	0.05	0.2	0.06	*	*	*	*	*
Tongue	33	3.0	0.24	3.7	0.29	14	1.0	0.12	1.2	0.15
Major salivary gland	14	1.4	0.18	1.7	0.21	14	1.0	0.13	1.2	0.15
Floor of mouth	9	0.7	0.11	0.9	0.14	4	0.3	0.06	0.3	0.08
Gum & other mouth	19	1.8	0.20	2.2	0.24	15	1.1	0.13	1.3	0.15
Nasopharynx	12	1.1	0.15	1.3	0.16	4	0.3	0.07	0.4	0.08
Oropharynx	16	1.4	0.17	1.8	0.20	3	0.2	0.05	0.2	0.07
Hypopharynx	17	1.5	0.18	1.9	0.22	3	0.2	0.06	0.3	0.07
Digestive System	1,129	113.0	1.61	136.4	1.90	996	74.8	1.09	88.8	1.27
Esophagus	62	6.2	0.38	7.5	0.44	29	2.1	0.18	2.6	0.22
Stomach	130	14.0	0.59	16.6	0.69	97	7.5	0.35	8.8	0.40
Small intestine	49	5.1	0.34	5.9	0.39	54	4.0	0.25	4.7	0.29
Colon (excl. rectum)	331	34.2	0.90	40.9	1.05	348	26.1	0.64	31.0	0.75
Rectum & rectosigmoid	136	13.1	0.53	15.9	0.63	105	8.0	0.36	9.4	0.41
Anus, anal canal, & anorectum	20	1.9	0.20	2.2	0.23	26	2.0	0.18	2.3	0.20
Liver	157	13.5	0.51	17.5	0.64	51	3.5	0.23	4.3	0.27
Gallbladder	14	1.5	0.20	1.8	0.22	27	1.9	0.17	2.3	0.20
Pancreas	182	18.4	0.65	22.0	0.76	203	15.3	0.49	18.2	0.58
Respiratory System	938	96.8	1.52	116.2	1.78	656	47.8	0.86	57.7	1.01
Larynx	97	9.4	0.46	11.6	0.55	21	1.4	0.14	1.8	0.18
Lung & bronchus	832	86.4	1.44	103.4	1.68	626	45.7	0.84	55.1	0.99
Bones & Joints	9	0.9	0.13	1.0	0.15	6	0.5	0.10	0.5	0.09
Soft Tissue (incl. heart)	35	3.6	0.28	3.9	0.31	36	2.9	0.22	3.2	0.24
Skin (excl. basal & sq.)	19	1.9	0.21	2.2	0.24	22	1.7	0.17	2.0	0.19
Melanoma of the skin	8	0.9	0.15	1.0	0.17	10	0.8	0.12	0.9	0.13
Breast (excl. <i>in situ</i>)	18	1.9	0.21	2.2	0.24	1,823	136.5	1.47	160.5	1.69
Female Genital System	N/A	N/A	N/A	N/A	N/A	644	47.3	0.86	56.2	1.00
Cervix uteri	N/A	N/A	N/A	N/A	N/A	95	7.5	0.35	8.3	0.38
Uterus corpus	N/A	N/A	N/A	N/A	N/A	361	25.5	0.62	31.1	0.74
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	21	1.6	0.16	1.9	0.19
Ovary	N/A	N/A	N/A	N/A	N/A	100	7.7	0.35	8.9	0.40
Male Genital System	2,050	189.0	1.98	235.6	2.40	N/A	N/A	N/A	N/A	N/A
Prostate	2,020	185.9	1.96	232.4	2.39	N/A	N/A	N/A	N/A	N/A
Testis	19	1.9	0.20	1.9	0.19	N/A	N/A	N/A	N/A	N/A
Penis	8	0.9	0.14	1.0	0.17	N/A	N/A	N/A	N/A	N/A
Urinary System	468	47.9	1.06	57.1	1.23	297	22.1	0.59	26.0	0.68
Bladder (incl. <i>in situ</i>)	174	19.6	0.72	23.1	0.83	93	6.9	0.33	8.2	0.38
Kidney & renal pelvis	286	27.4	0.76	32.9	0.89	196	14.6	0.48	17.1	0.55
Ureter	3	0.4	0.11	0.5	0.13	2	0.2	0.05	0.2	0.06
Eye & Orbit	3	0.4	0.09	0.4	0.09	4	0.3	0.07	0.3	0.07
Brain & Other CNS	54	5.3	0.34	5.7	0.36	41	3.3	0.24	3.5	0.24
Brain	50	4.9	0.33	5.4	0.35	36	2.9	0.22	3.1	0.23
Endocrine System	47	4.6	0.31	5.2	0.35	161	12.7	0.46	14.0	0.50
Thyroid gland	34	3.4	0.27	3.8	0.30	151	11.8	0.44	13.1	0.48
Lymphomas	207	20.5	0.67	23.4	0.76	181	13.9	0.47	15.8	0.53
Hodgkin lymphoma	35	3.2	0.25	3.3	0.26	31	2.5	0.20	2.6	0.21
Non-Hodgkin lymphoma	173	17.3	0.63	20.1	0.71	150	11.5	0.43	13.2	0.49
Multiple Myeloma	177	18.7	0.67	22.3	0.79	170	12.8	0.45	15.2	0.53
Leukemias	135	14.3	0.59	16.3	0.66	114	8.8	0.38	10.0	0.42
Acute lymphocytic	15	1.3	0.16	1.2	0.15	9	0.7	0.11	0.7	0.11
Chronic lymphocytic	43	4.8	0.35	5.6	0.40	34	2.5	0.20	3.0	0.23
Acute myeloid	44	4.7	0.34	5.3	0.38	41	3.2	0.22	3.6	0.25
Chronic myeloid	24	2.5	0.24	2.8	0.27	19	1.5	0.16	1.8	0.18
Other leukemias	10	1.1	0.16	1.3	0.19	10	0.8	0.11	0.9	0.13
Mesothelioma	5	0.6	0.12	0.6	0.13	3	0.2	0.05	0.2	0.06
Kaposi Sarcoma	10	1.0	0.14	1.0	0.14	*	*	*	*	*
Ill-Defined & Unknown	163	18.3	0.69	21.5	0.80	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	98	10.3	0.50	11.9	0.57	225	17.5	0.54	20.0	0.60
Breast (<i>in situ</i>)	2	0.2	0.07	0.2	0.08	433	31.8	0.70	37.9	0.82

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
North Carolina, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	255	242.9	7.43	285.0	8.69	381	273.6	6.62	319.5	7.72
Oral Cavity & Pharynx	11	9.2	1.29	10.8	1.53	7	5.0	0.92	5.8	1.06
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	4	3.2	0.76	3.7	0.89	3	2.3	0.67	2.6	0.76
Major salivary gland	*	*	*	*	*	2	1.0	0.36	1.2	0.44
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	2	2.4	0.72	2.8	0.87	*	*	*	*	*
Nasopharynx	2	1.6	0.50	1.8	0.58	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	72	68.7	3.96	81.6	4.66	65	53.0	3.14	62.3	3.64
Esophagus	2	1.3	0.46	1.6	0.58	*	*	*	*	*
Stomach	11	11.9	1.72	13.8	1.99	9	7.4	1.16	8.6	1.34
Small intestine	2	1.5	0.50	1.8	0.60	*	*	*	*	*
Colon (excl. rectum)	17	16.3	1.95	19.4	2.31	21	15.8	1.64	19.4	1.99
Rectum & rectosigmoid	11	8.6	1.26	10.5	1.53	9	6.5	1.05	7.6	1.22
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	15	14.6	1.78	17.7	2.13	5	4.9	0.98	5.7	1.14
Gallbladder	*	*	*	*	*	2	2.3	0.72	2.6	0.84
Pancreas	7	6.7	1.30	7.8	1.49	10	9.2	1.37	10.3	1.53
Respiratory System	32	31.7	2.73	38.0	3.22	40	33.5	2.49	40.1	2.93
Larynx	2	1.9	0.58	2.4	0.72	*	*	*	*	*
Lung & bronchus	29	28.5	2.61	34.3	3.08	39	32.5	2.46	38.9	2.89
Bones & Joints	2	1.1	0.41	1.3	0.49	*	*	*	*	*
Soft Tissue (incl. heart)	2	1.4	0.45	1.4	0.47	4	2.8	0.63	3.3	0.77
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	1	1.1	0.44	1.3	0.51	1	0.8	0.34	0.9	0.42
Breast (excl. <i>in situ</i>)	*	*	*	*	*	128	85.3	3.48	99.6	4.09
Female Genital System	N/A	N/A	N/A	N/A	N/A	49	32.9	2.18	39.5	2.61
Cervix uteri	N/A	N/A	N/A	N/A	N/A	8	5.3	0.87	6.1	1.02
Uterus corpus	N/A	N/A	N/A	N/A	N/A	24	15.8	1.50	19.6	1.85
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	13	8.7	1.12	10.3	1.31
Male Genital System	55	57.3	3.66	67.7	4.26	N/A	N/A	N/A	N/A	N/A
Prostate	52	55.5	3.62	66.0	4.24	N/A	N/A	N/A	N/A	N/A
Testis	3	1.6	0.43	1.5	0.39	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	20	20.3	2.29	23.8	2.66	9	7.4	1.18	8.9	1.40
Bladder (incl. <i>in situ</i>)	10	11.4	1.75	13.4	2.06	3	2.7	0.75	3.2	0.86
Kidney & renal pelvis	9	8.0	1.36	9.2	1.56	4	3.4	0.77	4.2	0.93
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	6	4.5	0.89	4.6	0.95	4	2.9	0.68	3.1	0.75
Brain	6	4.5	0.89	4.6	0.95	4	2.9	0.68	3.1	0.75
Endocrine System	9	6.0	0.94	6.2	1.00	35	20.9	1.61	23.0	1.81
Thyroid gland	8	5.1	0.85	5.2	0.89	35	20.6	1.60	22.6	1.80
Lymphomas	16	13.7	1.65	15.6	1.91	14	10.5	1.33	12.2	1.53
Hodgkin lymphoma	3	1.8	0.47	1.8	0.48	1	0.7	0.30	0.8	0.32
Non-Hodgkin lymphoma	13	11.9	1.58	13.8	1.85	13	9.8	1.30	11.4	1.50
Multiple Myeloma	3	3.2	0.83	3.9	1.01	4	3.2	0.77	3.8	0.89
Leukemias	13	11.8	1.62	13.8	1.93	6	4.5	0.85	4.7	0.92
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	2	1.6	0.49	1.4	0.45
Chronic lymphocytic	2	2.3	0.76	2.8	0.91	*	*	*	*	*
Acute myeloid	6	5.3	1.08	6.4	1.31	1	0.7	0.27	0.8	0.32
Chronic myeloid	3	2.6	0.79	3.1	0.96	1	0.8	0.34	0.9	0.39
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	10	11.1	1.71	13.0	2.00	12	9.5	1.33	10.7	1.50
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	8	6.9	1.14	8.2	1.37	21	15.5	1.60	17.5	1.82
Breast (<i>in situ</i>)	*	*	*	*	*	40	26.4	1.91	31.4	2.27

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
North Carolina, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	38	522.6	40.97	628.9	48.72	39	448.2	32.82	522.5	37.73
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	11	145.8	20.61	179.9	25.01	8	90.9	14.67	108.2	17.17
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	1	14.7	6.13	18.0	7.39	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	4	57.9	12.99	70.3	15.51	3	37.2	9.49	43.7	10.96
Rectum & rectosigmoid	1	15.3	5.82	20.9	7.91	2	16.8	6.07	20.9	7.40
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	2	23.1	7.50	29.1	9.29	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	7	100.9	18.92	114.8	21.37	7	73.6	13.13	89.3	15.77
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	6	94.8	18.40	108.6	20.90	7	73.6	13.13	89.3	15.77
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	1	15.5	5.96	18.4	6.97
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	9	102.7	15.68	117.1	17.53
Female Genital System	N/A	N/A	N/A	N/A	N/A	4	39.5	9.49	47.3	11.17
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2	18.8	6.39	22.6	7.57
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	7	86.3	15.88	111.0	20.14	N/A	N/A	N/A	N/A	N/A
Prostate	6	73.3	14.11	94.6	17.92	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	5	81.4	17.38	102.7	21.46	2	31.1	9.28	34.9	10.29
Bladder (incl. <i>in situ</i>)	2	37.0	12.44	46.8	15.24	*	*	*	*	*
Kidney & renal pelvis	3	44.4	12.14	55.9	15.10	2	19.5	7.14	21.3	7.55
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	2	17.5	5.88	22.6	7.54
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	1	14.7	6.18	15.8	6.46
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	28.7	10.75	31.9	12.22	1	13.9	5.90	17.2	7.32
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	1	20.1	7.70	19.8	7.49
Breast (<i>in situ</i>)	*	*	*	*	*	2	25.9	8.03	28.8	8.70

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
North Carolina, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	691	339.5	7.20	397.0	8.23	873	356.9	6.21	415.6	7.20
Oral Cavity & Pharynx	23	10.2	1.17	12.2	1.36	11	4.2	0.67	4.7	0.75
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	7	3.2	0.69	3.8	0.78	3	1.3	0.41	1.6	0.47
Major salivary gland	2	0.6	0.27	0.7	0.29	3	1.0	0.29	1.1	0.34
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	3	1.6	0.51	2.0	0.61	2	0.8	0.33	0.8	0.34
Nasopharynx	2	0.8	0.33	0.9	0.40	*	*	*	*	*
Oropharynx	1	0.5	0.18	0.6	0.25	*	*	*	*	*
Hypopharynx	2	1.1	0.43	1.2	0.48	*	*	*	*	*
Digestive System	160	77.3	3.38	91.3	3.89	137	64.5	2.79	75.7	3.23
Esophagus	7	3.6	0.75	4.3	0.88	2	1.2	0.42	1.3	0.46
Stomach	24	11.6	1.32	13.3	1.49	16	6.5	0.82	7.5	0.96
Small intestine	5	2.2	0.57	2.5	0.65	5	2.2	0.51	2.5	0.58
Colon (excl. rectum)	39	19.4	1.75	22.4	1.98	48	22.5	1.65	26.3	1.90
Rectum & rectosigmoid	22	9.3	1.07	11.1	1.25	15	6.3	0.82	7.5	0.95
Anus, anal canal, & anorectum	2	1.3	0.51	1.6	0.61	3	1.2	0.33	1.6	0.42
Liver	28	13.8	1.40	16.8	1.63	9	4.7	0.76	5.6	0.91
Gallbladder	2	1.0	0.39	1.2	0.46	6	2.6	0.56	3.1	0.65
Pancreas	21	10.5	1.28	12.3	1.47	22	11.8	1.27	13.8	1.46
Respiratory System	59	38.3	2.62	45.0	2.97	58	32.2	2.08	38.1	2.40
Larynx	6	3.0	0.64	3.6	0.76	2	1.2	0.44	1.3	0.46
Lung & bronchus	51	34.7	2.53	40.6	2.87	55	30.5	2.02	36.2	2.34
Bones & Joints	4	0.9	0.27	0.9	0.29	3	0.8	0.23	0.9	0.27
Soft Tissue (incl. heart)	11	3.6	0.66	4.2	0.77	9	2.9	0.51	3.3	0.59
Skin (excl. basal & sq.)	18	9.5	1.28	10.7	1.43	19	7.5	0.93	8.4	1.03
Melanoma of the skin	14	8.1	1.21	9.1	1.34	16	6.4	0.84	7.2	0.94
Breast (excl. <i>in situ</i>)	2	1.2	0.47	1.6	0.56	255	97.6	3.08	114.2	3.60
Female Genital System	N/A	N/A	N/A	N/A	N/A	138	51.4	2.23	60.3	2.61
Cervix uteri	N/A	N/A	N/A	N/A	N/A	34	11.4	1.01	12.6	1.15
Uterus corpus	N/A	N/A	N/A	N/A	N/A	66	25.5	1.56	30.6	1.87
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	0.6	0.21	0.8	0.26
Ovary	N/A	N/A	N/A	N/A	N/A	26	9.2	0.92	10.8	1.09
Male Genital System	175	91.2	3.64	109.1	4.19	N/A	N/A	N/A	N/A	N/A
Prostate	149	85.6	3.60	103.2	4.13	N/A	N/A	N/A	N/A	N/A
Testis	23	4.4	0.42	4.4	0.43	N/A	N/A	N/A	N/A	N/A
Penis	3	1.1	0.40	1.4	0.51	N/A	N/A	N/A	N/A	N/A
Urinary System	67	36.4	2.47	42.2	2.80	42	19.3	1.52	22.8	1.75
Bladder (incl. <i>in situ</i>)	22	16.1	1.78	18.4	2.01	11	6.4	0.94	7.4	1.06
Kidney & renal pelvis	43	19.5	1.67	22.6	1.88	30	12.4	1.16	14.7	1.36
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	2	0.3	0.11	0.3	0.13	1	0.4	0.16	0.4	0.21
Brain & Other CNS	18	5.4	0.78	5.9	0.89	12	3.7	0.58	4.1	0.66
Brain	15	4.8	0.75	5.4	0.87	11	3.5	0.56	3.8	0.63
Endocrine System	19	6.3	0.86	7.0	0.95	69	19.1	1.12	21.3	1.32
Thyroid gland	16	5.7	0.84	6.3	0.93	67	18.5	1.10	20.7	1.30
Lymphomas	51	20.8	1.70	24.2	1.99	46	19.8	1.53	22.8	1.74
Hodgkin lymphoma	8	2.3	0.52	2.6	0.62	7	2.2	0.44	2.4	0.49
Non-Hodgkin lymphoma	43	18.4	1.62	21.6	1.89	38	17.6	1.46	20.4	1.67
Multiple Myeloma	16	8.6	1.19	10.2	1.38	14	7.0	0.94	8.5	1.12
Leukemias	42	15.1	1.47	16.2	1.62	33	12.4	1.18	13.6	1.33
Acute lymphocytic	16	2.7	0.31	2.4	0.31	9	1.8	0.37	1.8	0.39
Chronic lymphocytic	6	4.6	0.96	5.3	1.08	6	3.4	0.68	4.0	0.78
Acute myeloid	12	4.7	0.83	5.1	0.91	10	3.2	0.56	3.5	0.62
Chronic myeloid	5	1.9	0.51	2.1	0.58	6	2.5	0.52	2.8	0.60
Other leukemias	2	1.2	0.43	1.3	0.46	3	1.4	0.46	1.5	0.49
Mesothelioma	2	0.9	0.39	1.0	0.41	*	*	*	*	*
Kaposi Sarcoma	2	0.4	0.14	0.5	0.16	*	*	*	*	*
Ill-Defined & Unknown	20	12.9	1.56	14.5	1.75	26	14.1	1.38	16.4	1.58
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	21	8.0	1.01	8.9	1.17	45	18.0	1.38	20.8	1.59
Breast (<i>in situ</i>)	*	*	*	*	*	56	20.3	1.34	24.0	1.59

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

NORTH CAROLINA

II-378 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
North Carolina, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	529	302.7	7.27	353.6	8.31	670	319.0	6.28	371.6	7.29
Oral Cavity & Pharynx	18	9.2	1.16	11.0	1.36	8	3.8	0.69	4.3	0.77
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	6	3.0	0.70	3.5	0.78	2	1.1	0.38	1.3	0.43
Major salivary gland	*	*	*	*	*	3	1.1	0.33	1.3	0.39
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	2	1.6	0.56	1.9	0.66	*	*	*	*	*
Nasopharynx	1	0.8	0.37	0.9	0.45	*	*	*	*	*
Oropharynx	1	0.5	0.19	0.6	0.26	*	*	*	*	*
Hypopharynx	1	0.7	0.28	0.8	0.34	*	*	*	*	*
Digestive System	123	69.7	3.46	82.1	3.97	103	55.6	2.75	65.2	3.19
Esophagus	5	3.3	0.78	3.9	0.92	2	1.1	0.43	1.3	0.47
Stomach	19	11.1	1.42	12.5	1.57	12	5.6	0.82	6.4	0.95
Small intestine	4	2.1	0.61	2.4	0.70	3	1.4	0.40	1.6	0.46
Colon (excl. rectum)	29	17.8	1.82	20.3	2.05	35	19.0	1.61	22.3	1.87
Rectum & rectosigmoid	17	8.5	1.12	10.1	1.29	11	5.6	0.83	6.6	0.96
Anus, anal canal, & anorectum	1	1.3	0.55	1.6	0.67	3	1.4	0.37	1.7	0.47
Liver	21	12.1	1.41	14.8	1.66	8	4.6	0.80	5.7	0.96
Gallbladder	1	0.5	0.24	0.6	0.27	4	2.1	0.55	2.5	0.63
Pancreas	16	8.9	1.22	10.6	1.40	16	10.0	1.25	11.6	1.43
Respiratory System	46	35.3	2.71	41.3	3.08	48	29.8	2.11	35.4	2.45
Larynx	5	3.2	0.72	3.9	0.84	1	0.9	0.40	1.0	0.43
Lung & bronchus	38	31.4	2.60	36.7	2.95	45	28.3	2.05	33.8	2.39
Bones & Joints	3	0.9	0.31	0.9	0.33	2	0.6	0.20	0.7	0.24
Soft Tissue (incl. heart)	9	3.7	0.73	4.3	0.85	6	2.4	0.50	2.8	0.60
Skin (excl. basal & sq.)	16	10.1	1.42	11.4	1.58	17	7.8	1.00	8.7	1.12
Melanoma of the skin	13	8.7	1.34	9.9	1.49	15	6.7	0.91	7.5	1.03
Breast (excl. <i>in situ</i>)	1	1.2	0.52	1.4	0.61	194	86.9	3.14	101.7	3.67
Female Genital System	N/A	N/A	N/A	N/A	N/A	107	46.8	2.28	54.9	2.68
Cervix uteri	N/A	N/A	N/A	N/A	N/A	26	10.0	1.01	11.0	1.14
Uterus corpus	N/A	N/A	N/A	N/A	N/A	52	23.2	1.59	28.1	1.91
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	20	8.2	0.93	9.5	1.10
Male Genital System	130	78.6	3.63	94.1	4.17	N/A	N/A	N/A	N/A	N/A
Prostate	111	74.1	3.59	89.4	4.13	N/A	N/A	N/A	N/A	N/A
Testis	17	3.8	0.42	3.8	0.43	N/A	N/A	N/A	N/A	N/A
Penis	2	0.7	0.32	0.9	0.40	N/A	N/A	N/A	N/A	N/A
Urinary System	51	32.4	2.50	37.4	2.82	31	16.9	1.51	20.1	1.76
Bladder (incl. <i>in situ</i>)	17	13.9	1.77	15.9	2.00	9	5.7	0.95	6.6	1.06
Kidney & renal pelvis	33	17.7	1.71	20.5	1.92	22	10.6	1.14	12.7	1.35
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	2	0.4	0.13	0.4	0.15	1	0.4	0.19	0.5	0.24
Brain & Other CNS	14	4.4	0.72	4.8	0.82	9	3.4	0.61	3.7	0.68
Brain	12	4.0	0.71	4.5	0.81	8	3.3	0.61	3.6	0.68
Endocrine System	15	5.8	0.87	6.4	0.97	53	17.5	1.17	19.6	1.37
Thyroid gland	13	5.1	0.85	5.7	0.94	52	17.1	1.15	19.0	1.35
Lymphomas	38	17.8	1.65	20.7	1.92	34	17.4	1.55	20.1	1.76
Hodgkin lymphoma	7	2.4	0.57	2.6	0.69	5	1.7	0.44	1.9	0.49
Non-Hodgkin lymphoma	32	15.4	1.54	18.0	1.79	29	15.7	1.49	18.2	1.69
Multiple Myeloma	11	6.9	1.09	8.2	1.27	9	5.0	0.85	6.1	1.02
Leukemias	35	14.7	1.54	16.0	1.72	26	11.3	1.19	12.4	1.34
Acute lymphocytic	14	2.9	0.36	2.7	0.36	7	1.9	0.41	1.8	0.44
Chronic lymphocytic	6	4.7	1.02	5.4	1.17	5	3.0	0.68	3.6	0.79
Acute myeloid	9	3.9	0.78	4.3	0.87	8	3.0	0.55	3.2	0.62
Chronic myeloid	4	2.0	0.58	2.2	0.66	5	2.2	0.52	2.4	0.60
Other leukemias	2	1.3	0.49	1.4	0.51	2	1.3	0.47	1.4	0.48
Mesothelioma	1	1.0	0.44	1.1	0.46	*	*	*	*	*
Kaposi Sarcoma	1	0.3	0.13	0.3	0.15	*	*	*	*	*
Ill-Defined & Unknown	15	10.3	1.47	11.7	1.64	22	13.2	1.41	15.4	1.62
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	16	7.3	1.07	8.0	1.20	35	15.9	1.38	18.4	1.59
Breast (<i>in situ</i>)	*	*	*	*	*	39	16.5	1.29	19.5	1.54

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
North Carolina, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	27	182.4	18.91	215.4	21.38	42	208.4	16.23	247.6	18.96
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	6	40.8	8.64	49.0	9.77	8	44.0	7.93	51.7	9.18
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	2	11.9	5.05	13.4	5.41	4	20.4	5.30	25.1	6.31
Rectum & rectosigmoid	*	*	*	*	*	1	4.8	2.55	5.0	2.60
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	2	10.8	4.41	13.2	5.03	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	4	26.5	7.33	32.3	8.56	3	22.5	6.09	26.3	6.84
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	3	25.5	7.27	30.9	8.43	3	19.4	5.61	22.9	6.37
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	13	57.4	7.86	69.5	9.41
Female Genital System	N/A	N/A	N/A	N/A	N/A	5	23.4	5.33	28.4	6.38
Cervix uteri	N/A	N/A	N/A	N/A	N/A	1	5.7	2.72	6.4	3.07
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2	12.8	4.09	15.9	4.93
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	8	52.0	9.57	61.5	10.71	N/A	N/A	N/A	N/A	N/A
Prostate	8	51.2	9.55	60.7	10.70	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	2	18.5	6.39	22.9	7.66	2	11.2	3.88	13.5	4.58
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	2	11.4	4.57	14.0	5.41	1	8.3	3.28	10.4	4.02
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	2	5.0	1.82	5.9	2.29
Thyroid gland	*	*	*	*	*	1	3.7	1.54	4.3	1.99
Lymphomas	2	13.0	5.36	14.4	5.87	2	7.8	2.46	8.8	2.84
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	3	14.8	4.43	18.0	5.27
Leukemias	*	*	*	*	*	2	7.5	2.82	8.4	3.18
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	2	9.6	3.41	11.4	4.19
Breast (<i>in situ</i>)	*	*	*	*	*	3	14.1	4.24	16.3	4.76

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.


N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	755,537	756,114	756,755	760,062	763,724
Non-Hispanic White	655,072	650,677	647,256	646,841	647,362
Non-Hispanic Black	21,443	24,165	25,590	27,227	28,175
Non-Hispanic Asian/Pacific Islander (NH API)	11,786	12,536	14,007	14,295	14,446
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	30,333	30,489	30,445	30,434	30,629


All Races Population 2015–2019: 3,792,192
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	26,396	27,616	28,701	30,317	31,939
Hispanic White	21,323	22,162	22,965	24,087	25,604
Hispanic Black	1,146	1,285	1,397	1,503	1,629

Hispanic/Latino Population, Census 2010: 13,467
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

NORTH DAKOTA CANCER REGISTRY

Initial Operation: 1997
Population-based Data Available: 1997
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	108.5	115.4	123.6	110.7	108.8	113.4
Missing Race	1.0	0.6	0.7	1.1	1.5	1.0
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.1	0.1	1.4	0.3	0.4
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.0	0.9	0.8	0.9	0.7	0.9
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.9	Ovary	92.7
Oral Cavity & Pharynx	98.9	Prostate	98.1
Esophagus	96.8	Testis	97.8
Stomach	96.4	Bladder (incl. <i>in situ</i>)	98.1
Colon & Rectum	96.9	Kidney & Renal Pelvis	87.3
Liver	58.5	Brain & Other CNS	83.4
Pancreas	84.6	Brain & Other CNS (non-malig)	32.5
Lung & Bronchus	92.1	Thyroid	99.8
Melanomas of the Skin	99.4	Hodgkin Lymphoma	100.0
Female Breast (excl. <i>in situ</i>)	98.9	Non-Hodgkin Lymphoma	97.8
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	90.6
Cervix Uteri	100.0	Leukemias	92.5
Uterus Corpus & Uterus NOS	99.5		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
North Dakota, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,037	487.0	4.97	577.0	5.77	1,857	433.8	4.71	503.7	5.35
Oral Cavity & Pharynx	73	17.4	0.94	21.1	1.12	32	7.3	0.60	8.7	0.71
Lip	15	3.7	0.44	4.4	0.51	4	1.0	0.22	1.1	0.24
Tongue	19	4.5	0.48	5.5	0.57	8	1.8	0.31	2.2	0.37
Major salivary gland	5	1.1	0.24	1.3	0.27	6	1.3	0.25	1.5	0.30
Floor of mouth	2	0.5	0.16	0.5	0.18	2	0.4	0.13	0.5	0.17
Gum & other mouth	6	1.5	0.28	1.8	0.32	6	1.2	0.24	1.4	0.28
Nasopharynx	2	0.4	0.15	0.5	0.17	*	*	*	*	*
Oropharynx	4	0.9	0.21	1.0	0.24	2	0.3	0.12	0.4	0.14
Hypopharynx	3	0.8	0.20	0.9	0.24	*	*	*	*	*
Digestive System	372	90.5	2.16	107.4	2.51	277	61.7	1.73	72.0	1.99
Esophagus	35	8.3	0.65	9.9	0.75	8	1.9	0.30	2.1	0.34
Stomach	30	7.2	0.61	8.6	0.71	15	3.3	0.40	3.8	0.46
Small intestine	12	2.8	0.38	3.4	0.45	9	2.1	0.33	2.5	0.38
Colon (excl. rectum)	123	30.3	1.26	35.7	1.45	113	25.4	1.12	29.1	1.26
Rectum & rectosigmoid	64	15.7	0.90	18.8	1.06	41	9.6	0.70	11.4	0.82
Anus, anal canal, & anorectum	6	1.3	0.25	1.6	0.31	9	2.2	0.33	2.6	0.39
Liver	29	6.6	0.57	8.1	0.68	9	1.9	0.29	2.3	0.34
Gallbladder	3	0.7	0.18	0.8	0.21	6	1.3	0.25	1.5	0.29
Pancreas	56	13.4	0.82	15.9	0.96	49	10.5	0.70	12.4	0.81
Respiratory System	280	67.6	1.85	79.8	2.15	248	54.8	1.60	64.6	1.86
Larynx	22	5.4	0.53	6.4	0.61	4	0.7	0.18	0.9	0.22
Lung & bronchus	256	61.6	1.77	72.7	2.05	243	53.6	1.58	63.2	1.84
Bones & Joints	3	0.7	0.19	0.7	0.20	*	*	*	*	*
Soft Tissue (incl. heart)	15	3.7	0.44	4.3	0.50	8	2.0	0.33	2.1	0.34
Skin (excl. basal & sq.)	111	27.6	1.21	32.0	1.38	95	24.0	1.17	26.9	1.27
Melanoma of the skin	103	25.5	1.16	29.7	1.32	89	22.9	1.15	25.6	1.24
Breast (excl. <i>in situ</i>)	6	1.7	0.31	2.0	0.35	566	135.4	2.67	159.1	3.06
Female Genital System	N/A	N/A	N/A	N/A	N/A	195	45.7	1.53	54.5	1.78
Cervix uteri	N/A	N/A	N/A	N/A	N/A	21	5.9	0.60	6.4	0.63
Uterus corpus	N/A	N/A	N/A	N/A	N/A	112	25.5	1.12	31.3	1.34
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	0.5	0.16	0.6	0.18
Ovary	N/A	N/A	N/A	N/A	N/A	38	8.8	0.67	10.5	0.77
Male Genital System	581	129.7	2.47	159.1	2.98	N/A	N/A	N/A	N/A	N/A
Prostate	549	121.6	2.39	151.0	2.90	N/A	N/A	N/A	N/A	N/A
Testis	27	6.8	0.60	6.7	0.59	N/A	N/A	N/A	N/A	N/A
Penis	4	1.0	0.23	1.1	0.26	N/A	N/A	N/A	N/A	N/A
Urinary System	239	59.4	1.77	69.1	2.02	93	20.4	0.99	24.1	1.15
Bladder (incl. <i>in situ</i>)	131	33.1	1.32	38.1	1.50	37	7.9	0.60	9.2	0.69
Kidney & renal pelvis	102	24.8	1.13	29.3	1.31	52	11.8	0.77	14.0	0.89
Ureter	3	0.8	0.22	1.0	0.24	2	0.3	0.12	0.4	0.14
Eye & Orbit	2	0.4	0.14	0.5	0.15	1	0.3	0.12	0.4	0.14
Brain & Other CNS	29	7.0	0.60	7.7	0.65	20	4.8	0.50	5.2	0.54
Brain	27	6.5	0.58	7.2	0.63	19	4.6	0.49	5.1	0.53
Endocrine System	38	9.5	0.72	10.7	0.79	94	26.8	1.29	28.5	1.34
Thyroid gland	36	9.0	0.70	10.2	0.77	92	26.3	1.28	27.9	1.33
Lymphomas	101	25.1	1.15	29.0	1.30	78	17.9	0.94	20.2	1.04
Hodgkin lymphoma	11	3.0	0.41	3.1	0.42	10	2.8	0.41	2.7	0.39
Non-Hodgkin lymphoma	90	22.1	1.07	25.8	1.23	68	15.1	0.85	17.5	0.97
Multiple Myeloma	29	7.2	0.61	8.5	0.71	24	5.2	0.49	6.1	0.57
Leukemias	80	19.9	1.02	22.4	1.13	57	12.6	0.78	14.3	0.87
Acute lymphocytic	8	2.3	0.36	2.0	0.31	4	1.2	0.25	1.1	0.25
Chronic lymphocytic	34	8.2	0.64	9.8	0.75	21	4.7	0.47	5.5	0.54
Acute myeloid	18	4.4	0.48	5.0	0.53	20	4.3	0.46	4.8	0.50
Chronic myeloid	11	2.7	0.38	3.0	0.42	8	1.7	0.27	2.0	0.32
Other leukemias	9	2.3	0.35	2.7	0.40	3	0.8	0.21	0.9	0.22
Mesothelioma	4	1.0	0.23	1.2	0.26	2	0.4	0.12	0.4	0.15
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	67	14.2	0.81	16.4	0.92
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	30	7.7	0.66	8.5	0.71	54	13.1	0.83	14.9	0.93
Breast (<i>in situ</i>)	*	*	*	*	*	99	25.2	1.19	29.4	1.35

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
North Dakota, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,897	482.4	5.11	570.2	5.92	1,719	430.7	4.92	499.7	5.56
Oral Cavity & Pharynx	68	17.3	0.97	21.0	1.15	30	7.3	0.63	8.7	0.73
Lip	15	3.9	0.47	4.6	0.54	4	1.0	0.23	1.1	0.25
Tongue	17	4.4	0.50	5.3	0.58	7	1.9	0.33	2.3	0.39
Major salivary gland	4	1.1	0.25	1.3	0.28	5	1.2	0.25	1.4	0.30
Floor of mouth	2	0.5	0.17	0.6	0.20	2	0.4	0.14	0.5	0.18
Gum & other mouth	6	1.6	0.30	1.9	0.34	6	1.3	0.26	1.5	0.30
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	3	0.9	0.22	1.0	0.25	2	0.3	0.13	0.4	0.15
Hypopharynx	3	0.9	0.22	1.0	0.26	*	*	*	*	*
Digestive System	337	87.1	2.19	103.1	2.54	250	58.8	1.76	68.5	2.01
Esophagus	32	8.2	0.67	9.7	0.77	7	1.7	0.30	2.0	0.33
Stomach	26	6.7	0.60	8.0	0.70	13	3.1	0.41	3.5	0.46
Small intestine	10	2.6	0.38	3.1	0.44	8	2.0	0.33	2.4	0.39
Colon (excl. rectum)	113	29.7	1.29	34.8	1.48	105	24.7	1.14	28.2	1.28
Rectum & rectosigmoid	58	15.0	0.91	18.0	1.07	37	9.1	0.72	10.9	0.83
Anus, anal canal, & anorectum	5	1.4	0.27	1.7	0.33	9	2.2	0.35	2.6	0.41
Liver	23	5.7	0.55	6.9	0.65	7	1.6	0.28	1.9	0.32
Gallbladder	3	0.7	0.19	0.8	0.22	4	0.9	0.21	1.1	0.25
Pancreas	53	13.4	0.85	15.8	0.98	45	10.2	0.71	12.0	0.82
Respiratory System	262	66.3	1.88	78.2	2.18	227	52.8	1.62	62.3	1.88
Larynx	20	5.3	0.54	6.2	0.62	4	0.8	0.19	1.0	0.24
Lung & bronchus	239	60.5	1.79	71.3	2.08	221	51.5	1.60	60.8	1.86
Bones & Joints	3	0.8	0.22	0.8	0.22	*	*	*	*	*
Soft Tissue (incl. heart)	14	3.7	0.46	4.2	0.51	7	1.9	0.34	2.0	0.35
Skin (excl. basal & sq.)	109	29.3	1.30	33.9	1.47	92	26.0	1.29	28.9	1.39
Melanoma of the skin	102	27.3	1.26	31.6	1.42	87	24.9	1.27	27.7	1.37
Breast (excl. <i>in situ</i>)	6	1.7	0.32	2.0	0.37	531	136.2	2.80	160.2	3.21
Female Genital System	N/A	N/A	N/A	N/A	N/A	179	44.8	1.58	53.6	1.84
Cervix uteri	N/A	N/A	N/A	N/A	N/A	17	5.3	0.61	5.6	0.63
Uterus corpus	N/A	N/A	N/A	N/A	N/A	105	25.5	1.17	31.3	1.40
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	0.4	0.15	0.5	0.17
Ovary	N/A	N/A	N/A	N/A	N/A	35	8.6	0.68	10.3	0.80
Male Genital System	540	128.0	2.54	156.7	3.04	N/A	N/A	N/A	N/A	N/A
Prostate	510	119.2	2.42	147.9	2.95	N/A	N/A	N/A	N/A	N/A
Testis	25	7.5	0.69	7.4	0.67	N/A	N/A	N/A	N/A	N/A
Penis	4	1.0	0.24	1.1	0.26	N/A	N/A	N/A	N/A	N/A
Urinary System	226	59.2	1.81	68.9	2.07	84	19.4	1.00	23.0	1.16
Bladder (incl. <i>in situ</i>)	127	33.4	1.36	38.5	1.54	36	8.0	0.63	9.4	0.72
Kidney & renal pelvis	94	24.3	1.16	28.7	1.34	45	10.8	0.76	12.8	0.88
Ureter	3	0.8	0.21	0.9	0.23	2	0.4	0.13	0.4	0.15
Eye & Orbit	2	0.4	0.14	0.4	0.15	1	0.3	0.13	0.4	0.15
Brain & Other CNS	27	7.4	0.66	8.0	0.70	19	5.2	0.56	5.6	0.59
Brain	25	7.0	0.64	7.6	0.68	18	5.0	0.55	5.4	0.58
Endocrine System	34	9.6	0.77	10.8	0.84	84	27.4	1.40	29.0	1.44
Thyroid gland	33	9.1	0.74	10.3	0.82	83	26.8	1.38	28.4	1.43
Lymphomas	95	25.3	1.20	29.2	1.35	73	18.0	0.99	20.3	1.09
Hodgkin lymphoma	11	3.2	0.45	3.3	0.46	9	2.9	0.45	2.8	0.43
Non-Hodgkin lymphoma	85	22.2	1.11	25.9	1.27	64	15.1	0.88	17.5	1.00
Multiple Myeloma	28	7.2	0.62	8.5	0.72	22	5.1	0.50	6.0	0.58
Leukemias	73	19.5	1.06	21.9	1.16	54	13.0	0.84	14.7	0.92
Acute lymphocytic	6	2.0	0.38	1.8	0.32	4	1.4	0.30	1.3	0.28
Chronic lymphocytic	33	8.2	0.66	9.8	0.78	21	4.8	0.49	5.7	0.57
Acute myeloid	16	4.4	0.50	4.9	0.54	19	4.4	0.48	4.9	0.53
Chronic myeloid	9	2.6	0.39	2.8	0.42	7	1.6	0.28	1.9	0.33
Other leukemias	8	2.3	0.37	2.6	0.41	3	0.9	0.23	1.0	0.24
Mesothelioma	4	1.0	0.23	1.2	0.27	2	0.3	0.12	0.4	0.15
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	62	13.9	0.84	15.9	0.93
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	27	7.7	0.69	8.4	0.74	49	12.8	0.87	14.7	0.97
Breast (<i>in situ</i>)	*	*	*	*	*	92	25.5	1.27	29.7	1.43

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
North Dakota, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	17	282.0	47.72	336.1	52.74	12	309.1	60.53	367.7	72.16
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	3	54.3	25.10	62.4	27.70	2	38.9	14.22	53.3	19.83
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	3	110.0	42.44	133.5	52.06
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	36.5	12.58	43.8	15.78
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	7	125.0	34.05	156.2	37.18	N/A	N/A	N/A	N/A	N/A
Prostate	6	124.1	34.04	155.4	37.17	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	2	15.2	5.56	18.5	6.94	2	18.7	6.95	17.3	6.76
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	1	8.7	3.78	7.7	3.50	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	1	21.9	8.75	25.7	10.71

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
North Dakota, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	7	319.3	69.12	361.3	76.64	13	329.7	51.38	383.2	59.93
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	1	55.2	28.66	63.0	33.53	3	91.2	30.48	107.9	35.55
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	5	97.7	24.23	111.4	28.03
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	30.2	11.05	39.4	15.14
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	1	47.9	24.13	57.4	28.36	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	2	32.0	10.48	32.2	10.99
Thyroid gland	*	*	*	*	*	2	32.0	10.48	32.2	10.99
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	*	*	*	*	*	1	23.7	9.27	25.5	10.60
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
North Dakota, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	57	624.4	41.43	742.5	48.19	67	577.6	33.39	680.5	38.75
Oral Cavity & Pharynx	2	25.6	7.77	29.2	8.65	1	8.9	3.70	11.3	4.63
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	18	189.0	22.46	224.6	25.95	13	111.2	14.49	132.4	16.90
Esophagus	1	11.5	4.50	15.0	5.74	*	*	*	*	*
Stomach	2	28.3	10.88	31.8	11.95	2	12.0	4.60	16.2	6.12
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	5	48.4	10.59	57.5	12.30	3	27.8	7.50	31.0	8.36
Rectum & rectosigmoid	4	39.1	10.01	46.8	12.00	2	21.3	6.74	25.1	7.71
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	3	29.9	8.32	35.9	9.55	1	13.4	5.23	15.2	5.77
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	1	16.6	6.71	19.4	7.64	2	14.0	4.83	17.5	5.88
Respiratory System	10	133.6	21.11	160.4	24.81	15	143.0	17.31	167.7	19.94
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	9	121.8	20.30	146.1	23.89	15	143.0	17.31	167.7	19.94
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	1	12.6	5.78	14.6	6.52	1	9.8	4.07	10.0	4.11
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	17	142.4	16.24	166.8	18.82
Female Genital System	N/A	N/A	N/A	N/A	N/A	7	52.0	9.01	61.8	10.58
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	14.8	4.51	17.7	5.40
Uterus corpus	N/A	N/A	N/A	N/A	N/A	3	21.5	5.96	26.7	7.19
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	1	10.4	4.02	12.1	4.64
Male Genital System	9	105.9	17.54	128.2	20.59	N/A	N/A	N/A	N/A	N/A
Prostate	9	103.3	17.35	125.4	20.40	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	5	55.5	11.38	61.7	12.51	4	36.2	8.13	43.8	9.75
Bladder (incl. <i>in situ</i>)	1	15.1	6.03	17.4	6.90	*	*	*	*	*
Kidney & renal pelvis	4	36.9	9.01	40.9	9.85	4	26.7	6.44	32.7	7.81
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	1	11.0	4.22	13.7	5.32	1	11.1	4.29	12.4	4.76
Thyroid gland	1	9.1	3.77	11.3	4.71	1	9.9	4.13	10.8	4.46
Lymphomas	2	20.9	6.56	25.3	7.74	2	25.7	8.28	28.3	9.37
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	3	24.7	7.10	28.6	8.16	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	3	27.7	8.02	34.9	9.84	3	25.8	7.42	32.0	8.93
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	1	12.3	4.75	13.2	5.09	1	10.1	3.95	10.1	3.97
Breast (<i>in situ</i>)	*	*	*	*	*	1	10.1	3.90	13.1	4.96

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
North Dakota, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	14	290.0	46.20	351.6	54.55	13	231.2	33.56	261.0	38.17
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	4	94.0	27.83	115.0	32.38	3	58.1	18.38	67.2	20.86
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	1	35.4	15.82	38.4	16.86
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	2	44.3	19.18	54.4	23.44	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	2	29.0	13.12	35.5	15.27	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	3	53.7	16.27	56.8	17.56
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	39.3	13.19	46.6	15.62
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	3	54.9	18.74	66.8	21.73	N/A	N/A	N/A	N/A	N/A
Prostate	2	49.9	18.50	61.1	21.44	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	2	39.6	16.46	45.0	18.05	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	2	29.0	12.53	33.8	14.09	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	2	19.7	6.55	19.3	6.55
Thyroid gland	*	*	*	*	*	2	19.7	6.55	19.3	6.55
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	1	16.1	6.76	19.4	8.70

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

NORTH DAKOTA

II-388 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
North Dakota, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	11	247.8	45.72	296.4	53.00	10	195.9	32.43	224.3	37.21
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	3	95.7	31.34	115.9	36.15	2	45.7	17.05	54.4	19.74
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	1	27.8	14.21	33.9	16.40	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	2	32.4	12.95	34.2	14.11
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	41.4	14.40	49.7	17.07
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	2	43.8	18.78	50.7	20.83	N/A	N/A	N/A	N/A	N/A
Prostate	1	38.1	18.48	44.2	20.44	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	2	29.9	13.80	35.0	15.51	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	1	18.0	6.92	22.3	9.00	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	1	14.1	5.93	14.5	6.31
Thyroid gland	*	*	*	*	*	1	14.1	5.93	14.5	6.31
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
North Dakota, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	*	*	*	*	*	*	*	*	*	*
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.


N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Race-Specific Population Counts by Year¹


Race	2015	2016	2017	2018	2019
All Races	11,622,315	11,640,060	11,665,706	11,680,892	11,696,507
Non-Hispanic White	9,367,845	9,344,041	9,325,847	9,300,345	9,277,877
Non-Hispanic Black	1,537,738	1,551,312	1,565,906	1,580,374	1,593,464
Non-Hispanic Asian/Pacific Islander (NH API)	270,555	284,777	298,340	308,566	319,457
Non-Hispanic American Indian/Alaskan Native PRCA (NH AI/AN)	0	0	0	0	0

All Races Population 2015–2019: 58,305,480
Distribution of Population by Race Only (excludes Hispanics)


**Hispanic/Latino Population Counts by Year¹**

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	416,768	430,203	445,674	461,379	475,203
Hispanic White	350,177	361,127	373,651	385,929	397,123
Hispanic Black	46,944	48,804	50,797	53,199	54,965

Hispanic/Latino Population, Census 2010: 354,674
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

OHIO CANCER REGISTRY

Initial Operation: 1992
Population-based Data Available: 1996
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	105.3	103.2	102.8	104.6	104.9	104.1
Missing Race	1.0	1.2	1.1	1.2	1.2	1.2
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	4.2	3.0	3.0	3.5	2.0	3.1
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.7	Ovary	93.5
Oral Cavity & Pharynx	97.8	Prostate	97.4
Esophagus	94.3	Testis	99.7
Stomach	96.0	Bladder (incl. <i>in situ</i>)	97.8
Colon & Rectum	96.1	Kidney & Renal Pelvis	92.5
Liver	55.4	Brain & Other CNS	88.2
Pancreas	84.0	Brain & Other CNS (non-malig)	49.9
Lung & Bronchus	89.6	Thyroid	99.6
Melanomas of the Skin	99.0	Hodgkin Lymphoma	98.7
Female Breast (excl. <i>in situ</i>)	98.7	Non-Hodgkin Lymphoma	96.5
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	88.3
Cervix Uteri	98.2	Leukemias	84.5
Uterus Corpus & Uterus NOS	98.9		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Ohio, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	34,771	510.7	1.26	607.2	1.47	34,200	446.8	1.13	522.0	1.28
Oral Cavity & Pharynx	1,322	18.8	0.24	23.1	0.29	528	6.8	0.14	8.1	0.16
Lip	25	0.4	0.04	0.4	0.04	11	0.1	0.02	0.2	0.02
Tongue	460	6.4	0.14	7.9	0.17	163	2.1	0.08	2.5	0.09
Major salivary gland	98	1.5	0.07	1.8	0.08	75	1.0	0.06	1.2	0.06
Floor of mouth	62	0.8	0.05	1.1	0.06	26	0.3	0.03	0.4	0.04
Gum & other mouth	151	2.2	0.08	2.7	0.10	115	1.5	0.06	1.7	0.07
Nasopharynx	41	0.6	0.04	0.7	0.05	17	0.2	0.03	0.3	0.03
Oropharynx	88	1.2	0.06	1.5	0.07	21	0.3	0.03	0.3	0.03
Hypopharynx	64	0.9	0.05	1.1	0.06	23	0.3	0.03	0.4	0.03
Digestive System	6,745	99.9	0.56	119.2	0.66	5,422	68.0	0.43	80.1	0.49
Esophagus	684	9.9	0.17	11.9	0.21	169	2.1	0.07	2.5	0.09
Stomach	550	8.3	0.16	9.8	0.19	315	4.0	0.11	4.7	0.12
Small intestine	204	3.1	0.10	3.6	0.11	191	2.5	0.08	2.9	0.10
Colon (excl. rectum)	2,072	31.5	0.32	37.2	0.37	2,119	26.6	0.27	31.0	0.31
Rectum & rectosigmoid	987	14.8	0.22	17.6	0.25	691	9.1	0.16	10.8	0.19
Anus, anal canal, & anorectum	96	1.4	0.07	1.7	0.08	200	2.6	0.08	3.1	0.10
Liver	699	9.5	0.17	11.9	0.20	236	2.8	0.09	3.4	0.10
Gallbladder	52	0.8	0.05	0.9	0.06	111	1.4	0.06	1.6	0.07
Pancreas	1,072	15.8	0.22	18.8	0.26	999	12.0	0.17	14.3	0.21
Respiratory System	5,828	84.8	0.51	101.5	0.60	5,046	61.2	0.39	73.4	0.47
Larynx	455	6.4	0.14	7.9	0.17	134	1.7	0.07	2.1	0.08
Lung & bronchus	5,290	77.1	0.49	92.2	0.57	4,865	58.9	0.39	70.6	0.46
Bones & Joints	66	1.1	0.06	1.2	0.06	49	0.8	0.05	0.8	0.05
Soft Tissue (incl. heart)	236	3.8	0.11	4.2	0.12	195	2.8	0.09	3.1	0.10
Skin (excl. basal & sq.)	2,160	33.3	0.33	38.7	0.38	1,625	23.0	0.27	26.0	0.29
Melanoma of the skin	2,027	31.2	0.32	36.3	0.36	1,537	21.9	0.26	24.7	0.29
Breast (excl. <i>in situ</i>)	78	1.1	0.06	1.4	0.07	9,871	130.8	0.61	153.6	0.70
Female Genital System	N/A	N/A	N/A	N/A	N/A	4,174	54.9	0.40	65.2	0.46
Cervix uteri	N/A	N/A	N/A	N/A	N/A	485	7.9	0.17	8.5	0.17
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2,385	30.0	0.28	36.6	0.34
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	115	1.5	0.06	1.8	0.08
Ovary	N/A	N/A	N/A	N/A	N/A	763	10.0	0.17	11.8	0.19
Male Genital System	8,671	119.3	0.59	145.9	0.71	N/A	N/A	N/A	N/A	N/A
Prostate	8,293	112.5	0.57	139.0	0.69	N/A	N/A	N/A	N/A	N/A
Testis	307	5.8	0.15	5.7	0.15	N/A	N/A	N/A	N/A	N/A
Penis	59	0.9	0.05	1.1	0.06	N/A	N/A	N/A	N/A	N/A
Urinary System	4,154	62.6	0.45	73.7	0.52	1,823	23.0	0.25	27.0	0.29
Bladder (incl. <i>in situ</i>)	2,483	37.7	0.35	44.3	0.40	788	9.4	0.15	11.2	0.18
Kidney & renal pelvis	1,584	23.5	0.27	27.9	0.32	987	13.0	0.19	15.2	0.22
Ureter	57	0.9	0.05	1.0	0.06	33	0.4	0.03	0.5	0.04
Eye & Orbit	75	1.2	0.06	1.3	0.07	69	1.0	0.05	1.1	0.06
Brain & Other CNS	522	8.4	0.17	9.2	0.18	414	5.9	0.14	6.5	0.14
Brain	494	7.9	0.16	8.7	0.18	390	5.5	0.13	6.1	0.14
Endocrine System	521	8.4	0.17	9.3	0.18	1,449	23.3	0.29	25.1	0.30
Thyroid gland	468	7.5	0.16	8.4	0.17	1,397	22.5	0.28	24.3	0.29
Lymphomas	1,716	26.6	0.30	30.6	0.33	1,398	18.4	0.23	21.1	0.26
Hodgkin lymphoma	183	3.2	0.11	3.3	0.11	146	2.4	0.09	2.5	0.09
Non-Hodgkin lymphoma	1,533	23.5	0.28	27.3	0.31	1,252	16.0	0.21	18.6	0.24
Multiple Myeloma	525	7.8	0.16	9.3	0.18	408	5.0	0.11	5.9	0.13
Leukemias	1,004	15.7	0.23	17.9	0.25	738	9.8	0.17	11.0	0.18
Acute lymphocytic	101	1.8	0.08	1.7	0.08	81	1.4	0.07	1.3	0.06
Chronic lymphocytic	332	4.9	0.12	5.9	0.15	199	2.4	0.08	2.8	0.09
Acute myeloid	315	4.9	0.13	5.6	0.14	265	3.5	0.10	4.0	0.11
Chronic myeloid	135	2.2	0.09	2.4	0.10	100	1.4	0.07	1.6	0.07
Other leukemias	122	2.0	0.08	2.2	0.09	94	1.2	0.06	1.4	0.06
Mesothelioma	96	1.5	0.07	1.7	0.08	34	0.4	0.03	0.5	0.04
Kaposi Sarcoma	20	0.4	0.04	0.4	0.04	3	0.0	0.01	0.0	0.01
Ill-Defined & Unknown	1,032	16.0	0.23	18.6	0.26	953	11.6	0.17	13.4	0.20
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	476	7.6	0.16	8.5	0.18	927	12.8	0.20	14.6	0.22
Breast (<i>in situ</i>)	6	0.1	0.02	0.1	0.02	2,079	28.1	0.29	33.3	0.33

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Ohio, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	30,054	508.9	1.35	603.6	1.57	29,585	454.1	1.24	529.7	1.41
Oral Cavity & Pharynx	1,194	19.6	0.26	24.2	0.32	467	7.1	0.15	8.4	0.18
Lip	24	0.4	0.04	0.5	0.05	9	0.1	0.02	0.2	0.02
Tongue	428	6.9	0.16	8.6	0.19	149	2.3	0.09	2.7	0.10
Major salivary gland	86	1.6	0.08	1.8	0.09	62	1.0	0.06	1.1	0.07
Floor of mouth	55	0.9	0.05	1.1	0.07	23	0.4	0.03	0.4	0.04
Gum & other mouth	134	2.3	0.09	2.7	0.11	101	1.5	0.07	1.7	0.08
Nasopharynx	32	0.5	0.04	0.6	0.05	15	0.2	0.03	0.3	0.03
Oropharynx	80	1.2	0.06	1.6	0.08	19	0.3	0.03	0.3	0.03
Hypopharynx	53	0.9	0.05	1.1	0.07	18	0.3	0.03	0.3	0.04
Digestive System	5,746	98.0	0.60	116.7	0.70	4,590	66.9	0.46	78.6	0.53
Esophagus	632	10.4	0.19	12.6	0.23	149	2.1	0.08	2.5	0.09
Stomach	451	7.8	0.17	9.2	0.20	236	3.5	0.11	4.1	0.12
Small intestine	171	3.0	0.11	3.5	0.12	154	2.3	0.09	2.7	0.10
Colon (excl. rectum)	1,768	31.0	0.34	36.5	0.39	1,822	26.5	0.29	30.9	0.33
Rectum & rectosigmoid	853	14.8	0.24	17.7	0.27	593	9.2	0.18	10.9	0.20
Anus, anal canal, & anorectum	78	1.3	0.07	1.6	0.08	177	2.7	0.09	3.3	0.11
Liver	534	8.4	0.17	10.5	0.20	181	2.6	0.09	3.0	0.10
Gallbladder	41	0.7	0.05	0.8	0.06	92	1.3	0.06	1.5	0.07
Pancreas	936	15.7	0.24	18.7	0.28	845	11.7	0.19	14.0	0.22
Respiratory System	5,135	85.3	0.55	102.1	0.64	4,412	62.1	0.43	74.3	0.51
Larynx	386	6.3	0.15	7.7	0.18	116	1.8	0.08	2.2	0.09
Lung & bronchus	4,681	77.8	0.52	92.9	0.61	4,258	59.8	0.42	71.5	0.50
Bones & Joints	56	1.2	0.07	1.2	0.07	42	0.9	0.06	0.9	0.06
Soft Tissue (incl. heart)	200	3.7	0.12	4.2	0.13	160	2.7	0.10	3.0	0.11
Skin (excl. basal & sq.)	1,949	34.7	0.36	40.3	0.41	1,400	23.8	0.30	26.8	0.33
Melanoma of the skin	1,831	32.5	0.35	37.8	0.40	1,326	22.7	0.30	25.5	0.32
Breast (excl. <i>in situ</i>)	66	1.1	0.06	1.3	0.07	8,550	132.9	0.68	156.2	0.77
Female Genital System	N/A	N/A	N/A	N/A	N/A	3,647	56.7	0.44	67.2	0.51
Cervix uteri	N/A	N/A	N/A	N/A	N/A	399	8.1	0.19	8.6	0.20
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2,090	30.9	0.32	37.7	0.38
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	97	1.5	0.07	1.8	0.08
Ovary	N/A	N/A	N/A	N/A	N/A	680	10.6	0.19	12.4	0.22
Male Genital System	7,133	113.2	0.62	137.7	0.74	N/A	N/A	N/A	N/A	N/A
Prostate	6,790	105.4	0.59	129.8	0.71	N/A	N/A	N/A	N/A	N/A
Testis	283	6.7	0.18	6.6	0.18	N/A	N/A	N/A	N/A	N/A
Penis	51	0.9	0.06	1.0	0.07	N/A	N/A	N/A	N/A	N/A
Urinary System	3,748	64.7	0.49	76.1	0.56	1,603	23.6	0.28	27.6	0.32
Bladder (incl. <i>in situ</i>)	2,304	39.7	0.38	46.7	0.44	712	9.8	0.17	11.6	0.20
Kidney & renal pelvis	1,363	23.5	0.30	27.8	0.34	849	13.2	0.21	15.3	0.24
Ureter	54	0.9	0.06	1.1	0.07	30	0.4	0.03	0.5	0.04
Eye & Orbit	71	1.3	0.07	1.5	0.08	65	1.1	0.06	1.2	0.07
Brain & Other CNS	465	8.9	0.19	9.7	0.20	369	6.4	0.16	6.9	0.17
Brain	441	8.3	0.18	9.2	0.20	349	5.9	0.15	6.5	0.16
Endocrine System	459	8.8	0.19	9.8	0.21	1,239	24.6	0.33	26.4	0.34
Thyroid gland	419	8.0	0.18	8.9	0.20	1,199	23.8	0.32	25.6	0.34
Lymphomas	1,525	27.4	0.32	31.5	0.36	1,235	19.0	0.25	21.9	0.28
Hodgkin lymphoma	152	3.2	0.12	3.4	0.12	121	2.5	0.11	2.6	0.11
Non-Hodgkin lymphoma	1,373	24.2	0.30	28.1	0.34	1,114	16.5	0.23	19.3	0.26
Multiple Myeloma	410	7.0	0.16	8.3	0.18	305	4.3	0.11	5.1	0.13
Leukemias	884	16.1	0.25	18.3	0.28	639	10.0	0.19	11.2	0.20
Acute lymphocytic	83	1.9	0.10	1.8	0.09	66	1.4	0.08	1.3	0.07
Chronic lymphocytic	295	5.0	0.13	6.0	0.16	177	2.4	0.08	2.9	0.10
Acute myeloid	282	5.1	0.14	5.8	0.16	229	3.5	0.11	4.0	0.12
Chronic myeloid	116	2.1	0.09	2.4	0.10	85	1.4	0.07	1.6	0.08
Other leukemias	108	2.0	0.09	2.3	0.10	83	1.2	0.06	1.4	0.07
Mesothelioma	90	1.6	0.08	1.8	0.09	32	0.5	0.04	0.5	0.04
Kaposi Sarcoma	11	0.2	0.03	0.2	0.03	2	0.0	0.01	0.0	0.01
Ill-Defined & Unknown	913	16.1	0.24	18.8	0.28	827	11.6	0.19	13.4	0.21
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	403	7.6	0.18	8.5	0.19	785	12.9	0.22	14.6	0.24
Breast (<i>in situ</i>)	4	0.1	0.02	0.1	0.02	1,754	28.2	0.32	33.3	0.36

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Ohio, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3,465	521.4	4.15	631.4	4.90	3,446	411.7	3.21	486.3	3.73
Oral Cavity & Pharynx	94	13.8	0.66	16.7	0.78	43	5.2	0.36	6.0	0.42
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	23	3.2	0.32	3.9	0.38	10	1.1	0.16	1.4	0.20
Major salivary gland	9	1.4	0.22	1.6	0.24	9	1.1	0.17	1.2	0.19
Floor of mouth	5	0.6	0.14	0.8	0.17	3	0.3	0.09	0.4	0.10
Gum & other mouth	12	1.7	0.23	2.0	0.27	9	1.2	0.18	1.3	0.19
Nasopharynx	6	0.9	0.17	1.0	0.19	1	0.1	0.06	0.2	0.07
Oropharynx	8	1.1	0.19	1.4	0.23	1	0.2	0.07	0.2	0.07
Hypopharynx	9	1.4	0.22	1.7	0.27	4	0.4	0.10	0.5	0.12
Digestive System	741	113.5	1.95	137.0	2.30	646	76.8	1.38	91.4	1.62
Esophagus	39	5.9	0.45	7.2	0.53	18	2.1	0.23	2.5	0.27
Stomach	77	12.8	0.68	14.9	0.78	60	7.4	0.43	8.5	0.49
Small intestine	27	4.4	0.39	5.1	0.45	32	3.9	0.32	4.6	0.37
Colon (excl. rectum)	212	33.3	1.07	39.9	1.25	221	26.4	0.81	31.3	0.95
Rectum & rectosigmoid	82	12.4	0.64	15.0	0.75	67	8.1	0.45	9.7	0.53
Anus, anal canal, & anorectum	16	2.4	0.27	2.7	0.31	18	2.1	0.22	2.6	0.28
Liver	129	17.4	0.71	22.3	0.89	44	4.6	0.32	5.9	0.40
Gallbladder	9	1.5	0.24	1.8	0.28	16	2.0	0.22	2.3	0.26
Pancreas	114	18.1	0.79	21.6	0.93	129	15.3	0.61	18.2	0.72
Respiratory System	604	95.2	1.82	114.6	2.13	553	63.9	1.24	77.9	1.49
Larynx	61	9.2	0.55	11.2	0.65	16	1.8	0.21	2.2	0.26
Lung & bronchus	532	84.5	1.72	101.6	2.01	531	61.3	1.22	74.7	1.46
Bones & Joints	6	0.8	0.15	0.9	0.16	4	0.5	0.11	0.5	0.11
Soft Tissue (incl. heart)	29	4.3	0.38	4.7	0.40	26	3.2	0.28	3.5	0.31
Skin (excl. basal & sq.)	12	1.8	0.25	2.1	0.28	13	1.6	0.20	1.8	0.23
Melanoma of the skin	5	0.9	0.18	1.0	0.20	6	0.7	0.13	0.8	0.15
Breast (excl. <i>in situ</i>)	11	1.7	0.24	2.0	0.28	1,050	127.3	1.80	150.0	2.08
Female Genital System	N/A	N/A	N/A	N/A	N/A	392	46.2	1.07	55.1	1.25
Cervix uteri	N/A	N/A	N/A	N/A	N/A	61	7.8	0.46	8.7	0.50
Uterus corpus	N/A	N/A	N/A	N/A	N/A	224	25.7	0.79	31.3	0.94
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	13	1.6	0.20	1.9	0.23
Ovary	N/A	N/A	N/A	N/A	N/A	57	6.7	0.40	8.0	0.47
Male Genital System	1,187	168.0	2.28	211.0	2.78	N/A	N/A	N/A	N/A	N/A
Prostate	1,170	165.4	2.26	208.2	2.76	N/A	N/A	N/A	N/A	N/A
Testis	11	1.5	0.22	1.5	0.22	N/A	N/A	N/A	N/A	N/A
Penis	5	0.9	0.19	1.1	0.21	N/A	N/A	N/A	N/A	N/A
Urinary System	307	48.4	1.29	57.5	1.50	179	21.3	0.73	25.0	0.84
Bladder (incl. <i>in situ</i>)	125	21.1	0.88	25.0	1.03	59	7.0	0.41	8.3	0.49
Kidney & renal pelvis	177	26.5	0.93	31.5	1.08	114	13.7	0.59	16.0	0.67
Ureter	2	0.3	0.11	0.4	0.12	2	0.2	0.08	0.3	0.09
Eye & Orbit	2	0.3	0.09	0.3	0.09	3	0.3	0.09	0.3	0.08
Brain & Other CNS	38	5.5	0.41	6.0	0.45	31	3.8	0.31	3.9	0.33
Brain	35	5.0	0.39	5.4	0.43	28	3.4	0.30	3.6	0.31
Endocrine System	38	5.5	0.42	6.5	0.48	139	17.6	0.69	19.7	0.75
Thyroid gland	28	4.2	0.36	4.9	0.42	129	16.5	0.67	18.4	0.73
Lymphomas	130	19.8	0.81	22.5	0.91	112	13.6	0.59	15.6	0.66
Hodgkin lymphoma	22	3.2	0.31	3.3	0.32	20	2.5	0.26	2.6	0.26
Non-Hodgkin lymphoma	108	16.6	0.75	19.3	0.86	93	11.1	0.53	13.0	0.61
Multiple Myeloma	95	15.3	0.73	18.1	0.85	87	10.4	0.51	12.4	0.60
Leukemias	71	11.1	0.61	12.5	0.69	69	8.3	0.46	9.3	0.51
Acute lymphocytic	8	1.1	0.17	1.0	0.17	9	1.0	0.15	1.0	0.15
Chronic lymphocytic	20	3.3	0.34	3.9	0.40	13	1.5	0.19	1.8	0.23
Acute myeloid	22	3.3	0.33	3.8	0.38	27	3.4	0.29	3.8	0.33
Chronic myeloid	13	2.2	0.28	2.3	0.29	11	1.4	0.19	1.5	0.21
Other leukemias	8	1.3	0.22	1.5	0.24	9	1.1	0.17	1.2	0.19
Mesothelioma	5	0.8	0.18	0.9	0.20	1	0.1	0.06	0.2	0.07
Kaposi Sarcoma	7	1.0	0.18	1.1	0.18	*	*	*	*	*
Ill-Defined & Unknown	88	14.5	0.73	17.1	0.84	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	48	7.4	0.50	8.4	0.56	109	13.3	0.59	15.3	0.66
Breast (<i>in situ</i>)	*	*	*	*	*	261	31.0	0.88	37.4	1.04

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Ohio, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	229	226.9	7.19	264.7	8.36	331	256.9	6.55	298.5	7.61
Oral Cavity & Pharynx	13	11.4	1.53	13.2	1.77	7	5.5	0.93	6.5	1.09
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	4	3.4	0.80	4.0	0.94	2	1.7	0.55	1.9	0.62
Major salivary gland	2	1.5	0.53	1.6	0.58	2	1.6	0.48	1.9	0.58
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	3	2.3	0.66	2.8	0.81	1	1.1	0.42	1.2	0.45
Nasopharynx	2	1.7	0.52	1.8	0.56	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	64	63.8	3.80	76.6	4.51	55	46.2	2.89	54.6	3.38
Esophagus	3	3.2	1.03	3.5	1.14	1	1.1	0.46	1.3	0.54
Stomach	8	8.3	1.38	9.9	1.64	7	5.5	0.98	6.3	1.12
Small intestine	2	1.7	0.61	2.2	0.74	*	*	*	*	*
Colon (excl. rectum)	15	15.5	1.94	18.5	2.28	18	14.7	1.63	17.3	1.90
Rectum & rectosigmoid	12	10.6	1.44	12.8	1.74	6	4.3	0.79	5.3	0.98
Anus, anal canal, & anorectum	*	*	*	*	*	2	1.3	0.48	1.6	0.57
Liver	13	12.2	1.58	14.9	1.91	5	4.3	0.89	5.4	1.08
Gallbladder	*	*	*	*	*	2	1.4	0.52	1.7	0.62
Pancreas	7	7.1	1.31	8.5	1.54	9	8.4	1.30	9.7	1.50
Respiratory System	29	33.1	2.94	38.3	3.37	34	31.2	2.49	36.4	2.86
Larynx	2	2.1	0.66	2.5	0.78	*	*	*	*	*
Lung & bronchus	25	29.0	2.76	33.9	3.18	33	30.5	2.46	35.5	2.82
Bones & Joints	1	1.0	0.37	0.9	0.36	*	*	*	*	*
Soft Tissue (incl. heart)	2	1.8	0.54	2.2	0.67	3	2.2	0.59	2.4	0.64
Skin (excl. basal & sq.)	*	*	*	*	*	1	1.0	0.42	1.3	0.53
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	116	85.9	3.66	99.5	4.26
Female Genital System	N/A	N/A	N/A	N/A	N/A	45	33.2	2.25	40.1	2.73
Cervix uteri	N/A	N/A	N/A	N/A	N/A	5	3.4	0.71	4.3	0.89
Uterus corpus	N/A	N/A	N/A	N/A	N/A	26	19.1	1.69	23.2	2.06
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	1.3	0.49	1.6	0.59
Ovary	N/A	N/A	N/A	N/A	N/A	11	7.9	1.10	9.2	1.30
Male Genital System	47	48.6	3.32	57.7	3.88	N/A	N/A	N/A	N/A	N/A
Prostate	44	46.2	3.26	55.2	3.82	N/A	N/A	N/A	N/A	N/A
Testis	2	1.3	0.40	1.3	0.41	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	19	20.6	2.31	24.4	2.69	10	8.6	1.27	10.3	1.51
Bladder (incl. <i>in situ</i>)	10	11.2	1.73	13.0	1.99	4	4.1	0.91	4.9	1.06
Kidney & renal pelvis	9	8.6	1.44	10.3	1.70	5	3.6	0.79	4.4	0.95
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	5	3.6	0.79	3.8	0.86	3	2.2	0.57	2.1	0.56
Brain	4	3.3	0.74	3.6	0.82	3	2.2	0.57	2.1	0.56
Endocrine System	10	6.8	1.02	7.1	1.10	26	16.8	1.52	18.4	1.69
Thyroid gland	9	6.0	0.96	6.3	1.04	25	16.1	1.48	17.7	1.66
Lymphomas	14	13.3	1.68	15.1	1.92	14	10.9	1.38	12.2	1.56
Hodgkin lymphoma	3	1.7	0.47	1.7	0.52	1	0.7	0.29	0.7	0.27
Non-Hodgkin lymphoma	12	11.7	1.61	13.3	1.85	12	10.2	1.35	11.6	1.53
Multiple Myeloma	5	5.4	1.16	6.2	1.35	2	1.6	0.57	1.8	0.64
Leukemias	10	7.4	1.09	8.0	1.22	8	5.7	0.96	5.9	1.01
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	2	1.1	0.38	0.9	0.32
Chronic lymphocytic	1	1.1	0.47	1.4	0.58	*	*	*	*	*
Acute myeloid	3	2.0	0.54	2.2	0.62	4	2.6	0.65	2.8	0.71
Chronic myeloid	2	1.4	0.49	1.5	0.53	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	8	8.7	1.48	9.5	1.64	6	5.4	1.03	6.4	1.20
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	9	8.0	1.32	9.2	1.54	14	10.0	1.26	11.3	1.44
Breast (<i>in situ</i>)	*	*	*	*	*	34	24.9	1.96	29.5	2.32

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Ohio, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	362	296.8	7.71	354.0	9.01	378	266.8	6.41	312.7	7.51
Oral Cavity & Pharynx	9	6.4	0.99	8.2	1.26	6	3.5	0.69	4.3	0.85
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	1.6	0.52	2.0	0.64	1	0.8	0.35	1.0	0.43
Major salivary gland	*	*	*	*	*	2	1.0	0.34	1.3	0.45
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	1.1	0.45	1.4	0.57	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	89	73.8	3.82	89.2	4.51	63	48.4	2.83	56.9	3.30
Esophagus	5	4.4	1.01	5.2	1.16	*	*	*	*	*
Stomach	9	7.6	1.20	9.2	1.41	8	5.5	0.91	6.6	1.09
Small intestine	1	0.8	0.30	1.0	0.38	3	2.3	0.63	2.7	0.73
Colon (excl. rectum)	22	17.6	1.88	21.4	2.23	21	15.9	1.62	18.4	1.86
Rectum & rectosigmoid	16	12.6	1.55	14.9	1.81	8	6.1	0.98	7.3	1.16
Anus, anal canal, & anorectum	1	0.9	0.40	1.0	0.44	2	1.6	0.52	1.8	0.60
Liver	19	14.5	1.63	18.6	2.02	5	3.7	0.77	4.4	0.92
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	11	9.7	1.43	11.7	1.68	11	8.8	1.23	10.5	1.45
Respiratory System	39	36.7	2.87	43.7	3.31	31	24.9	2.08	29.6	2.42
Larynx	4	2.5	0.62	3.3	0.81	1	0.8	0.34	1.1	0.45
Lung & bronchus	34	33.5	2.79	39.5	3.19	29	23.6	2.03	27.8	2.35
Bones & Joints	1	0.6	0.23	0.6	0.27	1	0.5	0.22	0.6	0.26
Soft Tissue (incl. heart)	2	1.3	0.43	1.6	0.52	4	2.1	0.53	2.4	0.62
Skin (excl. basal & sq.)	6	5.3	1.04	6.1	1.17	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	5	4.4	0.94	5.1	1.07	5	3.8	0.78	4.4	0.92
Breast (excl. <i>in situ</i>)	*	*	*	*	*	102	71.9	3.29	84.5	3.86
Female Genital System	N/A	N/A	N/A	N/A	N/A	58	39.1	2.37	46.6	2.83
Cervix uteri	N/A	N/A	N/A	N/A	N/A	12	7.7	1.02	8.7	1.17
Uterus corpus	N/A	N/A	N/A	N/A	N/A	29	19.5	1.67	23.8	2.04
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	1.6	0.50	1.9	0.58
Ovary	N/A	N/A	N/A	N/A	N/A	11	7.4	1.04	8.6	1.22
Male Genital System	96	80.9	4.01	97.9	4.71	N/A	N/A	N/A	N/A	N/A
Prostate	85	75.8	3.93	92.3	4.63	N/A	N/A	N/A	N/A	N/A
Testis	8	3.3	0.55	3.4	0.57	N/A	N/A	N/A	N/A	N/A
Penis	2	1.5	0.44	1.9	0.57	N/A	N/A	N/A	N/A	N/A
Urinary System	42	35.4	2.72	42.3	3.19	19	13.7	1.48	16.3	1.75
Bladder (incl. <i>in situ</i>)	18	19.0	2.16	22.4	2.50	5	4.1	0.83	4.9	0.98
Kidney & renal pelvis	23	15.7	1.59	19.1	1.93	13	9.6	1.22	11.4	1.45
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	8	4.4	0.79	4.9	0.91	6	3.3	0.68	3.8	0.79
Brain	7	4.1	0.78	4.6	0.88	5	3.2	0.67	3.7	0.79
Endocrine System	7	4.2	0.80	4.3	0.86	30	17.1	1.43	18.8	1.61
Thyroid gland	6	3.6	0.72	3.7	0.77	29	16.6	1.41	18.2	1.59
Lymphomas	26	18.7	1.83	21.7	2.13	21	15.3	1.58	18.0	1.85
Hodgkin lymphoma	4	2.4	0.58	2.5	0.62	3	1.6	0.49	1.9	0.58
Non-Hodgkin lymphoma	22	16.3	1.73	19.2	2.04	18	13.6	1.51	16.1	1.75
Multiple Myeloma	7	6.8	1.25	7.9	1.42	8	5.8	0.98	7.0	1.17
Leukemias	16	11.1	1.44	12.5	1.64	10	5.6	0.89	5.9	0.97
Acute lymphocytic	5	2.0	0.49	2.0	0.52	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	2	1.9	0.64	2.2	0.71	2	1.2	0.46	1.5	0.54
Acute myeloid	6	4.4	0.95	5.2	1.12	3	1.5	0.43	1.6	0.48
Chronic myeloid	2	1.4	0.56	1.4	0.57	1	0.9	0.40	1.0	0.43
Other leukemias	2	1.3	0.45	1.6	0.56	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	9	8.2	1.35	9.7	1.58	12	9.8	1.31	11.4	1.51
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	11	7.7	1.23	8.6	1.39	11	6.8	0.98	8.1	1.17
Breast (<i>in situ</i>)	*	*	*	*	*	20	13.5	1.39	16.6	1.71

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

OHIO

II-398 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Ohio, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	263	250.2	7.55	298.0	8.81	289	235.4	6.43	276.0	7.53
Oral Cavity & Pharynx	6	5.1	0.95	6.5	1.20	4	3.0	0.69	3.8	0.86
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	1.5	0.55	1.9	0.67	1	0.9	0.39	1.2	0.49
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	67	63.0	3.72	76.9	4.42	49	42.5	2.81	50.1	3.29
Esophagus	3	3.3	0.94	4.0	1.09	*	*	*	*	*
Stomach	7	6.4	1.11	8.0	1.37	5	4.3	0.86	5.1	1.03
Small intestine	*	*	*	*	*	2	2.1	0.61	2.5	0.73
Colon (excl. rectum)	15	14.5	1.81	17.6	2.14	16	13.7	1.59	15.9	1.83
Rectum & rectosigmoid	11	10.9	1.55	12.8	1.80	7	5.6	1.02	6.7	1.19
Anus, anal canal, & anorectum	*	*	*	*	*	2	1.4	0.53	1.7	0.61
Liver	15	13.5	1.65	17.4	2.07	3	3.1	0.77	3.5	0.87
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	8	8.5	1.39	10.2	1.64	9	8.0	1.23	9.7	1.46
Respiratory System	30	32.7	2.88	38.8	3.32	27	24.8	2.19	29.5	2.56
Larynx	3	2.4	0.66	3.2	0.86	1	0.9	0.39	1.3	0.52
Lung & bronchus	27	29.7	2.79	34.9	3.18	26	23.6	2.15	27.9	2.49
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	2	1.2	0.39	1.4	0.46	4	2.5	0.61	2.7	0.71
Skin (excl. basal & sq.)	5	4.5	1.01	5.2	1.15	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	4	3.4	0.88	4.0	1.02	4	3.0	0.73	3.5	0.86
Breast (excl. <i>in situ</i>)	*	*	*	*	*	76	61.7	3.27	72.1	3.81
Female Genital System	N/A	N/A	N/A	N/A	N/A	45	34.9	2.40	41.6	2.86
Cervix uteri	N/A	N/A	N/A	N/A	N/A	10	7.4	1.08	8.3	1.23
Uterus corpus	N/A	N/A	N/A	N/A	N/A	21	16.4	1.63	20.2	2.00
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	1.4	0.50	1.5	0.56
Ovary	N/A	N/A	N/A	N/A	N/A	8	6.4	1.05	7.6	1.23
Male Genital System	66	64.0	3.80	77.1	4.46	N/A	N/A	N/A	N/A	N/A
Prostate	59	59.9	3.73	72.7	4.38	N/A	N/A	N/A	N/A	N/A
Testis	5	2.3	0.49	2.3	0.48	N/A	N/A	N/A	N/A	N/A
Penis	2	1.4	0.45	1.7	0.56	N/A	N/A	N/A	N/A	N/A
Urinary System	33	33.2	2.83	39.5	3.31	14	12.4	1.52	14.7	1.79
Bladder (incl. <i>in situ</i>)	16	19.2	2.29	22.7	2.64	4	3.9	0.87	4.7	1.04
Kidney & renal pelvis	16	13.2	1.61	16.0	1.93	10	8.5	1.24	10.1	1.47
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	5	3.3	0.72	3.7	0.82	4	2.7	0.68	3.1	0.79
Brain	5	3.1	0.70	3.4	0.79	3	2.6	0.67	3.0	0.79
Endocrine System	5	3.3	0.80	3.3	0.83	24	16.0	1.49	17.4	1.67
Thyroid gland	4	2.8	0.71	2.8	0.75	23	15.4	1.47	16.7	1.64
Lymphomas	18	15.7	1.83	18.4	2.12	16	12.9	1.53	15.6	1.83
Hodgkin lymphoma	3	1.7	0.56	1.7	0.57	2	1.4	0.48	1.6	0.57
Non-Hodgkin lymphoma	16	14.0	1.74	16.6	2.05	14	11.5	1.45	14.0	1.74
Multiple Myeloma	5	5.3	1.18	6.2	1.34	6	5.0	0.96	6.0	1.14
Leukemias	11	9.6	1.47	10.6	1.64	6	3.7	0.79	3.7	0.81
Acute lymphocytic	4	2.1	0.55	2.0	0.57	3	1.2	0.36	1.1	0.35
Chronic lymphocytic	2	1.7	0.64	1.9	0.70	*	*	*	*	*
Acute myeloid	3	3.3	0.93	3.8	1.07	1	0.8	0.36	0.9	0.38
Chronic myeloid	1	1.3	0.59	1.3	0.61	*	*	*	*	*
Other leukemias	2	1.3	0.47	1.6	0.61	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	7	7.2	1.34	8.5	1.56	10	8.6	1.29	10.2	1.51
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	7	6.3	1.20	7.1	1.35	8	5.8	0.96	7.0	1.15
Breast (<i>in situ</i>)	*	*	*	*	*	13	10.6	1.32	13.3	1.65

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Ohio, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	12	133.1	20.86	155.8	23.57	10	81.6	13.00	96.5	15.26
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	2	30.7	10.58	35.1	11.66	1	14.8	5.98	16.7	6.50
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	1	17.3	7.40	20.4	8.24	1	13.2	5.71	15.7	6.59
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	1	15.7	7.23	18.4	8.00	1	13.2	5.71	15.7	6.59
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	3	28.3	7.41	34.5	8.96
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	4	49.5	11.77	60.9	13.77	N/A	N/A	N/A	N/A	N/A
Prostate	4	47.0	11.63	58.4	13.65	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	1	9.2	3.76	12.5	5.14

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


OHIO

II-400 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	3,910,518	3,928,143	3,933,602	3,943,488	3,960,676
Non-Hispanic White	2,713,458	2,709,167	2,697,855	2,690,099	2,689,742
Non-Hispanic Black	327,009	329,592	331,326	333,094	336,158
Non-Hispanic Asian/Pacific Islander (NH API)	98,384	101,154	102,863	105,165	107,721
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	374,861	378,158	380,706	383,132	385,037


All Races Population 2015–2019: 19,676,427
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	396,806	410,072	420,852	431,998	442,018
Hispanic White	329,587	339,996	348,033	355,840	363,416
Hispanic Black	17,313	17,974	18,597	19,333	20,156

Hispanic/Latino Population, Census 2010: 332,007
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

OKLAHOMA CANCER REGISTRY

Initial Operation: 1997
Population-based Data Available: 1997
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	99.8	96.2	93.9	94.0	97.0	96.2
Missing Race	0.9	0.6	1.2	0.5	1.0	0.9
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.8	2.4	2.1	2.6	2.7	2.5
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.2	Ovary	90.9
Oral Cavity & Pharynx	96.7	Prostate	96.7
Esophagus	93.5	Testis	98.6
Stomach	94.2	Bladder (incl. <i>in situ</i>)	97.0
Colon & Rectum	95.5	Kidney & Renal Pelvis	90.7
Liver	50.1	Brain & Other CNS	81.8
Pancreas	80.1	Brain & Other CNS (non-malig)	45.2
Lung & Bronchus	86.4	Thyroid	98.7
Melanomas of the Skin	99.3	Hodgkin Lymphoma	98.4
Female Breast (excl. <i>in situ</i>)	98.0	Non-Hodgkin Lymphoma	97.0
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	92.2
Cervix Uteri	96.6	Leukemias	88.7
Uterus Corpus & Uterus NOS	98.4		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Oklahoma, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	10,572	490.2	2.18	583.5	2.56	10,133	424.2	1.94	497.1	2.24
Oral Cavity & Pharynx	434	19.9	0.44	24.3	0.53	169	6.9	0.24	8.2	0.29
Lip	40	1.9	0.14	2.3	0.16	16	0.6	0.07	0.7	0.08
Tongue	131	6.0	0.24	7.3	0.29	50	2.0	0.13	2.5	0.16
Major salivary gland	44	2.2	0.15	2.5	0.17	25	1.1	0.10	1.2	0.11
Floor of mouth	12	0.5	0.07	0.7	0.09	7	0.3	0.05	0.3	0.06
Gum & other mouth	42	1.9	0.13	2.3	0.16	28	1.2	0.10	1.4	0.12
Nasopharynx	16	0.8	0.09	0.9	0.10	8	0.3	0.05	0.4	0.06
Oropharynx	27	1.2	0.11	1.5	0.13	8	0.3	0.05	0.4	0.06
Hypopharynx	17	0.7	0.08	0.9	0.10	6	0.2	0.04	0.3	0.05
Digestive System	2,085	96.8	0.97	116.2	1.15	1,620	65.9	0.75	78.1	0.88
Esophagus	178	8.0	0.28	9.8	0.33	43	1.7	0.12	2.1	0.14
Stomach	149	7.1	0.27	8.5	0.31	100	4.1	0.19	4.8	0.22
Small intestine	61	2.8	0.17	3.4	0.19	57	2.4	0.15	2.9	0.17
Colon (excl. rectum)	676	32.3	0.57	38.0	0.66	643	26.4	0.48	30.8	0.55
Rectum & rectosigmoid	317	14.9	0.38	17.8	0.45	226	9.5	0.29	11.4	0.35
Anus, anal canal, & anorectum	30	1.4	0.12	1.7	0.14	65	2.7	0.15	3.2	0.18
Liver	282	12.1	0.33	15.3	0.41	103	4.0	0.18	4.9	0.22
Gallbladder	11	0.5	0.07	0.6	0.08	29	1.2	0.10	1.4	0.12
Pancreas	290	13.5	0.36	16.1	0.43	270	10.5	0.29	12.6	0.35
Respiratory System	1,816	83.2	0.89	99.6	1.06	1,528	59.7	0.69	71.7	0.83
Larynx	126	5.6	0.23	6.9	0.28	43	1.8	0.12	2.2	0.15
Lung & bronchus	1,664	76.4	0.86	91.4	1.01	1,470	57.3	0.68	68.9	0.81
Bones & Joints	25	1.2	0.11	1.3	0.12	22	1.1	0.10	1.1	0.10
Soft Tissue (incl. heart)	78	3.9	0.20	4.3	0.22	56	2.5	0.15	2.7	0.16
Skin (excl. basal & sq.)	623	30.3	0.55	35.3	0.64	396	17.6	0.41	19.9	0.45
Melanoma of the skin	587	28.5	0.54	33.3	0.62	372	16.6	0.40	18.8	0.44
Breast (excl. <i>in situ</i>)	26	1.2	0.11	1.4	0.13	2,932	124.3	1.06	146.8	1.23
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,130	49.0	0.68	57.4	0.77
Cervix uteri	N/A	N/A	N/A	N/A	N/A	188	9.7	0.33	10.3	0.34
Uterus corpus	N/A	N/A	N/A	N/A	N/A	560	23.1	0.45	28.0	0.54
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	21	0.9	0.09	1.0	0.10
Ovary	N/A	N/A	N/A	N/A	N/A	259	11.1	0.32	12.9	0.36
Male Genital System	2,421	107.0	0.99	130.2	1.19	N/A	N/A	N/A	N/A	N/A
Prostate	2,295	100.4	0.96	123.4	1.16	N/A	N/A	N/A	N/A	N/A
Testis	102	5.5	0.25	5.4	0.24	N/A	N/A	N/A	N/A	N/A
Penis	19	0.9	0.10	1.1	0.11	N/A	N/A	N/A	N/A	N/A
Urinary System	1,275	60.6	0.78	71.6	0.91	587	24.0	0.46	28.3	0.53
Bladder (incl. <i>in situ</i>)	684	32.9	0.57	38.7	0.67	190	7.5	0.25	8.8	0.29
Kidney & renal pelvis	569	26.5	0.51	31.6	0.60	383	16.0	0.38	18.9	0.44
Ureter	14	0.7	0.08	0.8	0.10	10	0.4	0.06	0.5	0.06
Eye & Orbit	24	1.1	0.10	1.3	0.12	17	0.7	0.08	0.8	0.09
Brain & Other CNS	152	7.4	0.27	8.2	0.30	127	5.5	0.23	6.2	0.25
Brain	144	7.0	0.27	7.8	0.29	121	5.3	0.22	5.9	0.24
Endocrine System	148	7.3	0.27	8.2	0.30	392	19.4	0.45	20.9	0.48
Thyroid gland	131	6.5	0.26	7.3	0.29	376	18.7	0.44	20.1	0.47
Lymphomas	469	22.6	0.48	25.9	0.54	407	17.0	0.39	19.6	0.44
Hodgkin lymphoma	46	2.3	0.15	2.4	0.16	40	2.0	0.14	2.1	0.15
Non-Hodgkin lymphoma	423	20.3	0.45	23.5	0.52	367	15.1	0.36	17.6	0.42
Multiple Myeloma	171	8.0	0.28	9.5	0.33	125	5.0	0.21	5.9	0.24
Leukemias	354	17.1	0.41	19.4	0.47	247	10.5	0.31	11.8	0.34
Acute lymphocytic	38	1.9	0.14	1.8	0.13	27	1.4	0.12	1.3	0.11
Chronic lymphocytic	125	5.9	0.24	7.0	0.28	82	3.1	0.16	3.8	0.19
Acute myeloid	101	4.9	0.22	5.6	0.25	79	3.4	0.18	3.8	0.19
Chronic myeloid	54	2.7	0.17	3.0	0.19	35	1.5	0.12	1.7	0.13
Other leukemias	36	1.7	0.13	2.0	0.15	24	1.0	0.10	1.1	0.11
Mesothelioma	22	1.1	0.10	1.2	0.12	9	0.4	0.05	0.4	0.06
Kaposi Sarcoma	8	0.4	0.07	0.5	0.07	*	*	*	*	*
Ill-Defined & Unknown	441	21.2	0.46	25.0	0.54	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	158	7.7	0.28	8.7	0.31	303	13.3	0.35	15.1	0.40
Breast (<i>in situ</i>)	1	0.1	0.03	0.1	0.03	485	21.0	0.44	24.9	0.51

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Oklahoma, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	8,380	478.0	2.40	568.6	2.81	7,932	415.2	2.19	486.5	2.51
Oral Cavity & Pharynx	364	20.8	0.50	25.4	0.61	134	6.8	0.27	8.1	0.32
Lip	35	2.0	0.16	2.4	0.19	14	0.7	0.08	0.8	0.10
Tongue	114	6.5	0.28	8.0	0.34	43	2.2	0.16	2.6	0.19
Major salivary gland	37	2.2	0.16	2.6	0.19	19	1.0	0.11	1.2	0.13
Floor of mouth	10	0.5	0.08	0.7	0.10	5	0.2	0.05	0.3	0.06
Gum & other mouth	35	1.9	0.15	2.4	0.18	22	1.1	0.11	1.3	0.12
Nasopharynx	11	0.7	0.10	0.8	0.11	4	0.2	0.05	0.3	0.06
Oropharynx	21	1.2	0.12	1.5	0.15	7	0.3	0.06	0.4	0.07
Hypopharynx	13	0.7	0.09	0.9	0.11	5	0.2	0.04	0.3	0.05
Digestive System	1,596	91.7	1.06	109.8	1.25	1,224	61.3	0.82	72.6	0.95
Esophagus	151	8.4	0.31	10.2	0.38	33	1.6	0.13	1.9	0.15
Stomach	108	6.3	0.28	7.4	0.32	67	3.3	0.19	3.9	0.22
Small intestine	46	2.7	0.18	3.2	0.21	46	2.4	0.17	2.9	0.20
Colon (excl. rectum)	521	30.8	0.62	36.1	0.72	495	24.8	0.52	29.1	0.60
Rectum & rectosigmoid	241	14.3	0.43	17.0	0.50	174	9.2	0.33	11.0	0.38
Anus, anal canal, & anorectum	24	1.4	0.13	1.7	0.16	54	2.9	0.18	3.4	0.21
Liver	195	10.4	0.34	13.2	0.43	64	3.1	0.18	3.7	0.21
Gallbladder	8	0.5	0.07	0.5	0.08	18	0.9	0.09	1.0	0.11
Pancreas	233	13.2	0.40	15.8	0.47	210	10.0	0.32	11.9	0.37
Respiratory System	1,488	82.1	0.97	98.6	1.15	1,252	59.6	0.77	71.7	0.92
Larynx	97	5.3	0.24	6.5	0.30	34	1.8	0.14	2.1	0.17
Lung & bronchus	1,371	75.7	0.93	90.7	1.11	1,206	57.2	0.75	68.9	0.90
Bones & Joints	18	1.2	0.13	1.3	0.14	16	1.0	0.12	1.0	0.12
Soft Tissue (incl. heart)	59	3.8	0.23	4.2	0.25	40	2.3	0.17	2.5	0.18
Skin (excl. basal & sq.)	548	32.7	0.64	38.2	0.74	336	19.3	0.50	21.8	0.55
Melanoma of the skin	518	30.9	0.62	36.1	0.72	316	18.3	0.49	20.6	0.53
Breast (excl. <i>in situ</i>)	21	1.2	0.12	1.4	0.14	2,320	123.6	1.21	146.0	1.40
Female Genital System	N/A	N/A	N/A	N/A	N/A	851	46.8	0.76	55.0	0.87
Cervix uteri	N/A	N/A	N/A	N/A	N/A	127	8.9	0.37	9.5	0.39
Uterus corpus	N/A	N/A	N/A	N/A	N/A	427	22.0	0.50	26.9	0.60
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	14	0.7	0.09	0.9	0.11
Ovary	N/A	N/A	N/A	N/A	N/A	200	10.8	0.36	12.6	0.41
Male Genital System	1,835	99.5	1.06	120.8	1.28	N/A	N/A	N/A	N/A	N/A
Prostate	1,743	92.6	1.01	113.7	1.23	N/A	N/A	N/A	N/A	N/A
Testis	73	5.8	0.31	5.8	0.31	N/A	N/A	N/A	N/A	N/A
Penis	15	0.9	0.11	1.1	0.12	N/A	N/A	N/A	N/A	N/A
Urinary System	1,035	59.7	0.85	70.6	0.99	457	23.1	0.51	27.2	0.58
Bladder (incl. <i>in situ</i>)	596	34.3	0.64	40.2	0.75	160	7.6	0.28	8.9	0.32
Kidney & renal pelvis	420	24.2	0.55	29.0	0.64	285	15.0	0.42	17.6	0.48
Ureter	12	0.7	0.09	0.8	0.11	9	0.4	0.06	0.5	0.07
Eye & Orbit	20	1.2	0.12	1.4	0.14	15	0.8	0.10	0.9	0.11
Brain & Other CNS	121	7.9	0.33	8.7	0.36	102	5.8	0.27	6.5	0.29
Brain	115	7.4	0.32	8.2	0.35	97	5.5	0.27	6.1	0.29
Endocrine System	113	7.3	0.32	8.2	0.35	284	19.0	0.53	20.5	0.56
Thyroid gland	101	6.6	0.30	7.4	0.33	271	18.2	0.52	19.6	0.54
Lymphomas	374	22.7	0.54	26.0	0.61	324	16.8	0.44	19.4	0.50
Hodgkin lymphoma	33	2.4	0.19	2.5	0.19	29	2.0	0.18	2.1	0.18
Non-Hodgkin lymphoma	341	20.3	0.51	23.5	0.58	295	14.8	0.40	17.3	0.46
Multiple Myeloma	129	7.2	0.29	8.6	0.34	84	4.1	0.21	4.8	0.24
Leukemias	278	16.7	0.46	19.0	0.52	191	10.1	0.35	11.4	0.38
Acute lymphocytic	22	1.7	0.17	1.6	0.15	14	1.1	0.14	1.0	0.12
Chronic lymphocytic	108	6.1	0.27	7.2	0.32	71	3.3	0.18	4.0	0.22
Acute myeloid	78	4.6	0.24	5.3	0.27	61	3.3	0.20	3.8	0.22
Chronic myeloid	40	2.5	0.18	2.8	0.20	25	1.4	0.13	1.6	0.15
Other leukemias	30	1.8	0.15	2.1	0.17	18	0.9	0.10	1.0	0.11
Mesothelioma	19	1.1	0.11	1.2	0.13	7	0.4	0.06	0.4	0.07
Kaposi Sarcoma	4	0.3	0.07	0.3	0.07	*	*	*	*	*
Ill-Defined & Unknown	360	21.0	0.51	24.8	0.59	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	123	7.6	0.32	8.6	0.35	225	12.6	0.40	14.4	0.44
Breast (<i>in situ</i>)	*	*	*	*	*	369	20.1	0.50	23.9	0.57

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Oklahoma, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	651	508.2	9.62	612.5	11.31	607	403.1	7.55	475.4	8.75
Oral Cavity & Pharynx	14	11.3	1.45	13.3	1.69	8	4.6	0.76	5.8	0.93
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	4	3.3	0.80	3.6	0.88	1	0.8	0.33	1.0	0.40
Major salivary gland	2	2.0	0.67	2.3	0.80	1	0.8	0.30	1.0	0.37
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	0.8	0.31	1.1	0.41	*	*	*	*	*
Nasopharynx	*	*	*	*	*	1	0.8	0.30	1.0	0.38
Oropharynx	1	1.0	0.40	1.2	0.47	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	132	101.3	4.26	123.0	5.03	121	80.4	3.37	96.6	3.98
Esophagus	6	4.9	0.97	5.8	1.11	3	1.9	0.49	2.5	0.62
Stomach	13	11.5	1.53	13.6	1.77	11	7.4	1.05	8.8	1.22
Small intestine	6	4.4	0.87	5.2	1.00	5	3.3	0.65	4.1	0.79
Colon (excl. rectum)	43	35.5	2.62	42.0	3.04	44	29.7	2.07	34.9	2.40
Rectum & rectosigmoid	17	12.3	1.43	15.2	1.72	15	9.9	1.16	12.3	1.42
Anus, anal canal, & anorectum	3	2.1	0.56	2.4	0.63	3	2.2	0.56	2.7	0.65
Liver	21	12.8	1.30	17.0	1.69	8	4.9	0.81	6.1	1.00
Gallbladder	*	*	*	*	*	3	2.1	0.57	2.6	0.67
Pancreas	18	13.8	1.58	17.0	1.88	21	14.3	1.43	17.3	1.69
Respiratory System	107	91.0	4.25	107.3	4.89	82	54.2	2.77	65.7	3.29
Larynx	9	7.9	1.26	9.3	1.44	2	1.1	0.36	1.5	0.47
Lung & bronchus	96	81.7	4.02	96.4	4.63	79	52.6	2.73	63.6	3.24
Bones & Joints	1	0.8	0.29	0.8	0.31	2	1.0	0.38	1.0	0.36
Soft Tissue (incl. heart)	6	4.2	0.86	4.5	0.96	5	3.2	0.67	3.6	0.76
Skin (excl. basal & sq.)	1	1.0	0.40	1.2	0.46	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	*	*	*	*	*	2	1.1	0.42	1.3	0.46
Breast (excl. <i>in situ</i>)	3	2.4	0.68	2.7	0.76	188	126.3	4.25	147.5	4.87
Female Genital System	N/A	N/A	N/A	N/A	N/A	70	45.5	2.50	53.4	2.88
Cervix uteri	N/A	N/A	N/A	N/A	N/A	13	8.7	1.10	9.7	1.21
Uterus corpus	N/A	N/A	N/A	N/A	N/A	39	25.0	1.83	30.1	2.17
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	1.4	0.44	1.7	0.51
Ovary	N/A	N/A	N/A	N/A	N/A	12	8.1	1.06	9.3	1.19
Male Genital System	232	172.5	5.44	214.3	6.54	N/A	N/A	N/A	N/A	N/A
Prostate	228	170.3	5.41	211.9	6.51	N/A	N/A	N/A	N/A	N/A
Testis	2	1.3	0.44	1.3	0.41	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	56	47.0	3.08	56.7	3.64	32	21.4	1.74	25.5	2.03
Bladder (incl. <i>in situ</i>)	22	20.1	2.10	23.9	2.44	11	7.9	1.08	9.3	1.27
Kidney & renal pelvis	33	25.3	2.15	31.0	2.59	21	13.4	1.35	16.0	1.58
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	1	0.7	0.29	0.6	0.27	*	*	*	*	*
Brain & Other CNS	6	5.0	0.97	5.4	1.07	4	2.6	0.57	3.0	0.65
Brain	6	5.0	0.97	5.4	1.07	4	2.6	0.57	3.0	0.65
Endocrine System	7	4.8	0.88	5.6	1.02	20	13.8	1.41	15.2	1.53
Thyroid gland	5	3.6	0.78	4.2	0.90	19	13.0	1.36	14.3	1.49
Lymphomas	23	17.7	1.76	20.1	1.97	20	12.6	1.31	14.5	1.49
Hodgkin lymphoma	3	1.8	0.46	1.9	0.49	4	2.7	0.60	2.8	0.62
Non-Hodgkin lymphoma	20	15.9	1.70	18.2	1.91	15	10.0	1.17	11.7	1.35
Multiple Myeloma	20	16.1	1.73	19.4	2.03	18	12.4	1.34	14.8	1.57
Leukemias	20	15.3	1.65	17.7	1.88	13	8.3	1.07	9.4	1.21
Acute lymphocytic	1	0.7	0.28	0.7	0.26	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	6	4.1	0.81	5.3	1.01	3	2.0	0.54	2.3	0.63
Acute myeloid	7	6.1	1.12	6.9	1.25	5	3.1	0.65	3.6	0.75
Chronic myeloid	4	2.9	0.71	3.3	0.78	2	1.3	0.41	1.3	0.43
Other leukemias	2	1.4	0.49	1.5	0.52	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	1	0.8	0.33	0.8	0.34	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	21	14.8	1.48	17.5	1.72
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	11	8.3	1.16	9.5	1.32	23	15.0	1.44	16.9	1.60
Breast (<i>in situ</i>)	*	*	*	*	*	38	24.7	1.86	29.4	2.16

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Oklahoma, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	97	307.1	15.40	359.3	17.72	140	314.2	12.48	361.8	14.32
Oral Cavity & Pharynx	4	12.5	2.80	13.8	3.15	2	5.0	1.59	5.7	1.82
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	2	4.9	1.76	5.4	2.03	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	29	91.9	8.26	108.0	9.59	26	64.6	5.92	75.7	6.88
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	4	10.5	2.49	12.5	2.92	3	8.0	2.00	8.9	2.24
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	8	25.9	4.59	30.0	5.33	10	23.0	3.48	27.2	4.11
Rectum & rectosigmoid	4	10.2	2.48	11.8	2.79	4	8.6	2.10	10.7	2.57
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	8	24.4	4.22	29.4	5.01	2	5.7	1.73	6.6	1.99
Gallbladder	*	*	*	*	*	1	3.4	1.31	4.0	1.57
Pancreas	2	5.6	1.73	6.9	2.09	3	8.7	2.30	10.0	2.62
Respiratory System	12	40.2	5.73	48.7	6.69	14	36.5	4.53	42.8	5.21
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	11	37.6	5.63	45.0	6.52	14	36.5	4.53	42.8	5.21
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	1	3.7	1.47	3.9	1.60
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	44	92.6	6.48	108.1	7.53
Female Genital System	N/A	N/A	N/A	N/A	N/A	21	45.8	4.64	53.3	5.36
Cervix uteri	N/A	N/A	N/A	N/A	N/A	5	9.8	2.10	11.0	2.39
Uterus corpus	N/A	N/A	N/A	N/A	N/A	8	16.5	2.73	19.5	3.20
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	7	16.0	2.79	18.7	3.19
Male Genital System	20	63.1	6.82	75.2	7.91	N/A	N/A	N/A	N/A	N/A
Prostate	19	62.0	6.79	74.2	7.89	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	8	27.3	4.94	32.1	5.64	3	6.7	1.88	8.1	2.24
Bladder (incl. <i>in situ</i>)	3	12.6	3.52	14.4	3.93	*	*	*	*	*
Kidney & renal pelvis	4	13.2	3.27	16.0	3.86	2	4.6	1.51	5.6	1.84
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	4.0	1.41	4.6	1.64	2	3.4	1.18	3.7	1.36
Brain	2	3.6	1.35	4.3	1.61	2	3.1	1.16	3.5	1.33
Endocrine System	4	8.6	2.05	10.1	2.46	11	20.5	2.88	20.7	2.97
Thyroid gland	3	7.3	1.84	8.6	2.23	11	20.0	2.85	20.3	2.95
Lymphomas	6	20.1	4.14	22.5	4.59	6	14.5	2.78	16.4	3.09
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	2	4.7	1.76	5.3	1.94
Leukemias	4	12.4	2.95	13.7	3.33	4	8.7	1.97	9.5	2.20
Acute lymphocytic	1	2.2	0.93	2.1	0.89	1	2.0	0.85	2.0	0.85
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	2	5.9	2.07	6.8	2.39	1	2.8	1.17	3.1	1.36
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	4	16.9	4.25	19.7	4.84	2	5.7	1.76	7.0	2.12
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	2	5.2	1.87	5.6	2.10	6	11.4	2.25	13.5	2.64
Breast (<i>in situ</i>)	*	*	*	*	*	10	20.0	2.96	23.7	3.47

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Oklahoma, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	996	675.3	10.23	801.2	12.01	1,018	576.6	8.31	672.7	9.58
Oral Cavity & Pharynx	40	25.2	1.87	30.7	2.25	16	8.7	1.01	10.4	1.19
Lip	4	2.7	0.66	3.3	0.78	1	0.9	0.34	1.0	0.40
Tongue	9	5.6	0.84	6.8	1.01	4	2.2	0.49	2.8	0.59
Major salivary gland	3	1.9	0.57	2.1	0.62	2	1.2	0.39	1.3	0.43
Floor of mouth	1	0.7	0.31	1.0	0.41	*	*	*	*	*
Gum & other mouth	4	2.4	0.60	2.9	0.74	3	1.5	0.42	1.9	0.51
Nasopharynx	2	1.3	0.48	1.5	0.55	1	0.6	0.24	0.7	0.29
Oropharynx	4	2.3	0.56	2.7	0.66	*	*	*	*	*
Hypopharynx	2	1.5	0.46	1.8	0.55	*	*	*	*	*
Digestive System	237	159.6	4.97	193.6	5.94	182	104.5	3.58	123.8	4.19
Esophagus	18	12.0	1.40	14.8	1.70	5	2.8	0.59	3.4	0.70
Stomach	14	11.1	1.42	13.2	1.68	13	7.2	0.92	8.4	1.06
Small intestine	6	4.2	0.84	5.0	0.97	4	2.2	0.51	2.5	0.58
Colon (excl. rectum)	77	54.6	3.02	65.4	3.58	70	40.5	2.23	47.5	2.59
Rectum & rectosigmoid	38	24.2	1.82	29.3	2.18	25	14.6	1.33	17.2	1.56
Anus, anal canal, & anorectum	3	1.6	0.45	2.0	0.55	5	3.1	0.62	3.7	0.72
Liver	45	26.9	1.88	33.6	2.30	22	12.0	1.19	14.6	1.44
Gallbladder	*	*	*	*	*	4	2.1	0.49	2.7	0.60
Pancreas	25	16.7	1.58	20.3	1.87	25	14.7	1.36	17.5	1.60
Respiratory System	175	123.6	4.47	147.0	5.23	150	85.0	3.20	102.2	3.79
Larynx	15	9.7	1.16	11.9	1.39	6	3.5	0.65	4.3	0.78
Lung & bronchus	156	111.9	4.28	132.5	5.00	143	80.9	3.13	97.2	3.70
Bones & Joints	4	2.2	0.52	2.2	0.54	2	1.1	0.37	1.1	0.36
Soft Tissue (incl. heart)	8	5.1	0.88	5.7	0.99	5	2.9	0.58	3.1	0.63
Skin (excl. basal & sq.)	37	23.3	1.79	27.2	2.06	30	17.2	1.45	19.4	1.63
Melanoma of the skin	34	21.7	1.73	25.5	2.00	27	15.7	1.38	17.8	1.56
Breast (excl. <i>in situ</i>)	1	0.9	0.36	1.1	0.41	265	148.3	4.18	174.4	4.84
Female Genital System	N/A	N/A	N/A	N/A	N/A	121	67.7	2.82	78.1	3.22
Cervix uteri	N/A	N/A	N/A	N/A	N/A	25	15.1	1.37	15.8	1.43
Uterus corpus	N/A	N/A	N/A	N/A	N/A	56	30.2	1.85	36.2	2.18
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	3	1.6	0.44	1.9	0.51
Ovary	N/A	N/A	N/A	N/A	N/A	26	14.7	1.32	16.8	1.50
Male Genital System	195	127.9	4.37	154.4	5.19	N/A	N/A	N/A	N/A	N/A
Prostate	176	117.2	4.22	143.4	5.07	N/A	N/A	N/A	N/A	N/A
Testis	17	9.2	1.03	9.0	1.01	N/A	N/A	N/A	N/A	N/A
Penis	2	1.4	0.43	1.8	0.52	N/A	N/A	N/A	N/A	N/A
Urinary System	134	94.2	3.88	110.0	4.50	73	41.2	2.22	48.4	2.57
Bladder (incl. <i>in situ</i>)	46	36.5	2.61	42.7	3.05	14	7.9	0.98	9.5	1.16
Kidney & renal pelvis	88	57.2	2.86	66.9	3.31	58	32.9	1.98	38.4	2.28
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	2	1.1	0.36	1.3	0.41	2	0.8	0.28	0.8	0.31
Brain & Other CNS	14	8.8	1.15	9.7	1.32	12	6.8	0.90	7.5	0.99
Brain	13	8.4	1.13	9.3	1.30	11	6.3	0.86	6.9	0.95
Endocrine System	15	10.0	1.24	11.0	1.40	47	27.4	1.82	29.1	1.93
Thyroid gland	13	8.6	1.15	9.6	1.30	45	26.1	1.77	27.9	1.89
Lymphomas	43	28.8	2.10	33.3	2.43	37	21.5	1.61	24.2	1.80
Hodgkin lymphoma	5	2.8	0.58	2.9	0.61	4	2.2	0.49	2.4	0.53
Non-Hodgkin lymphoma	38	25.9	2.02	30.4	2.35	33	19.3	1.54	21.8	1.72
Multiple Myeloma	15	10.6	1.29	12.5	1.50	16	9.1	1.06	10.7	1.24
Leukemias	33	22.2	1.87	24.7	2.11	22	12.2	1.19	13.6	1.34
Acute lymphocytic	7	3.4	0.62	3.3	0.65	5	2.6	0.52	2.4	0.50
Chronic lymphocytic	7	5.5	1.01	6.3	1.15	5	2.8	0.60	3.4	0.72
Acute myeloid	10	6.7	1.02	7.6	1.16	6	3.3	0.60	3.7	0.67
Chronic myeloid	6	4.6	0.87	5.2	1.01	4	2.4	0.54	2.7	0.61
Other leukemias	3	2.0	0.53	2.3	0.60	2	1.2	0.38	1.3	0.44
Mesothelioma	2	1.7	0.52	1.8	0.57	*	*	*	*	*
Kaposi Sarcoma	2	0.9	0.31	0.9	0.32	*	*	*	*	*
Ill-Defined & Unknown	39	29.2	2.23	34.1	2.58	37	21.6	1.63	25.3	1.88
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	15	9.9	1.23	11.2	1.37	32	19.0	1.55	21.2	1.73
Breast (<i>in situ</i>)	*	*	*	*	*	44	24.0	1.65	28.8	1.95

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Oklahoma, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	306	325.4	9.81	385.6	11.39	357	339.8	8.96	397.8	10.46
Oral Cavity & Pharynx	8	8.9	1.59	10.6	1.85	5	4.8	1.01	5.7	1.20
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	3	3.1	0.97	3.6	1.11	*	*	*	*	*
Major salivary gland	*	*	*	*	*	2	1.3	0.55	1.5	0.61
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	79	84.8	4.97	101.0	5.78	59	63.3	4.10	74.6	4.75
Esophagus	3	3.6	1.13	4.1	1.25	*	*	*	*	*
Stomach	8	9.6	1.76	11.2	2.03	6	6.1	1.27	6.8	1.38
Small intestine	1	0.9	0.36	1.0	0.43	2	1.5	0.59	1.8	0.72
Colon (excl. rectum)	24	25.0	2.67	30.0	3.13	21	23.3	2.53	26.4	2.86
Rectum & rectosigmoid	14	13.8	1.95	16.2	2.25	7	5.9	1.09	7.2	1.31
Anus, anal canal, & anorectum	*	*	*	*	*	2	3.0	0.99	3.5	1.12
Liver	13	12.6	1.80	15.8	2.18	7	7.5	1.38	9.4	1.68
Gallbladder	2	1.9	0.75	2.3	0.84	2	1.9	0.69	2.2	0.79
Pancreas	10	12.2	1.94	14.4	2.22	8	9.3	1.59	11.3	1.89
Respiratory System	31	39.2	3.56	47.5	4.20	26	32.7	3.07	37.8	3.47
Larynx	3	3.9	1.13	4.5	1.26	*	*	*	*	*
Lung & bronchus	26	34.4	3.35	41.9	3.98	24	30.4	2.98	35.2	3.37
Bones & Joints	1	1.0	0.52	1.0	0.58	2	0.8	0.28	0.8	0.29
Soft Tissue (incl. heart)	5	3.8	0.92	4.2	1.06	3	2.5	0.70	2.7	0.77
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	7	7.1	1.44	8.4	1.68	6	5.9	1.25	7.0	1.49
Breast (excl. <i>in situ</i>)	*	*	*	*	*	100	92.0	4.47	109.5	5.32
Female Genital System	N/A	N/A	N/A	N/A	N/A	58	50.3	3.24	59.5	3.84
Cervix uteri	N/A	N/A	N/A	N/A	N/A	17	12.2	1.43	13.5	1.65
Uterus corpus	N/A	N/A	N/A	N/A	N/A	26	24.8	2.38	30.2	2.85
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	1	1.4	0.61	1.7	0.73
Ovary	N/A	N/A	N/A	N/A	N/A	12	10.1	1.43	11.8	1.67
Male Genital System	69	75.1	4.70	89.3	5.40	N/A	N/A	N/A	N/A	N/A
Prostate	58	69.9	4.62	83.8	5.32	N/A	N/A	N/A	N/A	N/A
Testis	9	4.0	0.59	3.9	0.59	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	34	40.1	3.62	47.8	4.24	19	18.7	2.16	22.1	2.52
Bladder (incl. <i>in situ</i>)	11	17.1	2.61	20.6	3.09	3	3.5	1.03	4.1	1.18
Kidney & renal pelvis	23	22.1	2.43	26.0	2.83	16	14.8	1.86	17.6	2.19
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	8	5.1	0.99	5.8	1.13	6	4.2	0.92	4.7	1.07
Brain	8	5.1	0.99	5.7	1.13	6	4.1	0.91	4.6	1.07
Endocrine System	8	6.0	1.20	7.0	1.42	25	17.2	1.66	18.8	1.88
Thyroid gland	7	5.3	1.17	6.2	1.37	25	17.0	1.65	18.5	1.87
Lymphomas	19	17.0	2.02	20.3	2.36	16	16.1	1.99	19.0	2.32
Hodgkin lymphoma	4	2.5	0.62	3.0	0.77	2	1.2	0.51	1.2	0.56
Non-Hodgkin lymphoma	15	14.5	1.93	17.2	2.23	15	14.9	1.93	17.7	2.25
Multiple Myeloma	5	5.6	1.31	6.4	1.47	5	5.6	1.19	6.8	1.42
Leukemias	15	11.4	1.68	12.7	1.90	14	11.5	1.64	12.8	1.89
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	4	2.0	0.52	1.9	0.55
Chronic lymphocytic	1	2.1	0.92	2.4	1.06	2	2.8	0.96	3.4	1.15
Acute myeloid	4	3.1	0.86	3.5	0.96	5	4.1	0.99	4.6	1.13
Chronic myeloid	3	2.7	0.77	3.1	0.90	2	1.1	0.40	1.2	0.44
Other leukemias	*	*	*	*	*	2	1.5	0.61	1.7	0.69
Mesothelioma	1	1.6	0.68	2.0	0.82	*	*	*	*	*
Kaposi Sarcoma	1	0.8	0.34	1.0	0.46	*	*	*	*	*
Ill-Defined & Unknown	13	16.4	2.43	19.0	2.78	11	12.6	1.90	14.3	2.15
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	6	4.4	1.04	4.9	1.17	16	16.8	2.16	18.7	2.41
Breast (<i>in situ</i>)	*	*	*	*	*	20	18.3	1.98	21.2	2.28

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

OKLAHOMA

II-408 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Oklahoma, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	234	280.1	9.54	331.9	11.06	293	313.9	9.01	366.2	10.49
Oral Cavity & Pharynx	7	8.8	1.71	10.5	1.97	4	4.6	1.06	5.5	1.26
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	3.1	1.05	3.5	1.19	*	*	*	*	*
Major salivary gland	*	*	*	*	*	1	1.2	0.55	1.2	0.59
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	58	71.2	4.81	84.0	5.54	47	56.6	4.03	66.4	4.67
Esophagus	1	2.3	0.94	2.5	1.02	*	*	*	*	*
Stomach	6	8.9	1.82	10.3	2.09	4	5.3	1.24	5.9	1.35
Small intestine	1	0.9	0.38	1.0	0.46	1	1.1	0.44	1.3	0.56
Colon (excl. rectum)	18	21.8	2.71	25.9	3.14	17	20.4	2.44	22.8	2.73
Rectum & rectosigmoid	11	12.3	1.92	14.4	2.20	5	5.3	1.10	6.5	1.33
Anus, anal canal, & anorectum	*	*	*	*	*	2	3.3	1.07	3.9	1.21
Liver	9	10.3	1.70	12.8	2.05	6	7.2	1.43	9.0	1.73
Gallbladder	*	*	*	*	*	2	2.2	0.76	2.5	0.87
Pancreas	8	10.2	1.85	11.8	2.07	6	7.8	1.53	9.5	1.84
Respiratory System	24	33.3	3.38	40.4	4.01	22	30.8	3.13	35.3	3.52
Larynx	3	3.7	1.13	4.3	1.28	*	*	*	*	*
Lung & bronchus	20	28.8	3.16	35.3	3.77	20	28.6	3.03	32.8	3.41
Bones & Joints	1	1.0	0.58	1.0	0.64	*	*	*	*	*
Soft Tissue (incl. heart)	3	2.1	0.73	2.3	0.86	2	1.5	0.54	1.6	0.61
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	6	7.6	1.57	9.1	1.82	5	5.4	1.20	6.3	1.42
Breast (excl. <i>in situ</i>)	*	*	*	*	*	85	88.7	4.63	105.3	5.50
Female Genital System	N/A	N/A	N/A	N/A	N/A	47	45.8	3.24	53.9	3.83
Cervix uteri	N/A	N/A	N/A	N/A	N/A	13	10.6	1.39	11.5	1.56
Uterus corpus	N/A	N/A	N/A	N/A	N/A	22	23.0	2.39	27.7	2.86
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	9	9.3	1.46	10.9	1.71
Male Genital System	53	64.3	4.56	76.3	5.24	N/A	N/A	N/A	N/A	N/A
Prostate	44	59.6	4.48	71.3	5.15	N/A	N/A	N/A	N/A	N/A
Testis	7	3.5	0.60	3.5	0.59	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	29	37.4	3.63	44.6	4.27	16	17.5	2.17	20.6	2.52
Bladder (incl. <i>in situ</i>)	9	15.7	2.58	19.0	3.06	2	2.8	0.93	3.2	1.04
Kidney & renal pelvis	19	20.6	2.46	24.4	2.88	13	14.3	1.91	17.0	2.26
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	5	4.1	0.98	4.9	1.13	5	4.2	0.98	4.8	1.16
Brain	5	4.1	0.97	4.8	1.13	5	4.1	0.98	4.7	1.15
Endocrine System	6	4.9	1.13	5.5	1.29	21	16.7	1.74	18.1	1.96
Thyroid gland	5	4.5	1.11	5.2	1.28	21	16.7	1.74	18.1	1.96
Lymphomas	15	15.3	2.06	18.3	2.41	12	13.6	1.92	15.9	2.20
Hodgkin lymphoma	3	2.1	0.62	2.6	0.78	*	*	*	*	*
Non-Hodgkin lymphoma	12	13.2	1.97	15.7	2.28	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	3	4.2	1.18	4.9	1.34	4	5.2	1.21	6.4	1.45
Leukemias	11	9.6	1.63	10.6	1.82	10	9.5	1.56	10.6	1.80
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	3	1.6	0.51	1.5	0.52
Chronic lymphocytic	1	2.3	1.00	2.6	1.15	1	2.0	0.83	2.7	1.06
Acute myeloid	3	2.8	0.86	3.1	0.95	3	3.1	0.92	3.5	1.04
Chronic myeloid	2	2.1	0.76	2.5	0.85	2	1.3	0.46	1.3	0.50
Other leukemias	*	*	*	*	*	1	1.4	0.64	1.6	0.73
Mesothelioma	1	1.8	0.76	2.2	0.91	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	9	12.7	2.18	15.0	2.52	9	11.8	1.90	13.2	2.14
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	4	4.2	1.09	4.6	1.21	12	14.5	2.08	16.0	2.32
Breast (<i>in situ</i>)	*	*	*	*	*	17	17.9	2.08	20.6	2.38

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Oklahoma, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3	146.6	44.21	175.9	51.46	5	183.2	44.86	215.5	50.53
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	1	36.9	16.26	45.6	19.82
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	1	48.9	23.86	59.4	27.90
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.


N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	4,018,542	4,093,271	4,147,294	4,183,538	4,216,116
Non-Hispanic White	3,155,338	3,195,669	3,220,857	3,234,116	3,245,175
Non-Hispanic Black	95,053	98,825	101,825	104,657	107,305
Non-Hispanic Asian/Pacific Islander (NH API)	207,712	220,806	229,017	234,674	239,495
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	53,138	53,968	54,463	54,933	55,394


All Races Population 2015–2019: 20,658,761
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	505,555	522,214	539,292	553,289	566,811
Hispanic White	448,970	463,168	478,037	489,706	501,146
Hispanic Black	13,499	14,099	14,611	15,200	15,736

Hispanic/Latino Population, Census 2010: 450,062
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

OREGON CANCER REGISTRY

Initial Operation: 1996
Population-based Data Available: 1996
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	104.8	101.4	103.8	96.2	96.2	100.5
Missing Race	0.5	0.9	1.3	0.8	0.9	0.9
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	3.1	3.0	2.1	1.6	2.1	2.4
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.5	Ovary	91.0
Oral Cavity & Pharynx	98.1	Prostate	96.6
Esophagus	95.3	Testis	99.7
Stomach	96.1	Bladder (incl. <i>in situ</i>)	97.6
Colon & Rectum	95.2	Kidney & Renal Pelvis	91.1
Liver	41.1	Brain & Other CNS	86.2
Pancreas	84.1	Brain & Other CNS (non-malig)	53.0
Lung & Bronchus	84.1	Thyroid	99.4
Melanomas of the Skin	99.3	Hodgkin Lymphoma	99.0
Female Breast (excl. <i>in situ</i>)	98.8	Non-Hodgkin Lymphoma	96.5
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	88.6
Cervix Uteri	95.9	Leukemias	90.9
Uterus Corpus & Uterus NOS	98.6		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Oregon, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	11,180	449.3	1.96	532.5	2.29	11,147	416.5	1.83	486.5	2.10
Oral Cavity & Pharynx	469	18.5	0.39	22.6	0.47	183	6.8	0.23	8.0	0.27
Lip	17	0.7	0.08	0.8	0.09	10	0.4	0.05	0.4	0.06
Tongue	171	6.6	0.23	8.2	0.28	60	2.2	0.14	2.7	0.16
Major salivary gland	30	1.3	0.11	1.5	0.12	27	1.0	0.09	1.2	0.11
Floor of mouth	19	0.8	0.08	0.9	0.10	9	0.3	0.05	0.4	0.06
Gum & other mouth	45	1.8	0.13	2.2	0.15	37	1.3	0.10	1.6	0.12
Nasopharynx	15	0.7	0.08	0.8	0.09	5	0.2	0.04	0.2	0.05
Oropharynx	29	1.1	0.10	1.4	0.12	8	0.3	0.05	0.3	0.05
Hypopharynx	18	0.7	0.07	0.8	0.09	7	0.2	0.04	0.3	0.05
Digestive System	2,225	89.6	0.87	107.6	1.04	1,657	60.3	0.69	71.1	0.80
Esophagus	216	8.5	0.27	10.2	0.32	50	1.8	0.11	2.1	0.14
Stomach	166	6.8	0.24	8.1	0.29	91	3.4	0.17	3.9	0.19
Small intestine	67	2.8	0.15	3.3	0.18	52	1.9	0.12	2.3	0.14
Colon (excl. rectum)	586	24.6	0.47	29.0	0.55	599	22.1	0.42	25.7	0.48
Rectum & rectosigmoid	318	13.1	0.34	15.8	0.40	203	7.8	0.25	9.3	0.30
Anus, anal canal, & anorectum	38	1.6	0.12	1.9	0.14	77	2.7	0.14	3.3	0.17
Liver	335	12.1	0.30	15.5	0.38	108	3.7	0.16	4.5	0.20
Gallbladder	20	0.9	0.09	1.0	0.10	34	1.2	0.09	1.4	0.11
Pancreas	367	14.7	0.35	17.5	0.41	324	11.3	0.29	13.4	0.34
Respiratory System	1,481	59.3	0.71	70.5	0.83	1,447	50.3	0.61	59.7	0.71
Larynx	92	3.5	0.17	4.4	0.21	22	0.7	0.07	0.9	0.09
Lung & bronchus	1,364	54.7	0.68	64.9	0.80	1,409	49.0	0.60	58.1	0.70
Bones & Joints	25	1.2	0.11	1.2	0.11	16	0.8	0.09	0.8	0.09
Soft Tissue (incl. heart)	78	3.4	0.18	3.9	0.20	70	2.8	0.16	3.1	0.17
Skin (excl. basal & sq.)	777	32.2	0.53	37.8	0.62	578	22.7	0.44	26.0	0.49
Melanoma of the skin	736	30.5	0.52	35.8	0.60	552	21.7	0.43	24.9	0.48
Breast (excl. <i>in situ</i>)	26	1.1	0.10	1.3	0.12	3,468	130.8	1.04	153.9	1.20
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,402	52.2	0.65	62.0	0.76
Cervix uteri	N/A	N/A	N/A	N/A	N/A	146	6.8	0.26	7.2	0.27
Uterus corpus	N/A	N/A	N/A	N/A	N/A	797	28.6	0.47	35.0	0.57
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	28	1.1	0.09	1.3	0.11
Ovary	N/A	N/A	N/A	N/A	N/A	289	10.8	0.30	12.7	0.34
Male Genital System	2,764	103.9	0.91	125.8	1.09	N/A	N/A	N/A	N/A	N/A
Prostate	2,610	96.4	0.87	118.2	1.05	N/A	N/A	N/A	N/A	N/A
Testis	131	6.5	0.26	6.5	0.25	N/A	N/A	N/A	N/A	N/A
Penis	17	0.7	0.08	0.9	0.09	N/A	N/A	N/A	N/A	N/A
Urinary System	1,424	58.6	0.71	69.0	0.83	547	19.7	0.39	23.2	0.45
Bladder (incl. <i>in situ</i>)	853	35.3	0.55	41.4	0.65	254	8.9	0.26	10.5	0.30
Kidney & renal pelvis	540	22.0	0.44	26.0	0.51	277	10.3	0.29	12.1	0.33
Ureter	19	0.8	0.09	1.0	0.10	11	0.4	0.05	0.4	0.06
Eye & Orbit	33	1.4	0.11	1.6	0.13	29	1.1	0.09	1.2	0.10
Brain & Other CNS	185	8.1	0.27	8.9	0.30	128	5.4	0.22	5.7	0.23
Brain	180	7.9	0.27	8.7	0.29	121	5.0	0.21	5.4	0.22
Endocrine System	173	7.7	0.27	8.5	0.29	447	20.2	0.44	21.7	0.47
Thyroid gland	151	6.7	0.25	7.4	0.27	432	19.5	0.44	21.0	0.46
Lymphomas	584	24.7	0.47	28.3	0.53	452	17.0	0.37	19.5	0.42
Hodgkin lymphoma	57	2.6	0.16	2.8	0.17	45	2.2	0.15	2.2	0.15
Non-Hodgkin lymphoma	527	22.1	0.44	25.6	0.51	406	14.9	0.34	17.4	0.39
Multiple Myeloma	168	6.8	0.24	8.1	0.28	116	4.1	0.18	4.9	0.21
Leukemias	376	16.2	0.38	18.3	0.43	272	10.4	0.29	11.7	0.32
Acute lymphocytic	36	1.9	0.14	1.7	0.13	30	1.6	0.13	1.4	0.12
Chronic lymphocytic	142	5.8	0.22	6.9	0.26	99	3.4	0.16	4.1	0.19
Acute myeloid	113	4.8	0.21	5.5	0.24	90	3.4	0.17	3.9	0.19
Chronic myeloid	43	1.9	0.13	2.1	0.15	32	1.2	0.10	1.4	0.11
Other leukemias	41	1.8	0.13	2.0	0.14	22	0.8	0.08	0.9	0.09
Mesothelioma	32	1.4	0.11	1.5	0.12	10	0.4	0.06	0.4	0.06
Kaposi Sarcoma	8	0.4	0.06	0.4	0.06	*	*	*	*	*
Ill-Defined & Unknown	351	14.8	0.36	17.2	0.42	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	162	7.1	0.26	8.0	0.28	304	12.0	0.32	13.7	0.36
Breast (<i>in situ</i>)	2	0.1	0.02	0.1	0.03	652	25.2	0.46	29.9	0.54

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Oregon, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	10,017	454.7	2.11	538.6	2.46	9,906	423.3	2.02	494.0	2.30
Oral Cavity & Pharynx	431	19.4	0.43	23.7	0.52	167	7.1	0.26	8.3	0.30
Lip	16	0.7	0.09	0.9	0.10	9	0.4	0.06	0.4	0.07
Tongue	161	7.1	0.26	8.7	0.31	55	2.4	0.16	2.9	0.18
Major salivary gland	28	1.4	0.12	1.6	0.14	22	1.0	0.10	1.1	0.11
Floor of mouth	18	0.8	0.09	1.0	0.10	9	0.4	0.06	0.5	0.07
Gum & other mouth	41	1.9	0.14	2.2	0.16	34	1.4	0.11	1.6	0.13
Nasopharynx	9	0.5	0.07	0.5	0.08	3	0.1	0.03	0.2	0.04
Oropharynx	28	1.2	0.11	1.5	0.13	7	0.3	0.05	0.4	0.06
Hypopharynx	15	0.6	0.07	0.8	0.09	6	0.3	0.05	0.3	0.06
Digestive System	1,937	88.1	0.93	105.8	1.10	1,432	58.6	0.73	69.0	0.84
Esophagus	203	9.0	0.29	10.8	0.34	46	1.8	0.12	2.2	0.15
Stomach	138	6.3	0.25	7.5	0.29	64	2.7	0.16	3.1	0.18
Small intestine	60	2.8	0.17	3.3	0.19	45	1.9	0.13	2.2	0.15
Colon (excl. rectum)	518	24.7	0.50	29.1	0.59	534	22.2	0.45	25.8	0.52
Rectum & rectosigmoid	276	13.1	0.37	15.8	0.43	174	7.7	0.28	9.1	0.32
Anus, anal canal, & anorectum	36	1.7	0.13	2.0	0.16	71	2.8	0.16	3.5	0.19
Liver	267	10.8	0.30	13.8	0.39	83	3.2	0.16	3.9	0.20
Gallbladder	17	0.8	0.09	0.9	0.10	27	1.0	0.09	1.2	0.11
Pancreas	330	14.8	0.37	17.5	0.44	290	11.3	0.31	13.3	0.36
Respiratory System	1,351	60.0	0.75	71.4	0.89	1,325	51.2	0.65	60.9	0.76
Larynx	85	3.7	0.19	4.6	0.23	19	0.8	0.08	1.0	0.10
Lung & bronchus	1,243	55.2	0.72	65.5	0.85	1,291	49.8	0.64	59.2	0.75
Bones & Joints	19	1.2	0.13	1.2	0.12	13	0.8	0.10	0.8	0.10
Soft Tissue (incl. heart)	68	3.4	0.19	3.9	0.22	59	2.9	0.18	3.2	0.19
Skin (excl. basal & sq.)	754	35.7	0.60	41.7	0.69	553	25.8	0.52	29.4	0.58
Melanoma of the skin	716	33.9	0.59	39.6	0.68	529	24.8	0.51	28.2	0.57
Breast (excl. <i>in situ</i>)	24	1.1	0.11	1.4	0.13	3,095	134.1	1.15	157.6	1.31
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,235	52.7	0.71	62.7	0.82
Cervix uteri	N/A	N/A	N/A	N/A	N/A	121	6.9	0.30	7.3	0.31
Uterus corpus	N/A	N/A	N/A	N/A	N/A	707	28.8	0.51	35.3	0.61
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	25	1.1	0.10	1.2	0.11
Ovary	N/A	N/A	N/A	N/A	N/A	253	10.8	0.32	12.7	0.37
Male Genital System	2,444	103.2	0.96	124.8	1.15	N/A	N/A	N/A	N/A	N/A
Prostate	2,317	95.1	0.91	116.7	1.10	N/A	N/A	N/A	N/A	N/A
Testis	107	7.1	0.31	7.1	0.31	N/A	N/A	N/A	N/A	N/A
Penis	14	0.7	0.08	0.8	0.09	N/A	N/A	N/A	N/A	N/A
Urinary System	1,295	59.6	0.76	70.1	0.89	490	19.8	0.42	23.4	0.49
Bladder (incl. <i>in situ</i>)	788	36.0	0.59	42.3	0.69	234	9.1	0.27	10.7	0.32
Kidney & renal pelvis	480	22.3	0.47	26.3	0.55	240	10.2	0.31	12.0	0.36
Ureter	17	0.8	0.09	0.9	0.10	10	0.4	0.06	0.4	0.06
Eye & Orbit	30	1.5	0.13	1.7	0.14	28	1.2	0.11	1.4	0.12
Brain & Other CNS	163	8.5	0.32	9.4	0.34	113	5.7	0.26	6.1	0.26
Brain	158	8.3	0.31	9.1	0.33	107	5.3	0.25	5.7	0.25
Endocrine System	148	8.0	0.31	8.8	0.33	355	19.7	0.49	21.1	0.51
Thyroid gland	130	7.0	0.29	7.7	0.31	343	19.0	0.49	20.5	0.51
Lymphomas	516	25.1	0.52	28.8	0.58	399	17.3	0.41	19.8	0.46
Hodgkin lymphoma	47	2.8	0.19	3.0	0.20	38	2.4	0.18	2.4	0.18
Non-Hodgkin lymphoma	469	22.3	0.48	25.8	0.55	362	14.9	0.37	17.4	0.42
Multiple Myeloma	149	6.7	0.25	8.0	0.30	101	4.0	0.18	4.7	0.22
Leukemias	334	16.4	0.42	18.7	0.47	241	10.5	0.33	11.9	0.35
Acute lymphocytic	24	1.7	0.16	1.5	0.14	21	1.5	0.15	1.3	0.13
Chronic lymphocytic	135	6.2	0.25	7.3	0.29	94	3.6	0.17	4.3	0.20
Acute myeloid	99	4.8	0.22	5.5	0.25	78	3.4	0.18	3.8	0.20
Chronic myeloid	38	1.9	0.14	2.1	0.16	29	1.2	0.11	1.4	0.12
Other leukemias	38	1.9	0.14	2.2	0.16	19	0.9	0.09	1.0	0.10
Mesothelioma	29	1.4	0.12	1.5	0.13	10	0.4	0.06	0.5	0.07
Kaposi Sarcoma	5	0.3	0.06	0.3	0.06	*	*	*	*	*
Ill-Defined & Unknown	320	15.0	0.39	17.5	0.45	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	140	7.3	0.29	8.1	0.32	257	11.8	0.35	13.5	0.39
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.03	569	25.4	0.51	30.1	0.59

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

OREGON

II-414 Incidence – NH White

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Oregon, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	199	526.9	18.61	630.9	21.60	133	373.5	14.98	441.9	17.57
Oral Cavity & Pharynx	5	10.5	2.33	12.3	2.65	2	6.1	1.90	6.9	2.13
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	43	112.3	8.39	133.0	9.60	26	77.1	6.94	91.6	8.13
Esophagus	2	4.5	1.74	5.0	1.85	*	*	*	*	*
Stomach	4	13.3	3.14	15.3	3.50	2	7.9	2.34	9.1	2.66
Small intestine	2	5.2	1.97	5.5	2.12	*	*	*	*	*
Colon (excl. rectum)	10	25.3	4.01	29.6	4.60	7	20.9	3.70	24.1	4.22
Rectum & rectosigmoid	3	7.7	1.98	9.5	2.36	3	8.0	2.18	9.4	2.53
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	13	31.3	4.15	38.8	4.93	4	9.8	2.39	12.4	2.93
Gallbladder	*	*	*	*	*	1	3.8	1.58	4.4	1.82
Pancreas	7	19.6	3.68	22.6	4.11	6	16.9	3.24	20.4	3.86
Respiratory System	27	82.6	8.06	98.9	9.40	18	53.4	5.82	65.4	6.98
Larynx	2	4.8	1.87	6.0	2.21	*	*	*	*	*
Lung & bronchus	25	75.6	7.69	90.0	8.92	18	52.2	5.75	63.8	6.89
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	40	110.7	8.01	130.1	9.33
Female Genital System	N/A	N/A	N/A	N/A	N/A	12	32.1	4.25	39.0	5.10
Cervix uteri	N/A	N/A	N/A	N/A	N/A	1	3.3	1.39	3.4	1.43
Uterus corpus	N/A	N/A	N/A	N/A	N/A	8	20.4	3.30	26.0	4.13
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	1	4.3	1.68	4.7	1.86
Male Genital System	67	171.0	10.41	209.6	12.21	N/A	N/A	N/A	N/A	N/A
Prostate	65	166.8	10.29	204.9	12.08	N/A	N/A	N/A	N/A	N/A
Testis	2	3.9	1.53	4.2	1.70	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	23	57.7	5.94	70.1	7.00	8	24.3	3.86	29.7	4.67
Bladder (incl. <i>in situ</i>)	8	20.9	3.57	25.1	4.09	3	10.7	2.66	13.1	3.22
Kidney & renal pelvis	14	34.6	4.53	42.5	5.44	5	13.7	2.80	16.6	3.39
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	3	6.3	1.81	7.2	2.10	2	4.1	1.51	4.7	1.73
Brain	3	6.0	1.78	6.9	2.09	*	*	*	*	*
Endocrine System	2	4.7	1.59	5.1	1.70	7	19.1	3.27	21.6	3.68
Thyroid gland	2	3.8	1.46	4.1	1.52	7	18.2	3.21	20.3	3.58
Lymphomas	9	19.9	3.24	23.0	3.67	5	13.5	2.92	14.8	3.22
Hodgkin lymphoma	1	2.1	0.86	2.3	0.96	1	3.4	1.36	3.3	1.34
Non-Hodgkin lymphoma	7	17.8	3.12	20.8	3.54	3	10.1	2.58	11.4	2.93
Multiple Myeloma	6	18.1	3.59	20.9	4.09	3	8.5	2.32	9.6	2.62
Leukemias	5	14.8	3.32	17.2	3.80	3	6.9	1.94	8.0	2.28
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	2	5.0	1.94	5.8	2.18	*	*	*	*	*
Acute myeloid	2	4.8	1.90	5.7	2.17	1	3.5	1.36	4.1	1.63
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	5	16.7	3.73	20.6	4.52	4	13.3	2.95	16.4	3.56
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	2	6.4	2.23	7.1	2.44	5	13.9	2.82	15.8	3.21
Breast (<i>in situ</i>)	*	*	*	*	*	8	20.9	3.43	25.6	4.12

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Oregon, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	253	313.3	9.25	367.3	10.72	350	303.9	7.47	352.0	8.61
Oral Cavity & Pharynx	12	13.3	1.80	15.1	2.05	6	5.2	0.95	6.1	1.12
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	3	2.9	0.82	3.3	0.95	1	1.2	0.48	1.4	0.55
Major salivary gland	*	*	*	*	*	1	1.1	0.41	1.3	0.51
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	1.6	0.62	1.8	0.70	1	1.1	0.46	1.3	0.54
Nasopharynx	5	5.2	1.05	6.2	1.25	2	1.5	0.50	1.6	0.56
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	81	99.5	5.17	117.8	6.04	69	62.7	3.47	74.1	4.05
Esophagus	4	4.9	1.17	5.9	1.39	*	*	*	*	*
Stomach	9	11.7	1.83	13.8	2.13	10	9.5	1.35	10.8	1.53
Small intestine	2	2.7	0.87	3.2	1.05	2	1.8	0.60	2.1	0.68
Colon (excl. rectum)	18	22.3	2.49	25.6	2.80	21	18.5	1.85	21.9	2.18
Rectum & rectosigmoid	13	14.4	1.86	17.4	2.24	9	7.5	1.17	9.0	1.40
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	19	22.0	2.38	26.3	2.80	8	7.4	1.22	8.7	1.41
Gallbladder	1	1.9	0.77	2.2	0.87	1	1.2	0.46	1.5	0.59
Pancreas	10	12.4	1.83	15.1	2.21	10	9.7	1.41	11.5	1.63
Respiratory System	41	54.1	3.96	64.6	4.63	36	33.3	2.56	39.4	3.00
Larynx	1	1.4	0.61	1.8	0.74	*	*	*	*	*
Lung & bronchus	39	51.9	3.88	61.8	4.54	35	32.8	2.55	38.8	2.98
Bones & Joints	1	1.5	0.61	1.7	0.70	*	*	*	*	*
Soft Tissue (incl. heart)	3	3.0	0.82	3.3	0.90	2	1.5	0.52	1.7	0.59
Skin (excl. basal & sq.)	*	*	*	*	*	1	0.9	0.36	0.9	0.40
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	112	95.1	4.11	110.8	4.77
Female Genital System	N/A	N/A	N/A	N/A	N/A	49	40.8	2.66	47.9	3.11
Cervix uteri	N/A	N/A	N/A	N/A	N/A	7	5.8	1.02	6.2	1.11
Uterus corpus	N/A	N/A	N/A	N/A	N/A	26	20.7	1.87	25.1	2.25
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	1	1.0	0.43	1.3	0.53
Ovary	N/A	N/A	N/A	N/A	N/A	11	9.2	1.28	10.7	1.48
Male Genital System	44	54.7	3.86	65.8	4.53	N/A	N/A	N/A	N/A	N/A
Prostate	42	52.1	3.78	63.3	4.46	N/A	N/A	N/A	N/A	N/A
Testis	2	1.3	0.45	1.2	0.42	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	18	24.7	2.72	28.2	3.09	7	7.0	1.20	8.0	1.36
Bladder (incl. <i>in situ</i>)	11	15.9	2.27	18.1	2.56	2	2.3	0.68	2.7	0.79
Kidney & renal pelvis	6	6.5	1.23	7.2	1.37	4	4.3	0.95	4.9	1.06
Ureter	1	1.7	0.72	2.1	0.90	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	5	5.4	1.15	5.6	1.23	2	1.9	0.61	2.0	0.64
Brain	5	5.4	1.15	5.6	1.23	2	1.9	0.61	2.0	0.64
Endocrine System	9	9.3	1.46	10.5	1.65	29	23.1	1.93	24.8	2.10
Thyroid gland	7	7.7	1.33	8.8	1.51	28	22.1	1.88	23.9	2.05
Lymphomas	16	19.6	2.35	22.5	2.71	13	12.1	1.56	13.6	1.74
Hodgkin lymphoma	2	1.2	0.42	1.2	0.41	*	*	*	*	*
Non-Hodgkin lymphoma	14	18.4	2.31	21.4	2.68	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	4	4.3	1.05	5.1	1.23	4	4.0	0.88	4.6	1.01
Leukemias	8	9.1	1.49	10.6	1.77	8	6.9	1.14	7.5	1.23
Acute lymphocytic	2	1.6	0.59	1.4	0.52	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	4	4.4	1.10	5.5	1.37	4	4.0	0.89	4.4	0.96
Chronic myeloid	1	1.2	0.47	1.5	0.58	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	9	11.4	1.80	12.6	1.99	9	8.6	1.31	9.6	1.45
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	6	7.8	1.48	8.8	1.66	13	10.8	1.38	12.8	1.62
Breast (<i>in situ</i>)	*	*	*	*	*	32	25.9	2.06	30.6	2.44

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Oregon, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	138	526.6	21.25	626.0	24.82	151	515.4	19.85	601.5	22.65
Oral Cavity & Pharynx	5	17.2	3.51	22.1	4.40	2	6.8	2.13	8.5	2.57
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	1	3.7	1.54	4.7	1.92
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	38	136.7	10.49	168.4	12.64	26	88.1	8.28	104.2	9.55
Esophagus	2	8.7	2.76	10.3	3.16	*	*	*	*	*
Stomach	*	*	*	*	*	1	4.0	1.77	4.9	2.08
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	8	28.9	4.96	35.0	5.87	7	27.2	4.68	30.7	5.22
Rectum & rectosigmoid	6	24.0	4.64	27.8	5.30	3	8.4	2.44	10.2	2.91
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	10	30.2	4.41	40.2	5.79	3	10.5	2.95	13.0	3.53
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	6	23.1	4.27	28.3	5.13	6	19.5	3.91	24.0	4.62
Respiratory System	23	93.1	9.24	111.7	10.86	25	89.5	8.41	103.8	9.55
Larynx	1	4.9	2.08	5.2	2.16	*	*	*	*	*
Lung & bronchus	22	88.1	9.00	106.4	10.65	25	87.8	8.34	101.5	9.46
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	1	4.7	2.04	5.5	2.40
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	5	20.3	4.58	23.5	5.25	4	15.1	3.60	15.7	3.72
Breast (excl. <i>in situ</i>)	*	*	*	*	*	38	123.9	9.42	146.8	10.88
Female Genital System	N/A	N/A	N/A	N/A	N/A	21	68.0	7.05	82.0	8.27
Cervix uteri	N/A	N/A	N/A	N/A	N/A	3	11.7	3.07	12.4	3.18
Uterus corpus	N/A	N/A	N/A	N/A	N/A	11	31.5	4.53	40.1	5.60
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	5	20.1	4.12	23.7	4.79
Male Genital System	24	89.8	8.63	105.9	9.98	N/A	N/A	N/A	N/A	N/A
Prostate	22	83.0	8.31	99.0	9.70	N/A	N/A	N/A	N/A	N/A
Testis	1	5.1	1.97	5.3	2.02	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	17	68.9	7.90	81.4	9.24	8	26.8	4.57	31.8	5.28
Bladder (incl. <i>in situ</i>)	9	40.4	6.39	47.9	7.53	2	8.8	2.67	10.0	2.96
Kidney & renal pelvis	8	28.5	4.64	33.5	5.35	5	18.1	3.70	21.8	4.38
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	9.7	2.90	10.7	3.19	*	*	*	*	*
Brain	2	9.7	2.90	10.7	3.19	*	*	*	*	*
Endocrine System	2	6.7	2.31	7.5	2.52	6	20.2	3.81	21.8	4.01
Thyroid gland	2	6.0	2.20	6.8	2.44	6	20.2	3.81	21.8	4.01
Lymphomas	8	28.3	4.60	32.7	5.25	7	27.7	4.84	32.0	5.52
Hodgkin lymphoma	*	*	*	*	*	1	4.3	1.80	4.2	1.73
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	6	23.4	4.49	27.8	5.24
Multiple Myeloma	1	5.7	2.47	6.3	2.76	2	5.4	1.87	6.6	2.22
Leukemias	3	13.5	3.37	14.2	3.57	3	11.8	2.99	13.1	3.26
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	2	8.0	2.74	8.2	2.86	1	5.2	2.09	6.0	2.35
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	5	21.7	4.63	25.1	5.21	5	21.4	4.31	23.4	4.72
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	1	5.5	2.12	5.9	2.26	4	13.4	3.04	15.5	3.43
Breast (<i>in situ</i>)	*	*	*	*	*	5	17.5	3.78	20.4	4.30

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Oregon, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	428	331.7	8.51	391.5	9.86	539	362.5	7.79	424.1	9.06
Oral Cavity & Pharynx	13	10.3	1.48	12.2	1.73	5	4.0	0.84	4.7	0.99
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	5	4.5	1.05	5.3	1.21	2	1.2	0.43	1.5	0.54
Major salivary gland	1	1.1	0.48	1.2	0.58	2	0.9	0.31	1.1	0.38
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	0.7	0.32	0.9	0.38	1	1.3	0.56	1.4	0.62
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	1	1.1	0.54	1.4	0.64	*	*	*	*	*
Digestive System	115	88.1	4.28	106.0	4.99	95	68.7	3.47	81.9	4.08
Esophagus	5	4.5	1.08	5.1	1.21	2	2.0	0.66	2.3	0.75
Stomach	13	10.4	1.50	12.2	1.72	12	8.8	1.24	10.0	1.41
Small intestine	3	2.1	0.67	2.5	0.77	3	2.4	0.64	2.9	0.75
Colon (excl. rectum)	29	20.9	2.05	25.3	2.44	26	18.2	1.78	21.8	2.11
Rectum & rectosigmoid	17	11.6	1.44	14.2	1.73	13	8.4	1.12	10.2	1.34
Anus, anal canal, & anorectum	*	*	*	*	*	3	1.8	0.46	2.2	0.57
Liver	26	20.9	2.06	25.5	2.42	10	7.9	1.21	9.7	1.44
Gallbladder	2	1.1	0.45	1.3	0.51	3	2.2	0.56	2.7	0.70
Pancreas	13	11.0	1.56	13.2	1.79	12	9.5	1.33	11.3	1.55
Respiratory System	32	34.4	3.07	40.5	3.53	36	32.4	2.61	38.0	2.98
Larynx	2	1.6	0.51	2.0	0.62	*	*	*	*	*
Lung & bronchus	29	32.0	3.00	37.5	3.44	35	31.9	2.60	37.4	2.97
Bones & Joints	3	0.9	0.24	0.8	0.25	2	0.9	0.34	0.9	0.39
Soft Tissue (incl. heart)	6	3.2	0.75	3.5	0.84	5	3.6	0.81	4.1	0.93
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	11	8.6	1.30	9.6	1.42
Melanoma of the skin	7	6.1	1.19	6.7	1.29	10	7.5	1.19	8.5	1.32
Breast (excl. <i>in situ</i>)	*	*	*	*	*	162	107.3	4.11	126.7	4.82
Female Genital System	N/A	N/A	N/A	N/A	N/A	78	46.7	2.58	55.5	3.08
Cervix uteri	N/A	N/A	N/A	N/A	N/A	14	7.1	0.91	7.6	1.02
Uterus corpus	N/A	N/A	N/A	N/A	N/A	42	24.9	1.81	30.5	2.23
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	1	1.2	0.50	1.5	0.61
Ovary	N/A	N/A	N/A	N/A	N/A	17	10.8	1.34	12.8	1.56
Male Genital System	107	83.3	4.17	100.0	4.87	N/A	N/A	N/A	N/A	N/A
Prostate	88	76.7	4.10	93.1	4.79	N/A	N/A	N/A	N/A	N/A
Testis	17	5.3	0.58	5.3	0.59	N/A	N/A	N/A	N/A	N/A
Penis	1	1.0	0.44	1.3	0.58	N/A	N/A	N/A	N/A	N/A
Urinary System	50	41.7	3.11	49.6	3.64	27	19.0	1.80	23.0	2.15
Bladder (incl. <i>in situ</i>)	20	20.4	2.31	24.1	2.69	6	5.2	1.04	6.0	1.20
Kidney & renal pelvis	28	19.3	1.92	23.2	2.27	20	13.2	1.43	16.1	1.73
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	2	1.3	0.60	1.5	0.68	*	*	*	*	*
Brain & Other CNS	11	6.5	1.17	7.0	1.31	10	5.3	0.87	5.8	0.99
Brain	11	6.4	1.17	6.9	1.31	9	4.8	0.85	5.2	0.96
Endocrine System	10	5.5	0.96	6.1	1.07	47	22.5	1.62	24.0	1.79
Thyroid gland	9	5.0	0.92	5.6	1.03	45	21.5	1.57	22.8	1.74
Lymphomas	31	18.9	1.86	21.8	2.15	24	15.4	1.62	18.2	1.91
Hodgkin lymphoma	5	1.9	0.40	2.1	0.49	4	1.8	0.50	1.9	0.55
Non-Hodgkin lymphoma	26	17.0	1.81	19.7	2.09	20	13.7	1.54	16.2	1.83
Multiple Myeloma	8	6.4	1.20	7.8	1.40	5	4.6	1.00	5.3	1.11
Leukemias	22	12.9	1.59	13.9	1.75	16	8.8	1.12	10.0	1.31
Acute lymphocytic	9	2.9	0.48	2.5	0.45	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	2	2.1	0.70	2.6	0.82	3	2.1	0.62	2.6	0.75
Acute myeloid	7	5.4	1.11	5.9	1.21	5	2.6	0.59	3.0	0.70
Chronic myeloid	2	1.7	0.60	2.0	0.69	2	1.0	0.36	1.2	0.41
Other leukemias	1	0.8	0.44	1.0	0.49	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	1	0.6	0.23	0.7	0.26	*	*	*	*	*
Ill-Defined & Unknown	9	9.0	1.60	10.7	1.86	14	14.3	1.86	16.2	2.09
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	10	5.3	0.89	6.0	1.01	24	15.5	1.60	17.4	1.80
Breast (<i>in situ</i>)	*	*	*	*	*	33	21.0	1.76	24.8	2.08

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

OREGON

II-418 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Oregon, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	404	342.7	8.96	404.4	10.39	515	379.8	8.28	444.3	9.65
Oral Cavity & Pharynx	13	11.1	1.59	13.0	1.86	5	4.4	0.91	5.2	1.08
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	5	4.8	1.13	5.6	1.30	2	1.3	0.48	1.6	0.59
Major salivary gland	1	1.2	0.52	1.3	0.62	2	1.0	0.35	1.2	0.43
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	0.8	0.36	0.9	0.42	1	1.4	0.60	1.5	0.67
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	1	1.2	0.58	1.5	0.68	*	*	*	*	*
Digestive System	108	90.6	4.50	109.0	5.25	90	70.1	3.62	83.8	4.27
Esophagus	4	4.2	1.06	4.8	1.18	2	1.9	0.66	2.1	0.74
Stomach	13	10.6	1.55	12.4	1.77	12	9.4	1.32	10.7	1.50
Small intestine	3	2.3	0.73	2.8	0.84	3	2.5	0.68	3.0	0.79
Colon (excl. rectum)	28	21.8	2.18	26.2	2.59	24	18.7	1.88	22.3	2.23
Rectum & rectosigmoid	17	12.3	1.53	15.1	1.85	13	9.0	1.21	10.9	1.45
Anus, anal canal, & anorectum	*	*	*	*	*	3	1.8	0.49	2.1	0.60
Liver	23	20.9	2.16	25.6	2.54	10	8.5	1.31	10.5	1.57
Gallbladder	2	1.2	0.49	1.4	0.56	3	2.0	0.54	2.5	0.68
Pancreas	12	11.3	1.66	13.5	1.89	11	9.2	1.34	11.1	1.59
Respiratory System	30	34.8	3.19	41.0	3.67	33	32.4	2.71	38.1	3.11
Larynx	2	1.2	0.40	1.7	0.55	*	*	*	*	*
Lung & bronchus	27	32.6	3.14	38.2	3.60	32	31.9	2.70	37.4	3.09
Bones & Joints	3	0.9	0.26	0.9	0.27	2	0.9	0.36	1.0	0.42
Soft Tissue (incl. heart)	5	3.1	0.69	3.3	0.76	5	3.9	0.88	4.4	1.01
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	11	9.3	1.40	10.4	1.54
Melanoma of the skin	7	6.5	1.28	7.1	1.39	10	8.1	1.29	9.2	1.44
Breast (excl. <i>in situ</i>)	*	*	*	*	*	157	114.5	4.43	135.2	5.20
Female Genital System	N/A	N/A	N/A	N/A	N/A	75	50.2	2.80	59.6	3.35
Cervix uteri	N/A	N/A	N/A	N/A	N/A	14	7.6	0.99	8.2	1.10
Uterus corpus	N/A	N/A	N/A	N/A	N/A	41	26.8	1.98	32.8	2.43
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	1	1.3	0.54	1.6	0.66
Ovary	N/A	N/A	N/A	N/A	N/A	16	11.6	1.45	13.7	1.69
Male Genital System	101	85.8	4.39	103.2	5.14	N/A	N/A	N/A	N/A	N/A
Prostate	82	78.7	4.31	95.7	5.05	N/A	N/A	N/A	N/A	N/A
Testis	17	5.8	0.65	5.8	0.65	N/A	N/A	N/A	N/A	N/A
Penis	1	1.1	0.48	1.4	0.62	N/A	N/A	N/A	N/A	N/A
Urinary System	47	42.9	3.28	50.9	3.82	25	19.6	1.89	23.7	2.27
Bladder (incl. <i>in situ</i>)	19	20.4	2.41	24.0	2.79	5	5.2	1.08	6.0	1.24
Kidney & renal pelvis	27	20.3	2.04	24.4	2.42	19	13.7	1.51	16.7	1.83
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	2	1.4	0.65	1.6	0.73	*	*	*	*	*
Brain & Other CNS	10	6.5	1.24	6.9	1.37	10	5.8	0.95	6.2	1.07
Brain	10	6.4	1.24	6.9	1.37	9	5.2	0.92	5.6	1.03
Endocrine System	10	6.1	1.04	6.7	1.17	44	23.9	1.76	25.5	1.94
Thyroid gland	9	5.5	1.00	6.1	1.12	42	22.8	1.70	24.2	1.88
Lymphomas	30	20.5	2.01	23.7	2.33	22	15.6	1.67	18.2	1.96
Hodgkin lymphoma	5	2.1	0.44	2.3	0.54	3	1.8	0.53	1.9	0.57
Non-Hodgkin lymphoma	25	18.5	1.96	21.3	2.27	19	13.8	1.58	16.3	1.87
Multiple Myeloma	8	6.9	1.29	8.3	1.51	5	4.7	1.03	5.4	1.16
Leukemias	21	13.2	1.64	14.3	1.83	15	9.4	1.21	10.5	1.41
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	2	2.3	0.76	2.8	0.89	2	2.0	0.64	2.5	0.78
Acute myeloid	7	5.3	1.12	5.9	1.24	4	2.7	0.64	3.2	0.77
Chronic myeloid	2	1.6	0.60	1.9	0.71	2	1.2	0.40	1.3	0.46
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	9	9.6	1.71	11.3	1.99	14	14.7	1.95	16.7	2.20
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	10	5.6	0.96	6.3	1.09	23	16.7	1.73	18.7	1.95
Breast (<i>in situ</i>)	*	*	*	*	*	32	22.5	1.90	26.7	2.25

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Oregon, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3	74.6	22.93	95.8	29.05	2	50.7	16.20	60.7	20.52
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


OREGON

II-420 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	12,789,838	12,788,468	12,794,679	12,809,107	12,798,883
Non-Hispanic White	10,004,532	9,949,258	9,897,541	9,848,434	9,796,666
Non-Hispanic Black	1,447,097	1,454,395	1,461,945	1,470,820	1,476,568
Non-Hispanic Asian/Pacific Islander (NH API)	445,393	459,794	473,893	486,642	497,079
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	106	106	103	108	112


All Races Population 2015–2019: 63,980,975
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	870,319	902,298	938,461	980,162	1,005,387
Hispanic White	677,776	700,669	726,031	755,441	772,197
Hispanic Black	143,618	150,196	158,521	167,809	174,028

Hispanic/Latino Population, Census 2010: 719,660
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

PENNSYLVANIA CANCER REGISTRY

Initial Operation: 1982
Population-based Data Available: 1985
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	111.3	110.2	109.8	107.1	105.4	108.8
Missing Race	1.3	1.5	1.2	1.3	1.4	1.3
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.3	2.5	2.7	2.7	2.8	2.6
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.8	Ovary	92.6
Oral Cavity & Pharynx	98.1	Prostate	96.9
Esophagus	95.3	Testis	99.3
Stomach	96.6	Bladder (incl. <i>in situ</i>)	97.6
Colon & Rectum	95.7	Kidney & Renal Pelvis	89.2
Liver	49.5	Brain & Other CNS	82.7
Pancreas	85.1	Brain & Other CNS (non-malig)	33.9
Lung & Bronchus	86.9	Thyroid	99.6
Melanomas of the Skin	99.5	Hodgkin Lymphoma	99.0
Female Breast (excl. <i>in situ</i>)	98.6	Non-Hodgkin Lymphoma	96.9
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	90.9
Cervix Uteri	98.3	Leukemias	90.0
Uterus Corpus & Uterus NOS	98.7		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Pennsylvania, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	40,236	513.7	1.18	610.2	1.37	40,021	455.1	1.07	530.5	1.21
Oral Cavity & Pharynx	1,472	18.5	0.22	22.6	0.27	624	6.9	0.13	8.2	0.15
Lip	48	0.6	0.04	0.8	0.05	25	0.3	0.02	0.3	0.03
Tongue	489	6.1	0.13	7.5	0.15	198	2.2	0.07	2.6	0.09
Major salivary gland	115	1.5	0.07	1.8	0.08	96	1.2	0.06	1.3	0.06
Floor of mouth	69	0.8	0.05	1.0	0.06	28	0.3	0.03	0.4	0.03
Gum & other mouth	170	2.2	0.08	2.6	0.09	137	1.4	0.06	1.7	0.07
Nasopharynx	54	0.7	0.05	0.9	0.05	23	0.3	0.03	0.3	0.03
Oropharynx	78	0.9	0.05	1.2	0.06	22	0.2	0.02	0.3	0.03
Hypopharynx	90	1.1	0.05	1.3	0.06	21	0.2	0.02	0.3	0.03
Digestive System	7,929	101.8	0.53	121.4	0.62	6,320	67.8	0.40	79.7	0.46
Esophagus	750	9.4	0.16	11.3	0.19	193	2.0	0.07	2.4	0.08
Stomach	657	8.5	0.15	10.1	0.18	367	4.0	0.10	4.7	0.11
Small intestine	235	3.1	0.09	3.6	0.11	206	2.3	0.07	2.7	0.09
Colon (excl. rectum)	2,301	30.4	0.29	35.8	0.34	2,432	26.0	0.25	30.3	0.28
Rectum & rectosigmoid	1,138	14.9	0.20	17.8	0.24	788	9.1	0.15	10.7	0.18
Anus, anal canal, & anorectum	119	1.6	0.07	1.9	0.08	228	2.5	0.08	3.1	0.09
Liver	945	11.2	0.17	14.0	0.21	283	3.0	0.08	3.5	0.10
Gallbladder	63	0.8	0.05	1.0	0.05	128	1.3	0.05	1.5	0.06
Pancreas	1,328	16.9	0.21	20.1	0.25	1,241	12.8	0.17	15.1	0.20
Respiratory System	6,083	76.7	0.45	91.3	0.53	5,560	57.8	0.36	69.2	0.42
Larynx	456	5.6	0.12	6.9	0.15	130	1.4	0.06	1.7	0.07
Lung & bronchus	5,541	69.9	0.43	83.1	0.50	5,372	55.7	0.35	66.7	0.41
Bones & Joints	75	1.1	0.06	1.2	0.06	56	0.8	0.05	0.8	0.05
Soft Tissue (incl. heart)	270	3.8	0.11	4.2	0.12	221	2.8	0.09	3.1	0.09
Skin (excl. basal & sq.)	2,314	30.6	0.29	35.8	0.34	1,623	20.0	0.24	22.6	0.26
Melanoma of the skin	2,133	28.1	0.28	32.9	0.32	1,507	18.7	0.23	21.2	0.25
Breast (excl. <i>in situ</i>)	107	1.4	0.06	1.6	0.07	11,293	132.2	0.59	154.9	0.67
Female Genital System	N/A	N/A	N/A	N/A	N/A	5,039	57.5	0.38	68.5	0.44
Cervix uteri	N/A	N/A	N/A	N/A	N/A	510	7.4	0.15	7.9	0.16
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2,965	32.5	0.28	39.8	0.33
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	47	0.5	0.03	0.6	0.04
Ovary	N/A	N/A	N/A	N/A	N/A	986	11.4	0.17	13.3	0.19
Male Genital System	9,741	116.8	0.54	143.1	0.65	N/A	N/A	N/A	N/A	N/A
Prostate	9,274	109.2	0.52	135.4	0.63	N/A	N/A	N/A	N/A	N/A
Testis	386	6.5	0.15	6.5	0.15	N/A	N/A	N/A	N/A	N/A
Penis	63	0.8	0.05	1.0	0.06	N/A	N/A	N/A	N/A	N/A
Urinary System	4,960	64.7	0.42	76.0	0.49	2,091	22.7	0.23	26.6	0.27
Bladder (incl. <i>in situ</i>)	3,001	39.1	0.33	45.9	0.38	990	10.2	0.15	12.0	0.17
Kidney & renal pelvis	1,841	24.0	0.26	28.3	0.30	1,037	11.9	0.17	13.8	0.20
Ureter	72	1.0	0.05	1.1	0.06	41	0.4	0.03	0.5	0.03
Eye & Orbit	72	1.0	0.05	1.1	0.06	64	0.8	0.05	0.9	0.05
Brain & Other CNS	594	8.4	0.16	9.2	0.17	464	5.9	0.13	6.3	0.13
Brain	566	7.9	0.15	8.8	0.17	433	5.4	0.12	5.9	0.13
Endocrine System	740	10.5	0.18	11.7	0.19	1,881	27.3	0.30	29.4	0.31
Thyroid gland	674	9.5	0.17	10.7	0.19	1,816	26.4	0.29	28.4	0.30
Lymphomas	2,048	27.7	0.28	31.8	0.32	1,749	20.0	0.23	22.9	0.25
Hodgkin lymphoma	230	3.5	0.11	3.7	0.11	180	2.7	0.09	2.8	0.09
Non-Hodgkin lymphoma	1,819	24.2	0.26	28.1	0.30	1,569	17.3	0.20	20.1	0.23
Multiple Myeloma	673	8.6	0.15	10.2	0.18	533	5.6	0.11	6.7	0.13
Leukemias	1,421	19.2	0.23	21.9	0.26	1,004	11.6	0.17	13.0	0.19
Acute lymphocytic	113	1.9	0.08	1.7	0.07	97	1.6	0.07	1.4	0.07
Chronic lymphocytic	538	6.8	0.14	8.2	0.16	336	3.4	0.09	4.1	0.10
Acute myeloid	429	5.8	0.13	6.6	0.14	329	3.8	0.10	4.3	0.11
Chronic myeloid	177	2.4	0.08	2.8	0.09	137	1.6	0.07	1.9	0.07
Other leukemias	165	2.2	0.08	2.6	0.09	105	1.2	0.05	1.3	0.06
Mesothelioma	128	1.7	0.07	2.0	0.08	47	0.5	0.03	0.6	0.04
Kaposi Sarcoma	25	0.4	0.04	0.4	0.04	5	0.0	0.01	0.1	0.01
Ill-Defined & Unknown	1,584	21.0	0.24	24.5	0.28	1,447	14.8	0.18	17.2	0.21
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	769	10.7	0.18	12.1	0.20	1,515	17.8	0.22	20.4	0.24
Breast (<i>in situ</i>)	10	0.1	0.02	0.1	0.02	2,623	32.1	0.30	37.8	0.34

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Pennsylvania, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	34,586	511.3	1.27	605.5	1.47	34,272	461.5	1.20	536.9	1.35
Oral Cavity & Pharynx	1,305	19.1	0.25	23.4	0.29	539	7.1	0.15	8.4	0.17
Lip	45	0.7	0.05	0.8	0.05	22	0.3	0.03	0.3	0.03
Tongue	449	6.5	0.14	8.0	0.17	176	2.3	0.08	2.8	0.10
Major salivary gland	99	1.5	0.07	1.8	0.08	79	1.2	0.06	1.3	0.07
Floor of mouth	62	0.9	0.05	1.1	0.06	26	0.3	0.03	0.4	0.04
Gum & other mouth	148	2.2	0.08	2.6	0.10	121	1.5	0.06	1.7	0.07
Nasopharynx	36	0.5	0.04	0.7	0.05	15	0.2	0.03	0.3	0.03
Oropharynx	70	1.0	0.06	1.2	0.07	19	0.3	0.03	0.3	0.03
Hypopharynx	77	1.1	0.06	1.3	0.07	16	0.2	0.02	0.2	0.03
Digestive System	6,723	99.8	0.56	118.7	0.66	5,289	65.9	0.43	77.2	0.49
Esophagus	683	9.8	0.17	11.8	0.20	161	1.9	0.07	2.3	0.08
Stomach	534	7.9	0.16	9.4	0.18	277	3.5	0.10	4.0	0.11
Small intestine	197	3.0	0.10	3.5	0.11	158	2.0	0.08	2.4	0.09
Colon (excl. rectum)	1,985	30.3	0.31	35.5	0.36	2,103	26.1	0.27	30.3	0.31
Rectum & rectosigmoid	982	15.1	0.22	17.9	0.26	654	8.9	0.17	10.5	0.19
Anus, anal canal, & anorectum	94	1.4	0.07	1.7	0.08	194	2.5	0.09	3.1	0.10
Liver	685	9.5	0.17	11.8	0.20	202	2.5	0.08	2.9	0.10
Gallbladder	52	0.8	0.05	0.9	0.06	94	1.1	0.05	1.3	0.06
Pancreas	1,166	16.9	0.23	20.2	0.27	1,055	12.5	0.18	14.7	0.21
Respiratory System	5,360	77.1	0.48	91.7	0.57	4,822	58.2	0.39	69.6	0.46
Larynx	398	5.7	0.13	6.9	0.16	112	1.4	0.06	1.8	0.08
Lung & bronchus	4,889	70.2	0.46	83.5	0.54	4,661	56.1	0.38	67.1	0.45
Bones & Joints	63	1.2	0.07	1.3	0.07	46	0.8	0.06	0.8	0.06
Soft Tissue (incl. heart)	232	3.8	0.12	4.3	0.13	182	2.8	0.10	3.1	0.11
Skin (excl. basal & sq.)	2,132	32.7	0.33	38.2	0.37	1,454	21.9	0.28	24.6	0.30
Melanoma of the skin	1,972	30.2	0.32	35.3	0.36	1,355	20.6	0.27	23.2	0.29
Breast (excl. <i>in situ</i>)	91	1.4	0.07	1.6	0.08	9,719	135.1	0.66	158.2	0.74
Female Genital System	N/A	N/A	N/A	N/A	N/A	4,295	58.2	0.42	69.3	0.49
Cervix uteri	N/A	N/A	N/A	N/A	N/A	384	7.0	0.17	7.5	0.18
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2,550	33.1	0.31	40.5	0.37
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	34	0.4	0.03	0.5	0.04
Ovary	N/A	N/A	N/A	N/A	N/A	859	11.7	0.19	13.7	0.22
Male Genital System	7,875	109.4	0.57	133.4	0.68	N/A	N/A	N/A	N/A	N/A
Prostate	7,461	100.6	0.53	124.5	0.65	N/A	N/A	N/A	N/A	N/A
Testis	343	7.8	0.19	7.7	0.19	N/A	N/A	N/A	N/A	N/A
Penis	53	0.8	0.05	1.0	0.06	N/A	N/A	N/A	N/A	N/A
Urinary System	4,456	66.5	0.46	78.1	0.53	1,819	23.1	0.26	27.0	0.29
Bladder (incl. <i>in situ</i>)	2,782	41.1	0.36	48.2	0.41	896	10.7	0.17	12.6	0.19
Kidney & renal pelvis	1,564	23.7	0.28	28.0	0.32	868	11.8	0.19	13.7	0.21
Ureter	68	1.0	0.06	1.2	0.06	37	0.4	0.03	0.5	0.04
Eye & Orbit	52	0.8	0.05	1.0	0.06	44	0.6	0.05	0.7	0.05
Brain & Other CNS	522	8.9	0.18	9.8	0.19	406	6.3	0.15	6.7	0.16
Brain	500	8.5	0.18	9.3	0.19	379	5.8	0.15	6.3	0.15
Endocrine System	646	11.2	0.21	12.5	0.22	1,547	28.5	0.35	30.6	0.36
Thyroid gland	596	10.3	0.20	11.5	0.22	1,494	27.7	0.34	29.7	0.35
Lymphomas	1,787	28.3	0.31	32.4	0.35	1,528	20.7	0.25	23.6	0.28
Hodgkin lymphoma	187	3.7	0.13	3.8	0.13	148	2.9	0.11	3.0	0.11
Non-Hodgkin lymphoma	1,600	24.6	0.29	28.5	0.32	1,380	17.8	0.23	20.6	0.26
Multiple Myeloma	537	7.9	0.16	9.3	0.18	400	4.9	0.11	5.8	0.13
Leukemias	1,264	19.8	0.26	22.7	0.29	876	12.0	0.20	13.4	0.21
Acute lymphocytic	87	1.9	0.10	1.8	0.09	76	1.7	0.09	1.5	0.08
Chronic lymphocytic	494	7.2	0.15	8.6	0.17	308	3.6	0.10	4.3	0.11
Acute myeloid	383	6.0	0.14	6.8	0.16	284	3.9	0.11	4.4	0.12
Chronic myeloid	154	2.5	0.09	2.8	0.10	117	1.7	0.08	1.9	0.08
Other leukemias	147	2.3	0.09	2.6	0.10	90	1.2	0.06	1.3	0.06
Mesothelioma	120	1.8	0.08	2.1	0.09	43	0.5	0.04	0.6	0.04
Kaposi Sarcoma	10	0.2	0.03	0.2	0.03	3	0.0	0.01	0.0	0.01
Ill-Defined & Unknown	1,411	21.3	0.26	24.8	0.30	1,264	14.8	0.20	17.2	0.23
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	653	10.8	0.20	12.1	0.22	1,266	17.8	0.24	20.3	0.27
Breast (<i>in situ</i>)	7	0.1	0.02	0.1	0.02	2,182	32.2	0.33	37.8	0.37

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Pennsylvania, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3,303	543.5	4.45	658.1	5.26	3,555	441.5	3.39	521.7	3.93
Oral Cavity & Pharynx	96	15.1	0.72	18.3	0.85	49	6.0	0.40	7.1	0.46
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	25	3.8	0.36	4.8	0.44	10	1.2	0.18	1.5	0.21
Major salivary gland	9	1.5	0.23	1.7	0.26	12	1.5	0.20	1.7	0.22
Floor of mouth	4	0.7	0.15	0.8	0.18	1	0.2	0.06	0.2	0.08
Gum & other mouth	9	1.5	0.23	1.8	0.27	9	1.1	0.17	1.3	0.20
Nasopharynx	7	1.2	0.20	1.3	0.23	4	0.5	0.12	0.5	0.13
Oropharynx	5	0.8	0.17	1.0	0.20	2	0.3	0.09	0.3	0.10
Hypopharynx	9	1.6	0.25	1.9	0.28	4	0.5	0.11	0.6	0.14
Digestive System	745	123.8	2.14	150.3	2.53	666	81.7	1.45	97.9	1.70
Esophagus	42	7.0	0.51	8.6	0.61	25	3.0	0.27	3.7	0.33
Stomach	68	12.2	0.70	14.6	0.82	52	6.5	0.41	7.7	0.48
Small intestine	31	5.0	0.43	6.0	0.49	38	4.8	0.36	5.7	0.41
Colon (excl. rectum)	195	33.7	1.14	40.2	1.33	210	26.1	0.82	31.0	0.96
Rectum & rectosigmoid	84	13.6	0.70	16.4	0.82	71	8.9	0.48	10.7	0.57
Anus, anal canal, & anorectum	20	3.1	0.33	3.7	0.38	21	2.7	0.26	3.2	0.31
Liver	163	23.8	0.87	30.6	1.09	51	5.9	0.38	7.3	0.46
Gallbladder	7	1.4	0.25	1.6	0.29	23	2.7	0.26	3.3	0.31
Pancreas	110	19.3	0.87	23.1	1.01	137	16.7	0.65	20.0	0.77
Respiratory System	513	89.7	1.87	107.5	2.18	573	69.1	1.32	83.7	1.57
Larynx	38	6.4	0.48	7.7	0.57	14	1.6	0.20	2.0	0.24
Lung & bronchus	466	82.0	1.79	98.2	2.09	554	66.9	1.29	80.9	1.54
Bones & Joints	5	0.7	0.15	0.7	0.16	5	0.7	0.14	0.7	0.14
Soft Tissue (incl. heart)	20	3.1	0.33	3.6	0.37	23	3.0	0.29	3.3	0.31
Skin (excl. basal & sq.)	14	2.3	0.29	2.6	0.32	13	1.6	0.21	1.9	0.24
Melanoma of the skin	5	0.9	0.18	1.1	0.22	7	0.8	0.15	0.9	0.17
Breast (excl. <i>in situ</i>)	11	1.9	0.27	2.2	0.31	1,007	127.6	1.84	149.8	2.12
Female Genital System	N/A	N/A	N/A	N/A	N/A	448	54.6	1.18	65.5	1.39
Cervix uteri	N/A	N/A	N/A	N/A	N/A	66	8.8	0.50	9.8	0.54
Uterus corpus	N/A	N/A	N/A	N/A	N/A	264	31.0	0.87	38.4	1.06
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	10	1.1	0.17	1.4	0.20
Ovary	N/A	N/A	N/A	N/A	N/A	69	8.6	0.47	10.1	0.55
Male Genital System	1,079	166.4	2.37	208.6	2.89	N/A	N/A	N/A	N/A	N/A
Prostate	1,063	164.0	2.36	206.2	2.88	N/A	N/A	N/A	N/A	N/A
Testis	11	1.7	0.23	1.7	0.22	N/A	N/A	N/A	N/A	N/A
Penis	3	0.6	0.15	0.6	0.16	N/A	N/A	N/A	N/A	N/A
Urinary System	314	54.0	1.43	64.0	1.66	186	23.0	0.77	27.2	0.90
Bladder (incl. <i>in situ</i>)	126	23.4	0.98	27.8	1.14	64	7.9	0.45	9.3	0.52
Kidney & renal pelvis	183	29.6	1.02	35.2	1.19	118	14.5	0.61	17.2	0.71
Ureter	3	0.6	0.16	0.7	0.18	2	0.2	0.08	0.3	0.09
Eye & Orbit	2	0.2	0.09	0.2	0.09	2	0.2	0.08	0.2	0.07
Brain & Other CNS	31	4.8	0.41	5.3	0.44	28	3.5	0.31	3.7	0.32
Brain	29	4.5	0.39	4.9	0.43	25	3.2	0.29	3.4	0.31
Endocrine System	41	6.4	0.47	7.3	0.53	139	18.5	0.72	20.4	0.78
Thyroid gland	32	5.1	0.41	5.8	0.47	131	17.5	0.70	19.3	0.76
Lymphomas	135	21.8	0.88	25.1	1.00	110	13.9	0.61	15.9	0.68
Hodgkin lymphoma	23	3.4	0.33	3.6	0.35	16	2.1	0.24	2.2	0.25
Non-Hodgkin lymphoma	112	18.3	0.81	21.5	0.94	94	11.7	0.56	13.7	0.64
Multiple Myeloma	99	17.2	0.82	20.6	0.95	107	13.3	0.59	15.9	0.69
Leukemias	79	13.7	0.73	15.6	0.82	71	8.8	0.48	10.1	0.54
Acute lymphocytic	10	1.5	0.22	1.4	0.21	8	0.9	0.15	0.9	0.16
Chronic lymphocytic	23	4.1	0.41	4.9	0.47	17	2.1	0.23	2.5	0.27
Acute myeloid	27	4.8	0.43	5.5	0.49	28	3.4	0.29	4.0	0.34
Chronic myeloid	10	1.5	0.23	1.8	0.27	11	1.4	0.19	1.6	0.21
Other leukemias	10	1.7	0.26	2.0	0.30	8	1.0	0.16	1.1	0.18
Mesothelioma	5	1.1	0.23	1.3	0.26	2	0.3	0.09	0.3	0.10
Kaposi Sarcoma	9	1.4	0.21	1.4	0.22	*	*	*	*	*
Ill-Defined & Unknown	107	19.9	0.91	23.5	1.05	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	61	10.3	0.62	11.9	0.71	139	17.8	0.69	20.4	0.78
Breast (<i>in situ</i>)	1	0.2	0.09	0.3	0.10	278	34.9	0.96	41.6	1.12

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Pennsylvania, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	486	272.2	5.85	322.2	6.85	626	283.1	5.22	327.6	6.03
Oral Cavity & Pharynx	24	11.8	1.12	14.1	1.34	12	5.8	0.78	6.6	0.88
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	3	1.9	0.47	2.2	0.54	4	1.9	0.44	2.2	0.50
Major salivary gland	2	1.0	0.34	1.2	0.40	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	6	2.9	0.54	3.5	0.66	2	1.3	0.39	1.4	0.44
Nasopharynx	7	3.4	0.57	3.8	0.66	3	1.5	0.38	1.6	0.43
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	1	0.7	0.32	0.9	0.39	*	*	*	*	*
Digestive System	142	80.7	3.20	96.5	3.77	117	56.8	2.44	66.7	2.84
Esophagus	9	5.4	0.87	6.4	1.01	*	*	*	*	*
Stomach	18	10.8	1.22	12.9	1.42	15	7.3	0.89	8.5	1.03
Small intestine	1	0.5	0.22	0.7	0.28	1	0.7	0.26	0.8	0.30
Colon (excl. rectum)	31	18.9	1.60	22.3	1.87	37	17.7	1.34	20.6	1.56
Rectum & rectosigmoid	23	12.0	1.17	14.3	1.38	21	9.4	0.96	11.3	1.14
Anus, anal canal, & anorectum	*	*	*	*	*	2	0.8	0.31	1.0	0.37
Liver	33	17.3	1.38	21.3	1.68	10	5.4	0.78	6.2	0.88
Gallbladder	2	1.1	0.37	1.2	0.41	3	1.7	0.42	2.0	0.50
Pancreas	16	9.6	1.13	11.2	1.31	17	8.6	0.96	10.0	1.11
Respiratory System	70	42.1	2.38	50.2	2.80	61	30.2	1.81	35.9	2.10
Larynx	3	1.8	0.46	2.3	0.56	*	*	*	*	*
Lung & bronchus	65	39.5	2.32	47.0	2.72	59	29.6	1.79	35.2	2.09
Bones & Joints	2	0.9	0.38	1.0	0.41	1	0.6	0.22	0.6	0.24
Soft Tissue (incl. heart)	4	2.0	0.52	2.3	0.59	4	1.8	0.42	2.0	0.46
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	4	1.8	0.42	2.0	0.47
Melanoma of the skin	2	1.0	0.35	1.3	0.43	2	1.0	0.31	1.1	0.35
Breast (excl. <i>in situ</i>)	2	1.0	0.33	1.2	0.41	191	83.4	2.75	96.5	3.19
Female Genital System	N/A	N/A	N/A	N/A	N/A	86	36.9	1.83	43.9	2.17
Cervix uteri	N/A	N/A	N/A	N/A	N/A	13	5.5	0.71	6.1	0.79
Uterus corpus	N/A	N/A	N/A	N/A	N/A	43	18.0	1.25	22.0	1.53
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	24	10.3	0.96	12.1	1.14
Male Genital System	94	51.9	2.50	62.3	2.95	N/A	N/A	N/A	N/A	N/A
Prostate	88	49.5	2.46	59.7	2.91	N/A	N/A	N/A	N/A	N/A
Testis	5	1.8	0.39	1.9	0.41	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	42	25.7	1.91	29.8	2.18	18	9.0	0.98	10.1	1.10
Bladder (incl. <i>in situ</i>)	24	15.2	1.51	17.5	1.71	8	4.1	0.69	4.7	0.78
Kidney & renal pelvis	18	10.0	1.14	11.7	1.31	9	4.2	0.65	4.6	0.72
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	12	6.1	0.81	7.0	0.95	7	3.0	0.52	3.1	0.54
Brain	12	5.8	0.79	6.7	0.94	7	2.8	0.50	2.9	0.52
Endocrine System	21	9.8	0.98	11.2	1.13	64	25.5	1.45	28.1	1.62
Thyroid gland	18	8.5	0.91	9.7	1.05	63	24.9	1.43	27.4	1.60
Lymphomas	25	13.5	1.29	15.5	1.48	26	11.5	1.04	12.8	1.17
Hodgkin lymphoma	4	1.8	0.38	1.8	0.39	3	1.0	0.27	0.9	0.25
Non-Hodgkin lymphoma	21	11.8	1.23	13.7	1.43	23	10.5	1.01	11.9	1.14
Multiple Myeloma	11	6.1	0.86	7.3	1.01	4	1.8	0.44	2.2	0.51
Leukemias	16	9.0	1.06	10.3	1.23	12	5.9	0.77	6.4	0.85
Acute lymphocytic	3	1.2	0.32	1.1	0.28	2	1.2	0.35	1.1	0.33
Chronic lymphocytic	3	1.7	0.46	2.0	0.56	1	0.7	0.30	0.8	0.33
Acute myeloid	6	3.8	0.74	4.4	0.84	5	2.2	0.46	2.6	0.53
Chronic myeloid	3	1.5	0.38	1.9	0.50	2	0.9	0.30	1.1	0.36
Other leukemias	1	0.8	0.33	0.9	0.38	2	0.8	0.29	0.9	0.30
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	17	9.8	1.12	11.4	1.29	17	8.6	0.96	9.9	1.11
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	17	9.0	1.01	10.5	1.17	30	13.5	1.15	16.0	1.35
Breast (<i>in situ</i>)	*	*	*	*	*	62	26.0	1.49	30.4	1.76

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Pennsylvania, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,011	408.1	6.43	485.1	7.48	1,128	361.3	5.10	422.9	5.96
Oral Cavity & Pharynx	31	11.8	1.05	14.4	1.25	14	4.6	0.59	5.4	0.68
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	8	2.9	0.53	3.6	0.64	4	1.5	0.35	1.7	0.40
Major salivary gland	3	1.0	0.27	1.2	0.32	4	1.0	0.25	1.1	0.28
Floor of mouth	2	0.7	0.26	0.8	0.30	*	*	*	*	*
Gum & other mouth	4	1.7	0.44	2.0	0.50	2	0.7	0.25	0.8	0.29
Nasopharynx	3	0.8	0.25	1.0	0.30	1	0.4	0.15	0.4	0.18
Oropharynx	2	0.6	0.23	0.8	0.30	*	*	*	*	*
Hypopharynx	2	0.9	0.31	1.1	0.35	*	*	*	*	*
Digestive System	250	102.0	3.22	122.1	3.76	192	66.6	2.27	79.1	2.67
Esophagus	12	5.5	0.79	6.6	0.92	5	1.8	0.40	2.1	0.45
Stomach	30	13.8	1.25	16.0	1.42	19	6.5	0.72	7.6	0.83
Small intestine	5	1.7	0.36	2.0	0.43	7	2.2	0.40	2.6	0.48
Colon (excl. rectum)	64	26.1	1.64	30.7	1.89	61	21.1	1.28	24.9	1.50
Rectum & rectosigmoid	32	12.5	1.10	14.9	1.28	29	9.1	0.80	10.7	0.93
Anus, anal canal, & anorectum	5	1.6	0.37	2.0	0.44	9	2.8	0.43	3.6	0.55
Liver	58	21.5	1.38	27.0	1.68	16	5.3	0.64	6.6	0.77
Gallbladder	2	1.2	0.40	1.5	0.49	6	2.4	0.46	2.9	0.53
Pancreas	30	13.0	1.17	15.7	1.37	27	10.6	0.95	12.4	1.10
Respiratory System	109	51.6	2.43	60.8	2.80	83	31.2	1.62	37.3	1.89
Larynx	12	5.1	0.73	6.0	0.84	3	1.0	0.29	1.2	0.34
Lung & bronchus	94	45.6	2.30	53.7	2.65	78	29.6	1.58	35.4	1.84
Bones & Joints	4	0.9	0.25	0.9	0.26	3	0.8	0.22	0.8	0.24
Soft Tissue (incl. heart)	10	3.1	0.51	3.5	0.59	8	2.3	0.39	2.6	0.44
Skin (excl. basal & sq.)	13	5.7	0.80	6.7	0.93	20	6.5	0.68	7.5	0.80
Melanoma of the skin	10	4.8	0.75	5.7	0.87	17	5.5	0.63	6.4	0.74
Breast (excl. <i>in situ</i>)	2	0.8	0.25	0.9	0.30	315	99.0	2.61	116.4	3.07
Female Genital System	N/A	N/A	N/A	N/A	N/A	167	50.7	1.84	59.9	2.18
Cervix uteri	N/A	N/A	N/A	N/A	N/A	39	10.4	0.78	11.2	0.86
Uterus corpus	N/A	N/A	N/A	N/A	N/A	84	26.2	1.33	32.1	1.62
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	0.7	0.23	0.8	0.27
Ovary	N/A	N/A	N/A	N/A	N/A	30	9.1	0.78	10.8	0.92
Male Genital System	270	107.8	3.22	131.6	3.80	N/A	N/A	N/A	N/A	N/A
Prostate	245	101.9	3.16	125.2	3.74	N/A	N/A	N/A	N/A	N/A
Testis	20	3.7	0.39	3.7	0.39	N/A	N/A	N/A	N/A	N/A
Penis	5	2.2	0.49	2.6	0.58	N/A	N/A	N/A	N/A	N/A
Urinary System	105	44.1	2.15	52.1	2.49	54	17.5	1.13	20.5	1.33
Bladder (incl. <i>in situ</i>)	44	22.2	1.64	26.0	1.87	15	5.4	0.67	6.4	0.78
Kidney & renal pelvis	60	21.2	1.37	25.4	1.61	38	11.2	0.87	13.1	1.02
Ureter	*	*	*	*	*	1	0.6	0.25	0.7	0.29
Eye & Orbit	2	0.8	0.30	0.9	0.33	2	0.6	0.21	0.7	0.24
Brain & Other CNS	21	5.9	0.70	6.3	0.77	20	5.9	0.65	6.7	0.74
Brain	19	5.4	0.67	5.9	0.75	19	5.5	0.62	6.1	0.71
Endocrine System	20	5.4	0.59	6.1	0.68	101	26.3	1.21	28.8	1.36
Thyroid gland	16	4.7	0.57	5.4	0.65	98	25.5	1.19	28.0	1.34
Lymphomas	70	25.0	1.53	28.6	1.75	64	21.4	1.28	24.9	1.48
Hodgkin lymphoma	13	3.4	0.50	3.6	0.57	10	2.5	0.36	2.7	0.41
Non-Hodgkin lymphoma	57	21.6	1.45	25.0	1.66	54	18.9	1.23	22.2	1.42
Multiple Myeloma	22	10.1	1.06	12.1	1.24	17	6.0	0.67	7.4	0.81
Leukemias	42	15.3	1.24	17.3	1.40	34	9.6	0.82	10.6	0.93
Acute lymphocytic	10	2.3	0.38	2.3	0.40	10	1.9	0.30	1.8	0.29
Chronic lymphocytic	10	5.0	0.78	5.8	0.88	5	1.8	0.39	2.1	0.46
Acute myeloid	9	3.6	0.61	4.1	0.70	11	3.3	0.48	3.6	0.54
Chronic myeloid	8	2.8	0.51	3.2	0.58	4	1.2	0.29	1.4	0.35
Other leukemias	5	1.6	0.38	1.9	0.44	5	1.5	0.34	1.7	0.39
Mesothelioma	2	0.9	0.32	1.0	0.37	*	*	*	*	*
Kaposi Sarcoma	4	1.2	0.32	1.2	0.34	*	*	*	*	*
Ill-Defined & Unknown	35	16.0	1.35	18.6	1.56	32	11.9	1.00	13.9	1.16
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	28	10.1	0.98	11.3	1.12	62	19.4	1.17	22.5	1.36
Breast (<i>in situ</i>)	*	*	*	*	*	84	25.8	1.30	30.9	1.55

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

PENNSYLVANIA

II-428 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Pennsylvania, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	685	338.8	6.42	402.3	7.47	801	314.4	5.21	368.3	6.10
Oral Cavity & Pharynx	23	11.1	1.14	13.6	1.35	9	3.4	0.54	4.0	0.64
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	6	3.0	0.59	3.7	0.72	2	1.0	0.30	1.1	0.36
Major salivary gland	2	0.7	0.27	0.9	0.32	2	0.9	0.27	1.0	0.30
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	4	1.9	0.51	2.3	0.58	*	*	*	*	*
Nasopharynx	2	0.8	0.28	0.9	0.31	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	2	0.8	0.33	1.0	0.37	*	*	*	*	*
Digestive System	175	85.8	3.22	102.5	3.75	135	56.3	2.27	67.0	2.68
Esophagus	8	4.6	0.79	5.3	0.90	3	1.5	0.39	1.7	0.43
Stomach	22	11.5	1.22	13.3	1.40	14	5.7	0.72	6.6	0.84
Small intestine	3	1.3	0.36	1.6	0.42	5	1.9	0.41	2.3	0.50
Colon (excl. rectum)	43	20.9	1.59	24.4	1.83	42	17.8	1.29	21.0	1.50
Rectum & rectosigmoid	24	11.3	1.15	13.4	1.34	21	8.1	0.82	9.5	0.96
Anus, anal canal, & anorectum	3	1.3	0.36	1.5	0.43	7	2.7	0.46	3.5	0.60
Liver	40	17.9	1.36	22.5	1.66	11	4.6	0.66	5.8	0.81
Gallbladder	2	1.1	0.42	1.3	0.52	3	1.4	0.36	1.7	0.41
Pancreas	22	11.5	1.20	13.8	1.40	19	8.7	0.94	10.1	1.08
Respiratory System	76	43.6	2.44	51.3	2.80	58	26.4	1.63	31.3	1.90
Larynx	7	3.9	0.72	4.5	0.82	2	0.8	0.26	0.9	0.33
Lung & bronchus	67	39.2	2.32	46.2	2.67	54	24.9	1.59	29.6	1.85
Bones & Joints	2	0.7	0.22	0.8	0.24	2	0.6	0.22	0.6	0.24
Soft Tissue (incl. heart)	7	2.7	0.53	3.0	0.61	4	1.7	0.37	2.0	0.44
Skin (excl. basal & sq.)	11	5.8	0.89	6.8	1.03	16	6.0	0.71	7.0	0.83
Melanoma of the skin	9	5.2	0.86	6.1	1.00	13	5.1	0.66	6.1	0.78
Breast (excl. <i>in situ</i>)	2	0.8	0.28	0.9	0.34	231	88.6	2.71	103.8	3.17
Female Genital System	N/A	N/A	N/A	N/A	N/A	120	45.0	1.91	53.2	2.26
Cervix uteri	N/A	N/A	N/A	N/A	N/A	26	8.8	0.80	9.4	0.87
Uterus corpus	N/A	N/A	N/A	N/A	N/A	61	23.3	1.38	28.6	1.68
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	1	0.6	0.23	0.6	0.26
Ovary	N/A	N/A	N/A	N/A	N/A	23	8.7	0.84	10.3	0.99
Male Genital System	168	81.0	3.06	98.8	3.61	N/A	N/A	N/A	N/A	N/A
Prostate	150	75.7	2.99	93.0	3.54	N/A	N/A	N/A	N/A	N/A
Testis	14	3.4	0.41	3.4	0.42	N/A	N/A	N/A	N/A	N/A
Penis	4	1.9	0.49	2.4	0.59	N/A	N/A	N/A	N/A	N/A
Urinary System	77	39.3	2.22	46.6	2.58	39	15.7	1.18	18.4	1.38
Bladder (incl. <i>in situ</i>)	32	19.6	1.68	22.9	1.92	11	4.8	0.68	5.7	0.79
Kidney & renal pelvis	44	19.4	1.44	23.5	1.71	27	10.2	0.92	11.9	1.08
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	2	0.7	0.29	0.7	0.29	2	0.5	0.21	0.6	0.24
Brain & Other CNS	11	4.5	0.72	4.9	0.78	13	5.0	0.65	5.7	0.76
Brain	10	4.2	0.69	4.6	0.75	13	4.8	0.65	5.6	0.75
Endocrine System	13	4.7	0.63	5.4	0.73	70	22.6	1.25	24.9	1.41
Thyroid gland	11	4.1	0.60	4.7	0.70	67	21.9	1.22	24.1	1.38
Lymphomas	47	21.4	1.58	24.3	1.79	44	17.9	1.28	20.8	1.48
Hodgkin lymphoma	7	2.5	0.48	2.7	0.52	7	1.9	0.34	2.1	0.39
Non-Hodgkin lymphoma	39	18.8	1.51	21.6	1.71	37	16.0	1.24	18.8	1.43
Multiple Myeloma	16	8.5	1.03	10.3	1.22	13	5.6	0.71	6.8	0.86
Leukemias	28	13.0	1.25	14.9	1.43	23	8.5	0.86	9.6	0.98
Acute lymphocytic	5	1.7	0.36	1.7	0.40	5	1.5	0.30	1.4	0.30
Chronic lymphocytic	8	4.7	0.81	5.6	0.94	4	1.6	0.39	1.9	0.46
Acute myeloid	5	2.3	0.52	2.6	0.61	8	3.0	0.52	3.4	0.58
Chronic myeloid	7	3.0	0.58	3.3	0.66	3	1.2	0.33	1.5	0.40
Other leukemias	3	1.4	0.42	1.6	0.46	3	1.3	0.33	1.5	0.40
Mesothelioma	2	1.0	0.37	1.1	0.42	*	*	*	*	*
Kaposi Sarcoma	2	0.8	0.29	0.9	0.31	*	*	*	*	*
Ill-Defined & Unknown	23	13.4	1.36	15.5	1.56	23	10.6	1.04	12.3	1.19
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	20	9.4	1.06	10.5	1.20	43	16.5	1.17	19.1	1.37
Breast (<i>in situ</i>)	*	*	*	*	*	62	23.5	1.37	28.1	1.63

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Pennsylvania, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	65	188.2	11.93	226.1	13.86	83	203.1	11.19	237.4	12.96
Oral Cavity & Pharynx	1	2.5	1.06	3.1	1.33	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	14	44.1	5.94	53.3	6.90	14	39.8	5.26	46.8	6.05
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	2	5.4	2.12	6.3	2.41	1	2.5	1.08	2.8	1.23
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	4	12.9	3.35	15.0	3.75	3	9.6	2.67	11.3	3.08
Rectum & rectosigmoid	2	4.8	1.91	6.0	2.30	2	6.2	2.03	7.1	2.25
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	3	8.3	2.37	11.0	2.94	1	4.1	1.66	4.9	1.91
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	2	6.0	2.26	7.2	2.62	3	8.1	2.40	10.2	2.93
Respiratory System	8	24.7	4.49	29.7	5.26	7	22.7	4.32	26.6	4.90
Larynx	2	5.7	2.23	6.7	2.53	*	*	*	*	*
Lung & bronchus	6	19.0	3.90	23.0	4.61	6	22.3	4.30	25.9	4.85
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	1	1.4	0.63	1.3	0.62
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	25	58.9	5.80	69.7	6.81
Female Genital System	N/A	N/A	N/A	N/A	N/A	13	30.9	4.22	36.4	4.96
Cervix uteri	N/A	N/A	N/A	N/A	N/A	4	7.6	1.88	8.1	2.05
Uterus corpus	N/A	N/A	N/A	N/A	N/A	6	15.9	3.06	19.6	3.68
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	4.4	1.58	5.3	1.94
Male Genital System	22	67.7	7.11	84.2	8.47	N/A	N/A	N/A	N/A	N/A
Prostate	21	63.1	6.78	79.5	8.16	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	6	16.5	3.58	17.9	3.79	3	6.4	1.71	8.3	2.19
Bladder (incl. <i>in situ</i>)	1	3.6	1.68	4.1	1.84	*	*	*	*	*
Kidney & renal pelvis	5	10.2	2.53	11.2	2.74	3	5.6	1.61	7.2	2.05
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	2.2	0.91	2.1	0.99	3	5.1	1.74	5.4	1.88
Brain	1	2.0	0.90	2.0	0.98	2	4.7	1.69	4.8	1.76
Endocrine System	*	*	*	*	*	7	13.9	2.48	15.2	2.79
Thyroid gland	*	*	*	*	*	7	13.9	2.48	15.2	2.79
Lymphomas	4	9.5	2.34	11.8	2.86	4	9.5	2.52	11.2	2.91
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	1	4.7	1.88	5.3	2.10	*	*	*	*	*
Leukemias	3	9.5	2.92	10.6	3.16	2	1.8	0.68	1.7	0.66
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	1	5.4	2.40	5.9	2.56	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	2	6.0	2.13	7.3	2.52
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	2	3.0	1.09	3.5	1.34	5	11.5	2.44	13.6	3.00
Breast (<i>in situ</i>)	*	*	*	*	*	6	12.4	2.38	15.5	2.99

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.


N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	1,056,886	1,057,816	1,056,554	1,059,338	1,058,158
Non-Hispanic White	790,225	784,484	778,270	772,814	766,835
Non-Hispanic Black	68,680	69,811	70,629	72,165	73,136
Non-Hispanic Asian/Pacific Islander (NH API)	38,610	39,460	39,371	40,193	40,100
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	1,124	1,092	1,104	1,076	1,048


All Races Population 2015–2019: 5,288,752
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	154,108	158,803	163,060	168,910	172,793
Hispanic White	118,651	122,094	124,986	129,150	131,837
Hispanic Black	25,617	26,508	27,356	28,567	29,440

Hispanic/Latino Population, Census 2010: 130,655
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

RHODE ISLAND CANCER REGISTRY

Initial Operation: 1986
Population-based Data Available: 1986
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	112.3	116.3	112.3	106.7	103.6	110.2
Missing Race	0.6	0.8	1.3	0.7	1.7	1.0
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.1	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.4	1.9	2.1	2.1	1.9	2.1
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.4	Ovary	93.9
Oral Cavity & Pharynx	98.7	Prostate	97.4
Esophagus	97.2	Testis	98.2
Stomach	96.7	Bladder (incl. <i>in situ</i>)	98.5
Colon & Rectum	96.8	Kidney & Renal Pelvis	90.4
Liver	62.3	Brain & Other CNS	89.0
Pancreas	85.7	Brain & Other CNS (non-malig)	50.7
Lung & Bronchus	88.7	Thyroid	99.9
Melanomas of the Skin	99.2	Hodgkin Lymphoma	99.4
Female Breast (excl. <i>in situ</i>)	99.2	Non-Hodgkin Lymphoma	96.8
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	94.1
Cervix Uteri	99.0	Leukemias	92.0
Uterus Corpus & Uterus NOS	98.9		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Rhode Island, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3,155	511.8	4.20	607.2	4.88	3,252	456.5	3.75	532.0	4.25
Oral Cavity & Pharynx	109	17.1	0.76	20.9	0.90	55	7.3	0.45	8.8	0.54
Lip	3	0.5	0.14	0.6	0.16	2	0.2	0.07	0.2	0.08
Tongue	37	5.8	0.44	7.1	0.53	15	2.0	0.24	2.4	0.28
Major salivary gland	9	1.6	0.24	1.7	0.26	9	1.2	0.19	1.5	0.23
Floor of mouth	4	0.7	0.16	0.8	0.18	3	0.4	0.10	0.5	0.12
Gum & other mouth	13	2.0	0.26	2.5	0.32	12	1.6	0.22	1.9	0.25
Nasopharynx	4	0.7	0.16	0.8	0.18	3	0.4	0.10	0.5	0.13
Oropharynx	9	1.4	0.22	1.7	0.26	3	0.4	0.10	0.5	0.13
Hypopharynx	5	0.8	0.16	1.0	0.19	2	0.2	0.08	0.3	0.09
Digestive System	580	95.0	1.82	113.2	2.12	470	63.2	1.36	74.3	1.57
Esophagus	54	8.4	0.52	10.3	0.63	17	2.2	0.25	2.6	0.29
Stomach	55	9.2	0.57	10.9	0.66	37	5.1	0.40	5.8	0.44
Small intestine	21	3.5	0.35	4.1	0.40	18	2.7	0.29	3.1	0.33
Colon (excl. rectum)	151	25.4	0.95	30.0	1.10	161	21.4	0.79	25.1	0.91
Rectum & rectosigmoid	76	12.6	0.67	15.1	0.78	56	7.8	0.49	9.2	0.56
Anus, anal canal, & anorectum	8	1.3	0.22	1.6	0.25	21	2.9	0.29	3.6	0.35
Liver	76	11.8	0.63	14.4	0.75	25	3.3	0.31	3.9	0.36
Gallbladder	5	0.8	0.17	0.9	0.19	13	1.8	0.23	2.1	0.26
Pancreas	96	15.7	0.74	18.6	0.86	86	11.1	0.56	13.1	0.65
Respiratory System	503	81.8	1.67	96.8	1.95	502	65.5	1.34	78.0	1.58
Larynx	36	5.8	0.45	6.9	0.52	10	1.4	0.20	1.7	0.24
Lung & bronchus	459	74.6	1.60	88.2	1.86	489	63.8	1.32	75.9	1.55
Bones & Joints	7	1.4	0.24	1.4	0.23	5	0.8	0.17	0.9	0.17
Soft Tissue (incl. heart)	23	4.1	0.39	4.6	0.43	19	2.9	0.31	3.2	0.33
Skin (excl. basal & sq.)	180	30.2	1.03	35.4	1.19	141	20.2	0.80	23.2	0.89
Melanoma of the skin	168	28.2	1.00	33.0	1.15	133	19.1	0.78	22.0	0.87
Breast (excl. <i>in situ</i>)	12	1.8	0.25	2.2	0.28	987	142.3	2.12	166.8	2.42
Female Genital System	N/A	N/A	N/A	N/A	N/A	373	52.5	1.27	62.4	1.47
Cervix uteri	N/A	N/A	N/A	N/A	N/A	39	6.9	0.52	7.3	0.53
Uterus corpus	N/A	N/A	N/A	N/A	N/A	210	28.3	0.90	34.7	1.09
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	7	0.8	0.15	1.0	0.18
Ovary	N/A	N/A	N/A	N/A	N/A	65	9.4	0.54	11.0	0.62
Male Genital System	807	122.5	1.98	149.8	2.38	N/A	N/A	N/A	N/A	N/A
Prostate	768	114.9	1.90	142.1	2.31	N/A	N/A	N/A	N/A	N/A
Testis	33	6.4	0.52	6.4	0.51	N/A	N/A	N/A	N/A	N/A
Penis	6	1.0	0.19	1.1	0.21	N/A	N/A	N/A	N/A	N/A
Urinary System	413	68.8	1.55	80.7	1.79	177	23.5	0.83	27.7	0.95
Bladder (incl. <i>in situ</i>)	265	44.7	1.26	52.2	1.45	88	11.1	0.55	13.1	0.64
Kidney & renal pelvis	139	22.6	0.89	26.8	1.03	83	11.6	0.60	13.6	0.68
Ureter	6	1.0	0.18	1.2	0.22	4	0.5	0.12	0.6	0.13
Eye & Orbit	5	0.8	0.18	0.9	0.19	2	0.4	0.11	0.4	0.11
Brain & Other CNS	43	7.4	0.52	8.2	0.57	41	6.3	0.47	6.9	0.49
Brain	42	7.1	0.51	8.0	0.56	38	5.9	0.45	6.4	0.47
Endocrine System	59	10.2	0.62	11.5	0.68	149	26.0	1.00	27.9	1.03
Thyroid gland	54	9.2	0.58	10.5	0.65	144	25.2	0.98	27.1	1.02
Lymphomas	155	26.5	0.98	30.5	1.11	131	18.7	0.76	21.3	0.85
Hodgkin lymphoma	17	3.1	0.35	3.3	0.36	16	2.9	0.34	3.0	0.33
Non-Hodgkin lymphoma	138	23.4	0.92	27.2	1.05	115	15.7	0.69	18.3	0.78
Multiple Myeloma	47	7.6	0.51	9.1	0.60	35	4.6	0.36	5.4	0.42
Leukemias	112	19.5	0.85	22.1	0.94	73	10.8	0.60	11.9	0.64
Acute lymphocytic	9	1.9	0.29	1.8	0.27	8	1.6	0.27	1.5	0.24
Chronic lymphocytic	42	6.9	0.49	8.2	0.57	24	3.1	0.29	3.7	0.34
Acute myeloid	33	5.8	0.46	6.6	0.52	23	3.3	0.32	3.7	0.35
Chronic myeloid	15	2.6	0.31	2.9	0.34	11	1.5	0.22	1.8	0.25
Other leukemias	13	2.2	0.29	2.5	0.32	8	1.2	0.21	1.3	0.21
Mesothelioma	11	2.0	0.27	2.2	0.30	3	0.4	0.12	0.5	0.12
Kaposi Sarcoma	2	0.4	0.12	0.4	0.14	*	*	*	*	*
Ill-Defined & Unknown	88	14.8	0.72	17.3	0.83	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	41	6.8	0.49	7.9	0.56	73	11.3	0.62	12.7	0.68
Breast (<i>in situ</i>)	*	*	*	*	*	250	37.5	1.11	44.2	1.27

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Rhode Island, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,763	522.6	4.62	618.8	5.33	2,838	471.4	4.26	548.8	4.78
Oral Cavity & Pharynx	99	18.3	0.86	22.4	1.02	48	7.5	0.51	9.0	0.60
Lip	3	0.6	0.18	0.7	0.19	1	0.2	0.07	0.2	0.08
Tongue	36	6.5	0.51	8.0	0.61	13	2.1	0.28	2.5	0.32
Major salivary gland	8	1.8	0.29	2.0	0.31	8	1.3	0.21	1.5	0.25
Floor of mouth	3	0.6	0.16	0.7	0.18	2	0.3	0.09	0.4	0.11
Gum & other mouth	12	2.1	0.29	2.6	0.35	11	1.8	0.26	2.1	0.29
Nasopharynx	2	0.5	0.16	0.6	0.17	2	0.3	0.10	0.4	0.14
Oropharynx	8	1.5	0.24	1.8	0.29	3	0.4	0.12	0.5	0.15
Hypopharynx	5	0.8	0.17	1.0	0.21	2	0.2	0.09	0.3	0.11
Digestive System	497	94.2	1.96	112.5	2.28	403	62.5	1.48	73.6	1.70
Esophagus	49	8.8	0.57	10.8	0.69	15	2.4	0.28	2.8	0.33
Stomach	46	8.7	0.59	10.4	0.69	28	4.3	0.39	5.0	0.44
Small intestine	18	3.5	0.38	4.1	0.43	16	2.8	0.33	3.2	0.37
Colon (excl. rectum)	130	25.3	1.03	29.9	1.19	139	21.1	0.85	24.9	0.98
Rectum & rectosigmoid	65	12.7	0.74	15.1	0.85	47	7.8	0.55	9.2	0.63
Anus, anal canal, & anorectum	7	1.6	0.27	1.8	0.30	19	3.1	0.34	3.8	0.40
Liver	60	10.7	0.64	13.2	0.77	19	2.9	0.32	3.5	0.37
Gallbladder	4	0.8	0.18	0.9	0.20	10	1.5	0.23	1.8	0.26
Pancreas	86	16.3	0.81	19.2	0.94	77	11.4	0.61	13.5	0.71
Respiratory System	453	84.4	1.82	99.9	2.12	463	69.7	1.50	82.9	1.76
Larynx	33	6.3	0.50	7.5	0.59	9	1.4	0.23	1.7	0.27
Lung & bronchus	413	76.7	1.73	90.7	2.02	452	68.0	1.48	80.7	1.73
Bones & Joints	6	1.5	0.29	1.5	0.27	4	0.9	0.21	0.9	0.20
Soft Tissue (incl. heart)	20	4.4	0.47	4.8	0.49	16	2.9	0.36	3.2	0.38
Skin (excl. basal & sq.)	165	32.4	1.18	37.8	1.34	128	22.4	0.97	25.5	1.05
Melanoma of the skin	153	30.2	1.14	35.2	1.29	120	21.2	0.95	24.1	1.03
Breast (excl. <i>in situ</i>)	10	1.9	0.28	2.2	0.31	860	147.7	2.42	172.9	2.73
Female Genital System	N/A	N/A	N/A	N/A	N/A	320	53.4	1.43	63.6	1.64
Cervix uteri	N/A	N/A	N/A	N/A	N/A	29	7.0	0.63	7.2	0.62
Uterus corpus	N/A	N/A	N/A	N/A	N/A	183	28.8	1.00	35.4	1.20
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	6	0.8	0.16	1.0	0.20
Ovary	N/A	N/A	N/A	N/A	N/A	56	9.6	0.62	11.2	0.69
Male Genital System	675	119.4	2.12	145.6	2.53	N/A	N/A	N/A	N/A	N/A
Prostate	643	110.6	2.00	136.8	2.43	N/A	N/A	N/A	N/A	N/A
Testis	28	7.8	0.68	7.7	0.66	N/A	N/A	N/A	N/A	N/A
Penis	4	0.9	0.19	1.0	0.21	N/A	N/A	N/A	N/A	N/A
Urinary System	384	73.4	1.73	86.1	1.99	161	24.8	0.94	29.2	1.07
Bladder (incl. <i>in situ</i>)	252	48.3	1.40	56.4	1.61	83	12.0	0.62	14.1	0.72
Kidney & renal pelvis	124	23.8	1.00	28.1	1.15	72	12.0	0.68	14.1	0.77
Ureter	5	0.9	0.18	1.1	0.22	4	0.6	0.13	0.6	0.15
Eye & Orbit	4	1.0	0.24	1.1	0.24	2	0.3	0.13	0.4	0.12
Brain & Other CNS	37	7.9	0.62	8.7	0.65	36	6.8	0.56	7.4	0.58
Brain	37	7.6	0.60	8.6	0.64	33	6.4	0.54	6.9	0.56
Endocrine System	49	10.8	0.74	12.1	0.79	118	27.3	1.20	29.0	1.22
Thyroid gland	45	9.9	0.70	11.1	0.76	115	26.5	1.18	28.2	1.21
Lymphomas	138	28.1	1.12	32.2	1.24	113	19.3	0.88	22.0	0.96
Hodgkin lymphoma	15	3.6	0.44	3.8	0.45	13	3.1	0.41	3.2	0.41
Non-Hodgkin lymphoma	123	24.5	1.03	28.3	1.16	101	16.2	0.77	18.8	0.87
Multiple Myeloma	36	6.8	0.52	8.2	0.62	26	3.9	0.36	4.6	0.41
Leukemias	99	20.3	0.96	23.0	1.05	61	10.7	0.68	11.8	0.71
Acute lymphocytic	7	2.1	0.38	1.9	0.33	4	1.3	0.31	1.2	0.27
Chronic lymphocytic	40	7.6	0.55	9.0	0.64	22	3.2	0.32	3.8	0.38
Acute myeloid	30	6.0	0.52	6.9	0.57	19	3.2	0.36	3.5	0.38
Chronic myeloid	12	2.6	0.35	2.9	0.38	8	1.5	0.25	1.7	0.27
Other leukemias	10	2.1	0.30	2.4	0.34	8	1.5	0.28	1.5	0.27
Mesothelioma	10	2.0	0.29	2.3	0.33	3	0.5	0.13	0.5	0.14
Kaposi Sarcoma	2	0.4	0.14	0.5	0.16	*	*	*	*	*
Ill-Defined & Unknown	79	15.3	0.79	17.8	0.91	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	33	6.6	0.54	7.7	0.61	64	12.2	0.74	13.6	0.79
Breast (<i>in situ</i>)	*	*	*	*	*	214	39.3	1.30	45.9	1.45

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Rhode Island, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	121	422.9	18.57	515.8	21.93	115	368.3	15.69	428.7	18.06
Oral Cavity & Pharynx	3	10.2	2.69	12.5	3.26	1	5.0	1.91	5.6	2.14
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	25	89.2	8.58	107.5	10.01	19	60.6	6.37	70.8	7.34
Esophagus	2	8.9	2.83	10.7	3.19	*	*	*	*	*
Stomach	3	14.5	3.77	16.2	4.10	2	7.6	2.24	8.3	2.43
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	7	23.8	4.48	28.5	5.26	5	15.8	3.22	18.3	3.71
Rectum & rectosigmoid	2	5.8	1.84	7.2	2.28	2	7.1	2.17	8.5	2.57
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	5	13.8	2.99	18.3	3.91	2	5.5	1.77	7.1	2.24
Gallbladder	*	*	*	*	*	1	4.3	1.80	4.9	2.02
Pancreas	4	13.2	3.30	16.0	3.81	3	8.9	2.43	10.7	2.87
Respiratory System	19	70.1	7.74	85.5	9.11	15	50.4	5.97	60.0	6.97
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	18	68.1	7.64	83.0	8.99	15	49.2	5.91	58.5	6.89
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	38	120.9	8.93	140.5	10.24
Female Genital System	N/A	N/A	N/A	N/A	N/A	14	45.2	5.49	53.9	6.45
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	6.5	1.98	8.1	2.46
Uterus corpus	N/A	N/A	N/A	N/A	N/A	8	24.4	4.04	28.9	4.72
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	5.2	1.88	6.4	2.27
Male Genital System	44	147.8	10.78	186.6	13.09	N/A	N/A	N/A	N/A	N/A
Prostate	43	145.8	10.73	184.4	13.04	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	8	29.3	5.00	35.2	5.81	6	18.5	3.56	21.6	4.12
Bladder (incl. <i>in situ</i>)	3	12.9	3.61	15.3	4.14	3	7.9	2.25	10.1	2.82
Kidney & renal pelvis	4	14.4	3.27	17.4	3.83	3	10.5	2.75	11.5	3.01
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	5.0	1.69	5.0	1.72	*	*	*	*	*
Brain	1	3.9	1.48	4.0	1.59	*	*	*	*	*
Endocrine System	2	7.4	2.42	9.0	2.85	6	18.7	3.45	19.2	3.57
Thyroid gland	2	6.0	1.97	7.4	2.36	5	16.3	3.25	16.7	3.33
Lymphomas	4	14.4	3.64	16.1	4.07	5	16.4	3.25	18.5	3.63
Hodgkin lymphoma	*	*	*	*	*	1	3.5	1.46	3.6	1.49
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	4	12.9	2.90	14.9	3.32
Multiple Myeloma	5	19.8	4.23	23.9	4.95	4	13.3	3.05	15.8	3.55
Leukemias	3	10.3	2.58	11.8	2.92	2	5.0	1.70	6.0	2.06
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	1	3.2	1.33	4.2	1.75	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	3	8.5	2.51	10.6	3.01	2	6.5	2.08	8.1	2.56
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	2	5.9	1.94	6.9	2.26	3	8.2	2.22	9.4	2.58
Breast (<i>in situ</i>)	*	*	*	*	*	9	29.4	4.39	35.3	5.19

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Rhode Island, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	35	264.0	21.04	308.9	24.34	53	324.8	20.91	382.7	24.47
Oral Cavity & Pharynx	2	13.6	4.64	15.8	5.31	1	6.7	2.78	9.0	3.71
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	14	106.4	13.61	123.9	15.67	10	71.1	10.31	84.8	12.10
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	1	8.2	3.48	9.1	3.80
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	4	34.7	7.81	40.6	9.02	3	22.0	5.56	26.8	6.63
Rectum & rectosigmoid	2	13.1	4.68	16.4	5.76	2	12.2	4.34	14.9	5.23
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	4	29.5	6.70	34.0	7.69	2	14.6	5.03	16.8	5.76
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	5	38.2	8.10	45.2	9.40	5	32.9	7.05	40.9	8.52
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	5	36.0	7.81	43.1	9.15	5	30.8	6.73	38.5	8.18
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	19	110.6	11.70	130.7	13.76
Female Genital System	N/A	N/A	N/A	N/A	N/A	7	42.7	7.87	48.9	9.01
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	8.4	3.06	10.0	3.65
Uterus corpus	N/A	N/A	N/A	N/A	N/A	3	16.5	4.79	18.8	5.47
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	12.3	4.61	14.0	5.24
Male Genital System	5	31.7	6.95	40.4	8.66	N/A	N/A	N/A	N/A	N/A
Prostate	4	31.0	6.92	39.8	8.64	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	2	14.8	4.87	16.9	5.46	1	7.7	2.95	10.0	3.88
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	1	9.7	3.80	11.3	4.40	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	1	6.3	2.66	6.7	2.90	3	17.3	4.33	18.8	4.83
Thyroid gland	*	*	*	*	*	3	17.3	4.33	18.8	4.83
Lymphomas	2	12.7	4.47	13.3	4.72	1	7.0	3.05	7.4	3.21
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	2	14.4	4.54	15.6	4.92
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	4	20.7	4.78	25.2	5.86

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Rhode Island, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	4	624.4	151.80	729.5	174.70	3	591.9	159.36	656.4	174.78
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	1	172.1	74.64	191.7	81.20
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	1	209.0	94.75	250.1	111.47
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Rhode Island, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	143	333.1	13.96	392.5	16.11	182	313.5	10.97	366.4	12.76
Oral Cavity & Pharynx	3	6.9	1.88	8.9	2.34	2	4.5	1.37	5.5	1.61
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	33	79.2	6.93	93.3	8.01	28	51.4	4.56	59.8	5.28
Esophagus	1	2.8	1.26	3.2	1.49	*	*	*	*	*
Stomach	5	9.7	2.29	11.1	2.58	4	7.1	1.73	7.7	1.87
Small intestine	2	4.4	1.63	5.1	1.85	1	2.2	0.93	2.5	1.07
Colon (excl. rectum)	7	15.3	3.03	17.9	3.48	9	16.0	2.56	18.1	2.89
Rectum & rectosigmoid	6	13.7	2.88	16.1	3.28	3	5.5	1.39	6.2	1.59
Anus, anal canal, & anorectum	*	*	*	*	*	1	1.9	0.77	2.4	1.00
Liver	5	13.0	2.73	15.5	3.21	1	2.7	1.11	3.3	1.33
Gallbladder	*	*	*	*	*	2	2.8	0.98	3.7	1.25
Pancreas	4	12.7	3.10	14.7	3.52	5	8.5	1.84	10.1	2.18
Respiratory System	18	48.7	5.54	56.1	6.26	14	27.0	3.43	33.0	4.09
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	17	45.8	5.44	53.0	6.15	13	26.1	3.40	31.9	4.04
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	2	3.3	1.42	3.8	1.62	2	2.6	1.04	2.9	1.17
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Melanoma of the skin	2	5.9	2.13	6.4	2.30	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	59	98.4	5.99	115.4	6.99
Female Genital System	N/A	N/A	N/A	N/A	N/A	25	43.1	4.06	51.1	4.77
Cervix uteri	N/A	N/A	N/A	N/A	N/A	5	8.7	1.79	9.9	2.03
Uterus corpus	N/A	N/A	N/A	N/A	N/A	13	23.0	2.94	27.9	3.51
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	4	6.4	1.58	7.4	1.81
Male Genital System	42	101.4	7.70	121.1	8.90	N/A	N/A	N/A	N/A	N/A
Prostate	39	96.2	7.52	115.5	8.71	N/A	N/A	N/A	N/A	N/A
Testis	3	2.8	0.80	2.7	0.78	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	13	30.2	4.20	35.7	4.85	7	12.1	2.19	14.5	2.58
Bladder (incl. <i>in situ</i>)	6	14.2	3.00	16.7	3.45	2	2.4	0.86	3.4	1.20
Kidney & renal pelvis	7	14.2	2.63	16.9	3.06	5	9.7	2.02	11.1	2.28
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	4.0	1.38	4.5	1.60	4	5.7	1.43	6.0	1.54
Brain	2	3.7	1.34	4.2	1.58	4	5.5	1.40	5.7	1.53
Endocrine System	5	8.5	1.84	9.8	2.14	17	25.2	2.80	29.1	3.28
Thyroid gland	5	7.7	1.78	9.2	2.11	17	24.1	2.69	28.0	3.19
Lymphomas	9	15.5	2.62	19.0	3.19	8	14.3	2.41	16.4	2.75
Hodgkin lymphoma	*	*	*	*	*	2	2.2	0.78	2.2	0.82
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	6	12.1	2.28	14.1	2.63
Multiple Myeloma	3	8.6	2.31	10.1	2.63	4	7.9	1.81	9.7	2.18
Leukemias	6	12.4	2.58	14.5	3.06	6	9.5	1.84	10.1	2.02
Acute lymphocytic	2	2.2	0.74	2.3	0.85	2	2.5	0.76	2.2	0.69
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	2	3.8	1.62	4.6	1.98	2	3.1	1.10	3.7	1.30
Chronic myeloid	1	2.9	1.31	3.5	1.56	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	6.4	2.13	7.2	2.42	4	8.9	2.03	9.9	2.25
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	4	8.8	2.18	10.0	2.45	4	6.4	1.40	7.5	1.67
Breast (<i>in situ</i>)	*	*	*	*	*	20	31.1	3.25	38.0	3.94

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

RHODE ISLAND

II-438 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Rhode Island, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	89	270.6	14.37	317.7	16.51	111	240.4	10.72	282.2	12.57
Oral Cavity & Pharynx	2	6.4	2.01	8.5	2.57	2	3.4	1.26	4.5	1.62
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	24	73.3	7.56	86.5	8.74	15	34.0	4.19	39.4	4.83
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	3	9.7	2.74	11.1	3.06	2	5.0	1.66	5.4	1.81
Small intestine	1	3.3	1.53	4.1	1.85	*	*	*	*	*
Colon (excl. rectum)	5	13.3	3.17	15.5	3.68	4	9.8	2.22	10.9	2.48
Rectum & rectosigmoid	4	12.0	3.19	13.6	3.53	2	4.1	1.36	4.3	1.45
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	5	14.3	3.22	17.0	3.74	*	*	*	*	*
Gallbladder	*	*	*	*	*	1	3.0	1.17	3.7	1.44
Pancreas	3	12.8	3.42	15.1	3.96	3	6.8	1.90	8.4	2.30
Respiratory System	11	38.5	5.55	44.1	6.22	8	19.6	3.25	24.1	3.92
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	10	35.9	5.42	41.2	6.09	7	18.5	3.19	22.7	3.83
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Melanoma of the skin	1	5.9	2.48	6.5	2.70	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	40	84.6	6.25	99.9	7.36
Female Genital System	N/A	N/A	N/A	N/A	N/A	14	30.2	3.79	36.5	4.55
Cervix uteri	N/A	N/A	N/A	N/A	N/A	3	4.9	1.37	6.0	1.71
Uterus corpus	N/A	N/A	N/A	N/A	N/A	8	17.7	2.87	21.6	3.45
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	1	2.6	1.14	2.9	1.30
Male Genital System	25	78.0	7.73	92.3	8.86	N/A	N/A	N/A	N/A	N/A
Prostate	23	73.9	7.55	88.1	8.69	N/A	N/A	N/A	N/A	N/A
Testis	2	2.1	0.76	2.0	0.69	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	8	23.8	4.25	28.4	4.89	3	6.1	1.71	7.7	2.13
Bladder (incl. <i>in situ</i>)	3	9.2	2.67	11.1	3.09	*	*	*	*	*
Kidney & renal pelvis	5	13.4	3.09	15.9	3.54	2	4.9	1.56	6.0	1.90
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	1	3.5	1.60	3.8	1.81	3	5.5	1.59	5.6	1.71
Brain	1	3.5	1.60	3.8	1.81	3	5.1	1.55	5.3	1.68
Endocrine System	4	7.2	1.84	8.3	2.17	13	24.3	3.15	27.7	3.64
Thyroid gland	3	6.9	1.82	8.1	2.16	13	23.6	3.05	27.0	3.57
Lymphomas	5	11.0	2.48	13.6	3.06	5	11.4	2.38	13.0	2.69
Hodgkin lymphoma	*	*	*	*	*	2	2.6	0.97	2.6	1.02
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	4	8.8	2.17	10.4	2.49
Multiple Myeloma	2	7.6	2.60	8.8	2.94	2	4.8	1.58	5.9	1.91
Leukemias	3	8.1	2.46	9.2	2.86	3	5.7	1.55	5.8	1.66
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	3	6.6	1.94	7.5	2.19
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	3	7.3	2.31	8.4	2.63	3	5.3	1.49	6.0	1.74
Breast (<i>in situ</i>)	*	*	*	*	*	12	26.1	3.44	31.6	4.13

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Rhode Island, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	11	159.0	23.10	189.4	26.94	14	153.7	19.55	176.6	22.25
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	4	38.8	9.56	41.5	10.21
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	1	13.1	5.58	14.2	6.03
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	1	15.8	6.08	19.0	7.41	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	1	13.9	5.79	17.4	7.25	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	5	52.6	11.74	61.8	13.63
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	18.2	6.32	22.4	7.58
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	5	71.2	16.10	84.1	18.47	N/A	N/A	N/A	N/A	N/A
Prostate	5	71.2	16.10	84.1	18.47	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	1	11.8	4.84	15.6	6.49	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	3	28.0	7.66	34.0	9.28

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.


N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	4,896,006	4,963,031	5,027,102	5,091,702	5,157,702
Non-Hispanic White	3,166,693	3,209,341	3,248,737	3,286,770	3,325,354
Non-Hispanic Black	1,360,259	1,371,215	1,380,135	1,390,070	1,399,718
Non-Hispanic Asian/Pacific Islander (NH API)	84,351	88,906	93,316	97,766	102,665
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	19,554	19,898	20,129	20,317	20,676


All Races Population 2015–2019: 25,135,543
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	265,149	273,671	284,785	296,779	309,289
Hispanic White	223,391	230,319	239,547	249,488	260,001
Hispanic Black	27,362	28,531	29,913	31,237	32,611

Hispanic/Latino Population, Census 2010: 235,682
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

SOUTH CAROLINA CANCER REGISTRY

Initial Operation: 1996
Population-based Data Available: 1996
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	107.5	106.2	105.3	103.5	98.7	104.2
Missing Race	0.4	0.3	0.5	1.0	1.5	0.7
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.5	0.1
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.2	2.0	1.7	2.3	1.3	1.9
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.1	Ovary	93.1
Oral Cavity & Pharynx	97.6	Prostate	96.7
Esophagus	94.0	Testis	99.4
Stomach	95.1	Bladder (incl. <i>in situ</i>)	96.9
Colon & Rectum	95.6	Kidney & Renal Pelvis	89.0
Liver	57.6	Brain & Other CNS	86.0
Pancreas	85.1	Brain & Other CNS (non-malig)	39.3
Lung & Bronchus	88.9	Thyroid	99.4
Melanomas of the Skin	99.3	Hodgkin Lymphoma	99.0
Female Breast (excl. <i>in situ</i>)	98.5	Non-Hodgkin Lymphoma	95.4
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	89.4
Cervix Uteri	97.0	Leukemias	87.8
Uterus Corpus & Uterus NOS	98.6		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
South Carolina, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	14,688	493.6	1.88	590.0	2.22	13,645	407.5	1.62	476.5	1.86
Oral Cavity & Pharynx	595	19.5	0.37	24.1	0.45	212	6.2	0.20	7.4	0.23
Lip	14	0.5	0.06	0.6	0.07	5	0.1	0.03	0.2	0.04
Tongue	184	6.0	0.20	7.4	0.25	66	1.9	0.11	2.3	0.13
Major salivary gland	46	1.6	0.11	1.9	0.13	29	0.9	0.08	1.0	0.09
Floor of mouth	29	0.9	0.08	1.2	0.10	11	0.3	0.04	0.4	0.05
Gum & other mouth	61	2.1	0.13	2.6	0.15	46	1.3	0.09	1.6	0.10
Nasopharynx	19	0.7	0.07	0.8	0.08	8	0.3	0.05	0.3	0.05
Oropharynx	43	1.3	0.09	1.7	0.12	9	0.3	0.04	0.3	0.05
Hypopharynx	49	1.5	0.10	1.9	0.13	8	0.2	0.03	0.3	0.04
Digestive System	2,834	96.2	0.84	115.8	0.99	2,198	64.2	0.63	75.9	0.74
Esophagus	237	7.7	0.23	9.4	0.28	61	1.7	0.10	2.1	0.12
Stomach	253	8.7	0.25	10.4	0.30	151	4.4	0.17	5.2	0.19
Small intestine	96	3.3	0.16	3.9	0.18	92	2.7	0.13	3.2	0.15
Colon (excl. rectum)	857	30.0	0.48	35.7	0.56	842	25.0	0.40	29.3	0.46
Rectum & rectosigmoid	378	13.2	0.31	15.8	0.37	243	7.5	0.22	8.8	0.26
Anus, anal canal, & anorectum	41	1.4	0.10	1.7	0.12	81	2.3	0.12	2.8	0.14
Liver	345	10.7	0.26	13.7	0.33	106	2.9	0.13	3.6	0.16
Gallbladder	19	0.7	0.07	0.8	0.08	38	1.1	0.08	1.3	0.09
Pancreas	464	15.7	0.34	18.7	0.40	418	11.9	0.27	14.1	0.31
Respiratory System	2,495	82.6	0.76	99.2	0.91	1,928	52.9	0.55	63.6	0.66
Larynx	216	7.0	0.22	8.7	0.27	51	1.5	0.09	1.8	0.12
Lung & bronchus	2,248	74.5	0.72	89.3	0.86	1,858	50.8	0.54	61.1	0.64
Bones & Joints	32	1.2	0.10	1.3	0.11	22	0.8	0.08	0.8	0.08
Soft Tissue (incl. heart)	102	3.8	0.17	4.3	0.19	81	2.6	0.14	2.9	0.15
Skin (excl. basal & sq.)	919	32.5	0.50	38.1	0.58	589	18.7	0.36	21.3	0.40
Melanoma of the skin	856	30.1	0.48	35.4	0.55	557	17.7	0.35	20.2	0.39
Breast (excl. <i>in situ</i>)	44	1.5	0.11	1.8	0.12	4,320	131.0	0.93	153.5	1.07
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,482	44.8	0.54	52.8	0.62
Cervix uteri	N/A	N/A	N/A	N/A	N/A	214	7.9	0.25	8.5	0.26
Uterus corpus	N/A	N/A	N/A	N/A	N/A	788	22.3	0.37	27.3	0.44
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	27	0.8	0.07	1.0	0.08
Ovary	N/A	N/A	N/A	N/A	N/A	283	8.6	0.24	10.0	0.27
Male Genital System	3,790	118.7	0.89	145.8	1.08	N/A	N/A	N/A	N/A	N/A
Prostate	3,659	113.3	0.86	140.2	1.06	N/A	N/A	N/A	N/A	N/A
Testis	101	4.3	0.20	4.3	0.19	N/A	N/A	N/A	N/A	N/A
Penis	26	0.9	0.08	1.0	0.09	N/A	N/A	N/A	N/A	N/A
Urinary System	1,596	55.6	0.64	65.4	0.75	718	20.8	0.36	24.4	0.42
Bladder (incl. <i>in situ</i>)	850	30.0	0.48	35.2	0.56	279	7.9	0.21	9.2	0.25
Kidney & renal pelvis	715	24.4	0.42	28.9	0.49	415	12.3	0.28	14.4	0.32
Ureter	19	0.7	0.07	0.8	0.09	15	0.4	0.05	0.5	0.06
Eye & Orbit	25	0.9	0.08	1.0	0.09	23	0.7	0.07	0.8	0.08
Brain & Other CNS	204	7.3	0.24	8.2	0.26	162	5.3	0.19	5.8	0.21
Brain	196	7.0	0.23	7.9	0.26	153	5.0	0.19	5.4	0.20
Endocrine System	177	6.6	0.23	7.3	0.25	437	15.6	0.35	16.9	0.37
Thyroid gland	156	5.8	0.22	6.5	0.24	416	14.9	0.34	16.1	0.36
Lymphomas	621	22.5	0.42	25.7	0.47	495	15.0	0.31	17.1	0.35
Hodgkin lymphoma	63	2.5	0.15	2.7	0.15	55	2.1	0.13	2.1	0.13
Non-Hodgkin lymphoma	558	19.9	0.39	23.0	0.45	440	12.9	0.28	15.0	0.32
Multiple Myeloma	266	9.2	0.26	10.9	0.31	228	6.5	0.20	7.7	0.23
Leukemias	437	15.8	0.35	18.0	0.39	319	9.9	0.26	11.1	0.28
Acute lymphocytic	37	1.5	0.11	1.4	0.11	32	1.3	0.10	1.2	0.09
Chronic lymphocytic	148	5.1	0.19	6.0	0.23	99	2.8	0.13	3.3	0.15
Acute myeloid	134	4.7	0.19	5.5	0.22	101	3.2	0.15	3.6	0.16
Chronic myeloid	62	2.3	0.14	2.6	0.15	54	1.7	0.11	1.9	0.12
Other leukemias	56	2.1	0.13	2.5	0.15	33	1.0	0.08	1.1	0.09
Mesothelioma	37	1.4	0.10	1.5	0.12	13	0.4	0.05	0.4	0.06
Kaposi Sarcoma	11	0.5	0.06	0.5	0.06	*	*	*	*	*
Ill-Defined & Unknown	502	18.0	0.37	21.1	0.43	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	209	7.6	0.24	8.6	0.27	464	14.5	0.31	16.6	0.35
Breast (<i>in situ</i>)	5	0.2	0.03	0.2	0.04	990	30.1	0.45	35.7	0.52

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
South Carolina, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	10,914	492.5	2.19	585.8	2.57	10,019	421.0	1.99	491.2	2.27
Oral Cavity & Pharynx	481	21.5	0.46	26.5	0.55	170	6.9	0.25	8.3	0.29
Lip	13	0.6	0.08	0.7	0.09	5	0.2	0.04	0.2	0.05
Tongue	160	7.1	0.26	8.7	0.31	59	2.5	0.15	3.0	0.18
Major salivary gland	39	1.8	0.14	2.2	0.16	19	0.8	0.09	1.0	0.10
Floor of mouth	21	0.9	0.09	1.1	0.11	8	0.3	0.05	0.4	0.06
Gum & other mouth	44	2.0	0.14	2.5	0.17	38	1.5	0.11	1.8	0.13
Nasopharynx	11	0.6	0.08	0.7	0.09	4	0.2	0.04	0.2	0.05
Oropharynx	34	1.5	0.12	1.9	0.14	6	0.3	0.05	0.3	0.06
Hypopharynx	34	1.5	0.12	1.8	0.14	6	0.2	0.04	0.3	0.05
Digestive System	2,017	92.1	0.95	110.6	1.13	1,492	60.4	0.73	71.3	0.85
Esophagus	179	7.8	0.27	9.6	0.33	43	1.7	0.12	2.0	0.14
Stomach	159	7.3	0.27	8.7	0.32	82	3.3	0.17	3.9	0.20
Small intestine	67	3.0	0.17	3.6	0.20	57	2.4	0.15	2.8	0.17
Colon (excl. rectum)	605	28.6	0.54	33.9	0.63	583	24.1	0.47	28.1	0.54
Rectum & rectosigmoid	267	12.9	0.37	15.4	0.43	171	7.5	0.27	8.9	0.31
Anus, anal canal, & anorectum	28	1.3	0.11	1.6	0.13	65	2.6	0.15	3.2	0.19
Liver	246	10.4	0.30	13.2	0.38	72	2.7	0.15	3.3	0.18
Gallbladder	11	0.5	0.07	0.6	0.08	20	0.8	0.08	0.9	0.09
Pancreas	346	15.5	0.38	18.4	0.45	277	10.6	0.29	12.6	0.35
Respiratory System	1,871	81.7	0.87	97.9	1.04	1,534	57.7	0.68	69.4	0.81
Larynx	144	6.3	0.24	7.8	0.30	36	1.5	0.12	1.9	0.14
Lung & bronchus	1,705	74.3	0.83	88.9	0.99	1,484	55.6	0.66	66.9	0.79
Bones & Joints	24	1.3	0.12	1.4	0.13	13	0.7	0.10	0.7	0.09
Soft Tissue (incl. heart)	74	3.8	0.21	4.2	0.23	53	2.4	0.16	2.7	0.17
Skin (excl. basal & sq.)	902	42.6	0.66	49.9	0.76	565	26.0	0.52	29.6	0.58
Melanoma of the skin	845	39.8	0.64	46.7	0.74	541	25.1	0.52	28.5	0.57
Breast (excl. <i>in situ</i>)	32	1.4	0.12	1.7	0.14	3,115	133.0	1.13	155.7	1.29
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,029	44.9	0.67	52.6	0.76
Cervix uteri	N/A	N/A	N/A	N/A	N/A	131	7.5	0.31	8.0	0.32
Uterus corpus	N/A	N/A	N/A	N/A	N/A	535	21.8	0.45	26.5	0.53
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	14	0.6	0.07	0.7	0.09
Ovary	N/A	N/A	N/A	N/A	N/A	212	9.1	0.30	10.6	0.34
Male Genital System	2,479	104.0	0.96	126.6	1.16	N/A	N/A	N/A	N/A	N/A
Prostate	2,373	97.3	0.92	119.7	1.12	N/A	N/A	N/A	N/A	N/A
Testis	85	5.7	0.29	5.7	0.28	N/A	N/A	N/A	N/A	N/A
Penis	19	0.9	0.09	1.0	0.11	N/A	N/A	N/A	N/A	N/A
Urinary System	1,286	59.2	0.77	69.7	0.89	535	21.7	0.44	25.3	0.50
Bladder (incl. <i>in situ</i>)	735	33.6	0.57	39.4	0.67	223	8.5	0.26	10.0	0.31
Kidney & renal pelvis	523	24.4	0.50	28.7	0.58	294	12.5	0.35	14.5	0.39
Ureter	18	0.8	0.09	1.0	0.11	12	0.5	0.06	0.5	0.07
Eye & Orbit	22	1.0	0.10	1.2	0.12	21	0.9	0.10	1.1	0.11
Brain & Other CNS	168	8.5	0.31	9.5	0.34	130	6.2	0.26	6.7	0.27
Brain	163	8.1	0.30	9.2	0.33	124	5.9	0.25	6.4	0.26
Endocrine System	139	7.4	0.30	8.1	0.32	313	17.1	0.46	18.4	0.48
Thyroid gland	125	6.6	0.28	7.3	0.30	300	16.4	0.45	17.7	0.47
Lymphomas	488	23.7	0.50	27.2	0.56	385	16.1	0.39	18.5	0.43
Hodgkin lymphoma	44	2.6	0.18	2.7	0.19	38	2.2	0.17	2.3	0.17
Non-Hodgkin lymphoma	444	21.1	0.47	24.4	0.53	347	13.9	0.35	16.2	0.40
Multiple Myeloma	159	7.2	0.27	8.6	0.31	121	4.7	0.20	5.5	0.23
Leukemias	346	16.9	0.42	19.2	0.47	231	10.1	0.32	11.2	0.34
Acute lymphocytic	26	1.7	0.15	1.5	0.14	22	1.4	0.14	1.3	0.13
Chronic lymphocytic	120	5.4	0.23	6.4	0.27	75	2.8	0.15	3.3	0.17
Acute myeloid	110	5.2	0.23	6.0	0.26	72	3.2	0.18	3.6	0.20
Chronic myeloid	48	2.4	0.16	2.7	0.18	37	1.7	0.13	1.9	0.14
Other leukemias	43	2.2	0.16	2.5	0.18	25	1.0	0.10	1.1	0.11
Mesothelioma	32	1.5	0.12	1.7	0.14	11	0.4	0.06	0.5	0.07
Kaposi Sarcoma	4	0.3	0.06	0.3	0.06	*	*	*	*	*
Ill-Defined & Unknown	390	18.4	0.43	21.5	0.50	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	160	8.1	0.30	9.1	0.33	323	14.4	0.38	16.4	0.42
Breast (<i>in situ</i>)	3	0.1	0.03	0.2	0.04	686	30.1	0.55	35.4	0.63

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
South Carolina, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3,323	517.9	4.27	626.3	5.04	3,123	379.7	3.14	446.6	3.61
Oral Cavity & Pharynx	101	14.8	0.69	18.2	0.83	36	4.4	0.34	5.1	0.38
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	21	3.1	0.31	3.8	0.38	5	0.6	0.13	0.7	0.14
Major salivary gland	6	1.0	0.19	1.1	0.21	8	1.0	0.16	1.1	0.18
Floor of mouth	8	1.1	0.19	1.4	0.23	3	0.3	0.09	0.4	0.11
Gum & other mouth	14	2.2	0.28	2.7	0.33	7	0.8	0.14	1.0	0.17
Nasopharynx	7	1.0	0.17	1.2	0.20	4	0.5	0.13	0.5	0.12
Oropharynx	8	1.1	0.18	1.4	0.22	3	0.3	0.09	0.4	0.10
Hypopharynx	14	2.0	0.24	2.5	0.30	2	0.3	0.08	0.3	0.09
Digestive System	727	116.0	2.05	140.1	2.42	617	75.2	1.39	89.1	1.62
Esophagus	53	8.0	0.52	9.9	0.62	16	1.9	0.21	2.3	0.26
Stomach	85	14.3	0.74	17.1	0.87	59	7.2	0.43	8.5	0.50
Small intestine	27	4.5	0.41	5.3	0.46	32	3.9	0.32	4.6	0.37
Colon (excl. rectum)	225	37.3	1.18	44.4	1.38	227	27.6	0.84	32.7	0.98
Rectum & rectosigmoid	93	14.7	0.72	17.7	0.86	60	7.4	0.44	8.8	0.51
Anus, anal canal, & anorectum	12	2.0	0.27	2.3	0.30	14	1.6	0.20	2.0	0.24
Liver	87	11.6	0.58	15.3	0.75	28	3.1	0.27	3.9	0.33
Gallbladder	7	1.4	0.25	1.6	0.28	15	1.8	0.21	2.2	0.25
Pancreas	108	17.5	0.81	21.2	0.95	127	15.7	0.64	18.5	0.74
Respiratory System	584	92.6	1.83	111.9	2.15	351	40.8	1.00	49.4	1.19
Larynx	69	10.1	0.58	12.7	0.70	14	1.5	0.19	1.9	0.23
Lung & bronchus	507	81.3	1.72	97.8	2.02	332	38.7	0.98	46.8	1.16
Bones & Joints	6	0.9	0.17	0.9	0.16	6	0.8	0.15	0.8	0.15
Soft Tissue (incl. heart)	23	3.7	0.36	4.1	0.40	24	3.0	0.29	3.4	0.31
Skin (excl. basal & sq.)	9	1.5	0.24	1.7	0.27	12	1.5	0.21	1.7	0.22
Melanoma of the skin	4	0.8	0.18	0.9	0.21	6	0.7	0.14	0.8	0.15
Breast (excl. <i>in situ</i>)	11	1.9	0.26	2.2	0.30	1,056	129.2	1.84	151.8	2.11
Female Genital System	N/A	N/A	N/A	N/A	N/A	386	45.6	1.07	54.3	1.25
Cervix uteri	N/A	N/A	N/A	N/A	N/A	65	8.6	0.49	9.5	0.53
Uterus corpus	N/A	N/A	N/A	N/A	N/A	224	25.2	0.78	30.9	0.93
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	12	1.4	0.19	1.7	0.22
Ovary	N/A	N/A	N/A	N/A	N/A	59	7.2	0.43	8.4	0.49
Male Genital System	1,161	169.8	2.36	211.2	2.85	N/A	N/A	N/A	N/A	N/A
Prostate	1,146	167.5	2.34	208.7	2.83	N/A	N/A	N/A	N/A	N/A
Testis	7	1.1	0.20	1.1	0.20	N/A	N/A	N/A	N/A	N/A
Penis	6	0.9	0.18	1.1	0.21	N/A	N/A	N/A	N/A	N/A
Urinary System	268	43.9	1.28	52.1	1.49	164	19.6	0.71	23.4	0.83
Bladder (incl. <i>in situ</i>)	92	17.0	0.85	20.0	0.99	49	6.2	0.40	7.2	0.47
Kidney & renal pelvis	172	26.2	0.94	31.3	1.09	110	12.8	0.56	15.4	0.66
Ureter	*	*	*	*	*	2	0.2	0.08	0.3	0.10
Eye & Orbit	1	0.2	0.10	0.2	0.10	2	0.2	0.08	0.2	0.07
Brain & Other CNS	29	4.6	0.40	5.0	0.44	26	3.3	0.30	3.6	0.32
Brain	27	4.3	0.39	4.7	0.43	24	3.1	0.29	3.4	0.31
Endocrine System	27	4.3	0.39	4.8	0.42	91	11.7	0.57	13.0	0.61
Thyroid gland	21	3.4	0.34	3.9	0.38	84	10.9	0.55	12.0	0.59
Lymphomas	106	17.5	0.80	19.7	0.89	92	11.6	0.56	13.0	0.62
Hodgkin lymphoma	17	2.5	0.28	2.6	0.29	15	2.0	0.23	2.1	0.24
Non-Hodgkin lymphoma	89	15.0	0.75	17.1	0.84	77	9.6	0.50	11.0	0.57
Multiple Myeloma	101	17.3	0.82	20.2	0.94	101	12.3	0.56	14.5	0.65
Leukemias	67	11.3	0.66	13.1	0.76	64	8.4	0.48	9.4	0.53
Acute lymphocytic	6	0.9	0.17	0.9	0.17	6	0.9	0.16	0.8	0.15
Chronic lymphocytic	20	3.2	0.35	3.9	0.41	17	2.1	0.23	2.5	0.27
Acute myeloid	21	3.6	0.37	4.2	0.43	25	3.3	0.30	3.7	0.33
Chronic myeloid	9	1.5	0.24	1.7	0.26	10	1.3	0.19	1.5	0.21
Other leukemias	11	2.1	0.31	2.4	0.36	7	0.9	0.16	1.0	0.18
Mesothelioma	4	0.8	0.18	0.9	0.20	2	0.3	0.09	0.3	0.10
Kaposi Sarcoma	6	0.9	0.18	1.0	0.18	*	*	*	*	*
Ill-Defined & Unknown	92	15.9	0.80	18.9	0.93	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	43	6.9	0.49	7.9	0.56	122	15.4	0.64	17.7	0.72
Breast (<i>in situ</i>)	2	0.3	0.10	0.3	0.11	268	31.9	0.90	38.2	1.05

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
South Carolina, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	72	215.7	12.17	249.8	13.99	127	272.2	11.26	317.7	13.07
Oral Cavity & Pharynx	4	11.7	2.62	14.0	3.12	2	3.7	1.18	4.9	1.54
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	3.8	1.61	4.1	1.77	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	21	62.0	6.45	71.7	7.41	25	58.2	5.52	69.7	6.51
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	1	3.0	1.23	3.8	1.54	3	8.0	2.03	9.7	2.41
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	4	12.0	2.71	14.2	3.20	8	19.3	3.19	23.4	3.78
Rectum & rectosigmoid	5	15.5	3.55	18.2	4.08	3	8.0	2.05	9.8	2.46
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	3	8.8	2.24	10.5	2.64	2	4.1	1.42	5.0	1.71
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	3	9.3	2.57	10.0	2.77	3	8.1	2.11	9.2	2.40
Respiratory System	8	23.2	3.79	27.6	4.44	16	37.6	4.45	43.8	5.12
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	7	21.2	3.60	25.2	4.19	15	36.9	4.42	43.0	5.08
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	*	*	*	*	*	1	2.9	1.14	3.3	1.30
Breast (excl. <i>in situ</i>)	*	*	*	*	*	40	80.5	5.80	94.3	6.77
Female Genital System	N/A	N/A	N/A	N/A	N/A	13	26.7	3.33	30.9	3.86
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	4.6	1.34	5.0	1.47
Uterus corpus	N/A	N/A	N/A	N/A	N/A	6	12.1	2.21	14.1	2.57
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	3	5.1	1.44	6.1	1.71
Male Genital System	18	52.9	5.81	61.9	6.74	N/A	N/A	N/A	N/A	N/A
Prostate	17	50.7	5.74	59.6	6.68	N/A	N/A	N/A	N/A	N/A
Testis	1	2.2	0.90	2.3	0.92	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	6	20.1	4.04	23.0	4.57	4	7.2	1.75	9.1	2.17
Bladder (incl. <i>in situ</i>)	3	11.7	3.34	13.1	3.70	*	*	*	*	*
Kidney & renal pelvis	3	7.4	2.03	8.8	2.44	2	4.6	1.39	6.0	1.76
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	2	3.7	1.35	4.2	1.55
Brain	*	*	*	*	*	1	3.3	1.29	3.8	1.48
Endocrine System	2	4.4	1.41	4.5	1.45	9	17.1	2.62	18.4	2.85
Thyroid gland	2	3.5	1.26	3.7	1.34	8	16.2	2.54	17.6	2.79
Lymphomas	4	10.0	2.26	11.9	2.70	5	11.7	2.34	13.3	2.66
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	1	4.1	1.76	4.8	2.08	1	3.4	1.45	3.9	1.64
Leukemias	2	7.8	2.44	9.2	2.86	3	6.0	1.66	6.7	1.88
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	3	12.1	3.44	13.1	3.78	4	10.8	2.39	11.7	2.62
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	2	5.3	1.69	6.0	1.93	5	10.8	2.25	12.9	2.70
Breast (<i>in situ</i>)	*	*	*	*	*	10	19.4	2.76	24.1	3.39

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
South Carolina, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	22	192.5	20.45	228.8	23.60	24	195.3	18.58	225.0	20.94
Oral Cavity & Pharynx	1	12.1	4.92	14.8	5.83	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	3	29.7	7.68	35.9	9.02	5	39.6	8.42	46.8	9.67
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	1	9.8	4.35	12.9	5.50	2	20.0	6.26	22.4	6.82
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	5	37.4	7.96	46.0	9.58	3	24.1	6.56	26.5	7.16
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	4	31.2	7.33	38.9	8.91	3	24.1	6.56	26.5	7.16
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	7	59.0	9.99	68.5	11.38
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	15.2	4.70	19.7	5.99
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	5	45.9	10.68	54.2	12.29	N/A	N/A	N/A	N/A	N/A
Prostate	5	43.7	10.45	51.8	12.05	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	2	17.7	5.98	21.0	6.87	1	12.3	4.77	13.9	5.33
Bladder (incl. <i>in situ</i>)	1	12.4	5.00	15.4	6.02	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	2	15.8	5.49	17.3	5.81
Thyroid gland	*	*	*	*	*	2	15.8	5.49	17.3	5.81
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	2	17.9	5.90	19.8	6.37

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
South Carolina, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	209	290.6	10.56	343.4	12.25	231	282.7	9.13	328.0	10.61
Oral Cavity & Pharynx	5	5.4	1.17	7.0	1.49	2	3.0	0.98	3.4	1.11
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	1	1.7	0.78	2.2	0.92	1	2.0	0.88	2.3	0.96
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	48	65.1	4.84	78.9	5.74	40	57.3	4.39	68.2	5.15
Esophagus	3	5.2	1.50	6.3	1.74	*	*	*	*	*
Stomach	7	9.9	1.91	12.2	2.31	4	5.5	1.27	6.7	1.51
Small intestine	1	2.1	0.94	2.5	1.10	1	1.7	0.64	2.1	0.82
Colon (excl. rectum)	12	15.4	2.37	18.4	2.77	13	18.0	2.41	21.4	2.84
Rectum & rectosigmoid	9	9.7	1.52	12.1	1.92	3	4.6	1.23	5.4	1.44
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	7	11.2	2.08	13.5	2.44	3	4.2	1.15	5.4	1.44
Gallbladder	*	*	*	*	*	2	3.7	1.18	4.3	1.33
Pancreas	5	7.3	1.68	8.6	1.91	8	11.9	2.07	14.0	2.39
Respiratory System	17	30.8	3.73	36.3	4.30	15	21.1	2.68	25.3	3.14
Larynx	2	3.6	1.32	4.0	1.45	*	*	*	*	*
Lung & bronchus	15	26.5	3.46	31.6	4.02	14	20.1	2.62	24.1	3.07
Bones & Joints	1	0.7	0.31	0.8	0.35	2	1.6	0.66	1.6	0.69
Soft Tissue (incl. heart)	3	2.4	0.64	2.8	0.79	2	1.9	0.77	2.0	0.85
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	6	6.5	1.33	7.4	1.52
Melanoma of the skin	3	4.1	1.23	4.8	1.37	4	4.7	1.08	5.3	1.22
Breast (excl. <i>in situ</i>)	*	*	*	*	*	76	88.6	4.93	103.7	5.79
Female Genital System	N/A	N/A	N/A	N/A	N/A	34	36.3	2.99	41.8	3.47
Cervix uteri	N/A	N/A	N/A	N/A	N/A	11	9.8	1.40	9.9	1.47
Uterus corpus	N/A	N/A	N/A	N/A	N/A	14	16.4	2.07	20.0	2.50
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	6	7.5	1.45	8.6	1.65
Male Genital System	58	90.0	6.04	107.0	6.97	N/A	N/A	N/A	N/A	N/A
Prostate	51	84.6	5.96	101.6	6.89	N/A	N/A	N/A	N/A	N/A
Testis	7	4.4	0.77	4.4	0.79	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	24	37.0	3.95	43.4	4.54	10	13.4	2.07	15.4	2.38
Bladder (incl. <i>in situ</i>)	9	19.0	3.14	21.4	3.52	3	4.7	1.33	5.6	1.57
Kidney & renal pelvis	15	18.1	2.40	22.0	2.87	7	8.0	1.51	9.0	1.71
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	5	3.4	0.81	3.8	0.95	4	4.3	1.09	4.7	1.22
Brain	4	3.3	0.80	3.6	0.95	3	3.6	1.03	4.0	1.14
Endocrine System	7	5.7	1.01	6.4	1.17	15	15.5	1.98	16.9	2.21
Thyroid gland	7	5.5	0.99	6.2	1.16	15	15.2	1.97	16.6	2.21
Lymphomas	17	20.4	2.70	23.2	3.07	8	10.8	1.90	12.5	2.18
Hodgkin lymphoma	3	2.3	0.77	2.5	0.84	1	1.0	0.43	1.2	0.52
Non-Hodgkin lymphoma	14	18.0	2.59	20.6	2.95	7	9.8	1.85	11.3	2.11
Multiple Myeloma	3	4.6	1.31	5.6	1.55	3	3.2	0.93	3.9	1.13
Leukemias	11	10.8	1.95	12.0	2.23	9	9.7	1.68	10.2	1.80
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	2	3.4	1.38	4.0	1.61	2	3.2	1.08	3.5	1.15
Acute myeloid	2	2.2	0.95	2.3	1.05	2	2.5	0.85	2.6	0.90
Chronic myeloid	2	2.2	0.77	2.5	0.87	1	1.5	0.62	1.7	0.73
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	5	8.1	1.90	9.3	2.20	6	8.3	1.72	9.6	1.99
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	3	2.8	0.87	3.2	1.01	9	11.4	1.81	14.0	2.20
Breast (<i>in situ</i>)	*	*	*	*	*	17	19.8	2.30	23.9	2.74

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

SOUTH CAROLINA

II-448 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
South Carolina, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	163	259.7	10.57	306.6	12.25	193	271.5	9.54	312.3	10.99
Oral Cavity & Pharynx	4	5.4	1.26	7.0	1.60	2	3.2	1.09	3.6	1.21
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	1	2.3	1.01	2.6	1.10
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	41	62.0	4.96	75.5	5.92	34	54.6	4.49	64.7	5.25
Esophagus	3	5.2	1.60	6.3	1.86	*	*	*	*	*
Stomach	5	7.7	1.83	9.3	2.20	4	5.8	1.37	7.0	1.65
Small intestine	1	1.9	0.94	2.3	1.14	1	1.7	0.70	2.1	0.87
Colon (excl. rectum)	10	15.3	2.43	18.4	2.87	12	18.0	2.51	21.4	2.97
Rectum & rectosigmoid	8	9.4	1.51	11.8	1.97	2	3.8	1.14	4.3	1.31
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	6	10.8	2.20	13.0	2.56	3	4.3	1.25	5.4	1.55
Gallbladder	*	*	*	*	*	1	2.7	1.06	3.0	1.16
Pancreas	4	6.9	1.68	8.4	1.97	6	10.9	2.07	12.4	2.32
Respiratory System	13	25.0	3.50	29.5	4.03	12	18.9	2.67	22.5	3.11
Larynx	1	3.1	1.31	3.5	1.45	*	*	*	*	*
Lung & bronchus	11	21.6	3.23	25.7	3.76	11	17.8	2.60	21.4	3.03
Bones & Joints	*	*	*	*	*	1	1.4	0.69	1.4	0.69
Soft Tissue (incl. heart)	2	1.6	0.61	2.1	0.82	1	1.9	0.84	2.0	0.89
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	5	7.1	1.51	8.2	1.73
Melanoma of the skin	3	4.5	1.38	5.1	1.53	4	5.1	1.22	5.7	1.38
Breast (excl. <i>in situ</i>)	*	*	*	*	*	63	85.4	5.21	98.5	6.05
Female Genital System	N/A	N/A	N/A	N/A	N/A	29	35.8	3.21	40.7	3.68
Cervix uteri	N/A	N/A	N/A	N/A	N/A	9	9.3	1.48	9.3	1.52
Uterus corpus	N/A	N/A	N/A	N/A	N/A	12	16.1	2.21	19.5	2.67
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	6	7.9	1.60	8.8	1.79
Male Genital System	44	76.8	5.91	91.0	6.81	N/A	N/A	N/A	N/A	N/A
Prostate	37	71.5	5.84	85.8	6.74	N/A	N/A	N/A	N/A	N/A
Testis	7	4.7	0.85	4.6	0.87	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	19	34.2	4.07	39.9	4.65	7	11.6	2.09	13.3	2.39
Bladder (incl. <i>in situ</i>)	8	18.5	3.26	20.9	3.64	2	3.5	1.23	4.3	1.48
Kidney & renal pelvis	11	15.7	2.44	19.0	2.89	5	7.3	1.59	8.2	1.78
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	3	3.2	0.88	3.5	1.03	3	4.3	1.21	4.7	1.32
Brain	3	3.1	0.87	3.4	1.02	3	3.6	1.14	3.9	1.23
Endocrine System	6	5.6	1.08	6.3	1.26	13	15.0	2.01	16.4	2.26
Thyroid gland	5	5.3	1.07	6.1	1.25	13	14.6	1.99	16.1	2.25
Lymphomas	13	18.8	2.79	21.1	3.11	7	11.1	2.06	12.7	2.35
Hodgkin lymphoma	2	1.9	0.79	2.0	0.82	*	*	*	*	*
Non-Hodgkin lymphoma	11	16.9	2.68	19.1	3.00	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	3	4.8	1.45	5.8	1.71	2	2.4	0.90	2.9	1.07
Leukemias	8	9.2	1.95	10.0	2.24	8	9.7	1.80	10.4	1.95
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	1	3.1	1.43	3.6	1.67	2	3.0	1.14	3.4	1.24
Acute myeloid	2	2.4	1.07	2.5	1.17	2	2.4	0.89	2.5	0.94
Chronic myeloid	1	1.1	0.47	1.4	0.60	1	1.5	0.67	1.8	0.80
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	4	7.1	1.89	8.1	2.12	5	7.9	1.72	9.1	1.97
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	3	3.0	0.97	3.3	1.10	7	9.3	1.72	11.6	2.12
Breast (<i>in situ</i>)	*	*	*	*	*	15	20.5	2.54	24.4	2.99

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
South Carolina, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	11	275.7	78.44	320.5	86.56	11	256.0	58.88	317.7	73.44
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	2	111.4	73.12	122.9	80.01	2	64.7	29.29	80.5	36.64
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	2	68.2	36.86	86.9	46.95
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	2	68.2	36.86	86.9	46.95
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	3	34.9	8.84	43.1	11.04
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	5	107.3	24.55	129.8	28.63	N/A	N/A	N/A	N/A	N/A
Prostate	5	107.3	24.55	129.8	28.63	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	1	14.2	6.07	17.6	7.51	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.


N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	854,663	863,693	873,732	879,386	887,127
Non-Hispanic White	716,412	719,780	723,912	727,036	731,551
Non-Hispanic Black	18,700	20,652	22,428	23,066	24,087
Non-Hispanic Asian/Pacific Islander (NH API)	12,350	13,685	14,950	14,821	15,574
Non-Hispanic American Indian/Alaskan Native PRCA (NH AI/AN)	66,069	66,329	66,439	66,579	66,504


All Races Population 2015–2019: 4,358,601
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	30,972	32,805	35,290	36,998	38,388
Hispanic White	22,910	24,097	26,047	27,142	28,353
Hispanic Black	1,003	1,050	1,134	1,199	1,294

Hispanic/Latino Population, Census 2010: 22,119
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

SOUTH DAKOTA CANCER REGISTRY

Initial Operation: 2001
Population-based Data Available: 2001
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	102.8	115.2	108.8	108.9	96.8	106.5
Missing Race	0.1	0.3	0.1	0.0	0.0	0.1
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.9	0.8	0.8	1.2	0.6	0.8
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.7	Ovary	95.4
Oral Cavity & Pharynx	99.0	Prostate	97.6
Esophagus	96.1	Testis	98.0
Stomach	94.9	Bladder (incl. <i>in situ</i>)	98.4
Colon & Rectum	95.3	Kidney & Renal Pelvis	88.1
Liver	45.6	Brain & Other CNS	78.0
Pancreas	85.8	Brain & Other CNS (non-malig)	24.1
Lung & Bronchus	90.3	Thyroid	99.2
Melanomas of the Skin	99.6	Hodgkin Lymphoma	98.1
Female Breast (excl. <i>in situ</i>)	99.0	Non-Hodgkin Lymphoma	97.1
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	92.3
Cervix Uteri	98.5	Leukemias	84.1
Uterus Corpus & Uterus NOS	99.3		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
South Dakota, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,490	487.6	4.52	577.3	5.24	2,259	429.1	4.24	496.7	4.79
Oral Cavity & Pharynx	89	17.5	0.86	21.1	1.02	34	6.3	0.50	7.5	0.59
Lip	12	2.5	0.34	2.9	0.38	3	0.6	0.15	0.7	0.17
Tongue	26	5.1	0.47	6.1	0.55	9	1.5	0.24	1.9	0.30
Major salivary gland	7	1.5	0.25	1.7	0.29	5	1.0	0.21	1.2	0.24
Floor of mouth	3	0.5	0.14	0.7	0.18	2	0.5	0.15	0.5	0.16
Gum & other mouth	8	1.4	0.22	1.8	0.28	7	1.2	0.20	1.4	0.25
Nasopharynx	4	0.7	0.18	0.8	0.20	*	*	*	*	*
Oropharynx	3	0.6	0.16	0.7	0.19	2	0.4	0.11	0.5	0.14
Hypopharynx	4	0.8	0.18	0.9	0.21	*	*	*	*	*
Digestive System	470	93.6	2.00	110.8	2.32	352	63.4	1.58	74.1	1.81
Esophagus	45	8.5	0.59	10.2	0.69	11	2.0	0.27	2.4	0.32
Stomach	33	6.7	0.54	7.9	0.62	14	2.6	0.32	3.0	0.37
Small intestine	17	3.5	0.40	4.1	0.45	11	2.2	0.31	2.5	0.34
Colon (excl. rectum)	152	31.1	1.16	36.4	1.34	149	26.4	1.02	30.4	1.15
Rectum & rectosigmoid	72	14.8	0.81	17.4	0.93	44	8.6	0.61	10.1	0.70
Anus, anal canal, & anorectum	5	1.0	0.20	1.3	0.25	12	2.1	0.28	2.6	0.34
Liver	43	8.1	0.57	10.0	0.69	12	2.1	0.29	2.5	0.33
Gallbladder	2	0.5	0.15	0.6	0.16	8	1.4	0.23	1.6	0.26
Pancreas	73	13.8	0.75	16.6	0.88	65	11.4	0.66	13.4	0.76
Respiratory System	337	65.9	1.65	78.1	1.92	315	55.2	1.43	65.6	1.67
Larynx	23	4.3	0.41	5.3	0.50	8	1.4	0.24	1.7	0.28
Lung & bronchus	310	60.8	1.59	71.7	1.84	305	53.4	1.40	63.4	1.64
Bones & Joints	3	0.7	0.18	0.7	0.17	1	0.3	0.13	0.3	0.13
Soft Tissue (incl. heart)	15	3.2	0.38	3.6	0.42	14	2.6	0.32	2.9	0.36
Skin (excl. basal & sq.)	162	32.9	1.20	38.4	1.37	119	25.0	1.09	27.8	1.17
Melanoma of the skin	150	30.4	1.15	35.5	1.31	114	24.1	1.07	26.9	1.15
Breast (excl. <i>in situ</i>)	4	0.8	0.19	0.9	0.21	648	125.7	2.33	146.5	2.64
Female Genital System	N/A	N/A	N/A	N/A	N/A	271	51.4	1.47	60.7	1.69
Cervix uteri	N/A	N/A	N/A	N/A	N/A	27	6.3	0.58	6.7	0.59
Uterus corpus	N/A	N/A	N/A	N/A	N/A	149	27.4	1.06	33.2	1.24
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	3	0.4	0.13	0.5	0.16
Ovary	N/A	N/A	N/A	N/A	N/A	56	10.6	0.67	12.6	0.77
Male Genital System	690	126.4	2.22	153.9	2.65	N/A	N/A	N/A	N/A	N/A
Prostate	664	120.3	2.15	147.7	2.59	N/A	N/A	N/A	N/A	N/A
Testis	20	5.0	0.51	4.9	0.50	N/A	N/A	N/A	N/A	N/A
Penis	4	0.9	0.21	1.0	0.23	N/A	N/A	N/A	N/A	N/A
Urinary System	277	55.2	1.53	65.2	1.77	114	21.4	0.95	24.8	1.07
Bladder (incl. <i>in situ</i>)	160	32.4	1.18	37.7	1.35	44	7.8	0.55	9.2	0.63
Kidney & renal pelvis	113	21.8	0.96	26.4	1.13	66	13.1	0.76	14.9	0.84
Ureter	3	0.6	0.16	0.7	0.19	2	0.3	0.10	0.4	0.13
Eye & Orbit	4	0.8	0.18	1.0	0.21	4	0.8	0.19	0.9	0.21
Brain & Other CNS	35	7.7	0.60	8.4	0.64	23	4.5	0.44	5.0	0.48
Brain	35	7.5	0.59	8.2	0.64	22	4.3	0.43	4.8	0.47
Endocrine System	41	9.1	0.66	10.1	0.72	92	22.4	1.09	23.6	1.12
Thyroid gland	39	8.5	0.63	9.5	0.70	89	21.7	1.08	22.9	1.10
Lymphomas	123	25.1	1.04	28.8	1.18	94	17.7	0.85	20.1	0.95
Hodgkin lymphoma	13	2.7	0.35	2.9	0.37	9	2.2	0.33	2.2	0.33
Non-Hodgkin lymphoma	111	22.3	0.98	26.0	1.12	85	15.5	0.79	17.9	0.89
Multiple Myeloma	46	9.1	0.62	10.8	0.72	29	5.1	0.44	6.1	0.52
Leukemias	97	20.0	0.93	22.8	1.05	69	13.4	0.76	14.9	0.82
Acute lymphocytic	6	1.4	0.25	1.1	0.21	7	1.6	0.28	1.3	0.24
Chronic lymphocytic	43	8.6	0.60	10.2	0.70	24	4.2	0.40	5.0	0.47
Acute myeloid	26	5.3	0.48	6.1	0.54	23	4.6	0.45	5.0	0.48
Chronic myeloid	13	2.8	0.36	3.1	0.39	11	2.3	0.32	2.6	0.36
Other leukemias	9	1.9	0.30	2.2	0.33	5	0.8	0.18	0.9	0.19
Mesothelioma	4	0.7	0.17	0.8	0.20	2	0.4	0.13	0.5	0.14
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	42	8.7	0.62	9.9	0.70	78	15.0	0.80	17.3	0.90
Breast (<i>in situ</i>)	*	*	*	*	*	137	27.9	1.13	32.7	1.28

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
South Dakota, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,320	489.2	4.71	578.8	5.46	2,079	432.1	4.52	499.6	5.07
Oral Cavity & Pharynx	82	17.4	0.90	21.1	1.06	32	6.3	0.53	7.6	0.62
Lip	11	2.6	0.35	2.9	0.40	3	0.6	0.17	0.7	0.19
Tongue	23	5.0	0.49	6.0	0.57	8	1.5	0.25	1.9	0.31
Major salivary gland	7	1.5	0.27	1.8	0.30	5	1.1	0.23	1.3	0.26
Floor of mouth	3	0.5	0.14	0.6	0.18	2	0.4	0.15	0.5	0.16
Gum & other mouth	8	1.4	0.23	1.8	0.30	6	1.1	0.21	1.4	0.25
Nasopharynx	3	0.6	0.16	0.7	0.19	*	*	*	*	*
Oropharynx	3	0.7	0.18	0.8	0.21	2	0.4	0.11	0.5	0.14
Hypopharynx	3	0.7	0.18	0.8	0.21	*	*	*	*	*
Digestive System	427	91.7	2.06	108.3	2.39	320	62.1	1.64	72.4	1.88
Esophagus	41	8.4	0.61	10.1	0.71	10	1.9	0.28	2.3	0.33
Stomach	29	6.2	0.54	7.3	0.62	12	2.3	0.32	2.7	0.37
Small intestine	16	3.7	0.43	4.3	0.49	11	2.3	0.33	2.6	0.37
Colon (excl. rectum)	141	30.9	1.21	36.3	1.39	138	26.4	1.07	30.3	1.20
Rectum & rectosigmoid	65	14.7	0.84	17.3	0.98	39	8.3	0.63	9.8	0.73
Anus, anal canal, & anorectum	5	1.1	0.22	1.3	0.27	11	2.0	0.29	2.5	0.36
Liver	34	6.8	0.54	8.4	0.65	9	1.7	0.27	1.9	0.31
Gallbladder	2	0.4	0.13	0.4	0.15	7	1.3	0.23	1.5	0.26
Pancreas	68	13.7	0.77	16.4	0.90	60	11.4	0.69	13.3	0.79
Respiratory System	313	65.1	1.69	77.1	1.97	291	54.7	1.47	64.9	1.73
Larynx	19	3.9	0.41	4.8	0.50	7	1.3	0.25	1.6	0.29
Lung & bronchus	290	60.4	1.63	71.3	1.89	283	52.9	1.45	62.8	1.70
Bones & Joints	3	0.8	0.21	0.8	0.19	*	*	*	*	*
Soft Tissue (incl. heart)	13	3.3	0.41	3.6	0.45	13	2.8	0.37	3.1	0.39
Skin (excl. basal & sq.)	159	35.2	1.30	40.9	1.48	116	27.8	1.24	30.8	1.32
Melanoma of the skin	148	32.6	1.26	38.0	1.42	112	27.0	1.23	29.9	1.30
Breast (excl. <i>in situ</i>)	4	0.9	0.21	1.0	0.23	600	128.0	2.50	149.0	2.81
Female Genital System	N/A	N/A	N/A	N/A	N/A	246	50.9	1.55	60.4	1.78
Cervix uteri	N/A	N/A	N/A	N/A	N/A	21	5.7	0.59	6.0	0.60
Uterus corpus	N/A	N/A	N/A	N/A	N/A	137	27.3	1.11	33.2	1.31
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	0.5	0.14	0.5	0.17
Ovary	N/A	N/A	N/A	N/A	N/A	52	10.7	0.71	12.7	0.82
Male Genital System	642	126.4	2.31	153.8	2.75	N/A	N/A	N/A	N/A	N/A
Prostate	619	119.8	2.22	147.1	2.68	N/A	N/A	N/A	N/A	N/A
Testis	18	5.6	0.60	5.6	0.58	N/A	N/A	N/A	N/A	N/A
Penis	3	0.7	0.18	0.8	0.21	N/A	N/A	N/A	N/A	N/A
Urinary System	261	55.3	1.58	65.5	1.84	103	21.1	1.00	24.4	1.11
Bladder (incl. <i>in situ</i>)	155	33.2	1.22	38.7	1.41	42	8.0	0.58	9.4	0.67
Kidney & renal pelvis	101	21.1	0.98	25.6	1.16	58	12.5	0.80	14.3	0.87
Ureter	3	0.6	0.16	0.7	0.19	2	0.3	0.10	0.4	0.13
Eye & Orbit	4	0.8	0.20	1.0	0.23	4	0.9	0.23	1.0	0.24
Brain & Other CNS	32	8.0	0.65	8.7	0.70	21	4.6	0.48	5.1	0.52
Brain	32	7.8	0.65	8.6	0.69	20	4.4	0.48	4.9	0.51
Endocrine System	37	9.3	0.72	10.4	0.78	82	22.8	1.19	24.0	1.22
Thyroid gland	35	8.8	0.69	9.8	0.76	79	22.0	1.17	23.2	1.20
Lymphomas	117	25.9	1.12	29.8	1.25	87	17.9	0.91	20.3	1.01
Hodgkin lymphoma	12	3.0	0.41	3.2	0.42	8	2.4	0.39	2.4	0.39
Non-Hodgkin lymphoma	105	22.9	1.04	26.6	1.18	78	15.5	0.83	17.9	0.93
Multiple Myeloma	42	8.8	0.63	10.4	0.73	28	5.2	0.46	6.2	0.54
Leukemias	91	20.5	0.99	23.4	1.11	62	13.4	0.81	14.8	0.87
Acute lymphocytic	4	1.2	0.27	1.0	0.23	5	1.5	0.30	1.2	0.25
Chronic lymphocytic	42	8.9	0.63	10.5	0.74	23	4.4	0.43	5.2	0.50
Acute myeloid	25	5.5	0.51	6.4	0.58	21	4.7	0.49	5.1	0.52
Chronic myeloid	12	2.8	0.38	3.2	0.41	10	2.2	0.34	2.6	0.38
Other leukemias	9	2.1	0.33	2.3	0.36	3	0.7	0.17	0.7	0.18
Mesothelioma	4	0.8	0.18	0.9	0.21	2	0.4	0.12	0.4	0.13
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	72	13.0	0.72	14.9	0.82
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	40	9.1	0.67	10.3	0.74	71	15.1	0.85	17.2	0.95
Breast (<i>in situ</i>)	*	*	*	*	*	128	28.9	1.23	33.6	1.37

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
South Dakota, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	21	376.0	48.48	460.5	56.64	9	230.1	40.27	266.4	45.54
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	4	60.9	16.20	72.9	18.79	1	35.2	14.65	41.7	17.14
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	1	14.2	6.06	17.0	7.59	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	2	48.6	20.26	56.4	21.55	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	2	43.3	19.90	49.3	20.93	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	2	53.0	16.35	68.5	21.33
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	8	143.2	25.99	184.0	31.55	N/A	N/A	N/A	N/A	N/A
Prostate	8	140.7	25.88	181.3	31.44	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	2	34.3	17.93	37.3	18.47	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	1	16.2	6.71	19.6	8.36	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	1	20.1	7.73	26.7	10.40	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	*	*	*	*	*	2	39.6	18.23	45.4	19.92
Breast (<i>in situ</i>)	*	*	*	*	*	2	47.6	15.11	59.8	19.21

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
South Dakota, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	9	304.7	55.51	361.3	64.51	13	292.4	42.16	341.8	47.93
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	4	118.9	33.06	136.8	36.63	2	44.6	17.56	56.0	20.68
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	2	45.9	21.72	52.3	23.15	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	2	48.0	19.68	58.1	22.28
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	2	48.0	19.68	58.1	22.28
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	5	107.9	25.58	119.1	27.81
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	43.3	14.94	50.9	17.00
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1	28.9	13.33	31.6	14.20
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	1	64.0	28.16	78.3	34.23	N/A	N/A	N/A	N/A	N/A
Prostate	1	64.0	28.16	78.3	34.23	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	2	23.6	8.37	25.4	9.22
Thyroid gland	*	*	*	*	*	2	23.6	8.37	25.4	9.22
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
South Dakota, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	101	547.8	27.31	655.3	32.07	109	459.6	20.70	537.6	23.96
Oral Cavity & Pharynx	4	21.0	5.28	25.1	6.31	2	7.9	2.74	9.1	3.05
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	1	7.0	2.85	8.3	3.24	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	26	142.1	13.92	170.4	16.36	21	89.5	9.30	107.7	11.00
Esophagus	2	9.6	3.31	12.6	4.14	*	*	*	*	*
Stomach	2	10.3	3.71	11.6	4.14	2	6.0	2.26	8.2	3.04
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	7	45.9	8.60	54.2	10.09	6	26.9	5.09	31.2	5.86
Rectum & rectosigmoid	5	19.4	4.12	23.9	5.03	4	16.8	3.92	19.9	4.58
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	6	32.9	6.89	39.1	8.02	1	6.4	2.51	7.4	2.88
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	3	15.2	4.23	18.5	4.91	3	15.4	3.99	19.0	4.82
Respiratory System	16	96.8	12.29	114.9	14.20	18	81.4	8.95	96.8	10.47
Larynx	2	12.6	4.20	15.5	4.94	*	*	*	*	*
Lung & bronchus	13	80.4	11.31	95.7	13.11	18	78.1	8.78	93.2	10.30
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	26	102.3	9.28	122.4	10.94
Female Genital System	N/A	N/A	N/A	N/A	N/A	14	58.0	7.33	66.3	8.40
Cervix uteri	N/A	N/A	N/A	N/A	N/A	4	16.6	3.87	18.4	4.32
Uterus corpus	N/A	N/A	N/A	N/A	N/A	6	25.8	4.73	29.7	5.43
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	10.3	3.42	11.6	3.86
Male Genital System	28	150.8	13.99	184.5	16.63	N/A	N/A	N/A	N/A	N/A
Prostate	28	147.8	13.91	181.6	16.55	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	11	56.4	8.38	65.4	9.46	7	27.7	4.95	32.8	5.76
Bladder (incl. <i>in situ</i>)	3	16.1	4.76	17.6	5.12	1	6.6	2.77	7.5	3.11
Kidney & renal pelvis	8	38.4	6.62	45.9	7.72	5	20.5	4.06	24.5	4.76
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	2	9.3	3.21	10.0	3.40	5	19.8	4.19	19.6	4.15
Thyroid gland	2	8.3	3.04	9.2	3.29	5	19.8	4.19	19.6	4.15
Lymphomas	4	23.9	6.53	28.4	8.02	4	15.3	3.73	17.3	4.25
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	2	10.5	3.40	12.2	3.93	1	4.1	1.71	5.3	2.16
Leukemias	3	8.3	2.44	9.4	2.93	4	18.4	4.36	20.4	4.96
Acute lymphocytic	1	3.5	1.39	3.3	1.49	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	2	9.3	3.33	11.1	4.00
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	4	18.7	5.07	23.5	6.30	5	26.0	5.28	30.1	6.02
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	1	6.3	3.39	8.4	4.43	2	10.5	3.23	12.1	3.74
Breast (<i>in situ</i>)	*	*	*	*	*	4	14.0	3.20	18.3	4.10

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
South Dakota, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	19	277.5	35.88	327.8	41.62	22	309.8	33.41	356.5	38.22
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	4	58.7	15.63	70.6	17.99	4	61.9	15.34	70.2	17.54
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	2	33.9	13.38	41.1	15.83	1	27.7	11.25	31.1	12.38
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	1	31.2	13.11	37.6	15.44	1	25.6	11.05	28.8	12.17
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	6	74.1	15.62	88.5	18.40
Female Genital System	N/A	N/A	N/A	N/A	N/A	3	31.1	8.34	36.9	10.22
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2	22.6	7.36	27.2	9.10
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	6	84.8	19.72	100.9	23.04	N/A	N/A	N/A	N/A	N/A
Prostate	4	77.4	19.51	93.7	22.86	N/A	N/A	N/A	N/A	N/A
Testis	1	5.9	2.47	5.5	2.30	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	2	22.3	8.88	27.9	11.11	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	2	22.3	7.44	24.3	8.35
Thyroid gland	*	*	*	*	*	2	22.3	7.44	24.3	8.35
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	1	30.7	14.93	32.9	16.39	1	17.9	9.27	19.9	10.12
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	1	15.6	5.94	18.6	7.25

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

SOUTH DAKOTA

II-458 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
South Dakota, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	14	274.2	41.22	318.5	47.03	16	280.6	35.18	320.7	39.95
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	3	61.4	18.86	71.9	21.23	2	41.4	13.52	46.9	15.89
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	1	30.3	12.56	38.6	15.84	1	27.9	12.36	30.4	13.13
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	1	27.1	12.15	34.5	15.30	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	4	56.0	14.58	67.4	17.12
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	30.2	9.08	35.5	11.01
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2	22.3	8.11	27.2	10.06
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	4	83.3	22.60	96.6	25.64	N/A	N/A	N/A	N/A	N/A
Prostate	3	78.4	22.46	92.0	25.53	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	1	17.0	7.36	17.6	7.89
Thyroid gland	*	*	*	*	*	1	17.0	7.36	17.6	7.89
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
South Dakota, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	*	*	*	*	*	*	*	*	*	*
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.


N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	6,595,354	6,651,277	6,714,748	6,778,180	6,830,325
Non-Hispanic White	4,971,981	5,001,325	5,032,656	5,064,186	5,091,198
Non-Hispanic Black	1,142,408	1,152,522	1,164,211	1,174,865	1,183,477
Non-Hispanic Asian/Pacific Islander (NH API)	124,243	128,727	133,940	139,959	143,297
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	0	0	0	0	0


All Races Population 2015–2019: 33,569,884
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	337,444	349,036	363,896	378,723	391,469
Hispanic White	294,052	303,955	316,574	329,573	340,639
Hispanic Black	23,173	24,157	25,345	26,303	27,177

Hispanic/Latino Population, Census 2010: 290,059
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

TENNESSEE CANCER REGISTRY

Initial Operation: 1986
Population-based Data Available: 1986
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	104.3	102.1	105.6	104.7	98.7	103.1
Missing Race	0.1	0.1	0.3	0.9	2.1	0.7
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.3	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.2	2.3	2.3	2.4	2.5	2.4
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.4	Ovary	91.9
Oral Cavity & Pharynx	97.2	Prostate	97.2
Esophagus	94.6	Testis	97.2
Stomach	95.8	Bladder (incl. <i>in situ</i>)	97.6
Colon & Rectum	95.7	Kidney & Renal Pelvis	90.2
Liver	56.7	Brain & Other CNS	85.8
Pancreas	83.4	Brain & Other CNS (non-malig)	34.6
Lung & Bronchus	88.4	Thyroid	99.4
Melanomas of the Skin	98.6	Hodgkin Lymphoma	98.2
Female Breast (excl. <i>in situ</i>)	98.0	Non-Hodgkin Lymphoma	94.2
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	84.3
Cervix Uteri	97.1	Leukemias	82.5
Uterus Corpus & Uterus NOS	98.5		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Tennessee, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	19,992	523.8	1.71	625.5	2.01	18,334	425.2	1.45	498.4	1.67
Oral Cavity & Pharynx	808	20.6	0.33	25.3	0.40	286	6.5	0.18	7.8	0.21
Lip	24	0.7	0.06	0.8	0.07	6	0.1	0.03	0.2	0.03
Tongue	263	6.6	0.19	8.1	0.23	89	2.0	0.10	2.4	0.12
Major salivary gland	61	1.8	0.10	2.0	0.12	36	0.9	0.07	1.0	0.07
Floor of mouth	32	0.8	0.06	1.0	0.08	14	0.3	0.04	0.4	0.04
Gum & other mouth	88	2.3	0.11	2.7	0.13	62	1.4	0.08	1.6	0.09
Nasopharynx	29	0.8	0.07	0.9	0.08	12	0.3	0.04	0.3	0.04
Oropharynx	57	1.4	0.09	1.8	0.11	12	0.3	0.04	0.3	0.04
Hypopharynx	40	1.0	0.07	1.2	0.09	10	0.2	0.03	0.3	0.04
Digestive System	3,749	98.8	0.74	118.6	0.88	2,909	65.9	0.56	78.1	0.65
Esophagus	338	8.6	0.22	10.5	0.26	74	1.6	0.08	2.0	0.10
Stomach	287	7.7	0.21	9.1	0.24	171	4.0	0.14	4.6	0.16
Small intestine	124	3.3	0.14	3.9	0.16	117	2.7	0.11	3.2	0.13
Colon (excl. rectum)	1,179	31.8	0.43	37.8	0.50	1,135	25.8	0.35	30.4	0.41
Rectum & rectosigmoid	534	14.2	0.28	17.1	0.33	372	8.9	0.21	10.4	0.24
Anus, anal canal, & anorectum	63	1.7	0.10	2.0	0.12	130	2.9	0.12	3.6	0.14
Liver	483	11.8	0.25	14.8	0.31	161	3.5	0.13	4.3	0.15
Gallbladder	26	0.7	0.07	0.8	0.07	47	1.0	0.07	1.2	0.08
Pancreas	540	14.2	0.28	17.0	0.33	506	11.1	0.23	13.2	0.27
Respiratory System	3,670	95.3	0.72	114.5	0.86	2,981	64.6	0.54	77.8	0.64
Larynx	274	6.8	0.19	8.5	0.23	80	1.8	0.09	2.2	0.11
Lung & bronchus	3,351	87.2	0.69	104.6	0.82	2,871	62.1	0.53	74.7	0.63
Bones & Joints	40	1.2	0.09	1.2	0.09	34	0.9	0.07	0.9	0.07
Soft Tissue (incl. heart)	145	4.1	0.16	4.6	0.17	108	2.7	0.12	3.0	0.13
Skin (excl. basal & sq.)	1,059	29.1	0.41	34.0	0.48	702	17.2	0.30	19.7	0.34
Melanoma of the skin	991	27.1	0.40	31.7	0.46	664	16.3	0.29	18.7	0.33
Breast (excl. <i>in situ</i>)	48	1.3	0.09	1.5	0.10	5,287	123.9	0.79	146.0	0.91
Female Genital System	N/A	N/A	N/A	N/A	N/A	2,094	49.4	0.50	58.1	0.57
Cervix uteri	N/A	N/A	N/A	N/A	N/A	292	8.1	0.22	8.7	0.23
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,095	24.8	0.35	30.0	0.41
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	43	1.0	0.07	1.2	0.08
Ovary	N/A	N/A	N/A	N/A	N/A	425	10.0	0.22	11.7	0.26
Male Genital System	5,022	123.9	0.80	151.5	0.97	N/A	N/A	N/A	N/A	N/A
Prostate	4,803	117.1	0.78	144.6	0.95	N/A	N/A	N/A	N/A	N/A
Testis	176	5.6	0.19	5.6	0.19	N/A	N/A	N/A	N/A	N/A
Penis	36	0.9	0.07	1.1	0.09	N/A	N/A	N/A	N/A	N/A
Urinary System	2,355	63.7	0.61	75.1	0.71	1,031	23.4	0.34	27.6	0.39
Bladder (incl. <i>in situ</i>)	1,277	35.2	0.45	41.3	0.53	398	8.7	0.20	10.3	0.23
Kidney & renal pelvis	1,025	27.1	0.39	32.2	0.45	602	14.0	0.26	16.5	0.30
Ureter	31	0.8	0.07	1.0	0.08	21	0.5	0.05	0.5	0.05
Eye & Orbit	43	1.2	0.08	1.3	0.09	42	1.0	0.07	1.2	0.08
Brain & Other CNS	266	7.4	0.21	8.3	0.23	220	5.6	0.18	6.1	0.19
Brain	255	7.1	0.20	8.0	0.23	206	5.2	0.17	5.7	0.18
Endocrine System	271	7.5	0.21	8.5	0.23	643	17.7	0.32	19.0	0.34
Thyroid gland	236	6.5	0.20	7.4	0.22	623	17.2	0.32	18.5	0.33
Lymphomas	890	24.6	0.38	28.4	0.43	714	16.7	0.29	19.2	0.32
Hodgkin lymphoma	98	2.9	0.13	3.1	0.14	77	2.2	0.12	2.3	0.12
Non-Hodgkin lymphoma	793	21.7	0.35	25.3	0.41	636	14.5	0.26	16.9	0.30
Multiple Myeloma	310	8.3	0.22	9.8	0.25	238	5.3	0.16	6.3	0.18
Leukemias	583	16.3	0.31	18.6	0.35	429	10.3	0.23	11.5	0.25
Acute lymphocytic	54	1.7	0.11	1.6	0.10	43	1.3	0.09	1.2	0.08
Chronic lymphocytic	197	5.3	0.17	6.3	0.21	121	2.6	0.11	3.1	0.13
Acute myeloid	177	4.9	0.17	5.6	0.19	134	3.2	0.13	3.6	0.14
Chronic myeloid	81	2.3	0.12	2.6	0.13	76	1.9	0.10	2.1	0.11
Other leukemias	74	2.1	0.11	2.5	0.13	55	1.3	0.08	1.5	0.09
Mesothelioma	41	1.2	0.08	1.3	0.10	11	0.2	0.03	0.3	0.04
Kaposi Sarcoma	15	0.4	0.05	0.5	0.06	*	*	*	*	*
Ill-Defined & Unknown	677	18.8	0.33	22.3	0.39	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	312	8.8	0.23	10.0	0.26	709	17.1	0.30	19.5	0.33
Breast (<i>in situ</i>)	6	0.1	0.03	0.2	0.03	1,019	23.8	0.35	28.3	0.40

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Tennessee, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	16,762	522.9	1.86	622.7	2.19	15,287	434.0	1.64	508.3	1.88
Oral Cavity & Pharynx	714	21.9	0.38	26.8	0.46	251	7.0	0.21	8.3	0.24
Lip	23	0.7	0.07	0.9	0.08	6	0.2	0.03	0.2	0.04
Tongue	240	7.2	0.21	8.8	0.26	81	2.3	0.12	2.7	0.14
Major salivary gland	55	1.8	0.11	2.1	0.13	30	0.9	0.08	1.0	0.08
Floor of mouth	29	0.8	0.07	1.1	0.09	12	0.3	0.04	0.4	0.05
Gum & other mouth	76	2.3	0.12	2.8	0.15	54	1.5	0.09	1.7	0.11
Nasopharynx	20	0.6	0.07	0.8	0.08	9	0.3	0.04	0.3	0.05
Oropharynx	48	1.5	0.10	1.8	0.12	10	0.3	0.04	0.4	0.05
Hypopharynx	30	0.9	0.07	1.1	0.09	9	0.2	0.04	0.3	0.05
Digestive System	3,076	96.8	0.81	115.9	0.95	2,338	64.0	0.61	75.7	0.71
Esophagus	298	9.1	0.24	11.0	0.29	61	1.6	0.09	1.9	0.11
Stomach	222	7.0	0.22	8.3	0.25	123	3.4	0.14	4.0	0.16
Small intestine	100	3.2	0.15	3.8	0.17	89	2.5	0.12	2.9	0.14
Colon (excl. rectum)	968	31.3	0.46	36.9	0.54	926	25.4	0.39	29.9	0.45
Rectum & rectosigmoid	445	14.3	0.31	17.1	0.37	299	8.8	0.24	10.3	0.27
Anus, anal canal, & anorectum	53	1.8	0.11	2.1	0.13	117	3.2	0.14	4.0	0.17
Liver	373	10.9	0.26	13.7	0.32	122	3.2	0.14	3.9	0.16
Gallbladder	20	0.7	0.07	0.7	0.08	34	0.9	0.07	1.1	0.08
Pancreas	453	14.0	0.30	16.8	0.36	406	10.7	0.24	12.7	0.29
Respiratory System	3,176	96.8	0.79	116.3	0.94	2,604	67.8	0.61	81.8	0.73
Larynx	227	6.8	0.21	8.5	0.25	69	1.9	0.11	2.4	0.13
Lung & bronchus	2,910	88.7	0.75	106.3	0.90	2,510	65.1	0.59	78.5	0.71
Bones & Joints	33	1.3	0.10	1.3	0.10	28	0.9	0.09	1.0	0.09
Soft Tissue (incl. heart)	119	4.1	0.17	4.6	0.19	82	2.6	0.13	2.8	0.14
Skin (excl. basal & sq.)	1,003	32.8	0.48	38.3	0.55	652	20.2	0.37	22.9	0.41
Melanoma of the skin	941	30.6	0.46	35.8	0.53	623	19.4	0.37	22.0	0.40
Breast (excl. <i>in situ</i>)	39	1.3	0.09	1.5	0.11	4,362	125.2	0.89	147.5	1.02
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,714	50.3	0.57	59.0	0.65
Cervix uteri	N/A	N/A	N/A	N/A	N/A	223	8.2	0.26	8.7	0.26
Uterus corpus	N/A	N/A	N/A	N/A	N/A	901	25.1	0.39	30.5	0.46
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	27	0.8	0.07	0.9	0.08
Ovary	N/A	N/A	N/A	N/A	N/A	358	10.4	0.26	12.1	0.29
Male Genital System	3,897	114.5	0.84	139.1	1.01	N/A	N/A	N/A	N/A	N/A
Prostate	3,707	106.7	0.80	131.2	0.98	N/A	N/A	N/A	N/A	N/A
Testis	152	6.7	0.25	6.5	0.24	N/A	N/A	N/A	N/A	N/A
Penis	30	1.0	0.08	1.1	0.09	N/A	N/A	N/A	N/A	N/A
Urinary System	2,072	66.2	0.67	78.0	0.78	859	23.6	0.37	27.8	0.43
Bladder (incl. <i>in situ</i>)	1,172	37.5	0.50	44.0	0.59	354	9.3	0.23	11.0	0.27
Kidney & renal pelvis	853	27.1	0.43	32.2	0.50	478	13.7	0.29	16.1	0.34
Ureter	30	0.9	0.08	1.1	0.09	19	0.5	0.05	0.6	0.06
Eye & Orbit	39	1.3	0.10	1.5	0.11	39	1.2	0.09	1.3	0.10
Brain & Other CNS	230	8.0	0.24	8.9	0.27	190	6.2	0.21	6.7	0.22
Brain	221	7.6	0.24	8.5	0.26	179	5.7	0.20	6.2	0.21
Endocrine System	236	8.2	0.25	9.2	0.27	529	19.1	0.39	20.4	0.40
Thyroid gland	213	7.3	0.23	8.3	0.26	515	18.6	0.39	19.9	0.40
Lymphomas	774	25.5	0.42	29.5	0.48	609	17.3	0.33	20.0	0.37
Hodgkin lymphoma	75	2.9	0.15	3.1	0.16	61	2.3	0.14	2.4	0.14
Non-Hodgkin lymphoma	700	22.6	0.39	26.5	0.46	548	15.0	0.30	17.6	0.34
Multiple Myeloma	233	7.3	0.22	8.6	0.26	160	4.2	0.15	5.0	0.18
Leukemias	500	16.9	0.35	19.2	0.39	356	10.5	0.26	11.8	0.28
Acute lymphocytic	41	1.8	0.13	1.7	0.12	32	1.4	0.11	1.2	0.10
Chronic lymphocytic	173	5.4	0.19	6.5	0.22	104	2.7	0.12	3.2	0.14
Acute myeloid	150	5.0	0.19	5.8	0.21	111	3.2	0.14	3.7	0.16
Chronic myeloid	69	2.4	0.13	2.7	0.15	62	1.9	0.11	2.1	0.12
Other leukemias	66	2.2	0.13	2.6	0.15	48	1.3	0.09	1.5	0.10
Mesothelioma	39	1.3	0.09	1.5	0.11	10	0.2	0.04	0.3	0.04
Kaposi Sarcoma	5	0.2	0.04	0.2	0.04	*	*	*	*	*
Ill-Defined & Unknown	575	18.8	0.36	22.2	0.42	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	264	9.1	0.26	10.2	0.29	588	17.5	0.34	20.0	0.38
Breast (<i>in situ</i>)	4	0.1	0.03	0.2	0.03	827	23.8	0.39	28.4	0.45

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

TENNESSEE

II-464 Incidence – NH White

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Tennessee, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,588	552.8	5.32	670.3	6.26	2,433	396.4	3.71	466.8	4.28
Oral Cavity & Pharynx	74	15.1	0.84	18.3	1.00	26	4.1	0.38	5.0	0.44
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	17	3.3	0.38	4.1	0.46	5	0.8	0.17	1.0	0.20
Major salivary gland	5	1.3	0.27	1.5	0.31	5	0.8	0.17	0.9	0.18
Floor of mouth	3	0.5	0.14	0.6	0.17	2	0.3	0.09	0.3	0.12
Gum & other mouth	8	1.8	0.30	2.2	0.36	5	0.9	0.18	1.0	0.21
Nasopharynx	6	1.1	0.20	1.3	0.24	3	0.4	0.12	0.5	0.14
Oropharynx	8	1.7	0.29	2.1	0.34	1	0.2	0.09	0.3	0.11
Hypopharynx	10	2.0	0.31	2.5	0.36	1	0.2	0.07	0.3	0.10
Digestive System	549	117.1	2.45	142.3	2.88	479	78.4	1.66	93.4	1.93
Esophagus	31	6.3	0.55	7.8	0.66	11	1.7	0.24	2.2	0.29
Stomach	52	12.1	0.83	14.3	0.95	39	6.7	0.49	7.7	0.56
Small intestine	21	4.4	0.47	5.2	0.53	26	4.2	0.37	4.9	0.43
Colon (excl. rectum)	180	39.2	1.43	47.4	1.68	180	29.6	1.02	35.2	1.19
Rectum & rectosigmoid	70	15.2	0.89	18.2	1.04	58	9.4	0.57	11.2	0.67
Anus, anal canal, & anorectum	9	1.8	0.28	2.1	0.32	11	1.8	0.26	2.1	0.29
Liver	87	15.4	0.78	20.0	0.98	30	4.4	0.38	5.5	0.46
Gallbladder	5	1.3	0.27	1.5	0.31	9	1.5	0.23	1.9	0.28
Pancreas	73	16.6	0.95	19.9	1.11	87	14.6	0.73	17.3	0.84
Respiratory System	435	98.0	2.31	118.7	2.71	323	52.3	1.35	63.1	1.59
Larynx	41	8.2	0.62	10.2	0.74	10	1.5	0.22	1.9	0.27
Lung & bronchus	389	88.6	2.21	107.1	2.59	309	50.2	1.32	60.5	1.56
Bones & Joints	4	1.0	0.25	1.1	0.27	4	0.6	0.14	0.6	0.15
Soft Tissue (incl. heart)	19	4.2	0.46	4.5	0.51	20	3.4	0.35	3.8	0.39
Skin (excl. basal & sq.)	6	1.3	0.24	1.4	0.25	11	1.8	0.26	2.0	0.28
Melanoma of the skin	3	0.5	0.16	0.6	0.17	4	0.7	0.16	0.8	0.18
Breast (excl. <i>in situ</i>)	8	2.0	0.33	2.3	0.37	755	122.1	2.05	143.7	2.36
Female Genital System	N/A	N/A	N/A	N/A	N/A	300	47.7	1.28	56.4	1.47
Cervix uteri	N/A	N/A	N/A	N/A	N/A	53	8.7	0.55	9.8	0.61
Uterus corpus	N/A	N/A	N/A	N/A	N/A	154	23.8	0.89	28.7	1.04
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	15	2.6	0.30	3.0	0.35
Ovary	N/A	N/A	N/A	N/A	N/A	50	8.0	0.52	9.5	0.61
Male Genital System	932	188.6	3.00	234.8	3.61	N/A	N/A	N/A	N/A	N/A
Prostate	920	186.3	2.99	232.4	3.59	N/A	N/A	N/A	N/A	N/A
Testis	7	1.4	0.24	1.4	0.23	N/A	N/A	N/A	N/A	N/A
Penis	4	0.8	0.20	1.0	0.23	N/A	N/A	N/A	N/A	N/A
Urinary System	226	50.1	1.63	59.6	1.89	145	23.9	0.92	28.2	1.06
Bladder (incl. <i>in situ</i>)	79	19.5	1.09	23.3	1.27	38	6.4	0.49	7.6	0.56
Kidney & renal pelvis	143	29.7	1.19	35.2	1.37	105	17.0	0.77	20.0	0.89
Ureter	1	0.3	0.12	0.3	0.14	2	0.3	0.12	0.3	0.12
Eye & Orbit	1	0.2	0.08	0.2	0.07	*	*	*	*	*
Brain & Other CNS	25	4.9	0.47	5.5	0.53	20	3.5	0.36	3.6	0.37
Brain	23	4.5	0.45	5.0	0.50	18	3.1	0.34	3.2	0.35
Endocrine System	19	3.8	0.41	4.3	0.46	73	12.0	0.64	13.2	0.70
Thyroid gland	12	2.4	0.33	2.7	0.36	69	11.3	0.62	12.4	0.67
Lymphomas	81	17.3	0.94	19.6	1.06	79	13.2	0.68	14.7	0.75
Hodgkin lymphoma	17	3.1	0.36	3.1	0.37	11	1.8	0.25	1.8	0.25
Non-Hodgkin lymphoma	64	14.2	0.87	16.5	0.99	67	11.3	0.63	12.9	0.71
Multiple Myeloma	67	15.6	0.93	18.4	1.07	69	11.6	0.65	13.7	0.75
Leukemias	54	12.5	0.84	14.3	0.95	46	7.6	0.52	8.7	0.58
Acute lymphocytic	5	0.9	0.19	0.9	0.21	4	0.6	0.14	0.7	0.15
Chronic lymphocytic	16	4.2	0.51	4.9	0.59	11	1.9	0.26	2.3	0.31
Acute myeloid	19	4.4	0.50	4.9	0.55	17	2.8	0.31	3.2	0.35
Chronic myeloid	10	2.0	0.32	2.4	0.38	9	1.4	0.22	1.6	0.24
Other leukemias	4	1.0	0.24	1.2	0.27	5	0.9	0.17	1.0	0.20
Mesothelioma	1	0.3	0.13	0.3	0.14	*	*	*	*	*
Kaposi Sarcoma	8	1.3	0.22	1.4	0.23	*	*	*	*	*
Ill-Defined & Unknown	79	19.6	1.10	23.3	1.29	81	13.8	0.71	16.1	0.81
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	39	9.3	0.73	10.5	0.83	94	15.6	0.74	18.0	0.84
Breast (<i>in situ</i>)	*	*	*	*	*	162	25.8	0.94	30.7	1.09

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Tennessee, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	116	246.5	11.12	292.5	13.08	155	248.1	9.36	285.6	10.78
Oral Cavity & Pharynx	6	10.8	1.93	13.1	2.38	4	6.1	1.46	7.4	1.74
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	1	2.3	0.87	2.9	1.14	*	*	*	*	*
Major salivary gland	*	*	*	*	*	1	1.8	0.78	2.3	0.96
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	2	2.9	1.02	3.5	1.25	2	2.7	0.98	3.1	1.11
Nasopharynx	1	2.3	0.86	2.5	0.96	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	32	69.2	6.02	84.4	7.20	25	42.8	4.09	50.6	4.77
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	3	7.1	1.87	8.6	2.25	3	4.2	1.22	5.1	1.44
Small intestine	1	2.2	0.90	2.7	1.11	*	*	*	*	*
Colon (excl. rectum)	7	15.4	2.75	18.0	3.19	7	10.5	1.96	13.2	2.39
Rectum & rectosigmoid	6	12.9	2.59	15.8	3.14	5	7.5	1.53	8.8	1.79
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	8	17.6	3.17	21.8	3.79	3	6.1	1.76	7.1	2.01
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	3	8.2	2.34	10.0	2.77	4	8.3	1.92	9.3	2.14
Respiratory System	17	42.0	4.95	49.5	5.74	18	30.3	3.37	35.2	3.90
Larynx	1	2.6	1.08	3.1	1.28	*	*	*	*	*
Lung & bronchus	15	38.8	4.81	45.6	5.56	17	29.4	3.33	34.3	3.86
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	1	1.9	0.71	1.9	0.75
Skin (excl. basal & sq.)	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	*	*	*	*	*	2	3.0	1.10	3.4	1.26
Breast (excl. <i>in situ</i>)	*	*	*	*	*	49	72.9	4.82	85.8	5.69
Female Genital System	N/A	N/A	N/A	N/A	N/A	19	30.8	3.29	36.2	3.85
Cervix uteri	N/A	N/A	N/A	N/A	N/A	3	4.8	1.36	5.7	1.62
Uterus corpus	N/A	N/A	N/A	N/A	N/A	9	14.0	2.12	16.9	2.53
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	5	8.2	1.68	9.5	1.96
Male Genital System	26	56.8	5.24	68.4	6.21	N/A	N/A	N/A	N/A	N/A
Prostate	24	53.5	5.15	65.2	6.14	N/A	N/A	N/A	N/A	N/A
Testis	2	2.9	0.88	2.7	0.82	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	9	19.7	3.07	23.0	3.55	5	8.9	1.83	10.1	2.08
Bladder (incl. <i>in situ</i>)	5	11.1	2.43	13.4	2.88	1	2.3	0.89	2.8	1.11
Kidney & renal pelvis	5	8.6	1.86	9.6	2.09	3	5.6	1.43	6.1	1.55
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	4.1	1.19	4.3	1.30	3	4.0	1.13	3.8	1.09
Brain	2	3.4	1.09	3.5	1.17	3	4.0	1.13	3.8	1.09
Endocrine System	4	6.3	1.53	7.2	1.77	13	19.2	2.45	19.9	2.60
Thyroid gland	2	4.2	1.26	4.7	1.42	13	18.3	2.40	19.2	2.57
Lymphomas	7	13.7	2.62	15.8	3.06	6	10.5	2.08	11.4	2.28
Hodgkin lymphoma	1	1.6	0.67	1.8	0.75	*	*	*	*	*
Non-Hodgkin lymphoma	5	12.1	2.53	14.0	2.97	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	2	2.6	0.94	3.2	1.14	2	3.2	1.11	3.8	1.31
Leukemias	4	10.1	2.56	10.9	2.83	5	8.0	1.63	8.8	1.81
Acute lymphocytic	*	*	*	*	*	1	1.7	0.70	1.5	0.64
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	2	4.3	1.56	4.7	1.72	1	2.1	0.81	2.4	0.93
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	3	5.7	1.53	6.7	1.84	3	5.3	1.54	6.0	1.76
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	3	5.1	1.55	5.8	1.82	7	11.6	2.12	12.6	2.31
Breast (<i>in situ</i>)	*	*	*	*	*	11	17.6	2.41	20.8	2.84

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

TENNESSEE

II-466 Incidence – NH API

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Tennessee, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	264	317.8	10.43	375.7	12.08	289	321.4	9.63	372.8	11.17
Oral Cavity & Pharynx	7	7.2	1.34	9.2	1.69	4	4.3	1.14	4.9	1.32
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	3	2.3	0.65	3.1	0.91	1	0.9	0.39	1.1	0.49
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	62	73.4	4.92	88.4	5.76	43	55.8	4.24	65.5	4.90
Esophagus	5	6.0	1.34	6.9	1.49	*	*	*	*	*
Stomach	9	10.3	1.87	11.9	2.11	5	6.2	1.35	7.5	1.61
Small intestine	1	1.0	0.44	1.3	0.59	*	*	*	*	*
Colon (excl. rectum)	13	14.8	2.23	18.4	2.70	12	14.8	2.15	17.4	2.53
Rectum & rectosigmoid	8	9.2	1.71	10.9	1.99	6	5.5	1.13	6.3	1.35
Anus, anal canal, & anorectum	*	*	*	*	*	1	1.5	0.65	1.9	0.78
Liver	11	13.4	2.06	16.7	2.49	6	9.2	1.87	10.6	2.10
Gallbladder	*	*	*	*	*	2	3.5	1.19	3.8	1.26
Pancreas	8	11.5	2.07	13.6	2.36	6	9.6	1.84	11.4	2.10
Respiratory System	28	42.4	4.09	51.1	4.78	24	34.8	3.45	42.0	4.03
Larynx	3	4.3	1.34	5.0	1.54	1	1.4	0.53	1.8	0.71
Lung & bronchus	25	37.6	3.82	45.4	4.47	22	32.9	3.40	39.6	3.95
Bones & Joints	2	0.8	0.30	0.8	0.31	*	*	*	*	*
Soft Tissue (incl. heart)	5	4.1	1.01	4.5	1.15	2	2.2	0.84	2.2	0.92
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	8	9.4	1.69	11.4	2.01
Melanoma of the skin	6	9.2	1.95	10.8	2.22	6	8.2	1.60	9.9	1.90
Breast (excl. <i>in situ</i>)	*	*	*	*	*	82	91.1	4.97	106.9	5.82
Female Genital System	N/A	N/A	N/A	N/A	N/A	43	43.9	3.40	50.4	3.93
Cervix uteri	N/A	N/A	N/A	N/A	N/A	11	9.9	1.53	11.1	1.72
Uterus corpus	N/A	N/A	N/A	N/A	N/A	21	21.8	2.42	25.4	2.82
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	8	8.2	1.45	9.2	1.67
Male Genital System	63	84.7	5.54	100.9	6.40	N/A	N/A	N/A	N/A	N/A
Prostate	52	79.5	5.50	95.5	6.35	N/A	N/A	N/A	N/A	N/A
Testis	11	5.0	0.71	5.1	0.74	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	30	38.6	3.73	45.6	4.31	15	17.3	2.27	19.7	2.61
Bladder (incl. <i>in situ</i>)	11	18.6	2.80	21.4	3.14	3	4.5	1.37	5.2	1.56
Kidney & renal pelvis	19	19.9	2.46	23.9	2.93	12	11.9	1.71	13.5	1.98
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	1	1.4	0.77	1.4	0.86	2	1.4	0.62	1.5	0.73
Brain & Other CNS	7	5.0	0.97	5.4	1.13	5	4.2	1.02	4.8	1.21
Brain	7	4.8	0.96	5.3	1.12	4	4.0	1.00	4.6	1.20
Endocrine System	8	5.7	1.09	6.4	1.24	20	15.3	1.72	15.8	1.83
Thyroid gland	6	4.5	0.96	5.1	1.11	20	14.8	1.67	15.1	1.77
Lymphomas	16	16.9	2.29	18.7	2.54	12	13.3	1.99	15.4	2.30
Hodgkin lymphoma	3	3.3	0.99	3.6	1.08	3	2.0	0.51	2.1	0.57
Non-Hodgkin lymphoma	13	13.6	2.06	15.1	2.30	9	11.4	1.92	13.3	2.23
Multiple Myeloma	5	6.4	1.57	7.0	1.72	4	4.3	1.05	5.3	1.28
Leukemias	15	10.8	1.57	12.2	1.83	13	10.6	1.59	12.0	1.88
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	2	2.9	1.02	3.5	1.17	2	1.7	0.65	2.2	0.82
Acute myeloid	4	3.2	0.80	4.0	1.02	4	3.2	0.83	3.8	1.03
Chronic myeloid	2	0.9	0.35	1.0	0.42	2	2.8	0.95	3.3	1.10
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	8	9.2	1.76	10.9	2.04	10	12.6	2.12	14.1	2.37
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	5	5.1	1.26	5.8	1.38	14	13.9	1.85	16.6	2.28
Breast (<i>in situ</i>)	*	*	*	*	*	13	13.3	1.79	15.8	2.15

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

TENNESSEE

II-468 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Tennessee, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	200	269.1	10.07	317.8	11.64	226	283.9	9.60	329.1	11.12
Oral Cavity & Pharynx	6	6.1	1.20	7.9	1.57	3	3.7	1.18	4.3	1.35
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	2.3	0.69	3.2	0.96	1	1.0	0.44	1.3	0.55
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	48	63.4	4.86	75.8	5.65	33	49.4	4.25	57.7	4.90
Esophagus	4	5.5	1.37	6.3	1.52	*	*	*	*	*
Stomach	6	8.4	1.79	9.9	2.04	4	5.0	1.25	6.1	1.53
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	10	13.1	2.22	16.2	2.67	10	14.2	2.24	16.7	2.62
Rectum & rectosigmoid	7	8.8	1.80	10.3	2.06	4	4.7	1.08	5.4	1.30
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	9	11.7	2.03	14.6	2.46	5	8.3	1.86	9.5	2.10
Gallbladder	*	*	*	*	*	2	3.5	1.28	3.8	1.35
Pancreas	5	8.6	1.93	9.8	2.14	5	8.1	1.85	9.5	2.07
Respiratory System	22	36.0	3.88	43.5	4.55	19	30.5	3.43	36.6	3.98
Larynx	2	3.2	1.22	3.6	1.35	*	*	*	*	*
Lung & bronchus	20	32.8	3.69	39.9	4.35	17	29.1	3.39	34.8	3.91
Bones & Joints	1	0.7	0.31	0.7	0.32	*	*	*	*	*
Soft Tissue (incl. heart)	4	3.4	1.00	3.9	1.16	2	2.3	0.94	2.4	1.04
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	5	9.2	2.03	10.9	2.34	6	7.9	1.64	9.7	1.98
Breast (excl. <i>in situ</i>)	*	*	*	*	*	66	82.5	5.02	96.8	5.87
Female Genital System	N/A	N/A	N/A	N/A	N/A	33	36.8	3.25	42.2	3.75
Cervix uteri	N/A	N/A	N/A	N/A	N/A	8	7.6	1.44	8.5	1.62
Uterus corpus	N/A	N/A	N/A	N/A	N/A	17	19.3	2.38	22.6	2.77
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	7	7.6	1.49	8.5	1.72
Male Genital System	42	66.2	5.20	78.4	5.97	N/A	N/A	N/A	N/A	N/A
Prostate	36	62.8	5.16	75.0	5.93	N/A	N/A	N/A	N/A	N/A
Testis	6	3.2	0.62	3.3	0.66	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	24	34.7	3.67	40.7	4.21	11	14.8	2.30	17.0	2.63
Bladder (incl. <i>in situ</i>)	10	17.6	2.79	20.4	3.14	2	4.6	1.50	5.3	1.72
Kidney & renal pelvis	14	16.9	2.37	20.0	2.78	9	9.3	1.60	10.6	1.85
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	1	1.4	0.70	1.6	0.83
Brain & Other CNS	6	5.1	1.06	5.7	1.23	4	3.9	1.06	4.4	1.23
Brain	6	5.1	1.06	5.7	1.23	3	3.7	1.05	4.2	1.22
Endocrine System	7	5.4	1.09	6.1	1.26	16	14.2	1.78	14.6	1.89
Thyroid gland	5	4.4	1.02	5.0	1.19	16	13.8	1.74	14.2	1.84
Lymphomas	13	14.4	2.17	16.1	2.42	10	12.6	2.07	14.5	2.39
Hodgkin lymphoma	3	2.7	0.86	2.9	0.95	3	1.8	0.52	1.9	0.59
Non-Hodgkin lymphoma	10	11.7	1.99	13.1	2.23	7	10.7	2.01	12.6	2.32
Multiple Myeloma	3	4.5	1.38	5.0	1.54	3	3.9	1.03	4.8	1.28
Leukemias	12	10.0	1.65	11.3	1.90	9	8.8	1.47	10.3	1.81
Acute lymphocytic	5	2.5	0.52	2.4	0.55	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	2	3.2	1.13	3.9	1.30	1	1.4	0.59	1.9	0.78
Acute myeloid	3	2.6	0.77	3.3	0.98	3	3.0	0.87	3.6	1.09
Chronic myeloid	*	*	*	*	*	2	2.5	0.88	3.0	1.08
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	6	7.5	1.68	8.9	1.96	7	9.2	1.88	10.4	2.12
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	5	5.2	1.35	5.8	1.47	11	12.4	1.85	14.8	2.27
Breast (<i>in situ</i>)	*	*	*	*	*	10	11.2	1.77	13.3	2.12

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Tennessee, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	8	204.9	40.61	251.5	47.89	10	181.5	28.58	219.9	34.34
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	2	55.4	20.82	70.9	25.12	1	25.3	11.39	30.0	13.12
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	1	30.1	12.10	39.9	15.41
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	3	51.8	12.97	61.0	15.98
Female Genital System	N/A	N/A	N/A	N/A	N/A	1	18.6	7.88	25.1	10.87
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	2	46.9	17.16	59.5	20.33	N/A	N/A	N/A	N/A	N/A
Prostate	2	45.4	17.09	58.0	20.27	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	2	47.2	22.97	58.6	28.08	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	1	28.3	16.39	36.1	21.04	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


TENNESSEE

II-470 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	27,468,531	27,914,064	28,291,024	28,624,564	28,986,794
Non-Hispanic White	12,033,409	12,093,581	12,126,570	12,150,756	12,188,877
Non-Hispanic Black	3,332,232	3,411,704	3,485,906	3,553,809	3,624,100
Non-Hispanic Asian/Pacific Islander (NH API)	1,344,795	1,413,077	1,475,453	1,524,514	1,574,712
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	4,103	4,057	4,113	4,148	4,123


All Races Population 2015–2019: 141,284,977
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	10,656,323	10,892,261	11,098,277	11,289,269	11,491,337
Hispanic White	10,137,084	10,355,340	10,544,252	10,718,029	10,900,818
Hispanic Black	234,398	244,830	254,733	264,690	274,279

Hispanic/Latino Population, Census 2010: 9,460,921
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

TEXAS CANCER REGISTRY

Initial Operation: 1976
Population-based Data Available: 1995
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	102.6	102.8	102.5	103.8	101.4	102.6
Missing Race	0.2	0.3	0.3	0.4	1.2	0.5
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.4	2.5	2.2	2.4	1.8	2.3
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	90.2	Ovary	89.9
Oral Cavity & Pharynx	95.3	Prostate	93.6
Esophagus	91.0	Testis	97.1
Stomach	93.5	Bladder (incl. <i>in situ</i>)	95.7
Colon & Rectum	94.7	Kidney & Renal Pelvis	85.6
Liver	47.7	Brain & Other CNS	80.9
Pancreas	80.7	Brain & Other CNS (non-malig)	35.1
Lung & Bronchus	86.4	Thyroid	98.4
Melanomas of the Skin	98.2	Hodgkin Lymphoma	96.5
Female Breast (excl. <i>in situ</i>)	97.6	Non-Hodgkin Lymphoma	93.9
Female Breast (<i>in situ</i>)	99.9	Multiple Myeloma	87.0
Cervix Uteri	94.2	Leukemias	86.1
Uterus Corpus & Uterus NOS	97.3		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Texas, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	60,563	458.8	0.86	545.0	1.01	57,875	385.1	0.73	449.2	0.84
Oral Cavity & Pharynx	2,422	17.5	0.16	21.3	0.20	883	5.8	0.09	6.9	0.10
Lip	77	0.6	0.03	0.7	0.04	16	0.1	0.01	0.1	0.01
Tongue	767	5.5	0.09	6.7	0.11	278	1.8	0.05	2.2	0.06
Major salivary gland	209	1.7	0.05	1.9	0.06	142	1.0	0.04	1.1	0.04
Floor of mouth	82	0.6	0.03	0.7	0.04	32	0.2	0.02	0.3	0.02
Gum & other mouth	241	1.8	0.05	2.2	0.06	174	1.2	0.04	1.3	0.05
Nasopharynx	96	0.7	0.03	0.8	0.04	43	0.3	0.02	0.3	0.02
Oropharynx	200	1.4	0.05	1.7	0.06	45	0.3	0.02	0.4	0.02
Hypopharynx	130	0.9	0.04	1.1	0.05	31	0.2	0.02	0.2	0.02
Digestive System	13,660	102.6	0.40	123.4	0.48	9,884	65.1	0.30	77.2	0.35
Esophagus	910	6.9	0.10	8.3	0.12	231	1.5	0.04	1.8	0.05
Stomach	1,090	8.5	0.12	10.0	0.14	750	5.0	0.08	5.9	0.10
Small intestine	381	2.9	0.07	3.4	0.08	307	2.0	0.05	2.4	0.06
Colon (excl. rectum)	3,978	30.5	0.22	36.2	0.26	3,530	23.4	0.18	27.6	0.21
Rectum & rectosigmoid	2,014	14.8	0.15	17.8	0.18	1,260	8.3	0.11	9.9	0.13
Anus, anal canal, & anorectum	197	1.5	0.05	1.7	0.06	317	2.0	0.05	2.5	0.06
Liver	2,376	16.5	0.16	20.9	0.19	807	5.2	0.08	6.3	0.10
Gallbladder	110	0.9	0.04	1.0	0.04	228	1.5	0.04	1.8	0.05
Pancreas	1,891	14.7	0.16	17.6	0.18	1,723	11.3	0.12	13.4	0.15
Respiratory System	8,128	63.7	0.33	75.5	0.38	6,506	42.6	0.24	50.6	0.28
Larynx	692	5.1	0.09	6.2	0.11	151	1.0	0.04	1.2	0.04
Lung & bronchus	7,291	57.6	0.31	68.1	0.36	6,270	41.1	0.24	48.8	0.28
Bones & Joints	158	1.1	0.04	1.2	0.04	131	0.9	0.04	0.9	0.04
Soft Tissue (incl. heart)	489	3.8	0.08	4.2	0.09	390	2.7	0.06	2.9	0.07
Skin (excl. basal & sq.)	2,637	20.8	0.19	24.3	0.22	1,653	11.2	0.13	12.8	0.14
Melanoma of the skin	2,433	19.1	0.18	22.3	0.21	1,525	10.4	0.12	11.8	0.14
Breast (excl. <i>in situ</i>)	166	1.3	0.05	1.5	0.05	17,596	117.1	0.40	137.7	0.47
Female Genital System	N/A	N/A	N/A	N/A	N/A	7,177	47.7	0.26	55.6	0.29
Cervix uteri	N/A	N/A	N/A	N/A	N/A	1,318	9.4	0.12	10.1	0.12
Uterus corpus	N/A	N/A	N/A	N/A	N/A	3,490	22.5	0.17	27.1	0.21
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	213	1.4	0.04	1.7	0.05
Ovary	N/A	N/A	N/A	N/A	N/A	1,564	10.5	0.12	12.2	0.14
Male Genital System	15,095	109.3	0.41	132.6	0.49	N/A	N/A	N/A	N/A	N/A
Prostate	14,171	102.6	0.40	125.9	0.48	N/A	N/A	N/A	N/A	N/A
Testis	778	5.5	0.09	5.4	0.09	N/A	N/A	N/A	N/A	N/A
Penis	122	1.0	0.04	1.1	0.05	N/A	N/A	N/A	N/A	N/A
Urinary System	6,822	53.4	0.30	63.0	0.35	3,138	20.7	0.17	24.3	0.20
Bladder (incl. <i>in situ</i>)	3,153	25.9	0.21	30.4	0.25	921	6.1	0.09	7.1	0.11
Kidney & renal pelvis	3,552	26.4	0.20	31.4	0.24	2,144	14.1	0.14	16.6	0.16
Ureter	68	0.6	0.03	0.7	0.04	47	0.3	0.02	0.4	0.02
Eye & Orbit	131	1.0	0.04	1.1	0.04	107	0.7	0.03	0.8	0.03
Brain & Other CNS	954	7.0	0.10	7.8	0.12	793	5.4	0.09	5.9	0.09
Brain	891	6.6	0.10	7.4	0.11	728	4.9	0.08	5.4	0.09
Endocrine System	968	7.1	0.10	8.0	0.12	2,581	18.1	0.16	19.6	0.17
Thyroid gland	860	6.3	0.10	7.1	0.11	2,479	17.4	0.16	18.9	0.17
Lymphomas	3,055	23.6	0.20	27.1	0.22	2,441	16.4	0.15	18.8	0.17
Hodgkin lymphoma	366	2.7	0.06	2.8	0.07	292	2.0	0.05	2.1	0.06
Non-Hodgkin lymphoma	2,689	20.9	0.19	24.3	0.21	2,149	14.3	0.14	16.6	0.16
Multiple Myeloma	1,165	9.1	0.12	10.8	0.14	944	6.3	0.09	7.4	0.11
Leukemias	2,261	17.7	0.17	20.0	0.19	1,635	11.1	0.12	12.3	0.14
Acute lymphocytic	307	2.1	0.06	2.0	0.05	238	1.7	0.05	1.5	0.05
Chronic lymphocytic	760	6.0	0.10	7.2	0.12	495	3.3	0.07	3.9	0.08
Acute myeloid	553	4.4	0.09	5.0	0.10	458	3.1	0.07	3.5	0.07
Chronic myeloid	338	2.7	0.07	3.0	0.07	228	1.5	0.05	1.8	0.05
Other leukemias	304	2.5	0.07	2.8	0.07	216	1.5	0.05	1.6	0.05
Mesothelioma	144	1.2	0.05	1.4	0.05	46	0.3	0.02	0.4	0.02
Kaposi Sarcoma	114	0.8	0.04	0.9	0.04	12	0.1	0.01	0.1	0.01
Ill-Defined & Unknown	2,193	17.8	0.18	20.8	0.20	1,957	13.1	0.13	15.1	0.15
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	1,282	9.9	0.13	11.2	0.14	2,767	18.6	0.16	21.4	0.18
Breast (<i>in situ</i>)	15	0.1	0.01	0.1	0.02	3,384	22.4	0.18	26.6	0.21

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Texas, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	38,419	495.8	1.16	587.6	1.36	34,766	419.1	1.05	487.8	1.19
Oral Cavity & Pharynx	1,801	22.6	0.25	27.7	0.30	600	7.0	0.13	8.4	0.16
Lip	62	0.8	0.05	1.0	0.06	13	0.1	0.02	0.2	0.02
Tongue	606	7.5	0.14	9.2	0.17	202	2.4	0.08	2.8	0.09
Major salivary gland	154	2.1	0.08	2.4	0.09	79	1.0	0.05	1.1	0.06
Floor of mouth	60	0.7	0.04	0.9	0.05	24	0.3	0.03	0.3	0.03
Gum & other mouth	162	2.1	0.08	2.5	0.09	117	1.3	0.06	1.6	0.07
Nasopharynx	52	0.7	0.04	0.8	0.05	21	0.3	0.03	0.3	0.03
Oropharynx	150	1.8	0.07	2.3	0.08	32	0.4	0.03	0.4	0.04
Hypopharynx	83	1.0	0.05	1.2	0.06	22	0.2	0.02	0.3	0.03
Digestive System	7,577	97.8	0.52	117.1	0.61	5,430	62.5	0.39	73.8	0.46
Esophagus	661	8.3	0.15	10.0	0.18	159	1.8	0.06	2.1	0.08
Stomach	502	6.5	0.13	7.7	0.16	278	3.3	0.09	3.8	0.10
Small intestine	225	3.0	0.09	3.5	0.11	179	2.1	0.07	2.5	0.09
Colon (excl. rectum)	2,298	30.5	0.29	36.0	0.34	2,044	23.8	0.24	27.8	0.28
Rectum & rectosigmoid	1,101	14.5	0.20	17.4	0.24	718	8.8	0.15	10.4	0.18
Anus, anal canal, & anorectum	137	1.8	0.07	2.2	0.08	244	2.8	0.08	3.4	0.10
Liver	1,007	11.9	0.17	15.1	0.21	314	3.5	0.09	4.2	0.11
Gallbladder	46	0.6	0.04	0.7	0.05	86	0.9	0.05	1.1	0.05
Pancreas	1,204	15.5	0.21	18.5	0.24	1,008	11.0	0.16	13.2	0.19
Respiratory System	5,691	72.1	0.44	85.6	0.51	4,795	52.6	0.35	62.6	0.41
Larynx	429	5.3	0.12	6.5	0.14	108	1.2	0.06	1.5	0.07
Lung & bronchus	5,175	65.6	0.42	77.8	0.49	4,637	50.8	0.34	60.4	0.40
Bones & Joints	75	1.2	0.06	1.2	0.06	65	1.0	0.06	1.0	0.06
Soft Tissue (incl. heart)	278	4.0	0.11	4.4	0.12	202	2.6	0.09	2.9	0.09
Skin (excl. basal & sq.)	2,336	31.4	0.30	36.6	0.34	1,380	18.4	0.23	20.6	0.25
Melanoma of the skin	2,182	29.3	0.29	34.2	0.33	1,304	17.5	0.23	19.6	0.25
Breast (excl. <i>in situ</i>)	104	1.3	0.06	1.6	0.07	10,639	130.2	0.59	152.9	0.68
Female Genital System	N/A	N/A	N/A	N/A	N/A	3,794	47.1	0.36	55.0	0.41
Cervix uteri	N/A	N/A	N/A	N/A	N/A	557	8.8	0.17	9.2	0.18
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,876	21.8	0.24	26.6	0.28
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	93	1.1	0.05	1.3	0.06
Ovary	N/A	N/A	N/A	N/A	N/A	886	11.0	0.17	12.7	0.19
Male Genital System	9,124	111.3	0.53	134.8	0.64	N/A	N/A	N/A	N/A	N/A
Prostate	8,669	103.6	0.51	127.0	0.62	N/A	N/A	N/A	N/A	N/A
Testis	387	6.8	0.16	6.7	0.15	N/A	N/A	N/A	N/A	N/A
Penis	52	0.7	0.04	0.8	0.05	N/A	N/A	N/A	N/A	N/A
Urinary System	4,562	59.6	0.41	70.3	0.47	1,831	21.0	0.23	24.7	0.26
Bladder (incl. <i>in situ</i>)	2,447	32.1	0.30	37.7	0.35	669	7.3	0.13	8.6	0.15
Kidney & renal pelvis	2,028	26.3	0.27	31.2	0.31	1,113	13.2	0.18	15.4	0.21
Ureter	51	0.7	0.04	0.8	0.05	33	0.4	0.03	0.4	0.03
Eye & Orbit	99	1.4	0.06	1.6	0.07	80	1.0	0.05	1.1	0.06
Brain & Other CNS	614	8.8	0.16	9.7	0.18	487	6.6	0.14	7.2	0.15
Brain	579	8.2	0.16	9.2	0.17	452	6.1	0.13	6.6	0.14
Endocrine System	585	8.4	0.16	9.4	0.18	1,266	19.1	0.25	20.5	0.26
Thyroid gland	529	7.5	0.15	8.5	0.17	1,216	18.5	0.25	19.8	0.26
Lymphomas	1,877	25.7	0.27	29.5	0.31	1,452	17.6	0.22	20.2	0.24
Hodgkin lymphoma	176	2.9	0.10	3.0	0.10	150	2.4	0.09	2.5	0.09
Non-Hodgkin lymphoma	1,701	22.9	0.26	26.5	0.29	1,302	15.2	0.20	17.7	0.22
Multiple Myeloma	644	8.4	0.15	9.9	0.18	480	5.4	0.11	6.4	0.13
Leukemias	1,458	20.1	0.24	22.9	0.27	1,003	12.3	0.18	13.8	0.20
Acute lymphocytic	99	1.8	0.08	1.6	0.07	80	1.4	0.07	1.3	0.07
Chronic lymphocytic	595	7.7	0.14	9.2	0.17	386	4.3	0.10	5.0	0.12
Acute myeloid	356	4.9	0.12	5.6	0.13	269	3.3	0.10	3.7	0.10
Chronic myeloid	207	2.9	0.09	3.3	0.10	139	1.7	0.07	2.0	0.08
Other leukemias	201	2.8	0.09	3.2	0.10	129	1.6	0.07	1.8	0.07
Mesothelioma	99	1.3	0.06	1.5	0.07	31	0.4	0.03	0.4	0.03
Kaposi Sarcoma	28	0.4	0.04	0.5	0.04	4	0.0	0.01	0.0	0.01
Ill-Defined & Unknown	1,466	19.9	0.24	23.2	0.27	1,228	14.1	0.19	16.3	0.21
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	756	10.8	0.18	12.1	0.20	1,585	19.8	0.23	22.5	0.26
Breast (<i>in situ</i>)	8	0.1	0.02	0.1	0.02	1,945	24.4	0.26	28.7	0.30

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Texas, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	7,083	529.0	3.08	638.6	3.62	6,784	397.7	2.23	467.4	2.58
Oral Cavity & Pharynx	166	11.4	0.43	13.9	0.51	88	5.0	0.25	5.9	0.29
Lip	1	0.1	0.04	0.1	0.04	*	*	*	*	*
Tongue	38	2.7	0.22	3.3	0.25	16	0.9	0.10	1.1	0.12
Major salivary gland	15	1.1	0.13	1.2	0.15	22	1.3	0.13	1.5	0.14
Floor of mouth	7	0.5	0.09	0.6	0.11	4	0.2	0.05	0.3	0.06
Gum & other mouth	19	1.3	0.15	1.6	0.18	18	1.1	0.12	1.2	0.13
Nasopharynx	12	0.8	0.11	1.0	0.13	8	0.4	0.07	0.5	0.08
Oropharynx	15	1.1	0.14	1.3	0.16	6	0.3	0.06	0.4	0.07
Hypopharynx	14	1.0	0.13	1.2	0.16	3	0.2	0.04	0.2	0.05
Digestive System	1,699	125.7	1.50	152.7	1.77	1,357	80.6	1.01	96.4	1.19
Esophagus	61	4.6	0.29	5.7	0.35	28	1.7	0.15	2.0	0.17
Stomach	167	13.5	0.52	15.9	0.59	113	7.0	0.31	8.2	0.35
Small intestine	63	5.1	0.31	6.0	0.36	60	3.4	0.21	4.1	0.24
Colon (excl. rectum)	523	39.6	0.85	47.5	0.99	514	30.7	0.63	36.6	0.73
Rectum & rectosigmoid	220	15.8	0.52	19.2	0.61	154	8.8	0.33	10.6	0.39
Anus, anal canal, & anorectum	30	2.0	0.17	2.3	0.20	27	1.5	0.14	1.9	0.16
Liver	328	20.7	0.55	26.9	0.68	99	5.4	0.25	6.8	0.31
Gallbladder	18	1.4	0.17	1.7	0.20	32	1.9	0.16	2.3	0.19
Pancreas	223	18.0	0.59	21.5	0.69	245	15.0	0.44	17.8	0.52
Respiratory System	1,044	86.0	1.31	102.7	1.52	779	47.4	0.79	56.7	0.92
Larynx	99	7.4	0.37	9.1	0.43	25	1.4	0.13	1.7	0.15
Lung & bronchus	934	77.9	1.25	92.8	1.45	744	45.4	0.77	54.3	0.91
Bones & Joints	15	0.9	0.10	0.9	0.11	14	0.8	0.10	0.8	0.10
Soft Tissue (incl. heart)	52	3.6	0.24	3.9	0.26	58	3.4	0.20	3.7	0.22
Skin (excl. basal & sq.)	26	2.0	0.20	2.3	0.23	29	1.7	0.14	1.9	0.17
Melanoma of the skin	12	1.1	0.15	1.3	0.18	16	0.9	0.11	1.1	0.13
Breast (excl. <i>in situ</i>)	28	2.1	0.20	2.6	0.23	2,151	123.6	1.23	144.8	1.42
Female Genital System	N/A	N/A	N/A	N/A	N/A	830	47.0	0.75	55.6	0.88
Cervix uteri	N/A	N/A	N/A	N/A	N/A	160	9.1	0.33	10.0	0.36
Uterus corpus	N/A	N/A	N/A	N/A	N/A	406	22.5	0.52	27.6	0.62
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	44	2.6	0.18	3.1	0.21
Ovary	N/A	N/A	N/A	N/A	N/A	161	9.3	0.34	10.9	0.39
Male Genital System	2,388	169.9	1.69	210.8	2.02	N/A	N/A	N/A	N/A	N/A
Prostate	2,351	167.3	1.68	208.1	2.01	N/A	N/A	N/A	N/A	N/A
Testis	24	1.5	0.14	1.5	0.14	N/A	N/A	N/A	N/A	N/A
Penis	10	0.8	0.13	1.0	0.15	N/A	N/A	N/A	N/A	N/A
Urinary System	586	45.7	0.93	54.4	1.08	349	20.9	0.52	24.7	0.60
Bladder (incl. <i>in situ</i>)	192	16.8	0.60	20.0	0.69	87	5.4	0.27	6.4	0.31
Kidney & renal pelvis	386	28.2	0.70	33.6	0.81	256	15.0	0.44	17.7	0.50
Ureter	4	0.3	0.07	0.3	0.08	3	0.2	0.05	0.2	0.06
Eye & Orbit	4	0.2	0.05	0.2	0.06	4	0.2	0.06	0.2	0.06
Brain & Other CNS	74	4.9	0.27	5.4	0.30	64	3.7	0.21	4.0	0.23
Brain	67	4.4	0.26	4.9	0.29	56	3.3	0.20	3.5	0.22
Endocrine System	71	4.8	0.27	5.5	0.31	206	11.7	0.37	13.0	0.41
Thyroid gland	52	3.5	0.23	4.1	0.27	187	10.6	0.35	11.8	0.39
Lymphomas	279	19.3	0.56	22.1	0.64	247	14.3	0.42	16.3	0.47
Hodgkin lymphoma	55	3.3	0.21	3.5	0.22	41	2.3	0.16	2.4	0.17
Non-Hodgkin lymphoma	225	16.0	0.52	18.6	0.60	206	12.1	0.39	13.9	0.44
Multiple Myeloma	219	18.0	0.60	21.5	0.70	218	13.3	0.42	15.7	0.48
Leukemias	186	14.3	0.52	16.3	0.59	155	9.4	0.35	10.6	0.39
Acute lymphocytic	20	1.1	0.12	1.1	0.11	13	0.7	0.09	0.6	0.08
Chronic lymphocytic	66	5.6	0.34	6.6	0.39	38	2.4	0.18	2.8	0.21
Acute myeloid	43	3.3	0.25	3.8	0.28	52	3.2	0.20	3.6	0.23
Chronic myeloid	34	2.5	0.20	2.7	0.23	25	1.5	0.14	1.8	0.16
Other leukemias	23	1.8	0.19	2.1	0.22	26	1.5	0.14	1.8	0.16
Mesothelioma	11	0.9	0.14	1.1	0.16	2	0.1	0.04	0.2	0.05
Kaposi Sarcoma	35	2.0	0.16	2.0	0.16	4	0.2	0.05	0.3	0.06
Ill-Defined & Unknown	202	17.3	0.61	20.3	0.70	230	14.2	0.43	16.5	0.50
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	147	11.1	0.45	12.7	0.51	364	21.9	0.53	25.3	0.61
Breast (<i>in situ</i>)	4	0.2	0.06	0.3	0.07	487	27.6	0.58	32.8	0.67

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Texas, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,513	269.3	3.34	317.7	3.89	1,797	257.6	2.83	298.7	3.28
Oral Cavity & Pharynx	64	10.4	0.62	12.4	0.73	32	4.5	0.37	5.2	0.43
Lip	1	0.2	0.07	0.2	0.09	*	*	*	*	*
Tongue	15	2.6	0.31	3.0	0.36	9	1.3	0.20	1.6	0.24
Major salivary gland	5	0.9	0.18	1.0	0.21	5	0.6	0.13	0.7	0.15
Floor of mouth	2	0.2	0.08	0.3	0.10	*	*	*	*	*
Gum & other mouth	14	2.2	0.28	2.7	0.34	7	1.1	0.19	1.3	0.22
Nasopharynx	14	2.0	0.24	2.3	0.29	7	1.0	0.16	1.1	0.18
Oropharynx	2	0.5	0.19	0.6	0.22	*	*	*	*	*
Hypopharynx	4	0.7	0.15	0.8	0.19	*	*	*	*	*
Digestive System	449	79.3	1.80	94.7	2.12	317	50.0	1.32	58.6	1.53
Esophagus	16	2.7	0.33	3.3	0.39	5	0.7	0.17	0.9	0.20
Stomach	50	9.5	0.65	11.0	0.75	38	5.8	0.45	6.8	0.52
Small intestine	10	1.6	0.23	1.9	0.28	5	0.7	0.14	0.8	0.17
Colon (excl. rectum)	114	19.7	0.90	23.6	1.06	96	15.0	0.72	17.6	0.84
Rectum & rectosigmoid	70	11.3	0.64	13.8	0.77	53	7.8	0.50	9.2	0.59
Anus, anal canal, & anorectum	2	0.3	0.09	0.3	0.10	2	0.3	0.11	0.4	0.13
Liver	100	17.7	0.85	21.3	1.00	33	5.4	0.45	6.3	0.51
Gallbladder	6	1.2	0.24	1.4	0.28	9	1.5	0.23	1.7	0.26
Pancreas	49	9.2	0.64	11.0	0.74	49	8.2	0.55	9.6	0.64
Respiratory System	208	39.2	1.32	46.8	1.55	154	24.4	0.92	28.7	1.07
Larynx	9	1.5	0.24	1.8	0.28	*	*	*	*	*
Lung & bronchus	193	36.8	1.29	43.9	1.51	149	23.7	0.91	28.0	1.06
Bones & Joints	7	1.1	0.19	1.0	0.18	5	0.8	0.16	0.8	0.17
Soft Tissue (incl. heart)	18	2.9	0.32	3.2	0.36	13	1.7	0.22	1.9	0.25
Skin (excl. basal & sq.)	12	2.1	0.30	2.4	0.34	10	1.4	0.21	1.5	0.23
Melanoma of the skin	8	1.5	0.27	1.8	0.32	5	0.7	0.15	0.8	0.17
Breast (excl. <i>in situ</i>)	6	1.0	0.20	1.1	0.22	626	84.1	1.54	98.4	1.81
Female Genital System	N/A	N/A	N/A	N/A	N/A	234	32.0	0.97	37.8	1.14
Cervix uteri	N/A	N/A	N/A	N/A	N/A	45	5.9	0.41	6.7	0.47
Uterus corpus	N/A	N/A	N/A	N/A	N/A	107	14.4	0.64	17.5	0.77
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	7	1.0	0.18	1.1	0.21
Ovary	N/A	N/A	N/A	N/A	N/A	62	8.7	0.51	10.1	0.59
Male Genital System	309	55.8	1.51	67.2	1.78	N/A	N/A	N/A	N/A	N/A
Prostate	295	53.8	1.49	65.2	1.76	N/A	N/A	N/A	N/A	N/A
Testis	12	1.6	0.21	1.6	0.22	N/A	N/A	N/A	N/A	N/A
Penis	2	0.3	0.10	0.4	0.12	N/A	N/A	N/A	N/A	N/A
Urinary System	122	23.0	1.01	27.1	1.18	46	7.3	0.50	8.5	0.59
Bladder (incl. <i>in situ</i>)	62	12.9	0.79	15.1	0.92	14	2.4	0.30	2.9	0.36
Kidney & renal pelvis	57	9.4	0.59	11.1	0.70	29	4.4	0.38	5.1	0.44
Ureter	3	0.7	0.19	0.8	0.22	2	0.3	0.10	0.3	0.12
Eye & Orbit	1	0.2	0.08	0.2	0.08	2	0.3	0.09	0.3	0.09
Brain & Other CNS	32	5.1	0.44	5.5	0.49	22	3.2	0.31	3.4	0.34
Brain	30	4.9	0.43	5.3	0.48	20	2.8	0.29	3.0	0.31
Endocrine System	46	6.8	0.46	7.5	0.52	148	19.2	0.72	20.8	0.80
Thyroid gland	40	5.8	0.43	6.5	0.49	141	18.1	0.70	19.7	0.77
Lymphomas	94	16.0	0.79	18.4	0.90	74	10.8	0.59	12.1	0.66
Hodgkin lymphoma	11	1.5	0.21	1.6	0.23	10	1.3	0.19	1.3	0.19
Non-Hodgkin lymphoma	83	14.5	0.76	16.8	0.87	64	9.5	0.56	10.9	0.63
Multiple Myeloma	33	6.3	0.53	7.5	0.62	21	3.2	0.33	3.8	0.38
Leukemias	62	10.5	0.65	11.5	0.72	42	6.1	0.44	6.6	0.48
Acute lymphocytic	12	1.7	0.22	1.5	0.21	7	1.0	0.17	0.9	0.15
Chronic lymphocytic	10	1.9	0.29	2.2	0.33	5	0.7	0.16	0.8	0.18
Acute myeloid	22	3.9	0.40	4.3	0.45	20	2.9	0.30	3.2	0.34
Chronic myeloid	8	1.4	0.23	1.6	0.26	6	0.8	0.16	1.0	0.19
Other leukemias	9	1.6	0.27	1.8	0.30	4	0.6	0.13	0.6	0.15
Mesothelioma	2	0.3	0.11	0.4	0.13	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	50	8.7	0.58	9.9	0.66
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	55	9.8	0.65	11.2	0.75	106	15.7	0.72	18.1	0.82
Breast (<i>in situ</i>)	1	0.2	0.08	0.2	0.09	173	22.9	0.79	27.3	0.95

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Texas, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	6	327.3	60.17	405.2	73.94	4	236.4	51.42	261.4	56.33
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	1	82.2	31.49	83.5	31.81
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	2	117.6	36.13	136.5	41.84	N/A	N/A	N/A	N/A	N/A
Prostate	2	87.5	31.56	108.5	38.43	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	1	78.7	30.63	91.3	35.62	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Texas, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	12,952	372.3	1.58	440.0	1.85	14,127	331.9	1.29	386.5	1.50
Oral Cavity & Pharynx	373	10.2	0.25	12.4	0.30	157	3.8	0.14	4.4	0.16
Lip	12	0.4	0.05	0.5	0.06	3	0.1	0.02	0.1	0.02
Tongue	102	2.7	0.13	3.3	0.15	49	1.2	0.08	1.4	0.09
Major salivary gland	33	1.0	0.08	1.1	0.09	36	0.8	0.06	1.0	0.07
Floor of mouth	13	0.3	0.05	0.4	0.06	4	0.1	0.02	0.1	0.03
Gum & other mouth	43	1.2	0.09	1.5	0.11	29	0.7	0.06	0.9	0.07
Nasopharynx	18	0.4	0.05	0.5	0.06	6	0.1	0.03	0.2	0.03
Oropharynx	31	0.8	0.07	1.0	0.09	6	0.1	0.03	0.2	0.03
Hypopharynx	29	0.9	0.08	1.0	0.09	5	0.1	0.02	0.1	0.03
Digestive System	3,867	110.4	0.85	133.1	1.01	2,732	68.4	0.60	81.0	0.71
Esophagus	169	5.1	0.19	6.1	0.22	37	1.0	0.07	1.1	0.09
Stomach	365	11.1	0.28	13.0	0.32	317	7.8	0.20	9.1	0.23
Small intestine	82	2.2	0.12	2.7	0.14	61	1.5	0.09	1.7	0.10
Colon (excl. rectum)	1,021	29.4	0.44	35.2	0.52	860	21.2	0.33	25.1	0.39
Rectum & rectosigmoid	607	16.3	0.32	19.7	0.37	329	7.6	0.19	9.1	0.23
Anus, anal canal, & anorectum	28	0.7	0.06	0.8	0.08	42	1.0	0.07	1.2	0.09
Liver	929	25.4	0.40	31.5	0.48	357	9.4	0.23	11.1	0.27
Gallbladder	40	1.2	0.09	1.5	0.11	99	2.5	0.12	3.0	0.14
Pancreas	407	12.4	0.29	14.8	0.35	415	11.0	0.25	12.9	0.29
Respiratory System	1,155	38.8	0.55	45.4	0.63	749	19.9	0.33	23.5	0.39
Larynx	153	4.6	0.18	5.6	0.21	17	0.4	0.05	0.5	0.06
Lung & bronchus	962	33.3	0.51	38.8	0.58	711	19.0	0.33	22.4	0.38
Bones & Joints	61	1.2	0.07	1.2	0.08	46	0.9	0.06	0.9	0.07
Soft Tissue (incl. heart)	136	3.4	0.14	3.7	0.16	115	2.5	0.11	2.7	0.12
Skin (excl. basal & sq.)	160	4.8	0.18	5.5	0.21	175	4.2	0.14	4.7	0.16
Melanoma of the skin	131	3.9	0.17	4.5	0.19	142	3.3	0.13	3.7	0.15
Breast (excl. <i>in situ</i>)	27	0.8	0.08	1.0	0.09	4,059	93.5	0.67	110.4	0.79
Female Genital System	N/A	N/A	N/A	N/A	N/A	2,274	50.5	0.49	58.5	0.56
Cervix uteri	N/A	N/A	N/A	N/A	N/A	549	11.6	0.23	12.5	0.25
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,079	23.8	0.33	28.3	0.39
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	68	1.6	0.09	1.9	0.10
Ovary	N/A	N/A	N/A	N/A	N/A	444	10.2	0.22	11.9	0.26
Male Genital System	3,023	87.3	0.76	104.4	0.90	N/A	N/A	N/A	N/A	N/A
Prostate	2,612	79.7	0.74	96.4	0.87	N/A	N/A	N/A	N/A	N/A
Testis	348	5.8	0.14	5.7	0.14	N/A	N/A	N/A	N/A	N/A
Penis	58	1.7	0.11	2.0	0.13	N/A	N/A	N/A	N/A	N/A
Urinary System	1,515	44.4	0.55	52.4	0.64	900	21.8	0.33	25.7	0.39
Bladder (incl. <i>in situ</i>)	431	14.9	0.34	17.5	0.40	148	4.0	0.15	4.6	0.17
Kidney & renal pelvis	1,065	28.8	0.42	34.2	0.50	736	17.4	0.29	20.5	0.35
Ureter	10	0.4	0.05	0.4	0.06	10	0.3	0.04	0.3	0.05
Eye & Orbit	25	0.6	0.06	0.7	0.07	20	0.4	0.04	0.5	0.05
Brain & Other CNS	229	5.2	0.17	5.8	0.19	215	4.6	0.15	5.0	0.16
Brain	210	4.9	0.17	5.4	0.19	196	4.2	0.14	4.6	0.16
Endocrine System	257	6.0	0.18	6.7	0.20	938	19.5	0.29	21.4	0.32
Thyroid gland	230	5.4	0.17	6.1	0.19	912	18.9	0.29	20.8	0.32
Lymphomas	780	21.2	0.37	24.6	0.43	651	15.6	0.28	18.0	0.33
Hodgkin lymphoma	122	2.7	0.12	2.9	0.13	90	1.8	0.09	1.9	0.10
Non-Hodgkin lymphoma	659	18.6	0.35	21.7	0.41	561	13.8	0.27	16.1	0.31
Multiple Myeloma	262	8.1	0.24	9.6	0.28	220	5.6	0.18	6.7	0.21
Leukemias	538	13.1	0.28	14.3	0.32	422	9.1	0.21	9.8	0.23
Acute lymphocytic	173	2.8	0.10	2.6	0.10	136	2.3	0.09	2.2	0.09
Chronic lymphocytic	82	2.7	0.14	3.2	0.17	63	1.7	0.10	2.0	0.11
Acute myeloid	130	3.5	0.15	3.9	0.17	115	2.6	0.11	2.9	0.13
Chronic myeloid	85	2.2	0.11	2.4	0.13	55	1.2	0.08	1.4	0.09
Other leukemias	68	1.9	0.12	2.1	0.13	54	1.2	0.08	1.4	0.09
Mesothelioma	31	1.1	0.09	1.3	0.11	12	0.3	0.04	0.3	0.04
Kaposi Sarcoma	48	1.2	0.08	1.3	0.09	5	0.1	0.03	0.2	0.03
Ill-Defined & Unknown	464	14.6	0.33	16.9	0.38	437	11.4	0.25	13.1	0.29
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	314	8.3	0.23	9.5	0.26	693	16.5	0.29	19.1	0.34
Breast (<i>in situ</i>)	2	0.1	0.02	0.1	0.02	756	17.1	0.28	20.4	0.34

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

TEXAS

II-478 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Texas, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	12,592	375.6	1.62	443.8	1.88	13,802	336.6	1.32	392.0	1.53
Oral Cavity & Pharynx	364	10.4	0.26	12.5	0.31	153	3.8	0.14	4.4	0.17
Lip	12	0.4	0.06	0.5	0.06	3	0.1	0.02	0.1	0.02
Tongue	99	2.7	0.13	3.3	0.16	48	1.2	0.08	1.4	0.09
Major salivary gland	32	1.0	0.08	1.1	0.10	35	0.8	0.07	1.0	0.08
Floor of mouth	13	0.3	0.05	0.4	0.06	3	0.1	0.02	0.1	0.03
Gum & other mouth	42	1.3	0.09	1.5	0.11	29	0.8	0.07	0.9	0.08
Nasopharynx	17	0.4	0.05	0.5	0.06	6	0.1	0.03	0.2	0.03
Oropharynx	31	0.9	0.07	1.1	0.09	6	0.2	0.03	0.2	0.03
Hypopharynx	28	0.9	0.08	1.1	0.09	5	0.1	0.02	0.1	0.03
Digestive System	3,810	112.8	0.88	136.0	1.04	2,681	69.4	0.62	82.2	0.72
Esophagus	167	5.2	0.19	6.2	0.22	36	1.0	0.07	1.2	0.09
Stomach	360	11.3	0.29	13.3	0.33	312	7.9	0.21	9.3	0.24
Small intestine	79	2.3	0.12	2.7	0.14	59	1.5	0.09	1.8	0.10
Colon (excl. rectum)	1,001	29.9	0.45	35.8	0.53	843	21.5	0.34	25.5	0.40
Rectum & rectosigmoid	599	16.7	0.33	20.2	0.39	319	7.7	0.20	9.2	0.23
Anus, anal canal, & anorectum	26	0.7	0.07	0.8	0.08	41	1.0	0.07	1.3	0.09
Liver	920	26.1	0.41	32.4	0.50	354	9.6	0.23	11.3	0.27
Gallbladder	39	1.3	0.10	1.5	0.11	97	2.6	0.12	3.1	0.14
Pancreas	402	12.7	0.30	15.1	0.36	407	11.1	0.25	13.1	0.29
Respiratory System	1,137	39.5	0.56	46.2	0.64	735	20.2	0.34	23.8	0.40
Larynx	149	4.7	0.18	5.7	0.22	16	0.4	0.05	0.5	0.06
Lung & bronchus	949	33.9	0.52	39.5	0.60	698	19.3	0.34	22.7	0.39
Bones & Joints	60	1.2	0.08	1.3	0.08	44	0.9	0.06	0.9	0.07
Soft Tissue (incl. heart)	131	3.4	0.15	3.7	0.16	112	2.5	0.11	2.8	0.12
Skin (excl. basal & sq.)	150	4.7	0.19	5.4	0.21	164	4.1	0.15	4.6	0.17
Melanoma of the skin	122	3.8	0.17	4.5	0.19	133	3.2	0.13	3.7	0.15
Breast (excl. <i>in situ</i>)	26	0.8	0.08	1.0	0.09	3,967	94.9	0.69	112.0	0.81
Female Genital System	N/A	N/A	N/A	N/A	N/A	2,217	51.3	0.50	59.4	0.58
Cervix uteri	N/A	N/A	N/A	N/A	N/A	533	11.8	0.23	12.7	0.25
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,051	24.1	0.34	28.7	0.40
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	67	1.6	0.09	1.9	0.11
Ovary	N/A	N/A	N/A	N/A	N/A	434	10.4	0.23	12.1	0.27
Male Genital System	2,860	85.6	0.77	102.2	0.90	N/A	N/A	N/A	N/A	N/A
Prostate	2,462	77.9	0.75	94.2	0.88	N/A	N/A	N/A	N/A	N/A
Testis	337	5.9	0.15	5.8	0.15	N/A	N/A	N/A	N/A	N/A
Penis	56	1.7	0.11	2.0	0.13	N/A	N/A	N/A	N/A	N/A
Urinary System	1,481	45.1	0.56	53.2	0.66	883	22.1	0.34	26.1	0.40
Bladder (incl. <i>in situ</i>)	422	15.1	0.35	17.7	0.40	144	4.0	0.15	4.7	0.18
Kidney & renal pelvis	1,041	29.3	0.43	34.7	0.51	724	17.7	0.30	20.9	0.36
Ureter	10	0.4	0.05	0.4	0.06	10	0.3	0.04	0.3	0.05
Eye & Orbit	24	0.6	0.06	0.6	0.07	19	0.4	0.04	0.4	0.05
Brain & Other CNS	225	5.4	0.18	5.9	0.20	211	4.7	0.15	5.1	0.17
Brain	206	5.0	0.17	5.5	0.19	192	4.3	0.14	4.7	0.16
Endocrine System	249	6.0	0.18	6.8	0.21	914	19.8	0.30	21.7	0.33
Thyroid gland	222	5.5	0.17	6.2	0.20	888	19.3	0.29	21.1	0.33
Lymphomas	763	21.6	0.38	25.0	0.44	631	15.7	0.29	18.1	0.33
Hodgkin lymphoma	118	2.7	0.12	3.0	0.14	86	1.8	0.09	1.9	0.10
Non-Hodgkin lymphoma	645	18.9	0.36	22.0	0.42	545	13.9	0.27	16.2	0.32
Multiple Myeloma	257	8.2	0.25	9.7	0.28	214	5.7	0.18	6.7	0.21
Leukemias	526	13.3	0.29	14.5	0.33	415	9.3	0.21	10.0	0.24
Acute lymphocytic	171	2.9	0.10	2.7	0.10	134	2.4	0.10	2.3	0.10
Chronic lymphocytic	79	2.7	0.15	3.2	0.17	61	1.7	0.10	2.0	0.12
Acute myeloid	127	3.5	0.16	4.0	0.18	113	2.7	0.12	2.9	0.13
Chronic myeloid	82	2.2	0.12	2.4	0.13	53	1.3	0.08	1.4	0.09
Other leukemias	66	1.9	0.12	2.2	0.13	54	1.3	0.08	1.4	0.09
Mesothelioma	31	1.1	0.10	1.3	0.11	11	0.3	0.04	0.3	0.05
Kaposi Sarcoma	45	1.1	0.08	1.2	0.09	4	0.1	0.03	0.1	0.03
Ill-Defined & Unknown	454	14.8	0.34	17.2	0.39	427	11.5	0.26	13.2	0.29
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	306	8.4	0.24	9.6	0.27	673	16.7	0.30	19.3	0.34
Breast (<i>in situ</i>)	2	0.1	0.02	0.1	0.02	729	17.1	0.29	20.4	0.34

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Texas, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	75	175.1	11.06	211.9	12.97	95	163.8	8.70	191.0	10.02
Oral Cavity & Pharynx	1	1.7	0.74	2.4	1.04	1	1.6	0.78	1.8	0.89
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	17	39.9	5.30	47.6	6.00	16	33.5	4.16	39.3	4.75
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	2	5.5	2.15	6.3	2.36	2	3.9	1.52	4.3	1.64
Small intestine	2	2.9	1.10	3.5	1.32	*	*	*	*	*
Colon (excl. rectum)	5	12.8	3.17	14.9	3.55	6	12.7	2.61	14.9	2.98
Rectum & rectosigmoid	2	5.2	1.93	6.0	2.08	2	4.1	1.38	4.7	1.60
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	3	6.7	2.02	8.4	2.30	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	1	3.3	1.48	4.0	1.64	2	5.2	1.73	6.2	1.96
Respiratory System	7	18.2	3.72	22.1	4.38	7	13.6	2.61	16.8	3.14
Larynx	1	4.0	1.82	4.5	2.03	*	*	*	*	*
Lung & bronchus	5	14.0	3.24	17.4	3.88	6	12.6	2.57	15.6	3.07
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	1	2.2	1.24	2.2	1.26	*	*	*	*	*
Skin (excl. basal & sq.)	1	1.8	0.89	2.0	0.98	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	27	46.3	4.49	54.1	5.19
Female Genital System	N/A	N/A	N/A	N/A	N/A	16	26.5	3.47	30.8	3.97
Cervix uteri	N/A	N/A	N/A	N/A	N/A	3	2.8	0.78	3.2	0.97
Uterus corpus	N/A	N/A	N/A	N/A	N/A	8	14.8	2.72	17.4	3.10
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	3	5.9	1.72	6.2	1.85
Male Genital System	29	71.7	7.07	88.9	8.42	N/A	N/A	N/A	N/A	N/A
Prostate	28	70.5	6.96	87.3	8.27	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	5	14.6	3.28	17.3	3.79	6	10.9	2.33	13.1	2.72
Bladder (incl. <i>in situ</i>)	2	7.0	2.51	8.4	2.95	1	2.9	1.22	3.5	1.43
Kidney & renal pelvis	3	7.6	2.12	9.0	2.38	4	7.1	1.88	8.5	2.18
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	1.5	0.58	1.6	0.64	1	0.9	0.39	1.0	0.45
Brain	2	1.5	0.58	1.6	0.64	1	0.9	0.39	1.0	0.45
Endocrine System	*	*	*	*	*	4	3.9	1.00	4.1	1.09
Thyroid gland	*	*	*	*	*	4	3.7	0.98	3.9	1.08
Lymphomas	3	3.5	0.97	4.0	1.21	6	8.0	1.58	9.5	1.94
Hodgkin lymphoma	1	0.9	0.38	0.8	0.34	2	1.6	0.55	1.7	0.60
Non-Hodgkin lymphoma	2	2.6	0.89	3.3	1.16	4	6.4	1.48	7.8	1.85
Multiple Myeloma	*	*	*	*	*	2	4.6	1.74	5.2	1.90
Leukemias	3	4.8	1.91	5.4	2.19	4	4.1	1.17	4.3	1.29
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	3	9.5	2.96	11.6	3.58	3	6.5	2.02	7.1	2.21
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	2	2.4	1.01	2.8	1.18	5	8.3	1.94	9.9	2.29
Breast (<i>in situ</i>)	*	*	*	*	*	6	8.4	1.63	10.4	2.04

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


TEXAS

II-480 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	2,983,626	3,044,241	3,103,540	3,155,153	3,203,383
Non-Hispanic White	2,401,081	2,439,729	2,475,521	2,507,085	2,537,073
Non-Hispanic Black	39,399	41,635	44,035	45,860	47,760
Non-Hispanic Asian/Pacific Islander (NH API)	107,317	112,679	118,157	122,590	126,472
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	18,900	19,012	19,159	19,270	19,534


All Races Population 2015–2019: 15,489,943
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	404,560	418,556	433,750	447,226	459,119
Hispanic White	366,397	378,887	392,326	404,103	414,325
Hispanic Black	10,551	11,029	11,483	11,982	12,557

Hispanic/Latino Population, Census 2010: 358,340
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

UTAH CANCER REGISTRY

Initial Operation: 1966
Population-based Data Available: 1966
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	104.5	102.5	107.9	109.1	106.5	106.1
Missing Race	0.0	0.1	0.9	1.1	2.2	0.9
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.5	0.3	0.8	1.1	1.2	0.8
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.1	Ovary	91.9
Oral Cavity & Pharynx	98.5	Prostate	96.9
Esophagus	96.0	Testis	99.1
Stomach	96.4	Bladder (incl. <i>in situ</i>)	98.2
Colon & Rectum	96.4	Kidney & Renal Pelvis	87.5
Liver	48.8	Brain & Other CNS	84.5
Pancreas	80.6	Brain & Other CNS (non-malig)	28.9
Lung & Bronchus	87.2	Thyroid	99.7
Melanomas of the Skin	99.8	Hodgkin Lymphoma	98.9
Female Breast (excl. <i>in situ</i>)	98.8	Non-Hodgkin Lymphoma	96.9
Female Breast (<i>in situ</i>)	99.9	Multiple Myeloma	88.0
Cervix Uteri	98.7	Leukemias	92.6
Uterus Corpus & Uterus NOS	98.2		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Utah, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	5,838	445.7	2.67	526.0	3.13	5,374	378.6	2.35	438.9	2.71
Oral Cavity & Pharynx	191	14.2	0.47	17.3	0.57	87	6.1	0.30	7.2	0.35
Lip	23	1.9	0.18	2.2	0.21	8	0.6	0.09	0.7	0.11
Tongue	61	4.3	0.25	5.4	0.31	30	2.1	0.17	2.5	0.21
Major salivary gland	21	1.7	0.16	1.9	0.19	15	1.1	0.12	1.2	0.14
Floor of mouth	6	0.4	0.08	0.5	0.09	2	0.2	0.05	0.2	0.06
Gum & other mouth	18	1.5	0.16	1.7	0.18	18	1.3	0.14	1.5	0.16
Nasopharynx	8	0.6	0.09	0.6	0.10	2	0.2	0.05	0.2	0.06
Oropharynx	11	0.8	0.11	1.0	0.13	2	0.2	0.05	0.2	0.06
Hypopharynx	4	0.3	0.07	0.4	0.09	2	0.2	0.05	0.2	0.05
Digestive System	948	73.5	1.09	87.1	1.28	739	52.6	0.88	61.6	1.02
Esophagus	72	5.5	0.30	6.6	0.35	13	0.9	0.12	1.1	0.14
Stomach	79	6.3	0.32	7.3	0.37	44	3.2	0.22	3.7	0.25
Small intestine	42	3.2	0.23	3.8	0.26	32	2.3	0.18	2.6	0.21
Colon (excl. rectum)	267	21.0	0.59	24.6	0.69	271	19.4	0.53	22.4	0.62
Rectum & rectosigmoid	143	10.9	0.42	12.9	0.49	99	7.1	0.32	8.4	0.38
Anus, anal canal, & anorectum	11	0.9	0.12	1.1	0.14	28	1.9	0.16	2.4	0.20
Liver	112	8.0	0.35	10.0	0.43	41	2.8	0.20	3.3	0.23
Gallbladder	7	0.7	0.11	0.7	0.12	17	1.2	0.13	1.4	0.16
Pancreas	164	12.9	0.46	15.4	0.54	139	10.0	0.38	11.7	0.45
Respiratory System	421	33.7	0.75	39.6	0.88	345	24.2	0.59	28.7	0.70
Larynx	31	2.4	0.19	2.8	0.23	7	0.4	0.08	0.6	0.10
Lung & bronchus	374	30.1	0.71	35.5	0.83	329	23.1	0.58	27.5	0.68
Bones & Joints	21	1.4	0.14	1.5	0.16	17	1.1	0.12	1.1	0.13
Soft Tissue (incl. heart)	56	4.1	0.25	4.6	0.28	41	2.8	0.20	3.0	0.22
Skin (excl. basal & sq.)	690	53.8	0.94	62.8	1.09	515	36.5	0.73	41.5	0.83
Melanoma of the skin	644	49.9	0.90	58.3	1.05	487	34.5	0.71	39.2	0.81
Breast (excl. <i>in situ</i>)	11	0.9	0.13	1.1	0.15	1,626	115.8	1.30	135.9	1.52
Female Genital System	N/A	N/A	N/A	N/A	N/A	675	46.8	0.82	55.6	0.97
Cervix uteri	N/A	N/A	N/A	N/A	N/A	76	5.5	0.29	6.0	0.31
Uterus corpus	N/A	N/A	N/A	N/A	N/A	375	25.7	0.60	31.2	0.73
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	9	0.6	0.09	0.7	0.11
Ovary	N/A	N/A	N/A	N/A	N/A	150	10.5	0.39	12.3	0.45
Male Genital System	1,723	125.8	1.39	152.2	1.66	N/A	N/A	N/A	N/A	N/A
Prostate	1,591	117.2	1.35	143.5	1.62	N/A	N/A	N/A	N/A	N/A
Testis	117	7.5	0.32	7.4	0.32	N/A	N/A	N/A	N/A	N/A
Penis	8	0.7	0.11	0.8	0.12	N/A	N/A	N/A	N/A	N/A
Urinary System	639	51.0	0.92	59.9	1.08	240	16.9	0.49	19.7	0.58
Bladder (incl. <i>in situ</i>)	366	30.2	0.72	35.4	0.84	84	6.0	0.30	7.1	0.35
Kidney & renal pelvis	261	19.8	0.56	23.4	0.66	148	10.3	0.39	12.0	0.45
Ureter	6	0.5	0.09	0.6	0.11	4	0.3	0.06	0.3	0.07
Eye & Orbit	13	1.0	0.12	1.1	0.14	14	0.9	0.11	1.1	0.13
Brain & Other CNS	116	8.2	0.35	9.1	0.39	84	5.7	0.28	6.2	0.31
Brain	112	8.0	0.34	8.8	0.39	81	5.5	0.28	6.0	0.31
Endocrine System	135	9.7	0.38	10.9	0.43	368	25.9	0.61	27.6	0.66
Thyroid gland	127	9.2	0.37	10.3	0.42	359	25.3	0.61	27.0	0.65
Lymphomas	322	24.6	0.63	28.2	0.72	246	17.1	0.49	19.4	0.56
Hodgkin lymphoma	38	2.5	0.18	2.6	0.20	37	2.3	0.17	2.4	0.18
Non-Hodgkin lymphoma	283	22.1	0.60	25.6	0.70	210	14.8	0.46	17.0	0.53
Multiple Myeloma	105	8.1	0.36	9.8	0.43	70	4.9	0.27	5.9	0.32
Leukemias	241	18.5	0.55	20.9	0.62	160	10.9	0.39	12.3	0.44
Acute lymphocytic	28	1.7	0.14	1.5	0.13	23	1.4	0.13	1.2	0.12
Chronic lymphocytic	90	7.2	0.35	8.5	0.41	51	3.5	0.22	4.2	0.27
Acute myeloid	68	5.3	0.30	6.1	0.34	48	3.3	0.22	3.7	0.24
Chronic myeloid	30	2.3	0.19	2.6	0.22	24	1.7	0.16	1.9	0.18
Other leukemias	25	2.0	0.18	2.2	0.21	15	1.1	0.13	1.2	0.14
Mesothelioma	15	1.3	0.15	1.5	0.17	6	0.4	0.08	0.5	0.09
Kaposi Sarcoma	5	0.4	0.07	0.4	0.08	*	*	*	*	*
Ill-Defined & Unknown	187	15.5	0.52	17.8	0.59	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	251	19.4	0.56	22.0	0.64	522	37.2	0.74	42.7	0.85
Breast (<i>in situ</i>)	1	0.1	0.04	0.1	0.05	310	22.1	0.57	26.2	0.67

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Utah, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	5,189	451.2	2.86	532.5	3.35	4,635	379.3	2.54	439.6	2.93
Oral Cavity & Pharynx	169	14.4	0.51	17.6	0.61	77	6.2	0.32	7.3	0.38
Lip	21	1.9	0.19	2.2	0.22	8	0.7	0.11	0.8	0.13
Tongue	57	4.6	0.28	5.8	0.35	27	2.2	0.19	2.6	0.23
Major salivary gland	17	1.5	0.17	1.8	0.20	14	1.1	0.14	1.3	0.16
Floor of mouth	5	0.4	0.09	0.5	0.11	2	0.2	0.05	0.2	0.06
Gum & other mouth	15	1.5	0.17	1.7	0.19	14	1.2	0.14	1.4	0.16
Nasopharynx	4	0.4	0.08	0.4	0.09	2	0.1	0.05	0.1	0.05
Oropharynx	10	0.8	0.12	1.0	0.14	2	0.2	0.05	0.2	0.07
Hypopharynx	4	0.3	0.07	0.4	0.09	2	0.2	0.05	0.2	0.06
Digestive System	795	70.7	1.14	83.5	1.34	612	49.9	0.92	58.4	1.07
Esophagus	64	5.6	0.32	6.7	0.38	12	0.9	0.12	1.1	0.14
Stomach	60	5.4	0.32	6.3	0.37	29	2.4	0.20	2.8	0.23
Small intestine	38	3.3	0.25	3.9	0.29	28	2.3	0.20	2.7	0.23
Colon (excl. rectum)	228	20.7	0.62	24.1	0.72	230	18.9	0.57	21.9	0.65
Rectum & rectosigmoid	119	10.7	0.45	12.6	0.52	79	6.7	0.34	7.9	0.40
Anus, anal canal, & anorectum	10	0.9	0.13	1.1	0.15	26	2.1	0.19	2.6	0.23
Liver	77	6.3	0.33	7.9	0.41	29	2.3	0.19	2.6	0.22
Gallbladder	6	0.6	0.11	0.7	0.12	13	1.1	0.13	1.2	0.15
Pancreas	147	13.1	0.49	15.6	0.58	122	9.8	0.40	11.5	0.47
Respiratory System	379	33.6	0.79	39.8	0.92	305	24.2	0.63	28.8	0.74
Larynx	27	2.3	0.20	2.8	0.24	6	0.4	0.08	0.6	0.11
Lung & bronchus	337	30.1	0.75	35.5	0.88	292	23.1	0.61	27.5	0.72
Bones & Joints	16	1.4	0.15	1.5	0.17	13	1.0	0.13	1.1	0.14
Soft Tissue (incl. heart)	48	4.1	0.27	4.6	0.31	34	2.8	0.22	3.0	0.24
Skin (excl. basal & sq.)	662	58.9	1.04	68.6	1.21	480	40.3	0.84	45.7	0.95
Melanoma of the skin	618	54.7	1.00	63.8	1.17	456	38.3	0.82	43.4	0.92
Breast (excl. <i>in situ</i>)	10	0.9	0.13	1.1	0.16	1,417	116.8	1.42	137.1	1.65
Female Genital System	N/A	N/A	N/A	N/A	N/A	570	45.9	0.88	54.8	1.04
Cervix uteri	N/A	N/A	N/A	N/A	N/A	58	5.0	0.30	5.5	0.33
Uterus corpus	N/A	N/A	N/A	N/A	N/A	320	25.3	0.64	30.9	0.78
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	7	0.5	0.09	0.7	0.11
Ovary	N/A	N/A	N/A	N/A	N/A	128	10.4	0.42	12.2	0.49
Male Genital System	1,533	126.9	1.48	153.7	1.77	N/A	N/A	N/A	N/A	N/A
Prostate	1,425	117.9	1.43	144.5	1.73	N/A	N/A	N/A	N/A	N/A
Testis	96	7.9	0.37	7.9	0.37	N/A	N/A	N/A	N/A	N/A
Penis	7	0.6	0.11	0.7	0.13	N/A	N/A	N/A	N/A	N/A
Urinary System	582	52.3	0.99	61.5	1.15	206	16.6	0.53	19.4	0.61
Bladder (incl. <i>in situ</i>)	345	31.5	0.77	37.0	0.90	77	6.1	0.32	7.3	0.37
Kidney & renal pelvis	227	19.8	0.60	23.4	0.70	122	9.9	0.41	11.5	0.47
Ureter	6	0.5	0.10	0.6	0.12	3	0.3	0.07	0.3	0.08
Eye & Orbit	12	1.0	0.14	1.2	0.16	13	1.0	0.13	1.2	0.15
Brain & Other CNS	104	8.7	0.39	9.6	0.43	72	5.9	0.32	6.3	0.34
Brain	100	8.4	0.38	9.3	0.43	69	5.7	0.31	6.1	0.34
Endocrine System	118	10.2	0.43	11.5	0.48	301	25.9	0.68	27.5	0.72
Thyroid gland	112	9.7	0.42	10.9	0.47	294	25.3	0.67	26.9	0.72
Lymphomas	278	24.5	0.67	28.1	0.77	210	16.9	0.53	19.2	0.60
Hodgkin lymphoma	32	2.5	0.21	2.7	0.22	31	2.5	0.20	2.5	0.21
Non-Hodgkin lymphoma	246	22.0	0.64	25.4	0.74	179	14.5	0.49	16.7	0.56
Multiple Myeloma	90	7.8	0.38	9.4	0.45	60	4.8	0.28	5.7	0.33
Leukemias	211	18.7	0.59	21.3	0.67	135	10.8	0.42	12.2	0.48
Acute lymphocytic	19	1.4	0.15	1.3	0.14	15	1.2	0.14	1.1	0.13
Chronic lymphocytic	84	7.5	0.37	8.9	0.44	46	3.6	0.24	4.3	0.29
Acute myeloid	60	5.4	0.32	6.2	0.36	41	3.3	0.23	3.7	0.26
Chronic myeloid	26	2.3	0.21	2.6	0.24	20	1.7	0.17	1.9	0.19
Other leukemias	22	2.1	0.20	2.3	0.23	13	1.1	0.14	1.2	0.15
Mesothelioma	13	1.3	0.16	1.5	0.18	5	0.4	0.09	0.5	0.10
Kaposi Sarcoma	3	0.2	0.06	0.3	0.07	*	*	*	*	*
Ill-Defined & Unknown	168	15.6	0.55	18.0	0.63	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	219	19.6	0.60	22.2	0.68	456	37.5	0.80	43.1	0.91
Breast (<i>in situ</i>)	1	0.1	0.04	0.1	0.06	268	22.2	0.62	26.4	0.73

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Utah, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	55	473.3	35.30	565.9	40.08	33	348.9	30.06	409.1	35.29
Oral Cavity & Pharynx	2	11.0	3.53	14.8	4.80	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	14	129.3	18.24	157.3	21.06	6	71.3	13.56	87.4	16.53
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	3	34.7	10.85	40.5	12.29	2	27.0	8.38	33.3	10.36
Rectum & rectosigmoid	2	13.9	6.20	16.6	7.28	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	4	30.8	7.72	38.9	9.33	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	3	22.7	7.42	27.8	8.41	1	13.2	5.65	16.5	6.83
Respiratory System	4	55.8	14.82	61.3	16.00	3	47.0	12.45	55.9	14.62
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	3	53.5	14.74	58.5	15.87	3	47.0	12.45	55.9	14.62
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	8	95.1	15.82	109.6	17.88
Female Genital System	N/A	N/A	N/A	N/A	N/A	5	48.8	10.36	59.7	12.81
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	16.0	5.74	18.4	6.62
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2	15.4	5.25	19.9	6.92
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	19	155.8	19.08	191.9	21.81	N/A	N/A	N/A	N/A	N/A
Prostate	18	153.2	19.02	189.6	21.77	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	4	20.7	5.02	26.5	6.55	1	12.2	5.62	14.7	6.78
Bladder (incl. <i>in situ</i>)	1	6.7	2.79	9.1	3.85	*	*	*	*	*
Kidney & renal pelvis	2	11.9	3.87	14.8	4.96	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	2	14.6	5.05	13.7	4.88
Thyroid gland	*	*	*	*	*	2	14.0	5.01	13.3	4.86
Lymphomas	4	29.3	9.65	32.3	10.72	2	25.1	8.62	29.0	9.93
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	3	26.9	7.80	32.5	8.86	*	*	*	*	*
Leukemias	*	*	*	*	*	1	7.3	3.36	8.8	4.38
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	19.0	8.52	21.5	9.57	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	2	15.8	4.99	19.2	5.95	4	41.5	10.34	48.5	11.95
Breast (<i>in situ</i>)	*	*	*	*	*	3	29.6	8.64	36.1	10.41

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Utah, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	105	300.4	14.33	354.3	16.66	151	316.1	12.00	366.1	13.94
Oral Cavity & Pharynx	6	16.4	3.17	18.7	3.57	3	5.7	1.66	6.3	1.82
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	1	3.9	1.56	4.8	1.84	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	1	3.0	1.37	3.4	1.52	*	*	*	*	*
Nasopharynx	2	5.2	1.58	5.5	1.69	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	33	95.0	7.98	113.7	9.36	27	64.4	5.82	75.4	6.75
Esophagus	1	3.2	1.46	3.7	1.62	*	*	*	*	*
Stomach	5	16.9	3.64	19.5	4.14	4	9.1	2.23	10.7	2.58
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	7	20.8	3.88	25.1	4.59	7	17.3	2.97	20.0	3.43
Rectum & rectosigmoid	6	14.7	2.84	17.7	3.35	4	9.3	2.11	10.9	2.46
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	7	20.3	3.53	23.8	4.03	2	5.7	1.70	6.6	1.96
Gallbladder	*	*	*	*	*	1	3.9	1.53	4.7	1.81
Pancreas	3	9.5	2.54	11.8	3.06	4	11.0	2.44	13.1	2.90
Respiratory System	11	33.4	5.03	39.7	5.81	10	23.8	3.54	28.9	4.23
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	10	31.8	4.97	37.7	5.72	9	21.4	3.33	26.2	4.00
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	3	5.6	1.53	6.3	1.77	*	*	*	*	*
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	2	4.2	1.52	4.9	1.77
Melanoma of the skin	1	3.3	1.52	3.8	1.72	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	43	85.8	5.99	100.5	7.04
Female Genital System	N/A	N/A	N/A	N/A	N/A	32	61.7	5.01	71.8	5.90
Cervix uteri	N/A	N/A	N/A	N/A	N/A	4	8.3	1.81	9.2	2.05
Uterus corpus	N/A	N/A	N/A	N/A	N/A	20	38.5	3.95	45.1	4.68
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	6	11.4	2.17	13.2	2.54
Male Genital System	21	60.4	6.40	72.2	7.48	N/A	N/A	N/A	N/A	N/A
Prostate	19	57.2	6.32	69.0	7.41	N/A	N/A	N/A	N/A	N/A
Testis	2	2.7	0.87	2.5	0.81	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	7	21.7	3.83	25.8	4.52	5	11.8	2.42	13.8	2.80
Bladder (incl. <i>in situ</i>)	4	11.5	2.95	13.6	3.42	2	5.2	1.77	5.7	1.92
Kidney & renal pelvis	4	9.9	2.43	11.9	2.95	3	6.0	1.53	7.3	1.88
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	3	5.4	1.52	5.9	1.71	2	3.1	0.99	3.2	1.06
Brain	3	5.4	1.52	5.9	1.71	2	3.1	0.99	3.2	1.06
Endocrine System	4	10.2	2.64	12.6	3.24	12	21.1	2.82	22.0	3.01
Thyroid gland	4	9.3	2.47	11.4	3.02	11	20.2	2.77	21.2	2.97
Lymphomas	5	14.7	3.25	17.3	3.80	5	11.7	2.49	13.8	2.91
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	3	8.8	2.65	10.5	3.04	1	3.7	1.47	4.4	1.72
Leukemias	3	9.1	2.53	9.8	2.78	5	8.7	1.86	9.2	2.00
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	2	5.6	2.05	6.1	2.25	3	5.1	1.48	5.4	1.61
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	3	10.4	2.79	11.6	3.15	4	8.3	2.07	9.4	2.34
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	6	20.2	3.99	23.5	4.57	12	26.8	3.64	31.8	4.25
Breast (<i>in situ</i>)	*	*	*	*	*	11	22.9	3.20	27.8	3.82

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Utah, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	22	345.3	35.22	395.4	40.14	21	250.7	25.29	282.2	28.16
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	6	89.3	17.42	108.2	20.57	7	81.9	14.63	95.9	16.71
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	2	24.6	8.57	29.2	9.90	2	18.7	6.81	22.0	7.85
Rectum & rectosigmoid	1	16.5	7.10	20.5	8.50	1	14.8	5.72	19.0	7.18
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	2	39.3	13.02	44.4	14.80	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	2	37.1	12.83	41.1	14.42	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	4	55.0	11.99	63.8	13.83
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	17.4	6.27	21.1	7.55
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	4	62.3	14.47	69.6	16.17	N/A	N/A	N/A	N/A	N/A
Prostate	3	52.3	13.53	60.2	15.43	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	3	53.4	13.67	60.8	15.65	2	28.1	8.75	29.2	8.98
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	2	30.0	9.20	33.9	10.34	2	28.1	8.75	29.2	8.98
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	1	15.7	6.08	16.0	6.11
Thyroid gland	*	*	*	*	*	1	15.7	6.08	16.0	6.11
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	1	22.0	9.94	24.8	11.39	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	2	26.3	8.50	28.2	9.15
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Utah, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	387	395.0	10.46	461.5	12.01	486	391.9	8.74	454.1	10.14
Oral Cavity & Pharynx	10	9.1	1.54	10.7	1.78	5	4.6	0.97	5.7	1.17
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	1.6	0.62	1.9	0.70	2	1.1	0.42	1.4	0.53
Major salivary gland	2	2.4	0.81	2.7	0.91	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	2	2.3	0.73	2.8	0.87
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	95	97.9	5.12	116.7	5.95	81	74.3	4.03	87.2	4.68
Esophagus	5	5.4	1.23	6.2	1.36	*	*	*	*	*
Stomach	11	12.8	1.96	14.6	2.17	9	8.2	1.33	9.1	1.49
Small intestine	2	2.4	0.85	2.7	0.96	2	1.3	0.50	1.5	0.58
Colon (excl. rectum)	25	25.2	2.62	30.1	3.09	28	23.4	2.17	27.8	2.58
Rectum & rectosigmoid	15	12.5	1.64	15.2	1.94	13	10.3	1.40	12.5	1.69
Anus, anal canal, & anorectum	*	*	*	*	*	1	1.1	0.47	1.4	0.57
Liver	22	22.9	2.43	28.5	2.91	8	7.8	1.35	9.2	1.55
Gallbladder	*	*	*	*	*	1	1.3	0.55	1.6	0.63
Pancreas	10	10.8	1.73	12.9	1.99	11	11.5	1.68	13.4	1.91
Respiratory System	24	34.4	3.45	39.1	3.90	24	23.8	2.31	28.5	2.71
Larynx	3	3.2	0.95	3.8	1.14	*	*	*	*	*
Lung & bronchus	20	30.3	3.28	34.3	3.68	24	23.1	2.27	27.7	2.67
Bones & Joints	4	2.4	0.76	2.5	0.85	3	1.5	0.44	1.6	0.51
Soft Tissue (incl. heart)	4	2.5	0.62	2.8	0.72	5	3.8	0.86	4.2	0.99
Skin (excl. basal & sq.)	10	10.1	1.69	11.8	1.95	15	11.2	1.41	12.4	1.59
Melanoma of the skin	9	8.2	1.46	9.8	1.70	14	9.4	1.26	10.4	1.42
Breast (excl. <i>in situ</i>)	*	*	*	*	*	147	115.4	4.58	135.2	5.37
Female Genital System	N/A	N/A	N/A	N/A	N/A	61	44.9	2.78	52.8	3.30
Cervix uteri	N/A	N/A	N/A	N/A	N/A	11	6.6	0.89	7.0	0.98
Uterus corpus	N/A	N/A	N/A	N/A	N/A	30	22.7	1.96	27.5	2.37
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	14	11.4	1.50	13.4	1.78
Male Genital System	106	110.1	5.44	131.6	6.32	N/A	N/A	N/A	N/A	N/A
Prostate	89	102.8	5.37	124.1	6.25	N/A	N/A	N/A	N/A	N/A
Testis	16	6.3	0.73	6.3	0.75	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	40	44.7	3.62	52.2	4.17	24	21.7	2.18	25.0	2.50
Bladder (incl. <i>in situ</i>)	14	20.5	2.68	23.5	3.04	5	4.9	1.10	5.5	1.23
Kidney & renal pelvis	25	23.8	2.43	28.2	2.83	18	16.1	1.83	18.7	2.13
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	1	0.5	0.23	0.6	0.29	*	*	*	*	*
Brain & Other CNS	8	5.3	0.93	6.1	1.10	9	6.0	0.96	6.8	1.12
Brain	8	5.1	0.92	5.8	1.09	9	5.7	0.93	6.4	1.08
Endocrine System	11	7.8	1.24	8.4	1.36	49	30.5	2.07	33.6	2.35
Thyroid gland	10	7.2	1.22	7.9	1.34	48	29.8	2.05	32.9	2.32
Lymphomas	31	28.6	2.78	32.5	3.13	26	22.8	2.27	25.6	2.55
Hodgkin lymphoma	5	3.3	0.81	3.5	0.90	4	2.4	0.57	2.5	0.65
Non-Hodgkin lymphoma	26	25.4	2.66	29.0	3.00	21	20.5	2.19	23.0	2.46
Multiple Myeloma	7	8.8	1.65	10.3	1.90	7	7.2	1.30	8.4	1.49
Leukemias	21	16.6	2.08	18.1	2.34	15	10.5	1.41	11.8	1.61
Acute lymphocytic	8	2.9	0.52	2.5	0.47	5	1.8	0.37	1.6	0.37
Chronic lymphocytic	3	4.6	1.23	5.3	1.43	3	2.9	0.86	3.4	0.98
Acute myeloid	5	5.6	1.31	6.2	1.46	4	2.4	0.64	2.7	0.75
Chronic myeloid	3	2.0	0.59	2.4	0.71	3	2.0	0.60	2.5	0.73
Other leukemias	2	1.5	0.66	1.6	0.77	1	1.4	0.58	1.5	0.62
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	2	1.1	0.49	1.1	0.54	*	*	*	*	*
Ill-Defined & Unknown	11	13.5	2.07	15.1	2.30	12	12.9	1.81	14.4	2.04
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	22	20.1	2.39	22.6	2.71	46	37.3	2.72	42.4	3.08
Breast (<i>in situ</i>)	*	*	*	*	*	27	21.3	1.96	24.4	2.25

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

UTAH

II-488 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Utah, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	360	396.3	10.82	462.5	12.41	461	399.0	9.07	462.4	10.52
Oral Cavity & Pharynx	9	8.8	1.54	10.3	1.75	5	4.5	0.99	5.5	1.20
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	1.8	0.67	2.0	0.75	*	*	*	*	*
Major salivary gland	2	2.5	0.87	2.9	0.98	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	2	2.4	0.77	3.0	0.92
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	89	99.4	5.35	118.4	6.19	78	77.0	4.22	90.3	4.90
Esophagus	5	5.8	1.32	6.7	1.46	*	*	*	*	*
Stomach	11	13.2	2.06	15.0	2.29	9	8.4	1.37	9.4	1.54
Small intestine	2	2.4	0.89	2.6	1.00	1	1.3	0.52	1.5	0.60
Colon (excl. rectum)	22	25.0	2.69	29.9	3.17	28	24.9	2.30	29.6	2.74
Rectum & rectosigmoid	13	12.1	1.65	14.8	1.97	12	10.8	1.48	13.0	1.78
Anus, anal canal, & anorectum	*	*	*	*	*	1	1.2	0.50	1.5	0.61
Liver	21	23.5	2.56	29.1	3.05	7	8.1	1.43	9.6	1.64
Gallbladder	*	*	*	*	*	1	1.4	0.59	1.7	0.68
Pancreas	9	11.1	1.82	13.3	2.09	10	11.5	1.73	13.4	1.97
Respiratory System	23	35.0	3.59	39.7	4.04	23	24.0	2.37	28.7	2.79
Larynx	3	3.4	1.01	4.0	1.21	*	*	*	*	*
Lung & bronchus	19	30.7	3.40	34.7	3.80	22	23.2	2.33	27.8	2.75
Bones & Joints	4	2.6	0.82	2.7	0.91	3	1.6	0.48	1.8	0.55
Soft Tissue (incl. heart)	4	2.6	0.67	2.9	0.78	5	3.7	0.86	4.0	0.97
Skin (excl. basal & sq.)	10	10.7	1.81	12.6	2.08	15	11.9	1.50	13.2	1.69
Melanoma of the skin	8	8.7	1.56	10.4	1.81	14	10.2	1.35	11.3	1.52
Breast (excl. <i>in situ</i>)	*	*	*	*	*	139	116.8	4.74	137.0	5.56
Female Genital System	N/A	N/A	N/A	N/A	N/A	59	47.2	2.95	55.5	3.50
Cervix uteri	N/A	N/A	N/A	N/A	N/A	11	6.7	0.92	7.2	1.02
Uterus corpus	N/A	N/A	N/A	N/A	N/A	30	24.1	2.09	29.2	2.54
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	14	12.0	1.59	14.1	1.88
Male Genital System	95	107.1	5.55	127.7	6.43	N/A	N/A	N/A	N/A	N/A
Prostate	79	99.5	5.47	120.0	6.35	N/A	N/A	N/A	N/A	N/A
Testis	15	6.6	0.78	6.5	0.80	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	38	45.3	3.75	53.2	4.34	22	21.4	2.23	24.6	2.56
Bladder (incl. <i>in situ</i>)	14	21.5	2.81	24.6	3.19	4	4.4	1.08	4.9	1.19
Kidney & renal pelvis	23	23.5	2.47	28.1	2.91	17	16.4	1.91	18.9	2.21
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	1	0.6	0.25	0.6	0.32	*	*	*	*	*
Brain & Other CNS	8	5.8	1.01	6.6	1.19	9	6.5	1.03	7.4	1.21
Brain	8	5.6	1.00	6.3	1.17	9	6.2	1.01	6.9	1.17
Endocrine System	10	7.4	1.23	8.0	1.36	46	30.7	2.16	33.9	2.45
Thyroid gland	9	6.9	1.20	7.5	1.34	45	30.0	2.14	33.1	2.42
Lymphomas	30	29.2	2.89	33.2	3.26	25	23.5	2.36	26.2	2.65
Hodgkin lymphoma	5	3.6	0.87	3.8	0.96	4	2.2	0.52	2.3	0.56
Non-Hodgkin lymphoma	24	25.6	2.75	29.4	3.11	20	21.2	2.30	23.9	2.58
Multiple Myeloma	6	8.2	1.65	9.6	1.87	6	6.9	1.32	8.1	1.52
Leukemias	20	17.0	2.18	18.4	2.45	14	10.0	1.39	11.3	1.60
Acute lymphocytic	8	3.2	0.56	2.6	0.51	5	1.8	0.40	1.6	0.39
Chronic lymphocytic	3	4.7	1.29	5.4	1.49	2	2.2	0.73	2.6	0.85
Acute myeloid	5	5.7	1.38	6.3	1.52	3	2.4	0.67	2.8	0.79
Chronic myeloid	3	1.9	0.61	2.3	0.73	3	2.2	0.64	2.7	0.79
Other leukemias	2	1.6	0.70	1.8	0.81	1	1.4	0.61	1.6	0.66
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	1	0.9	0.51	1.0	0.56	*	*	*	*	*
Ill-Defined & Unknown	11	14.1	2.19	15.7	2.43	11	12.4	1.81	13.7	2.02
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	20	20.8	2.53	23.3	2.85	43	37.4	2.79	42.4	3.17
Breast (<i>in situ</i>)	*	*	*	*	*	25	21.0	2.01	24.1	2.31

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Utah, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3	190.4	65.97	219.4	71.87	3	124.6	45.28	136.1	51.37
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	1	71.7	32.70	89.0	39.85	N/A	N/A	N/A	N/A	N/A
Prostate	1	71.7	32.70	89.0	39.85	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


UTAH

II-490 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	625,810	624,366	625,132	624,802	624,046
Non-Hispanic White	591,364	588,800	587,757	586,662	584,975
Non-Hispanic Black	9,361	9,568	9,872	10,089	10,446
Non-Hispanic Asian/Pacific Islander (NH API)	11,233	11,703	12,669	12,806	13,032
Non-Hispanic American Indian/Alaskan Native PRCA (NH AI/AN)	0	0	0	0	0


All Races Population 2015–2019: 3,124,156
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	11,214	11,640	12,162	12,559	12,918
Hispanic White	9,789	10,130	10,593	10,922	11,218
Hispanic Black	781	811	842	907	960

Hispanic/Latino Population, Census 2010: 9,208
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

VERMONT CANCER REGISTRY

Initial Operation: 1992
Population-based Data Available: 1992
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	103.1	106.7	110.3	107.2	106.9	106.8
Missing Race	0.5	0.4	0.7	1.3	1.2	0.8
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.5	0.1
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.2	1.9	2.0	2.0	1.6	1.7
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.1	Ovary	91.4
Oral Cavity & Pharynx	97.8	Prostate	96.4
Esophagus	96.0	Testis	99.1
Stomach	97.8	Bladder (incl. <i>in situ</i>)	97.0
Colon & Rectum	96.1	Kidney & Renal Pelvis	90.8
Liver	50.0	Brain & Other CNS	88.1
Pancreas	83.4	Brain & Other CNS (non-malig)	41.4
Lung & Bronchus	87.2	Thyroid	99.6
Melanomas of the Skin	99.7	Hodgkin Lymphoma	98.8
Female Breast (excl. <i>in situ</i>)	98.2	Non-Hodgkin Lymphoma	96.8
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	89.7
Cervix Uteri	97.6	Leukemias	80.8
Uterus Corpus & Uterus NOS	98.6		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Vermont, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,963	479.0	5.05	566.9	5.84	1,940	445.1	4.79	517.7	5.39
Oral Cavity & Pharynx	79	18.9	1.00	23.0	1.18	28	6.7	0.60	7.9	0.68
Lip	1	0.4	0.16	0.4	0.17	*	*	*	*	*
Tongue	27	6.2	0.56	7.7	0.68	8	1.9	0.32	2.2	0.35
Major salivary gland	6	1.7	0.32	2.0	0.36	3	1.0	0.25	1.1	0.27
Floor of mouth	4	0.8	0.18	1.0	0.23	2	0.4	0.15	0.5	0.17
Gum & other mouth	8	1.8	0.31	2.2	0.36	5	1.1	0.23	1.3	0.27
Nasopharynx	4	1.1	0.26	1.2	0.29	*	*	*	*	*
Oropharynx	6	1.6	0.30	1.9	0.34	1	0.3	0.13	0.4	0.16
Hypopharynx	4	0.9	0.21	1.1	0.26	2	0.3	0.12	0.4	0.15
Digestive System	349	86.6	2.16	102.5	2.51	271	59.2	1.69	69.4	1.93
Esophagus	40	9.3	0.69	11.3	0.82	11	2.2	0.31	2.8	0.38
Stomach	30	7.4	0.63	8.8	0.74	16	3.7	0.43	4.3	0.49
Small intestine	10	2.5	0.37	2.9	0.42	8	1.8	0.30	2.1	0.34
Colon (excl. rectum)	101	26.2	1.22	30.5	1.38	102	22.7	1.05	26.1	1.18
Rectum & rectosigmoid	52	12.9	0.84	15.4	0.98	33	7.4	0.62	8.9	0.72
Anus, anal canal, & anorectum	6	1.7	0.32	2.0	0.36	14	3.0	0.37	3.6	0.44
Liver	34	7.7	0.61	9.5	0.74	8	2.0	0.33	2.1	0.34
Gallbladder	2	0.5	0.16	0.6	0.18	6	1.3	0.25	1.5	0.28
Pancreas	57	13.8	0.85	16.4	0.99	54	11.3	0.71	13.3	0.82
Respiratory System	293	69.9	1.90	83.6	2.23	267	56.5	1.59	67.6	1.88
Larynx	20	4.7	0.49	5.6	0.58	7	1.7	0.30	1.9	0.33
Lung & bronchus	269	64.1	1.82	76.7	2.13	257	54.3	1.56	64.9	1.84
Bones & Joints	4	1.3	0.30	1.4	0.30	3	0.7	0.21	0.8	0.21
Soft Tissue (incl. heart)	11	2.9	0.41	3.3	0.45	9	2.8	0.44	2.8	0.43
Skin (excl. basal & sq.)	178	45.7	1.60	52.9	1.81	139	34.3	1.40	38.9	1.52
Melanoma of the skin	169	43.1	1.55	50.0	1.76	134	33.4	1.38	37.9	1.50
Breast (excl. <i>in situ</i>)	6	1.5	0.29	1.8	0.33	568	132.8	2.65	154.8	2.98
Female Genital System	N/A	N/A	N/A	N/A	N/A	245	54.0	1.62	64.4	1.88
Cervix uteri	N/A	N/A	N/A	N/A	N/A	16	4.8	0.57	5.1	0.58
Uterus corpus	N/A	N/A	N/A	N/A	N/A	156	32.7	1.23	40.0	1.46
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	4	1.0	0.24	1.2	0.26
Ovary	N/A	N/A	N/A	N/A	N/A	40	9.1	0.68	10.6	0.77
Male Genital System	476	106.9	2.28	130.0	2.71	N/A	N/A	N/A	N/A	N/A
Prostate	451	98.6	2.14	121.5	2.60	N/A	N/A	N/A	N/A	N/A
Testis	22	7.5	0.74	7.6	0.74	N/A	N/A	N/A	N/A	N/A
Penis	3	0.6	0.17	0.7	0.20	N/A	N/A	N/A	N/A	N/A
Urinary System	241	59.9	1.80	70.7	2.08	104	22.5	1.04	26.6	1.19
Bladder (incl. <i>in situ</i>)	151	37.7	1.42	44.5	1.66	52	10.5	0.68	12.6	0.80
Kidney & renal pelvis	84	20.7	1.06	24.4	1.22	49	11.4	0.77	13.3	0.87
Ureter	3	0.8	0.20	1.0	0.24	2	0.5	0.14	0.5	0.16
Eye & Orbit	2	0.6	0.20	0.7	0.21	2	0.6	0.19	0.7	0.20
Brain & Other CNS	30	8.5	0.73	9.3	0.77	22	5.9	0.60	6.3	0.62
Brain	29	8.0	0.71	8.8	0.75	20	5.4	0.57	5.9	0.60
Endocrine System	31	8.5	0.73	9.6	0.79	75	22.8	1.25	24.2	1.27
Thyroid gland	28	7.8	0.69	8.8	0.76	72	21.9	1.23	23.2	1.25
Lymphomas	98	25.5	1.21	29.3	1.35	81	18.5	0.97	21.4	1.09
Hodgkin lymphoma	9	2.9	0.44	3.0	0.45	8	2.4	0.40	2.5	0.40
Non-Hodgkin lymphoma	89	22.7	1.12	26.3	1.28	73	16.1	0.89	18.9	1.01
Multiple Myeloma	29	7.0	0.61	8.2	0.70	22	4.6	0.46	5.4	0.53
Leukemias	60	15.8	0.96	17.9	1.06	40	9.4	0.71	10.8	0.78
Acute lymphocytic	5	1.8	0.38	1.6	0.33	4	1.5	0.35	1.4	0.31
Chronic lymphocytic	23	5.5	0.54	6.7	0.63	14	2.8	0.34	3.5	0.42
Acute myeloid	18	4.8	0.53	5.5	0.59	13	2.9	0.37	3.4	0.43
Chronic myeloid	7	2.0	0.35	2.3	0.39	5	1.4	0.30	1.5	0.31
Other leukemias	6	1.6	0.30	1.9	0.34	3	0.8	0.20	0.9	0.23
Mesothelioma	6	1.8	0.32	2.0	0.36	1	0.3	0.11	0.3	0.12
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	36	9.9	0.78	11.0	0.84	70	16.6	0.95	19.2	1.06
Breast (<i>in situ</i>)	*	*	*	*	*	103	24.0	1.13	28.3	1.28

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Vermont, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,908	479.9	5.15	567.7	5.94	1,888	447.3	4.90	520.3	5.51
Oral Cavity & Pharynx	76	18.8	1.02	23.0	1.20	27	6.7	0.61	7.8	0.69
Lip	1	0.4	0.17	0.5	0.18	*	*	*	*	*
Tongue	27	6.4	0.58	7.9	0.70	7	1.8	0.32	2.1	0.35
Major salivary gland	6	1.6	0.31	1.9	0.36	3	1.0	0.26	1.1	0.28
Floor of mouth	4	0.8	0.19	1.0	0.24	2	0.4	0.16	0.5	0.18
Gum & other mouth	8	1.9	0.32	2.2	0.37	5	1.2	0.24	1.4	0.28
Nasopharynx	3	0.8	0.23	0.9	0.26	*	*	*	*	*
Oropharynx	6	1.5	0.29	1.8	0.34	1	0.3	0.13	0.4	0.16
Hypopharynx	4	0.9	0.21	1.1	0.26	2	0.4	0.12	0.4	0.15
Digestive System	339	86.8	2.20	102.7	2.55	261	58.6	1.70	68.7	1.95
Esophagus	39	9.4	0.70	11.3	0.83	11	2.2	0.31	2.8	0.38
Stomach	29	7.5	0.64	8.9	0.75	16	3.6	0.42	4.2	0.49
Small intestine	10	2.5	0.38	3.0	0.44	8	1.9	0.31	2.2	0.35
Colon (excl. rectum)	98	26.4	1.25	30.7	1.41	98	22.4	1.07	25.8	1.19
Rectum & rectosigmoid	50	13.0	0.86	15.4	1.00	31	7.3	0.63	8.9	0.73
Anus, anal canal, & anorectum	6	1.8	0.33	2.0	0.37	14	3.0	0.38	3.7	0.46
Liver	31	7.4	0.61	9.1	0.74	8	1.9	0.32	2.0	0.34
Gallbladder	2	0.5	0.16	0.6	0.19	6	1.3	0.25	1.5	0.29
Pancreas	56	14.0	0.87	16.6	1.01	51	11.0	0.71	13.0	0.82
Respiratory System	287	70.3	1.93	84.1	2.27	264	57.4	1.63	68.7	1.92
Larynx	20	4.8	0.51	5.7	0.59	7	1.7	0.32	2.0	0.35
Lung & bronchus	263	64.4	1.85	77.0	2.17	254	55.1	1.59	65.9	1.88
Bones & Joints	4	1.3	0.32	1.4	0.31	3	0.8	0.23	0.8	0.23
Soft Tissue (incl. heart)	11	2.9	0.43	3.3	0.46	9	2.9	0.46	2.9	0.45
Skin (excl. basal & sq.)	173	45.9	1.63	53.1	1.85	135	35.0	1.45	39.5	1.57
Melanoma of the skin	165	43.4	1.59	50.3	1.79	131	34.1	1.44	38.5	1.55
Breast (excl. <i>in situ</i>)	6	1.5	0.29	1.7	0.33	550	132.7	2.70	154.9	3.04
Female Genital System	N/A	N/A	N/A	N/A	N/A	240	54.3	1.66	64.8	1.92
Cervix uteri	N/A	N/A	N/A	N/A	N/A	15	4.6	0.57	4.9	0.58
Uterus corpus	N/A	N/A	N/A	N/A	N/A	154	33.3	1.26	40.7	1.50
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	4	1.1	0.25	1.2	0.27
Ovary	N/A	N/A	N/A	N/A	N/A	38	9.0	0.69	10.4	0.78
Male Genital System	462	106.6	2.31	129.6	2.75	N/A	N/A	N/A	N/A	N/A
Prostate	437	98.0	2.16	120.8	2.63	N/A	N/A	N/A	N/A	N/A
Testis	21	7.8	0.78	7.9	0.78	N/A	N/A	N/A	N/A	N/A
Penis	3	0.6	0.18	0.7	0.21	N/A	N/A	N/A	N/A	N/A
Urinary System	235	60.1	1.83	70.8	2.12	102	22.9	1.07	27.0	1.22
Bladder (incl. <i>in situ</i>)	149	38.1	1.45	45.0	1.69	51	10.6	0.69	12.7	0.81
Kidney & renal pelvis	80	20.5	1.08	24.0	1.23	48	11.6	0.80	13.5	0.89
Ureter	3	0.8	0.21	1.0	0.25	2	0.5	0.14	0.6	0.16
Eye & Orbit	2	0.6	0.21	0.7	0.22	2	0.6	0.20	0.7	0.21
Brain & Other CNS	29	8.6	0.76	9.4	0.80	21	5.8	0.61	6.3	0.64
Brain	28	8.1	0.74	8.9	0.78	20	5.3	0.58	5.9	0.61
Endocrine System	30	8.6	0.76	9.6	0.81	73	23.6	1.32	24.9	1.33
Thyroid gland	27	7.8	0.71	8.9	0.78	70	22.7	1.29	23.9	1.31
Lymphomas	95	25.9	1.24	29.7	1.39	78	18.3	0.98	21.1	1.10
Hodgkin lymphoma	9	3.0	0.47	3.1	0.47	7	2.2	0.40	2.3	0.40
Non-Hodgkin lymphoma	87	22.9	1.15	26.6	1.31	71	16.0	0.90	18.8	1.03
Multiple Myeloma	27	6.8	0.62	8.0	0.70	21	4.6	0.47	5.4	0.54
Leukemias	58	15.9	0.98	18.0	1.08	40	9.6	0.73	11.0	0.80
Acute lymphocytic	5	1.9	0.41	1.7	0.35	4	1.5	0.36	1.4	0.32
Chronic lymphocytic	22	5.5	0.54	6.6	0.64	14	2.9	0.35	3.5	0.43
Acute myeloid	17	4.8	0.53	5.5	0.60	13	3.0	0.38	3.5	0.45
Chronic myeloid	7	2.0	0.36	2.3	0.40	5	1.3	0.30	1.5	0.32
Other leukemias	6	1.7	0.32	2.0	0.36	3	0.8	0.22	1.0	0.24
Mesothelioma	6	1.8	0.33	2.1	0.37	1	0.3	0.11	0.3	0.12
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	35	10.1	0.81	11.2	0.87	68	16.9	0.98	19.5	1.09
Breast (<i>in situ</i>)	*	*	*	*	*	101	24.4	1.17	28.8	1.32

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Vermont, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	13	408.9	58.31	498.4	67.56	7	285.4	53.92	330.7	61.81
Oral Cavity & Pharynx	1	24.0	10.28	26.1	11.25	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	2	36.8	13.13	49.7	17.64	2	102.4	36.25	115.5	39.87
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	2	77.0	26.14	91.3	31.14
Female Genital System	N/A	N/A	N/A	N/A	N/A	1	52.0	22.30	64.2	27.35
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	5	187.0	42.47	224.7	47.63	N/A	N/A	N/A	N/A	N/A
Prostate	5	187.0	42.47	224.7	47.63	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	2	43.7	17.46	55.5	21.14	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	1	36.7	16.71	46.6	20.06	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	1	29.4	12.07	36.0	14.81	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Vermont, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	8	275.7	46.54	313.5	52.04	13	221.6	30.09	251.8	34.10
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	3	86.2	24.58	104.4	29.01	2	38.1	13.17	43.1	14.89
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	1	49.8	21.61	56.8	24.09	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	5	80.0	16.49	93.4	19.36
Female Genital System	N/A	N/A	N/A	N/A	N/A	1	26.6	10.84	31.3	12.35
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Vermont, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	8	201.3	34.51	233.6	39.53	11	242.4	35.96	272.9	40.24
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	2	40.1	15.59	46.5	17.57	2	34.4	12.76	40.6	15.23
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	1	30.6	12.68	36.6	14.97	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	1	30.6	12.68	36.6	14.97	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	4	96.5	22.76	101.0	24.03
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	1	29.5	13.02	35.8	15.74	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	1	37.9	17.00	45.6	19.56	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

VERMONT

II-498 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Vermont, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	6	167.4	33.26	191.9	37.86	9	239.9	38.55	268.3	42.72
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	1	34.6	13.47	41.0	16.13
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	1	33.3	13.77	39.9	16.31	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	1	33.3	13.77	39.9	16.31	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	4	102.0	24.93	107.7	26.39
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	1	28.8	13.85	33.5	16.20	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Vermont, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	*	*	*	*	*	*	*	*	*	*
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


VERMONT

II-500 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	8,367,303	8,417,651	8,471,011	8,510,920	8,556,642
Non-Hispanic White	5,361,510	5,358,792	5,356,002	5,350,301	5,346,316
Non-Hispanic Black	1,662,355	1,674,608	1,687,947	1,699,397	1,711,902
Non-Hispanic Asian/Pacific Islander (NH API)	575,063	593,196	610,697	622,651	637,569
Non-Hispanic American Indian/Alaskan Native PRCA (NH AI/AN)	2,827	2,827	2,834	2,878	2,886


All Races Population 2015–2019: 42,323,527
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	743,385	765,849	790,839	812,901	835,102
Hispanic White	634,576	652,972	673,557	691,273	709,397
Hispanic Black	66,756	69,204	72,168	75,205	77,683

Hispanic/Latino Population, Census 2010: 631,825
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

VIRGINIA CANCER REGISTRY

Initial Operation: 1970
Population-based Data Available: 1990
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	97.7	99.8	98.7	97.2	97.1	98.1
Missing Race	1.6	1.5	2.1	1.1	1.2	1.5
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.1	0.4	0.2	0.4	0.2
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	3.2	2.9	2.6	2.7	2.8	2.8
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.6	Ovary	91.2
Oral Cavity & Pharynx	97.5	Prostate	96.7
Esophagus	93.2	Testis	99.3
Stomach	95.3	Bladder (incl. <i>in situ</i>)	97.1
Colon & Rectum	95.1	Kidney & Renal Pelvis	92.0
Liver	50.5	Brain & Other CNS	87.0
Pancreas	85.2	Brain & Other CNS (non-malig)	46.8
Lung & Bronchus	88.1	Thyroid	99.6
Melanomas of the Skin	99.1	Hodgkin Lymphoma	98.6
Female Breast (excl. <i>in situ</i>)	98.6	Non-Hodgkin Lymphoma	96.8
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	89.9
Cervix Uteri	96.9	Leukemias	88.4
Uterus Corpus & Uterus NOS	98.4		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Virginia, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	20,279	437.7	1.41	521.9	1.66	20,524	391.6	1.25	457.6	1.44
Oral Cavity & Pharynx	831	17.3	0.28	21.2	0.33	319	6.0	0.15	7.1	0.18
Lip	25	0.6	0.05	0.7	0.06	7	0.1	0.02	0.2	0.03
Tongue	262	5.4	0.15	6.6	0.18	99	1.8	0.08	2.2	0.10
Major salivary gland	70	1.6	0.09	1.9	0.10	48	1.0	0.06	1.1	0.07
Floor of mouth	38	0.8	0.06	0.9	0.07	15	0.3	0.03	0.3	0.04
Gum & other mouth	87	1.9	0.09	2.3	0.11	67	1.3	0.07	1.5	0.08
Nasopharynx	27	0.6	0.05	0.7	0.06	13	0.3	0.03	0.3	0.04
Oropharynx	59	1.2	0.07	1.5	0.09	17	0.3	0.04	0.4	0.04
Hypopharynx	48	1.0	0.07	1.2	0.08	12	0.2	0.03	0.3	0.03
Digestive System	4,036	87.8	0.64	105.1	0.75	3,218	60.1	0.48	70.8	0.56
Esophagus	330	7.0	0.18	8.5	0.21	92	1.7	0.08	2.0	0.09
Stomach	364	8.1	0.19	9.5	0.23	212	4.0	0.13	4.7	0.15
Small intestine	152	3.3	0.12	3.9	0.14	124	2.3	0.10	2.7	0.11
Colon (excl. rectum)	1,211	27.1	0.36	32.0	0.42	1,215	22.9	0.30	26.7	0.35
Rectum & rectosigmoid	550	11.9	0.23	14.2	0.27	404	7.8	0.18	9.2	0.21
Anus, anal canal, & anorectum	60	1.3	0.08	1.5	0.09	116	2.1	0.09	2.6	0.11
Liver	490	9.8	0.20	12.3	0.25	163	3.0	0.11	3.5	0.13
Gallbladder	29	0.7	0.06	0.8	0.07	62	1.2	0.07	1.4	0.08
Pancreas	636	13.9	0.25	16.7	0.30	609	11.1	0.20	13.1	0.24
Respiratory System	3,114	67.5	0.56	80.7	0.66	2,746	49.6	0.43	59.3	0.51
Larynx	250	5.2	0.15	6.4	0.18	66	1.2	0.07	1.5	0.08
Lung & bronchus	2,816	61.2	0.53	73.1	0.63	2,650	47.8	0.42	57.2	0.50
Bones & Joints	45	1.1	0.07	1.1	0.07	32	0.7	0.06	0.7	0.06
Soft Tissue (incl. heart)	162	3.7	0.13	4.2	0.15	132	2.7	0.11	3.0	0.12
Skin (excl. basal & sq.)	1,281	28.9	0.37	33.7	0.43	866	17.1	0.27	19.6	0.30
Melanoma of the skin	1,205	27.0	0.36	31.7	0.41	809	16.0	0.26	18.3	0.29
Breast (excl. <i>in situ</i>)	57	1.3	0.08	1.5	0.09	6,558	126.2	0.72	148.2	0.83
Female Genital System	N/A	N/A	N/A	N/A	N/A	2,435	45.9	0.43	54.6	0.50
Cervix uteri	N/A	N/A	N/A	N/A	N/A	271	6.0	0.17	6.5	0.18
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,364	24.7	0.31	30.3	0.37
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	48	0.9	0.06	1.1	0.07
Ovary	N/A	N/A	N/A	N/A	N/A	494	9.5	0.20	11.1	0.23
Male Genital System	5,222	105.4	0.67	129.7	0.81	N/A	N/A	N/A	N/A	N/A
Prostate	5,010	100.3	0.65	124.4	0.79	N/A	N/A	N/A	N/A	N/A
Testis	175	4.2	0.15	4.2	0.14	N/A	N/A	N/A	N/A	N/A
Penis	30	0.7	0.06	0.8	0.07	N/A	N/A	N/A	N/A	N/A
Urinary System	2,308	51.5	0.49	60.8	0.57	1,001	18.7	0.27	21.9	0.31
Bladder (incl. <i>in situ</i>)	1,258	29.0	0.38	34.0	0.44	417	7.6	0.17	8.9	0.20
Kidney & renal pelvis	1,000	21.4	0.31	25.4	0.36	554	10.6	0.21	12.3	0.24
Ureter	29	0.7	0.06	0.8	0.07	20	0.4	0.04	0.4	0.04
Eye & Orbit	38	0.8	0.06	1.0	0.07	29	0.6	0.05	0.7	0.05
Brain & Other CNS	308	7.0	0.18	7.7	0.20	246	5.1	0.15	5.5	0.16
Brain	295	6.6	0.18	7.4	0.20	234	4.8	0.14	5.2	0.15
Endocrine System	314	7.1	0.18	7.9	0.20	847	18.7	0.30	20.2	0.31
Thyroid gland	279	6.2	0.17	7.0	0.19	820	18.2	0.29	19.6	0.31
Lymphomas	990	22.4	0.33	25.6	0.37	826	16.0	0.26	18.3	0.29
Hodgkin lymphoma	101	2.3	0.11	2.4	0.11	91	2.1	0.10	2.1	0.10
Non-Hodgkin lymphoma	889	20.0	0.31	23.2	0.35	735	13.9	0.24	16.2	0.27
Multiple Myeloma	370	8.2	0.20	9.7	0.23	287	5.3	0.14	6.3	0.17
Leukemias	571	13.2	0.25	14.9	0.28	453	9.0	0.20	10.0	0.21
Acute lymphocytic	62	1.5	0.09	1.4	0.08	59	1.5	0.09	1.3	0.08
Chronic lymphocytic	167	3.8	0.13	4.5	0.16	105	1.9	0.08	2.3	0.10
Acute myeloid	194	4.4	0.15	5.1	0.17	172	3.4	0.12	3.8	0.13
Chronic myeloid	76	1.8	0.09	2.0	0.11	61	1.2	0.07	1.4	0.08
Other leukemias	72	1.7	0.09	1.9	0.10	55	1.1	0.07	1.2	0.07
Mesothelioma	64	1.6	0.09	1.8	0.10	20	0.4	0.04	0.4	0.04
Kaposi Sarcoma	17	0.4	0.05	0.4	0.05	1	0.0	0.01	0.0	0.01
Ill-Defined & Unknown	552	12.8	0.25	14.9	0.29	508	9.5	0.19	11.0	0.22
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	299	6.8	0.18	7.7	0.20	627	12.3	0.23	14.1	0.25
Breast (<i>in situ</i>)	7	0.2	0.03	0.2	0.03	1,591	31.0	0.36	36.5	0.41

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Virginia, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	14,879	437.3	1.65	519.1	1.93	14,933	404.7	1.55	472.3	1.76
Oral Cavity & Pharynx	663	19.1	0.34	23.4	0.41	243	6.4	0.19	7.6	0.22
Lip	22	0.7	0.07	0.8	0.08	6	0.1	0.03	0.2	0.03
Tongue	223	6.3	0.19	7.8	0.24	80	2.1	0.11	2.6	0.13
Major salivary gland	54	1.7	0.11	2.0	0.12	37	1.0	0.08	1.2	0.09
Floor of mouth	30	0.8	0.07	1.0	0.08	12	0.3	0.04	0.4	0.05
Gum & other mouth	63	1.9	0.11	2.2	0.13	49	1.2	0.08	1.5	0.09
Nasopharynx	13	0.4	0.05	0.5	0.06	7	0.2	0.03	0.2	0.04
Oropharynx	46	1.3	0.09	1.6	0.11	14	0.4	0.05	0.4	0.05
Hypopharynx	34	1.0	0.08	1.2	0.09	8	0.2	0.03	0.3	0.04
Digestive System	2,872	84.9	0.73	101.4	0.86	2,229	58.0	0.57	68.2	0.66
Esophagus	278	8.0	0.22	9.7	0.26	70	1.7	0.10	2.1	0.11
Stomach	230	6.8	0.20	8.1	0.24	119	3.0	0.13	3.6	0.15
Small intestine	108	3.3	0.15	3.8	0.17	84	2.2	0.11	2.6	0.13
Colon (excl. rectum)	864	26.4	0.41	31.0	0.48	869	23.0	0.36	26.6	0.41
Rectum & rectosigmoid	395	11.9	0.28	14.2	0.32	284	7.9	0.22	9.3	0.25
Anus, anal canal, & anorectum	44	1.3	0.09	1.6	0.11	95	2.5	0.12	3.0	0.14
Liver	321	8.8	0.22	11.0	0.28	99	2.5	0.12	3.0	0.14
Gallbladder	17	0.5	0.06	0.6	0.07	34	0.9	0.07	1.0	0.08
Pancreas	462	13.5	0.29	16.2	0.34	419	10.3	0.23	12.3	0.27
Respiratory System	2,371	68.2	0.64	81.5	0.76	2,126	52.7	0.52	63.1	0.62
Larynx	182	5.2	0.18	6.4	0.21	48	1.2	0.08	1.5	0.10
Lung & bronchus	2,154	61.9	0.61	74.0	0.72	2,056	50.9	0.51	60.9	0.61
Bones & Joints	29	1.1	0.09	1.1	0.09	20	0.7	0.08	0.7	0.07
Soft Tissue (incl. heart)	120	3.9	0.16	4.4	0.18	86	2.6	0.13	2.9	0.14
Skin (excl. basal & sq.)	1,244	38.0	0.50	44.4	0.57	826	24.0	0.39	27.3	0.43
Melanoma of the skin	1,179	35.9	0.48	42.0	0.55	780	22.8	0.38	26.0	0.42
Breast (excl. <i>in situ</i>)	41	1.2	0.09	1.4	0.10	4,704	129.4	0.88	152.0	1.01
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,722	46.5	0.52	55.3	0.61
Cervix uteri	N/A	N/A	N/A	N/A	N/A	158	5.5	0.21	5.8	0.21
Uterus corpus	N/A	N/A	N/A	N/A	N/A	977	25.3	0.38	30.9	0.45
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	26	0.7	0.06	0.8	0.07
Ovary	N/A	N/A	N/A	N/A	N/A	363	10.0	0.24	11.7	0.28
Male Genital System	3,338	91.8	0.73	111.9	0.88	N/A	N/A	N/A	N/A	N/A
Prostate	3,171	85.5	0.69	105.5	0.85	N/A	N/A	N/A	N/A	N/A
Testis	140	5.5	0.21	5.5	0.21	N/A	N/A	N/A	N/A	N/A
Penis	22	0.7	0.07	0.8	0.07	N/A	N/A	N/A	N/A	N/A
Urinary System	1,786	53.5	0.58	63.1	0.68	719	18.7	0.32	21.9	0.37
Bladder (incl. <i>in situ</i>)	1,051	31.7	0.45	37.2	0.52	327	8.1	0.21	9.6	0.24
Kidney & renal pelvis	694	20.5	0.36	24.4	0.42	369	10.1	0.25	11.7	0.28
Ureter	24	0.7	0.07	0.9	0.08	16	0.4	0.05	0.5	0.05
Eye & Orbit	32	1.0	0.08	1.1	0.09	25	0.7	0.07	0.8	0.07
Brain & Other CNS	239	7.8	0.23	8.6	0.25	182	5.5	0.19	6.0	0.20
Brain	231	7.5	0.23	8.3	0.25	174	5.2	0.19	5.8	0.20
Endocrine System	230	7.6	0.23	8.5	0.25	532	18.4	0.37	19.7	0.39
Thyroid gland	207	6.8	0.22	7.6	0.24	514	17.9	0.37	19.1	0.38
Lymphomas	759	23.6	0.40	27.0	0.44	629	17.3	0.32	19.7	0.36
Hodgkin lymphoma	64	2.3	0.13	2.4	0.14	62	2.3	0.13	2.3	0.13
Non-Hodgkin lymphoma	695	21.3	0.37	24.6	0.42	568	15.0	0.29	17.4	0.33
Multiple Myeloma	230	6.8	0.21	8.0	0.24	168	4.2	0.15	5.0	0.18
Leukemias	436	13.9	0.31	15.7	0.34	327	9.3	0.24	10.3	0.26
Acute lymphocytic	40	1.6	0.12	1.5	0.11	36	1.5	0.11	1.3	0.10
Chronic lymphocytic	137	4.1	0.16	4.9	0.19	85	2.1	0.11	2.5	0.12
Acute myeloid	150	4.7	0.18	5.3	0.20	122	3.4	0.14	3.8	0.16
Chronic myeloid	54	1.7	0.11	2.0	0.12	43	1.2	0.09	1.4	0.10
Other leukemias	55	1.8	0.11	2.0	0.12	41	1.2	0.09	1.3	0.09
Mesothelioma	52	1.7	0.10	1.9	0.12	17	0.4	0.05	0.5	0.06
Kaposi Sarcoma	5	0.2	0.04	0.2	0.04	*	*	*	*	*
Ill-Defined & Unknown	433	13.3	0.29	15.5	0.34	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	223	7.2	0.22	8.1	0.24	445	12.7	0.28	14.5	0.31
Breast (<i>in situ</i>)	4	0.1	0.03	0.1	0.03	1,082	30.7	0.44	36.2	0.50

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Virginia, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3,808	491.9	3.78	595.0	4.46	3,730	386.6	2.91	454.7	3.35
Oral Cavity & Pharynx	107	13.2	0.60	16.2	0.72	43	4.2	0.30	5.1	0.35
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	22	2.6	0.27	3.3	0.32	7	0.7	0.12	0.8	0.14
Major salivary gland	11	1.5	0.21	1.7	0.25	7	0.7	0.12	0.8	0.14
Floor of mouth	6	0.7	0.14	0.9	0.16	2	0.2	0.07	0.3	0.09
Gum & other mouth	10	1.3	0.20	1.6	0.23	9	0.9	0.14	1.1	0.16
Nasopharynx	8	1.0	0.16	1.1	0.18	3	0.4	0.09	0.4	0.10
Oropharynx	11	1.3	0.18	1.6	0.22	3	0.3	0.07	0.3	0.09
Hypopharynx	12	1.5	0.20	1.8	0.24	3	0.3	0.07	0.3	0.09
Digestive System	789	104.6	1.77	126.3	2.09	680	70.7	1.24	83.7	1.45
Esophagus	37	4.7	0.37	5.9	0.45	16	1.6	0.18	1.9	0.22
Stomach	81	11.7	0.62	13.7	0.72	53	5.7	0.36	6.6	0.41
Small intestine	35	4.7	0.38	5.7	0.45	35	3.7	0.29	4.3	0.33
Colon (excl. rectum)	248	33.9	1.02	40.5	1.20	248	25.8	0.75	30.5	0.87
Rectum & rectosigmoid	95	12.5	0.60	14.9	0.71	74	7.7	0.41	9.1	0.47
Anus, anal canal, & anorectum	13	1.6	0.21	1.9	0.25	13	1.4	0.18	1.7	0.20
Liver	109	12.4	0.56	16.0	0.70	37	3.6	0.27	4.4	0.33
Gallbladder	8	1.2	0.21	1.5	0.25	18	1.9	0.21	2.3	0.24
Pancreas	127	17.1	0.72	20.5	0.84	145	15.0	0.57	17.9	0.67
Respiratory System	591	80.6	1.58	96.7	1.85	475	48.3	1.02	58.0	1.20
Larynx	58	7.2	0.45	9.0	0.54	17	1.7	0.19	2.0	0.22
Lung & bronchus	524	72.2	1.50	86.4	1.75	454	46.1	0.99	55.4	1.17
Bones & Joints	8	1.1	0.17	1.2	0.19	6	0.7	0.13	0.7	0.13
Soft Tissue (incl. heart)	23	3.0	0.29	3.3	0.32	27	2.9	0.25	3.2	0.28
Skin (excl. basal & sq.)	16	2.3	0.28	2.6	0.32	17	2.0	0.22	2.1	0.23
Melanoma of the skin	9	1.3	0.21	1.5	0.25	9	0.9	0.15	1.1	0.17
Breast (excl. <i>in situ</i>)	12	1.7	0.23	2.0	0.26	1,274	132.4	1.71	155.5	1.96
Female Genital System	N/A	N/A	N/A	N/A	N/A	444	44.7	0.98	53.4	1.14
Cervix uteri	N/A	N/A	N/A	N/A	N/A	60	6.7	0.40	7.3	0.43
Uterus corpus	N/A	N/A	N/A	N/A	N/A	254	24.5	0.71	30.1	0.85
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	17	1.8	0.20	2.1	0.23
Ovary	N/A	N/A	N/A	N/A	N/A	76	7.8	0.41	9.3	0.48
Male Genital System	1,382	166.2	2.11	207.9	2.56	N/A	N/A	N/A	N/A	N/A
Prostate	1,365	164.0	2.09	205.6	2.55	N/A	N/A	N/A	N/A	N/A
Testis	11	1.5	0.20	1.4	0.19	N/A	N/A	N/A	N/A	N/A
Penis	5	0.7	0.14	0.8	0.16	N/A	N/A	N/A	N/A	N/A
Urinary System	373	50.6	1.24	59.8	1.44	210	21.6	0.68	25.6	0.79
Bladder (incl. <i>in situ</i>)	131	19.5	0.81	22.8	0.93	66	6.9	0.39	8.2	0.45
Kidney & renal pelvis	238	30.5	0.93	36.2	1.08	139	14.2	0.55	16.8	0.64
Ureter	2	0.3	0.09	0.4	0.10	2	0.2	0.07	0.3	0.08
Eye & Orbit	3	0.4	0.12	0.4	0.13	3	0.3	0.08	0.3	0.09
Brain & Other CNS	37	4.7	0.36	5.3	0.40	34	3.6	0.28	3.9	0.30
Brain	35	4.4	0.35	4.9	0.39	31	3.3	0.27	3.6	0.29
Endocrine System	36	4.4	0.34	5.0	0.38	118	12.9	0.54	14.3	0.59
Thyroid gland	27	3.3	0.30	3.9	0.34	113	12.3	0.53	13.7	0.58
Lymphomas	135	17.5	0.71	20.1	0.81	120	12.4	0.52	14.4	0.59
Hodgkin lymphoma	22	2.6	0.26	2.8	0.27	19	2.1	0.22	2.2	0.23
Non-Hodgkin lymphoma	113	14.9	0.66	17.3	0.76	100	10.3	0.47	12.2	0.55
Multiple Myeloma	114	15.9	0.71	18.9	0.83	103	10.9	0.49	12.9	0.57
Leukemias	79	11.1	0.59	12.6	0.66	78	8.4	0.44	9.5	0.48
Acute lymphocytic	8	1.1	0.17	1.0	0.16	9	1.0	0.16	1.0	0.15
Chronic lymphocytic	22	3.2	0.32	3.8	0.38	13	1.4	0.18	1.7	0.21
Acute myeloid	26	3.7	0.34	4.2	0.38	34	3.6	0.28	4.1	0.32
Chronic myeloid	13	1.7	0.22	2.0	0.25	13	1.4	0.18	1.6	0.20
Other leukemias	10	1.4	0.22	1.6	0.24	9	1.0	0.15	1.1	0.16
Mesothelioma	8	1.2	0.20	1.3	0.22	2	0.2	0.06	0.2	0.07
Kaposi Sarcoma	9	1.1	0.17	1.1	0.17	*	*	*	*	*
Ill-Defined & Unknown	85	12.2	0.63	14.2	0.72	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	48	6.6	0.45	7.5	0.50	119	12.6	0.53	14.5	0.60
Breast (<i>in situ</i>)	2	0.4	0.11	0.4	0.13	322	32.9	0.84	39.2	0.98

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Virginia, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	566	239.0	4.74	281.6	5.53	754	238.0	3.98	276.3	4.61
Oral Cavity & Pharynx	20	7.5	0.81	9.3	0.99	8	2.5	0.41	3.0	0.47
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	5	1.6	0.33	2.1	0.43	3	1.0	0.25	1.2	0.29
Major salivary gland	2	0.9	0.34	1.0	0.37	2	0.5	0.19	0.6	0.22
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	4	1.7	0.39	2.1	0.47	*	*	*	*	*
Nasopharynx	4	1.5	0.34	1.8	0.41	1	0.4	0.17	0.5	0.18
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	1	0.6	0.30	0.7	0.34	*	*	*	*	*
Digestive System	168	71.5	2.60	84.0	3.02	126	43.3	1.78	50.7	2.07
Esophagus	4	1.6	0.35	1.9	0.42	3	1.1	0.30	1.3	0.35
Stomach	24	10.3	0.99	11.9	1.13	20	6.6	0.68	7.5	0.78
Small intestine	3	1.2	0.34	1.4	0.39	2	0.6	0.20	0.7	0.25
Colon (excl. rectum)	38	16.0	1.22	18.8	1.42	36	12.3	0.95	14.4	1.11
Rectum & rectosigmoid	27	10.9	0.99	12.7	1.15	18	5.8	0.62	6.8	0.73
Anus, anal canal, & anorectum	*	*	*	*	*	2	0.6	0.21	0.8	0.26
Liver	34	14.0	1.13	16.6	1.32	11	3.9	0.55	4.5	0.63
Gallbladder	2	0.8	0.27	1.0	0.33	5	1.5	0.32	1.8	0.37
Pancreas	24	11.0	1.07	12.9	1.24	20	7.2	0.75	8.4	0.87
Respiratory System	79	35.3	1.88	41.9	2.20	68	23.7	1.33	28.0	1.55
Larynx	4	1.6	0.37	2.0	0.45	*	*	*	*	*
Lung & bronchus	72	32.8	1.83	38.9	2.14	67	23.2	1.31	27.4	1.53
Bones & Joints	2	0.8	0.24	0.8	0.23	2	0.6	0.20	0.6	0.19
Soft Tissue (incl. heart)	6	2.5	0.46	2.7	0.49	5	1.7	0.33	1.9	0.37
Skin (excl. basal & sq.)	4	1.7	0.40	2.1	0.50	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	3	1.1	0.31	1.3	0.38	3	1.0	0.25	1.1	0.28
Breast (excl. <i>in situ</i>)	2	0.7	0.23	0.9	0.30	258	77.9	2.22	91.3	2.60
Female Genital System	N/A	N/A	N/A	N/A	N/A	102	30.5	1.38	36.4	1.64
Cervix uteri	N/A	N/A	N/A	N/A	N/A	16	4.7	0.53	5.4	0.62
Uterus corpus	N/A	N/A	N/A	N/A	N/A	53	15.8	0.98	19.1	1.19
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	1	0.3	0.14	0.4	0.18
Ovary	N/A	N/A	N/A	N/A	N/A	23	6.9	0.67	8.1	0.78
Male Genital System	129	54.3	2.23	65.1	2.64	N/A	N/A	N/A	N/A	N/A
Prostate	122	51.9	2.19	62.6	2.60	N/A	N/A	N/A	N/A	N/A
Testis	5	1.5	0.31	1.5	0.31	N/A	N/A	N/A	N/A	N/A
Penis	1	0.6	0.24	0.7	0.29	N/A	N/A	N/A	N/A	N/A
Urinary System	52	22.8	1.47	26.8	1.72	22	7.5	0.74	8.9	0.86
Bladder (incl. <i>in situ</i>)	28	13.4	1.18	15.7	1.37	6	2.0	0.37	2.4	0.44
Kidney & renal pelvis	23	8.7	0.84	10.3	0.99	15	5.1	0.61	5.9	0.70
Ureter	1	0.6	0.24	0.6	0.27	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	8	3.0	0.49	3.5	0.58	9	2.9	0.44	3.3	0.50
Brain	8	2.8	0.48	3.3	0.56	8	2.7	0.42	3.1	0.49
Endocrine System	22	7.7	0.74	8.7	0.85	89	26.0	1.24	28.5	1.37
Thyroid gland	21	7.2	0.72	8.1	0.82	87	25.4	1.23	27.7	1.35
Lymphomas	33	13.7	1.13	15.8	1.31	28	9.1	0.79	10.4	0.90
Hodgkin lymphoma	5	1.8	0.39	2.0	0.43	3	1.0	0.25	1.0	0.24
Non-Hodgkin lymphoma	28	11.8	1.07	13.8	1.24	25	8.1	0.75	9.4	0.87
Multiple Myeloma	9	4.1	0.63	4.9	0.74	6	2.1	0.41	2.5	0.47
Leukemias	16	6.5	0.77	7.2	0.86	13	4.6	0.57	4.8	0.61
Acute lymphocytic	4	1.4	0.32	1.3	0.32	3	0.9	0.25	0.8	0.20
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	6	2.8	0.53	3.3	0.62	6	2.1	0.38	2.4	0.43
Chronic myeloid	3	1.1	0.33	1.2	0.36	1	0.5	0.18	0.5	0.19
Other leukemias	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	12	6.2	0.85	7.2	0.99	12	4.1	0.55	4.7	0.63
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	9	3.4	0.53	3.8	0.59	22	6.9	0.67	7.9	0.77
Breast (<i>in situ</i>)	*	*	*	*	*	95	28.4	1.32	33.4	1.55

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Virginia, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	5	260.5	56.46	302.6	63.72	4	190.9	46.76	224.3	52.36
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	1	60.7	25.64	75.4	30.97	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	1	74.5	30.20	83.9	32.11
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Virginia, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	494	254.2	6.25	298.8	7.15	694	270.2	5.05	312.2	5.84
Oral Cavity & Pharynx	14	7.3	1.07	8.7	1.25	8	2.9	0.48	3.3	0.56
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	4	1.9	0.54	2.3	0.64	2	0.8	0.26	1.0	0.32
Major salivary gland	2	0.7	0.32	0.8	0.34	2	0.6	0.21	0.7	0.23
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	2	1.3	0.46	1.5	0.55	2	0.7	0.21	0.8	0.26
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	117	60.4	3.04	71.4	3.50	114	51.1	2.34	59.5	2.70
Esophagus	5	2.9	0.69	3.4	0.81	2	1.0	0.33	1.2	0.39
Stomach	21	11.1	1.35	12.7	1.51	16	6.3	0.80	7.1	0.90
Small intestine	3	1.8	0.57	2.0	0.61	2	0.9	0.31	1.1	0.37
Colon (excl. rectum)	33	16.5	1.58	19.7	1.84	36	15.9	1.30	18.6	1.51
Rectum & rectosigmoid	18	7.1	0.91	8.7	1.09	16	5.7	0.69	6.6	0.81
Anus, anal canal, & anorectum	*	*	*	*	*	3	1.3	0.37	1.5	0.44
Liver	14	7.8	1.09	9.3	1.26	12	5.9	0.83	6.8	0.95
Gallbladder	2	0.7	0.25	0.9	0.30	3	1.6	0.42	1.9	0.49
Pancreas	13	8.2	1.18	9.5	1.34	16	8.7	1.03	10.1	1.17
Respiratory System	37	25.3	2.16	29.7	2.47	46	22.6	1.61	26.5	1.85
Larynx	3	1.6	0.49	1.9	0.55	*	*	*	*	*
Lung & bronchus	32	23.2	2.09	27.1	2.39	43	21.4	1.56	25.2	1.80
Bones & Joints	3	1.0	0.29	1.0	0.32	2	0.6	0.18	0.6	0.21
Soft Tissue (incl. heart)	8	2.5	0.51	2.7	0.57	8	3.1	0.57	3.3	0.62
Skin (excl. basal & sq.)	8	4.3	0.83	4.9	0.90	13	4.6	0.62	5.2	0.70
Melanoma of the skin	7	3.7	0.76	4.1	0.84	12	3.9	0.55	4.4	0.63
Breast (excl. <i>in situ</i>)	2	0.8	0.35	0.9	0.40	209	77.9	2.61	90.9	3.05
Female Genital System	N/A	N/A	N/A	N/A	N/A	102	37.6	1.81	44.4	2.14
Cervix uteri	N/A	N/A	N/A	N/A	N/A	27	8.5	0.78	9.6	0.91
Uterus corpus	N/A	N/A	N/A	N/A	N/A	46	17.6	1.25	21.2	1.50
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	1.0	0.32	1.2	0.38
Ovary	N/A	N/A	N/A	N/A	N/A	21	8.1	0.88	9.5	1.02
Male Genital System	134	72.4	3.27	87.2	3.76	N/A	N/A	N/A	N/A	N/A
Prostate	122	68.9	3.22	83.5	3.71	N/A	N/A	N/A	N/A	N/A
Testis	11	2.7	0.43	2.7	0.46	N/A	N/A	N/A	N/A	N/A
Penis	1	0.8	0.39	0.9	0.42	N/A	N/A	N/A	N/A	N/A
Urinary System	50	27.5	2.11	32.3	2.41	30	12.4	1.10	14.5	1.29
Bladder (incl. <i>in situ</i>)	20	13.6	1.63	15.9	1.85	8	4.0	0.69	4.9	0.81
Kidney & renal pelvis	30	13.2	1.30	15.7	1.50	22	7.9	0.82	9.0	0.96
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	1	0.3	0.12	0.3	0.15	1	0.4	0.18	0.5	0.21
Brain & Other CNS	17	6.5	0.92	7.2	1.03	15	5.1	0.69	5.3	0.74
Brain	15	5.8	0.87	6.5	0.98	14	5.0	0.69	5.2	0.74
Endocrine System	17	5.9	0.82	6.5	0.94	73	21.9	1.23	24.1	1.39
Thyroid gland	15	5.6	0.81	6.3	0.93	71	21.4	1.21	23.5	1.36
Lymphomas	39	18.0	1.63	20.6	1.84	32	13.3	1.17	14.9	1.32
Hodgkin lymphoma	7	1.6	0.29	1.7	0.34	5	1.5	0.32	1.5	0.34
Non-Hodgkin lymphoma	32	16.5	1.60	18.9	1.81	27	11.8	1.13	13.4	1.27
Multiple Myeloma	9	5.2	0.93	6.2	1.08	6	2.7	0.54	3.4	0.66
Leukemias	24	8.9	1.07	10.0	1.22	22	7.8	0.85	8.5	0.97
Acute lymphocytic	8	1.7	0.28	1.6	0.29	8	1.9	0.31	1.6	0.28
Chronic lymphocytic	2	0.6	0.22	0.9	0.31	3	1.6	0.45	2.0	0.53
Acute myeloid	7	4.0	0.83	4.5	0.93	7	2.6	0.50	2.9	0.56
Chronic myeloid	4	1.4	0.43	1.6	0.51	2	0.6	0.19	0.7	0.23
Other leukemias	3	1.2	0.38	1.3	0.41	2	1.1	0.36	1.3	0.44
Mesothelioma	2	1.1	0.41	1.4	0.50	*	*	*	*	*
Kaposi Sarcoma	2	0.6	0.30	0.6	0.33	*	*	*	*	*
Ill-Defined & Unknown	9	6.3	1.11	7.0	1.24	13	6.2	0.85	7.2	0.99
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	12	5.3	0.89	5.8	0.98	25	9.6	0.94	10.9	1.08
Breast (<i>in situ</i>)	*	*	*	*	*	65	24.2	1.44	28.5	1.69

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

VIRGINIA

II-508 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Virginia, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	347	206.6	6.00	242.0	6.85	492	220.2	4.84	254.4	5.60
Oral Cavity & Pharynx	10	6.1	1.02	7.3	1.20	7	2.8	0.50	3.1	0.58
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	3	2.0	0.60	2.4	0.70	2	0.7	0.26	0.8	0.31
Major salivary gland	1	0.7	0.35	0.7	0.36	2	0.7	0.24	0.7	0.26
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	2	1.1	0.47	1.4	0.57	2	0.8	0.24	0.9	0.30
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	82	49.2	2.94	57.7	3.35	83	42.4	2.27	49.3	2.61
Esophagus	4	2.6	0.68	3.1	0.80	1	0.7	0.31	0.8	0.37
Stomach	15	8.9	1.29	10.1	1.42	11	5.1	0.74	5.6	0.83
Small intestine	2	1.4	0.55	1.6	0.60	1	0.6	0.24	0.7	0.29
Colon (excl. rectum)	24	14.1	1.57	16.7	1.82	27	13.9	1.29	16.3	1.50
Rectum & rectosigmoid	13	6.0	0.90	7.3	1.08	12	5.2	0.72	6.1	0.84
Anus, anal canal, & anorectum	*	*	*	*	*	2	1.0	0.33	1.2	0.38
Liver	9	5.8	1.05	6.8	1.19	6	3.9	0.73	4.4	0.82
Gallbladder	1	0.7	0.27	0.8	0.32	2	1.4	0.43	1.6	0.50
Pancreas	8	5.9	1.07	6.6	1.18	12	7.2	1.00	8.4	1.14
Respiratory System	29	22.6	2.17	26.2	2.46	34	18.7	1.54	21.9	1.77
Larynx	2	1.6	0.53	1.8	0.58	*	*	*	*	*
Lung & bronchus	25	20.7	2.10	24.0	2.39	32	17.7	1.50	20.9	1.73
Bones & Joints	2	0.9	0.32	1.0	0.36	*	*	*	*	*
Soft Tissue (incl. heart)	6	1.9	0.43	2.0	0.46	5	2.4	0.54	2.7	0.60
Skin (excl. basal & sq.)	8	4.7	0.92	5.3	1.00	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	7	4.0	0.85	4.5	0.92	11	4.2	0.59	4.7	0.68
Breast (excl. <i>in situ</i>)	*	*	*	*	*	156	66.8	2.58	78.1	3.01
Female Genital System	N/A	N/A	N/A	N/A	N/A	67	27.9	1.63	33.1	1.94
Cervix uteri	N/A	N/A	N/A	N/A	N/A	17	6.0	0.69	6.9	0.81
Uterus corpus	N/A	N/A	N/A	N/A	N/A	30	12.4	1.08	14.9	1.30
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	0.8	0.29	0.9	0.35
Ovary	N/A	N/A	N/A	N/A	N/A	15	6.7	0.85	7.8	0.99
Male Genital System	92	56.4	3.07	67.8	3.53	N/A	N/A	N/A	N/A	N/A
Prostate	83	53.6	3.02	64.9	3.48	N/A	N/A	N/A	N/A	N/A
Testis	8	2.2	0.44	2.3	0.47	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	34	21.2	1.95	25.1	2.23	20	9.5	1.04	10.9	1.20
Bladder (incl. <i>in situ</i>)	13	10.0	1.45	11.7	1.65	6	3.3	0.67	4.0	0.78
Kidney & renal pelvis	21	10.6	1.24	12.8	1.46	13	5.6	0.75	6.3	0.85
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	11	5.4	0.94	6.0	1.06	10	4.0	0.65	4.2	0.70
Brain	10	4.7	0.88	5.3	0.99	9	3.9	0.64	4.1	0.69
Endocrine System	13	5.2	0.83	5.8	0.94	49	17.1	1.15	18.7	1.30
Thyroid gland	11	4.9	0.82	5.5	0.94	48	16.6	1.13	18.1	1.27
Lymphomas	27	14.0	1.50	16.1	1.71	22	10.7	1.13	12.0	1.27
Hodgkin lymphoma	6	1.6	0.31	1.7	0.37	3	1.2	0.32	1.2	0.35
Non-Hodgkin lymphoma	22	12.5	1.47	14.4	1.67	19	9.5	1.08	10.8	1.22
Multiple Myeloma	6	3.2	0.73	3.9	0.87	3	1.6	0.46	2.1	0.56
Leukemias	16	7.8	1.14	8.9	1.29	15	6.1	0.80	6.7	0.91
Acute lymphocytic	5	1.2	0.25	1.1	0.26	5	1.4	0.30	1.2	0.26
Chronic lymphocytic	1	0.6	0.24	0.8	0.33	2	1.4	0.44	1.7	0.52
Acute myeloid	4	3.4	0.88	3.9	0.98	5	2.1	0.47	2.3	0.51
Chronic myeloid	3	1.4	0.46	1.7	0.56	1	0.4	0.17	0.5	0.22
Other leukemias	2	1.2	0.42	1.4	0.46	1	0.9	0.34	1.1	0.44
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	2	0.7	0.33	0.7	0.37	*	*	*	*	*
Ill-Defined & Unknown	7	5.7	1.13	6.4	1.26	9	4.7	0.79	5.5	0.90
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	7	4.1	0.84	4.6	0.93	19	8.4	0.93	9.6	1.08
Breast (<i>in situ</i>)	*	*	*	*	*	49	20.6	1.40	24.2	1.64

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Virginia, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	21	179.1	23.12	215.1	27.12	25	145.8	15.61	166.5	17.79
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	4	29.7	9.93	37.0	12.17	4	29.3	7.81	33.8	9.03
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	1	9.0	4.78	10.4	5.10	1	10.8	5.06	12.2	5.59
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	1	8.7	3.73	11.2	4.63	2	22.3	6.84	24.9	7.53
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	2	22.3	6.84	24.9	7.53
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	8	35.5	7.13	39.5	8.26
Female Genital System	N/A	N/A	N/A	N/A	N/A	4	24.9	6.19	28.2	6.88
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2	15.1	5.06	16.3	5.36
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	8	72.9	14.80	86.5	17.23	N/A	N/A	N/A	N/A	N/A
Prostate	7	71.2	14.77	84.8	17.20	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	4	33.8	10.38	40.6	11.91	2	8.9	3.08	11.0	3.79
Bladder (incl. <i>in situ</i>)	2	24.2	9.55	29.4	10.96	*	*	*	*	*
Kidney & renal pelvis	1	9.6	4.08	11.2	4.65	2	7.8	2.85	9.6	3.49
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	1	6.0	3.02	6.3	3.17
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	3	12.9	3.89	15.5	4.57

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.


VIRGINIA

II-510 Incidence – Hispanic Black

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	7,167,287	7,299,961	7,427,951	7,526,793	7,614,024
Non-Hispanic White	5,152,423	5,205,464	5,251,419	5,277,048	5,292,459
Non-Hispanic Black	329,595	341,239	353,704	365,908	376,932
Non-Hispanic Asian/Pacific Islander (NH API)	696,322	729,552	766,293	800,009	830,311
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	106,604	107,459	108,537	109,239	109,857


All Races Population 2015–2019: 37,036,016
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	879,223	913,064	944,711	971,214	1,001,089
Hispanic White	763,971	792,124	817,644	839,271	864,245
Hispanic Black	34,198	35,873	37,678	39,133	40,717

Hispanic/Latino Population, Census 2010: 755,790
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

WASHINGTON CANCER REGISTRY

Initial Operation: 1992
Population-based Data Available: 1992
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	104.9	106.3	104.8	104.4	102.9	104.7
Missing Race	1.2	1.4	1.6	2.3	1.8	1.7
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.4	1.8	1.7	2.0	1.8	1.9
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	91.8	Ovary	91.6
Oral Cavity & Pharynx	97.3	Prostate	96.1
Esophagus	93.7	Testis	99.2
Stomach	96.1	Bladder (incl. <i>in situ</i>)	96.8
Colon & Rectum	95.3	Kidney & Renal Pelvis	86.7
Liver	35.9	Brain & Other CNS	83.7
Pancreas	81.7	Brain & Other CNS (non-malig)	32.3
Lung & Bronchus	84.8	Thyroid	99.1
Melanomas of the Skin	99.5	Hodgkin Lymphoma	99.1
Female Breast (excl. <i>in situ</i>)	98.8	Non-Hodgkin Lymphoma	96.0
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	89.0
Cervix Uteri	96.7	Leukemias	91.4
Uterus Corpus & Uterus NOS	98.3		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Washington, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	19,048	467.6	1.56	553.2	1.82	18,941	426.1	1.43	496.8	1.63
Oral Cavity & Pharynx	760	18.2	0.30	22.0	0.36	335	7.4	0.19	8.7	0.22
Lip	57	1.5	0.09	1.7	0.11	39	0.8	0.06	1.0	0.07
Tongue	275	6.4	0.18	7.8	0.21	103	2.3	0.10	2.7	0.12
Major salivary gland	51	1.3	0.09	1.5	0.10	48	1.1	0.07	1.3	0.08
Floor of mouth	26	0.6	0.05	0.7	0.07	13	0.3	0.04	0.3	0.04
Gum & other mouth	82	2.1	0.11	2.4	0.12	67	1.5	0.08	1.7	0.09
Nasopharynx	29	0.7	0.06	0.8	0.07	11	0.3	0.04	0.3	0.04
Oropharynx	37	0.8	0.06	1.0	0.08	10	0.2	0.03	0.3	0.04
Hypopharynx	32	0.8	0.06	0.9	0.07	10	0.2	0.03	0.3	0.04
Digestive System	3,731	91.6	0.69	109.5	0.81	2,865	63.4	0.54	74.6	0.63
Esophagus	341	8.2	0.21	9.9	0.24	93	2.0	0.09	2.4	0.11
Stomach	289	7.2	0.20	8.5	0.23	174	3.9	0.14	4.6	0.16
Small intestine	105	2.6	0.12	3.1	0.13	89	2.0	0.10	2.4	0.11
Colon (excl. rectum)	994	25.4	0.37	29.7	0.43	990	22.3	0.33	26.0	0.37
Rectum & rectosigmoid	548	13.4	0.26	16.1	0.31	378	8.7	0.21	10.2	0.24
Anus, anal canal, & anorectum	64	1.5	0.09	1.9	0.11	119	2.5	0.11	3.1	0.13
Liver	516	11.5	0.23	14.5	0.29	181	3.8	0.13	4.6	0.15
Gallbladder	31	0.8	0.07	0.9	0.08	64	1.4	0.08	1.6	0.09
Pancreas	599	14.9	0.28	17.7	0.33	546	11.7	0.23	13.8	0.27
Respiratory System	2,406	59.7	0.56	70.7	0.66	2,351	50.5	0.48	59.7	0.56
Larynx	152	3.6	0.13	4.4	0.16	34	0.7	0.06	0.9	0.07
Lung & bronchus	2,208	54.9	0.54	65.0	0.63	2,290	49.1	0.47	58.1	0.55
Bones & Joints	43	1.1	0.08	1.2	0.08	32	0.8	0.07	0.9	0.07
Soft Tissue (incl. heart)	152	4.0	0.15	4.4	0.16	106	2.6	0.11	2.8	0.12
Skin (excl. basal & sq.)	1,407	35.8	0.44	41.7	0.51	1,030	23.9	0.34	27.4	0.39
Melanoma of the skin	1,269	31.9	0.41	37.3	0.48	946	22.0	0.33	25.2	0.37
Breast (excl. <i>in situ</i>)	43	1.1	0.08	1.3	0.09	5,894	133.5	0.80	156.8	0.93
Female Genital System	N/A	N/A	N/A	N/A	N/A	2,232	49.7	0.49	58.9	0.56
Cervix uteri	N/A	N/A	N/A	N/A	N/A	253	6.7	0.19	7.1	0.20
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,223	26.2	0.34	32.1	0.41
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	21	0.5	0.05	0.5	0.05
Ovary	N/A	N/A	N/A	N/A	N/A	450	10.2	0.22	11.9	0.25
Male Genital System	4,668	107.1	0.72	130.0	0.86	N/A	N/A	N/A	N/A	N/A
Prostate	4,401	100.0	0.69	122.7	0.84	N/A	N/A	N/A	N/A	N/A
Testis	227	6.0	0.18	6.0	0.18	N/A	N/A	N/A	N/A	N/A
Penis	28	0.8	0.07	0.9	0.08	N/A	N/A	N/A	N/A	N/A
Urinary System	2,284	57.9	0.56	68.1	0.65	920	20.2	0.31	23.6	0.35
Bladder (incl. <i>in situ</i>)	1,367	35.4	0.44	41.4	0.51	403	8.7	0.20	10.1	0.23
Kidney & renal pelvis	859	21.0	0.33	24.9	0.39	489	10.9	0.23	12.7	0.26
Ureter	29	0.8	0.06	0.9	0.07	17	0.4	0.04	0.4	0.05
Eye & Orbit	50	1.2	0.08	1.4	0.09	40	0.9	0.07	1.0	0.07
Brain & Other CNS	344	8.7	0.22	9.7	0.24	243	5.9	0.18	6.4	0.18
Brain	326	8.2	0.21	9.2	0.23	226	5.5	0.17	5.9	0.18
Endocrine System	297	7.5	0.20	8.3	0.22	755	19.4	0.32	20.8	0.34
Thyroid gland	266	6.7	0.19	7.5	0.21	729	18.7	0.32	20.1	0.34
Lymphomas	1,021	26.0	0.37	29.9	0.43	798	18.1	0.29	20.8	0.33
Hodgkin lymphoma	101	2.6	0.12	2.8	0.13	80	2.1	0.11	2.2	0.11
Non-Hodgkin lymphoma	920	23.3	0.35	27.1	0.41	718	15.9	0.27	18.6	0.31
Multiple Myeloma	339	8.5	0.21	10.0	0.25	227	5.0	0.15	5.9	0.18
Leukemias	719	18.4	0.32	20.9	0.35	485	11.1	0.23	12.5	0.26
Acute lymphocytic	63	1.8	0.10	1.6	0.09	56	1.6	0.10	1.5	0.09
Chronic lymphocytic	306	7.5	0.20	9.0	0.23	175	3.8	0.13	4.5	0.15
Acute myeloid	189	4.9	0.16	5.6	0.18	157	3.5	0.13	4.0	0.15
Chronic myeloid	98	2.6	0.12	2.9	0.13	58	1.3	0.08	1.5	0.09
Other leukemias	63	1.6	0.10	1.9	0.11	40	0.9	0.07	1.0	0.07
Mesothelioma	68	1.9	0.11	2.2	0.12	20	0.5	0.05	0.5	0.05
Kaposi Sarcoma	18	0.5	0.05	0.5	0.05	3	0.1	0.02	0.1	0.02
Ill-Defined & Unknown	701	18.6	0.32	21.5	0.37	605	13.3	0.25	15.3	0.28
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	499	12.7	0.26	14.5	0.29	1,034	23.8	0.34	27.3	0.38
Breast (<i>in situ</i>)	3	0.1	0.02	0.1	0.02	1,372	31.4	0.39	37.2	0.46

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Washington, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	16,129	476.2	1.73	562.6	2.01	15,717	434.6	1.63	506.8	1.85
Oral Cavity & Pharynx	659	19.1	0.34	23.1	0.41	285	7.7	0.21	9.1	0.25
Lip	48	1.5	0.10	1.7	0.11	34	0.9	0.07	1.0	0.08
Tongue	248	7.0	0.21	8.5	0.25	91	2.5	0.12	2.9	0.14
Major salivary gland	43	1.4	0.10	1.6	0.11	36	1.1	0.08	1.2	0.09
Floor of mouth	24	0.7	0.06	0.8	0.08	12	0.3	0.04	0.4	0.05
Gum & other mouth	72	2.2	0.12	2.5	0.14	59	1.6	0.09	1.8	0.11
Nasopharynx	13	0.4	0.05	0.5	0.06	6	0.2	0.03	0.2	0.04
Oropharynx	33	0.9	0.08	1.2	0.09	9	0.2	0.04	0.3	0.04
Hypopharynx	28	0.8	0.07	1.0	0.08	8	0.2	0.03	0.2	0.04
Digestive System	2,997	88.8	0.75	105.9	0.88	2,302	61.8	0.60	72.6	0.69
Esophagus	301	8.7	0.23	10.5	0.27	80	2.1	0.11	2.5	0.13
Stomach	219	6.5	0.20	7.7	0.24	113	3.1	0.13	3.6	0.15
Small intestine	87	2.6	0.13	3.1	0.15	72	2.0	0.11	2.3	0.13
Colon (excl. rectum)	810	25.2	0.41	29.4	0.47	815	22.4	0.37	25.9	0.42
Rectum & rectosigmoid	427	12.8	0.29	15.4	0.34	298	8.6	0.23	10.1	0.27
Anus, anal canal, & anorectum	57	1.6	0.10	2.0	0.12	107	2.8	0.13	3.4	0.15
Liver	363	9.6	0.23	12.1	0.29	118	2.9	0.13	3.6	0.15
Gallbladder	24	0.7	0.07	0.9	0.08	47	1.2	0.08	1.4	0.09
Pancreas	512	15.1	0.31	17.9	0.36	464	11.8	0.25	14.0	0.30
Respiratory System	2,085	60.9	0.61	72.1	0.72	2,049	52.3	0.53	62.0	0.62
Larynx	127	3.6	0.15	4.4	0.18	28	0.7	0.06	0.9	0.08
Lung & bronchus	1,921	56.1	0.59	66.4	0.69	2,001	51.1	0.52	60.4	0.61
Bones & Joints	33	1.1	0.09	1.2	0.10	23	0.8	0.08	0.8	0.08
Soft Tissue (incl. heart)	120	4.0	0.17	4.4	0.18	82	2.5	0.13	2.8	0.14
Skin (excl. basal & sq.)	1,302	40.2	0.52	46.7	0.59	932	27.7	0.43	31.5	0.47
Melanoma of the skin	1,181	36.2	0.49	42.1	0.56	864	25.8	0.42	29.4	0.46
Breast (excl. <i>in situ</i>)	37	1.1	0.08	1.3	0.10	4,896	136.9	0.92	160.9	1.05
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,807	49.5	0.55	58.9	0.63
Cervix uteri	N/A	N/A	N/A	N/A	N/A	179	6.4	0.22	6.7	0.23
Uterus corpus	N/A	N/A	N/A	N/A	N/A	998	26.0	0.38	31.9	0.46
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	17	0.4	0.05	0.5	0.06
Ovary	N/A	N/A	N/A	N/A	N/A	367	10.2	0.25	12.0	0.29
Male Genital System	3,903	107.0	0.79	129.7	0.94	N/A	N/A	N/A	N/A	N/A
Prostate	3,697	99.2	0.75	121.7	0.91	N/A	N/A	N/A	N/A	N/A
Testis	175	6.8	0.23	6.8	0.23	N/A	N/A	N/A	N/A	N/A
Penis	21	0.7	0.07	0.8	0.08	N/A	N/A	N/A	N/A	N/A
Urinary System	1,995	60.0	0.62	70.5	0.72	778	20.7	0.35	24.1	0.39
Bladder (incl. <i>in situ</i>)	1,240	37.6	0.49	44.0	0.57	357	9.1	0.22	10.7	0.26
Kidney & renal pelvis	705	20.9	0.36	24.7	0.42	398	10.9	0.26	12.7	0.29
Ureter	26	0.8	0.07	0.9	0.08	15	0.4	0.05	0.4	0.05
Eye & Orbit	45	1.4	0.10	1.6	0.11	35	1.1	0.09	1.2	0.09
Brain & Other CNS	293	9.6	0.26	10.6	0.28	204	6.5	0.22	6.9	0.22
Brain	278	9.0	0.25	10.0	0.27	191	6.0	0.21	6.5	0.21
Endocrine System	239	7.8	0.24	8.7	0.26	552	19.1	0.38	20.5	0.40
Thyroid gland	217	7.0	0.22	7.9	0.24	532	18.4	0.38	19.8	0.39
Lymphomas	858	26.7	0.42	30.8	0.48	658	18.5	0.34	21.2	0.38
Hodgkin lymphoma	78	2.9	0.15	3.0	0.15	62	2.4	0.14	2.4	0.14
Non-Hodgkin lymphoma	779	23.9	0.40	27.8	0.45	596	16.1	0.31	18.7	0.35
Multiple Myeloma	276	8.2	0.23	9.7	0.27	184	4.8	0.16	5.7	0.19
Leukemias	611	19.0	0.36	21.7	0.40	395	11.0	0.26	12.5	0.29
Acute lymphocytic	39	1.6	0.12	1.5	0.11	31	1.3	0.11	1.2	0.10
Chronic lymphocytic	280	8.1	0.22	9.7	0.26	159	4.1	0.15	4.9	0.18
Acute myeloid	159	5.0	0.18	5.7	0.20	128	3.5	0.15	4.1	0.16
Chronic myeloid	80	2.6	0.13	2.9	0.15	45	1.2	0.09	1.4	0.10
Other leukemias	52	1.7	0.11	1.9	0.12	32	0.9	0.07	1.0	0.08
Mesothelioma	63	2.0	0.12	2.3	0.13	17	0.5	0.05	0.5	0.06
Kaposi Sarcoma	10	0.4	0.05	0.4	0.05	1	0.0	0.02	0.0	0.02
Ill-Defined & Unknown	602	18.9	0.35	21.9	0.41	515	13.4	0.27	15.5	0.31
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	402	12.8	0.30	14.6	0.33	810	23.3	0.39	26.7	0.43
Breast (<i>in situ</i>)	3	0.1	0.03	0.1	0.03	1,088	31.0	0.44	36.8	0.51

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Washington, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	639	485.2	9.74	582.7	11.33	488	395.7	8.47	465.2	9.80
Oral Cavity & Pharynx	17	12.8	1.53	14.9	1.74	6	4.1	0.80	5.1	0.98
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	5	3.8	0.88	4.5	1.00	*	*	*	*	*
Major salivary gland	2	1.5	0.58	1.7	0.66	2	1.3	0.42	1.5	0.50
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	2	1.2	0.38	1.5	0.47	*	*	*	*	*
Nasopharynx	1	0.9	0.35	1.0	0.39	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	146	109.6	4.60	132.6	5.36	99	83.6	3.99	98.8	4.63
Esophagus	8	5.9	1.02	7.3	1.19	3	2.8	0.71	3.4	0.83
Stomach	12	10.7	1.58	12.9	1.84	8	7.1	1.19	8.1	1.34
Small intestine	6	4.5	0.92	5.7	1.12	6	5.1	0.94	6.1	1.11
Colon (excl. rectum)	38	28.7	2.35	33.9	2.68	32	27.6	2.31	32.7	2.70
Rectum & rectosigmoid	18	12.7	1.49	15.1	1.75	13	10.3	1.37	12.2	1.58
Anus, anal canal, & anorectum	2	1.2	0.49	1.5	0.58	3	3.0	0.78	3.5	0.90
Liver	32	22.4	1.99	28.2	2.38	11	8.2	1.17	10.0	1.40
Gallbladder	*	*	*	*	*	2	2.1	0.69	2.4	0.79
Pancreas	22	17.6	1.91	21.4	2.24	13	11.1	1.47	13.2	1.70
Respiratory System	78	68.0	3.88	81.1	4.49	56	50.6	3.20	59.8	3.67
Larynx	8	5.4	0.97	6.8	1.17	2	1.9	0.69	2.1	0.75
Lung & bronchus	69	61.6	3.74	73.2	4.32	55	48.5	3.11	57.5	3.58
Bones & Joints	1	0.7	0.26	0.6	0.21	*	*	*	*	*
Soft Tissue (incl. heart)	7	4.2	0.76	4.3	0.80	5	3.1	0.68	3.5	0.78
Skin (excl. basal & sq.)	3	3.1	0.91	3.6	1.08	4	2.8	0.71	3.2	0.80
Melanoma of the skin	2	1.7	0.68	2.0	0.80	2	1.6	0.56	1.8	0.62
Breast (excl. <i>in situ</i>)	2	1.5	0.54	1.8	0.60	142	112.1	4.41	131.6	5.11
Female Genital System	N/A	N/A	N/A	N/A	N/A	61	46.9	2.83	56.4	3.35
Cervix uteri	N/A	N/A	N/A	N/A	N/A	11	8.0	1.09	9.0	1.25
Uterus corpus	N/A	N/A	N/A	N/A	N/A	33	25.7	2.10	31.8	2.53
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	10	8.4	1.24	9.9	1.44
Male Genital System	211	149.8	5.14	186.3	6.11	N/A	N/A	N/A	N/A	N/A
Prostate	206	146.8	5.08	183.1	6.05	N/A	N/A	N/A	N/A	N/A
Testis	3	1.7	0.51	1.7	0.53	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	63	51.5	3.32	61.4	3.84	28	22.9	2.03	27.3	2.38
Bladder (incl. <i>in situ</i>)	23	22.9	2.41	26.6	2.74	7	6.4	1.16	7.4	1.33
Kidney & renal pelvis	39	26.9	2.16	32.8	2.55	21	15.9	1.62	19.2	1.93
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	8	5.5	0.98	5.9	1.07	6	4.2	0.85	4.6	0.95
Brain	7	5.2	0.96	5.5	1.05	5	3.6	0.80	4.0	0.90
Endocrine System	8	4.9	0.91	5.6	1.07	17	12.1	1.35	13.7	1.53
Thyroid gland	7	4.1	0.80	4.8	0.94	17	11.5	1.30	13.1	1.48
Lymphomas	27	18.9	1.84	21.0	2.04	21	16.0	1.65	18.4	1.89
Hodgkin lymphoma	5	2.6	0.54	2.9	0.61	4	2.6	0.58	2.8	0.64
Non-Hodgkin lymphoma	22	16.3	1.76	18.1	1.94	17	13.4	1.55	15.6	1.78
Multiple Myeloma	23	18.1	1.94	21.8	2.27	14	12.5	1.58	14.6	1.81
Leukemias	19	14.3	1.67	16.0	1.89	13	10.7	1.41	12.0	1.58
Acute lymphocytic	2	1.0	0.33	0.9	0.30	1	0.9	0.34	0.9	0.37
Chronic lymphocytic	7	4.7	0.87	5.6	0.99	4	3.2	0.75	3.8	0.86
Acute myeloid	6	4.8	1.02	5.3	1.13	4	3.5	0.84	3.9	0.93
Chronic myeloid	3	2.8	0.82	3.1	0.95	2	1.9	0.60	2.1	0.64
Other leukemias	1	0.9	0.45	1.2	0.57	1	1.2	0.51	1.4	0.59
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	3	1.8	0.45	1.9	0.49	*	*	*	*	*
Ill-Defined & Unknown	21	19.5	2.19	22.5	2.51	15	12.8	1.57	14.8	1.78
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	17	12.7	1.55	14.9	1.80	34	27.4	2.24	31.4	2.53
Breast (<i>in situ</i>)	*	*	*	*	*	39	29.8	2.23	36.1	2.64

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Washington, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	926	322.0	4.95	378.7	5.76	1,276	317.4	4.05	366.6	4.66
Oral Cavity & Pharynx	35	11.3	0.88	13.5	1.05	21	5.0	0.50	5.8	0.57
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	9	3.0	0.47	3.6	0.55	6	1.4	0.27	1.7	0.32
Major salivary gland	2	0.7	0.22	0.8	0.26	5	1.2	0.24	1.4	0.27
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	4	1.5	0.34	1.8	0.41	4	1.0	0.23	1.1	0.25
Nasopharynx	12	3.5	0.46	4.2	0.56	4	0.8	0.20	1.0	0.23
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	1	0.5	0.22	0.6	0.25	*	*	*	*	*
Digestive System	286	99.8	2.75	118.3	3.22	236	60.8	1.81	71.5	2.10
Esophagus	12	4.0	0.54	4.8	0.64	4	1.0	0.22	1.2	0.27
Stomach	32	11.9	0.97	13.9	1.13	30	7.7	0.64	9.0	0.75
Small intestine	4	1.4	0.32	1.6	0.36	5	1.3	0.25	1.5	0.29
Colon (excl. rectum)	69	23.7	1.34	28.1	1.57	70	18.0	0.98	21.0	1.14
Rectum & rectosigmoid	48	16.1	1.08	19.2	1.27	30	7.5	0.62	9.0	0.73
Anus, anal canal, & anorectum	2	0.7	0.25	0.8	0.29	2	0.5	0.17	0.7	0.20
Liver	65	22.0	1.26	26.5	1.50	30	8.1	0.67	9.3	0.77
Gallbladder	3	1.1	0.28	1.3	0.32	7	1.7	0.30	2.1	0.36
Pancreas	32	11.9	0.99	13.9	1.14	37	10.0	0.75	11.7	0.86
Respiratory System	130	48.6	1.99	57.7	2.33	125	33.2	1.36	38.8	1.56
Larynx	6	2.1	0.42	2.6	0.49	1	0.3	0.12	0.3	0.13
Lung & bronchus	122	45.8	1.93	54.3	2.26	121	32.1	1.34	37.6	1.54
Bones & Joints	4	1.0	0.25	1.1	0.27	3	0.7	0.20	0.7	0.20
Soft Tissue (incl. heart)	11	3.5	0.50	3.7	0.54	7	1.7	0.30	1.8	0.31
Skin (excl. basal & sq.)	6	2.2	0.43	2.4	0.47	11	2.7	0.38	3.0	0.42
Melanoma of the skin	3	1.0	0.29	1.1	0.31	6	1.4	0.28	1.5	0.30
Breast (excl. <i>in situ</i>)	2	0.6	0.20	0.8	0.25	425	102.6	2.26	119.3	2.62
Female Genital System	N/A	N/A	N/A	N/A	N/A	174	41.6	1.43	49.0	1.68
Cervix uteri	N/A	N/A	N/A	N/A	N/A	30	7.1	0.59	7.7	0.64
Uterus corpus	N/A	N/A	N/A	N/A	N/A	93	22.0	1.04	26.5	1.24
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	1	0.3	0.14	0.4	0.16
Ovary	N/A	N/A	N/A	N/A	N/A	33	8.0	0.63	9.4	0.74
Male Genital System	180	61.4	2.13	74.0	2.52	N/A	N/A	N/A	N/A	N/A
Prostate	169	58.3	2.08	70.8	2.48	N/A	N/A	N/A	N/A	N/A
Testis	9	2.2	0.33	2.1	0.32	N/A	N/A	N/A	N/A	N/A
Penis	1	0.5	0.21	0.6	0.23	N/A	N/A	N/A	N/A	N/A
Urinary System	87	31.2	1.57	36.6	1.82	40	10.3	0.75	12.0	0.86
Bladder (incl. <i>in situ</i>)	41	16.2	1.19	18.8	1.36	17	4.7	0.52	5.5	0.59
Kidney & renal pelvis	42	13.6	0.97	16.2	1.15	21	5.2	0.52	6.1	0.60
Ureter	2	0.8	0.27	0.8	0.30	*	*	*	*	*
Eye & Orbit	2	0.5	0.18	0.5	0.18	*	*	*	*	*
Brain & Other CNS	16	5.1	0.59	5.4	0.65	12	3.0	0.40	3.1	0.41
Brain	15	4.8	0.58	5.1	0.63	11	2.7	0.38	2.9	0.40
Endocrine System	25	7.4	0.69	7.9	0.75	85	20.3	1.00	21.6	1.07
Thyroid gland	21	6.2	0.63	6.8	0.70	83	19.6	0.98	20.8	1.05
Lymphomas	55	18.2	1.15	21.1	1.32	53	13.2	0.83	15.3	0.95
Hodgkin lymphoma	4	1.0	0.24	1.0	0.25	3	0.8	0.20	0.7	0.19
Non-Hodgkin lymphoma	52	17.2	1.12	20.0	1.30	50	12.4	0.80	14.5	0.93
Multiple Myeloma	15	5.6	0.67	6.5	0.77	14	4.0	0.48	4.4	0.53
Leukemias	31	10.3	0.86	11.3	0.96	30	7.8	0.65	8.4	0.70
Acute lymphocytic	5	1.4	0.29	1.2	0.24	5	1.5	0.29	1.3	0.26
Chronic lymphocytic	6	2.2	0.41	2.6	0.48	4	1.0	0.24	1.2	0.26
Acute myeloid	12	3.9	0.53	4.4	0.60	13	3.4	0.43	3.7	0.47
Chronic myeloid	5	1.6	0.32	1.8	0.36	5	1.2	0.26	1.3	0.28
Other leukemias	3	1.2	0.33	1.4	0.38	3	0.7	0.20	0.8	0.22
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	1	0.3	0.13	0.4	0.15	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	38	10.1	0.75	11.5	0.84
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & other CNS (non-malig)	37	12.7	0.98	14.6	1.12	98	24.5	1.13	28.5	1.31
Breast (<i>in situ</i>)	*	*	*	*	*	145	35.2	1.33	41.1	1.54

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Washington, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	241	507.2	15.95	601.7	18.60	296	536.6	14.65	624.0	16.73
Oral Cavity & Pharynx	12	22.9	3.21	27.7	3.75	4	9.0	2.05	10.7	2.41
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	4	8.7	2.15	10.8	2.53	1	2.9	1.15	3.4	1.33
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	2	3.5	1.23	4.2	1.43	*	*	*	*	*
Digestive System	72	149.8	8.68	180.8	10.31	55	100.9	6.42	117.8	7.35
Esophagus	5	11.6	2.49	13.9	2.90	3	4.1	1.17	5.1	1.42
Stomach	5	12.9	2.99	14.9	3.47	4	8.8	2.00	9.5	2.12
Small intestine	2	3.9	1.19	4.6	1.41	1	1.8	0.74	2.2	0.91
Colon (excl. rectum)	15	31.5	3.89	37.6	4.60	19	35.2	3.83	40.8	4.36
Rectum & rectosigmoid	11	23.8	3.39	27.6	3.93	8	14.7	2.40	17.1	2.76
Anus, anal canal, & anorectum	1	3.0	1.19	3.2	1.22	*	*	*	*	*
Liver	17	30.3	3.60	39.6	4.54	5	7.8	1.68	9.6	1.97
Gallbladder	*	*	*	*	*	2	3.7	1.27	4.6	1.52
Pancreas	8	19.0	3.35	22.6	3.92	7	12.8	2.26	15.5	2.69
Respiratory System	32	67.6	5.80	81.2	6.78	41	78.3	5.77	91.3	6.59
Larynx	4	6.2	1.49	7.9	1.87	1	1.9	0.84	2.5	1.07
Lung & bronchus	28	61.1	5.60	72.9	6.51	39	73.8	5.59	86.2	6.40
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	2	4.8	1.60	5.5	1.88	1	1.8	0.77	2.2	0.90
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	5	11.2	2.43	13.0	2.81	5	8.8	1.87	9.7	2.03
Breast (excl. <i>in situ</i>)	*	*	*	*	*	84	149.1	7.61	176.2	8.82
Female Genital System	N/A	N/A	N/A	N/A	N/A	38	65.2	4.96	75.7	5.62
Cervix uteri	N/A	N/A	N/A	N/A	N/A	5	9.6	1.93	9.9	1.96
Uterus corpus	N/A	N/A	N/A	N/A	N/A	19	32.1	3.41	39.1	4.04
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	8	14.6	2.34	16.7	2.61
Male Genital System	42	88.5	6.61	105.0	7.69	N/A	N/A	N/A	N/A	N/A
Prostate	37	78.2	6.23	94.2	7.31	N/A	N/A	N/A	N/A	N/A
Testis	4	9.0	2.07	9.2	2.22	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	28	63.4	5.88	74.8	6.86	12	22.1	3.01	26.4	3.51
Bladder (incl. <i>in situ</i>)	13	30.5	4.22	36.6	4.95	4	8.2	2.04	9.5	2.37
Kidney & renal pelvis	15	32.5	4.09	37.8	4.73	9	13.9	2.22	16.8	2.59
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	4	8.3	1.98	9.0	2.17	3	4.5	1.27	4.6	1.28
Brain	4	7.8	1.93	8.7	2.14	2	3.8	1.18	3.8	1.17
Endocrine System	2	4.0	1.25	4.8	1.46	17	31.7	3.48	33.2	3.59
Thyroid gland	2	3.4	1.18	4.0	1.34	17	30.8	3.42	32.2	3.52
Lymphomas	13	27.1	3.52	31.8	4.05	11	20.4	2.94	23.9	3.40
Hodgkin lymphoma	2	3.9	1.37	3.9	1.40	*	*	*	*	*
Non-Hodgkin lymphoma	12	23.2	3.24	27.9	3.80	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	5	11.4	2.32	13.2	2.62	4	8.0	1.80	9.6	2.13
Leukemias	9	19.9	3.11	22.2	3.49	8	13.9	2.30	15.4	2.51
Acute lymphocytic	2	3.5	1.17	3.0	1.01	2	3.7	1.18	3.4	1.08
Chronic lymphocytic	2	4.9	1.55	5.6	1.76	*	*	*	*	*
Acute myeloid	4	7.9	2.05	9.5	2.44	3	5.3	1.43	6.1	1.63
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	10	22.7	3.50	27.0	4.11	9	17.1	2.65	20.8	3.15
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	6	11.7	2.33	13.0	2.55	17	30.7	3.45	34.9	3.85
Breast (<i>in situ</i>)	*	*	*	*	*	19	32.0	3.44	37.3	3.91

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Washington, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	720	346.8	6.90	408.8	7.98	911	366.7	6.07	428.9	7.07
Oral Cavity & Pharynx	22	9.3	1.05	11.1	1.23	11	4.4	0.65	5.4	0.80
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	6	3.0	0.59	3.6	0.70	3	1.4	0.40	1.8	0.47
Major salivary gland	3	1.0	0.36	1.1	0.40	3	1.2	0.34	1.4	0.42
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	2	0.9	0.35	1.1	0.40	2	0.8	0.26	0.9	0.31
Nasopharynx	2	0.5	0.16	0.6	0.21	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	185	90.2	3.47	108.2	4.05	146	64.3	2.64	76.1	3.09
Esophagus	12	5.8	0.89	7.3	1.08	2	0.8	0.28	0.9	0.32
Stomach	18	9.4	1.15	11.2	1.34	17	7.2	0.86	8.3	0.99
Small intestine	4	1.9	0.49	2.3	0.57	2	0.7	0.23	0.9	0.28
Colon (excl. rectum)	45	22.1	1.75	25.6	1.99	43	18.5	1.42	21.9	1.67
Rectum & rectosigmoid	30	12.4	1.18	15.1	1.40	20	7.6	0.83	9.0	0.98
Anus, anal canal, & anorectum	2	0.8	0.31	0.9	0.34	5	2.1	0.45	2.7	0.56
Liver	36	16.5	1.41	20.6	1.68	16	8.0	0.98	9.4	1.14
Gallbladder	3	2.0	0.62	2.3	0.70	5	2.8	0.59	3.3	0.67
Pancreas	22	12.8	1.41	15.4	1.65	23	11.3	1.15	13.3	1.32
Respiratory System	70	41.2	2.53	48.3	2.89	70	35.8	2.07	42.4	2.38
Larynx	8	3.6	0.65	4.4	0.79	2	0.8	0.28	1.0	0.34
Lung & bronchus	58	36.6	2.43	42.8	2.76	65	34.0	2.03	40.2	2.34
Bones & Joints	3	0.7	0.24	0.7	0.25	4	1.2	0.34	1.3	0.36
Soft Tissue (incl. heart)	9	3.0	0.60	3.3	0.68	9	2.9	0.49	3.3	0.58
Skin (excl. basal & sq.)	17	8.9	1.13	10.4	1.29	27	10.4	1.01	12.1	1.16
Melanoma of the skin	14	7.4	1.03	8.5	1.16	23	8.6	0.88	10.1	1.04
Breast (excl. <i>in situ</i>)	2	0.8	0.30	1.0	0.39	267	106.6	3.19	125.2	3.73
Female Genital System	N/A	N/A	N/A	N/A	N/A	130	48.6	2.10	58.0	2.50
Cervix uteri	N/A	N/A	N/A	N/A	N/A	25	7.5	0.73	8.2	0.82
Uterus corpus	N/A	N/A	N/A	N/A	N/A	67	25.4	1.51	31.5	1.85
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	28	10.2	0.97	12.2	1.15
Male Genital System	160	78.5	3.25	93.6	3.78	N/A	N/A	N/A	N/A	N/A
Prostate	130	72.0	3.18	86.8	3.70	N/A	N/A	N/A	N/A	N/A
Testis	26	5.1	0.53	5.2	0.57	N/A	N/A	N/A	N/A	N/A
Penis	3	1.4	0.46	1.6	0.52	N/A	N/A	N/A	N/A	N/A
Urinary System	79	42.0	2.51	49.2	2.88	49	21.9	1.57	25.6	1.81
Bladder (incl. <i>in situ</i>)	28	19.7	1.87	22.9	2.16	12	6.8	0.96	7.9	1.09
Kidney & renal pelvis	49	21.0	1.59	24.8	1.84	35	14.3	1.19	16.7	1.39
Ureter	1	0.8	0.36	0.9	0.40	*	*	*	*	*
Eye & Orbit	2	0.6	0.21	0.6	0.23	2	0.7	0.25	0.8	0.29
Brain & Other CNS	21	6.5	0.78	7.3	0.90	17	4.7	0.64	4.9	0.71
Brain	19	6.2	0.77	7.0	0.89	15	4.5	0.63	4.7	0.71
Endocrine System	19	6.2	0.78	7.0	0.89	68	19.4	1.14	21.0	1.29
Thyroid gland	17	5.3	0.70	6.1	0.82	67	18.8	1.12	20.4	1.26
Lymphomas	49	20.6	1.62	23.9	1.88	46	18.9	1.42	21.9	1.64
Hodgkin lymphoma	10	3.2	0.61	3.6	0.72	8	2.1	0.40	2.2	0.43
Non-Hodgkin lymphoma	40	17.4	1.50	20.3	1.73	38	16.8	1.36	19.7	1.58
Multiple Myeloma	19	9.2	1.10	11.1	1.28	9	4.2	0.67	4.9	0.78
Leukemias	37	12.5	1.20	13.9	1.38	33	10.7	1.00	12.0	1.14
Acute lymphocytic	14	2.7	0.41	2.6	0.43	14	3.0	0.42	3.0	0.46
Chronic lymphocytic	6	3.3	0.70	3.9	0.80	5	2.2	0.51	2.6	0.59
Acute myeloid	8	3.2	0.65	3.8	0.77	9	3.3	0.59	3.8	0.67
Chronic myeloid	6	1.8	0.40	2.0	0.48	4	1.5	0.36	1.8	0.43
Other leukemias	4	1.5	0.45	1.7	0.52	2	0.7	0.28	0.8	0.34
Mesothelioma	3	1.7	0.54	2.1	0.64	1	0.4	0.18	0.5	0.22
Kaposi Sarcoma	2	0.9	0.40	1.1	0.47	*	*	*	*	*
Ill-Defined & Unknown	22	13.9	1.54	16.1	1.77	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	25	8.2	0.90	9.1	1.03	54	20.8	1.42	24.4	1.67
Breast (<i>in situ</i>)	*	*	*	*	*	58	21.1	1.32	24.8	1.55

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

WASHINGTON

II-518 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Washington, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	633	335.7	7.02	395.7	8.12	806	362.2	6.31	423.8	7.35
Oral Cavity & Pharynx	20	9.5	1.10	11.4	1.28	10	4.5	0.68	5.6	0.84
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	6	3.1	0.63	3.8	0.75	3	1.5	0.42	1.8	0.50
Major salivary gland	2	1.0	0.38	1.2	0.42	3	1.2	0.36	1.5	0.45
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	2	1.0	0.38	1.1	0.43	2	0.8	0.28	1.0	0.35
Nasopharynx	2	0.6	0.19	0.7	0.24	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	161	86.3	3.52	103.8	4.11	131	64.0	2.74	76.0	3.22
Esophagus	11	5.7	0.89	7.2	1.09	2	0.8	0.28	0.9	0.32
Stomach	16	9.2	1.18	10.9	1.37	16	7.6	0.92	8.8	1.06
Small intestine	4	2.0	0.52	2.4	0.61	2	0.8	0.25	1.0	0.31
Colon (excl. rectum)	40	21.9	1.81	25.4	2.07	38	18.5	1.48	22.0	1.75
Rectum & rectosigmoid	27	11.9	1.18	14.7	1.43	19	7.6	0.85	9.0	1.01
Anus, anal canal, & anorectum	1	0.8	0.33	0.9	0.36	5	2.2	0.48	2.8	0.60
Liver	30	15.5	1.44	19.1	1.70	13	7.6	1.00	8.9	1.15
Gallbladder	2	2.1	0.66	2.4	0.74	5	2.6	0.57	3.0	0.67
Pancreas	19	11.7	1.38	14.3	1.63	21	11.3	1.20	13.3	1.38
Respiratory System	62	40.5	2.61	47.5	2.98	63	35.7	2.15	42.4	2.49
Larynx	7	3.7	0.70	4.5	0.84	2	0.9	0.31	1.1	0.38
Lung & bronchus	52	35.9	2.49	42.0	2.84	58	33.7	2.11	40.1	2.44
Bones & Joints	2	0.7	0.26	0.7	0.27	4	1.3	0.37	1.4	0.39
Soft Tissue (incl. heart)	7	2.8	0.62	3.0	0.70	7	2.5	0.48	2.9	0.57
Skin (excl. basal & sq.)	16	9.4	1.20	10.9	1.37	22	9.8	1.04	11.4	1.20
Melanoma of the skin	13	7.7	1.10	8.9	1.23	19	8.3	0.93	9.8	1.08
Breast (excl. <i>in situ</i>)	2	0.7	0.31	0.9	0.39	241	106.4	3.32	124.9	3.89
Female Genital System	N/A	N/A	N/A	N/A	N/A	108	45.7	2.15	54.7	2.57
Cervix uteri	N/A	N/A	N/A	N/A	N/A	19	6.6	0.71	7.3	0.81
Uterus corpus	N/A	N/A	N/A	N/A	N/A	55	23.6	1.53	29.3	1.88
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	23	9.9	1.02	11.8	1.20
Male Genital System	137	73.6	3.25	87.6	3.78	N/A	N/A	N/A	N/A	N/A
Prostate	111	67.2	3.18	81.0	3.70	N/A	N/A	N/A	N/A	N/A
Testis	23	5.1	0.52	5.1	0.55	N/A	N/A	N/A	N/A	N/A
Penis	3	1.3	0.47	1.5	0.54	N/A	N/A	N/A	N/A	N/A
Urinary System	69	40.7	2.55	47.6	2.93	43	21.8	1.63	25.6	1.89
Bladder (incl. <i>in situ</i>)	24	18.6	1.88	21.6	2.16	10	6.6	0.99	7.8	1.13
Kidney & renal pelvis	43	20.7	1.64	24.4	1.89	31	14.2	1.24	16.7	1.46
Ureter	1	0.9	0.39	1.0	0.43	*	*	*	*	*
Eye & Orbit	2	0.7	0.23	0.7	0.26	2	0.8	0.27	0.9	0.32
Brain & Other CNS	19	6.6	0.83	7.3	0.95	15	4.7	0.65	4.9	0.72
Brain	17	6.2	0.81	7.0	0.93	14	4.4	0.64	4.7	0.71
Endocrine System	18	6.2	0.80	7.1	0.92	61	19.1	1.19	20.7	1.34
Thyroid gland	16	5.5	0.75	6.4	0.87	59	18.5	1.16	20.0	1.31
Lymphomas	45	20.7	1.67	24.0	1.93	42	19.4	1.51	22.5	1.74
Hodgkin lymphoma	9	2.9	0.58	3.2	0.67	7	2.0	0.40	2.0	0.43
Non-Hodgkin lymphoma	37	17.8	1.56	20.8	1.81	35	17.4	1.46	20.5	1.69
Multiple Myeloma	17	9.1	1.14	11.0	1.33	8	4.1	0.71	4.8	0.82
Leukemias	31	11.9	1.21	13.2	1.38	29	10.5	1.02	11.7	1.17
Acute lymphocytic	11	2.4	0.42	2.3	0.44	12	3.0	0.46	3.0	0.49
Chronic lymphocytic	5	3.0	0.67	3.5	0.77	5	2.4	0.55	2.8	0.64
Acute myeloid	7	3.0	0.65	3.5	0.75	8	3.0	0.57	3.4	0.65
Chronic myeloid	6	2.0	0.44	2.2	0.51	4	1.5	0.37	1.8	0.44
Other leukemias	3	1.5	0.48	1.8	0.55	1	0.6	0.25	0.7	0.30
Mesothelioma	3	1.9	0.58	2.3	0.68	*	*	*	*	*
Kaposi Sarcoma	2	0.8	0.35	0.9	0.44	*	*	*	*	*
Ill-Defined & Unknown	20	13.5	1.56	15.6	1.79	20	11.4	1.25	13.1	1.43
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	23	8.2	0.93	9.1	1.07	50	21.4	1.50	25.2	1.76
Breast (<i>in situ</i>)	*	*	*	*	*	53	21.6	1.41	25.4	1.67

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Washington, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	10	291.7	78.48	344.1	92.66	14	233.8	35.99	276.8	41.40
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	2	30.6	12.27	36.6	13.77	1	29.2	14.39	32.3	15.75
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	2	44.2	17.44	50.3	18.97
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	2	44.2	17.44	50.3	18.97
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	4	50.5	13.77	61.7	16.60
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	34.3	13.43	41.4	14.97
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	3	72.7	20.80	88.5	24.27	N/A	N/A	N/A	N/A	N/A
Prostate	3	59.4	16.86	73.7	19.89	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	1	13.1	5.02	15.4	6.03

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.


* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

SEATTLE/PUGET SOUND CANCER REGISTRY

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	4,934,837	5,034,249	5,126,284	5,194,985	5,252,087
Non-Hispanic White	3,482,248	3,519,828	3,546,903	3,557,700	3,559,543
Non-Hispanic Black	287,351	297,347	308,022	318,445	327,907
Non-Hispanic Asian/Pacific Islander (NH API)	626,595	657,500	691,292	722,621	750,517
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	67,812	68,388	69,110	69,367	69,687


All Races Population 2015–2019: 25,542,442
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	470,831	491,186	510,957	526,852	544,433
Hispanic White	394,505	411,091	426,944	439,900	454,386
Hispanic Black	25,026	26,335	27,726	28,690	29,844

Hispanic/Latino Population, Census 2010: 399,157
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

SEATTLE/PUGET SOUND CANCER REGISTRY

Initial Operation: 1974
Population-based Data Available: 1974
Coverage Area: County

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	114.5	114.0	113.7	115.2	115.7	114.6
Missing Race	0.7	0.8	0.9	0.9	1.9	1.1
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.4	0.4	0.6	0.3	0.4	0.4
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.7	Ovary	93.0
Oral Cavity & Pharynx	98.6	Prostate	96.4
Esophagus	97.0	Testis	99.4
Stomach	97.2	Bladder (incl. <i>in situ</i>)	97.1
Colon & Rectum	96.4	Kidney & Renal Pelvis	85.5
Liver	36.0	Brain & Other CNS	85.1
Pancreas	81.8	Brain & Other CNS (non-malig)	29.0
Lung & Bronchus	87.0	Thyroid	99.2
Melanomas of the Skin	99.7	Hodgkin Lymphoma	99.2
Female Breast (excl. <i>in situ</i>)	99.3	Non-Hodgkin Lymphoma	96.8
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	89.4
Cervix Uteri	97.9	Leukemias	93.7
Uterus Corpus & Uterus NOS	98.7		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Seattle/Puget Sound, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	13,959	507.5	1.98	599.8	2.31	13,710	449.2	1.77	523.5	2.02
Oral Cavity & Pharynx	574	20.2	0.39	24.3	0.46	254	8.2	0.24	9.7	0.27
Lip	43	1.7	0.12	2.0	0.14	32	1.0	0.08	1.2	0.10
Tongue	208	7.1	0.23	8.6	0.27	78	2.5	0.13	3.0	0.15
Major salivary gland	37	1.5	0.11	1.7	0.12	36	1.2	0.09	1.4	0.10
Floor of mouth	18	0.6	0.07	0.8	0.08	10	0.3	0.05	0.4	0.06
Gum & other mouth	60	2.3	0.13	2.7	0.16	50	1.6	0.10	1.8	0.12
Nasopharynx	23	0.8	0.08	1.0	0.09	8	0.3	0.04	0.3	0.05
Oropharynx	26	0.9	0.08	1.1	0.10	8	0.2	0.04	0.3	0.05
Hypopharynx	23	0.8	0.08	1.0	0.09	7	0.2	0.04	0.3	0.05
Digestive System	2,652	96.4	0.86	114.8	1.01	2,032	65.6	0.67	77.2	0.77
Esophagus	221	8.0	0.25	9.6	0.29	63	2.0	0.11	2.4	0.14
Stomach	211	7.9	0.25	9.3	0.29	133	4.4	0.17	5.1	0.20
Small intestine	73	2.7	0.14	3.1	0.17	65	2.1	0.12	2.5	0.14
Colon (excl. rectum)	712	26.8	0.46	31.4	0.53	697	22.9	0.40	26.6	0.46
Rectum & rectosigmoid	400	14.4	0.33	17.2	0.39	267	8.9	0.25	10.5	0.29
Anus, anal canal, & anorectum	49	1.8	0.11	2.1	0.14	85	2.6	0.13	3.2	0.16
Liver	380	12.4	0.29	15.6	0.36	128	3.9	0.16	4.7	0.19
Gallbladder	21	0.8	0.08	0.9	0.09	45	1.4	0.10	1.7	0.11
Pancreas	404	15.1	0.35	17.8	0.40	381	12.0	0.28	14.1	0.33
Respiratory System	1,673	62.2	0.70	73.4	0.82	1,646	51.9	0.58	61.3	0.68
Larynx	108	3.8	0.17	4.6	0.20	24	0.7	0.07	0.9	0.08
Lung & bronchus	1,534	57.2	0.68	67.5	0.78	1,603	50.5	0.58	59.6	0.67
Bones & Joints	29	1.1	0.10	1.2	0.10	21	0.8	0.08	0.8	0.08
Soft Tissue (incl. heart)	100	3.9	0.18	4.3	0.19	70	2.4	0.13	2.7	0.15
Skin (excl. basal & sq.)	1,104	41.6	0.58	48.4	0.66	818	27.5	0.44	31.5	0.50
Melanoma of the skin	984	36.6	0.54	42.7	0.62	749	25.3	0.43	28.9	0.48
Breast (excl. <i>in situ</i>)	30	1.1	0.09	1.3	0.11	4,291	141.5	1.00	166.1	1.15
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,616	52.1	0.60	61.9	0.70
Cervix uteri	N/A	N/A	N/A	N/A	N/A	184	6.8	0.23	7.3	0.24
Uterus corpus	N/A	N/A	N/A	N/A	N/A	882	27.4	0.42	33.6	0.51
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	7	0.2	0.04	0.3	0.05
Ovary	N/A	N/A	N/A	N/A	N/A	307	10.1	0.27	11.8	0.31
Male Genital System	3,555	120.6	0.93	146.5	1.11	N/A	N/A	N/A	N/A	N/A
Prostate	3,357	113.2	0.90	138.9	1.09	N/A	N/A	N/A	N/A	N/A
Testis	167	6.2	0.22	6.2	0.22	N/A	N/A	N/A	N/A	N/A
Penis	19	0.8	0.08	0.9	0.09	N/A	N/A	N/A	N/A	N/A
Urinary System	1,640	61.7	0.70	72.5	0.82	646	20.7	0.37	24.2	0.43
Bladder (incl. <i>in situ</i>)	982	37.8	0.56	44.2	0.64	287	9.1	0.24	10.6	0.28
Kidney & renal pelvis	617	22.2	0.41	26.4	0.48	340	11.1	0.28	12.9	0.32
Ureter	19	0.8	0.08	0.9	0.09	11	0.3	0.05	0.4	0.05
Eye & Orbit	33	1.2	0.10	1.4	0.11	26	0.9	0.08	1.0	0.09
Brain & Other CNS	241	8.9	0.26	10.0	0.29	170	6.1	0.21	6.5	0.23
Brain	229	8.5	0.26	9.5	0.29	158	5.6	0.21	6.0	0.22
Endocrine System	223	8.1	0.25	9.0	0.27	558	20.4	0.40	22.0	0.42
Thyroid gland	200	7.3	0.24	8.1	0.26	539	19.7	0.39	21.2	0.41
Lymphomas	751	28.3	0.48	32.5	0.54	578	19.1	0.36	21.9	0.41
Hodgkin lymphoma	73	2.8	0.15	2.9	0.15	57	2.2	0.13	2.2	0.13
Non-Hodgkin lymphoma	678	25.5	0.45	29.6	0.52	521	16.9	0.34	19.7	0.39
Multiple Myeloma	249	9.3	0.27	11.0	0.32	168	5.4	0.19	6.4	0.22
Leukemias	531	20.1	0.40	22.9	0.45	357	11.8	0.29	13.4	0.32
Acute lymphocytic	43	1.8	0.13	1.6	0.11	34	1.4	0.11	1.3	0.10
Chronic lymphocytic	239	8.7	0.26	10.4	0.31	136	4.3	0.17	5.1	0.20
Acute myeloid	134	5.1	0.20	5.8	0.23	116	3.8	0.16	4.4	0.18
Chronic myeloid	73	2.8	0.15	3.2	0.17	45	1.5	0.10	1.7	0.12
Other leukemias	43	1.6	0.12	1.9	0.13	26	0.9	0.08	1.0	0.09
Mesothelioma	48	2.0	0.13	2.3	0.15	13	0.4	0.06	0.5	0.06
Kaposi Sarcoma	15	0.6	0.07	0.6	0.07	2	0.1	0.02	0.1	0.03
Ill-Defined & Unknown	511	20.3	0.41	23.5	0.47	442	14.3	0.31	16.4	0.35
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	412	15.4	0.35	17.7	0.40	873	29.1	0.45	33.4	0.51
Breast (<i>in situ</i>)	2	0.1	0.02	0.1	0.03	1,030	34.3	0.49	40.6	0.57

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Seattle/Puget Sound, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	11,663	521.5	2.23	615.5	2.59	11,149	462.2	2.05	538.6	2.33
Oral Cavity & Pharynx	491	21.4	0.45	25.9	0.53	213	8.6	0.28	10.2	0.32
Lip	38	1.8	0.13	2.1	0.16	29	1.1	0.10	1.3	0.11
Tongue	186	7.9	0.27	9.6	0.32	68	2.8	0.16	3.3	0.18
Major salivary gland	32	1.5	0.12	1.7	0.14	26	1.1	0.11	1.3	0.12
Floor of mouth	16	0.7	0.08	0.8	0.09	10	0.4	0.06	0.5	0.07
Gum & other mouth	53	2.4	0.15	2.8	0.18	43	1.7	0.12	2.0	0.14
Nasopharynx	9	0.4	0.06	0.5	0.07	4	0.2	0.04	0.2	0.04
Oropharynx	23	1.0	0.10	1.2	0.11	7	0.3	0.04	0.3	0.05
Hypopharynx	19	0.8	0.09	1.0	0.10	5	0.2	0.04	0.2	0.05
Digestive System	2,066	92.8	0.94	110.4	1.10	1,575	63.4	0.74	74.4	0.86
Esophagus	191	8.4	0.28	10.1	0.33	52	2.0	0.13	2.4	0.15
Stomach	154	7.0	0.26	8.3	0.30	81	3.3	0.17	3.8	0.19
Small intestine	59	2.7	0.16	3.1	0.18	51	2.1	0.14	2.5	0.16
Colon (excl. rectum)	567	26.7	0.52	31.1	0.59	560	23.0	0.45	26.7	0.52
Rectum & rectosigmoid	304	13.8	0.36	16.4	0.43	201	8.7	0.29	10.2	0.33
Anus, anal canal, & anorectum	43	1.9	0.13	2.3	0.16	75	2.9	0.16	3.6	0.19
Liver	254	10.1	0.29	12.7	0.36	77	2.9	0.15	3.5	0.18
Gallbladder	16	0.7	0.09	0.9	0.10	31	1.2	0.10	1.4	0.12
Pancreas	334	15.1	0.38	17.8	0.44	315	12.1	0.31	14.2	0.37
Respiratory System	1,403	62.9	0.77	74.1	0.90	1,395	53.7	0.66	63.5	0.77
Larynx	87	3.8	0.19	4.6	0.22	19	0.7	0.08	0.9	0.09
Lung & bronchus	1,289	57.8	0.74	68.1	0.86	1,363	52.4	0.65	62.0	0.76
Bones & Joints	23	1.2	0.12	1.3	0.12	15	0.8	0.10	0.8	0.10
Soft Tissue (incl. heart)	77	3.8	0.20	4.2	0.22	52	2.3	0.15	2.6	0.16
Skin (excl. basal & sq.)	1,038	48.4	0.69	56.1	0.79	752	33.4	0.57	37.9	0.63
Melanoma of the skin	932	43.1	0.65	50.1	0.74	696	31.1	0.55	35.3	0.61
Breast (excl. <i>in situ</i>)	24	1.1	0.10	1.3	0.12	3,488	146.3	1.16	171.8	1.33
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,283	52.2	0.68	62.3	0.79
Cervix uteri	N/A	N/A	N/A	N/A	N/A	127	6.6	0.27	7.0	0.28
Uterus corpus	N/A	N/A	N/A	N/A	N/A	705	27.4	0.48	33.8	0.58
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	6	0.2	0.04	0.3	0.05
Ovary	N/A	N/A	N/A	N/A	N/A	244	10.1	0.30	11.9	0.35
Male Genital System	2,964	123.0	1.04	149.1	1.24	N/A	N/A	N/A	N/A	N/A
Prostate	2,810	114.5	0.99	140.5	1.20	N/A	N/A	N/A	N/A	N/A
Testis	131	7.3	0.29	7.3	0.29	N/A	N/A	N/A	N/A	N/A
Penis	14	0.7	0.09	0.8	0.10	N/A	N/A	N/A	N/A	N/A
Urinary System	1,412	64.5	0.79	75.7	0.92	539	21.5	0.43	25.0	0.49
Bladder (incl. <i>in situ</i>)	883	40.6	0.63	47.6	0.73	251	9.6	0.28	11.3	0.32
Kidney & renal pelvis	495	22.2	0.46	26.2	0.53	271	11.2	0.32	13.0	0.36
Ureter	16	0.8	0.09	0.9	0.10	10	0.4	0.05	0.4	0.06
Eye & Orbit	29	1.3	0.12	1.6	0.13	23	1.0	0.10	1.1	0.11
Brain & Other CNS	203	9.8	0.32	11.0	0.35	143	6.8	0.27	7.3	0.28
Brain	194	9.2	0.31	10.4	0.34	135	6.4	0.26	6.9	0.27
Endocrine System	175	8.5	0.30	9.4	0.32	396	20.1	0.47	21.6	0.49
Thyroid gland	160	7.7	0.28	8.6	0.31	382	19.4	0.46	20.9	0.49
Lymphomas	624	29.5	0.55	33.9	0.62	470	19.7	0.43	22.6	0.48
Hodgkin lymphoma	58	3.1	0.19	3.3	0.19	42	2.4	0.17	2.4	0.17
Non-Hodgkin lymphoma	566	26.4	0.51	30.6	0.58	427	17.3	0.39	20.2	0.45
Multiple Myeloma	201	9.1	0.30	10.7	0.34	133	5.2	0.21	6.2	0.24
Leukemias	449	21.1	0.46	24.2	0.52	293	12.1	0.33	13.9	0.37
Acute lymphocytic	26	1.7	0.15	1.5	0.13	19	1.2	0.13	1.1	0.11
Chronic lymphocytic	219	9.6	0.30	11.6	0.36	124	4.7	0.20	5.7	0.23
Acute myeloid	110	5.2	0.23	5.9	0.26	95	3.9	0.19	4.5	0.21
Chronic myeloid	59	2.8	0.17	3.2	0.19	34	1.4	0.11	1.6	0.13
Other leukemias	35	1.7	0.13	2.0	0.15	21	0.9	0.09	1.0	0.10
Mesothelioma	44	2.2	0.15	2.5	0.17	11	0.4	0.06	0.5	0.07
Kaposi Sarcoma	9	0.4	0.07	0.5	0.07	1	0.1	0.02	0.1	0.02
Ill-Defined & Unknown	431	20.6	0.46	23.8	0.52	367	14.5	0.35	16.7	0.40
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	331	15.7	0.40	18.0	0.45	676	28.8	0.52	33.1	0.58
Breast (<i>in situ</i>)	2	0.1	0.03	0.1	0.03	788	33.6	0.56	39.9	0.65

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Seattle/Puget Sound, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	609	534.1	10.96	640.8	12.74	463	420.6	9.25	495.1	10.70
Oral Cavity & Pharynx	17	14.0	1.71	16.4	1.94	5	4.3	0.88	5.5	1.09
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	4	3.8	0.93	4.5	1.06	*	*	*	*	*
Major salivary gland	2	1.7	0.66	1.9	0.76	2	1.1	0.41	1.4	0.50
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	2	1.1	0.37	1.5	0.47	*	*	*	*	*
Nasopharynx	1	1.2	0.51	1.3	0.54	*	*	*	*	*
Oropharynx	1	1.0	0.45	1.1	0.48	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	139	121.0	5.20	145.4	6.02	95	90.1	4.38	106.7	5.09
Esophagus	8	6.5	1.17	7.9	1.35	3	3.0	0.78	3.6	0.91
Stomach	12	12.1	1.80	14.5	2.09	8	8.2	1.34	9.5	1.53
Small intestine	5	4.3	0.93	5.3	1.12	6	5.4	1.03	6.4	1.21
Colon (excl. rectum)	36	32.2	2.67	37.8	3.04	31	29.7	2.54	35.2	2.97
Rectum & rectosigmoid	17	14.1	1.70	16.6	1.99	13	11.3	1.51	13.4	1.75
Anus, anal canal, & anorectum	2	1.1	0.40	1.5	0.51	3	3.1	0.83	3.8	0.98
Liver	30	24.4	2.23	30.7	2.66	10	8.6	1.28	10.5	1.52
Gallbladder	*	*	*	*	*	2	2.7	0.84	3.2	0.96
Pancreas	20	19.0	2.16	22.7	2.49	13	12.3	1.64	14.6	1.89
Respiratory System	74	72.9	4.30	87.2	4.97	54	54.2	3.52	63.8	4.02
Larynx	7	5.5	1.04	7.0	1.27	2	2.1	0.77	2.3	0.84
Lung & bronchus	65	66.4	4.16	79.0	4.79	52	51.6	3.41	60.9	3.91
Bones & Joints	1	0.8	0.30	0.7	0.25	*	*	*	*	*
Soft Tissue (incl. heart)	6	3.9	0.79	4.2	0.85	4	3.1	0.76	3.6	0.88
Skin (excl. basal & sq.)	3	3.4	1.03	3.8	1.21	3	2.3	0.63	2.5	0.69
Melanoma of the skin	1	1.6	0.75	1.9	0.89	1	1.2	0.46	1.3	0.50
Breast (excl. <i>in situ</i>)	2	1.7	0.61	2.0	0.68	136	120.6	4.86	141.7	5.63
Female Genital System	N/A	N/A	N/A	N/A	N/A	57	48.5	3.04	58.3	3.59
Cervix uteri	N/A	N/A	N/A	N/A	N/A	10	7.8	1.15	8.8	1.32
Uterus corpus	N/A	N/A	N/A	N/A	N/A	32	27.0	2.26	33.3	2.72
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	10	8.7	1.32	10.1	1.53
Male Genital System	206	171.0	5.93	211.7	7.02	N/A	N/A	N/A	N/A	N/A
Prostate	203	168.3	5.88	208.9	6.98	N/A	N/A	N/A	N/A	N/A
Testis	2	1.3	0.39	1.2	0.37	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	61	56.7	3.73	67.6	4.31	27	24.4	2.21	29.1	2.59
Bladder (incl. <i>in situ</i>)	22	24.8	2.66	28.8	3.02	7	7.1	1.29	8.2	1.48
Kidney & renal pelvis	38	30.0	2.47	36.5	2.91	20	16.6	1.74	20.1	2.08
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	7	5.9	1.13	6.4	1.25	5	4.1	0.91	4.4	1.00
Brain	7	5.5	1.11	6.0	1.22	4	3.5	0.85	3.9	0.96
Endocrine System	7	5.3	1.03	6.1	1.21	18	14.3	1.56	16.2	1.77
Thyroid gland	6	4.4	0.91	5.1	1.05	17	13.4	1.50	15.2	1.70
Lymphomas	25	20.4	2.04	22.8	2.26	19	16.1	1.73	18.7	1.99
Hodgkin lymphoma	4	2.6	0.58	2.9	0.66	4	2.6	0.62	2.8	0.68
Non-Hodgkin lymphoma	21	17.9	1.95	19.8	2.16	15	13.5	1.61	15.8	1.87
Multiple Myeloma	19	17.0	2.01	20.6	2.35	13	12.6	1.68	14.8	1.93
Leukemias	18	15.3	1.83	17.3	2.09	12	10.9	1.50	12.4	1.70
Acute lymphocytic	2	1.1	0.37	1.0	0.34	1	1.0	0.39	1.0	0.42
Chronic lymphocytic	7	5.6	1.01	6.6	1.15	4	3.4	0.81	4.0	0.93
Acute myeloid	5	4.4	1.04	4.9	1.16	3	3.0	0.78	3.4	0.89
Chronic myeloid	3	3.2	0.93	3.5	1.08	2	2.2	0.71	2.5	0.79
Other leukemias	1	1.1	0.51	1.4	0.65	1	1.3	0.58	1.5	0.66
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	3	1.9	0.50	2.1	0.55	*	*	*	*	*
Ill-Defined & Unknown	20	21.6	2.45	25.2	2.84	15	14.0	1.72	16.1	1.96
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	17	14.8	1.85	17.2	2.13	31	29.1	2.45	33.5	2.79
Breast (<i>in situ</i>)	*	*	*	*	*	37	31.5	2.44	38.0	2.87

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Seattle/Puget Sound, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	883	339.9	5.35	400.1	6.23	1,203	332.3	4.37	383.9	5.02
Oral Cavity & Pharynx	34	12.0	0.96	14.3	1.14	21	5.6	0.56	6.4	0.64
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	8	3.0	0.49	3.6	0.58	6	1.5	0.29	1.9	0.35
Major salivary gland	2	0.7	0.23	0.8	0.27	5	1.4	0.27	1.5	0.30
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	4	1.6	0.37	1.9	0.45	4	1.1	0.26	1.2	0.28
Nasopharynx	11	3.6	0.50	4.3	0.59	4	0.9	0.22	1.1	0.26
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	2	0.7	0.26	0.9	0.31	*	*	*	*	*
Digestive System	273	104.9	2.97	124.7	3.48	222	63.3	1.94	74.5	2.26
Esophagus	12	4.4	0.60	5.4	0.72	4	1.1	0.24	1.3	0.30
Stomach	31	12.6	1.05	14.8	1.22	28	8.1	0.69	9.5	0.81
Small intestine	4	1.3	0.32	1.5	0.37	5	1.4	0.28	1.6	0.32
Colon (excl. rectum)	66	24.9	1.44	29.7	1.70	65	18.5	1.05	21.7	1.22
Rectum & rectosigmoid	46	16.7	1.15	19.9	1.35	30	8.2	0.68	9.8	0.81
Anus, anal canal, & anorectum	2	0.9	0.30	1.1	0.34	2	0.6	0.19	0.7	0.22
Liver	62	23.0	1.35	27.8	1.61	28	8.1	0.71	9.4	0.81
Gallbladder	3	1.2	0.31	1.4	0.36	7	1.9	0.33	2.4	0.40
Pancreas	29	12.3	1.06	14.4	1.23	34	10.2	0.80	11.9	0.92
Respiratory System	122	50.6	2.14	60.2	2.50	117	34.1	1.45	39.9	1.67
Larynx	5	2.0	0.42	2.4	0.50	*	*	*	*	*
Lung & bronchus	116	48.0	2.08	57.1	2.44	113	33.1	1.43	38.8	1.65
Bones & Joints	3	1.1	0.27	1.1	0.29	2	0.7	0.20	0.6	0.19
Soft Tissue (incl. heart)	10	3.7	0.54	3.9	0.58	7	2.0	0.33	2.1	0.36
Skin (excl. basal & sq.)	6	2.5	0.47	2.7	0.53	11	3.0	0.42	3.4	0.47
Melanoma of the skin	3	1.1	0.32	1.2	0.34	6	1.6	0.31	1.8	0.34
Breast (excl. <i>in situ</i>)	2	0.7	0.23	0.9	0.28	400	107.4	2.44	124.7	2.82
Female Genital System	N/A	N/A	N/A	N/A	N/A	164	43.6	1.55	51.5	1.82
Cervix uteri	N/A	N/A	N/A	N/A	N/A	27	7.1	0.62	7.7	0.68
Uterus corpus	N/A	N/A	N/A	N/A	N/A	89	23.4	1.13	28.3	1.36
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	31	8.2	0.68	9.6	0.79
Male Genital System	177	67.0	2.34	80.8	2.77	N/A	N/A	N/A	N/A	N/A
Prostate	166	63.6	2.29	77.4	2.73	N/A	N/A	N/A	N/A	N/A
Testis	9	2.4	0.36	2.4	0.36	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	83	33.0	1.70	38.6	1.97	37	10.7	0.80	12.4	0.92
Bladder (incl. <i>in situ</i>)	41	17.6	1.29	20.4	1.48	17	5.0	0.56	5.8	0.64
Kidney & renal pelvis	39	13.9	1.03	16.6	1.22	19	5.3	0.55	6.2	0.64
Ureter	2	0.8	0.28	0.8	0.31	*	*	*	*	*
Eye & Orbit	2	0.6	0.20	0.6	0.19	*	*	*	*	*
Brain & Other CNS	14	5.0	0.62	5.4	0.68	11	3.1	0.43	3.1	0.43
Brain	14	4.8	0.60	5.1	0.66	10	2.8	0.40	2.9	0.42
Endocrine System	24	7.8	0.74	8.3	0.80	81	21.3	1.08	22.7	1.16
Thyroid gland	20	6.6	0.69	7.2	0.76	78	20.5	1.05	21.9	1.13
Lymphomas	53	19.2	1.24	22.3	1.43	50	13.8	0.89	15.9	1.02
Hodgkin lymphoma	3	1.1	0.26	1.1	0.28	3	0.9	0.22	0.8	0.21
Non-Hodgkin lymphoma	49	18.2	1.21	21.2	1.40	47	13.0	0.87	15.1	1.00
Multiple Myeloma	15	6.2	0.74	7.2	0.85	13	4.0	0.52	4.5	0.56
Leukemias	28	10.3	0.91	11.3	1.01	28	8.0	0.70	8.6	0.75
Acute lymphocytic	4	1.4	0.31	1.2	0.25	5	1.4	0.30	1.3	0.27
Chronic lymphocytic	4	1.5	0.36	1.8	0.42	4	1.1	0.26	1.3	0.29
Acute myeloid	11	4.0	0.57	4.6	0.65	12	3.5	0.46	3.8	0.50
Chronic myeloid	6	2.0	0.38	2.2	0.44	5	1.3	0.29	1.5	0.32
Other leukemias	3	1.3	0.36	1.5	0.41	3	0.7	0.20	0.8	0.22
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	1	0.3	0.14	0.4	0.16	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	38	11.1	0.82	12.7	0.93
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	37	14.1	1.09	16.1	1.24	95	26.7	1.25	30.9	1.44
Breast (<i>in situ</i>)	*	*	*	*	*	139	37.4	1.44	43.6	1.67

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Seattle/Puget Sound, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	179	625.6	23.46	741.3	27.35	209	604.7	19.86	704.2	22.77
Oral Cavity & Pharynx	10	30.4	4.76	37.4	5.60	4	11.0	2.85	13.6	3.49
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	4	12.3	3.39	15.2	3.95	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	1	3.4	1.47	4.3	1.79	*	*	*	*	*
Digestive System	50	171.7	12.39	207.5	14.74	38	109.7	8.45	128.7	9.72
Esophagus	3	11.8	3.29	14.1	3.81	2	5.8	1.75	7.4	2.15
Stomach	2	11.9	4.10	14.2	4.85	2	7.4	2.34	7.9	2.48
Small intestine	1	3.8	1.49	4.6	1.76	*	*	*	*	*
Colon (excl. rectum)	11	34.8	5.23	41.0	6.10	11	35.3	4.97	40.7	5.65
Rectum & rectosigmoid	7	23.6	4.29	27.2	4.93	6	17.9	3.35	21.1	3.91
Anus, anal canal, & anorectum	1	4.1	1.75	4.4	1.84	*	*	*	*	*
Liver	13	38.8	5.40	49.9	6.67	4	9.6	2.34	12.0	2.78
Gallbladder	*	*	*	*	*	1	3.2	1.41	4.1	1.73
Pancreas	7	27.9	5.68	33.4	6.74	5	12.8	2.73	15.1	3.15
Respiratory System	26	94.3	9.27	113.1	10.85	29	91.6	8.07	106.6	9.23
Larynx	3	8.1	2.25	10.0	2.71	*	*	*	*	*
Lung & bronchus	23	86.2	8.99	103.0	10.50	28	85.3	7.76	99.6	8.90
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	2	7.2	2.64	8.3	3.14	*	*	*	*	*
Skin (excl. basal & sq.)	5	18.2	4.03	20.3	4.44	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	4	13.6	3.52	15.6	3.99	4	12.7	2.85	14.1	3.10
Breast (excl. <i>in situ</i>)	*	*	*	*	*	61	173.3	10.49	204.0	12.16
Female Genital System	N/A	N/A	N/A	N/A	N/A	25	68.2	6.36	79.1	7.21
Cervix uteri	N/A	N/A	N/A	N/A	N/A	3	8.4	2.23	8.6	2.24
Uterus corpus	N/A	N/A	N/A	N/A	N/A	12	32.1	4.27	39.4	5.08
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	7	19.0	3.38	21.3	3.70
Male Genital System	34	118.6	10.17	140.7	11.86	N/A	N/A	N/A	N/A	N/A
Prostate	30	106.2	9.65	127.4	11.29	N/A	N/A	N/A	N/A	N/A
Testis	3	9.4	2.83	10.1	3.23	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	20	74.1	8.48	87.2	9.86	9	25.1	4.14	30.3	4.89
Bladder (incl. <i>in situ</i>)	9	34.8	6.07	41.4	7.06	3	9.6	2.88	11.6	3.45
Kidney & renal pelvis	10	38.0	5.86	44.3	6.81	6	15.5	2.98	18.7	3.47
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	8.3	2.57	8.9	2.78	1	3.6	1.38	3.8	1.45
Brain	2	7.6	2.48	8.3	2.72	*	*	*	*	*
Endocrine System	2	5.2	1.84	6.2	2.10	13	36.8	4.63	38.7	4.80
Thyroid gland	1	4.2	1.69	4.9	1.88	13	36.2	4.60	38.0	4.75
Lymphomas	9	31.0	4.99	35.5	5.62	7	22.9	4.06	26.9	4.75
Hodgkin lymphoma	1	4.1	1.60	4.1	1.56	*	*	*	*	*
Non-Hodgkin lymphoma	8	26.9	4.72	31.4	5.40	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	4	12.7	3.23	14.8	3.64	3	9.4	2.63	11.6	3.22
Leukemias	7	22.3	4.17	24.5	4.60	5	14.2	3.05	15.2	3.28
Acute lymphocytic	1	4.4	1.66	3.8	1.45	2	4.5	1.62	4.3	1.53
Chronic lymphocytic	2	6.3	2.25	7.4	2.60	*	*	*	*	*
Acute myeloid	2	6.4	2.31	7.4	2.64	2	5.2	1.94	5.6	2.14
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	8	27.9	4.94	33.4	5.78	6	16.5	3.31	20.3	3.98
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	4	13.6	3.28	15.5	3.66	14	40.9	5.09	46.1	5.66
Breast (<i>in situ</i>)	*	*	*	*	*	13	35.0	4.53	40.6	5.14

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Seattle/Puget Sound, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	447	433.6	11.22	510.5	12.92	576	436.4	9.14	511.5	10.64
Oral Cavity & Pharynx	15	12.2	1.70	14.8	1.97	8	5.5	0.98	6.9	1.24
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	4	3.5	0.83	4.4	1.00	2	1.7	0.56	2.1	0.68
Major salivary gland	2	1.8	0.78	2.1	0.86	2	1.7	0.56	2.1	0.72
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	1	0.7	0.28	0.8	0.35
Nasopharynx	1	0.7	0.27	0.9	0.37	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	108	104.5	5.43	125.0	6.32	91	76.4	4.01	90.7	4.69
Esophagus	6	5.9	1.26	7.3	1.52	1	0.8	0.35	1.0	0.42
Stomach	11	11.3	1.81	13.6	2.13	12	9.8	1.42	11.5	1.64
Small intestine	3	2.9	0.94	3.4	1.09	*	*	*	*	*
Colon (excl. rectum)	27	27.3	2.92	32.0	3.36	26	20.8	2.07	24.8	2.43
Rectum & rectosigmoid	18	14.5	1.82	17.5	2.14	13	9.5	1.31	11.3	1.55
Anus, anal canal, & anorectum	1	1.1	0.54	1.2	0.57	4	3.4	0.83	4.4	1.01
Liver	20	17.9	2.09	22.1	2.47	9	9.2	1.50	10.8	1.72
Gallbladder	1	1.7	0.78	2.0	0.93	3	3.0	0.86	3.6	0.99
Pancreas	13	14.8	2.13	17.6	2.45	15	13.2	1.71	15.4	1.96
Respiratory System	47	57.6	4.35	67.4	4.95	49	46.7	3.25	55.1	3.72
Larynx	6	5.9	1.27	7.3	1.52	1	0.9	0.38	1.1	0.47
Lung & bronchus	40	50.8	4.15	59.0	4.69	45	44.4	3.19	52.5	3.66
Bones & Joints	*	*	*	*	*	2	0.7	0.26	0.7	0.31
Soft Tissue (incl. heart)	5	3.4	0.94	3.8	1.08	5	3.5	0.80	4.0	0.91
Skin (excl. basal & sq.)	14	15.4	2.20	17.9	2.51	21	15.2	1.66	17.6	1.91
Melanoma of the skin	11	12.3	1.99	14.1	2.23	18	12.5	1.44	14.8	1.70
Breast (excl. <i>in situ</i>)	2	1.0	0.35	1.2	0.45	178	131.8	4.87	155.5	5.71
Female Genital System	N/A	N/A	N/A	N/A	N/A	77	53.5	3.04	63.7	3.59
Cervix uteri	N/A	N/A	N/A	N/A	N/A	15	8.1	1.03	8.7	1.15
Uterus corpus	N/A	N/A	N/A	N/A	N/A	38	26.7	2.08	33.3	2.56
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	15	10.1	1.33	12.0	1.56
Male Genital System	97	92.6	5.01	110.7	5.80	N/A	N/A	N/A	N/A	N/A
Prostate	80	85.5	4.89	103.2	5.67	N/A	N/A	N/A	N/A	N/A
Testis	15	5.8	0.87	6.1	0.97	N/A	N/A	N/A	N/A	N/A
Penis	2	1.3	0.65	1.5	0.72	N/A	N/A	N/A	N/A	N/A
Urinary System	51	54.7	4.15	63.5	4.71	29	26.1	2.41	30.4	2.76
Bladder (incl. <i>in situ</i>)	19	26.5	3.12	30.4	3.54	8	9.0	1.56	10.3	1.75
Kidney & renal pelvis	30	25.4	2.53	30.0	2.90	21	16.2	1.79	19.2	2.08
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	1	0.9	0.35	1.0	0.43
Brain & Other CNS	12	7.6	1.27	8.7	1.47	9	5.5	1.00	6.0	1.12
Brain	11	7.2	1.24	8.2	1.43	8	5.3	0.99	5.7	1.12
Endocrine System	13	8.3	1.31	9.5	1.49	42	22.0	1.68	23.8	1.89
Thyroid gland	11	6.9	1.16	8.1	1.36	40	20.8	1.60	22.5	1.81
Lymphomas	30	26.9	2.80	31.1	3.23	28	20.7	1.99	23.9	2.30
Hodgkin lymphoma	4	3.3	0.95	3.9	1.13	6	2.4	0.50	2.5	0.55
Non-Hodgkin lymphoma	26	23.6	2.64	27.3	3.02	23	18.3	1.92	21.5	2.23
Multiple Myeloma	10	10.6	1.77	12.7	2.05	6	5.3	1.06	6.2	1.19
Leukemias	23	15.8	1.94	17.7	2.25	16	10.6	1.42	12.1	1.63
Acute lymphocytic	8	2.8	0.46	2.6	0.47	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	3	3.9	1.06	4.5	1.21	3	2.7	0.82	3.1	0.92
Acute myeloid	6	5.6	1.30	6.5	1.54	4	3.2	0.78	3.7	0.92
Chronic myeloid	4	2.4	0.74	2.7	0.88	3	1.8	0.56	2.2	0.66
Other leukemias	2	1.2	0.43	1.3	0.49	*	*	*	*	*
Mesothelioma	2	2.3	0.85	2.8	0.97	*	*	*	*	*
Kaposi Sarcoma	1	0.9	0.51	1.0	0.64	*	*	*	*	*
Ill-Defined & Unknown	15	18.6	2.66	21.7	3.07	13	11.0	1.58	12.7	1.84
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	16	10.5	1.61	11.8	1.88	40	28.9	2.30	34.0	2.70
Breast (<i>in situ</i>)	*	*	*	*	*	42	27.5	2.03	32.4	2.40

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Seattle/Puget Sound

II-528 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Seattle/Puget Sound, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	394	426.8	11.52	503.0	13.30	512	442.3	9.70	518.9	11.30
Oral Cavity & Pharynx	14	12.5	1.77	15.3	2.06	7	5.3	0.99	6.7	1.27
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	4	3.6	0.89	4.7	1.09	2	1.7	0.60	2.1	0.73
Major salivary gland	2	2.0	0.84	2.3	0.93	2	1.8	0.61	2.2	0.78
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	1	0.8	0.32	0.9	0.40
Nasopharynx	1	0.8	0.31	1.0	0.43	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	95	103.0	5.60	123.8	6.54	82	77.6	4.24	92.2	4.97
Esophagus	6	6.3	1.36	7.8	1.64	*	*	*	*	*
Stomach	9	11.1	1.86	13.5	2.19	11	10.5	1.56	12.3	1.80
Small intestine	2	3.1	1.01	3.6	1.17	*	*	*	*	*
Colon (excl. rectum)	25	29.3	3.14	34.3	3.61	24	21.5	2.19	25.8	2.59
Rectum & rectosigmoid	15	12.9	1.72	15.7	2.07	12	9.3	1.32	11.1	1.59
Anus, anal canal, & anorectum	*	*	*	*	*	4	3.6	0.90	4.6	1.11
Liver	17	17.0	2.14	21.2	2.55	8	8.7	1.55	10.1	1.76
Gallbladder	1	1.9	0.84	2.2	0.99	3	3.1	0.92	3.6	1.06
Pancreas	11	14.3	2.20	17.1	2.54	13	13.8	1.84	16.0	2.10
Respiratory System	41	55.4	4.41	65.0	5.05	44	47.3	3.42	56.2	3.96
Larynx	5	5.9	1.33	7.2	1.60	1	1.0	0.43	1.3	0.54
Lung & bronchus	35	48.9	4.20	57.1	4.78	41	44.7	3.35	53.3	3.87
Bones & Joints	*	*	*	*	*	1	0.7	0.29	0.8	0.35
Soft Tissue (incl. heart)	4	3.4	0.99	3.8	1.13	4	3.0	0.82	3.5	0.93
Skin (excl. basal & sq.)	13	16.3	2.36	18.8	2.69	19	15.7	1.79	18.2	2.06
Melanoma of the skin	10	13.0	2.13	14.8	2.39	17	13.2	1.58	15.5	1.86
Breast (excl. <i>in situ</i>)	1	1.0	0.38	1.2	0.48	159	134.4	5.19	158.6	6.09
Female Genital System	N/A	N/A	N/A	N/A	N/A	66	53.6	3.26	63.9	3.86
Cervix uteri	N/A	N/A	N/A	N/A	N/A	12	7.4	1.04	8.2	1.19
Uterus corpus	N/A	N/A	N/A	N/A	N/A	33	26.6	2.22	33.2	2.74
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	13	10.4	1.45	12.3	1.71
Male Genital System	83	89.1	5.11	106.7	5.94	N/A	N/A	N/A	N/A	N/A
Prostate	68	82.1	5.00	99.4	5.82	N/A	N/A	N/A	N/A	N/A
Testis	14	5.6	0.81	5.9	0.90	N/A	N/A	N/A	N/A	N/A
Penis	2	1.3	0.67	1.5	0.74	N/A	N/A	N/A	N/A	N/A
Urinary System	46	54.7	4.29	63.3	4.85	26	26.6	2.55	31.3	2.95
Bladder (incl. <i>in situ</i>)	17	26.0	3.19	29.8	3.60	7	9.1	1.64	10.6	1.86
Kidney & renal pelvis	27	25.6	2.64	30.2	3.02	18	16.5	1.89	19.7	2.22
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	1	1.0	0.41	1.2	0.50
Brain & Other CNS	11	8.1	1.38	9.0	1.58	8	5.7	1.06	6.1	1.18
Brain	10	7.6	1.34	8.5	1.54	8	5.4	1.04	5.9	1.17
Endocrine System	12	8.3	1.34	9.5	1.55	38	22.8	1.82	24.5	2.03
Thyroid gland	10	7.3	1.24	8.5	1.46	36	21.5	1.74	23.2	1.94
Lymphomas	27	27.7	2.95	32.0	3.40	26	21.4	2.15	24.7	2.49
Hodgkin lymphoma	4	3.3	0.97	3.8	1.17	5	2.3	0.49	2.3	0.52
Non-Hodgkin lymphoma	23	24.4	2.79	28.2	3.19	21	19.2	2.10	22.4	2.43
Multiple Myeloma	9	11.0	1.88	13.0	2.16	5	5.3	1.14	6.3	1.29
Leukemias	19	14.6	1.89	16.3	2.19	15	10.6	1.46	12.0	1.66
Acute lymphocytic	7	2.8	0.50	2.5	0.50	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	3	3.8	1.10	4.5	1.27	2	2.7	0.84	3.0	0.93
Acute myeloid	5	4.6	1.19	5.4	1.39	3	2.4	0.68	2.8	0.81
Chronic myeloid	3	2.2	0.67	2.6	0.84	3	2.1	0.63	2.5	0.75
Other leukemias	2	1.2	0.47	1.4	0.55	*	*	*	*	*
Mesothelioma	2	2.4	0.90	2.8	1.03	*	*	*	*	*
Kaposi Sarcoma	1	0.9	0.54	1.1	0.66	*	*	*	*	*
Ill-Defined & Unknown	13	17.3	2.61	20.1	3.01	11	10.7	1.62	12.1	1.85
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	15	11.0	1.69	12.2	1.96	36	30.0	2.45	35.1	2.87
Breast (<i>in situ</i>)	*	*	*	*	*	38	29.2	2.25	34.5	2.66

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Seattle/Puget Sound, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	12	540.2	149.56	630.3	175.91	14	325.3	52.42	390.0	61.47
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	2	42.6	17.24	51.1	19.33	1	41.0	20.25	45.4	22.25
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	2	52.6	23.08	57.8	24.08	2	59.0	24.18	67.4	26.39
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	1	48.7	22.87	53.1	23.78	2	59.0	24.18	67.4	26.39
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	4	76.0	19.94	94.5	24.31
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	46.5	18.09	56.3	20.26
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	4	115.3	31.30	139.6	36.26	N/A	N/A	N/A	N/A	N/A
Prostate	3	96.3	25.91	118.3	30.21	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	1	97.5	73.05	108.3	80.10	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	1	11.9	5.62	13.5	6.81
Breast (<i>in situ</i>)	*	*	*	*	*	1	17.4	6.66	20.4	8.04

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.


N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	1,843,332	1,832,435	1,818,683	1,805,953	1,795,263
Non-Hispanic White	1,722,504	1,710,376	1,696,340	1,682,887	1,670,635
Non-Hispanic Black	72,581	72,510	72,382	72,437	72,617
Non-Hispanic Asian/Pacific Islander (NH API)	16,664	17,067	16,898	16,670	16,938
Non-Hispanic American Indian/Alaskan Native PRCA (NH AI/AN)	0	0	0	0	0


All Races Population 2015–2019: 9,095,666
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	27,693	28,580	29,162	30,081	31,152
Hispanic White	24,569	25,326	25,738	26,568	27,476
Hispanic Black	2,000	2,048	2,138	2,185	2,278

Hispanic/Latino Population, Census 2010: 22,268
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

WEST VIRGINIA CANCER REGISTRY

Initial Operation: 1993
Population-based Data Available: 1993
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	103.6	106.7	112.4	109.4	105.3	107.5
Missing Race	0.4	0.4	0.4	0.5	0.3	0.4
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.0	0.7	0.7	0.6	0.6	0.7
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.9	Ovary	93.9
Oral Cavity & Pharynx	98.1	Prostate	97.8
Esophagus	97.0	Testis	100.0
Stomach	97.1	Bladder (incl. <i>in situ</i>)	97.8
Colon & Rectum	96.4	Kidney & Renal Pelvis	88.5
Liver	63.1	Brain & Other CNS	87.4
Pancreas	85.9	Brain & Other CNS (non-malig)	34.4
Lung & Bronchus	85.6	Thyroid	99.7
Melanomas of the Skin	99.0	Hodgkin Lymphoma	98.7
Female Breast (excl. <i>in situ</i>)	98.6	Non-Hodgkin Lymphoma	97.1
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	91.5
Cervix Uteri	98.7	Leukemias	88.4
Uterus Corpus & Uterus NOS	99.1		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
West Virginia, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	6,241	517.6	3.04	615.8	3.55	5,976	468.0	2.86	547.4	3.26
Oral Cavity & Pharynx	257	21.5	0.62	26.3	0.75	92	7.1	0.35	8.4	0.41
Lip	8	0.7	0.12	0.9	0.14	3	0.2	0.05	0.2	0.06
Tongue	77	6.2	0.33	7.7	0.40	27	2.1	0.19	2.5	0.22
Major salivary gland	17	1.6	0.18	1.8	0.20	13	1.1	0.15	1.3	0.16
Floor of mouth	11	0.9	0.13	1.2	0.16	4	0.3	0.07	0.3	0.08
Gum & other mouth	32	2.7	0.22	3.2	0.26	20	1.5	0.15	1.8	0.18
Nasopharynx	8	0.7	0.12	0.9	0.14	4	0.3	0.08	0.4	0.09
Oropharynx	20	1.7	0.17	2.1	0.21	5	0.3	0.08	0.4	0.09
Hypopharynx	16	1.2	0.14	1.6	0.18	3	0.2	0.06	0.3	0.07
Digestive System	1,207	101.3	1.35	121.0	1.59	952	70.8	1.07	83.7	1.25
Esophagus	125	10.1	0.42	12.3	0.50	28	2.0	0.17	2.5	0.21
Stomach	89	7.4	0.37	8.8	0.43	50	3.6	0.24	4.3	0.28
Small intestine	30	2.6	0.22	3.1	0.26	29	2.3	0.20	2.7	0.23
Colon (excl. rectum)	409	35.0	0.80	41.4	0.93	397	29.6	0.70	34.6	0.80
Rectum & rectosigmoid	192	16.6	0.56	19.8	0.65	131	10.3	0.42	12.1	0.49
Anus, anal canal, & anorectum	15	1.3	0.16	1.6	0.19	36	2.9	0.22	3.5	0.27
Liver	126	9.9	0.40	12.4	0.50	44	3.2	0.22	3.8	0.26
Gallbladder	6	0.5	0.09	0.6	0.11	14	1.0	0.12	1.2	0.14
Pancreas	163	13.5	0.49	16.1	0.57	161	11.6	0.43	13.8	0.50
Respiratory System	1,219	97.5	1.28	117.9	1.54	1,013	72.2	1.05	87.3	1.25
Larynx	93	7.4	0.35	9.2	0.44	29	2.3	0.20	2.8	0.24
Lung & bronchus	1,112	89.0	1.23	107.4	1.46	975	69.3	1.02	83.8	1.22
Bones & Joints	10	1.1	0.16	1.1	0.16	9	1.0	0.15	1.0	0.15
Soft Tissue (incl. heart)	41	3.9	0.29	4.4	0.31	31	2.8	0.24	3.0	0.25
Skin (excl. basal & sq.)	336	29.3	0.74	34.3	0.85	231	20.1	0.63	22.6	0.69
Melanoma of the skin	312	27.2	0.71	31.8	0.82	215	18.9	0.61	21.3	0.67
Breast (excl. <i>in situ</i>)	14	1.2	0.15	1.4	0.17	1,537	121.8	1.47	143.3	1.68
Female Genital System	N/A	N/A	N/A	N/A	N/A	757	61.4	1.06	72.4	1.21
Cervix uteri	N/A	N/A	N/A	N/A	N/A	90	9.4	0.47	10.0	0.48
Uterus corpus	N/A	N/A	N/A	N/A	N/A	431	33.6	0.77	40.6	0.90
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	13	1.0	0.13	1.2	0.15
Ovary	N/A	N/A	N/A	N/A	N/A	146	11.7	0.46	13.7	0.52
Male Genital System	1,360	105.6	1.32	128.3	1.58	N/A	N/A	N/A	N/A	N/A
Prostate	1,293	98.3	1.25	120.7	1.53	N/A	N/A	N/A	N/A	N/A
Testis	47	5.7	0.38	5.6	0.37	N/A	N/A	N/A	N/A	N/A
Penis	16	1.4	0.16	1.6	0.18	N/A	N/A	N/A	N/A	N/A
Urinary System	767	64.7	1.08	76.3	1.26	345	26.1	0.66	30.6	0.76
Bladder (incl. <i>in situ</i>)	440	36.5	0.80	43.0	0.93	134	9.7	0.39	11.3	0.45
Kidney & renal pelvis	312	27.0	0.71	31.9	0.82	203	15.8	0.53	18.6	0.60
Ureter	9	0.7	0.11	0.9	0.13	6	0.4	0.08	0.5	0.09
Eye & Orbit	14	1.3	0.17	1.5	0.18	10	0.8	0.12	0.9	0.13
Brain & Other CNS	82	7.8	0.40	8.6	0.43	69	6.2	0.36	6.8	0.37
Brain	78	7.4	0.39	8.1	0.42	65	5.8	0.34	6.3	0.36
Endocrine System	93	9.1	0.44	10.0	0.47	256	26.1	0.77	28.0	0.80
Thyroid gland	84	8.2	0.42	9.1	0.45	252	25.7	0.77	27.6	0.79
Lymphomas	300	26.4	0.71	30.2	0.80	243	18.8	0.57	21.8	0.64
Hodgkin lymphoma	28	2.9	0.26	3.1	0.27	18	1.9	0.22	2.0	0.21
Non-Hodgkin lymphoma	272	23.4	0.66	27.1	0.75	226	16.9	0.53	19.8	0.60
Multiple Myeloma	89	7.3	0.36	8.7	0.42	67	4.8	0.27	5.7	0.31
Leukemias	217	19.2	0.61	22.0	0.68	158	12.6	0.48	14.3	0.52
Acute lymphocytic	14	1.6	0.20	1.5	0.18	9	1.0	0.15	0.9	0.14
Chronic lymphocytic	92	7.6	0.36	9.1	0.43	57	4.0	0.24	4.7	0.29
Acute myeloid	59	5.3	0.32	6.0	0.36	53	4.3	0.28	4.9	0.31
Chronic myeloid	29	2.6	0.23	3.0	0.25	26	2.3	0.21	2.5	0.23
Other leukemias	23	2.1	0.20	2.4	0.23	13	1.1	0.14	1.2	0.15
Mesothelioma	23	2.0	0.19	2.3	0.22	6	0.5	0.08	0.5	0.09
Kaposi Sarcoma	3	0.3	0.08	0.3	0.08	*	*	*	*	*
Ill-Defined & Unknown	210	18.0	0.57	21.2	0.67	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	101	9.7	0.45	10.8	0.49	202	16.7	0.56	19.2	0.62
Breast (<i>in situ</i>)	*	*	*	*	*	275	22.4	0.64	26.6	0.74

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
West Virginia, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	5,973	519.4	3.12	617.7	3.65	5,763	473.0	2.95	552.9	3.36
Oral Cavity & Pharynx	249	21.9	0.65	26.8	0.77	88	7.0	0.35	8.4	0.41
Lip	8	0.7	0.12	0.8	0.14	3	0.2	0.05	0.2	0.06
Tongue	75	6.4	0.35	7.9	0.42	26	2.1	0.20	2.5	0.23
Major salivary gland	17	1.6	0.19	1.8	0.21	12	1.0	0.14	1.2	0.16
Floor of mouth	11	0.9	0.13	1.2	0.17	4	0.3	0.07	0.3	0.08
Gum & other mouth	32	2.8	0.23	3.3	0.27	20	1.5	0.15	1.8	0.18
Nasopharynx	7	0.6	0.12	0.8	0.13	3	0.3	0.08	0.3	0.09
Oropharynx	20	1.8	0.18	2.2	0.22	5	0.4	0.08	0.5	0.10
Hypopharynx	14	1.1	0.14	1.5	0.18	3	0.2	0.06	0.3	0.08
Digestive System	1,156	101.7	1.39	121.5	1.63	913	71.2	1.10	84.0	1.28
Esophagus	123	10.4	0.43	12.6	0.52	27	2.0	0.18	2.5	0.22
Stomach	86	7.5	0.38	8.9	0.44	46	3.5	0.24	4.1	0.28
Small intestine	28	2.5	0.22	3.0	0.26	28	2.3	0.21	2.7	0.24
Colon (excl. rectum)	395	35.3	0.83	41.7	0.96	381	29.8	0.72	34.8	0.82
Rectum & rectosigmoid	184	16.8	0.58	19.9	0.67	127	10.4	0.44	12.2	0.50
Anus, anal canal, & anorectum	14	1.3	0.16	1.6	0.19	35	3.0	0.24	3.6	0.28
Liver	118	9.7	0.41	12.1	0.51	42	3.2	0.23	3.8	0.27
Gallbladder	5	0.5	0.09	0.6	0.11	14	1.0	0.12	1.2	0.15
Pancreas	155	13.4	0.50	15.9	0.58	155	11.7	0.44	13.9	0.51
Respiratory System	1,181	98.8	1.32	119.4	1.58	984	73.4	1.08	88.7	1.29
Larynx	91	7.6	0.37	9.5	0.45	28	2.3	0.20	2.8	0.25
Lung & bronchus	1,077	90.0	1.26	108.6	1.51	948	70.4	1.05	85.1	1.26
Bones & Joints	8	1.0	0.16	1.0	0.16	9	1.0	0.16	1.0	0.16
Soft Tissue (incl. heart)	39	3.9	0.30	4.4	0.32	29	2.8	0.25	3.1	0.26
Skin (excl. basal & sq.)	327	29.9	0.77	35.0	0.88	222	20.4	0.65	22.9	0.71
Melanoma of the skin	304	27.8	0.74	32.5	0.85	207	19.1	0.64	21.5	0.69
Breast (excl. <i>in situ</i>)	14	1.3	0.16	1.5	0.18	1,474	122.3	1.51	143.9	1.73
Female Genital System	N/A	N/A	N/A	N/A	N/A	734	62.6	1.10	73.7	1.25
Cervix uteri	N/A	N/A	N/A	N/A	N/A	85	9.5	0.49	10.1	0.50
Uterus corpus	N/A	N/A	N/A	N/A	N/A	419	34.3	0.80	41.4	0.93
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	13	1.0	0.13	1.2	0.15
Ovary	N/A	N/A	N/A	N/A	N/A	142	11.9	0.47	14.0	0.54
Male Genital System	1,266	103.1	1.34	125.0	1.60	N/A	N/A	N/A	N/A	N/A
Prostate	1,201	95.3	1.26	116.9	1.53	N/A	N/A	N/A	N/A	N/A
Testis	46	6.1	0.41	6.1	0.40	N/A	N/A	N/A	N/A	N/A
Penis	16	1.4	0.17	1.7	0.19	N/A	N/A	N/A	N/A	N/A
Urinary System	747	65.9	1.12	77.7	1.30	336	26.6	0.69	31.1	0.78
Bladder (incl. <i>in situ</i>)	432	37.3	0.83	44.0	0.96	130	9.8	0.40	11.5	0.46
Kidney & renal pelvis	300	27.4	0.74	32.3	0.85	197	16.2	0.55	18.9	0.62
Ureter	9	0.8	0.12	0.9	0.14	6	0.5	0.08	0.5	0.10
Eye & Orbit	14	1.4	0.17	1.6	0.19	10	0.8	0.13	1.0	0.14
Brain & Other CNS	80	8.0	0.42	8.8	0.45	66	6.3	0.37	6.9	0.39
Brain	76	7.5	0.41	8.3	0.44	62	5.8	0.35	6.4	0.37
Endocrine System	88	9.1	0.46	10.1	0.49	247	26.7	0.81	28.6	0.83
Thyroid gland	81	8.4	0.44	9.3	0.47	243	26.3	0.80	28.2	0.83
Lymphomas	289	26.7	0.73	30.6	0.82	237	19.2	0.59	22.2	0.67
Hodgkin lymphoma	26	3.0	0.27	3.2	0.28	17	2.0	0.23	2.0	0.23
Non-Hodgkin lymphoma	263	23.7	0.68	27.5	0.77	220	17.2	0.55	20.2	0.63
Multiple Myeloma	83	7.2	0.36	8.5	0.43	63	4.6	0.27	5.5	0.32
Leukemias	206	19.2	0.62	21.9	0.70	152	12.7	0.49	14.4	0.54
Acute lymphocytic	13	1.6	0.21	1.5	0.19	9	1.0	0.16	0.9	0.14
Chronic lymphocytic	88	7.6	0.37	9.1	0.44	54	3.9	0.25	4.7	0.29
Acute myeloid	56	5.3	0.33	6.0	0.37	52	4.4	0.29	5.0	0.32
Chronic myeloid	27	2.6	0.23	2.9	0.26	25	2.3	0.22	2.6	0.24
Other leukemias	22	2.1	0.21	2.4	0.23	13	1.1	0.15	1.2	0.16
Mesothelioma	23	2.1	0.20	2.4	0.23	6	0.5	0.09	0.5	0.10
Kaposi Sarcoma	2	0.2	0.07	0.3	0.08	*	*	*	*	*
Ill-Defined & Unknown	201	18.1	0.59	21.3	0.68	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	95	9.7	0.46	10.7	0.50	196	17.0	0.58	19.5	0.64
Breast (<i>in situ</i>)	*	*	*	*	*	263	22.4	0.66	26.7	0.76

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
West Virginia, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	188	530.2	18.84	638.7	22.07	135	381.3	15.21	452.3	17.65
Oral Cavity & Pharynx	5	16.2	3.49	18.9	4.00	2	7.5	2.29	8.1	2.36
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	1	3.5	1.39	4.4	1.66	*	*	*	*	*
Digestive System	39	108.8	8.51	130.9	10.00	27	71.9	6.44	87.5	7.67
Esophagus	2	5.9	1.93	6.7	2.15	*	*	*	*	*
Stomach	2	6.7	2.18	7.9	2.49	2	5.5	1.79	6.4	2.06
Small intestine	2	7.3	2.47	7.8	2.68	2	4.9	1.78	5.7	2.04
Colon (excl. rectum)	11	31.3	4.56	37.4	5.33	11	29.1	4.13	34.9	4.85
Rectum & rectosigmoid	6	14.6	2.93	17.8	3.47	4	9.9	2.41	12.0	2.87
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	7	14.6	2.50	19.8	3.36	2	3.7	1.32	4.9	1.75
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	6	20.5	4.12	24.4	4.78	5	13.5	2.80	16.5	3.34
Respiratory System	30	91.3	8.23	109.6	9.57	21	57.3	5.67	70.1	6.83
Larynx	2	4.2	1.65	5.3	2.01	*	*	*	*	*
Lung & bronchus	28	84.8	7.94	101.7	9.22	21	55.0	5.56	67.1	6.67
Bones & Joints	1	4.0	1.78	4.3	1.91	*	*	*	*	*
Soft Tissue (incl. heart)	2	5.3	1.90	5.9	2.10	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	42	122.5	8.80	144.7	10.15
Female Genital System	N/A	N/A	N/A	N/A	N/A	15	42.0	5.05	50.0	5.85
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	7.6	2.27	8.8	2.57
Uterus corpus	N/A	N/A	N/A	N/A	N/A	8	19.4	3.27	24.1	3.97
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	4	10.7	2.57	12.1	2.89
Male Genital System	71	185.6	10.68	230.3	12.76	N/A	N/A	N/A	N/A	N/A
Prostate	70	183.3	10.62	228.4	12.72	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	13	36.0	4.84	42.7	5.60	6	18.2	3.32	21.5	3.87
Bladder (incl. <i>in situ</i>)	6	16.2	3.34	19.6	3.98	3	6.5	1.83	7.9	2.20
Kidney & renal pelvis	7	19.8	3.50	23.1	3.94	4	11.0	2.67	13.0	3.11
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	1	3.3	1.38	3.1	1.30	*	*	*	*	*
Brain	1	3.3	1.38	3.1	1.30	*	*	*	*	*
Endocrine System	3	7.3	2.11	7.5	2.15	4	14.0	3.10	15.1	3.28
Thyroid gland	2	5.6	1.86	5.8	1.92	4	14.0	3.10	15.1	3.28
Lymphomas	7	18.7	3.39	21.4	3.80	4	11.7	2.60	14.2	3.06
Hodgkin lymphoma	1	2.8	1.19	2.8	1.18	*	*	*	*	*
Non-Hodgkin lymphoma	6	15.9	3.17	18.5	3.61	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	5	13.3	3.06	16.2	3.63	3	7.9	2.12	9.5	2.47
Leukemias	6	19.7	3.99	22.5	4.56	3	9.4	2.53	10.4	2.72
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	2	5.2	2.07	6.4	2.53	*	*	*	*	*
Acute myeloid	2	7.1	2.56	7.9	2.76	*	*	*	*	*
Chronic myeloid	1	4.6	1.88	5.3	2.23	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	5	16.8	3.64	20.4	4.44	4	11.7	2.60	13.9	3.07
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	4	13.1	3.14	15.2	3.62	5	14.7	3.18	15.8	3.35
Breast (<i>in situ</i>)	*	*	*	*	*	8	21.7	3.66	26.2	4.31

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
West Virginia, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	13	205.2	28.70	249.1	34.25	20	220.9	22.87	254.3	26.29
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	3	53.2	15.13	66.8	18.41	3	37.8	9.51	47.6	11.77
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	3	36.6	9.95	46.5	12.58	2	18.5	5.97	22.7	7.31
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	3	36.6	9.95	46.5	12.58	2	17.0	5.78	20.8	7.04
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	8	90.1	14.38	104.0	16.60
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	2	36.6	12.74	44.8	14.96	N/A	N/A	N/A	N/A	N/A
Prostate	2	32.6	12.07	40.1	14.21	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	1	20.3	7.81	23.6	9.12	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	1	13.2	5.43	12.2	5.02
Thyroid gland	*	*	*	*	*	1	13.2	5.43	12.2	5.02
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	1	11.8	4.89	14.0	5.76

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

insufficient data for the calculation of AI/AN PRCDA statistics

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
West Virginia, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	23	254.0	24.88	297.9	28.62	23	228.0	21.59	272.9	25.89
Oral Cavity & Pharynx	1	10.5	4.41	13.1	5.53	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	4	45.2	10.60	54.1	12.35	4	40.8	9.22	48.8	10.98
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	1	14.9	5.70	17.6	6.69
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	2	20.2	6.66	24.9	7.99	2	20.4	6.16	28.0	8.49
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	2	17.0	6.25	20.6	7.37	2	20.4	6.16	28.0	8.49
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	7	70.3	11.96	85.2	14.52
Female Genital System	N/A	N/A	N/A	N/A	N/A	2	23.1	6.81	26.5	7.94
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1	14.3	5.51	16.5	6.40
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	7	86.2	14.82	101.8	17.02	N/A	N/A	N/A	N/A	N/A
Prostate	7	86.2	14.82	101.8	17.02	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	3	35.5	9.35	40.2	10.55	1	12.3	5.17	15.1	6.22
Bladder (incl. <i>in situ</i>)	1	16.6	6.81	18.4	7.58	*	*	*	*	*
Kidney & renal pelvis	2	18.9	6.40	21.8	7.33	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	2	14.7	5.05	16.4	5.81
Thyroid gland	*	*	*	*	*	2	14.7	5.05	16.4	5.81
Lymphomas	1	14.6	6.37	16.5	7.11	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	1	10.6	4.71	11.3	5.07	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	2	20.9	6.37	24.5	7.54

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

WEST VIRGINIA

II-538 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
West Virginia, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	17	222.0	24.75	258.8	28.30	16	176.8	19.80	214.7	23.99
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	3	37.3	10.34	43.1	11.73	3	30.7	8.28	36.3	9.78
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	2	18.7	6.84	22.0	7.90	2	17.8	5.93	25.0	8.37
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	1	16.9	6.60	20.0	7.66	2	17.8	5.93	25.0	8.37
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	6	61.1	11.61	72.9	13.87
Female Genital System	N/A	N/A	N/A	N/A	N/A	1	14.8	5.62	18.2	6.99
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	6	75.5	14.55	87.6	16.51	N/A	N/A	N/A	N/A	N/A
Prostate	6	75.5	14.55	87.6	16.51	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	3	33.6	9.59	38.5	10.90	1	13.0	5.48	16.0	6.58
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	2	18.6	6.78	21.7	7.83	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	1	14.9	5.69	18.1	6.87

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
West Virginia, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	*	*	*	*	*	*	*	*	*	*
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.


N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	5,762,927	5,775,170	5,793,147	5,809,319	5,824,581
Non-Hispanic White	4,762,702	4,756,026	4,754,252	4,751,687	4,751,572
Non-Hispanic Black	396,011	399,140	403,245	406,669	409,094
Non-Hispanic Asian/Pacific Islander (NH API)	169,461	175,309	180,976	183,789	188,423
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	37,933	38,180	38,343	38,525	38,816


All Races Population 2015–2019: 28,965,144
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	379,053	388,633	398,244	410,486	418,289
Hispanic White	335,277	343,128	351,090	361,346	367,665
Hispanic Black	21,309	22,050	22,699	23,645	24,335

Hispanic/Latino Population, Census 2010: 336,056
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

WISCONSIN CANCER REGISTRY

Initial Operation: 1976
Population-based Data Available: 1978
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	111.7	109.8	110.0	110.5	111.9	110.8
Missing Race	0.6	0.8	0.6	0.7	0.4	0.6
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.1	1.0	1.1	1.1	1.3	1.1
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.3	Ovary	94.2
Oral Cavity & Pharynx	98.7	Prostate	97.3
Esophagus	97.3	Testis	99.9
Stomach	98.1	Bladder (incl. <i>in situ</i>)	98.0
Colon & Rectum	96.5	Kidney & Renal Pelvis	90.1
Liver	53.3	Brain & Other CNS	84.3
Pancreas	87.2	Brain & Other CNS (non-malig)	33.4
Lung & Bronchus	89.7	Thyroid	99.6
Melanomas of the Skin	99.8	Hodgkin Lymphoma	99.4
Female Breast (excl. <i>in situ</i>)	99.2	Non-Hodgkin Lymphoma	97.7
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	93.8
Cervix Uteri	98.6	Leukemias	91.3
Uterus Corpus & Uterus NOS	99.1		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Wisconsin, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	17,725	512.1	1.77	607.4	2.06	16,448	442.6	1.61	516.1	1.83
Oral Cavity & Pharynx	652	18.2	0.33	22.3	0.39	281	7.3	0.20	8.7	0.24
Lip	39	1.2	0.09	1.4	0.10	14	0.4	0.04	0.4	0.05
Tongue	207	5.7	0.18	7.0	0.22	84	2.2	0.11	2.7	0.13
Major salivary gland	53	1.6	0.10	1.9	0.12	40	1.1	0.08	1.2	0.09
Floor of mouth	33	0.9	0.07	1.1	0.09	19	0.4	0.05	0.6	0.06
Gum & other mouth	70	2.0	0.11	2.4	0.13	62	1.6	0.09	1.9	0.11
Nasopharynx	15	0.5	0.06	0.5	0.06	9	0.3	0.04	0.3	0.05
Oropharynx	39	1.0	0.08	1.3	0.09	11	0.3	0.04	0.3	0.05
Hypopharynx	41	1.1	0.08	1.4	0.10	13	0.3	0.04	0.4	0.05
Digestive System	3,202	94.0	0.77	111.5	0.89	2,450	63.5	0.59	74.6	0.68
Esophagus	311	8.9	0.23	10.6	0.27	90	2.2	0.11	2.7	0.13
Stomach	294	8.6	0.23	10.2	0.27	145	3.8	0.15	4.5	0.17
Small intestine	115	3.4	0.15	4.0	0.17	87	2.3	0.12	2.7	0.13
Colon (excl. rectum)	904	27.3	0.42	32.1	0.48	922	24.0	0.37	27.8	0.42
Rectum & rectosigmoid	451	13.4	0.29	15.9	0.34	301	8.2	0.22	9.7	0.25
Anus, anal canal, & anorectum	40	1.2	0.09	1.4	0.10	91	2.4	0.11	2.9	0.14
Liver	333	9.0	0.23	11.1	0.27	108	2.7	0.12	3.3	0.14
Gallbladder	27	0.8	0.07	1.0	0.08	49	1.3	0.08	1.5	0.10
Pancreas	557	16.3	0.32	19.3	0.37	474	11.7	0.25	14.0	0.29
Respiratory System	2,502	71.8	0.66	85.4	0.77	2,214	55.3	0.54	66.0	0.63
Larynx	195	5.4	0.18	6.6	0.21	44	1.1	0.08	1.4	0.09
Lung & bronchus	2,269	65.3	0.63	77.5	0.74	2,148	53.6	0.53	63.9	0.62
Bones & Joints	28	0.9	0.08	1.0	0.08	23	0.7	0.07	0.8	0.07
Soft Tissue (incl. heart)	124	4.0	0.16	4.4	0.18	100	2.9	0.14	3.2	0.15
Skin (excl. basal & sq.)	1,030	31.0	0.45	36.1	0.51	742	21.7	0.37	24.6	0.41
Melanoma of the skin	972	29.2	0.43	34.0	0.49	698	20.5	0.36	23.3	0.40
Breast (excl. <i>in situ</i>)	45	1.3	0.09	1.6	0.10	4,914	135.2	0.90	158.6	1.03
Female Genital System	N/A	N/A	N/A	N/A	N/A	2,019	54.0	0.56	64.2	0.65
Cervix uteri	N/A	N/A	N/A	N/A	N/A	191	6.5	0.22	6.8	0.22
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,198	30.7	0.41	37.5	0.49
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	42	1.1	0.08	1.3	0.09
Ovary	N/A	N/A	N/A	N/A	N/A	395	10.7	0.25	12.6	0.29
Male Genital System	4,714	126.8	0.85	155.2	1.02	N/A	N/A	N/A	N/A	N/A
Prostate	4,478	118.2	0.81	146.6	0.99	N/A	N/A	N/A	N/A	N/A
Testis	199	7.4	0.24	7.3	0.23	N/A	N/A	N/A	N/A	N/A
Penis	27	0.9	0.07	1.0	0.08	N/A	N/A	N/A	N/A	N/A
Urinary System	2,220	65.8	0.64	77.4	0.74	865	22.4	0.35	26.1	0.40
Bladder (incl. <i>in situ</i>)	1,270	38.2	0.49	44.8	0.57	380	9.5	0.22	11.1	0.26
Kidney & renal pelvis	912	26.4	0.40	31.3	0.47	461	12.3	0.27	14.3	0.30
Ureter	27	0.8	0.07	1.0	0.08	17	0.4	0.05	0.5	0.05
Eye & Orbit	38	1.1	0.08	1.3	0.09	33	0.9	0.08	1.0	0.08
Brain & Other CNS	267	8.3	0.24	9.3	0.26	198	5.8	0.19	6.3	0.20
Brain	254	7.9	0.23	8.8	0.25	186	5.4	0.18	5.9	0.20
Endocrine System	261	8.2	0.24	9.2	0.26	623	20.6	0.38	22.0	0.40
Thyroid gland	237	7.4	0.22	8.4	0.25	601	19.9	0.38	21.3	0.39
Lymphomas	951	29.1	0.43	33.3	0.49	736	19.9	0.34	22.8	0.38
Hodgkin lymphoma	104	3.5	0.16	3.7	0.16	75	2.5	0.13	2.6	0.14
Non-Hodgkin lymphoma	847	25.6	0.41	29.7	0.46	661	17.4	0.31	20.2	0.36
Multiple Myeloma	295	8.7	0.23	10.3	0.27	229	5.7	0.17	6.9	0.21
Leukemias	700	21.2	0.37	24.3	0.42	460	12.5	0.27	14.1	0.30
Acute lymphocytic	53	1.9	0.12	1.8	0.11	41	1.4	0.10	1.3	0.09
Chronic lymphocytic	305	8.8	0.23	10.5	0.27	171	4.2	0.15	5.1	0.18
Acute myeloid	177	5.4	0.19	6.2	0.21	144	3.9	0.15	4.5	0.17
Chronic myeloid	97	3.0	0.14	3.4	0.16	68	1.9	0.11	2.1	0.12
Other leukemias	68	2.1	0.12	2.4	0.13	37	1.0	0.07	1.1	0.08
Mesothelioma	60	1.9	0.11	2.2	0.13	18	0.5	0.05	0.5	0.06
Kaposi Sarcoma	6	0.2	0.04	0.2	0.04	*	*	*	*	*
Ill-Defined & Unknown	629	19.6	0.36	22.6	0.41	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	338	10.6	0.27	12.0	0.30	751	21.0	0.36	23.9	0.40
Breast (<i>in situ</i>)	4	0.1	0.03	0.2	0.03	1,193	33.7	0.46	39.6	0.52

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Wisconsin, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	16,123	509.2	1.86	602.8	2.15	14,853	443.2	1.72	516.1	1.94
Oral Cavity & Pharynx	606	18.6	0.35	22.8	0.42	254	7.2	0.21	8.6	0.25
Lip	38	1.2	0.09	1.4	0.11	14	0.4	0.05	0.4	0.05
Tongue	195	5.9	0.20	7.3	0.24	79	2.3	0.12	2.8	0.14
Major salivary gland	48	1.6	0.11	1.9	0.12	34	1.1	0.09	1.2	0.09
Floor of mouth	30	0.9	0.08	1.1	0.09	18	0.5	0.05	0.6	0.07
Gum & other mouth	64	2.0	0.12	2.4	0.14	57	1.6	0.10	1.9	0.11
Nasopharynx	11	0.4	0.05	0.4	0.06	4	0.1	0.02	0.1	0.03
Oropharynx	36	1.1	0.08	1.3	0.10	10	0.3	0.04	0.3	0.05
Hypopharynx	37	1.1	0.08	1.3	0.10	11	0.3	0.04	0.4	0.05
Digestive System	2,836	91.1	0.79	107.8	0.92	2,168	61.4	0.62	72.0	0.71
Esophagus	294	9.1	0.24	10.8	0.29	81	2.2	0.11	2.6	0.13
Stomach	251	8.0	0.23	9.4	0.27	117	3.3	0.14	3.9	0.17
Small intestine	102	3.3	0.15	3.9	0.18	77	2.3	0.12	2.6	0.14
Colon (excl. rectum)	806	26.8	0.44	31.3	0.50	826	23.5	0.38	27.1	0.43
Rectum & rectosigmoid	398	13.1	0.31	15.6	0.35	266	8.1	0.24	9.6	0.27
Anus, anal canal, & anorectum	36	1.1	0.09	1.4	0.10	86	2.4	0.12	3.0	0.15
Liver	260	7.7	0.22	9.4	0.26	85	2.4	0.12	2.8	0.14
Gallbladder	23	0.7	0.07	0.9	0.08	41	1.1	0.08	1.3	0.09
Pancreas	510	16.2	0.33	19.1	0.38	425	11.5	0.26	13.6	0.30
Respiratory System	2,268	70.3	0.68	83.5	0.79	2,024	55.0	0.56	65.5	0.66
Larynx	171	5.1	0.18	6.3	0.22	39	1.1	0.08	1.4	0.10
Lung & bronchus	2,062	64.0	0.65	75.9	0.76	1,964	53.3	0.55	63.4	0.65
Bones & Joints	25	1.0	0.09	1.0	0.09	20	0.8	0.08	0.8	0.08
Soft Tissue (incl. heart)	109	3.9	0.17	4.3	0.19	85	2.8	0.15	3.1	0.15
Skin (excl. basal & sq.)	983	32.5	0.48	37.8	0.55	693	23.2	0.42	26.1	0.46
Melanoma of the skin	928	30.6	0.47	35.6	0.53	652	21.9	0.41	24.7	0.45
Breast (excl. <i>in situ</i>)	41	1.3	0.10	1.6	0.11	4,466	136.8	0.97	160.3	1.10
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,815	53.8	0.60	64.0	0.69
Cervix uteri	N/A	N/A	N/A	N/A	N/A	151	6.1	0.23	6.4	0.24
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1,088	30.7	0.44	37.6	0.52
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	35	1.0	0.08	1.2	0.09
Ovary	N/A	N/A	N/A	N/A	N/A	360	10.8	0.27	12.7	0.31
Male Genital System	4,241	124.5	0.88	152.0	1.06	N/A	N/A	N/A	N/A	N/A
Prostate	4,033	115.3	0.83	142.7	1.01	N/A	N/A	N/A	N/A	N/A
Testis	175	8.1	0.28	8.0	0.27	N/A	N/A	N/A	N/A	N/A
Penis	24	0.8	0.08	0.9	0.09	N/A	N/A	N/A	N/A	N/A
Urinary System	2,068	66.3	0.67	78.1	0.78	777	22.0	0.37	25.6	0.42
Bladder (incl. <i>in situ</i>)	1,212	39.1	0.51	45.9	0.60	355	9.6	0.24	11.3	0.27
Kidney & renal pelvis	818	26.0	0.42	30.8	0.49	400	11.7	0.28	13.7	0.31
Ureter	27	0.9	0.08	1.0	0.09	16	0.4	0.05	0.5	0.05
Eye & Orbit	37	1.2	0.09	1.4	0.10	30	1.0	0.08	1.1	0.09
Brain & Other CNS	242	8.6	0.26	9.5	0.28	181	6.1	0.22	6.7	0.23
Brain	231	8.2	0.25	9.1	0.27	171	5.7	0.21	6.3	0.22
Endocrine System	236	8.5	0.26	9.5	0.28	544	21.3	0.43	22.7	0.44
Thyroid gland	216	7.8	0.25	8.7	0.27	526	20.6	0.43	22.0	0.44
Lymphomas	880	29.8	0.47	34.0	0.52	668	20.1	0.37	23.0	0.41
Hodgkin lymphoma	90	3.6	0.18	3.8	0.18	66	2.7	0.16	2.8	0.16
Non-Hodgkin lymphoma	790	26.1	0.43	30.3	0.49	602	17.3	0.33	20.2	0.38
Multiple Myeloma	261	8.3	0.24	9.8	0.27	193	5.2	0.17	6.3	0.20
Leukemias	646	21.6	0.39	24.7	0.44	416	12.5	0.29	14.2	0.32
Acute lymphocytic	41	1.9	0.14	1.7	0.12	31	1.4	0.12	1.3	0.11
Chronic lymphocytic	290	9.1	0.24	10.8	0.29	161	4.4	0.16	5.2	0.19
Acute myeloid	164	5.5	0.20	6.3	0.22	131	4.0	0.16	4.5	0.18
Chronic myeloid	90	3.1	0.15	3.5	0.17	59	1.8	0.11	2.0	0.12
Other leukemias	62	2.1	0.12	2.4	0.14	33	1.0	0.08	1.1	0.09
Mesothelioma	57	2.0	0.12	2.2	0.13	17	0.5	0.05	0.6	0.06
Kaposi Sarcoma	3	0.1	0.03	0.1	0.03	*	*	*	*	*
Ill-Defined & Unknown	583	19.6	0.37	22.6	0.42	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	298	10.4	0.28	11.8	0.31	642	20.1	0.38	22.8	0.41
Breast (<i>in situ</i>)	4	0.1	0.03	0.2	0.03	1,060	33.7	0.49	39.5	0.56

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Wisconsin, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	873	664.2	11.00	807.0	12.99	798	487.3	8.01	577.7	9.36
Oral Cavity & Pharynx	23	16.0	1.63	19.9	1.99	12	6.7	0.91	8.3	1.10
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	6	4.1	0.79	5.4	1.02	2	0.9	0.33	1.1	0.40
Major salivary gland	2	1.0	0.39	1.3	0.47	2	1.5	0.45	1.9	0.56
Floor of mouth	2	1.0	0.37	1.3	0.47	*	*	*	*	*
Gum & other mouth	3	1.9	0.50	2.3	0.60	3	1.5	0.45	1.9	0.53
Nasopharynx	*	*	*	*	*	1	0.7	0.28	0.9	0.34
Oropharynx	2	1.1	0.43	1.3	0.49	*	*	*	*	*
Hypopharynx	3	2.4	0.71	3.1	0.87	1	0.8	0.29	0.9	0.35
Digestive System	191	145.7	5.13	175.5	6.01	151	94.1	3.56	113.3	4.21
Esophagus	8	5.9	0.98	7.0	1.13	7	3.9	0.70	5.1	0.88
Stomach	21	17.7	1.89	20.7	2.18	12	8.1	1.09	9.4	1.25
Small intestine	8	5.4	0.89	6.4	1.04	7	4.4	0.74	5.4	0.90
Colon (excl. rectum)	55	44.3	2.90	52.2	3.34	52	32.1	2.07	38.3	2.43
Rectum & rectosigmoid	24	17.4	1.70	20.7	1.98	18	10.8	1.18	12.9	1.39
Anus, anal canal, & anorectum	2	1.5	0.47	1.7	0.52	3	1.8	0.47	2.3	0.59
Liver	39	26.1	1.99	33.7	2.49	10	5.8	0.85	7.1	1.04
Gallbladder	2	2.2	0.70	2.5	0.81	4	2.7	0.65	3.1	0.74
Pancreas	25	19.8	1.91	24.1	2.27	32	20.0	1.66	24.4	1.97
Respiratory System	154	127.7	5.04	154.8	5.92	116	73.1	3.17	89.2	3.76
Larynx	14	10.0	1.29	12.2	1.53	4	2.4	0.53	3.0	0.66
Lung & bronchus	139	116.8	4.85	141.6	5.71	111	70.5	3.12	86.0	3.70
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	9	5.9	1.00	6.6	1.12	9	5.8	0.87	6.1	0.93
Skin (excl. basal & sq.)	2	1.7	0.59	1.7	0.63	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	*	*	*	*	*	1	0.7	0.26	0.9	0.34
Breast (excl. <i>in situ</i>)	3	2.5	0.64	3.0	0.74	234	141.1	4.26	165.7	4.93
Female Genital System	N/A	N/A	N/A	N/A	N/A	93	54.9	2.64	65.6	3.11
Cervix uteri	N/A	N/A	N/A	N/A	N/A	19	11.4	1.19	12.4	1.30
Uterus corpus	N/A	N/A	N/A	N/A	N/A	51	29.9	1.94	37.3	2.36
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	4	2.2	0.53	2.7	0.64
Ovary	N/A	N/A	N/A	N/A	N/A	13	8.1	1.03	9.3	1.18
Male Genital System	279	199.4	5.77	251.9	7.02	N/A	N/A	N/A	N/A	N/A
Prostate	275	196.4	5.72	248.7	6.97	N/A	N/A	N/A	N/A	N/A
Testis	3	1.4	0.38	1.5	0.41	N/A	N/A	N/A	N/A	N/A
Penis	1	1.3	0.51	1.4	0.55	N/A	N/A	N/A	N/A	N/A
Urinary System	83	66.1	3.57	78.4	4.13	48	29.7	1.98	35.6	2.33
Bladder (incl. <i>in situ</i>)	31	28.4	2.51	33.5	2.89	14	9.1	1.14	10.9	1.33
Kidney & renal pelvis	52	37.3	2.52	44.4	2.94	33	19.8	1.59	23.8	1.87
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	10	5.4	0.85	6.1	1.00	7	3.8	0.65	3.9	0.69
Brain	9	4.8	0.78	5.5	0.94	6	3.2	0.61	3.4	0.66
Endocrine System	8	5.3	0.90	6.2	1.05	28	15.7	1.37	17.7	1.55
Thyroid gland	6	4.4	0.85	5.2	0.98	26	14.5	1.32	16.4	1.49
Lymphomas	34	24.5	2.07	27.4	2.30	31	18.2	1.54	20.8	1.75
Hodgkin lymphoma	8	5.5	0.94	5.8	1.02	4	2.0	0.45	2.2	0.49
Non-Hodgkin lymphoma	25	19.1	1.85	21.6	2.05	26	16.2	1.47	18.6	1.68
Multiple Myeloma	25	20.6	2.02	24.2	2.30	25	15.6	1.46	18.8	1.72
Leukemias	24	18.7	1.90	21.9	2.23	18	11.7	1.29	13.0	1.43
Acute lymphocytic	2	1.3	0.46	1.4	0.55	2	0.7	0.27	0.7	0.28
Chronic lymphocytic	8	6.9	1.18	8.4	1.38	5	3.1	0.67	3.8	0.81
Acute myeloid	6	5.0	1.01	6.0	1.19	5	3.6	0.74	3.8	0.78
Chronic myeloid	4	2.5	0.65	2.8	0.74	4	2.9	0.63	3.0	0.68
Other leukemias	4	2.9	0.76	3.3	0.90	2	1.4	0.44	1.6	0.49
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	2	0.8	0.31	0.8	0.28	*	*	*	*	*
Ill-Defined & Unknown	25	22.7	2.27	27.2	2.66	22	14.5	1.45	16.8	1.67
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	18	14.7	1.72	16.8	1.97	57	35.5	2.18	40.6	2.48
Breast (<i>in situ</i>)	*	*	*	*	*	78	46.7	2.44	55.5	2.85

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Wisconsin, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	119	266.2	12.19	317.9	14.38	181	298.6	10.57	345.0	12.25
Oral Cavity & Pharynx	7	12.9	2.44	14.0	2.67	6	7.7	1.50	8.9	1.76
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	3.5	1.38	3.9	1.51	*	*	*	*	*
Major salivary gland	*	*	*	*	*	2	2.3	0.88	2.5	0.96
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	3	4.3	1.32	4.3	1.37	3	3.4	0.96	3.9	1.13
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	36	84.9	6.94	103.4	8.25	35	61.9	4.98	73.9	5.87
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	4	12.7	3.00	15.4	3.56	4	8.0	1.87	9.6	2.21
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	8	15.7	2.79	19.5	3.41	10	17.3	2.63	20.3	3.04
Rectum & rectosigmoid	7	14.0	2.53	17.6	3.12	6	9.8	1.85	11.7	2.21
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	8	20.2	3.41	24.3	4.02	4	8.2	1.86	10.0	2.25
Gallbladder	*	*	*	*	*	2	3.5	1.28	3.9	1.40
Pancreas	4	12.0	2.77	13.8	3.11	5	8.8	1.92	10.8	2.32
Respiratory System	15	44.5	5.42	51.6	6.19	19	38.1	4.02	45.1	4.69
Larynx	2	4.2	1.50	5.0	1.69	*	*	*	*	*
Lung & bronchus	13	38.9	5.05	45.2	5.79	19	37.8	4.01	44.6	4.67
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	1	2.4	1.02	2.7	1.10
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	51	81.1	5.33	94.4	6.24
Female Genital System	N/A	N/A	N/A	N/A	N/A	26	39.0	3.66	43.9	4.18
Cervix uteri	N/A	N/A	N/A	N/A	N/A	4	7.5	1.73	8.4	1.93
Uterus corpus	N/A	N/A	N/A	N/A	N/A	13	18.1	2.42	20.4	2.80
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	7	10.1	1.82	11.5	2.11
Male Genital System	22	50.4	5.24	60.8	6.19	N/A	N/A	N/A	N/A	N/A
Prostate	20	47.6	5.14	57.9	6.10	N/A	N/A	N/A	N/A	N/A
Testis	2	1.8	0.54	1.7	0.51	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	9	22.1	3.54	26.3	4.18	6	10.8	2.11	12.4	2.41
Bladder (incl. <i>in situ</i>)	4	11.0	2.59	12.7	2.99	1	3.1	1.22	3.6	1.40
Kidney & renal pelvis	5	11.1	2.41	13.6	2.92	4	7.0	1.63	7.8	1.82
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	4	5.8	1.56	6.8	1.89	2	1.9	0.65	1.7	0.63
Brain	4	5.8	1.56	6.8	1.89	1	1.5	0.59	1.5	0.60
Endocrine System	4	6.8	1.71	8.0	2.09	14	17.4	2.27	18.6	2.49
Thyroid gland	4	5.5	1.40	6.4	1.68	14	16.8	2.24	17.9	2.46
Lymphomas	8	14.3	2.51	17.0	3.03	9	16.0	2.56	18.6	2.95
Hodgkin lymphoma	1	1.5	0.60	1.5	0.61	*	*	*	*	*
Non-Hodgkin lymphoma	7	12.8	2.43	15.6	2.97	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	1	2.6	1.02	3.6	1.38	2	3.3	1.15	4.0	1.35
Leukemias	5	8.5	2.18	10.2	2.66	5	7.9	1.74	8.9	2.00
Acute lymphocytic	2	1.7	0.62	1.6	0.65	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	1	4.0	1.75	4.8	2.11	2	3.4	1.15	3.8	1.34
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	4	7.8	2.06	9.5	2.54	5	9.9	2.15	11.0	2.40
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	5	10.8	2.43	12.4	2.78	14	23.6	2.95	28.0	3.50
Breast (<i>in situ</i>)	*	*	*	*	*	15	23.2	2.76	26.8	3.21

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Wisconsin, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	101	677.9	34.31	811.5	40.37	107	593.4	26.76	701.4	31.09
Oral Cavity & Pharynx	4	23.0	5.13	28.6	6.26	2	9.4	3.08	12.4	3.93
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	2	8.5	3.05	11.3	4.00	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	27	178.6	17.71	217.7	20.94	17	95.7	10.71	111.6	12.23
Esophagus	2	19.1	6.48	22.5	7.37	*	*	*	*	*
Stomach	3	19.7	5.83	23.8	6.86	1	8.4	3.25	9.1	3.46
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	7	49.1	9.48	60.2	11.33	7	37.4	6.70	44.8	7.90
Rectum & rectosigmoid	5	33.5	6.81	40.0	7.92	2	13.8	4.15	15.8	4.58
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	4	28.2	7.68	35.8	9.38	2	7.8	2.81	9.8	3.47
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	3	20.9	5.65	25.3	6.58	2	11.2	3.64	12.5	4.00
Respiratory System	16	110.3	13.87	132.9	16.42	19	100.9	10.89	125.4	13.24
Larynx	2	10.5	3.51	13.9	4.45	*	*	*	*	*
Lung & bronchus	14	98.4	13.35	117.5	15.74	18	98.5	10.80	121.9	13.08
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	*	*	*	*	*	1	7.9	3.07	9.0	3.40
Breast (excl. <i>in situ</i>)	*	*	*	*	*	29	158.7	13.72	188.3	15.93
Female Genital System	N/A	N/A	N/A	N/A	N/A	13	71.5	9.41	82.9	10.79
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	14.4	4.30	14.9	4.40
Uterus corpus	N/A	N/A	N/A	N/A	N/A	8	43.6	7.36	52.2	8.71
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	8.8	3.19	10.1	3.59
Male Genital System	24	149.6	14.55	177.5	16.74	N/A	N/A	N/A	N/A	N/A
Prostate	22	135.4	13.93	163.7	16.24	N/A	N/A	N/A	N/A	N/A
Testis	2	13.0	4.06	12.4	3.80	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	11	73.1	11.55	90.5	14.22	7	36.6	6.72	44.7	8.05
Bladder (incl. <i>in situ</i>)	4	32.9	9.30	40.7	11.56	2	10.9	3.81	12.8	4.39
Kidney & renal pelvis	7	40.2	6.85	49.8	8.28	5	24.9	5.48	30.7	6.65
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	9.3	3.47	9.9	3.69	*	*	*	*	*
Brain	2	9.3	3.47	9.9	3.69	*	*	*	*	*
Endocrine System	2	12.6	5.35	14.1	6.40	4	20.9	4.68	23.3	5.15
Thyroid gland	*	*	*	*	*	4	20.9	4.68	23.3	5.15
Lymphomas	6	37.9	8.11	44.8	9.58	3	19.6	5.17	23.1	6.10
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	2	14.7	5.79	17.9	7.06	2	14.1	4.29	16.6	5.01
Leukemias	3	22.2	6.65	24.1	7.19	3	17.2	4.49	19.1	5.08
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	1	8.6	3.41	9.7	3.93
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	3	33.4	9.87	37.7	11.22	4	28.2	6.34	30.8	6.88
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	2	12.6	3.94	14.0	4.35	5	29.2	6.01	31.1	6.32
Breast (<i>in situ</i>)	*	*	*	*	*	6	27.8	5.39	34.9	6.63

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Wisconsin, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	338	363.4	10.52	428.3	12.10	368	345.4	8.85	404.9	10.34
Oral Cavity & Pharynx	8	8.7	1.62	10.4	1.90	6	5.0	1.00	5.7	1.16
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	2	1.8	0.65	2.1	0.74
Major salivary gland	*	*	*	*	*	1	0.9	0.41	0.9	0.43
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	93	101.6	5.51	121.6	6.37	61	65.1	4.06	76.8	4.73
Esophagus	4	4.1	1.02	4.9	1.17	*	*	*	*	*
Stomach	13	13.5	1.95	16.0	2.25	9	9.4	1.55	10.6	1.74
Small intestine	3	3.0	1.00	3.6	1.12	2	2.1	0.75	2.3	0.82
Colon (excl. rectum)	22	23.9	2.72	28.2	3.13	20	20.7	2.25	24.5	2.64
Rectum & rectosigmoid	13	12.9	1.86	15.2	2.13	6	5.7	1.13	6.7	1.32
Anus, anal canal, & anorectum	*	*	*	*	*	1	1.5	0.61	1.7	0.71
Liver	19	20.1	2.36	25.2	2.85	6	6.2	1.23	7.8	1.51
Gallbladder	*	*	*	*	*	2	2.2	0.69	2.5	0.78
Pancreas	12	16.6	2.42	19.2	2.72	8	11.0	1.78	12.8	2.04
Respiratory System	34	47.6	4.19	55.1	4.68	24	27.8	2.68	33.4	3.14
Larynx	5	6.3	1.41	7.4	1.61	*	*	*	*	*
Lung & bronchus	27	40.0	3.90	46.0	4.34	24	27.6	2.68	33.1	3.13
Bones & Joints	2	1.1	0.51	1.3	0.63	*	*	*	*	*
Soft Tissue (incl. heart)	5	3.1	0.79	3.1	0.80	4	2.9	0.71	3.4	0.89
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	4	5.0	1.35	5.9	1.56	4	3.3	0.80	4.0	0.97
Breast (excl. <i>in situ</i>)	*	*	*	*	*	104	94.6	4.48	112.3	5.31
Female Genital System	N/A	N/A	N/A	N/A	N/A	57	50.4	3.23	59.8	3.84
Cervix uteri	N/A	N/A	N/A	N/A	N/A	11	7.6	1.09	7.9	1.21
Uterus corpus	N/A	N/A	N/A	N/A	N/A	30	26.9	2.34	33.1	2.86
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	1.7	0.62	1.9	0.72
Ovary	N/A	N/A	N/A	N/A	N/A	11	10.3	1.50	12.4	1.80
Male Genital System	87	91.0	5.11	109.5	5.92	N/A	N/A	N/A	N/A	N/A
Prostate	71	83.5	5.03	102.0	5.85	N/A	N/A	N/A	N/A	N/A
Testis	14	6.5	0.78	6.3	0.77	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	36	35.9	3.16	42.8	3.73	21	20.6	2.24	24.0	2.58
Bladder (incl. <i>in situ</i>)	11	14.9	2.34	17.6	2.72	5	5.4	1.21	6.5	1.44
Kidney & renal pelvis	25	20.8	2.12	25.0	2.54	16	14.7	1.84	16.8	2.09
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	9	5.8	1.08	6.3	1.21	5	3.4	0.79	3.7	0.91
Brain	8	5.6	1.08	6.2	1.20	5	3.2	0.78	3.5	0.90
Endocrine System	9	5.9	1.09	6.3	1.21	28	19.3	1.77	21.2	2.02
Thyroid gland	7	4.7	0.89	5.1	1.03	27	18.8	1.74	20.7	1.99
Lymphomas	19	18.1	2.28	21.0	2.65	21	20.3	2.22	23.1	2.51
Hodgkin lymphoma	3	2.5	0.76	2.9	0.90	3	1.5	0.43	1.5	0.46
Non-Hodgkin lymphoma	16	15.7	2.15	18.2	2.49	18	18.8	2.18	21.7	2.46
Multiple Myeloma	5	6.6	1.51	7.8	1.75	6	7.3	1.41	8.5	1.60
Leukemias	18	13.3	1.88	14.6	2.13	14	11.1	1.55	12.3	1.78
Acute lymphocytic	8	2.7	0.45	2.4	0.42	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	4	6.1	1.51	7.2	1.75	2	2.4	0.80	2.7	0.92
Acute myeloid	3	2.8	0.90	3.0	0.99	3	2.8	0.76	3.2	0.89
Chronic myeloid	2	0.9	0.34	1.1	0.42	2	1.8	0.66	2.0	0.69
Other leukemias	1	0.8	0.34	1.0	0.43	*	*	*	*	*
Mesothelioma	2	4.4	1.45	5.0	1.63	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	9	13.4	2.29	15.6	2.65	10	11.5	1.80	13.3	2.08
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	12	11.3	1.91	12.8	2.17	27	25.3	2.42	29.5	2.83
Breast (<i>in situ</i>)	*	*	*	*	*	31	27.8	2.37	33.1	2.82

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

WISCONSIN

II-548 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Wisconsin, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	308	364.7	11.01	428.9	12.65	341	351.1	9.29	411.5	10.87
Oral Cavity & Pharynx	7	9.1	1.74	10.9	2.04	6	5.3	1.08	6.2	1.26
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	2	2.0	0.70	2.3	0.80
Major salivary gland	*	*	*	*	*	1	1.0	0.45	1.0	0.47
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	85	103.0	5.81	122.6	6.69	56	65.6	4.24	77.2	4.93
Esophagus	4	4.5	1.11	5.3	1.27	*	*	*	*	*
Stomach	12	13.7	2.03	16.3	2.35	8	9.7	1.64	11.0	1.84
Small intestine	3	3.2	1.08	3.7	1.20	1	1.6	0.66	1.9	0.74
Colon (excl. rectum)	20	24.0	2.87	28.1	3.29	19	21.1	2.36	24.9	2.77
Rectum & rectosigmoid	12	13.4	1.99	15.6	2.27	6	5.8	1.19	6.8	1.39
Anus, anal canal, & anorectum	*	*	*	*	*	1	1.6	0.66	1.9	0.77
Liver	18	20.5	2.47	25.8	2.98	5	6.0	1.29	7.4	1.55
Gallbladder	*	*	*	*	*	2	2.2	0.72	2.4	0.80
Pancreas	11	16.2	2.53	18.4	2.80	8	11.1	1.87	12.9	2.14
Respiratory System	31	48.3	4.42	55.8	4.92	22	27.8	2.77	33.6	3.27
Larynx	5	6.5	1.52	7.7	1.72	*	*	*	*	*
Lung & bronchus	25	40.3	4.09	46.2	4.55	22	27.5	2.76	33.2	3.26
Bones & Joints	2	1.2	0.55	1.4	0.68	*	*	*	*	*
Soft Tissue (incl. heart)	4	3.1	0.84	3.1	0.86	4	3.2	0.78	3.8	0.97
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	3	4.7	1.35	5.5	1.54	3	3.0	0.75	3.7	0.95
Breast (excl. <i>in situ</i>)	*	*	*	*	*	96	96.7	4.74	115.0	5.61
Female Genital System	N/A	N/A	N/A	N/A	N/A	52	50.6	3.38	60.1	4.03
Cervix uteri	N/A	N/A	N/A	N/A	N/A	9	7.3	1.14	7.8	1.28
Uterus corpus	N/A	N/A	N/A	N/A	N/A	28	27.6	2.48	33.9	3.03
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	1.7	0.66	1.9	0.76
Ovary	N/A	N/A	N/A	N/A	N/A	10	9.7	1.48	11.7	1.79
Male Genital System	78	89.6	5.31	107.9	6.16	N/A	N/A	N/A	N/A	N/A
Prostate	64	82.0	5.22	100.1	6.08	N/A	N/A	N/A	N/A	N/A
Testis	13	6.6	0.84	6.5	0.83	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	33	35.6	3.25	42.5	3.84	18	20.1	2.32	23.2	2.67
Bladder (incl. <i>in situ</i>)	10	15.1	2.47	17.7	2.86	4	5.1	1.21	6.1	1.45
Kidney & renal pelvis	23	20.3	2.10	24.6	2.56	13	14.4	1.93	16.4	2.18
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	8	5.7	1.14	6.1	1.24	5	3.7	0.86	4.0	0.99
Brain	7	5.5	1.13	6.0	1.24	4	3.5	0.85	3.8	0.98
Endocrine System	7	4.6	0.83	4.9	0.92	26	20.2	1.89	22.1	2.16
Thyroid gland	6	3.8	0.72	4.1	0.81	26	19.6	1.87	21.5	2.12
Lymphomas	18	18.9	2.46	21.8	2.84	19	20.7	2.35	23.6	2.65
Hodgkin lymphoma	3	2.3	0.80	2.6	0.91	2	1.4	0.43	1.4	0.46
Non-Hodgkin lymphoma	15	16.6	2.32	19.3	2.69	17	19.4	2.31	22.2	2.61
Multiple Myeloma	5	7.0	1.63	8.2	1.88	6	8.0	1.52	9.2	1.74
Leukemias	16	13.4	1.93	14.9	2.20	13	11.1	1.59	12.2	1.82
Acute lymphocytic	7	2.8	0.50	2.5	0.46	N/A	N/A	N/A	N/A	N/A
Chronic lymphocytic	4	6.2	1.60	7.4	1.85	1	1.7	0.68	1.9	0.79
Acute myeloid	3	2.5	0.80	2.7	0.86	3	3.0	0.83	3.5	0.97
Chronic myeloid	2	1.0	0.37	1.2	0.46	2	1.9	0.69	1.9	0.72
Other leukemias	1	0.9	0.37	1.1	0.47	*	*	*	*	*
Mesothelioma	2	4.8	1.57	5.4	1.77	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	8	13.5	2.40	15.7	2.77	10	12.5	1.94	14.4	2.24
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	11	12.0	2.07	13.6	2.36	24	25.9	2.56	30.2	2.99
Breast (<i>in situ</i>)	*	*	*	*	*	28	27.2	2.45	32.3	2.90

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Wisconsin, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	5	148.3	35.44	181.9	41.30	5	101.8	24.06	132.9	30.77
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	1	36.4	17.21	44.5	19.96	1	26.5	12.10	35.8	16.28
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	1	31.7	15.77	41.0	19.30	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	1	31.1	14.80	38.3	17.84
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	2	44.6	17.69	58.5	21.43	N/A	N/A	N/A	N/A	N/A
Prostate	2	44.6	17.69	58.5	21.43	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.


N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Race-Specific Population Counts by Year¹

Race	2015	2016	2017	2018	2019
All Races	586,389	585,243	579,994	579,054	580,116
Non-Hispanic White	501,013	498,947	493,560	491,835	492,134
Non-Hispanic Black	8,396	8,339	8,305	8,272	8,327
Non-Hispanic Asian/Pacific Islander (NH API)	6,268	6,520	6,771	7,030	7,037
Non-Hispanic American Indian/Alaskan Native PRCDA (NH AI/AN)	9,002	8,983	8,901	8,895	8,815


All Races Population 2015–2019: 2,910,796
Distribution of Population by Race Only (excludes Hispanics)




Hispanic/Latino Population Counts by Year¹

Ethnicity	2015	2016	2017	2018	2019
Hispanic/Latino, All Races	57,415	58,206	58,246	58,741	59,515
Hispanic White	51,140	51,723	51,573	51,785	52,433
Hispanic Black	1,308	1,364	1,404	1,494	1,538

Hispanic/Latino Population, Census 2010: 50,231
Distribution of Hispanic/Latino Populations²



% Hispanic/Latino of Total Population
By Census Year²



¹ Source: NCI SEER Program, U.S. Population Data

² Source: U.S. Census Bureau, 2010 Census

WYOMING CANCER REGISTRY

Initial Operation: 1967
Population-based Data Available: 1962
Coverage Area: State

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	97.3	100.1	99.9	102.9	102.3	100.5
Missing Race	0.0	0.0	0.0	0.4	0.1	0.1
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.1	0.7	0.9	0.4	1.5	0.9
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	94.7	Ovary	93.5
Oral Cavity & Pharynx	98.7	Prostate	97.9
Esophagus	97.9	Testis	100.0
Stomach	97.4	Bladder (incl. <i>in situ</i>)	98.1
Colon & Rectum	96.7	Kidney & Renal Pelvis	93.2
Liver	59.0	Brain & Other CNS	88.3
Pancreas	82.3	Brain & Other CNS (non-malig)	50.0
Lung & Bronchus	87.2	Thyroid	100.0
Melanomas of the Skin	99.9	Hodgkin Lymphoma	97.2
Female Breast (excl. <i>in situ</i>)	99.2	Non-Hodgkin Lymphoma	98.9
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	92.4
Cervix Uteri	97.5	Leukemias	91.1
Uterus Corpus & Uterus NOS	98.8		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Wyoming, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,518	432.9	5.17	512.7	6.01	1,328	385.0	4.93	448.0	5.60
Oral Cavity & Pharynx	52	14.8	0.95	17.8	1.12	22	6.1	0.60	7.3	0.71
Lip	2	0.6	0.19	0.7	0.22	*	*	*	*	*
Tongue	18	5.1	0.56	6.3	0.66	8	2.0	0.34	2.5	0.41
Major salivary gland	5	1.5	0.32	1.7	0.36	2	0.7	0.21	0.8	0.24
Floor of mouth	1	0.4	0.17	0.5	0.19	*	*	*	*	*
Gum & other mouth	5	1.5	0.31	1.8	0.36	5	1.5	0.31	1.8	0.36
Nasopharynx	2	0.5	0.20	0.6	0.20	*	*	*	*	*
Oropharynx	3	0.9	0.21	1.1	0.28	*	*	*	*	*
Hypopharynx	2	0.6	0.18	0.7	0.21	*	*	*	*	*
Digestive System	276	79.4	2.22	94.3	2.59	192	54.4	1.82	64.1	2.11
Esophagus	22	6.2	0.61	7.3	0.71	6	1.7	0.32	1.9	0.36
Stomach	22	6.4	0.64	7.5	0.73	9	2.5	0.40	2.8	0.44
Small intestine	9	2.6	0.40	3.1	0.48	7	2.2	0.38	2.6	0.44
Colon (excl. rectum)	79	23.9	1.25	27.7	1.42	74	21.4	1.15	24.9	1.31
Rectum & rectosigmoid	48	14.1	0.95	16.7	1.10	31	9.0	0.76	10.6	0.88
Anus, anal canal, & anorectum	4	1.0	0.24	1.1	0.27	7	1.8	0.31	2.3	0.41
Liver	34	8.4	0.67	11.0	0.85	8	2.1	0.33	2.6	0.41
Gallbladder	2	0.6	0.18	0.7	0.23	5	1.3	0.26	1.6	0.32
Pancreas	46	13.1	0.90	15.6	1.06	32	8.7	0.71	10.4	0.83
Respiratory System	167	47.7	1.71	56.5	1.99	156	42.7	1.57	50.6	1.83
Larynx	13	3.3	0.44	4.2	0.53	6	1.6	0.30	1.9	0.36
Lung & bronchus	151	43.2	1.63	51.1	1.90	150	40.9	1.53	48.3	1.79
Bones & Joints	3	1.2	0.30	1.2	0.29	3	1.1	0.30	1.1	0.28
Soft Tissue (incl. heart)	12	3.8	0.49	4.3	0.56	9	2.8	0.43	3.0	0.46
Skin (excl. basal & sq.)	103	30.7	1.40	35.5	1.60	77	23.0	1.23	26.6	1.39
Melanoma of the skin	95	28.1	1.34	32.5	1.52	71	21.4	1.19	24.8	1.34
Breast (excl. <i>in situ</i>)	5	1.4	0.30	1.7	0.35	390	113.1	2.69	133.0	3.08
Female Genital System	N/A	N/A	N/A	N/A	N/A	158	45.2	1.69	53.8	1.95
Cervix uteri	N/A	N/A	N/A	N/A	N/A	24	8.2	0.79	8.7	0.81
Uterus corpus	N/A	N/A	N/A	N/A	N/A	82	22.1	1.14	27.5	1.38
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	3	0.8	0.21	1.0	0.26
Ovary	N/A	N/A	N/A	N/A	N/A	34	10.0	0.80	11.8	0.93
Male Genital System	462	122.2	2.64	148.3	3.14	N/A	N/A	N/A	N/A	N/A
Prostate	437	113.5	2.52	139.5	3.04	N/A	N/A	N/A	N/A	N/A
Testis	21	7.5	0.75	7.5	0.74	N/A	N/A	N/A	N/A	N/A
Penis	3	0.9	0.25	1.1	0.29	N/A	N/A	N/A	N/A	N/A
Urinary System	185	55.3	1.89	64.8	2.18	72	20.0	1.09	23.6	1.26
Bladder (incl. <i>in situ</i>)	115	34.4	1.49	40.5	1.73	32	8.7	0.71	10.4	0.84
Kidney & renal pelvis	68	20.0	1.14	23.3	1.30	39	10.9	0.82	12.8	0.93
Ureter	3	0.8	0.24	0.9	0.26	*	*	*	*	*
Eye & Orbit	3	0.8	0.22	1.0	0.26	2	0.6	0.20	0.7	0.23
Brain & Other CNS	20	6.3	0.65	7.0	0.71	21	6.5	0.66	7.1	0.71
Brain	19	6.0	0.63	6.7	0.70	19	5.9	0.63	6.6	0.68
Endocrine System	27	8.3	0.74	9.4	0.82	70	25.2	1.39	26.2	1.42
Thyroid gland	25	7.8	0.72	8.8	0.79	68	24.6	1.38	25.5	1.40
Lymphomas	73	22.4	1.22	25.9	1.39	55	16.2	1.01	18.7	1.14
Hodgkin lymphoma	8	2.6	0.42	2.8	0.45	6	2.3	0.42	2.3	0.41
Non-Hodgkin lymphoma	65	19.9	1.14	23.1	1.31	49	13.9	0.92	16.4	1.07
Multiple Myeloma	23	6.5	0.63	7.9	0.75	16	4.5	0.51	5.2	0.57
Leukemias	52	15.7	1.01	18.0	1.14	36	10.0	0.78	11.6	0.89
Acute lymphocytic	4	1.6	0.34	1.4	0.31	3	1.2	0.31	1.1	0.28
Chronic lymphocytic	18	5.2	0.56	6.2	0.66	12	3.0	0.40	3.7	0.49
Acute myeloid	16	5.1	0.59	5.9	0.67	13	3.6	0.46	4.3	0.54
Chronic myeloid	8	2.4	0.40	2.8	0.45	4	1.2	0.28	1.4	0.32
Other leukemias	5	1.5	0.31	1.7	0.35	4	1.0	0.24	1.2	0.28
Mesothelioma	5	1.6	0.34	1.8	0.38	2	0.6	0.18	0.7	0.21
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	28	8.9	0.77	9.9	0.85	48	14.6	0.99	16.6	1.10
Breast (<i>in situ</i>)	1	0.4	0.15	0.4	0.17	58	18.0	1.11	21.0	1.26

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Wyoming, 2015–2019, Non-Hispanic White (NH White)**

SITES	MALES (NH WHITE)					FEMALES (NH WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,411	438.7	5.45	520.3	6.33	1,221	389.1	5.24	453.0	5.94
Oral Cavity & Pharynx	48	15.2	1.02	18.3	1.20	20	6.1	0.64	7.4	0.75
Lip	2	0.6	0.21	0.7	0.24	*	*	*	*	*
Tongue	17	5.3	0.61	6.5	0.71	7	2.1	0.36	2.6	0.43
Major salivary gland	4	1.5	0.33	1.7	0.38	2	0.6	0.20	0.7	0.24
Floor of mouth	1	0.5	0.19	0.6	0.21	*	*	*	*	*
Gum & other mouth	5	1.7	0.33	2.0	0.39	5	1.6	0.33	1.9	0.39
Nasopharynx	1	0.6	0.23	0.6	0.23	*	*	*	*	*
Oropharynx	3	0.8	0.22	1.1	0.29	*	*	*	*	*
Hypopharynx	2	0.5	0.18	0.6	0.21	*	*	*	*	*
Digestive System	248	77.7	2.30	92.4	2.68	172	53.2	1.89	62.5	2.18
Esophagus	20	6.2	0.64	7.3	0.74	5	1.6	0.33	1.9	0.37
Stomach	20	6.3	0.66	7.4	0.76	7	2.2	0.40	2.4	0.43
Small intestine	9	2.8	0.44	3.4	0.53	7	2.5	0.42	2.9	0.48
Colon (excl. rectum)	70	23.1	1.28	26.8	1.46	67	21.2	1.20	24.5	1.37
Rectum & rectosigmoid	43	13.7	0.98	16.1	1.13	28	9.0	0.80	10.6	0.92
Anus, anal canal, & anorectum	4	1.1	0.26	1.2	0.30	6	1.7	0.32	2.3	0.42
Liver	30	7.9	0.67	10.3	0.86	7	1.8	0.32	2.3	0.39
Gallbladder	2	0.5	0.17	0.6	0.22	4	1.1	0.26	1.4	0.31
Pancreas	42	13.1	0.95	15.7	1.11	30	8.8	0.74	10.4	0.87
Respiratory System	155	47.8	1.78	56.7	2.08	146	43.2	1.64	51.3	1.93
Larynx	12	3.4	0.47	4.2	0.57	5	1.6	0.32	2.0	0.39
Lung & bronchus	140	43.3	1.70	51.3	1.98	140	41.4	1.61	49.1	1.88
Bones & Joints	3	1.2	0.32	1.2	0.31	3	1.2	0.32	1.1	0.31
Soft Tissue (incl. heart)	11	3.8	0.54	4.3	0.60	8	2.9	0.48	3.2	0.50
Skin (excl. basal & sq.)	100	32.8	1.53	37.9	1.73	74	25.0	1.37	28.8	1.54
Melanoma of the skin	93	30.2	1.47	34.8	1.65	69	23.4	1.33	27.0	1.49
Breast (excl. <i>in situ</i>)	5	1.4	0.31	1.7	0.37	362	115.6	2.87	135.8	3.28
Female Genital System	N/A	N/A	N/A	N/A	N/A	143	44.8	1.77	53.4	2.04
Cervix uteri	N/A	N/A	N/A	N/A	N/A	21	8.1	0.84	8.6	0.86
Uterus corpus	N/A	N/A	N/A	N/A	N/A	76	22.2	1.20	27.7	1.45
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	0.7	0.20	0.8	0.24
Ovary	N/A	N/A	N/A	N/A	N/A	30	9.8	0.84	11.4	0.96
Male Genital System	434	124.8	2.78	151.9	3.32	N/A	N/A	N/A	N/A	N/A
Prostate	412	116.0	2.64	142.8	3.20	N/A	N/A	N/A	N/A	N/A
Testis	18	7.7	0.82	7.7	0.81	N/A	N/A	N/A	N/A	N/A
Penis	3	0.9	0.26	1.1	0.31	N/A	N/A	N/A	N/A	N/A
Urinary System	174	56.4	1.99	66.1	2.29	65	19.8	1.14	23.3	1.32
Bladder (incl. <i>in situ</i>)	111	35.8	1.57	42.1	1.83	29	8.7	0.75	10.4	0.88
Kidney & renal pelvis	61	19.7	1.19	23.0	1.35	35	10.7	0.85	12.6	0.97
Ureter	3	0.9	0.26	1.0	0.29	*	*	*	*	*
Eye & Orbit	3	0.9	0.25	1.1	0.29	2	0.6	0.21	0.7	0.24
Brain & Other CNS	18	6.4	0.70	7.1	0.76	19	6.4	0.70	7.0	0.75
Brain	17	6.0	0.68	6.8	0.75	17	5.8	0.66	6.5	0.72
Endocrine System	24	8.3	0.79	9.4	0.87	64	26.3	1.53	27.5	1.56
Thyroid gland	23	7.9	0.77	8.9	0.85	62	25.7	1.52	26.7	1.54
Lymphomas	68	23.0	1.30	26.6	1.48	51	16.4	1.07	18.8	1.20
Hodgkin lymphoma	7	2.7	0.47	2.8	0.49	5	2.2	0.44	2.1	0.42
Non-Hodgkin lymphoma	61	20.3	1.22	23.7	1.39	46	14.2	0.98	16.7	1.13
Multiple Myeloma	21	6.6	0.66	8.0	0.79	14	4.2	0.51	4.9	0.58
Leukemias	48	15.8	1.07	18.1	1.20	32	9.9	0.82	11.5	0.93
Acute lymphocytic	3	1.5	0.36	1.4	0.34	2	1.2	0.34	1.0	0.30
Chronic lymphocytic	17	5.2	0.58	6.3	0.69	12	3.3	0.44	4.0	0.53
Acute myeloid	15	5.0	0.61	5.8	0.69	11	3.4	0.48	4.0	0.55
Chronic myeloid	8	2.5	0.43	2.9	0.49	3	1.0	0.28	1.2	0.31
Other leukemias	5	1.6	0.34	1.8	0.38	4	1.1	0.26	1.3	0.31
Mesothelioma	5	1.7	0.37	2.0	0.41	2	0.7	0.20	0.8	0.23
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	26	9.0	0.83	10.1	0.91	43	14.5	1.05	16.5	1.16
Breast (<i>in situ</i>)	1	0.4	0.17	0.5	0.19	55	18.9	1.21	21.9	1.36

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Wyoming, 2015–2019, Non-Hispanic Black (NH Black)**

SITES	MALES (NH BLACK)					FEMALES (NH BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	10	318.7	54.21	366.3	60.34	5	171.6	37.72	191.9	42.05
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	3	91.7	30.82	100.3	32.04	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	3	104.3	30.75	124.2	35.96	N/A	N/A	N/A	N/A	N/A
Prostate	3	104.3	30.75	124.2	35.96	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Wyoming, 2015–2019, Non-Hispanic Asian/Pacific Islander (NH API)**

SITES	MALES (NH API)					FEMALES (NH API)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	5	270.1	56.57	308.8	63.76	7	238.1	41.88	281.4	48.56
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	2	152.1	45.37	169.3	49.63	2	59.9	22.38	71.5	26.32
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	2	58.6	19.46	75.5	24.76
Female Genital System	N/A	N/A	N/A	N/A	N/A	1	34.9	14.35	39.3	16.14
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Wyoming, 2015–2019, Non-Hispanic American Indian/Alaskan Native (NH AI/AN) for PRCDA Counties**

SITES	MALES (NH AI/AN)					FEMALES (NH AI/AN)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	16	702.5	102.22	819.5	118.76	17	464.3	51.62	538.3	58.91
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	4	189.1	55.45	226.1	65.47	3	84.3	20.93	105.8	25.88
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	2	37.5	13.48	47.7	16.91
Rectum & rectosigmoid	2	61.7	25.11	76.3	30.97	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	2	84.4	36.37	97.9	41.44	2	62.8	20.89	70.3	22.72
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	1	72.7	35.41	83.7	40.21	2	56.8	20.00	63.9	21.81
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	5	137.9	27.22	164.2	31.96
Female Genital System	N/A	N/A	N/A	N/A	N/A	3	76.5	20.94	89.2	24.05
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	1	36.5	13.92	44.8	16.93
Male Genital System	3	106.4	30.65	126.1	36.49	N/A	N/A	N/A	N/A	N/A
Prostate	3	101.4	30.25	121.3	36.18	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	2	153.2	57.73	183.2	67.33	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	2	111.5	48.51	134.3	56.87	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; PRCDA, Indian Health Services Purchased/Referred Care Delivery Area; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Wyoming, 2015–2019, Hispanic/Latino, All Races**

SITES	MALES (HISPANIC/LATINO)					FEMALES (HISPANIC/LATINA)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	64	336.1	20.10	394.2	23.29	66	338.9	19.43	388.6	22.27
Oral Cavity & Pharynx	2	11.4	3.84	12.6	4.13	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	17	89.2	10.38	108.0	12.44	13	69.3	9.00	82.5	10.63
Esophagus	1	5.4	2.22	6.8	2.78	*	*	*	*	*
Stomach	1	10.2	4.08	11.7	4.76	1	6.7	2.77	7.7	3.20
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	5	29.7	6.09	34.5	7.12	4	24.6	5.46	29.2	6.33
Rectum & rectosigmoid	3	11.7	3.28	14.0	3.95	2	9.1	3.15	10.9	3.80
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	3	13.7	3.90	18.1	5.01	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	3	13.9	4.15	17.3	4.99	2	8.8	3.16	10.8	3.84
Respiratory System	8	45.9	7.90	53.1	9.08	6	38.2	7.22	40.9	7.70
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	7	42.6	7.75	48.9	8.84	6	37.2	7.15	40.1	7.65
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	1	5.8	2.21	7.4	2.83	2	7.5	2.68	8.6	3.12
Breast (excl. <i>in situ</i>)	*	*	*	*	*	16	83.6	9.47	96.4	10.94
Female Genital System	N/A	N/A	N/A	N/A	N/A	9	43.3	6.57	51.9	7.85
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	10.0	3.06	10.4	3.23
Uterus corpus	N/A	N/A	N/A	N/A	N/A	4	20.0	4.48	24.2	5.39
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	11.7	3.50	15.0	4.42
Male Genital System	18	90.8	10.25	106.4	11.77	N/A	N/A	N/A	N/A	N/A
Prostate	15	82.3	9.94	98.2	11.50	N/A	N/A	N/A	N/A	N/A
Testis	2	7.8	2.40	7.1	2.20	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	7	34.1	6.26	39.0	7.08	5	27.2	5.89	30.9	6.59
Bladder (incl. <i>in situ</i>)	2	11.0	3.63	12.9	4.19	1	9.3	3.60	10.5	3.99
Kidney & renal pelvis	5	23.2	5.10	26.1	5.71	3	16.2	4.36	18.8	4.99
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	5.2	1.90	5.9	2.28	2	7.5	2.69	7.8	2.85
Brain	2	5.2	1.90	5.9	2.28	2	7.5	2.69	7.8	2.85
Endocrine System	1	5.2	2.01	5.4	2.15	4	15.7	3.66	15.7	3.75
Thyroid gland	1	5.2	2.01	5.4	2.15	4	15.7	3.66	15.7	3.75
Lymphomas	3	17.3	4.71	20.1	5.42	3	14.1	3.90	17.1	4.77
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	2	11.4	4.18	12.2	4.60	2	9.6	3.08	10.9	3.61
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	10.9	3.52	13.2	4.16	2	10.7	3.18	12.5	3.79
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	2	9.4	3.23	10.2	3.56	3	15.6	4.00	18.5	4.67
Breast (<i>in situ</i>)	*	*	*	*	*	2	12.1	3.55	14.7	4.32

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

WYOMING

II-558 Incidence – Hispanic/Latino, All Races

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Wyoming, 2015–2019, Hispanic White**

SITES	MALES (HISPANIC WHITE)					FEMALES (HISPANIC WHITE)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	60	336.0	20.71	394.1	24.01	62	341.6	20.11	393.2	23.15
Oral Cavity & Pharynx	2	11.4	4.02	12.3	4.26	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	16	90.2	10.75	108.9	12.82	12	70.6	9.36	83.8	11.03
Esophagus	1	5.8	2.38	7.3	3.00	*	*	*	*	*
Stomach	1	10.0	4.22	11.8	4.97	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	5	28.0	6.05	31.9	6.90	4	25.4	5.73	29.8	6.62
Rectum & rectosigmoid	3	12.6	3.54	15.2	4.27	2	9.8	3.37	11.7	4.06
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	3	13.9	4.08	18.2	5.22	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	3	14.9	4.42	18.6	5.34	2	9.4	3.36	11.5	4.10
Respiratory System	7	42.3	7.80	49.5	9.07	5	34.4	7.01	37.2	7.53
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	6	38.6	7.61	44.7	8.78	5	33.4	6.92	36.3	7.48
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	1	6.4	2.41	8.1	3.09	1	6.9	2.65	8.0	3.12
Breast (excl. <i>in situ</i>)	*	*	*	*	*	15	84.7	9.89	98.1	11.47
Female Genital System	N/A	N/A	N/A	N/A	N/A	9	45.8	6.99	54.9	8.38
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	9.8	3.15	10.1	3.30
Uterus corpus	N/A	N/A	N/A	N/A	N/A	4	21.5	4.81	26.1	5.81
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	12.6	3.76	16.2	4.76
Male Genital System	16	88.7	10.40	104.5	12.02	N/A	N/A	N/A	N/A	N/A
Prostate	14	79.3	10.02	95.4	11.70	N/A	N/A	N/A	N/A	N/A
Testis	2	8.6	2.65	7.8	2.43	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	6	35.1	6.60	40.4	7.49	4	26.3	5.94	30.2	6.71
Bladder (incl. <i>in situ</i>)	2	11.7	3.87	13.9	4.48	1	9.9	3.80	11.1	4.22
Kidney & renal pelvis	4	23.4	5.34	26.5	6.00	3	14.7	4.24	17.4	4.93
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	2	5.8	2.09	6.6	2.50	1	6.8	2.73	7.4	2.96
Brain	2	5.8	2.09	6.6	2.50	1	6.8	2.73	7.4	2.96
Endocrine System	1	5.7	2.19	5.9	2.33	4	17.3	4.02	17.2	4.11
Thyroid gland	1	5.7	2.19	5.9	2.33	4	17.3	4.02	17.2	4.11
Lymphomas	3	17.8	4.97	20.3	5.65	3	15.2	4.18	18.4	5.11
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	2	12.2	4.42	13.0	4.85	2	10.6	3.35	11.9	3.90
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	10.9	3.68	13.0	4.29	2	9.7	3.16	11.5	3.80
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	2	8.8	3.33	9.7	3.70	3	16.9	4.31	19.9	5.04
Breast (<i>in situ</i>)	*	*	*	*	*	2	10.8	3.46	13.3	4.21

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Wyoming, 2015–2019, Hispanic Black**

SITES	MALES (HISPANIC BLACK)					FEMALES (HISPANIC BLACK)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	*	*	*	*	*	*	*	*	*	*
Oral Cavity & Pharynx	*	*	*	*	*	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	*	*	*	*	*	*	*	*	*	*
Esophagus	*	*	*	*	*	*	*	*	*	*
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	*	*	*	*	*	*	*	*	*	*
Rectum & rectosigmoid	*	*	*	*	*	*	*	*	*	*
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	*	*	*	*	*
Respiratory System	*	*	*	*	*	*	*	*	*	*
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	*	*	*	*	*	*	*	*	*	*
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Female Genital System	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Cervix uteri	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus corpus	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Prostate	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	*	*	*	*	*	*	*	*	*	*
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	*	*	*	*	*
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	*	*	*	*	*
Thyroid gland	*	*	*	*	*	*	*	*	*	*
Lymphomas	*	*	*	*	*	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	*	*	*	*	*	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population.

In areas with small Latino populations, methods to indirectly identify Latinos (like NHIAv2) can overestimate the ethnicity-specific counts of cancer cases. Also, even small errors in Latino population estimates can affect the magnitude of the cancer rates.

N/A Information about data not collected.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

WYOMING

II-560 Incidence – Hispanic Black

PUERTO RICO CANCER REGISTRY

Initial Operation: 1950
Population-based Data Available: 1950
Coverage Area: U.S. Territory

Total Population Counts by Year

2015	2016	2017	2018	2019
3,473,232	3,406,672	1,662,642	3,193,344	3,193,553

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	95.1	93.8	101.3	99.9	97.4	97.5
Missing Race	na	na	na	na	na	na
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.8	0.5	0.4	0.5	0.4	0.5
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	2.8	2.4	2.1	2.7	2.5	2.5
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	91.9	Ovary	88.1
Oral Cavity & Pharynx	96.6	Prostate	96.0
Esophagus	90.4	Testis	98.7
Stomach	91.7	Bladder (incl. <i>in situ</i>)	96.1
Colon & Rectum	94.0	Kidney & Renal Pelvis	90.6
Liver	52.4	Brain & Other CNS	79.8
Pancreas	75.3	Brain & Other CNS (non-malig)	64.2
Lung & Bronchus	83.2	Thyroid	99.3
Melanomas of the Skin	95.9	Hodgkin Lymphoma	95.5
Female Breast (excl. <i>in situ</i>)	98.1	Non-Hodgkin Lymphoma	94.2
Female Breast (<i>in situ</i>)	99.8	Multiple Myeloma	83.2
Cervix Uteri	96.3	Leukemias	88.4
Uterus Corpus & Uterus NOS	97.5		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Puerto Rico, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	7,750	411.8	2.14	490.9	2.53	7,057	337.5	1.89	389.3	2.13
Oral Cavity & Pharynx	278	15.0	0.41	18.1	0.49	113	5.1	0.22	5.9	0.26
Lip	19	1.0	0.11	1.2	0.13	9	0.4	0.06	0.4	0.07
Tongue	63	3.4	0.19	4.1	0.24	30	1.4	0.12	1.6	0.13
Major salivary gland	30	1.7	0.14	2.0	0.16	19	0.9	0.10	1.0	0.11
Floor of mouth	12	0.6	0.08	0.7	0.10	3	0.1	0.04	0.2	0.04
Gum & other mouth	42	2.2	0.16	2.7	0.19	27	1.2	0.11	1.4	0.12
Nasopharynx	11	0.6	0.09	0.8	0.10	6	0.3	0.05	0.3	0.06
Oropharynx	22	1.2	0.11	1.5	0.14	4	0.2	0.05	0.2	0.05
Hypopharynx	22	1.1	0.11	1.4	0.13	3	0.1	0.03	0.2	0.04
Digestive System	1,775	94.6	1.03	113.3	1.22	1,359	59.0	0.74	69.5	0.87
Esophagus	102	5.2	0.24	6.3	0.28	22	0.9	0.08	1.0	0.10
Stomach	168	8.9	0.31	10.6	0.37	136	5.8	0.23	6.7	0.26
Small intestine	40	2.2	0.16	2.6	0.19	31	1.4	0.11	1.6	0.13
Colon (excl. rectum)	622	33.6	0.62	39.7	0.72	553	24.3	0.48	28.6	0.56
Rectum & rectosigmoid	282	15.2	0.42	18.5	0.50	211	9.7	0.31	11.6	0.37
Anus, anal canal, & anorectum	21	1.2	0.12	1.4	0.14	47	2.0	0.13	2.4	0.16
Liver	243	12.5	0.36	15.4	0.45	88	3.6	0.18	4.3	0.21
Gallbladder	13	0.7	0.08	0.8	0.10	24	1.0	0.09	1.2	0.11
Pancreas	187	9.9	0.33	11.8	0.39	174	7.3	0.25	8.5	0.30
Respiratory System	560	29.1	0.56	34.7	0.66	299	12.4	0.33	14.7	0.39
Larynx	123	6.4	0.26	7.8	0.32	12	0.5	0.07	0.6	0.08
Lung & bronchus	418	21.7	0.48	25.6	0.57	276	11.4	0.31	13.5	0.37
Bones & Joints	13	0.8	0.10	0.9	0.11	11	0.7	0.09	0.7	0.09
Soft Tissue (incl. heart)	52	3.2	0.21	3.5	0.22	43	2.2	0.16	2.5	0.17
Skin (excl. basal & sq.)	113	6.4	0.27	7.4	0.32	82	4.0	0.21	4.6	0.23
Melanoma of the skin	81	4.6	0.24	5.4	0.27	59	2.9	0.18	3.3	0.20
Breast (excl. <i>in situ</i>)	17	0.9	0.10	1.1	0.12	2,092	98.5	1.01	116.0	1.17
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,102	55.3	0.79	63.9	0.88
Cervix uteri	N/A	N/A	N/A	N/A	N/A	207	12.6	0.41	13.2	0.42
Uterus corpus	N/A	N/A	N/A	N/A	N/A	624	29.9	0.56	35.8	0.66
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	24	1.1	0.11	1.3	0.13
Ovary	N/A	N/A	N/A	N/A	N/A	162	8.0	0.30	9.2	0.33
Male Genital System	3,097	157.5	1.29	192.1	1.57	N/A	N/A	N/A	N/A	N/A
Prostate	2,969	148.7	1.24	183.0	1.52	N/A	N/A	N/A	N/A	N/A
Testis	79	6.1	0.31	5.9	0.30	N/A	N/A	N/A	N/A	N/A
Penis	44	2.4	0.17	2.9	0.20	N/A	N/A	N/A	N/A	N/A
Urinary System	579	30.9	0.59	36.6	0.69	252	11.2	0.33	13.0	0.38
Bladder (incl. <i>in situ</i>)	325	17.0	0.43	20.0	0.50	112	4.5	0.20	5.3	0.23
Kidney & renal pelvis	239	13.2	0.39	15.7	0.46	131	6.3	0.26	7.3	0.29
Ureter	7	0.4	0.06	0.4	0.07	5	0.2	0.04	0.2	0.05
Eye & Orbit	15	0.8	0.10	0.9	0.11	10	0.5	0.08	0.6	0.08
Brain & Other CNS	78	4.9	0.26	5.3	0.27	66	3.4	0.20	3.7	0.21
Brain	73	4.6	0.25	4.9	0.26	61	3.2	0.19	3.4	0.20
Endocrine System	196	12.4	0.41	13.9	0.45	750	44.5	0.76	48.2	0.80
Thyroid gland	186	11.7	0.40	13.2	0.44	740	43.9	0.75	47.6	0.80
Lymphomas	349	20.4	0.50	23.1	0.56	311	14.9	0.40	17.0	0.44
Hodgkin lymphoma	46	3.1	0.21	3.2	0.22	38	2.4	0.18	2.4	0.18
Non-Hodgkin lymphoma	303	17.3	0.46	19.9	0.52	273	12.5	0.35	14.6	0.41
Multiple Myeloma	138	7.4	0.29	8.7	0.34	134	5.8	0.23	6.9	0.27
Leukemias	216	12.5	0.39	13.9	0.43	174	8.7	0.32	9.4	0.33
Acute lymphocytic	19	1.4	0.15	1.3	0.14	22	1.6	0.16	1.5	0.14
Chronic lymphocytic	66	3.5	0.20	4.1	0.23	44	1.9	0.13	2.1	0.15
Acute myeloid	55	3.2	0.19	3.6	0.22	55	2.8	0.18	3.1	0.19
Chronic myeloid	43	2.6	0.18	2.9	0.20	29	1.4	0.12	1.6	0.13
Other leukemias	32	1.8	0.15	2.0	0.16	24	1.0	0.10	1.2	0.11
Mesothelioma	6	0.3	0.06	0.4	0.07	2	0.1	0.03	0.1	0.03
Kaposi Sarcoma	13	0.9	0.11	0.9	0.11	4	0.2	0.04	0.2	0.04
Ill-Defined & Unknown	254	13.7	0.39	15.9	0.45	254	11.0	0.32	12.6	0.36
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malig)	58	3.5	0.21	3.9	0.23	112	5.6	0.25	6.4	0.28
Breast (<i>in situ</i>)	1	0.1	0.03	0.1	0.03	403	19.3	0.45	22.9	0.52

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Initial Operation: 1942
 Population-based Data Available: 1974
 Coverage Area: Province

Total Population Counts by Year

2015	2016	2017	2018	2019
4,144,491	4,196,061	4,241,100	4,298,275	4,362,576

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	109.5	106.2	101.8	103.6	105.6	105.3
Missing Race	na	na	na	na	na	na
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.1	0.1	0.1	0.1	0.1	0.1
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.8	Ovary	92.9
Oral Cavity & Pharynx	98.7	Prostate	93.5
Esophagus	98.8	Testis	99.7
Stomach	97.6	Bladder (incl. <i>in situ</i>)	97.2
Colon & Rectum	96.1	Kidney & Renal Pelvis	86.9
Liver	51.4	Brain & Other CNS	81.8
Pancreas	79.1	Brain & Other CNS (non-malig)	55.5
Lung & Bronchus	83.9	Thyroid	99.7
Melanomas of the Skin	100.0	Hodgkin Lymphoma	100.0
Female Breast (excl. <i>in situ</i>)	99.3	Non-Hodgkin Lymphoma	98.1
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	93.6
Cervix Uteri	99.4	Leukemias	99.2
Uterus Corpus & Uterus NOS	99.0		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Alberta, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	10,156	479.8	2.20	567.4	2.56	9,667	421.5	1.95	492.3	2.25
Oral Cavity & Pharynx	324	14.2	0.36	17.3	0.43	142	6.1	0.23	7.2	0.27
Lip	16	0.8	0.10	0.9	0.11	4	0.2	0.04	0.2	0.05
Tongue	104	4.4	0.20	5.5	0.24	43	1.9	0.13	2.2	0.15
Major salivary gland	21	1.0	0.10	1.1	0.11	21	0.9	0.09	1.0	0.10
Floor of mouth	16	0.7	0.08	0.9	0.09	8	0.3	0.05	0.4	0.06
Gum & other mouth	32	1.4	0.12	1.7	0.14	30	1.3	0.11	1.5	0.13
Nasopharynx	22	1.0	0.10	1.1	0.11	8	0.4	0.06	0.4	0.06
Oropharynx	19	0.8	0.08	1.0	0.11	5	0.2	0.04	0.2	0.05
Hypopharynx	16	0.8	0.09	0.9	0.10	5	0.2	0.05	0.3	0.05
Digestive System	2,226	105.3	1.03	125.4	1.21	1,586	68.9	0.79	81.1	0.92
Esophagus	167	7.7	0.28	9.3	0.33	46	2.0	0.13	2.4	0.16
Stomach	192	9.2	0.31	11.0	0.36	97	4.2	0.19	4.9	0.22
Small intestine	58	2.7	0.17	3.2	0.19	48	2.1	0.14	2.5	0.16
Colon (excl. rectum)	745	36.1	0.61	42.5	0.71	641	28.0	0.50	32.7	0.58
Rectum & rectosigmoid	427	19.6	0.44	23.5	0.51	245	10.6	0.31	12.5	0.36
Anus, anal canal, & anorectum	20	0.9	0.10	1.1	0.11	49	2.0	0.13	2.5	0.16
Liver	214	9.3	0.29	11.5	0.35	63	2.7	0.16	3.2	0.18
Gallbladder	21	1.1	0.11	1.2	0.12	34	1.5	0.11	1.8	0.14
Pancreas	273	13.3	0.37	15.7	0.43	243	10.6	0.31	12.5	0.36
Respiratory System	1,221	60.6	0.80	71.2	0.93	1,229	53.9	0.70	63.5	0.81
Larynx	64	3.0	0.17	3.6	0.20	9	0.4	0.06	0.5	0.07
Lung & bronchus	1,132	56.4	0.78	66.2	0.89	1,207	52.9	0.69	62.3	0.81
Bones & Joints	21	1.0	0.10	1.1	0.10	15	0.7	0.09	0.7	0.08
Soft Tissue (incl. heart)	76	3.7	0.20	4.1	0.22	59	2.6	0.16	2.9	0.17
Skin (excl. basal & sq.)	494	23.6	0.49	27.6	0.57	411	18.0	0.40	20.7	0.46
Melanoma of the skin	447	21.2	0.46	24.9	0.54	383	16.7	0.39	19.3	0.44
Breast (excl. <i>in situ</i>)	21	1.0	0.10	1.2	0.12	2,923	127.1	1.07	149.6	1.24
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,211	51.8	0.68	61.4	0.79
Cervix uteri	N/A	N/A	N/A	N/A	N/A	175	7.9	0.27	8.4	0.29
Uterus corpus	N/A	N/A	N/A	N/A	N/A	662	27.7	0.49	33.9	0.59
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	6	0.3	0.05	0.3	0.06
Ovary	N/A	N/A	N/A	N/A	N/A	212	9.2	0.29	10.8	0.33
Male Genital System	2,682	120.4	1.08	145.8	1.28	N/A	N/A	N/A	N/A	N/A
Prostate	2,503	112.3	1.04	137.5	1.24	N/A	N/A	N/A	N/A	N/A
Testis	147	6.5	0.24	6.4	0.24	N/A	N/A	N/A	N/A	N/A
Penis	27	1.4	0.12	1.6	0.14	N/A	N/A	N/A	N/A	N/A
Urinary System	1,229	59.9	0.79	70.4	0.91	457	19.7	0.42	23.4	0.49
Bladder (incl. <i>in situ</i>)	745	37.7	0.64	43.9	0.73	212	9.1	0.29	10.9	0.33
Kidney & renal pelvis	449	20.4	0.44	24.3	0.52	226	9.8	0.30	11.6	0.35
Ureter	18	0.9	0.10	1.1	0.12	10	0.4	0.06	0.5	0.07
Eye & Orbit	28	1.3	0.11	1.5	0.13	23	1.0	0.09	1.2	0.11
Brain & Other CNS	168	7.7	0.27	8.7	0.31	113	5.1	0.22	5.6	0.24
Brain	161	7.4	0.27	8.4	0.30	109	4.9	0.21	5.4	0.23
Endocrine System	172	7.8	0.27	8.7	0.30	426	19.4	0.43	20.9	0.46
Thyroid gland	151	6.8	0.25	7.6	0.28	409	18.7	0.42	20.1	0.45
Lymphomas	552	26.3	0.51	30.1	0.58	418	18.5	0.41	21.2	0.47
Hodgkin lymphoma	67	3.1	0.17	3.2	0.18	49	2.3	0.15	2.4	0.15
Non-Hodgkin lymphoma	485	23.2	0.49	26.9	0.56	369	16.2	0.38	18.9	0.44
Multiple Myeloma	156	7.7	0.28	9.1	0.33	96	4.1	0.19	4.9	0.23
Leukemias	387	18.8	0.44	21.6	0.50	251	11.3	0.32	12.6	0.36
Acute lymphocytic	28	1.3	0.12	1.2	0.11	24	1.2	0.11	1.1	0.10
Chronic lymphocytic	160	7.5	0.28	9.1	0.33	89	3.9	0.19	4.6	0.22
Acute myeloid	105	5.3	0.24	6.0	0.27	79	3.6	0.18	4.0	0.20
Chronic myeloid	52	2.5	0.16	2.9	0.18	35	1.6	0.12	1.8	0.13
Other leukemias	42	2.1	0.15	2.4	0.17	24	1.1	0.10	1.2	0.11
Mesothelioma	44	2.4	0.17	2.7	0.19	11	0.5	0.07	0.6	0.08
Kaposi Sarcoma	6	0.3	0.06	0.3	0.06	*	*	*	*	*
Ill-Defined & Unknown	349	17.9	0.44	20.8	0.51	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	146	7.0	0.27	7.9	0.30	239	10.6	0.31	12.0	0.35
Breast (<i>in situ</i>)	*	*	*	*	*	395	17.1	0.39	20.4	0.46

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Initial Operation: 1966
 Population-based Data Available: 1969
 Coverage Area: Province

Total Population Counts by Year

2015	2016	2017	2018	2019
4,776,388	4,859,250	4,929,384	5,010,476	5,094,796

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	100.8	98.2	95.7	98.8	101.4	99.0
Missing Race	na	na	na	na	na	na
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.5	0.6	1.3	1.1	1.0	0.9
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	90.7	Ovary	90.9
Oral Cavity & Pharynx	97.1	Prostate	94.1
Esophagus	95.4	Testis	99.0
Stomach	95.6	Bladder (incl. <i>in situ</i>)	96.1
Colon & Rectum	94.3	Kidney & Renal Pelvis	87.8
Liver	32.1	Brain & Other CNS	83.7
Pancreas	70.8	Brain & Other CNS (non-malig)	65.9
Lung & Bronchus	79.5	Thyroid	98.8
Melanomas of the Skin	99.2	Hodgkin Lymphoma	100.0
Female Breast (excl. <i>in situ</i>)	98.7	Non-Hodgkin Lymphoma	96.6
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	92.4
Cervix Uteri	98.3	Leukemias	98.2
Uterus Corpus & Uterus NOS	98.8		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
British Columbia, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	14,159	448.0	1.72	527.1	2.00	13,233	388.1	1.56	452.3	1.78
Oral Cavity & Pharynx	522	16.1	0.32	19.6	0.39	218	6.4	0.20	7.5	0.23
Lip	23	0.7	0.07	0.9	0.08	12	0.3	0.05	0.4	0.05
Tongue	174	5.2	0.18	6.4	0.22	67	1.9	0.11	2.3	0.13
Major salivary gland	41	1.4	0.10	1.6	0.11	31	1.0	0.08	1.1	0.09
Floor of mouth	18	0.6	0.06	0.7	0.07	12	0.3	0.05	0.4	0.05
Gum & other mouth	58	1.8	0.11	2.1	0.13	45	1.3	0.09	1.5	0.10
Nasopharynx	38	1.2	0.09	1.5	0.11	16	0.5	0.06	0.6	0.07
Oropharynx	36	1.0	0.08	1.3	0.10	7	0.2	0.04	0.2	0.04
Hypopharynx	21	0.6	0.06	0.7	0.07	5	0.1	0.03	0.2	0.04
Digestive System	3,397	106.4	0.84	126.7	0.98	2,522	71.1	0.65	83.6	0.75
Esophagus	271	8.3	0.23	10.0	0.27	89	2.4	0.12	2.9	0.14
Stomach	267	8.5	0.24	10.0	0.28	143	4.1	0.16	4.8	0.18
Small intestine	73	2.3	0.12	2.7	0.14	53	1.6	0.10	1.8	0.11
Colon (excl. rectum)	1,076	34.4	0.48	40.4	0.56	1,004	28.3	0.41	33.0	0.47
Rectum & rectosigmoid	639	19.8	0.36	23.9	0.43	388	11.2	0.26	13.3	0.31
Anus, anal canal, & anorectum	38	1.2	0.09	1.4	0.10	85	2.4	0.12	2.9	0.14
Liver	385	11.2	0.26	14.0	0.32	114	3.1	0.13	3.8	0.16
Gallbladder	25	0.8	0.07	0.9	0.08	49	1.4	0.09	1.6	0.11
Pancreas	426	13.4	0.30	15.9	0.35	390	10.7	0.25	12.7	0.29
Respiratory System	1,846	57.8	0.61	68.3	0.72	1,859	51.5	0.54	60.6	0.63
Larynx	109	3.3	0.15	4.0	0.17	15	0.4	0.05	0.5	0.06
Lung & bronchus	1,703	53.3	0.59	63.0	0.69	1,822	50.4	0.54	59.3	0.63
Bones & Joints	27	1.0	0.09	1.1	0.10	21	0.8	0.08	0.8	0.08
Soft Tissue (incl. heart)	101	3.5	0.16	3.9	0.18	76	2.5	0.14	2.8	0.14
Skin (excl. basal & sq.)	721	23.6	0.40	27.3	0.46	567	17.1	0.33	19.7	0.37
Melanoma of the skin	662	21.5	0.38	25.1	0.44	531	16.0	0.32	18.5	0.36
Breast (excl. <i>in situ</i>)	30	0.9	0.08	1.1	0.09	3,746	112.1	0.85	131.4	0.97
Female Genital System	N/A	N/A	N/A	N/A	N/A	1,571	46.4	0.54	54.9	0.63
Cervix uteri	N/A	N/A	N/A	N/A	N/A	195	7.0	0.23	7.5	0.24
Uterus corpus	N/A	N/A	N/A	N/A	N/A	827	23.3	0.37	28.5	0.45
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	15	0.4	0.05	0.5	0.06
Ovary	N/A	N/A	N/A	N/A	N/A	309	9.3	0.24	10.8	0.28
Male Genital System	3,303	100.4	0.80	119.4	0.94	N/A	N/A	N/A	N/A	N/A
Prostate	3,112	92.8	0.76	111.7	0.90	N/A	N/A	N/A	N/A	N/A
Testis	156	6.5	0.24	6.4	0.23	N/A	N/A	N/A	N/A	N/A
Penis	25	0.8	0.07	0.9	0.08	N/A	N/A	N/A	N/A	N/A
Urinary System	1,763	56.5	0.61	66.2	0.71	672	19.2	0.34	22.3	0.39
Bladder (incl. <i>in situ</i>)	1,165	37.5	0.50	43.8	0.58	353	9.9	0.24	11.4	0.28
Kidney & renal pelvis	549	17.4	0.34	20.6	0.40	295	8.6	0.23	10.0	0.26
Ureter	29	1.0	0.08	1.1	0.09	17	0.5	0.05	0.5	0.06
Eye & Orbit	28	0.9	0.08	1.0	0.09	25	0.8	0.07	0.9	0.08
Brain & Other CNS	232	8.1	0.25	9.0	0.27	145	4.8	0.19	5.3	0.20
Brain	226	7.8	0.24	8.7	0.26	140	4.6	0.19	5.1	0.19
Endocrine System	161	5.7	0.21	6.3	0.22	356	12.5	0.31	13.6	0.33
Thyroid gland	135	4.7	0.19	5.3	0.21	332	11.7	0.30	12.7	0.32
Lymphomas	756	25.0	0.42	28.7	0.47	565	17.0	0.33	19.5	0.37
Hodgkin lymphoma	75	2.9	0.15	3.0	0.16	57	2.2	0.14	2.3	0.14
Non-Hodgkin lymphoma	681	22.2	0.39	25.7	0.44	508	14.8	0.30	17.3	0.35
Multiple Myeloma	244	7.8	0.23	9.2	0.26	164	4.6	0.16	5.4	0.19
Leukemias	482	16.1	0.34	18.3	0.38	307	9.5	0.26	10.6	0.27
Acute lymphocytic	30	1.4	0.12	1.3	0.10	29	1.4	0.12	1.2	0.10
Chronic lymphocytic	197	6.1	0.20	7.3	0.24	107	2.9	0.13	3.5	0.15
Acute myeloid	140	4.7	0.18	5.3	0.20	97	2.9	0.14	3.3	0.15
Chronic myeloid	60	2.1	0.12	2.3	0.14	43	1.3	0.10	1.5	0.10
Other leukemias	55	1.8	0.11	2.1	0.13	32	1.0	0.08	1.1	0.09
Mesothelioma	79	2.6	0.13	3.0	0.15	19	0.5	0.06	0.6	0.06
Kaposi Sarcoma	7	0.3	0.04	0.3	0.05	*	*	*	*	*
Ill-Defined & Unknown	460	15.3	0.33	17.6	0.37	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	146	5.3	0.20	5.7	0.21	252	7.9	0.23	9.1	0.26
Breast (<i>in situ</i>)	2	0.1	0.02	0.1	0.02	596	18.0	0.34	21.5	0.40

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Initial Operation: 1937
Population-based Data Available: 1956
Coverage Area: Province

Total Population Counts by Year

2015	2016	2017	2018	2019
1,292,227	1,314,139	1,334,790	1,352,825	1,369,954

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	101.9	103.3	98.5	107.1	110.1	104.2
Missing Race	na	na	na	na	na	na
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.0	0.0	0.0	0.0	0.1	0.0
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	91.3	Ovary	92.0
Oral Cavity & Pharynx	99.3	Prostate	94.5
Esophagus	98.0	Testis	99.5
Stomach	97.4	Bladder (incl. <i>in situ</i>)	97.3
Colon & Rectum	95.8	Kidney & Renal Pelvis	83.5
Liver	31.0	Brain & Other CNS	79.0
Pancreas	69.7	Brain & Other CNS (non-malig)	53.7
Lung & Bronchus	77.6	Thyroid	99.6
Melanomas of the Skin	99.9	Hodgkin Lymphoma	100.0
Female Breast (excl. <i>in situ</i>)	99.1	Non-Hodgkin Lymphoma	97.7
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	93.0
Cervix Uteri	99.1	Leukemias	99.7
Uterus Corpus & Uterus NOS	99.3		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Manitoba, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3,554	482.4	3.70	568.1	4.29	3,452	424.9	3.32	497.5	3.83
Oral Cavity & Pharynx	130	17.0	0.69	20.7	0.82	57	6.9	0.42	8.1	0.49
Lip	34	4.9	0.38	5.6	0.43	14	1.5	0.19	1.8	0.22
Tongue	33	4.3	0.34	5.2	0.40	14	1.8	0.22	2.1	0.25
Major salivary gland	5	0.7	0.14	0.8	0.16	6	0.7	0.13	0.8	0.15
Floor of mouth	5	0.6	0.13	0.8	0.16	2	0.2	0.07	0.3	0.10
Gum & other mouth	8	1.0	0.16	1.2	0.19	10	1.3	0.19	1.4	0.21
Nasopharynx	7	0.9	0.16	1.2	0.20	2	0.3	0.10	0.3	0.10
Oropharynx	7	0.9	0.15	1.1	0.19	2	0.3	0.08	0.4	0.10
Hypopharynx	8	1.0	0.16	1.2	0.20	1	0.2	0.06	0.2	0.08
Digestive System	827	111.6	1.77	132.9	2.08	631	74.8	1.37	88.3	1.60
Esophagus	53	7.1	0.44	8.6	0.53	16	1.9	0.22	2.3	0.26
Stomach	80	10.9	0.56	12.9	0.65	42	5.0	0.36	5.9	0.41
Small intestine	17	2.3	0.26	2.8	0.30	14	1.7	0.20	2.0	0.24
Colon (excl. rectum)	286	39.2	1.06	46.1	1.23	271	31.9	0.89	37.4	1.03
Rectum & rectosigmoid	181	24.2	0.82	29.1	0.97	106	13.0	0.58	15.4	0.68
Anus, anal canal, & anorectum	8	1.0	0.17	1.3	0.21	16	1.9	0.22	2.3	0.26
Liver	57	7.3	0.44	9.0	0.53	20	2.4	0.25	2.9	0.29
Gallbladder	9	1.2	0.18	1.4	0.21	16	1.8	0.21	2.2	0.25
Pancreas	91	12.2	0.59	14.6	0.69	93	10.8	0.52	12.8	0.60
Respiratory System	473	64.3	1.35	75.9	1.57	490	57.8	1.19	68.5	1.40
Larynx	29	3.7	0.32	4.6	0.38	4	0.5	0.11	0.6	0.14
Lung & bronchus	436	59.4	1.30	70.0	1.51	481	56.8	1.18	67.3	1.38
Bones & Joints	6	0.9	0.16	1.0	0.18	5	0.8	0.16	0.8	0.16
Soft Tissue (incl. heart)	29	4.2	0.36	4.7	0.39	20	2.7	0.28	2.9	0.30
Skin (excl. basal & sq.)	169	23.4	0.82	27.3	0.95	135	16.9	0.67	19.4	0.76
Melanoma of the skin	154	21.3	0.78	25.0	0.90	120	15.1	0.64	17.4	0.72
Breast (excl. <i>in situ</i>)	5	0.7	0.14	0.8	0.16	929	116.4	1.76	137.1	2.04
Female Genital System	N/A	N/A	N/A	N/A	N/A	456	57.4	1.24	68.1	1.44
Cervix uteri	N/A	N/A	N/A	N/A	N/A	45	6.8	0.46	7.1	0.48
Uterus corpus	N/A	N/A	N/A	N/A	N/A	277	33.9	0.94	41.2	1.12
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	7	0.8	0.15	1.0	0.18
Ovary	N/A	N/A	N/A	N/A	N/A	83	10.5	0.53	12.3	0.61
Male Genital System	839	110.5	1.74	131.7	2.05	N/A	N/A	N/A	N/A	N/A
Prostate	786	102.6	1.67	123.5	1.98	N/A	N/A	N/A	N/A	N/A
Testis	39	6.0	0.43	6.0	0.43	N/A	N/A	N/A	N/A	N/A
Penis	13	1.8	0.23	2.1	0.26	N/A	N/A	N/A	N/A	N/A
Urinary System	439	60.8	1.32	71.5	1.54	166	20.1	0.72	23.5	0.83
Bladder (incl. <i>in situ</i>)	260	36.5	1.03	42.6	1.19	80	9.5	0.48	11.0	0.56
Kidney & renal pelvis	167	22.5	0.80	26.8	0.93	81	10.0	0.51	11.8	0.59
Ureter	6	0.8	0.15	1.0	0.18	3	0.3	0.09	0.4	0.10
Eye & Orbit	4	0.6	0.13	0.7	0.15	5	0.6	0.14	0.7	0.14
Brain & Other CNS	55	7.8	0.48	8.5	0.52	41	5.4	0.39	5.9	0.42
Brain	51	7.2	0.46	8.0	0.50	38	5.1	0.38	5.6	0.41
Endocrine System	43	6.1	0.43	6.7	0.46	114	16.5	0.71	17.8	0.75
Thyroid gland	37	5.2	0.40	5.8	0.43	108	15.7	0.69	17.0	0.74
Lymphomas	198	27.3	0.89	31.5	1.01	155	19.1	0.70	22.1	0.80
Hodgkin lymphoma	21	3.0	0.30	3.2	0.32	17	2.5	0.28	2.5	0.28
Non-Hodgkin lymphoma	178	24.3	0.83	28.3	0.96	138	16.6	0.65	19.6	0.75
Multiple Myeloma	61	8.3	0.48	9.8	0.57	44	5.1	0.36	6.2	0.42
Leukemias	124	17.4	0.71	19.7	0.80	82	10.1	0.51	11.5	0.57
Acute lymphocytic	11	1.7	0.23	1.5	0.20	9	1.4	0.21	1.3	0.19
Chronic lymphocytic	59	7.8	0.47	9.4	0.55	33	3.7	0.30	4.5	0.36
Acute myeloid	30	4.2	0.35	4.7	0.39	23	2.8	0.27	3.2	0.31
Chronic myeloid	15	2.2	0.26	2.4	0.28	11	1.4	0.19	1.5	0.21
Other leukemias	10	1.5	0.22	1.6	0.23	7	0.8	0.15	0.9	0.16
Mesothelioma	16	2.2	0.25	2.6	0.29	4	0.5	0.11	0.6	0.13
Kaposi Sarcoma	2	0.3	0.10	0.3	0.10	*	*	*	*	*
Ill-Defined & Unknown	135	18.9	0.74	21.8	0.85	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	42	5.8	0.41	6.7	0.47	78	9.9	0.52	11.4	0.58
Breast (<i>in situ</i>)	*	*	*	*	*	108	13.4	0.59	16.2	0.70

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Initial Operation: 1952
Population-based Data Available: 1989
Coverage Area: Province

Total Population Counts by Year

2015	2016	2017	2018	2019
758,842	763,350	766,621	770,301	777,128

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	111.6	110.7	104.1	102.9	108.3	107.5
Missing Race	na	na	na	na	na	na
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.1	0.1	0.2	0.2	0.2	0.2
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	92.4	Ovary	90.7
Oral Cavity & Pharynx	98.8	Prostate	96.4
Esophagus	96.9	Testis	98.3
Stomach	94.5	Bladder (incl. <i>in situ</i>)	96.9
Colon & Rectum	94.4	Kidney & Renal Pelvis	90.4
Liver	61.8	Brain & Other CNS	82.2
Pancreas	71.3	Brain & Other CNS (non-malig)	68.6
Lung & Bronchus	82.3	Thyroid	99.0
Melanomas of the Skin	100.0	Hodgkin Lymphoma	100.0
Female Breast (excl. <i>in situ</i>)	98.0	Non-Hodgkin Lymphoma	98.3
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	96.3
Cervix Uteri	99.4	Leukemias	99.1
Uterus Corpus & Uterus NOS	98.8		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
New Brunswick, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	2,700	494.0	4.43	585.0	5.14	2,452	421.5	4.01	492.2	4.55
Oral Cavity & Pharynx	94	16.9	0.81	20.6	0.97	37	6.4	0.49	7.5	0.56
Lip	6	1.2	0.23	1.4	0.26	2	0.4	0.12	0.5	0.14
Tongue	33	5.9	0.47	7.2	0.57	10	1.7	0.25	2.0	0.28
Major salivary gland	4	0.8	0.18	0.9	0.20	3	0.7	0.19	0.7	0.18
Floor of mouth	4	0.7	0.16	0.8	0.19	3	0.4	0.12	0.5	0.15
Gum & other mouth	8	1.5	0.25	1.8	0.29	9	1.4	0.23	1.7	0.26
Nasopharynx	3	0.5	0.14	0.6	0.16	1	0.2	0.09	0.3	0.11
Oropharynx	5	0.9	0.19	1.1	0.23	*	*	*	*	*
Hypopharynx	3	0.6	0.15	0.7	0.17	*	*	*	*	*
Digestive System	606	111.7	2.11	132.4	2.46	443	72.4	1.60	84.8	1.84
Esophagus	45	8.1	0.56	9.7	0.66	12	2.0	0.27	2.4	0.31
Stomach	58	10.8	0.66	12.8	0.77	30	4.8	0.41	5.7	0.47
Small intestine	16	2.8	0.32	3.4	0.39	11	1.8	0.26	2.1	0.29
Colon (excl. rectum)	212	39.8	1.27	46.9	1.47	203	33.2	1.08	38.5	1.23
Rectum & rectosigmoid	131	23.6	0.96	28.2	1.12	64	11.2	0.66	13.1	0.75
Anus, anal canal, & anorectum	6	1.1	0.21	1.3	0.25	13	2.2	0.28	2.6	0.33
Liver	32	5.7	0.46	6.7	0.54	10	1.7	0.25	2.0	0.28
Gallbladder	3	0.5	0.15	0.6	0.17	6	1.0	0.18	1.2	0.22
Pancreas	76	14.3	0.76	16.9	0.89	64	9.9	0.57	11.8	0.67
Respiratory System	471	86.0	1.83	101.1	2.13	395	61.8	1.42	74.1	1.69
Larynx	25	4.5	0.41	5.3	0.48	5	0.8	0.17	1.0	0.21
Lung & bronchus	442	80.9	1.77	95.1	2.06	387	60.5	1.40	72.6	1.67
Bones & Joints	4	0.9	0.23	0.9	0.22	3	0.9	0.25	0.9	0.22
Soft Tissue (incl. heart)	14	3.2	0.39	3.5	0.42	14	2.7	0.35	3.0	0.37
Skin (excl. basal & sq.)	130	24.9	1.02	29.2	1.17	113	21.2	0.95	24.2	1.05
Melanoma of the skin	115	21.8	0.95	25.7	1.09	103	19.5	0.92	22.3	1.01
Breast (excl. <i>in situ</i>)	5	1.1	0.22	1.2	0.24	629	110.4	2.08	129.4	2.36
Female Genital System	N/A	N/A	N/A	N/A	N/A	280	50.0	1.42	58.7	1.61
Cervix uteri	N/A	N/A	N/A	N/A	N/A	31	8.1	0.68	8.2	0.67
Uterus corpus	N/A	N/A	N/A	N/A	N/A	162	26.4	0.97	32.7	1.17
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	2	0.3	0.10	0.3	0.11
Ovary	N/A	N/A	N/A	N/A	N/A	60	10.7	0.66	12.3	0.73
Male Genital System	592	99.6	1.90	122.2	2.29	N/A	N/A	N/A	N/A	N/A
Prostate	561	91.4	1.77	113.9	2.18	N/A	N/A	N/A	N/A	N/A
Testis	23	6.9	0.65	6.7	0.63	N/A	N/A	N/A	N/A	N/A
Penis	6	1.1	0.21	1.3	0.24	N/A	N/A	N/A	N/A	N/A
Urinary System	339	62.9	1.58	73.8	1.83	146	24.3	0.93	28.7	1.08
Bladder (incl. <i>in situ</i>)	201	37.2	1.21	43.5	1.40	66	10.8	0.61	12.7	0.71
Kidney & renal pelvis	128	23.6	0.98	27.9	1.12	74	12.6	0.69	15.0	0.80
Ureter	6	1.1	0.21	1.3	0.25	3	0.5	0.13	0.6	0.15
Eye & Orbit	2	0.3	0.11	0.4	0.13	2	0.3	0.12	0.4	0.13
Brain & Other CNS	38	7.4	0.57	8.5	0.64	27	5.4	0.52	5.8	0.52
Brain	37	7.3	0.57	8.4	0.63	25	5.1	0.49	5.5	0.50
Endocrine System	34	7.3	0.59	8.2	0.64	75	16.2	0.90	17.7	0.94
Thyroid gland	31	6.6	0.56	7.5	0.61	72	15.7	0.89	17.2	0.93
Lymphomas	143	28.1	1.10	32.3	1.23	111	19.5	0.88	22.6	0.98
Hodgkin lymphoma	15	3.7	0.45	3.8	0.45	8	2.1	0.34	2.1	0.33
Non-Hodgkin lymphoma	129	24.4	1.01	28.5	1.15	103	17.4	0.81	20.5	0.92
Multiple Myeloma	38	7.1	0.54	8.3	0.61	27	4.6	0.40	5.3	0.46
Leukemias	99	18.8	0.88	21.8	1.00	72	12.7	0.72	14.6	0.78
Acute lymphocytic	4	1.2	0.28	1.1	0.25	5	1.4	0.31	1.3	0.27
Chronic lymphocytic	51	9.2	0.60	10.9	0.70	34	5.3	0.41	6.5	0.50
Acute myeloid	25	4.6	0.43	5.4	0.50	20	3.6	0.38	4.1	0.42
Chronic myeloid	11	2.2	0.30	2.5	0.34	10	1.8	0.27	2.0	0.29
Other leukemias	8	1.6	0.25	1.8	0.30	4	0.7	0.17	0.8	0.18
Mesothelioma	10	2.1	0.29	2.4	0.34	3	0.4	0.12	0.5	0.14
Kaposi Sarcoma	1	0.3	0.12	0.3	0.13	*	*	*	*	*
Ill-Defined & Unknown	79	15.5	0.81	17.8	0.92	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	17	3.7	0.43	4.2	0.46	34	6.5	0.54	7.2	0.57
Breast (<i>in situ</i>)	*	*	*	*	*	66	11.6	0.68	13.9	0.78

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

NEWFOUNDLAND AND LABRADOR CANCER REGISTRY

Initial Operation: 1955
 Population-based Data Available: 1955
 Coverage Area: Newfoundland and Labrador

Total Population Counts by Year

2015	2016	2017	2018	2019
528,117	529,426	528,249	525,560	523,427

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	107.2	109.8	106.8	106.7	107.9	107.7
Missing Race	na	na	na	na	na	na
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.7	0.3	0.6	0.0	0.0	0.3
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	91.8	Ovary	88.3
Oral Cavity & Pharynx	98.6	Prostate	98.2
Esophagus	97.9	Testis	98.3
Stomach	97.0	Bladder (incl. <i>in situ</i>)	99.1
Colon & Rectum	95.9	Kidney & Renal Pelvis	88.4
Liver	44.6	Brain & Other CNS	87.6
Pancreas	61.1	Brain & Other CNS (non-malig)	75.3
Lung & Bronchus	76.5	Thyroid	99.8
Melanomas of the Skin	99.8	Hodgkin Lymphoma	98.7
Female Breast (excl. <i>in situ</i>)	98.8	Non-Hodgkin Lymphoma	97.5
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	91.3
Cervix Uteri	95.7	Leukemias	91.3
Uterus Corpus & Uterus NOS	98.9		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Newfoundland and Labrador, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	1,938	512.0	5.49	606.8	6.36	1,819	465.4	5.12	543.9	5.81
Oral Cavity & Pharynx	63	15.9	0.94	19.4	1.12	22	5.8	0.58	6.7	0.65
Lip	10	2.7	0.40	3.2	0.46	2	0.5	0.16	0.6	0.19
Tongue	16	4.1	0.49	4.8	0.56	8	2.0	0.34	2.4	0.39
Major salivary gland	3	0.8	0.22	1.0	0.26	3	0.9	0.25	1.1	0.27
Floor of mouth	2	0.5	0.17	0.7	0.20	*	*	*	*	*
Gum & other mouth	6	1.5	0.29	1.7	0.33	2	0.6	0.19	0.7	0.21
Nasopharynx	4	0.9	0.22	1.1	0.26	*	*	*	*	*
Oropharynx	3	0.6	0.17	0.8	0.21	*	*	*	*	*
Hypopharynx	4	0.9	0.22	1.1	0.28	*	*	*	*	*
Digestive System	526	140.9	2.89	166.7	3.36	390	97.9	2.29	114.5	2.63
Esophagus	31	7.9	0.68	9.6	0.80	8	1.8	0.30	2.3	0.37
Stomach	51	14.2	0.93	17.1	1.11	29	7.5	0.65	8.5	0.72
Small intestine	12	3.2	0.44	4.0	0.52	10	2.4	0.35	3.0	0.42
Colon (excl. rectum)	218	58.2	1.85	68.5	2.14	194	48.9	1.62	57.0	1.85
Rectum & rectosigmoid	131	34.9	1.43	41.5	1.67	67	17.2	0.98	20.1	1.12
Anus, anal canal, & anorectum	4	1.2	0.27	1.4	0.31	8	1.8	0.30	2.3	0.37
Liver	18	5.3	0.58	6.2	0.67	8	2.0	0.34	2.2	0.36
Gallbladder	4	1.0	0.23	1.1	0.27	5	1.1	0.24	1.3	0.28
Pancreas	36	9.2	0.72	10.9	0.85	35	8.6	0.67	10.2	0.78
Respiratory System	303	78.9	2.12	92.9	2.46	256	60.1	1.73	71.6	2.03
Larynx	19	4.7	0.50	5.9	0.61	3	0.8	0.22	1.0	0.25
Lung & bronchus	281	73.4	2.04	86.0	2.37	251	58.9	1.70	70.2	2.00
Bones & Joints	3	1.0	0.30	1.1	0.28	*	*	*	*	*
Soft Tissue (incl. heart)	10	3.1	0.47	3.3	0.49	5	1.6	0.34	1.7	0.34
Skin (excl. basal & sq.)	72	20.8	1.17	23.7	1.29	57	16.1	1.01	18.1	1.10
Melanoma of the skin	66	18.9	1.11	21.6	1.23	51	14.5	0.97	16.2	1.04
Breast (excl. <i>in situ</i>)	4	1.1	0.26	1.4	0.31	471	120.7	2.61	141.5	2.97
Female Genital System	N/A	N/A	N/A	N/A	N/A	221	57.7	1.84	68.1	2.09
Cervix uteri	N/A	N/A	N/A	N/A	N/A	28	9.6	0.86	10.1	0.87
Uterus corpus	N/A	N/A	N/A	N/A	N/A	124	30.4	1.27	37.2	1.52
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	1	0.4	0.15	0.4	0.17
Ovary	N/A	N/A	N/A	N/A	N/A	36	9.5	0.75	11.0	0.84
Male Genital System	450	108.7	2.40	133.6	2.89	N/A	N/A	N/A	N/A	N/A
Prostate	433	102.2	2.29	126.9	2.80	N/A	N/A	N/A	N/A	N/A
Testis	12	5.1	0.68	5.0	0.66	N/A	N/A	N/A	N/A	N/A
Penis	5	1.4	0.28	1.7	0.33	N/A	N/A	N/A	N/A	N/A
Urinary System	239	64.1	1.95	76.3	2.28	108	26.7	1.21	31.6	1.38
Bladder (incl. <i>in situ</i>)	135	36.8	1.49	43.5	1.74	51	12.0	0.77	14.1	0.90
Kidney & renal pelvis	98	25.4	1.21	30.6	1.43	55	14.2	0.91	16.7	1.03
Ureter	4	1.0	0.25	1.2	0.29	2	0.5	0.16	0.6	0.19
Eye & Orbit	2	0.6	0.19	0.7	0.23	2	0.5	0.17	0.6	0.19
Brain & Other CNS	27	8.2	0.76	9.2	0.82	24	6.9	0.67	7.6	0.71
Brain	27	8.1	0.76	9.1	0.81	23	6.4	0.64	7.1	0.69
Endocrine System	32	10.0	0.84	11.1	0.90	93	28.2	1.40	31.5	1.50
Thyroid gland	30	8.9	0.78	10.0	0.84	91	27.5	1.38	30.7	1.48
Lymphomas	98	26.9	1.30	31.5	1.47	84	21.1	1.09	25.0	1.25
Hodgkin lymphoma	9	2.9	0.47	3.1	0.48	6	2.4	0.44	2.5	0.45
Non-Hodgkin lymphoma	89	24.1	1.21	28.4	1.39	77	18.8	0.99	22.6	1.16
Multiple Myeloma	24	6.3	0.60	7.5	0.71	18	3.8	0.42	4.7	0.51
Leukemias	33	10.1	0.85	10.9	0.87	25	6.6	0.64	7.4	0.69
Acute lymphocytic	3	1.5	0.41	1.3	0.33	2	0.7	0.26	0.6	0.23
Chronic lymphocytic	7	1.9	0.34	2.2	0.38	3	0.7	0.19	0.9	0.22
Acute myeloid	15	4.0	0.50	4.6	0.55	9	2.3	0.36	2.7	0.40
Chronic myeloid	6	1.8	0.36	2.0	0.37	6	1.6	0.32	1.8	0.36
Other leukemias	3	0.8	0.24	0.9	0.25	5	1.2	0.27	1.4	0.29
Mesothelioma	4	1.1	0.26	1.3	0.30	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	N/A	N/A	N/A	N/A	N/A	43	10.8	0.76	12.6	0.87
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	12	3.2	0.44	3.9	0.51	20	5.7	0.61	6.5	0.66
Breast (<i>in situ</i>)	*	*	*	*	*	78	19.6	1.04	23.1	1.19

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

NEWFOUNDLAND AND LABRADOR

II-572 Incidence – All Races

NORTHWEST TERRITORIES CANCER REGISTRY

Initial Operation: 1986
 Population-based Data Available: 1950
 Coverage Area: Territory

Total Population Counts by Year

2015	2016	2017	2018	2019
44,237	44,649	44,891	44,981	45,070

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	148.9	161.5	180.8	154.1	186.7	166.4
Missing Race	na	na	na	na	na	na
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	2.0	0.0	0.0	0.0	0.0	0.4
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.0	0.5	0.0	0.5	1.0	0.4
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	93.0	Ovary	100.0
Oral Cavity & Pharynx	100.0	Prostate	93.5
Esophagus	100.0	Testis	83.3
Stomach	100.0	Bladder (incl. <i>in situ</i>)	96.0
Colon & Rectum	98.1	Kidney & Renal Pelvis	85.4
Liver	55.6	Brain & Other CNS	100.0
Pancreas	75.0	Brain & Other CNS (non-malig)	~
Lung & Bronchus	80.7	Thyroid	100.0
Melanomas of the Skin	100.0	Hodgkin Lymphoma	100.0
Female Breast (excl. <i>in situ</i>)	100.0	Non-Hodgkin Lymphoma	100.0
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	90.9
Cervix Uteri	100.0	Leukemias	100.0
Uterus Corpus & Uterus NOS	100.0		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Northwest Territories, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	90	508.1	28.12	593.5	31.86	84	486.1	26.93	566.5	30.71
Oral Cavity & Pharynx	3	15.2	4.19	17.9	4.70	*	*	*	*	*
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	1	4.4	1.80	5.7	2.34	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	30	174.3	16.57	200.5	18.63	20	124.2	14.09	144.7	15.81
Esophagus	1	10.6	4.45	11.3	4.57	*	*	*	*	*
Stomach	3	15.9	4.87	18.3	5.63	2	10.5	4.26	11.9	4.73
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	10	65.8	10.84	74.5	12.16	7	42.7	8.59	48.7	9.43
Rectum & rectosigmoid	9	48.6	8.16	57.5	9.44	6	27.8	5.98	33.5	6.90
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	2	7.7	3.11	9.5	3.67	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	2	10.1	3.12	12.5	3.69	2	14.6	4.80	18.1	5.74
Respiratory System	13	89.4	13.10	102.7	14.68	11	83.2	12.40	97.9	14.23
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	12	86.7	13.01	99.6	14.57	11	83.2	12.40	97.9	14.23
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Melanoma of the skin	2	9.0	3.44	10.4	3.73	2	8.7	2.99	10.0	3.43
Breast (excl. <i>in situ</i>)	*	*	*	*	*	23	122.4	12.85	145.4	15.01
Female Genital System	N/A	N/A	N/A	N/A	N/A	11	55.1	8.15	63.5	9.23
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	7.7	2.85	7.5	2.79
Uterus corpus	N/A	N/A	N/A	N/A	N/A	5	24.8	5.21	29.7	6.01
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	10.2	2.97	12.1	3.53
Male Genital System	20	91.8	10.52	114.5	12.56	N/A	N/A	N/A	N/A	N/A
Prostate	18	86.7	10.34	109.0	12.39	N/A	N/A	N/A	N/A	N/A
Testis	1	4.5	1.83	4.5	1.86	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	11	60.5	9.40	70.4	10.62	3	17.6	5.18	20.4	5.76
Bladder (incl. <i>in situ</i>)	4	18.3	4.63	23.2	5.61	*	*	*	*	*
Kidney & renal pelvis	7	37.7	7.53	42.4	8.35	2	9.7	3.76	11.5	4.31
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	2	7.7	2.62	8.6	2.90
Brain	*	*	*	*	*	2	7.7	2.62	8.6	2.90
Endocrine System	*	*	*	*	*	3	11.4	3.19	12.2	3.46
Thyroid gland	*	*	*	*	*	2	10.3	3.01	11.3	3.34
Lymphomas	4	23.8	6.51	26.1	6.95	3	15.3	4.79	18.0	5.60
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Multiple Myeloma	*	*	*	*	*	1	10.2	4.29	11.7	4.94
Leukemias	2	13.2	4.77	16.6	5.87	1	7.1	3.31	7.6	3.69
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	1	5.6	2.70	7.2	3.29	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	10.8	4.16	12.2	4.57	2	14.4	4.84	15.7	5.27
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	3	16.4	4.95	20.5	6.06

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

NORTHWEST TERRITORIES

II-574 Incidence – All Races

Initial Operation: 1999 (1950 as part of Northwest Territories)
 Population-based Data Available: 1999 (1950 as part of Northwest Territories)
 Coverage Area: Territory

Total Population Counts by Year

2015	2016	2017	2018	2019
36,488	36,975	37,546	38,143	38,592

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	108.3	97.1	111.2	152.9	127.9	119.5
Missing Race	na	na	na	na	na	na
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.0	0.0	0.0	0.0	0.0	0.0
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	95.7	Ovary	100.0
Oral Cavity & Pharynx	100.0	Prostate	100.0
Esophagus	100.0	Testis	100.0
Stomach	100.0	Bladder (incl. <i>in situ</i>)	100.0
Colon & Rectum	96.2	Kidney & Renal Pelvis	91.7
Liver	33.3	Brain & Other CNS	100.0
Pancreas	90.0	Brain & Other CNS (non-malig)	100.0
Lung & Bronchus	92.2	Thyroid	100.0
Melanomas of the Skin	100.0	Hodgkin Lymphoma	~
Female Breast (excl. <i>in situ</i>)	100.0	Non-Hodgkin Lymphoma	100.0
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	100.0
Cervix Uteri	100.0	Leukemias	100.0
Uterus Corpus & Uterus NOS	100.0		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Nunavut, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	36	388.8	35.20	452.6	39.51	39	458.6	41.14	537.8	46.94
Oral Cavity & Pharynx	2	20.1	7.58	21.8	8.07	1	11.4	5.06	14.1	6.08
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	*	*	*	*	*	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	14	131.2	18.38	157.3	21.25	10	131.3	23.13	156.5	26.91
Esophagus	2	16.5	6.81	18.3	7.27	*	*	*	*	*
Stomach	2	22.4	8.63	27.1	10.09	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	4	37.5	9.52	43.3	10.58	5	85.5	20.42	99.5	23.37
Rectum & rectosigmoid	4	33.1	7.51	43.3	9.56	2	17.8	5.25	22.7	6.89
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	*	*	*	*	*	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	*	*	*	*	*	1	10.4	4.37	13.3	5.66
Respiratory System	9	133.2	22.90	154.0	25.26	12	169.2	26.29	196.9	29.38
Larynx	*	*	*	*	*	*	*	*	*	*
Lung & bronchus	9	126.9	22.31	147.0	24.69	11	167.5	26.24	194.3	29.26
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	*	*	*	*	*	*	*	*	*	*
Melanoma of the skin	*	*	*	*	*	*	*	*	*	*
Breast (excl. <i>in situ</i>)	*	*	*	*	*	6	54.5	11.54	66.0	13.89
Female Genital System	N/A	N/A	N/A	N/A	N/A	4	31.0	7.47	37.6	9.21
Cervix uteri	N/A	N/A	N/A	N/A	N/A	2	10.9	3.69	11.4	3.95
Uterus corpus	N/A	N/A	N/A	N/A	N/A	1	11.4	4.48	15.5	6.14
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Male Genital System	2	28.1	9.10	31.9	9.90	N/A	N/A	N/A	N/A	N/A
Prostate	2	23.2	8.45	26.4	9.20	N/A	N/A	N/A	N/A	N/A
Testis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	2	15.8	7.35	19.5	8.72	2	31.0	12.33	33.6	13.27
Bladder (incl. <i>in situ</i>)	*	*	*	*	*	*	*	*	*	*
Kidney & renal pelvis	*	*	*	*	*	2	29.7	12.26	32.0	13.17
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	*	*	*	*	*
Brain	*	*	*	*	*	*	*	*	*	*
Endocrine System	*	*	*	*	*	1	8.2	3.20	8.4	3.27
Thyroid gland	*	*	*	*	*	1	8.2	3.20	8.4	3.27
Lymphomas	1	9.3	3.63	11.6	4.68	*	*	*	*	*
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	1	9.3	3.63	11.6	4.68	*	*	*	*	*
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	2	13.2	4.71	15.4	5.58	*	*	*	*	*
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	*	*	*	*	*	*	*	*	*	*
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	*	*	*	*	*

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

NUNAVUT

II-576 Incidence – All Races

Initial Operation: 1964
Population-based Data Available: 1964
Coverage Area: Province

Total Population Counts by Year

2015	2016	2017	2018	2019
13,707,118	13,875,394	14,070,141	14,308,697	14,544,701

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	105.4	103.6	106.8	104.4	107.2	105.5
Missing Race	na	na	na	na	na	na
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	1.4	1.4	1.4	1.1	1.2	1.3
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	90.0	Ovary	90.2
Oral Cavity & Pharynx	96.0	Prostate	96.3
Esophagus	93.7	Testis	96.4
Stomach	93.1	Bladder (incl. <i>in situ</i>)	97.6
Colon & Rectum	93.0	Kidney & Renal Pelvis	91.6
Liver	54.0	Brain & Other CNS	82.6
Pancreas	69.4	Brain & Other CNS (non-malig)	36.0
Lung & Bronchus	84.7	Thyroid	99.3
Melanomas of the Skin	98.7	Hodgkin Lymphoma	93.3
Female Breast (excl. <i>in situ</i>)	97.7	Non-Hodgkin Lymphoma	95.7
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	65.9
Cervix Uteri	98.0	Leukemias	72.9
Uterus Corpus & Uterus NOS	97.9		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Ontario, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	41,755	499.4	1.12	587.8	1.29	41,890	450.0	1.01	524.5	1.16
Oral Cavity & Pharynx	1,480	17.1	0.20	20.8	0.24	667	7.0	0.12	8.3	0.15
Lip	76	0.9	0.05	1.1	0.06	37	0.4	0.03	0.4	0.03
Tongue	451	5.1	0.11	6.3	0.13	188	2.0	0.07	2.4	0.08
Major salivary gland	167	2.1	0.07	2.4	0.08	99	1.1	0.05	1.3	0.06
Floor of mouth	80	0.9	0.04	1.1	0.06	38	0.4	0.03	0.5	0.03
Gum & other mouth	195	2.3	0.08	2.8	0.09	150	1.5	0.06	1.8	0.07
Nasopharynx	90	1.1	0.05	1.3	0.06	35	0.4	0.03	0.5	0.04
Oropharynx	66	0.7	0.04	0.9	0.05	22	0.2	0.02	0.3	0.03
Hypopharynx	74	0.8	0.04	1.0	0.05	12	0.1	0.02	0.1	0.02
Digestive System	9,351	111.7	0.53	132.3	0.62	7,171	73.5	0.40	86.3	0.46
Esophagus	623	7.2	0.13	8.7	0.16	214	2.1	0.07	2.5	0.08
Stomach	1,005	12.1	0.17	14.3	0.20	551	5.7	0.11	6.7	0.13
Small intestine	272	3.3	0.09	3.9	0.10	248	2.6	0.08	3.1	0.09
Colon (excl. rectum)	3,110	37.8	0.31	44.2	0.36	2,922	30.0	0.25	35.0	0.29
Rectum & rectosigmoid	1,692	20.1	0.22	23.9	0.26	1,093	11.6	0.16	13.6	0.19
Anus, anal canal, & anorectum	121	1.4	0.06	1.7	0.07	215	2.2	0.07	2.7	0.08
Liver	754	8.6	0.14	10.5	0.17	249	2.5	0.07	2.9	0.08
Gallbladder	65	0.8	0.04	0.9	0.05	125	1.3	0.05	1.5	0.06
Pancreas	1,109	13.2	0.18	15.7	0.21	995	9.9	0.14	11.7	0.17
Respiratory System	5,510	65.3	0.40	77.2	0.47	5,279	53.0	0.33	63.0	0.39
Larynx	353	4.0	0.10	4.9	0.12	64	0.6	0.04	0.8	0.04
Lung & bronchus	5,050	59.9	0.38	70.8	0.45	5,145	51.6	0.33	61.4	0.39
Bones & Joints	99	1.3	0.06	1.4	0.06	78	1.0	0.05	1.0	0.05
Soft Tissue (incl. heart)	394	5.0	0.12	5.7	0.13	307	3.6	0.10	4.0	0.10
Skin (excl. basal & sq.)	2,489	30.5	0.28	35.6	0.32	1,901	20.9	0.22	24.0	0.25
Melanoma of the skin	2,201	26.8	0.26	31.3	0.30	1,689	18.7	0.21	21.5	0.24
Breast (excl. <i>in situ</i>)	94	1.1	0.05	1.3	0.06	11,406	124.4	0.54	146.3	0.62
Female Genital System	N/A	N/A	N/A	N/A	N/A	5,352	57.9	0.36	68.5	0.42
Cervix uteri	N/A	N/A	N/A	N/A	N/A	621	8.1	0.15	8.6	0.15
Uterus corpus	N/A	N/A	N/A	N/A	N/A	2,869	29.7	0.25	36.5	0.31
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	55	0.6	0.03	0.7	0.04
Ovary	N/A	N/A	N/A	N/A	N/A	1,268	13.8	0.18	16.2	0.21
Male Genital System	9,339	107.0	0.50	128.4	0.60	N/A	N/A	N/A	N/A	N/A
Prostate	8,740	98.5	0.48	119.7	0.58	N/A	N/A	N/A	N/A	N/A
Testis	466	6.8	0.14	6.8	0.14	N/A	N/A	N/A	N/A	N/A
Penis	101	1.3	0.06	1.5	0.07	N/A	N/A	N/A	N/A	N/A
Urinary System	5,202	62.9	0.40	73.8	0.46	2,063	21.2	0.21	25.0	0.25
Bladder (incl. <i>in situ</i>)	3,189	38.9	0.31	45.5	0.36	995	10.0	0.14	11.7	0.17
Kidney & renal pelvis	1,690	20.0	0.22	23.8	0.26	921	9.8	0.15	11.5	0.17
Ureter	41	0.5	0.04	0.6	0.04	25	0.2	0.02	0.3	0.03
Eye & Orbit	99	1.2	0.06	1.4	0.06	78	0.9	0.05	1.0	0.05
Brain & Other CNS	626	8.0	0.15	8.9	0.16	483	5.7	0.12	6.2	0.13
Brain	588	7.5	0.14	8.3	0.15	458	5.3	0.12	5.9	0.12
Endocrine System	887	11.3	0.18	12.7	0.19	2,299	29.3	0.28	31.9	0.30
Thyroid gland	797	10.2	0.17	11.4	0.18	2,216	28.3	0.28	30.8	0.29
Lymphomas	2,079	25.7	0.26	29.5	0.29	1,672	18.4	0.21	21.0	0.23
Hodgkin lymphoma	224	3.1	0.09	3.2	0.10	187	2.5	0.09	2.6	0.09
Non-Hodgkin lymphoma	N/A	N/A	N/A	N/A	N/A	1,484	15.8	0.19	18.4	0.22
Multiple Myeloma	795	9.6	0.15	11.3	0.18	628	6.4	0.12	7.5	0.14
Leukemias	1,728	21.6	0.24	24.6	0.27	1,198	13.1	0.18	14.7	0.19
Acute lymphocytic	144	2.3	0.09	2.1	0.08	99	1.6	0.07	1.4	0.06
Chronic lymphocytic	828	9.8	0.15	11.7	0.18	537	5.4	0.11	6.4	0.12
Acute myeloid	353	4.4	0.11	5.0	0.12	280	3.1	0.08	3.5	0.09
Chronic myeloid	197	2.5	0.08	2.8	0.09	134	1.5	0.06	1.7	0.07
Other leukemias	206	2.6	0.08	3.0	0.09	148	1.6	0.06	1.8	0.07
Mesothelioma	165	2.1	0.07	2.4	0.08	50	0.5	0.03	0.6	0.04
Kaposi Sarcoma	40	0.5	0.04	0.6	0.04	8	0.1	0.01	0.1	0.01
Ill-Defined & Unknown	1,378	17.4	0.21	20.0	0.24	1,249	13.2	0.17	15.0	0.19
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	945	12.2	0.18	13.6	0.20	1,411	15.9	0.20	18.1	0.22
Breast (<i>in situ</i>)	7	0.1	0.01	0.1	0.02	1,561	17.1	0.20	20.5	0.23

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

PRINCE EDWARD ISLAND CANCER REGISTRY

Initial Operation: 1969
Population-based Data Available: 1969
Coverage Area: Province

Total Population Counts by Year

2015	2016	2017	2018	2019
144,546	146,969	150,402	153,396	157,419

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	121.0	113.5	110.2	96.8	108.6	110.0
Missing Race	na	na	na	na	na	na
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.3	0.1	0.3	0.5	0.2	0.3
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	88.5	Ovary	90.3
Oral Cavity & Pharynx	98.0	Prostate	95.3
Esophagus	90.2	Testis	100.0
Stomach	96.0	Bladder (incl. <i>in situ</i>)	99.2
Colon & Rectum	92.0	Kidney & Renal Pelvis	82.6
Liver	55.6	Brain & Other CNS	73.8
Pancreas	64.3	Brain & Other CNS (non-malig)	53.6
Lung & Bronchus	70.8	Thyroid	100.0
Melanomas of the Skin	99.4	Hodgkin Lymphoma	100.0
Female Breast (excl. <i>in situ</i>)	98.7	Non-Hodgkin Lymphoma	96.1
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	93.8
Cervix Uteri	100.0	Leukemias	98.0
Uterus Corpus & Uterus NOS	98.1		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Prince Edward Island, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	515	516.3	10.56	608.4	12.25	461	419.8	9.15	489.3	10.38
Oral Cavity & Pharynx	22	21.8	2.19	26.6	2.60	9	8.4	1.35	9.8	1.50
Lip	6	5.8	1.13	7.0	1.35	2	1.3	0.45	1.6	0.57
Tongue	6	5.7	1.11	7.0	1.34	2	1.9	0.67	2.1	0.72
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	1	1.1	0.44	1.5	0.59	*	*	*	*	*
Gum & other mouth	2	1.9	0.66	2.2	0.75	2	1.8	0.60	2.0	0.65
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	1	1.6	0.62	1.6	0.63	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	116	114.8	4.93	136.4	5.78	84	73.5	3.71	85.9	4.26
Esophagus	10	9.6	1.44	11.7	1.72	3	2.0	0.56	2.4	0.68
Stomach	11	11.1	1.54	13.3	1.81	4	3.3	0.77	3.9	0.90
Small intestine	1	1.4	0.59	1.6	0.67	2	1.9	0.58	2.2	0.66
Colon (excl. rectum)	41	40.6	2.92	47.8	3.41	39	33.6	2.48	39.5	2.88
Rectum & rectosigmoid	23	22.9	2.19	27.0	2.54	15	13.7	1.69	15.9	1.89
Anus, anal canal, & anorectum	*	*	*	*	*	2	1.9	0.62	2.3	0.70
Liver	8	7.8	1.24	9.3	1.46	2	2.3	0.68	2.5	0.73
Gallbladder	*	*	*	*	*	1	1.2	0.48	1.4	0.55
Pancreas	12	12.8	1.67	15.3	1.98	11	8.9	1.25	10.3	1.44
Respiratory System	80	80.1	4.14	93.4	4.78	75	63.8	3.35	74.6	3.88
Larynx	4	3.8	0.92	4.4	1.05	1	1.3	0.51	1.4	0.56
Lung & bronchus	75	75.5	4.01	88.2	4.64	73	61.5	3.28	71.9	3.81
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	4	4.9	1.08	5.2	1.12	2	1.6	0.62	1.7	0.63
Skin (excl. basal & sq.)	37	40.2	3.07	46.2	3.46	31	29.6	2.51	34.7	2.85
Melanoma of the skin	35	37.9	2.97	43.7	3.36	29	27.6	2.43	32.3	2.76
Breast (excl. <i>in situ</i>)	*	*	*	*	*	121	111.9	4.78	130.8	5.43
Female Genital System	N/A	N/A	N/A	N/A	N/A	57	52.9	3.32	62.0	3.76
Cervix uteri	N/A	N/A	N/A	N/A	N/A	8	9.3	1.59	9.9	1.63
Uterus corpus	N/A	N/A	N/A	N/A	N/A	31	26.1	2.19	32.4	2.66
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	12	12.1	1.64	13.7	1.78
Male Genital System	109	99.8	4.43	122.1	5.35	N/A	N/A	N/A	N/A	N/A
Prostate	106	95.5	4.28	117.8	5.22	N/A	N/A	N/A	N/A	N/A
Testis	3	4.1	1.11	4.1	1.11	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	58	58.8	3.57	69.0	4.14	25	21.2	1.96	25.2	2.29
Bladder (incl. <i>in situ</i>)	36	35.6	2.76	41.4	3.18	12	9.8	1.31	11.6	1.53
Kidney & renal pelvis	22	22.2	2.23	26.4	2.59	12	10.3	1.40	12.3	1.63
Ureter	*	*	*	*	*	1	1.1	0.43	1.3	0.51
Eye & Orbit	*	*	*	*	*	1	1.2	0.50	1.5	0.60
Brain & Other CNS	8	8.6	1.48	9.6	1.59	5	4.7	1.03	5.5	1.17
Brain	7	8.4	1.46	9.3	1.56	4	4.5	1.02	5.3	1.14
Endocrine System	5	5.8	1.18	6.6	1.30	8	9.0	1.54	9.6	1.58
Thyroid gland	4	4.5	1.04	5.2	1.16	7	8.3	1.46	9.1	1.52
Lymphomas	26	28.3	2.57	32.3	2.87	15	14.5	1.80	16.3	1.94
Hodgkin lymphoma	3	3.8	1.04	3.8	1.02	2	2.9	0.91	2.9	0.88
Non-Hodgkin lymphoma	23	24.5	2.36	28.5	2.69	13	11.7	1.56	13.4	1.73
Multiple Myeloma	8	7.7	1.30	9.1	1.51	5	4.6	0.92	5.4	1.07
Leukemias	12	14.3	1.90	15.6	2.02	8	7.9	1.38	8.5	1.42
Acute lymphocytic	1	1.7	0.72	1.6	0.65	1	2.1	0.89	1.7	0.71
Chronic lymphocytic	4	4.6	1.02	5.7	1.23	2	1.8	0.59	2.2	0.70
Acute myeloid	4	4.3	1.08	4.3	1.05	2	1.9	0.57	2.2	0.68
Chronic myeloid	2	2.9	0.86	3.0	0.89	*	*	*	*	*
Other leukemias	*	*	*	*	*	2	1.5	0.56	1.7	0.61
Mesothelioma	2	2.4	0.73	2.7	0.83	1	1.2	0.49	1.3	0.54
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	25	25.9	2.40	30.1	2.78	15	12.9	1.51	15.4	1.78
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	4	3.6	0.86	4.4	1.02	7	7.3	1.25	8.4	1.41
Breast (<i>in situ</i>)	*	*	*	*	*	18	16.8	1.84	19.7	2.09

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Initial Operation: 1932
 Population-based Data Available: 1932
 Coverage Area: Province

Total Population Counts by Year

2015	2016	2017	2018	2019
1,120,967	1,135,987	1,150,331	1,161,767	1,172,479

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	105.9	117.3	112.5	107.7	104.5	109.6
Missing Race	na	na	na	na	na	na
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.6	0.6	0.5	0.7	0.4	0.6
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	91.7	Ovary	88.0
Oral Cavity & Pharynx	98.4	Prostate	92.0
Esophagus	96.7	Testis	100.0
Stomach	96.5	Bladder (incl. <i>in situ</i>)	96.6
Colon & Rectum	95.7	Kidney & Renal Pelvis	88.5
Liver	73.7	Brain & Other CNS	89.2
Pancreas	76.9	Brain & Other CNS (non-malig)	71.8
Lung & Bronchus	80.3	Thyroid	98.9
Melanomas of the Skin	99.8	Hodgkin Lymphoma	98.4
Female Breast (excl. <i>in situ</i>)	98.4	Non-Hodgkin Lymphoma	96.9
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	92.2
Cervix Uteri	96.8	Leukemias	94.6
Uterus Corpus & Uterus NOS	99.0		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Saskatchewan, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	3,035	467.4	3.88	552.6	4.51	2,857	411.8	3.56	479.9	4.08
Oral Cavity & Pharynx	87	13.0	0.64	15.8	0.76	39	5.6	0.41	6.6	0.48
Lip	7	1.2	0.20	1.3	0.22	2	0.2	0.08	0.3	0.10
Tongue	25	3.7	0.34	4.6	0.41	12	1.6	0.22	1.9	0.26
Major salivary gland	7	1.2	0.21	1.3	0.22	5	0.7	0.15	0.8	0.17
Floor of mouth	4	0.6	0.14	0.7	0.16	4	0.5	0.11	0.7	0.15
Gum & other mouth	9	1.4	0.21	1.6	0.25	8	1.2	0.19	1.3	0.21
Nasopharynx	3	0.5	0.12	0.6	0.15	2	0.3	0.11	0.4	0.13
Oropharynx	4	0.7	0.15	0.8	0.17	2	0.3	0.09	0.3	0.10
Hypopharynx	5	0.7	0.15	0.9	0.18	1	0.2	0.08	0.2	0.08
Digestive System	718	110.6	1.89	131.7	2.21	520	71.5	1.45	83.8	1.68
Esophagus	49	7.4	0.49	9.0	0.58	12	1.6	0.21	2.0	0.25
Stomach	64	10.2	0.58	11.9	0.67	31	4.3	0.36	5.1	0.42
Small intestine	17	2.8	0.30	3.2	0.35	18	2.6	0.28	3.1	0.33
Colon (excl. rectum)	257	40.3	1.15	47.5	1.33	235	32.3	0.97	37.4	1.11
Rectum & rectosigmoid	155	23.4	0.86	28.3	1.02	80	11.3	0.59	13.4	0.68
Anus, anal canal, & anorectum	5	0.7	0.15	0.9	0.18	13	1.8	0.23	2.2	0.28
Liver	41	6.0	0.43	7.3	0.52	13	1.8	0.23	2.1	0.26
Gallbladder	7	1.0	0.18	1.2	0.22	10	1.4	0.20	1.7	0.23
Pancreas	80	12.3	0.63	14.6	0.73	72	9.5	0.51	11.3	0.61
Respiratory System	401	62.6	1.43	73.5	1.65	425	58.3	1.29	68.8	1.51
Larynx	24	3.6	0.33	4.4	0.40	4	0.5	0.12	0.6	0.14
Lung & bronchus	370	57.9	1.37	67.9	1.59	417	57.1	1.27	67.5	1.49
Bones & Joints	6	1.0	0.18	1.1	0.20	4	0.7	0.15	0.7	0.16
Soft Tissue (incl. heart)	19	3.0	0.31	3.5	0.36	18	2.7	0.30	3.0	0.32
Skin (excl. basal & sq.)	119	18.8	0.79	21.9	0.90	108	16.6	0.74	19.0	0.83
Melanoma of the skin	107	16.8	0.74	19.6	0.85	100	15.4	0.72	17.7	0.80
Breast (excl. <i>in situ</i>)	6	0.9	0.17	1.1	0.20	778	115.6	1.92	135.7	2.21
Female Genital System	N/A	N/A	N/A	N/A	N/A	356	52.8	1.30	61.8	1.48
Cervix uteri	N/A	N/A	N/A	N/A	N/A	57	10.4	0.63	10.6	0.64
Uterus corpus	N/A	N/A	N/A	N/A	N/A	188	26.4	0.89	32.5	1.07
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	4	0.5	0.13	0.6	0.15
Ovary	N/A	N/A	N/A	N/A	N/A	70	10.3	0.57	12.0	0.65
Male Genital System	750	110.9	1.85	134.0	2.20	N/A	N/A	N/A	N/A	N/A
Prostate	702	102.8	1.77	125.7	2.13	N/A	N/A	N/A	N/A	N/A
Testis	37	6.3	0.47	6.3	0.47	N/A	N/A	N/A	N/A	N/A
Penis	9	1.4	0.22	1.7	0.25	N/A	N/A	N/A	N/A	N/A
Urinary System	389	60.9	1.41	71.5	1.63	156	21.7	0.80	25.5	0.93
Bladder (incl. <i>in situ</i>)	235	36.9	1.10	43.4	1.27	74	9.7	0.52	11.5	0.61
Kidney & renal pelvis	145	22.5	0.86	26.5	0.99	77	11.4	0.60	13.3	0.69
Ureter	6	0.9	0.18	1.0	0.20	3	0.5	0.11	0.5	0.13
Eye & Orbit	4	0.7	0.15	0.8	0.17	3	0.5	0.12	0.6	0.14
Brain & Other CNS	43	7.0	0.48	7.7	0.52	32	5.0	0.41	5.6	0.45
Brain	42	6.7	0.47	7.4	0.51	31	4.9	0.41	5.4	0.44
Endocrine System	38	6.3	0.46	7.0	0.51	76	12.9	0.68	14.0	0.73
Thyroid gland	34	5.6	0.44	6.3	0.49	73	12.4	0.67	13.5	0.71
Lymphomas	161	25.2	0.91	29.1	1.03	134	19.5	0.78	22.4	0.88
Hodgkin lymphoma	15	2.4	0.29	2.6	0.30	11	1.9	0.26	2.0	0.27
Non-Hodgkin lymphoma	146	22.8	0.86	26.5	0.99	124	17.6	0.73	20.4	0.83
Multiple Myeloma	54	8.4	0.52	9.9	0.60	33	4.6	0.36	5.4	0.42
Leukemias	131	20.7	0.83	23.9	0.94	83	11.9	0.61	13.3	0.67
Acute lymphocytic	N/A	N/A	N/A	N/A	N/A	7	1.3	0.22	1.1	0.19
Chronic lymphocytic	63	9.7	0.56	11.6	0.65	37	5.1	0.39	6.1	0.45
Acute myeloid	29	4.7	0.40	5.4	0.45	20	2.9	0.30	3.3	0.33
Chronic myeloid	13	2.2	0.27	2.5	0.31	10	1.4	0.21	1.5	0.22
Other leukemias	15	2.4	0.28	2.7	0.32	N/A	N/A	N/A	N/A	N/A
Mesothelioma	13	2.2	0.27	2.5	0.31	3	0.5	0.12	0.5	0.14
Kaposi Sarcoma	2	0.3	0.10	0.3	0.10	*	*	*	*	*
Ill-Defined & Unknown	94	15.0	0.71	17.4	0.80	87	11.5	0.57	13.2	0.65
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	26	4.1	0.38	4.7	0.42	40	6.3	0.46	6.9	0.50
Breast (<i>in situ</i>)	*	*	*	*	*	103	15.5	0.70	18.6	0.83

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.

Initial Operation: 1987
 Population-based Data Available: 1987
 Coverage Area: Territory

Total Population Counts by Year

2015	2016	2017	2018	2019
37,690	38,547	39,610	40,519	41,362

Data Quality Indicators (2015–2019)

Indicators (%)	2015	2016	2017	2018	2019	2015–2019
Met Inclusion Criteria for Combined Rates	Yes	Yes	Yes	Yes	Yes	Yes
Completeness of Case Ascertainment	196.9	224.5	189.0	210.1	193.3	202.8
Missing Race	na	na	na	na	na	na
Missing Sex	0.0	0.0	0.0	0.0	0.0	0.0
Missing County	0.0	0.0	0.0	0.0	0.0	0.0
Missing Age	0.0	0.0	0.0	0.0	0.0	0.0
Death Certificate Only Cases	0.0	0.0	0.0	0.0	0.0	0.0
Passing Edits	100.0	100.0	100.0	100.0	100.0	100.0

Site-Specific Microscopic Confirmation (2015–2019)

Cancer Site	% Micro. Confirm	Cancer Site	% Micro. Confirm
All Sites	95.4	Ovary	100.0
Oral Cavity & Pharynx	100.0	Prostate	97.4
Esophagus	94.4	Testis	100.0
Stomach	100.0	Bladder (incl. <i>in situ</i>)	100.0
Colon & Rectum	98.4	Kidney & Renal Pelvis	87.0
Liver	50.0	Brain & Other CNS	84.6
Pancreas	94.4	Brain & Other CNS (non-malig)	87.5
Lung & Bronchus	87.5	Thyroid	100.0
Melanomas of the Skin	100.0	Hodgkin Lymphoma	100.0
Female Breast (excl. <i>in situ</i>)	100.0	Non-Hodgkin Lymphoma	100.0
Female Breast (<i>in situ</i>)	100.0	Multiple Myeloma	100.0
Cervix Uteri	100.0	Leukemias	100.0
Uterus Corpus & Uterus NOS	100.0		

Abbreviations: NOS, Not Otherwise Specified; CNS, Central Nervous System

**Average Annual Cancer Cases and Age-Adjusted Incidence Rates
Yukon, 2015–2019, All Races**

SITES	MALES (ALL RACES)					FEMALES (ALL RACES)				
	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>	<i>Average Annual Cases</i>	<i>Adj. Rate 2000 U.S.</i>	<i>S.E.</i>	<i>Adj. Rate 2011 CAN</i>	<i>S.E.</i>
All Sites (invasive & <i>in situ</i> bladder)	97	458.1	23.12	540.7	26.65	80	390.8	21.32	459.0	24.28
Oral Cavity & Pharynx	5	19.2	4.08	25.1	5.12	2	7.0	2.68	9.0	3.40
Lip	*	*	*	*	*	*	*	*	*	*
Tongue	1	5.7	2.30	7.0	2.72	*	*	*	*	*
Major salivary gland	*	*	*	*	*	*	*	*	*	*
Floor of mouth	*	*	*	*	*	*	*	*	*	*
Gum & other mouth	*	*	*	*	*	*	*	*	*	*
Nasopharynx	*	*	*	*	*	*	*	*	*	*
Oropharynx	*	*	*	*	*	*	*	*	*	*
Hypopharynx	*	*	*	*	*	*	*	*	*	*
Digestive System	26	120.2	11.77	144.4	13.80	15	78.7	9.88	93.1	11.31
Esophagus	2	12.3	4.08	14.2	4.75	1	6.1	2.50	7.7	3.08
Stomach	*	*	*	*	*	*	*	*	*	*
Small intestine	*	*	*	*	*	*	*	*	*	*
Colon (excl. rectum)	10	46.3	7.30	55.9	8.60	7	43.4	7.79	49.8	8.73
Rectum & rectosigmoid	6	28.0	5.59	33.9	6.64	2	10.0	3.33	12.5	4.02
Anus, anal canal, & anorectum	*	*	*	*	*	*	*	*	*	*
Liver	3	10.0	3.06	12.3	3.52	*	*	*	*	*
Gallbladder	*	*	*	*	*	*	*	*	*	*
Pancreas	2	9.3	3.46	10.8	3.93	2	7.1	2.42	8.6	2.90
Respiratory System	15	78.0	10.07	89.5	11.42	10	53.9	8.44	64.2	9.65
Larynx	1	5.6	2.15	6.7	2.52	*	*	*	*	*
Lung & bronchus	13	71.3	9.78	82.0	11.10	9	50.3	8.14	60.0	9.32
Bones & Joints	*	*	*	*	*	*	*	*	*	*
Soft Tissue (incl. heart)	*	*	*	*	*	*	*	*	*	*
Skin (excl. basal & sq.)	1	3.5	1.44	5.0	2.04	2	11.7	3.66	14.1	4.28
Melanoma of the skin	1	3.5	1.44	5.0	2.04	2	9.3	3.15	11.0	3.56
Breast (excl. <i>in situ</i>)	*	*	*	*	*	26	117.6	11.08	141.0	12.82
Female Genital System	N/A	N/A	N/A	N/A	N/A	10	46.4	6.99	53.9	7.87
Cervix uteri	N/A	N/A	N/A	N/A	N/A	1	6.0	2.28	6.5	2.47
Uterus corpus	N/A	N/A	N/A	N/A	N/A	6	23.9	4.73	28.7	5.43
Uterus, NOS	N/A	N/A	N/A	N/A	N/A	*	*	*	*	*
Ovary	N/A	N/A	N/A	N/A	N/A	2	11.7	3.95	12.8	4.30
Male Genital System	26	110.4	10.55	129.4	11.95	N/A	N/A	N/A	N/A	N/A
Prostate	23	96.8	9.89	116.1	11.41	N/A	N/A	N/A	N/A	N/A
Testis	3	13.6	3.68	13.3	3.56	N/A	N/A	N/A	N/A	N/A
Penis	*	*	*	*	*	N/A	N/A	N/A	N/A	N/A
Urinary System	9	51.5	8.45	60.8	9.98	3	17.4	4.85	19.4	5.27
Bladder (incl. <i>in situ</i>)	7	31.7	6.17	37.3	7.17	*	*	*	*	*
Kidney & renal pelvis	3	17.5	5.32	20.6	6.31	2	9.9	3.43	11.3	3.73
Ureter	*	*	*	*	*	*	*	*	*	*
Eye & Orbit	*	*	*	*	*	*	*	*	*	*
Brain & Other CNS	*	*	*	*	*	2	7.9	2.96	8.5	3.18
Brain	*	*	*	*	*	2	7.9	2.96	8.5	3.18
Endocrine System	*	*	*	*	*	2	8.6	2.78	9.4	2.98
Thyroid gland	*	*	*	*	*	2	8.6	2.78	9.4	2.98
Lymphomas	6	33.2	6.78	38.5	7.68	3	15.6	4.56	17.9	5.10
Hodgkin lymphoma	*	*	*	*	*	*	*	*	*	*
Non-Hodgkin lymphoma	6	28.5	6.17	33.3	6.92	3	14.5	4.42	16.9	5.01
Multiple Myeloma	*	*	*	*	*	*	*	*	*	*
Leukemias	3	13.2	3.68	14.5	3.94	1	9.5	3.64	9.7	3.81
Acute lymphocytic	*	*	*	*	*	*	*	*	*	*
Chronic lymphocytic	*	*	*	*	*	*	*	*	*	*
Acute myeloid	*	*	*	*	*	*	*	*	*	*
Chronic myeloid	*	*	*	*	*	*	*	*	*	*
Other leukemias	*	*	*	*	*	*	*	*	*	*
Mesothelioma	*	*	*	*	*	*	*	*	*	*
Kaposi Sarcoma	*	*	*	*	*	*	*	*	*	*
Ill-Defined & Unknown	2	8.8	2.85	11.6	3.58	N/A	N/A	N/A	N/A	N/A
Selected Sites (Non-Malignant or <i>in situ</i>)										
Brain & Other CNS (non-malignant)	*	*	*	*	*	*	*	*	*	*
Breast (<i>in situ</i>)	*	*	*	*	*	2	8.7	3.21	10.8	3.84

Abbreviations: CAN, Canadian; CNS, Central Nervous System; NOS, Not Otherwise Specified; S.E., Standard Error

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population as well as the 2011 Canadian Standard Population

N/A Information about data not collected

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer. The suppressed cases, however, are included in the counts and rates for All Sites combined.



Section III

Registry-Specific Stage at Diagnosis by Age for Select Cancer Sites



**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Alabama, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	105	43.3	4.4	70	45.2	4.5	27	36.7	4.0	*	*	*	2	52.9	4.6	4	51.4	4.5
Regional	72	30.0	2.8	46	29.7	2.7	22	30.9	3.2	*	*	*	1	41.2	3.3	2	29.7	3.1
Distant	30	12.6	1.1	20	13.1	1.0	9	12.7	1.3	*	*	*	*	*	*	*	*	*
Unknown	34	14.1	1.3	18	11.9	1.0	14	19.6	2.0	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	53	3.8	1.8	39	3.9	1.8	12	3.8	2.1	*	*	*	*	*	*	*	*	*
Localized	492	35.7	17.9	363	35.7	17.5	108	33.9	19.1	*	*	*	3	31.1	9.3	6	41.1	10.1
Regional	478	34.6	17.5	366	36.0	17.7	101	31.6	18.6	*	*	*	4	48.9	15.7	5	34.2	9.8
Distant	259	18.8	9.5	186	18.3	9.1	69	21.5	12.2	*	*	*	1	15.6	5.4	2	15.1	3.7
Unknown	98	7.1	3.7	64	6.3	3.2	30	9.3	5.6	*	*	*	*	*	*	1	9.6	2.9
<i>Age < 50</i>																		
<i>In Situ</i>	4	2.3	0.3	3	2.3	0.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	51	32.1	3.5	36	32.8	3.7	10	27.4	3.0	*	*	*	*	*	*	2	42.9	2.2
Regional	57	36.1	4.0	42	38.0	4.4	13	34.2	3.7	*	*	*	*	*	*	*	*	*
Distant	39	24.7	2.7	25	22.7	2.6	11	30.0	3.3	*	*	*	*	*	*	*	*	*
Unknown	8	4.8	0.5	5	4.1	0.5	2	6.3	0.7	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	49	4.0	5.9	37	4.0	5.7	*	*	*	*	*	*	*	*	*	*	*	*
Localized	442	36.1	55.7	326	36.0	53.6	98	34.8	61.2	*	*	*	*	*	*	4	40.4	30.7
Regional	421	34.4	52.7	323	35.7	52.6	88	31.2	57.7	*	*	*	*	*	*	*	*	*
Distant	220	18.0	27.4	160	17.7	26.0	57	20.4	35.6	*	*	*	*	*	*	*	*	*
Unknown	90	7.4	12.0	59	6.5	10.3	27	9.7	18.7	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	39	3.1	1.2	26	3.0	1.1	12	3.7	1.5	*	*	*	*	*	*	*	*	*
Localized	456	36.6	14.0	324	36.7	13.5	110	34.3	14.3	*	*	*	4	36.4	11.4	5	37.1	8.5
Regional	430	34.5	13.3	318	36.1	13.6	103	32.0	13.8	*	*	*	4	36.4	11.0	5	37.1	9.0
Distant	222	17.9	7.0	150	16.9	6.4	68	21.1	9.2	*	*	*	2	21.8	6.3	2	16.1	4.1
Unknown	97	7.8	2.9	65	7.3	2.6	28	8.8	3.6	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	3	2.0	0.2	2	2.5	0.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	51	34.1	3.3	32	32.5	3.3	15	35.3	3.2	*	*	*	*	*	*	2	40.0	2.5
Regional	54	36.4	3.6	39	39.7	4.0	13	30.4	2.9	*	*	*	*	*	*	2	40.0	2.4
Distant	30	20.1	2.0	18	18.0	1.8	11	26.1	2.5	*	*	*	*	*	*	*	*	*
Unknown	11	7.4	0.7	7	7.4	0.7	3	6.8	0.7	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	36	3.3	3.7	24	3.0	3.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	406	37.0	42.0	292	37.2	40.4	96	34.2	43.2	*	*	*	*	*	*	3	35.7	24.2
Regional	376	34.3	38.9	279	35.6	38.5	90	32.3	42.5	*	*	*	*	*	*	3	35.7	26.0
Distant	193	17.6	20.0	132	16.8	18.4	57	20.4	26.4	*	*	*	*	*	*	*	*	*
Unknown	86	7.9	8.6	58	7.3	7.6	25	9.1	11.5	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Alabama, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	747	16.2	23.7	524	15.8	23.4	199	17.0	25.8	*	*	*	11	25.1	26.5	5	13.6	9.2
Localized	2,506	54.2	78.6	1,887	56.8	81.0	556	47.5	73.2	*	*	*	17	39.8	42.9	21	52.5	34.9
Regional	984	21.3	32.3	668	20.1	30.8	291	24.8	38.5	*	*	*	11	25.6	26.2	11	26.8	17.2
Distant	232	5.0	7.2	143	4.3	6.1	84	7.2	11.0	*	*	*	1	2.8	3.2	1	3.5	2.3
Unknown	151	3.3	4.7	100	3.0	4.1	40	3.5	5.4	*	*	*	3	6.6	8.3	1	3.5	2.2
<i>Age < 50</i>																		
<i>In Situ</i>	129	16.2	8.8	87	17.1	9.1	34	14.0	8.1	*	*	*	4	23.3	13.8	2	8.9	2.8
Localized	388	48.9	26.0	256	50.5	26.4	110	45.9	25.8	*	*	*	8	42.2	25.4	9	50.0	15.4
Regional	218	27.4	14.7	135	26.6	14.0	71	29.6	16.6	*	*	*	5	30.0	17.6	6	31.1	9.5
Distant	36	4.5	2.4	19	3.7	1.9	16	6.6	3.7	*	*	*	*	*	*	*	*	*
Unknown	23	2.9	1.5	10	2.1	1.1	9	3.9	2.1	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	618	16.2	62.9	437	15.5	60.8	166	17.8	72.2	*	*	*	6	26.4	59.8	4	17.6	25.8
Localized	2,118	55.4	216.2	1,631	57.9	224.0	446	47.9	197.2	*	*	*	9	38.0	88.8	12	54.6	86.1
Regional	766	20.0	78.7	534	19.0	74.6	220	23.6	95.9	*	*	*	5	22.3	48.8	5	23.1	37.2
Distant	196	5.1	19.8	125	4.4	17.1	68	7.4	30.1	*	*	*	*	*	*	*	*	*
Unknown	128	3.3	13.0	89	3.2	12.0	31	3.3	14.0	*	*	*	*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	5	0.2	0.2	5	0.3	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	510	22.5	18.2	418	23.6	19.2	85	18.2	14.8	*	*	*	2	17.3	8.3	2	26.8	6.2
Regional	545	24.1	18.7	432	24.4	19.3	108	23.2	18.5	*	*	*	2	23.1	10.5	*	*	*
Distant	930	41.1	32.3	699	39.5	31.7	221	47.4	37.5	*	*	*	5	48.1	19.7	3	41.5	7.9
Unknown	274	12.1	10.2	217	12.2	10.4	52	11.1	10.2	*	*	*	1	11.5	4.7	2	22.0	5.3
<i>Female</i>																		
<i>In Situ</i>	5	0.3	0.1	4	0.3	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	490	28.4	14.1	412	29.2	15.8	70	24.3	9.0	*	*	*	3	26.9	9.1	3	34.1	7.0
Regional	394	22.8	11.3	325	23.0	12.5	64	22.3	8.2	*	*	*	2	17.3	4.9	2	26.8	5.0
Distant	646	37.5	18.6	516	36.6	20.0	121	42.1	15.5	*	*	*	5	48.1	15.8	3	36.6	6.3
Unknown	189	11.0	5.4	153	10.9	5.8	32	11.1	4.4	*	*	*	*	*	*	*	*	*

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	2,834	75.9	93.0	1,745	75.8	75.0	860	73.8	134.0	1	87.5	30.8	9	61.1	34.3	23	79.7	49.2
Regional	392	10.5	12.3	278	12.1	11.6	107	9.2	15.7	*	*	*	2	16.7	7.9	3	9.1	4.3
Distant	185	5.0	6.6	105	4.6	5.0	77	6.6	13.4	*	*	*	*	*	*	2	6.3	3.7
Unknown	320	8.6	12.0	172	7.5	8.4	121	10.4	24.5	*	*	*	3	18.1	14.3	1	4.9	4.1
<i>Age < 65</i>																		
Localized	1,187	77.6	42.0	646	77.8	31.1	459	76.2	71.1	*	*	*	3	72.7	10.0	11	77.1	17.3
Regional	189	12.4	6.6	121	14.6	5.7	65	10.8	10.1	*	*	*	*	*	*	*	*	*
Distant	62	4.0	2.2	24	2.8	1.1	37	6.1	5.6	*	*	*	*	*	*	*	*	*
Unknown	91	6.0	3.3	40	4.8	2.0	42	6.9	6.4	*	*	*	*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	1,646	74.8	445.5	1,099	74.7	378.2	401	71.3	569.1	*	*	*	6	56.0	202.3	12	82.2	269.9
Regional	203	9.2	51.9	157	10.7	51.7	42	7.5	54.6	*	*	*	*	*	*	*	*	*
Distant	124	5.6	37.4	82	5.6	31.5	41	7.2	67.3	*	*	*	*	*	*	*	*	*
Unknown	229	10.4	72.2	133	9.0	52.6	79	14.0	149.1	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Alaska, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	15	55.9	4.3	10	57.6	4.1	*	*	*	3	45.5	5.6	2	71.4	6.7	*	*	*
Regional	7	25.7	2.0	4	23.5	1.6	*	*	*	2	33.3	4.6	*	*	*	*	*	*
Distant	4	14.7	1.0	3	15.3	1.0	*	*	*	1	21.2	2.7	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	3	2.1	0.9	1	1.1	0.4	*	*	*	2	5.2	4.6	*	*	*	*	*	*
Localized	53	32.3	14.5	36	33.2	12.8	1	41.2	16.4	13	31.0	31.0	1	23.3	7.0	*	*	*
Regional	60	36.3	16.5	40	36.6	14.7	1	41.2	16.8	14	33.8	31.5	3	46.7	15.0	1	35.0	9.5
Distant	37	22.4	10.0	22	20.4	8.4	*	*	*	12	28.1	26.0	1	23.3	4.3	*	*	*
Unknown	12	7.0	3.3	10	8.7	3.7	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	7	33.3	3.1	4	31.3	2.8	*	*	*	2	31.3	6.6	*	*	*	*	*	*
Regional	7	33.3	3.1	5	38.8	3.4	*	*	*	1	21.9	4.5	*	*	*	*	*	*
Distant	6	28.7	2.6	4	26.9	2.3	*	*	*	2	37.5	7.0	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	1	1.2	1.4	*	*	*	*	*	*	*	*	*	*	*	*
Localized	46	32.1	44.3	32	33.4	39.3	*	*	*	11	30.9	94.8	*	*	*	*	*	*
Regional	53	36.7	51.5	35	36.3	44.4	*	*	*	13	36.0	102.0	*	*	*	*	*	*
Distant	31	21.4	29.2	19	19.5	24.1	*	*	*	9	26.4	75.8	1	25.0	15.5	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	3	1.9	0.7	1	1.8	0.6	*	*	*	*	*	*	*	*	*	*	*	*
Localized	46	34.1	13.0	25	32.3	10.5	1	46.2	13.0	16	36.1	30.5	2	25.8	4.4	2	50.0	16.2
Regional	52	38.6	15.2	31	38.9	12.4	*	*	*	17	40.3	38.0	2	38.7	8.3	*	*	*
Distant	25	18.9	7.4	15	18.8	6.0	*	*	*	8	19.4	17.9	*	*	*	*	*	*
Unknown	9	6.4	2.8	6	8.1	2.8	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	9	40.7	4.1	5	38.7	3.5	*	*	*	3	53.1	11.4	*	*	*	*	*	*
Regional	7	31.5	3.3	4	32.3	3.0	*	*	*	2	25.0	5.3	*	*	*	*	*	*
Distant	5	21.3	2.2	3	22.6	2.0	*	*	*	1	18.8	3.9	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	37	32.9	36.3	21	31.1	29.1	1	50.0	47.1	12	33.2	80.7	*	*	*	*	*	*
Regional	45	40.0	46.5	27	40.2	37.1	*	*	*	16	42.9	123.5	*	*	*	*	*	*
Distant	21	18.5	21.3	12	18.1	16.5	*	*	*	7	19.6	54.5	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Alaska, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	90	16.9	24.0	68	17.8	25.6	3	22.4	31.3	13	14.4	24.1	4	14.0	13.8	3	12.5	16.7
Localized	283	53.0	77.1	207	54.3	80.0	5	38.8	51.5	48	54.6	92.5	14	46.7	43.9	9	42.3	67.2
Regional	119	22.4	33.3	80	20.9	31.9	4	29.9	36.3	20	23.1	40.1	9	30.7	27.6	6	29.8	43.7
Distant	29	5.5	8.1	18	4.6	6.8	*	*	*	6	7.3	12.5	2	7.3	7.4	2	10.6	11.1
Unknown	12	2.2	3.4	9	2.4	3.8	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	18	16.0	9.2	15	18.7	11.2	*	*	*	3	13.3	9.0	*	*	*	*	*	*
Localized	53	46.3	26.0	38	47.6	28.0	1	33.3	18.3	9	46.9	31.4	3	42.4	13.3	2	40.0	17.8
Regional	34	29.4	16.0	21	26.8	15.5	2	50.0	23.0	6	29.6	18.7	3	45.5	13.8	2	33.3	13.9
Distant	7	5.9	3.2	3	3.8	2.1	*	*	*	2	9.2	6.0	*	*	*	*	*	*
Unknown	3	2.3	1.2	2	3.0	1.7	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	72	17.2	62.8	53	17.6	63.4	*	*	*	10	14.7	63.8	*	*	*	*	*	*
Localized	230	54.8	211.1	169	56.1	216.0	4	40.8	138.5	39	56.8	252.4	11	47.9	124.0	6	43.2	196.3
Regional	86	20.4	78.7	58	19.4	74.6	2	22.4	71.2	14	21.2	96.1	6	26.5	63.8	4	28.4	121.8
Distant	23	5.4	21.0	15	4.8	19.3	*	*	*	5	6.8	29.5	*	*	*	*	*	*
Unknown	9	2.2	9.3	7	2.2	9.2	*	*	*	*	*	*	*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	41	20.6	12.9	31	21.5	12.7	*	*	*	7	18.2	18.1	*	*	*	1	31.6	14.8
Regional	44	21.9	12.6	29	20.2	11.0	2	39.1	17.4	11	29.7	28.6	1	14.0	7.3	*	*	*
Distant	96	48.1	27.4	70	48.1	25.6	1	30.4	16.7	19	48.4	45.4	5	55.8	22.4	2	52.6	22.4
Unknown	19	9.4	6.3	15	10.2	6.3	*	*	*	1	3.6	3.7	2	18.6	10.6	*	*	*
<i>Female</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	43	24.7	11.7	31	26.4	11.3	*	*	*	10	23.5	19.1	1	14.0	5.3	*	*	*
Regional	41	23.7	11.6	29	24.8	11.1	*	*	*	9	21.6	17.8	2	20.9	6.8	*	*	*
Distant	77	44.2	22.0	46	40.0	18.4	3	59.1	31.0	21	51.5	42.4	5	58.1	18.1	2	47.1	17.2
Unknown	12	7.0	3.9	10	8.4	4.3	*	*	*	1	2.9	3.1	*	*	*	*	*	*

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	216	60.3	52.6	176	60.3	55.5	9	61.1	67.2	17	60.4	38.6	6	55.6	27.5	5	58.5	37.9
Regional	49	13.8	11.6	41	14.1	12.5	2	13.9	12.9	4	13.9	8.6	1	11.1	3.9	*	*	*
Distant	36	10.1	11.2	28	9.5	11.0	*	*	*	6	19.4	14.2	1	13.0	7.5	*	*	*
Unknown	56	15.7	16.7	47	16.2	18.0	3	20.8	30.6	2	6.3	7.4	2	20.4	9.9	1	17.1	14.2
<i>Age < 65</i>																		
Localized	91	64.5	20.1	72	64.3	21.1	6	64.6	42.8	7	67.3	13.1	2	47.6	7.2	2	66.7	12.3
Regional	24	16.8	5.2	19	16.6	5.5	*	*	*	2	21.2	3.9	*	*	*	*	*	*
Distant	9	6.5	2.0	7	6.6	2.1	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	17	12.2	3.7	14	12.5	4.0	2	16.7	11.0	*	*	*	*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	125	57.6	277.2	104	57.8	293.1	3	54.2	235.8	10	56.5	215.1	4	60.6	168.1	3	53.8	215.2
Regional	26	11.8	55.8	22	12.5	61.1	*	*	*	2	9.8	40.9	*	*	*	*	*	*
Distant	27	12.5	75.1	20	11.2	71.9	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	39	18.0	106.5	33	18.5	114.5	1	29.2	166.1	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Arizona, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	105	45.5	3.2	58	45.7	3.0	3	45.7	2.2	3	32.6	1.9	3	61.5	2.2	37	45.7	3.9
Regional	62	27.1	1.7	34	26.9	1.6	3	37.1	1.6	4	41.3	2.9	*	*	*	21	25.7	2.4
Distant	32	13.9	0.8	19	15.3	0.7	*	*	*	1	13.0	0.9	*	*	*	10	12.3	1.2
Unknown	31	13.5	0.8	15	12.1	0.6	*	*	*	1	13.0	0.9	*	*	*	13	16.3	1.5

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	25	1.7	0.6	18	1.6	0.6	1	3.0	0.9	*	*	*	*	*	*	4	1.7	0.6
Localized	460	31.1	11.2	353	32.0	11.6	14	29.9	9.6	14	33.0	11.2	5	21.8	4.7	70	27.5	10.3
Regional	516	34.9	12.7	384	34.9	12.9	15	31.6	10.7	13	31.6	11.5	9	40.9	9.0	92	36.1	14.0
Distant	312	21.1	7.8	226	20.5	7.8	12	25.5	8.2	9	21.8	8.2	5	23.6	4.7	59	22.9	8.3
Unknown	165	11.1	4.1	121	11.0	4.0	5	10.0	4.2	5	11.2	5.0	3	11.8	2.7	30	11.9	4.9
<i>Age < 50</i>																		
<i>In Situ</i>	2	1.4	0.1	1	1.3	0.1	*	*	*	*	*	*	*	*	*	*	*	*
Localized	42	27.1	1.9	26	28.1	2.3	2	30.0	2.1	2	27.0	2.4	*	*	*	11	24.7	1.4
Regional	55	35.6	2.6	33	35.8	2.9	2	22.5	1.6	2	21.6	1.9	2	50.0	2.1	17	39.5	2.5
Distant	44	28.1	2.1	26	28.6	2.3	3	35.0	2.5	3	37.8	3.4	1	30.0	1.3	11	24.7	1.6
Unknown	12	7.7	0.6	6	6.2	0.5	*	*	*	*	*	*	*	*	*	4	10.2	0.6
<i>Age ≥ 50</i>																		
<i>In Situ</i>	23	1.8	2.0	17	1.7	1.9	*	*	*	*	*	*	*	*	*	*	*	*
Localized	418	31.6	35.5	327	32.4	36.1	11	29.8	29.3	12	34.3	34.0	*	*	*	60	28.0	33.6
Regional	460	34.8	39.1	351	34.8	38.8	13	33.5	34.6	11	33.7	36.8	7	38.9	27.2	75	35.4	44.1
Distant	268	20.3	22.7	200	19.8	22.3	9	23.6	23.3	6	18.3	20.8	4	22.2	13.5	48	22.5	26.0
Unknown	153	11.5	13.4	115	11.4	13.0	*	*	*	*	*	*	*	*	*	26	12.2	16.1
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	18	1.5	0.4	13	1.3	0.4	*	*	*	1	4.1	0.8	*	*	*	3	1.2	0.3
Localized	406	32.1	9.0	309	32.9	9.5	12	28.0	8.5	10	28.1	6.7	7	26.8	5.3	63	29.8	8.1
Regional	461	36.5	10.4	344	36.6	10.5	17	38.8	12.2	12	36.3	9.7	9	33.3	6.6	78	36.8	10.1
Distant	234	18.5	5.3	169	18.0	5.2	9	20.6	6.5	7	19.9	4.9	6	22.5	4.4	43	20.2	5.4
Unknown	144	11.4	3.1	104	11.1	2.9	4	10.3	3.3	4	11.7	3.1	4	15.9	3.5	25	12.0	3.5
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	43	31.4	2.1	28	35.9	2.6	1	19.4	1.3	1	19.4	1.4	*	*	*	12	28.2	1.7
Regional	53	38.3	2.6	29	37.2	2.7	4	50.0	3.6	3	41.9	3.0	2	44.4	2.3	16	37.3	2.4
Distant	31	22.4	1.5	16	20.8	1.5	2	22.2	1.7	2	25.8	1.9	1	22.2	1.1	10	24.9	1.5
Unknown	10	7.2	0.5	4	5.7	0.4	*	*	*	*	*	*	*	*	*	4	8.6	0.5
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	1	5.0	3.0	*	*	*	*	*	*
Localized	362	32.2	27.0	281	32.6	27.5	11	29.8	27.3	8	30.0	20.4	*	*	*	51	30.2	25.0
Regional	408	36.3	30.6	315	36.6	31.0	13	36.5	34.6	10	35.0	27.0	7	30.6	18.1	62	36.6	30.4
Distant	203	18.1	15.1	153	17.8	14.9	7	20.2	19.1	5	18.6	13.0	5	22.5	13.1	32	19.1	15.6
Unknown	134	11.9	9.8	100	11.6	9.3	*	*	*	*	*	*	*	*	*	22	12.8	11.2

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Arizona, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	1,044	17.2	24.2	780	16.9	26.5	41	21.5	28.1	16	17.2	11.4	32	20.6	21.3	164	17.2	19.3
Localized	3,280	54.1	73.6	2,580	56.0	81.2	83	43.7	58.1	43	45.3	30.3	79	50.2	53.5	465	48.8	56.4
Regional	1,216	20.1	29.3	880	19.1	31.4	44	23.3	30.4	24	25.8	17.2	35	22.0	23.1	225	23.7	26.6
Distant	252	4.2	5.8	183	4.0	6.0	11	6.0	7.9	6	6.6	4.7	6	3.7	4.1	45	4.7	5.4
Unknown	268	4.4	6.0	186	4.0	5.5	10	5.4	7.5	5	5.1	3.8	6	3.6	4.0	55	5.7	6.7
<i>Age < 50</i>																		
<i>In Situ</i>	183	18.4	9.1	115	19.2	10.7	9	17.8	9.5	3	15.6	3.5	10	18.1	9.0	44	16.9	6.7
Localized	449	45.1	22.0	277	46.2	25.7	20	38.2	19.5	7	38.5	8.7	25	47.5	23.7	115	44.0	17.3
Regional	282	28.4	13.8	169	28.3	15.7	15	29.3	15.1	5	27.1	5.9	15	28.7	14.2	75	28.7	11.2
Distant	41	4.2	2.0	23	3.9	2.1	4	8.5	4.3	2	12.5	2.8	*	*	*	10	3.8	1.4
Unknown	39	3.9	1.9	14	2.4	1.3	3	6.2	3.1	1	6.3	1.4	2	3.8	1.9	17	6.5	2.5
<i>Age ≥ 50</i>																		
<i>In Situ</i>	861	17.0	64.0	666	16.6	67.9	32	23.0	77.0	13	17.6	32.1	23	21.8	53.3	119	17.3	52.3
Localized	2,832	55.9	208.5	2,303	57.4	226.7	63	45.8	158.9	35	47.1	87.0	54	51.5	131.7	349	50.5	158.9
Regional	934	18.4	69.8	711	17.7	72.3	29	21.1	70.5	19	25.5	46.6	19	18.6	46.6	150	21.7	66.9
Distant	211	4.2	15.8	159	4.0	16.1	7	5.1	17.3	4	5.1	9.6	*	*	*	35	5.0	15.8
Unknown	229	4.5	16.7	172	4.3	16.3	7	5.1	19.2	4	4.8	10.1	4	3.4	9.6	38	5.4	17.6

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	2	0.1	0.1	2	0.1	0.1	*	*	*	*	*	*	*	*	*	*	*	*
Localized	473	23.4	11.1	417	24.2	12.2	14	21.5	13.4	3	17.6	3.4	4	14.6	4.7	33	18.0	6.1
Regional	403	19.9	9.3	345	20.0	10.1	14	20.9	11.7	5	29.4	5.4	5	18.8	5.9	33	18.1	5.8
Distant	865	42.7	20.2	723	41.9	21.6	28	41.8	24.2	7	41.2	7.9	17	59.0	17.9	88	48.0	15.4
Unknown	282	13.9	6.7	236	13.7	7.0	11	15.8	8.5	2	11.8	1.9	2	7.6	2.3	29	15.8	5.6
<i>Female</i>																		
<i>In Situ</i>	8	0.4	0.2	5	0.3	0.1	*	*	*	*	*	*	*	*	*	2	0.9	0.2
Localized	565	28.3	11.5	496	29.1	13.1	16	27.4	12.4	4	22.2	3.0	8	20.7	5.8	40	23.8	5.9
Regional	378	19.0	7.7	324	19.0	8.6	10	18.2	7.2	5	27.8	3.5	6	16.3	4.4	33	19.4	4.6
Distant	775	38.9	16.0	653	38.3	17.7	22	39.3	15.8	7	40.0	5.6	18	48.9	13.0	71	42.3	10.1
Unknown	268	13.5	5.5	228	13.4	6.0	8	14.4	6.2	2	10.0	1.6	5	13.6	4.2	23	13.5	3.4

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	2,296	66.8	51.3	1,801	67.6	52.9	111	66.9	74.0	23	48.7	21.6	26	67.9	25.7	275	62.7	40.3
Regional	469	13.7	10.4	367	13.8	10.8	24	14.4	15.9	6	13.4	5.8	6	15.5	5.4	63	14.3	8.4
Distant	280	8.2	6.6	206	7.7	6.2	13	8.1	10.3	8	17.7	9.3	3	7.8	3.8	48	11.0	8.5
Unknown	391	11.4	9.3	292	10.9	8.7	18	10.6	15.8	9	20.3	11.0	3	8.8	4.6	53	12.0	9.9
<i>Age < 65</i>																		
Localized	826	71.0	22.0	595	72.6	23.4	66	70.4	42.3	7	50.0	5.6	10	73.8	8.7	127	65.5	16.1
Regional	196	16.9	5.2	140	17.1	5.5	13	14.3	8.4	2	14.3	1.6	3	20.0	2.4	36	18.4	4.5
Distant	68	5.8	1.8	41	5.0	1.5	7	7.1	4.1	2	15.7	1.8	*	*	*	18	9.1	2.2
Unknown	74	6.3	1.9	43	5.3	1.7	8	8.1	4.8	3	20.0	2.2	*	*	*	14	7.0	1.7
<i>Age ≥ 65</i>																		
Localized	1,470	64.7	253.2	1,206	65.3	256.5	45	62.4	293.3	16	48.1	131.6	17	64.8	143.1	148	60.5	207.3
Regional	273	12.0	46.0	226	12.3	47.3	10	14.4	67.5	4	13.0	34.6	3	13.3	25.9	27	11.1	35.4
Distant	213	9.4	40.3	166	9.0	38.0	7	9.4	53.1	6	18.5	61.1	*	*	*	31	12.5	52.1
Unknown	318	14.0	60.6	248	13.5	57.2	10	13.8	91.9	7	20.4	71.3	*	*	*	39	15.9	66.7

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Arkansas, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	63	42.0	4.2	47	43.2	4.2	8	36.2	3.4	Insufficient data for the calculation of AI/AN PRCDA statistics			1	46.2	4.2	4	52.5	5.2
Regional	50	33.8	3.1	38	34.4	3.0	9	38.8	3.7				*	*	*	2	30.0	3.9
Distant	20	13.7	1.3	16	14.3	1.3	4	15.5	1.6				*	*	*	*	*	*
Unknown	16	10.6	1.0	9	8.1	0.6	2	9.5	0.9				*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	16	1.8	0.9	13	1.8	0.8	2	1.6	1.0	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	259	29.3	15.2	213	29.9	15.0	34	26.7	17.5				2	29.4	9.1	4	25.6	5.8
Regional	331	37.4	19.8	274	38.5	19.7	43	33.4	22.2				2	29.4	9.3	6	39.7	9.2
Distant	195	22.0	11.5	153	21.5	11.0	33	25.9	16.7				3	38.2	13.0	4	24.4	5.9
Unknown	84	9.5	5.0	59	8.3	4.2	16	12.5	8.5				*	*	*	1	7.7	1.3
<i>Age < 50</i>																		
<i>In Situ</i>	2	1.5	0.2	*	*	*	*	*	*				*	*	*	*	*	*
Localized	26	24.4	2.9	19	25.0	3.0	4	23.8	3.1				*	*	*	*	*	*
Regional	44	42.4	5.1	34	43.8	5.3	6	37.5	4.8				*	*	*	2	41.4	3.1
Distant	26	25.0	3.0	19	24.5	2.9	4	27.5	3.6				*	*	*	2	27.6	2.2
Unknown	7	6.7	0.8	4	5.7	0.7	1	8.8	1.1				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	14	1.8	2.7	*	*	*	*	*	*				*	*	*	*	*	*
Localized	233	29.9	47.3	194	30.5	46.5	30	27.1	55.1				*	*	*	*	*	*
Regional	286	36.7	58.1	240	37.8	57.4	37	32.8	67.5				*	*	*	4	38.8	25.1
Distant	168	21.6	33.8	134	21.2	32.1	29	25.7	50.8				*	*	*	2	22.4	15.5
Unknown	77	9.9	16.0	55	8.6	13.5	15	13.0	27.7				*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	13	1.7	0.7	10	1.6	0.6	2	2.0	0.9	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	230	30.1	11.7	186	30.5	11.6	33	27.0	13.5				3	50.0	16.0	4	31.9	11.1
Regional	286	37.4	14.6	232	38.0	14.3	44	35.8	17.8				2	26.5	9.3	6	42.0	10.8
Distant	150	19.7	7.7	118	19.4	7.3	29	23.4	11.8				1	17.6	5.0	2	17.4	3.8
Unknown	85	11.2	4.1	64	10.5	3.7	14	11.8	5.9				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	1	1.7	0.2	*	*	*	*	*	*				*	*	*	*	*	*
Localized	23	28.5	2.5	18	30.2	2.7	3	21.9	2.1				*	*	*	*	*	*
Regional	30	36.9	3.3	23	37.5	3.5	5	34.2	3.4				*	*	*	1	46.7	2.0
Distant	20	24.5	2.2	14	22.6	2.1	5	31.5	3.2				*	*	*	1	40.0	1.8
Unknown	7	8.4	0.8	5	8.0	0.7	1	9.6	1.0				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	12	1.7	2.0	*	*	*	*	*	*				*	*	*	*	*	*
Localized	207	30.3	36.0	168	30.6	34.7	30	27.7	43.4				*	*	*	*	*	*
Regional	256	37.4	44.0	209	38.1	42.6	39	36.1	55.4				*	*	*	4	40.7	33.8
Distant	131	19.1	22.1	104	19.0	21.0	24	22.3	34.2				*	*	*	1	11.1	8.8
Unknown	79	11.5	13.0	59	10.7	11.4	13	12.1	18.9				*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Arkansas, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	506	17.9	27.2	398	17.5	26.6	74	19.3	28.9				8	23.3	32.6	12	18.0	19.1
Localized	1,421	50.4	73.9	1,175	51.8	74.6	173	44.9	68.5				17	47.7	68.4	32	47.6	55.0
Regional	588	20.9	32.5	466	20.5	31.9	94	24.3	37.8				7	20.5	27.2	14	21.0	20.6
Distant	149	5.3	7.9	111	4.9	7.3	31	8.0	12.3				2	5.1	6.7	2	3.6	4.1
Unknown	156	5.5	8.1	118	5.2	7.3	14	3.5	5.5				1	3.4	4.3	7	9.9	14.5
<i>Age < 50</i>																		
<i>In Situ</i>	89	19.4	10.3	66	20.0	10.4	12	15.1	8.8	Insufficient data for the calculation of AI/AN PRCDA statistics			3	29.3	16.9	4	17.6	6.5
Localized	196	42.7	22.1	144	43.6	22.3	34	41.2	23.1				4	37.9	19.6	11	45.4	16.2
Regional	125	27.3	14.3	89	27.1	14.0	26	32.2	18.2				3	22.4	12.0	6	24.4	8.6
Distant	26	5.7	2.9	17	5.2	2.6	7	8.0	4.6				*	*	*	*	*	*
Unknown	23	4.9	2.6	14	4.1	2.1	3	3.4	1.9				*	*	*	2	9.2	3.5
<i>Age ≥ 50</i>																		
<i>In Situ</i>	417	17.7	71.4	332	17.1	69.1	62	20.4	81.6				5	20.3	73.5	8	18.1	52.0
Localized	1,225	51.9	209.4	1,031	53.2	211.5	140	46.0	187.3				12	52.5	196.3	21	48.8	156.6
Regional	463	19.6	80.2	377	19.4	78.8	67	22.1	88.9				5	19.5	66.9	8	19.1	51.9
Distant	123	5.2	20.9	94	4.9	19.4	24	8.0	32.2				*	*	*	*	*	*
Unknown	134	5.7	22.5	105	5.4	20.9	11	3.6	14.8				*	*	*	4	10.2	43.4

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	1	0.1	0.1	1	0.1	0.1	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	397	24.4	22.5	348	25.2	23.0	43	21.2	23.1				*	*	*	3	15.2	7.4
Regional	353	21.7	19.6	302	21.9	19.8	43	21.4	21.4				1	14.6	6.0	4	19.6	8.3
Distant	742	45.6	41.6	619	44.9	40.9	101	49.8	51.0				6	73.2	35.7	9	51.1	21.5
Unknown	133	8.2	7.9	108	7.8	7.5	15	7.6	9.4				*	*	*	3	14.1	5.1
<i>Female</i>																		
<i>In Situ</i>	3	0.3	0.2	3	0.2	0.1	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	357	27.4	17.0	310	27.5	17.5	35	26.1	14.4				3	35.0	14.3	6	34.9	15.3
Regional	289	22.2	13.9	252	22.4	14.5	32	23.4	12.1				1	15.0	7.5	2	14.5	5.9
Distant	544	41.6	26.3	467	41.4	27.1	60	44.5	23.6				4	45.0	12.8	7	41.0	16.6
Unknown	112	8.6	5.3	96	8.5	5.4	8	5.6	2.9				*	*	*	2	9.6	5.2

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	1,694	76.8	90.2	1,298	77.2	81.9	336	79.9	156.7	Insufficient data for the calculation of AI/AN PRCDA statistics			6	63.8	39.9	27	76.0	58.5
Regional	232	10.5	12.1	185	11.0	11.4	39	9.2	17.2				2	19.1	12.8	5	12.8	10.1
Distant	145	6.6	8.5	112	6.7	7.7	29	6.9	15.3				1	14.9	8.6	2	5.6	5.8
Unknown	134	6.1	7.7	86	5.1	5.8	17	4.0	10.3				*	*	*	2	5.6	5.6
<i>Age < 65</i>																		
Localized	646	78.4	37.9	446	78.6	32.5	175	81.2	76.2	Insufficient data for the calculation of AI/AN PRCDA statistics			2	58.8	9.7	13	81.3	18.6
Regional	102	12.3	5.9	76	13.4	5.5	23	10.6	10.1				*	*	*	2	11.3	2.5
Distant	42	5.1	2.5	26	4.5	1.9	14	6.4	5.8				*	*	*	*	*	*
Unknown	34	4.1	2.0	20	3.5	1.4	4	1.9	1.7				*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	1,048	75.8	451.7	852	76.6	423.3	161	78.5	712.7				4	66.7	249.0	14	71.7	334.5
Regional	130	9.4	54.4	109	9.8	52.3	16	7.8	66.3				*	*	*	3	14.1	62.5
Distant	103	7.5	50.4	86	7.7	47.9	15	7.3	81.3				*	*	*	*	*	*
Unknown	100	7.3	47.2	66	5.9	36.1	13	6.3	69.3				*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
California, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	663	44.2	3.4	248	45.2	3.2	32	35.3	2.7	3	42.1	4.9	107	45.2	3.0	262	44.1	3.9
Regional	520	34.7	2.5	186	34.0	2.1	31	34.0	2.5	3	42.1	4.9	83	35.1	2.2	214	35.9	3.3
Distant	224	14.9	1.0	88	16.0	0.9	21	23.0	1.6	*	*	*	35	14.9	0.9	79	13.3	1.3
Unknown	92	6.2	0.4	26	4.8	0.3	7	7.7	0.6	*	*	*	11	4.8	0.3	40	6.7	0.7

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	235	2.9	1.1	115	2.7	1.1	14	2.7	1.2	2	5.8	2.7	38	3.3	1.2	55	2.8	1.1
Localized	2,596	32.2	12.9	1,400	33.0	13.2	157	30.6	13.7	9	29.9	14.3	382	32.8	12.1	597	30.3	11.8
Regional	2,998	37.2	15.0	1,588	37.5	15.3	170	33.1	14.8	10	32.5	15.2	450	38.6	14.5	755	38.4	15.1
Distant	1,670	20.7	8.3	884	20.9	8.4	128	24.9	11.3	7	23.4	10.4	218	18.7	7.1	424	21.5	8.3
Unknown	558	6.9	2.9	252	5.9	2.4	45	8.7	4.2	3	8.4	4.8	77	6.6	2.6	138	7.0	3.1
<i>Age < 50</i>																		
<i>In Situ</i>	16	1.5	0.1	7	1.7	0.2	*	*	*	*	*	*	1	1.0	0.1	5	1.3	0.1
Localized	280	27.6	2.2	121	28.8	2.6	15	23.6	2.0	*	*	*	37	25.3	1.8	99	27.2	1.9
Regional	417	41.0	3.3	174	41.6	3.8	25	38.3	3.3	1	50.0	3.2	66	45.1	3.3	146	40.3	2.9
Distant	260	25.6	2.1	103	24.7	2.2	20	30.4	2.7	*	*	*	37	25.1	1.8	98	27.1	1.9
Unknown	43	4.2	0.3	13	3.2	0.3	4	6.1	0.5	*	*	*	5	3.6	0.3	15	4.1	0.3
<i>Age ≥ 50</i>																		
<i>In Situ</i>	220	3.1	3.8	108	2.8	3.4	*	*	*	2	6.3	9.7	37	3.6	4.2	51	3.2	3.7
Localized	2,316	32.9	40.8	1,280	33.5	41.2	141	31.6	44.3	*	*	*	345	33.9	39.0	498	31.0	37.7
Regional	2,581	36.7	45.7	1,413	37.0	45.4	145	32.4	44.9	9	31.0	46.7	384	37.7	44.0	609	37.9	47.1
Distant	1,410	20.0	24.6	781	20.4	24.7	108	24.1	33.8	*	*	*	181	17.8	20.8	325	20.3	24.9
Unknown	515	7.3	9.5	239	6.2	7.8	41	9.1	13.9	3	9.2	17.3	72	7.0	8.7	123	7.7	10.4
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	191	2.6	0.8	81	2.1	0.7	16	3.1	1.1	*	*	*	34	3.3	0.9	49	2.9	0.8
Localized	2,391	33.1	10.4	1,254	32.9	10.8	171	34.3	12.5	10	34.0	13.0	340	32.2	8.7	569	33.3	9.6
Regional	2,687	37.2	11.7	1,455	38.1	12.3	163	32.8	12.0	13	43.8	16.0	404	38.3	10.4	632	37.1	10.9
Distant	1,434	19.8	6.3	763	20.0	6.6	117	23.4	8.5	5	16.7	6.5	203	19.2	5.2	338	19.8	5.8
Unknown	526	7.3	2.1	261	6.8	1.8	32	6.4	2.4	1	4.9	1.9	75	7.1	1.8	118	6.9	2.1
<i>Age < 50</i>																		
<i>In Situ</i>	18	1.9	0.1	6	1.6	0.1	1	2.1	0.1	*	*	*	3	2.0	0.1	7	2.0	0.1
Localized	300	32.2	2.4	120	33.8	2.8	20	35.8	2.7	*	*	*	37	26.6	1.6	112	31.6	2.2
Regional	347	37.3	2.8	134	37.6	3.1	20	34.7	2.6	*	*	*	56	40.3	2.5	133	37.6	2.7
Distant	229	24.6	1.8	87	24.3	2.0	14	23.9	1.8	*	*	*	39	28.2	1.7	87	24.5	1.8
Unknown	36	3.9	0.3	10	2.7	0.2	2	3.5	0.3	*	*	*	4	2.9	0.2	15	4.3	0.3
<i>Age ≥ 50</i>																		
<i>In Situ</i>	173	2.8	2.6	76	2.2	2.2	14	3.3	3.6	*	*	*	32	3.4	2.8	42	3.1	2.6
Localized	2,091	33.2	31.4	1,134	32.8	31.7	151	34.1	38.0	*	*	*	303	33.0	27.2	456	33.8	29.0
Regional	2,340	37.1	35.0	1,321	38.2	36.5	144	32.5	36.5	*	*	*	348	37.9	31.2	499	36.9	32.2
Distant	1,205	19.1	17.9	677	19.6	18.6	103	23.4	25.8	*	*	*	163	17.8	14.5	250	18.5	16.2
Unknown	490	7.8	6.9	251	7.3	6.1	30	6.8	7.9	1	5.3	6.9	71	7.8	6.2	103	7.6	6.8

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
California, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	6,133	18.1	27.4	3,068	16.6	28.9	413	19.4	29.8	15	15.2	19.9	1,218	22.7	31.6	1,302	18.0	20.9
Localized	17,974	53.1	79.0	10,505	56.7	92.6	1,004	47.3	73.2	53	51.9	68.4	2,704	50.4	70.0	3,498	48.4	57.5
Regional	7,483	22.1	34.2	3,785	20.4	36.4	526	24.8	39.5	26	25.2	33.3	1,158	21.6	30.8	1,910	26.4	30.4
Distant	1,516	4.5	6.8	822	4.4	7.5	134	6.3	10.1	5	4.5	5.9	204	3.8	5.4	338	4.7	5.6
Unknown	766	2.3	3.3	339	1.8	2.7	47	2.2	3.4	3	3.2	4.6	83	1.6	2.2	178	2.5	3.1
<i>Age < 50</i>																		
<i>In Situ</i>	1,236	18.8	10.1	499	19.1	11.5	64	16.6	8.8	3	18.7	9.1	301	21.4	13.1	342	16.7	7.2
Localized	2,960	44.9	24.1	1,234	47.1	28.4	156	40.2	21.0	8	42.9	21.1	646	46.0	28.0	877	42.8	18.2
Regional	1,970	29.9	16.0	740	28.2	17.0	128	32.9	17.2	6	30.8	15.0	386	27.5	16.8	692	33.8	14.2
Distant	307	4.7	2.5	117	4.5	2.7	33	8.5	4.4	*	*	*	56	4.0	2.4	97	4.7	2.0
Unknown	111	1.7	0.9	29	1.1	0.7	7	1.8	0.9	*	*	*	16	1.1	0.7	42	2.0	0.9
<i>Age ≥ 50</i>																		
<i>In Situ</i>	4,897	17.9	72.6	2,568	16.2	74.2	348	20.1	84.8	12	14.4	48.0	918	23.2	80.1	960	18.5	56.9
Localized	15,014	55.0	222.6	9,271	58.3	260.7	847	48.8	210.0	45	53.8	192.2	2,058	51.9	180.0	2,621	50.6	160.5
Regional	5,512	20.2	81.8	3,046	19.2	87.2	398	23.0	98.0	20	24.0	81.1	772	19.5	67.6	1,217	23.5	72.5
Distant	1,209	4.4	17.9	705	4.4	19.8	101	5.8	24.9	*	*	*	148	3.7	13.1	241	4.7	15.0
Unknown	655	2.4	9.5	310	1.9	8.0	40	2.3	9.8	*	*	*	67	1.7	6.0	136	2.6	8.8

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	28	0.3	0.1	16	0.3	0.1	1	0.2	0.1	*	*	*	6	0.5	0.2	4	0.3	0.1
Localized	1,866	21.9	9.8	1,292	24.1	11.7	120	18.6	11.8	7	19.3	10.6	242	18.7	8.1	193	17.1	5.1
Regional	1,729	20.3	8.8	1,106	20.6	9.9	130	20.1	11.8	8	23.9	11.8	252	19.5	8.3	219	19.5	5.5
Distant	4,191	49.2	21.4	2,509	46.8	22.4	339	52.4	30.4	17	47.7	24.9	702	54.2	23.1	602	53.5	14.9
Unknown	703	8.3	3.8	435	8.1	4.0	56	8.6	5.5	3	8.5	5.5	92	7.1	3.2	107	9.5	3.0
<i>Female</i>																		
<i>In Situ</i>	44	0.5	0.2	29	0.5	0.2	3	0.4	0.2	*	*	*	6	0.6	0.2	6	0.5	0.1
Localized	2,371	27.6	10.1	1,645	29.1	12.8	158	25.1	11.4	10	24.7	12.3	274	24.6	7.0	268	24.8	5.2
Regional	1,686	19.7	7.2	1,151	20.3	8.9	128	20.3	9.0	7	18.7	9.4	188	16.9	4.8	206	19.0	3.9
Distant	3,851	44.9	16.3	2,420	42.7	18.8	305	48.5	21.6	19	48.5	23.7	576	51.7	14.6	511	47.3	9.6
Unknown	628	7.3	2.5	416	7.4	2.9	36	5.7	2.5	3	7.6	3.7	69	6.2	1.7	90	8.3	1.8

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	13,234	65.6	61.6	7,856	68.0	65.8	1,255	68.9	97.6	34	70.0	45.3	1,125	67.3	34.5	2,367	63.1	49.6
Regional	2,971	14.7	13.4	1,864	16.1	15.3	249	13.7	18.6	5	10.7	6.6	265	15.8	7.9	552	14.7	10.8
Distant	1,901	9.4	9.8	1,110	9.6	10.0	211	11.6	19.5	5	10.7	7.1	171	10.2	5.8	384	10.2	9.5
Unknown	2,076	10.3	10.5	728	6.3	6.5	107	5.9	10.0	4	8.6	7.0	112	6.7	3.9	450	12.0	11.1
<i>Age < 65</i>																		
Localized	5,111	69.2	23.6	2,800	72.0	25.9	676	72.3	50.4	15	70.1	19.8	378	70.6	11.5	1,025	65.8	16.9
Regional	1,267	17.1	5.8	723	18.6	6.6	146	15.6	10.8	2	11.2	3.2	105	19.7	3.2	275	17.7	4.5
Distant	474	6.4	2.2	231	5.9	2.1	76	8.1	5.5	3	14.0	4.0	36	6.7	1.1	124	7.9	2.1
Unknown	539	7.3	2.4	137	3.5	1.2	37	4.0	2.7	*	*	*	16	3.0	0.5	133	8.6	2.2
<i>Age ≥ 65</i>																		
Localized	8,124	63.5	324.2	5,056	65.9	341.6	579	65.2	423.6	19	69.9	221.4	747	65.7	193.3	1,342	61.1	275.0
Regional	1,704	13.3	65.9	1,141	14.9	75.0	104	11.7	71.9	3	10.3	29.8	159	14.0	40.2	277	12.6	53.8
Distant	1,427	11.2	62.3	879	11.5	63.9	135	15.2	115.8	2	8.1	28.3	135	11.8	38.1	260	11.8	60.8
Unknown	1,537	12.0	65.8	591	7.7	42.9	70	7.9	61.0	*	*	*	96	8.4	27.4	317	14.4	72.3

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Greater California, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	365	43.0	3.5	161	43.5	3.4	14	35.2	2.7	3	43.6	5.3	41	42.4	2.9	141	43.3	3.9
Regional	304	35.8	2.7	131	35.4	2.5	15	37.2	2.8	3	41.0	4.9	37	38.2	2.6	117	36.1	3.4
Distant	129	15.2	1.1	60	16.1	1.0	8	21.1	1.6	*	*	*	15	15.9	1.0	45	13.9	1.4
Unknown	51	6.0	0.4	19	5.0	0.3	3	6.5	0.5	*	*	*	3	3.5	0.2	22	6.7	0.7

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	130	2.9	1.1	71	2.7	1.0	6	3.0	1.3	2	6.3	3.1	15	3.4	1.2	28	2.7	1.0
Localized	1,451	32.4	12.9	882	33.2	13.2	67	31.2	13.4	10	30.0	14.9	136	31.3	11.5	325	30.7	12.1
Regional	1,647	36.7	14.9	974	36.6	14.9	76	35.5	15.3	10	31.9	15.4	172	39.5	14.5	402	37.9	15.3
Distant	949	21.2	8.5	572	21.5	8.7	48	22.6	9.7	7	22.5	10.4	84	19.2	7.2	232	21.9	8.5
Unknown	308	6.9	2.8	160	6.0	2.4	17	7.7	3.7	3	9.4	5.3	29	6.7	2.6	72	6.8	3.0
<i>Age < 50</i>																		
<i>In Situ</i>	9	1.7	0.1	4	1.8	0.2	*	*	*	*	*	*	*	*	*	2	1.2	0.1
Localized	150	27.4	2.2	71	28.8	2.5	8	25.3	2.0	*	*	*	13	21.6	1.7	53	27.2	1.9
Regional	212	38.8	3.2	98	39.6	3.6	12	40.0	3.4	1	46.2	3.2	27	43.5	3.4	72	37.2	2.6
Distant	152	27.8	2.3	66	26.5	2.4	9	31.3	2.6	*	*	*	18	29.7	2.3	58	29.8	2.1
Unknown	24	4.4	0.4	8	3.3	0.3	*	*	*	*	*	*	2	3.6	0.3	9	4.6	0.3
<i>Age ≥ 50</i>																		
<i>In Situ</i>	121	3.1	3.7	67	2.8	3.3	*	*	*	2	6.8	11.1	*	*	*	26	3.0	3.6
Localized	1,300	33.0	41.1	811	33.6	41.2	59	32.1	43.3	*	*	*	123	32.8	37.2	273	31.5	38.7
Regional	1,435	36.4	45.5	876	36.3	44.4	64	34.7	46.4	9	30.6	47.5	145	38.8	43.8	330	38.1	48.5
Distant	797	20.2	24.8	506	21.0	25.2	39	21.2	28.2	*	*	*	66	17.5	20.1	174	20.1	25.1
Unknown	284	7.2	9.3	152	6.3	7.8	*	*	*	3	10.2	19.1	27	7.2	8.7	63	7.3	10.2
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	101	2.5	0.8	51	2.1	0.7	6	3.4	1.2	*	*	*	14	3.5	0.9	24	2.6	0.8
Localized	1,337	33.2	10.5	807	33.2	10.8	67	35.3	12.3	10	34.5	13.3	118	30.2	7.9	305	33.6	9.8
Regional	1,503	37.4	11.9	929	38.2	12.4	64	33.6	12.0	13	44.1	16.3	157	40.3	10.8	330	36.4	10.7
Distant	796	19.8	6.4	481	19.8	6.5	42	22.2	7.5	5	16.6	6.5	77	19.8	5.3	186	20.6	6.0
Unknown	285	7.1	2.1	165	6.8	1.9	10	5.5	2.1	1	4.1	1.6	24	6.2	1.7	62	6.8	2.1
<i>Age < 50</i>																		
<i>In Situ</i>	9	1.7	0.1	3	1.5	0.1	*	*	*	*	*	*	1	1.9	0.1	3	1.6	0.1
Localized	161	31.3	2.4	70	32.6	2.6	8	32.3	2.4	*	*	*	16	25.5	1.7	62	31.0	2.2
Regional	198	38.4	3.0	84	39.0	3.2	11	42.7	3.1	*	*	*	25	41.0	2.8	76	37.9	2.8
Distant	126	24.6	1.9	52	24.3	2.0	5	20.2	1.5	*	*	*	18	28.7	1.9	50	24.9	1.9
Unknown	20	4.0	0.3	6	2.6	0.2	*	*	*	*	*	*	2	2.9	0.2	9	4.7	0.4
<i>Age ≥ 50</i>																		
<i>In Situ</i>	92	2.6	2.5	48	2.2	2.2	*	*	*	*	*	*	12	3.8	2.8	20	2.9	2.4
Localized	1,176	33.5	31.9	737	33.2	32.1	59	35.8	38.4	*	*	*	102	31.1	24.2	242	34.4	29.8
Regional	1,305	37.2	35.4	846	38.1	36.6	54	32.3	35.0	*	*	*	132	40.2	31.7	253	36.0	31.4
Distant	670	19.1	18.0	429	19.3	18.5	37	22.5	23.3	*	*	*	60	18.2	14.1	136	19.3	16.8
Unknown	265	7.5	6.9	159	7.2	6.2	*	*	*	1	4.5	5.8	22	6.8	5.5	52	7.4	6.7

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Greater California, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	3,215	17.4	26.1	1,858	16.3	27.2	155	18.4	27.3	16	15.4	20.5	438	22.2	29.3	675	17.4	20.7
Localized	9,866	53.3	78.5	6,442	56.6	88.7	390	46.1	70.5	54	51.7	69.6	981	49.7	65.9	1,877	48.4	58.9
Regional	4,105	22.2	34.2	2,336	20.5	35.2	225	26.6	41.5	26	25.5	34.7	447	22.7	30.7	1,031	26.6	30.9
Distant	862	4.7	7.0	525	4.6	7.6	58	6.9	10.6	5	4.4	6.0	76	3.8	5.1	192	5.0	6.1
Unknown	447	2.4	3.5	216	1.9	2.7	16	1.9	3.1	3	2.9	4.4	32	1.6	2.2	100	2.6	3.3
<i>Age < 50</i>																		
<i>In Situ</i>	607	18.0	9.4	277	18.6	10.5	25	15.4	7.8	3	18.3	9.1	107	20.4	11.8	179	16.1	7.0
Localized	1,501	44.5	23.0	698	46.8	26.5	60	36.9	18.7	8	41.9	21.1	241	45.9	26.5	475	42.6	18.2
Regional	1,028	30.5	15.7	421	28.3	16.0	59	36.5	18.3	6	32.3	16.0	151	28.8	16.7	382	34.2	14.5
Distant	169	5.0	2.6	78	5.2	3.0	15	9.0	4.3	*	*	*	18	3.5	2.0	56	5.0	2.1
Unknown	64	1.9	1.0	18	1.2	0.7	4	2.2	1.1	*	*	*	8	1.5	0.9	24	2.1	0.9
<i>Age ≥ 50</i>																		
<i>In Situ</i>	2,608	17.2	69.8	1,581	16.0	71.0	130	19.1	78.4	13	14.8	50.5	331	22.9	75.3	496	18.0	56.5
Localized	8,365	55.3	223.7	5,744	58.1	251.5	331	48.3	206.0	46	53.9	196.7	739	51.1	169.2	1,402	50.8	165.5
Regional	3,077	20.3	82.5	1,915	19.4	85.4	166	24.3	102.3	20	24.0	83.5	296	20.4	67.5	649	23.5	73.9
Distant	693	4.6	18.6	447	4.5	19.7	44	6.4	27.1	*	*	*	58	4.0	13.3	136	4.9	16.5
Unknown	382	2.5	10.1	198	2.0	8.1	13	1.9	8.4	*	*	*	24	1.6	5.6	76	2.7	9.7

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	14	0.3	0.1	9	0.3	0.1	*	*	*	*	*	*	2	0.4	0.2	2	0.3	0.1
Localized	1,113	22.2	10.4	851	23.7	12.1	51	19.7	12.0	7	19.2	10.9	88	18.4	7.8	108	17.6	5.4
Regional	1,050	21.0	9.5	761	21.2	10.7	57	21.9	12.1	9	24.2	12.3	92	19.4	8.1	124	20.2	6.0
Distant	2,418	48.3	21.9	1,673	46.6	23.5	132	50.9	28.2	17	47.3	25.4	264	55.5	22.9	321	52.3	14.9
Unknown	409	8.2	3.9	293	8.2	4.2	19	7.4	4.5	3	8.8	5.9	30	6.3	2.9	59	9.6	3.1
<i>Female</i>																		
<i>In Situ</i>	21	0.4	0.2	16	0.4	0.2	*	*	*	*	*	*	*	*	*	2	0.4	0.1
Localized	1,454	28.2	11.2	1,112	29.0	13.5	65	26.5	12.3	10	25.1	12.6	107	26.1	7.3	151	25.3	5.7
Regional	1,051	20.4	8.0	800	20.9	9.7	51	20.9	9.2	7	18.6	9.4	72	17.6	4.9	116	19.4	4.3
Distant	2,264	43.9	17.3	1,629	42.5	19.8	116	47.5	20.8	19	48.2	23.7	204	49.7	13.8	285	47.5	10.4
Unknown	366	7.1	2.7	272	7.1	3.0	12	4.7	2.2	3	7.5	3.6	26	6.4	1.8	45	7.5	1.8

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	7,627	65.2	63.3	4,940	67.4	65.1	558	69.0	100.0	35	70.0	47.4	423	67.1	34.2	1,307	63.2	51.9
Regional	1,737	14.9	13.9	1,193	16.3	15.3	118	14.6	20.0	5	10.7	6.8	99	15.7	7.7	301	14.6	11.0
Distant	1,100	9.4	10.0	714	9.8	10.0	90	11.1	19.9	5	10.3	7.1	68	10.7	6.1	211	10.2	9.9
Unknown	1,227	10.5	11.0	477	6.5	6.7	44	5.4	10.0	5	9.1	6.7	41	6.6	3.9	249	12.0	11.6
<i>Age < 65</i>																		
Localized	2,844	68.3	23.8	1,705	70.8	25.3	307	72.0	50.8	15	67.3	20.0	138	69.0	10.9	554	65.6	17.3
Regional	732	17.6	6.1	463	19.2	6.8	71	16.6	11.6	3	11.5	3.5	39	19.7	3.1	148	17.5	4.6
Distant	279	6.7	2.3	156	6.5	2.3	34	7.9	5.5	3	13.3	4.0	16	8.2	1.3	68	8.0	2.1
Unknown	312	7.5	2.6	85	3.5	1.2	15	3.6	2.5	2	8.0	2.2	6	3.1	0.5	75	8.9	2.3
<i>Age ≥ 65</i>																		
Localized	4,783	63.6	336.4	3,235	65.8	340.3	252	65.6	439.5	20	72.1	236.3	285	66.2	195.6	752	61.6	291.4
Regional	1,006	13.4	68.1	730	14.9	74.5	47	12.3	77.7	3	10.0	29.8	60	13.8	39.4	153	12.5	55.4
Distant	821	10.9	63.4	558	11.4	63.4	56	14.6	119.4	2	7.9	28.3	51	11.9	38.9	143	11.7	63.8
Unknown	915	12.2	69.3	393	8.0	44.8	29	7.5	61.8	3	10.0	38.0	35	8.2	27.6	174	14.2	75.2

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Greater Bay Area, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	113	48.9	2.9	42	51.1	2.8	6	39.2	2.8	Insufficient data for the calculation of AI/AN PRCDA statistics			33	47.9	2.6	31	49.5	3.6
Regional	74	32.1	1.8	26	30.8	1.4	5	33.8	2.3				23	33.2	1.8	21	33.3	2.6
Distant	35	15.0	0.8	14	16.4	0.7	4	24.3	1.4				9	12.6	0.7	9	13.9	1.1
Unknown	9	4.1	0.2	1	1.7	0.1	*	*	*				4	6.2	0.3	2	3.2	0.3

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	34	2.3	0.8	17	2.3	0.8	2	1.6	0.7				9	2.6	0.9	3	1.4	0.5
Localized	515	34.8	12.8	269	35.4	13.4	31	31.1	13.3				133	37.2	12.3	72	30.7	11.3
Regional	565	38.2	14.3	295	38.7	15.0	34	34.1	14.7				137	38.3	13.1	95	40.3	14.4
Distant	302	20.4	7.6	151	19.8	7.6	28	27.9	12.3				66	18.3	6.3	54	23.0	8.4
Unknown	64	4.3	1.7	29	3.8	1.5	5	5.2	2.6				13	3.6	1.3	11	4.7	2.1
<i>Age < 50</i>																		
<i>In Situ</i>	2	1.2	0.1	*	*	*	*	*	*				*	*	*	*	*	*
Localized	60	29.1	2.3	25	28.9	2.6	3	23.7	2.1				14	30.0	1.9	15	29.1	2.2
Regional	91	44.4	3.6	40	46.0	4.3	4	37.3	3.0				23	47.1	3.0	23	43.0	3.4
Distant	47	23.1	1.9	20	22.6	2.1	4	33.9	2.9				10	20.0	1.3	13	24.9	2.0
Unknown	4	2.1	0.2	1	1.4	0.1	*	*	*				1	2.5	0.2	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	31	2.5	2.8	*	*	*	*	*	*				*	*	*	*	*	*
Localized	455	35.7	40.4	244	36.2	41.4	28	32.1	42.7				119	38.3	39.5	57	31.2	35.1
Regional	474	37.2	42.4	254	37.7	43.0	30	33.7	45.4				114	36.9	39.3	72	39.5	43.3
Distant	254	20.0	22.6	131	19.5	22.0	24	27.1	37.0				56	18.1	19.3	41	22.4	25.2
Unknown	59	4.6	5.7	28	4.2	5.0	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			12	3.8	4.4	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	28	2.1	0.6	11	1.6	0.5	1	1.2	0.4				8	2.3	0.6	6	2.9	0.9
Localized	474	35.3	10.6	233	34.6	10.9	36	36.1	13.8				125	37.2	9.6	72	34.0	9.8
Regional	507	37.8	11.3	265	39.2	12.0	35	34.3	12.9				120	35.7	9.3	84	40.0	12.2
Distant	263	19.6	5.9	134	19.9	6.2	24	23.4	8.8				64	19.0	4.9	39	18.5	5.5
Unknown	71	5.3	1.4	31	4.7	1.1	5	5.0	1.8				20	5.9	1.4	10	4.6	1.4
<i>Age < 50</i>																		
<i>In Situ</i>	3	1.5	0.1	1	1.7	0.1	*	*	*				*	*	*	*	*	*
Localized	61	35.9	2.5	26	37.5	3.1	5	42.9	3.4				13	29.6	1.5	15	35.4	2.3
Regional	62	36.2	2.5	25	35.5	2.9	3	30.4	2.4				17	40.4	2.1	16	37.3	2.5
Distant	41	23.9	1.7	17	23.8	1.9	3	23.2	2.0				12	27.2	1.4	10	23.1	1.6
Unknown	4	2.5	0.2	*	*	*	*	*	*				*	*	*	1	2.8	0.2
<i>Age ≥ 50</i>																		
<i>In Situ</i>	25	2.2	2.0	10	1.6	1.5	1	1.3	1.5				*	*	*	*	*	*
Localized	413	35.2	32.0	207	34.2	31.5	32	35.3	41.3				112	38.3	30.7	57	33.6	29.3
Regional	445	38.0	34.4	240	39.6	36.0	31	34.8	40.5				103	35.0	27.9	69	40.6	37.4
Distant	222	18.9	16.9	118	19.5	17.4	21	23.4	26.8				52	17.8	14.2	29	17.3	15.9
Unknown	66	5.7	4.6	*	*	*	*	*	*				*	*	*	9	5.1	4.6

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Greater Bay Area, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	1,328	19.2	30.8	619	17.0	31.2	87	21.1	33.1				438	23.6	34.1	166	17.9	21.6
Localized	3,779	54.6	85.8	2,121	58.3	100.7	195	47.2	73.9				955	51.5	74.1	472	50.8	63.1
Regional	1,464	21.2	34.6	724	19.9	37.4	100	24.2	39.3				382	20.6	30.2	244	26.3	31.4
Distant	269	3.9	6.1	139	3.8	6.5	27	6.5	10.8				66	3.5	5.1	35	3.8	4.8
Unknown	77	1.1	1.6	34	0.9	1.4	4	0.9	1.4				15	0.8	1.2	11	1.2	1.6
<i>Age < 50</i>																		
<i>In Situ</i>	301	20.3	12.4	111	19.4	12.8	16	19.9	11.6	Insufficient data for the calculation of AI/AN PRCDA statistics			118	22.5	14.6	52	17.9	8.7
Localized	691	46.5	28.3	281	49.1	32.0	31	38.3	22.0				242	46.2	29.6	129	44.4	21.3
Regional	431	29.0	17.6	161	28.1	18.4	25	31.3	17.9				142	27.2	17.3	99	34.0	16.1
Distant	54	3.7	2.2	17	3.0	2.0	8	9.7	5.5				20	3.7	2.4	9	3.2	1.5
Unknown	9	0.6	0.4	3	0.5	0.3	*	*	*				2	0.4	0.3	2	0.5	0.3
<i>Age ≥ 50</i>																		
<i>In Situ</i>	1,027	18.9	78.7	508	16.6	79.5	71	21.4	89.5				320	24.0	85.2	114	17.9	55.3
Localized	3,089	56.9	236.6	1,840	60.0	280.4	165	49.4	209.7				713	53.5	190.8	343	53.8	172.6
Regional	1,033	19.0	79.2	563	18.4	87.1	75	22.4	95.2				240	18.0	64.0	145	22.7	71.5
Distant	215	4.0	16.4	122	4.0	18.3	19	5.8	24.5				46	3.5	12.4	26	4.1	13.4
Unknown	68	1.3	5.0	31	1.0	4.2	*	*	*				13	1.0	3.7	10	1.5	5.0

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	5	0.3	0.1	2	0.3	0.1	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			2	0.5	0.2	*	*	*
Localized	378	24.1	10.2	225	27.0	11.1	32	23.1	15.4				91	20.6	9.2	29	19.6	6.3
Regional	314	20.0	8.2	171	20.5	8.2	27	19.6	12.2				84	19.1	8.3	30	20.3	6.2
Distant	792	50.5	20.6	394	47.3	18.9	70	51.2	31.3				242	55.0	24.0	81	55.3	16.2
Unknown	78	5.0	2.2	41	4.9	2.0	8	5.7	3.9				21	4.8	2.3	7	4.8	1.5
<i>Female</i>																		
<i>In Situ</i>	8	0.5	0.2	4	0.4	0.2	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			2	0.6	0.2	*	*	*
Localized	450	27.8	9.9	276	29.6	11.6	36	26.8	13.1				95	24.0	7.2	41	27.7	6.4
Regional	309	19.1	6.8	189	20.3	8.0	27	20.4	9.6				64	16.3	5.0	27	18.4	4.3
Distant	777	48.0	16.8	423	45.3	17.7	65	48.7	23.4				216	54.8	16.5	70	47.4	10.8
Unknown	73	4.5	1.4	42	4.5	1.5	5	3.9	1.8				17	4.3	1.2	9	5.8	1.4

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	2,769	71.6	65.8	1,583	71.7	70.3	270	71.7	103.6	Insufficient data for the calculation of AI/AN PRCDA statistics			434	71.6	40.4	322	68.9	55.2
Regional	525	13.6	12.2	333	15.1	14.5	48	12.7	18.5				79	13.1	7.1	61	13.1	9.4
Distant	390	10.1	10.3	220	10.0	10.7	48	12.8	21.4				66	10.9	6.8	54	11.5	10.6
Unknown	182	4.7	4.6	72	3.3	3.3	10	2.8	4.9				27	4.4	2.8	31	6.5	6.1
<i>Age < 65</i>																		
Localized	1,092	74.6	25.7	593	75.6	28.2	148	75.4	56.5	Insufficient data for the calculation of AI/AN PRCDA statistics			145	74.0	13.2	146	69.4	19.3
Regional	233	15.9	5.5	134	17.1	6.4	27	13.8	10.6				36	18.1	3.3	35	16.8	4.6
Distant	90	6.2	2.1	41	5.2	1.9	18	9.2	6.7				13	6.4	1.1	18	8.6	2.4
Unknown	49	3.3	1.1	17	2.1	0.8	3	1.6	1.3				3	1.5	0.3	11	5.1	1.4
<i>Age ≥ 65</i>																		
Localized	1,678	69.8	343.4	990	69.6	361.2	122	67.6	429.4				289	70.5	228.5	176	68.4	303.3
Regional	292	12.2	58.0	199	14.0	70.8	21	11.6	73.3				44	10.7	33.3	26	10.0	42.5
Distant	300	12.5	67.1	179	12.6	71.7	30	16.8	122.7				53	13.0	45.7	36	13.9	67.3
Unknown	133	5.5	29.0	55	3.9	20.9	7	4.0	29.8				24	5.8	20.6	20	7.7	38.3

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Los Angeles, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	184	44.0	3.5	44	46.6	3.0	12	32.8	2.6	Insufficient data for the calculation of AI/AN PRCDA statistics			33	45.8	3.5	91	43.9	4.0
Regional	146	34.7	2.7	31	32.9	1.8	12	32.2	2.3				24	33.2	2.4	77	37.2	3.5
Distant	60	14.4	1.1	15	15.4	0.7	9	24.6	1.7				12	15.9	1.1	25	12.1	1.2
Unknown	29	6.8	0.5	5	5.1	0.3	4	10.4	0.7				4	5.2	0.4	14	6.8	0.7

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	73	3.5	1.4	27	3.3	1.4	6	3.1	1.5	Insufficient data for the calculation of AI/AN PRCDA statistics			14	3.9	1.6	24	3.5	1.4
Localized	655	31.3	13.3	264	32.3	14.0	59	29.9	14.1				116	31.3	13.1	203	30.2	11.8
Regional	780	37.3	15.9	313	38.3	16.7	60	30.5	14.5				140	37.8	16.3	258	38.4	14.9
Distant	423	20.2	8.5	163	19.9	8.6	51	25.9	12.3				69	18.5	7.9	138	20.5	8.0
Unknown	162	7.8	3.4	50	6.2	2.6	21	10.6	5.2				32	8.6	3.6	50	7.4	3.2
<i>Age < 50</i>																		
<i>In Situ</i>	4	1.5	0.1	2	1.9	0.2	*	*	*				*	*	*	2	1.4	0.1
Localized	73	27.5	2.2	25	30.5	2.8	5	21.4	1.9				10	25.9	2.0	31	26.7	1.8
Regional	113	42.8	3.4	35	41.8	3.8	9	37.6	3.4				17	46.0	3.6	51	43.9	3.1
Distant	61	23.2	1.8	18	21.9	2.0	7	28.2	2.7				9	23.8	1.9	27	23.6	1.6
Unknown	13	5.0	0.4	3	3.8	0.3	3	12.0	1.0				1	3.7	0.3	5	4.5	0.3
<i>Age ≥ 50</i>																		
<i>In Situ</i>	69	3.8	4.9	26	3.5	4.6	*	*	*				*	*	*	22	4.0	4.7
Localized	583	31.8	42.3	239	32.5	43.4	54	31.0	46.2				106	31.9	41.9	172	31.0	37.9
Regional	667	36.5	48.7	278	37.9	50.3	51	29.5	43.7				123	36.9	49.3	207	37.2	46.0
Distant	361	19.7	26.0	145	19.7	26.0	45	25.6	37.5				60	17.9	23.6	110	19.9	24.5
Unknown	149	8.2	11.3	47	6.4	8.6	18	10.4	16.2				30	9.1	12.4	44	8.0	10.7
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	64	3.4	1.1	19	2.7	0.9	8	3.9	1.4	Insufficient data for the calculation of AI/AN PRCDA statistics			13	4.1	1.2	20	3.5	1.0
Localized	603	32.3	10.3	227	32.0	11.1	68	32.6	12.0				102	30.7	8.9	196	33.5	9.3
Regional	671	36.0	11.4	260	36.7	12.2	65	31.3	11.5				124	37.6	10.9	216	36.8	10.4
Distant	377	20.2	6.5	149	21.0	7.2	51	24.4	9.1				62	18.8	5.6	112	19.2	5.4
Unknown	150	8.0	2.4	53	7.5	2.1	16	7.9	2.9				29	8.8	2.3	41	7.0	2.1
<i>Age < 50</i>																		
<i>In Situ</i>	7	2.8	0.2	1	1.6	0.1	*	*	*				1	3.4	0.2	4	3.3	0.2
Localized	80	32.7	2.4	26	35.0	3.1	8	35.8	2.7				9	26.7	1.6	36	32.2	2.1
Regional	87	35.4	2.6	26	35.5	3.1	6	28.3	2.1				13	38.1	2.3	40	36.4	2.5
Distant	62	25.4	1.9	18	24.6	2.1	6	28.3	2.2				10	29.5	1.8	27	24.6	1.7
Unknown	9	3.7	0.3	2	3.3	0.3	*	*	*				*	*	*	4	3.4	0.2
<i>Age ≥ 50</i>																		
<i>In Situ</i>	57	3.5	3.3	18	2.9	2.9	*	*	*				12	4.1	3.7	17	3.5	2.9
Localized	523	32.3	31.0	201	31.6	32.1	60	32.2	36.4				92	31.2	28.1	160	33.8	28.3
Regional	584	36.1	34.5	234	36.9	36.3	59	31.7	36.1				111	37.5	33.4	175	36.9	31.3
Distant	315	19.4	18.5	131	20.6	20.3	45	23.9	27.4				52	17.5	15.7	85	17.9	15.3
Unknown	141	8.7	7.9	51	8.0	6.9	*	*	*				*	*	*	37	7.9	6.9

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Los Angeles, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	1,590	18.8	27.7	592	16.8	32.0	170	19.7	30.6				343	22.3	31.9	457	19.0	20.9
Localized	4,349	51.4	75.0	1,963	55.8	98.8	419	48.5	76.1				772	50.1	71.2	1,142	47.6	53.2
Regional	1,943	23.0	34.4	744	21.1	40.5	205	23.7	38.2				334	21.7	32.1	633	26.4	28.9
Distant	386	4.6	6.7	159	4.5	8.0	49	5.6	9.2				62	4.0	6.0	111	4.6	5.1
Unknown	189	2.2	3.1	64	1.8	2.8	21	2.5	3.7				29	1.9	2.6	56	2.3	2.6
<i>Age < 50</i>																		
<i>In Situ</i>	328	18.9	10.0	112	19.8	13.4	23	15.9	8.6	Insufficient data for the calculation of AI/AN PRCDA statistics			76	21.2	13.2	111	17.3	6.9
Localized	774	44.6	23.4	261	46.4	31.1	67	45.4	23.4				164	46.1	28.5	271	42.4	16.9
Regional	518	29.8	15.7	161	28.6	19.4	44	29.7	15.6				94	26.5	16.6	211	33.0	13.1
Distant	84	4.9	2.6	23	4.1	2.7	11	7.4	3.9				17	4.9	3.1	32	5.0	2.0
Unknown	32	1.8	0.9	6	1.1	0.8	2	1.6	0.8				4	1.2	0.7	14	2.2	0.9
<i>Age ≥ 50</i>																		
<i>In Situ</i>	1,261	18.8	74.0	480	16.2	80.6	146	20.4	88.3				268	22.6	80.9	346	19.7	57.3
Localized	3,575	53.2	210.3	1,702	57.5	276.2	353	49.2	214.0				608	51.3	182.9	870	49.5	148.2
Regional	1,426	21.2	83.6	583	19.7	96.0	161	22.5	97.4				239	20.2	72.8	422	24.0	70.4
Distant	301	4.5	17.7	136	4.6	21.8	38	5.3	22.9				45	3.8	13.8	79	4.5	13.4
Unknown	158	2.3	8.9	57	1.9	8.1	19	2.6	11.2				25	2.1	7.5	42	2.4	7.2

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	10	0.5	0.2	5	0.5	0.2	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			2	0.5	0.2	2	0.6	0.2
Localized	383	19.7	8.4	220	23.6	11.4	38	15.1	9.8				65	17.2	7.4	57	15.6	4.4
Regional	378	19.4	8.0	182	19.5	9.3	48	19.0	11.5				77	20.2	8.6	67	18.5	4.8
Distant	999	51.4	21.0	453	48.4	22.8	138	55.1	32.7				200	52.7	22.8	202	55.6	14.5
Unknown	176	9.0	3.9	75	8.0	3.8	26	10.5	6.7				36	9.4	4.2	35	9.7	2.9
<i>Female</i>																		
<i>In Situ</i>	16	0.9	0.3	9	1.0	0.4	2	0.6	0.3	Insufficient data for the calculation of AI/AN PRCDA statistics			3	1.0	0.3	2	0.7	0.1
Localized	470	26.0	8.0	263	29.2	11.6	56	22.3	9.8				72	23.4	6.3	75	22.7	4.0
Regional	337	18.7	5.7	170	18.9	7.5	51	20.4	8.7				51	16.5	4.3	63	19.3	3.3
Distant	827	45.8	13.9	379	42.1	16.8	126	50.3	21.8				160	51.5	13.8	156	47.7	8.1
Unknown	155	8.6	2.5	80	8.9	3.2	16	6.3	2.6				24	7.6	1.9	31	9.6	1.7

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	2,964	64.1	56.6	1,379	68.1	65.8	433	68.1	92.8	Insufficient data for the calculation of AI/AN PRCDA statistics			279	64.0	29.3	756	62.1	45.1
Regional	719	15.6	13.5	346	17.1	16.3	84	13.2	17.1				86	19.7	8.9	192	15.8	10.9
Distant	413	8.9	8.8	176	8.7	8.9	73	11.5	18.1				38	8.6	4.4	120	9.9	8.5
Unknown	525	11.4	11.0	122	6.0	6.2	45	7.1	11.3				34	7.7	3.9	148	12.2	10.5
<i>Age < 65</i>																		
Localized	1,215	68.6	22.2	515	73.1	26.2	226	72.2	47.7	Insufficient data for the calculation of AI/AN PRCDA statistics			97	69.3	10.6	330	65.7	15.8
Regional	309	17.4	5.6	131	18.5	6.6	49	15.6	10.2				30	21.7	3.3	94	18.6	4.5
Distant	106	6.0	2.0	35	4.9	1.8	25	7.9	5.1				7	5.1	0.8	37	7.4	1.8
Unknown	141	8.0	2.5	24	3.4	1.2	14	4.4	2.8				5	3.9	0.6	42	8.3	2.0
<i>Age ≥ 65</i>																		
Localized	1,749	61.4	294.4	864	65.5	339.4	207	64.2	404.7				181	61.4	158.9	425	59.6	247.4
Regional	410	14.4	67.5	215	16.3	83.2	35	11.0	64.8				55	18.8	48.0	99	13.8	55.5
Distant	307	10.8	56.0	142	10.7	58.1	49	15.1	108.3				30	10.3	29.1	83	11.6	54.5
Unknown	384	13.5	69.1	98	7.4	40.3	31	9.7	69.9				28	9.5	26.6	107	14.9	69.1

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Colorado, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	94	53.5	3.4	65	54.7	3.3	4	54.3	3.6	*	*	*	4	57.1	3.5	18	48.2	3.5
Regional	50	28.2	1.7	32	27.0	1.5	2	25.7	1.5	*	*	*	2	31.4	2.0	13	33.5	2.6
Distant	25	14.2	0.8	16	13.8	0.7	1	17.1	1.2	*	*	*	*	*	*	6	16.2	1.4
Unknown	7	4.1	0.2	5	4.5	0.2	*	*	*	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	38	3.5	1.2	30	3.7	1.2	*	*	*	*	*	*	*	*	*	6	3.5	1.3
Localized	359	33.5	12.4	273	33.2	11.8	14	35.1	15.0	*	*	*	10	39.7	14.2	54	32.7	13.7
Regional	398	37.1	13.9	312	37.9	13.7	12	29.2	12.6	*	*	*	10	38.2	13.4	59	35.6	16.2
Distant	230	21.4	7.9	173	21.0	7.6	11	27.2	10.8	*	*	*	5	19.1	5.6	38	23.2	10.0
Unknown	47	4.4	1.8	34	4.2	1.6	3	6.4	3.0	*	*	*	*	*	*	8	5.0	2.6
<i>Age < 50</i>																		
<i>In Situ</i>	3	1.8	0.1	2	1.9	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	45	31.0	2.4	31	30.5	2.4	2	27.8	2.0	*	*	*	1	25.0	1.6	9	34.1	2.1
Regional	56	38.5	3.0	42	40.4	3.3	2	27.8	2.2	*	*	*	2	45.8	3.3	10	35.6	2.4
Distant	38	26.3	2.1	26	25.6	2.1	3	36.1	3.0	*	*	*	1	29.2	1.8	7	25.2	1.7
Unknown	3	2.3	0.2	2	1.6	0.1	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	35	3.8	4.1	28	3.9	4.1	*	*	*	*	*	*	*	*	*	*	*	*
Localized	314	33.9	38.5	242	33.6	36.4	12	36.7	48.8	*	*	*	9	43.0	47.1	45	32.5	44.0
Regional	342	36.9	42.4	270	37.6	40.9	10	29.5	39.8	*	*	*	8	36.4	39.6	49	35.7	52.4
Distant	192	20.7	23.3	146	20.4	22.0	8	25.3	31.4	*	*	*	4	16.8	15.5	31	22.8	31.8
Unknown	44	4.7	6.2	33	4.5	5.6	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	31	3.3	1.0	25	3.4	1.0	1	3.2	1.1	*	*	*	*	*	*	4	3.1	0.9
Localized	322	34.2	10.2	255	34.4	10.2	14	37.3	13.1	*	*	*	6	28.8	5.8	41	32.5	9.9
Regional	346	36.7	11.0	272	36.7	10.9	14	37.3	13.6	*	*	*	9	41.3	8.0	47	36.8	11.4
Distant	189	20.0	6.0	146	19.7	5.8	7	20.0	7.3	*	*	*	5	22.1	4.7	27	21.2	6.8
Unknown	55	5.8	1.7	43	5.8	1.6	*	*	*	*	*	*	*	*	*	8	6.3	2.4
<i>Age < 50</i>																		
<i>In Situ</i>	3	2.5	0.2	3	2.9	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	44	33.8	2.4	32	35.2	2.6	4	52.9	4.6	*	*	*	*	*	*	6	25.4	1.4
Regional	51	39.7	3.0	35	38.7	2.9	2	32.4	3.0	*	*	*	2	43.5	2.4	11	48.2	3.1
Distant	29	22.3	1.6	19	21.3	1.6	*	*	*	*	*	*	2	34.8	1.9	6	24.6	1.5
Unknown	2	1.7	0.1	2	2.0	0.1	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	28	3.5	3.0	23	3.5	3.0	1	4.0	3.8	*	*	*	*	*	*	*	*	*
Localized	279	34.2	30.6	223	34.3	30.1	10	33.8	35.2	*	*	*	*	*	*	36	34.1	32.0
Regional	295	36.2	32.2	237	36.4	31.6	12	38.4	41.2	*	*	*	7	40.7	22.8	36	34.3	33.1
Distant	160	19.6	17.5	127	19.5	16.8	*	*	*	*	*	*	3	18.5	12.1	21	20.5	20.6
Unknown	52	6.4	5.8	41	6.4	5.4	*	*	*	*	*	*	*	*	*	8	7.7	8.7

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Colorado, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	872	17.4	27.5	704	17.2	28.7	27	17.8	24.9	*	*	*	28	22.3	25.5	98	16.9	21.9
Localized	2,770	55.2	86.1	2,300	56.2	90.4	73	47.7	71.1	*	*	*	64	51.3	58.9	292	50.4	66.6
Regional	1,091	21.7	35.4	854	20.9	35.9	42	27.2	38.0	*	*	*	26	21.2	23.8	154	26.5	33.3
Distant	214	4.3	6.7	173	4.2	6.9	8	5.5	7.4	*	*	*	5	4.2	5.1	26	4.5	6.1
Unknown	75	1.5	2.3	60	1.5	2.2	3	1.8	3.0	*	*	*	1	1.1	1.5	10	1.7	2.6
<i>Age < 50</i>																		
<i>In Situ</i>	180	18.4	10.5	139	19.2	11.7	4	12.8	6.4	*	*	*	8	17.2	9.2	25	15.7	7.0
Localized	452	46.2	26.2	339	46.8	28.3	15	43.0	20.6	*	*	*	21	46.6	24.9	69	43.5	18.8
Regional	306	31.2	17.5	217	29.9	18.0	13	36.6	16.7	*	*	*	13	30.3	16.2	58	36.5	15.6
Distant	37	3.8	2.1	27	3.7	2.2	2	5.8	2.6	*	*	*	2	5.0	2.7	6	3.5	1.5
Unknown	5	0.5	0.3	3	0.4	0.2	*	*	*	*	*	*	*	*	*	1	0.8	0.3
<i>Age ≥ 50</i>																		
<i>In Situ</i>	692	17.1	71.9	566	16.8	73.1	23	19.3	73.2	*	*	*	20	25.1	68.1	73	17.4	61.1
Localized	2,318	57.3	242.9	1,962	58.3	252.9	58	49.0	203.2	*	*	*	43	53.8	148.0	223	53.0	191.5
Regional	785	19.4	82.4	637	18.9	83.0	29	24.5	93.7	*	*	*	13	16.1	43.4	96	22.8	79.6
Distant	178	4.4	18.9	146	4.3	19.1	6	5.4	19.9	*	*	*	3	3.7	11.6	20	4.8	18.1
Unknown	69	1.7	7.4	57	1.7	7.2	*	*	*	*	*	*	*	*	*	9	2.0	8.5

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	5	0.5	0.2	5	0.5	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	305	26.2	11.0	261	26.7	11.3	12	28.2	13.8	*	*	*	6	26.3	10.5	23	20.7	7.6
Regional	259	22.2	9.1	218	22.4	9.2	8	19.0	9.1	*	*	*	4	18.6	6.5	26	23.0	8.7
Distant	518	44.5	18.2	429	43.9	18.2	21	47.7	21.6	*	*	*	11	48.3	17.0	53	47.7	16.9
Unknown	77	6.6	3.1	63	6.5	3.0	2	5.1	3.8	*	*	*	2	6.8	2.5	9	8.3	3.9
<i>Female</i>																		
<i>In Situ</i>	5	0.4	0.1	3	0.3	0.1	*	*	*	*	*	*	*	*	*	*	*	*
Localized	386	30.8	11.9	331	31.3	12.3	12	33.0	12.2	*	*	*	6	22.0	6.8	31	26.7	8.5
Regional	265	21.2	8.1	221	20.9	8.2	8	22.7	8.3	*	*	*	6	19.9	6.7	27	23.3	7.5
Distant	513	41.0	15.7	432	40.9	16.1	14	37.3	13.7	*	*	*	14	48.2	14.9	50	42.4	13.4
Unknown	83	6.6	2.6	69	6.6	2.6	2	4.9	1.8	*	*	*	3	9.2	3.1	9	7.3	2.7

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	2,074	70.8	64.2	1,652	70.4	62.4	112	74.2	97.1	*	*	*	23	69.3	32.3	161	65.1	43.8
Regional	402	13.7	12.1	340	14.5	12.4	18	11.6	14.7	*	*	*	3	10.4	4.1	36	14.5	9.3
Distant	292	10.0	10.8	234	10.0	10.5	16	10.6	18.6	*	*	*	3	10.4	6.4	34	13.8	11.5
Unknown	160	5.5	6.1	122	5.2	5.6	5	3.6	8.5	*	*	*	3	9.8	5.4	16	6.6	6.1
<i>Age < 65</i>																		
Localized	856	75.2	26.6	653	75.1	25.7	67	77.5	52.0	*	*	*	7	63.5	8.1	74	69.9	17.0
Regional	174	15.3	5.4	138	15.9	5.3	12	13.9	9.5	*	*	*	*	*	*	18	16.9	4.1
Distant	73	6.4	2.3	54	6.3	2.1	6	7.4	4.9	*	*	*	*	*	*	10	9.8	2.4
Unknown	35	3.1	1.1	24	2.8	0.9	*	*	*	*	*	*	*	*	*	4	3.4	0.8
<i>Age ≥ 65</i>																		
Localized	1,218	68.1	324.0	1,000	67.6	315.7	45	69.8	409.1	*	*	*	16	72.1	200.1	87	61.5	229.5
Regional	229	12.8	58.7	202	13.6	61.5	6	8.6	50.8	*	*	*	*	*	*	18	12.6	45.0
Distant	219	12.2	69.7	180	12.1	68.0	10	14.8	113.2	*	*	*	*	*	*	24	16.9	74.6
Unknown	125	7.0	41.0	98	6.6	38.3	*	*	*	*	*	*	*	*	*	13	8.9	42.9

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Connecticut, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	48	43.5	2.8	30	42.9	2.7	3	22.7	1.5	*	*	*	1	43.8	1.7	12	57.0	4.5
Regional	38	34.9	1.8	23	32.8	1.5	7	51.5	3.3	*	*	*	1	37.5	1.2	7	31.8	2.8
Distant	19	16.9	0.8	14	19.8	0.8	3	22.7	1.3	*	*	*	*	*	*	1	5.6	0.5
Unknown	5	4.7	0.3	3	4.5	0.3	*	*	*	*	*	*	*	*	*	1	5.6	0.6

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	49	5.7	2.3	39	5.6	2.2	4	5.6	2.5	*	*	*	*	*	*	5	5.8	3.1
Localized	336	38.7	16.2	266	39.0	16.0	28	37.8	17.8	*	*	*	6	35.0	8.1	31	38.0	18.5
Regional	265	30.6	13.0	208	30.5	12.8	22	28.7	13.6	*	*	*	6	36.3	9.0	27	32.2	16.0
Distant	174	20.0	8.5	139	20.3	8.5	17	22.1	10.8	*	*	*	2	15.0	3.3	15	18.6	8.3
Unknown	43	5.0	2.1	32	4.7	1.9	4	5.9	2.9	*	*	*	1	8.8	2.0	4	5.3	2.8
<i>Age < 50</i>																		
<i>In Situ</i>	5	4.4	0.4	3	4.3	0.4	*	*	*	*	*	*	*	*	*	*	*	*
Localized	35	34.2	3.3	25	35.9	3.6	3	20.9	2.3	*	*	*	1	40.0	2.0	6	34.9	2.9
Regional	34	33.0	3.2	23	33.6	3.4	4	29.9	3.4	*	*	*	*	*	*	5	32.5	2.8
Distant	26	25.1	2.5	16	23.6	2.4	5	37.3	4.0	*	*	*	*	*	*	4	26.5	2.3
Unknown	3	3.3	0.3	2	2.6	0.3	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	45	5.8	7.2	36	5.8	7.0	*	*	*	*	*	*	*	*	*	*	*	*
Localized	300	39.3	49.9	241	39.3	48.5	26	41.4	58.3	*	*	*	4	33.8	24.3	26	38.8	59.2
Regional	231	30.3	38.5	185	30.1	37.4	18	28.5	40.2	*	*	*	*	*	*	21	32.1	50.7
Distant	148	19.3	24.4	122	19.9	24.4	12	18.8	28.4	*	*	*	*	*	*	11	16.7	23.8
Unknown	40	5.2	6.9	30	4.9	6.2	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	40	5.0	1.6	30	4.8	1.6	4	5.1	2.0	*	*	*	*	*	*	5	6.8	2.2
Localized	294	36.8	12.0	230	36.4	11.7	30	38.4	14.2	*	*	*	5	35.2	6.7	26	37.9	11.4
Regional	258	32.2	10.2	204	32.4	9.9	24	30.7	11.6	*	*	*	5	38.0	6.8	22	32.2	10.4
Distant	159	19.9	6.3	127	20.1	6.1	17	22.0	8.3	*	*	*	2	15.5	3.3	12	18.0	5.9
Unknown	48	6.0	1.7	40	6.3	1.6	3	3.8	1.5	*	*	*	*	*	*	3	5.0	1.9
<i>Age < 50</i>																		
<i>In Situ</i>	4	4.5	0.3	2	5.0	0.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	36	42.5	3.2	21	43.7	3.0	5	38.6	3.9	*	*	*	*	*	*	8	44.6	4.1
Regional	28	33.3	2.5	16	32.8	2.2	4	30.0	3.3	*	*	*	2	66.7	2.3	6	31.5	2.9
Distant	14	16.9	1.3	8	17.2	1.1	3	21.4	2.3	*	*	*	*	*	*	3	16.3	1.5
Unknown	2	2.9	0.2	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	36	5.1	5.0	28	4.8	4.8	*	*	*	*	*	*	*	*	*	*	*	*
Localized	259	36.2	35.0	209	35.8	34.5	25	38.3	41.2	*	*	*	*	*	*	17	35.4	30.6
Regional	230	32.1	30.4	189	32.3	30.2	20	30.8	33.0	*	*	*	4	32.2	18.3	16	32.5	29.9
Distant	145	20.3	19.4	119	20.3	19.2	14	22.1	24.0	*	*	*	2	18.6	12.1	9	18.7	17.6
Unknown	46	6.4	5.4	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Connecticut, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	948	22.2	42.5	732	21.6	43.6	84	23.1	39.6	*	*	*	31	28.7	34.6	91	24.7	38.4
Localized	2,334	54.6	97.9	1,915	56.5	103.3	167	45.8	78.5	3	48.4	64.6	52	48.5	61.3	180	48.5	81.4
Regional	752	17.6	33.7	553	16.3	32.8	89	24.5	42.6	2	32.3	41.9	19	17.7	21.0	83	22.3	35.0
Distant	180	4.2	7.4	142	4.2	7.3	19	5.2	8.8	*	*	*	4	3.7	4.8	13	3.6	5.9
Unknown	60	1.4	2.3	48	1.4	2.2	5	1.3	2.3	*	*	*	1	1.3	1.6	4	1.0	1.6
<i>Age < 50</i>																		
<i>In Situ</i>	231	28.3	20.8	158	28.4	21.8	21	25.5	16.4	*	*	*	13	33.7	19.3	36	28.7	18.7
Localized	360	44.1	32.3	256	46.0	35.6	29	35.4	22.6	1	54.5	43.5	17	43.2	24.9	51	40.9	26.5
Regional	193	23.7	17.7	124	22.2	17.8	27	32.5	20.9	*	*	*	9	21.6	12.3	32	25.6	16.2
Distant	26	3.2	2.3	15	2.7	2.1	5	5.8	3.6	*	*	*	*	*	*	5	4.0	2.5
Unknown	6	0.8	0.6	4	0.8	0.6	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	717	20.7	99.3	574	20.3	100.5	63	22.4	100.3	*	*	*	17	25.8	74.5	56	22.7	90.1
Localized	1,974	57.1	269.4	1,659	58.6	280.7	137	48.9	224.8	2	45.0	119.9	35	51.6	156.7	129	52.3	225.1
Regional	559	16.2	75.5	429	15.2	72.1	62	22.1	99.3	*	*	*	10	15.4	43.8	51	20.6	84.2
Distant	154	4.5	20.6	127	4.5	20.8	14	5.1	22.3	*	*	*	*	*	*	8	3.3	14.8
Unknown	53	1.5	6.7	43	1.5	6.5	*	*	*	*	*	*	*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	3	0.2	0.1	2	0.2	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	379	29.0	18.2	328	29.7	18.9	25	24.3	17.4	*	*	*	3	15.7	4.4	20	27.8	14.5
Regional	279	21.4	13.1	236	21.3	13.3	21	20.5	14.5	*	*	*	4	25.3	6.9	15	21.0	11.2
Distant	603	46.1	28.5	504	45.5	28.6	53	51.5	37.0	*	*	*	8	48.2	13.7	35	48.2	24.2
Unknown	44	3.4	2.2	36	3.3	2.1	4	3.7	3.1	*	*	*	2	10.8	3.0	2	2.7	1.4
<i>Female</i>																		
<i>In Situ</i>	7	0.5	0.3	5	0.4	0.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	469	32.9	18.2	412	33.3	19.6	29	28.5	13.6	*	*	*	5	34.2	6.8	21	30.9	11.1
Regional	280	19.6	10.8	241	19.5	11.4	20	19.5	9.4	*	*	*	2	13.7	3.0	16	23.8	8.5
Distant	615	43.1	23.5	531	42.9	24.8	48	47.6	22.4	1	54.5	19.6	7	47.9	9.8	27	40.0	14.4
Unknown	55	3.9	2.0	48	3.9	2.0	4	3.6	1.7	*	*	*	*	*	*	3	4.4	1.8

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	2,065	73.5	89.9	1,633	73.3	86.4	243	77.2	143.7	2	70.6	55.7	20	67.3	31.8	133	71.5	78.2
Regional	390	13.9	16.4	317	14.2	16.3	37	11.7	20.9	*	*	*	6	20.0	10.3	26	13.9	14.2
Distant	229	8.2	11.1	183	8.2	10.5	24	7.7	16.5	*	*	*	3	8.7	4.4	18	9.6	14.4
Unknown	123	4.4	5.7	96	4.3	5.3	11	3.4	8.3	*	*	*	1	4.0	1.8	9	4.9	6.4
<i>Age < 65</i>																		
Localized	843	75.5	37.0	621	75.3	34.3	128	77.9	69.2	*	*	*	8	72.7	10.9	68	73.5	32.4
Regional	186	16.6	8.2	144	17.4	7.9	22	13.6	12.3	*	*	*	2	18.2	2.7	16	17.1	7.6
Distant	48	4.3	2.1	31	3.8	1.8	11	6.6	5.7	*	*	*	*	*	*	5	5.2	2.3
Unknown	40	3.6	1.8	29	3.5	1.6	3	1.9	1.7	*	*	*	*	*	*	4	4.1	1.9
<i>Age ≥ 65</i>																		
Localized	1,223	72.3	455.6	1,012	72.1	446.6	115	76.5	658.5	*	*	*	12	64.2	176.4	66	69.5	395.4
Regional	205	12.1	73.5	174	12.4	73.8	14	9.6	80.1	*	*	*	4	21.1	63.0	10	10.8	60.4
Distant	182	10.7	73.3	152	10.8	71.2	14	9.0	91.5	*	*	*	*	*	*	13	14.0	97.9
Unknown	83	4.9	32.7	67	4.8	30.6	7	4.9	53.6	*	*	*	*	*	*	5	5.7	37.7

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Delaware, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	20	48.8	4.1	15	54.2	5.0	3	42.5	3.3	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Regional	10	25.6	1.9	7	23.9	1.8	3	32.5	2.2				*	*	*	*	*	*
Distant	7	17.2	1.2	5	16.2	1.1	2	20.0	1.4				*	*	*	*	*	*
Unknown	3	8.4	0.5	2	5.6	0.3	*	*	*				*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	9	3.8	1.6	7	3.6	1.5	2	4.8	2.7				*	*	*	*	*	*
Localized	80	32.3	14.1	62	33.1	14.1	14	29.8	15.0				1	35.3	7.0	3	31.3	11.6
Regional	94	37.7	16.7	74	39.4	17.5	15	33.3	17.1				2	47.1	10.6	3	29.2	10.9
Distant	50	20.2	9.0	36	19.3	8.7	11	23.2	11.8				*	*	*	3	29.2	11.7
Unknown	15	5.9	2.9	8	4.5	2.4	4	8.8	4.6				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*
Localized	8	28.7	2.9	4	25.3	2.5	2	32.1	3.0				*	*	*	1	40.0	4.3
Regional	11	39.0	3.9	7	43.4	4.5	1	25.0	2.0				*	*	*	*	*	*
Distant	6	22.1	2.3	4	22.9	2.5	2	28.6	2.5				*	*	*	*	*	*
Unknown	2	8.1	0.9	1	7.2	0.8	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*
Localized	72	32.8	43.3	58	33.9	44.2	12	29.5	46.5				*	*	*	2	27.3	31.0
Regional	83	37.6	50.3	66	39.1	51.8	14	34.5	56.6				*	*	*	*	*	*
Distant	44	20.0	26.6	32	18.9	24.9	9	22.5	36.2				*	*	*	*	*	*
Unknown	12	5.6	8.2	7	4.2	6.4	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	6	2.7	0.9	4	2.2	0.7	2	4.6	1.7				*	*	*	*	*	*
Localized	87	38.8	12.8	63	37.6	12.5	18	42.2	14.1				1	46.2	5.9	4	42.6	18.6
Regional	70	31.1	10.5	53	31.7	10.9	12	28.4	10.3				1	46.2	6.1	3	34.0	14.2
Distant	44	19.4	6.7	33	19.8	7.0	9	20.6	7.3				*	*	*	1	12.8	3.7
Unknown	18	7.9	2.5	14	8.7	2.6	2	4.1	1.6				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*
Localized	9	36.4	3.0	6	34.9	3.6	2	40.0	2.6				*	*	*	*	*	*
Regional	8	31.4	2.7	6	32.6	3.2	1	28.0	2.0				*	*	*	*	*	*
Distant	6	26.4	2.2	5	26.7	2.7	1	28.0	1.9				*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*
Localized	78	39.1	38.3	57	37.9	36.1	16	42.5	44.1				*	*	*	*	*	*
Regional	62	31.1	31.1	47	31.6	30.8	11	28.5	32.0				*	*	*	*	*	*
Distant	37	18.6	18.3	28	19.0	18.3	8	19.7	21.5				*	*	*	*	*	*
Unknown	*	*	*	*	*	*	2	4.7	5.7				*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Delaware, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	196	18.3	30.7	137	17.4	30.1	43	19.9	34.5				7	26.3	35.2	8	22.2	26.3
Localized	595	55.4	90.3	452	57.6	93.5	107	49.2	84.9				15	53.3	73.1	18	49.4	67.9
Regional	217	20.2	35.8	150	19.2	35.3	53	24.4	43.1				5	16.8	21.1	8	21.7	25.5
Distant	48	4.5	7.5	35	4.5	7.5	11	4.9	8.3				*	*	*	2	5.0	6.5
Unknown	18	1.7	2.6	11	1.3	1.9	4	1.7	3.4				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	34	19.8	12.2	22	19.9	12.9	7	17.1	10.1	Insufficient data for the calculation of AI/AN PRCDA statistics			2	28.6	17.3	3	25.0	11.5
Localized	78	44.7	27.8	50	45.3	29.7	19	45.5	27.2				4	47.6	28.9	4	33.3	14.3
Regional	52	30.1	18.6	33	29.9	19.4	13	31.3	19.4				2	19.0	10.1	4	35.0	14.9
Distant	8	4.4	2.7	5	4.2	2.9	2	4.7	2.7				*	*	*	*	*	*
Unknown	2	1.0	0.6	*	*	*	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	162	18.0	79.4	115	17.0	75.3	36	20.6	98.2				5	25.3	82.1	5	20.8	65.2
Localized	518	57.5	253.9	403	59.6	260.7	87	50.1	236.0				11	55.8	188.9	14	57.5	208.4
Regional	164	18.3	80.9	118	17.4	76.8	40	22.7	105.3				3	15.8	50.0	4	15.0	53.3
Distant	41	4.5	19.8	31	4.5	19.6	9	4.9	23.0				*	*	*	*	*	*
Unknown	16	1.8	7.8	*	*	*	*	*	*				*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	106	25.6	17.5	89	26.0	18.5	12	21.5	13.7				*	*	*	3	40.6	14.1
Regional	96	23.2	15.8	79	22.9	16.6	14	24.2	16.4				*	*	*	2	31.3	11.7
Distant	186	45.1	31.1	153	44.6	33.1	29	49.8	30.1				2	57.1	17.7	2	25.0	8.3
Unknown	25	6.1	4.4	22	6.4	4.8	3	4.5	3.5				*	*	*	*	*	*
<i>Female</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	123	29.7	16.7	104	30.4	18.3	16	26.7	13.2				*	*	*	2	36.0	10.2
Regional	92	22.3	12.5	76	22.3	13.6	14	23.0	11.0				1	31.8	7.7	*	*	*
Distant	174	42.0	23.8	142	41.3	25.5	27	45.0	22.1				2	45.5	10.1	2	48.0	10.9
Unknown	24	5.8	3.2	20	5.8	3.4	3	5.0	2.6				*	*	*	*	*	*

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	569	70.1	87.5	392	72.7	77.3	145	73.2	136.1				8	74.5	48.7	14	65.1	65.4
Regional	77	9.5	11.8	54	9.9	10.7	18	9.2	16.6				2	20.0	12.9	2	11.0	10.4
Distant	56	6.9	9.5	39	7.3	8.6	14	7.3	15.5				*	*	*	1	5.5	5.6
Unknown	110	13.6	17.2	54	10.1	10.9	20	10.3	19.9				*	*	*	4	18.3	20.9
<i>Age < 65</i>																		
Localized	219	69.4	38.4	128	72.3	30.6	78	75.0	72.1	Insufficient data for the calculation of AI/AN PRCDA statistics			3	68.4	15.2	6	61.5	22.4
Regional	39	12.4	7.1	25	14.2	6.3	11	10.6	10.5				*	*	*	*	*	*
Distant	13	4.3	2.4	7	4.1	1.8	6	5.6	5.2				*	*	*	*	*	*
Unknown	44	13.9	7.5	17	9.4	3.8	9	8.9	8.6				*	*	*	2	17.3	6.5
<i>Age ≥ 65</i>																		
Localized	350	70.5	427.0	264	72.9	399.9	67	71.3	578.7				6	77.8	280.0	8	68.4	362.1
Regional	38	7.6	44.3	28	7.9	41.4	7	7.6	58.4				*	*	*	*	*	*
Distant	42	8.5	59.0	32	8.8	55.2	9	9.1	86.7				*	*	*	*	*	*
Unknown	66	13.3	84.1	38	10.4	59.9	11	11.9	98.2				*	*	*	2	19.3	120.5

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
District of Columbia, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	11	38.6	3.1	2	37.5	1.8	6	36.1	3.3	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	2	61.1	6.2
Regional	9	31.7	2.4	3	43.8	2.0	5	32.5	2.7				*	*	*	*	*	*
Distant	4	12.4	1.0	*	*	*	2	14.5	1.2				*	*	*	*	*	*
Unknown	5	17.2	1.3	*	*	*	3	16.9	1.4				*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	9	7.0	2.8	2	7.6	2.0	4	5.1	2.5	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	40	31.6	13.4	10	31.8	8.2	26	33.3	17.7				*	*	*	*	*	*
Regional	37	29.6	12.6	10	32.5	8.9	22	28.3	15.2				1	46.7	16.0	3	46.4	12.9
Distant	25	20.1	8.5	6	17.8	4.6	18	22.7	11.9				*	*	*	*	*	*
Unknown	15	11.7	5.0	3	10.2	3.0	8	10.6	5.8				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	2	8.0	0.8	*	*	*	*	*	*				*	*	*	*	*	*
Localized	7	30.1	2.8	3	32.5	2.1	3	26.4	3.4				*	*	*	*	*	*
Regional	7	30.1	3.1	2	30.0	2.4	3	32.1	4.1				*	*	*	*	*	*
Distant	5	23.9	2.4	2	30.0	2.2	3	24.5	3.0				*	*	*	*	*	*
Unknown	2	8.0	0.8	*	*	*	1	13.2	1.6				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	7	6.7	8.1	*	*	*	*	*	*				*	*	*	*	*	*
Localized	33	32.0	41.1	7	31.6	24.3	24	34.4	55.4				*	*	*	*	*	*
Regional	31	29.5	37.5	8	33.3	25.7	19	27.7	44.2				*	*	*	*	*	*
Distant	20	19.3	24.4	3	13.7	10.7	15	22.4	35.3				*	*	*	*	*	*
Unknown	13	12.5	16.0	*	*	*	7	10.2	16.7				*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	9	7.3	2.6	2	7.0	2.0	4	4.2	1.6	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	42	32.1	11.1	9	30.1	7.4	28	32.5	12.6				1	42.9	9.9	3	51.7	13.5
Regional	33	25.2	8.9	8	29.4	7.5	22	26.4	10.3				*	*	*	1	20.7	4.5
Distant	31	23.6	8.2	6	21.7	5.0	23	26.9	10.7				*	*	*	*	*	*
Unknown	15	11.7	3.7	3	11.9	2.5	8	9.9	3.6				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	1	5.7	0.6	*	*	*	*	*	*				*	*	*	*	*	*
Localized	7	33.0	3.0	2	27.8	2.3	3	34.0	3.4				*	*	*	*	*	*
Regional	5	24.5	2.3	3	38.9	3.4	2	18.0	1.7				*	*	*	*	*	*
Distant	6	30.2	2.6	2	25.0	1.5	4	38.0	3.6				*	*	*	*	*	*
Unknown	1	6.6	0.5	*	*	*	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	8	7.6	7.9	*	*	*	*	*	*				*	*	*	*	*	*
Localized	35	32.0	32.4	7	30.8	20.7	24	32.4	36.6				*	*	*	*	*	*
Regional	27	25.3	26.2	6	26.2	18.3	21	27.5	32.7				*	*	*	*	*	*
Distant	24	22.4	22.9	4	20.6	14.0	19	25.4	29.3				*	*	*	*	*	*
Unknown	14	12.8	12.2	3	15.9	8.9	*	*	*				*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
District of Columbia, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	136	21.6	38.9	41	20.3	39.1	77	21.0	37.7				6	32.6	40.1	10	31.4	34.5
Localized	310	49.3	86.0	109	54.5	100.1	173	47.0	81.6				8	45.7	57.4	14	44.0	51.2
Regional	132	21.0	36.5	37	18.7	33.4	83	22.5	40.3				3	18.5	22.0	7	20.8	24.8
Distant	35	5.5	9.5	7	3.7	6.8	25	6.9	11.9				*	*	*	*	*	*
Unknown	17	2.7	4.6	6	2.9	5.5	10	2.7	4.5				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	34	23.3	16.5	12	21.0	16.7	13	22.3	14.0	Insufficient data for the calculation of AI/AN PRCDA statistics			3	31.4	23.0	5	34.8	21.0
Localized	64	43.9	29.0	27	48.8	34.9	25	41.3	25.0				5	45.1	35.0	5	36.4	20.8
Regional	38	26.1	16.2	15	26.0	17.5	17	29.0	17.0				2	17.6	11.7	3	21.2	12.3
Distant	6	4.3	2.7	1	2.1	1.5	3	5.3	3.1				*	*	*	*	*	*
Unknown	3	2.3	1.5	1	2.1	1.7	1	2.0	1.1				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	102	21.0	97.6	29	20.0	97.8	64	20.7	100.0				3	34.1	84.6	5	29.0	69.8
Localized	247	50.8	235.1	82	56.7	270.8	148	48.1	229.7				4	46.3	116.0	9	49.5	131.0
Regional	94	19.5	89.5	23	15.8	74.9	65	21.3	101.2				2	19.5	48.8	4	20.4	57.6
Distant	29	5.9	27.5	6	4.3	20.8	22	7.2	34.7				*	*	*	*	*	*
Unknown	13	2.8	12.6	5	3.2	15.3	9	2.8	13.2				*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	30	21.3	10.4	6	22.1	5.5	23	21.7	15.0				*	*	*	*	*	*
Regional	24	17.2	8.4	5	16.9	4.2	19	17.8	12.4				*	*	*	*	*	*
Distant	62	44.0	21.2	12	42.6	10.1	46	43.4	30.4				2	53.3	23.5	3	73.7	12.4
Unknown	24	16.9	8.6	5	16.9	4.3	18	16.9	12.2				*	*	*	*	*	*
<i>Female</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	41	26.1	10.7	10	32.7	8.9	31	25.2	12.9				*	*	*	*	*	*
Regional	34	21.2	8.9	6	20.7	5.3	26	21.6	11.6				*	*	*	*	*	*
Distant	64	40.7	16.7	11	36.0	9.3	50	40.9	21.0				2	58.8	17.9	1	50.0	5.6
Unknown	18	11.6	4.7	3	10.0	2.7	15	12.2	6.1				*	*	*	*	*	*

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	269	66.6	86.5	77	67.9	67.0	170	68.2	102.0	Insufficient data for the calculation of AI/AN PRCDA statistics			5	86.2	64.7	8	66.7	37.1
Regional	52	12.7	16.1	21	18.6	17.8	27	10.9	16.0				*	*	*	1	10.0	5.3
Distant	36	8.9	12.5	7	5.8	6.0	28	11.1	18.0				*	*	*	1	10.0	9.7
Unknown	48	11.8	16.2	9	7.7	7.9	24	9.8	15.6				*	*	*	2	13.3	8.7
<i>Age < 65</i>																		
Localized	120	68.0	37.9	27	67.2	24.8	81	69.6	48.4	Insufficient data for the calculation of AI/AN PRCDA statistics			3	86.7	32.0	6	80.0	20.7
Regional	26	15.0	8.7	9	23.4	8.8	16	13.6	10.1				*	*	*	*	*	*
Distant	11	6.5	3.6	1	3.0	1.1	10	8.7	5.9				*	*	*	*	*	*
Unknown	18	10.5	5.9	3	6.5	2.5	9	8.1	5.6				*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	150	65.4	421.9	50	68.3	359.0	89	66.9	472.5				2	85.7	290.5	2	48.0	150.2
Regional	25	11.0	67.6	12	16.0	79.7	11	8.6	56.9				*	*	*	*	*	*
Distant	25	10.7	73.9	5	7.3	39.6	18	13.2	101.4				*	*	*	1	24.0	77.1
Unknown	29	12.8	87.7	6	8.4	45.6	15	11.3	84.7				*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Florida, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	418	39.2	3.9	220	39.0	3.9	68	34.8	4.1	*	*	*	8	38.0	1.9	116	43.0	4.2
Regional	361	33.8	3.0	198	35.1	3.1	68	35.0	4.0	*	*	*	6	32.0	1.7	85	31.6	3.0
Distant	163	15.3	1.3	90	15.9	1.2	33	16.7	1.9	*	*	*	4	19.0	1.0	36	13.5	1.3
Unknown	126	11.8	1.0	56	10.0	0.8	27	13.6	1.5	*	*	*	2	11.0	0.6	32	11.9	1.1

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	294	5.0	2.1	212	5.3	2.2	31	4.6	2.1	*	*	*	3	4.2	1.1	43	4.2	1.8
Localized	1,687	28.8	12.3	1,186	29.8	12.5	170	25.5	12.4	*	*	*	25	30.8	8.2	289	28.3	12.4
Regional	2,030	34.7	15.1	1,376	34.6	15.1	229	34.2	16.2	*	*	*	32	38.9	10.6	372	36.4	15.9
Distant	1,216	20.8	9.1	821	20.7	9.2	171	25.6	12.1	*	*	*	15	18.7	5.2	198	19.4	8.4
Unknown	624	10.7	4.5	382	9.6	4.0	68	10.2	5.1	*	*	*	6	7.4	2.0	118	11.6	5.3
<i>Age < 50</i>																		
<i>In Situ</i>	16	2.9	0.3	8	2.7	0.3	3	3.5	0.3	*	*	*	*	*	*	4	2.7	0.2
Localized	135	24.0	2.1	78	24.9	2.5	16	17.7	1.6	*	*	*	3	25.8	1.5	36	26.3	1.9
Regional	221	39.5	3.6	122	39.0	3.9	36	38.9	3.6	*	*	*	5	38.7	2.2	55	40.8	2.9
Distant	148	26.5	2.4	82	26.4	2.6	30	32.4	3.1	*	*	*	4	29.0	1.7	32	23.7	1.7
Unknown	39	7.0	0.6	22	7.0	0.7	7	7.4	0.7	*	*	*	*	*	*	9	6.5	0.5
<i>Age ≥ 50</i>																		
<i>In Situ</i>	277	5.2	7.0	204	5.6	7.2	27	4.7	6.6	*	*	*	*	*	*	40	4.5	6.1
Localized	1,553	29.3	38.8	1,109	30.2	38.6	154	26.7	40.7	*	*	*	22	31.7	25.7	253	28.6	40.0
Regional	1,809	34.2	45.4	1,254	34.2	44.4	193	33.5	49.3	*	*	*	27	39.0	32.5	317	35.8	49.8
Distant	1,068	20.2	26.8	739	20.2	26.5	141	24.5	35.6	*	*	*	12	16.9	14.3	166	18.8	25.8
Unknown	585	11.0	14.6	360	9.8	12.5	61	10.6	16.8	*	*	*	6	8.7	7.3	109	12.3	17.9
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	223	4.3	1.4	156	4.5	1.5	30	4.9	1.7	*	*	*	2	2.3	0.4	33	3.6	1.1
Localized	1,568	30.4	10.0	1,091	31.6	10.4	168	27.2	9.5	*	*	*	19	25.2	5.0	272	29.2	9.2
Regional	1,826	35.4	11.8	1,233	35.8	11.9	204	33.1	11.8	*	*	*	30	39.2	8.2	342	36.7	11.7
Distant	1,020	19.8	6.8	664	19.2	6.8	156	25.3	8.9	*	*	*	21	26.8	5.7	172	18.5	5.9
Unknown	517	10.0	3.1	305	8.8	2.6	59	9.5	3.5	*	*	*	5	6.5	1.4	112	12.1	3.7
<i>Age < 50</i>																		
<i>In Situ</i>	14	2.7	0.2	10	3.5	0.3	*	*	*	*	*	*	*	*	*	3	2.0	0.1
Localized	138	26.9	2.2	76	28.1	2.6	19	22.8	1.8	*	*	*	5	30.9	1.9	34	26.9	1.8
Regional	190	37.2	3.0	99	36.3	3.2	31	36.5	2.9	*	*	*	6	35.8	2.2	52	40.4	2.7
Distant	135	26.5	2.2	72	26.6	2.4	26	30.6	2.4	*	*	*	5	29.6	1.9	30	23.6	1.6
Unknown	34	6.7	0.5	15	5.4	0.5	8	8.9	0.7	*	*	*	*	*	*	9	7.0	0.5
<i>Age ≥ 50</i>																		
<i>In Situ</i>	210	4.5	4.5	146	4.6	4.7	*	*	*	*	*	*	*	*	*	31	3.8	3.6
Localized	1,431	30.8	30.3	1,015	31.9	31.0	148	27.9	29.7	*	*	*	14	23.7	13.0	237	29.5	28.6
Regional	1,636	35.2	34.7	1,135	35.7	34.6	173	32.6	34.9	*	*	*	24	40.1	24.0	290	36.1	35.0
Distant	885	19.0	19.0	591	18.6	18.5	130	24.4	26.0	*	*	*	16	26.0	15.6	142	17.7	17.1
Unknown	483	10.4	9.8	290	9.1	8.2	51	9.6	10.7	*	*	*	*	*	*	103	12.9	12.3

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Florida, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	3,964	18.2	27.7	2,571	17.5	28.4	494	20.0	27.6	*	*	*	94	22.9	23.2	733	19.1	25.2
Localized	11,280	51.7	75.0	8,094	55.2	82.2	1,027	41.5	58.2	4	56.3	59.6	197	47.9	49.0	1,834	47.7	62.8
Regional	4,620	21.2	34.0	2,881	19.6	34.0	677	27.3	38.7	1	21.9	21.4	92	22.3	23.1	921	24.0	31.9
Distant	1,054	4.8	7.4	673	4.6	7.2	174	7.0	10.0	*	*	*	21	5.2	5.3	175	4.6	6.0
Unknown	907	4.2	6.0	454	3.1	4.5	104	4.2	6.0	*	*	*	7	1.7	1.9	178	4.6	6.0
<i>Age < 50</i>																		
<i>In Situ</i>	654	19.0	10.5	341	19.2	11.2	88	15.8	8.4	*	*	*	25	21.9	9.7	186	20.3	10.0
Localized	1,423	41.3	22.7	787	44.2	25.8	197	35.2	18.5	*	*	*	51	44.4	19.7	366	39.9	19.5
Regional	1,052	30.5	16.9	519	29.2	17.3	202	36.0	18.8	*	*	*	31	26.8	11.9	283	30.9	15.2
Distant	191	5.6	3.1	85	4.8	2.9	49	8.8	4.6	*	*	*	7	5.7	2.6	48	5.3	2.6
Unknown	125	3.6	2.0	48	2.7	1.6	24	4.3	2.2	*	*	*	1	1.2	0.5	33	3.6	1.8
<i>Age ≥ 50</i>																		
<i>In Situ</i>	3,310	18.0	72.7	2,230	17.3	73.2	406	21.2	77.7	*	*	*	69	23.3	58.3	547	18.7	65.2
Localized	9,856	53.6	211.9	7,307	56.7	230.0	830	43.3	162.2	*	*	*	146	49.3	125.7	1,467	50.2	176.1
Regional	3,568	19.4	78.9	2,362	18.3	77.6	474	24.8	91.0	*	*	*	61	20.5	52.5	637	21.8	75.8
Distant	863	4.7	18.7	588	4.6	18.7	125	6.5	24.3	*	*	*	15	5.0	12.4	127	4.3	15.1
Unknown	782	4.3	16.4	406	3.2	12.2	80	4.2	15.9	*	*	*	6	2.0	5.5	145	5.0	17.2

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	18	0.2	0.1	14	0.2	0.1	*	*	*	*	*	*	*	*	*	2	0.2	0.1
Localized	2,008	21.8	13.8	1,618	22.8	15.1	132	17.0	10.2	*	*	*	15	17.8	5.1	224	20.4	10.5
Regional	1,980	21.5	13.6	1,547	21.8	14.8	167	21.5	11.9	*	*	*	14	17.5	4.9	238	21.7	10.7
Distant	4,088	44.4	28.4	3,131	44.0	30.5	393	50.6	28.1	*	*	*	48	57.9	16.3	489	44.5	21.8
Unknown	1,116	12.1	7.7	800	11.3	7.5	83	10.7	6.7	*	*	*	5	6.6	2.2	145	13.2	6.8
<i>Female</i>																		
<i>In Situ</i>	26	0.3	0.2	22	0.3	0.2	2	0.3	0.1	*	*	*	*	*	*	3	0.3	0.1
Localized	2,313	27.2	13.5	1,903	27.7	15.9	145	24.7	8.3	*	*	*	21	23.5	5.2	233	27.4	8.0
Regional	1,846	21.7	11.0	1,511	22.0	13.2	124	21.2	6.9	*	*	*	16	17.8	4.0	186	21.8	6.3
Distant	3,485	41.0	20.8	2,832	41.2	24.8	255	43.6	14.3	*	*	*	49	55.6	12.9	330	38.8	11.2
Unknown	824	9.7	4.7	610	8.9	5.0	60	10.2	3.4	*	*	*	3	3.0	0.7	100	11.7	3.3

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	9,690	67.0	65.4	6,471	69.9	61.0	1,533	69.7	100.8	3	72.7	44.8	87	72.1	28.0	1,474	65.1	62.2
Regional	1,712	11.8	11.5	1,129	12.2	10.8	232	10.5	14.6	*	*	*	17	13.7	5.2	316	14.0	12.8
Distant	1,039	7.2	7.1	664	7.2	6.2	193	8.8	14.4	*	*	*	10	8.1	3.5	161	7.1	7.3
Unknown	2,021	14.0	13.8	992	10.7	9.2	240	10.9	18.5	*	*	*	7	6.1	2.9	312	13.8	14.6
<i>Age < 65</i>																		
Localized	3,323	71.0	27.3	1,909	72.1	24.6	755	72.2	47.9	1	70.0	19.1	28	73.7	9.1	583	68.9	23.4
Regional	726	15.5	6.0	421	15.9	5.4	140	13.4	8.9	*	*	*	6	15.3	1.9	151	17.8	6.1
Distant	265	5.7	2.2	135	5.1	1.7	73	7.0	4.6	*	*	*	3	8.4	1.0	49	5.8	2.0
Unknown	365	7.8	2.9	183	6.9	2.3	78	7.4	4.8	*	*	*	*	*	*	63	7.4	2.5
<i>Age ≥ 65</i>																		
Localized	6,367	65.1	328.9	4,562	69.0	313.1	778	67.5	466.2	2	75.0	222.1	59	71.4	158.6	890	62.8	330.0
Regional	986	10.1	50.1	708	10.7	47.9	92	8.0	53.9	*	*	*	11	13.0	28.2	165	11.7	59.5
Distant	774	7.9	41.6	530	8.0	37.2	120	10.4	82.3	*	*	*	7	7.9	21.0	112	7.9	43.9
Unknown	1,657	16.9	88.9	809	12.2	56.7	163	14.1	112.7	*	*	*	*	*	*	249	17.6	98.2

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Georgia, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	183	41.9	3.5	101	43.5	3.7	51	35.8	2.9	Insufficient data for the calculation of AI/AN PRCDA statistics			7	50.0	2.9	21	49.1	5.5
Regional	154	35.3	2.8	80	34.3	2.6	54	37.6	3.2				5	32.9	2.0	15	35.0	4.0
Distant	71	16.4	1.2	39	16.6	1.2	27	18.9	1.5				2	14.3	0.8	3	7.9	1.0
Unknown	28	6.5	0.5	13	5.5	0.4	11	7.7	0.7				*	*	*	3	7.9	1.0

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	45	1.8	0.9	25	1.6	0.7	16	2.3	1.2	Insufficient data for the calculation of AI/AN PRCDA statistics			1	1.8	0.8	2	1.8	0.7
Localized	912	36.7	17.6	597	37.0	17.5	254	35.9	19.3				23	34.8	12.7	32	36.7	13.8
Regional	806	32.4	15.5	540	33.5	15.8	209	29.6	16.4				25	38.5	13.5	29	32.9	12.8
Distant	560	22.5	10.8	349	21.6	10.3	177	25.0	13.5				11	17.0	6.1	22	25.2	8.7
Unknown	163	6.5	3.4	102	6.3	3.2	50	7.1	4.5				5	7.9	3.4	3	3.4	1.5
<i>Age < 50</i>																		
<i>In Situ</i>	7	2.2	0.2	4	1.9	0.2	3	3.3	0.3				*	*	*	*	*	*
Localized	96	30.2	2.9	60	31.5	3.4	27	28.2	2.8				2	19.6	1.1	7	30.8	1.7
Regional	117	36.8	3.6	70	36.8	4.0	35	36.2	3.6				6	56.9	3.4	7	30.8	1.8
Distant	83	26.1	2.6	48	25.2	2.8	26	27.3	2.7				2	19.6	1.2	7	33.6	2.0
Unknown	15	4.6	0.4	9	4.7	0.5	5	5.0	0.5				*	*	*	*	*	*
<i>Age ≥ 50</i>										Insufficient data for the calculation of AI/AN PRCDA statistics								
<i>In Situ</i>	38	1.7	2.5	22	1.5	2.1	13	2.1	3.7				1	2.2	2.7	*	*	*
Localized	816	37.7	55.9	538	37.7	54.3	227	37.2	62.5				21	37.6	43.0	26	38.6	45.2
Regional	689	31.8	46.8	471	33.0	46.7	174	28.6	49.9				20	35.1	39.9	22	33.5	41.5
Distant	477	22.0	32.3	301	21.2	30.1	150	24.6	41.8				9	16.5	19.0	15	22.5	26.0
Unknown	148	6.8	11.2	93	6.6	10.2	46	7.5	15.0				*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	43	2.0	0.7	28	2.1	0.7	14	2.0	0.8				*	*	*	1	1.3	0.3
Localized	802	37.0	13.0	497	37.5	12.8	252	36.4	14.1				18	35.0	8.9	32	35.5	12.8
Regional	698	32.2	11.5	440	33.2	11.3	207	29.9	12.0				20	39.0	9.5	30	33.3	13.3
Distant	480	22.2	7.9	275	20.8	7.1	171	24.7	9.9				11	21.3	5.2	22	24.4	9.0
Unknown	144	6.6	2.3	86	6.5	2.1	49	7.0	3.0				2	3.9	1.1	5	5.5	2.3
<i>Age < 50</i>																		
<i>In Situ</i>	4	1.3	0.1	1	1.0	0.1	2	1.7	0.2				*	*	*	*	*	*
Localized	102	35.1	2.9	55	37.3	3.1	34	31.8	2.9				4	41.9	1.9	9	35.2	2.6
Regional	95	32.9	2.8	51	34.6	2.9	33	30.5	2.8				2	27.9	1.3	9	36.0	2.9
Distant	78	26.8	2.3	36	24.4	2.1	34	31.6	2.9				2	27.9	1.3	5	20.8	1.7
Unknown	11	3.9	0.3	4	2.7	0.2	5	4.5	0.4				*	*	*	1	5.6	0.4
<i>Age ≥ 50</i>																		
<i>In Situ</i>	39	2.1	2.2	26	2.2	2.2	12	2.0	2.3				*	*	*	*	*	*
Localized	700	37.3	39.6	442	37.5	38.0	218	37.2	43.4				14	33.6	27.0	23	35.6	39.4
Regional	603	32.1	34.2	389	33.0	33.3	175	29.8	36.1				17	41.2	30.9	21	32.2	40.6
Distant	403	21.4	22.5	240	20.3	20.4	137	23.4	28.3				8	19.9	15.3	17	25.8	28.2
Unknown	132	7.1	7.6	82	7.0	6.9	44	7.5	9.6				*	*	*	4	5.5	7.3

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Georgia, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	1,724	17.9	28.1	1,019	17.0	27.1	572	19.5	31.4				54	20.3	23.2	72	18.3	24.1
Localized	4,989	51.9	80.8	3,331	55.6	85.6	1,335	45.6	74.9				126	46.8	55.7	185	47.0	68.8
Regional	2,263	23.6	38.0	1,279	21.3	35.2	793	27.1	44.2				71	26.6	31.1	114	28.9	37.1
Distant	518	5.4	8.6	288	4.8	7.6	195	6.7	10.9				15	5.4	7.0	20	5.0	7.5
Unknown	114	1.2	1.9	72	1.2	1.7	34	1.2	2.1				2	0.9	0.9	3	0.9	1.4
<i>Age < 50</i>																		
<i>In Situ</i>	355	18.8	10.4	181	19.2	10.3	123	17.7	10.6	Insufficient data for the calculation of AI/AN PRCDA statistics			23	24.0	12.4	26	17.5	8.6
Localized	818	43.2	23.9	437	46.3	25.0	280	40.1	24.0				37	38.6	19.9	61	40.9	19.6
Regional	605	31.9	17.7	275	29.2	16.0	241	34.5	20.5				31	32.4	16.6	55	36.5	17.5
Distant	105	5.6	3.1	45	4.8	2.6	49	7.0	4.1				4	4.2	2.1	7	4.5	2.1
Unknown	11	0.6	0.3	4	0.5	0.2	5	0.7	0.4				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	1,369	17.7	74.2	839	16.6	71.1	448	20.1	85.7				31	18.2	51.4	46	18.8	64.8
Localized	4,171	54.1	229.8	2,895	57.4	244.2	1,055	47.3	208.0				89	51.4	149.5	124	50.7	197.6
Regional	1,658	21.5	91.0	1,003	19.9	85.6	552	24.7	106.2				40	23.4	69.1	59	24.2	88.5
Distant	413	5.4	22.9	243	4.8	20.6	147	6.6	28.7				11	6.1	19.9	13	5.2	21.6
Unknown	103	1.3	5.9	67	1.3	5.6	30	1.3	6.4				*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	10	0.3	0.2	6	0.2	0.2	3	0.4	0.3				*	*	*	*	*	*
Localized	791	21.2	16.0	604	22.3	17.2	162	18.0	14.1				8	17.4	5.8	15	21.9	10.2
Regional	815	21.9	15.8	593	21.9	16.4	194	21.6	16.2				10	21.3	6.8	15	23.1	10.0
Distant	1,919	51.5	36.8	1,355	50.1	37.7	500	55.5	40.0	Insufficient data for the calculation of AI/AN PRCDA statistics			26	55.7	16.6	34	51.7	18.2
Unknown	193	5.2	4.2	146	5.4	4.4	41	4.5	4.0				2	4.7	1.8	2	2.7	1.5
<i>Female</i>																		
<i>In Situ</i>	14	0.4	0.2	10	0.4	0.2	3	0.5	0.2				*	*	*	*	*	*
Localized	848	26.7	13.5	661	28.0	15.8	161	23.1	9.5				9	20.6	4.8	16	22.5	8.1
Regional	692	21.8	10.8	514	21.8	12.1	156	22.4	9.1				6	14.0	3.0	15	21.1	7.4
Distant	1,473	46.4	23.1	1,057	44.8	25.2	351	50.3	20.2				26	59.8	13.4	37	52.7	18.6
Unknown	148	4.7	2.4	116	4.9	2.8	26	3.8	1.7				2	5.1	1.4	2	2.8	1.3

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	5,672	76.9	100.4	3,193	76.2	83.2	2,210	78.5	156.2				77	76.9	48.0	152	72.1	77.6
Regional	773	10.5	13.1	490	11.7	12.4	239	8.5	15.6				14	13.7	7.1	27	13.0	12.9
Distant	482	6.5	9.9	256	6.1	7.7	201	7.1	17.7				4	4.4	3.4	18	8.5	11.0
Unknown	451	6.1	9.2	253	6.0	7.4	165	5.9	14.7				5	5.0	2.8	13	6.4	8.1
<i>Age < 65</i>																		
Localized	2,388	77.6	42.5	1,124	76.5	31.6	1,152	79.5	74.2	Insufficient data for the calculation of AI/AN PRCDA statistics			24	70.8	12.0	69	71.6	22.7
Regional	388	12.6	6.9	216	14.7	6.1	149	10.3	9.7				7	20.5	3.5	14	14.9	4.7
Distant	157	5.1	2.8	65	4.4	1.9	83	5.7	5.3				*	*	*	7	7.5	2.3
Unknown	143	4.7	2.5	64	4.4	1.8	65	4.5	4.2				2	5.8	1.0	6	6.0	2.0
<i>Age ≥ 65</i>																		
Localized	3,284	76.4	500.0	2,069	76.0	440.2	1,058	77.4	722.8				53	80.1	296.5	83	72.5	457.1
Regional	385	9.0	55.8	274	10.1	55.8	90	6.6	56.7				7	10.2	32.7	13	11.4	69.2
Distant	325	7.6	59.0	192	7.0	47.8	118	8.6	103.9				*	*	*	11	9.5	70.5
Unknown	307	7.1	54.9	189	6.9	46.4	100	7.3	87.5				3	4.5	14.9	8	6.7	50.2

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Hawaii, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	25	49.4	3.6	6	52.5	4.5	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			15	48.4	3.3	2	43.5	3.6
Regional	14	27.7	1.8	3	21.3	2.0	*	*	*				9	29.6	1.7	2	39.1	3.9
Distant	8	16.5	0.9	2	19.7	0.9	*	*	*				5	15.7	0.9	*	*	*
Unknown	3	6.4	0.4	*	*	*	*	*	*				2	6.3	0.4	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	12	3.1	1.4	4	3.7	1.5	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			8	3.1	1.5	*	*	*
Localized	147	36.9	17.3	38	36.7	15.9	*	*	*				100	37.6	18.5	8	36.8	25.0
Regional	137	34.4	16.3	36	34.7	15.6	3	46.7	21.9				90	33.9	16.6	8	37.7	24.2
Distant	75	18.8	8.9	18	17.4	7.5	2	30.0	11.8				51	19.2	9.6	4	17.9	14.0
Unknown	27	6.8	3.3	8	7.5	3.5	*	*	*				16	6.2	3.0	1	6.6	5.1
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*
Localized	15	33.2	3.4	4	30.5	4.2	*	*	*				10	35.3	3.5	*	*	*
Regional	16	36.4	3.7	5	44.1	5.3	*	*	*				9	32.4	3.3	*	*	*
Distant	11	24.1	2.5	2	18.6	2.2	*	*	*				7	25.9	2.6	*	*	*
Unknown	2	5.5	0.6	*	*	*	*	*	*				1	5.0	0.5	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	4	4.1	5.4	*	*	*				*	*	*	*	*	*
Localized	133	37.4	53.8	34	37.5	46.6	*	*	*				90	37.9	57.8	*	*	*
Regional	121	34.1	49.0	31	33.6	42.3	*	*	*				81	34.1	51.6	*	*	*
Distant	65	18.2	25.9	16	17.2	21.3	*	*	*				44	18.5	27.9	*	*	*
Unknown	25	7.0	10.3	*	*	*	*	*	*				15	6.3	9.5	1	7.4	18.3
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	7	2.3	0.8	2	2.2	1.0	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			5	2.4	0.8	*	*	*
Localized	112	34.4	12.0	26	36.9	13.3	*	*	*				76	33.6	11.5	8	39.2	16.5
Regional	119	36.5	12.7	25	34.6	12.0	1	50.0	22.1				84	37.1	12.6	7	34.0	18.7
Distant	61	18.8	6.4	14	19.3	6.8	*	*	*				44	19.3	6.6	3	14.4	8.7
Unknown	26	8.0	2.4	5	7.0	2.3	*	*	*				17	7.6	2.0	2	11.3	6.9
<i>Age < 50</i>																		
<i>In Situ</i>	1	2.9	0.3	*	*	*	*	*	*				*	*	*	*	*	*
Localized	12	30.2	2.9	4	40.9	4.7	*	*	*				8	27.7	2.7	*	*	*
Regional	16	39.0	3.9	2	27.3	3.0	*	*	*				12	41.1	4.0	*	*	*
Distant	9	22.0	2.1	2	20.5	2.4	*	*	*				7	24.1	2.2	*	*	*
Unknown	2	5.9	0.6	*	*	*	*	*	*				1	5.0	0.4	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	6	2.2	2.3	*	*	*	*	*	*				*	*	*	*	*	*
Localized	100	35.0	35.7	23	36.3	35.9	*	*	*				69	34.4	34.7	*	*	*
Regional	103	36.1	35.7	22	35.7	35.6	*	*	*				73	36.5	35.2	*	*	*
Distant	52	18.4	17.7	12	19.1	18.2	*	*	*				37	18.7	18.2	*	*	*
Unknown	24	8.3	7.1	*	*	*	*	*	*				16	7.9	6.2	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Hawaii, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	307	19.7	35.2	54	16.1	28.0	2	14.7	23.9				231	20.9	38.2	16	18.9	35.3
Localized	872	55.9	96.0	186	54.8	88.1	8	60.3	88.6				626	56.5	99.8	47	55.0	112.9
Regional	284	18.2	33.7	72	21.2	38.6	2	17.6	25.6				190	17.2	32.4	17	19.6	39.9
Distant	63	4.0	7.0	16	4.6	8.2	*	*	*				41	3.7	6.5	5	5.6	11.5
Unknown	35	2.2	3.5	11	3.3	4.4	*	*	*				19	1.8	2.7	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	50	18.7	12.4	10	17.7	13.7	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			35	19.1	12.1	4	19.8	12.2
Localized	131	48.5	31.6	25	45.8	34.7	3	70.0	31.5				93	50.3	31.5	9	40.6	24.4
Regional	73	27.0	17.6	17	30.0	23.6	*	*	*				47	25.5	16.0	7	34.0	20.3
Distant	11	4.2	2.7	3	5.4	4.0	*	*	*				7	3.9	2.4	*	*	*
Unknown	4	1.6	1.0	*	*	*	*	*	*				2	1.2	0.7	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	256	19.9	95.0	45	15.8	65.6	*	*	*				196	21.3	106.6	12	18.6	95.7
Localized	741	57.4	264.8	160	56.6	227.8	5	56.3	237.9				532	57.7	278.9	39	59.8	344.5
Regional	211	16.4	75.8	55	19.5	77.8	*	*	*				143	15.5	75.3	10	14.9	91.1
Distant	51	4.0	18.2	13	4.5	19.1	*	*	*				33	3.6	17.1	*	*	*
Unknown	30	2.3	10.0	*	*	*	*	*	*				17	1.9	7.8	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*
Localized	85	18.3	9.8	21	19.0	7.9	*	*	*				60	18.5	10.7	3	13.6	11.3
Regional	87	18.7	9.9	22	19.6	7.7	2	32.0	14.9				57	17.6	10.2	6	27.1	22.0
Distant	255	54.7	28.9	58	51.9	21.0	3	52.0	22.3	Insufficient data for the calculation of AI/AN PRCDA statistics			181	55.9	32.0	12	51.7	46.6
Unknown	38	8.1	4.4	11	9.5	4.7	*	*	*				25	7.6	4.3	2	7.6	10.2
<i>Female</i>																		
<i>In Situ</i>	2	0.5	0.2	*	*	*	*	*	*				1	0.6	0.2	*	*	*
Localized	76	20.7	7.4	21	23.6	9.5	*	*	*				50	20.1	6.7	5	18.0	13.8
Regional	69	18.8	6.8	20	22.7	8.4	*	*	*				42	17.2	6.1	5	20.3	15.0
Distant	186	50.7	18.3	38	43.5	16.4	1	58.3	21.3				130	52.8	18.1	15	55.6	44.7
Unknown	34	9.4	3.0	9	9.8	3.6	*	*	*				23	9.4	2.6	2	6.0	6.6

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	621	67.5	67.9	191	65.8	65.7	17	74.4	120.4				377	68.2	65.8	23	65.0	74.3
Regional	154	16.7	16.0	50	17.4	16.0	3	12.0	18.1				91	16.6	15.6	8	22.8	19.7
Distant	93	10.1	10.6	33	11.4	13.0	3	11.1	19.6				54	9.7	9.3	3	9.4	15.3
Unknown	52	5.6	5.8	16	5.4	5.9	*	*	*				30	5.5	5.2	*	*	*
<i>Age < 65</i>																		
Localized	178	69.1	21.2	58	71.4	22.4	11	75.7	72.3	Insufficient data for the calculation of AI/AN PRCDA statistics			95	67.7	18.8	8	59.4	17.6
Regional	50	19.2	5.9	15	18.3	5.6	*	*	*				28	19.8	5.6	5	33.3	9.9
Distant	19	7.5	2.2	6	7.3	2.0	1	8.1	7.5				12	8.3	2.3	*	*	*
Unknown	11	4.1	1.2	2	2.9	0.9	*	*	*				6	4.3	1.2	*	*	*
<i>Age ≥ 65</i>																		
Localized	443	66.8	390.3	132	63.7	364.8	6	72.1	453.1				282	68.4	390.6	15	68.5	466.6
Regional	104	15.8	86.3	35	17.0	87.4	*	*	*				64	15.5	85.2	4	16.2	87.1
Distant	74	11.2	68.0	27	13.0	89.1	1	16.3	103.2				42	10.3	57.1	*	*	*
Unknown	41	6.3	37.2	13	6.3	40.3	*	*	*				24	5.9	33.0	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Idaho, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	30	48.9	3.9	25	48.3	3.8	*	*	*	*	*	*	*	*	*	4	59.5	5.3
Regional	21	34.3	2.4	18	35.1	2.4	*	*	*	*	*	*	*	*	*	2	29.7	2.5
Distant	8	12.3	0.8	7	12.7	0.8	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	3	4.5	0.3	2	3.9	0.2	*	*	*	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	7	1.8	0.7	6	1.9	0.7	*	*	*	*	*	*	*	*	*	*	*	*
Localized	120	32.0	12.7	111	32.0	12.7	*	*	*	*	*	*	*	*	*	6	30.9	11.6
Regional	144	38.3	15.4	130	37.6	15.4	2	66.7	26.2	*	*	*	*	*	*	10	49.5	15.7
Distant	83	22.0	8.9	78	22.5	9.2	*	*	*	*	*	*	*	*	*	3	16.5	5.1
Unknown	22	5.9	2.5	21	6.0	2.5	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	11	26.2	2.1	9	25.9	2.1	*	*	*	*	*	*	*	*	*	1	28.6	1.7
Regional	17	41.6	3.4	14	41.4	3.5	*	*	*	*	*	*	*	*	*	2	42.9	2.8
Distant	12	28.7	2.3	10	29.3	2.4	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	110	32.7	40.5	102	32.7	40.5	*	*	*	*	*	*	*	*	*	5	31.6	37.4
Regional	127	37.9	47.0	116	37.2	46.5	*	*	*	*	*	*	*	*	*	8	51.3	49.4
Distant	71	21.2	26.3	68	21.8	26.9	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	4	1.3	0.4	4	1.4	0.5	*	*	*	*	*	*	*	*	*	*	*	*
Localized	97	30.4	9.6	88	30.4	9.7	*	*	*	*	*	*	1	33.3	7.9	5	32.1	8.3
Regional	129	40.7	12.9	120	41.2	12.9	*	*	*	1	46.7	24.3	*	*	*	6	35.9	10.1
Distant	68	21.3	6.9	61	21.0	6.8	*	*	*	*	*	*	1	33.3	8.0	4	26.9	7.0
Unknown	20	6.2	1.9	18	6.1	1.8	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	13	34.4	2.5	11	36.1	2.7	*	*	*	*	*	*	*	*	*	*	*	*
Regional	14	38.8	2.9	12	37.3	2.9	*	*	*	*	*	*	*	*	*	2	50.0	2.7
Distant	9	23.5	1.8	7	23.4	1.8	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	84	29.9	28.4	77	29.7	28.1	*	*	*	*	*	*	*	*	*	*	*	*
Regional	115	41.0	38.8	108	41.6	39.1	*	*	*	1	46.7	87.9	*	*	*	4	32.3	29.6
Distant	59	21.1	20.3	54	20.7	19.7	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Idaho, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	226	14.9	23.0	209	15.1	23.6	*	*	*	*	*	*	3	15.0	19.1	10	13.3	15.4
Localized	845	55.9	83.6	782	56.3	85.0	1	43.8	48.1	6	50.9	95.0	11	53.0	67.6	36	48.5	61.4
Regional	353	23.3	37.1	316	22.7	36.9	*	*	*	5	40.4	73.3	5	27.0	31.9	24	32.8	37.6
Distant	72	4.8	7.3	67	4.8	7.4	*	*	*	*	*	*	*	*	*	4	5.1	6.3
Unknown	17	1.1	1.6	15	1.1	1.5	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	41	16.5	8.5	36	17.2	9.0	*	*	*	*	*	*	*	*	*	3	13.7	5.9
Localized	111	45.3	23.1	96	46.4	23.9	*	*	*	*	*	*	2	44.4	20.6	9	37.1	16.2
Regional	81	33.2	16.7	66	31.7	16.2	*	*	*	1	66.7	29.8	2	33.3	15.4	11	44.4	19.0
Distant	11	4.4	2.2	9	4.3	2.2	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	1	0.6	0.3	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	185	14.6	60.8	174	14.7	62.1	*	*	*	*	*	*	*	*	*	6	13.1	40.4
Localized	734	57.9	241.9	686	58.0	245.0	*	*	*	*	*	*	8	56.2	190.5	27	54.3	179.6
Regional	272	21.4	90.5	250	21.2	91.0	*	*	*	3	35.4	187.4	4	24.7	75.3	13	26.9	86.5
Distant	62	4.9	20.9	58	4.9	21.2	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	15	1.2	5.0	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	2	0.3	0.2	1	0.3	0.1	*	*	*	*	*	*	*	*	*	*	*	*
Localized	121	24.3	12.7	116	24.6	13.1	*	*	*	*	*	*	*	*	*	2	19.0	8.0
Regional	87	17.6	8.8	82	17.5	9.0	*	*	*	*	*	*	1	27.3	12.1	3	22.2	6.2
Distant	260	52.5	27.0	247	52.3	27.5	1	42.9	38.2	2	81.8	37.5	2	54.5	23.4	7	54.0	18.8
Unknown	26	5.3	2.9	25	5.4	3.0	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>In Situ</i>	2	0.3	0.2	2	0.4	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	138	28.6	13.0	131	29.1	13.2	*	*	*	2	38.5	32.6	1	23.1	8.1	3	17.5	6.5
Regional	92	19.0	8.6	84	18.7	8.5	*	*	*	*	*	*	*	*	*	4	25.0	9.0
Distant	232	48.2	22.0	217	48.0	22.1	*	*	*	3	50.0	43.1	3	57.7	23.6	8	52.5	19.4
Unknown	19	3.9	1.8	18	3.9	1.8	*	*	*	*	*	*	*	*	*	*	*	*

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	834	69.6	79.4	769	70.2	79.2	8	81.3	165.2	3	60.7	54.3	4	59.5	44.9	28	68.7	56.7
Regional	157	13.1	14.4	146	13.3	14.4	*	*	*	1	25.0	18.9	1	16.2	14.1	5	13.4	11.9
Distant	96	8.0	10.2	88	8.0	10.1	*	*	*	*	*	*	1	18.9	14.7	5	12.4	11.6
Unknown	111	9.3	11.4	93	8.5	10.4	*	*	*	*	*	*	*	*	*	2	5.5	5.5
<i>Age < 65</i>																		
Localized	278	72.3	29.0	251	73.4	29.4	5	86.2	76.1	1	54.5	18.2	2	69.2	15.1	11	69.1	16.2
Regional	59	15.3	6.0	54	15.7	6.1	*	*	*	*	*	*	*	*	*	2	13.6	3.1
Distant	21	5.4	2.2	17	5.0	2.0	*	*	*	*	*	*	*	*	*	2	13.6	3.1
Unknown	27	7.0	2.8	20	5.9	2.4	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	556	68.4	427.2	518	68.7	423.5	3	73.7	781.1	2	64.7	304.2	3	54.2	251.1	16	68.3	336.8
Regional	98	12.1	72.5	92	12.2	72.0	*	*	*	*	*	*	*	*	*	3	13.3	72.1
Distant	75	9.2	65.7	71	9.4	65.6	*	*	*	*	*	*	*	*	*	3	11.7	69.8
Unknown	84	10.3	71.2	73	9.7	65.8	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Illinois, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	237	45.8	3.7	138	44.9	3.4	43	43.1	4.5	Insufficient data for the calculation of AI/AN PRCDA statistics			8	39.6	2.0	46	54.5	5.2
Regional	176	34.1	2.5	104	33.8	2.2	36	35.6	3.5				9	44.3	2.3	26	30.7	3.1
Distant	78	15.1	1.0	50	16.3	1.0	17	16.9	1.6				2	9.4	0.5	9	10.5	1.1
Unknown	26	5.0	0.3	15	5.0	0.3	4	4.4	0.4				1	6.6	0.4	4	4.3	0.5

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	192	5.6	2.7	128	5.1	2.5	37	7.4	4.7				7	5.9	2.1	16	5.5	2.3
Localized	1,106	32.1	16.1	823	32.9	16.4	143	28.9	18.1				41	33.2	12.3	86	30.7	12.3
Regional	1,244	36.2	18.3	922	36.8	18.5	162	32.6	21.0				48	38.6	14.8	104	37.1	15.9
Distant	695	20.2	10.1	496	19.8	9.8	113	22.9	14.2				22	17.6	6.3	60	21.2	8.5
Unknown	204	5.9	3.2	136	5.4	2.8	40	8.1	5.6				6	4.6	1.8	15	5.5	2.5
<i>Age < 50</i>																		
<i>In Situ</i>	15	4.2	0.4	10	4.2	0.4	2	4.2	0.4				*	*	*	2	4.0	0.3
Localized	111	30.2	2.8	76	30.9	3.1	14	29.2	2.6				5	27.4	1.8	16	28.5	2.0
Regional	142	38.3	3.6	95	38.6	4.0	18	39.0	3.6				7	42.9	2.8	19	35.0	2.5
Distant	87	23.5	2.2	56	22.8	2.4	11	23.7	2.2				3	20.2	1.3	16	28.8	2.0
Unknown	14	3.8	0.4	9	3.5	0.4	2	3.8	0.3				*	*	*	2	3.6	0.3
<i>Age ≥ 50</i>																		
<i>In Situ</i>	176	5.7	8.9	117	5.2	7.9	35	7.8	15.9				*	*	*	13	5.9	7.5
Localized	994	32.4	51.1	747	33.1	51.2	129	28.9	58.7				37	34.1	39.8	71	31.2	39.4
Regional	1,102	35.9	56.7	827	36.6	56.3	143	32.0	66.6				41	38.0	46.1	85	37.6	51.1
Distant	608	19.8	30.6	440	19.5	29.5	102	22.8	45.7				19	17.2	19.5	44	19.4	25.4
Unknown	190	6.2	10.5	128	5.7	9.3	38	8.6	19.3	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	13	5.9	8.5
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	149	4.8	1.8	96	4.3	1.6	37	7.1	3.3				3	3.3	0.7	11	5.0	1.6
Localized	1,017	32.9	12.6	732	32.8	12.5	166	31.9	15.0				31	33.8	7.9	77	34.8	10.5
Regional	1,148	37.1	14.1	852	38.2	14.3	170	32.7	15.5				38	41.2	9.6	83	37.4	11.7
Distant	574	18.6	7.1	401	18.0	6.8	116	22.3	10.6				15	15.9	3.7	40	18.1	5.7
Unknown	203	6.6	2.2	151	6.7	2.2	31	5.9	2.7				5	5.9	1.5	10	4.7	1.6
<i>Age < 50</i>																		
<i>In Situ</i>	13	3.8	0.3	8	3.6	0.3	3	5.5	0.5				*	*	*	2	3.5	0.2
Localized	117	34.7	2.9	75	35.6	3.2	19	33.8	3.1				3	20.7	1.2	18	35.0	2.4
Regional	124	36.6	3.1	78	36.7	3.3	18	32.4	2.9				8	50.0	2.8	19	37.3	2.7
Distant	73	21.7	1.9	44	20.8	1.9	14	26.2	2.4				4	23.2	1.3	11	21.2	1.5
Unknown	11	3.3	0.3	7	3.3	0.3	1	2.2	0.2				*	*	*	2	3.1	0.2
<i>Age ≥ 50</i>																		
<i>In Situ</i>	136	4.9	5.8	88	4.4	5.1	34	7.3	10.9				*	*	*	9	5.4	5.1
Localized	899	32.7	37.9	657	32.5	37.0	147	31.7	46.2				28	36.6	25.5	59	34.8	31.8
Regional	1,024	37.2	42.9	775	38.3	43.2	152	32.7	48.3				30	39.3	27.5	63	37.4	35.0
Distant	501	18.2	20.8	357	17.7	19.8	101	21.9	32.2				11	14.3	9.8	29	17.2	16.7
Unknown	192	7.0	7.4	144	7.1	7.1	30	6.4	9.4				*	*	*	9	5.2	5.4

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Illinois, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	2,443	18.9	32.2	1,711	18.2	32.9	381	20.5	34.4				131	23.3	32.2	203	20.3	25.3
Localized	6,894	53.4	87.3	5,216	55.4	92.9	865	46.5	78.9				284	50.5	69.4	488	48.9	63.9
Regional	2,741	21.2	36.4	1,904	20.2	36.4	445	23.9	41.9				121	21.5	29.4	255	25.6	31.2
Distant	648	5.0	8.2	443	4.7	7.8	138	7.4	12.8				21	3.8	5.4	42	4.2	5.2
Unknown	195	1.5	2.3	143	1.5	2.3	33	1.8	3.0				5	0.9	1.3	11	1.1	1.4
<i>Age < 50</i>																		
<i>In Situ</i>	522	21.8	13.4	343	22.6	14.7	64	18.5	10.7	Insufficient data for the calculation of AI/AN PRCDA statistics			42	25.1	15.0	70	20.6	10.2
Localized	1,073	44.9	27.2	701	46.1	29.7	135	39.0	22.6				81	48.7	28.7	146	43.1	21.1
Regional	670	28.0	17.0	405	26.7	17.4	117	33.8	19.5				37	22.3	13.0	106	31.2	15.0
Distant	100	4.2	2.5	57	3.7	2.4	25	7.2	4.1				5	2.9	1.7	13	3.7	1.7
Unknown	26	1.1	0.6	14	0.9	0.6	5	1.6	0.9				2	1.0	0.6	5	1.4	0.6
<i>Age ≥ 50</i>																		
<i>In Situ</i>	1,920	18.2	81.3	1,367	17.3	80.3	317	20.9	96.4				90	22.6	77.2	133	20.1	64.9
Localized	5,820	55.3	244.5	4,515	57.2	258.3	730	48.2	226.5				203	51.2	176.0	342	51.9	176.1
Regional	2,071	19.7	87.0	1,498	19.0	86.3	328	21.7	100.8				84	21.2	72.3	150	22.7	73.7
Distant	548	5.2	23.0	386	4.9	21.8	113	7.5	35.4				17	4.2	15.1	29	4.4	14.5
Unknown	169	1.6	6.6	129	1.6	6.6	27	1.8	8.5				3	0.8	3.3	6	0.9	3.3

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	9	0.2	0.1	7	0.2	0.1	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	1,131	23.8	16.8	946	25.0	18.4	132	19.8	17.1				21	18.9	6.7	28	16.6	5.5
Regional	1,093	23.0	15.7	872	23.0	16.5	155	23.3	19.8				25	22.5	7.9	37	22.0	6.7
Distant	2,192	46.2	31.6	1,716	45.3	32.8	322	48.3	40.9				60	53.2	18.6	89	53.3	16.6
Unknown	323	6.8	4.9	247	6.5	4.9	56	8.5	7.8				6	5.4	2.1	13	7.7	2.9
<i>Female</i>																		
<i>In Situ</i>	16	0.3	0.2	13	0.3	0.2	2	0.3	0.2	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	1,384	29.3	16.5	1,138	30.1	18.2	186	26.3	16.6				19	22.1	4.6	37	24.4	5.9
Regional	1,052	22.2	12.5	830	22.0	13.3	171	24.1	14.9				17	19.7	4.4	33	21.7	5.3
Distant	2,018	42.7	23.9	1,587	42.0	25.3	311	43.9	27.4				44	52.7	11.8	73	48.2	11.7
Unknown	259	5.5	2.9	208	5.5	3.0	38	5.4	3.5				4	5.0	1.2	8	5.5	1.5

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	6,034	71.4	80.1	4,333	72.2	77.1	1,099	71.7	124.3	Insufficient data for the calculation of AI/AN PRCDA statistics			129	68.9	37.5	385	69.8	60.9
Regional	1,290	15.3	16.5	947	15.8	16.2	206	13.5	22.8				33	17.6	9.1	94	17.1	13.7
Distant	657	7.8	9.8	443	7.4	8.7	149	9.7	19.1				18	9.6	6.0	43	7.7	8.2
Unknown	471	5.6	7.0	276	4.6	5.3	79	5.1	11.5				7	3.9	2.4	29	5.3	6.1
<i>Age < 65</i>																		
Localized	2,529	72.9	34.0	1,678	73.3	31.5	593	74.1	65.6	Insufficient data for the calculation of AI/AN PRCDA statistics			40	70.1	11.9	180	70.7	21.9
Regional	645	18.6	8.7	453	19.8	8.5	122	15.2	13.6				13	22.9	3.9	52	20.5	6.3
Distant	175	5.0	2.3	97	4.2	1.8	60	7.5	6.6				2	3.8	0.6	15	5.7	1.8
Unknown	123	3.5	1.6	62	2.7	1.1	25	3.2	2.8				2	3.1	0.5	8	3.1	1.0
<i>Age ≥ 65</i>																		
Localized	3,505	70.4	398.9	2,656	71.6	392.3	506	69.0	529.8				88	68.4	213.9	205	69.1	331.1
Regional	646	13.0	70.3	494	13.3	69.8	85	11.6	85.9				20	15.2	45.3	42	14.2	64.5
Distant	482	9.7	61.1	346	9.3	56.4	89	12.1	105.8				16	12.2	43.6	28	9.4	52.6
Unknown	348	7.0	44.0	214	5.8	34.2	53	7.3	71.8				5	4.2	15.1	22	7.3	41.8

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Indiana, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	125	44.0	3.9	105	45.2	4.1	9	32.8	2.7	*	*	*	1	42.9	1.6	9	44.7	5.2
Regional	106	37.2	3.0	83	35.8	2.9	13	50.0	4.1	*	*	*	*	*	*	8	36.9	4.8
Distant	44	15.5	1.2	37	15.7	1.2	4	13.4	1.1	*	*	*	*	*	*	3	15.5	1.8
Unknown	9	3.3	0.3	8	3.3	0.3	*	*	*	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	58	3.4	1.6	52	3.4	1.6	4	2.9	1.6	*	*	*	*	*	*	1	3.6	1.6
Localized	554	31.9	15.3	495	32.1	15.5	35	26.7	13.7	*	*	*	5	41.5	10.6	14	36.3	12.6
Regional	647	37.3	18.2	578	37.5	18.6	49	38.0	20.0	*	*	*	5	35.4	8.9	13	33.7	11.4
Distant	373	21.5	10.4	329	21.4	10.4	33	25.5	14.5	*	*	*	2	16.9	4.7	8	21.8	7.4
Unknown	101	5.8	3.0	87	5.7	2.9	9	6.9	4.4	*	*	*	*	*	*	2	4.7	1.6
<i>Age < 50</i>																		
<i>In Situ</i>	4	1.9	0.2	3	2.1	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	53	27.8	2.6	45	27.8	2.8	4	21.3	1.9	*	*	*	*	*	*	3	36.1	1.5
Regional	78	41.1	3.9	67	41.7	4.3	7	39.3	3.7	*	*	*	*	*	*	2	33.3	1.6
Distant	50	26.7	2.5	42	26.2	2.7	6	31.5	3.0	*	*	*	*	*	*	2	27.8	1.3
Unknown	5	2.5	0.2	3	2.1	0.2	1	6.7	0.7	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	55	3.5	5.2	49	3.5	5.1	*	*	*	*	*	*	*	*	*	1	4.5	5.9
Localized	501	32.4	48.5	450	32.6	48.8	31	27.5	44.6	*	*	*	*	*	*	11	36.3	41.6
Regional	569	36.9	55.7	511	37.0	56.0	42	37.7	63.0	*	*	*	*	*	*	11	33.8	37.0
Distant	323	20.9	31.0	287	20.8	30.7	27	24.5	44.4	*	*	*	*	*	*	6	20.4	23.3
Unknown	96	6.2	10.3	84	6.1	10.0	8	7.0	14.2	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	52	3.3	1.2	47	3.3	1.3	4	3.0	1.1	*	*	*	*	*	*	1	3.3	1.1
Localized	535	34.0	12.8	474	33.9	12.9	44	36.0	13.6	*	*	*	3	35.4	5.3	10	28.3	8.3
Regional	575	36.5	13.8	515	36.8	14.1	41	34.0	12.9	*	*	*	3	33.3	5.7	15	42.2	12.8
Distant	317	20.2	7.6	281	20.1	7.7	26	21.8	8.1	*	*	*	2	20.8	2.6	7	19.4	6.0
Unknown	94	6.0	2.1	81	5.8	2.0	6	5.1	2.0	*	*	*	*	*	*	2	6.7	2.0
<i>Age < 50</i>																		
<i>In Situ</i>	5	2.6	0.2	4	2.8	0.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	54	30.9	2.7	45	30.1	2.8	6	39.0	2.8	*	*	*	*	*	*	2	26.3	1.3
Regional	70	40.0	3.5	60	40.5	3.8	6	36.4	2.6	*	*	*	*	*	*	3	44.7	2.5
Distant	42	24.0	2.1	36	24.3	2.3	3	18.2	1.3	*	*	*	*	*	*	2	26.3	1.5
Unknown	4	2.5	0.2	3	2.3	0.2	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	48	3.4	3.9	42	3.4	3.9	*	*	*	*	*	*	*	*	*	1	4.2	3.9
Localized	481	34.4	39.2	430	34.4	39.3	38	35.6	41.7	*	*	*	*	*	*	8	28.9	26.7
Regional	505	36.1	40.8	455	36.4	41.2	36	33.7	39.9	*	*	*	*	*	*	12	41.5	39.5
Distant	275	19.7	22.0	245	19.6	22.0	24	22.3	25.9	*	*	*	*	*	*	5	17.6	17.7
Unknown	89	6.4	6.8	78	6.2	6.6	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Indiana, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	1,084	17.6	26.8	926	17.1	26.5	102	20.3	30.9	*	*	*	16	21.6	25.4	35	21.3	25.6
Localized	3,431	55.5	82.7	3,059	56.5	84.7	243	48.2	73.6	*	*	*	37	50.5	57.6	77	47.6	59.9
Regional	1,279	20.7	32.4	1,096	20.3	32.3	120	23.8	36.6	*	*	*	17	22.7	24.4	41	25.4	28.8
Distant	308	5.0	7.5	264	4.9	7.3	33	6.6	10.4	*	*	*	3	4.3	5.0	7	4.6	5.2
Unknown	76	1.2	1.7	66	1.2	1.6	6	1.2	1.9	*	*	*	*	*	*	2	1.1	1.5
<i>Age < 50</i>																		
<i>In Situ</i>	186	19.0	9.5	150	19.0	9.6	18	18.9	9.3	*	*	*	5	17.1	8.9	11	19.9	8.7
Localized	459	46.9	23.2	378	48.0	24.0	39	40.2	19.2	*	*	*	14	49.3	24.9	24	42.0	18.3
Regional	282	28.8	14.3	223	28.3	14.2	32	32.4	15.3	*	*	*	8	28.8	14.1	17	30.4	12.5
Distant	46	4.7	2.3	33	4.2	2.1	8	7.8	3.7	*	*	*	1	4.8	2.3	4	7.3	3.2
Unknown	6	0.6	0.3	4	0.6	0.3	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	898	17.3	72.0	776	16.8	70.8	84	20.6	87.5	*	*	*	11	24.6	68.6	23	22.1	70.0
Localized	2,972	57.2	238.6	2,682	58.0	243.5	204	50.1	216.2	*	*	*	23	51.3	143.2	53	50.7	168.8
Regional	997	19.2	80.0	873	18.9	79.6	88	21.8	92.1	*	*	*	8	18.8	51.4	24	22.7	71.6
Distant	262	5.0	21.2	231	5.0	21.2	25	6.3	27.7	*	*	*	2	4.0	11.9	3	3.0	10.4
Unknown	70	1.3	5.3	61	1.3	5.1	*	*	*	*	*	*	*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	5	0.2	0.1	5	0.2	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	664	22.5	18.4	621	22.9	19.1	34	17.9	15.6	*	*	*	2	16.1	4.2	4	16.7	5.3
Regional	670	22.7	18.0	620	22.8	18.6	42	21.7	18.0	*	*	*	3	24.2	6.6	4	15.8	4.8
Distant	1,452	49.1	39.3	1,321	48.6	40.1	105	54.7	43.2	*	*	*	7	59.7	14.5	15	61.7	15.4
Unknown	165	5.6	4.8	152	5.6	4.9	11	5.6	5.1	*	*	*	*	*	*	1	5.8	1.7
<i>Female</i>																		
<i>In Situ</i>	7	0.3	0.2	6	0.2	0.1	*	*	*	*	*	*	*	*	*	*	*	*
Localized	753	28.1	17.1	689	28.3	17.6	50	26.2	15.7	*	*	*	3	23.9	5.7	9	29.1	8.6
Regional	590	22.0	13.4	537	22.0	13.8	41	21.6	12.3	*	*	*	2	17.9	4.3	7	25.0	7.4
Distant	1,222	45.6	28.0	1,108	45.4	28.8	92	48.4	28.6	*	*	*	7	53.7	13.8	12	41.9	11.1
Unknown	106	4.0	2.3	98	4.0	2.4	7	3.5	2.2	*	*	*	*	*	*	*	*	*

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	2,834	72.5	71.7	2,415	72.7	68.6	327	73.1	122.8	*	*	*	14	68.6	31.9	57	72.2	55.4
Regional	583	14.9	13.9	507	15.2	13.6	59	13.3	20.4	*	*	*	4	18.6	8.9	10	12.4	8.3
Distant	318	8.1	9.0	263	7.9	8.4	43	9.7	18.7	*	*	*	2	11.8	6.2	8	10.4	9.2
Unknown	175	4.5	5.1	140	4.2	4.6	18	3.9	9.1	*	*	*	*	*	*	4	5.1	4.2
<i>Age < 65</i>																		
Localized	1,082	72.8	27.5	882	72.9	25.7	161	73.0	54.6	*	*	*	6	71.8	10.5	25	73.3	17.4
Regional	280	18.8	7.1	235	19.4	6.8	38	17.4	13.1	*	*	*	*	*	*	5	13.4	3.2
Distant	86	5.8	2.2	65	5.4	1.9	17	7.6	5.6	*	*	*	1	15.4	2.3	3	9.3	2.2
Unknown	38	2.6	1.0	28	2.3	0.8	4	1.9	1.5	*	*	*	*	*	*	1	4.1	1.0
<i>Age ≥ 65</i>																		
Localized	1,752	72.3	377.2	1,533	72.5	365.2	166	73.2	594.0	*	*	*	8	66.7	179.8	32	71.3	317.7
Regional	303	12.5	60.9	272	12.9	60.5	21	9.3	70.8	*	*	*	*	*	*	5	11.7	43.9
Distant	231	9.5	56.2	198	9.3	53.0	26	11.6	109.9	*	*	*	1	9.5	33.6	5	11.2	57.6
Unknown	136	5.6	34.0	112	5.3	30.8	13	5.9	61.8	*	*	*	*	*	*	3	5.8	26.3

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Iowa, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	55	46.3	3.8	48	46.6	3.9	2	47.6	4.0	*	*	*	*	*	*	3	41.7	3.9
Regional	45	37.5	2.7	38	37.0	2.6	1	28.6	2.8	*	*	*	*	*	*	3	47.2	7.5
Distant	16	13.1	0.9	14	13.9	0.9	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	4	3.0	0.2	3	2.5	0.1	*	*	*	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	9	1.1	0.5	9	1.1	0.5	*	*	*	*	*	*	*	*	*	*	*	*
Localized	310	36.4	17.3	292	36.4	17.4	7	35.6	24.0	*	*	*	2	23.7	8.2	6	40.5	14.3
Regional	309	36.3	17.4	293	36.5	17.6	6	29.8	17.4	*	*	*	4	52.6	24.2	5	35.1	11.3
Distant	182	21.3	10.1	171	21.2	10.2	6	28.8	19.3	*	*	*	2	23.7	5.4	3	18.9	8.8
Unknown	42	4.9	2.5	39	4.9	2.4	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	28	31.5	3.1	26	31.8	3.3	*	*	*	*	*	*	*	*	*	*	*	*
Regional	36	40.7	4.0	33	40.6	4.2	1	42.9	2.9	*	*	*	*	*	*	1	46.7	2.2
Distant	22	25.1	2.5	21	25.9	2.7	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	2	2.5	0.2	1	1.5	0.2	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	282	37.0	54.6	266	36.9	54.2	*	*	*	*	*	*	2	30.0	29.7	*	*	*
Regional	273	35.8	52.6	260	36.0	52.7	5	27.8	55.1	*	*	*	*	*	*	4	32.2	35.2
Distant	159	20.9	30.2	150	20.7	29.9	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	40	5.2	8.3	38	5.3	8.3	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	9	1.2	0.4	9	1.2	0.4	*	*	*	*	*	*	*	*	*	*	*	*
Localized	302	37.8	14.8	287	37.8	14.8	7	40.7	16.8	*	*	*	3	35.9	10.5	4	35.0	8.4
Regional	280	35.0	13.6	266	35.0	13.7	4	25.9	12.2	*	*	*	4	46.2	11.4	5	40.0	11.5
Distant	151	18.9	7.3	142	18.8	7.3	5	28.4	13.8	*	*	*	*	*	*	2	18.3	6.0
Unknown	57	7.2	2.2	55	7.3	2.2	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	37	42.8	4.0	32	42.3	4.1	2	40.9	4.4	*	*	*	*	*	*	2	47.4	3.5
Regional	29	33.6	3.3	26	34.6	3.4	1	27.3	3.8	*	*	*	*	*	*	1	31.6	1.8
Distant	18	20.8	2.1	16	20.5	2.0	1	31.8	4.6	*	*	*	*	*	*	*	*	*
Unknown	2	2.3	0.2	2	2.1	0.2	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	265	37.2	42.9	254	37.3	42.9	5	40.7	49.4	*	*	*	*	*	*	2	29.3	21.1
Regional	250	35.2	40.5	239	35.1	40.5	3	25.4	34.1	*	*	*	*	*	*	4	43.9	36.9
Distant	133	18.6	21.0	127	18.6	21.0	3	27.1	37.8	*	*	*	*	*	*	*	*	*
Unknown	55	7.8	7.4	54	7.9	7.4	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Iowa, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	553	17.4	29.7	520	17.2	30.0	12	19.2	32.6	*	*	*	9	23.0	26.3	10	21.8	19.4
Localized	1,793	56.3	90.7	1,721	56.9	92.6	29	47.1	81.5	2	70.6	174.2	18	46.6	56.2	18	38.7	36.2
Regional	664	20.9	36.1	619	20.5	36.2	17	26.9	41.7	*	*	*	10	26.2	32.1	15	32.4	30.4
Distant	141	4.4	7.1	132	4.4	7.1	4	6.5	9.8	*	*	*	1	3.1	3.5	3	5.5	4.3
Unknown	35	1.1	1.4	32	1.1	1.4	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	101	20.0	11.9	90	20.2	12.2	3	15.8	10.2	*	*	*	3	20.9	10.1	5	22.8	9.3
Localized	231	45.7	26.6	207	46.2	27.4	8	39.6	25.3	*	*	*	7	50.7	23.7	8	37.6	15.3
Regional	150	29.7	17.3	131	29.1	17.4	8	38.6	25.0	*	*	*	4	28.4	12.7	6	30.7	12.3
Distant	21	4.2	2.4	18	4.1	2.4	1	5.9	3.2	*	*	*	*	*	*	*	*	*
Unknown	2	0.4	0.2	2	0.4	0.2	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	451	16.8	76.3	430	16.7	76.7	9	20.8	91.3	*	*	*	6	24.2	68.6	6	21.2	45.7
Localized	1,562	58.3	258.4	1,513	58.8	263.1	21	50.7	228.8	*	*	*	11	44.4	141.5	11	39.4	91.0
Regional	514	19.2	85.3	489	19.0	85.4	9	21.3	85.6	*	*	*	6	25.0	82.8	9	33.6	77.8
Distant	119	4.5	19.5	114	4.4	19.5	3	6.8	26.8	*	*	*	1	4.8	12.8	*	*	*
Unknown	33	1.2	4.6	30	1.2	4.5	*	*	*	*	*	*	*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	5	0.4	0.3	5	0.4	0.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	291	21.4	15.6	280	21.5	15.8	6	21.3	21.4	*	*	*	2	22.9	19.8	*	*	*
Regional	275	20.3	14.5	269	20.6	14.9	4	12.0	11.4	*	*	*	*	*	*	2	21.4	5.1
Distant	721	53.2	38.5	689	52.8	38.6	18	60.0	55.7	*	*	*	6	66.7	32.2	6	66.7	17.1
Unknown	63	4.7	3.6	62	4.7	3.6	2	5.3	5.9	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>In Situ</i>	3	0.2	0.1	3	0.2	0.1	*	*	*	*	*	*	*	*	*	*	*	*
Localized	293	24.6	13.6	284	24.7	13.8	5	23.0	15.3	*	*	*	2	21.6	6.6	2	24.4	5.2
Regional	240	20.1	11.2	233	20.3	11.5	3	15.0	10.8	*	*	*	*	*	*	2	22.0	5.0
Distant	599	50.2	27.7	575	49.9	27.9	13	58.4	39.8	*	*	*	5	62.2	19.9	4	51.2	11.0
Unknown	57	4.8	2.4	56	4.9	2.4	*	*	*	*	*	*	*	*	*	*	*	*

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	1,716	72.8	86.4	1,630	72.9	86.4	52	74.0	142.4	*	*	*	4	57.9	19.7	14	59.3	40.6
Regional	399	16.9	19.2	380	17.0	19.4	10	13.6	21.7	*	*	*	1	18.4	6.9	6	25.4	13.1
Distant	203	8.6	11.2	190	8.5	10.9	8	11.9	23.3	*	*	*	1	18.4	15.5	4	15.3	9.7
Unknown	39	1.7	2.1	37	1.6	2.1	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 65</i>																		
Localized	638	72.6	33.5	591	72.8	33.4	31	71.2	68.3	*	*	*	2	76.9	7.8	7	58.6	12.8
Regional	188	21.4	9.9	176	21.7	10.0	7	16.7	16.0	*	*	*	*	*	*	3	25.9	5.5
Distant	45	5.1	2.4	37	4.6	2.1	5	12.1	11.6	*	*	*	*	*	*	2	15.5	3.3
Unknown	8	0.9	0.4	7	0.9	0.4	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	1,078	72.9	452.2	1,038	72.9	452.7	22	78.4	654.5	*	*	*	2	48.0	101.9	7	60.0	233.4
Regional	211	14.3	83.8	204	14.3	84.4	2	8.6	61.2	*	*	*	*	*	*	3	25.0	65.4
Distant	159	10.7	71.8	152	10.7	71.5	3	11.5	104.7	*	*	*	*	*	*	2	15.0	54.2
Unknown	31	2.1	13.8	29	2.1	13.7	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Kansas, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	46	40.4	3.4	35	40.4	3.2	1	29.2	1.7	*	*	*	1	40.0	2.7	6	42.6	4.6
Regional	40	35.0	2.9	31	36.0	2.8	2	41.7	2.3	*	*	*	*	*	*	5	36.8	4.6
Distant	18	15.6	1.2	14	16.2	1.2	1	25.0	1.3	*	*	*	*	*	*	2	11.8	1.3
Unknown	10	9.0	0.7	6	7.4	0.5	*	*	*	*	*	*	*	*	*	1	8.8	1.0

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	27	3.7	1.7	21	3.3	1.5	2	6.5	2.5	*	*	*	*	*	*	*	*	*
Localized	262	35.7	16.6	227	35.8	16.6	12	36.7	17.2	*	*	*	4	32.2	11.6	12	36.3	14.6
Regional	253	34.5	16.3	224	35.3	16.6	11	31.4	15.3	*	*	*	6	47.5	17.3	9	27.4	10.3
Distant	149	20.3	9.5	127	20.1	9.4	7	20.7	9.4	*	*	*	2	16.9	7.2	10	28.6	10.1
Unknown	43	5.8	2.7	35	5.5	2.5	2	4.7	2.1	*	*	*	*	*	*	2	4.8	2.2
<i>Age < 50</i>																		
<i>In Situ</i>	2	1.9	0.2	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	27	32.4	3.1	21	31.7	3.2	1	35.0	1.9	*	*	*	*	*	*	3	34.9	2.7
Regional	32	38.6	3.9	26	39.6	4.1	1	30.0	2.3	*	*	*	2	53.3	5.2	3	37.2	2.9
Distant	20	24.3	2.5	17	25.3	2.6	*	*	*	*	*	*	*	*	*	2	23.3	2.0
Unknown	2	2.9	0.3	1	1.8	0.2	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	26	3.9	5.5	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	235	36.1	52.1	206	36.3	51.7	11	36.9	57.3	*	*	*	*	*	*	9	36.8	45.8
Regional	220	33.9	48.8	198	34.8	49.3	9	31.5	49.4	*	*	*	4	45.5	49.1	6	24.0	29.7
Distant	129	19.8	28.0	111	19.5	27.3	*	*	*	*	*	*	*	*	*	8	30.4	31.4
Unknown	40	6.2	9.2	34	5.9	8.6	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	22	3.4	1.3	19	3.4	1.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	232	36.0	13.0	208	37.4	13.3	9	28.8	11.0	*	*	*	2	20.3	6.7	9	29.9	9.6
Regional	223	34.7	12.5	188	33.9	12.0	12	39.1	15.7	1	53.8	102.1	5	44.1	13.8	13	43.8	13.7
Distant	124	19.2	7.1	105	19.0	7.1	6	20.5	7.9	*	*	*	3	27.1	8.2	6	20.1	5.7
Unknown	43	6.7	2.3	35	6.3	2.1	3	8.3	3.0	*	*	*	*	*	*	1	4.9	2.0
<i>Age < 50</i>																		
<i>In Situ</i>	3	4.5	0.4	3	5.3	0.5	*	*	*	*	*	*	*	*	*	*	*	*
Localized	25	32.3	2.8	21	34.2	3.1	*	*	*	*	*	*	*	*	*	2	30.6	2.0
Regional	27	35.2	3.2	19	31.6	2.9	2	57.9	4.7	*	*	*	*	*	*	4	50.0	3.7
Distant	19	24.9	2.3	16	25.9	2.5	*	*	*	*	*	*	*	*	*	1	16.7	1.1
Unknown	2	3.1	0.3	2	3.0	0.3	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	19	3.3	3.7	15	3.1	3.4	*	*	*	*	*	*	*	*	*	*	*	*
Localized	207	36.5	39.4	187	37.8	39.8	*	*	*	*	*	*	*	*	*	6	29.6	29.5
Regional	197	34.6	37.0	169	34.2	35.7	10	36.5	44.5	*	*	*	*	*	*	9	41.7	39.9
Distant	105	18.4	19.6	90	18.1	19.0	*	*	*	*	*	*	*	*	*	5	21.3	17.5
Unknown	41	7.1	7.4	33	6.8	6.7	*	*	*	*	*	*	*	*	*	1	6.5	7.3

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Kansas, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	432	15.8	25.7	372	15.6	25.9	21	16.2	25.1	*	*	*	11	24.1	27.1	17	15.1	17.0
Localized	1,517	55.5	86.8	1,349	56.5	89.0	64	49.9	77.2	2	52.9	88.4	22	49.6	53.8	56	48.3	56.6
Regional	577	21.1	34.9	493	20.6	35.0	34	26.5	41.9	*	*	*	9	19.2	20.4	32	27.5	30.4
Distant	119	4.4	6.8	103	4.3	6.7	6	4.9	7.3	*	*	*	2	4.0	4.1	6	5.5	6.1
Unknown	89	3.2	4.9	71	3.0	4.4	3	2.5	4.0	*	*	*	1	3.1	3.1	4	3.6	3.8
<i>Age < 50</i>																		
<i>In Situ</i>	74	16.8	9.3	60	17.2	9.7	3	11.6	6.3	*	*	*	3	22.1	9.0	7	16.1	7.5
Localized	208	47.3	25.8	165	47.8	26.5	12	46.5	25.3	*	*	*	6	45.6	18.3	19	45.0	20.4
Regional	127	28.9	15.5	100	28.9	15.9	9	34.1	18.1	*	*	*	3	25.0	9.6	12	28.9	12.8
Distant	17	3.9	2.1	13	3.6	2.1	1	4.7	2.1	*	*	*	*	*	*	2	5.2	2.4
Unknown	14	3.1	1.6	9	2.5	1.3	*	*	*	*	*	*	*	*	*	2	4.7	2.0
<i>Age ≥ 50</i>																		
<i>In Situ</i>	358	15.6	68.5	313	15.3	68.2	18	17.3	74.0	*	*	*	8	25.0	74.7	11	14.4	41.8
Localized	1,309	57.1	246.5	1,184	58.0	252.5	52	50.8	213.2	*	*	*	16	51.3	146.7	37	50.1	151.4
Regional	450	19.6	85.5	393	19.2	85.0	25	24.6	104.3	*	*	*	5	16.7	48.9	20	26.7	76.2
Distant	102	4.5	19.0	90	4.4	18.9	5	4.9	20.9	*	*	*	*	*	*	4	5.7	15.9
Unknown	75	3.3	13.4	63	3.1	12.5	*	*	*	*	*	*	*	*	*	2	3.0	8.3

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	3	0.3	0.2	2	0.2	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	230	23.2	14.6	207	23.1	14.7	14	26.3	19.4	*	*	*	1	15.6	4.6	4	19.6	6.7
Regional	246	24.8	15.2	222	24.8	15.4	14	25.9	20.0	*	*	*	2	20.0	6.6	5	26.5	8.2
Distant	446	44.9	27.4	403	45.0	27.9	22	41.1	29.2	*	*	*	6	62.2	17.3	10	47.1	15.1
Unknown	68	6.8	4.3	61	6.8	4.4	3	5.6	4.2	*	*	*	*	*	*	1	5.9	2.1
<i>Female</i>																		
<i>In Situ</i>	4	0.4	0.2	3	0.4	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	262	27.8	13.8	239	28.2	14.2	11	26.4	14.4	*	*	*	4	32.4	13.4	4	17.3	5.6
Regional	224	23.8	11.9	201	23.8	12.1	11	25.5	12.8	*	*	*	2	16.2	5.8	6	25.5	6.8
Distant	397	42.2	21.0	357	42.1	21.3	19	44.0	22.0	*	*	*	6	45.6	16.5	10	47.3	13.4
Unknown	55	5.9	2.9	48	5.6	2.8	2	4.2	2.4	*	*	*	*	*	*	2	10.0	2.9

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	1,444	73.9	83.9	1,212	74.6	79.7	99	74.8	122.7	*	*	*	9	72.3	32.9	45	68.6	58.6
Regional	228	11.7	12.6	196	12.1	12.4	14	10.6	15.1	*	*	*	2	13.8	5.5	10	15.4	12.3
Distant	127	6.5	7.9	105	6.5	7.3	11	8.5	15.7	*	*	*	*	*	*	7	10.3	9.7
Unknown	156	8.0	9.6	112	6.9	7.9	8	6.1	12.1	*	*	*	1	9.2	5.2	4	5.7	5.6
<i>Age < 65</i>																		
Localized	537	75.1	31.8	433	76.2	30.0	54	73.8	60.1	*	*	*	4	64.3	10.6	21	69.6	19.0
Regional	104	14.5	6.2	86	15.2	6.1	10	13.8	10.9	*	*	*	*	*	*	5	15.5	4.3
Distant	37	5.2	2.2	27	4.7	1.8	6	8.3	6.5	*	*	*	*	*	*	3	10.1	2.8
Unknown	38	5.3	2.2	22	3.9	1.6	3	4.1	3.1	*	*	*	*	*	*	1	4.7	1.3
<i>Age ≥ 65</i>																		
Localized	907	73.2	444.0	779	73.7	422.9	45	76.0	555.2	*	*	*	6	78.4	186.9	25	67.8	332.8
Regional	124	10.0	57.5	110	10.4	56.5	4	6.8	43.8	*	*	*	*	*	*	6	15.3	67.5
Distant	90	7.2	47.0	79	7.4	45.2	5	8.8	79.7	*	*	*	*	*	*	4	10.4	57.8
Unknown	118	9.5	60.9	90	8.5	51.6	5	8.4	74.1	*	*	*	*	*	*	2	6.6	35.4

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Kentucky, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	97	43.6	4.5	84	42.6	4.5	7	46.1	3.9	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	3	60.7	5.7
Regional	86	38.5	3.6	78	39.4	3.7	5	30.3	2.6				*	*	*	2	32.1	4.0
Distant	36	16.0	1.5	32	16.1	1.5	3	21.1	1.6				*	*	*	*	*	*
Unknown	4	1.9	0.2	4	1.8	0.2	*	*	*				*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	76	5.3	3.0	66	5.1	2.8	6	6.6	4.1	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	555	38.8	22.2	503	38.5	22.1	36	37.7	23.2				4	44.2	16.0	5	35.4	9.4
Regional	472	33.0	19.1	437	33.5	19.6	27	28.6	17.5				3	30.2	11.0	5	36.9	10.9
Distant	267	18.6	10.7	240	18.4	10.6	22	23.7	14.8				*	*	*	3	21.5	9.2
Unknown	62	4.3	2.7	58	4.4	2.8	3	3.4	2.6				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	6	3.6	0.5	5	3.7	0.5	*	*	*				*	*	*	*	*	*
Localized	58	34.6	4.2	49	33.4	4.2	5	35.9	4.0				*	*	*	2	47.8	3.3
Regional	61	36.4	4.5	55	37.5	4.8	4	31.3	3.7				*	*	*	1	30.4	2.2
Distant	38	23.0	2.9	34	23.3	3.0	4	28.1	3.3				*	*	*	*	*	*
Unknown	4	2.4	0.3	3	2.2	0.3	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	70	5.5	9.5	61	5.3	9.1	*	*	*				*	*	*	*	*	*
Localized	497	39.3	69.2	454	39.2	69.0	31	38.0	73.6				*	*	*	2	28.6	25.3
Regional	412	32.6	57.5	382	33.0	58.3	23	28.2	53.6				*	*	*	3	40.5	33.8
Distant	228	18.0	31.2	206	17.8	30.7	19	23.0	45.0				*	*	*	*	*	*
Unknown	58	4.6	9.1	54	4.7	9.3	*	*	*				*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	55	4.4	2.0	46	4.1	1.8	7	7.5	3.6	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	498	40.1	17.4	444	39.6	17.1	42	46.0	21.6				2	24.3	6.8	4	33.9	9.1
Regional	391	31.5	13.6	361	32.2	13.8	22	24.3	11.6				4	51.4	13.8	3	28.8	7.1
Distant	238	19.1	8.3	216	19.3	8.4	17	19.0	9.1				1	16.2	3.8	3	25.4	7.9
Unknown	60	4.8	1.9	55	4.9	1.9	3	3.1	1.5				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	7	4.5	0.5	5	4.3	0.5	*	*	*				*	*	*	*	*	*
Localized	59	40.8	4.3	51	40.0	4.3	6	50.0	5.0				*	*	*	*	*	*
Regional	45	31.1	3.3	39	30.7	3.3	3	30.4	3.0				*	*	*	2	44.4	2.8
Distant	32	22.0	2.4	29	23.3	2.5	1	12.5	1.3				*	*	*	*	*	*
Unknown	2	1.5	0.2	2	1.7	0.2	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	49	4.4	5.8	40	4.1	5.3	*	*	*				*	*	*	*	*	*
Localized	439	40.1	51.5	394	39.5	50.5	36	45.5	64.9				*	*	*	*	*	*
Regional	345	31.5	40.6	322	32.3	41.3	19	23.5	34.1				*	*	*	2	22.0	18.4
Distant	206	18.8	23.9	187	18.7	23.7	16	19.9	29.4				*	*	*	*	*	*
Unknown	58	5.3	6.6	53	5.3	6.5	3	3.5	5.6				*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Kentucky, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	734	16.9	26.2	655	16.6	26.0	62	19.9	32.3				8	25.0	24.2	7	13.5	14.8
Localized	2,439	56.1	85.4	2,231	56.6	86.2	158	50.4	83.6				16	48.8	48.6	27	54.9	61.3
Regional	919	21.1	33.9	822	20.9	33.7	75	24.0	40.2				7	20.7	20.0	12	24.2	25.5
Distant	218	5.0	7.7	196	5.0	7.6	17	5.3	8.8				2	5.5	4.9	3	6.6	8.2
Unknown	41	0.9	1.3	38	1.0	1.4	1	0.4	0.7				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	132	18.4	10.0	117	18.9	10.2	11	17.0	10.3	Insufficient data for the calculation of AI/AN PRCDA statistics			2	16.1	7.1	2	10.5	4.7
Localized	347	48.2	25.9	299	48.4	25.9	29	44.5	26.6				6	50.0	21.5	10	54.7	23.5
Regional	206	28.7	15.5	174	28.1	15.1	22	33.9	20.4				3	24.2	10.3	6	30.5	13.1
Distant	31	4.3	2.3	26	4.2	2.3	3	4.5	2.8				*	*	*	*	*	*
Unknown	3	0.4	0.2	2	0.4	0.2	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	601	16.6	68.7	538	16.2	67.6	51	20.7	90.0				6	30.4	68.9	5	15.4	41.3
Localized	2,091	57.6	241.3	1,932	58.1	244.2	129	51.9	232.7				10	48.0	119.6	16	55.0	160.5
Regional	712	19.6	82.3	648	19.5	82.2	53	21.4	92.0				4	18.6	45.2	6	20.1	58.0
Distant	187	5.1	21.7	170	5.1	21.6	14	5.5	24.5				*	*	*	*	*	*
Unknown	38	1.0	4.3	36	1.1	4.4	1	0.6	2.6				*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	5	0.2	0.2	4	0.2	0.2	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	553	21.4	21.7	520	21.5	22.1	27	20.2	19.0				2	26.3	8.5	3	20.0	9.5
Regional	575	22.3	21.9	539	22.3	22.3	31	22.7	21.5				1	15.8	5.9	4	27.7	10.1
Distant	1,285	49.8	50.2	1,204	49.8	51.3	69	50.7	47.7				4	55.3	22.9	6	47.7	18.9
Unknown	162	6.3	7.0	153	6.3	7.1	9	6.3	7.0				*	*	*	*	*	*
<i>Female</i>																		
<i>In Situ</i>	6	0.2	0.2	5	0.2	0.2	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	586	24.9	19.2	550	25.1	19.7	31	22.9	16.4				2	24.4	8.3	1	14.0	4.2
Regional	553	23.5	18.1	518	23.6	18.6	30	22.0	16.0				2	24.4	8.2	2	18.0	6.5
Distant	1,096	46.6	36.0	1,015	46.3	36.5	70	50.9	37.5				4	46.7	16.3	6	64.0	19.5
Unknown	111	4.7	3.6	104	4.8	3.7	6	4.2	3.2				*	*	*	*	*	*

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	2,135	72.6	77.3	1,821	72.5	72.1	199	73.1	115.6	Insufficient data for the calculation of AI/AN PRCDA statistics			4	72.4	21.0	15	64.0	44.3
Regional	349	11.8	12.2	315	12.5	12.1	26	9.7	14.3				*	*	*	4	18.4	13.2
Distant	202	6.9	8.4	176	7.0	8.0	22	8.0	14.5				*	*	*	3	11.4	8.7
Unknown	256	8.7	10.0	199	7.9	8.5	25	9.2	17.6				*	*	*	1	6.1	6.6
<i>Age < 65</i>																		
Localized	859	72.9	32.5	689	73.0	28.9	110	74.5	58.6	Insufficient data for the calculation of AI/AN PRCDA statistics			2	100.0	6.8	7	73.9	13.4
Regional	172	14.6	6.6	151	16.0	6.4	19	12.8	10.3				*	*	*	1	15.2	2.6
Distant	60	5.1	2.3	48	5.1	2.0	11	7.3	5.6				*	*	*	*	*	*
Unknown	86	7.3	3.3	56	6.0	2.3	8	5.4	4.1				*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	1,276	72.3	387.2	1,132	72.3	370.9	90	71.6	509.5				2	60.0	119.4	8	57.4	257.7
Regional	176	10.0	51.1	164	10.4	51.1	8	6.1	42.0				*	*	*	3	20.6	86.0
Distant	142	8.0	50.6	129	8.2	49.4	11	8.8	76.0				*	*	*	*	*	*
Unknown	170	9.6	56.7	142	9.1	51.5	17	13.6	111.0				*	*	*	1	10.3	52.4

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Louisiana, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	91	40.9	3.9	58	46.2	4.2	27	32.6	3.6	*	*	*	*	*	*	5	44.6	5.3
Regional	81	36.5	3.3	39	31.5	2.6	37	43.9	4.8	*	*	*	1	50.0	2.7	4	35.7	4.3
Distant	36	16.4	1.4	19	15.6	1.2	15	18.5	2.0	*	*	*	*	*	*	1	10.7	1.4
Unknown	14	6.3	0.6	8	6.7	0.6	4	5.0	0.6	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	43	3.2	1.6	25	2.9	1.4	16	3.7	2.3	*	*	*	*	*	*	1	4.5	1.3
Localized	492	36.5	19.7	324	37.2	19.1	148	34.5	22.7	*	*	*	7	40.0	18.7	11	41.7	13.6
Regional	449	33.3	18.3	305	35.0	18.4	129	30.2	20.3	*	*	*	5	30.6	13.4	8	28.8	8.1
Distant	294	21.8	11.7	175	20.1	10.3	109	25.5	16.7	*	*	*	3	16.5	7.2	5	18.9	5.5
Unknown	71	5.3	3.0	41	4.7	2.5	26	6.1	4.5	*	*	*	2	9.4	4.4	2	6.1	1.8
<i>Age < 50</i>																		
<i>In Situ</i>	2	1.3	0.1	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	43	30.8	3.1	30	32.3	3.6	10	26.5	2.6	*	*	*	*	*	*	2	37.9	2.5
Regional	56	40.2	4.2	39	42.4	4.8	15	37.8	3.8	*	*	*	*	*	*	1	20.7	1.5
Distant	35	25.0	2.6	21	22.6	2.6	12	29.6	3.0	*	*	*	*	*	*	2	34.5	2.5
Unknown	4	2.7	0.3	2	1.9	0.2	2	4.1	0.4	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	41	3.4	5.5	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	449	37.1	63.2	294	37.8	59.7	137	35.3	75.2	*	*	*	*	*	*	9	42.7	42.7
Regional	393	32.5	55.2	266	34.2	53.8	115	29.4	63.5	*	*	*	*	*	*	6	31.1	25.3
Distant	259	21.4	35.4	154	19.8	30.5	98	25.1	52.6	*	*	*	*	*	*	3	14.6	13.5
Unknown	67	5.6	10.1	39	5.1	8.4	25	6.3	15.3	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	31	2.7	1.1	19	2.6	1.0	11	2.8	1.2	*	*	*	*	*	*	*	*	*
Localized	428	37.1	14.9	271	37.1	14.4	141	36.6	16.8	*	*	*	5	39.7	10.7	9	45.6	10.1
Regional	389	33.7	13.4	256	34.9	13.2	122	31.8	14.8	*	*	*	4	37.9	10.8	6	28.2	6.7
Distant	247	21.4	8.6	153	20.9	8.0	89	23.0	11.0	*	*	*	*	*	*	4	17.5	4.0
Unknown	59	5.1	2.0	34	4.6	1.7	22	5.8	2.8	*	*	*	1	12.1	3.9	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	3	2.3	0.2	2	2.0	0.2	1	2.4	0.2	*	*	*	*	*	*	*	*	*
Localized	59	40.6	4.2	36	40.5	4.3	19	39.0	4.2	*	*	*	*	*	*	3	55.2	4.3
Regional	42	28.9	3.0	28	31.2	3.3	13	25.7	2.8	*	*	*	*	*	*	1	24.1	2.2
Distant	35	24.3	2.5	20	22.4	2.4	14	28.5	3.1	*	*	*	*	*	*	*	*	*
Unknown	6	3.8	0.4	3	3.8	0.4	2	4.4	0.5	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	28	2.8	3.2	17	2.7	3.0	10	2.9	3.8	*	*	*	*	*	*	*	*	*
Localized	369	36.6	43.1	236	36.6	40.7	121	36.2	49.8	*	*	*	*	*	*	6	41.9	25.1
Regional	347	34.4	40.5	228	35.4	39.2	109	32.7	46.1	*	*	*	*	*	*	4	29.7	18.4
Distant	211	21.0	24.4	133	20.7	22.6	74	22.2	31.6	*	*	*	*	*	*	*	*	*
Unknown	53	5.3	6.2	30	4.7	5.0	20	6.0	8.8	*	*	*	1	13.2	14.1	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Louisiana, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCD			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	724	16.6	25.4	451	15.8	24.4	245	18.1	28.9	*	*	*	7	15.2	14.1	18	18.0	20.3
Localized	2,291	52.5	80.0	1,575	55.3	83.1	638	47.0	77.4	*	*	*	22	48.7	48.9	50	51.2	58.0
Regional	1,042	23.9	37.9	641	22.5	35.8	363	26.8	44.8	*	*	*	12	27.2	26.8	23	23.5	25.5
Distant	251	5.8	8.8	146	5.1	7.8	95	7.0	11.6	*	*	*	3	7.1	7.7	6	5.7	6.2
Unknown	53	1.2	1.8	35	1.2	1.7	16	1.2	2.0	*	*	*	*	*	*	2	1.6	2.0
<i>Age < 50</i>																		
<i>In Situ</i>	111	15.2	8.2	66	15.7	8.1	38	14.5	8.6	*	*	*	2	11.6	5.1	4	16.2	6.9
Localized	338	46.4	24.6	201	48.0	24.8	116	43.9	25.4	*	*	*	6	46.4	20.5	13	48.5	19.8
Regional	233	31.9	16.7	126	30.2	15.5	91	34.6	19.7	*	*	*	4	31.9	13.8	9	32.4	13.1
Distant	43	5.9	3.1	23	5.5	2.8	18	6.7	3.7	*	*	*	*	*	*	*	*	*
Unknown	4	0.6	0.3	3	0.7	0.3	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	613	16.9	70.3	386	15.9	66.9	207	18.9	82.2	*	*	*	5	16.8	37.7	13	18.6	55.5
Localized	1,953	53.8	225.2	1,374	56.6	235.8	522	47.8	213.4	*	*	*	15	49.7	123.4	37	52.3	158.0
Regional	810	22.3	93.5	514	21.2	88.9	272	24.9	110.6	*	*	*	8	25.2	60.7	14	20.1	58.0
Distant	208	5.7	23.9	123	5.1	20.9	78	7.1	32.1	*	*	*	*	*	*	*	*	*
Unknown	49	1.3	5.5	32	1.3	5.1	*	*	*	*	*	*	*	*	*	2	2.3	7.2

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCD			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	5	0.3	0.2	3	0.2	0.2	2	0.4	0.4	*	*	*	*	*	*	*	*	*
Localized	402	20.3	16.3	285	21.3	16.4	109	18.4	17.5	*	*	*	3	17.9	9.7	3	14.9	4.2
Regional	444	22.5	17.5	301	22.5	17.0	135	22.7	20.8	*	*	*	4	22.1	10.8	3	13.8	2.9
Distant	1,042	52.7	40.8	693	51.8	39.0	322	54.3	50.1	*	*	*	11	57.9	30.9	12	64.9	15.4
Unknown	83	4.2	3.5	56	4.2	3.4	25	4.2	4.3	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>In Situ</i>	7	0.4	0.2	5	0.4	0.2	1	0.3	0.2	*	*	*	*	*	*	*	*	*
Localized	407	25.6	13.4	310	26.5	15.1	89	23.2	10.5	*	*	*	4	26.4	9.7	4	17.6	4.3
Regional	366	23.0	12.0	266	22.8	12.9	93	24.2	10.7	*	*	*	3	18.1	6.8	4	20.6	4.9
Distant	748	47.0	24.5	541	46.2	26.3	185	48.3	21.9	*	*	*	7	51.4	19.5	11	54.9	13.3
Unknown	64	4.0	2.1	47	4.1	2.2	15	3.9	1.8	*	*	*	*	*	*	1	5.9	1.5

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCD			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	2,875	76.5	105.5	1,757	76.3	93.2	1,022	76.7	145.6	*	*	*	17	77.8	43.5	52	73.5	64.7
Regional	535	14.2	18.8	343	14.9	17.6	177	13.3	23.1	*	*	*	3	14.8	8.4	10	13.7	11.1
Distant	223	5.9	9.1	127	5.5	7.5	88	6.6	14.3	*	*	*	1	5.6	3.5	6	8.3	8.2
Unknown	126	3.4	5.1	75	3.2	4.3	46	3.5	7.7	*	*	*	*	*	*	3	4.6	4.3
<i>Age < 65</i>																		
Localized	1,216	76.4	46.1	673	76.4	38.4	501	76.3	68.1	*	*	*	7	76.7	15.0	22	72.7	23.0
Regional	267	16.8	10.1	156	17.7	8.9	104	15.8	14.1	*	*	*	2	18.6	3.5	5	17.3	5.4
Distant	73	4.6	2.7	35	3.9	2.0	36	5.4	4.7	*	*	*	*	*	*	2	7.3	2.3
Unknown	35	2.2	1.3	18	2.0	1.0	17	2.5	2.2	*	*	*	*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	1,659	76.5	516.5	1,084	76.3	471.8	521	77.1	681.1	*	*	*	10	78.5	240.5	30	74.1	352.9
Regional	268	12.4	78.6	187	13.2	77.5	73	10.8	85.6	*	*	*	2	12.3	42.4	4	10.9	50.1
Distant	150	6.9	52.9	92	6.5	45.2	52	7.7	80.3	*	*	*	*	*	*	4	9.0	48.5
Unknown	91	4.2	31.3	57	4.0	27.1	30	4.4	46.0	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCD, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Maine, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	21	53.0	3.1	19	51.9	3.0	*	*	*	*	*	*	*	*	*	*	*	*
Regional	13	31.8	1.7	12	33.2	1.7	*	*	*	*	*	*	*	*	*	*	*	*
Distant	6	14.1	0.6	5	13.9	0.6	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	11	3.1	1.1	11	3.2	1.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	130	36.3	14.8	125	36.0	14.7	1	46.2	21.7	*	*	*	*	*	*	*	*	*
Regional	122	34.3	13.9	120	34.5	14.0	*	*	*	*	*	*	*	*	*	*	*	*
Distant	74	20.7	8.6	71	20.5	8.5	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	20	5.5	2.3	20	5.7	2.4	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	13	35.1	3.3	12	35.0	3.4	*	*	*	*	*	*	*	*	*	*	*	*
Regional	13	35.1	3.3	13	35.6	3.4	*	*	*	*	*	*	*	*	*	*	*	*
Distant	10	27.6	2.6	10	27.1	2.6	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	117	36.5	44.9	112	36.2	44.3	*	*	*	*	*	*	*	*	*	*	*	*
Regional	109	34.2	41.7	107	34.4	41.8	*	*	*	*	*	*	*	*	*	*	*	*
Distant	64	19.9	24.3	61	19.8	23.9	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	12	3.6	1.3	12	3.6	1.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	124	35.9	12.6	120	35.6	12.6	*	*	*	*	*	*	1	54.5	12.8	*	*	*
Regional	128	37.0	12.7	126	37.4	12.9	*	*	*	*	*	*	*	*	*	*	*	*
Distant	60	17.5	6.1	59	17.5	6.1	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	20	5.9	1.7	20	5.9	1.7	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	1	3.8	0.4	1	4.0	0.4	*	*	*	*	*	*	*	*	*	*	*	*
Localized	15	41.2	3.8	14	39.8	3.8	*	*	*	*	*	*	*	*	*	*	*	*
Regional	12	33.5	3.1	12	34.1	3.2	*	*	*	*	*	*	*	*	*	*	*	*
Distant	8	20.9	1.8	8	21.6	2.0	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	11	3.6	3.6	11	3.5	3.6	*	*	*	*	*	*	*	*	*	*	*	*
Localized	109	35.3	35.8	106	35.1	35.8	*	*	*	*	*	*	*	*	*	*	*	*
Regional	115	37.5	37.8	114	37.8	38.2	*	*	*	*	*	*	*	*	*	*	*	*
Distant	53	17.1	17.1	51	17.1	17.1	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Maine, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	266	17.6	28.1	261	17.7	28.5	1	21.2	30.1	*	*	*	2	18.6	15.1	*	*	*
Localized	868	57.6	88.0	850	57.8	88.7	2	36.4	35.9	3	57.1	120.7	4	51.2	45.0	4	55.0	54.8
Regional	289	19.2	31.8	281	19.1	32.0	1	21.2	19.6	1	25.0	38.4	2	23.3	19.0	2	25.0	22.7
Distant	66	4.4	6.8	62	4.2	6.6	1	18.2	17.6	*	*	*	*	*	*	*	*	*
Unknown	18	1.2	1.6	17	1.1	1.5	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	44	19.0	11.0	42	19.1	11.1	*	*	*	*	*	*	*	*	*	*	*	*
Localized	115	49.6	29.0	109	49.7	29.3	*	*	*	*	*	*	2	47.1	21.3	2	64.3	28.2
Regional	62	26.9	16.0	59	27.1	16.2	*	*	*	*	*	*	*	*	*	*	*	*
Distant	9	4.1	2.4	8	3.7	2.2	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	222	17.4	72.8	219	17.5	73.9	*	*	*	*	*	*	*	*	*	*	*	*
Localized	753	59.0	242.5	741	59.2	244.3	*	*	*	*	*	*	3	53.8	107.2	3	50.0	124.6
Regional	227	17.8	73.4	221	17.7	73.3	*	*	*	1	31.8	139.1	*	*	*	*	*	*
Distant	57	4.4	18.3	54	4.3	18.0	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	1	0.2	0.1	1	0.2	0.1	*	*	*	*	*	*	*	*	*	*	*	*
Localized	168	23.4	17.7	165	23.5	17.7	*	*	*	*	*	*	*	*	*	*	*	*
Regional	183	25.5	19.1	178	25.3	19.1	1	33.3	12.5	*	*	*	*	*	*	*	*	*
Distant	322	44.8	34.0	316	44.8	34.1	1	33.3	26.0	1	46.7	48.4	1	60.0	29.6	*	*	*
Unknown	45	6.2	5.1	44	6.2	5.1	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>In Situ</i>	2	0.3	0.2	2	0.3	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	200	27.9	18.7	197	28.0	19.0	*	*	*	1	33.3	53.4	*	*	*	*	*	*
Regional	174	24.3	16.1	171	24.2	16.2	*	*	*	1	33.3	47.4	*	*	*	*	*	*
Distant	305	42.6	28.5	300	42.6	28.8	*	*	*	1	33.3	37.4	2	81.8	17.6	*	*	*
Unknown	36	5.0	3.2	35	5.0	3.1	*	*	*	*	*	*	*	*	*	*	*	*

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	717	72.4	69.4	699	72.5	69.3	7	80.0	122.6	2	80.0	77.2	*	*	*	3	82.4	45.4
Regional	144	14.5	13.3	141	14.6	13.3	*	*	*	*	*	*	*	*	*	*	*	*
Distant	104	10.5	11.3	101	10.4	11.2	1	13.3	25.0	*	*	*	*	*	*	*	*	*
Unknown	26	2.6	3.0	24	2.5	2.8	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 65</i>																		
Localized	241	73.8	25.0	232	74.0	24.9	3	78.9	35.3	*	*	*	*	*	*	1	77.8	19.0
Regional	58	17.7	6.0	57	18.0	6.0	*	*	*	*	*	*	*	*	*	*	*	*
Distant	23	6.9	2.5	21	6.8	2.4	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	5	1.5	0.5	4	1.2	0.4	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	476	71.6	376.2	467	71.8	376.2	4	80.8	726.4	*	*	*	*	*	*	1	87.5	228.2
Regional	86	13.0	64.0	84	12.9	63.7	*	*	*	*	*	*	*	*	*	*	*	*
Distant	81	12.2	72.7	79	12.2	72.3	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	21	3.2	20.3	20	3.1	19.6	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Maryland, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	96	42.8	3.0	49	43.3	3.1	30	39.3	2.9	Insufficient data for the calculation of AI/AN PRCDA statistics			5	44.2	1.9	12	55.0	4.5
Regional	72	32.1	2.1	38	33.5	2.1	22	29.7	2.0				3	32.7	1.4	7	32.4	3.2
Distant	34	15.2	1.0	17	15.1	0.9	14	18.3	1.3				*	*	*	2	8.1	0.9
Unknown	22	9.8	0.6	9	8.1	0.5	10	12.7	0.9				1	13.5	0.6	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	149	10.5	4.4	97	10.8	4.7	37	9.2	4.3	Insufficient data for the calculation of AI/AN PRCDA statistics			8	12.1	4.2	4	9.6	2.7
Localized	384	27.0	12.0	253	28.2	12.6	98	24.4	12.2				18	25.3	9.4	14	30.3	6.7
Regional	471	33.1	14.9	304	33.9	15.3	126	31.5	16.1				22	32.2	11.6	17	37.7	9.1
Distant	270	19.0	8.4	165	18.3	8.2	86	21.5	10.7				13	19.0	6.5	5	11.8	3.0
Unknown	148	10.4	4.7	79	8.8	3.9	54	13.4	7.2				8	11.5	4.0	5	10.5	3.1
<i>Age < 50</i>																		
<i>In Situ</i>	12	7.4	0.7	8	8.8	0.9	2	4.8	0.4				*	*	*	*	*	*
Localized	45	27.7	2.4	28	30.5	3.0	10	21.8	1.8				3	27.5	2.0	4	30.8	1.7
Regional	62	38.3	3.4	33	36.5	3.7	20	42.8	3.6				3	29.4	2.1	6	46.2	2.6
Distant	33	20.4	1.8	18	19.8	2.0	10	22.3	1.8				3	27.5	2.0	2	13.8	0.8
Unknown	10	6.3	0.6	4	4.4	0.5	4	8.3	0.7				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	137	10.9	14.3	89	11.0	14.6	35	9.8	14.5				*	*	*	*	*	*
Localized	340	26.9	37.2	225	27.9	37.8	88	24.7	39.4				15	24.9	28.8	10	30.1	19.9
Regional	409	32.5	45.1	271	33.6	45.8	106	30.0	48.8				19	32.7	36.3	11	34.4	25.9
Distant	237	18.8	25.7	147	18.2	24.4	76	21.4	34.0				10	17.5	18.5	4	11.0	8.7
Unknown	138	10.9	15.6	75	9.3	13.0	50	14.1	24.3				*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	135	9.6	3.4	80	9.3	3.5	40	9.6	3.5	Insufficient data for the calculation of AI/AN PRCDA statistics			7	12.2	3.0	5	11.2	2.8
Localized	415	29.6	10.8	264	30.5	11.6	120	28.6	10.8				14	24.4	5.9	15	30.6	7.7
Regional	454	32.4	11.8	288	33.3	12.4	127	30.2	11.6				20	35.5	8.9	16	32.6	8.5
Distant	254	18.2	6.6	154	17.8	6.6	84	19.9	7.7				7	12.2	2.9	8	16.1	4.2
Unknown	143	10.2	3.6	78	9.0	3.1	49	11.6	4.5				9	15.7	4.0	5	9.5	2.3
<i>Age < 50</i>																		
<i>In Situ</i>	13	7.2	0.6	6	6.2	0.6	5	8.5	0.7				*	*	*	1	9.1	0.6
Localized	55	31.2	2.8	34	36.3	3.6	15	25.9	2.3				2	18.8	1.1	4	30.3	1.9
Regional	58	33.0	2.9	31	33.1	3.3	17	30.5	2.6				4	41.7	2.4	5	39.4	2.6
Distant	35	20.2	1.8	18	18.8	1.9	13	23.0	1.9				2	20.8	1.2	2	13.6	0.9
Unknown	15	8.4	0.7	5	5.6	0.5	7	12.1	1.0				1	12.5	0.7	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	122	10.0	10.8	75	9.7	10.9	36	9.8	10.7				*	*	*	4	11.9	8.6
Localized	360	29.4	31.8	230	29.8	32.5	106	29.0	33.1				12	25.5	18.4	11	30.7	22.7
Regional	396	32.3	35.1	257	33.4	36.2	110	30.2	34.9				16	34.3	26.1	11	30.1	24.2
Distant	219	17.9	19.1	136	17.7	19.0	71	19.4	22.7				5	10.5	7.4	6	17.0	13.0
Unknown	128	10.4	11.0	73	9.4	9.7	42	11.5	13.6				8	16.3	12.5	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Maryland, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	1,128	18.2	30.2	646	17.2	30.5	366	19.7	32.2				70	22.5	28.7	39	18.3	18.1
Localized	3,241	52.4	84.8	2,106	56.0	94.1	873	46.9	77.8				149	47.5	60.8	100	46.8	52.8
Regional	1,342	21.7	36.8	752	20.0	36.2	455	24.5	41.2				73	23.4	30.3	54	25.1	24.8
Distant	277	4.5	7.2	154	4.1	6.7	101	5.4	9.0				12	3.8	4.9	9	4.1	4.2
Unknown	194	3.1	4.9	102	2.7	4.2	65	3.5	6.0				9	2.9	4.1	12	5.6	6.3
<i>Age < 50</i>																		
<i>In Situ</i>	243	20.4	12.7	124	20.7	13.5	74	18.6	11.6	Insufficient data for the calculation of AI/AN PRCDA statistics			28	25.9	17.1	14	19.7	7.5
Localized	526	44.2	27.1	284	47.3	30.6	167	41.9	25.9				44	40.1	26.3	29	40.2	14.8
Regional	349	29.3	18.2	164	27.3	18.0	127	31.9	19.9				33	29.7	19.5	22	30.7	11.1
Distant	43	3.6	2.2	17	2.9	1.9	19	4.8	3.0				3	2.6	1.7	3	4.4	1.6
Unknown	29	2.4	1.5	11	1.9	1.2	11	2.8	1.7				2	1.6	1.1	4	5.0	1.8
<i>Age ≥ 50</i>																		
<i>In Situ</i>	885	17.7	76.1	521	16.5	75.1	291	20.0	86.2				42	20.6	59.0	25	17.6	45.9
Localized	2,715	54.4	235.9	1,822	57.7	260.1	706	48.3	213.6				105	51.4	151.0	71	50.2	152.3
Regional	993	19.9	85.7	588	18.6	83.9	328	22.5	96.9				41	19.9	58.7	31	22.3	60.7
Distant	234	4.7	20.3	137	4.3	19.2	82	5.6	24.8				9	4.4	13.2	6	4.0	11.2
Unknown	165	3.3	13.9	91	2.9	11.9	54	3.7	17.1				7	3.6	12.1	8	6.0	18.3

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	5	0.3	0.2	4	0.3	0.2	2	0.3	0.2	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	444	23.4	14.1	328	24.5	15.6	99	21.1	13.2				13	21.0	6.9	4	18.4	3.5
Regional	448	23.6	13.8	324	24.2	15.0	104	22.2	13.3				14	22.7	7.4	4	19.3	3.8
Distant	812	42.8	25.2	566	42.3	26.7	203	43.1	26.0				29	49.0	15.8	11	49.1	8.3
Unknown	187	9.9	6.1	117	8.7	5.7	62	13.2	8.6				4	7.3	2.7	3	13.2	3.2
<i>Female</i>																		
<i>In Situ</i>	12	0.6	0.3	9	0.6	0.3	3	0.5	0.2	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	584	28.6	14.5	418	29.4	16.7	146	27.6	13.1				11	21.4	4.9	7	23.3	4.3
Regional	472	23.1	11.7	332	23.3	13.3	121	23.0	10.7				11	21.4	4.9	7	22.7	3.8
Distant	799	39.2	19.7	546	38.3	21.7	213	40.4	18.9				25	47.4	11.0	13	42.7	8.1
Unknown	172	8.5	4.2	119	8.4	4.4	45	8.5	4.3				5	9.0	2.4	3	11.3	2.4

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	3,063	65.8	86.2	1,723	65.5	75.4	1,148	66.6	125.9	Insufficient data for the calculation of AI/AN PRCDA statistics			82	64.4	41.4	76	64.1	51.5
Regional	493	10.6	13.3	300	11.4	12.6	160	9.3	16.7				16	12.4	7.5	15	12.6	9.2
Distant	264	5.7	8.4	143	5.4	6.9	103	6.0	13.4				7	5.6	4.3	9	7.3	8.5
Unknown	838	18.0	24.8	466	17.7	20.8	313	18.2	39.1				22	17.6	11.7	19	16.0	15.0
<i>Age < 65</i>																		
Localized	1,383	67.9	39.4	671	66.9	31.0	624	69.2	65.6	Insufficient data for the calculation of AI/AN PRCDA statistics			32	68.8	15.4	42	67.1	20.0
Regional	268	13.2	7.7	145	14.4	6.7	106	11.8	11.3				7	16.0	3.6	10	15.5	4.6
Distant	74	3.6	2.1	31	3.1	1.4	39	4.3	4.0				*	*	*	3	4.5	1.3
Unknown	311	15.3	8.7	155	15.5	7.0	133	14.7	13.8				6	13.4	2.9	8	12.9	3.9
<i>Age ≥ 65</i>																		
Localized	1,679	64.1	410.0	1,052	64.6	381.8	523	63.7	542.2				50	61.9	221.2	34	60.8	269.0
Regional	224	8.6	52.3	156	9.5	53.5	54	6.5	54.1				8	10.3	34.5	5	9.5	41.4
Distant	190	7.3	51.9	112	6.8	44.5	64	7.8	78.2				*	*	*	6	10.2	57.8
Unknown	527	20.1	136.1	310	19.0	116.4	180	21.9	213.8				16	19.9	72.6	11	19.4	91.5

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Massachusetts, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	95	46.9	2.7	64	47.8	2.5	8	32.5	2.9	*	*	*	6	51.9	2.1	13	48.9	3.8
Regional	72	35.6	1.8	45	33.9	1.5	12	49.6	4.6	*	*	*	4	37.0	1.6	10	36.5	2.9
Distant	28	13.9	0.6	20	14.8	0.6	4	15.4	1.4	*	*	*	*	*	*	3	10.2	1.0
Unknown	7	3.5	0.2	5	3.6	0.1	*	*	*	*	*	*	*	*	*	1	4.4	0.4

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	57	3.9	1.4	50	4.0	1.5	1	1.6	0.7	*	*	*	2	3.4	0.9	3	3.6	1.1
Localized	557	37.5	14.8	461	37.3	14.7	32	35.9	15.5	*	*	*	26	43.4	14.2	27	37.3	12.2
Regional	517	34.8	13.9	433	35.0	14.0	31	34.4	15.1	*	*	*	20	33.0	11.2	25	34.2	11.2
Distant	286	19.2	7.5	236	19.1	7.4	22	24.2	10.7	*	*	*	8	13.8	4.3	15	20.3	6.5
Unknown	70	4.7	1.9	57	4.6	1.8	4	4.0	2.0	*	*	*	4	6.4	2.7	3	4.7	2.0
<i>Age < 50</i>																		
<i>In Situ</i>	3	2.0	0.2	2	1.9	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	56	32.9	2.7	42	32.8	2.9	3	21.2	1.7	*	*	*	3	29.5	1.5	7	40.7	2.5
Regional	67	39.6	3.3	52	40.4	3.6	6	43.9	3.6	*	*	*	3	31.8	1.7	6	34.6	2.3
Distant	39	22.8	1.8	29	22.6	1.9	4	31.8	2.6	*	*	*	2	27.3	1.4	3	17.3	1.1
Unknown	5	2.7	0.2	3	2.3	0.2	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	54	4.1	4.7	47	4.3	4.9	1	1.8	2.5	*	*	*	*	*	*	*	*	*
Localized	501	38.1	46.5	419	37.8	45.7	30	38.4	51.8	*	*	*	23	45.8	47.6	21	36.3	37.7
Regional	450	34.1	41.6	381	34.4	41.3	25	32.7	45.2	*	*	*	17	33.2	36.3	19	34.2	34.8
Distant	247	18.8	22.3	207	18.7	21.9	18	22.9	32.1	*	*	*	6	11.5	11.8	12	21.1	20.7
Unknown	65	4.9	6.4	54	4.9	6.1	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	40	2.8	0.9	33	2.8	0.9	2	2.5	0.8	*	*	*	2	3.0	0.7	2	3.6	0.7
Localized	534	37.9	11.8	449	37.8	12.0	32	39.6	11.9	*	*	*	20	37.3	9.3	24	36.5	8.1
Regional	501	35.5	10.9	422	35.5	10.9	28	34.8	11.2	*	*	*	20	38.4	9.6	23	35.0	7.9
Distant	255	18.1	5.7	212	17.8	5.6	16	20.3	6.4	*	*	*	9	16.7	4.1	14	21.6	4.8
Unknown	81	5.7	1.5	72	6.1	1.5	2	2.8	0.9	*	*	*	2	4.6	1.3	2	3.3	1.0
<i>Age < 50</i>																		
<i>In Situ</i>	4	2.2	0.2	3	2.1	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	67	40.7	3.1	53	44.1	3.5	5	36.9	2.7	*	*	*	2	22.2	1.3	6	34.1	2.2
Regional	56	34.0	2.6	39	32.5	2.6	4	32.3	2.5	*	*	*	5	46.3	2.6	6	33.0	2.2
Distant	36	22.0	1.7	25	20.3	1.6	3	26.2	2.0	*	*	*	3	27.8	1.7	5	30.7	2.1
Unknown	2	1.2	0.1	1	1.0	0.1	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	36	2.9	2.7	30	2.8	2.6	*	*	*	*	*	*	2	3.8	2.6	*	*	*
Localized	467	37.5	34.5	396	37.1	34.5	27	40.1	36.1	*	*	*	17	41.1	30.4	18	37.3	23.5
Regional	444	35.7	32.5	383	35.9	32.7	24	35.3	34.1	*	*	*	15	36.4	28.1	17	35.7	22.9
Distant	218	17.5	16.0	187	17.5	16.1	13	19.2	18.0	*	*	*	6	13.9	10.5	9	18.3	12.1
Unknown	79	6.3	5.0	71	6.7	5.1	*	*	*	*	*	*	*	*	*	2	4.6	3.6

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Massachusetts, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	1,568	20.7	37.3	1,294	20.2	38.6	90	22.1	34.2	2	34.6	41.8	75	25.2	32.5	80	21.9	25.3
Localized	4,418	58.2	99.8	3,798	59.3	104.7	202	49.3	77.4	2	38.5	38.2	161	54.2	70.2	191	52.1	62.5
Regional	1,282	16.9	30.9	1,036	16.2	31.3	95	23.2	36.4	1	23.1	27.9	53	17.7	22.6	79	21.6	24.6
Distant	237	3.1	5.3	198	3.1	5.3	17	4.2	6.7	*	*	*	6	1.9	2.5	13	3.5	4.1
Unknown	89	1.2	1.8	75	1.2	1.8	5	1.2	2.0	*	*	*	3	1.0	1.5	3	0.9	1.1
<i>Age < 50</i>																		
<i>In Situ</i>	365	25.1	17.3	281	25.9	18.6	23	20.6	13.8	*	*	*	29	25.8	16.2	24	20.3	9.4
Localized	697	48.0	32.8	524	48.4	34.7	51	45.7	30.0	*	*	*	57	50.5	30.8	55	46.9	21.1
Regional	342	23.6	16.2	246	22.7	16.6	33	29.4	19.4	*	*	*	24	21.2	12.6	33	27.6	12.2
Distant	38	2.6	1.8	25	2.3	1.7	4	3.6	2.3	*	*	*	2	2.1	1.3	5	4.2	1.8
Unknown	10	0.7	0.5	7	0.7	0.5	*	*	*	*	*	*	*	*	*	1	1.0	0.5
<i>Age ≥ 50</i>																		
<i>In Situ</i>	1,203	19.6	89.7	1,013	19.0	90.9	68	22.6	87.7	*	*	*	46	24.8	75.1	56	22.6	66.8
Localized	3,721	60.6	275.2	3,274	61.6	287.9	151	50.7	201.3	2	45.5	138.2	104	56.4	173.5	136	54.6	170.7
Regional	940	15.3	69.4	790	14.9	69.9	63	21.0	81.1	*	*	*	29	15.6	48.7	47	18.8	57.3
Distant	199	3.2	14.4	173	3.3	14.7	13	4.4	18.1	*	*	*	3	1.8	5.6	8	3.2	10.0
Unknown	79	1.3	5.3	68	1.3	5.2	*	*	*	*	*	*	*	*	*	2	0.8	2.9

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	7	0.3	0.2	6	0.3	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	699	28.7	18.2	625	29.2	18.8	27	26.4	14.0	*	*	*	16	19.4	9.8	21	27.4	11.3
Regional	543	22.3	13.9	472	22.1	14.1	23	23.1	11.7	*	*	*	18	21.8	11.2	19	25.3	10.2
Distant	1,036	42.5	26.8	894	41.8	26.9	47	46.7	24.6	*	*	*	45	53.3	27.3	32	42.0	17.3
Unknown	154	6.3	4.3	141	6.6	4.5	4	3.6	2.3	*	*	*	5	5.5	3.8	4	4.8	3.2
<i>Female</i>																		
<i>In Situ</i>	18	0.6	0.4	16	0.6	0.4	*	*	*	*	*	*	*	*	*	*	*	*
Localized	969	34.2	20.2	876	34.4	21.6	33	32.6	12.7	*	*	*	15	25.8	7.5	22	32.2	8.4
Regional	637	22.5	13.3	575	22.5	14.2	23	23.1	8.7	*	*	*	8	14.2	4.4	17	26.0	6.4
Distant	1,040	36.7	21.6	928	36.4	22.7	40	39.9	15.1	*	*	*	29	48.8	14.2	24	36.4	9.0
Unknown	170	6.0	3.2	155	6.1	3.3	4	3.8	1.5	*	*	*	6	10.2	3.7	4	5.4	1.5

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	3,398	72.3	80.1	2,716	72.2	75.3	284	73.1	124.6	1	63.6	25.5	68	71.3	39.0	156	71.3	69.7
Regional	738	15.7	16.8	612	16.3	16.3	56	14.4	24.8	*	*	*	17	17.8	9.6	35	16.1	15.2
Distant	343	7.3	9.2	272	7.2	8.5	35	8.9	20.0	*	*	*	8	8.0	5.4	19	8.5	9.9
Unknown	219	4.7	5.6	163	4.3	4.9	14	3.5	7.9	*	*	*	3	2.9	2.1	9	4.1	5.1
<i>Age < 65</i>																		
Localized	1,446	74.3	34.8	1,104	73.7	32.1	163	77.7	66.1	*	*	*	24	73.0	12.0	81	73.8	29.8
Regional	357	18.3	8.5	291	19.4	8.4	32	15.3	13.0	*	*	*	6	19.6	3.2	18	16.7	6.7
Distant	79	4.1	1.9	57	3.8	1.7	10	4.9	4.2	*	*	*	2	5.5	0.9	7	6.6	2.7
Unknown	64	3.3	1.5	46	3.1	1.4	4	2.0	1.6	*	*	*	*	*	*	3	2.9	1.2
<i>Age ≥ 65</i>																		
Localized	1,951	70.9	393.3	1,612	71.2	373.8	121	67.7	529.2	*	*	*	44	70.4	225.6	75	68.8	345.6
Regional	381	13.9	73.7	321	14.2	71.2	24	13.3	106.6	*	*	*	11	16.9	53.9	17	15.5	74.4
Distant	264	9.6	59.3	215	9.5	55.2	24	13.5	129.4	*	*	*	6	9.2	36.7	11	10.4	59.7
Unknown	155	5.6	33.8	117	5.1	29.2	10	5.4	51.1	*	*	*	*	*	*	6	5.3	32.2

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Michigan, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	163	46.2	3.4	125	46.7	3.5	22	39.1	3.0	*	*	*	4	64.7	2.6	9	58.0	4.5
Regional	116	32.9	2.2	88	33.0	2.2	21	38.0	2.7	*	*	*	2	23.5	1.0	4	25.9	2.0
Distant	55	15.6	0.9	41	15.4	0.9	11	20.3	1.5	*	*	*	*	*	*	2	11.1	1.1
Unknown	19	5.4	0.3	13	4.9	0.3	1	2.5	0.2	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	80	3.3	1.3	65	3.3	1.3	9	2.7	1.3	*	*	*	1	3.8	1.0	3	6.4	2.0
Localized	803	32.9	13.9	651	32.8	13.4	118	35.0	19.2	3	26.4	15.6	9	29.4	7.3	15	29.6	9.7
Regional	873	35.7	15.3	728	36.7	15.3	103	30.5	16.7	5	49.1	26.6	12	37.5	9.4	19	37.2	13.0
Distant	509	20.8	9.0	397	20.0	8.4	87	25.7	14.3	2	18.9	13.3	7	22.5	5.7	11	22.8	8.6
Unknown	179	7.3	3.2	145	7.3	3.1	21	6.2	3.8	*	*	*	2	6.9	2.0	2	4.0	1.7
<i>Age < 50</i>																		
<i>In Situ</i>	5	1.7	0.2	4	1.8	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	82	29.8	2.7	64	30.6	2.8	13	28.8	3.2	*	*	*	*	*	*	3	33.3	1.6
Regional	103	37.7	3.5	80	38.4	3.6	16	35.0	4.0	*	*	*	2	31.0	1.4	4	50.0	2.6
Distant	72	26.2	2.5	52	24.7	2.3	14	30.5	3.4	*	*	*	3	51.7	2.5	1	14.3	0.8
Unknown	13	4.6	0.4	9	4.5	0.4	2	4.9	0.5	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	75	3.5	4.3	61	3.4	4.1	*	*	*	*	*	*	1	4.6	3.6	3	7.7	7.4
Localized	722	33.3	43.2	587	33.0	41.3	105	35.9	60.8	*	*	*	*	*	*	12	28.8	30.8
Regional	770	35.5	46.3	648	36.5	45.9	87	29.8	50.1	*	*	*	10	38.9	30.5	14	34.6	40.3
Distant	437	20.1	26.0	345	19.4	24.2	73	24.9	42.9	*	*	*	4	16.0	14.1	10	24.5	29.1
Unknown	167	7.7	10.6	136	7.7	10.1	19	6.4	12.2	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	63	2.8	1.0	55	3.0	1.0	6	1.9	0.7	*	*	*	*	*	*	*	*	*
Localized	748	33.3	11.4	596	32.7	11.0	116	36.3	14.2	3	34.2	11.3	12	33.1	8.0	14	34.3	9.0
Regional	812	36.1	12.3	673	36.8	12.3	106	33.1	13.1	2	31.6	13.3	14	38.9	9.9	13	31.3	7.5
Distant	454	20.2	6.9	358	19.6	6.7	74	23.2	9.1	2	26.3	9.3	7	18.9	4.7	11	26.4	6.5
Unknown	172	7.6	2.4	143	7.9	2.4	18	5.5	2.0	*	*	*	2	6.9	1.9	2	6.0	1.7
<i>Age < 50</i>																		
<i>In Situ</i>	7	2.7	0.2	5	2.9	0.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	84	33.0	2.8	61	32.4	2.7	15	35.2	3.2	*	*	*	3	38.9	2.2	3	30.8	2.0
Regional	91	35.7	3.1	68	36.5	3.1	15	35.2	3.3	*	*	*	2	33.3	1.8	3	28.8	1.9
Distant	61	24.1	2.1	44	23.6	2.0	11	25.9	2.4	*	*	*	1	19.4	1.1	3	32.7	2.3
Unknown	11	4.4	0.4	9	4.6	0.4	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	56	2.8	2.9	50	3.0	3.1	*	*	*	*	*	*	*	*	*	*	*	*
Localized	664	33.3	34.0	536	32.7	32.7	101	36.4	42.9	*	*	*	9	31.7	23.3	11	35.6	27.5
Regional	721	36.2	36.3	604	36.9	36.3	91	32.8	38.7	*	*	*	11	40.3	30.9	10	32.2	22.2
Distant	392	19.7	19.7	314	19.2	18.8	63	22.8	26.6	*	*	*	5	18.7	14.0	7	24.2	17.6
Unknown	161	8.1	7.6	135	8.2	7.5	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Michigan, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	1,916	19.4	30.7	1,525	18.7	30.4	277	22.4	34.1	7	21.3	29.8	47	25.1	29.8	38	23.4	22.6
Localized	5,290	53.6	81.3	4,502	55.2	84.6	572	46.1	70.5	12	38.7	58.2	97	51.7	61.6	75	46.2	45.5
Regional	2,023	20.5	33.3	1,631	20.0	33.5	291	23.4	36.6	10	32.9	48.8	36	19.0	21.9	40	24.6	22.5
Distant	452	4.6	7.0	347	4.3	6.5	86	6.9	10.7	*	*	*	6	3.1	3.8	7	4.3	4.0
Unknown	185	1.9	2.8	146	1.8	2.6	15	1.2	1.9	1	3.9	6.4	2	1.2	1.6	2	1.5	1.5
<i>Age < 50</i>																		
<i>In Situ</i>	365	21.8	12.6	284	21.9	13.1	44	19.0	9.7	*	*	*	18	27.4	14.2	13	25.6	8.8
Localized	739	44.2	25.1	584	44.9	26.7	97	41.8	21.1	3	41.9	23.0	31	46.5	23.8	17	35.0	11.8
Regional	480	28.7	16.5	370	28.5	17.1	72	31.2	15.8	3	41.9	21.8	15	22.5	11.5	17	34.1	11.1
Distant	66	3.9	2.3	47	3.6	2.2	15	6.4	3.2	*	*	*	2	2.4	1.2	2	4.1	1.3
Unknown	23	1.4	0.8	14	1.1	0.7	4	1.6	0.8	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	1,551	18.9	78.2	1,241	18.1	75.4	233	23.1	97.9	*	*	*	29	23.9	70.6	25	22.4	58.7
Localized	4,552	55.6	228.4	3,919	57.2	236.0	475	47.1	200.0	9	37.9	150.5	66	54.4	160.7	58	51.1	133.7
Regional	1,543	18.8	77.4	1,261	18.4	76.2	218	21.6	91.0	8	30.6	119.6	21	17.0	49.0	23	20.5	52.5
Distant	386	4.7	19.2	300	4.4	17.9	71	7.1	30.3	*	*	*	4	3.4	10.6	5	4.4	11.1
Unknown	163	2.0	7.9	132	1.9	7.6	11	1.1	4.8	*	*	*	*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	9	0.2	0.1	8	0.2	0.1	*	*	*	*	*	*	*	*	*	*	*	*
Localized	893	21.7	15.1	781	22.2	15.4	89	18.5	15.2	5	22.5	28.6	7	21.5	6.7	7	20.2	6.4
Regional	913	22.2	15.0	789	22.5	15.2	99	20.5	16.8	6	30.4	30.6	6	20.3	5.4	6	17.4	4.8
Distant	1,955	47.5	32.5	1,628	46.4	31.7	269	55.7	43.9	7	34.3	40.3	17	55.1	15.1	18	49.4	15.3
Unknown	343	8.3	6.0	306	8.7	6.2	25	5.1	4.3	3	12.7	13.1	*	*	*	5	12.9	4.3
<i>Female</i>																		
<i>In Situ</i>	20	0.5	0.3	16	0.5	0.3	2	0.5	0.2	*	*	*	*	*	*	*	*	*
Localized	1,051	26.2	14.9	915	26.9	15.5	106	22.2	12.6	4	18.3	20.8	7	20.6	5.1	12	26.5	8.9
Regional	898	22.4	12.7	763	22.4	13.0	109	22.8	13.0	6	26.7	33.2	7	21.2	5.5	8	17.0	5.4
Distant	1,762	44.0	25.0	1,461	43.0	24.9	239	50.1	28.6	9	36.7	40.2	18	54.5	13.3	22	47.8	15.1
Unknown	277	6.9	3.8	245	7.2	4.0	21	4.4	2.6	4	17.5	21.7	1	3.6	1.0	4	7.8	2.7

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	5,085	71.4	78.6	3,983	72.1	72.3	818	74.8	121.4	11	65.9	56.0	44	69.6	36.3	65	67.2	47.2
Regional	1,036	14.6	15.3	850	15.4	14.8	148	13.6	20.7	4	22.0	14.6	11	18.2	8.9	14	14.8	10.3
Distant	447	6.3	7.7	339	6.1	6.8	89	8.1	14.9	1	8.5	7.2	5	8.3	4.9	8	8.5	7.5
Unknown	549	7.7	9.0	348	6.3	6.7	38	3.5	6.6	*	*	*	2	3.8	2.4	9	9.5	8.1
<i>Age < 65</i>																		
Localized	2,081	72.4	33.5	1,529	72.8	29.3	433	75.7	63.6	5	59.5	24.2	17	70.2	12.3	30	69.6	17.5
Regional	502	17.5	8.0	392	18.7	7.5	91	16.0	13.3	*	*	*	5	22.3	3.9	7	16.4	4.1
Distant	128	4.5	2.1	87	4.1	1.7	35	6.2	5.2	*	*	*	*	*	*	3	7.5	1.9
Unknown	164	5.7	2.6	92	4.4	1.7	12	2.1	1.7	*	*	*	*	*	*	3	6.5	1.6
<i>Age ≥ 65</i>																		
Localized	3,004	70.8	390.1	2,454	71.8	369.4	385	73.8	520.5	6	72.5	276.3	27	69.3	201.6	35	65.3	252.5
Regional	534	12.6	65.8	457	13.4	65.2	57	10.9	71.8	*	*	*	6	15.6	43.0	7	13.7	52.9
Distant	319	7.5	46.4	252	7.4	42.5	54	10.3	81.8	*	*	*	*	*	*	5	9.2	46.4
Unknown	385	9.1	53.4	256	7.5	41.4	26	5.0	40.7	*	*	*	*	*	*	6	11.8	52.8

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Metropolitan Detroit, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	61	43.9	3.1	40	45.9	3.3	14	36.2	2.8	Insufficient data for the calculation of AI/AN PRCDA statistics			2	61.5	1.8	4	52.9	4.6
Regional	48	34.8	2.3	30	34.5	2.2	15	37.2	2.7				*	*	*	2	29.4	2.5
Distant	27	19.4	1.1	16	18.4	1.0	9	23.1	1.7				*	*	*	1	17.6	1.9
Unknown	3	1.9	0.1	*	*	*	1	3.5	0.2				*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	12	1.2	0.5	5	0.8	0.3	6	2.2	1.1	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	357	35.6	16.5	244	34.9	15.4	99	37.9	23.1				6	34.1	6.8	6	26.8	11.6
Regional	362	36.1	17.1	264	37.9	17.1	80	30.6	18.6				6	37.6	7.8	10	44.6	20.9
Distant	230	22.9	11.0	155	22.2	10.1	65	25.0	15.4				4	23.5	5.3	5	24.1	11.5
Unknown	43	4.2	2.1	29	4.2	1.9	11	4.2	3.0				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*
Localized	32	28.9	2.7	21	28.7	2.7	10	31.0	3.7				*	*	*	*	*	*
Regional	46	41.8	3.9	32	43.8	4.1	12	37.3	4.6				*	*	*	2	57.9	3.7
Distant	30	27.1	2.6	19	25.6	2.5	9	29.1	3.4				1	63.6	1.8	*	*	*
Unknown	2	1.6	0.1	1	1.7	0.2	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*
Localized	325	36.4	52.8	223	35.7	48.6	89	38.8	73.8				*	*	*	*	*	*
Regional	316	35.3	51.8	233	37.3	51.4	68	29.7	55.3				*	*	*	8	41.9	65.9
Distant	200	22.4	32.9	136	21.8	30.0	56	24.5	46.8				3	17.6	14.3	*	*	*
Unknown	41	4.6	7.4	28	4.5	6.6	*	*	*				*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	10	1.0	0.4	5	0.8	0.3	4	1.6	0.7	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	339	35.1	13.2	229	34.5	12.6	93	36.3	15.3				7	35.6	7.7	8	38.5	15.1
Regional	359	37.1	13.9	257	38.8	14.0	87	34.0	14.5				8	36.5	9.4	6	27.9	9.8
Distant	217	22.4	8.4	143	21.6	7.8	61	23.7	9.9				5	25.0	5.9	6	27.9	10.1
Unknown	43	4.4	1.4	29	4.4	1.3	11	4.4	1.7				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	1	1.3	0.1	*	*	*	*	*	*				*	*	*	*	*	*
Localized	38	34.9	3.1	23	35.1	3.0	11	33.9	3.3				2	41.7	2.5	2	37.0	3.4
Regional	40	36.4	3.3	25	38.2	3.3	12	35.8	3.6				2	33.3	2.1	1	25.9	2.6
Distant	29	26.0	2.3	17	25.8	2.2	9	26.1	2.5				*	*	*	2	29.6	2.9
Unknown	2	1.5	0.1	*	*	*	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	9	1.0	1.1	*	*	*	*	*	*				*	*	*	*	*	*
Localized	301	35.1	39.8	206	34.4	37.8	82	36.7	46.8				5	33.8	21.3	6	39.0	45.9
Regional	319	37.1	41.5	232	38.8	41.9	75	33.8	43.2				6	37.5	28.4	4	28.6	28.8
Distant	189	22.0	24.2	126	21.1	22.5	52	23.4	29.4				*	*	*	4	27.3	29.0
Unknown	41	4.8	4.8	*	*	*	*	*	*				*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Metropolitan Detroit, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	862	20.4	35.1	597	19.7	35.8	214	21.8	35.8				28	25.7	28.1	17	19.4	29.3
Localized	2,203	52.1	87.2	1,643	54.3	93.8	448	45.8	75.0				59	53.8	60.0	46	51.4	74.3
Regional	910	21.5	37.8	630	20.8	38.5	239	24.4	40.9				18	16.3	17.8	21	23.2	32.8
Distant	218	5.2	8.6	134	4.4	7.5	73	7.4	12.2				4	3.7	4.1	5	5.4	8.0
Unknown	32	0.8	1.1	24	0.8	1.1	6	0.6	1.1				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	176	22.7	14.3	123	23.7	16.3	34	18.5	10.3	Insufficient data for the calculation of AI/AN PRCDA statistics			11	30.3	14.7	5	17.4	8.5
Localized	340	44.0	27.6	233	44.9	30.8	77	41.6	23.0				18	47.9	23.1	11	40.9	19.5
Regional	222	28.7	18.1	143	27.6	19.2	61	33.2	18.3				7	18.1	8.6	9	35.6	16.7
Distant	33	4.2	2.7	18	3.4	2.4	12	6.4	3.6				1	3.7	1.7	1	5.3	2.6
Unknown	3	0.4	0.2	2	0.3	0.2	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	686	19.9	89.5	474	18.9	87.1	179	22.6	102.5				17	23.2	63.2	13	20.2	83.8
Localized	1,863	54.0	243.4	1,411	56.2	258.7	371	46.7	211.3				41	56.9	156.7	35	55.8	217.7
Regional	688	19.9	89.4	487	19.4	89.0	177	22.3	99.9				11	15.4	41.9	11	17.9	75.1
Distant	186	5.4	24.0	116	4.6	20.8	61	7.7	34.9				3	3.6	10.5	3	5.4	22.2
Unknown	29	0.9	3.5	22	0.9	3.5	*	*	*				*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	2	0.1	0.1	2	0.1	0.1	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	333	21.3	15.9	266	22.9	16.9	58	16.6	13.8				4	18.2	6.3	4	19.4	8.9
Regional	321	20.5	14.8	244	20.9	14.9	67	19.3	16.3				4	18.2	5.3	4	20.4	9.4
Distant	854	54.6	39.4	610	52.5	37.7	213	61.0	49.6				14	62.7	19.1	10	54.8	26.2
Unknown	55	3.5	2.7	41	3.6	2.7	11	3.0	2.7				*	*	*	*	*	*
<i>Female</i>																		
<i>In Situ</i>	7	0.4	0.3	5	0.4	0.3	2	0.5	0.3	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	433	26.2	16.1	341	27.7	17.6	80	21.6	12.9				2	12.4	2.5	7	27.5	12.2
Regional	350	21.1	13.0	259	21.1	13.5	82	22.1	13.3				3	16.9	3.8	3	12.5	6.4
Distant	822	49.6	30.2	589	47.9	30.1	201	54.1	32.3				12	68.5	15.0	13	55.0	25.2
Unknown	44	2.7	1.6	36	2.9	1.7	6	1.6	1.0				*	*	*	1	5.0	2.3

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	2,386	76.3	101.8	1,614	76.8	92.6	617	75.0	131.7	Insufficient data for the calculation of AI/AN PRCDA statistics			35	74.4	46.2	38	76.8	81.6
Regional	448	14.3	17.9	316	15.0	17.1	116	14.1	22.9				8	16.4	9.7	7	13.2	12.4
Distant	198	6.3	9.3	119	5.7	7.5	72	8.7	16.8				3	7.1	4.6	3	6.8	8.5
Unknown	96	3.1	4.4	54	2.6	3.3	17	2.1	4.5				*	*	*	2	3.2	3.6
<i>Age < 65</i>																		
Localized	1,014	75.4	43.2	637	75.8	36.7	319	74.8	68.7	Insufficient data for the calculation of AI/AN PRCDA statistics			13	74.4	14.2	17	77.3	27.3
Regional	239	17.7	10.0	159	18.9	9.1	74	17.3	15.5				3	17.4	3.4	3	12.7	4.5
Distant	61	4.5	2.6	29	3.5	1.6	29	6.8	6.1				*	*	*	1	6.4	2.3
Unknown	31	2.3	1.3	15	1.8	0.9	5	1.1	1.0				*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	1,372	76.9	506.9	977	77.4	478.9	298	75.3	566.9				23	74.3	267.4	21	76.4	456.8
Regional	209	11.7	72.4	157	12.4	72.3	42	10.7	74.1				5	15.8	53.2	4	13.6	66.5
Distant	137	7.7	55.8	90	7.1	48.2	43	10.8	90.9				*	*	*	2	7.1	51.7
Unknown	65	3.7	25.5	39	3.1	20.3	13	3.2	28.0				*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Minnesota, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	83	51.7	3.1	67	54.0	3.1	5	41.7	3.4	*	*	*	5	48.0	3.4	4	46.3	4.0
Regional	45	28.3	1.5	34	27.5	1.3	5	38.3	3.9	*	*	*	3	28.0	2.5	2	26.8	2.8
Distant	17	10.8	0.5	13	10.4	0.5	1	10.0	1.1	*	*	*	*	*	*	1	14.6	2.0
Unknown	15	9.3	0.5	10	8.1	0.4	1	10.0	0.7	*	*	*	1	14.0	1.4	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	23	1.7	0.7	21	1.8	0.7	*	*	*	*	*	*	*	*	*	*	*	*
Localized	461	35.5	15.0	419	35.8	15.1	19	34.8	14.8	3	31.1	22.9	9	29.6	12.0	7	32.4	9.9
Regional	471	36.2	15.5	424	36.2	15.4	19	34.8	18.2	4	40.0	27.5	14	44.7	15.7	6	27.9	9.2
Distant	264	20.3	8.7	233	19.9	8.4	12	22.5	13.5	2	26.7	16.8	7	22.6	7.7	7	29.7	11.9
Unknown	80	6.2	2.7	73	6.3	2.7	3	6.0	4.5	*	*	*	*	*	*	2	7.2	2.7
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	57	34.4	3.3	47	35.7	3.4	5	40.0	4.1	*	*	*	*	*	*	3	39.4	2.4
Regional	63	38.1	3.7	50	37.7	3.7	4	30.8	3.5	1	66.7	12.7	5	56.3	5.9	2	30.3	2.0
Distant	39	23.8	2.3	31	23.3	2.3	3	23.1	2.7	*	*	*	3	29.2	3.0	2	27.3	1.9
Unknown	5	3.0	0.3	4	2.7	0.3	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	404	35.7	45.9	372	35.8	45.8	13	33.2	42.8	*	*	*	*	*	*	5	29.5	29.4
Regional	408	36.0	46.3	374	36.1	45.9	15	36.1	56.9	2	33.3	66.1	9	39.6	41.3	4	26.9	28.1
Distant	225	19.8	25.2	202	19.5	24.6	9	22.3	41.8	*	*	*	4	19.8	20.3	5	30.8	38.1
Unknown	75	6.6	9.1	70	6.7	9.0	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	14	1.2	0.4	12	1.1	0.4	*	*	*	*	*	*	*	*	*	*	*	*
Localized	414	36.1	12.0	372	35.7	11.8	13	35.5	11.8	4	40.8	24.5	10	39.8	10.3	9	39.1	13.0
Regional	413	36.0	12.0	378	36.3	11.9	12	32.8	9.7	3	34.7	23.2	10	39.1	10.3	7	29.6	10.2
Distant	212	18.4	6.2	192	18.5	6.2	9	24.6	7.3	2	16.3	10.2	4	14.1	4.1	4	19.1	6.9
Unknown	95	8.3	2.5	88	8.4	2.4	2	4.4	1.8	*	*	*	1	5.5	1.6	3	11.3	5.2
<i>Age < 50</i>																		
<i>In Situ</i>	1	1.1	0.1	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	44	34.5	2.6	34	33.7	2.6	3	30.4	2.5	*	*	*	3	37.1	2.6	3	41.9	2.6
Regional	46	35.9	2.8	36	35.2	2.7	4	45.7	3.8	*	*	*	3	42.9	3.0	2	25.8	1.7
Distant	30	23.4	1.8	25	25.0	1.9	2	19.6	1.6	*	*	*	*	*	*	1	22.6	1.6
Unknown	7	5.1	0.4	5	5.1	0.4	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	12	1.2	1.3	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	370	36.3	36.6	338	35.9	36.1	10	37.2	36.1	*	*	*	8	40.9	30.3	6	38.1	40.0
Regional	367	36.0	35.9	343	36.4	36.1	8	28.5	25.2	*	*	*	7	37.6	29.4	5	31.0	32.4
Distant	182	17.8	17.5	167	17.8	17.3	7	26.3	22.1	*	*	*	*	*	*	3	17.9	20.6
Unknown	89	8.7	7.9	83	8.8	7.8	2	5.8	6.5	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Minnesota, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	973	17.7	29.9	888	17.5	30.8	30	18.5	22.6	3	16.1	17.4	25	20.8	22.3	21	21.0	27.8
Localized	3,078	55.8	90.7	2,869	56.5	93.6	74	46.3	61.3	10	52.7	57.9	58	49.1	52.0	50	48.9	67.0
Regional	1,108	20.1	34.9	996	19.6	35.4	45	27.9	34.2	4	20.4	24.4	29	24.9	25.4	25	25.0	28.2
Distant	217	3.9	6.5	194	3.8	6.4	10	6.0	8.5	2	9.7	11.1	5	4.6	4.6	3	3.3	5.0
Unknown	135	2.5	3.7	127	2.5	3.7	2	1.4	1.6	*	*	*	*	*	*	2	1.8	3.2
<i>Age < 50</i>																		
<i>In Situ</i>	192	19.9	12.0	166	20.4	12.8	7	13.6	6.7	*	*	*	10	19.0	10.4	7	19.3	8.7
Localized	432	44.8	26.8	367	45.3	28.2	22	40.9	20.0	2	42.1	17.3	23	44.8	23.0	16	42.2	18.2
Regional	293	30.4	18.0	241	29.6	18.4	20	38.3	17.8	1	31.6	14.2	15	30.2	15.4	13	35.8	15.2
Distant	36	3.7	2.2	29	3.5	2.2	3	4.9	2.4	*	*	*	3	6.0	2.9	*	*	*
Unknown	11	1.2	0.7	9	1.2	0.7	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	781	17.2	76.9	723	17.0	78.0	22	20.8	64.2	*	*	*	15	22.1	53.3	14	22.0	78.1
Localized	2,646	58.2	257.9	2,502	58.7	264.9	53	48.9	169.6	8	55.4	164.0	35	52.2	127.9	34	52.8	194.9
Regional	815	17.9	79.1	755	17.7	80.0	25	22.9	77.1	3	17.6	51.3	14	20.9	51.7	12	18.6	62.1
Distant	181	4.0	17.6	166	3.9	17.4	7	6.5	24.4	*	*	*	2	3.5	9.0	*	*	*
Unknown	124	2.7	11.4	117	2.7	11.5	*	*	*	*	*	*	*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	5	0.3	0.2	5	0.3	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	472	25.0	15.2	438	25.2	15.2	16	23.4	18.6	5	27.7	44.2	8	23.4	12.8	2	15.2	6.0
Regional	418	22.1	13.1	385	22.1	13.0	16	22.2	14.6	4	22.3	29.7	7	19.9	10.3	4	25.3	8.5
Distant	811	42.9	25.6	742	42.6	25.2	33	47.0	36.6	9	46.8	68.4	16	46.2	23.8	9	54.4	15.4
Unknown	183	9.7	6.2	171	9.8	6.2	5	7.1	5.3	*	*	*	4	10.5	5.9	*	*	*
<i>Female</i>																		
<i>In Situ</i>	7	0.4	0.2	6	0.4	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	560	29.5	15.7	515	29.4	15.6	17	31.3	15.3	12	41.1	69.9	7	22.2	7.2	6	32.3	12.5
Regional	382	20.1	10.5	353	20.2	10.6	13	24.9	12.2	4	14.9	24.8	5	14.6	4.7	3	18.3	5.5
Distant	750	39.5	20.7	691	39.4	20.6	19	36.6	18.2	10	35.5	60.9	17	52.5	19.0	8	40.9	12.6
Unknown	201	10.6	5.4	186	10.6	5.3	3	6.4	4.0	2	8.5	16.1	3	10.1	4.3	2	8.6	3.4

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	2,634	68.2	76.3	2,430	68.8	76.2	127	70.6	114.7	10	70.0	68.7	22	66.1	30.4	33	67.5	58.7
Regional	650	16.8	18.2	603	17.1	18.4	28	15.3	23.4	2	15.7	13.4	6	18.2	8.4	8	16.0	12.9
Distant	330	8.5	10.8	299	8.5	10.5	19	10.8	23.6	2	11.4	15.5	3	10.3	7.8	4	9.1	10.3
Unknown	247	6.4	7.8	199	5.6	6.8	6	3.3	7.7	*	*	*	2	5.5	3.5	4	7.4	9.0
<i>Age < 65</i>																		
Localized	1,078	71.4	31.6	966	72.0	31.4	78	71.4	57.1	4	68.8	25.0	8	73.2	9.2	16	71.7	19.5
Regional	289	19.2	8.4	261	19.5	8.4	19	17.4	14.0	*	*	*	2	19.6	2.5	4	15.9	4.4
Distant	76	5.0	2.2	64	4.7	2.1	9	8.4	6.8	*	*	*	*	*	*	2	8.0	2.1
Unknown	66	4.4	2.0	51	3.8	1.7	3	2.8	2.2	*	*	*	*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	1,556	66.2	385.3	1,464	66.9	386.1	49	69.3	512.6	5	71.1	371.0	14	62.4	176.9	17	63.8	329.8
Regional	361	15.4	86.1	342	15.6	86.9	9	12.1	88.0	*	*	*	4	17.4	49.2	4	16.2	71.7
Distant	254	10.8	70.2	235	10.7	68.7	10	14.4	139.6	*	*	*	*	*	*	3	10.0	66.6
Unknown	181	7.7	48.4	148	6.8	42.2	3	4.2	45.2	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Mississippi, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	60	41.7	4.1	40	46.7	4.8	20	35.1	3.5	*	*	*	*	*	*	*	*	*
Regional	57	39.5	3.5	30	35.8	3.2	25	44.4	4.2	*	*	*	*	*	*	*	*	*
Distant	22	15.1	1.3	11	13.2	1.2	10	17.2	1.6	*	*	*	*	*	*	*	*	*
Unknown	5	3.7	0.3	4	4.2	0.3	2	3.2	0.3	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	42	4.4	2.5	24	4.1	2.1	18	5.2	3.7	*	*	*	*	*	*	*	*	*
Localized	300	31.7	18.4	189	32.4	17.1	104	30.4	22.1	2	53.3	76.9	2	46.2	16.3	2	24.5	7.7
Regional	352	37.3	22.0	224	38.4	21.1	120	35.2	25.1	*	*	*	2	42.3	18.3	4	38.8	11.7
Distant	204	21.7	12.9	121	20.7	11.5	80	23.4	17.6	*	*	*	*	*	*	3	30.6	9.6
Unknown	46	4.9	3.0	26	4.4	2.4	20	5.8	4.6	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	2	2.4	0.3	1	2.3	0.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	24	24.0	2.8	14	22.5	2.7	9	26.3	3.0	*	*	*	*	*	*	*	*	*
Regional	42	41.9	4.9	27	44.6	5.5	13	38.0	4.2	*	*	*	*	*	*	1	35.3	3.2
Distant	29	28.4	3.4	17	28.0	3.5	10	28.7	3.2	*	*	*	*	*	*	1	41.2	3.9
Unknown	3	3.4	0.4	2	2.6	0.3	1	4.1	0.5	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	39	4.7	8.4	22	4.3	7.0	*	*	*	*	*	*	*	*	*	*	*	*
Localized	275	32.7	59.4	175	33.5	54.6	95	30.9	72.0	*	*	*	*	*	*	*	*	*
Regional	310	36.7	66.6	197	37.7	61.9	107	34.9	79.8	*	*	*	2	47.8	66.1	3	40.6	33.7
Distant	176	20.8	37.8	104	19.9	32.3	70	22.8	55.4	*	*	*	*	*	*	2	25.0	24.5
Unknown	43	5.1	10.0	24	4.6	8.0	18	6.0	15.4	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	29	3.5	1.5	15	2.9	1.2	13	4.3	2.0	*	*	*	*	*	*	*	*	*
Localized	277	33.5	14.5	178	35.0	14.2	95	31.4	15.2	*	*	*	2	43.5	9.1	1	26.9	5.7
Regional	312	37.7	16.3	196	38.5	15.7	110	36.3	17.5	2	44.4	67.8	1	26.1	7.3	2	46.2	9.2
Distant	170	20.6	9.0	100	19.7	8.1	66	21.9	10.9	1	25.9	46.2	1	30.4	7.0	*	*	*
Unknown	38	4.6	2.0	20	3.9	1.4	18	6.0	3.1	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	3	3.4	0.3	1	2.4	0.2	2	4.5	0.4	*	*	*	*	*	*	*	*	*
Localized	27	30.0	2.9	16	32.7	3.2	10	28.1	2.7	*	*	*	*	*	*	*	*	*
Regional	34	38.6	3.8	20	39.9	4.0	12	34.8	3.4	*	*	*	*	*	*	*	*	*
Distant	21	23.5	2.3	11	21.8	2.1	9	26.4	2.6	*	*	*	*	*	*	*	*	*
Unknown	4	4.5	0.4	2	3.2	0.3	2	6.2	0.6	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	26	3.5	4.5	14	3.0	3.6	11	4.3	6.2	*	*	*	*	*	*	*	*	*
Localized	251	33.9	44.8	162	35.2	42.9	85	31.9	48.2	*	*	*	*	*	*	*	*	*
Regional	278	37.6	48.9	176	38.3	46.4	97	36.5	54.3	*	*	*	*	*	*	*	*	*
Distant	150	20.3	26.5	90	19.5	23.6	57	21.3	32.7	*	*	*	*	*	*	*	*	*
Unknown	34	4.7	6.0	18	3.9	4.4	16	6.0	9.8	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Mississippi, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	458	16.7	24.6	269	15.6	23.0	181	18.5	28.4	*	*	*	4	22.4	23.7	2	13.6	7.9
Localized	1,406	51.4	75.1	949	55.2	78.3	438	44.9	70.8	1	41.2	37.7	9	43.9	50.4	7	45.7	26.8
Regional	658	24.0	36.8	382	22.2	33.8	264	27.1	43.4	*	*	*	6	28.6	28.3	5	32.1	17.6
Distant	166	6.1	8.9	85	4.9	7.1	79	8.1	12.8	*	*	*	*	*	*	1	7.4	4.7
Unknown	50	1.8	2.6	35	2.0	2.9	13	1.4	2.3	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	72	15.7	8.0	40	16.1	8.0	29	15.0	8.1	*	*	*	1	20.0	9.4	*	*	*
Localized	208	45.4	23.2	119	47.9	23.9	82	42.0	22.8	*	*	*	3	46.7	21.1	3	40.5	11.8
Regional	145	31.6	16.2	73	29.3	14.7	68	34.8	18.7	*	*	*	2	30.0	13.4	3	35.1	10.7
Distant	27	5.8	2.9	11	4.4	2.2	15	7.7	4.1	*	*	*	*	*	*	*	*	*
Unknown	7	1.5	0.8	5	2.2	1.1	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	386	16.9	67.9	229	15.6	62.4	152	19.4	81.3	*	*	*	3	23.5	61.2	*	*	*
Localized	1,198	52.6	211.0	830	56.4	220.8	356	45.6	196.5	*	*	*	6	42.6	126.9	4	50.0	66.0
Regional	513	22.5	90.9	309	21.0	83.9	196	25.1	108.2	*	*	*	4	27.9	67.4	3	29.5	35.8
Distant	139	6.1	24.7	74	5.0	19.8	64	8.2	35.8	*	*	*	*	*	*	*	*	*
Unknown	43	1.9	7.5	30	2.0	7.6	*	*	*	*	*	*	*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	2	0.1	0.1	1	0.1	0.1	*	*	*	*	*	*	*	*	*	*	*	*
Localized	346	22.8	21.4	247	23.9	21.6	95	20.0	21.9	*	*	*	2	38.1	16.2	2	33.3	8.2
Regional	369	24.3	22.3	255	24.6	21.9	112	23.7	24.2	*	*	*	*	*	*	1	22.2	4.3
Distant	724	47.7	44.0	477	46.1	41.7	243	51.4	51.4	*	*	*	2	47.6	18.1	2	33.3	6.4
Unknown	77	5.1	5.1	54	5.2	5.0	22	4.7	5.7	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>In Situ</i>	3	0.2	0.1	2	0.3	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	336	28.8	16.6	255	29.5	18.6	76	26.8	12.5	*	*	*	2	30.6	16.0	2	37.0	11.0
Regional	283	24.3	14.0	216	25.0	16.1	63	22.0	10.0	*	*	*	1	19.4	9.7	2	29.6	7.3
Distant	495	42.5	24.7	359	41.5	27.3	130	45.6	20.7	*	*	*	4	50.0	22.4	2	33.3	7.8
Unknown	48	4.1	2.3	33	3.8	2.3	15	5.3	2.6	*	*	*	*	*	*	*	*	*

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	1,849	77.7	104.7	1,030	76.9	85.3	798	78.6	153.9	1	77.8	58.5	6	70.0	39.7	10	82.0	43.1
Regional	285	12.0	15.5	176	13.2	14.1	107	10.5	18.8	*	*	*	1	15.0	7.0	1	11.5	5.7
Distant	155	6.5	9.7	82	6.2	7.6	72	7.1	15.7	*	*	*	*	*	*	*	*	*
Unknown	91	3.8	5.7	51	3.8	4.6	38	3.8	8.8	*	*	*	*	*	*	*	*	*
<i>Age < 65</i>																		
Localized	755	77.1	45.5	350	76.3	32.9	395	77.7	72.5	*	*	*	3	71.4	20.3	3	89.5	10.5
Regional	137	14.0	8.2	73	15.9	6.8	64	12.5	11.6	*	*	*	*	*	*	*	*	*
Distant	59	6.1	3.6	23	5.1	2.2	36	7.0	6.5	*	*	*	*	*	*	*	*	*
Unknown	27	2.8	1.6	12	2.7	1.2	14	2.8	2.6	*	*	*	*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	1,094	78.1	514.0	680	77.2	447.9	403	79.6	716.9	*	*	*	3	68.4	173.8	7	78.6	268.2
Regional	148	10.6	65.6	103	11.7	64.9	43	8.5	69.2	*	*	*	*	*	*	*	*	*
Distant	96	6.8	52.2	59	6.7	44.4	36	7.2	79.0	*	*	*	*	*	*	*	*	*
Unknown	64	4.6	34.1	38	4.4	28.2	24	4.7	51.9	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Missouri, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	120	45.0	4.0	100	46.3	4.2	13	35.6	3.4	Insufficient data for the calculation of AI/AN PRCDA statistics			3	60.0	4.0	2	36.0	2.1
Regional	98	36.9	3.0	80	36.9	3.0	13	36.7	3.6				2	40.0	2.8	3	52.0	2.7
Distant	37	13.7	1.0	28	12.8	0.9	8	23.3	2.1				*	*	*	*	*	*
Unknown	12	4.4	0.3	9	4.0	0.3	2	4.4	0.4				*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	72	4.4	2.0	58	4.1	1.8	11	7.1	3.7				*	*	*	*	*	*
Localized	501	30.9	14.5	433	30.8	14.4	49	30.2	16.0				5	37.0	11.9	8	36.5	13.5
Regional	615	37.9	18.0	541	38.5	18.1	56	34.8	19.2				6	38.4	13.6	7	32.2	11.0
Distant	338	20.9	9.8	292	20.8	9.8	35	21.9	11.9				2	15.1	4.4	6	25.2	7.0
Unknown	95	5.8	2.9	81	5.8	2.8	10	6.1	3.8				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	3	1.9	0.2	3	2.0	0.2	*	*	*				*	*	*	*	*	*
Localized	48	26.9	2.7	40	26.7	2.7	6	29.0	2.8				*	*	*	2	28.1	2.1
Regional	75	41.7	4.2	62	41.8	4.3	9	43.0	4.2				2	61.5	3.3	2	31.3	2.5
Distant	48	26.6	2.7	40	26.8	2.8	5	23.0	2.4				*	*	*	2	31.3	2.4
Unknown	5	2.9	0.3	4	2.7	0.3	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	68	4.7	6.6	55	4.4	6.1	*	*	*				*	*	*	*	*	*
Localized	453	31.4	45.7	394	31.3	45.0	43	30.4	50.8				*	*	*	7	39.8	43.1
Regional	540	37.5	54.1	479	38.1	54.2	47	33.6	58.5				4	33.3	40.4	5	32.5	33.2
Distant	291	20.2	28.6	252	20.1	28.1	31	21.7	36.8				*	*	*	4	22.9	19.1
Unknown	90	6.2	9.7	77	6.1	9.3	*	*	*				*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	53	3.6	1.3	43	3.4	1.2	7	4.4	1.8				*	*	*	*	*	*
Localized	474	32.3	11.7	401	31.9	11.5	57	34.8	14.1				5	29.5	8.2	6	35.2	8.8
Regional	558	38.0	13.8	485	38.6	13.9	56	34.2	14.2				8	44.3	12.4	6	31.9	8.1
Distant	296	20.2	7.4	253	20.1	7.3	35	21.7	9.0				3	15.9	3.9	4	20.9	4.9
Unknown	87	5.9	1.9	75	5.9	1.9	8	4.9	2.0				*	*	*	1	6.6	1.6
<i>Age < 50</i>																		
<i>In Situ</i>	5	3.0	0.3	4	3.2	0.3	*	*	*				*	*	*	*	*	*
Localized	49	32.1	2.7	39	31.6	2.7	6	30.4	2.3				1	33.3	2.6	2	37.5	2.3
Regional	59	38.7	3.3	49	39.7	3.4	7	39.1	3.1				1	28.6	2.2	1	25.0	1.5
Distant	37	24.0	2.1	29	23.2	2.0	5	27.2	2.2				2	38.1	2.9	1	29.2	1.8
Unknown	3	2.2	0.2	3	2.3	0.2	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	48	3.7	4.1	39	3.4	3.8	*	*	*				*	*	*	*	*	*
Localized	425	32.3	35.5	362	31.9	34.5	51	35.4	44.8				4	28.4	22.9	5	34.3	26.0
Regional	499	37.9	41.4	436	38.5	41.3	49	33.6	43.3				7	49.3	39.1	5	34.3	25.4
Distant	259	19.7	21.4	224	19.8	21.2	30	21.0	26.6				1	9.0	6.6	2	17.9	12.9
Unknown	83	6.3	6.4	72	6.4	6.2	*	*	*				*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Missouri, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	1,036	16.9	27.0	861	16.3	26.5	132	20.2	33.4				21	24.2	30.5	13	18.4	17.6
Localized	3,392	55.2	86.4	2,990	56.6	88.9	301	45.9	75.2				43	49.7	65.5	37	50.7	50.5
Regional	1,307	21.3	35.6	1,088	20.6	34.9	170	26.0	44.4				18	21.0	26.3	20	26.8	22.7
Distant	317	5.2	8.0	263	5.0	7.7	46	7.0	12.0				3	3.9	5.3	2	3.3	3.2
Unknown	90	1.5	2.0	79	1.5	2.0	6	0.9	1.5				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	175	17.5	9.9	140	17.5	10.0	23	17.0	10.4	Insufficient data for the calculation of AI/AN PRCDA statistics			6	23.0	12.2	4	14.5	5.1
Localized	468	46.8	26.4	389	48.4	27.5	52	38.4	22.9				11	41.0	21.6	11	44.4	15.4
Regional	310	31.0	17.4	239	29.8	16.9	50	36.9	21.8				9	31.7	16.1	9	37.1	12.6
Distant	41	4.1	2.3	30	3.7	2.1	10	7.4	4.4				*	*	*	*	*	*
Unknown	6	0.6	0.3	5	0.6	0.3	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	861	16.7	71.8	721	16.1	69.7	109	21.0	93.7				15	24.8	78.6	10	20.3	50.3
Localized	2,923	56.9	243.5	2,601	58.1	249.7	249	47.8	212.2				32	53.7	180.5	26	53.9	142.6
Regional	996	19.4	83.4	849	19.0	82.0	121	23.2	103.6				9	16.0	53.2	10	21.6	49.3
Distant	276	5.4	22.9	234	5.2	22.3	36	7.0	31.7				*	*	*	*	*	*
Unknown	84	1.6	6.5	74	1.7	6.5	*	*	*				*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	6	0.2	0.2	6	0.2	0.2	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	670	23.4	19.0	601	23.7	19.1	60	22.0	21.8				3	19.1	7.6	3	18.2	6.5
Regional	633	22.1	17.5	561	22.1	17.4	61	22.3	21.6				3	18.0	7.3	4	23.9	6.4
Distant	1,292	45.2	35.7	1,134	44.7	35.4	130	47.8	44.1				11	59.6	25.8	9	52.3	16.2
Unknown	259	9.0	7.6	235	9.3	7.7	21	7.7	8.0				*	*	*	*	*	*
<i>Female</i>																		
<i>In Situ</i>	6	0.2	0.2	6	0.2	0.2	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	773	28.9	18.0	692	29.3	18.4	69	27.0	17.5				4	20.2	6.5	4	19.6	6.5
Regional	599	22.4	14.1	527	22.3	14.3	61	23.7	14.7				4	21.3	6.5	4	21.6	6.6
Distant	1,111	41.6	26.0	969	41.0	26.1	116	45.2	28.3				10	51.1	15.5	11	52.0	16.0
Unknown	181	6.8	4.1	168	7.1	4.2	10	3.8	2.6				1	6.4	2.9	1	6.9	2.2

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	2,653	72.7	68.7	2,251	73.0	66.1	340	71.4	102.7	Insufficient data for the calculation of AI/AN PRCDA statistics			16	76.9	34.9	24	67.4	37.7
Regional	543	14.9	13.6	463	15.0	13.2	66	13.9	19.1				3	16.3	8.7	6	16.6	9.0
Distant	295	8.1	8.5	238	7.7	7.7	50	10.6	17.4				1	5.8	3.5	3	8.8	6.9
Unknown	158	4.3	4.8	132	4.3	4.5	20	4.1	7.8				*	*	*	3	7.2	5.4
<i>Age < 65</i>																		
Localized	1,063	74.3	29.3	846	74.7	27.0	191	72.4	55.4	Insufficient data for the calculation of AI/AN PRCDA statistics			6	91.4	12.7	11	75.0	13.3
Regional	257	18.0	7.0	211	18.6	6.6	42	15.8	12.2				*	*	*	2	13.9	2.4
Distant	84	5.8	2.3	57	5.0	1.8	24	9.3	6.9				*	*	*	*	*	*
Unknown	26	1.8	0.7	18	1.6	0.6	7	2.6	1.9				*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	1,590	71.7	341.0	1,405	72.0	336.3	149	70.3	430.3				10	69.6	188.3	14	62.4	206.2
Regional	286	12.9	59.4	252	12.9	58.6	24	11.5	66.9				*	*	*	4	18.3	54.4
Distant	212	9.5	51.4	181	9.3	48.7	26	12.2	89.6				1	8.7	27.8	*	*	*
Unknown	131	5.9	32.7	114	5.8	31.4	13	6.0	48.1				*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Montana, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	19	50.0	3.6	17	50.0	3.6	*	*	*	1	54.5	4.8	*	*	*	*	*	*
Regional	13	33.2	2.4	11	31.9	2.1	*	*	*	*	*	*	*	*	*	*	*	*
Distant	4	11.1	0.7	4	12.0	0.7	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	2	5.8	0.3	2	6.0	0.3	*	*	*	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	4	1.5	0.6	4	1.5	0.6	*	*	*	*	*	*	*	*	*	*	*	*
Localized	90	31.6	13.8	85	32.8	14.0	*	*	*	3	19.1	14.8	*	*	*	1	25.0	12.8
Regional	110	38.3	16.7	100	38.2	16.1	*	*	*	5	38.2	31.6	*	*	*	2	50.0	25.1
Distant	60	21.1	9.2	54	20.7	8.8	*	*	*	3	23.5	14.4	*	*	*	1	25.0	12.7
Unknown	21	7.3	3.3	18	6.8	3.0	*	*	*	2	16.2	13.5	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	6	24.4	2.2	6	26.5	2.3	*	*	*	*	*	*	*	*	*	*	*	*
Regional	11	40.5	3.5	9	38.9	3.3	*	*	*	*	*	*	*	*	*	*	*	*
Distant	8	30.5	2.7	7	29.2	2.5	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	84	32.4	44.4	79	33.4	44.5	*	*	*	*	*	*	*	*	*	1	27.3	46.5
Regional	99	38.1	51.2	91	38.2	49.8	*	*	*	*	*	*	*	*	*	*	*	*
Distant	52	20.2	26.2	47	19.9	25.3	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	2	19.0	48.9	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	4	1.8	0.6	3	1.7	0.6	*	*	*	*	*	*	*	*	*	*	*	*
Localized	81	36.6	11.9	75	37.2	12.0	*	*	*	4	31.3	15.1	*	*	*	*	*	*
Regional	79	36.0	11.4	73	35.9	11.3	*	*	*	5	39.1	21.1	*	*	*	*	*	*
Distant	44	20.0	6.5	40	19.7	6.4	*	*	*	3	23.4	13.3	*	*	*	*	*	*
Unknown	12	5.6	1.7	11	5.6	1.6	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	9	38.8	3.1	8	36.8	3.1	*	*	*	*	*	*	*	*	*	*	*	*
Regional	7	30.2	2.5	7	31.1	2.7	*	*	*	*	*	*	*	*	*	*	*	*
Distant	6	25.0	2.0	6	26.4	2.2	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	72	36.3	35.0	67	37.2	35.3	*	*	*	*	*	*	*	*	*	*	*	*
Regional	72	36.6	34.8	66	36.4	33.8	*	*	*	*	*	*	*	*	*	*	*	*
Distant	38	19.4	18.4	34	18.9	17.6	*	*	*	3	26.3	48.1	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Montana, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	166	15.3	25.0	155	15.4	25.4	*	*	*	6	12.8	24.3	2	25.6	30.4	*	*	*
Localized	622	57.2	90.8	584	58.0	92.3	*	*	*	21	46.9	84.6	3	43.6	54.7	7	53.6	60.9
Regional	230	21.1	36.5	209	20.8	36.2	*	*	*	12	26.5	50.3	2	23.1	30.6	4	31.9	35.7
Distant	46	4.2	6.7	40	3.9	6.0	*	*	*	4	8.8	16.9	*	*	*	*	*	*
Unknown	23	2.2	3.1	18	1.8	2.5	*	*	*	2	4.9	9.9	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	26	16.2	9.3	23	16.5	9.6	*	*	*	*	*	*	*	*	*	*	*	*
Localized	74	46.7	26.5	68	48.1	27.6	*	*	*	3	33.3	19.5	*	*	*	1	40.0	11.8
Regional	52	32.9	18.5	46	32.4	18.6	*	*	*	3	37.8	22.8	*	*	*	1	40.0	11.4
Distant	6	3.5	2.0	3	2.4	1.4	*	*	*	1	15.6	8.6	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	140	15.1	66.0	132	15.3	66.8	*	*	*	*	*	*	*	*	*	*	*	*
Localized	548	59.0	259.3	516	59.7	261.4	*	*	*	18	50.3	255.2	*	*	*	6	57.4	189.6
Regional	177	19.1	83.6	163	18.9	82.4	*	*	*	9	23.8	122.5	*	*	*	3	29.6	99.2
Distant	40	4.3	18.9	36	4.2	18.1	*	*	*	3	7.2	38.8	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	4	1.1	0.5	4	1.1	0.5	*	*	*	*	*	*	*	*	*	*	*	*
Localized	83	23.3	11.9	79	23.8	11.9	*	*	*	1	9.9	10.1	*	*	*	*	*	*
Regional	79	22.2	11.3	73	22.0	11.1	*	*	*	5	33.8	22.9	*	*	*	*	*	*
Distant	162	45.6	22.9	150	45.5	22.5	*	*	*	7	46.5	33.5	*	*	*	*	*	*
Unknown	27	7.7	4.2	25	7.6	4.1	*	*	*	1	8.5	7.6	*	*	*	*	*	*
<i>Female</i>																		
<i>In Situ</i>	5	1.4	0.7	5	1.4	0.7	*	*	*	*	*	*	*	*	*	*	*	*
Localized	111	28.8	14.9	101	28.8	14.5	*	*	*	6	33.7	29.9	*	*	*	*	*	*
Regional	80	20.9	10.5	73	20.7	10.1	*	*	*	4	20.0	17.6	*	*	*	*	*	*
Distant	160	41.7	21.2	147	42.0	20.8	*	*	*	6	33.7	30.4	*	*	*	2	47.4	16.5
Unknown	28	7.2	3.5	25	7.2	3.3	*	*	*	2	11.6	12.4	*	*	*	*	*	*

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	744	75.1	96.8	693	75.5	95.3	3	71.4	133.4	20	70.3	96.5	*	*	*	6	68.3	64.8
Regional	128	12.9	16.3	120	13.1	16.3	*	*	*	4	14.5	20.1	*	*	*	2	19.5	11.3
Distant	82	8.3	11.8	77	8.3	11.6	*	*	*	3	11.0	17.1	*	*	*	*	*	*
Unknown	37	3.7	5.7	28	3.1	4.7	*	*	*	1	4.1	10.7	*	*	*	*	*	*
<i>Age < 65</i>																		
Localized	249	78.1	36.4	231	79.0	36.4	*	*	*	9	72.6	36.2	*	*	*	2	58.8	15.9
Regional	46	14.3	6.7	42	14.4	6.7	*	*	*	2	14.5	7.5	*	*	*	*	*	*
Distant	19	6.0	2.8	17	5.7	2.6	*	*	*	1	11.3	6.8	*	*	*	*	*	*
Unknown	5	1.7	0.8	3	1.0	0.5	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	495	73.6	514.5	462	73.8	502.2	*	*	*	11	68.7	512.9	*	*	*	4	75.0	403.3
Regional	82	12.2	82.8	78	12.5	82.7	*	*	*	2	14.5	106.9	*	*	*	*	*	*
Distant	63	9.4	74.2	60	9.6	73.6	*	*	*	2	10.8	88.2	*	*	*	*	*	*
Unknown	32	4.7	39.2	25	4.1	33.7	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Nebraska, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	36	50.0	4.1	30	50.5	4.2	2	57.9	5.3	*	*	*	*	*	*	3	46.7	4.4
Regional	21	29.5	2.2	17	28.5	2.0	1	31.6	3.4	*	*	*	*	*	*	2	26.7	3.0
Distant	10	14.3	1.1	8	14.2	1.1	*	*	*	*	*	*	*	*	*	1	20.0	2.3
Unknown	4	6.2	0.4	4	6.8	0.4	*	*	*	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	15	3.0	1.4	12	2.8	1.3	*	*	*	*	*	*	*	*	*	1	6.9	2.3
Localized	164	33.6	16.1	147	33.6	16.0	5	27.5	15.1	*	*	*	2	32.0	15.2	8	37.3	16.2
Regional	175	35.8	17.1	157	35.8	17.2	7	39.6	20.7	*	*	*	2	48.0	15.9	7	35.3	12.7
Distant	93	19.0	9.0	85	19.4	9.2	3	18.7	10.5	*	*	*	*	*	*	2	11.8	7.1
Unknown	42	8.5	4.0	37	8.4	3.9	2	9.9	5.4	*	*	*	*	*	*	2	8.8	3.6
<i>Age < 50</i>																		
<i>In Situ</i>	1	2.7	0.2	1	2.7	0.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	13	25.4	2.3	11	25.5	2.5	*	*	*	*	*	*	*	*	*	*	*	*
Regional	23	43.8	4.0	19	42.7	4.2	1	40.0	3.8	*	*	*	*	*	*	2	60.0	2.3
Distant	12	22.3	2.1	10	23.6	2.4	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	3	5.8	0.5	2	5.5	0.5	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	13	3.1	4.3	11	2.8	4.0	*	*	*	*	*	*	*	*	*	1	8.0	8.1
Localized	151	34.6	52.4	136	34.5	51.4	*	*	*	*	*	*	*	*	*	*	*	*
Regional	152	34.9	51.2	138	35.0	50.9	6	39.5	64.9	*	*	*	*	*	*	5	31.0	39.8
Distant	81	18.6	27.1	74	18.9	27.2	*	*	*	*	*	*	*	*	*	2	13.8	25.6
Unknown	39	8.8	13.0	34	8.7	12.7	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	11	2.4	1.0	9	2.1	0.9	*	*	*	*	*	*	*	*	*	*	*	*
Localized	152	33.0	13.0	138	33.1	13.2	4	30.1	11.4	*	*	*	1	27.3	5.9	6	33.7	10.0
Regional	172	37.3	14.7	156	37.5	14.7	5	35.6	15.2	1	42.9	21.4	2	40.9	11.7	6	36.0	12.9
Distant	84	18.3	7.4	77	18.6	7.6	3	17.8	6.4	*	*	*	*	*	*	3	18.0	8.0
Unknown	41	9.0	3.0	36	8.6	2.8	1	9.6	3.5	*	*	*	*	*	*	1	7.9	2.9
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	18	37.1	3.1	15	36.5	3.5	*	*	*	*	*	*	*	*	*	2	42.1	2.3
Regional	16	32.5	2.8	13	31.8	3.1	*	*	*	*	*	*	*	*	*	1	31.6	2.0
Distant	12	24.6	2.2	11	25.6	2.5	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	2	4.2	0.3	2	4.3	0.4	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	134	32.5	39.0	122	32.8	38.5	*	*	*	*	*	*	*	*	*	4	31.4	30.0
Regional	157	37.9	45.7	143	38.2	45.1	*	*	*	*	*	*	*	*	*	5	37.1	41.3
Distant	73	17.6	20.9	67	17.8	20.9	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	39	9.5	10.0	34	9.1	9.1	1	10.1	12.8	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Nebraska, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	311	17.4	28.9	279	17.2	29.4	12	20.9	32.2	*	*	*	6	28.2	29.1	9	14.1	15.6
Localized	974	54.6	85.8	898	55.5	88.6	27	45.3	68.0	3	43.2	56.7	8	39.8	39.6	31	48.8	58.9
Regional	379	21.2	35.7	333	20.6	35.7	16	26.4	42.3	3	35.1	51.5	6	27.2	25.1	20	30.6	37.0
Distant	72	4.0	6.4	64	4.0	6.3	3	5.4	8.5	*	*	*	*	*	*	3	5.3	5.9
Unknown	48	2.7	3.9	44	2.7	4.0	1	2.0	3.4	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	60	20.0	11.6	51	20.2	12.1	2	17.0	6.8	*	*	*	3	31.3	17.8	3	14.3	6.3
Localized	134	44.9	25.5	114	45.6	27.0	4	35.8	13.9	*	*	*	3	33.3	18.1	11	46.2	19.8
Regional	88	29.5	16.5	73	29.0	16.9	4	41.5	16.8	*	*	*	3	27.1	13.4	8	31.9	13.8
Distant	12	3.9	2.2	9	3.4	2.0	*	*	*	*	*	*	*	*	*	2	6.7	2.9
Unknown	5	1.7	0.9	4	1.8	1.0	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	251	16.9	74.4	228	16.7	74.6	11	21.8	98.8	*	*	*	3	25.5	58.8	6	13.9	39.9
Localized	840	56.5	243.7	784	57.3	249.8	23	47.3	209.8	*	*	*	5	45.5	96.1	20	50.2	161.3
Regional	291	19.6	86.0	261	19.1	85.0	11	23.0	109.2	*	*	*	3	27.3	55.7	12	29.9	97.8
Distant	61	4.1	17.4	56	4.1	17.4	*	*	*	*	*	*	*	*	*	2	4.5	13.7
Unknown	43	2.9	11.8	40	2.9	11.7	1	2.5	12.3	*	*	*	*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	1	0.2	0.1	1	0.2	0.1	*	*	*	*	*	*	*	*	*	*	*	*
Localized	165	25.3	15.7	155	25.6	15.9	5	21.6	16.2	*	*	*	1	23.3	13.7	3	24.6	10.7
Regional	151	23.2	14.1	141	23.2	14.4	6	25.0	17.5	*	*	*	1	23.3	15.4	2	14.8	4.5
Distant	282	43.4	26.3	259	42.8	26.4	12	50.0	37.3	1	58.3	30.6	3	50.0	26.3	7	54.1	16.1
Unknown	52	8.0	5.0	49	8.1	5.1	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>In Situ</i>	2	0.4	0.2	2	0.4	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	177	28.9	14.5	162	28.6	14.5	8	31.7	20.3	1	36.8	26.8	2	32.0	11.8	4	29.6	11.1
Regional	133	21.6	11.0	123	21.7	11.1	7	28.5	18.7	*	*	*	*	*	*	2	15.5	4.9
Distant	253	41.1	20.7	233	41.3	20.9	9	35.8	24.3	2	47.4	45.1	2	44.0	13.8	6	40.8	14.8
Unknown	49	8.0	3.8	45	7.9	3.7	*	*	*	*	*	*	*	*	*	2	14.1	5.2

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	1,010	69.8	88.7	907	70.5	87.2	43	65.3	122.9	1	50.0	36.1	4	68.8	38.2	26	67.7	61.9
Regional	223	15.4	18.7	201	15.6	18.5	12	18.2	32.2	1	42.9	27.6	1	21.9	10.7	7	18.8	13.3
Distant	91	6.3	8.9	80	6.2	8.5	7	10.9	23.3	*	*	*	*	*	*	2	5.7	7.7
Unknown	123	8.5	11.6	99	7.7	10.2	4	5.5	12.4	*	*	*	*	*	*	3	7.8	8.3
<i>Age < 65</i>																		
Localized	387	72.4	34.6	342	73.6	34.7	23	67.7	53.5	*	*	*	2	66.7	10.4	11	63.5	17.4
Regional	97	18.1	8.7	85	18.3	8.6	6	18.0	14.0	*	*	*	*	*	*	5	27.1	7.3
Distant	20	3.7	1.8	15	3.3	1.6	3	9.6	7.6	*	*	*	*	*	*	*	*	*
Unknown	31	5.8	2.8	22	4.8	2.2	2	4.8	3.9	*	*	*	*	*	*	1	7.1	2.0
<i>Age ≥ 65</i>																		
Localized	623	68.3	462.4	565	68.7	450.4	20	63.0	602.5	*	*	*	3	70.0	230.2	15	71.0	369.7
Regional	126	13.8	88.0	116	14.1	87.2	6	18.5	158.6	*	*	*	*	*	*	3	12.1	54.6
Distant	71	7.8	57.8	65	7.9	56.2	4	12.3	132.1	*	*	*	*	*	*	*	*	*
Unknown	92	10.0	72.6	77	9.3	65.1	2	6.2	71.3	*	*	*	*	*	*	2	8.4	51.7

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Nevada, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	53	41.0	3.7	28	39.9	3.8	4	34.5	3.1	1	70.0	8.9	4	30.2	2.2	14	48.3	3.6
Regional	39	30.0	2.5	22	31.2	2.7	3	22.4	1.9	*	*	*	4	33.3	2.2	9	32.2	2.6
Distant	19	14.5	1.1	11	14.9	1.1	2	19.0	1.5	*	*	*	2	15.9	1.0	3	11.9	1.0
Unknown	19	14.5	1.2	10	14.0	1.2	3	24.1	1.9	*	*	*	3	20.6	1.4	2	7.7	0.7

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	11	1.7	0.6	8	1.9	0.7	*	*	*	*	*	*	*	*	*	1	1.5	0.4
Localized	186	28.4	10.9	129	29.1	10.9	12	22.5	9.2	2	34.5	13.6	17	30.2	12.0	23	27.7	9.3
Regional	220	33.6	13.2	152	34.4	13.6	17	32.4	14.0	2	31.0	12.7	17	30.9	12.7	28	34.1	10.8
Distant	138	21.1	8.3	93	21.1	8.3	13	25.6	10.8	*	*	*	12	21.6	8.3	17	20.4	6.3
Unknown	100	15.2	6.3	60	13.6	5.4	10	18.3	9.1	*	*	*	9	16.5	7.4	13	16.3	5.8
<i>Age < 50</i>																		
<i>In Situ</i>	1	1.8	0.1	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	14	20.0	1.4	8	20.8	1.6	1	19.4	1.5	*	*	*	2	22.9	1.8	3	18.6	0.9
Regional	27	39.1	2.8	16	43.2	3.2	2	30.6	2.4	*	*	*	2	34.3	2.7	6	41.4	2.1
Distant	20	28.8	2.0	10	26.8	2.0	3	41.7	3.3	*	*	*	2	28.6	2.1	4	28.6	1.4
Unknown	7	10.3	0.7	2	6.6	0.5	*	*	*	*	*	*	*	*	*	1	10.0	0.5
<i>Age ≥ 50</i>																		
<i>In Situ</i>	10	1.7	1.9	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	173	29.4	35.7	121	29.8	35.5	10	23.0	29.3	2	40.0	49.3	15	31.3	38.8	20	29.6	31.3
Regional	193	32.9	40.6	137	33.6	40.8	15	32.7	44.4	2	36.0	46.0	15	30.5	39.0	22	32.6	33.8
Distant	119	20.2	24.6	83	20.5	24.9	10	23.0	30.5	*	*	*	10	20.6	24.3	13	18.8	19.2
Unknown	93	15.8	20.8	58	14.2	18.4	*	*	*	*	*	*	*	*	*	12	17.6	19.6
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	9	1.6	0.5	6	1.7	0.6	*	*	*	*	*	*	*	*	*	2	2.3	0.5
Localized	158	29.6	9.0	106	29.6	9.5	13	30.4	9.2	2	42.1	8.6	12	27.7	6.5	21	30.8	6.8
Regional	186	34.8	10.4	129	35.9	11.3	14	31.3	9.5	1	36.8	6.9	15	34.5	7.9	23	33.7	8.9
Distant	105	19.7	6.0	69	19.2	6.1	10	23.0	7.2	*	*	*	9	20.9	4.6	14	20.3	4.8
Unknown	76	14.3	4.4	49	13.7	4.2	6	14.3	4.7	*	*	*	7	15.9	3.8	9	12.8	3.2
<i>Age < 50</i>																		
<i>In Situ</i>	2	2.5	0.2	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	20	32.2	2.2	11	32.3	2.5	2	26.5	2.0	*	*	*	1	26.1	1.2	6	36.4	2.1
Regional	20	31.9	2.2	11	33.5	2.5	2	32.4	2.4	*	*	*	2	43.5	1.7	5	26.1	1.7
Distant	14	22.4	1.5	7	20.7	1.5	2	26.5	1.8	*	*	*	*	*	*	5	26.1	1.6
Unknown	7	11.0	0.7	3	10.4	0.7	*	*	*	*	*	*	*	*	*	2	9.1	0.6
<i>Age ≥ 50</i>																		
<i>In Situ</i>	7	1.5	1.4	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	138	29.3	26.7	96	29.3	27.8	11	31.1	28.0	*	*	*	11	27.9	20.3	15	28.9	19.2
Regional	165	35.2	32.1	118	36.1	34.2	11	31.1	27.9	1	38.9	25.1	13	33.5	24.1	19	36.3	27.8
Distant	91	19.3	17.7	62	19.0	18.2	8	22.4	21.4	*	*	*	*	*	*	9	18.4	13.3
Unknown	69	14.7	13.8	46	14.0	13.3	*	*	*	*	*	*	*	*	*	7	14.1	10.1

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Nevada, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	363	15.8	20.2	225	14.7	20.2	29	16.0	20.3	3	16.2	18.3	49	20.9	23.8	49	17.2	15.6
Localized	1,210	52.8	67.4	845	55.0	74.2	81	45.3	57.2	9	44.8	55.1	115	49.2	56.9	142	49.5	47.3
Regional	508	22.2	30.0	326	21.3	31.9	48	26.7	34.4	7	35.2	42.6	52	22.1	26.2	70	24.4	21.7
Distant	119	5.2	6.8	78	5.1	7.0	13	7.4	9.4	*	*	*	11	4.8	6.0	16	5.5	5.0
Unknown	90	3.9	5.2	61	4.0	5.4	8	4.6	6.2	*	*	*	7	3.0	3.8	10	3.4	3.8
<i>Age < 50</i>																		
<i>In Situ</i>	63	15.2	6.9	32	14.9	7.4	6	13.3	6.3	*	*	*	10	19.5	8.8	13	14.0	4.9
Localized	185	44.4	19.8	100	46.0	22.1	14	32.2	15.0	2	45.8	23.1	23	45.5	20.6	43	45.8	15.9
Regional	132	31.5	14.2	68	31.3	15.5	17	39.3	18.3	2	37.5	18.1	14	26.5	12.1	30	31.8	10.9
Distant	24	5.7	2.5	11	4.9	2.4	4	8.5	3.9	*	*	*	3	5.8	2.7	6	6.4	2.1
Unknown	14	3.3	1.5	6	2.9	1.5	3	6.6	3.1	*	*	*	1	2.7	1.2	2	2.1	0.7
<i>Age ≥ 50</i>																		
<i>In Situ</i>	300	16.0	55.1	193	14.6	53.9	23	16.8	56.9	*	*	*	39	21.4	63.3	36	18.8	43.6
Localized	1,025	54.7	192.0	745	56.5	210.6	67	49.3	167.6	7	44.4	138.9	92	50.3	152.1	98	51.4	129.4
Regional	377	20.1	71.3	258	19.6	74.9	31	22.8	76.5	6	34.6	106.5	38	20.8	63.3	40	20.7	50.0
Distant	95	5.1	18.1	67	5.1	19.2	10	7.0	23.6	*	*	*	8	4.5	14.4	10	5.0	12.6
Unknown	77	4.1	14.9	55	4.2	15.5	5	4.0	14.4	*	*	*	6	3.1	10.6	8	4.1	11.8

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	3	0.4	0.2	3	0.4	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	163	20.5	9.7	136	21.6	11.0	9	16.4	8.4	*	*	*	9	19.0	6.5	6	13.4	3.7
Regional	158	19.8	9.0	125	20.0	9.9	10	17.1	8.7	2	34.8	11.9	9	18.2	6.7	10	22.1	4.9
Distant	338	42.4	19.6	259	41.2	21.0	27	46.7	23.4	1	26.1	6.3	24	48.2	17.0	21	46.3	9.9
Unknown	135	17.0	8.5	106	16.8	9.2	11	19.5	9.7	*	*	*	7	14.6	5.2	8	18.2	4.7
<i>Female</i>																		
<i>In Situ</i>	5	0.6	0.3	4	0.6	0.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	202	23.4	10.9	163	24.2	12.8	10	17.2	7.6	*	*	*	14	24.8	6.7	12	20.4	5.5
Regional	161	18.7	8.4	127	18.9	9.9	12	20.9	8.7	2	30.8	10.0	8	14.5	3.7	12	19.7	4.5
Distant	334	38.8	18.0	254	37.7	20.3	24	40.2	16.9	2	38.5	12.0	26	45.4	12.6	25	43.2	10.1
Unknown	159	18.5	8.9	125	18.6	10.1	13	21.3	9.4	*	*	*	8	14.5	4.2	10	16.3	4.4

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	1,133	71.6	60.5	803	72.0	60.7	97	64.9	73.8	9	67.6	53.0	54	68.2	34.2	105	69.9	44.2
Regional	180	11.4	9.3	129	11.6	9.6	18	12.2	12.8	1	10.3	8.0	10	12.5	6.0	18	12.1	6.0
Distant	133	8.4	8.1	90	8.1	7.7	16	10.7	13.3	1	10.3	10.8	9	11.5	6.8	15	9.7	7.7
Unknown	136	8.6	8.5	93	8.4	8.1	18	12.2	17.8	2	11.8	10.9	6	7.9	5.3	12	8.3	6.2
<i>Age < 65</i>																		
Localized	382	70.6	22.1	251	71.9	22.7	45	64.5	32.7	4	77.8	24.1	14	62.6	9.6	47	67.8	15.4
Regional	90	16.6	5.4	58	16.6	5.3	13	18.5	9.8	*	*	*	4	18.3	2.9	12	17.5	4.0
Distant	37	6.8	2.2	22	6.2	2.0	6	9.0	4.6	*	*	*	3	12.2	2.0	6	8.3	1.9
Unknown	32	5.9	1.8	19	5.3	1.6	6	8.1	4.1	*	*	*	2	7.0	1.1	4	6.3	1.5
<i>Age ≥ 65</i>																		
Localized	751	72.2	325.8	552	72.1	323.2	52	65.3	358.5	5	61.0	252.4	39	70.5	203.9	58	71.7	243.3
Regional	90	8.7	36.5	71	9.3	39.4	5	6.8	33.8	*	*	*	6	10.1	27.3	6	7.4	20.2
Distant	96	9.2	49.1	68	8.9	47.0	10	12.3	72.7	*	*	*	6	11.2	39.8	9	10.9	47.8
Unknown	104	10.0	54.6	75	9.7	52.5	13	15.8	112.9	*	*	*	5	8.3	34.4	8	9.9	38.7

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
New Hampshire, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	20	49.7	2.9	18	49.4	2.8	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Regional	11	28.1	1.4	10	28.3	1.4	*	*	*				*	*	*	*	*	*
Distant	7	17.1	0.8	6	17.2	0.7	*	*	*				*	*	*	*	*	*
Unknown	2	5.0	0.2	2	5.0	0.2	*	*	*				*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	24	6.7	2.9	22	6.5	2.8	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	120	33.2	14.4	113	32.8	14.2	*	*	*				2	47.6	14.7	2	30.8	9.7
Regional	128	35.3	15.9	123	35.8	16.2	*	*	*				1	33.3	9.7	2	30.8	11.8
Distant	70	19.5	8.4	69	20.0	8.6	*	*	*				*	*	*	1	23.1	12.0
Unknown	19	5.4	2.6	17	4.9	2.4	*	*	*				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	2	3.8	0.4	1	3.6	0.4	*	*	*				*	*	*	*	*	*
Localized	14	34.1	3.6	13	33.8	3.8	*	*	*				*	*	*	*	*	*
Regional	16	37.9	4.1	15	39.0	4.4	*	*	*				*	*	*	*	*	*
Distant	8	18.5	1.9	7	19.0	2.1	*	*	*				*	*	*	*	*	*
Unknown	2	5.7	0.7	2	4.6	0.5	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	23	7.1	9.3	21	6.9	9.0	*	*	*				*	*	*	*	*	*
Localized	106	33.0	42.6	99	32.6	41.6	*	*	*				*	*	*	*	*	*
Regional	112	34.9	46.8	108	35.4	47.2	*	*	*				1	41.2	35.2	*	*	*
Distant	63	19.6	25.4	61	20.1	25.8	*	*	*				*	*	*	*	*	*
Unknown	17	5.3	7.7	15	5.0	7.3	*	*	*				*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	18	5.9	1.9	17	5.7	1.9	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	105	33.8	11.6	101	33.9	11.9	*	*	*				*	*	*	*	*	*
Regional	115	37.2	12.3	113	37.6	12.6	*	*	*				*	*	*	*	*	*
Distant	51	16.5	5.7	49	16.3	5.7	*	*	*				*	*	*	*	*	*
Unknown	21	6.6	2.0	19	6.5	1.9	*	*	*				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	2	5.2	0.5	2	5.0	0.5	*	*	*				*	*	*	*	*	*
Localized	15	37.8	3.6	14	38.9	3.8	*	*	*				*	*	*	*	*	*
Regional	13	32.6	3.1	12	33.9	3.3	*	*	*				*	*	*	*	*	*
Distant	8	21.8	2.1	7	20.0	2.0	*	*	*				*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	16	6.0	5.7	15	5.8	5.6	*	*	*				*	*	*	*	*	*
Localized	90	33.2	32.7	87	33.2	32.9	*	*	*				*	*	*	*	*	*
Regional	103	37.9	36.3	100	38.1	36.7	*	*	*				*	*	*	*	*	*
Distant	43	15.7	15.3	42	15.8	15.5	*	*	*				*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
New Hampshire, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	303	19.0	34.5	294	19.0	35.3	*	*	*				3	16.5	14.8	4	18.5	26.0
Localized	907	56.6	98.1	878	56.9	99.8	4	54.3	51.2				9	51.6	47.4	12	49.6	74.6
Regional	302	18.9	34.7	289	18.7	35.2	2	25.7	36.1				4	22.0	18.0	6	25.2	36.0
Distant	64	4.0	6.9	61	3.9	7.0	*	*	*				1	6.6	6.7	*	*	*
Unknown	24	1.5	2.6	22	1.5	2.4	*	*	*				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	60	22.4	14.9	56	22.5	15.5	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			1	17.9	8.9	2	23.5	11.0
Localized	130	48.6	32.1	121	48.5	33.1	1	60.0	19.8				4	46.2	22.8	4	52.9	23.4
Regional	66	24.5	16.4	61	24.5	17.0	*	*	*				2	28.2	13.2	1	20.6	9.0
Distant	9	3.4	2.3	8	3.4	2.3	*	*	*				*	*	*	*	*	*
Unknown	3	1.2	0.8	3	1.1	0.8	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	243	18.3	85.6	237	18.3	87.2	*	*	*				2	15.4	30.2	3	16.5	65.3
Localized	776	58.3	270.7	756	58.5	274.3	3	52.0	133.5				6	55.8	111.9	8	48.2	208.7
Regional	237	17.8	82.6	228	17.6	82.9	*	*	*				2	17.3	30.5	5	27.1	106.6
Distant	55	4.1	19.2	52	4.1	19.1	*	*	*				*	*	*	*	*	*
Unknown	21	1.6	7.2	20	1.5	6.8	*	*	*				*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	2	0.3	0.2	2	0.3	0.2	*	*	*				*	*	*	*	*	*
Localized	137	24.4	16.0	134	24.5	16.3	*	*	*				*	*	*	*	*	*
Regional	134	23.7	15.2	131	23.8	15.5	*	*	*				*	*	*	*	*	*
Distant	255	45.2	29.4	247	45.0	29.6	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			3	65.0	24.2	2	52.4	15.0
Unknown	36	6.4	4.6	35	6.3	4.6	*	*	*				*	*	*	*	*	*
<i>Female</i>																		
<i>In Situ</i>	2	0.4	0.2	2	0.4	0.2	*	*	*				*	*	*	*	*	*
Localized	180	29.6	18.3	176	29.7	18.6	*	*	*				2	33.3	12.6	1	25.0	7.4
Regional	144	23.7	14.4	141	23.8	14.7	*	*	*				*	*	*	*	*	*
Distant	254	41.7	25.5	247	41.7	25.8	*	*	*				2	50.0	14.6	3	54.2	21.0
Unknown	28	4.6	2.7	26	4.4	2.6	*	*	*				*	*	*	*	*	*

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	818	74.7	83.7	780	74.9	83.0	9	75.8	108.8				4	73.1	31.0	9	75.4	79.2
Regional	147	13.4	14.6	140	13.5	14.6	2	17.7	25.9				*	*	*	1	11.5	8.5
Distant	82	7.5	10.0	78	7.5	9.9	*	*	*				*	*	*	1	9.8	13.9
Unknown	48	4.4	5.8	43	4.1	5.4	*	*	*				*	*	*	*	*	*
<i>Age < 65</i>																		
Localized	328	77.3	34.3	311	77.6	34.1	6	76.9	59.2	Insufficient data for the calculation of AI/AN PRCDA statistics			1	77.8	9.4	4	76.0	22.9
Regional	67	15.8	7.0	63	15.7	6.9	*	*	*				*	*	*	*	*	*
Distant	16	3.7	1.7	15	3.8	1.7	*	*	*				*	*	*	*	*	*
Unknown	14	3.2	1.4	12	2.9	1.3	*	*	*				*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	489	73.1	425.1	469	73.3	420.7	3	73.9	451.4				2	70.6	180.7	5	75.0	468.9
Regional	80	11.9	67.4	77	12.1	67.7	*	*	*				*	*	*	*	*	*
Distant	66	9.8	67.7	63	9.8	66.6	*	*	*				*	*	*	*	*	*
Unknown	35	5.2	36.4	31	4.9	34.0	*	*	*				*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
New Jersey, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	148	38.5	3.2	77	38.7	3.1	24	35.3	3.6	Insufficient data for the calculation of AI/AN PRCDA statistics			9	33.3	1.8	38	42.1	4.4
Regional	141	36.8	2.7	69	34.5	2.2	27	40.1	3.9				11	44.2	2.3	34	37.6	4.1
Distant	66	17.2	1.2	39	19.8	1.1	11	16.8	1.6				4	14.7	0.8	12	13.1	1.5
Unknown	29	7.5	0.6	14	6.9	0.5	5	7.8	0.8				2	7.8	0.4	6	7.1	0.8

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	104	4.4	2.1	70	4.3	2.0	13	4.7	2.6				5	3.9	1.2	13	4.8	2.1
Localized	788	33.5	16.0	559	34.3	16.7	82	29.1	16.2				45	33.9	11.3	89	32.1	14.2
Regional	781	33.2	16.0	554	34.0	16.5	85	30.0	16.7				46	35.0	11.5	92	33.2	14.8
Distant	494	21.0	10.0	327	20.0	9.8	78	27.8	15.4				27	20.3	6.3	61	22.0	9.9
Unknown	185	7.9	3.9	121	7.4	3.6	24	8.4	5.0				9	6.8	2.3	22	7.9	4.1
<i>Age < 50</i>																		
<i>In Situ</i>	7	2.7	0.2	3	2.4	0.2	1	3.4	0.3				*	*	*	1	2.9	0.2
Localized	82	32.7	2.9	49	34.8	3.4	10	28.8	2.8				6	30.1	1.9	15	30.5	2.2
Regional	88	34.9	3.2	48	34.1	3.4	10	29.4	2.8				7	35.9	2.3	20	41.4	3.1
Distant	61	24.2	2.2	34	23.9	2.4	12	32.8	3.1				5	25.2	1.5	10	20.5	1.6
Unknown	14	5.4	0.5	7	4.8	0.5	2	5.6	0.5				1	6.8	0.4	2	4.6	0.3
<i>Age ≥ 50</i>																		
<i>In Situ</i>	98	4.6	6.8	66	4.4	6.6	12	4.9	8.8				*	*	*	12	5.2	7.1
Localized	706	33.6	50.4	509	34.2	51.4	72	29.2	51.2				39	34.6	36.1	74	32.4	45.6
Regional	694	33.0	49.5	506	34.0	51.0	74	30.1	53.1				39	34.8	35.7	72	31.4	45.3
Distant	434	20.6	30.4	293	19.7	29.1	67	27.1	47.4				22	19.4	18.9	51	22.3	31.9
Unknown	172	8.2	12.7	114	7.7	11.7	22	8.8	16.6	Insufficient data for the calculation of AI/AN PRCDA statistics			8	6.8	7.3	20	8.6	14.0
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	89	4.1	1.5	58	3.8	1.4	10	3.6	1.4				5	4.4	1.0	13	5.6	1.8
Localized	712	32.6	12.1	499	32.7	12.7	89	31.1	12.4				31	28.7	6.6	82	34.3	10.9
Regional	746	34.2	12.5	533	34.9	13.1	90	31.7	12.8				43	39.6	9.6	76	32.0	10.2
Distant	453	20.7	7.6	314	20.6	7.7	71	25.1	10.0				18	17.0	3.9	48	20.1	6.4
Unknown	185	8.5	2.8	121	7.9	2.5	24	8.5	3.4				11	10.2	2.7	19	7.9	2.6
<i>Age < 50</i>																		
<i>In Situ</i>	6	2.6	0.2	3	2.7	0.2	*	*	*				*	*	*	2	3.6	0.3
Localized	84	35.9	3.0	48	37.6	3.3	11	30.2	2.6				5	29.0	1.5	17	36.9	2.6
Regional	80	34.5	2.8	45	35.1	3.0	12	34.1	2.9				8	43.0	2.3	14	31.6	2.3
Distant	50	21.4	1.7	26	20.3	1.7	11	29.6	2.6				3	15.1	0.8	10	22.7	1.7
Unknown	13	5.7	0.5	6	4.4	0.4	2	5.6	0.5				2	9.7	0.5	2	5.3	0.4
<i>Age ≥ 50</i>																		
<i>In Situ</i>	83	4.3	4.7	55	3.9	4.5	*	*	*				*	*	*	12	6.1	5.9
Localized	628	32.2	36.1	451	32.3	37.1	78	31.3	38.0				26	28.6	20.0	65	33.7	32.4
Regional	666	34.1	37.9	488	34.9	39.6	78	31.4	38.5				35	38.9	28.7	62	32.1	31.0
Distant	403	20.7	22.8	288	20.6	23.3	61	24.4	29.5				16	17.4	12.1	38	19.5	18.8
Unknown	172	8.8	9.0	116	8.3	8.1	22	8.9	11.2				9	10.3	8.4	16	8.5	8.4

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
New Jersey, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	2,277	22.4	41.4	1,518	21.7	44.6	276	22.2	38.2				199	27.9	40.6	253	22.5	31.0
Localized	5,203	51.1	90.6	3,751	53.6	100.6	538	43.3	75.3				339	47.4	69.5	543	48.1	69.1
Regional	1,896	18.6	34.8	1,207	17.2	35.2	294	23.6	41.6				132	18.4	26.9	247	21.9	30.3
Distant	526	5.2	8.9	353	5.0	8.9	92	7.4	13.0				29	4.0	6.2	49	4.3	6.3
Unknown	281	2.8	4.7	174	2.5	4.1	43	3.5	6.1				16	2.2	3.4	35	3.1	4.7
<i>Age < 50</i>																		
<i>In Situ</i>	540	26.9	19.0	327	28.1	21.9	56	21.6	13.6	Insufficient data for the calculation of AI/AN PRCDA statistics			68	28.9	19.6	80	24.4	13.4
Localized	866	43.1	30.4	524	45.0	35.3	99	38.5	24.3				102	43.2	29.3	135	40.9	22.3
Regional	487	24.2	17.4	260	22.4	18.1	72	28.0	17.8				55	23.1	15.6	95	28.9	15.7
Distant	73	3.6	2.6	36	3.1	2.5	20	7.9	5.0				6	2.6	1.8	10	3.0	1.6
Unknown	43	2.1	1.5	16	1.4	1.1	10	4.0	2.5				5	2.1	1.4	9	2.8	1.5
<i>Age ≥ 50</i>																		
<i>In Situ</i>	1,737	21.3	100.2	1,191	20.4	103.9	221	22.4	102.8				131	27.4	95.7	173	21.7	77.1
Localized	4,337	53.1	248.1	3,228	55.3	271.6	439	44.5	208.7				237	49.5	174.9	408	51.1	191.6
Regional	1,409	17.2	80.3	947	16.2	79.9	222	22.5	104.0				77	16.1	56.5	152	19.0	68.6
Distant	453	5.5	25.5	317	5.4	25.7	72	7.3	34.0				23	4.7	18.0	39	4.9	18.4
Unknown	238	2.9	12.9	158	2.7	11.8	33	3.3	15.6				11	2.3	8.8	26	3.3	13.0

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	6	0.2	0.1	5	0.2	0.1	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	675	23.7	14.0	560	25.2	16.2	53	17.2	11.3				22	18.4	6.2	38	19.3	7.5
Regional	608	21.3	12.4	472	21.3	13.5	66	21.5	13.4				26	21.7	7.4	41	20.8	7.7
Distant	1,355	47.5	27.5	1,027	46.2	29.3	158	51.6	32.1				63	52.6	16.8	104	52.8	18.9
Unknown	209	7.3	4.5	157	7.1	4.6	29	9.5	6.6				9	7.1	2.7	13	6.7	3.1
<i>Female</i>																		
<i>In Situ</i>	9	0.3	0.2	8	0.3	0.2	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	922	29.3	14.9	771	30.6	17.9	76	23.3	10.5				21	23.0	4.8	50	25.6	7.2
Regional	630	20.0	10.2	512	20.3	12.0	63	19.3	8.6				11	12.3	2.5	42	21.6	5.9
Distant	1,359	43.2	21.8	1,054	41.8	24.4	165	50.2	22.4				52	57.5	11.8	85	43.8	11.8
Unknown	224	7.1	3.3	176	7.0	3.6	24	7.3	3.2				6	7.0	1.7	16	8.5	2.4

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	5,076	67.9	94.5	3,443	70.5	91.7	803	68.3	142.5	Insufficient data for the calculation of AI/AN PRCDA statistics			180	67.9	44.3	519	68.6	83.7
Regional	751	10.0	13.4	545	11.2	14.0	97	8.2	16.3				32	11.9	7.6	69	9.1	10.0
Distant	446	6.0	9.1	291	6.0	8.3	91	7.8	18.5				19	7.1	5.2	42	5.5	8.1
Unknown	1,202	16.1	23.1	606	12.4	16.6	185	15.8	36.8				35	13.1	9.6	128	16.9	22.9
<i>Age < 65</i>																		
Localized	2,118	69.4	39.4	1,330	72.1	37.3	424	71.4	70.4	Insufficient data for the calculation of AI/AN PRCDA statistics			61	70.9	13.7	243	70.9	31.8
Regional	388	12.7	7.2	271	14.7	7.6	61	10.3	10.2				12	14.2	2.7	39	11.5	5.2
Distant	117	3.8	2.1	63	3.4	1.8	36	6.1	5.9				4	4.4	0.8	12	3.6	1.6
Unknown	429	14.1	7.9	180	9.8	4.9	72	12.2	11.8				9	10.5	2.0	48	14.0	6.3
<i>Age ≥ 65</i>																		
Localized	2,957	66.9	475.3	2,113	69.5	467.9	379	65.1	640.6				119	66.5	255.7	277	66.7	442.2
Regional	363	8.2	56.0	274	9.0	58.3	35	6.1	58.8				19	10.8	41.3	29	7.0	43.3
Distant	329	7.4	57.4	228	7.5	53.6	55	9.4	105.4				15	8.4	35.8	29	7.1	52.8
Unknown	773	17.5	128.6	426	14.0	97.0	113	19.4	209.3				26	14.4	61.7	80	19.2	137.4

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
New Mexico, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	40	46.4	4.2	15	46.4	4.3	*	*	*	2	33.3	2.3	*	*	*	21	47.7	4.5
Regional	28	32.1	2.5	11	34.3	2.4	*	*	*	3	39.4	3.0	*	*	*	13	30.1	2.7
Distant	12	13.6	1.0	4	12.7	0.8	*	*	*	*	*	*	*	*	*	6	14.4	1.3
Unknown	7	7.9	0.7	2	6.6	0.5	*	*	*	*	*	*	*	*	*	3	7.9	0.8

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	12	2.6	1.0	6	2.6	0.9	*	*	*	*	*	*	*	*	*	5	2.4	1.0
Localized	153	33.3	12.7	75	33.6	11.7	2	28.1	7.9	11	34.6	16.0	2	42.1	11.4	62	32.7	13.9
Regional	149	32.5	12.5	71	31.9	11.4	2	34.4	7.9	10	32.1	13.6	*	*	*	64	33.7	14.3
Distant	102	22.3	8.6	51	22.6	8.4	1	21.9	6.4	7	21.2	8.9	*	*	*	42	22.3	9.2
Unknown	42	9.2	3.6	21	9.3	3.2	*	*	*	3	9.0	4.6	*	*	*	17	8.9	4.1
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	16	31.0	2.6	4	23.5	1.9	*	*	*	3	43.3	5.0	*	*	*	9	33.1	2.8
Regional	17	33.7	2.9	6	34.6	2.6	*	*	*	2	26.7	2.7	*	*	*	9	34.6	3.1
Distant	14	27.4	2.3	5	32.1	2.4	*	*	*	1	23.3	2.6	*	*	*	7	25.4	2.2
Unknown	3	6.7	0.6	1	8.6	0.6	*	*	*	*	*	*	*	*	*	2	6.2	0.6
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	137	33.6	39.3	71	34.4	37.3	*	*	*	8	32.5	44.7	*	*	*	53	32.6	43.0
Regional	132	32.4	37.8	66	31.7	34.5	*	*	*	8	33.3	42.1	*	*	*	55	33.5	43.8
Distant	89	21.7	25.1	45	21.9	24.0	*	*	*	5	20.6	25.4	*	*	*	36	21.8	27.3
Unknown	39	9.5	11.6	19	9.3	9.9	*	*	*	*	*	*	*	*	*	15	9.3	13.4
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	7	1.7	0.5	3	1.5	0.4	*	*	*	*	*	*	*	*	*	3	2.1	0.6
Localized	143	35.4	10.6	71	37.1	10.1	2	30.8	8.6	9	27.5	9.8	1	33.3	6.4	58	34.9	11.4
Regional	126	31.2	9.4	59	30.9	8.4	1	26.9	6.9	13	37.7	13.1	*	*	*	51	30.8	10.0
Distant	86	21.3	6.5	37	19.6	5.7	1	26.9	6.6	9	25.7	9.7	2	42.9	7.8	36	22.0	7.2
Unknown	42	10.3	3.0	21	10.9	2.8	*	*	*	3	7.8	2.9	*	*	*	17	10.3	3.4
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	13	29.9	2.2	5	32.0	2.4	*	*	*	*	*	*	*	*	*	7	29.7	2.2
Regional	15	34.4	2.6	5	32.0	2.3	*	*	*	2	45.8	3.6	*	*	*	8	34.7	2.7
Distant	13	29.0	2.2	4	26.7	2.0	*	*	*	2	33.3	2.8	*	*	*	7	31.4	2.5
Unknown	3	5.8	0.5	1	9.3	0.7	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	3	1.6	1.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	129	36.1	32.6	66	37.5	30.5	*	*	*	*	*	*	1	35.0	23.1	51	35.7	35.4
Regional	110	30.8	27.1	54	30.8	24.3	*	*	*	10	36.4	37.8	*	*	*	43	30.1	29.2
Distant	73	20.3	17.8	33	19.0	15.3	1	31.8	23.9	7	24.5	27.8	2	45.0	28.2	29	20.5	19.7
Unknown	39	10.9	9.6	19	11.1	8.4	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
New Mexico, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	235	13.4	17.9	129	13.3	20.1	3	11.1	13.3	8	10.4	8.2	4	16.9	17.9	88	14.1	17.1
Localized	974	55.8	72.3	565	58.4	81.0	12	48.4	61.0	40	51.8	41.2	13	53.2	56.8	330	52.8	64.9
Regional	389	22.3	31.1	198	20.5	31.5	7	28.6	37.2	20	25.6	21.4	5	21.0	22.3	154	24.6	31.3
Distant	86	4.9	6.7	43	4.5	7.0	2	7.1	9.0	5	6.7	5.7	2	6.5	6.6	34	5.4	6.5
Unknown	63	3.6	4.4	33	3.4	4.2	1	4.8	6.5	4	5.4	4.6	*	*	*	19	3.1	3.7
<i>Age < 50</i>																		
<i>In Situ</i>	36	14.3	6.2	15	16.0	7.4	*	*	*	2	11.2	3.5	1	23.3	9.4	16	12.6	5.4
Localized	119	46.8	20.4	47	48.8	22.6	2	30.8	15.1	9	48.3	15.6	3	46.7	18.7	57	46.0	19.3
Regional	79	31.0	13.5	25	26.5	12.4	2	34.6	16.4	5	28.1	9.1	1	23.3	9.3	44	35.6	14.9
Distant	16	6.2	2.7	7	7.7	3.6	*	*	*	2	9.0	2.7	*	*	*	6	4.7	1.9
Unknown	4	1.7	0.8	*	*	*	*	*	*	*	*	*	*	*	*	1	1.1	0.5
<i>Age ≥ 50</i>																		
<i>In Situ</i>	199	13.3	48.6	113	13.0	53.3	*	*	*	6	10.1	20.6	3	14.9	40.2	72	14.5	47.9
Localized	855	57.3	208.2	519	59.4	233.9	11	53.0	181.3	31	52.9	108.3	10	55.3	156.8	273	54.5	184.3
Regional	310	20.8	77.3	173	19.8	81.3	5	27.0	91.9	15	24.9	53.7	4	20.2	56.3	110	21.9	74.2
Distant	70	4.7	17.1	36	4.1	16.1	*	*	*	4	6.1	13.7	*	*	*	28	5.5	18.6
Unknown	58	3.9	13.9	*	*	*	*	*	*	*	*	*	*	*	*	18	3.6	12.2

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	91	18.2	7.5	68	20.4	9.6	2	21.8	12.0	*	*	*	*	*	*	19	13.8	4.8
Regional	94	18.9	7.5	66	19.8	9.3	2	18.2	9.9	2	23.4	3.8	*	*	*	23	16.5	5.5
Distant	215	43.0	17.0	138	41.2	19.2	5	41.8	21.7	5	48.9	8.0	2	52.9	13.5	66	47.1	15.1
Unknown	99	19.8	8.5	61	18.4	8.8	2	18.2	9.7	2	21.3	3.3	*	*	*	32	22.7	8.3
<i>Female</i>																		
<i>In Situ</i>	1	0.3	0.1	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	109	23.0	7.5	75	24.0	9.2	3	35.7	14.5	1	13.3	1.4	1	18.4	6.3	28	21.0	5.7
Regional	86	18.2	5.9	56	17.9	7.2	1	16.7	6.4	2	17.8	1.8	3	34.2	12.3	24	18.0	4.7
Distant	185	39.2	12.7	120	38.4	15.2	4	45.2	17.9	5	51.1	5.1	3	34.2	11.0	53	40.2	10.4
Unknown	91	19.4	6.3	61	19.4	7.6	*	*	*	2	17.8	2.0	*	*	*	27	20.7	5.5

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	825	73.7	61.4	490	74.6	65.2	25	71.7	91.1	23	64.8	33.9	9	67.7	57.0	237	71.7	50.8
Regional	126	11.3	9.0	76	11.5	9.8	3	9.8	11.7	3	9.7	4.4	2	16.9	14.6	39	11.7	7.7
Distant	105	9.4	8.4	55	8.3	7.7	5	15.0	18.5	7	19.9	11.6	*	*	*	36	10.9	8.4
Unknown	63	5.6	5.3	36	5.5	5.1	1	3.5	8.5	2	5.7	3.3	*	*	*	19	5.7	5.0
<i>Age < 65</i>																		
Localized	289	76.3	24.1	160	78.6	27.3	13	71.0	47.0	9	68.7	11.1	3	63.0	21.3	91	73.6	19.1
Regional	50	13.1	4.1	26	12.9	4.4	*	*	*	1	10.4	1.6	*	*	*	19	15.0	3.8
Distant	31	8.2	2.6	13	6.4	2.2	3	16.1	10.5	2	14.9	2.5	*	*	*	12	9.7	2.5
Unknown	9	2.4	0.7	4	2.1	0.7	*	*	*	*	*	*	*	*	*	2	1.8	0.4
<i>Age ≥ 65</i>																		
Localized	536	72.4	319.7	331	72.8	327.1	12	72.5	396.4	14	62.4	191.5	5	71.1	303.7	146	70.6	269.9
Regional	77	10.4	43.3	50	10.9	46.9	*	*	*	2	9.2	23.7	*	*	*	20	9.7	34.5
Distant	74	10.0	48.4	42	9.2	45.5	2	13.8	73.7	5	22.9	74.2	*	*	*	24	11.6	48.5
Unknown	54	7.3	37.1	32	7.0	35.8	1	7.5	66.9	*	*	*	*	*	*	17	8.1	36.8

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
New York, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	363	43.2	3.6	181	44.9	3.2	57	33.6	3.4	*	*	*	37	46.1	3.8	83	47.9	4.6
Regional	298	35.4	2.6	135	33.5	2.0	69	40.5	3.9	*	*	*	29	35.5	2.9	62	36.1	3.5
Distant	119	14.2	1.0	56	14.0	0.8	32	18.8	1.8	*	*	*	9	10.8	0.9	20	11.8	1.1
Unknown	60	7.2	0.5	30	7.6	0.5	12	7.1	0.7	*	*	*	6	7.6	0.6	7	4.3	0.4

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	354	7.1	3.2	227	6.9	3.1	44	6.8	3.2	*	*	*	25	7.1	2.9	53	8.6	3.7
Localized	1,591	32.0	14.8	1,090	33.0	15.2	180	27.6	13.8	2	42.1	10.9	113	32.3	13.1	192	31.0	14.0
Regional	1,706	34.4	16.1	1,146	34.7	16.2	213	32.5	16.6	*	*	*	127	36.1	14.8	213	34.3	15.6
Distant	972	19.6	9.1	627	19.0	8.9	162	24.7	12.5	1	31.6	9.9	54	15.5	6.5	125	20.1	9.2
Unknown	344	6.9	3.3	209	6.3	2.9	55	8.4	4.5	*	*	*	31	8.9	3.9	37	6.0	2.9
<i>Age < 50</i>																		
<i>In Situ</i>	26	4.6	0.4	14	4.3	0.4	3	4.1	0.4	*	*	*	2	4.3	0.3	6	5.8	0.5
Localized	163	29.0	2.7	99	30.2	3.0	18	23.8	2.2	*	*	*	13	28.1	2.3	30	29.2	2.4
Regional	211	37.5	3.6	124	37.8	3.8	28	36.3	3.3	*	*	*	19	39.6	3.3	40	38.4	3.2
Distant	131	23.3	2.2	76	23.2	2.3	23	29.3	2.6	*	*	*	9	19.1	1.6	23	22.1	1.8
Unknown	32	5.7	0.5	15	4.5	0.5	5	6.5	0.6	*	*	*	4	8.9	0.7	5	4.6	0.4
<i>Age ≥ 50</i>																		
<i>In Situ</i>	328	7.5	10.4	213	7.2	10.0	41	7.1	10.6	*	*	*	23	7.6	9.8	47	9.2	12.0
Localized	1,428	32.4	46.4	992	33.4	47.1	162	28.1	44.3	*	*	*	100	33.0	41.4	161	31.3	44.5
Regional	1,495	33.9	48.8	1,023	34.4	48.6	185	32.0	51.4	*	*	*	108	35.6	44.9	173	33.5	48.0
Distant	841	19.1	27.3	552	18.6	26.0	139	24.1	38.5	*	*	*	45	15.0	19.5	102	19.7	28.3
Unknown	312	7.1	10.5	194	6.5	9.4	50	8.7	14.7	*	*	*	27	8.9	12.2	32	6.3	9.3
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	281	6.1	2.2	176	5.8	2.2	42	6.1	2.2	*	*	*	16	5.5	1.6	44	7.9	2.4
Localized	1,512	32.6	11.7	987	32.3	11.9	227	32.8	12.2	2	34.4	12.2	96	33.6	9.7	188	33.4	10.5
Regional	1,579	34.0	12.1	1,075	35.1	12.6	202	29.2	10.8	3	43.8	17.4	103	36.2	10.8	187	33.3	10.7
Distant	909	19.6	7.0	586	19.2	6.9	165	23.8	8.9	1	18.8	7.3	48	16.7	4.9	106	18.9	6.1
Unknown	360	7.8	2.5	235	7.7	2.4	56	8.1	3.0	*	*	*	23	8.0	2.4	37	6.6	2.1
<i>Age < 50</i>																		
<i>In Situ</i>	29	5.6	0.5	17	5.9	0.5	4	4.5	0.4	*	*	*	3	5.3	0.4	6	6.0	0.5
Localized	179	34.1	2.9	103	35.9	3.2	27	31.9	2.7	*	*	*	15	31.7	2.3	31	32.0	2.4
Regional	173	33.0	2.8	93	32.5	2.9	26	31.2	2.7	*	*	*	18	37.4	2.8	33	33.7	2.7
Distant	111	21.2	1.8	57	19.9	1.8	21	24.8	2.1	*	*	*	11	22.2	1.6	22	22.8	1.8
Unknown	32	6.1	0.5	17	5.8	0.5	6	7.6	0.6	*	*	*	2	3.3	0.2	5	5.5	0.4
<i>Age ≥ 50</i>																		
<i>In Situ</i>	252	6.1	6.6	160	5.8	6.5	39	6.3	7.0	*	*	*	13	5.6	4.8	38	8.3	7.6
Localized	1,333	32.4	34.8	884	31.9	34.8	201	33.0	37.0	*	*	*	81	34.0	29.1	157	33.7	31.7
Regional	1,406	34.1	36.2	982	35.4	38.0	176	28.9	32.1	*	*	*	85	35.9	32.0	154	33.2	31.9
Distant	798	19.4	20.4	529	19.1	20.4	144	23.7	26.5	*	*	*	37	15.5	13.6	84	18.1	17.2
Unknown	328	8.0	7.7	218	7.9	7.3	49	8.1	9.0	*	*	*	21	8.9	8.0	32	6.8	6.5

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
New York, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	5,073	23.2	42.9	3,184	21.9	44.6	718	23.7	39.4	4	18.6	22.9	441	29.4	44.6	673	25.5	37.3
Localized	11,313	51.7	90.4	7,934	54.6	101.1	1,334	44.0	72.8	10	50.0	65.1	707	47.1	70.7	1,267	48.0	70.5
Regional	4,067	18.6	34.3	2,529	17.4	34.9	698	23.0	39.5	5	23.5	31.7	280	18.7	28.1	532	20.2	29.4
Distant	971	4.4	7.7	591	4.1	7.3	210	6.9	11.6	1	5.9	9.1	49	3.2	4.8	114	4.3	6.4
Unknown	467	2.1	3.4	284	2.0	3.0	71	2.3	3.8	*	*	*	25	1.7	2.7	53	2.0	3.0
<i>Age < 50</i>																		
<i>In Situ</i>	1,203	27.8	20.1	691	28.2	21.9	144	22.9	14.9	*	*	*	158	32.3	24.6	192	27.6	16.1
Localized	1,859	43.0	30.7	1,107	45.1	34.6	241	38.3	24.8	2	41.4	29.5	205	41.9	31.5	290	41.7	23.8
Regional	1,049	24.3	17.3	562	22.9	17.7	190	30.2	19.7	2	31.0	21.7	106	21.8	16.0	178	25.7	14.6
Distant	156	3.6	2.6	73	3.0	2.3	45	7.1	4.6	*	*	*	13	2.7	2.0	23	3.3	1.9
Unknown	56	1.3	0.9	19	0.8	0.6	9	1.4	0.9	*	*	*	7	1.4	1.0	12	1.7	1.0
<i>Age ≥ 50</i>																		
<i>In Situ</i>	3,871	22.0	102.5	2,493	20.7	104.1	574	23.9	103.3	*	*	*	283	27.9	97.0	482	24.8	93.0
Localized	9,454	53.8	246.8	6,827	56.6	275.2	1,093	45.5	198.6	8	53.4	158.5	502	49.6	173.4	977	50.3	192.9
Regional	3,019	17.2	78.8	1,966	16.3	79.8	508	21.1	91.4	3	20.5	57.9	174	17.2	59.7	354	18.2	68.4
Distant	815	4.6	21.0	518	4.3	20.3	165	6.9	30.1	*	*	*	36	3.5	12.2	91	4.7	18.2
Unknown	412	2.3	10.0	265	2.2	9.3	62	2.6	11.3	*	*	*	18	1.8	6.9	41	2.1	8.3

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	21	0.3	0.2	15	0.3	0.2	2	0.2	0.1	*	*	*	4	0.9	0.5	*	*	*
Localized	1,837	26.5	17.0	1,427	27.8	19.0	151	19.5	11.8	2	25.0	13.6	130	28.1	16.0	121	22.9	10.1
Regional	1,514	21.9	13.8	1,120	21.8	14.8	177	23.0	13.8	2	30.6	18.8	98	21.2	11.9	113	21.4	8.9
Distant	3,175	45.9	29.2	2,292	44.7	30.6	401	51.9	30.6	2	33.3	19.2	210	45.1	26.1	264	50.0	21.3
Unknown	375	5.4	3.6	277	5.4	3.8	41	5.3	3.6	*	*	*	22	4.8	3.3	31	5.8	2.7
<i>Female</i>																		
<i>In Situ</i>	33	0.4	0.2	25	0.4	0.3	2	0.3	0.1	*	*	*	2	0.7	0.3	2	0.5	0.1
Localized	2,403	32.6	17.7	1,889	33.2	21.1	223	28.6	11.6	2	24.0	14.3	121	34.6	12.3	161	30.7	9.2
Regional	1,536	20.8	11.2	1,203	21.2	13.5	170	21.8	8.8	2	22.0	11.3	57	16.4	5.9	101	19.3	5.7
Distant	3,000	40.7	21.9	2,259	39.7	25.0	348	44.5	18.1	5	50.0	27.3	151	43.0	15.6	233	44.5	13.3
Unknown	395	5.4	2.7	310	5.5	3.0	37	4.8	2.0	*	*	*	19	5.4	2.0	26	5.0	1.5

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	10,296	67.6	87.6	6,793	68.6	84.8	1,988	68.4	138.5	12	74.4	85.8	343	60.1	38.8	1,072	66.0	76.4
Regional	1,822	12.0	15.1	1,277	12.9	15.7	268	9.2	17.9	2	13.4	12.0	83	14.5	9.0	181	11.2	12.4
Distant	1,089	7.1	10.1	653	6.6	8.7	253	8.7	20.3	*	*	*	45	7.9	5.9	132	8.1	11.2
Unknown	2,034	13.3	17.9	1,173	11.9	14.9	397	13.6	29.5	1	7.3	7.4	100	17.5	12.0	238	14.7	18.5
<i>Age < 65</i>																		
Localized	4,297	70.0	37.6	2,606	71.4	35.1	1,018	70.7	68.0	4	70.0	26.1	122	61.7	12.7	503	68.4	32.0
Regional	861	14.0	7.6	559	15.3	7.6	161	11.2	10.9	*	*	*	34	17.1	3.6	101	13.8	6.4
Distant	271	4.4	2.4	132	3.6	1.8	88	6.1	5.9	*	*	*	10	5.2	1.1	39	5.2	2.5
Unknown	707	11.5	6.1	353	9.7	4.6	173	12.0	11.4	*	*	*	32	16.0	3.3	93	12.6	5.8
<i>Age ≥ 65</i>																		
Localized	5,999	65.9	433.3	4,186	67.0	428.9	970	66.2	626.0	8	76.9	498.4	222	59.3	218.9	569	64.1	383.5
Regional	960	10.5	67.5	719	11.5	71.6	107	7.3	66.9	*	*	*	49	13.0	46.7	80	9.0	53.6
Distant	819	9.0	63.9	521	8.3	56.5	165	11.3	120.4	*	*	*	35	9.4	38.9	93	10.5	71.6
Unknown	1,328	14.6	99.4	820	13.1	86.1	224	15.3	154.7	*	*	*	69	18.3	72.3	146	16.4	106.2

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
North Carolina, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	171	44.0	3.3	104	43.4	3.1	37	39.1	3.0	*	*	*	4	47.5	2.6	20	58.2	6.0
Regional	140	36.2	2.4	89	37.0	2.4	36	37.8	2.8	*	*	*	3	35.0	1.7	10	28.8	3.6
Distant	61	15.6	1.0	36	15.1	0.9	19	20.0	1.5	*	*	*	*	*	*	3	9.4	1.2
Unknown	16	4.2	0.3	11	4.5	0.3	3	3.2	0.2	*	*	*	*	*	*	1	3.5	0.6

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	96	4.0	1.6	70	4.0	1.6	21	4.3	2.0	*	*	*	*	*	*	2	3.8	1.0
Localized	748	31.1	13.3	552	31.4	13.1	150	30.8	14.9	3	44.8	28.9	8	29.8	7.6	18	27.6	8.3
Regional	896	37.3	16.1	676	38.4	16.3	166	34.1	17.0	1	24.1	16.7	12	43.3	10.6	26	40.8	12.0
Distant	527	21.9	9.4	376	21.4	9.1	123	25.1	12.2	1	20.7	18.5	5	17.7	4.7	15	23.8	6.8
Unknown	135	5.6	2.6	86	4.9	2.1	28	5.7	3.2	*	*	*	2	7.1	2.3	3	4.1	1.5
<i>Age < 50</i>																		
<i>In Situ</i>	6	2.1	0.2	4	2.2	0.2	1	2.1	0.2	*	*	*	*	*	*	*	*	*
Localized	79	26.3	2.5	54	27.1	2.7	14	21.7	2.1	*	*	*	2	22.9	1.3	6	29.5	1.6
Regional	124	41.4	4.0	82	41.2	4.1	29	44.0	4.5	*	*	*	3	48.6	2.8	8	41.1	2.3
Distant	80	26.8	2.5	54	27.0	2.7	19	29.1	3.0	*	*	*	2	25.7	1.5	5	26.3	1.5
Unknown	10	3.4	0.3	5	2.5	0.2	2	3.1	0.3	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	90	4.3	5.3	66	4.2	5.1	19	4.6	6.7	*	*	*	*	*	*	2	5.4	3.7
Localized	670	31.8	41.6	498	31.9	40.4	136	32.3	48.4	*	*	*	7	32.1	24.1	12	26.8	26.1
Regional	772	36.7	48.0	594	38.0	48.1	137	32.5	49.8	1	25.9	60.3	9	41.5	31.1	18	40.6	37.4
Distant	447	21.2	27.3	323	20.7	26.0	104	24.5	36.4	*	*	*	3	15.1	13.2	10	22.8	20.9
Unknown	125	5.9	8.5	81	5.2	7.1	26	6.1	10.9	*	*	*	2	9.4	8.3	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	76	3.5	1.1	53	3.4	1.1	19	4.0	1.3	*	*	*	*	*	*	1	1.9	0.3
Localized	714	32.7	10.8	500	32.1	10.3	162	34.2	12.1	1	25.9	16.0	11	38.3	8.9	20	31.2	8.2
Regional	797	36.5	12.1	590	37.8	12.2	157	33.2	11.8	2	44.4	26.6	11	38.3	7.8	26	40.8	12.6
Distant	461	21.1	7.0	324	20.8	6.8	110	23.2	8.3	*	*	*	5	18.1	4.1	14	22.1	6.5
Unknown	137	6.3	2.0	93	5.9	1.7	25	5.3	1.9	*	*	*	1	4.7	1.6	3	4.0	1.6
<i>Age < 50</i>																		
<i>In Situ</i>	6	2.3	0.2	5	2.5	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	89	31.9	2.7	57	30.7	2.8	20	33.2	2.6	*	*	*	3	43.3	2.1	7	38.0	2.2
Regional	103	36.6	3.1	69	37.1	3.4	22	36.2	2.9	*	*	*	3	46.7	2.2	7	35.9	2.2
Distant	70	24.9	2.1	49	26.3	2.4	16	26.4	2.2	*	*	*	*	*	*	4	19.6	1.2
Unknown	12	4.4	0.4	6	3.4	0.3	2	2.6	0.2	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	69	3.6	3.5	48	3.5	3.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	624	32.8	32.0	443	32.3	30.2	141	34.4	36.9	1	28.0	57.8	9	37.0	26.5	13	28.4	23.9
Regional	695	36.5	35.5	521	37.9	35.4	135	32.8	34.9	*	*	*	9	36.1	22.5	20	42.8	40.0
Distant	391	20.5	19.8	275	20.0	18.4	93	22.7	24.3	*	*	*	*	*	*	11	23.1	20.3
Unknown	125	6.6	6.2	86	6.3	5.5	24	5.7	6.5	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
North Carolina, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	1,932	17.7	29.9	1,369	17.1	29.8	433	19.2	31.8	2	19.6	25.9	40	23.8	26.4	56	17.9	20.3
Localized	6,049	55.4	91.2	4,640	58.0	96.4	1,095	48.5	81.5	6	50.0	64.7	84	49.8	56.2	147	47.2	58.5
Regional	2,268	20.8	36.4	1,545	19.3	34.9	556	24.6	42.1	2	21.4	26.9	38	22.4	24.4	88	28.4	30.9
Distant	517	4.7	8.0	349	4.4	7.4	138	6.1	10.3	*	*	*	5	3.0	3.3	16	5.2	6.2
Unknown	154	1.4	2.2	103	1.3	2.0	34	1.5	2.6	*	*	*	2	1.1	1.5	4	1.2	2.0
<i>Age < 50</i>																		
<i>In Situ</i>	362	18.9	11.2	237	19.2	11.6	78	17.5	10.4	*	*	*	14	21.5	11.0	24	18.1	8.2
Localized	885	46.1	27.1	596	48.3	29.1	185	41.5	24.5	1	42.9	24.5	31	49.1	24.6	55	42.1	18.8
Regional	563	29.3	17.4	340	27.5	16.8	148	33.1	19.6	*	*	*	17	26.6	12.9	45	34.2	14.9
Distant	92	4.8	2.8	53	4.3	2.6	29	6.6	3.9	*	*	*	1	2.2	1.1	6	4.7	2.0
Unknown	19	1.0	0.6	9	0.7	0.5	6	1.3	0.8	*	*	*	*	*	*	1	0.9	0.4
<i>Age ≥ 50</i>																		
<i>In Situ</i>	1,570	17.4	78.8	1,132	16.7	77.4	355	19.6	87.7	*	*	*	26	25.1	66.6	32	17.8	52.0
Localized	5,164	57.4	259.2	4,044	59.7	272.7	910	50.3	230.7	4	52.4	170.0	53	50.2	139.1	92	50.9	162.3
Regional	1,706	19.0	86.1	1,205	17.8	82.3	408	22.5	101.0	*	*	*	21	20.0	54.4	44	24.3	72.6
Distant	426	4.7	21.4	296	4.4	20.1	108	6.0	27.1	*	*	*	4	3.4	9.2	10	5.5	17.3
Unknown	135	1.5	6.6	93	1.4	5.9	28	1.6	7.5	*	*	*	*	*	*	3	1.4	6.3

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	10	0.2	0.2	9	0.2	0.2	1	0.1	0.2	*	*	*	*	*	*	*	*	*
Localized	1,054	23.7	18.7	861	24.9	19.4	162	19.5	17.2	2	25.8	18.7	5	18.1	5.6	11	21.3	8.1
Regional	983	22.1	17.0	761	22.0	16.9	188	22.6	19.3	1	19.4	18.4	5	17.4	4.8	11	22.0	8.0
Distant	2,144	48.2	37.2	1,635	47.3	36.8	430	51.6	43.8	3	41.9	47.1	18	62.5	17.7	27	52.8	16.8
Unknown	254	5.7	4.8	194	5.6	4.7	52	6.2	6.0	*	*	*	*	*	*	2	3.9	1.9
<i>Female</i>																		
<i>In Situ</i>	12	0.3	0.2	10	0.3	0.2	2	0.3	0.1	*	*	*	*	*	*	*	*	*
Localized	1,090	27.8	15.4	907	28.8	17.0	150	23.9	11.0	2	27.3	20.0	8	19.3	6.7	14	26.3	8.3
Regional	909	23.2	12.9	723	22.9	13.7	155	24.7	11.2	1	18.2	13.2	8	20.3	6.1	10	19.0	5.4
Distant	1,713	43.7	24.3	1,349	42.8	25.6	291	46.4	21.2	3	45.5	32.8	22	56.9	18.5	27	50.0	15.1
Unknown	199	5.1	2.8	162	5.1	3.0	29	4.7	2.3	*	*	*	*	*	*	3	4.7	1.6

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	5,756	76.0	92.1	3,909	77.2	81.7	1,547	76.6	138.5	4	73.3	53.2	39	75.1	41.3	109	72.8	61.0
Regional	874	11.5	13.5	620	12.2	12.6	217	10.7	18.4	*	*	*	7	12.6	6.1	19	12.9	10.0
Distant	555	7.3	10.2	359	7.1	8.5	171	8.5	18.8	*	*	*	5	10.3	7.2	12	8.3	8.8
Unknown	384	5.1	7.1	177	3.5	4.4	84	4.2	10.3	*	*	*	*	*	*	9	6.0	5.7
<i>Age < 65</i>																		
Localized	2,369	77.8	40.6	1,426	78.7	33.6	811	78.8	71.4	2	68.8	27.8	13	81.0	10.9	55	74.1	20.2
Regional	423	13.9	7.3	274	15.1	6.5	130	12.6	11.4	*	*	*	2	13.9	1.9	11	14.9	4.1
Distant	149	4.9	2.6	77	4.2	1.8	65	6.3	5.7	*	*	*	*	*	*	4	5.4	1.4
Unknown	105	3.4	1.8	35	1.9	0.8	24	2.3	2.0	*	*	*	*	*	*	4	5.7	1.6
<i>Age ≥ 65</i>																		
Localized	3,387	74.9	447.8	2,483	76.3	414.3	736	74.3	601.8	2	78.6	229.2	26	72.5	251.6	54	71.5	343.4
Regional	452	10.0	56.8	346	10.6	55.3	87	8.8	66.6	*	*	*	4	12.1	35.1	8	10.9	50.9
Distant	406	9.0	63.1	283	8.7	55.0	106	10.7	109.4	*	*	*	*	*	*	8	11.2	59.9
Unknown	280	6.2	43.6	143	4.4	29.0	61	6.1	67.6	*	*	*	*	*	*	5	6.4	34.5

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
North Dakota, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	9	43.0	2.8	8	47.0	2.8	*	*	*	*	*	*	*	*	*	*	*	*
Regional	7	32.7	1.8	5	28.9	1.4	*	*	*	*	*	*	*	*	*	*	*	*
Distant	4	20.6	1.0	3	20.5	0.9	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	2	1.2	0.5	2	1.2	0.5	*	*	*	*	*	*	*	*	*	*	*	*
Localized	66	34.8	15.8	60	34.8	15.4	*	*	*	3	37.2	29.4	*	*	*	*	*	*
Regional	76	40.3	18.7	69	40.1	18.0	*	*	*	3	37.2	34.1	*	*	*	*	*	*
Distant	36	18.8	9.0	32	18.8	8.7	*	*	*	2	23.3	22.4	*	*	*	*	*	*
Unknown	9	5.0	2.4	9	5.2	2.4	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	5	25.3	2.3	5	27.7	2.5	*	*	*	*	*	*	*	*	*	*	*	*
Regional	8	41.4	3.7	6	37.3	3.4	*	*	*	*	*	*	*	*	*	*	*	*
Distant	6	28.3	2.6	5	28.9	2.6	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	61	35.9	51.2	55	35.5	49.3	*	*	*	*	*	*	*	*	*	*	*	*
Regional	68	40.1	58.0	63	40.4	56.3	*	*	*	*	*	*	*	*	*	*	*	*
Distant	30	17.7	25.7	28	17.7	24.8	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	2	1.5	0.5	2	1.5	0.5	*	*	*	*	*	*	*	*	*	*	*	*
Localized	56	35.9	12.9	51	35.6	12.4	*	*	*	2	35.7	20.1	*	*	*	*	*	*
Regional	63	40.1	14.2	58	40.4	13.8	*	*	*	2	35.7	16.9	1	100.0	36.4	*	*	*
Distant	29	18.6	6.7	26	18.3	6.3	*	*	*	1	25.0	12.0	*	*	*	*	*	*
Unknown	6	3.9	1.3	6	4.2	1.3	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	6	37.2	3.2	5	37.1	3.0	*	*	*	*	*	*	*	*	*	*	*	*
Regional	7	39.5	3.5	6	41.4	3.5	*	*	*	*	*	*	*	*	*	*	*	*
Distant	3	19.8	1.7	2	17.1	1.4	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	50	35.7	38.2	46	35.4	37.0	*	*	*	*	*	*	*	*	*	*	*	*
Regional	56	40.1	42.0	52	40.3	40.8	*	*	*	*	*	*	*	*	*	*	*	*
Distant	26	18.4	19.8	24	18.4	19.0	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
North Dakota, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	99	14.8	25.2	92	14.8	25.5	1	31.8	21.9	1	7.7	10.1	*	*	*	1	30.0	16.1
Localized	381	57.3	89.7	359	57.6	90.2	1	31.8	68.8	11	58.2	92.1	3	59.3	74.6	2	50.0	34.7
Regional	145	21.8	36.7	134	21.5	36.9	1	27.3	32.3	5	29.7	43.1	1	25.9	23.2	*	*	*
Distant	30	4.5	6.8	29	4.6	7.0	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	10	1.5	2.2	9	1.4	2.2	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	21	19.6	11.5	19	20.0	11.9	*	*	*	*	*	*	*	*	*	*	*	*
Localized	46	42.4	24.4	39	41.8	24.0	*	*	*	2	47.6	26.0	2	53.3	36.1	*	*	*
Regional	34	31.4	17.5	29	31.3	17.7	*	*	*	2	42.9	22.1	*	*	*	*	*	*
Distant	5	4.4	2.4	4	4.7	2.6	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	2	2.2	1.2	2	2.1	1.2	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	77	13.9	61.1	73	13.8	61.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	335	60.2	260.8	320	60.4	263.6	*	*	*	9	61.4	265.0	2	66.7	175.2	*	*	*
Regional	111	20.0	87.0	105	19.8	87.2	*	*	*	4	25.7	98.2	*	*	*	*	*	*
Distant	25	4.5	18.3	24	4.6	18.6	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	7	1.3	4.8	7	1.3	4.8	*	*	*	*	*	*	*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	62	24.3	15.0	60	24.8	15.0	*	*	*	2	17.4	24.1	*	*	*	*	*	*
Regional	66	25.9	16.0	63	26.3	15.9	*	*	*	2	17.4	20.6	*	*	*	*	*	*
Distant	113	44.2	27.1	105	43.6	26.3	*	*	*	5	50.0	59.5	*	*	*	1	87.5	18.4
Unknown	14	5.3	3.5	12	5.0	3.3	*	*	*	1	15.2	17.1	*	*	*	*	*	*
<i>Female</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	75	30.6	16.5	68	30.6	15.7	*	*	*	4	29.3	46.8	*	*	*	*	*	*
Regional	54	22.1	11.9	50	22.5	11.7	*	*	*	3	20.0	26.2	*	*	*	*	*	*
Distant	104	42.7	23.2	94	42.3	22.1	*	*	*	7	45.3	60.2	*	*	*	*	*	*
Unknown	10	4.2	2.1	9	4.2	2.0	*	*	*	*	*	*	*	*	*	*	*	*

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	420	76.5	92.8	390	76.4	91.0	5	71.9	67.9	6	67.4	68.1	*	*	*	2	90.0	44.7
Regional	80	14.5	17.0	74	14.6	16.8	*	*	*	1	15.2	15.1	*	*	*	*	*	*
Distant	43	7.9	10.3	40	7.8	10.0	*	*	*	2	17.4	19.7	*	*	*	*	*	*
Unknown	6	1.2	1.5	6	1.2	1.4	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 65</i>																		
Localized	166	76.1	37.1	150	76.0	36.2	*	*	*	2	61.1	18.9	*	*	*	*	*	*
Regional	39	18.0	8.8	36	18.2	8.7	*	*	*	*	*	*	*	*	*	*	*	*
Distant	12	5.3	2.6	10	5.1	2.4	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	1	0.6	0.3	1	0.7	0.3	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	253	76.7	477.6	240	76.7	469.9	*	*	*	4	71.4	408.4	*	*	*	*	*	*
Regional	40	12.2	73.3	38	12.3	72.9	*	*	*	*	*	*	*	*	*	*	*	*
Distant	32	9.6	63.3	30	9.6	62.5	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	5	1.5	9.8	5	1.5	9.3	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Ohio, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	222	45.9	3.9	188	47.1	4.1	25	41.1	3.2	Insufficient data for the calculation of AI/AN PRCDA statistics			2	37.5	1.2	6	46.8	3.3
Regional	171	35.2	2.7	139	34.8	2.7	24	38.8	3.1				2	45.8	1.7	5	41.9	3.5
Distant	73	15.0	1.1	61	15.3	1.1	10	16.8	1.2				*	*	*	*	*	*
Unknown	19	3.9	0.3	11	2.8	0.2	2	3.3	0.2				*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	127	4.0	1.8	103	3.8	1.7	18	5.8	2.7	Insufficient data for the calculation of AI/AN PRCDA statistics			2	5.6	1.5	1	3.1	0.7
Localized	937	29.4	14.1	822	30.2	14.3	91	29.0	13.6				7	23.1	6.1	11	28.5	9.3
Regional	1,212	38.1	18.4	1,069	39.2	18.8	107	34.1	16.4				13	46.2	13.4	17	44.6	13.5
Distant	627	19.7	9.4	543	19.9	9.4	71	22.8	11.1				5	18.2	4.6	5	11.9	4.2
Unknown	282	8.8	4.3	186	6.8	3.3	26	8.4	4.5				2	7.0	2.2	5	11.9	3.3
<i>Age < 50</i>																		
<i>In Situ</i>	8	2.4	0.2	6	2.2	0.2	*	*	*				*	*	*	*	*	*
Localized	87	26.3	2.5	73	27.2	2.6	11	27.1	2.4				*	*	*	2	24.4	1.4
Regional	135	40.9	3.9	114	42.7	4.1	14	35.2	3.4				2	37.9	2.1	4	46.3	2.6
Distant	81	24.4	2.4	66	24.6	2.4	12	30.7	2.9				2	31.0	1.6	*	*	*
Unknown	20	6.0	0.6	9	3.3	0.3	2	4.5	0.4				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	119	4.2	6.1	97	4.0	5.7	*	*	*				*	*	*	*	*	*
Localized	850	29.8	44.6	750	30.5	45.1	80	29.2	43.0				*	*	*	9	29.6	29.8
Regional	1,077	37.7	56.3	955	38.9	57.1	93	33.9	50.6				11	48.2	42.9	13	44.1	41.9
Distant	546	19.1	28.0	478	19.4	27.9	59	21.6	32.4				3	14.9	12.4	*	*	*
Unknown	262	9.2	14.1	178	7.2	11.1	24	8.9	15.2				*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	107	3.7	1.4	88	3.5	1.3	14	4.6	1.6	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	2	5.2	1.2
Localized	929	31.8	11.9	804	32.1	12.0	98	32.4	11.6				10	40.3	8.0	11	36.8	8.4
Regional	1,082	37.1	13.8	959	38.3	14.2	99	32.7	12.0				9	34.7	6.8	10	33.5	7.5
Distant	539	18.5	7.0	460	18.4	7.0	70	23.2	8.4				3	13.7	2.8	5	15.5	3.7
Unknown	260	8.9	3.1	192	7.7	2.6	22	7.1	2.6				2	7.3	1.4	3	9.0	2.4
<i>Age < 50</i>																		
<i>In Situ</i>	13	4.1	0.4	10	4.2	0.4	2	4.6	0.4				*	*	*	*	*	*
Localized	92	29.7	2.6	77	30.9	2.8	11	27.2	2.2				1	27.3	1.1	2	27.3	1.2
Regional	117	37.9	3.4	96	38.5	3.5	14	35.9	3.0				2	54.5	2.0	3	51.5	2.7
Distant	72	23.4	2.1	58	23.2	2.1	12	30.3	2.5				*	*	*	1	18.2	0.9
Unknown	15	5.0	0.4	8	3.3	0.3	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	94	3.6	4.0	78	3.5	3.9	12	4.6	4.8				*	*	*	2	6.6	4.4
Localized	837	32.1	36.1	727	32.3	36.1	87	33.2	36.1				9	43.1	26.1	10	39.3	27.3
Regional	965	37.0	41.1	863	38.3	42.2	85	32.2	35.4				6	30.4	19.4	7	28.7	20.1
Distant	467	17.9	19.9	402	17.8	19.8	58	22.1	23.8				*	*	*	4	14.8	11.0
Unknown	245	9.4	10.1	184	8.2	8.5	*	*	*				2	8.8	5.2	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Ohio, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	2,079	17.4	28.1	1,754	17.0	28.2	261	19.9	31.0				34	22.6	24.9	20	16.2	13.5
Localized	6,523	54.6	85.0	5,737	55.7	87.7	617	47.1	73.8				75	49.8	56.1	62	51.1	44.8
Regional	2,545	21.3	35.5	2,129	20.7	35.1	334	25.5	41.4				36	23.8	25.5	31	25.7	21.0
Distant	613	5.1	8.0	517	5.0	7.9	82	6.2	10.0				4	2.5	2.9	5	4.4	3.7
Unknown	190	1.6	2.3	166	1.6	2.3	17	1.3	2.0				2	1.3	1.5	3	2.6	2.4
<i>Age < 50</i>																		
<i>In Situ</i>	362	19.2	10.6	304	19.7	11.1	39	16.4	8.7	Insufficient data for the calculation of AI/AN PRCDA statistics			12	21.6	11.2	4	11.4	3.3
Localized	858	45.4	24.9	716	46.3	26.0	95	39.9	20.8				24	44.8	22.5	17	47.3	14.2
Regional	562	29.7	16.4	442	28.6	16.2	84	35.4	18.4				16	30.2	14.7	13	34.2	9.8
Distant	90	4.7	2.6	68	4.4	2.5	18	7.5	3.8				1	2.2	1.0	2	4.3	1.3
Unknown	18	1.0	0.5	15	0.9	0.5	2	0.8	0.5				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	1,716	17.1	73.8	1,450	16.6	72.8	222	20.7	89.5				22	23.1	60.9	16	18.3	40.1
Localized	5,665	56.3	242.4	5,021	57.3	249.2	523	48.7	212.6				51	52.6	144.0	45	52.7	125.1
Regional	1,983	19.7	85.4	1,687	19.3	84.5	250	23.3	101.8				19	20.2	54.0	19	22.0	50.2
Distant	523	5.2	22.2	450	5.1	22.0	64	5.9	26.4				3	2.7	7.8	4	4.4	10.0
Unknown	171	1.7	6.8	152	1.7	6.9	15	1.4	6.0				*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	10	0.2	0.2	10	0.2	0.2	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	1,188	22.4	17.5	1,060	22.6	17.8	112	20.9	18.2				5	19.7	5.2	8	22.4	7.9
Regional	1,278	24.1	18.3	1,138	24.3	18.6	123	23.0	19.0				5	18.9	5.1	6	18.8	6.1
Distant	2,372	44.7	34.3	2,085	44.4	34.5	251	47.0	39.1				13	52.8	15.6	17	50.0	16.7
Unknown	452	8.5	6.9	398	8.5	6.8	47	8.9	8.1				2	7.9	3.2	3	8.8	2.8
<i>Female</i>																		
<i>In Situ</i>	14	0.3	0.2	12	0.3	0.2	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	1,363	27.9	16.6	1,196	28.0	16.8	149	27.9	17.4				7	21.6	6.6	7	25.5	6.4
Regional	1,150	23.6	14.0	997	23.3	14.1	137	25.7	15.6				8	22.8	7.5	6	21.4	5.0
Distant	2,014	41.3	24.5	1,761	41.2	24.9	217	40.8	25.1				16	46.2	14.0	13	44.8	10.2
Unknown	337	6.9	3.9	304	7.1	4.0	29	5.4	3.3				2	6.4	2.3	2	8.3	2.0

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	5,681	68.5	76.4	4,720	69.5	72.7	824	70.4	114.5	Insufficient data for the calculation of AI/AN PRCDA statistics			29	66.5	30.0	60	70.2	54.2
Regional	1,219	14.7	15.8	1,036	15.3	15.4	155	13.2	20.5				8	17.6	7.4	15	17.1	11.2
Distant	565	6.8	8.4	455	6.7	7.8	99	8.4	15.4				4	8.6	6.3	6	6.8	5.6
Unknown	828	10.0	11.8	578	8.5	9.5	93	7.9	15.0				3	7.2	3.1	5	5.9	4.8
<i>Age < 65</i>																		
Localized	2,290	70.2	31.9	1,782	71.0	28.8	454	72.7	61.2	Insufficient data for the calculation of AI/AN PRCDA statistics			10	71.4	9.1	24	65.4	16.9
Regional	587	18.0	8.3	474	18.9	7.8	98	15.7	13.4				3	20.0	2.5	9	23.2	6.0
Distant	152	4.7	2.1	108	4.3	1.8	41	6.6	5.4				*	*	*	2	5.4	1.4
Unknown	235	7.2	3.2	146	5.8	2.3	32	5.1	4.2				*	*	*	2	5.9	1.5
<i>Age ≥ 65</i>																		
Localized	3,391	67.4	384.3	2,938	68.7	376.4	370	67.8	482.6				19	64.2	173.9	36	73.9	311.8
Regional	632	12.6	67.8	562	13.1	68.2	56	10.3	69.8				5	16.6	41.3	6	12.4	47.2
Distant	413	8.2	51.9	346	8.1	49.2	58	10.6	84.6				*	*	*	4	7.9	34.9
Unknown	593	11.8	71.5	432	10.1	59.2	61	11.2	89.6				*	*	*	3	5.8	27.3

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Oklahoma, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	71	37.9	3.8	47	36.8	3.5	5	38.5	3.4	10	40.5	6.1	2	50.0	4.6	7	38.8	4.3
Regional	65	34.3	3.3	44	35.1	3.1	4	30.8	2.7	7	28.6	4.2	2	41.7	4.5	7	38.8	5.0
Distant	34	18.1	1.7	23	18.3	1.5	3	23.1	1.9	5	20.6	3.2	*	*	*	2	11.8	1.7
Unknown	18	9.7	0.9	12	9.8	0.8	*	*	*	3	10.3	1.7	*	*	*	2	10.6	1.2

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	23	2.3	1.1	18	2.3	1.0	1	2.0	1.0	2	1.7	1.4	*	*	*	*	*	*
Localized	318	31.3	15.1	252	32.3	14.7	19	30.3	15.1	31	26.7	22.1	3	21.7	9.1	12	31.4	13.2
Regional	340	33.4	16.1	265	33.9	15.7	19	30.3	14.1	40	34.5	27.8	4	36.7	13.3	10	25.8	10.4
Distant	214	21.0	10.1	159	20.3	9.5	16	26.4	13.2	26	21.9	16.0	2	20.0	8.0	10	25.8	9.3
Unknown	122	12.0	5.9	87	11.1	5.2	7	11.1	5.4	18	15.2	12.8	2	18.3	5.8	6	15.5	6.0
<i>Age < 50</i>																		
<i>In Situ</i>	2	1.5	0.2	2	2.0	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	31	26.4	2.6	22	27.8	2.8	2	25.0	2.3	4	25.0	3.6	*	*	*	2	23.9	1.7
Regional	42	36.1	3.7	28	35.6	3.7	2	27.5	2.3	7	48.7	7.1	1	35.3	3.4	3	30.4	2.2
Distant	31	26.4	2.7	21	26.1	2.7	4	45.0	3.9	3	18.4	2.7	*	*	*	3	28.3	1.9
Unknown	11	9.6	1.0	7	8.5	0.9	*	*	*	*	*	*	*	*	*	2	17.4	1.2
<i>Age ≥ 50</i>																		
<i>In Situ</i>	21	2.4	3.5	16	2.3	3.3	1	2.2	3.7	*	*	*	*	*	*	*	*	*
Localized	288	32.0	47.6	230	32.8	45.9	17	31.1	48.7	27	26.9	70.3	*	*	*	10	33.8	43.5
Regional	298	33.1	48.7	236	33.7	47.2	16	30.7	45.2	33	32.4	82.0	3	37.2	39.3	7	24.3	31.7
Distant	183	20.3	29.4	138	19.7	27.3	13	23.6	37.4	23	22.4	50.9	*	*	*	7	25.0	28.5
Unknown	111	12.3	18.8	80	11.4	16.5	*	*	*	*	*	*	*	*	*	4	14.9	18.7
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	19	2.2	0.8	15	2.2	0.8	*	*	*	2	2.3	1.2	*	*	*	*	*	*
Localized	302	34.0	12.5	238	34.8	12.1	19	31.0	12.5	30	30.6	17.0	5	38.2	12.5	9	32.4	9.1
Regional	297	33.5	12.3	232	33.9	11.9	17	28.0	10.9	33	34.1	19.6	5	35.3	12.0	10	35.2	11.0
Distant	179	20.1	7.4	133	19.5	6.9	17	29.0	11.9	20	20.3	11.6	2	17.6	4.9	5	19.0	5.2
Unknown	91	10.3	3.6	66	9.6	3.1	6	10.3	4.3	12	12.7	7.0	*	*	*	3	12.0	3.9
<i>Age < 50</i>																		
<i>In Situ</i>	2	1.7	0.2	2	2.4	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	36	34.9	3.1	24	35.6	2.9	2	23.3	1.9	6	33.7	5.1	2	50.0	4.7	3	36.8	2.1
Regional	35	34.0	3.1	23	35.3	2.9	3	32.6	2.8	5	31.4	5.1	*	*	*	3	34.2	2.1
Distant	24	23.0	2.1	15	22.1	1.9	3	30.2	2.9	4	24.4	3.8	*	*	*	2	23.7	1.4
Unknown	7	6.4	0.6	3	4.5	0.4	*	*	*	2	10.5	1.7	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	17	2.2	2.5	13	2.2	2.3	*	*	*	2	2.7	4.5	*	*	*	*	*	*
Localized	265	33.8	37.2	214	34.7	36.2	17	32.3	40.5	24	29.9	48.0	3	34.0	33.0	6	30.8	27.5
Regional	262	33.4	36.5	209	33.8	35.4	14	27.2	32.3	28	34.7	57.5	*	*	*	7	35.6	34.1
Distant	155	19.7	21.5	118	19.2	20.1	15	28.8	35.2	16	19.5	31.8	*	*	*	4	17.3	15.1
Unknown	84	10.8	11.5	63	10.2	10.2	*	*	*	11	13.2	21.1	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Oklahoma, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	485	14.2	21.0	369	13.7	20.1	38	16.7	24.7	44	14.3	24.0	10	18.0	20.0	20	16.7	18.3
Localized	1,801	52.7	75.3	1,448	53.9	75.7	99	43.8	66.0	167	53.8	93.2	27	51.3	57.1	55	45.7	51.3
Regional	788	23.1	34.6	607	22.6	34.1	61	27.2	41.2	71	22.8	39.0	11	21.3	24.1	35	29.4	29.6
Distant	196	5.7	8.4	149	5.5	8.0	19	8.4	13.1	18	5.7	10.3	2	4.5	5.1	7	5.8	8.1
Unknown	148	4.3	6.0	117	4.3	5.8	9	3.9	6.0	10	3.4	5.8	3	4.9	6.4	3	2.3	2.9
<i>Age < 50</i>																		
<i>In Situ</i>	86	15.5	7.7	56	15.1	7.3	8	16.3	9.1	9	12.7	8.2	3	17.6	8.7	8	20.0	7.9
Localized	247	44.8	22.0	169	45.4	21.6	19	39.6	21.2	33	47.8	30.8	8	47.1	22.0	17	40.5	15.0
Regional	170	30.8	15.0	114	30.8	14.7	16	32.2	16.8	21	30.5	19.2	4	24.7	11.8	14	34.6	12.6
Distant	34	6.1	3.0	23	6.2	2.9	4	8.2	4.1	4	6.3	4.2	*	*	*	1	3.4	1.3
Unknown	15	2.8	1.4	10	2.6	1.2	2	3.7	2.0	2	2.6	1.7	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	400	13.9	55.7	313	13.5	53.9	30	16.8	65.7	35	14.7	65.2	7	18.1	49.7	12	15.0	45.5
Localized	1,554	54.2	215.0	1,279	55.2	217.2	79	44.9	183.5	133	55.5	256.6	19	53.3	149.0	38	48.5	146.5
Regional	617	21.6	86.0	493	21.3	84.8	45	25.8	105.1	49	20.6	90.7	7	19.8	56.1	21	26.6	74.3
Distant	162	5.6	22.4	126	5.4	21.4	15	8.5	36.6	13	5.6	26.3	*	*	*	6	7.1	26.0
Unknown	132	4.6	18.2	107	4.6	17.8	7	4.0	16.5	9	3.6	16.7	*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	2	0.1	0.1	2	0.1	0.1	*	*	*	*	*	*	*	*	*	*	*	*
Localized	341	20.4	15.9	290	21.1	16.1	13	13.3	11.3	30	19.1	22.4	2	14.3	5.5	5	18.9	7.4
Regional	344	20.6	15.6	284	20.7	15.5	19	19.4	15.2	34	21.5	24.1	2	16.1	6.8	6	22.0	6.9
Distant	738	44.3	33.4	597	43.5	32.7	52	53.8	42.3	70	44.7	47.3	7	60.7	23.7	12	45.5	14.1
Unknown	242	14.5	11.5	200	14.6	11.3	13	13.5	12.9	23	14.6	18.0	*	*	*	3	12.9	6.0
<i>Female</i>																		
<i>In Situ</i>	3	0.2	0.1	2	0.2	0.1	*	*	*	*	*	*	*	*	*	*	*	*
Localized	349	23.7	13.6	287	23.8	13.6	19	24.1	13.2	35	24.2	19.5	2	11.1	4.6	6	25.0	8.1
Regional	318	21.6	12.4	257	21.3	12.2	19	23.4	12.6	35	24.2	19.9	2	16.7	5.4	4	17.5	5.0
Distant	632	42.9	24.7	522	43.2	25.0	35	44.5	22.6	56	39.1	30.5	7	48.6	17.5	12	48.3	14.2
Unknown	170	11.6	6.6	140	11.6	6.4	6	7.5	4.2	18	12.3	11.0	3	23.6	9.0	2	9.2	3.1

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	1,552	67.6	67.1	1,211	69.5	63.7	152	66.5	109.4	119	67.4	76.3	14	74.7	45.1	37	63.7	43.5
Regional	254	11.1	10.5	192	11.0	9.8	28	12.3	19.0	23	12.9	13.1	2	11.6	6.3	8	13.5	8.1
Distant	166	7.2	7.7	124	7.1	6.9	20	8.7	16.2	15	8.6	12.2	1	6.3	5.1	5	9.3	7.8
Unknown	323	14.1	15.1	215	12.4	12.2	29	12.5	25.6	19	11.0	15.6	1	7.4	5.6	8	13.5	10.4
<i>Age < 65</i>																		
Localized	594	70.0	27.2	433	72.3	25.3	81	69.1	53.9	50	68.7	30.1	5	81.3	13.1	17	61.8	13.5
Regional	118	13.9	5.3	81	13.6	4.6	17	14.4	11.0	14	18.5	8.1	*	*	*	5	19.1	4.2
Distant	47	5.6	2.2	32	5.3	1.8	9	8.0	6.3	4	5.4	2.4	*	*	*	2	8.1	1.7
Unknown	89	10.4	4.1	53	8.9	3.2	10	8.5	6.4	5	7.4	3.1	*	*	*	3	11.0	2.4
<i>Age ≥ 65</i>																		
Localized	958	66.2	342.7	778	68.0	329.1	70	63.7	493.2	68	66.5	396.0	9	71.4	265.8	20	65.4	251.0
Regional	136	9.4	46.5	111	9.7	45.3	11	10.1	74.1	9	8.9	47.8	*	*	*	3	8.5	35.2
Distant	119	8.2	46.1	93	8.1	42.0	10	9.4	84.9	11	10.9	80.0	*	*	*	3	10.5	49.4
Unknown	234	16.2	91.1	162	14.2	73.9	19	16.8	158.4	14	13.6	101.5	*	*	*	5	15.7	65.8

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Oregon, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	81	55.5	4.0	67	55.6	4.2	*	*	*	1	43.8	5.7	4	55.9	2.9	8	60.0	4.1
Regional	40	27.3	1.7	33	27.0	1.7	*	*	*	1	37.5	4.0	1	20.6	1.2	4	27.1	1.7
Distant	17	11.9	0.7	15	12.1	0.7	*	*	*	*	*	*	1	20.6	1.4	*	*	*
Unknown	8	5.3	0.3	6	5.3	0.3	*	*	*	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	60	6.2	2.4	51	6.0	2.4	1	8.3	2.9	*	*	*	2	6.7	2.4	4	8.3	2.5
Localized	303	31.4	12.5	268	31.8	12.6	3	23.6	7.8	4	28.8	19.2	10	31.7	11.6	15	28.9	10.1
Regional	368	38.2	15.4	321	38.1	15.5	6	40.3	13.9	5	37.0	18.2	12	36.0	15.0	21	41.1	14.8
Distant	179	18.6	7.4	157	18.5	7.5	3	19.4	7.8	3	19.2	9.6	7	20.7	8.0	10	19.0	6.3
Unknown	55	5.7	2.4	48	5.6	2.3	1	8.3	3.5	1	8.2	6.3	2	4.9	2.1	1	2.8	1.4
<i>Age < 50</i>																		
<i>In Situ</i>	4	3.3	0.3	3	3.0	0.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	29	26.7	2.2	22	25.3	2.2	*	*	*	1	70.0	8.2	2	37.0	2.5	3	27.9	1.8
Regional	49	44.7	3.8	39	45.5	4.0	1	50.0	4.3	*	*	*	2	33.3	2.3	5	44.3	2.8
Distant	25	22.9	1.9	21	24.1	2.1	*	*	*	*	*	*	1	25.9	2.0	2	19.7	1.3
Unknown	3	2.4	0.2	2	2.1	0.2	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	56	6.6	8.1	48	6.4	7.9	1	10.3	10.7	*	*	*	*	*	*	*	*	*
Localized	274	32.0	39.4	246	32.5	39.8	*	*	*	3	22.2	48.0	8	30.7	35.3	11	29.2	31.6
Regional	319	37.3	46.0	282	37.2	45.6	4	37.9	38.8	*	*	*	10	36.5	48.2	15	40.1	46.2
Distant	154	18.0	21.9	136	17.9	21.7	*	*	*	*	*	*	5	19.7	23.9	7	18.8	19.5
Unknown	52	6.1	8.1	46	6.0	7.8	*	*	*	1	9.5	22.9	2	5.8	7.4	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	43	5.1	1.6	36	4.9	1.6	*	*	*	1	10.7	3.9	1	3.9	1.0	3	7.6	1.9
Localized	277	32.8	10.4	249	33.5	10.6	3	32.7	10.3	3	26.8	11.1	10	32.5	8.7	10	24.8	6.8
Regional	307	36.3	11.6	266	35.7	11.4	4	38.5	11.6	5	44.6	16.4	11	35.7	9.6	18	42.4	11.9
Distant	161	19.0	6.0	143	19.2	6.1	2	15.4	4.8	*	*	*	6	20.8	5.5	9	20.5	6.2
Unknown	57	6.8	1.9	50	6.7	1.8	*	*	*	*	*	*	2	7.1	2.2	2	4.8	1.8
<i>Age < 50</i>																		
<i>In Situ</i>	4	4.2	0.3	3	3.8	0.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	28	30.3	2.2	22	31.4	2.3	*	*	*	*	*	*	2	29.0	1.9	3	26.8	1.7
Regional	35	38.2	2.7	25	36.6	2.6	*	*	*	*	*	*	3	45.2	2.9	5	41.1	2.6
Distant	22	24.3	1.8	17	25.3	1.8	*	*	*	*	*	*	1	22.6	1.5	3	23.2	1.7
Unknown	3	3.1	0.2	2	2.9	0.2	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	39	5.2	5.1	34	5.0	4.9	*	*	*	*	*	*	1	4.9	3.5	*	*	*
Localized	249	33.1	31.8	228	33.7	32.4	*	*	*	*	*	*	8	33.3	26.4	7	24.0	20.0
Regional	272	36.1	34.9	241	35.6	34.5	*	*	*	*	*	*	8	33.3	27.2	13	42.9	36.0
Distant	138	18.4	17.1	125	18.6	17.3	*	*	*	*	*	*	5	20.3	15.9	6	19.5	18.2
Unknown	54	7.2	6.5	48	7.1	6.1	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Oregon, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	652	15.8	25.2	569	15.5	25.4	8	16.3	20.9	5	11.2	17.3	32	22.4	25.9	33	17.1	21.0
Localized	2,373	57.6	87.7	2,141	58.4	90.4	23	48.8	64.7	21	49.3	68.9	74	51.5	63.8	101	51.4	68.2
Regional	866	21.0	34.5	756	20.6	35.4	12	24.6	31.9	12	28.4	39.3	29	19.9	23.5	52	26.5	32.3
Distant	167	4.1	6.4	143	3.9	6.2	5	10.0	13.4	3	7.9	11.0	7	5.1	6.4	7	3.7	4.3
Unknown	62	1.5	2.2	55	1.5	2.1	*	*	*	1	3.3	4.8	2	1.1	1.4	3	1.4	2.6
<i>Age < 50</i>																		
<i>In Situ</i>	120	18.0	9.7	92	17.3	9.6	*	*	*	1	17.1	8.7	13	28.3	14.2	12	17.9	7.4
Localized	306	45.9	24.3	247	46.6	25.6	6	49.1	21.6	3	39.0	18.5	19	41.3	20.7	29	44.4	18.2
Regional	206	30.8	16.3	166	31.3	17.3	4	35.1	14.8	3	34.1	17.7	11	23.5	11.4	21	32.1	13.1
Distant	30	4.6	2.4	23	4.3	2.4	*	*	*	*	*	*	3	7.0	3.5	3	4.0	1.6
Unknown	5	0.7	0.4	3	0.6	0.3	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	531	15.4	65.8	477	15.2	66.6	*	*	*	3	9.8	40.1	19	19.7	56.5	22	16.6	56.7
Localized	2,067	59.9	253.7	1,894	60.5	260.0	18	48.6	177.7	18	51.7	201.0	55	56.2	176.8	72	54.8	198.9
Regional	660	19.1	82.2	590	18.8	82.8	8	21.3	76.5	9	27.0	95.7	18	18.3	55.1	31	23.7	82.8
Distant	137	4.0	16.7	120	3.8	16.3	*	*	*	*	*	*	4	4.3	14.0	5	3.5	11.4
Unknown	57	1.7	6.9	52	1.7	6.9	*	*	*	1	4.0	17.3	2	1.6	5.1	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	6	0.4	0.2	5	0.4	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	367	26.8	14.7	336	26.9	14.8	8	32.5	26.6	6	25.2	23.0	9	21.5	12.3	7	22.9	7.7
Regional	301	22.0	12.0	272	21.8	12.1	5	22.0	16.5	6	26.1	22.1	8	21.0	9.9	8	28.5	8.8
Distant	594	43.4	23.6	541	43.3	23.9	10	42.3	29.3	9	41.4	35.7	21	51.5	26.8	12	42.4	12.9
Unknown	101	7.4	4.3	95	7.6	4.4	*	*	*	2	7.2	6.8	2	4.5	2.9	2	6.3	2.5
<i>Female</i>																		
<i>In Situ</i>	5	0.4	0.2	5	0.4	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	420	29.7	14.6	391	30.2	15.1	4	23.9	11.8	7	26.6	25.7	9	24.7	8.3	7	20.0	6.4
Regional	306	21.6	10.6	279	21.5	10.7	4	23.9	12.8	5	21.0	16.6	7	20.2	6.7	9	26.9	8.6
Distant	578	40.9	20.2	524	40.5	20.3	8	46.6	24.3	11	44.4	36.7	18	50.0	16.3	15	44.0	13.6
Unknown	105	7.4	3.6	97	7.5	3.7	*	*	*	2	8.1	8.9	1	3.9	1.4	3	9.1	3.3

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	1,813	69.5	65.9	1,610	69.5	65.1	44	68.7	111.6	13	60.0	48.9	28	67.0	33.5	58	65.8	50.1
Regional	436	16.7	15.7	394	17.0	15.8	9	13.3	18.7	5	21.8	17.8	8	18.2	9.6	18	20.7	13.2
Distant	225	8.6	9.2	198	8.5	9.0	9	14.6	29.0	2	10.0	8.7	4	10.0	5.9	10	10.9	10.5
Unknown	136	5.2	5.6	115	5.0	5.2	2	3.4	7.4	2	8.2	7.6	2	4.8	3.2	2	2.5	2.9
<i>Age < 65</i>																		
Localized	609	72.3	24.5	524	72.7	24.4	25	71.3	52.5	5	59.0	16.6	12	72.5	12.2	25	66.1	15.3
Regional	158	18.8	6.4	137	18.9	6.4	6	16.7	12.0	2	30.8	7.7	2	15.0	2.6	10	26.6	6.2
Distant	49	5.8	2.0	40	5.6	1.9	4	10.3	7.6	*	*	*	1	8.8	1.5	3	6.8	1.6
Unknown	27	3.2	1.1	20	2.7	0.9	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	1,204	68.1	352.4	1,085	68.0	346.1	20	65.8	520.2	9	60.6	271.7	16	63.6	180.4	32	65.6	290.3
Regional	278	15.7	79.9	258	16.1	80.8	3	9.4	64.6	2	16.9	87.3	5	20.2	58.2	8	16.2	61.5
Distant	176	10.0	59.2	158	9.9	57.6	6	19.5	176.9	*	*	*	3	10.9	36.3	7	14.2	72.2
Unknown	109	6.2	36.9	95	6.0	34.9	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Pennsylvania, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	224	43.9	3.5	166	43.3	3.4	28	41.9	3.8	Insufficient data for the calculation of AI/AN PRCDA statistics			7	57.8	2.9	20	52.6	5.0
Regional	183	35.9	2.6	138	35.9	2.4	24	36.7	3.2				4	31.3	1.9	15	38.1	4.3
Distant	80	15.7	1.0	65	16.8	1.0	11	16.3	1.3				1	9.4	0.5	3	6.7	0.8
Unknown	23	4.4	0.3	15	4.0	0.2	3	5.1	0.5				*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	260	7.0	3.3	214	6.7	3.1	26	8.5	4.1				6	9.4	3.2	9	8.2	3.2
Localized	1,095	29.6	14.3	950	29.9	14.4	84	27.6	14.1				18	29.8	9.9	28	26.5	10.2
Regional	1,349	36.5	17.8	1,177	37.0	18.1	104	34.1	17.7				22	37.1	12.7	38	35.8	15.3
Distant	755	20.4	10.0	648	20.4	10.0	69	22.6	11.4				12	19.7	6.8	23	22.1	8.7
Unknown	241	6.5	3.2	192	6.0	2.9	22	7.3	4.1				2	4.0	1.3	8	7.4	4.4
<i>Age < 50</i>																		
<i>In Situ</i>	18	4.9	0.5	14	4.9	0.5	2	5.8	0.5				*	*	*	1	5.5	0.4
Localized	92	25.3	2.4	74	25.3	2.5	9	23.3	2.1				1	17.9	0.8	7	30.9	2.1
Regional	146	39.8	3.9	117	40.2	4.1	15	39.7	3.6				3	41.0	2.0	9	41.8	3.1
Distant	96	26.4	2.6	78	26.9	2.7	11	28.0	2.6				2	28.2	1.3	4	20.0	1.5
Unknown	13	3.6	0.3	8	2.7	0.3	1	3.2	0.3				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	242	7.2	10.6	199	6.9	10.1	24	8.9	13.4				*	*	*	7	8.9	10.6
Localized	1,002	30.1	45.3	876	30.3	45.4	75	28.2	45.5				16	31.5	33.6	21	25.3	31.3
Regional	1,203	36.1	54.4	1,059	36.7	54.6	89	33.3	54.9				19	36.5	40.8	28	34.2	47.1
Distant	659	19.8	29.4	569	19.7	29.1	58	21.8	34.6				10	18.5	21.2	19	22.7	27.6
Unknown	227	6.8	10.7	185	6.4	9.9	21	7.9	14.0	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	207	6.0	2.3	167	5.7	2.2	24	8.0	3.0				3	4.3	1.1	8	8.6	2.7
Localized	1,033	30.1	11.4	892	30.5	11.5	88	28.9	10.9				19	30.7	8.7	25	25.3	8.0
Regional	1,270	37.0	13.9	1,099	37.6	14.0	98	32.1	12.3				25	41.3	11.7	40	40.7	13.3
Distant	674	19.7	7.5	568	19.4	7.4	74	24.3	9.3				11	18.8	5.0	18	18.5	6.3
Unknown	244	7.1	2.3	199	6.8	2.1	21	6.7	2.4				3	5.0	1.8	7	6.9	2.7
<i>Age < 50</i>																		
<i>In Situ</i>	16	4.9	0.4	13	5.1	0.5	1	4.0	0.3				*	*	*	*	*	*
Localized	103	30.7	2.7	80	31.2	2.8	10	28.8	2.2				3	22.2	1.5	8	33.9	2.8
Regional	127	37.9	3.4	97	37.7	3.4	13	36.7	2.9				6	49.2	3.5	10	39.7	3.3
Distant	76	22.8	2.0	60	23.3	2.1	9	26.0	2.1				3	22.2	1.6	4	17.4	1.5
Unknown	12	3.7	0.3	7	2.8	0.3	2	4.5	0.4				*	*	*	1	5.0	0.4
<i>Age ≥ 50</i>																		
<i>In Situ</i>	190	6.2	7.1	154	5.8	6.7	23	8.5	10.1				*	*	*	*	*	*
Localized	930	30.1	34.3	812	30.4	34.4	78	28.9	33.9				16	32.9	27.6	17	22.4	21.6
Regional	1,143	37.0	41.6	1,002	37.6	41.8	85	31.5	36.9				19	39.2	33.1	30	41.1	39.4
Distant	598	19.3	21.7	508	19.0	21.2	65	24.0	28.2				9	17.9	14.0	14	18.9	18.9
Unknown	231	7.5	7.5	191	7.2	6.8	19	7.0	7.9				*	*	*	6	7.6	8.5

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Pennsylvania, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	2,623	18.8	32.1	2,182	18.3	32.2	278	21.6	34.9				62	24.5	26.0	84	21.2	25.8
Localized	7,583	54.5	87.3	6,651	55.9	90.9	593	46.2	74.3				124	48.9	54.5	186	46.6	59.9
Regional	2,745	19.7	34.3	2,263	19.0	33.9	307	23.9	39.9				57	22.3	23.8	102	25.7	30.3
Distant	734	5.3	8.3	617	5.2	8.2	83	6.4	10.4				9	3.6	4.1	21	5.3	7.1
Unknown	231	1.7	2.3	188	1.6	2.1	24	1.9	3.0				2	0.7	0.9	5	1.3	1.6
<i>Age < 50</i>																		
<i>In Situ</i>	506	22.0	13.6	397	22.1	14.0	55	21.0	12.6	Insufficient data for the calculation of AI/AN PRCDA statistics			24	26.1	13.9	25	19.5	9.4
Localized	1,037	45.1	27.6	839	46.7	29.4	102	39.0	23.2				40	43.6	23.1	50	39.0	18.0
Regional	639	27.8	17.2	477	26.5	17.0	87	33.2	19.6				23	25.1	12.8	46	35.3	16.1
Distant	97	4.2	2.6	72	4.0	2.5	15	5.9	3.5				4	4.1	2.1	6	4.6	2.1
Unknown	21	0.9	0.5	13	0.7	0.4	2	0.9	0.5				*	*	*	2	1.5	0.7
<i>Age ≥ 50</i>																		
<i>In Situ</i>	2,117	18.2	80.3	1,785	17.7	79.8	223	21.8	93.3				38	23.5	57.6	59	21.9	68.6
Localized	6,546	56.4	243.4	5,812	57.5	251.8	492	48.0	208.1				83	51.9	136.8	135	50.2	169.8
Regional	2,106	18.1	79.0	1,786	17.7	78.3	220	21.5	93.1				33	20.8	52.7	57	21.1	67.5
Distant	636	5.5	23.3	545	5.4	23.1	67	6.6	28.4				5	3.4	9.2	15	5.6	20.3
Unknown	210	1.8	6.9	175	1.7	6.5	22	2.1	9.3				*	*	*	3	1.2	4.0

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	10	0.2	0.1	9	0.2	0.1	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	1,302	23.4	16.5	1,163	23.7	16.8	103	22.0	18.3				12	19.0	7.7	17	17.6	8.8
Regional	1,284	23.1	16.0	1,136	23.2	16.1	101	21.6	17.2				16	23.9	9.4	24	25.7	11.7
Distant	2,556	46.0	32.1	2,247	45.9	32.2	222	47.6	38.7				34	51.5	19.9	46	48.8	21.1
Unknown	400	7.2	5.2	344	7.0	5.0	41	8.7	7.9				3	5.2	2.6	7	7.4	3.9
<i>Female</i>																		
<i>In Situ</i>	22	0.4	0.2	19	0.4	0.2	1	0.3	0.2	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	1,566	29.0	16.4	1,357	29.0	16.5	164	29.4	20.1				14	23.9	7.0	26	32.6	9.7
Regional	1,223	22.7	12.8	1,051	22.5	12.8	135	24.3	16.0				13	21.5	6.3	20	25.2	7.3
Distant	2,223	41.2	23.2	1,940	41.4	23.6	221	39.8	26.5				29	49.5	14.7	28	35.1	10.5
Unknown	359	6.7	3.3	313	6.7	3.3	35	6.3	4.2				3	4.4	1.5	5	6.4	2.1

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	6,577	70.9	76.9	5,339	71.6	71.6	750	70.5	112.8	Insufficient data for the calculation of AI/AN PRCDA statistics			62	70.5	34.2	165	67.2	66.9
Regional	1,268	13.7	14.3	1,061	14.2	13.8	145	13.7	21.1				13	14.5	6.8	39	15.9	13.8
Distant	762	8.2	9.8	619	8.3	9.0	108	10.2	18.7				8	9.3	5.0	21	8.6	10.8
Unknown	667	7.2	8.2	441	5.9	6.2	60	5.6	11.3				5	5.7	3.3	20	8.3	10.3
<i>Age < 65</i>																		
Localized	2,686	72.5	33.1	2,062	73.4	29.8	411	72.2	59.1	Insufficient data for the calculation of AI/AN PRCDA statistics			22	75.7	11.3	80	67.4	26.0
Regional	627	16.9	7.7	503	17.9	7.3	91	16.0	13.1				4	14.2	2.1	25	20.6	8.0
Distant	194	5.2	2.4	137	4.9	2.0	46	8.1	6.7				2	6.8	1.0	8	6.7	2.6
Unknown	196	5.3	2.4	109	3.9	1.6	21	3.7	2.9				*	*	*	6	5.2	2.0
<i>Age ≥ 65</i>																		
Localized	3,891	69.9	378.9	3,278	70.5	360.0	339	68.7	484.1				40	67.8	192.8	84	66.9	349.2
Regional	641	11.5	59.8	559	12.0	58.7	54	10.9	76.6				9	14.7	39.3	14	11.4	53.9
Distant	568	10.2	60.6	483	10.4	57.6	62	12.5	101.9				6	10.6	32.8	13	10.5	68.0
Unknown	471	8.4	48.5	332	7.1	38.6	39	7.9	69.4				*	*	*	14	11.3	67.5

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Rhode Island, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	20	52.0	4.1	15	52.4	4.3	*	*	*	*	*	*	1	75.0	5.7	2	44.4	3.2
Regional	13	34.2	2.1	9	31.7	1.8	*	*	*	*	*	*	*	*	*	3	48.1	4.6
Distant	5	12.2	0.7	4	14.5	0.8	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	5	2.3	0.9	4	2.1	0.8	*	*	*	*	*	*	*	*	*	*	*	*
Localized	82	35.4	13.7	72	36.4	14.1	2	25.0	6.9	*	*	*	1	21.2	10.5	5	36.9	11.0
Regional	83	35.7	13.9	70	35.2	13.8	4	47.7	15.2	*	*	*	3	39.4	21.9	4	32.3	9.0
Distant	46	19.9	7.8	39	19.6	7.6	2	18.2	5.5	*	*	*	2	27.3	12.6	3	24.6	7.7
Unknown	16	6.7	2.6	13	6.6	2.5	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	6	27.0	1.9	5	29.5	2.0	*	*	*	*	*	*	*	*	*	*	*	*
Regional	10	43.2	3.1	6	41.0	2.9	1	75.0	5.2	*	*	*	*	*	*	1	40.0	2.6
Distant	5	24.3	1.7	4	24.4	1.6	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	76	36.3	44.8	68	37.0	45.8	2	30.6	25.1	*	*	*	*	*	*	*	*	*
Regional	73	34.9	42.2	64	34.7	42.1	3	41.7	41.2	*	*	*	*	*	*	3	30.0	25.9
Distant	41	19.4	23.6	35	19.2	23.3	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	5	2.2	0.7	4	2.2	0.7	*	*	*	*	*	*	*	*	*	*	*	*
Localized	71	32.1	9.5	61	31.9	9.4	3	37.8	9.2	*	*	*	2	46.2	16.2	4	30.2	6.4
Regional	86	38.6	11.7	73	38.5	11.5	3	37.8	8.8	*	*	*	1	26.9	9.4	6	50.8	11.5
Distant	44	19.8	6.1	38	20.1	6.3	1	18.9	4.4	*	*	*	1	26.9	8.9	2	15.9	3.5
Unknown	16	7.3	1.8	14	7.3	1.8	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	6	27.9	1.9	4	27.3	1.8	*	*	*	*	*	*	*	*	*	*	*	*
Regional	10	43.2	3.0	6	41.6	2.7	*	*	*	*	*	*	*	*	*	2	55.0	4.3
Distant	6	25.2	1.7	4	26.0	1.7	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	65	32.6	29.6	56	32.3	29.3	*	*	*	*	*	*	*	*	*	*	*	*
Regional	76	38.1	34.4	67	38.3	34.6	*	*	*	*	*	*	*	*	*	4	48.8	30.4
Distant	38	19.2	17.7	34	19.6	18.3	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Rhode Island, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	250	20.2	37.5	214	19.9	39.3	9	19.7	29.4	*	*	*	4	16.8	20.7	20	25.0	31.1
Localized	703	56.8	100.0	622	57.9	105.2	23	48.1	73.0	*	*	*	13	58.4	77.8	38	48.5	64.8
Regional	223	18.0	34.0	185	17.2	34.2	12	25.1	38.1	*	*	*	5	21.2	27.6	18	22.4	28.1
Distant	40	3.3	5.7	35	3.2	5.6	3	5.9	8.1	*	*	*	*	*	*	2	2.6	3.6
Unknown	21	1.7	2.6	18	1.7	2.6	*	*	*	*	*	*	*	*	*	1	1.5	2.0
<i>Age < 50</i>																		
<i>In Situ</i>	50	24.1	16.2	40	25.1	18.0	2	16.7	9.4	*	*	*	1	16.7	9.6	6	23.7	12.4
Localized	97	46.3	30.4	77	47.5	33.2	5	45.0	25.2	*	*	*	4	52.8	30.5	10	39.7	20.0
Regional	55	26.2	17.4	40	24.6	17.4	4	31.7	17.8	*	*	*	2	27.8	16.0	9	32.8	17.2
Distant	5	2.4	1.6	3	2.0	1.5	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	2	1.0	0.7	1	0.9	0.7	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	200	19.4	93.3	174	19.0	95.1	7	20.7	81.9	*	*	*	3	16.9	49.8	13	25.7	80.3
Localized	606	59.0	282.3	546	59.8	293.5	18	49.2	198.2	*	*	*	9	61.0	201.8	28	52.9	181.9
Regional	168	16.3	77.6	145	15.9	78.4	8	22.9	91.3	*	*	*	3	18.2	58.0	9	17.2	56.6
Distant	35	3.4	16.2	31	3.4	16.5	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	19	1.8	7.7	17	1.8	7.8	*	*	*	*	*	*	*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	128	27.9	21.0	117	28.3	22.0	5	28.3	16.5	*	*	*	*	*	*	4	24.1	12.2
Regional	107	23.2	17.0	96	23.1	17.5	6	30.4	23.3	*	*	*	1	26.1	8.7	4	21.7	7.7
Distant	196	42.6	31.6	174	42.0	32.1	7	40.2	27.8	*	*	*	2	52.2	20.7	8	48.2	23.5
Unknown	29	6.2	4.9	27	6.5	5.1	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>In Situ</i>	1	0.2	0.1	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	158	32.3	21.0	144	31.8	22.0	5	36.5	18.4	*	*	*	2	39.1	11.9	5	38.5	10.9
Regional	106	21.5	13.9	98	21.6	14.9	3	21.6	10.1	*	*	*	2	34.8	11.4	2	16.9	3.9
Distant	198	40.3	25.8	184	40.5	27.6	5	35.1	17.4	*	*	*	1	26.1	7.5	5	41.5	10.6
Unknown	28	5.6	3.2	26	5.8	3.4	*	*	*	*	*	*	*	*	*	*	*	*

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	505	65.7	75.2	434	67.6	74.6	27	63.1	89.9	*	*	*	3	68.2	20.7	23	59.1	55.7
Regional	103	13.4	14.7	90	13.9	14.9	5	12.1	15.1	*	*	*	*	*	*	6	14.5	11.3
Distant	63	8.2	10.4	51	7.9	9.4	5	12.6	21.9	*	*	*	*	*	*	6	15.0	16.1
Unknown	97	12.7	14.7	68	10.6	11.8	5	12.1	18.7	*	*	*	*	*	*	4	11.4	13.1
<i>Age < 65</i>																		
Localized	206	66.7	31.2	170	69.0	31.0	15	63.0	43.0	*	*	*	*	*	*	12	63.7	21.7
Regional	51	16.5	7.8	43	17.3	7.8	4	16.8	12.0	*	*	*	*	*	*	2	13.2	4.4
Distant	15	5.0	2.4	11	4.5	2.1	2	8.4	5.6	*	*	*	*	*	*	2	13.2	4.4
Unknown	36	11.8	5.3	23	9.2	3.9	3	11.8	8.2	*	*	*	*	*	*	2	9.9	3.3
<i>Age ≥ 65</i>																		
Localized	299	65.1	378.9	264	66.7	375.8	12	63.2	414.3	*	*	*	*	*	*	11	54.9	290.7
Regional	52	11.3	62.2	47	11.8	63.5	1	6.3	37.0	*	*	*	*	*	*	3	15.7	58.8
Distant	48	10.4	65.3	40	10.0	60.3	3	17.9	133.9	*	*	*	*	*	*	3	16.7	96.9
Unknown	61	13.2	79.6	45	11.5	66.3	2	12.6	91.6	*	*	*	*	*	*	3	12.7	81.1

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
South Carolina, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	90	42.2	3.5	58	44.3	3.6	24	36.4	3.2	*	*	*	1	50.0	2.3	6	53.7	5.0
Regional	74	34.4	2.7	44	33.2	2.5	26	39.1	3.4	*	*	*	*	*	*	3	25.9	2.4
Distant	33	15.4	1.1	20	14.9	0.9	12	18.3	1.4	*	*	*	*	*	*	1	13.0	1.4
Unknown	17	7.9	0.6	10	7.6	0.5	4	6.1	0.5	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	41	3.2	1.4	31	3.5	1.5	7	2.2	1.0	*	*	*	*	*	*	*	*	*
Localized	416	32.6	14.4	298	33.0	13.9	104	32.0	16.6	*	*	*	3	28.9	7.3	6	27.3	6.6
Regional	446	35.0	15.6	319	35.3	15.2	111	34.2	18.1	*	*	*	4	48.9	13.0	9	42.7	10.4
Distant	267	20.9	9.3	187	20.7	9.0	73	22.5	11.9	*	*	*	1	15.6	3.4	4	19.1	5.7
Unknown	106	8.3	3.9	68	7.5	3.3	30	9.2	5.4	*	*	*	*	*	*	1	6.4	2.4
<i>Age < 50</i>																		
<i>In Situ</i>	4	2.5	0.3	3	2.8	0.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	42	27.1	2.8	26	25.9	2.7	12	29.1	3.2	*	*	*	*	*	*	2	35.3	2.4
Regional	61	39.8	4.2	40	39.3	4.2	17	40.3	4.5	*	*	*	*	*	*	3	50.0	3.1
Distant	38	24.6	2.6	27	26.9	2.9	10	23.3	2.7	*	*	*	*	*	*	*	*	*
Unknown	9	6.0	0.6	5	5.1	0.5	3	6.3	0.7	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	37	3.3	4.3	28	3.5	4.6	*	*	*	*	*	*	*	*	*	*	*	*
Localized	374	33.3	44.6	272	33.9	43.2	92	32.4	51.6	*	*	*	*	*	*	4	23.7	17.6
Regional	385	34.3	45.7	279	34.8	44.2	94	33.3	53.7	*	*	*	*	*	*	6	39.5	29.5
Distant	229	20.4	26.8	160	20.0	25.1	64	22.4	36.0	*	*	*	*	*	*	*	*	*
Unknown	97	8.6	12.4	62	7.8	10.5	27	9.6	17.6	*	*	*	*	*	*	1	9.2	8.8
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	29	2.6	0.9	20	2.5	0.8	8	2.6	0.8	*	*	*	*	*	*	*	*	*
Localized	390	35.0	11.6	276	35.6	11.5	99	33.7	12.1	1	50.0	11.6	4	29.0	7.5	7	38.4	9.3
Regional	381	34.2	11.4	271	35.0	11.3	96	32.7	11.8	*	*	*	5	38.7	9.9	6	37.2	7.7
Distant	226	20.3	6.9	151	19.6	6.5	68	23.2	8.4	*	*	*	2	14.5	4.4	3	16.3	4.4
Unknown	88	7.9	2.6	56	7.3	2.3	23	7.9	2.8	*	*	*	2	12.9	5.2	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	2	1.6	0.1	2	2.1	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	47	34.5	3.0	30	35.4	3.1	14	33.5	3.2	*	*	*	*	*	*	*	*	*
Regional	49	36.1	3.2	29	33.6	3.0	17	40.6	3.9	*	*	*	*	*	*	2	47.1	1.7
Distant	32	23.6	2.1	21	24.6	2.2	10	23.1	2.3	*	*	*	*	*	*	*	*	*
Unknown	6	4.1	0.4	4	4.2	0.4	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	27	2.8	2.7	18	2.6	2.5	*	*	*	*	*	*	*	*	*	*	*	*
Localized	343	35.1	34.0	246	35.6	33.4	85	33.8	35.4	*	*	*	*	*	*	*	*	*
Regional	331	33.9	33.0	242	35.2	33.2	79	31.3	32.7	*	*	*	*	*	*	5	34.8	23.4
Distant	194	19.8	19.3	130	18.9	17.9	58	23.2	24.3	*	*	*	*	*	*	*	*	*
Unknown	83	8.5	8.3	53	7.7	7.2	*	*	*	*	*	*	2	15.1	18.9	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
South Carolina, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	990	18.6	30.1	686	18.0	30.1	268	20.2	31.9	2	21.3	17.9	10	20.2	19.4	17	18.1	19.8
Localized	2,811	52.9	83.6	2,120	55.8	88.6	606	45.8	73.1	4	42.6	32.9	27	54.2	54.3	44	47.6	54.9
Regional	1,140	21.5	36.3	754	19.8	34.3	345	26.1	43.2	3	36.2	26.2	11	22.5	22.7	24	25.6	24.8
Distant	239	4.5	7.3	156	4.1	6.7	75	5.7	9.2	*	*	*	1	2.8	3.1	6	6.0	5.8
Unknown	129	2.4	3.8	84	2.2	3.4	30	2.3	3.8	*	*	*	*	*	*	2	2.6	3.2
<i>Age < 50</i>																		
<i>In Situ</i>	174	19.8	11.5	119	21.3	12.4	45	17.4	10.3	*	*	*	2	14.1	6.1	5	14.7	6.5
Localized	392	44.7	25.7	261	46.7	27.1	106	40.7	24.3	*	*	*	8	52.6	22.7	15	41.8	17.7
Regional	256	29.2	16.9	149	26.6	15.7	90	34.6	20.6	*	*	*	5	32.1	13.6	12	32.8	12.9
Distant	41	4.7	2.7	22	4.0	2.3	15	5.7	3.4	*	*	*	*	*	*	3	9.0	3.7
Unknown	14	1.6	0.9	7	1.3	0.8	4	1.5	0.9	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	816	18.4	79.1	567	17.5	76.5	223	21.0	88.5	*	*	*	8	22.9	54.0	12	20.2	54.7
Localized	2,419	54.6	235.2	1,859	57.3	249.6	500	47.0	200.9	*	*	*	19	54.9	137.2	29	51.2	152.2
Regional	884	19.9	86.9	606	18.7	82.9	255	24.0	102.3	*	*	*	6	18.3	46.4	12	21.3	55.7
Distant	198	4.5	19.6	134	4.1	18.1	60	5.7	24.4	*	*	*	*	*	*	2	4.2	11.4
Unknown	115	2.6	11.4	77	2.4	10.3	26	2.5	11.4	*	*	*	*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	6	0.3	0.2	4	0.3	0.2	1	0.2	0.2	*	*	*	*	*	*	*	*	*
Localized	525	23.3	17.4	420	24.6	18.2	97	19.0	15.5	1	35.0	13.0	2	21.6	4.3	4	25.7	6.0
Regional	526	23.3	17.1	397	23.2	17.0	122	24.1	19.6	1	30.0	8.8	2	24.3	5.0	3	18.9	5.4
Distant	979	43.4	32.2	725	42.4	31.7	240	47.3	37.9	*	*	*	4	48.6	10.4	6	40.5	10.9
Unknown	219	9.7	7.7	163	9.5	7.5	48	9.4	8.4	*	*	*	*	*	*	2	13.5	4.2
<i>Female</i>																		
<i>In Situ</i>	7	0.4	0.2	6	0.4	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	526	28.2	14.4	433	29.1	16.1	83	25.0	9.9	*	*	*	4	27.3	11.4	3	22.9	4.5
Regional	422	22.7	11.4	337	22.6	12.6	76	22.9	8.6	*	*	*	4	23.4	8.1	4	28.6	5.4
Distant	749	40.2	20.5	590	39.6	22.2	147	44.0	17.0	1	50.0	11.9	6	40.3	14.4	5	32.9	6.8
Unknown	160	8.6	4.5	124	8.3	4.7	26	7.7	3.2	*	*	*	1	9.1	3.2	2	14.3	3.4

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	2,698	73.7	82.4	1,757	74.0	71.1	844	73.6	120.8	3	56.5	24.0	12	73.8	37.8	37	73.9	60.3
Regional	437	12.0	13.0	302	12.7	11.9	125	10.9	16.8	*	*	*	3	15.5	6.9	6	11.1	9.1
Distant	226	6.2	7.7	140	5.9	6.3	81	7.0	13.1	*	*	*	*	*	*	4	7.5	8.5
Unknown	298	8.1	10.2	174	7.3	7.9	97	8.5	16.8	*	*	*	*	*	*	4	7.5	6.7
<i>Age < 65</i>																		
Localized	1,028	74.3	35.5	587	75.0	28.4	406	73.8	58.2	*	*	*	3	82.4	7.2	17	77.7	19.5
Regional	198	14.3	6.8	119	15.2	5.7	75	13.7	10.7	*	*	*	*	*	*	2	10.7	2.7
Distant	74	5.3	2.5	37	4.7	1.8	36	6.5	5.0	*	*	*	*	*	*	*	*	*
Unknown	84	6.1	2.9	40	5.2	1.9	33	6.1	4.8	*	*	*	*	*	*	2	7.1	1.8
<i>Age ≥ 65</i>																		
Localized	1,669	73.4	406.4	1,171	73.6	366.1	438	73.4	553.1	*	*	*	10	71.6	249.4	20	70.9	342.5
Regional	239	10.5	55.6	183	11.5	54.9	50	8.3	59.1	*	*	*	*	*	*	3	11.3	53.7
Distant	152	6.7	43.6	103	6.5	37.8	45	7.5	68.8	*	*	*	*	*	*	*	*	*
Unknown	214	9.4	60.8	134	8.4	48.9	64	10.7	100.1	*	*	*	*	*	*	2	7.8	40.2

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
South Dakota, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	12	43.0	2.9	9	42.5	2.6	*	*	*	2	50.0	8.0	*	*	*	*	*	*
Regional	10	37.8	2.4	8	36.8	2.2	*	*	*	1	30.0	4.9	*	*	*	*	*	*
Distant	4	14.8	0.8	3	15.1	0.6	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	1	4.4	0.2	1	5.7	0.3	*	*	*	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	14	5.8	2.8	13	6.1	3.0	*	*	*	*	*	*	*	*	*	*	*	*
Localized	75	31.6	15.1	71	32.3	15.3	*	*	*	3	23.0	17.0	*	*	*	*	*	*
Regional	92	38.5	18.9	85	38.5	19.0	*	*	*	5	37.7	23.7	*	*	*	*	*	*
Distant	45	18.8	9.2	40	18.1	8.8	*	*	*	3	24.6	14.7	*	*	*	*	*	*
Unknown	12	5.2	2.6	11	5.0	2.5	*	*	*	1	11.5	9.9	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	4	16.7	1.4	3	18.9	1.6	*	*	*	*	*	*	*	*	*	*	*	*
Regional	11	50.9	4.5	9	48.9	4.4	*	*	*	1	66.7	8.2	*	*	*	*	*	*
Distant	5	22.2	2.0	4	20.0	1.8	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	1	5.6	0.5	1	6.7	0.6	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	72	33.1	51.1	68	33.5	51.4	*	*	*	3	26.9	61.6	*	*	*	*	*	*
Regional	81	37.3	56.7	76	37.6	57.1	*	*	*	3	32.7	64.5	*	*	*	*	*	*
Distant	40	18.5	28.0	36	17.9	27.0	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	11	5.2	8.1	10	4.9	7.6	*	*	*	1	13.5	35.7	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	10	5.1	1.9	10	5.2	2.0	*	*	*	*	*	*	*	*	*	*	*	*
Localized	71	34.8	13.4	67	35.7	13.6	*	*	*	3	25.0	11.3	*	*	*	*	*	*
Regional	70	34.4	12.6	64	34.0	12.4	*	*	*	4	40.4	18.5	*	*	*	*	*	*
Distant	39	19.4	7.1	35	18.8	6.8	*	*	*	2	23.1	10.0	*	*	*	*	*	*
Unknown	13	6.3	1.9	12	6.3	1.9	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	7	39.8	3.1	6	41.6	3.3	*	*	*	*	*	*	*	*	*	*	*	*
Regional	6	31.2	2.4	5	31.2	2.4	*	*	*	*	*	*	*	*	*	*	*	*
Distant	5	24.7	2.0	3	22.1	1.8	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	63	34.3	40.1	60	35.2	40.7	*	*	*	*	*	*	*	*	*	*	*	*
Regional	64	34.7	39.4	59	34.2	38.5	*	*	*	*	*	*	*	*	*	*	*	*
Distant	35	18.8	20.6	32	18.5	20.1	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
South Dakota, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	137	17.5	27.9	128	17.5	29.0	2	47.6	47.6	4	13.2	14.0	*	*	*	1	20.0	15.6
Localized	449	57.2	85.7	422	58.0	88.5	1	28.6	31.3	15	50.3	59.2	3	51.7	56.3	3	40.0	42.3
Regional	157	20.0	32.0	139	19.1	31.3	*	*	*	9	31.1	36.3	2	27.6	45.9	2	31.4	26.2
Distant	30	3.8	5.7	28	3.9	5.9	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	12	1.6	2.3	11	1.5	2.3	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	25	20.2	11.3	23	21.2	12.4	*	*	*	*	*	*	*	*	*	*	*	*
Localized	58	47.0	25.5	52	48.8	27.6	*	*	*	2	41.4	14.5	1	58.3	27.2	*	*	*
Regional	33	26.9	14.3	26	24.2	13.6	*	*	*	3	48.3	16.0	*	*	*	*	*	*
Distant	5	4.2	2.2	4	4.1	2.3	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	2	1.6	0.9	2	1.7	1.0	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	112	17.0	71.4	105	16.9	72.4	*	*	*	*	*	*	*	*	*	*	*	*
Localized	391	59.1	243.3	370	59.6	248.2	1	40.0	113.4	13	52.5	176.2	2	47.1	132.6	*	*	*
Regional	124	18.7	78.1	113	18.2	77.7	*	*	*	7	27.0	89.5	*	*	*	*	*	*
Distant	25	3.7	15.0	24	3.8	15.5	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	10	1.5	6.0	9	1.4	5.5	*	*	*	*	*	*	*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	1	0.5	0.3	1	0.5	0.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	76	24.5	15.2	73	25.0	15.4	*	*	*	2	17.2	12.0	*	*	*	*	*	*
Regional	63	20.3	12.2	60	20.7	12.4	*	*	*	2	17.2	14.7	*	*	*	*	*	*
Distant	157	50.5	30.6	145	49.8	30.0	1	66.7	29.4	7	57.8	47.5	*	*	*	*	*	*
Unknown	13	4.2	2.7	12	4.0	2.6	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	92	30.1	16.3	85	30.0	16.1	*	*	*	5	30.7	23.5	*	*	*	*	*	*
Regional	69	22.5	12.3	64	22.6	12.2	*	*	*	4	23.9	19.0	*	*	*	*	*	*
Distant	129	42.2	22.4	119	42.1	22.3	*	*	*	7	40.9	31.3	*	*	*	*	*	*
Unknown	15	5.0	2.4	14	5.1	2.3	*	*	*	*	*	*	*	*	*	*	*	*

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	498	75.0	89.6	467	75.4	89.9	5	65.8	73.6	19	68.1	99.6	*	*	*	3	81.0	68.9
Regional	102	15.4	17.7	94	15.2	17.6	2	26.3	46.2	4	13.8	19.9	*	*	*	*	*	*
Distant	40	6.1	8.2	36	5.8	7.8	*	*	*	4	13.0	17.7	*	*	*	*	*	*
Unknown	24	3.6	4.7	22	3.5	4.6	*	*	*	1	5.1	10.6	*	*	*	*	*	*
<i>Age < 65</i>																		
Localized	189	77.2	35.9	175	78.2	36.5	3	73.9	51.2	9	64.7	37.3	*	*	*	*	*	*
Regional	44	17.8	8.0	39	17.5	7.9	*	*	*	2	17.6	10.0	*	*	*	*	*	*
Distant	9	3.5	1.6	6	2.9	1.3	*	*	*	2	14.7	8.6	*	*	*	*	*	*
Unknown	4	1.5	0.7	3	1.4	0.7	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	309	73.7	460.9	292	73.9	458.9	2	53.3	228.8	10	71.4	530.2	*	*	*	*	*	*
Regional	58	13.9	85.1	55	13.9	84.6	*	*	*	1	10.0	88.5	*	*	*	*	*	*
Distant	32	7.6	53.8	30	7.5	53.1	*	*	*	2	11.4	81.2	*	*	*	*	*	*
Unknown	20	4.8	32.5	18	4.6	31.2	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Tennessee, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	134	46.0	3.9	107	48.2	4.2	19	36.5	3.1	Insufficient data for the calculation of AI/AN PRCDA statistics			1	46.7	1.9	5	46.4	3.8
Regional	100	34.2	2.7	75	33.5	2.6	20	36.8	3.2				*	*	*	4	37.5	4.3
Distant	43	14.6	1.1	30	13.7	1.0	11	20.7	1.8				*	*	*	*	*	*
Unknown	15	5.2	0.4	10	4.7	0.3	3	6.0	0.5				*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	40	2.3	1.0	34	2.4	1.0	4	1.7	0.9				*	*	*	*	*	*
Localized	545	31.1	14.6	464	32.1	14.9	65	25.6	13.7				3	20.9	6.2	7	32.7	6.6
Regional	663	37.8	17.9	559	38.6	18.1	89	34.9	19.4				5	37.3	9.9	7	32.7	7.9
Distant	369	21.0	9.8	287	19.8	9.2	71	27.8	15.2				4	31.3	8.7	4	18.7	5.6
Unknown	136	7.8	3.8	103	7.1	3.4	25	10.0	5.9				*	*	*	3	14.0	3.8
<i>Age < 50</i>																		
<i>In Situ</i>	3	1.4	0.1	2	1.4	0.2	*	*	*				*	*	*	*	*	*
Localized	65	31.0	3.2	53	32.2	3.5	7	22.2	2.3				*	*	*	2	48.0	1.9
Regional	81	38.8	4.0	66	40.0	4.3	12	37.1	3.9				*	*	*	1	28.0	1.1
Distant	50	23.8	2.4	37	22.6	2.4	10	30.5	3.1				1	46.2	2.5	*	*	*
Unknown	10	5.0	0.5	6	3.7	0.4	3	9.6	1.0				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	37	2.4	3.4	32	2.5	3.4	*	*	*				*	*	*	*	*	*
Localized	480	31.1	44.4	411	32.0	44.9	58	26.1	43.6				*	*	*	5	28.0	18.9
Regional	582	37.7	54.4	492	38.4	54.2	76	34.5	60.2				*	*	*	6	34.1	25.9
Distant	319	20.7	29.1	250	19.5	26.9	61	27.4	46.7				3	27.8	25.1	*	*	*
Unknown	126	8.2	12.2	97	7.6	11.2	22	10.0	19.0				*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	31	2.0	0.7	26	2.1	0.7	5	1.9	0.8				*	*	*	*	*	*
Localized	478	31.1	11.1	389	31.1	10.9	74	30.7	12.1				5	45.8	8.4	4	25.3	4.7
Regional	596	38.8	13.7	495	39.5	13.8	87	36.0	14.3				4	37.3	6.7	6	35.6	7.7
Distant	314	20.4	7.3	246	19.7	7.0	58	23.8	9.4				1	11.9	1.9	5	28.7	5.7
Unknown	119	7.7	2.7	95	7.6	2.5	18	7.6	3.2				*	*	*	2	9.2	2.2
<i>Age < 50</i>																		
<i>In Situ</i>	2	1.3	0.1	2	1.5	0.1	*	*	*				*	*	*	*	*	*
Localized	57	31.7	2.7	45	32.6	2.9	9	27.7	2.4				*	*	*	2	27.6	1.4
Regional	71	39.0	3.4	54	39.6	3.5	12	37.1	3.1				1	42.9	2.1	2	41.4	2.3
Distant	41	22.9	2.0	30	21.8	1.9	9	28.9	2.4				*	*	*	2	27.6	1.6
Unknown	9	5.0	0.4	6	4.7	0.4	2	5.0	0.4				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	29	2.1	2.2	24	2.2	2.2	*	*	*				*	*	*	*	*	*
Localized	421	31.0	32.9	345	30.9	32.1	66	31.1	37.6				*	*	*	3	24.1	13.4
Regional	526	38.7	40.7	440	39.5	40.7	76	35.9	43.4				3	35.6	18.8	4	32.8	21.8
Distant	272	20.1	21.1	217	19.4	20.2	49	23.1	27.7				*	*	*	3	29.3	16.7
Unknown	110	8.1	8.6	88	7.9	8.1	17	8.0	10.5				*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Tennessee, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	1,019	16.2	23.8	827	15.9	23.8	162	17.6	25.8				11	18.9	17.6	13	13.6	13.3
Localized	3,457	54.8	79.7	2,922	56.3	82.2	444	48.4	71.5				25	41.9	38.2	47	49.1	52.5
Regional	1,365	21.6	33.4	1,087	20.9	33.0	225	24.6	36.5				18	29.2	25.4	27	28.3	28.7
Distant	295	4.7	7.0	221	4.3	6.4	65	7.1	10.5				3	4.3	3.6	4	4.4	4.4
Unknown	170	2.7	3.9	132	2.5	3.6	21	2.3	3.6				3	5.6	5.6	4	4.6	5.4
<i>Age < 50</i>																		
<i>In Situ</i>	169	16.3	8.2	126	16.3	8.2	31	16.1	8.5	Insufficient data for the calculation of AI/AN PRCDA statistics			3	16.5	6.4	6	15.4	5.6
Localized	487	46.9	23.5	373	48.2	24.2	88	45.2	23.7				7	35.0	13.3	14	38.5	13.6
Regional	313	30.1	15.1	229	29.6	14.9	59	30.5	15.8				8	39.8	15.2	13	34.6	12.2
Distant	51	4.9	2.5	34	4.4	2.2	13	6.8	3.5				*	*	*	2	6.6	2.0
Unknown	19	1.8	0.9	12	1.5	0.8	3	1.4	0.8				*	*	*	2	4.9	1.9
<i>Age ≥ 50</i>																		
<i>In Situ</i>	850	16.1	64.7	701	15.9	64.8	130	18.1	71.2				8	20.2	47.0	7	12.5	33.4
Localized	2,970	56.4	226.9	2,549	57.7	234.1	356	49.3	196.5				18	45.5	103.4	33	55.6	154.4
Regional	1,052	20.0	81.2	858	19.4	80.3	166	23.0	90.8				9	23.7	52.1	14	24.4	71.8
Distant	244	4.6	18.8	187	4.2	17.4	52	7.2	28.8				*	*	*	2	3.1	10.7
Unknown	152	2.9	11.6	120	2.7	10.9	18	2.5	10.9				*	*	*	3	4.4	14.8

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	7	0.2	0.2	6	0.2	0.2	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	780	23.2	20.6	691	23.7	21.2	78	19.9	18.2				3	20.8	8.6	6	24.2	9.4
Regional	838	25.0	21.4	733	25.1	22.0	95	24.3	20.7				3	22.1	7.1	6	23.4	8.5
Distant	1,426	42.5	36.7	1,229	42.1	37.2	175	44.9	39.1				7	45.5	18.3	11	46.0	15.5
Unknown	307	9.2	8.5	258	8.8	8.3	42	10.8	10.5				2	11.7	4.6	2	6.5	4.2
<i>Female</i>																		
<i>In Situ</i>	9	0.3	0.2	8	0.3	0.2	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	791	27.5	17.0	702	27.9	18.1	76	24.6	12.6				4	21.2	6.2	6	25.5	8.5
Regional	731	25.4	15.7	636	25.3	16.5	85	27.5	13.8				5	27.1	8.2	4	18.2	6.2
Distant	1,132	39.3	24.6	984	39.1	25.8	128	41.2	20.3				8	49.4	14.2	10	47.3	15.5
Unknown	216	7.5	4.7	188	7.5	4.8	20	6.4	3.5				*	*	*	2	9.1	2.8

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	3,521	73.3	84.8	2,723	73.5	77.6	702	76.3	137.8				17	69.7	36.1	37	71.3	56.5
Regional	648	13.5	15.1	531	14.3	14.7	102	11.1	18.9				4	16.8	8.4	7	14.3	9.7
Distant	256	5.3	7.0	186	5.0	5.9	63	6.8	15.1				2	6.7	4.0	5	8.9	8.4
Unknown	378	7.9	10.3	267	7.2	8.5	53	5.8	14.5				2	6.7	5.0	3	5.4	4.8
<i>Age < 65</i>																		
Localized	1,389	75.4	36.0	990	75.5	31.6	367	78.5	66.0	Insufficient data for the calculation of AI/AN PRCDA statistics			5	65.8	9.6	14	67.3	13.7
Regional	277	15.1	7.1	212	16.2	6.7	57	12.2	10.2				2	26.3	3.8	4	18.8	3.9
Distant	76	4.1	1.9	47	3.6	1.5	27	5.8	4.7				*	*	*	2	7.9	1.6
Unknown	99	5.4	2.5	62	4.7	1.9	16	3.5	2.9				*	*	*	1	5.9	1.3
<i>Age ≥ 65</i>																		
Localized	2,132	72.0	422.1	1,734	72.3	395.6	335	74.0	633.7				12	71.6	219.1	23	73.9	352.6
Regional	371	12.5	70.5	318	13.3	69.9	45	9.9	79.2				2	12.3	39.9	4	11.5	50.3
Distant	180	6.1	41.7	139	5.8	36.9	36	7.9	86.9				*	*	*	3	9.6	55.8
Unknown	280	9.4	63.8	205	8.6	53.6	37	8.1	95.0				*	*	*	2	5.1	28.9

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Texas, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	548	41.6	4.0	241	43.2	4.0	53	33.2	3.0	*	*	*	21	47.1	2.6	229	41.8	4.7
Regional	418	31.7	3.0	160	28.8	2.5	59	36.8	3.3	*	*	*	13	28.3	1.8	184	33.5	4.0
Distant	178	13.5	1.2	74	13.3	1.1	26	16.1	1.5	*	*	*	6	12.6	0.8	72	13.1	1.6
Unknown	175	13.3	1.2	82	14.7	1.2	22	13.9	1.3	*	*	*	5	12.1	0.7	64	11.6	1.4

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	167	2.7	1.2	94	2.7	1.2	34	4.4	2.6	*	*	*	4	2.2	0.7	33	2.0	0.9
Localized	1,847	30.0	13.9	1,072	30.7	14.1	218	28.1	16.3	*	*	*	48	25.7	8.1	497	29.9	14.0
Regional	2,211	35.9	16.6	1,268	36.3	16.8	258	33.2	18.9	*	*	*	71	37.6	11.7	603	36.3	16.8
Distant	1,313	21.3	9.7	705	20.2	9.3	190	24.5	13.7	*	*	*	41	22.0	6.9	369	22.2	10.0
Unknown	622	10.1	4.9	353	10.1	4.8	77	9.9	6.4	*	*	*	23	12.4	4.4	160	9.6	4.9
<i>Age < 50</i>																		
<i>In Situ</i>	11	1.4	0.1	6	1.5	0.2	3	2.5	0.2	*	*	*	*	*	*	2	0.8	0.1
Localized	198	25.3	2.2	100	26.5	2.7	22	21.1	2.0	*	*	*	7	19.6	1.3	67	25.8	1.8
Regional	313	39.9	3.5	150	39.7	4.0	42	40.9	3.8	*	*	*	17	46.2	3.1	102	39.1	2.9
Distant	197	25.2	2.2	88	23.4	2.4	28	27.6	2.6	*	*	*	10	27.2	1.8	70	26.9	2.0
Unknown	65	8.2	0.7	34	8.9	0.9	8	7.8	0.8	*	*	*	2	6.0	0.4	20	7.5	0.5
<i>Age ≥ 50</i>																		
<i>In Situ</i>	156	2.9	4.1	89	2.8	3.9	31	4.7	8.6	*	*	*	*	*	*	31	2.2	3.3
Localized	1,648	30.7	44.8	972	31.2	44.1	197	29.1	53.9	*	*	*	41	27.2	25.8	430	30.7	46.1
Regional	1,898	35.3	51.0	1,118	35.9	50.3	216	32.0	58.4	*	*	*	54	35.4	34.2	501	35.8	53.2
Distant	1,115	20.8	29.3	617	19.8	27.3	162	24.0	42.7	*	*	*	31	20.8	20.1	299	21.3	31.1
Unknown	557	10.4	16.0	320	10.3	15.0	69	10.3	21.2	*	*	*	21	14.0	14.7	140	10.0	16.1
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	110	2.3	0.7	64	2.3	0.7	17	2.4	1.0	*	*	*	3	1.7	0.3	27	2.2	0.6
Localized	1,527	31.2	10.1	887	31.4	10.5	211	30.7	12.3	*	*	*	46	30.5	6.6	377	31.0	9.1
Regional	1,739	35.5	11.6	1,012	35.8	12.0	229	33.5	13.6	*	*	*	56	36.7	8.6	433	35.6	10.4
Distant	997	20.3	6.6	544	19.2	6.5	160	23.3	9.4	*	*	*	33	21.9	5.0	255	21.0	6.1
Unknown	528	10.8	3.5	319	11.3	3.5	69	10.1	4.3	*	*	*	14	9.2	2.5	123	10.1	3.1
<i>Age < 50</i>																		
<i>In Situ</i>	11	1.7	0.1	5	1.6	0.1	2	2.4	0.2	*	*	*	*	*	*	4	1.7	0.1
Localized	197	29.4	2.2	96	31.0	2.6	26	28.0	2.2	*	*	*	8	29.0	1.5	66	28.0	1.8
Regional	251	37.4	2.8	118	38.1	3.2	33	35.3	2.8	*	*	*	11	37.9	1.9	87	37.0	2.5
Distant	158	23.5	1.8	66	21.3	1.8	24	26.1	2.0	*	*	*	8	26.9	1.3	59	25.0	1.7
Unknown	54	8.0	0.6	25	7.9	0.7	8	8.2	0.7	*	*	*	2	6.2	0.3	19	8.3	0.6
<i>Age ≥ 50</i>																		
<i>In Situ</i>	99	2.3	2.3	59	2.3	2.3	14	2.4	3.1	*	*	*	3	2.1	1.2	23	2.4	2.0
Localized	1,330	31.4	30.9	791	31.5	31.2	185	31.2	38.6	*	*	*	38	30.8	20.1	311	31.7	28.2
Regional	1,488	35.2	34.5	894	35.5	35.0	196	33.2	41.8	*	*	*	45	36.4	26.2	346	35.3	31.2
Distant	839	19.8	19.3	478	19.0	18.7	136	22.9	28.5	*	*	*	25	20.7	14.6	197	20.0	17.8
Unknown	474	11.2	11.0	294	11.7	11.1	61	10.4	13.9	*	*	*	12	10.0	8.2	104	10.6	9.9

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Texas, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	3,384	16.1	22.4	1,945	15.5	24.4	487	18.4	27.6	*	*	*	173	21.7	22.9	756	15.7	17.1
Localized	10,800	51.5	71.4	6,902	54.8	83.2	1,145	43.4	65.8	*	*	*	377	47.2	50.7	2,309	48.0	53.6
Regional	4,622	22.0	31.2	2,524	20.1	32.4	674	25.6	38.5	*	*	*	173	21.6	22.6	1,222	25.4	27.4
Distant	1,010	4.8	6.7	531	4.2	6.4	184	7.0	10.6	*	*	*	34	4.3	4.8	255	5.3	6.0
Unknown	1,164	5.5	7.8	683	5.4	8.2	148	5.6	8.7	*	*	*	41	5.2	6.0	273	5.7	6.5
<i>Age < 50</i>																		
<i>In Situ</i>	717	16.4	8.2	344	17.0	9.6	100	15.6	8.7	*	*	*	55	19.9	9.6	210	15.3	6.2
Localized	1,944	44.6	21.9	969	47.7	26.6	255	39.5	21.9	*	*	*	127	46.0	21.8	575	41.9	16.7
Regional	1,265	29.0	14.2	536	26.4	14.8	206	31.9	17.5	*	*	*	71	25.9	12.1	443	32.3	12.7
Distant	208	4.8	2.3	75	3.7	2.0	48	7.4	4.1	*	*	*	11	4.1	1.9	71	5.2	2.0
Unknown	230	5.3	2.6	106	5.2	2.9	36	5.5	3.0	*	*	*	12	4.2	2.0	72	5.3	2.1
<i>Age ≥ 50</i>																		
<i>In Situ</i>	2,668	16.1	59.7	1,601	15.2	63.0	386	19.4	77.0	*	*	*	119	22.7	57.9	546	15.9	45.7
Localized	8,856	53.3	200.8	5,932	56.2	231.5	890	44.7	180.7	*	*	*	251	47.9	126.2	1,734	50.4	150.2
Regional	3,358	20.2	75.9	1,988	18.8	78.4	468	23.5	93.7	*	*	*	101	19.4	50.2	779	22.6	65.9
Distant	803	4.8	18.3	456	4.3	17.7	136	6.8	27.6	*	*	*	23	4.4	12.3	184	5.3	16.3
Unknown	934	5.6	21.3	577	5.5	22.1	113	5.7	23.7	*	*	*	30	5.7	16.5	201	5.8	18.2

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	12	0.2	0.1	10	0.2	0.1	1	0.1	0.1	*	*	*	*	*	*	*	*	*
Localized	1,565	21.4	12.8	1,176	22.7	15.2	182	19.4	15.8	*	*	*	33	17.1	6.6	165	17.2	5.9
Regional	1,560	21.4	12.1	1,129	21.8	14.1	201	21.4	16.2	*	*	*	36	18.7	6.8	189	19.7	6.4
Distant	3,282	44.9	25.4	2,251	43.4	28.2	441	47.1	35.6	*	*	*	101	52.5	18.9	479	49.8	16.2
Unknown	883	12.1	7.3	620	11.9	8.1	111	11.9	10.2	*	*	*	22	11.6	4.4	128	13.3	4.7
<i>Female</i>																		
<i>In Situ</i>	18	0.3	0.1	12	0.3	0.1	2	0.2	0.1	*	*	*	*	*	*	3	0.5	0.1
Localized	1,576	25.1	10.4	1,195	25.7	13.1	175	23.5	11.0	*	*	*	34	22.7	5.4	164	22.9	4.4
Regional	1,306	20.8	8.5	988	21.3	10.8	156	21.0	9.5	*	*	*	26	17.5	4.1	129	18.1	3.4
Distant	2,635	41.9	17.1	1,882	40.5	20.7	341	45.7	20.3	*	*	*	76	50.5	11.9	326	45.6	8.6
Unknown	753	12.0	5.0	572	12.3	6.2	71	9.6	4.7	*	*	*	13	8.9	2.4	92	12.9	2.6

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	8,759	61.8	61.7	5,427	62.6	63.7	1,511	64.3	102.6	1	75.0	67.9	178	60.2	30.7	1,543	59.1	45.0
Regional	1,779	12.6	12.0	1,142	13.2	13.0	275	11.7	17.3	*	*	*	44	15.0	7.3	306	11.7	8.2
Distant	1,070	7.6	8.6	598	6.9	7.8	202	8.6	17.1	*	*	*	21	7.3	4.8	245	9.4	8.4
Unknown	2,562	18.1	20.4	1,501	17.3	19.1	362	15.4	30.3	*	*	*	52	17.6	11.1	518	19.8	18.1
<i>Age < 65</i>																		
Localized	3,638	66.8	25.2	2,075	67.8	26.6	829	67.8	50.6	*	*	*	70	69.0	11.0	617	64.2	14.6
Regional	843	15.5	5.8	503	16.4	6.4	173	14.2	10.5	*	*	*	17	16.9	2.7	143	14.9	3.4
Distant	303	5.6	2.1	141	4.6	1.8	80	6.6	4.9	*	*	*	5	4.7	0.7	76	7.9	1.8
Unknown	664	12.2	4.5	340	11.1	4.2	140	11.5	8.4	*	*	*	10	9.4	1.5	126	13.1	3.0
<i>Age ≥ 65</i>																		
Localized	5,121	58.7	313.7	3,352	59.8	320.2	682	60.5	462.0	*	*	*	107	55.5	167.1	926	56.1	255.0
Regional	935	10.7	54.5	639	11.4	58.5	101	9.0	64.5	*	*	*	27	14.0	39.3	163	9.9	41.3
Distant	768	8.8	53.8	457	8.2	49.2	122	10.8	101.8	*	*	*	17	8.6	32.5	170	10.3	54.2
Unknown	1,899	21.8	129.8	1,161	20.7	122.0	222	19.7	182.1	*	*	*	42	21.9	77.6	392	23.7	122.2

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Utah, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	37	49.3	2.7	28	49.1	2.5	*	*	*	*	*	*	1	27.3	2.0	7	63.2	4.0
Regional	26	33.8	1.9	20	33.9	1.7	*	*	*	*	*	*	3	63.6	5.6	3	24.6	1.6
Distant	10	13.2	0.7	7	12.8	0.6	*	*	*	*	*	*	*	*	*	1	10.5	0.7
Unknown	3	3.7	0.2	2	4.2	0.2	*	*	*	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	7	1.7	0.5	6	1.8	0.6	*	*	*	*	*	*	*	*	*	*	*	*
Localized	153	36.8	11.8	128	36.2	11.4	2	33.3	11.7	1	40.0	20.5	5	37.5	12.6	16	39.7	15.0
Regional	138	33.2	10.8	118	33.2	10.7	1	25.0	15.5	*	*	*	4	31.3	11.0	15	37.2	13.9
Distant	99	23.7	7.6	85	24.1	7.6	1	29.2	11.2	1	46.7	16.0	3	25.0	9.4	7	18.6	7.2
Unknown	19	4.6	1.6	16	4.6	1.6	*	*	*	*	*	*	*	*	*	1	3.0	1.6
<i>Age < 50</i>																		
<i>In Situ</i>	1	1.6	0.1	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	28	36.6	2.8	23	35.5	2.9	*	*	*	*	*	*	1	70.0	3.9	3	34.9	2.1
Regional	30	39.0	3.2	25	39.6	3.4	*	*	*	*	*	*	*	*	*	4	41.9	2.7
Distant	17	21.7	1.8	14	22.3	2.0	*	*	*	*	*	*	*	*	*	2	18.6	1.1
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	6	1.7	1.5	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	125	36.9	35.3	105	36.3	33.7	*	*	*	*	*	*	3	31.5	35.3	13	41.0	48.9
Regional	108	31.9	30.8	92	31.8	29.8	*	*	*	*	*	*	*	*	*	11	35.9	43.0
Distant	82	24.2	22.8	71	24.5	22.3	*	*	*	*	*	*	*	*	*	6	18.6	23.3
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	1	3.8	5.6
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	7	1.9	0.5	6	1.8	0.5	*	*	*	*	*	*	*	*	*	*	*	*
Localized	142	37.8	10.0	118	37.5	9.7	*	*	*	*	*	*	4	30.5	8.7	17	41.1	13.6
Regional	127	33.8	9.2	107	34.0	8.9	1	50.0	16.2	1	46.7	15.9	4	35.6	9.9	13	30.9	10.5
Distant	80	21.1	5.7	67	21.2	5.6	*	*	*	*	*	*	3	28.8	7.2	9	20.8	7.7
Unknown	20	5.4	1.5	17	5.5	1.4	*	*	*	*	*	*	*	*	*	2	4.8	1.9
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	30	39.9	3.1	24	40.6	3.1	*	*	*	*	*	*	*	*	*	5	42.1	3.5
Regional	26	34.1	2.8	19	32.6	2.7	*	*	*	*	*	*	*	*	*	5	43.9	3.8
Distant	18	24.3	2.1	15	25.2	2.1	*	*	*	*	*	*	1	50.0	3.2	2	14.0	1.3
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	112	37.2	28.3	94	36.8	27.0	*	*	*	*	*	*	*	*	*	12	40.7	39.9
Regional	102	33.8	25.8	88	34.4	25.1	*	*	*	1	53.8	57.6	*	*	*	8	26.0	28.2
Distant	61	20.3	15.4	52	20.2	14.8	*	*	*	*	*	*	2	22.2	17.6	7	23.3	24.6
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	2	6.7	7.0

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Utah, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	310	16.0	22.1	268	15.9	22.2	3	23.6	29.6	*	*	*	11	20.1	22.9	27	15.6	21.3
Localized	1,031	53.2	73.0	908	53.9	74.0	4	38.2	51.0	2	48.0	29.5	25	45.7	49.3	88	50.2	70.3
Regional	474	24.5	34.2	406	24.1	34.3	3	30.9	38.2	*	*	*	15	28.3	30.1	48	27.3	34.9
Distant	99	5.1	7.1	83	5.0	7.0	*	*	*	*	*	*	3	5.2	5.2	11	6.5	9.1
Unknown	22	1.1	1.6	20	1.2	1.6	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	71	16.8	8.2	58	17.5	8.5	*	*	*	*	*	*	2	11.1	6.0	10	15.3	8.1
Localized	183	43.3	20.9	143	42.7	20.6	*	*	*	*	*	*	9	47.5	24.5	29	45.2	23.6
Regional	140	33.2	15.6	111	33.1	15.6	*	*	*	*	*	*	7	36.4	17.9	21	33.0	16.5
Distant	27	6.4	3.0	22	6.5	3.0	*	*	*	*	*	*	*	*	*	4	6.2	3.2
Unknown	1	0.3	0.2	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	239	15.8	58.6	209	15.5	58.3	*	*	*	*	*	*	9	25.3	67.1	17	15.8	55.7
Localized	848	56.0	209.2	765	56.7	213.7	*	*	*	*	*	*	15	44.7	114.3	59	53.1	192.9
Regional	334	22.1	82.8	295	21.9	83.2	*	*	*	*	*	*	8	23.5	62.1	26	23.9	82.9
Distant	72	4.7	17.8	62	4.6	17.4	*	*	*	*	*	*	*	*	*	7	6.7	24.4
Unknown	21	1.4	5.4	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	2	0.4	0.1	2	0.5	0.1	*	*	*	*	*	*	*	*	*	*	*	*
Localized	85	22.5	6.9	76	22.6	6.9	1	37.5	18.0	*	*	*	3	26.5	9.9	4	19.0	6.0
Regional	65	17.4	5.2	59	17.5	5.2	*	*	*	*	*	*	*	*	*	4	21.0	7.2
Distant	203	54.0	16.2	183	53.9	16.2	1	37.5	18.1	1	66.7	22.2	6	59.2	17.0	11	55.0	15.2
Unknown	21	5.6	1.8	19	5.5	1.7	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>In Situ</i>	3	0.8	0.2	3	1.0	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	85	25.6	6.0	77	26.2	6.2	*	*	*	*	*	*	2	24.4	5.6	4	18.6	4.2
Regional	67	20.2	4.7	58	19.6	4.6	2	50.0	23.4	*	*	*	1	13.3	2.7	6	25.4	6.6
Distant	157	47.4	10.9	139	47.1	10.8	*	*	*	*	*	*	5	57.8	11.9	12	49.2	10.0
Unknown	20	6.0	1.5	18	6.0	1.5	*	*	*	*	*	*	*	*	*	2	6.8	2.2

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	1,172	73.6	85.5	1,053	73.9	86.4	13	71.7	109.6	2	68.8	38.0	12	63.8	35.6	64	72.7	72.0
Regional	216	13.6	15.0	198	13.9	15.6	3	17.4	26.1	*	*	*	2	12.8	5.7	11	12.4	11.8
Distant	114	7.2	9.5	102	7.1	9.4	*	*	*	*	*	*	2	9.6	7.2	8	9.5	11.9
Unknown	89	5.6	7.2	72	5.0	6.5	1	6.5	12.5	*	*	*	3	13.8	8.7	5	5.4	7.3
<i>Age < 65</i>																		
Localized	420	74.0	30.5	372	74.2	31.8	7	63.6	43.1	*	*	*	5	63.2	11.6	26	76.6	20.9
Regional	100	17.6	7.3	90	17.9	7.7	*	*	*	*	*	*	*	*	*	5	13.5	3.6
Distant	25	4.4	1.8	21	4.1	1.8	*	*	*	*	*	*	*	*	*	2	7.0	1.8
Unknown	23	4.1	1.7	19	3.8	1.6	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	752	73.4	465.7	681	73.7	464.0	6	83.8	569.4	*	*	*	7	64.3	201.0	38	70.2	425.4
Regional	116	11.4	68.2	108	11.7	69.8	*	*	*	*	*	*	*	*	*	6	11.8	68.5
Distant	89	8.7	62.7	81	8.8	62.2	*	*	*	*	*	*	*	*	*	6	11.0	81.7
Unknown	66	6.5	45.3	53	5.7	39.8	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Vermont, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	9	52.4	2.7	8	52.0	2.6	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Regional	5	30.5	1.3	5	32.0	1.3	*	*	*				*	*	*	*	*	*
Distant	2	12.2	0.6	2	12.0	0.6	*	*	*				*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*

Colon and Rectum, 2015–2019

	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
Stage at Diagnosis																		
Male																		
All Ages																		
In Situ	7	4.1	1.6	6	4.1	1.7	*	*	*				*	*	*	*	*	*
Localized	61	38.6	15.3	60	38.5	15.4	*	*	*				*	*	*	*	*	*
Regional	52	32.4	13.4	50	32.4	13.4	*	*	*				*	*	*	*	*	*
Distant	32	19.8	8.3	31	19.9	8.5	*	*	*				*	*	*	*	*	*
Unknown	8	5.0	2.1	8	5.0	2.1	*	*	*				*	*	*	*	*	*
Age < 50																		
In Situ	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*
Localized	6	33.3	3.1	5	33.8	3.2	*	*	*				*	*	*	*	*	*
Regional	6	35.7	3.4	5	33.8	3.2	*	*	*				*	*	*	*	*	*
Distant	5	28.6	2.7	5	30.0	2.9	*	*	*				*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*
Age ≥ 50																		
In Situ	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*
Localized	56	39.2	47.1	54	39.0	47.2	*	*	*				*	*	*	*	*	*
Regional	46	32.0	39.5	45	32.3	39.9	*	*	*				*	*	*	*	*	*
Distant	27	18.8	23.0	26	18.7	23.0	*	*	*				*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*
Female																		
All Ages																		
In Situ	4	3.2	0.9	4	3.3	1.0	*	*	*				*	*	*	*	*	*
Localized	52	37.2	11.5	50	37.0	11.3	*	*	*				*	*	*	*	*	*
Regional	49	34.9	11.0	47	34.7	10.8	*	*	*				1	75.0	20.5	*	*	*
Distant	29	21.1	6.6	29	21.3	6.7	*	*	*				*	*	*	*	*	*
Unknown	5	3.6	1.0	5	3.7	1.0	*	*	*				*	*	*	*	*	*
Age < 50																		
In Situ	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*
Localized	4	31.0	2.4	4	31.8	2.5	*	*	*				*	*	*	*	*	*
Regional	6	42.3	3.2	5	39.4	3.0	*	*	*				*	*	*	*	*	*
Distant	3	23.9	1.9	3	25.8	2.1	*	*	*				*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*
Age ≥ 50																		
In Situ	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*
Localized	47	37.9	35.2	45	37.5	34.4	*	*	*				*	*	*	*	*	*
Regional	43	34.1	31.3	41	34.2	31.3	*	*	*				*	*	*	*	*	*
Distant	26	20.8	18.8	25	20.8	18.7	*	*	*				*	*	*	*	*	*
Unknown	5	4.0	3.6	5	4.1	3.6	*	*	*				*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Vermont, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	103	15.3	24.0	101	15.5	24.4	*	*	*				*	*	*	*	*	*
Localized	409	61.0	93.7	398	61.1	93.9	2	80.0	63.4				3	55.2	51.3	3	59.1	63.8
Regional	125	18.6	31.3	120	18.4	31.3	*	*	*				1	20.7	20.8	*	*	*
Distant	26	3.9	6.1	25	3.8	5.8	*	*	*				*	*	*	*	*	*
Unknown	8	1.2	1.7	8	1.2	1.7	*	*	*				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	16	15.5	8.9	15	15.6	9.0	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	53	52.6	29.8	50	52.6	29.8	*	*	*				1	70.0	30.2	*	*	*
Regional	28	28.0	15.7	27	28.1	15.8	*	*	*				*	*	*	*	*	*
Distant	3	3.2	1.8	3	2.7	1.5	*	*	*				*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	87	15.3	63.5	86	15.5	64.8	*	*	*				*	*	*	*	*	*
Localized	356	62.5	261.0	348	62.5	262.0	*	*	*				2	47.4	106.6	*	*	*
Regional	97	17.0	72.0	93	16.8	71.7	*	*	*				*	*	*	*	*	*
Distant	23	4.0	17.2	22	4.0	17.1	*	*	*				*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*

Lung and Bronchus, 2015–2019

	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races			
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	
Stage at Diagnosis																			
Male																			
In Situ	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*	
Localized	72	26.8	17.0	72	27.3	17.3	*	*	*				*	*	*	*	*	*	
Regional	62	23.2	14.8	60	22.9	14.6	*	*	*				*	*	*	*	*	*	
Distant	125	46.3	29.7	121	46.0	29.7	*	*	*				*	*	*	*	*	*	
Unknown	10	3.6	2.6	10	3.6	2.7	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*	
Female																			
In Situ	*	*	*	*	*	*	*	*	*					*	*	*	*	*	*
Localized	77	29.8	16.3	75	29.6	16.4	*	*	*					*	*	*	*	*	*
Regional	54	21.0	11.3	54	21.0	11.5	*	*	*					*	*	*	*	*	*
Distant	117	45.2	24.7	116	45.3	25.2	*	*	*					*	*	*	*	*	*
Unknown	10	3.8	2.0	10	3.8	2.0	*	*	*				*	*	*	*	*	*	

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	310	68.9	66.9	301	68.7	66.4	4	76.9	145.6				*	*	*	*	*	*
Regional	81	18.0	16.9	79	18.2	17.0	*	*	*				*	*	*	*	*	*
Distant	49	10.9	12.1	48	10.9	12.0	*	*	*				*	*	*	*	*	*
Unknown	10	2.3	2.6	10	2.2	2.6	*	*	*				*	*	*	*	*	*
<i>Age < 65</i>																		
Localized	109	70.8	24.6	104	70.6	24.3	2	73.3	53.5	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Regional	32	20.9	7.2	31	21.3	7.3	*	*	*				*	*	*	*	*	*
Distant	11	7.3	2.7	11	7.2	2.6	*	*	*				*	*	*	*	*	*
Unknown	2	1.0	0.4	1	0.9	0.3	*	*	*				*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	201	67.9	359.7	196	67.8	357.1	2	81.8	782.6				*	*	*	*	*	*
Regional	49	16.4	84.0	48	16.6	84.4	*	*	*				*	*	*	*	*	*
Distant	38	12.8	77.2	37	12.8	76.7	*	*	*				*	*	*	*	*	*
Unknown	9	2.9	18.1	8	2.9	18.0	*	*	*				*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Virginia, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	124	45.6	2.9	74	47.1	2.8	26	43.3	3.0	Insufficient data for the calculation of AI/AN PRCDA statistics			5	30.0	1.4	14	51.5	4.1
Regional	91	33.5	1.9	50	31.4	1.6	21	35.3	2.3				8	50.0	2.4	10	38.2	3.4
Distant	34	12.4	0.7	22	13.9	0.7	7	11.3	0.7				2	13.8	0.6	2	5.9	0.5
Unknown	23	8.5	0.5	12	7.6	0.4	6	10.0	0.7				*	*	*	1	4.4	0.6

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	76	4.1	1.6	53	4.0	1.6	16	4.6	2.1				2	3.0	0.8	2	3.1	0.8
Localized	571	31.1	12.5	412	31.4	12.3	109	30.2	14.5				20	29.4	7.9	14	27.5	7.0
Regional	666	36.3	14.8	487	37.1	14.9	122	33.8	16.4				27	40.1	11.0	22	41.2	9.7
Distant	387	21.0	8.5	271	20.7	8.2	86	23.9	11.4				14	20.2	5.5	11	21.0	4.4
Unknown	138	7.5	3.3	89	6.8	2.9	27	7.5	4.2				5	7.4	2.8	4	7.3	2.6
<i>Age < 50</i>																		
<i>In Situ</i>	5	2.5	0.2	3	2.4	0.2	2	3.6	0.3				*	*	*	*	*	*
Localized	58	26.8	2.1	34	25.4	2.1	13	29.3	2.6				4	28.6	1.6	4	28.8	1.2
Regional	86	39.8	3.3	57	42.0	3.5	16	36.4	3.3				5	39.7	2.2	6	45.5	2.0
Distant	52	24.0	2.0	33	24.6	2.1	12	25.8	2.3				3	27.0	1.5	2	18.2	0.8
Unknown	15	6.9	0.6	8	5.6	0.5	2	4.9	0.4				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	70	4.3	5.4	49	4.2	5.1	15	4.7	6.8				2	3.6	2.9	2	4.1	2.9
Localized	512	31.6	39.6	378	32.1	39.0	96	30.3	45.8				16	29.6	24.2	11	27.0	22.1
Regional	580	35.8	45.0	430	36.5	44.7	105	33.5	50.6				22	40.1	33.9	16	39.8	29.7
Distant	335	20.7	25.5	238	20.2	24.3	74	23.6	35.0				10	18.6	15.9	9	21.9	13.8
Unknown	123	7.6	10.4	82	6.9	9.2	25	7.9	14.2	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	57	3.4	1.1	37	3.1	1.0	13	4.0	1.4				1	2.5	0.5	2	4.1	1.0
Localized	559	33.3	10.6	397	33.4	10.7	110	32.7	11.3				17	30.9	5.8	17	32.3	7.1
Regional	581	34.6	11.1	425	35.7	11.4	105	31.3	11.0				23	41.0	7.2	20	36.8	8.3
Distant	327	19.5	6.2	231	19.4	6.2	72	21.6	7.5				9	16.9	3.2	10	19.0	4.3
Unknown	153	9.1	2.8	100	8.4	2.4	35	10.4	3.7				5	8.6	1.9	4	7.8	1.9
<i>Age < 50</i>																		
<i>In Situ</i>	5	2.3	0.2	2	1.6	0.1	1	3.7	0.3				*	*	*	*	*	*
Localized	71	34.3	2.7	47	34.7	3.0	12	32.8	2.3				2	19.6	0.8	5	35.5	1.9
Regional	73	35.2	2.7	50	36.3	3.1	13	33.9	2.4				5	49.0	2.0	5	30.3	1.7
Distant	48	23.0	1.8	31	22.8	1.9	9	23.3	1.7				3	25.5	1.0	4	23.7	1.3
Unknown	11	5.3	0.4	6	4.5	0.4	2	6.3	0.5				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	52	3.6	3.4	35	3.3	3.1	12	4.0	4.3				*	*	*	*	*	*
Localized	487	33.2	31.5	350	33.2	31.1	97	32.7	35.0				15	33.5	18.8	12	31.1	20.8
Regional	507	34.6	32.9	375	35.6	33.3	92	31.0	33.4				18	39.2	20.8	15	39.4	25.5
Distant	279	19.0	17.8	199	18.9	17.6	64	21.4	22.6				7	15.0	8.9	7	17.1	12.4
Unknown	142	9.7	9.0	94	8.9	7.8	32	10.9	12.3				*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Virginia, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	1,591	19.5	31.0	1,082	18.7	30.7	322	20.2	32.9				95	27.0	28.4	65	23.6	24.2
Localized	4,316	53.0	81.9	3,191	55.1	86.3	769	48.2	79.3				170	48.1	51.2	127	46.5	48.9
Regional	1,674	20.5	33.5	1,130	19.5	33.0	380	23.8	40.0				67	18.9	19.8	65	23.9	22.2
Distant	375	4.6	7.1	252	4.4	6.7	91	5.7	9.6				12	3.3	3.6	13	4.7	4.9
Unknown	193	2.4	3.6	131	2.3	3.4	34	2.1	3.6				10	2.8	3.2	4	1.4	1.9
<i>Age < 50</i>																		
<i>In Situ</i>	321	21.4	12.1	202	21.9	12.6	55	17.6	10.4	Insufficient data for the calculation of AI/AN PRCDA statistics			32	26.8	12.9	23	22.4	9.0
Localized	661	44.1	24.7	424	45.9	26.1	126	40.8	23.7				52	43.3	20.7	42	40.9	16.1
Regional	430	28.7	16.2	253	27.4	15.9	103	33.2	19.1				30	25.2	12.0	33	31.5	12.1
Distant	58	3.9	2.2	27	2.9	1.7	20	6.5	3.8				3	2.5	1.2	5	4.8	1.9
Unknown	29	1.9	1.1	17	1.9	1.1	6	1.9	1.1				3	2.2	1.0	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	1,270	19.1	80.3	880	18.1	78.3	267	20.8	92.0				63	27.1	69.1	42	24.4	64.2
Localized	3,655	55.0	231.8	2,767	56.9	243.8	643	50.0	224.7				118	50.5	131.2	85	49.8	134.9
Regional	1,243	18.7	78.8	877	18.0	77.9	277	21.6	94.6				36	15.6	40.4	33	19.2	48.8
Distant	317	4.8	20.2	225	4.6	19.7	71	5.5	24.8				9	3.7	10.0	8	4.6	12.8
Unknown	164	2.5	10.3	113	2.3	9.5	28	2.2	10.1				7	3.1	9.0	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	8	0.3	0.2	6	0.3	0.2	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	640	22.7	14.1	507	23.5	14.7	107	20.3	14.9				13	17.6	5.8	6	19.8	5.5
Regional	659	23.3	14.0	503	23.3	14.2	126	24.0	17.1				16	22.3	7.4	8	23.5	4.8
Distant	1,304	46.2	28.1	983	45.5	28.1	253	48.1	33.9				36	50.1	16.2	16	49.4	10.2
Unknown	213	7.5	5.0	161	7.5	4.9	39	7.5	6.2				7	9.4	3.4	2	7.4	2.6
<i>Female</i>																		
<i>In Situ</i>	10	0.4	0.2	8	0.4	0.2	1	0.3	0.1	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	727	27.3	13.1	587	28.4	14.5	108	23.7	11.0				15	22.7	5.4	11	24.9	5.7
Regional	596	22.4	10.7	465	22.5	11.6	106	23.3	10.5				13	18.8	4.2	6	14.7	3.0
Distant	1,093	41.1	19.7	824	39.9	20.5	199	43.8	20.2				33	48.7	11.0	23	53.0	11.0
Unknown	234	8.8	4.2	181	8.8	4.4	40	8.9	4.4				6	9.3	2.5	3	7.4	1.8

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	3,736	74.6	73.5	2,353	74.2	62.5	1,041	76.3	122.2	Insufficient data for the calculation of AI/AN PRCDA statistics			92	75.4	38.1	84	69.3	46.2
Regional	602	12.0	11.5	409	12.9	10.6	148	10.8	16.5				16	13.3	6.9	17	14.3	8.3
Distant	347	6.9	7.9	225	7.1	6.8	96	7.0	13.5				8	6.7	4.0	12	9.7	8.6
Unknown	326	6.5	7.4	185	5.8	5.6	80	5.9	11.9				6	4.6	2.9	8	6.7	5.8
<i>Age < 65</i>																		
Localized	1,600	76.1	32.7	894	76.0	25.8	555	77.1	62.9	Insufficient data for the calculation of AI/AN PRCDA statistics			28	74.7	10.5	44	71.2	16.6
Regional	304	14.4	6.2	190	16.2	5.5	92	12.8	10.4				6	16.1	2.2	11	17.3	3.9
Distant	94	4.5	1.9	46	3.9	1.3	41	5.6	4.5				2	4.8	0.7	3	5.4	1.3
Unknown	105	5.0	2.1	46	3.9	1.4	32	4.4	3.5				2	4.3	0.6	4	6.1	1.4
<i>Age ≥ 65</i>																		
Localized	2,136	73.5	355.2	1,459	73.1	315.9	486	75.3	531.8				64	75.7	228.9	40	67.3	251.1
Regional	298	10.3	48.1	219	11.0	45.8	55	8.6	58.2				10	12.1	39.1	7	11.1	38.4
Distant	252	8.7	49.3	179	9.0	44.9	55	8.6	75.9				6	7.6	27.4	8	14.1	59.0
Unknown	221	7.6	43.6	139	7.0	35.2	48	7.5	69.8				4	4.7	18.5	4	7.4	36.4

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Washington, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	128	50.5	3.5	87	48.5	3.3	6	56.1	4.2	2	46.2	4.5	17	55.7	3.9	13	52.4	3.7
Regional	75	29.4	1.9	53	29.4	1.8	3	29.8	2.7	2	34.6	3.3	9	29.5	2.2	8	31.5	2.5
Distant	33	13.0	0.8	26	14.4	0.8	*	*	*	*	*	*	3	10.1	0.7	3	12.1	1.0
Unknown	18	7.0	0.4	14	7.6	0.4	*	*	*	*	*	*	1	4.7	0.3	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	10	0.7	0.2	7	0.6	0.2	*	*	*	*	*	*	*	*	*	2	2.1	0.6
Localized	508	32.7	12.6	411	33.0	12.5	17	30.0	11.1	8	28.6	16.2	36	30.8	12.0	23	29.4	9.8
Regional	576	37.1	14.5	461	37.0	14.2	22	38.9	17.0	10	36.8	20.2	45	37.8	15.3	32	41.1	14.7
Distant	327	21.1	8.2	266	21.3	8.2	13	23.7	10.3	6	21.8	11.3	26	22.2	8.9	15	19.0	6.3
Unknown	131	8.4	3.4	100	8.0	3.1	4	6.4	3.0	3	12.8	7.6	10	8.6	3.6	6	8.3	3.6
<i>Age < 50</i>																		
<i>In Situ</i>	1	0.7	0.1	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	63	30.2	2.7	46	30.6	2.8	4	37.5	3.1	1	25.0	4.5	6	24.3	2.1	5	29.7	1.6
Regional	83	39.6	3.5	57	38.4	3.5	4	43.8	3.4	2	35.7	6.0	11	47.8	4.3	8	44.0	2.7
Distant	50	23.8	2.1	38	25.1	2.3	1	12.5	1.0	1	25.0	4.5	5	21.7	1.9	4	23.1	1.3
Unknown	12	5.7	0.5	8	5.2	0.5	*	*	*	*	*	*	1	5.2	0.5	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	9	0.7	0.7	*	*	*	*	*	*	*	*	*	*	*	*	2	2.7	2.2
Localized	444	33.1	38.7	365	33.4	38.0	13	28.5	32.2	6	29.5	46.9	31	32.4	37.8	17	29.4	31.3
Regional	493	36.7	43.4	403	36.8	42.2	18	37.9	52.6	8	37.1	57.2	34	35.4	44.1	24	40.3	46.3
Distant	277	20.7	24.2	228	20.8	23.7	12	26.0	34.6	4	21.0	29.3	21	22.3	27.1	10	17.7	19.5
Unknown	119	8.8	11.0	92	8.4	10.1	*	*	*	*	*	*	9	9.5	11.9	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	7	0.5	0.2	6	0.6	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	473	34.4	10.9	380	34.0	10.9	15	33.3	12.5	9	35.1	18.2	34	33.8	8.3	27	43.2	10.8
Regional	517	37.6	11.7	422	37.7	11.6	17	36.8	14.4	11	41.0	19.8	40	39.6	10.2	22	34.4	9.2
Distant	261	19.0	5.9	215	19.2	6.0	9	19.3	7.2	5	17.9	8.8	19	19.1	4.9	11	17.4	4.3
Unknown	117	8.5	2.5	95	8.5	2.4	4	9.2	3.9	2	6.0	3.1	7	7.4	2.0	3	4.7	1.7
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	69	35.9	3.0	48	35.4	3.1	4	36.0	3.1	2	36.4	4.5	5	27.8	1.6	9	47.5	2.9
Regional	72	37.1	3.1	49	35.7	3.1	4	36.0	3.5	2	54.5	6.6	8	46.7	2.9	6	32.3	2.3
Distant	43	22.5	1.9	33	24.3	2.1	2	22.0	2.2	*	*	*	4	21.1	1.3	4	19.2	1.4
Unknown	8	4.2	0.4	6	4.1	0.4	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	404	34.2	31.7	332	33.8	31.3	12	32.6	37.0	8	34.8	54.3	29	35.1	26.0	18	41.3	31.6
Regional	445	37.7	34.2	374	38.0	34.0	13	37.1	42.9	9	38.4	54.2	31	38.0	29.5	15	35.3	27.6
Distant	217	18.4	16.4	182	18.5	16.4	7	18.5	20.3	*	*	*	15	18.6	14.4	7	16.5	12.2
Unknown	109	9.2	8.2	90	9.1	7.8	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Washington, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	1,372	18.9	31.5	1,088	18.2	31.0	39	21.6	29.8	19	18.1	32.0	145	25.4	35.2	58	17.9	21.1
Localized	3,907	53.8	87.1	3,310	55.3	90.7	79	43.8	63.9	49	47.5	84.1	273	47.9	66.1	153	47.0	64.0
Regional	1,500	20.6	35.5	1,201	20.1	35.6	47	25.9	36.1	25	24.1	45.5	118	20.7	28.3	91	28.0	32.6
Distant	265	3.6	6.0	215	3.6	6.1	9	5.1	7.1	7	6.8	12.5	18	3.1	4.2	14	4.3	5.5
Unknown	222	3.1	4.9	170	2.8	4.5	7	3.7	5.0	4	3.5	7.0	16	2.9	4.1	9	2.8	4.4
<i>Age < 50</i>																		
<i>In Situ</i>	264	20.7	11.9	174	19.8	11.2	8	17.5	8.9	5	21.1	15.0	48	25.4	16.8	23	20.5	9.0
Localized	560	43.9	24.8	403	45.7	25.6	19	40.2	20.0	8	36.0	25.1	81	42.7	27.8	41	36.3	15.8
Regional	377	29.6	16.7	256	29.0	16.3	16	33.8	16.5	8	36.8	24.8	48	25.6	16.5	43	37.5	15.9
Distant	49	3.8	2.1	33	3.8	2.1	3	6.8	3.2	*	*	*	6	3.4	2.1	4	3.9	1.6
Unknown	27	2.1	1.2	15	1.7	1.0	*	*	*	*	*	*	5	2.9	1.9	2	1.8	0.7
<i>Age ≥ 50</i>																		
<i>In Situ</i>	1,108	18.5	82.7	914	17.9	82.7	31	23.0	84.3	14	17.3	76.4	97	25.4	83.4	35	16.5	52.8
Localized	3,347	55.9	250.2	2,907	57.0	261.2	60	45.1	178.8	41	50.8	238.7	192	50.5	166.3	111	52.7	190.2
Regional	1,123	18.7	84.5	945	18.5	86.2	31	23.1	87.2	16	20.5	99.5	70	18.3	59.2	48	22.8	76.3
Distant	217	3.6	16.3	182	3.6	16.5	6	4.5	17.5	*	*	*	11	2.9	9.6	10	4.5	15.8
Unknown	196	3.3	14.5	154	3.0	13.6	*	*	*	*	*	*	11	2.9	9.7	7	3.4	14.0

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	13	0.6	0.3	12	0.6	0.4	*	*	*	*	*	*	*	*	*	*	*	*
Localized	514	23.2	13.1	455	23.5	13.5	16	23.0	15.2	5	17.1	10.6	26	21.1	10.0	10	17.0	6.4
Regional	484	21.8	11.7	427	22.1	12.2	12	17.4	9.1	6	20.7	11.3	21	17.3	8.1	16	26.5	9.6
Distant	1,003	45.2	24.6	857	44.3	24.8	35	50.6	30.3	14	51.4	32.3	65	53.5	23.7	28	48.3	16.7
Unknown	207	9.3	5.4	182	9.4	5.5	6	9.0	7.0	3	10.7	6.8	10	7.9	4.0	4	7.5	4.0
<i>Female</i>																		
<i>In Situ</i>	26	1.1	0.6	23	1.1	0.6	*	*	*	*	*	*	2	1.8	0.6	*	*	*
Localized	638	27.5	13.8	561	27.7	14.4	14	25.4	12.8	9	24.0	17.2	31	25.5	8.5	19	29.1	9.8
Regional	485	21.0	10.3	434	21.4	10.9	12	22.1	10.6	7	17.3	12.8	19	15.3	4.8	12	18.7	6.2
Distant	958	41.4	20.6	822	40.6	21.1	25	44.6	21.6	19	47.4	35.7	61	49.4	15.9	29	44.6	15.4
Unknown	208	9.0	4.5	184	9.1	4.6	4	6.9	3.5	4	10.2	8.2	10	8.1	2.8	4	6.7	2.5

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	3,204	72.8	71.7	2,671	72.2	70.7	155	75.2	105.3	28	76.3	58.4	119	70.3	39.9	90	68.9	46.9
Regional	668	15.2	14.5	577	15.6	14.8	29	14.0	20.0	5	12.9	9.3	29	17.1	9.6	18	13.7	9.4
Distant	418	9.5	10.8	353	9.6	10.7	19	9.4	17.3	3	8.6	8.5	19	11.3	7.8	19	14.6	12.3
Unknown	111	2.5	3.0	96	2.6	3.0	3	1.5	4.1	*	*	*	2	1.4	0.9	4	2.9	3.5
<i>Age < 65</i>																		
Localized	1,169	75.6	26.7	925	74.6	26.1	93	79.6	54.1	10	73.2	17.9	40	75.3	12.3	41	73.2	14.8
Regional	269	17.4	6.1	229	18.4	6.4	16	13.7	9.4	2	16.9	4.1	10	19.5	3.2	8	15.0	3.1
Distant	93	6.0	2.1	74	6.0	2.1	8	6.5	4.4	1	8.5	2.0	3	4.9	0.8	6	11.1	2.2
Unknown	15	1.0	0.3	13	1.0	0.4	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	2,035	71.3	382.4	1,746	71.1	378.6	62	69.4	459.5	18	78.3	338.2	78	67.9	230.8	49	65.6	269.0
Regional	399	14.0	72.2	348	14.2	72.6	13	14.3	93.6	2	10.4	45.4	18	15.9	53.5	9	12.6	53.3
Distant	325	11.4	71.1	279	11.4	70.3	12	13.2	106.7	2	8.7	53.2	16	14.2	56.4	13	17.2	81.7
Unknown	96	3.4	21.6	83	3.4	21.5	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Seattle/Puget Sound, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	92	49.9	3.5	60	47.3	3.3	5	55.1	3.8	2	53.3	4.6	15	56.7	3.9	7	49.3	3.4
Regional	58	31.6	2.1	40	31.7	2.1	4	38.8	3.3	*	*	*	8	29.1	2.2	5	35.6	3.0
Distant	26	14.1	0.9	20	15.9	0.9	*	*	*	*	*	*	3	11.2	0.8	2	13.7	1.3
Unknown	8	4.3	0.3	7	5.2	0.3	*	*	*	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	2	0.2	0.1	1	0.1	0.0	*	*	*	*	*	*	*	*	*	*	*	*
Localized	382	34.3	13.9	300	34.4	13.7	17	32.0	13.3	6	34.1	20.5	35	31.7	12.8	17	37.4	15.6
Regional	420	37.6	15.6	329	37.7	15.3	21	39.0	18.8	6	31.8	17.6	44	39.0	16.4	17	38.3	16.2
Distant	242	21.7	8.9	192	22.0	8.9	13	23.4	11.2	4	25.0	13.8	25	22.4	9.5	8	18.5	7.6
Unknown	68	6.1	2.7	50	5.8	2.4	3	5.2	3.0	2	9.1	6.5	8	6.8	3.0	2	4.8	2.4
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	52	32.2	3.0	37	32.7	3.2	3	35.7	2.9	1	31.6	6.0	5	24.5	2.2	4	34.0	1.8
Regional	63	39.3	3.7	43	37.7	3.7	4	47.6	3.7	1	36.8	6.4	10	47.3	4.4	4	41.5	2.5
Distant	39	24.2	2.3	30	26.4	2.6	*	*	*	*	*	*	5	21.8	2.0	2	22.6	1.3
Unknown	7	4.1	0.4	4	3.2	0.3	*	*	*	*	*	*	1	5.5	0.5	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	1	0.2	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	331	34.6	42.4	263	34.6	41.1	14	31.3	40.6	5	34.8	58.5	30	33.4	40.4	13	38.5	51.9
Regional	357	37.4	46.9	287	37.7	45.9	17	37.4	58.3	4	30.4	46.9	33	37.0	47.8	13	37.4	51.9
Distant	203	21.3	26.3	162	21.3	25.5	*	*	*	*	*	*	20	22.5	28.9	6	17.2	24.0
Unknown	62	6.5	8.7	47	6.2	8.0	*	*	*	*	*	*	6	7.1	9.6	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	2	0.2	0.1	2	0.2	0.1	*	*	*	*	*	*	*	*	*	*	*	*
Localized	339	35.1	11.3	266	34.9	11.4	14	31.8	12.7	7	39.3	20.5	33	34.6	8.9	16	40.2	11.7
Regional	369	38.2	12.1	289	37.9	11.9	18	41.9	17.4	6	36.0	19.3	38	40.3	10.9	15	37.6	11.8
Distant	197	20.3	6.5	158	20.7	6.6	9	21.2	8.8	4	20.2	10.9	19	19.6	5.3	7	17.5	4.9
Unknown	60	6.2	1.9	47	6.2	1.8	2	5.1	2.2	*	*	*	5	5.3	1.5	2	4.6	2.0
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	49	35.5	3.0	34	35.8	3.2	3	34.7	3.4	*	*	*	5	29.8	1.8	4	41.2	2.3
Regional	53	37.8	3.2	35	36.7	3.2	4	40.8	4.3	1	46.7	5.8	8	47.6	3.0	3	33.3	2.1
Distant	32	23.0	2.0	23	24.2	2.1	2	22.4	2.5	*	*	*	3	20.2	1.3	2	23.5	1.5
Unknown	5	3.5	0.3	3	3.1	0.3	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	289	35.0	33.3	232	34.8	33.0	10	31.0	37.1	*	*	*	28	35.6	27.6	11	39.9	36.3
Regional	316	38.2	35.4	254	38.1	34.7	14	42.3	51.5	5	33.8	54.6	30	38.7	31.6	11	39.2	36.9
Distant	165	19.9	18.3	135	20.2	18.4	7	20.8	25.3	*	*	*	15	19.5	15.8	4	15.4	13.8
Unknown	55	6.7	6.0	44	6.6	5.6	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Seattle/Puget Sound, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	1,030	19.4	34.3	788	18.4	33.6	37	21.3	31.5	13	17.3	35.0	139	25.7	37.4	42	19.1	27.5
Localized	2,911	54.7	94.8	2,410	56.3	99.3	79	46.1	71.8	35	47.2	97.3	263	48.7	70.7	108	49.2	84.8
Regional	1,117	21.0	38.2	870	20.3	38.4	46	26.8	40.4	19	25.5	53.9	114	21.2	30.4	61	27.6	40.1
Distant	205	3.8	6.7	164	3.8	6.9	9	5.5	7.9	6	8.1	16.9	18	3.3	4.7	8	3.4	5.3
Unknown	58	1.1	1.8	45	1.1	1.8	*	*	*	1	1.9	5.1	6	1.1	1.7	1	0.6	1.6
<i>Age < 50</i>																		
<i>In Situ</i>	209	21.0	13.2	130	19.6	12.2	8	17.8	9.5	3	20.5	16.7	47	25.6	18.1	18	23.0	12.1
Localized	450	45.4	28.0	315	47.5	28.9	17	39.7	20.6	6	34.9	27.5	79	43.5	30.2	29	37.7	20.0
Regional	289	29.2	18.0	189	28.5	17.4	16	35.6	18.3	6	36.1	27.1	48	26.5	18.1	29	37.0	19.1
Distant	38	3.8	2.3	25	3.8	2.3	3	6.8	3.4	*	*	*	7	3.6	2.4	2	2.3	1.2
Unknown	6	0.6	0.4	4	0.6	0.3	*	*	*	*	*	*	1	0.8	0.6	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	821	19.0	89.6	658	18.2	89.8	29	22.4	89.1	9	16.4	82.9	92	25.8	88.2	24	17.1	67.7
Localized	2,461	56.9	269.5	2,095	58.0	283.8	62	48.3	205.6	29	50.7	280.2	183	51.4	176.8	79	55.4	254.7
Regional	828	19.1	91.1	681	18.8	93.3	31	23.8	98.0	13	22.4	124.1	66	18.4	62.6	32	22.5	95.0
Distant	167	3.9	18.3	138	3.8	18.7	6	5.0	19.7	*	*	*	11	3.1	10.5	6	4.1	16.2
Unknown	52	1.2	5.7	42	1.2	5.5	*	*	*	*	*	*	5	1.3	4.6	1	1.0	5.9

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	9	0.6	0.4	9	0.7	0.4	*	*	*	*	*	*	*	*	*	*	*	*
Localized	366	23.7	14.1	313	24.1	14.5	15	23.1	16.0	5	21.7	20.7	24	20.7	10.3	9	22.1	12.3
Regional	334	21.7	12.2	287	22.1	12.5	11	17.0	9.7	4	17.4	13.5	22	19.2	9.3	10	24.1	12.3
Distant	758	49.1	27.8	626	48.2	27.7	35	54.6	35.9	12	53.0	44.9	65	56.0	26.2	19	48.7	22.3
Unknown	75	4.9	3.1	64	4.9	3.1	3	5.2	4.8	2	7.8	7.1	5	4.0	2.1	2	4.5	4.0
<i>Female</i>																		
<i>In Situ</i>	23	1.4	0.7	20	1.5	0.8	*	*	*	*	*	*	2	1.4	0.4	*	*	*
Localized	469	28.8	14.9	403	29.1	15.6	14	27.6	14.7	8	29.0	25.5	30	26.2	9.0	12	27.2	12.1
Regional	334	20.5	10.4	288	20.8	10.9	12	23.0	11.6	6	22.5	18.5	18	15.7	5.2	9	20.2	9.2
Distant	719	44.2	22.7	601	43.4	23.2	23	44.4	22.8	13	45.7	38.2	59	51.6	17.1	22	48.7	21.6
Unknown	82	5.0	2.6	71	5.1	2.7	2	3.8	2.5	*	*	*	6	5.1	1.8	1	3.1	1.4

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	2,459	73.2	81.6	2,048	72.9	82.4	154	75.8	121.8	23	75.3	77.5	116	70.1	43.6	56	70.9	57.3
Regional	519	15.5	16.7	442	15.7	17.2	28	13.9	22.7	4	12.7	12.9	29	17.5	10.7	11	13.3	10.2
Distant	330	9.8	12.8	276	9.8	12.8	19	9.6	20.3	3	10.0	12.9	20	11.8	8.8	11	14.3	15.6
Unknown	50	1.5	2.1	44	1.6	2.2	2	0.8	3.4	*	*	*	*	*	*	1	1.5	2.6
<i>Age < 65</i>																		
Localized	912	75.9	30.1	718	75.0	29.9	87	78.7	57.6	8	71.9	21.9	40	75.3	13.7	26	76.6	18.2
Regional	215	17.8	7.1	179	18.7	7.4	16	14.1	10.6	2	14.0	4.4	11	19.9	3.6	5	14.0	3.4
Distant	70	5.8	2.3	55	5.7	2.3	8	7.2	5.3	1	12.3	3.7	3	4.9	0.9	3	9.4	2.2
Unknown	6	0.5	0.2	5	0.5	0.2	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	1,546	71.8	437.3	1,330	71.8	444.9	67	72.3	565.7	14	77.4	462.0	76	67.7	250.4	30	66.5	328.1
Regional	304	14.1	82.9	263	14.2	84.6	13	13.6	106.5	2	11.8	71.2	18	16.3	59.4	6	12.8	57.6
Distant	260	12.1	85.6	222	12.0	85.8	11	12.3	124.4	2	8.6	76.5	17	15.1	63.6	8	18.1	108.1
Unknown	44	2.0	15.2	39	2.1	15.5	2	1.7	27.0	*	*	*	*	*	*	1	2.6	20.7

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
West Virginia, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	42	46.7	4.7	41	47.5	4.9	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Regional	29	31.9	2.8	27	32.1	2.8	*	*	*				*	*	*	*	*	*
Distant	15	17.0	1.4	15	17.1	1.4	*	*	*				*	*	*	*	*	*
Unknown	4	4.5	0.4	3	3.3	0.3	*	*	*				*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	32	5.1	2.5	30	4.9	2.4	2	9.8	5.2	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	224	35.4	19.1	216	35.5	19.3	6	32.6	18.1				*	*	*	*	*	*
Regional	214	33.8	18.5	206	34.0	18.7	6	32.6	15.1				*	*	*	*	*	*
Distant	133	21.0	11.4	128	21.1	11.5	4	19.6	10.3				*	*	*	*	*	*
Unknown	30	4.7	2.6	28	4.5	2.5	*	*	*				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	1	1.9	0.2	*	*	*	*	*	*				*	*	*	*	*	*
Localized	23	35.8	4.2	21	35.3	4.2	2	44.4	7.3				*	*	*	*	*	*
Regional	24	37.0	4.4	23	37.3	4.5	1	33.3	5.6				*	*	*	*	*	*
Distant	15	23.5	2.8	14	23.8	2.9	*	*	*				*	*	*	*	*	*
Unknown	1	1.9	0.2	1	2.0	0.2	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>										Insufficient data for the calculation of AI/AN PRCDA statistics								
<i>In Situ</i>	31	5.5	8.6	*	*	*	2	12.2	18.7				*	*	*	*	*	*
Localized	201	35.4	58.1	194	35.5	58.7	4	29.7	46.3				*	*	*	*	*	*
Regional	190	33.4	55.2	184	33.6	55.9	5	32.4	40.0				*	*	*	*	*	*
Distant	118	20.7	33.8	114	20.8	34.3	*	*	*				*	*	*	*	*	*
Unknown	29	5.1	9.0	26	4.8	8.6	*	*	*				*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	23	4.2	1.7	22	4.2	1.7	*	*	*				*	*	*	*	*	*
Localized	213	38.6	16.2	206	38.9	16.4	4	28.9	11.4				*	*	*	*	*	*
Regional	182	32.9	13.7	174	32.8	13.7	6	38.2	16.9				*	*	*	*	*	*
Distant	104	18.8	7.9	99	18.7	8.0	3	22.4	9.0				*	*	*	*	*	*
Unknown	30	5.4	2.0	28	5.3	2.0	*	*	*				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	1	2.6	0.3	1	2.7	0.3	*	*	*				*	*	*	*	*	*
Localized	22	41.6	4.1	22	41.8	4.4	*	*	*				*	*	*	*	*	*
Regional	18	33.3	3.3	17	33.0	3.4	*	*	*				*	*	*	*	*	*
Distant	11	20.6	2.1	11	20.7	2.2	*	*	*				*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	22	4.4	5.6	21	4.4	5.5	*	*	*				*	*	*	*	*	*
Localized	191	38.3	47.7	185	38.6	48.1	*	*	*				*	*	*	*	*	*
Regional	164	32.9	41.0	157	32.8	40.9	*	*	*				*	*	*	*	*	*
Distant	93	18.6	23.3	89	18.5	23.2	3	23.9	32.7				*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*				*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
West Virginia, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	275	15.2	22.4	263	15.1	22.4	8	15.4	21.7				1	12.8	11.8	2	23.9	20.9
Localized	1,011	55.8	78.1	974	56.1	78.7	24	49.0	68.8				7	74.5	79.3	3	34.8	32.5
Regional	387	21.4	32.7	369	21.2	32.6	14	27.9	42.9				*	*	*	2	23.9	22.4
Distant	108	6.0	8.6	104	6.0	8.7	3	6.1	8.3				*	*	*	*	*	*
Unknown	30	1.7	2.4	28	1.6	2.3	*	*	*				*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	46	16.8	8.7	44	16.7	8.7	1	14.6	8.2	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	128	46.2	23.9	122	46.7	24.3	3	35.4	19.6				2	72.7	26.7	*	*	*
Regional	80	28.9	15.0	75	28.6	15.0	4	43.8	24.1				*	*	*	*	*	*
Distant	17	6.1	3.1	17	6.4	3.3	*	*	*				*	*	*	*	*	*
Unknown	5	2.0	1.0	4	1.6	0.8	*	*	*				*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	228	14.9	58.1	219	14.9	58.3	6	15.6	57.0				*	*	*	*	*	*
Localized	883	57.5	220.1	852	57.7	221.4	21	52.3	197.7				5	75.0	217.2	*	*	*
Regional	307	20.0	78.8	294	19.9	78.8	10	24.1	92.0				*	*	*	*	*	*
Distant	91	5.9	22.9	87	5.9	22.8	*	*	*				*	*	*	*	*	*
Unknown	25	1.6	6.0	23	1.6	6.0	*	*	*				*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	2	0.2	0.2	2	0.2	0.2	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	255	22.9	20.2	248	23.0	20.5	5	19.4	18.2				*	*	*	*	*	*
Regional	272	24.4	21.6	262	24.3	21.8	9	31.7	24.5				*	*	*	*	*	*
Distant	535	48.0	42.8	520	48.2	43.4	13	45.3	38.8				1	50.0	17.5	*	*	*
Unknown	50	4.5	4.2	47	4.4	4.2	*	*	*				*	*	*	*	*	*
<i>Female</i>																		
<i>In Situ</i>	3	0.3	0.2	3	0.3	0.2	*	*	*	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	*	*	*
Localized	285	29.2	20.0	278	29.2	20.4	6	28.8	15.2				*	*	*	*	*	*
Regional	226	23.1	16.1	220	23.1	16.4	5	24.0	14.1				*	*	*	*	*	*
Distant	431	44.1	30.9	419	44.1	31.4	9	42.3	23.9				1	66.7	12.2	*	*	*
Unknown	33	3.4	2.2	31	3.3	2.2	*	*	*				*	*	*	*	*	*

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	1,011	78.2	75.9	941	78.4	73.9	55	78.8	140.1				2	80.0	21.1	6	86.5	74.2
Regional	109	8.4	8.0	102	8.5	7.9	6	8.6	13.0				*	*	*	*	*	*
Distant	103	8.0	8.6	97	8.0	8.3	6	8.3	20.1				*	*	*	*	*	*
Unknown	70	5.4	5.7	61	5.1	5.2	3	4.3	10.5				*	*	*	*	*	*
<i>Age < 65</i>																		
Localized	352	79.4	29.9	317	79.3	28.4	28	81.5	68.8	Insufficient data for the calculation of AI/AN PRCDA statistics			*	*	*	2	80.0	22.6
Regional	49	11.0	4.2	44	11.1	4.0	5	13.3	11.6				*	*	*	*	*	*
Distant	24	5.4	2.0	23	5.7	2.0	*	*	*				*	*	*	*	*	*
Unknown	19	4.2	1.5	16	4.0	1.4	*	*	*				*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	658	77.5	393.9	624	77.9	388.4	27	76.1	632.9				*	*	*	4	90.9	430.6
Regional	60	7.0	34.7	58	7.2	35.1	1	4.0	23.1				*	*	*	*	*	*
Distant	80	9.4	53.9	74	9.2	52.1	*	*	*				*	*	*	*	*	*
Unknown	52	6.1	34.9	45	5.6	31.6	*	*	*				*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Wisconsin, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	98	51.5	3.5	79	52.3	3.4	9	46.9	4.9	*	*	*	2	42.9	2.7	6	55.6	3.7
Regional	62	32.6	2.0	48	31.6	1.8	7	38.5	4.7	1	50.0	7.2	1	28.6	2.5	4	33.3	2.7
Distant	27	14.2	0.8	22	14.7	0.8	2	11.5	1.4	*	*	*	*	*	*	1	11.1	1.2
Unknown	3	1.8	0.1	2	1.5	0.1	*	*	*	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	50	3.6	1.5	43	3.4	1.4	6	6.6	4.3	*	*	*	*	*	*	*	*	*
Localized	479	34.1	14.2	420	33.7	13.8	32	37.9	23.9	4	30.3	21.8	5	31.1	9.8	13	37.2	12.0
Regional	529	37.6	15.9	476	38.2	15.7	26	30.0	20.4	6	47.0	43.6	6	43.2	11.8	12	34.4	14.6
Distant	291	20.7	8.8	258	20.7	8.6	19	21.8	14.3	3	19.7	17.2	3	18.9	6.3	8	21.7	8.6
Unknown	57	4.1	1.8	50	4.0	1.7	3	3.7	2.9	*	*	*	*	*	*	1	3.9	1.7
<i>Age < 50</i>																		
<i>In Situ</i>	4	2.4	0.2	2	1.8	0.2	1	7.5	1.1	*	*	*	*	*	*	*	*	*
Localized	54	33.6	3.0	43	33.3	3.0	5	30.0	4.2	*	*	*	*	*	*	5	48.9	3.4
Regional	60	37.8	3.5	50	38.5	3.6	6	36.3	5.2	1	66.7	11.2	1	60.0	2.0	2	19.1	1.3
Distant	40	24.8	2.3	32	25.0	2.3	4	25.0	3.5	*	*	*	*	*	*	3	27.7	2.1
Unknown	2	1.4	0.1	2	1.4	0.1	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	47	3.7	4.7	41	3.6	4.5	4	6.3	12.8	*	*	*	*	*	*	*	*	*
Localized	425	34.1	43.4	377	33.8	41.9	28	39.8	75.4	*	*	*	*	*	*	9	33.1	34.5
Regional	469	37.6	48.5	426	38.1	47.6	20	28.5	60.1	5	43.9	128.2	5	40.6	37.6	11	39.8	49.4
Distant	251	20.1	25.7	225	20.2	25.0	15	21.0	42.6	*	*	*	*	*	*	5	19.5	25.8
Unknown	55	4.4	6.3	49	4.3	6.0	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	37	3.0	1.0	32	2.8	0.9	4	5.2	2.2	*	*	*	*	*	*	*	*	*
Localized	444	35.2	11.9	391	34.8	11.6	31	42.0	18.7	3	31.3	15.5	6	36.3	9.8	10	38.2	10.7
Regional	466	37.0	12.3	424	37.8	12.2	22	29.4	13.5	3	31.3	19.4	6	35.0	10.3	8	30.1	8.3
Distant	251	19.9	6.7	220	19.5	6.4	16	21.3	9.6	3	29.2	13.2	4	26.3	6.4	7	26.5	7.0
Unknown	62	4.9	1.4	57	5.1	1.4	2	2.2	1.0	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	3	2.5	0.2	2	2.0	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	51	37.7	3.0	42	38.6	3.1	4	33.8	3.6	*	*	*	*	*	*	3	35.9	2.4
Regional	46	33.7	2.7	38	34.8	2.8	4	27.7	3.1	*	*	*	1	31.6	2.0	2	28.2	2.0
Distant	34	24.9	2.0	26	23.4	1.9	4	32.3	3.6	*	*	*	2	42.1	2.2	2	28.2	1.7
Unknown	2	1.2	0.1	1	1.1	0.1	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	34	3.0	2.9	30	2.9	2.8	*	*	*	*	*	*	*	*	*	*	*	*
Localized	392	34.9	35.1	349	34.4	33.9	26	43.7	58.4	*	*	*	*	*	*	8	39.2	32.7
Regional	420	37.4	37.2	386	38.1	37.0	18	29.8	40.8	*	*	*	4	36.1	32.3	6	30.9	24.9
Distant	217	19.3	19.1	194	19.1	18.4	11	18.9	25.3	*	*	*	3	21.3	17.5	5	25.8	20.8
Unknown	60	5.4	4.9	56	5.5	4.8	2	2.6	3.7	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Wisconsin, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	1,193	19.5	33.7	1,060	19.2	33.7	78	25.0	46.7	6	16.2	27.8	15	22.8	23.2	31	23.1	27.8
Localized	3,373	55.2	91.2	3,100	56.1	93.0	140	45.1	85.7	19	54.3	102.5	33	49.5	52.9	64	47.6	61.0
Regional	1,250	20.5	36.3	1,108	20.1	36.3	74	23.9	44.0	8	24.3	45.5	16	23.7	24.1	33	24.7	27.4
Distant	252	4.1	6.8	223	4.0	6.6	18	5.7	10.6	2	4.6	9.3	2	3.3	3.3	5	4.0	5.4
Unknown	39	0.6	0.9	35	0.6	0.9	1	0.4	0.9	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	226	22.0	13.8	190	22.0	14.1	17	21.2	14.8	*	*	*	6	25.4	11.3	11	23.2	10.0
Localized	460	44.8	27.5	392	45.5	28.6	31	39.0	26.4	4	57.1	36.6	11	46.6	18.7	19	39.7	16.9
Regional	301	29.3	18.0	248	28.8	18.2	27	33.9	22.4	2	25.7	16.6	6	24.6	10.3	16	34.2	14.1
Distant	38	3.7	2.3	31	3.5	2.2	4	5.6	3.8	*	*	*	*	*	*	1	2.5	1.1
Unknown	2	0.2	0.1	1	0.1	0.1	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	968	19.0	86.0	870	18.6	84.9	61	26.2	130.3	*	*	*	9	21.3	54.6	20	23.0	74.2
Localized	2,913	57.3	258.0	2,707	58.1	261.7	110	47.1	241.1	15	53.6	274.9	22	51.2	142.4	46	51.9	176.4
Regional	949	18.7	84.3	860	18.4	83.7	48	20.5	100.5	7	23.9	121.2	10	23.2	60.4	17	19.6	62.2
Distant	214	4.2	18.5	192	4.1	18.2	13	5.7	28.3	*	*	*	*	*	*	4	4.8	16.8
Unknown	37	0.7	3.0	34	0.7	2.9	*	*	*	*	*	*	*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	7	0.3	0.2	6	0.3	0.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	569	25.0	16.6	525	25.4	16.5	31	22.2	28.7	2	17.6	16.9	2	17.9	7.4	6	22.8	9.1
Regional	529	23.2	15.0	480	23.2	14.7	34	24.5	28.5	2	16.2	15.7	3	19.4	8.5	7	24.3	9.1
Distant	1,093	48.0	31.2	984	47.6	30.4	71	51.0	57.0	9	63.2	63.0	8	61.2	22.3	13	49.3	20.7
Unknown	78	3.4	2.4	74	3.6	2.4	3	2.0	2.7	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>In Situ</i>	14	0.7	0.4	14	0.7	0.4	*	*	*	*	*	*	*	*	*	*	*	*
Localized	644	29.8	16.1	592	29.9	16.1	31	27.6	19.2	6	34.8	38.5	6	28.6	12.1	6	26.1	7.8
Regional	496	22.9	12.4	455	23.0	12.4	26	23.7	16.5	4	20.7	17.5	2	12.2	4.3	6	25.2	6.4
Distant	932	43.1	23.3	846	42.8	23.0	51	45.6	32.6	7	40.2	37.8	11	56.1	21.0	11	47.9	13.3
Unknown	76	3.5	1.8	71	3.6	1.8	3	3.1	2.2	*	*	*	*	*	*	*	*	*

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	3,263	72.9	84.9	2,943	73.0	83.1	203	73.9	141.7	15	67.6	88.0	17	84.8	38.9	50	69.5	55.0
Regional	698	15.6	17.6	635	15.7	17.3	42	15.4	28.1	4	19.4	23.1	2	8.1	3.3	10	14.6	10.3
Distant	430	9.6	13.0	386	9.6	12.5	27	9.7	24.0	2	11.1	19.1	1	7.1	5.5	11	15.1	16.9
Unknown	87	2.0	2.7	69	1.7	2.3	3	0.9	2.8	*	*	*	*	*	*	*	*	*
<i>Age < 65</i>																		
Localized	1,340	75.4	36.0	1,168	75.8	34.6	119	74.5	75.4	8	75.5	41.7	7	91.7	12.9	26	71.5	21.4
Regional	321	18.1	8.6	281	18.2	8.3	28	17.5	17.7	2	20.8	11.3	*	*	*	6	17.9	5.3
Distant	98	5.5	2.7	81	5.2	2.4	12	7.5	7.5	*	*	*	*	*	*	4	10.6	3.0
Unknown	18	1.0	0.5	11	0.7	0.3	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	1,922	71.2	423.4	1,774	71.2	417.9	84	73.1	600.4	7	60.0	408.0	10	81.0	219.2	24	67.4	287.4
Regional	378	14.0	79.8	353	14.2	79.9	15	12.7	99.7	2	18.2	104.6	*	*	*	4	11.2	44.5
Distant	332	12.3	84.4	306	12.3	82.4	15	12.7	137.6	*	*	*	1	11.1	43.9	7	19.7	113.4
Unknown	70	2.6	17.8	58	2.3	15.9	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Wyoming, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	12	52.5	4.4	12	56.7	4.7	*	*	*	*	*	*	*	*	*	*	*	*
Regional	6	27.1	2.4	6	26.9	2.3	*	*	*	*	*	*	*	*	*	*	*	*
Distant	4	16.1	1.1	3	15.4	0.9	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	1	1.1	0.4	1	1.1	0.4	*	*	*	*	*	*	*	*	*	*	*	*
Localized	45	34.8	13.1	39	34.4	12.4	*	*	*	2	61.5	49.4	*	*	*	2	24.4	10.6
Regional	50	39.2	15.1	46	40.0	15.0	*	*	*	*	*	*	*	*	*	4	46.3	19.1
Distant	24	18.7	7.4	21	18.2	7.0	*	*	*	*	*	*	*	*	*	2	19.5	8.1
Unknown	8	6.2	2.4	7	6.3	2.3	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	5	31.9	2.6	3	30.9	2.3	*	*	*	*	*	*	*	*	*	*	*	*
Regional	6	41.7	3.4	5	41.8	3.1	*	*	*	*	*	*	*	*	*	*	*	*
Distant	4	25.0	2.1	3	27.3	2.1	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	1	1.2	1.5	1	1.2	1.3	*	*	*	*	*	*	*	*	*	*	*	*
Localized	40	35.2	40.7	36	34.8	39.0	*	*	*	*	*	*	*	*	*	*	*	*
Regional	44	38.9	45.7	41	39.8	46.0	*	*	*	*	*	*	*	*	*	*	*	*
Distant	20	17.9	21.1	18	17.3	20.0	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	7	7.0	8.3	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>All Ages</i>																		
<i>In Situ</i>	2	2.1	0.6	2	2.3	0.7	*	*	*	*	*	*	*	*	*	*	*	*
Localized	36	33.8	10.6	33	34.0	10.6	*	*	*	*	*	*	*	*	*	2	29.0	10.0
Regional	36	33.6	10.6	31	32.4	10.2	*	*	*	*	*	*	*	*	*	3	51.6	17.9
Distant	26	24.1	7.4	24	24.5	7.4	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	7	6.5	1.9	7	6.8	1.9	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	4	35.1	2.4	3	34.0	2.4	*	*	*	*	*	*	*	*	*	*	*	*
Regional	5	40.4	2.9	4	44.0	3.2	*	*	*	*	*	*	*	*	*	*	*	*
Distant	2	19.3	1.4	2	18.0	1.3	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	32	33.6	32.2	30	34.0	32.3	*	*	*	*	*	*	*	*	*	*	*	*
Regional	31	32.8	30.6	27	31.0	28.4	*	*	*	*	*	*	*	*	*	3	57.1	64.7
Distant	24	24.6	23.0	22	25.3	23.4	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis,
Age, Race and Hispanic Ethnicity for Selected Cancer Sites
Wyoming, 2015–2019**

Female Breast, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
<i>In Situ</i>	58	13.0	18.0	55	13.2	18.9	*	*	*	*	*	*	*	*	*	2	12.8	12.1
Localized	252	56.3	72.0	235	56.5	73.9	*	*	*	4	66.7	102.8	1	60.0	34.2	10	52.1	49.0
Regional	105	23.3	31.8	95	22.9	32.1	*	*	*	1	20.0	33.5	*	*	*	6	29.8	28.5
Distant	23	5.0	6.3	21	5.1	6.5	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	10	2.3	3.0	10	2.4	3.1	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 50</i>																		
<i>In Situ</i>	13	17.2	8.3	12	17.7	8.8	*	*	*	*	*	*	*	*	*	*	*	*
Localized	34	46.1	22.0	30	46.0	22.5	*	*	*	*	*	*	*	*	*	3	53.3	21.3
Regional	23	31.4	14.5	20	31.1	14.8	*	*	*	*	*	*	*	*	*	2	30.0	11.1
Distant	3	4.0	1.8	2	3.7	1.7	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 50</i>																		
<i>In Situ</i>	46	12.2	43.5	43	12.3	45.2	*	*	*	*	*	*	*	*	*	*	*	*
Localized	218	58.3	203.0	205	58.4	208.5	*	*	*	*	*	*	*	*	*	7	51.6	121.6
Regional	81	21.7	77.2	75	21.4	77.5	*	*	*	*	*	*	*	*	*	4	29.7	74.1
Distant	20	5.2	18.1	19	5.4	18.9	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>Male</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	44	29.4	12.7	41	29.1	12.6	*	*	*	*	*	*	*	*	*	2	33.3	13.7
Regional	29	19.1	7.9	27	19.4	7.9	*	*	*	*	*	*	*	*	*	*	*	*
Distant	64	42.4	18.5	59	42.1	18.5	*	*	*	*	*	*	*	*	*	3	51.5	21.6
Unknown	14	9.0	4.1	13	9.4	4.3	*	*	*	*	*	*	*	*	*	*	*	*
<i>Female</i>																		
<i>In Situ</i>	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Localized	43	28.4	11.5	40	28.4	11.6	*	*	*	*	*	*	*	*	*	1	25.0	10.3
Regional	31	20.4	8.7	29	20.5	9.0	*	*	*	*	*	*	*	*	*	1	21.4	8.1
Distant	64	42.9	17.4	60	42.6	17.5	*	*	*	*	*	*	*	*	*	3	46.4	16.5
Unknown	12	8.0	3.3	11	8.1	3.3	*	*	*	*	*	*	*	*	*	*	*	*

Prostate, 2015–2019

Stage at Diagnosis	All Races			NH White			NH Black			NH AI/AN PRCDA			NH API			Hispanic, All Races		
	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate	Average Annual Cases	%	Rate
<i>All Ages</i>																		
Localized	344	78.7	89.2	324	78.6	91.0	2	66.7	69.6	2	78.6	84.0	*	*	*	13	85.5	69.6
Regional	52	11.9	12.5	50	12.1	12.9	*	*	*	*	*	*	*	*	*	1	7.9	5.5
Distant	30	7.0	9.0	28	6.9	9.1	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	10	2.4	2.8	10	2.4	2.9	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age < 65</i>																		
Localized	126	80.5	33.6	119	80.4	35.1	*	*	*	*	*	*	*	*	*	4	88.0	19.6
Regional	21	13.7	5.4	21	13.9	5.6	*	*	*	*	*	*	*	*	*	*	*	*
Distant	7	4.4	1.8	6	4.3	1.9	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	2	1.4	0.7	2	1.3	0.6	*	*	*	*	*	*	*	*	*	*	*	*
<i>Age ≥ 65</i>																		
Localized	218	77.7	473.3	205	77.6	477.9	*	*	*	*	*	*	*	*	*	9	84.3	415.4
Regional	31	10.9	61.4	29	11.1	63.1	*	*	*	*	*	*	*	*	*	*	*	*
Distant	24	8.4	58.6	22	8.3	58.7	*	*	*	*	*	*	*	*	*	*	*	*
Unknown	8	2.9	17.7	8	3.0	18.7	*	*	*	*	*	*	*	*	*	*	*	*

Abbreviations: AI/AN PRCDA, American Indian/Alaskan Native Indian Health Services Purchased/Referred Care Delivery Area; API, Asian/Pacific Islander; NH, Non-Hispanic

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
Puerto Rico, 2015–2019**

Cervix, 2015–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	83	40.2	5.4
Regional	52	25.3	3.1
Distant	16	7.6	0.9
Unknown	56	26.9	3.1

Colon and Rectum, 2015–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	21	2.3	1.1
Localized	362	39.1	19.4
Regional	294	31.7	15.9
Distant	131	14.2	7.1
Unknown	117	12.6	6.4
<i>Age < 50</i>			
<i>In Situ</i>	2	1.8	0.2
Localized	34	39.5	3.9
Regional	27	31.2	3.1
Distant	14	16.4	1.6
Unknown	10	11.1	1.1
<i>Age ≥ 50</i>			
<i>In Situ</i>	20	2.3	3.6
Localized	328	39.1	59.8
Regional	267	31.8	49.4
Distant	117	14.0	21.4
Unknown	107	12.8	20.1
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	19	2.5	0.8
Localized	315	40.2	14.0
Regional	236	30.1	10.5
Distant	108	13.7	4.9
Unknown	106	13.5	4.5
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	34	39.3	3.6
Regional	27	31.3	2.9
Distant	15	16.9	1.6
Unknown	10	11.6	1.1
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	280	40.3	41.3
Regional	209	30.0	30.6
Distant	93	13.3	13.7
Unknown	95	13.7	13.6

Female Breast, 2015–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	403	16.1	19.3
Localized	1,240	49.7	57.7
Regional	588	23.6	28.9
Distant	103	4.1	4.8
Unknown	161	6.4	7.1
<i>Age < 50</i>			
<i>In Situ</i>	69	17.0	7.3
Localized	181	44.9	19.3
Regional	119	29.6	12.8
Distant	15	3.7	1.6
Unknown	19	4.8	2.1
<i>Age ≥ 50</i>			
<i>In Situ</i>	334	16.0	50.8
Localized	1,059	50.6	158.3
Regional	469	22.4	71.1
Distant	88	4.2	13.2
Unknown	141	6.8	20.4

Lung and Bronchus, 2015–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	*	*	*
Localized	94	22.3	4.9
Regional	71	17.0	3.6
Distant	142	33.8	7.4
Unknown	112	26.7	5.8
<i>Female</i>			
<i>In Situ</i>	*	*	*
Localized	69	25.0	2.9
Regional	39	14.1	1.6
Distant	87	31.4	3.6
Unknown	81	29.1	3.2

Prostate, 2015–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	1,795	60.5	89.5
Regional	148	5.0	7.4
Distant	101	3.4	5.2
Unknown	925	31.2	46.7
<i>Age < 65</i>			
Localized	671	68.2	41.1
Regional	71	7.2	4.3
Distant	21	2.1	1.2
Unknown	221	22.5	13.2
<i>Age ≥ 65</i>			
Localized	1,124	56.6	423.9
Regional	78	3.9	28.9
Distant	80	4.0	32.7
Unknown	704	35.5	278.9

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the five year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
Alberta, 2015–2017**

Cervix, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	105	60.5	4.9
Regional	54	31.2	2.5
Distant	12	7.1	0.5
Unknown	2	1.2	0.1

Colon and Rectum, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	264	18.2	12.4
Localized	459	31.7	22.1
Regional	444	30.6	22.1
Distant	250	17.3	12.2
Unknown	33	2.3	2.0
<i>Age < 50</i>			
<i>In Situ</i>	11	9.0	0.8
Localized	43	34.0	2.9
Regional	40	32.1	2.8
Distant	31	24.7	2.1
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	252	19.1	43.1
Localized	416	31.5	72.5
Regional	403	30.5	72.5
Distant	219	16.6	38.8
Unknown	*	*	*
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	140	13.5	6.1
Localized	333	32.0	15.1
Regional	336	32.3	15.3
Distant	202	19.4	9.0
Unknown	29	2.8	1.2
<i>Age < 50</i>			
<i>In Situ</i>	10	9.3	0.8
Localized	37	33.7	2.6
Regional	36	32.2	2.6
Distant	27	24.7	2.0
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	130	14.0	20.0
Localized	295	31.8	47.7
Regional	301	32.4	48.5
Distant	175	18.8	27.4
Unknown	29	3.1	4.4

Female Breast, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	372	11.7	16.7
Localized	1,738	54.8	78.0
Regional	872	27.5	39.3
Distant	179	5.6	7.9
Unknown	10	0.3	0.4
<i>Age < 50</i>			
<i>In Situ</i>	83	12.9	6.1
Localized	295	46.1	21.7
Regional	230	36.0	16.7
Distant	32	5.0	2.3
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	290	11.4	44.3
Localized	1,443	57.0	225.5
Regional	642	25.4	98.5
Distant	147	5.8	22.7
Unknown	*	*	*

Lung and Bronchus, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	*	*	*
Localized	186	16.1	9.7
Regional	267	23.1	13.9
Distant	695	60.1	36.0
Unknown	7	0.6	0.4
<i>Female</i>			
<i>In Situ</i>	3	0.3	0.1
Localized	262	22.7	12.1
Regional	279	24.2	12.7
Distant	606	52.5	27.7
Unknown	4	0.3	0.2

Prostate, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	1,716	70.6	79.0
Regional	442	18.2	19.3
Distant	244	10.0	13.6
Unknown	27	1.1	1.8
<i>Age < 65</i>			
Localized	740	73.9	30.9
Regional	211	21.1	8.6
Distant	48	4.8	2.0
Unknown	*	*	*
<i>Age ≥ 65</i>			
Localized	976	68.4	411.0
Regional	231	16.2	93.1
Distant	195	13.7	93.7
Unknown	*	*	*

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the three year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
Alberta, 2018–2019**

Cervix, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	*	*	*
Localized/Regional ¹	121	68.2	5.3
Regional	42	23.7	1.8
Distant	7	3.9	0.3
Unknown	7	3.9	0.3

Colon and Rectum, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	122	9.7	5.2
Localized	322	25.6	13.9
Localized/Regional ¹	356	28.3	16.1
Regional	84	6.6	3.9
Regional/Distant ²	40	3.1	1.8
Distant	272	21.6	12.3
Unknown	64	5.1	3.5
<i>Age < 50</i>			
<i>In Situ</i>	6	4.6	0.4
Localized	31	23.4	2.1
Localized/Regional ¹	44	33.3	2.9
Regional	10	7.3	0.6
Regional/Distant ²	*	*	*
Distant	33	25.3	2.2
Unknown	6	4.2	0.4
<i>Age ≥ 50</i>			
<i>In Situ</i>	116	10.3	17.9
Localized	292	25.8	44.7
Localized/Regional ¹	313	27.7	50.8
Regional	74	6.6	12.5
Regional/Distant ²	37	3.3	6.0
Distant	239	21.1	38.9
Unknown	59	5.2	11.8
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	67	7.2	2.7
Localized	248	26.9	10.3
Localized/Regional ¹	270	29.3	11.3
Regional	59	6.4	2.5
Regional/Distant ²	45	4.8	1.9
Distant	171	18.5	7.1
Unknown	63	6.8	2.5
<i>Age < 50</i>			
<i>In Situ</i>	6	4.8	0.4
Localized	37	32.3	2.5
Localized/Regional ¹	36	31.0	2.5
Regional	7	5.7	0.4
Regional/Distant ²	5	4.4	0.3
Distant	23	19.7	1.6
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	61	7.6	8.9
Localized	211	26.2	30.7
Localized/Regional ¹	234	29.0	34.5
Regional	53	6.5	7.8
Regional/Distant ²	40	4.9	5.9
Distant	148	18.4	21.7
Unknown	61	7.5	8.7

Female Breast, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	430	12.1	17.7
Localized	4	0.1	0.2
Localized/Regional ¹	2,830	80.0	117.3
Regional	71	2.0	2.9
Distant	190	5.4	8.0
Unknown	15	0.4	0.6
<i>Age < 50</i>			
<i>In Situ</i>	74	11.3	5.2
Localized	*	*	*
Localized/Regional ¹	522	79.7	36.5
Regional	15	2.3	1.0
Distant	38	5.8	2.6
Unknown	4	0.6	0.3
<i>Age ≥ 50</i>			
<i>In Situ</i>	356	12.3	50.6
Localized	*	*	*
Localized/Regional ¹	2,309	80.0	328.8
Regional	56	1.9	7.8
Distant	152	5.3	22.0
Unknown	11	0.4	1.5

Lung and Bronchus, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	4	0.4	0.1
Localized	195	17.7	9.2
Localized/Regional ¹	197	17.8	9.5
Regional	76	6.9	3.5
Distant	554	50.2	25.3
Unknown	77	7.0	3.8
<i>Female</i>			
<i>In Situ</i>	6	0.4	0.2
Localized	301	23.2	12.4
Localized/Regional ¹	261	20.1	10.8
Regional	75	5.8	3.1
Distant	593	45.8	24.4
Unknown	62	4.7	2.6

Prostate, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	1,487	56.9	61.4
Regional	321	12.3	12.3
Regional/Distant ²	11	0.4	0.6
Distant	272	10.4	13.6
Unknown	524	20.0	22.7
<i>Age < 65</i>			
Localized	637	60.1	25.3
Regional	165	15.5	6.5
Regional/Distant ²	*	*	*
Distant	54	5.1	2.1
Unknown	202	19.1	8.1
<i>Age ≥ 65</i>			
Localized	851	54.7	310.8
Regional	157	10.1	52.6
Regional/Distant ²	9	0.6	4.3
Distant	218	14.0	92.9
Unknown	322	20.7	124.2

Percentages based upon small cell sizes should be used with caution.

For cases diagnosed 2018 or later, the Canadian registries began collecting AJCC stage information only. The Summary Stage values are based on a behavior and a combined TNM value. Please see technical notes for more information.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

¹ Information to distinguish between localized and regional is not available.

² Information to distinguish between regional and distant is not available.

* Counts and rates are suppressed when fewer than 6 cases were reported over the two year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
British Columbia, 2015–2017**

Cervix, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	84	46.9	3.3
Regional	62	34.6	2.2
Distant	26	14.4	0.9
Unknown	7	4.1	0.2

Colon and Rectum, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	159	8.3	4.9
Localized	677	35.3	21.4
Regional	622	32.4	20.2
Distant	321	16.7	10.5
Unknown	140	7.3	4.8
<i>Age < 50</i>			
<i>In Situ</i>	5	4.4	0.3
Localized	26	24.8	1.7
Regional	45	42.5	2.9
Distant	23	21.4	1.5
Unknown	7	6.9	0.5
<i>Age ≥ 50</i>			
<i>In Situ</i>	154	8.5	16.9
Localized	651	35.9	73.0
Regional	577	31.8	65.5
Distant	299	16.5	34.1
Unknown	133	7.3	16.1
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	81	5.5	2.4
Localized	539	36.5	15.9
Regional	477	32.3	14.0
Distant	250	16.9	7.4
Unknown	130	8.8	3.5
<i>Age < 50</i>			
<i>In Situ</i>	4	3.5	0.2
Localized	40	37.8	2.5
Regional	34	32.4	2.1
Distant	23	22.2	1.5
Unknown	4	4.1	0.3
<i>Age ≥ 50</i>			
<i>In Situ</i>	77	5.6	7.9
Localized	500	36.4	50.7
Regional	443	32.3	45.0
Distant	226	16.5	22.9
Unknown	125	9.1	12.1

Female Breast, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	594	14.2	18.2
Localized	2,214	52.9	67.0
Regional	1,148	27.4	36.1
Distant	188	4.5	5.7
Unknown	44	1.1	1.2
<i>Age < 50</i>			
<i>In Situ</i>	111	16.0	6.9
Localized	313	45.0	19.7
Regional	245	35.2	15.4
Distant	25	3.5	1.5
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	483	13.8	47.9
Localized	1,901	54.4	190.9
Regional	903	25.9	90.2
Distant	164	4.7	16.5
Unknown	*	*	*

Lung and Bronchus, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	3	0.2	0.1
Localized	249	14.8	8.0
Regional	462	27.5	15.1
Distant	911	54.1	29.3
Unknown	57	3.4	2.0
<i>Female</i>			
<i>In Situ</i>	8	0.5	0.2
Localized	331	18.4	9.5
Regional	476	26.5	13.7
Distant	925	51.5	26.3
Unknown	56	3.1	1.6

Prostate, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	1,868	65.1	57.2
Regional	538	18.8	15.7
Distant	348	12.1	11.6
Unknown	113	4.0	4.1
<i>Age < 65</i>			
Localized	530	68.2	16.3
Regional	174	22.3	5.3
Distant	61	7.8	1.9
Unknown	13	1.7	0.4
<i>Age ≥ 65</i>			
Localized	1,338	64.0	340.1
Regional	364	17.4	88.0
Distant	288	13.8	78.9
Unknown	100	4.8	29.2

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the three year time period for the specific cancer.

Page Intentionally Left Blank

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
Manitoba, 2015–2017**

Cervix, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	19	43.9	3.0
Regional	22	50.0	3.2
Distant	3	6.1	0.4
Unknown	*	*	*

Colon and Rectum, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	222	32.1	30.0
Localized	160	23.1	22.4
Regional	207	29.9	28.5
Distant	96	13.8	13.3
Unknown	7	1.0	1.2
<i>Age < 50</i>			
<i>In Situ</i>	11	24.8	2.8
Localized	11	24.1	2.5
Regional	15	33.8	3.7
Distant	7	16.5	1.9
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	211	32.6	101.1
Localized	149	23.1	74.4
Regional	192	29.6	93.4
Distant	88	13.6	43.2
Unknown	*	*	*
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	138	27.3	17.3
Localized	126	25.0	15.3
Regional	149	29.4	18.0
Distant	83	16.5	10.4
Unknown	9	1.8	0.9
<i>Age < 50</i>			
<i>In Situ</i>	11	23.6	2.7
Localized	11	23.6	2.7
Regional	12	25.0	2.9
Distant	13	27.9	3.2
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	127	27.6	55.4
Localized	115	25.1	48.5
Regional	137	29.9	57.7
Distant	70	15.3	29.3
Unknown	9	2.0	3.2

Female Breast, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	106	10.9	13.5
Localized	527	53.9	66.1
Regional	281	28.7	37.5
Distant	61	6.2	7.7
Unknown	3	0.3	0.3
<i>Age < 50</i>			
<i>In Situ</i>	15	9.9	3.7
Localized	63	42.4	16.0
Regional	62	41.9	15.9
Distant	9	5.8	2.2
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	92	11.0	39.1
Localized	464	55.9	197.3
Regional	219	26.4	94.0
Distant	52	6.3	22.0
Unknown	3	0.4	0.9

Lung and Bronchus, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	*	*	*
Localized	82	19.1	11.6
Regional	105	24.5	14.8
Distant	238	55.6	33.2
Unknown	3	0.6	0.4
<i>Female</i>			
<i>In Situ</i>	*	*	*
Localized	122	25.7	14.7
Regional	113	23.8	13.9
Distant	238	50.1	28.6
Unknown	2	0.4	0.2

Prostate, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	496	68.0	67.5
Regional	131	18.0	15.6
Distant	96	13.1	14.1
Unknown	7	1.0	1.1
<i>Age < 65</i>			
Localized	129	61.6	16.6
Regional	65	31.1	8.2
Distant	15	7.2	2.1
Unknown	*	*	*
<i>Age ≥ 65</i>			
Localized	367	70.5	419.3
Regional	66	12.7	66.2
Distant	81	15.5	97.2
Unknown	*	*	*

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the three year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
Manitoba, 2018–2019**

Cervix, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	*	*	*
Localized/Regional ¹	31	66.0	4.7
Regional	10	20.2	1.3
Distant	5	9.6	0.7
Unknown	*	*	*

Colon and Rectum, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	110	19.2	14.4
Localized	102	17.8	13.3
Localized/Regional ¹	171	29.9	22.6
Regional	40	7.0	5.2
Regional/Distant ²	21	3.6	2.5
Distant	102	17.8	13.0
Unknown	27	4.7	3.8
<i>Age < 50</i>			
<i>In Situ</i>	5	11.6	1.2
Localized	11	24.4	2.5
Localized/Regional ¹	16	36.0	3.7
Regional	4	9.3	0.9
Regional/Distant ²	*	*	*
Distant	6	12.8	1.4
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	105	19.9	48.9
Localized	91	17.2	41.4
Localized/Regional ¹	156	29.4	72.2
Regional	36	6.8	16.5
Regional/Distant ²	20	3.7	8.5
Distant	96	18.2	43.5
Unknown	26	4.8	12.8
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	69	15.1	8.0
Localized	81	17.7	10.1
Localized/Regional ¹	121	26.4	13.9
Regional	44	9.6	5.2
Regional/Distant ²	28	6.1	3.1
Distant	74	16.1	8.4
Unknown	41	9.0	4.3
<i>Age < 50</i>			
<i>In Situ</i>	4	11.3	1.0
Localized	11	29.6	2.5
Localized/Regional ¹	10	28.2	2.3
Regional	3	8.5	0.7
Regional/Distant ²	*	*	*
Distant	5	12.7	1.1
Unknown	3	8.5	0.7
<i>Age ≥ 50</i>			
<i>In Situ</i>	65	15.4	26.5
Localized	71	16.7	30.0
Localized/Regional ¹	111	26.3	44.3
Regional	41	9.7	17.0
Regional/Distant ²	28	6.5	10.9
Distant	69	16.4	27.6
Unknown	38	9.0	13.6

Female Breast, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	111	9.9	13.2
Localized	7	0.6	0.9
Localized/Regional ¹	915	81.3	111.4
Regional	28	2.5	3.1
Distant	59	5.2	7.3
Unknown	6	0.5	0.7
<i>Age < 50</i>			
<i>In Situ</i>	11	6.7	2.7
Localized	*	*	*
Localized/Regional ¹	141	85.2	34.6
Regional	*	*	*
Distant	9	5.5	2.2
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	100	10.4	40.7
Localized	7	0.7	3.0
Localized/Regional ¹	774	80.6	312.4
Regional	26	2.7	9.8
Distant	50	5.2	20.5
Unknown	5	0.5	1.5

Lung and Bronchus, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	*	*	*
Localized	82	18.2	10.4
Localized/Regional ¹	75	16.7	10.0
Regional	38	8.4	4.9
Distant	231	51.3	30.0
Unknown	24	5.3	3.2
<i>Female</i>			
<i>In Situ</i>	*	*	*
Localized	132	26.7	14.9
Localized/Regional ¹	80	16.2	9.3
Regional	35	7.0	4.0
Distant	223	45.3	25.2
Unknown	23	4.6	2.5

Prostate, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	456	52.4	55.9
Regional	117	13.5	12.7
Regional/Distant ²	*	*	*
Distant	123	14.1	16.6
Unknown	172	19.8	22.8
<i>Age < 65</i>			
Localized	141	55.6	17.4
Regional	66	25.8	7.9
Regional/Distant ²	*	*	*
Distant	21	8.1	2.4
Unknown	26	10.3	3.5
<i>Age ≥ 65</i>			
Localized	315	51.1	322.0
Regional	52	8.4	45.7
Regional/Distant ²	*	*	*
Distant	102	16.6	115.0
Unknown	146	23.7	156.2

Percentages based upon small cell sizes should be used with caution.

For cases diagnosed 2018 or later, the Canadian registries began collecting AJCC stage information only. The Summary Stage values are based on a behavior and a combined TNM value. Please see technical notes for more information.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

¹ Information to distinguish between localized and regional is not available.

² Information to distinguish between regional and distant is not available.

* Counts and rates are suppressed when fewer than 6 cases were reported over the two year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
New Brunswick, 2015–2017**

Cervix, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	31	100.0	8.0

Colon and Rectum, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	86	20.3	15.5
Localized	104	24.6	19.2
Regional	88	20.8	16.8
Distant	60	14.1	11.5
Unknown	86	20.2	16.7
<i>Age < 50</i>			
<i>In Situ</i>	3	12.5	1.1
Localized	2	9.4	0.8
Regional	5	23.4	2.0
Distant	5	21.9	2.0
Unknown	7	32.8	3.0
<i>Age ≥ 50</i>			
<i>In Situ</i>	84	20.8	53.1
Localized	102	25.4	67.6
Regional	83	20.7	55.6
Distant	55	13.6	36.5
Unknown	79	19.5	52.7
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	48	15.9	8.0
Localized	82	26.9	13.5
Regional	68	22.4	11.9
Distant	47	15.6	7.9
Unknown	59	19.3	9.9
<i>Age < 50</i>			
<i>In Situ</i>	2	10.3	0.8
Localized	3	17.2	1.4
Regional	7	34.5	2.9
Distant	3	15.5	1.3
Unknown	4	22.4	1.8
<i>Age ≥ 50</i>			
<i>In Situ</i>	46	16.3	26.8
Localized	78	27.5	45.3
Regional	61	21.5	35.4
Distant	44	15.6	25.4
Unknown	54	19.1	31.0

Female Breast, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	66	9.3	11.9
Localized	394	55.2	67.7
Regional	209	29.2	39.3
Distant	38	5.4	7.1
Unknown	7	1.0	0.9
<i>Age < 50</i>			
<i>In Situ</i>	10	10.6	4.3
Localized	39	39.6	16.0
Regional	42	43.0	17.9
Distant	7	6.8	2.8
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	56	9.1	31.8
Localized	355	57.6	202.8
Regional	167	27.0	95.2
Distant	32	5.1	18.2
Unknown	7	1.1	3.3

Lung and Bronchus, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	3	0.7	0.7
Localized	98	21.6	18.7
Regional	123	27.2	23.2
Distant	227	50.2	42.8
Unknown	*	*	*
<i>Female</i>			
<i>In Situ</i>	*	*	*
Localized	119	30.9	19.3
Regional	99	25.8	16.1
Distant	163	42.2	25.9
Unknown	3	0.7	0.4

Prostate, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	398	74.4	65.3
Regional	79	14.7	12.3
Distant	54	10.1	10.7
Unknown	4	0.7	0.9
<i>Age < 65</i>			
Localized	153	74.6	27.1
Regional	42	20.5	7.6
Distant	10	4.7	1.7
Unknown	*	*	*
<i>Age ≥ 65</i>			
Localized	245	74.3	329.5
Regional	37	11.1	44.7
Distant	44	13.4	73.0
Unknown	*	*	*

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the three year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
New Brunswick, 2018–2019**

Cervix, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	*	*	*
Localized/Regional ¹	11	34.4	2.6
Regional	5	14.8	1.1
Distant	*	*	*
Unknown	13	42.6	3.8

Colon and Rectum, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	53	13.0	8.8
Localized	89	22.1	15.4
Localized/Regional ¹	132	32.7	23.0
Regional	20	4.8	3.5
Regional/Distant ²	10	2.4	1.7
Distant	68	16.9	12.2
Unknown	33	8.1	6.3
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	4	18.9	1.4
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	4	21.6	1.7
Unknown	5	24.3	1.9
<i>Age ≥ 50</i>			
<i>In Situ</i>	51	13.2	29.8
Localized	87	22.5	52.9
Localized/Regional ¹	128	33.3	79.5
Regional	18	4.6	10.5
Regional/Distant ²	10	2.5	6.1
Distant	64	16.7	39.7
Unknown	28	7.3	17.9
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	26	8.4	3.9
Localized	59	19.0	9.1
Localized/Regional ¹	95	30.4	15.6
Regional	22	6.9	3.2
Regional/Distant ²	17	5.5	2.6
Distant	56	17.9	9.1
Unknown	37	11.9	6.5
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	8	38.1	3.3
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	5	21.4	2.0
Unknown	6	28.6	2.7
<i>Age ≥ 50</i>			
<i>In Situ</i>	26	8.8	13.5
Localized	58	19.9	31.3
Localized/Regional ¹	87	29.9	47.8
Regional	22	7.4	11.5
Regional/Distant ²	17	5.7	9.1
Distant	51	17.6	27.8
Unknown	31	10.7	16.4

Female Breast, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	66	9.9	11.2
Localized	*	*	*
Localized/Regional ¹	534	80.1	92.6
Regional	20	3.0	3.4
Distant	37	5.5	6.4
Unknown	9	1.3	1.1
<i>Age < 50</i>			
<i>In Situ</i>	8	9.2	3.5
Localized	*	*	*
Localized/Regional ¹	71	81.6	30.5
Regional	*	*	*
Distant	5	5.7	2.2
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	58	10.0	31.5
Localized	*	*	*
Localized/Regional ¹	463	79.9	255.1
Regional	18	3.0	9.4
Distant	32	5.4	17.3
Unknown	9	1.5	4.1

Lung and Bronchus, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	*	*	*
Localized	84	19.3	14.6
Localized/Regional ¹	100	23.1	17.4
Regional	21	4.8	3.7
Distant	213	49.0	36.6
Unknown	15	3.3	2.4
<i>Female</i>			
<i>In Situ</i>	*	*	*
Localized	106	26.8	15.6
Localized/Regional ¹	85	21.6	12.9
Regional	19	4.8	2.7
Distant	175	44.3	26.3
Unknown	9	2.2	1.3

Prostate, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	255	42.4	38.8
Regional	85	14.0	12.5
Regional/Distant ²	*	*	*
Distant	62	10.2	11.4
Unknown	199	33.0	30.9
<i>Age < 65</i>			
Localized	86	40.0	14.6
Regional	38	17.6	6.6
Regional/Distant ²	*	*	*
Distant	17	7.7	3.1
Unknown	74	34.4	12.6
<i>Age ≥ 65</i>			
Localized	170	43.7	206.4
Regional	47	12.1	53.4
Regional/Distant ²	*	*	*
Distant	45	11.6	68.4
Unknown	125	32.2	157.8

Percentages based upon small cell sizes should be used with caution.

For cases diagnosed 2018 or later, the Canadian registries began collecting AJCC stage information only. The Summary Stage values are based on a behavior and a combined TNM value. Please see technical notes for more information.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

¹ Information to distinguish between localized and regional is not available.

² Information to distinguish between regional and distant is not available.

* Counts and rates are suppressed when fewer than 6 cases were reported over the two year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
Newfoundland and Labrador, 2015–2017**

Cervix, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	16	53.8	6.1
Regional	11	36.3	3.6
Distant	*	*	*
Unknown	2	6.6	0.6

Colon and Rectum, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	103	22.6	26.0
Localized	149	32.6	40.7
Regional	131	28.7	35.1
Distant	66	14.4	18.0
Unknown	8	1.7	2.9
<i>Age < 50</i>			
<i>In Situ</i>	2	9.8	1.3
Localized	7	34.4	4.0
Regional	8	37.7	4.3
Distant	4	18.0	2.3
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	101	23.2	90.6
Localized	142	32.5	136.7
Regional	123	28.2	115.8
Distant	62	14.3	59.1
Unknown	8	1.8	10.4
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	75	21.8	18.5
Localized	120	34.7	30.5
Regional	96	27.9	24.8
Distant	46	13.2	11.4
Unknown	8	2.3	2.0
<i>Age < 50</i>			
<i>In Situ</i>	7	27.3	3.9
Localized	8	31.2	4.7
Regional	7	27.3	4.1
Distant	4	14.3	2.0
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	68	21.4	56.5
Localized	112	35.0	98.3
Regional	89	28.0	79.2
Distant	42	13.2	36.2
Unknown	8	2.5	7.4

Female Breast, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	75	13.5	18.3
Localized	296	53.5	74.9
Regional	143	25.8	39.1
Distant	36	6.5	9.8
Unknown	4	0.7	1.0
<i>Age < 50</i>			
<i>In Situ</i>	7	9.2	4.3
Localized	36	44.6	20.1
Regional	31	38.3	17.6
Distant	6	7.9	3.5
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	67	14.2	55.2
Localized	260	55.0	218.4
Regional	112	23.7	95.3
Distant	30	6.3	26.2
Unknown	4	0.8	3.6

Lung and Bronchus, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	2	0.7	0.5
Localized	69	24.7	19.3
Regional	64	22.9	16.5
Distant	138	49.6	36.9
Unknown	6	2.0	1.9
<i>Female</i>			
<i>In Situ</i>	3	1.1	0.6
Localized	77	32.4	18.6
Regional	49	20.6	12.0
Distant	105	44.0	25.6
Unknown	5	2.0	1.3

Prostate, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	326	75.7	77.0
Regional	71	16.5	16.1
Distant	30	7.0	9.0
Unknown	4	0.9	1.4
<i>Age < 65</i>			
Localized	126	72.7	31.4
Regional	40	23.2	10.3
Distant	7	3.8	1.7
Unknown	*	*	*
<i>Age ≥ 65</i>			
Localized	200	77.7	392.8
Regional	31	11.9	56.1
Distant	23	9.1	59.3
Unknown	*	*	*

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the three year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
Newfoundland and Labrador, 2018–2019**

Cervix, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	*	*	*
Localized/Regional ¹	16	64.6	6.1
Regional	5	20.8	1.3
Distant	*	*	*
Unknown	*	*	*

Colon and Rectum, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	101	22.7	24.0
Localized	72	16.1	17.5
Localized/Regional ¹	131	29.5	32.5
Regional	26	5.9	6.5
Regional/Distant ²	17	3.8	4.4
Distant	75	16.9	20.2
Unknown	23	5.1	6.4
<i>Age < 50</i>			
<i>In Situ</i>	5	23.7	3.0
Localized	*	*	*
Localized/Regional ¹	4	18.4	2.1
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	6	28.9	3.5
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	96	22.6	78.8
Localized	69	16.3	59.1
Localized/Regional ¹	128	30.0	112.0
Regional	25	5.9	22.0
Regional/Distant ²	16	3.8	14.3
Distant	70	16.4	64.0
Unknown	22	5.1	21.7
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	83	25.0	18.3
Localized	62	18.8	15.6
Localized/Regional ¹	88	26.6	21.8
Regional	24	7.3	6.1
Regional/Distant ²	15	4.6	3.7
Distant	42	12.6	10.1
Unknown	17	5.2	4.6
<i>Age < 50</i>			
<i>In Situ</i>	4	16.7	2.3
Localized	7	27.1	4.2
Localized/Regional ¹	7	29.2	4.4
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	4	14.6	2.2
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	79	25.7	60.0
Localized	56	18.2	45.3
Localized/Regional ¹	81	26.4	67.3
Regional	22	7.2	18.8
Regional/Distant ²	15	4.9	13.4
Distant	38	12.4	30.8
Unknown	16	5.2	14.8

Female Breast, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	84	15.4	21.5
Localized	*	*	*
Localized/Regional ¹	208	38.2	51.9
Regional	7	1.2	1.6
Distant	26	4.7	6.2
Unknown	219	40.4	55.0
<i>Age < 50</i>			
<i>In Situ</i>	13	18.7	7.9
Localized	*	*	*
Localized/Regional ¹	26	36.7	15.7
Regional	*	*	*
Distant	*	*	*
Unknown	29	41.0	17.8
<i>Age ≥ 50</i>			
<i>In Situ</i>	71	14.9	57.1
Localized	*	*	*
Localized/Regional ¹	182	38.5	146.7
Regional	6	1.3	5.0
Distant	24	5.0	19.0
Unknown	191	40.3	152.4

Lung and Bronchus, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	*	*	*
Localized	80	27.6	19.7
Localized/Regional ¹	45	15.5	11.3
Regional	16	5.6	3.7
Distant	107	37.2	26.4
Unknown	40	13.9	9.9
<i>Female</i>			
<i>In Situ</i>	4	1.4	0.9
Localized	100	35.8	21.9
Localized/Regional ¹	40	14.1	8.6
Regional	13	4.7	3.0
Distant	92	32.9	20.8
Unknown	31	11.1	6.8

Prostate, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	279	63.9	62.8
Regional	64	14.7	13.4
Regional/Distant ²	*	*	*
Distant	53	12.1	14.3
Unknown	40	9.2	9.6
<i>Age < 65</i>			
Localized	99	63.1	25.5
Regional	34	21.7	8.5
Regional/Distant ²	*	*	*
Distant	10	6.1	2.4
Unknown	14	8.9	3.5
<i>Age ≥ 65</i>			
Localized	180	64.4	320.9
Regional	30	10.7	47.8
Regional/Distant ²	*	*	*
Distant	44	15.6	96.1
Unknown	26	9.3	51.5

Percentages based upon small cell sizes should be used with caution.

For cases diagnosed 2018 or later, the Canadian registries began collecting AJCC stage information only. The Summary Stage values are based on a behavior and a combined TNM value. Please see technical notes for more information.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

¹ Information to distinguish between localized and regional is not available.

² Information to distinguish between regional and distant is not available.

* Counts and rates are suppressed when fewer than 6 cases were reported over the two year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
Northwest Territories, 2015–2017**

Cervix, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*

Colon and Rectum, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	*	*	*
Localized	7	44.9	46.2
Regional	6	34.7	29.5
Distant	3	20.4	24.1
Unknown	*	*	*
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	*	*	*
Localized	5	33.3	25.3
Regional	6	45.2	41.0
Distant	3	21.4	19.1
Unknown	*	*	*
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	*	*	*
Distant	3	24.3	69.3
Unknown	*	*	*

Female Breast, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	3	12.2	20.9
Localized	18	65.9	103.2
Regional	5	19.5	25.2
Distant	*	*	*
Unknown	*	*	*
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	4	68.8	24.5
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	14	65.2	309.2
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*

Lung and Bronchus, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	*	*	*
Localized	3	22.0	20.3
Regional	3	19.5	24.8
Distant	8	56.1	56.7
Unknown	*	*	*
<i>Female</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	3	27.3	23.2
Distant	6	57.6	51.1
Unknown	*	*	*

Prostate, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	8	54.8	32.4
Regional	3	21.4	15.8
Distant	3	21.4	18.3
Unknown	*	*	*
<i>Age < 65</i>			
Localized	4	59.1	16.1
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 65</i>			
Localized	3	50.0	145.7
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the three year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
Northwest Territories, 2018–2019**

Cervix, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	*	*	*
Localized/Regional ¹	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*

Colon and Rectum, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	*	*	*
Localized	7	29.8	37.6
Localized/Regional ¹	8	31.9	50.1
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	3	12.8	11.3
Unknown	*	*	*
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	*	*	*
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	7	33.3	127.7
Localized/Regional ¹	5	25.6	140.4
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	3	37.5	11.1
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	*	*	*
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	*	*	*
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	*	*	*
Unknown	*	*	*

Female Breast, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	19	75.5	93.4
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	6	84.6	35.4
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	13	72.2	245.4
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*

Lung and Bronchus, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	*	*	*
Regional	*	*	*
Distant	8	76.2	51.8
Unknown	*	*	*
<i>Female</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	*	*	*
Regional	*	*	*
Distant	7	58.3	37.6
Unknown	*	*	*

Prostate, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	13	52.0	50.1
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	5	20.0	28.7
Unknown	5	20.0	25.0
<i>Age < 65</i>			
Localized	8	59.3	26.4
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 65</i>			
Localized	5	43.5	214.0
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	4	30.4	193.6
Unknown	*	*	*

Percentages based upon small cell sizes should be used with caution.

For cases diagnosed 2018 or later, the Canadian registries began collecting AJCC stage information only. The Summary Stage values are based on a behavior and a combined TNM value. Please see technical notes for more information.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

¹ Information to distinguish between localized and regional is not available.

² Information to distinguish between regional and distant is not available.

* Counts and rates are suppressed when fewer than 6 cases were reported over the two year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
Nunavut, 2015–2017**

Cervix, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*

Colon and Rectum, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	3	34.5	32.9
Distant	3	27.6	21.6
Unknown	3	27.6	20.4
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	4	44.4	86.1
Distant	*	*	*
Unknown	3	33.3	29.1
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*

Female Breast, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	*	*	*
Localized	4	47.8	41.2
Regional	*	*	*
Distant	*	*	*
Unknown	2	26.1	15.1
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*

Lung and Bronchus, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	*	*	*
Localized	2	21.4	36.8
Regional	4	39.3	39.1
Distant	*	*	*
Unknown	2	21.4	29.9
<i>Female</i>			
<i>In Situ</i>	*	*	*
Localized	4	33.3	60.2
Regional	4	33.3	36.7
Distant	2	18.2	19.4
Unknown	*	*	*

Prostate, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age < 65</i>			
Localized	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 65</i>			
Localized	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the three year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
Nunavut, 2018–2019**

Cervix, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	*	*	*
Localized/Regional ¹	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*

Colon and Rectum, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	*	*	*
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	*	*	*
Unknown	5	64.3	31.3
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	*	*	*
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	*	*	*
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	*	*	*
Unknown	4	58.3	87.0
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	*	*	*
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	*	*	*
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	*	*	*
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	*	*	*
Unknown	*	*	*

Female Breast, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*

Lung and Bronchus, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Female</i>			
<i>In Situ</i>	*	*	*
Localized	6	50.0	122.1
Localized/Regional ¹	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*

Prostate, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	*	*	*
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age < 65</i>			
Localized	*	*	*
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 65</i>			
Localized	*	*	*
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	*	*	*
Unknown	*	*	*

Percentages based upon small cell sizes should be used with caution.

For cases diagnosed 2018 or later, the Canadian registries began collecting AJCC stage information only. The Summary Stage values are based on a behavior and a combined TNM value. Please see technical notes for more information.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

¹ Information to distinguish between localized and regional is not available.

² Information to distinguish between regional and distant is not available.

* Counts and rates are suppressed when fewer than 6 cases were reported over the two year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
Ontario, 2015–2017**

Cervix, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	292	49.3	4.1
Regional	178	30.0	2.2
Distant	55	9.3	0.7
Unknown	67	11.4	0.8

Colon and Rectum, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	*	*	*
Localized	1,708	35.7	21.2
Regional	1,563	32.6	19.2
Distant	797	16.6	9.8
Unknown	721	15.1	9.2
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	123	31.2	2.8
Regional	127	32.3	2.9
Distant	84	21.3	1.9
Unknown	59	15.1	1.4
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	1,585	36.1	69.5
Regional	1,435	32.7	62.1
Distant	713	16.2	30.6
Unknown	662	15.1	29.7
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	*	*	*
Localized	1,394	35.0	15.0
Regional	1,242	31.2	13.2
Distant	658	16.5	7.1
Unknown	686	17.2	6.9
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	126	33.8	2.8
Regional	115	30.7	2.5
Distant	81	21.7	1.8
Unknown	52	13.8	1.1
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	1,268	35.2	46.9
Regional	1,127	31.3	41.1
Distant	577	16.0	21.2
Unknown	634	17.6	21.9

Female Breast, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	1,536	12.2	17.1
Localized	6,351	50.2	69.5
Regional	3,365	26.6	38.7
Distant	722	5.7	8.1
Unknown	666	5.3	7.3
<i>Age < 50</i>			
<i>In Situ</i>	262	11.9	5.8
Localized	899	40.9	19.8
Regional	789	35.9	17.5
Distant	128	5.8	2.8
Unknown	120	5.5	2.7
<i>Age ≥ 50</i>			
<i>In Situ</i>	1,274	12.2	46.6
Localized	5,451	52.2	199.6
Regional	2,576	24.7	94.3
Distant	594	5.7	21.8
Unknown	546	5.2	19.4

Lung and Bronchus, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	*	*	*
Localized	823	16.4	10.2
Regional	1,026	20.5	12.5
Distant	2,275	45.4	27.6
Unknown	889	17.7	11.4
<i>Female</i>			
<i>In Situ</i>	*	*	*
Localized	1,052	20.9	11.1
Regional	1,002	19.9	10.4
Distant	2,057	40.8	21.3
Unknown	931	18.5	9.3

Prostate, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	5,645	66.6	65.4
Regional	1,320	15.6	14.4
Distant	1,453	17.2	17.9
Unknown	53	0.6	0.8
<i>Age < 65</i>			
Localized	1,885	66.1	21.8
Regional	565	19.8	6.5
Distant	402	14.1	4.7
Unknown	*	*	*
<i>Age ≥ 65</i>			
Localized	3,760	66.9	366.8
Regional	755	13.4	69.3
Distant	1,052	18.7	109.1
Unknown	*	*	*

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the three year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
Ontario, 2018–2019**

Cervix, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	*	*	*
Localized/Regional ¹	266	40.1	3.7
Regional	81	12.2	1.0
Distant	42	6.3	0.4
Unknown	274	41.3	3.4

Colon and Rectum, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	*	*	*
Localized	964	20.2	11.0
Localized/Regional ¹	1,300	27.2	15.1
Regional	293	6.1	3.4
Regional/Distant ²	140	2.9	1.6
Distant	794	16.6	9.2
Unknown	1,290	27.0	15.0
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	82	20.3	1.8
Localized/Regional ¹	106	26.1	2.4
Regional	28	6.9	0.6
Regional/Distant ²	12	3.0	0.3
Distant	82	20.3	1.8
Unknown	95	23.4	2.1
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	882	20.2	34.9
Localized/Regional ¹	1,194	27.3	48.4
Regional	265	6.1	10.8
Regional/Distant ²	128	2.9	5.1
Distant	712	16.3	28.6
Unknown	1,195	27.3	48.6
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	*	*	*
Localized	791	19.6	8.1
Localized/Regional ¹	1,093	27.1	11.1
Regional	290	7.2	2.9
Regional/Distant ²	160	4.0	1.6
Distant	585	14.5	5.9
Unknown	1,119	27.7	10.8
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	82	22.8	1.8
Localized/Regional ¹	97	26.8	2.1
Regional	29	8.1	0.6
Regional/Distant ²	11	2.9	0.2
Distant	62	17.2	1.3
Unknown	80	22.2	1.7
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	709	19.3	24.6
Localized/Regional ¹	996	27.1	34.6
Regional	261	7.1	9.0
Regional/Distant ²	149	4.1	5.1
Distant	523	14.2	17.9
Unknown	1,039	28.3	34.5

Female Breast, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	1,598	11.9	17.0
Localized	14	0.1	0.2
Localized/Regional ¹	9,508	70.6	101.0
Regional	291	2.2	3.1
Distant	540	4.0	5.7
Unknown	1,508	11.2	15.7
<i>Age < 50</i>			
<i>In Situ</i>	270	12.0	5.9
Localized	*	*	*
Localized/Regional ¹	1,603	71.6	35.2
Regional	52	2.3	1.1
Distant	83	3.7	1.8
Unknown	229	10.2	5.0
<i>Age ≥ 50</i>			
<i>In Situ</i>	1,328	11.8	46.2
Localized	12	0.1	0.4
Localized/Regional ¹	7,906	70.5	273.4
Regional	240	2.1	8.1
Distant	457	4.1	15.9
Unknown	1,280	11.4	43.6

Lung and Bronchus, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	*	*	*
Localized	813	15.9	9.2
Localized/Regional ¹	756	14.8	8.5
Regional	276	5.4	3.1
Distant	1,946	38.1	21.7
Unknown	1,317	25.8	15.1
<i>Female</i>			
<i>In Situ</i>	*	*	*
Localized	1,216	22.9	11.7
Localized/Regional ¹	803	15.2	7.7
Regional	221	4.2	2.1
Distant	1,763	33.3	17.0
Unknown	1,297	24.5	12.4

Prostate, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	5,886	64.4	63.0
Regional	1,052	11.5	10.5
Regional/Distant ²	15	0.2	0.2
Distant	954	10.4	11.0
Unknown	1,236	13.5	13.6
<i>Age < 65</i>			
Localized	1,826	64.0	20.0
Regional	506	17.7	5.6
Regional/Distant ²	3	0.1	0.0
Distant	180	6.3	2.0
Unknown	338	11.9	3.7
<i>Age ≥ 65</i>			
Localized	4,060	64.5	360.5
Regional	547	8.7	44.7
Regional/Distant ²	12	0.2	1.0
Distant	775	12.3	73.6
Unknown	898	14.3	82.6

Percentages based upon small cell sizes should be used with caution.

For cases diagnosed 2018 or later, the Canadian registries began collecting AJCC stage information only. The Summary Stage values are based on a behavior and a combined TNM value. Please see technical notes for more information.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

¹ Information to distinguish between localized and regional is not available.

² Information to distinguish between regional and distant is not available.

* Counts and rates are suppressed when fewer than 6 cases were reported over the two year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
Prince Edward Island, 2015–2017**

Cervix, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	3	40.0	4.5
Regional	4	44.0	3.8
Distant	*	*	*
Unknown	*	*	*

Colon and Rectum, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	24	26.1	22.7
Localized	24	26.1	23.2
Regional	28	31.3	30.1
Distant	14	15.8	14.8
Unknown	*	*	*
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	15	21.7	13.3
Localized	22	32.5	20.2
Regional	20	29.6	17.8
Distant	9	13.8	8.4
Unknown	*	*	*
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	2	46.2	4.5
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	20	31.6	61.4
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*

Female Breast, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	19	14.1	17.6
Localized	78	56.9	70.9
Regional	30	21.9	29.5
Distant	9	6.3	8.0
Unknown	*	*	*
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	7	46.8	15.8
Regional	6	38.3	13.4
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	71	58.2	215.4
Regional	24	19.8	71.4
Distant	*	*	*
Unknown	*	*	*

Lung and Bronchus, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	*	*	*
Localized	12	16.2	12.6
Regional	16	22.2	16.5
Distant	43	60.2	44.9
Unknown	*	*	*
<i>Female</i>			
<i>In Situ</i>	*	*	*
Localized	20	25.5	18.7
Regional	19	23.8	16.4
Distant	39	48.5	33.1
Unknown	*	*	*

Prostate, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	83	77.1	76.8
Regional	14	13.0	12.6
Distant	10	9.3	11.6
Unknown	*	*	*
<i>Age < 65</i>			
Localized	27	74.8	26.9
Regional	6	17.8	6.0
Distant	3	7.5	2.4
Unknown	*	*	*
<i>Age ≥ 65</i>			
Localized	56	78.2	421.3
Regional	8	10.6	58.1
Distant	7	10.2	75.6
Unknown	*	*	*

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the three year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
Prince Edward Island, 2018–2019**

Cervix, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	*	*	*
Localized/Regional ¹	4	61.5	5.6
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*

Colon and Rectum, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	*	*	*
Localized	14	23.0	12.7
Localized/Regional ¹	21	34.4	19.5
Regional	5	7.4	3.8
Regional/Distant ²	*	*	*
Distant	16	26.2	14.3
Unknown	*	*	*
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	*	*	*
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	14	23.5	45.9
Localized/Regional ¹	20	33.6	64.1
Regional	5	7.6	13.6
Regional/Distant ²	*	*	*
Distant	16	26.9	51.9
Unknown	*	*	*
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	*	*	*
Localized	11	20.4	9.9
Localized/Regional ¹	22	40.7	19.0
Regional	4	7.4	2.9
Regional/Distant ²	4	6.5	2.7
Distant	9	16.7	8.0
Unknown	5	8.3	3.4
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Localized/Regional ¹	*	*	*
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	10	19.0	28.2
Localized/Regional ¹	21	41.0	59.6
Regional	4	8.0	10.5
Regional/Distant ²	4	7.0	9.6
Distant	8	16.0	23.5
Unknown	5	9.0	12.4

Female Breast, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	17	11.9	15.4
Localized	*	*	*
Localized/Regional ¹	117	82.1	106.2
Regional	3	2.1	2.2
Distant	5	3.2	6.5
Unknown	*	*	*
<i>Age < 50</i>			
<i>In Situ</i>	3	12.5	6.7
Localized	*	*	*
Localized/Regional ¹	18	72.9	37.5
Regional	*	*	*
Distant	4	14.6	7.7
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	14	11.8	38.3
Localized	*	*	*
Localized/Regional ¹	100	84.0	286.1
Regional	3	2.5	8.1
Distant	*	*	*
Unknown	*	*	*

Lung and Bronchus, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	*	*	*
Localized	15	18.4	13.3
Localized/Regional ¹	17	20.9	16.2
Regional	6	7.4	5.5
Distant	38	46.6	35.6
Unknown	6	6.7	6.7
<i>Female</i>			
<i>In Situ</i>	*	*	*
Localized	15	24.0	12.2
Localized/Regional ¹	10	16.0	8.7
Regional	4	5.6	2.8
Distant	34	53.6	27.0
Unknown	*	*	*

Prostate, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	62	60.0	51.2
Regional	15	14.1	11.2
Regional/Distant ²	*	*	*
Distant	15	14.1	13.4
Unknown	12	11.2	10.3
<i>Age < 65</i>			
Localized	18	59.3	16.6
Regional	6	18.6	5.1
Regional/Distant ²	*	*	*
Distant	3	10.2	2.9
Unknown	4	11.9	3.2
<i>Age ≥ 65</i>			
Localized	44	60.3	290.3
Regional	9	12.3	53.9
Regional/Distant ²	*	*	*
Distant	12	15.8	85.6
Unknown	8	11.0	59.3

Percentages based upon small cell sizes should be used with caution.

For cases diagnosed 2018 or later, the Canadian registries began collecting AJCC stage information only. The Summary Stage values are based on a behavior and a combined TNM value. Please see technical notes for more information.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

¹ Information to distinguish between localized and regional is not available.

² Information to distinguish between regional and distant is not available.

* Counts and rates are suppressed when fewer than 6 cases were reported over the two year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
Saskatchewan, 2015–2017**

Cervix, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	24	47.4	4.8
Regional	18	35.1	3.2
Distant	7	13.6	1.2
Unknown	2	3.9	0.3

Colon and Rectum, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	120	22.1	18.5
Localized	183	33.8	29.0
Regional	135	24.9	21.4
Distant	92	16.9	14.3
Unknown	13	2.4	2.2
<i>Age < 50</i>			
<i>In Situ</i>	7	18.5	1.9
Localized	11	29.6	3.0
Regional	11	30.6	3.3
Distant	8	21.3	2.2
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	113	22.3	61.9
Localized	173	34.1	96.8
Regional	124	24.5	68.7
Distant	84	16.6	45.9
Unknown	13	2.6	7.9
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	73	18.7	10.6
Localized	132	33.9	18.9
Regional	102	26.1	14.2
Distant	71	18.1	10.0
Unknown	13	3.2	1.3
<i>Age < 50</i>			
<i>In Situ</i>	5	13.9	1.5
Localized	10	29.7	3.0
Regional	7	21.8	2.3
Distant	12	34.7	3.5
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	68	19.1	34.5
Localized	122	34.3	60.6
Regional	95	26.5	45.5
Distant	59	16.5	27.2
Unknown	13	3.5	4.7

Female Breast, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	101	11.8	15.6
Localized	443	51.6	66.2
Regional	246	28.7	38.6
Distant	61	7.1	8.6
Unknown	8	0.9	0.8
<i>Age < 50</i>			
<i>In Situ</i>	13	9.5	4.0
Localized	53	39.7	16.3
Regional	59	44.7	18.3
Distant	7	5.5	2.1
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	88	12.2	46.1
Localized	390	53.8	196.7
Regional	187	25.7	91.6
Distant	53	7.3	25.6
Unknown	*	*	*

Lung and Bronchus, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	*	*	*
Localized	59	15.5	9.6
Regional	82	21.7	13.1
Distant	232	61.4	36.9
Unknown	4	1.1	0.8
<i>Female</i>			
<i>In Situ</i>	*	*	*
Localized	75	18.5	10.5
Regional	95	23.4	13.3
Distant	229	56.6	32.0
Unknown	5	1.2	0.6

Prostate, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	450	64.7	66.7
Regional	120	17.3	17.0
Distant	104	15.0	16.9
Unknown	21	3.0	3.6
<i>Age < 65</i>			
Localized	179	73.3	26.2
Regional	51	20.7	7.1
Distant	14	5.9	2.0
Unknown	*	*	*
<i>Age ≥ 65</i>			
Localized	271	60.1	346.8
Regional	69	15.4	85.2
Distant	90	19.9	119.9
Unknown	*	*	*

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the three year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
Saskatchewan, 2018–2019**

Cervix, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	*	*	*
Localized/Regional ¹	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	65	99.2	11.7

Colon and Rectum, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	4	0.9	0.5
Localized	93	23.3	13.9
Localized/Regional ¹	129	32.3	18.8
Regional	27	6.6	4.1
Regional/Distant ²	11	2.8	1.8
Distant	96	24.0	14.1
Unknown	41	10.1	6.3
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	5	15.6	1.4
Localized/Regional ¹	6	17.2	1.6
Regional	4	10.9	1.0
Regional/Distant ²	*	*	*
Distant	10	29.7	2.6
Unknown	7	20.3	1.7
<i>Age ≥ 50</i>			
<i>In Situ</i>	4	1.0	1.9
Localized	88	23.9	46.6
Localized/Regional ¹	124	33.6	63.8
Regional	23	6.3	12.4
Regional/Distant ²	9	2.4	4.9
Distant	87	23.5	44.3
Unknown	34	9.3	18.5
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	3	1.0	0.4
Localized	66	20.9	9.6
Localized/Regional ¹	103	32.9	14.0
Regional	19	5.9	2.5
Regional/Distant ²	14	4.3	1.8
Distant	66	21.1	9.1
Unknown	44	14.0	5.7
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	5	19.2	1.5
Localized/Regional ¹	6	21.2	1.6
Regional	*	*	*
Regional/Distant ²	*	*	*
Distant	8	28.8	2.1
Unknown	6	23.1	1.7
<i>Age ≥ 50</i>			
<i>In Situ</i>	3	1.0	1.4
Localized	61	21.0	30.6
Localized/Regional ¹	98	33.9	46.5
Regional	18	6.1	8.4
Regional/Distant ²	13	4.3	5.9
Distant	59	20.3	27.3
Unknown	38	13.2	16.2

Female Breast, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	106	11.5	15.4
Localized	*	*	*
Localized/Regional ¹	377	41.2	55.3
Regional	13	1.4	1.8
Distant	22	2.3	3.1
Unknown	397	43.4	57.3
<i>Age < 50</i>			
<i>In Situ</i>	16	10.9	4.8
Localized	*	*	*
Localized/Regional ¹	68	46.4	20.1
Regional	*	*	*
Distant	4	2.4	0.9
Unknown	56	38.2	16.1
<i>Age ≥ 50</i>			
<i>In Situ</i>	90	11.6	43.3
Localized	*	*	*
Localized/Regional ¹	309	40.2	147.3
Regional	11	1.4	4.8
Distant	18	2.3	8.6
Unknown	341	44.3	165.1

Lung and Bronchus, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	*	*	*
Localized	25	6.8	3.8
Localized/Regional ¹	37	10.1	5.5
Regional	18	5.0	2.7
Distant	99	27.5	15.2
Unknown	182	50.5	27.4
<i>Female</i>			
<i>In Situ</i>	*	*	*
Localized	47	10.7	6.3
Localized/Regional ¹	41	9.2	5.4
Regional	15	3.4	2.0
Distant	107	24.3	14.0
Unknown	229	52.1	30.5

Prostate, 2018–2019

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	233	32.7	32.7
Regional	43	6.0	5.5
Regional/Distant ²	*	*	*
Distant	54	7.6	8.3
Unknown	382	53.7	54.2
<i>Age < 65</i>			
Localized	81	32.7	11.5
Regional	19	7.5	2.5
Regional/Distant ²	*	*	*
Distant	9	3.6	1.1
Unknown	139	56.0	19.5
<i>Age ≥ 65</i>			
Localized	152	32.7	179.4
Regional	24	5.2	25.7
Regional/Distant ²	*	*	*
Distant	45	9.7	57.9
Unknown	244	52.5	294.2

Percentages based upon small cell sizes should be used with caution.

For cases diagnosed 2018 or later, the Canadian registries began collecting AJCC stage information only. The Summary Stage values are based on a behavior and a combined TNM value. Please see technical notes for more information.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

¹ Information to distinguish between localized and regional is not available.

² Information to distinguish between regional and distant is not available.

* Counts and rates are suppressed when fewer than 6 cases were reported over the two year time period for the specific cancer.

**Average Annual Cases and Age-adjusted Rates by Stage at Diagnosis, Age and Race for Selected Cancer Sites
Yukon, 2015–2017**

Cervix, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*

Colon and Rectum, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>All Ages</i>			
<i>In Situ</i>	*	*	*
Localized	5	37.5	27.8
Regional	4	32.5	21.3
Distant	3	20.0	14.2
Unknown	*	*	*
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	5	37.5	100.8
Regional	4	32.5	77.2
Distant	3	20.0	51.2
Unknown	*	*	*
<i>Female</i>			
<i>All Ages</i>			
<i>In Situ</i>	*	*	*
Localized	3	38.1	18.7
Regional	3	42.9	14.6
Distant	*	*	*
Unknown	*	*	*
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	3	45.0	52.9
Distant	*	*	*
Unknown	*	*	*

Female Breast, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
<i>In Situ</i>	*	*	*
Localized	16	52.2	69.6
Regional	10	33.7	47.4
Distant	3	8.7	13.2
Unknown	*	*	*
<i>Age < 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	3	57.1	19.8
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 50</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	8	29.5	119.8
Distant	*	*	*
Unknown	*	*	*

Lung and Bronchus, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>Male</i>			
<i>In Situ</i>	*	*	*
Localized	2	18.4	10.6
Regional	3	21.1	16.7
Distant	7	55.3	44.6
Unknown	*	*	*
<i>Female</i>			
<i>In Situ</i>	*	*	*
Localized	*	*	*
Regional	3	34.5	22.6
Distant	5	51.7	26.0
Unknown	*	*	*

Prostate, 2015–2017

Stage at Diagnosis	All Races		
	Average Annual Cases	%	Rate
<i>All Ages</i>			
Localized	14	72.9	71.1
Regional	3	15.3	11.0
Distant	*	*	*
Unknown	*	*	*
<i>Age < 65</i>			
Localized	5	70.0	16.5
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*
<i>Age ≥ 65</i>			
Localized	10	74.4	448.7
Regional	*	*	*
Distant	*	*	*
Unknown	*	*	*

Note: Percentages based upon small cell sizes should be used with caution.

Rates are per 100,000 population and were age-adjusted using 20 age groups to the 2000 U.S. Standard Population.

* Counts and rates are suppressed when fewer than 6 cases were reported over the three year time period for the specific cancer.

Page Intentionally Left Blank